<SEC-DOCUMENT>0001558370-23-012722.txt : 20230801
<SEC-HEADER>0001558370-23-012722.hdr.sgml : 20230801
<ACCEPTANCE-DATETIME>20230801160539
ACCESSION NUMBER:		0001558370-23-012722
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		69
CONFORMED PERIOD OF REPORT:	20230630
FILED AS OF DATE:		20230801
DATE AS OF CHANGE:		20230801

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			RIGEL PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001034842
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				943248524
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29889
		FILM NUMBER:		231131660

	BUSINESS ADDRESS:	
		STREET 1:		611 GATEWAY BOULEVARD, SUITE 900
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		650-624-1100

	MAIL ADDRESS:	
		STREET 1:		611 GATEWAY BOULEVARD, SUITE 900
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>rigl-20230630x10q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.3.0.9 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 7/31/2023 8:05:52 PM -->
      <!-- iXBRL Library version: 1.0.8528.25195 -->
      <!-- iXBRL Service Job ID: 257530f0-7b03-4223-9f43-e33ea0c0ca97 -->

  <html xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2023" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:rigl="http://www.rigel.com/20230630" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" xs:nil="true" contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww" name="us-gaap:CommitmentsAndContingencies" id="Hidden_CZR7a5zKkEuoZzzA22JcKg"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" xs:nil="true" contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A" name="us-gaap:CommitmentsAndContingencies" id="Hidden_OAAck4EWKEOUhEAsCJb8iw"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" xs:nil="true" contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww" name="us-gaap:PreferredStockValue" id="Hidden_AbxTGvx4Q0CPiiy6Tx7JJg"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" xs:nil="true" contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A" name="us-gaap:PreferredStockValue" id="Hidden_Yl_yqQR19EOEkaV4777NXA"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_position_WoI3E1kTlEyL4Mc6Z0-iIg" contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" id="Hidden_ut8FmrekU0qEihlZMrnsbQ">0</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_sAWGlLehukGUN_F8wkmpLA" name="rigl:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardOfferingPeriod" id="Hidden_PQsDUEtR7km_2RPzqyzkJA">P24M</ix:nonNumeric><ix:nonFraction unitRef="Unit_Divide_USD_shares_Xu_N--yaaU6K7FdyMhFNnQ" sign="-" contextRef="Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_1vCSe6v77U-Pv5aEoT8NYw">0.04</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_Xu_N--yaaU6K7FdyMhFNnQ" sign="-" contextRef="Duration_4_1_2022_To_6_30_2022_ICCkO9pPUUSORAn1kecZBA" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_rANeXql6ykWq9e5A-w2NuA">0.08</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_Xu_N--yaaU6K7FdyMhFNnQ" sign="-" contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_L9LT0bCefkCJMaNCePj8fQ">0.12</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_Xu_N--yaaU6K7FdyMhFNnQ" sign="-" contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_WLazubqkGEyubmaVA5dzKw">0.24</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA" contextRef="Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_UyLeVOcoUUaabboWsjSswA">173748000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA" contextRef="Duration_4_1_2022_To_6_30_2022_ICCkO9pPUUSORAn1kecZBA" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_rxVm8W3E4E6qxzONFlRoZQ">172147000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA" contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_SQp-nWz5iEWvz4nR5H-ayw">173659000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA" contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_2wnfhWvUgEWjiutudXGVNg">171961000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" xs:nil="true" contextRef="Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ" name="rigl:NetSubleaseIncomeExpense" id="Hidden_if_nK6gayEetouowdVil5w"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" xs:nil="true" contextRef="Duration_4_1_2022_To_6_30_2022_ICCkO9pPUUSORAn1kecZBA" name="rigl:NetSubleaseIncomeExpense" id="Hidden_v_fUsNyOv0y60ttHM-hoPg"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" xs:nil="true" contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" name="rigl:NetSubleaseIncomeExpense" id="Hidden_n4oiXcFrkUefbhZElnx3QQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" xs:nil="true" contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g" name="rigl:NetSubleaseIncomeExpense" id="Hidden_RzHufXubkkibtQabd8gePg"></ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" name="dei:EntityRegistrantName" id="Hidden_ZClN4TxlXECXi30paBlJgA">RIGEL PHARMACEUTICALS INC</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" name="dei:EntityFilerCategory" id="Hidden_9W3VprSizE2GIycyz962gg">Accelerated Filer</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" name="dei:DocumentFiscalPeriodFocus" id="Tc_KaQnbPBX-kG6t4mnWtmamw_1_1">Q2</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" name="dei:EntityCentralIndexKey" id="Tc_N1JIIWD_dkqnYGRA1SuNuA_2_1">0001034842</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" name="dei:CurrentFiscalYearEndDate" id="Tc_cx0vSkDxPUCCnC7bLpJFBA_3_1">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" name="dei:AmendmentFlag" id="Tc_ufCvMqiuqUyhkklQbX1CxA_4_1">false</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" name="dei:DocumentPeriodEndDate" id="Tc_Xf9SiwJHW0yM2basTIH4pw_5_1">2023-06-30</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" name="dei:SecurityExchangeName" id="Hidden_evwQgBeMCkK3vHVn6qdmTA">NASDAQ</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_rigl_ShareBasedCompensationOptionsAndRsusMember__foVAAxJ0UaZLSEd-5d-Tw" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Hidden_gNM8FB3j1EmiM03O-NFNhA">P2Y7M24D</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_sAWGlLehukGUN_F8wkmpLA" name="rigl:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardOfferingPeriod" id="Hidden_zvVmLYm5wkGT80D-sHpXHw">P24M</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_sAWGlLehukGUN_F8wkmpLA" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Hidden_uq0rUsBH7E2jbRn6gMjYeg">P0Y8M26D</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_VJof-y5NIUmbhtjjV8-ZnQ" decimals="-5" name="rigl:CollaborativeArrangementRevenueRecognized" id="Hidden__wXnWXc-L0ayd7KDHxLEEA">5000000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2022_To_6_30_2022_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_AqH_Lz4Dqk2ULht1ffcBfQ" decimals="-5" name="rigl:CollaborativeArrangementRevenueRecognized" id="Hidden_DbLhvPAx_0Cf0r70yTVP_Q">5000000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_10_1_2022_To_12_31_2022_FhmwYe6SJ0ePT2UUdm49MA" decimals="-5" name="rigl:CollaborativeArrangementRevenueRecognized" id="Hidden_sIEQoBwV_0WCfNDnOrc4Wg">20000000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_3_31_2023_dei_LegalEntityAxis_rigl_FormaTherapeuticsHoldingsIncMember_rigl_AchievementOfMilestoneAxis_rigl_FdaApprovalAndFirstCommercialSaleOfProductMember_srt_ProductOrServiceAxis_rigl_RezlidhiaMember_Q2ZF2zilOEO-sSwctjZDng" decimals="-5" name="rigl:PaymentsOfMilestonePaymentObligations" id="Hidden_Muf8QwRdCECWl-UXgvN83Q">15000000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_rigl_HeadquartersOfficeSpaceSubleaseSouthSanFranciscoCaliforniaMember_RzRVSQYro0qfZzFsimZvQA" decimals="-5" name="us-gaap:OperatingLeaseLiability" id="Hidden_WC8UdES80kWQ1oTf-c3WYQ">1300000</ix:nonFraction><ix:nonNumeric contextRef="As_Of_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_rigl_HeadquartersOfficeSpaceSubleaseSouthSanFranciscoCaliforniaMember_Q7wBI-TD_USrGUm0m_WO2A" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Hidden_V6j-ReLR3UOlKbpOTUVtAQ">P1Y11M1D</ix:nonNumeric><ix:nonNumeric contextRef="Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ" name="ecd:Rule10b51ArrAdoptedFlag" id="Hidden_QCL7E72EDUS0cbuyFXFOTg">false</ix:nonNumeric><ix:nonNumeric contextRef="Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ" name="ecd:Rule10b51ArrTrmntdFlag" id="Hidden_k-kBHamybk-ItVew0754Ag">false</ix:nonNumeric><ix:nonNumeric contextRef="Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ" name="ecd:NonRule10b51ArrAdoptedFlag" id="Hidden__T-axW871EyqhlqnUc5L-w">false</ix:nonNumeric><ix:nonNumeric contextRef="Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ" name="ecd:NonRule10b51ArrTrmntdFlag" id="Hidden_GN8AxaIWvEm84zA14uJG0g">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="rigl-20230630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_1_1_2023_To_6_30_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember_5hmOTOINYUi1yMKOyqV_Tg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_GovernmentAndOtherRebatesMember_6P-es-h0okS3mUsko2UktA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">rigl:GovernmentAndOtherRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_ChargebacksDiscountsAndFeesMember_Fj8Wggl3gkGVVa1f_QMscg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">rigl:ChargebacksDiscountsAndFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember_ioiPIbSN6U6AmT1ftZXQ6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_GovernmentAndOtherRebatesMember_OChMZBgap0qvP6EMKEatOg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">rigl:GovernmentAndOtherRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_ChargebacksDiscountsAndFeesMember_t4iNGTcP0UaLBEDeXCMGOw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">rigl:ChargebacksDiscountsAndFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember_-dSzQZXVFEuMJw8h2iIHxw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_GovernmentAndOtherRebatesMember_jVuu0q4VHEWON15mELkW8g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">rigl:GovernmentAndOtherRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_ChargebacksDiscountsAndFeesMember_DfMT0NHFbUOWySs4XQGnsg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">rigl:ChargebacksDiscountsAndFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember_acq92gncQkKXH4cm6zevsA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_GovernmentAndOtherRebatesMember__X6NqDu8YU-SnfKyNeY8HA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">rigl:GovernmentAndOtherRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_ChargebacksDiscountsAndFeesMember_PB_xsJ2Rnka8evD4QKOfWg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">rigl:ChargebacksDiscountsAndFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember_jBU6vZXXI0qTA8tjSyNMHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_GovernmentAndOtherRebatesMember_bsvDCX99AUmyaU2yXJOh2w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">rigl:GovernmentAndOtherRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_ChargebacksDiscountsAndFeesMember_nboH8Ly9PkqdAPD6SogU6Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">rigl:ChargebacksDiscountsAndFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember_2U4Oj50ug0SqZPXE5_VdHg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_GovernmentAndOtherRebatesMember_eCxe-sGTfE-EJIbGHCs0Rw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">rigl:GovernmentAndOtherRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_ChargebacksDiscountsAndFeesMember_Pp0Xy4dvykCBp639HzD29g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">rigl:ChargebacksDiscountsAndFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2mIl79LxpkuN5mgFsNHdfg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1ylsF_WCdkeufVQaI9L5Qg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_X0BNnHhQVkGCCdDEwUQPOQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_h87Ta8IYBkSUtMHbuewiIg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_6WAzHoGFsEyRh9-_I-EgwA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_GsGkBqFtIEeF4t6uDl64RA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_uWcj3WWP8EKEJxuUNUBsng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_zZnbux6ITEas3Z5CntDoJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_OfzaBWn7ikCSgv7BTwXlfQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4ofcdRQIYUqAzW1HPzZ5vA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_BgUu_xw-pEOX64_3oVKFUQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_7r-CKjYwcEWPEVrhWmkNzw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_H75YemqVnEyPwV--MIGWGw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_lUJBYmkmN0mPdtrXTwmLYw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_SgCZ7AQnVkal8VnKIFXBDg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_8FRPOicKCUukQ6L7AAUMNw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_JNCe4Z95dE6Iw1LvI3RQ4g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_mUlMkH6yV0ev7oy48pw70w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_HUMQpp-hhUmkBPR7Q8NCIw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_DP28xveaSEKwPEHlfm8Vvg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_BK3VScSjz0OWZFv-nNNaXA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_j5agreqUq0C05wMxAlbdRg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_2EWYq3VBqUSwnhTDnAcB0w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_n7Oc0ne_BUqW0jhEW7x51g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NXFVM5fZJUmDlMyyzE1ttg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0zb7z7FwO0GI2RAEVAHXQw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xvjnxqS-hkCiR6PhUg5rig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8sjAYkMEXkWQKgqr3XNtXg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4k30MtA2pUm5iDpAhJLPrg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Mal6s5t5Z0qQ9EIsFrTGuQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_gbdA-1ad4EqysI7py3ChOA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2023_To_5_31_2023_Q3DEP_Nkn0q2GbxII4v6Iw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_4_30_2023_qr7JWxKMEU6rcNt5QqihYw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_DF-ET0UVsU-4JFbzSJC6wg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_om_Pkmw3FEmnJzDD0iVbRQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_tNXptyV-B0yupU7uhJiuDg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_phK8_7NtIEStEjkLueCcDw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_PpvU5eYgTEyg2sveoUrODg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nQp2Q6A6Z0qf5xAVDXOnBg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_dei_LegalEntityAxis_rigl_FormaTherapeuticsHoldingsIncMember_srt_ProductOrServiceAxis_rigl_RezlidhiaMember_holN4_ByhUmtcYY2H349MA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:FormaTherapeuticsHoldingsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:RezlidhiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_dei_LegalEntityAxis_rigl_FormaTherapeuticsHoldingsIncMember_srt_ProductOrServiceAxis_rigl_RezlidhiaMember_yxVUJk2G5k2qwTfZTVvH9Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:FormaTherapeuticsHoldingsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:RezlidhiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_VOQGD0Imek29F_UrLGFn-w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:KisseiPharmaceuticalCo.Ltd.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_rigl_AchievementOfMilestoneAxis_rigl_LicensedRightsMember_srt_ProductOrServiceAxis_rigl_CentralNervousSystemPenetrantIntellectualPropertyMember_nqY09VTQhkCP6kuB8E26vw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:LicensedRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:CentralNervousSystemPenetrantIntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_v4jyMWOILkimNDJi27bJNA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_GovernmentContractMember_WN0BoWdZGU-KXqAccwJ68A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GovernmentContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_RoyaltyDeliveryOfDrugSuppliesAndOthersMember_jqRyjOlFGUu5mu87xpyztg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:RoyaltyDeliveryOfDrugSuppliesAndOthersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_GrossProductMember_ene2KCce8kCbyUMQexHEMg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:GrossProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_DiscountsAndAllowancesMember_uHoWbEnKdU2tg1UhL6Vz-g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:DiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_ContractRevenuesFromCollaborationsMember_yU4TzCXKCkSEqjOPYCD5ig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:ContractRevenuesFromCollaborationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_C2EWGpiFxUGr9E995bXhCQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_GovernmentContractMember_9xcr5RYkM0WkIqJKKgDS8A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GovernmentContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_RoyaltyDeliveryOfDrugSuppliesAndOthersMember_V9FmeTwnFU20hq0tJetk3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:RoyaltyDeliveryOfDrugSuppliesAndOthersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_GrossProductMember_ufxFI3eqlEur3o5rbubmLA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:GrossProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_DiscountsAndAllowancesMember_POb1Otc_IkOne8fdyW38vA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:DiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_ContractRevenuesFromCollaborationsMember_TmFkSqljNUiYYmkDnr-3ag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:ContractRevenuesFromCollaborationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_Zl3JCD-6OEeEiUA808bVig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_LicenseMember_dRyVOn5NcEee-uU6cPlByQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_rigl_RoyaltyDeliveryOfDrugSuppliesAndOthersMember_v1BBxfjOM0iXxMM8ZntPkg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:RoyaltyDeliveryOfDrugSuppliesAndOthersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_rigl_GrossProductMember_95E_EFQSok-CYS8j9cMXTA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:GrossProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_rigl_DiscountsAndAllowancesMember_OH1BW4gyzU6mjxq6VfcyGg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:DiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_rigl_DevelopmentMilestonesMember_8XRCe7N2D0q0_dL4LzLrSw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:DevelopmentMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_rigl_ContractRevenuesFromCollaborationsMember_B3F0S8vRz0eWxrI-zbC5eQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:ContractRevenuesFromCollaborationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_I08rIoA1_0itpE8QmmW4zw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_LicenseMember_aC5yN2D_3U6wto3RbpNFkQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_rigl_RoyaltyDeliveryOfDrugSuppliesAndOthersMember_ClPsUsxGhkStEb_3uR8ZgA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:RoyaltyDeliveryOfDrugSuppliesAndOthersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_rigl_GrossProductMember_rXnbhU9tKUyNBTlYxDeWHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:GrossProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_rigl_DiscountsAndAllowancesMember_rYICJn1GSUmzENKUTvY70A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:DiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_rigl_DevelopmentMilestonesMember_HoBUCB_cmEGo56InBGrucg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:DevelopmentMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_rigl_ContractRevenuesFromCollaborationsMember_LOIZvjtJ4kefhhUMq6-K0Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:ContractRevenuesFromCollaborationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_12_31_2022_dei_LegalEntityAxis_rigl_FormaTherapeuticsHoldingsIncMember_rigl_AchievementOfMilestoneAxis_rigl_AchievementOfCertainNearTermRegulatoryMilestoneMember_mYsvlxGBhUyABmwFOCLmig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:FormaTherapeuticsHoldingsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:AchievementOfCertainNearTermRegulatoryMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_dei_LegalEntityAxis_rigl_FormaTherapeuticsHoldingsIncMember_gN0UrgqHwke5fJiA75tT0w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:FormaTherapeuticsHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_1_2020_To_2_29_2020_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_rigl_AchievementOfMilestoneAxis_rigl_CreditableAdvanceRoyaltyPaymentMember_srt_ProductOrServiceAxis_rigl_FostamatinibMember_aO7fdyjeKkKh-8rHnFGcDQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:GrifolsS.a.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:CreditableAdvanceRoyaltyPaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-01</xbrli:startDate><xbrli:endDate>2020-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_1_2020_To_2_29_2020_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember__7PyRX4jPECYeFKd4E3SHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:GrifolsS.a.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-01</xbrli:startDate><xbrli:endDate>2020-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_QxrzwDPl-02u7MxFvVCYNQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_hHQBvZ1Mi06kiRDiBIcvOg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3JpqoXaqL0SrqUrpHTj6kg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_n9loXyMYREivaHgcSKMHMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_srt_ProductOrServiceAxis_rigl_R552Member_srt_RangeAxis_srt_MaximumMember_nQDkYFvGfkGeTW-8GkyDkg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:R552Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_rigl_HeadquartersOfficeSpaceSubleaseSouthSanFranciscoCaliforniaMember_RzRVSQYro0qfZzFsimZvQA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rigl:HeadquartersOfficeSpaceSubleaseSouthSanFranciscoCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_BC0bgoovFkSFc26FtpY0vA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_lxmvkD9RK0qU7ZM5gMSIQw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_aR01SJIgMUW3MS43CRdmBw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_egDPK9MhIkOXkH42vVRrWw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_DebtInstrumentAxis_rigl_CreditAgreementTrancheOneMember_NdmHGNjm80GwagBp6p25SQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rigl:CreditAgreementTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_28_2023_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_DebtInstrumentAxis_rigl_CreditAgreementTrancheFiveMember_QUesi71yDkqy9WA84-x-ug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rigl:CreditAgreementTrancheFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_31_2022_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_DebtInstrumentAxis_rigl_CreditAgreementTrancheThreeMember_xE8L3bekvEKDIR_7sMJqCw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rigl:CreditAgreementTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_31_2022_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_DebtInstrumentAxis_rigl_CreditAgreementTrancheFourMember_YfMR144_eUWzw-ApIaAstA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rigl:CreditAgreementTrancheFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_31_2020_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_DebtInstrumentAxis_rigl_CreditAgreementTrancheTwoMember_Pt33AwlsAE-LZCXlY1xdSw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rigl:CreditAgreementTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryBillSecuritiesMember_9EFna87LuU6O4O7rLXT8_Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_-mpWze0ew0qh9kNZ1GgxZg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_6LWYDoMSGEuqSbON9szqUA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">rigl:CorporateBondSecuritiesAndCommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_E0z-Tucd60Gr3PRXDlh0xw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryBillSecuritiesMember_W5abtcgj4EewIThyL6s9KQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_89OSD-Eh70S-lOaWIkx8jg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_wFvchknSJ0iAyfGzH6qAww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_j804o1Qq5kW9BN0Wq8qKAw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">rigl:CorporateBondSecuritiesAndCommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_5w8Rm76YAUeQeOz8g-y38Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_aESIeqNLDEGTjQh7l8feaA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_QW_rs_VEA0KU4-yd8SrPbw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryBillSecuritiesMember_I8wfKfL5DU-wQrbo5YC4Eg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_DV0JpqqeFEG2yWKut9HiFw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_la2B--bWDkagQFiSFOzkrA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">rigl:CorporateBondSecuritiesAndCommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_u-RkEtQ-w0Oqm41OpKcIhw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryBillSecuritiesMember_Ttzv--YhbkeAEe271vcCHQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_wWiomWDuy0icYfW_HOwFgA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_rIYz9iBffUO8TYWENsIDrg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_5M7Ca4BjDU6p5rg68gEwqQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">rigl:CorporateBondSecuritiesAndCommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_D1RS1iCAi0Cf-ba1jen3jA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_d-_85Kk8g0mwIwHaIhvvxA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_fPNOItXmGU6NPrDN3d1kDg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_BJeMNksUxkWrPx4dQB6u3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_ePrDC_3ewk2JsGsYLAl0ZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_vq2GZ_j7vkilnhfg4of5cw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_CJn5TKw-Sk6p8v3y1c6mVA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_rigl_HeadquartersOfficeSpaceSubleaseSouthSanFranciscoCaliforniaMember_Q7wBI-TD_USrGUm0m_WO2A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rigl:HeadquartersOfficeSpaceSubleaseSouthSanFranciscoCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_bC736RZBjkmPBtBhrfONyg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_AwardTypeAxis_rigl_ShareBasedCompensationOptionsAndRsusMember_eHSX5niPTk2ia4BsC8uknQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rigl:ShareBasedCompensationOptionsAndRsusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_rigl_ShareBasedCompensationOptionsAndRsusMember__foVAAxJ0UaZLSEd-5d-Tw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rigl:ShareBasedCompensationOptionsAndRsusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_dWMxniyFJ06ygU7yM53x1w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:KisseiPharmaceuticalCo.Ltd.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_lZzWZsARrUq--he7HLPz4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_srt_StatementScenarioAxis_rigl_FollowingThirdAmendmentMember_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_LJSahnttvEiJdFf1pAqMfg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">rigl:FollowingThirdAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_srt_StatementScenarioAxis_rigl_PriorToThirdAmendmentMember_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_VariableRateAxis_rigl_LondonInterBankOfferedRateMember_PMVwcFXhgUW15_EzDLiLAw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">rigl:PriorToThirdAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">rigl:LondonInterBankOfferedRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_srt_StatementScenarioAxis_rigl_FollowingThirdAmendmentMember_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_VariableRateAxis_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_ShXm5jIvgkOs-ZS0wM0CGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">rigl:FollowingThirdAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_srt_StatementScenarioAxis_rigl_PriorToThirdAmendmentMember_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_VariableRateAxis_rigl_LondonInterBankOfferedRateMember_2WmOu592Mkqf1Hwsj0OZug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">rigl:PriorToThirdAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">rigl:LondonInterBankOfferedRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_srt_StatementScenarioAxis_rigl_FollowingThirdAmendmentMember_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_VariableRateAxis_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_4EMQf1c4MEiugud-VG7qaw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">rigl:FollowingThirdAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_srt_MajorCustomersAxis_rigl_MckessonSpecialtyCareDistributionCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_NFFFR5Op6EGibKqyThuK6g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rigl:MckessonSpecialtyCareDistributionCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_srt_MajorCustomersAxis_rigl_CardinalHealthcareMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_ZvGiZXP9CEeNn157o58OQQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rigl:CardinalHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_srt_MajorCustomersAxis_rigl_AsdHealthcareAndOncologySupplyMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_ezDA2vAhCkWEvWvApmdHcA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rigl:AsdHealthcareAndOncologySupplyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_srt_MajorCustomersAxis_rigl_MckessonSpecialtyCareDistributionCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_ijLIVbFhwE2dv-2rbK1hJw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rigl:MckessonSpecialtyCareDistributionCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_srt_MajorCustomersAxis_rigl_CardinalHealthcareMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_7kgMzAici0eIlntate3Qlw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rigl:CardinalHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_srt_MajorCustomersAxis_rigl_AsdHealthcareAndOncologySupplyMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_L3diTTLKsk23XOOP9fvJUg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rigl:AsdHealthcareAndOncologySupplyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_srt_MajorCustomersAxis_rigl_MckessonSpecialtyCareDistributionCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_Xm7pTW7phEG80_TFGMPzwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rigl:MckessonSpecialtyCareDistributionCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_srt_MajorCustomersAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_KKDtN8IagE6J4I_uAnU00A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rigl:KisseiPharmaceuticalCo.Ltd.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_srt_MajorCustomersAxis_rigl_CardinalHealthcareMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_crG-CxphyUmLeRthseHyVQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rigl:CardinalHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_srt_MajorCustomersAxis_rigl_AsdHealthcareAndOncologySupplyMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_sEWKR2JD6EG-XvczwGJTDg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rigl:AsdHealthcareAndOncologySupplyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_srt_MajorCustomersAxis_rigl_MckessonSpecialtyCareDistributionCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_hMd2onJOT0a7o-jJSOOdJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rigl:MckessonSpecialtyCareDistributionCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_srt_MajorCustomersAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_r58vna9bwkWOHGAEZRVhtg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rigl:KisseiPharmaceuticalCo.Ltd.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_srt_MajorCustomersAxis_rigl_CardinalHealthcareMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_XwGmaHgDQE6DlBxIrLRYjw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rigl:CardinalHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_srt_MajorCustomersAxis_rigl_AsdHealthcareAndOncologySupplyMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_Z_7YFCzct0KfoaZgxA9q_Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rigl:AsdHealthcareAndOncologySupplyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_zHK5kte7M02N-LF9t66ILA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_X6KPuRq2uEa6dhukywoGKw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_LY4sWUaA_UOIKxqqgZ5UAQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryBillSecuritiesMember_ASiSMIactUqwVwnqPY3_ew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_KL0hZTH2e063PXe0IU6-1g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_LfRnUUxRrEycHqB8YoPOOQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CashMember_qUTZZY9s90OHjG7EZblg4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_InvestmentTypeAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_1RwephmFh0WgSWKn57-wDg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">rigl:CorporateBondSecuritiesAndCommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryBillSecuritiesMember_sKjXaDQa5EiL5o0NsgoBFA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_M3axIPlo5k2k9b5gQJC25g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_1pcJHoW0nkC8Ko2b5ADUog"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CashMember_FLsEIySBfEaeRVBihq2f2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_InvestmentTypeAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_BtwQ3KLKc02gIILPkP43sw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">rigl:CorporateBondSecuritiesAndCommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember_9b5OdbmUeUi1NDAMA8H9Vg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_ReLJS_8Ua0iY--Vx8HxzUQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_FinancialInstrumentAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_EovRXwcsBU6PVsykL7sTEQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rigl:CorporateBondSecuritiesAndCommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember_afYkc85gT0m66xklaugfbw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_go32t6mGGEqSyKBPofyDEA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_FuBEs4QimEqUM83PeYRZcw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rigl:CorporateBondSecuritiesAndCommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_kUrHXkhzkEmFf7R8bUu2kA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_mJfwLdIwJE2PuCZyxHa0nA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_3tETexLm0UCBsN9ftHBwtg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_eLmQDXheSkOcwdRhfkuNbw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_FPUuaR2SyUSRDy3fSQcDRQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_3BL6mb7WlEWnOeX6FOCPaw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_WHRK7Ydr8Euv9ScMKMDa3Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_2SVbQAbboUOHtAeVDBUKZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_FormaTherapeuticsHoldingsIncMember_srt_ProductOrServiceAxis_rigl_RezlidhiaMember_Ggj-m6AMbkSlsqSSg-Oh4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:FormaTherapeuticsHoldingsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:RezlidhiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_FormaTherapeuticsHoldingsIncMember_srt_ProductOrServiceAxis_rigl_RezlidhiaMember_u5JNB-NKCE6uQDuM-ogIPw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:FormaTherapeuticsHoldingsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:RezlidhiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_OA1zy6euuUWd92D01bHyQA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_cNvDS3J20E2jpHrHJN-GXQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_YYP3i7dwZkyEj_jUho867Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_9G6CsmCnIE25iWXSTMDwUA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_5BqaR0t6HUmn3zbRET6b7A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_NPerFx0HTUiasJQZFwYc_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_qUKc9ZeBcEiFN-VeeuFO_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_WWdgQCoeWk-M5rmywXJFrQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_OPWXZu-4xESxTw7UEzGEfw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_pug8RCBYIkeZTp1-6vn_VQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_qfQwkxMZLU6ffGWe8LPnaQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_jRjTsJgDwE65v_ICJzPELw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_q29chwJC8UWqOM6gViWQCA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_NyURkj24PU2gRd22NkwY9w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_ld4nogTT4UKONA-CGQuvUQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_Z6JnOF8Gmkqq3XJoCK4JhA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaap_StatementEquityComponentsAxis_rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember_M4prG97dGEaaceW_5B5zCw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rigl:AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_FinancialInstrumentAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_us-gaap_StatementEquityComponentsAxis_rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember_qfBk03iVXEW6w48gjbjf7A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rigl:CorporateBondSecuritiesAndCommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rigl:AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_8i-ahQp_70mFJFvxxl02wA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember_P5cNTt7IlEa-Rhtic4nyvA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rigl:AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember_us-gaap_StatementEquityComponentsAxis_rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember_C6IhUCU3BkGDHmqFolJgdQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rigl:AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_O0JjjXe-ZE-RH42gPIxthQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaap_StatementEquityComponentsAxis_rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember_8aUcC__wTUGDPKa_b54-SQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rigl:AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_us-gaap_StatementEquityComponentsAxis_rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember_qoI-MShlREydakWlPmH8IA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rigl:CorporateBondSecuritiesAndCommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rigl:AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_dT29_JlvC0m0JlLh8k3msw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember_fV_8kfGMb0aVZbFHW8RnkA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rigl:AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_R552Member_nAWV78-1SEKxOb73Me78JA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:R552Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_rigl_R552Member_6cuFgoRx00e-zcShKPySYQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:R552Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_p5hH6L8EpUKDvP9iizwvIA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:KisseiPharmaceuticalCo.Ltd.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_dei_LegalEntityAxis_rigl_FormaTherapeuticsHoldingsIncMember_rigl_AchievementOfMilestoneAxis_rigl_FdaApprovalAndFirstCommercialSaleOfProductMember_srt_ProductOrServiceAxis_rigl_RezlidhiaMember_0GWFqUYggk2HSLP63Ny2Tg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:FormaTherapeuticsHoldingsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:FdaApprovalAndFirstCommercialSaleOfProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:RezlidhiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_sAWGlLehukGUN_F8wkmpLA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_us-gaap_BalanceSheetLocationAxis_rigl_AccountsReceivableAndPrepaidAndOtherCurrentAssetsMember__I6hFO6Y_0yiZKdPOpgk-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">rigl:AccountsReceivableAndPrepaidAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_us-gaap_BalanceSheetLocationAxis_rigl_AccountsReceivableAndPrepaidAndOtherCurrentAssetsMember_EmK1_sfXdkCE9z-LmqaUnw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">rigl:AccountsReceivableAndPrepaidAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_1_31_2019_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_srt_RangeAxis_srt_MaximumMember_G1KtN3XbpUSoL3F_Q5ONNQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:GrifolsS.a.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_dei_LegalEntityAxis_rigl_FormaTherapeuticsHoldingsIncMember_rigl_AchievementOfMilestoneAxis_rigl_FdaApprovalAndFirstCommercialSaleOfProductMember_srt_ProductOrServiceAxis_rigl_RezlidhiaMember_Q2ZF2zilOEO-sSwctjZDng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:FormaTherapeuticsHoldingsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:FdaApprovalAndFirstCommercialSaleOfProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:RezlidhiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_1_31_2021_srt_ProductOrServiceAxis_rigl_FostamatinibMember_CbO6IlzEuE-DlB2_dwCYvQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_ICCkO9pPUUSORAn1kecZBA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_dei_LegalEntityAxis_rigl_MedisonPharmaLtd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ProductFinancingArrangementMember_BIXtwMz280OZBubIreCp6g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:MedisonPharmaLtd.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ProductFinancingArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_dei_LegalEntityAxis_rigl_MedisonPharmaLtd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ProductFinancingArrangementMember_10kT5pgvQESOoSV7Z9NRdg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:MedisonPharmaLtd.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ProductFinancingArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_ProductOrServiceAxis_rigl_R552Member_0YBAFpZ08UOLKeVes5ohFA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:R552Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_srt_ProductOrServiceAxis_rigl_R552Member_JPs0ePqXlEKj9VOt8HSlUw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:R552Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_R552Member_-FMAVRdgk0G_DrmYiygA5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:R552Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_KnightTherapeuticsInternationalSaMember_rigl_AchievementOfMilestoneAxis_rigl_SpecifiedCommercialMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_rigl_CommercialAndLicenseAgreementMember_w0GRfq66bE20v4GiBSs-dQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:KnightTherapeuticsInternationalSaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:SpecifiedCommercialMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rigl:CommercialAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_rigl_AchievementOfMilestoneAxis_rigl_DevelopmentAndRegulatoryMilestonesByNonCentralNervousSystemDiseaseProductsMember_srt_StatementScenarioAxis_rigl_MilestonePaymentsOnProductByProductBasisMember_437LgKAaEUCSP1qghK8PUg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:DevelopmentAndRegulatoryMilestonesByNonCentralNervousSystemDiseaseProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">rigl:MilestonePaymentsOnProductByProductBasisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_rigl_AchievementOfMilestoneAxis_rigl_DevelopmentAndRegulatoryMilestonesByCentralNervousSystemDiseaseProductsMember_srt_StatementScenarioAxis_rigl_MilestonePaymentsOnProductByProductBasisMember_GdhaCtbSb0a6DDLJ7JX1QA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:DevelopmentAndRegulatoryMilestonesByCentralNervousSystemDiseaseProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">rigl:MilestonePaymentsOnProductByProductBasisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_rigl_AchievementOfMilestoneAxis_rigl_SpecifiedRegulatoryEventsMember_zr3FrB7HG0yHHKE65ZlQ0g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:SpecifiedRegulatoryEventsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_rigl_AchievementOfMilestoneAxis_rigl_SpecifiedProductLaunchEventsMember_kqeKijsRnkOOsVnTduINrw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:SpecifiedProductLaunchEventsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_rigl_AchievementOfMilestoneAxis_rigl_SpecifiedDevelopmentEventsMember_sRR_821DCEKRn49CXFeLEw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:SpecifiedDevelopmentEventsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_rigl_AchievementOfMilestoneAxis_rigl_DevelopmentAndRegulatoryMilestonesByNonCentralNervousSystemDiseaseProductsMember_qhsapuJyEU-hSuSu6wuzRA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:DevelopmentAndRegulatoryMilestonesByNonCentralNervousSystemDiseaseProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_rigl_AchievementOfMilestoneAxis_rigl_DevelopmentAndRegulatoryMilestonesByCentralNervousSystemDiseaseProductsMember_Rs41QnjvWk6gGclD-ADolA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:DevelopmentAndRegulatoryMilestonesByCentralNervousSystemDiseaseProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_1_2020_To_2_29_2020_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_rigl_AchievementOfMilestoneAxis_rigl_EuropeanMedicinesAgencyApprovalOfFostamatinibForTreatmentOfChronicImmuneThrombocytopenicPurpuraMember_srt_ProductOrServiceAxis_rigl_FostamatinibMember_jRYJphbQ30m9xYIoKA1dgg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:GrifolsS.a.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:EuropeanMedicinesAgencyApprovalOfFostamatinibForTreatmentOfChronicImmuneThrombocytopenicPurpuraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-01</xbrli:startDate><xbrli:endDate>2020-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_1_31_2019_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_rigl_AchievementOfMilestoneAxis_rigl_SpecifiedCommercialMilestonesMember_7nbfSECgx0WYA153JYabJQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:GrifolsS.a.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:SpecifiedCommercialMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_7_27_2022_dei_LegalEntityAxis_rigl_FormaTherapeuticsHoldingsIncMember_bDfSL0BJhEWrP72tbRoIWQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:FormaTherapeuticsHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_KnightTherapeuticsInternationalSaMember_us-gaap_TypeOfArrangementAxis_rigl_CommercialAndLicenseAgreementMember_lvwZmBPza0monsr9dfDiMw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:KnightTherapeuticsInternationalSaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rigl:CommercialAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_4_30_2021_JKmOcc6NLUygXEbnIz_jXg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2019_To_10_31_2019_dei_LegalEntityAxis_rigl_MedisonPharmaLtd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ProductFinancingArrangementMember_RZVg4VgmR0iEhiVJHe0OGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:MedisonPharmaLtd.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ProductFinancingArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2019_To_10_31_2019_dei_LegalEntityAxis_rigl_MedisonPharmaLtd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_us-gaap_TypeOfArrangementAxis_rigl_CommercialAndLicenseAgreementMember_zpx7xwCeskCPVInu1YwLlw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:MedisonPharmaLtd.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rigl:CommercialAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_1_31_2019_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_-3boqmgcW0u1hhv3nltpLw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:GrifolsS.a.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2018_To_10_31_2018_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_PZS9u-OE1EmIeqOd2HsFnw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:KisseiPharmaceuticalCo.Ltd.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_rigl_AchievementOfMilestoneAxis_rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember_srt_ProductOrServiceAxis_rigl_FostamatinibMember_iOGTC4JHqEqAcLNDtBnr0Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:KisseiPharmaceuticalCo.Ltd.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:OneTimeDeliveryOfDrugSupplyForCommercializationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_YoqQXBJjBkuRMnl_Is2ryA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:GrifolsS.a.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_rigl_AchievementOfMilestoneAxis_rigl_ResearchActivitiesMember_wKD8r5wj8UWbEX-iqfwrAA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:GrifolsS.a.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:ResearchActivitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_rigl_AchievementOfMilestoneAxis_rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember_ahEiLx0SUk2_jcyttC4ctw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:GrifolsS.a.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:OneTimeDeliveryOfDrugSupplyForCommercializationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_FostamatinibMember_lBFcNSb6mkeW8CR2ORtSjg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_CentralNervousSystemPenetrantIntellectualPropertyMember_u9CM64l4x06mzHqJqirPew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:CentralNervousSystemPenetrantIntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_rigl_AchievementOfMilestoneAxis_rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember_srt_ProductOrServiceAxis_rigl_FostamatinibMember_knn1moXg0kCR1PGoGmvEkA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:KisseiPharmaceuticalCo.Ltd.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:OneTimeDeliveryOfDrugSupplyForCommercializationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_BiD0k0-zyUKpI2kOTEgwHQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:GrifolsS.a.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_rigl_AchievementOfMilestoneAxis_rigl_ResearchActivitiesMember_86cJ5cqEH0CUdyuPMTHCqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:GrifolsS.a.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:ResearchActivitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_rigl_AchievementOfMilestoneAxis_rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember_6EJQsZyI7Ei65WKe6vURdw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:GrifolsS.a.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:OneTimeDeliveryOfDrugSupplyForCommercializationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_FostamatinibMember_FfcxPSwT3UW6Q9F1eb4nlg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_CentralNervousSystemPenetrantIntellectualPropertyMember_abvwS7ZRYkCRPqpRi8kUzA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:CentralNervousSystemPenetrantIntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_12_31_2022_dei_LegalEntityAxis_rigl_MedisonPharmaLtd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ProductFinancingArrangementMember_FDUx_RGlykuMMywGpuGo3Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:MedisonPharmaLtd.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ProductFinancingArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_12_31_2022_FhmwYe6SJ0ePT2UUdm49MA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_rigl_AchievementOfMilestoneAxis_rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember_srt_ProductOrServiceAxis_rigl_FostamatinibMember_X1jrjFNaUUi-0RSb2kWr2A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:KisseiPharmaceuticalCo.Ltd.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:OneTimeDeliveryOfDrugSupplyForCommercializationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_AqH_Lz4Dqk2ULht1ffcBfQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:KisseiPharmaceuticalCo.Ltd.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_UY3l2klaxkutbshAAhD9Eg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:GrifolsS.a.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_rigl_AchievementOfMilestoneAxis_rigl_ResearchActivitiesMember_bcLtqW_sUUGWAZXyYhABiQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:GrifolsS.a.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:ResearchActivitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_rigl_AchievementOfMilestoneAxis_rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember__2GzLf2h9Uy8zugKcIpR5Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:GrifolsS.a.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:OneTimeDeliveryOfDrugSupplyForCommercializationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_rigl_CentralNervousSystemPenetrantIntellectualPropertyMember_D23iXamso06lFysd2JS4lQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:CentralNervousSystemPenetrantIntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_rigl_AchievementOfMilestoneAxis_rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember_srt_ProductOrServiceAxis_rigl_FostamatinibMember_ijWIH4IdnkaOE9hajv0lhw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:KisseiPharmaceuticalCo.Ltd.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:OneTimeDeliveryOfDrugSupplyForCommercializationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_VJof-y5NIUmbhtjjV8-ZnQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:KisseiPharmaceuticalCo.Ltd.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_8nDIYOyABEq7e05lMjmqPw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:GrifolsS.a.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_rigl_AchievementOfMilestoneAxis_rigl_ResearchActivitiesMember_15-zZAIzYESjPJ56lMgsMg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:GrifolsS.a.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:ResearchActivitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_rigl_AchievementOfMilestoneAxis_rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember_2kS72QqQ3EiGnNpkGNQiwg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:GrifolsS.a.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:OneTimeDeliveryOfDrugSupplyForCommercializationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_rigl_CentralNervousSystemPenetrantIntellectualPropertyMember_sJI61AX-gkq7zwYyHj0Hgw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:CentralNervousSystemPenetrantIntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2023_srt_ProductOrServiceAxis_rigl_FostamatinibMember_khHoF3cNM0WfiX7y2atpOw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_srt_ProductOrServiceAxis_rigl_NonCentralNervousSystemPenetrantIntellectualPropertyMember_AzcLeTjz60Ckk-4IZ7Z2Yg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:NonCentralNervousSystemPenetrantIntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_7_27_2022_dei_LegalEntityAxis_rigl_FormaTherapeuticsHoldingsIncMember_rigl_AchievementOfMilestoneAxis_rigl_SpecifiedCommercialMilestonesMember_puSiFDremkCXvb9X1_0EfA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:FormaTherapeuticsHoldingsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:SpecifiedCommercialMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_7_27_2022_dei_LegalEntityAxis_rigl_FormaTherapeuticsHoldingsIncMember_rigl_AchievementOfMilestoneAxis_rigl_DevelopmentAndRegulatoryMilestonesMember_7OkGU0Mcw06DYh7peGdg4g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:FormaTherapeuticsHoldingsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:DevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_4hZ--7i_V0a3K3Xee2PShA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_27_2023_fIa718F-RUSNkmUlyUHJ_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-07-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_uVIKS5OYQEes3pxG5CV0tw"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_agreement_KRHA7hMTtE2mxosuhHYaSA"><xbrli:measure>rigl:agreement</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_period_q1X9Nu1d1EeTbsf56ZdECg"><xbrli:measure>rigl:period</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_item_goOMrhYK4U2jGn5r_GJRhQ"><xbrli:measure>rigl:item</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_position_WoI3E1kTlEyL4Mc6Z0-iIg"><xbrli:measure>rigl:position</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_Xu_N--yaaU6K7FdyMhFNnQ"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;min-height:28.8pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;min-height:9.2pt;"><a id="_21305650_9ef0_4231_acc9_206d03c6d7b2"></a><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-size:16pt;font-weight:bold;">UNITED STATES </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-size:16pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">WASHINGTON, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" name="dei:DocumentType" id="Narr_H2Qgw6preU-ZbdafRUAFng"><b style="font-weight:bold;">10-Q</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(Mark One)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><a id="_7c078f33_2b1c_4b17_9f0d_6542ecc848f5"></a><a id="Tc_vkXaXG_Cz0e8RCZrg3t6ow_1_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:7.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:92.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" name="dei:DocumentQuarterlyReport" id="Tc_3Q8gq7Pvv0G32lV-7EuzUw_1_0"><b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9746;</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:92.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><b style="font-weight:bold;">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">FOR THE QUARTERLY PERIOD ENDED JUNE 30, </b><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" name="dei:DocumentFiscalYearFocus" id="Narr_5Gwn16cB1kCzuT_O_RvJqw"><b style="font-size:9pt;font-weight:bold;">2023</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OR</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><a id="_8ed852e7_6746_4aa6_8ea2_dc443beef4a3"></a><a id="Tc_TRB9-z6TkkmzaVGWQWxlfA_1_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:7.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:92.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" name="dei:DocumentTransitionReport" id="Tc_kf3ZNU9gekid-IYvP0gfQw_1_0"><b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9744;</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:92.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><b style="font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FOR THE TRANSITION PERIOD FROM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;TO&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">Commission File Number </b><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" name="dei:EntityFileNumber" id="Narr_UjF5qDM7vU-N_Ide1yT-yw"><b style="font-size:9pt;font-weight:bold;">0-29889</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:72pt;text-align:center;text-indent:-72pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;text-align:center;margin:0pt;"><span style="-sec-ix-hidden:Hidden_ZClN4TxlXECXi30paBlJgA;"><b style="font-family:'Times New Roman','Times','serif';font-size:16pt;font-style:normal;font-weight:bold;">Rigel Pharmaceuticals,&#160;Inc.</b></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">(Exact name of registrant as specified in its charter)</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><a id="_023a4e94_b5ad_4817_9e5d_f28259f33558"></a><a id="Tc_W6a78cdID0CO6mWln2Od1Q_3_0"></a><a id="Tc_YvcDUPudTkanFATtgYfp5A_3_2"></a><a id="Tc_cSa4un_2H0yuowY-T_c4uQ_4_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:14.85pt;"><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" name="dei:EntityIncorporationStateCountryCode" id="Tc_R1RkvsxCrkyY4_uodX1_vw_2_0"><b style="font-size:9pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" name="dei:EntityTaxIdentificationNumber" id="Tc_PrB9BXxdI0OJQbyuJ6emMQ_2_2"><b style="font-size:9pt;font-weight:bold;">94-3248524</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(State or other jurisdiction of incorporation or</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(I.R.S. Employer Identification No.)</p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">organization)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><a id="_cbc86cf6_d39e_402f_aee3_de1dbee4865f"></a><a id="Tc_z_1G56stM0GXUlhlR0hrPA_3_0"></a><a id="Tc_ejss4C6aLku4s4jH5P3zcA_4_0"></a><a id="Tc_1kWW6Mn2kEmQidxEOMOFzA_4_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" name="dei:EntityAddressAddressLine1" id="Tc_Zppv8ctPUEyQ0fr3Q7BV0w_2_0"><b style="font-size:9pt;font-weight:bold;">611 Gateway Boulevard, Suite 900,</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" name="dei:EntityAddressCityOrTown" id="Narr_ZcTkIoHLiUCp-Jw5XWcrWg"><b style="font-size:9pt;font-weight:bold;">South San Francisco</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" name="dei:EntityAddressStateOrProvince" id="Narr_WyZaZD1Yeku-2DOPLx7WNw"><b style="font-size:9pt;font-weight:bold;">CA</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" name="dei:EntityAddressPostalZipCode" id="Tc_5NFcNfhMKkqe6uq5aOcYaQ_3_2"><b style="font-size:9pt;font-weight:bold;">94080</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Address of principal executive offices)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Zip Code)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" name="dei:CityAreaCode" id="Narr_Aoo2NMJREUufY_kJUOBMKA"><b style="font-size:9pt;font-weight:bold;">650</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" name="dei:LocalPhoneNumber" id="Narr_NnLK472__kSuadk_oQvOzg"><b style="font-size:9pt;font-weight:bold;">624-1100</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Registrant&#8217;s telephone number, including area code)</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:18pt;margin:0pt;">Securities registered pursuant to Section 12(b) of the Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><a id="_2528715e_2d4e_42b7_814d_3282a604a3cd"></a><a id="Tc_HoyXqfnk5UK5AdUKIiYCoA_2_0"></a><a id="Tc_J-v0JhBdXki0DZ0hz8gu2A_2_2"></a><a id="Tc_dhliQJYkYkCLzpyrYFXN6g_2_4"></a><a id="Tc_W5fQFcNdmkScATBpgNQ7xw_3_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.09%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:30.08%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:33.1%;margin:0pt;padding:0pt;"></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.09%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:30.08%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:33.1%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:33.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Title&#160;of&#160;each&#160;class:</b></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:top;width:30.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading Symbol</b></p></td><td style="vertical-align:bottom;width:1.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:33.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name&#160;of&#160;each&#160;exchange&#160;on&#160;which&#160;registered:</b></p></td></tr><tr><td style="vertical-align:top;width:33.09%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" name="dei:Security12bTitle" id="Tc_1HdmmcLE8U6EOV702269YA_3_0"><span style="font-size:9pt;">Common Stock, par value $0.001 per share</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:30.08%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" name="dei:TradingSymbol" id="Tc__RlQR8vZ_kKs-x_QSu7ngw_3_2"><span style="font-size:9pt;">RIGL</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.1%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:9pt;">The </span><span style="-sec-ix-hidden:Hidden_evwQgBeMCkK3vHVn6qdmTA;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">Nasdaq</span></span><span style="font-size:9pt;"> Stock Market LLC</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_Hlk42160639"></a><a id="_Hlk42160722"></a><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:9pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;</span><span style="font-size:9pt;white-space:pre-wrap;">days.  </span><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" name="dei:EntityCurrentReportingStatus" id="Narr_jo811cwFrUynToMz7z3y0Q"><span style="font-size:9pt;">Yes</span></ix:nonNumeric><span style="font-size:9pt;">&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span><span style="font-size:9pt;white-space:pre-wrap;">  No&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:9pt;">Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;</span><span style="font-size:9pt;white-space:pre-wrap;">months (or for such shorter period that the registrant was required to submit such files).  </span><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" name="dei:EntityInteractiveDataCurrent" id="Narr_zz4ubYedxkCouKbn1LMVxA"><span style="font-size:9pt;">Yes</span></ix:nonNumeric><span style="font-size:9pt;">&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span><span style="font-size:9pt;white-space:pre-wrap;">  No&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><a id="_cp_text_1_2"></a><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:18pt;margin:0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.02777481%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:26.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:35.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:26.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Large accelerated filer <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:35.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="-sec-ix-hidden:Hidden_9W3VprSizE2GIycyz962gg;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">Accelerated filer</span></span><span style="font-size:9pt;"> </span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span></p></td></tr><tr><td style="vertical-align:top;width:26.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Non-accelerated filer <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:35.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:9pt;">Smaller reporting company </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" name="dei:EntitySmallBusiness" id="Narr_8hPpQeeVoEyP_fV_6SHYmg"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:26.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:9pt;">Emerging Growth Company </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" name="dei:EntityEmergingGrowthCompany" id="Narr_iVsrfVn3SUOpaKOXhBvJXQ"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:35.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><a id="_cp_text_1_18"></a><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:18pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:9pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). Yes&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" name="dei:EntityShellCompany" id="Narr_vcWzkH8yjU2x6ZDvUqlIDg"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric><span style="font-size:9pt;">&#160;&#160;No&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:18pt;margin:0pt;"><span style="font-size:9pt;">As of July 27, 2023, there were </span><span style="font-size:9pt;"><ix:nonFraction unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_7_27_2023_fIa718F-RUSNkmUlyUHJ_A" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_aWDHvsSTJUah9eekU99pfQ">174,364,286</ix:nonFraction></span><span style="font-size:9pt;"> shares of the registrant&#8217;s Common Stock outstanding</span>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-size:12pt;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_cfe07234_54ce_4e8a_abef_df1d3e26be45"></a><a id="Toc"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">RIGEL PHARMACEUTICALS,&#160;IN</b><b style="font-weight:bold;">C.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">QUARTERLY REPORT ON FORM&#160;10-Q</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2023</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">INDEX</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:98.02%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:10.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:81.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:81.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:top;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="font-size:10pt;" href="#PARTIFINANCIALINFORMATION_587520"><b style="font-style:normal;font-weight:bold;">PART&#160;I</b></a></p></td><td style="vertical-align:top;width:81.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="font-size:10pt;" href="#PARTIFINANCIALINFORMATION_587520"><b style="font-style:normal;font-weight:bold;">FINANCIAL INFORMATION</b></a></p></td><td style="vertical-align:top;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.75%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;">3</span></p></td></tr><tr><td style="vertical-align:top;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="font-size:10pt;" href="#Item1FinancialStatements_419379"><b style="font-style:normal;font-weight:bold;">Item 1.</b></a></p></td><td style="vertical-align:top;width:81.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="font-size:10pt;" href="#Item1FinancialStatements_419379"><span style="font-style:normal;font-weight:normal;">Financial Statements</span></a></p></td><td style="vertical-align:top;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;">3</span></p></td></tr><tr><td style="vertical-align:top;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:81.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="font-size:10pt;" href="#BALANCESHEETS_710088"><span style="font-style:normal;font-weight:normal;">Condensed Balance Sheets (Unaudited) &#8212; June 30, 2023 and December 31, 2022</span></a></p></td><td style="vertical-align:top;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;">3</span></p></td></tr><tr><td style="vertical-align:top;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:81.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:10pt;" href="#STATEMENTSOFOPERATIONS_342998"><span style="font-style:normal;font-weight:normal;">Condensed Statements of Operations (Unaudited) &#8212; three and six months ended June 30, 2023 and 2022</span></a></p></td><td style="vertical-align:top;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;">4</span></p></td></tr><tr><td style="vertical-align:top;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:81.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:10pt;" href="#COMPREHENSIVE_LOSS"><span style="font-style:normal;font-weight:normal;">Condensed Statements of Comprehensive Loss (Unaudited) &#8212; three and six months ended June 30, 2023 and 2022</span></a></p></td><td style="vertical-align:top;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;">5</span></p></td></tr><tr><td style="vertical-align:top;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:81.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:10pt;" href="#STOCKHOLDERSEQUITY"><span style="font-style:normal;font-weight:normal;">Condensed Statements of Stockholders&#8217; (Deficit) Equity (Unaudited) &#8212; three and six months ended June 30, 2023 and 2022</span></a></p></td><td style="vertical-align:top;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;">6</span></p></td></tr><tr><td style="vertical-align:top;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:81.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:10pt;" href="#STATEMENTSOFCASHFLOWS_16439"><span style="font-style:normal;font-weight:normal;">Condensed Statements of Cash Flows (Unaudited) &#8212; six months ended June 30, 2023 and 2022</span></a></p></td><td style="vertical-align:top;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;">7</span></p></td></tr><tr><td style="vertical-align:top;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:81.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="font-size:10pt;" href="#NotestoCondensedFinancialStatements"><span style="font-style:normal;font-weight:normal;">Notes to Condensed Financial Statements (Unaudited)</span></a></p></td><td style="vertical-align:top;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;">8</span></p></td></tr><tr><td style="vertical-align:top;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="font-size:10pt;" href="#Item2_ManagementsDiscussionAndAna_120616"><b style="font-style:normal;font-weight:bold;">Item 2.</b></a></p></td><td style="vertical-align:top;width:81.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="font-size:10pt;" href="#Item2_ManagementsDiscussionAndAna_120616"><span style="font-style:normal;font-weight:normal;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:top;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;">23</span></p></td></tr><tr><td style="vertical-align:top;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="font-size:10pt;" href="#Item3_QuantitativeandQualitative_065227"><b style="font-style:normal;font-weight:bold;">Item 3.</b></a></p></td><td style="vertical-align:top;width:81.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="font-size:10pt;" href="#Item3_QuantitativeandQualitative_065227"><span style="font-style:normal;font-weight:normal;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td><td style="vertical-align:top;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;">45</span></p></td></tr><tr><td style="vertical-align:top;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="font-size:10pt;" href="#Item4_ControlsandProcedures_065229"><b style="font-style:normal;font-weight:bold;">Item 4.</b></a></p></td><td style="vertical-align:top;width:81.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="font-size:10pt;" href="#Item4_ControlsandProcedures_065229"><span style="font-style:normal;font-weight:normal;">Controls and Procedures</span></a></p></td><td style="vertical-align:top;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;">45</span></p></td></tr><tr><td style="vertical-align:top;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="font-size:10pt;" href="#PARTII_OTHERINFORMATION_065230"><b style="font-style:normal;font-weight:bold;">PART II</b></a></p></td><td style="vertical-align:top;width:81.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="font-size:10pt;" href="#PARTII_OTHERINFORMATION_065230"><b style="font-style:normal;font-weight:bold;">OTHER INFORMATION</b></a></p></td><td style="vertical-align:top;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;">46</span></p></td></tr><tr><td style="vertical-align:top;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="font-size:10pt;" href="#Item1_LegalProceedings_065231"><b style="font-style:normal;font-weight:bold;">Item 1.</b></a></p></td><td style="vertical-align:top;width:81.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="font-size:10pt;" href="#Item1_LegalProceedings_065231"><span style="font-style:normal;font-weight:normal;">Legal Proceedings</span></a></p></td><td style="vertical-align:top;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;">46</span></p></td></tr><tr><td style="vertical-align:top;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="font-size:10pt;" href="#Item1A_RiskFactors_065233"><b style="font-style:normal;font-weight:bold;">Item 1A.</b></a></p></td><td style="vertical-align:top;width:81.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="font-size:10pt;" href="#Item1A_RiskFactors_065233"><span style="font-style:normal;font-weight:normal;">Risk Factors</span></a></p></td><td style="vertical-align:top;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;">47</span></p></td></tr><tr><td style="vertical-align:top;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="font-size:10pt;" href="#Item2UnregisteredSalesofEquitySecurities"><b style="font-style:normal;font-weight:bold;">Item 2.</b></a></p></td><td style="vertical-align:top;width:81.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="font-size:10pt;" href="#Item2UnregisteredSalesofEquitySecurities"><span style="font-style:normal;font-weight:normal;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></p></td><td style="vertical-align:top;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;">91</span></p></td></tr><tr><td style="vertical-align:top;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="font-size:10pt;" href="#Item3DefaultsUponSeniorSecurities"><b style="font-style:normal;font-weight:bold;">Item 3.</b></a></p></td><td style="vertical-align:top;width:81.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="font-size:10pt;" href="#Item3DefaultsUponSeniorSecurities"><span style="font-style:normal;font-weight:normal;">Defaults Upon Senior Securities</span></a></p></td><td style="vertical-align:top;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;">91</span></p></td></tr><tr><td style="vertical-align:top;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="font-size:10pt;" href="#Item4MineSafetyDisclosures"><b style="font-style:normal;font-weight:bold;">Item 4.</b></a></p></td><td style="vertical-align:top;width:81.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="font-size:10pt;" href="#Item4MineSafetyDisclosures"><span style="font-style:normal;font-weight:normal;">Mine Safety Disclosures</span></a></p></td><td style="vertical-align:top;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;">91</span></p></td></tr><tr><td style="vertical-align:top;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="font-size:10pt;" href="#Item5OtherInformation"><b style="font-style:normal;font-weight:bold;">Item 5.</b></a></p></td><td style="vertical-align:top;width:81.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="font-size:10pt;" href="#Item5OtherInformation"><span style="font-style:normal;font-weight:normal;">Other Information</span></a></p></td><td style="vertical-align:top;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;">92</span></p></td></tr><tr><td style="vertical-align:top;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="font-size:10pt;" href="#Item6_Exhibits_122646"><b style="font-style:normal;font-weight:bold;">Item 6.</b></a></p></td><td style="vertical-align:top;width:81.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="font-size:10pt;" href="#Item6_Exhibits_122646"><span style="font-style:normal;font-weight:normal;">Exhibits</span></a></p></td><td style="vertical-align:top;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;">92</span></p></td></tr><tr><td style="vertical-align:top;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:81.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="font-size:10pt;" href="#Signatures_122812"><b style="font-style:normal;font-weight:bold;">Signatures</b></a></p></td><td style="vertical-align:top;width:81.12%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;">94</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><a id="_b3a1b230_5269_4717_99ef_d18dab4e45c9"></a><a id="PARTIFINANCIALINFORMATION_587520"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PART&#160;I. FINANCIAL INFORMATIO</b><b style="font-weight:bold;">N</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><a id="Item1FinancialStatements_419379"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item 1.</b></span><b style="font-weight:bold;">Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">RIGEL PHARMACEUTICALS, INC.</b></p><a id="BALANCESHEETS_710088"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CONDENSED BALANCE SHEET</b><b style="font-weight:bold;">S</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands) </b></p><a id="_6f1190be_dca3_4329_b200_46c7f37fa8c7"></a><a id="Tc_ZgyNUS4zjkS68wRnU6Ydeg_1_2"></a><a id="Tc_nUPg4q3QdkmdsrXwhUqKsQ_2_2"></a><a id="Tc_706w3AqvOkKhtSi3eF1jBw_2_5"></a><a id="Tc_ccm1LdRvpEKe4Xu0L4DH7A_3_2"></a><a id="Tc_Lbs-42ZMg0yo8PwRF7i3Tw_4_0"></a><a id="Tc_Nm7bMuODU06cJTnCSpuwTw_5_0"></a><a id="Tc_6Hx3ivkK2kKNjaCZ_18L1Q_6_0"></a><a id="Tc_yXxe5R_9LUuOoCoBx0naTw_6_2"></a><a id="Tc_6RprUuBSWkui1k2d-N3IZQ_6_5"></a><a id="Tc_CvJwOWYJ6Uyy-XtTyLGEfQ_7_0"></a><a id="Tc__hm2pAHZ1Uey4bd3Ig4XfA_8_0"></a><a id="Tc_kD8B0IgWVEuethOWY56fog_9_0"></a><a id="Tc_B9z0Ndt61UGqWE_rm-REzg_10_0"></a><a id="Tc_ars250kjxkO82IIKwGMfRA_11_0"></a><a id="Tc_jDsoEh4zr02KTMZtQUlPwg_12_0"></a><a id="Tc_FMzMCNNPUUy9nWIaymMvgA_13_0"></a><a id="Tc_1LvEweU320CYypWPBomXdw_14_0"></a><a id="Tc_MyaWjzFbYUOMDKScgVPl3g_15_0"></a><a id="Tc_PuXpoCQXJUeBUqOVhQ-wdg_16_0"></a><a id="Tc_a3nwlJhmQEeeieMQmHgGYA_16_2"></a><a id="Tc_DKpo08PS_EeVae0VyeXy_Q_16_5"></a><a id="Tc_ZrH-zH_bIUeyBOHi6dwSrQ_17_0"></a><a id="Tc_aBAo10dpU0qw7-Ht3_QpYQ_18_0"></a><a id="Tc_p1RSEK-yNky6EmJVyk0Nnw_19_0"></a><a id="Tc_v0nN69wsP0aZ87bXeB40fg_19_2"></a><a id="Tc_2lUVWIF7uEiHS0lkeKnNUw_19_5"></a><a id="Tc_9ijpoNh0KEGtrFHpBP4leQ_20_0"></a><a id="Tc_zWCfrPLo20ykH2GTlt3Cpg_21_0"></a><a id="Tc_AX3SaHZCrEKxX9W6yYO57A_22_0"></a><a id="Tc_HZd9bYWqUkawr1eZWFrmMg_23_0"></a><a id="Tc_5HHhs5nu6Uaby0ZgF-XCog_24_0"></a><a id="Tc_nQQgzFpwoUWhx40YrQ6FXg_25_0"></a><a id="Tc_Krj2fG_ceU2rOahjYC94tg_26_0"></a><a id="Tc_Pm_gH6ZEaEWLNh0m2odyOQ_27_0"></a><a id="Tc_2GkPrKXgnUeeUuMcN4nxBQ_28_0"></a><a id="Tc_pE48X1h22kyMcYQUftZFVQ_29_0"></a><a id="Tc_d2g6VvyyZEOMCJTuQQcq_A_30_0"></a><a id="Tc_o6HcuyRmX0yy27oo6bRmNw_31_0"></a><a id="Tc_7APq22Bcs0GCMt4DjXSMHg_33_0"></a><a id="Tc_GqOjGrvPn0yKOR_ZtWYlhw_35_0"></a><a id="Tc_zGyorcEE9EW5XKXH0TPrVg_36_0"></a><a id="Tc_J7zBAU4aX0y8rd_C7eCJpQ_37_0"></a><a id="Tc_mKlrNV36SUeeZvKr5fHrTw_38_0"></a><a id="Tc_FLWovK40HUavDCXrvUYzDQ_39_0"></a><a id="Tc_yoV0C8ku-E-LyeUtEaBUrg_40_0"></a><a id="Tc_242H9IUFpk-sdYfD4pdCuw_41_0"></a><a id="Tc_xBWwn9SqCUy43nZsK6sjIQ_42_0"></a><a id="Tc_udwmsduCVEup9xQx7LKZTQ_42_2"></a><a id="Tc_6YnJy65S5kGW_UfkEysN9Q_42_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:96.57%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:34.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of</b></p></td><td style="vertical-align:bottom;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:20.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2022 </b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:20.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;width:0.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current assets:</p></td><td style="vertical-align:bottom;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;width:0.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_jSu8PRRNJUu-kkzKuxPKgg_6_3">48,812</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_7aULfNOXV0Sj_zpprf3MHw_6_6">24,459</ix:nonFraction></p></td><td style="vertical-align:bottom;width:0.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Short-term investments</p></td><td style="vertical-align:bottom;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_0fwe7EJ8xEWsuHPyZWaY6Q_7_3">15,545</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_dH3EI8QT_kCpnWkrIy4Fcw_7_6">33,747</ix:nonFraction></p></td><td style="vertical-align:bottom;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accounts receivable, net</p></td><td style="vertical-align:bottom;width:0.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="Tc_Mvj0XWw8eE-z23AS_X-Asg_8_3">20,819</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="Tc_rbZ6Wy4BVESGnmbhN1Ir4Q_8_6">40,320</ix:nonFraction></p></td><td style="vertical-align:bottom;width:0.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Inventories</p></td><td style="vertical-align:bottom;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_hR-941ee6EeTD1TAzNqTvA_9_3">10,782</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_aaalVsEafUWZv7K--MYsiQ_9_6">9,118</ix:nonFraction></p></td><td style="vertical-align:bottom;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Prepaid and other current assets</p></td><td style="vertical-align:bottom;width:0.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_S73nBUob8UmppLls8W_Hwg_10_3">4,967</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_UPBLo-IV2kWq72mIn_6lkQ_10_6">8,259</ix:nonFraction></p></td><td style="vertical-align:bottom;width:0.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total current assets</p></td><td style="vertical-align:bottom;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_M6BkMCovjEa0oXwCsHYw9A_11_3">100,925</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_Nn7r0J4NyUWwPs7TbTSXsA_11_6">115,903</ix:nonFraction> </p></td><td style="vertical-align:bottom;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;width:0.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_AbJ81LH_WUG5mUitQWgGJw_12_3">215</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_OnSgtgK-UUm7m5ztFE9DFg_12_6">857</ix:nonFraction></p></td><td style="vertical-align:bottom;width:0.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Intangible asset, net</p></td><td style="vertical-align:bottom;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" scale="3" id="Tc_Lu7RwDI43E2TUof2PMNh2Q_13_3">14,413</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" scale="3" id="Tc_GP6twiNt_USvmrHueKxc2Q_13_6">14,949</ix:nonFraction></p></td><td style="vertical-align:bottom;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating lease right-of-use assets</p></td><td style="vertical-align:bottom;width:0.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_lQB12j3nmUuo2-QVr5Z-Fw_14_3">997</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_YsvhUGZRSkGuErMGRIi-FA_14_6">1,930</ix:nonFraction></p></td><td style="vertical-align:bottom;width:0.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other assets</p></td><td style="vertical-align:bottom;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_N9_E217oBUCe4cOi9O4XEw_15_3">541</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_Y34k5E-qGUCf6f9bUuIbDw_15_6">640</ix:nonFraction></p></td><td style="vertical-align:bottom;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total assets</p></td><td style="vertical-align:bottom;width:0.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_i-hqAc8jNkuwIv84auBrPQ_16_3">117,091</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_SwnvJVXmdUeyRVffiEjlhw_16_6">134,279</ix:nonFraction> </p></td><td style="vertical-align:bottom;width:0.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Liabilities and stockholders&#8217; deficit</b></p></td><td style="vertical-align:bottom;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current liabilities:</p></td><td style="vertical-align:bottom;width:0.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accounts payable</p></td><td style="vertical-align:bottom;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_HN87il0WuE2bGkEcUdPY6g_19_3">5,240</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_mhQVyEAzN0exMJzvwROAHA_19_6">22,508</ix:nonFraction></p></td><td style="vertical-align:bottom;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accrued compensation</p></td><td style="vertical-align:bottom;width:0.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_t538cbm6nE68w5Idp_dDTA_20_3">6,739</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_T301qmyAEU6gLd1TmTX9cQ_20_6">8,866</ix:nonFraction></p></td><td style="vertical-align:bottom;width:0.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accrued research and development</p></td><td style="vertical-align:bottom;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww" decimals="-3" format="ixt:numdotdecimal" name="rigl:AccruedResearchAndDevelopmentLiabilityCurrent" scale="3" id="Tc_DkHbQH9TikCMVa3plX03qw_21_3">5,826</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A" decimals="-3" format="ixt:numdotdecimal" name="rigl:AccruedResearchAndDevelopmentLiabilityCurrent" scale="3" id="Tc_F9EBNLVOdU6z8M2cG7UBqw_21_6">7,708</ix:nonFraction></p></td><td style="vertical-align:bottom;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Revenue reserves and refund liability</p></td><td style="vertical-align:bottom;width:0.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerRefundLiabilityCurrent" scale="3" id="Tc_AJqprIedvU2n4lq-KaNFAw_22_3">13,684</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerRefundLiabilityCurrent" scale="3" id="Tc_G2p9MkZME0yVWvyZKBpsAA_22_6">12,145</ix:nonFraction></p></td><td style="vertical-align:bottom;width:0.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Other accrued liabilities</p></td><td style="vertical-align:bottom;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_uIttbhHfmUiSuMpEdbaLtQ_23_3">5,013</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_N6S5SzpfV0Sl3SuCQdBXCg_23_6">6,485</ix:nonFraction></p></td><td style="vertical-align:bottom;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Lease liabilities, current portion</p></td><td style="vertical-align:bottom;width:0.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_ds-d2jYnFUiEAHrtzvCjag_24_3">466</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_p507IcdKE0u39YxTLilCaA_24_6">1,133</ix:nonFraction></p></td><td style="vertical-align:bottom;width:0.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Deferred revenue</p></td><td style="vertical-align:bottom;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="Tc_x1BtFuqafUy5OtgfqqUwAw_25_3">1,355</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="Tc_Zw3DU4340kifwlCqx09CeQ_25_6">1,369</ix:nonFraction></p></td><td style="vertical-align:bottom;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Other long-term liabilities, current portion</p></td><td style="vertical-align:bottom;width:0.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="Tc_2lO3pQN9q0GXAxvxrHa5MA_26_3">5,700</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="Tc_uJIyAw0cx0GTT958aT_BWQ_26_6">4,997</ix:nonFraction></p></td><td style="vertical-align:bottom;width:0.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total current liabilities</p></td><td style="vertical-align:bottom;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_J0ee9C9GDUmVtgzOBt4DGw_27_3">44,023</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_ObPFkSbTkEqkCthYipA-GA_27_6">65,211</ix:nonFraction> </p></td><td style="vertical-align:bottom;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Long-term portion of lease liabilities</p></td><td style="vertical-align:bottom;width:0.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_MMaCY97U3kOY5pqmNIfFFA_28_3">628</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_6PPgfdKBvEWpu0LdWLMECw_28_6">972</ix:nonFraction></p></td><td style="vertical-align:bottom;width:0.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loans payable, net of discount</p></td><td style="vertical-align:bottom;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermLoansPayable" scale="3" id="Tc_cswCv0r8HE2zLNd5ybEqiA_29_3">59,574</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermLoansPayable" scale="3" id="Tc_DcNUELMVekmnVvEabI1ywg_29_6">39,448</ix:nonFraction></p></td><td style="vertical-align:bottom;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other long-term liabilities</p></td><td style="vertical-align:bottom;width:0.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="Tc_WraFcgzxI0eSoO0_-07Ixw_30_3">40,981</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="Tc_cZSBHk0r3Eqa1HbmU0M8hg_30_6">42,264</ix:nonFraction></p></td><td style="vertical-align:bottom;width:0.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total liabilities</p></td><td style="vertical-align:bottom;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_qmzUVq7GhkuJehWJ8dl10w_31_3">145,206</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_2d5ZZ1_xB06bCl_U9sOHiA_31_6">147,895</ix:nonFraction></p></td><td style="vertical-align:bottom;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commitments</p></td><td style="vertical-align:bottom;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stockholders&#8217; deficit:</p></td><td style="vertical-align:bottom;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Preferred stock</p></td><td style="vertical-align:bottom;width:0.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_AbxTGvx4Q0CPiiy6Tx7JJg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_Yl_yqQR19EOEkaV4777NXA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;width:0.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Common stock</p></td><td style="vertical-align:bottom;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_-e6MfQOzmUifyTEhu1ntNw_37_3">175</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_wtlGTTLNa0iBamhCu-UPZA_37_6">174</ix:nonFraction></p></td><td style="vertical-align:bottom;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;width:0.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="Tc_BDOC9Irtd0OSIWObotgDnQ_38_3">1,374,330</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="Tc_aNmETaucNUuNEJm9s9Ag-g_38_6">1,368,822</ix:nonFraction></p></td><td style="vertical-align:bottom;width:0.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accumulated other comprehensive loss</p></td><td style="vertical-align:bottom;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" sign="-" scale="3" id="Tc_MLEyM-z53kC891Z75LATVA_39_3">25</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" sign="-" scale="3" id="Tc_Q7OlZ7npCkakiGnRXEvolA_39_6">153</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;width:0.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_9-CXquhw4UKeX9E0myePDQ_40_3">1,402,595</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_IJSB9j8VCk6bnwxP5YDDDQ_40_6">1,382,459</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:0.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total stockholders&#8217; deficit</p></td><td style="vertical-align:bottom;width:0.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_jC-BbyH7ekay44Vt-h5v3A_41_3">28,115</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_PP7n2efzr0eyGn8WgZX-UA_41_6">13,616</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total liabilities and stockholders&#8217; deficit</p></td><td style="vertical-align:bottom;width:0.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_14gvs43i4UWkSOA9qoyg-Q_42_3">117,091</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_UAy2XGC0M0W3hxE1lDORVQ_42_6">134,279</ix:nonFraction> </p></td><td style="vertical-align:bottom;width:0.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"><a id="_1d9d7ba2_5ecd_4806_a78d_7ee0fb7fffc9"></a><a id="_e5909fd6_dcf4_47b5_8886_23bec0eb441c"></a><a id="_4caea8af_7920_4589_a4ad_7ff3f8a7b746"></a></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">The balance sheet as of December 31, 2022 has been derived from the audited financial statements included in Rigel&#8217;s Annual Report on Form&#160;10-K for the year ended December 31, 2022 filed with the Securities and Exchange Commission (SEC) on March 7, 2023</span><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 36pt;">See Accompanying Notes to Condensed Financial Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_8f09fff4_f5e7_4f15_a507_282c3f0dfc56"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">RIGEL PHARMACEUTICALS,&#160;INC.</b></p><a id="STATEMENTSOFOPERATIONS_342998"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CONDENSED STATEMENTS OF OPERATION</b><b style="font-weight:bold;">S</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands, except per share amounts)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><a id="_9eb06f4e_9f95_4b56_9331_d7514de72237"></a><a id="Tc_FDk04usHs0e44gmhat4LIw_1_2"></a><a id="Tc_N-PF_9fLeEqOXDU2ZQcodw_1_8"></a><a id="Tc_AaBkWsqJmkuEnqPIk-Rl_Q_2_2"></a><a id="Tc_RHUMCt3dEkKK0KfYMjQrQA_2_5"></a><a id="Tc_jCUeNNv-Yku4RgCmKBcrcA_2_8"></a><a id="Tc_7flqlTy3gk24sonMLoQ74A_2_11"></a><a id="Tc_d5ErKfE2_ESNves12yv_8A_3_0"></a><a id="Tc_f4kjzTYRw0OkHFjkBhxlNw_4_0"></a><a id="Tc_Uunri95pdEO5ekn-QNJHgw_4_2"></a><a id="Tc_3fCrbPdHS02FQFoaxAPr1A_4_5"></a><a id="Tc_2CjVgzHiYEGFn_mKKKgQXg_4_8"></a><a id="Tc_kPkX7AMt5kioTdJUHM7WlA_4_11"></a><a id="Tc_NYEGeNYqs0KZkB5udam8Tw_5_0"></a><a id="Tc_nlkmVXcm0k6cq-T04wjMjQ_6_0"></a><a id="Tc_pNvpfH-M5EKR0hLdA4z_XQ_6_6"></a><a id="Tc_l7TmX2D6dUuhqGFAUVzqQQ_6_12"></a><a id="Tc_VWJNCyUaNkSK93EE6Y37jg_7_0"></a><a id="Tc_0pCWj7yNvkW0TUVfQRTlmQ_8_0"></a><a id="Tc_Z2aKmUulikaIjCmZBhIZ-g_9_0"></a><a id="Tc_IN8TAX6v8UWsJ0tAlMudSw_10_0"></a><a id="Tc_35GZkGXy2UWixEkmdzOO7Q_11_0"></a><a id="Tc_P7gD8ShmYUiWcGLVcCbAMQ_12_0"></a><a id="Tc_zp7WDkO2akSWM2nhrGOArg_13_0"></a><a id="Tc_80zN_EbM2EW1x7HZcOYVUA_14_0"></a><a id="Tc_nEQz8bs20k6VNt_PWO6-yQ_15_0"></a><a id="Tc_XjuFRH3KYUC8YUjQnlgCPw_16_0"></a><a id="Tc_8JC29t3I3E-2tQt68twz7Q_16_2"></a><a id="Tc_MkHksz08J0-WlXpdPeM0kQ_16_5"></a><a id="Tc_dXYisc8zL0-V_Vvpc0OD-Q_16_8"></a><a id="Tc_o-6e2TE000WA25gUWbk2aQ_16_11"></a><a id="Tc_iTpZmzVoHkiMSHz8TFbrSQ_18_0"></a><a id="Tc_byLk95w-t0S7zVUBywaPog_20_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:93.66%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:8.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:21.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:11.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Revenues:</p></td><td style="vertical-align:bottom;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Product sales, net</p></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_v4jyMWOILkimNDJi27bJNA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_AYR1u19h10GkURi7LSBdyg_4_3">23,881</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_Zl3JCD-6OEeEiUA808bVig" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_cFBiMaKO_0yrDrUhYwKNog_4_6">18,550</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_C2EWGpiFxUGr9E995bXhCQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_IVGjji-Mj0Gz5w2C8P9HNw_4_9">47,626</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_I08rIoA1_0itpE8QmmW4zw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_uyMTW8nPIUC2bCPv51ITBw_4_12">34,747</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:50.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Contract revenues from collaborations</p></td><td style="vertical-align:bottom;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_ContractRevenuesFromCollaborationsMember_yU4TzCXKCkSEqjOPYCD5ig" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_g1skwfyR1kyKIAWHLXKQrg_5_3">2,005</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_rigl_ContractRevenuesFromCollaborationsMember_B3F0S8vRz0eWxrI-zbC5eQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_kaW5Jpto3U69-G7SVSvDhg_5_6">11,269</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_ContractRevenuesFromCollaborationsMember_TmFkSqljNUiYYmkDnr-3ag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_pzW-twG2MkWkeNrjM51nBw_5_9">4,330</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_rigl_ContractRevenuesFromCollaborationsMember_LOIZvjtJ4kefhhUMq6-K0Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_4zPp_yZI8EG7U-D8frGshg_5_12">11,807</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:50.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Government contract</p></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_GovernmentContractMember_WN0BoWdZGU-KXqAccwJ68A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc__GyOGKM3ikK-NjMY67EPPw_6_3">1,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_GovernmentContractMember_9xcr5RYkM0WkIqJKKgDS8A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_9blN2CRkp0WRP1ar2J6O0Q_6_9">1,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:50.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total revenues</p></td><td style="vertical-align:bottom;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_ZI3Qc0DCGk6Ib4IqPWJsgA_7_3">26,886</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2022_To_6_30_2022_ICCkO9pPUUSORAn1kecZBA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_MQbkJMur2kuvrzj7thF76Q_7_6">29,819</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_XIvCZTN3fkWHLyyr5s-vow_7_9">52,956</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_TIEZLSeo50qq2pAy2P4hCA_7_12">46,554</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:50.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Costs and expenses:</p></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cost of product sales</p></td><td style="vertical-align:bottom;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="Tc_54XkK_D0F0evbpD2wddr1Q_9_3">1,075</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2022_To_6_30_2022_ICCkO9pPUUSORAn1kecZBA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="Tc_b3CdDAqhN0KvCMkkQO7-GA_9_6">1,036</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="Tc_vL9KNhrwlEmer2-k8k2EUg_9_9">2,052</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="Tc_rzPxjlSOeEeBD8vsFOenvg_9_12">1,157</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:50.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Research and development</p></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" id="Tc_2Vk4y4IeSkG44LHiqplz6Q_10_3">4,772</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2022_To_6_30_2022_ICCkO9pPUUSORAn1kecZBA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" id="Tc_27aLj4qVt0KPpOyiCAl_Mw_10_6">14,767</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" id="Tc_pRgG-FisYUinBt76A9x2_A_10_9">14,861</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" id="Tc_Z-epsfwgXky5riFBszGLSg_10_12">30,241</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:50.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Selling, general and administrative</p></td><td style="vertical-align:bottom;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_yEuQ7iCSzUGP7pIsTWtETw_11_3">26,306</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2022_To_6_30_2022_ICCkO9pPUUSORAn1kecZBA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_PS94dv1nCU-IwyR1h-zjxQ_11_6">26,981</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_sogkdc9mA06M34BD4fqaIg_11_9">54,035</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_9dFNIxc_PU6mgo9-zrY7mQ_11_12">54,382</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:50.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total costs and expenses</p></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="Tc_Jyp0by236kufzSD5XowOJg_12_3">32,153</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2022_To_6_30_2022_ICCkO9pPUUSORAn1kecZBA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="Tc_T-ttd5_npUKMRWWsPNRjnQ_12_6">42,784</ix:nonFraction> </p></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="Tc_ApDp64aWM0ym_Y7zUbBYAQ_12_9">70,948</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.04%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="Tc_foKObuF7xkO8kHFoDkXUHg_12_12">85,780</ix:nonFraction> </p></td></tr><tr><td style="vertical-align:bottom;width:50.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_6GU6cHyq8EGmkipN0S9Jvg_13_3">5,267</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2022_To_6_30_2022_ICCkO9pPUUSORAn1kecZBA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_SoZZwI3AQEuGGFDI7U9SlA_13_6">12,965</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_yr8u39e6hUSv_GJgx6AYHQ_13_9">17,992</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_oblCfl7ej0C1mSgHUJyvqw_13_12">39,226</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:50.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest income</p></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_6G3usvialESGceYyUfpmWg_14_3">529</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2022_To_6_30_2022_ICCkO9pPUUSORAn1kecZBA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_HqrvFXXEQUaIWIriVxSGcw_14_6">42</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_YKIP_yuP7kWASDDhntCBDw_14_9">922</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_d0t3KAlmwEywHf9PlUJH4A_14_12">63</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:50.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest expense</p></td><td style="vertical-align:bottom;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="Tc_jjxoT-DOZkOfBnZfJVjOxA_15_3">1,862</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2022_To_6_30_2022_ICCkO9pPUUSORAn1kecZBA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="Tc_5LWT2cWiJka6sAdO3x5NoQ_15_6">569</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="Tc_Sj9K6nZ8jkCu24uKMPn_Lg_15_9">3,066</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="Tc_Vx2ktfg57E6qUn31LzaNuQ_15_12">1,774</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:50.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_zqnjPA5HOkm9G-Bmyj1U3w_16_3">6,600</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2022_To_6_30_2022_ICCkO9pPUUSORAn1kecZBA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_WtOWZw6GokmVko9UaeJlBA_16_6">13,492</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_1I7Lzj8rWkScniC54J_2fQ_16_9">20,136</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_fOM0P11ID0eM25Wekyy2dw_16_12">40,937</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:50.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_1vCSe6v77U-Pv5aEoT8NYw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_Xu_N--yaaU6K7FdyMhFNnQ" contextRef="Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_2Pfn2326pkiZvQovL-BxVw_18_3">0.04</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_rANeXql6ykWq9e5A-w2NuA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_Xu_N--yaaU6K7FdyMhFNnQ" contextRef="Duration_4_1_2022_To_6_30_2022_ICCkO9pPUUSORAn1kecZBA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_PARv9DNHRUKXDTmGoU8qfw_18_6">0.08</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_L9LT0bCefkCJMaNCePj8fQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_Xu_N--yaaU6K7FdyMhFNnQ" contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_jhVgRMmfSkSYUHj8FSwexA_18_9">0.12</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_WLazubqkGEyubmaVA5dzKw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_Xu_N--yaaU6K7FdyMhFNnQ" contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_64ajk4oDeEOVPiORoqPMKA_18_12">0.24</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:50.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average shares used in computing net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA" contextRef="Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="Tc_VDNvISXPGEyrBomADsILVA_20_3">173,748</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA" contextRef="Duration_4_1_2022_To_6_30_2022_ICCkO9pPUUSORAn1kecZBA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="Tc_CypmmOM2LUe4F1JNYoAK2w_20_6">172,147</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA" contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="Tc_1AsAU20LOUO1lMDIevdOyw_20_9">173,659</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA" contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="Tc_Q9nMi9n1YkSF64FknV1XDA_20_12">171,961</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">See Accompanying Notes to Condensed Financial Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_24ef69ce_4e2d_4563_b6fe_94b49c6afeb7"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">RIGEL PHARMACEUTICALS,&#160;INC.</b></p><a id="COMPREHENSIVE_LOSS"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CONDENSED STATEMENTS OF COMPREHENSIVE </b><b style="font-weight:bold;">LOSS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><a id="_fdd9d852_5533_42f8_952d_7d81e44edbed"></a><a id="Tc_sSjVHj_9KkSiRPB355jo5w_1_2"></a><a id="Tc_-laTDzL0pUKroyaNiHB0TQ_1_8"></a><a id="Tc_EV6eUfASSEKUVNuHd5Lbdw_2_2"></a><a id="Tc_h1kOubpImUWoZslBI67Qww_2_5"></a><a id="Tc_gDqtQcTj0EelWsV3Hr5wYQ_2_8"></a><a id="Tc_kGb8-Zf9oUKqf3qcsLfnMQ_2_11"></a><a id="Tc_G4V32A5t_ku_GCN8y2vXlQ_3_0"></a><a id="Tc_DNKv2nK5Dk2dLaK4Ekx8Ng_3_2"></a><a id="Tc_bMySdtMgGEGjzyPqSFNYwg_3_5"></a><a id="Tc_XRRG2miNf0yJT32jhR0ofA_3_8"></a><a id="Tc_USpuZAb9nkCL-qJu7BLFxA_3_11"></a><a id="Tc_JHssM5V1BEylvnkazyZfOA_4_0"></a><a id="Tc_WtJLzf6G3Uqn4IdJsyAcIw_5_0"></a><a id="Tc_rUR34rzn4kShaGslpITOGQ_6_0"></a><a id="Tc_O_2ho4ihoUGSPeCrfd_4AQ_6_2"></a><a id="Tc_69pZgqpbC0OZhDfyxdsAhQ_6_5"></a><a id="Tc__uB9_8YdkEWJwgSx0xf0QQ_6_8"></a><a id="Tc_N_7oIbu66UeEGtkd_WfGmA_6_11"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.499691%;padding-left:0pt;padding-right:0pt;width:100.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:22.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:22.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_aJbpZrDx4UOSgWJgG3nBrg_3_3">6,600</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2022_To_6_30_2022_ICCkO9pPUUSORAn1kecZBA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_l84q1Q0Av0ipsqgT9oK2eg_3_6">13,492</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_5pLbk6NCIU-xP_vWkP026w_3_9">20,136</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_pIWP2_0ewk2d8ChV3tkyfA_3_12">40,937</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:51.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other comprehensive gain (loss):</p></td><td style="vertical-align:bottom;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Net unrealized gain (loss) on short-term investments</p></td><td style="vertical-align:bottom;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="Tc_rDawXEz0nEKtkEpguKwhtQ_5_3">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2022_To_6_30_2022_ICCkO9pPUUSORAn1kecZBA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" sign="-" scale="3" id="Tc_ImgVBkfx60-PrUE0KijI9A_5_6">22</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="Tc_CMmeF9OmYk2_1oqhuk_Iug_5_9">128</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" sign="-" scale="3" id="Tc_4MKZeBRy6USuYISk-8zkkw_5_12">336</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:51.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Comprehensive loss</p></td><td style="vertical-align:bottom;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_9DhexomIZ0yRHckqe1pn9A_6_3">6,598</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2022_To_6_30_2022_ICCkO9pPUUSORAn1kecZBA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_alWsbYQkkESMcxxsJL_kJg_6_6">13,514</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_eVIjV1qg4UisJf8E7k1AfQ_6_9">20,008</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_cyXvG7Uf1UqeDwKqAP6eJg_6_12">41,273</ix:nonFraction>)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">See Accompanying Notes to Condensed Financial Statements </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_ce427b93_84fa_42ee_b60d_3a52b304fc2d"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">RIGEL PHARMACEUTICALS,&#160;INC.</b></p><a id="STOCKHOLDERSEQUITY"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CONDENSED STATEMENTS OF STOCK</b><b style="font-weight:bold;">HOLDERS&#8217; (DEFICIT) EQUITY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands, except share amounts)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="_2989ac1d_e6e9_4515_a895_5bce1796dd19"></a><a id="Tc_gv946UNgek-_87L4S6oYFg_2_7"></a><a id="Tc_HTY1XcDv8k2Ckv3Of-ZbSQ_2_10"></a><a id="Tc_h2w9y3DgSUqQVtloNMrMew_2_16"></a><a id="Tc_kId_iUjg8UiPDNGOBP1RDA_3_2"></a><a id="Tc_YbCmvGHYLUeOSxkIsoeE_Q_3_7"></a><a id="Tc_h2_Dg1RVG0GrxdH3nzniEw_3_10"></a><a id="Tc__0NA1M14w0GvHUeasrTXxA_3_13"></a><a id="Tc_cyBDOOuV00SpUqJglibKTw_3_16"></a><a id="Tc_6ZW4dlkPhE6vcHUei4Yf0w_4_2"></a><a id="Tc_nXh_GWaeA0KtbRnwVeW9_w_4_4"></a><a id="Tc_lnDLxXa9iU6hbYzzXBoTQA_4_7"></a><a id="Tc_W5roQBre9Uyc_0Q2gVjJLQ_4_10"></a><a id="Tc_i_W_cuyiV0yePEzOlfT5Kg_4_13"></a><a id="Tc_Uq8t2pj4MEe5ym1ZMo4mbg_4_16"></a><a id="Tc_RBmh1IH5CEaqubtLMFevCQ_5_0"></a><a id="Tc_04bVRknXPkW2sLtNZb1K1w_5_4"></a><a id="Tc_TicGTiH6Iki5x0ZPt-DC5Q_5_7"></a><a id="Tc_wFPVSYHKakC0wGeYCR3NhQ_5_10"></a><a id="Tc_pMwQ7USIhEOZJeMRp19Keg_5_13"></a><a id="Tc_eHnptAbqBEimZ9WJD_UvOQ_5_16"></a><a id="Tc_QEIq-RO7g0yXhc52ueSC4A_6_0"></a><a id="Tc_EhywkC9fgUqtimxG3NO35Q_6_2"></a><a id="Tc_KxIoUHgVG0KrpgwaV8LEAg_6_5"></a><a id="Tc_8-o9_3PEmEe3-5FO8xtKRw_6_8"></a><a id="Tc_GS9yN2PJSkmQUys6QeXxuQ_6_11"></a><a id="Tc_oHWG6Sg4fUWiYsuyrQyOFA_7_0"></a><a id="Tc__nir4TwXwEquvDzL4YTTDg_7_2"></a><a id="Tc_LBp3nMPfsUWRbuhQqVMAxQ_7_5"></a><a id="Tc_4rSJRU7HaUO94ob6hz7Bgg_7_8"></a><a id="Tc_5Cv1j8tSc0mCabdUhV6LFw_7_14"></a><a id="Tc_LE1-A4LJZk-KxkFRQBf1ng_8_0"></a><a id="Tc_nvaoCWeceEGowOviZeMaLQ_8_5"></a><a id="Tc_wHrxoo3lK0Ct1wI83cSkEg_8_11"></a><a id="Tc_89n1PITzUUeXz1p8t4GaHA_8_14"></a><a id="Tc_scv95EYtfku24vfP3dJx-g_9_0"></a><a id="Tc_na0ab5W0aUmg0Om05nZzBQ_9_5"></a><a id="Tc_DhRJqTIaP0u0i-VhdeQRpw_9_8"></a><a id="Tc_bF53HFRCyk6TeTx4aCeWWw_9_11"></a><a id="Tc_oRnIrKW4HEG2f3-hkKtWqw_9_14"></a><a id="Tc_ueSQ1WKI5kK14hFJ4xNbjg_9_17"></a><a id="Tc_h9bnVlW0sUCuSm43Y21Yhw_10_0"></a><a id="Tc_G6lPeQnXr0CTlpeHNgMBew_10_2"></a><a id="Tc_P4v8IDGpCkS1sk1F5sA2IQ_10_5"></a><a id="Tc_P9SJi42uCEazFn1hzuXE-w_10_11"></a><a id="Tc_OL2-gi3qhUGlB2wMo8HuJQ_10_14"></a><a id="Tc_TyH0Sq3_rkOAtc64syRpKw_11_0"></a><a id="Tc_GmplIbFD7kCHMXhwV1aayw_12_0"></a><a id="Tc_juGA6tsTtkKKY45_05H0gg_12_2"></a><a id="Tc_xwN21jUE10GUfsO6cR4lhA_12_5"></a><a id="Tc_v5i06mL8mESIDcvdVSH9LA_12_8"></a><a id="Tc_Ienb5_hbxk-iZmvpmkIZdA_12_11"></a><a id="Tc_NnbrnWbxsEibIfvLxuCp6w_13_0"></a><a id="Tc_z1xk-uWxqUO-0yhanvozSg_13_2"></a><a id="Tc_gN2jxpJeX0i1fywzBCb-xQ_13_5"></a><a id="Tc_eGgtke3g4kSN0qIJqGEHhA_13_8"></a><a id="Tc_eGq5usN9wEOyEaNRoZVe9A_13_14"></a><a id="Tc_JE2shRKLBkGpZ45BU546Vw_14_0"></a><a id="Tc_19CAtgQxhEyj_Tzai-GSVw_14_11"></a><a id="Tc__OkRXnDje0eXRHKGLkgQxg_14_14"></a><a id="Tc_mUUzgjDgg0SoaglRLqZDeg_15_0"></a><a id="Tc_Z6JrUyZnZ026eqwxOS6icg_15_5"></a><a id="Tc_504bpdSFP0CFfjrm-_kChQ_15_8"></a><a id="Tc_XsPrK-3ZiUCBOQYxAwF-lw_15_11"></a><a id="Tc_UYrpuFYJlkKRq-N_HwIePQ_15_14"></a><a id="Tc_J82z7_xC3UG7qL3BYK08rg_15_17"></a><a id="Tc_BlYGK4TcjUOkrXjdcC3uRg_16_0"></a><a id="Tc_gNp653nXTESGm85CwUed2A_16_2"></a><a id="Tc_0QHE35xuNkSkqeW9vqL2YQ_16_5"></a><a id="Tc_Bp52fbg3VE2AXBdSMIhGtQ_16_11"></a><a id="Tc_PkWa8b81YkC-NbM6R1jKGw_16_14"></a><a id="Tc_Ah6r8BxgDE-Ch8At-6wgZg_17_0"></a><a id="Tc_AGqfbpzNkkG-lLLoCXTjlA_17_4"></a><a id="Tc_ot3dkW22oE6F3J7-yGrZPw_17_7"></a><a id="Tc__g_UsIK0Y0K4FhE-sbJgkw_17_10"></a><a id="Tc_nl-V2fkFRkSDrUwaclyZCw_17_13"></a><a id="Tc_PvRMXbt7pEucQeuZF2QryQ_17_16"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-4.0696487%;padding-left:0pt;padding-right:0pt;width:108.13%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:34.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:34.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:34.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:16.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Paid-in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Comprehensive</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stockholders&#8217;</b></p></td></tr><tr><td style="vertical-align:bottom;width:34.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deficit</b></p></td></tr><tr><td style="vertical-align:bottom;width:34.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Balance as of January 1, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xvjnxqS-hkCiR6PhUg5rig" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="Tc_JwfiQK7BNE64a7u4CS057Q_5_2">173,398,645</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xvjnxqS-hkCiR6PhUg5rig" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_ueNtVZ2OPEWA9FoYaeQczQ_5_5">174</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_H75YemqVnEyPwV--MIGWGw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_qhkCoLDXWki_T9qP5KPc_Q_5_8">1,368,822</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_lUJBYmkmN0mPdtrXTwmLYw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_-mheQl8DOkOJJ67ZaOBENA_5_11">153</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_7r-CKjYwcEWPEVrhWmkNzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_gJiRf3oUi02JMVv-4sFC7A_5_14">1,382,459</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_vKX1l1lh2k6_ZsypxObT9A_5_17">13,616</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:34.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_lxmvkD9RK0qU7ZM5gMSIQw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_mYF0xxicrkO_T7Exj5_tHw_6_14">13,536</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_3_31_2023_qfQwkxMZLU6ffGWe8LPnaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_qwI8mdLj7E-Ek14O49UCEA_6_17">13,536</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:34.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Net change in unrealized gain on short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_hHQBvZ1Mi06kiRDiBIcvOg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="Tc_msD9ZTGpbEyTu7D3m00xkg_7_11">126</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_3_31_2023_qfQwkxMZLU6ffGWe8LPnaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="Tc_VVTTIRmNu0GXk6Y4UYiQQg_7_17">126</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:34.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Issuance of common stock upon exercise of options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1ylsF_WCdkeufVQaI9L5Qg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="Tc_jwbJ8SxvS0i86p8pv9PtSw_8_2">952</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_pug8RCBYIkeZTp1-6vn_VQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="Tc_5X0IqEbAJUG7jXBpwAlWAw_8_8">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_3_31_2023_qfQwkxMZLU6ffGWe8LPnaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="Tc_aCUIjFCUUEqYpTe-fY3siA_8_17">1</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:34.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Issuance of common stock upon vesting of restricted stock units (RSUs)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1ylsF_WCdkeufVQaI9L5Qg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="Tc_Eq8NS4__qU6jo4AqaQJhxg_9_2">266,256</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:34.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_pug8RCBYIkeZTp1-6vn_VQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_quRM8UO-aE-uf9_OJ2p-9g_10_8">2,768</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_3_31_2023_qfQwkxMZLU6ffGWe8LPnaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_D1OqN_YNtE6IMB_SyasYJA_10_17">2,768</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:34.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Balance as of March 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA" contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0zb7z7FwO0GI2RAEVAHXQw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="Tc_T6cvZ--nvUSqmCQzpwlCLg_11_2">173,665,853</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0zb7z7FwO0GI2RAEVAHXQw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_u5WAMVqPc0uOpZg9ASoq-A_11_5">174</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_OfzaBWn7ikCSgv7BTwXlfQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_iqe6r69m_UONp2oot7FN6Q_11_8">1,371,591</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4ofcdRQIYUqAzW1HPzZ5vA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_VIsQZ5DRRUGuJqoHhgsBgQ_11_11">27</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_zZnbux6ITEas3Z5CntDoJA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_5umZPAHW-EWqNgs1isT-Yw_11_14">1,395,995</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_3_31_2023_BgUu_xw-pEOX64_3oVKFUQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_kq2HMy-7IkiLks0tea-y4w_11_17">24,257</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:34.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_BC0bgoovFkSFc26FtpY0vA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_LObPwnJd3ku2VXZfJGs0_g_12_14">6,600</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_u3zdg3RxDEOSZRFIpS7LpQ_12_17">6,600</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:34.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Net change in unrealized gain on short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_QxrzwDPl-02u7MxFvVCYNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="Tc_pLdRAopxMkGZizUv8BwKow_13_11">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="Tc_CvZ3Y8w2l0y231zOzX0-PA_13_17">2</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:34.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Issuance of common stock upon exercise of options and participation in Purchase Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2mIl79LxpkuN5mgFsNHdfg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="Tc_RigDEjXgG0mHzvrIdUoIDQ_14_2">523,795</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2mIl79LxpkuN5mgFsNHdfg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="Tc_moBZMR4lLE-R3W4gJxlJBw_14_5">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_OPWXZu-4xESxTw7UEzGEfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="Tc_oT7rh2ehm02VoSNOAOwq7g_14_8">553</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="Tc_P0pTmw4yekKkpiCuLSGxbg_14_17">554</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:34.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Issuance of common stock upon vesting of RSUs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2mIl79LxpkuN5mgFsNHdfg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="Tc_bklHtHdq5UWMTREPp1nirw_15_2">168,750</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:34.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_OPWXZu-4xESxTw7UEzGEfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_u-rJn-Fb0kSvt37rq1WBpA_16_8">2,186</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_lUXCqGeZO0ugoKOx_kPcug_16_17">2,186</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:34.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Balance as of June 30, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA" contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NXFVM5fZJUmDlMyyzE1ttg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="Tc_YQX8SDjrW0ayPLkrE1D8mA_17_2">174,358,398</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NXFVM5fZJUmDlMyyzE1ttg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_WV6wTmm9MUy6msu9fpFJ0Q_17_5">175</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_GsGkBqFtIEeF4t6uDl64RA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_9g9ZkuqDTkqe3ORi9rKspA_17_8">1,374,330</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_uWcj3WWP8EKEJxuUNUBsng" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_3Cr5--3bFEuy1ySTRLhAOg_17_11">25</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_6WAzHoGFsEyRh9-_I-EgwA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_zDGHfU8VBEu1GXsVUlq00A_17_14">1,402,595</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_9otVWMH_70CJIBQ__eYLdg_17_17">28,115</ix:nonFraction>)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_a8573618_07b1_4a35_ba2b_11c14d22ec67"></a><a id="Tc_zyR3NaA3REyKOn0eSFAKqQ_2_7"></a><a id="Tc_bAAoSoeGv0e6BEbHO74xKQ_2_10"></a><a id="Tc_4cl65fT8KU6ZocFP3t6BgQ_2_16"></a><a id="Tc_DJkSuOfVsUaF3PU01M9ZGg_3_2"></a><a id="Tc_EPGeqsag2UWGAm_hQ7rEEw_3_7"></a><a id="Tc_sI96pIdY2Uy66s8igjzo5A_3_10"></a><a id="Tc_uObYWDGnyEeBkBEcEay0AA_3_13"></a><a id="Tc_lTaiwdJ-9kGEN8Uib1LDMg_3_16"></a><a id="Tc_brDqer1pfkqBIREDRTdmAw_4_2"></a><a id="Tc_73KY0Qk21kGtnvA1hCOP-g_4_4"></a><a id="Tc_2OtKb5Nc8E2tXkf59cTYYg_4_7"></a><a id="Tc_1fxwIFZiEUOv7MI6hV7MSw_4_10"></a><a id="Tc_SuEMhhU0X0KHeqnkpG9dkA_4_13"></a><a id="Tc_dfQoEa1P2k2xUXibb2xegw_4_16"></a><a id="Tc_Ig_KWytb1EaDfoyjGdAjcQ_5_0"></a><a id="Tc_P8X_AxSG6kq9D4aY6x3gww_5_4"></a><a id="Tc_TutWDfWyv0iuHTo5X6PNYw_5_7"></a><a id="Tc_LEOWKGSoxU-UjC2kRsKa0w_5_10"></a><a id="Tc_vfnv1mTt9Ui4nHrwRpxJhg_5_13"></a><a id="Tc_bn0UrK5PG0msKW0rGAo_MQ_5_16"></a><a id="Tc_2SOF8dSk-Uyh2R8X7bfv9Q_6_0"></a><a id="Tc_X4BL3XXMn0W3BCbANoEOpw_6_2"></a><a id="Tc_7WKckFAS_kun4Px35XQshg_6_5"></a><a id="Tc__Kz5OTAK4EG3ca78YJjUOw_6_8"></a><a id="Tc_qlTBdpdKEEa43VNND_4uGA_6_11"></a><a id="Tc_avlZj1SjhEGsBCERR4DK4Q_7_0"></a><a id="Tc_G1mfMMathkSEl36MafqnkQ_7_2"></a><a id="Tc_82t9JIsgAUiVLImlXDU1GA_7_5"></a><a id="Tc_y_OkyXUs6ES16PXaJuOSAQ_7_8"></a><a id="Tc_XrLchlO7Qkax0nyfURcTgw_7_14"></a><a id="Tc_5xYOcjRxbEmjvgBBE5a8oQ_8_0"></a><a id="Tc_mmiKVMkPxkyflC36fqiLLg_8_5"></a><a id="Tc_hyCn68kwAkuhLG4aZghDyw_8_11"></a><a id="Tc_XnDBsKW_Fk6Q35JNjGWD-w_8_14"></a><a id="Tc_6z2rkXmruk-iNK2lCpCYaw_9_0"></a><a id="Tc_4EgIk5ySh0GFY6gf1lLwvw_9_5"></a><a id="Tc_ohwQ65yCg0CIS0C_-3aJvw_9_8"></a><a id="Tc_FBCjecM8fEW7Td9r0Gr9Dw_9_11"></a><a id="Tc_uT-PiFsia0GnbT250GayWw_9_14"></a><a id="Tc_VPUclavgokmNw3GJ-jX7eg_9_17"></a><a id="Tc_sNUHQnnDyk2pjNDQpG5XFw_10_0"></a><a id="Tc_u-f4qZjWCEesQequVn3DAA_10_2"></a><a id="Tc_Krwe5viZX0asoqM06y_xMQ_10_5"></a><a id="Tc_pcY6ofGWJ0K0yUVp7iJx7g_10_11"></a><a id="Tc_NJPYHV_MokOzY-4CTH5lmw_10_14"></a><a id="Tc_53rnCYKmFEGz_rVMnidQbg_11_0"></a><a id="Tc_s6enZv2T70CUJuwdAUqOsg_12_0"></a><a id="Tc_CEJOTdRAaUeKEHTv1f2iuw_12_2"></a><a id="Tc_RJTpndcr50iFmjH7KXdkVQ_12_5"></a><a id="Tc_euPr364ec0iQFXt_GZ9yHg_12_8"></a><a id="Tc_k5HB2groo0W3oz6sasEWag_12_11"></a><a id="Tc_XCLyh8YvLU-1IvsZm1OLUw_13_0"></a><a id="Tc_SM6lC_o8qES9SPaKQMFwUg_13_2"></a><a id="Tc_cT1ye0vWUEavVck4P6WuMw_13_5"></a><a id="Tc_7ozuQwjJGEKy8Bsv8uUruQ_13_8"></a><a id="Tc_Wj25ATYQbUyh_6WqAdIhdw_13_14"></a><a id="Tc_mtMgELHYHEWT0TG6MNVkxg_14_0"></a><a id="Tc_wPJSTZJ8xUua-QMyZF8fNA_14_11"></a><a id="Tc_axZOwKO_cEKh6IrF8Z_jHg_14_14"></a><a id="Tc_1yNOBt5yFk6I0SpJZ1utfg_15_0"></a><a id="Tc_Bw7BqhLD_k2uB124Ycw-Gw_15_5"></a><a id="Tc_0OyhQX1VfUGZl6uS2OJTcw_15_8"></a><a id="Tc_Jdxty0fddEuHKDL5VEWZiQ_15_11"></a><a id="Tc_6d9yy_zl00OBnqwxqgpiAw_15_14"></a><a id="Tc_Rr4AQipKwE-17SwKYGJC1w_15_17"></a><a id="Tc_ELJLwU0ZZ0q8CA67HLywjA_16_0"></a><a id="Tc_FVfSwhSWKUebzd1eDuezQQ_16_2"></a><a id="Tc_-VTwl_PnfEqOvAW971SZJw_16_5"></a><a id="Tc_RVPr-jKD_EuQfeuoLk9oyw_16_11"></a><a id="Tc_ELJ1qQoEMUOgFv6QQJyijg_16_14"></a><a id="Tc_SeuuntTHpEWeDHXyXV_rEg_17_0"></a><a id="Tc_JiYvQ7d-vkmGlqP9sqDzIw_17_4"></a><a id="Tc_serIVG7DzUSQsFX3D8FuXA_17_7"></a><a id="Tc_W35Cgpfn7Ue8CnGE5SrhNw_17_10"></a><a id="Tc_zUiFwsOOR02vHIW2TFU_sQ_17_13"></a><a id="Tc_T6nMldsQHEGBFNzwDcFYgg_17_16"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-4.1675262%;padding-left:0pt;padding-right:0pt;width:108.33%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:33.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:33.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:16.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Paid-in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Comprehensive</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stockholders&#8217;</b></p></td></tr><tr><td style="vertical-align:bottom;width:33.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Equity (Deficit)</b></p></td></tr><tr><td style="vertical-align:bottom;width:33.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Balance as of January 1, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Mal6s5t5Z0qQ9EIsFrTGuQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="Tc_9630uB8pm0eu8yrUab_FXw_5_2">171,602,226</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Mal6s5t5Z0qQ9EIsFrTGuQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_9w-moQH0mEOMF3lMNdp7aA_5_5">172</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_2EWYq3VBqUSwnhTDnAcB0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_umK9uqWS4UqMv7J2IPaK-A_5_8">1,354,190</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_n7Oc0ne_BUqW0jhEW7x51g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_XoBKpEu2DEi52PHtaXYXrw_5_11">102</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_j5agreqUq0C05wMxAlbdRg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_XKJ9onduHkuMu13cTAQmlA_5_14">1,323,886</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2021_LY4sWUaA_UOIKxqqgZ5UAQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_aKPgsf-zq0iLiYGbLxXyhg_5_17">30,374</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:33.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_egDPK9MhIkOXkH42vVRrWw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_Qp1k46t3S0qXqu8Pls812A_6_14">27,445</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_3_31_2022_NyURkj24PU2gRd22NkwY9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_zqbBUdwjgEKWZLHJ5hbPWg_6_17">27,445</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:33.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Net unrealized loss on short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_n9loXyMYREivaHgcSKMHMA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" sign="-" scale="3" id="Tc_1W1o91sItke2BWpNCH7K1g_7_11">314</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_3_31_2022_NyURkj24PU2gRd22NkwY9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" sign="-" scale="3" id="Tc_dRQC73AETEuJhm-vyM7uGw_7_17">314</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:33.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Issuance of common stock upon exercise of options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA" contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_h87Ta8IYBkSUtMHbuewiIg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="Tc_4G5-1bAMp0OordgwR0OiuQ_8_2">420,521</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_q29chwJC8UWqOM6gViWQCA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="Tc_7YzP15-M_UuhACsMs2VoMA_8_8">940</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_3_31_2022_NyURkj24PU2gRd22NkwY9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="Tc_H-rguhRj8kGMiFf18o7cKA_8_17">940</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:33.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Issuance of common stock upon vesting of RSUs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA" contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_h87Ta8IYBkSUtMHbuewiIg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="Tc_snYb7AveaEWB6eVhmWXRcw_9_2">22,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:33.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_q29chwJC8UWqOM6gViWQCA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_PjxE4CcEAkuOL8M27qvVOw_10_8">3,243</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_3_31_2022_NyURkj24PU2gRd22NkwY9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_Pz9QszP7YkWgSmSXQQtJMA_10_17">3,243</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:33.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Balance as of March 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA" contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4k30MtA2pUm5iDpAhJLPrg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="Tc_UOnkW_bFsEW7qZRyasE_HQ_11_2">172,045,247</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4k30MtA2pUm5iDpAhJLPrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_u4rTx_blik-tqzH379a7kg_11_5">172</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_HUMQpp-hhUmkBPR7Q8NCIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_jmFvzzJpI0CvWmuxW0DW1g_11_8">1,358,373</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_DP28xveaSEKwPEHlfm8Vvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_J8T2Jq7VtkO0ozKRTgq8Fw_11_11">416</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_mUlMkH6yV0ev7oy48pw70w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_o7wOu5KhLUau0W5cNy-1NQ_11_14">1,351,331</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_3_31_2022_BK3VScSjz0OWZFv-nNNaXA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_b4KTYJHWBUOOrQi5rW2EOQ_11_17">6,798</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:33.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_aR01SJIgMUW3MS43CRdmBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_ehHEDul5sEWHWqPJAyNylA_12_14">13,492</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2022_To_6_30_2022_ICCkO9pPUUSORAn1kecZBA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_OC7GP5CChkCPTh4KwGWVmQ_12_17">13,492</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:33.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Net unrealized loss on short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3JpqoXaqL0SrqUrpHTj6kg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" sign="-" scale="3" id="Tc_ry6oOFxT006Pn2Fnchtq9A_13_11">22</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2022_To_6_30_2022_ICCkO9pPUUSORAn1kecZBA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" sign="-" scale="3" id="Tc_CkXdx2h250u4aJLo-mDWGA_13_17">22</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:33.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Issuance of common stock upon exercise of options and participation in Purchase Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA" contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_X0BNnHhQVkGCCdDEwUQPOQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="Tc_FH_HfewjU0Gfq1awTrmVjw_14_2">609,839</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_X0BNnHhQVkGCCdDEwUQPOQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="Tc_A9l4HYicsU2D3Z6cQB9X_A_14_5">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_jRjTsJgDwE65v_ICJzPELw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="Tc_S44w--rqmku6NBjpuCDOvg_14_8">598</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2022_To_6_30_2022_ICCkO9pPUUSORAn1kecZBA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="Tc_FL8Ja8JHxE-8_sFG-508kg_14_17">599</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:33.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Issuance of common stock upon vesting of RSUs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA" contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_X0BNnHhQVkGCCdDEwUQPOQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="Tc_vLt95NLFc06L387u1tcGlw_15_2">181,250</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:33.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_jRjTsJgDwE65v_ICJzPELw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_SgPa9MskD0-LVkdeOZV6NA_16_8">2,440</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2022_To_6_30_2022_ICCkO9pPUUSORAn1kecZBA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_bmH6pTEHy0ipVH80kcdBow_16_17">2,440</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:33.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Balance as of June 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA" contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8sjAYkMEXkWQKgqr3XNtXg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="Tc_Lhy4m4NvZUiCAUU_bhQeTA_17_2">172,836,336</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8sjAYkMEXkWQKgqr3XNtXg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_5AEPm9y6WEqiChTC_URUsw_17_5">173</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_8FRPOicKCUukQ6L7AAUMNw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_mcDDSX6SxU-WpL-PWZgP6A_17_8">1,361,411</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_JNCe4Z95dE6Iw1LvI3RQ4g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_XEfNbS7o70-S0vm_bI88uQ_17_11">438</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_SgCZ7AQnVkal8VnKIFXBDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_yLFsJn6-dkeHrSC3aeU7kA_17_14">1,364,823</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2022_X6KPuRq2uEa6dhukywoGKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_is4BJMo8VkWh_Fm6HIEhog_17_17">3,677</ix:nonFraction>)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">See Accompanying Notes to Condensed Financial Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_136a7f13_ccf6_4749_8758_1a509c0abc3d"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">RIGEL PHARMACEUTICALS,&#160;INC.</b></p><a id="STATEMENTSOFCASHFLOWS_16439"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CONDENSED STATEMENTS OF CASH FLOW</b><b style="font-weight:bold;">S</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><a id="_2ea32c1a_3f39_42e8_ab9d_19c775316bc2"></a><a id="Tc_MUcm5gl8WEGFtVLaMQCI2Q_1_2"></a><a id="Tc_f4l89CR1MU2Mh5tnsnT4qQ_2_2"></a><a id="Tc_KTD3pzlPHUGx61GA3B-cfg_2_5"></a><a id="Tc_suFIiKIC8E-eHTMZ7eltWA_3_0"></a><a id="Tc_3P69joYwDUS72Wjw4vUAIw_4_0"></a><a id="Tc_Rydzny2DZkK6GhCByqEQ0Q_4_2"></a><a id="Tc_N-Ju0GlV_U6QqQ0wHs_VnQ_4_5"></a><a id="Tc_CXzc-uYO-0iMLmtXmtjfJg_5_0"></a><a id="Tc_im2Twx0S-EKXnkVS6AONYA_6_0"></a><a id="Tc_HwvQKX2HH0ayiGWzGqyJtg_7_0"></a><a id="Tc_zQAs0Hrxa0SvwCJeK7A2xA_8_0"></a><a id="Tc_XJ3yiv5MP06LQ14MAJW1Fw_9_0"></a><a id="Tc_1BMasUkHzk-0G1jKTqhOSQ_9_3"></a><a id="Tc_o975IqIFT0CS0XfLjbtdQA_10_0"></a><a id="Tc_02Xdqj7R0EWlbCXfuyyGtg_11_0"></a><a id="Tc_DTRaZ9QQvkaFG4bWtr9_Ag_12_0"></a><a id="Tc_Hlzx8NEZWkahePvQFf5XdQ_13_0"></a><a id="Tc_uVcsEMJb-EaN21QBfrLPeA_14_0"></a><a id="Tc_DVO3zsSiiU2OAQJSyvayzA_15_0"></a><a id="Tc_DDhjqjCf20eQi5gO8f7QHg_16_0"></a><a id="Tc_VDXzHkFld0GT9nuVeCdlzg_17_0"></a><a id="Tc_fgWbtLfwnUWsQS6cUEzAZw_18_0"></a><a id="Tc_eMVsNtT4wUeB0eDMbY6VPw_19_0"></a><a id="Tc_oqzP07Yw6k604IsRV37hXQ_20_0"></a><a id="Tc_Wf_Dvvtmx0GDlYjMDxtNQQ_21_0"></a><a id="Tc_qkBVocuaLEqSZZb0Ylof6A_22_0"></a><a id="Tc_jVOn_pA-2EieK_feCUQ-7g_23_0"></a><a id="Tc_otd7ml7IJ0KdD4we-BMQ1w_24_0"></a><a id="Tc_E9r_elvf0EyS_or2_6l6gg_25_0"></a><a id="Tc_t2ElLDc6J0mPOI5RCAXQUA_26_0"></a><a id="Tc_PrQKsw6oxU6x9qMevSVLPw_27_0"></a><a id="Tc_OsWghr-kukKyxz8S2nSXNQ_28_0"></a><a id="Tc_J64an8ndKkKJZ82iXn60xA_29_0"></a><a id="Tc__dZ8jamAbEqtC-pP3U2T2Q_29_6"></a><a id="Tc_FpZ6NnW9t0upxBv3gDB4Cg_30_0"></a><a id="Tc_szOXq0EaFEODcmEqLZhjKQ_31_0"></a><a id="Tc_dhFXDuug9k-dAuFwERjFiQ_31_3"></a><a id="Tc_ch_ShxLix0q_6KhKcnRIzw_32_0"></a><a id="Tc_USao_lZkK063vrl0F16Qpw_33_0"></a><a id="Tc_d_sJYHEGT0GfNZsdSbDLAg_34_0"></a><a id="Tc_1JHhBRtFyEOs7S9i15Wl4Q_35_0"></a><a id="Tc_O5in0N2NHkWIu7O1tqSwGA_36_0"></a><a id="Tc_KnkeaquaiUGUjRvwgnk-jQ_37_0"></a><a id="Tc_jyIEPr57kEiPvtw_neRd-w_38_0"></a><a id="Tc_6jxWb8zmqk-e82wTK-GqRw_39_0"></a><a id="Tc_-9wMpJSg70amZIvozTp82Q_40_0"></a><a id="Tc_x62ZBHFQNUO8EXHjYUPqBw_40_2"></a><a id="Tc_kyafNXM_L0CRNkayRpdNVw_40_5"></a><a id="Tc_Vrdis_E080iUYds9MC8dAg_41_0"></a><a id="Tc_pJ-FMrAxWk-AfevIbKTv6Q_42_0"></a><a id="Tc_7mdMJxXsCUCMdVdH14oedA_42_2"></a><a id="Tc_EOXheoQSFku9dluuoCbPuw_42_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.08757782%;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:11.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:9.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:24.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:12.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Operating activities</b></p></td><td style="vertical-align:bottom;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_sQ4fc-YV9kqIKYj2V0sdfw_4_3">20,136</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_KsOK0rm2bUKz8JcAKwPqBg_4_6">40,937</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td><td style="vertical-align:bottom;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_I5ie7dwVTEWrCjvuflNS4w_6_3">4,930</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_NGSIRKkmaUuM1_1R1rBF4Q_6_6">5,598</ix:nonFraction> </p></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Loss (gain) on sale and disposal of fixed assets</p></td><td style="vertical-align:bottom;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainLossOnDispositionOfAssets1" sign="-" scale="3" id="Tc_c8zg9Pve9kO82UoGmE45cA_7_3">398</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainLossOnDispositionOfAssets1" scale="3" id="Tc_fWlO1EQInk2U1U1NIEcWjw_7_6">253</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Depreciation and amortization</p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="Tc_Q6xqSJUbyEeTsUfMloTSag_8_3">653</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="Tc_x_5y2aLaVU2K_CV-XLjOCA_8_6">474</ix:nonFraction> </p></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Non-cash interest expense</p></td><td style="vertical-align:bottom;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g" decimals="-3" format="ixt:numdotdecimal" name="rigl:NoncashInterestExpense" scale="3" id="Tc_uIW070NAz0am0p7dX69VkQ_9_6">682</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Net amortization and accretion of discount on short-term investments and term loan</p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" scale="3" id="Tc_RqoEhhJFXEyGrMB8UeYPag_10_3">114</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" sign="-" scale="3" id="Tc_wgiW8gbEt0-i78Y_M_bAEg_10_6">107</ix:nonFraction> </p></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Changes in assets and liabilities:</p></td><td style="vertical-align:bottom;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Accounts receivable, net</p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" sign="-" scale="3" id="Tc_xxLCHvcmTkeqYUu7VQntVg_12_3">19,501</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="Tc_xV97d7QBok-WIOYsKBkKLA_12_6">1,726</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Inventories</p></td><td style="vertical-align:bottom;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="Tc_v6Ll9k0I5EeyB5BF-kfW7g_13_3">1,640</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" sign="-" scale="3" id="Tc_7cuzvsx5t0C5c251dO3qFg_13_6">483</ix:nonFraction> </p></td><td style="vertical-align:bottom;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Prepaid and other current assets</p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" sign="-" scale="3" id="Tc_6M7c0zhg_k-uQ3-YKT8Ljg_14_3">3,292</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="Tc_9x6FX2A5ekuq7lfl0qRjmg_14_6">527</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Other assets</p></td><td style="vertical-align:bottom;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" sign="-" scale="3" id="Tc_PLeQg27vuEyahQ-gJhAxZQ_15_3">99</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" sign="-" scale="3" id="Tc_Khu7_F_A_0KkdE4eu0Ls-w_15_6">571</ix:nonFraction> </p></td><td style="vertical-align:bottom;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Right-of-use assets</p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" decimals="-3" format="ixt:numdotdecimal" name="rigl:IncreaseDecreaseRightOfUseAssets" scale="3" id="Tc_KAEFJEAasUywUsQS4DQjwQ_16_3">933</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g" decimals="-3" format="ixt:numdotdecimal" name="rigl:IncreaseDecreaseRightOfUseAssets" scale="3" id="Tc_Id-CMQMKLEiyEBc4PcYR4A_16_6">4,458</ix:nonFraction> </p></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Accounts payable</p></td><td style="vertical-align:bottom;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" sign="-" scale="3" id="Tc_XRdgUQdBb0eGBfepFpf4qg_17_3">2,268</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" sign="-" scale="3" id="Tc_LWQKs_BQPkm-Yo9dJM6r4A_17_6">1,585</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Accrued compensation</p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" sign="-" scale="3" id="Tc__tL6liO5NUWiO1p6SEj7Jg_18_3">2,127</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" sign="-" scale="3" id="Tc_19g4Hv0OIkGvKzTUEurCAw_18_6">3,165</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Accrued research and development</p></td><td style="vertical-align:bottom;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" decimals="-3" format="ixt:numdotdecimal" name="rigl:IncreaseDecreaseInAccruedResearchAndDevelopmentLiability" sign="-" scale="3" id="Tc_H3hvx-g2XUWBUofagX_rpg_19_3">1,882</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g" decimals="-3" format="ixt:numdotdecimal" name="rigl:IncreaseDecreaseInAccruedResearchAndDevelopmentLiability" sign="-" scale="3" id="Tc_VUY5rb8uVkWev4uH27jfHg_19_6">1,171</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Revenue reserves and refund liability</p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" decimals="-3" format="ixt:numdotdecimal" name="rigl:RevenueReservesAndRefundLiability" scale="3" id="Tc_iH-GCwyFe0aTLQ10u1YZFA_20_3">1,539</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g" decimals="-3" format="ixt:numdotdecimal" name="rigl:RevenueReservesAndRefundLiability" scale="3" id="Tc_aHr2SnwpYE-8Rk6h5tVkSQ_20_6">2,316</ix:nonFraction> </p></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Other accrued liabilities</p></td><td style="vertical-align:bottom;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" sign="-" scale="3" id="Tc_kSFQUphowUahXO1HSfyvkg_21_3">1,472</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" scale="3" id="Tc_IYVubVA8hEmRdZHCZj6Rmg_21_6">1,878</ix:nonFraction> </p></td><td style="vertical-align:bottom;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Lease liability</p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" sign="-" scale="3" id="Tc_-kvqxRae3EiCC1tO6IB2hg_22_3">1,011</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" sign="-" scale="3" id="Tc_7yiN-KW-G0ag9KCOiiQ-Yg_22_6">4,840</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Deferred revenue</p></td><td style="vertical-align:bottom;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" sign="-" scale="3" id="Tc_ZX23pqvET0WQjasre79BKw_23_3">14</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" sign="-" scale="3" id="Tc_VjLm2PDSHkqmV1afZAEvNA_23_6">1,053</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Other current and long-term liabilities</p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" id="Tc_-TdMnFsRJUCKdHzxPBeQRg_24_3">1,175</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" id="Tc_aRk-e-ILz0ShUGkyzKxFyw_24_6">142</ix:nonFraction> </p></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Net cash provided by (used in) operating activities</p></td><td style="vertical-align:bottom;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:11.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="Tc_8tp93Ctfuk-ie4WwyNnZgg_25_3">1,856</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_ReiKUZKM8UKU1mrHJIQlLw_25_6">38,548</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Investing activities</b></p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Purchases of short-term investments</p></td><td style="vertical-align:bottom;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireShortTermInvestments" scale="3" id="Tc_376EaXZKmkGa0eNeExapqA_27_3">8,780</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireShortTermInvestments" scale="3" id="Tc_PSRho2B5VEq1Pil597U-og_27_6">6,997</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Maturities of short-term investments</p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" scale="3" id="Tc_ThBnYkOdukudC9kLa1olqA_28_3">27,400</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" scale="3" id="Tc_wHalOnwgo0akh-7IMcNdVw_28_6">50,645</ix:nonFraction> </p></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Purchases of intangible asset </p></td><td style="vertical-align:bottom;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="3" id="Tc_CQoWl3TQ5UmsZ7v2Ol-BZQ_29_3">15,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Proceeds from sale of property and equipment </p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="Tc_VUfw1k5_tkGTsL8AHPrrKw_30_3">127</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="Tc_N9urej_AFkmk-ANlqA6VFw_30_6">264</ix:nonFraction> </p></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Purchases of property and equipment</p></td><td style="vertical-align:bottom;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:11.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_FhltASC2a0SDEhZSbKBXrw_31_6">188</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Net cash provided by investing activities</p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="Tc_T7BAvF2tekCeo7pbjO4Gmg_32_3">3,747</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="Tc_zuhmfSIGJUqR4_GbJpjQmA_32_6">43,724</ix:nonFraction> </p></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Financing activities</b></p></td><td style="vertical-align:bottom;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cost share payments to a collaboration partner</p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" decimals="-3" format="ixt:numdotdecimal" name="rigl:PaymentOfCostShareToCollaborationPartner" scale="3" id="Tc_8lKzXXFXj0mAi23V4vC7Ww_34_3">1,754</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g" decimals="-3" format="ixt:numdotdecimal" name="rigl:PaymentOfCostShareToCollaborationPartner" scale="3" id="Tc_ZkdWYTZVrECjIBSzMg72RA_34_6">8,346</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Net proceeds from issuances of common stock upon exercise of options and participation in Purchase Plan</p></td><td style="vertical-align:bottom;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="Tc_jIYUUDNNeUuWbOb_ljTprg_35_3">554</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="Tc_BaOd7o-yoUORECQoYvqz4A_35_6">1,539</ix:nonFraction> </p></td><td style="vertical-align:bottom;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Net proceeds from term loan financing</p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromLongTermLinesOfCredit" scale="3" id="Tc_q_F38_KffE6ieg_s_Yc4Eg_36_3">19,950</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromLongTermLinesOfCredit" scale="3" id="Tc_bdrOHroyhUC0Q4pGpUmuIQ_36_6">9,942</ix:nonFraction> </p></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:11.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_9p6sh8w8NEePh756sNbBCg_37_3">18,750</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_M5nxbjTKUEqNDu_o6y_nQw_37_6">3,135</ix:nonFraction> </p></td><td style="vertical-align:bottom;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net increase in cash and cash equivalents</p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" id="Tc_4GU3ljYhNkW99yjqtvETgQ_38_3">24,353</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" id="Tc_Eb-hHKrOUE20TSHaBMdkEA_38_6">8,311</ix:nonFraction> </p></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents at beginning of period</p></td><td style="vertical-align:bottom;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:11.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_V6d8KC6JDUOBpDajC6lVyA_39_3">24,459</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2021_LY4sWUaA_UOIKxqqgZ5UAQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_Fh2pqaxGpESrvCn0q-oeTA_39_6">18,890</ix:nonFraction> </p></td><td style="vertical-align:bottom;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents at end of period</p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:11.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_NTaaoq3Dt0yNdr8WmHAcvw_40_3">48,812</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:9.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2022_X6KPuRq2uEa6dhukywoGKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_vsxxM8nUIkW1N3hyqyKETg_40_6">27,201</ix:nonFraction> </p></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Supplemental disclosure of cash flow information</b></p></td><td style="vertical-align:bottom;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest paid</p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:11.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_A0rOfg28JkWbjeTIhgcpCA_42_3">2,485</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:9.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_gmJHk-Khs0uHbam4f-dQOg_42_6">951</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">See Accompanying Notes to Condensed Financial Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_85d87bec_3ba0_4c8f_ab2c_75adeeea7af0"></a><a id="NotestoCondensedFinancialStatements"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Rigel Pharmaceuticals,&#160;In</b><b style="font-weight:bold;">c.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Notes to Condensed Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:9pt 0pt 9pt 0pt;">In this report, &#8220;Rigel,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Rigel Pharmaceuticals,&#160;Inc.</p><a id="_Hlk140826264"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" name="us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock" id="Tb_pHNbC0_rC0ahLFUdpI4IoQ" continuedAt="Tb_pHNbC0_rC0ahLFUdpI4IoQ_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;"><b style="font-size:10pt;font-weight:bold;">1.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;"><b style="font-size:10pt;font-weight:bold;">Organization and Summary of Significant Accounting Policies</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">Description of Business</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">We are a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. We focus on products that address signaling pathways that are critical to disease mechanisms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Our first product approved by the US Food and Drug Administration (FDA) is TAVALISSE<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (fostamatinib disodium hexahydrate) tablets, the only approved oral spleen tyrosine kinase (SYK) inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. The product is also commercially available in Europe and the United Kingdom (UK) (as TAVLESSE), and in Canada, Israel and Japan (as TAVALISSE) for the treatment of chronic ITP in adult patients. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Our second FDA approved product is REZLIDHIA<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;&#160;</sup><span style="color:#222222;background:#ffffff;">(olutasidenib) capsules for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. We began our commercialization of REZLIDHIA in December 2022. W</span>e in-licensed <span style="color:#222222;background:#ffffff;">olutasidenib</span> from Forma Therapeutics, Inc. (now Novo Nordisk), with exclusive, worldwide rights for its development, manufacturing and commercialization. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">We continue to advance the development of our interleukin receptor-associated kinase (IRAK) 1/4 inhibitor program, in an open-label, Phase 1b trial to determine the tolerability and preliminary efficacy of the drug in patients with lower-risk <span style="color:#222222;background:#ffffff;">myelodysplastic syndrome (MDS)</span> who are refractory or resistant to prior therapies. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Our other ongoing clinical programs include a fostamatinib Phase 2/3 trial, the Accelerating COVID-19 Therapeutic Inventions and Vaccines Phase 2/3 trial (ACTIV-4 Host Tissue Trial), for the treatment <span style="background:#ffffff;">of hospitalized high-risk patients with COVID-19</span> being conducted and sponsored by the National Institute of Health (NIH)/National Heart, Lung, and Blood Institute (NHLBI), and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with our partner Eli Lilly and Company (Lilly). We also have product candidates in clinical development with partners BerGenBio ASA (BerGenBio) and Daiichi Sankyo (Daiichi). </p><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Tb_hPFwR685F0OJyCS2qOP41A" continuedAt="Tb_hPFwR685F0OJyCS2qOP41A_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:9pt 0pt 9pt 18pt;"><span style="font-style:italic;font-weight:bold;">Basis of Presentation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Our accompanying unaudited condensed financial statements have been prepared in accordance with United States generally accepted accounting principles (US GAAP), for interim financial information and pursuant to the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities Act of 1933, as amended (Securities Act). Accordingly, they do not include all the information and notes required by US GAAP for complete financial statements. These unaudited condensed financial statements include only normal and recurring adjustments that we believe are necessary to fairly state our financial position and the results of our operations and cash flows. Interim-period results are not necessarily indicative of results of operations or cash flows for a full-year or any subsequent interim period. The balance sheet as of December 31, 2022 has been derived from audited financial statements at that date but does not include all disclosures required by US GAAP for complete financial statements. Because certain disclosures required by US GAAP for complete financial statements are not included herein, these interim unaudited condensed financial statements and the notes accompanying them should be read in conjunction with our audited financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC on March 7, 2023.</p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk70506756"></a><ix:continuation id="Tb_pHNbC0_rC0ahLFUdpI4IoQ_cont1"><ix:continuation id="Tb_hPFwR685F0OJyCS2qOP41A_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" name="us-gaap:UseOfEstimates" id="Tb_GkKGYiIZEk6g62ZIy7X77w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-indent:36pt;margin:9pt 0pt 0pt 0pt;">The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results could differ from these estimates.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Significant Accounting Policies</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-indent:36pt;background:#ffffff;margin:0pt;">Our significant accounting policies are described in &#8220;Note 1 &#8211; Description of Business and Summary of Significant Accounting Policies&#8221; to our&#160;&#8220;Notes to Financial Statements&#8221;&#160;contained in &#8220;Part II, Item&#160;8, Financial Statements and Supplementary Data&#8221; of our Annual Report on Form 10-K for the year ended December 31, 2022. There have been no material changes to these accounting policies.</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" name="rigl:LiquidityAndCapitalResourcesPolicyPolicyTextBlock" id="Tb_-7iJAurwVEKUbTUErTvlOA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Liquidity</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-indent:36pt;background:#ffffff;margin:0pt;">As of June 30, 2023, we had approximately $<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" id="Narr_gQzQAPLYMkOOp1ewbatTpw">64.4</ix:nonFraction> million in cash, cash equivalents and short-term investments. Since inception, we have financed our operations primarily through sales of equity securities, debt financing, contract payments under our collaboration agreements and from product sales. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-indent:36pt;background:#ffffff;margin:0pt;">Based on our current operating plan, we believe that our existing cash, cash equivalents, and short-term investments will be sufficient to fund our expenses and capital expenditure requirements for at least the next 12 months from the date of issuance of this Form 10-Q.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_4X0ahPd2i0SxuF0BH5V2UA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Recently Issued Accounting Standards </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt 0pt 9pt 0pt;">Recently issued accounting guidance is either not applicable or did not have, or is not expected to have, a material impact to us. </p></ix:nonNumeric></ix:continuation><a id="_6c9496ef_45c3_4d75_8325_12e3b78e00cb"></a><a id="Tc_sdeerCmGmky7koX_WoTNHg_1_2"></a><a id="Tc_L4OlTmo32UGiVI7xOKdQBw_1_8"></a><a id="Tc_WAGeBoMtBkK04bnOfjVQUg_2_2"></a><a id="Tc_rBPFUefMe0iW2JmF8liarw_2_5"></a><a id="Tc_z1_ztedGl0eV4UZYEdESQQ_2_8"></a><a id="Tc_w5AVxicJW0uWa-X0ZaWocw_2_11"></a><a id="Tc_qfTJgCMIqUqOXua7vAEeqA_3_0"></a><a id="Tc_6s9pVs_D2EeFdUNdK3yhtQ_4_0"></a><a id="Tc_xmlg7f1R4UWN8HxPGq8f4w_5_0"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" name="us-gaap:EarningsPerShareTextBlock" id="Tb_63D7Zi8QjU2iAMUYRFPZSQ" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;"><b style="font-size:10pt;font-weight:bold;">2.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;"><b style="font-size:10pt;font-weight:bold;">Net Loss Per Share</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period and the number of additional shares of common stock that would have been outstanding if potentially dilutive securities had been issued. Potentially dilutive securities include stock options, RSUs and shares issuable under our Employee Stock Purchase Plan (Purchase Plan). The dilutive effect of these potentially dilutive securities is reflected in diluted earnings per share using the treasury stock method. Under the treasury stock method, an increase in the fair market value of our common stock can result in a greater dilutive effect from potentially dilutive securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The potential shares of common stock that were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive are as follows (in thousands):</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Tb_UHW8epxnl0i5EC9_8eqLzw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:93.39%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:23.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:21.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding stock options</p></td><td style="vertical-align:bottom;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_mJfwLdIwJE2PuCZyxHa0nA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_72CaDYJTaEKIGD-VYUAGhA_3_3">35,244</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA" contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_3BL6mb7WlEWnOeX6FOCPaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_RjtoEqE0NkyeeaWn4GH-vA_3_6">33,081</ix:nonFraction> </p></td><td style="vertical-align:bottom;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_eLmQDXheSkOcwdRhfkuNbw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_o9E54pq50kaO2luPulZHHw_3_9">35,244</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA" contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_2SVbQAbboUOHtAeVDBUKZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_KjMokNKTxEy5BN6pg2Hgug_3_12">33,081</ix:nonFraction> </p></td></tr><tr><td style="vertical-align:bottom;width:51.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">RSUs</p></td><td style="vertical-align:bottom;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_kUrHXkhzkEmFf7R8bUu2kA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_8kexN_Dyz0K88N2mb80Wbg_4_3">1,963</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA" contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_FPUuaR2SyUSRDy3fSQcDRQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_Wxjj0KhNDUWaS5Ivs4X7zQ_4_6">1,191</ix:nonFraction> </p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_3tETexLm0UCBsN9ftHBwtg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_nGt-ziIZAkesciIsGVAosA_4_9">1,963</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA" contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_WHRK7Ydr8Euv9ScMKMDa3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_0-i23OEuLUCsJ5lVKSrdVA_4_12">1,191</ix:nonFraction> </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA" contextRef="Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_TKly2VVf80i5X40PNSdKWA_5_3">37,207</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA" contextRef="Duration_4_1_2022_To_6_30_2022_ICCkO9pPUUSORAn1kecZBA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_mzLTglFNNEewMD-f0BOX0w_5_6">34,272</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA" contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_HTIamhsSqkyIo1OxJfA0aQ_5_9">37,207</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA" contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_Cz_EXLW77k2fqodS7nJG7g_5_12">34,272</ix:nonFraction> </p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_b3093cc7_dfbb_4366_83cb_e49cc7c97489"></a><a id="Tc_kBrTAvFlO0ONR1O8eY92Tw_1_2"></a><a id="Tc_Oqj1A5LVBEuK5kkujv7ysg_1_8"></a><a id="Tc_DnX4b3jDTUSxc5-is3aHxw_2_2"></a><a id="Tc_UYLm2cCo-ECeP7Y602iQ8Q_2_5"></a><a id="Tc_slGBbONAwEaHrshmM-tCGw_2_8"></a><a id="Tc_Tza4TRNXQ0mWfh0wAbUpmw_2_11"></a><a id="Tc_dU1OjiiET0yiz3kUXDxb_Q_3_0"></a><a id="Tc_xcEergbb2U-U4i-qkpzafg_4_0"></a><a id="Tc_VOqp4jZVZkmaTnuLOYecJg_4_2"></a><a id="Tc_-Kk_C-fS9kWlRcAHuus-Ew_4_5"></a><a id="Tc_eA4v0apH9kWP_z8hFa2pQg_4_8"></a><a id="Tc_antOmA24Bky6xjEz0HVbkg_5_0"></a><a id="Tc_zeB9wTU_6EK7KVz5nfGP4Q_6_0"></a><a id="Tc_fCJDgJMlBketZTIFI1xuZg_7_0"></a><a id="Tc_4Szb5Hz2L0mSbbLmKxM1EA_8_0"></a><a id="Tc_IKvmBydtXUelCzXTqV43rg_8_3"></a><a id="Tc_0M0qBZ6w_kSdLIXHmtpKgA_8_9"></a><a id="Tc_riUOwS9I3kaGni0gsFtxPg_9_0"></a><a id="Tc_7C8VFg8CTk-L0iBZz8u-Vg_9_3"></a><a id="Tc_FekdXhnzVE-dGreEXEMO4Q_9_9"></a><a id="Tc_zgYmxRvAl0KFlLzfGAtw-A_10_0"></a><a id="Tc_n5LdLztUEUubbkV1r4-GUQ_11_0"></a><a id="Tc_3lYij_qlZUiNwyWnG_9JoA_12_0"></a><a id="Tc_tRHDvglutEWb2jMw89soCw_12_6"></a><a id="Tc_TyDG2FKmpEe3q7AX_cA_BA_12_12"></a><a id="Tc_mxuaDiguJ06B388gePKu3g_13_0"></a><a id="Tc_-FQus9mpckK85LZwVeG9IQ_13_2"></a><a id="Tc_0yjEy2EmtUapTcPqSEoaMw_13_5"></a><a id="Tc_EHLpQAY98Ey5xyLDCJCZ6Q_13_8"></a><a id="Tc_iNtzVQZPDkSr1t7OK5q_fg_13_11"></a><a id="_Hlk520203236"></a><a id="_1c87c8d6_1540_47df_bbdf_32fdaafb2e23"></a><a id="Tc_E2mTwrLg5EW5m75_3JGh-w_1_2"></a><a id="Tc_yJWi-MNYTEmAXaGD1HLx1g_1_5"></a><a id="Tc_1KI1LXqo80iDOXssH8F8Sg_2_2"></a><a id="Tc_ftifwGHBU0S5XsN6IeIWRg_2_5"></a><a id="Tc_Tet3QtPLS0GH_8LlSoQYBw_3_2"></a><a id="Tc_ck5GjxnpvkGZs9CcNwNz_Q_3_5"></a><a id="Tc_eCY40dDzrkODRtVP9Ucmew_3_8"></a><a id="Tc_Npad7vnGdE6VUbSErHvBlg_3_11"></a><a id="Tc_l99pGBBy2ES7DmdJUnZVJg_4_0"></a><a id="Tc_1pQlgDV4u0eGqm4xb3fDfQ_4_2"></a><a id="Tc_fC-UGbl0N0aEJ9wuxlnIgg_4_5"></a><a id="Tc_Nrua_kFZoUWh-mg5Tr1KcQ_4_8"></a><a id="Tc_K5GotoeHZ0OLjLrwDJNz3w_4_11"></a><a id="Tc_wSH5S73FoUKLlWzrb_6uUw_5_0"></a><a id="Tc_eeBbBbPyq0WQf0-LmqRpuA_6_0"></a><a id="Tc_y15ErEFvD02FZZK-MmdglA_7_0"></a><a id="Tc_7vXaDF23xUWJWcQqWy9edg_7_2"></a><a id="Tc_HR-8fLSJFUuhVu1w1Kfn0g_7_5"></a><a id="Tc_RbsBnD-c-kWLH362ZamVcg_7_8"></a><a id="Tc_hupF0tbirkO88lAboIEnxA_7_11"></a><a id="_1461d7d4_6c28_4ea2_b887_e1aadf9c5e3c"></a><a id="Tc_coTXSb8AnUqX_mZCTZXOww_1_2"></a><a id="Tc_TydBFHQeKU6X-lSrrfAYVw_1_5"></a><a id="Tc__3zKTsqbfkeNGVWFVDNgjQ_2_2"></a><a id="Tc_U_ea3aKaXUquMp-GTjRfog_2_5"></a><a id="Tc_yv5ZNnoha0yM8hdESHkfhQ_3_2"></a><a id="Tc_s1Qa2QNlUEuvX6SdJoueyw_3_5"></a><a id="Tc_qgy98tQmm0mC18JIZedOQw_3_8"></a><a id="Tc_NKwK7aXVNkO3BDLIMmNdaw_3_11"></a><a id="Tc_yASCYWukikGLDajzfla2WQ_4_0"></a><a id="Tc_K5PQEQ3vakKu6MvvqtbWig_4_2"></a><a id="Tc_0B_3cRPLMES558IL71CVng_4_5"></a><a id="Tc_JO_zN2025kaI9jMDnYrmRQ_4_8"></a><a id="Tc_1F6YxSMfnU-9CQFwk7Krhg_4_11"></a><a id="Tc_QERqRF60UE6RilfkRI9fRA_5_0"></a><a id="Tc_PsaL0IG7cEOr-scar71xMA_6_0"></a><a id="Tc_5OLykN3_DUqmFFz2eg5ZMQ_7_0"></a><a id="Tc_Otk4iKBHz0OaOyNNG2HF7g_7_2"></a><a id="Tc_z10g9HHQqUCJ0ntqC4akgw_7_5"></a><a id="Tc_i31_EQyIpUmgLkLDfRXTFw_7_8"></a><a id="Tc_JKqpVYtUaU-3E1c1UJH_eA_7_11"></a><a id="_7c0a45f2_7e2d_42a5_afc8_db31c91662ed"></a><a id="Tc_SRHgLXMjaE6GvQe_bnXA8Q_1_2"></a><a id="Tc_ioagKj2cPES1yOFjxB3_Dw_1_9"></a><a id="Tc_i81c2CEaeUutKESw6X0sCQ_2_2"></a><a id="Tc_py78mN1cQk2hSjOSbTVcIg_2_5"></a><a id="Tc_WspQc2iVQE6u4_FQRY-uZQ_2_9"></a><a id="Tc_sdhEouOq50K7y7mo1f6dlQ_2_12"></a><a id="Tc_bXiPv2sCtUiXbfJrScdorQ_3_0"></a><a id="Tc_N7TxWB9QNUKQmUYQNcs0ww_4_0"></a><a id="Tc_IJlvjEmDx06rnw9dW-BWKg_5_0"></a><a id="Tc_usAGkrEjMEuUmOPZjaYzUw_6_0"></a><a id="Tc_H0hX0LLOr02eORGgKYfmzA_6_3"></a><a id="Tc_08GSRLnQM0mLB1YXP_H_oQ_6_10"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="Tb_GU3iqFDY5E6-EIlXVsRv7Q" continuedAt="Tb_GU3iqFDY5E6-EIlXVsRv7Q_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-size:10pt;font-weight:bold;">3.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-size:10pt;font-weight:bold;">Revenues</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="Tb_ijgLq9LSZkuLf20lbgO0rg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Revenues disaggregated by category were as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:41.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:41.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:26.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Product sales:</p></td><td style="vertical-align:bottom;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Gross product sales</p></td><td style="vertical-align:bottom;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_GrossProductMember_ene2KCce8kCbyUMQexHEMg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_hnA9vQ9wN0CJDkzxttV6iA_4_3">33,456</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_rigl_GrossProductMember_95E_EFQSok-CYS8j9cMXTA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_IKiftc063EWbcctw1mJC-Q_4_6">26,427</ix:nonFraction> </p></td><td style="vertical-align:bottom;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_GrossProductMember_ufxFI3eqlEur3o5rbubmLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_dXMlfbUn-EmC6-uDy3H5Ig_4_9">66,654</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_rigl_GrossProductMember_rXnbhU9tKUyNBTlYxDeWHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_B0PZw9bKrkiBWg1XJ31LKg_4_12">49,045</ix:nonFraction> </p></td></tr><tr><td style="vertical-align:bottom;width:41.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Discounts and allowances</p></td><td style="vertical-align:bottom;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_DiscountsAndAllowancesMember_uHoWbEnKdU2tg1UhL6Vz-g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" sign="-" scale="3" id="Tc_dExZZmUF3kWtrcE-L79HLg_5_3">9,575</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_rigl_DiscountsAndAllowancesMember_OH1BW4gyzU6mjxq6VfcyGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" sign="-" scale="3" id="Tc_dDBsJky9ckKai0u34BHoGw_5_6">7,877</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_DiscountsAndAllowancesMember_POb1Otc_IkOne8fdyW38vA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" sign="-" scale="3" id="Tc_mtb6N4VYVUuez5lzOu97eA_5_9">19,028</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_rigl_DiscountsAndAllowancesMember_rYICJn1GSUmzENKUTvY70A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" sign="-" scale="3" id="Tc_nfEpx-7Xtk2bUcSdOyMBYQ_5_12">14,298</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:41.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total product sales, net</p></td><td style="vertical-align:bottom;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_v4jyMWOILkimNDJi27bJNA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_01b4mqvAREWk5EWyoqICGw_6_3">23,881</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_Zl3JCD-6OEeEiUA808bVig" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_OAHsRJ1NvU6qV8iXWmz_NQ_6_6">18,550</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_C2EWGpiFxUGr9E995bXhCQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_f_XjOSzELky4boa8FlmAlQ_6_9">47,626</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_I08rIoA1_0itpE8QmmW4zw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_gyHx8WStZ0213Qvgk_XSig_6_12">34,747</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Revenues from collaborations:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">License revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_LicenseMember_dRyVOn5NcEee-uU6cPlByQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_oQYwcyj5Q0alRODj0qf9Vg_8_6">2,337</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_LicenseMember_aC5yN2D_3U6wto3RbpNFkQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_6fEgd2Wje0OPxgAAiuVYlw_8_12">2,545</ix:nonFraction> </p></td></tr><tr><td style="vertical-align:bottom;width:41.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Development milestones</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_rigl_DevelopmentMilestonesMember_8XRCe7N2D0q0_dL4LzLrSw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc__hD0Pn76WU-TxRcJO7aRPw_9_6">5,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_rigl_DevelopmentMilestonesMember_HoBUCB_cmEGo56InBGrucg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_bxLIrVsMtU6mOVoAFZfmRg_9_12">5,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:41.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Royalty, delivery of drug supplies and others</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_RoyaltyDeliveryOfDrugSuppliesAndOthersMember_jqRyjOlFGUu5mu87xpyztg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_j7AN36tQS0KXqzIj8oKO1A_10_3">2,005</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_rigl_RoyaltyDeliveryOfDrugSuppliesAndOthersMember_v1BBxfjOM0iXxMM8ZntPkg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_2HOcBcg4gUyulFBHcsxY-g_10_6">3,932</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_RoyaltyDeliveryOfDrugSuppliesAndOthersMember_V9FmeTwnFU20hq0tJetk3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_5CCn-aplgUyV7D3FzToPog_10_9">4,330</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_rigl_RoyaltyDeliveryOfDrugSuppliesAndOthersMember_ClPsUsxGhkStEb_3uR8ZgA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_LoYCZrHTTUyqZip6QcWv_w_10_12">4,262</ix:nonFraction> </p></td></tr><tr><td style="vertical-align:bottom;width:41.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total revenues from collaborations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_ContractRevenuesFromCollaborationsMember_yU4TzCXKCkSEqjOPYCD5ig" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_oUGJXqlIEU-lF3dbseYV_w_11_3">2,005</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_rigl_ContractRevenuesFromCollaborationsMember_B3F0S8vRz0eWxrI-zbC5eQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_HM8QX56ASESyEYIvnuY_bw_11_6">11,269</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_ContractRevenuesFromCollaborationsMember_TmFkSqljNUiYYmkDnr-3ag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_NVwNNL6olkq8RBvmRYs9bg_11_9">4,330</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_rigl_ContractRevenuesFromCollaborationsMember_LOIZvjtJ4kefhhUMq6-K0Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_k5KIVVcqaE6v-lZIBqiSNA_11_12">11,807</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Government contract</p></td><td style="vertical-align:bottom;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_GovernmentContractMember_WN0BoWdZGU-KXqAccwJ68A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_DH38-MzEaUaYi4BEfU_uyA_12_3">1,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_GovernmentContractMember_9xcr5RYkM0WkIqJKKgDS8A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_kbkHm8GTDkKqaGZL7BlCgQ_12_9">1,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Total revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_rG4BZwwyFEa0tvc-wN5riQ_13_3">26,886</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2022_To_6_30_2022_ICCkO9pPUUSORAn1kecZBA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_MOqK6_JCE0uU_yasSQtJYQ_13_6">29,819</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_rXCKmw_NaEWBgZV5orVBYQ_13_9">52,956</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_lQwWtm1c5kOlCorvUphdIQ_13_12">46,554</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Revenue from product sales are related to sales of our commercial products, TAVALISSE and REZLIDHIA, to our specialty distributors. For detailed discussions of our revenues from collaboration and government contract, see &#8220;Note 4 &#8211; Sponsored Research and License Agreements and Government Contract&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Our net product sales include gross product sales, net of chargebacks, discounts and fees, government and other rebates and returns. Of the total discounts and allowances from gross product sales for the six months ended June 30, 2023 and 2022, $<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" decimals="-5" format="ixt:numdotdecimal" name="rigl:SalesDiscountsAndAllowances" scale="6" id="Narr_tvCbA1l-Ykepi2cXWZoG5Q">18.6</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g" decimals="-5" format="ixt:numdotdecimal" name="rigl:SalesDiscountsAndAllowances" scale="6" id="Narr_-eAAkLytZUytOqLdqvbnzw">13.0</ix:nonFraction> million, respectively, was accounted for as additions to revenue reserves and refund liability, and $<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_BalanceSheetLocationAxis_rigl_AccountsReceivableAndPrepaidAndOtherCurrentAssetsMember__I6hFO6Y_0yiZKdPOpgk-Q" decimals="-5" format="ixt:numdotdecimal" name="rigl:SalesDiscountsAndAllowances" scale="6" id="Narr_DtM7uejankuPhEk2pUIBRg">0.4</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_BalanceSheetLocationAxis_rigl_AccountsReceivableAndPrepaidAndOtherCurrentAssetsMember_EmK1_sfXdkCE9z-LmqaUnw" decimals="-5" format="ixt:numdotdecimal" name="rigl:SalesDiscountsAndAllowances" scale="6" id="Narr_ycfPZjcFEk2tB4codrM8dw">1.3</ix:nonFraction> million, respectively, as reductions in accounts receivable (as it relates to allowance for prompt pay discount) and prepaid and other current assets (as it relates to certain chargebacks and other fees that were prepaid) in the condensed balance sheet. The following tables summarize the activities in chargebacks, discounts and fees, government and other rebates and returns that were accounted for within revenue reserves and refund liability, for each of the periods presented (in thousands):</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" name="srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" id="Tb_RBPZQi6yFk65KWTW1V-Oug" escape="true"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:38.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Chargebacks,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Government</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Discounts&#160;and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">and Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fees</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Rebates</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Returns</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance as of January 1, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_ChargebacksDiscountsAndFeesMember_PB_xsJ2Rnka8evD4QKOfWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="Tc_sFb1qOlSnUuSHLVZtarL0A_4_3">6,213</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_GovernmentAndOtherRebatesMember__X6NqDu8YU-SnfKyNeY8HA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="Tc_xHWJBsN2Wkm_AVywDk39-A_4_6">2,636</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember_acq92gncQkKXH4cm6zevsA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="Tc_sPITMmTvbEubXT2QPjs83A_4_9">3,296</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="Tc_PmK8xFG1K0Si2SRLG6HGig_4_12">12,145</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:38.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Provision related to current period sales</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_ChargebacksDiscountsAndFeesMember_Fj8Wggl3gkGVVa1f_QMscg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="3" id="Tc_CfWcuW6PR0Cby6ZoT2_0tg_5_3">14,439</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_GovernmentAndOtherRebatesMember_6P-es-h0okS3mUsko2UktA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="3" id="Tc_uZ_CORzsZEyUt6pGsjCOaQ_5_6">3,725</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember_5hmOTOINYUi1yMKOyqV_Tg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="3" id="Tc_bo6dM6DFykG0gXLzSUnUfw_5_9">395</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="3" id="Tc_2yDqcPPNNEO8bOQaPj5vzQ_5_12">18,559</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:38.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Credit or payments made during the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_ChargebacksDiscountsAndFeesMember_Fj8Wggl3gkGVVa1f_QMscg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="3" id="Tc_OKttO_H2rUSmWr1DMbsUVA_6_3">13,139</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_GovernmentAndOtherRebatesMember_6P-es-h0okS3mUsko2UktA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="3" id="Tc_KbLqZeu4SkuPKF-_xusQtw_6_6">3,765</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember_5hmOTOINYUi1yMKOyqV_Tg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="3" id="Tc_uNKU2b5RXUSLFy43uwj7FA_6_9">116</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="3" id="Tc_eVzI66W0jUGR10f_lmeU_Q_6_12">17,020</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:38.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance as of June 30, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_ChargebacksDiscountsAndFeesMember_DfMT0NHFbUOWySs4XQGnsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="Tc_hJJkYrHlqUywrzL_5hNRRg_7_3">7,513</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_GovernmentAndOtherRebatesMember_jVuu0q4VHEWON15mELkW8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="Tc_vDWorq33kUaz0wrkckILMg_7_6">2,596</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember_-dSzQZXVFEuMJw8h2iIHxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="Tc_eu947VLQhkeAkxd8Y-0J9w_7_9">3,575</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="Tc_H-UWPFMejUCuGcQ749A3iA_7_12">13,684</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:38.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Chargebacks,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Government</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Discounts&#160;and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">and Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fees</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Rebates</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Returns</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance as of January 1, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2021_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_ChargebacksDiscountsAndFeesMember_Pp0Xy4dvykCBp639HzD29g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="Tc_ZBYfPnc-XkWA3zdtpS-2Tg_4_3">3,404</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2021_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_GovernmentAndOtherRebatesMember_eCxe-sGTfE-EJIbGHCs0Rw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="Tc_BRPHGl8S_EuUUYlqsm-R2Q_4_6">2,494</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2021_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember_2U4Oj50ug0SqZPXE5_VdHg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="Tc_PkUbI-NB-EqovAAuFXcQ1w_4_9">2,017</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2021_LY4sWUaA_UOIKxqqgZ5UAQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="Tc_MWDNB97fdU2NC8kY-8nRXQ_4_12">7,915</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:38.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Provision related to current period sales</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_ChargebacksDiscountsAndFeesMember_t4iNGTcP0UaLBEDeXCMGOw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="3" id="Tc_y7Syt8G1UUqfE3AiXoaGVQ_5_3">9,680</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_GovernmentAndOtherRebatesMember_OChMZBgap0qvP6EMKEatOg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="3" id="Tc_ZpsciorR_Uy29OnMuADvGg_5_6">2,711</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember_ioiPIbSN6U6AmT1ftZXQ6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="3" id="Tc_JnssMOOvTU-0_h1BTdVXzQ_5_9">613</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="3" id="Tc_aeGreS2PHkSEOo_15MDg4A_5_12">13,004</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:38.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Credit or payments made during the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_ChargebacksDiscountsAndFeesMember_t4iNGTcP0UaLBEDeXCMGOw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="3" id="Tc_yoNDZPhhh02GTO2YxVOrQQ_6_3">7,748</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_GovernmentAndOtherRebatesMember_OChMZBgap0qvP6EMKEatOg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="3" id="Tc_J1mV1rzACUmFAcDtzxKjGw_6_6">2,901</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember_ioiPIbSN6U6AmT1ftZXQ6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="3" id="Tc_hIQxxnoKu02Qsvg0bBiN2w_6_9">39</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="3" id="Tc_R1wp-e-ib0eVaFQs8Lx61w_6_12">10,688</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:38.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance as of June 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2022_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_ChargebacksDiscountsAndFeesMember_nboH8Ly9PkqdAPD6SogU6Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="Tc_eN_jqnrGZUaQbGqWUHBD2w_7_3">5,336</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2022_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_GovernmentAndOtherRebatesMember_bsvDCX99AUmyaU2yXJOh2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="Tc_e8bCAa9ky0mU2u9qiu6wIw_7_6">2,304</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2022_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember_jBU6vZXXI0qTA8tjSyNMHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="Tc_kXFTQikaHUeC9LFGdsT0kA_7_9">2,591</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2022_X6KPuRq2uEa6dhukywoGKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="Tc_582L0VgYI0yXRmWcqJicOA_7_12">10,231</ix:nonFraction></p></td></tr></table></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" name="rigl:DisaggregationOfRevenueByCustomerTableTextBlock" id="Tb_VpaO109tk0GzPQJELPtydA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 6pt 0pt;">The following table summarizes the percentages of revenues from each of our customers who individually accounted for 10% or more of the total net product sales and revenues from collaborations:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:96.98%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:43.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:24.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">McKesson Specialty Care Distribution Corporation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_uVIKS5OYQEes3pxG5CV0tw" contextRef="Duration_4_1_2023_To_6_30_2023_srt_MajorCustomersAxis_rigl_MckessonSpecialtyCareDistributionCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_NFFFR5Op6EGibKqyThuK6g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc_PlW5HdNn6kW2RpOG5abFbQ_3_3">44</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_uVIKS5OYQEes3pxG5CV0tw" contextRef="Duration_4_1_2022_To_6_30_2022_srt_MajorCustomersAxis_rigl_MckessonSpecialtyCareDistributionCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_Xm7pTW7phEG80_TFGMPzwQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc_g8Z1Z2ptcE6zMmxsXV_Zqg_3_6">34</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_uVIKS5OYQEes3pxG5CV0tw" contextRef="Duration_1_1_2023_To_6_30_2023_srt_MajorCustomersAxis_rigl_MckessonSpecialtyCareDistributionCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_ijLIVbFhwE2dv-2rbK1hJw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc_rpY6W4AH3kKH-Y7apWqvUg_3_10">45</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_uVIKS5OYQEes3pxG5CV0tw" contextRef="Duration_1_1_2022_To_6_30_2022_srt_MajorCustomersAxis_rigl_MckessonSpecialtyCareDistributionCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_hMd2onJOT0a7o-jJSOOdJA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc_bx05ELwDmUGUGeTdfm6azw_3_13">36</ix:nonFraction>%</p></td></tr><tr><td style="vertical-align:bottom;width:43.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cardinal Healthcare</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_uVIKS5OYQEes3pxG5CV0tw" contextRef="Duration_4_1_2023_To_6_30_2023_srt_MajorCustomersAxis_rigl_CardinalHealthcareMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_ZvGiZXP9CEeNn157o58OQQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc_SLSdDI_KhES8oMW_-4KA5g_4_3">28</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_uVIKS5OYQEes3pxG5CV0tw" contextRef="Duration_4_1_2022_To_6_30_2022_srt_MajorCustomersAxis_rigl_CardinalHealthcareMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_crG-CxphyUmLeRthseHyVQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc_TTv1RMndE0Ss1jXzGfdezA_4_6">16</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_uVIKS5OYQEes3pxG5CV0tw" contextRef="Duration_1_1_2023_To_6_30_2023_srt_MajorCustomersAxis_rigl_CardinalHealthcareMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_7kgMzAici0eIlntate3Qlw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc_lwfhSzFmVkGZwO8YMqPI4Q_4_10">26</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_uVIKS5OYQEes3pxG5CV0tw" contextRef="Duration_1_1_2022_To_6_30_2022_srt_MajorCustomersAxis_rigl_CardinalHealthcareMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_XwGmaHgDQE6DlBxIrLRYjw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc_P58gLCs_nEeGE8zSJpUywg_4_13">20</ix:nonFraction>%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ASD Healthcare and Oncology Supply</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_uVIKS5OYQEes3pxG5CV0tw" contextRef="Duration_4_1_2023_To_6_30_2023_srt_MajorCustomersAxis_rigl_AsdHealthcareAndOncologySupplyMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_ezDA2vAhCkWEvWvApmdHcA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc_fwSV7eAXtUK8p-EMw1_CuQ_5_3">19</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_uVIKS5OYQEes3pxG5CV0tw" contextRef="Duration_4_1_2022_To_6_30_2022_srt_MajorCustomersAxis_rigl_AsdHealthcareAndOncologySupplyMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_sEWKR2JD6EG-XvczwGJTDg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc_-Os1sZBO9EW_mXrN3bZq3w_5_6">12</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_uVIKS5OYQEes3pxG5CV0tw" contextRef="Duration_1_1_2023_To_6_30_2023_srt_MajorCustomersAxis_rigl_AsdHealthcareAndOncologySupplyMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_L3diTTLKsk23XOOP9fvJUg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc_vBSraoislk6aGAcqRrSBkA_5_10">21</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_uVIKS5OYQEes3pxG5CV0tw" contextRef="Duration_1_1_2022_To_6_30_2022_srt_MajorCustomersAxis_rigl_AsdHealthcareAndOncologySupplyMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_Z_7YFCzct0KfoaZgxA9q_Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc_Rsz3ub__Q0Sv1o33mZkpnw_5_13">19</ix:nonFraction>%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Kissei</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_uVIKS5OYQEes3pxG5CV0tw" contextRef="Duration_4_1_2022_To_6_30_2022_srt_MajorCustomersAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_KKDtN8IagE6J4I_uAnU00A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc_LdsdoLcg10yFSjgGz2Uovg_6_6">25</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_uVIKS5OYQEes3pxG5CV0tw" contextRef="Duration_1_1_2022_To_6_30_2022_srt_MajorCustomersAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_r58vna9bwkWOHGAEZRVhtg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc_QSFQ-mISNE6lQ2ueYVMmYg_6_13">16</ix:nonFraction>%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_GU3iqFDY5E6-EIlXVsRv7Q_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="Tb_mwKcNqqDbE--8uXFTO1p2Q" continuedAt="Tb_mwKcNqqDbE--8uXFTO1p2Q_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:10pt;font-weight:bold;">4.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:10pt;font-weight:bold;">Sponsored Research and License Agreements and Government Contract</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Sponsored Research and License Agreements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">We conduct research and development programs independently and in connection with our corporate collaborators. As of June 30, 2023, we are a party to collaboration agreements with Lilly to develop and commercialize R552, a RIPK1 inhibitor, for the treatment of non-central nervous system (non-CNS) diseases and collaboration aimed at developing additional RIPK1 inhibitors for the treatment of central nervous system (CNS) diseases; with Grifols S.A. (Grifols) to commercialize fostamatinib for human diseases in all indications, including chronic ITP and <span style="color:#202124;background:#ffffff;">autoimmune hemolytic anemia</span> (AIHA), in Grifols territory which includes Europe, the UK, Turkey, the Middle East, North Africa and Russia (including Commonwealth of Independent States); with Kissei Pharmaceutical Co., Ltd. (Kissei) to develop and commercialize fostamatinib in Kissei territory which includes Japan, China, Taiwan and the Republic of Korea; with Medison Pharma Trading AG (Medison Canada) and Medison Pharma Ltd. (Medison Israel and, together with Medison Canada, Medison) to commercialize fostamatinib in all indications, including chronic ITP and AIHA, in Medison territory which includes Canada and Israel; and with Knight Therapeutics International SA (Knight) to commercialize fostamatinib in all indications, including chronic ITP and AIHA, in Knight territory which includes Latin America, consisting of Mexico, Central and South America, and the Caribbean (Knight territory).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Further, we are also a party to collaboration agreements, but do not have ongoing performance obligations with BerGenBio for the development and commercialization of <span style="background:#ffffff;">AXL receptor tyrosine kinase (</span>AXL) inhibitors in oncology, and with Daiichi to pursue research related to <span style="background:#ffffff;">murine double minute 2&#160;(</span>MDM2) inhibitors, a novel class of drug targets called ligases. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Under the above existing agreements that we entered into in the ordinary course of business, we received or may be entitled to receive upfront cash payments, payments contingent upon specified events achieved by such partners and royalties on any net sales of products sold by such partners under the agreements. As of June 30, 2023, total future contingent payments to us under all of the above existing agreements, excluding terminated agreements, could exceed $<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" decimals="-8" format="ixt:numdotdecimal" name="rigl:ContingentPaymentsUnderAgreement" scale="9" id="Narr__A8pDX1TFk2g-aZXP7H0dA">1.3</ix:nonFraction> billion if all potential product candidates achieved all of the payment triggering events under all of our current agreements. Of this amount, $<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_rigl_AchievementOfMilestoneAxis_rigl_SpecifiedDevelopmentEventsMember_sRR_821DCEKRn49CXFeLEw" decimals="-5" format="ixt:numdotdecimal" name="rigl:ContingentPaymentsUnderAgreement" scale="6" id="Narr_F-Nzc6P33kaiDpU97yL_Mg">279.5</ix:nonFraction>&#160;million relates to the achievement of development events, $<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_rigl_AchievementOfMilestoneAxis_rigl_SpecifiedRegulatoryEventsMember_zr3FrB7HG0yHHKE65ZlQ0g" decimals="-5" format="ixt:numdotdecimal" name="rigl:ContingentPaymentsUnderAgreement" scale="6" id="Narr_wMpSSGueA0OEY0uOMBecFQ">263.1</ix:nonFraction> million relates to the achievement of regulatory events and $<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_rigl_AchievementOfMilestoneAxis_rigl_SpecifiedProductLaunchEventsMember_kqeKijsRnkOOsVnTduINrw" decimals="-5" format="ixt:numdotdecimal" name="rigl:ContingentPaymentsUnderAgreement" scale="6" id="Narr_eSck76dcTU-lxYzMncNnXQ">796.0</ix:nonFraction>&#160;million relates to the achievement of certain commercial events. This estimated future contingent amount does not include any estimated royalties that could be due to us if the partners successfully commercialize any of the licensed products. Future events that may trigger payments to us under the agreements are based solely on our partners&#8217; future efforts and achievements of specified development, regulatory and/or commercial events. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:11pt 0pt 11pt 0pt;"><i style="font-style:italic;">Global Exclusive License Agreement with Lilly </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:11pt 0pt 11pt 0pt;">We have a global exclusive license agreement and strategic collaboration with Lilly (Lilly Agreement) entered in February 2021, which became effective on March 27, 2021, upon clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, to develop and commercialize R552 for the treatment of non-CNS diseases. In addition, the collaboration is aimed at developing additional RIPK1 inhibitors for the treatment of CNS diseases. Pursuant to the terms of the license agreement, we granted to Lilly exclusive rights to develop and commercialize R552 and related RIPK1 inhibitors in all indications worldwide. The parties&#8217; collaboration is governed through a joint governance committee and appropriate subcommittees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:11pt 0pt 0pt 0pt;">Under the terms of the Lilly Agreement, we were entitled to receive a non-refundable and non-creditable upfront cash payment amounting to $<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2021_To_4_30_2021_JKmOcc6NLUygXEbnIz_jXg" decimals="-5" format="ixt:numdotdecimal" name="rigl:CollaborativeArrangementUpfrontFeeReceived" scale="6" id="Narr_d-wkqLHIAE2Y6H7Bb86TJA">125.0</ix:nonFraction> million, which we received in April 2021. We are also entitled to additional milestone payments for non-CNS disease products consisting of up to $<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_rigl_AchievementOfMilestoneAxis_rigl_DevelopmentAndRegulatoryMilestonesByNonCentralNervousSystemDiseaseProductsMember_qhsapuJyEU-hSuSu6wuzRA" decimals="-5" format="ixt:numdotdecimal" name="rigl:ContingentPaymentsUnderAgreement" scale="6" id="Narr__QJ209mIBEmWLEHGhhJwFg">330.0</ix:nonFraction> million in milestone payments upon the achievement of specified development, regulatory and commercial milestones, and up to $<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_rigl_AchievementOfMilestoneAxis_rigl_DevelopmentAndRegulatoryMilestonesByNonCentralNervousSystemDiseaseProductsMember_srt_StatementScenarioAxis_rigl_MilestonePaymentsOnProductByProductBasisMember_437LgKAaEUCSP1qghK8PUg" decimals="-5" format="ixt:numdotdecimal" name="rigl:ContingentPaymentsUnderAgreement" scale="6" id="Narr_m92PYVZ7pUiav8fjdO__Gw">100.0</ix:nonFraction> million in sales milestone payments on a product-by-product basis. In addition, depending on the extent of our co-funding of R552 development activities, we would be entitled to receive tiered royalty payments on net sales of non-CNS disease products at percentages ranging from the mid-single digits to high-teens, subject to certain standard reductions and offsets. We are also eligible to receive milestone payments for CNS disease products consisting of up to $<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_rigl_AchievementOfMilestoneAxis_rigl_DevelopmentAndRegulatoryMilestonesByCentralNervousSystemDiseaseProductsMember_Rs41QnjvWk6gGclD-ADolA" decimals="-5" format="ixt:numdotdecimal" name="rigl:ContingentPaymentsUnderAgreement" scale="6" id="Narr_24MlmSH6PE6U0hqNE7-LZA">255.0</ix:nonFraction> million in milestone payments upon the achievement of specified development, regulatory and commercial milestones, and up to $<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_rigl_AchievementOfMilestoneAxis_rigl_DevelopmentAndRegulatoryMilestonesByCentralNervousSystemDiseaseProductsMember_srt_StatementScenarioAxis_rigl_MilestonePaymentsOnProductByProductBasisMember_GdhaCtbSb0a6DDLJ7JX1QA" decimals="-5" format="ixt:numdotdecimal" name="rigl:ContingentPaymentsUnderAgreement" scale="6" id="Narr_6HiKX46zikmC60s8YolK2g">150.0</ix:nonFraction> million in sales milestone payments on a product-by-product basis. We would be entitled to receive tiered royalty </p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk85058675"></a><a id="_Hlk85468656"></a><ix:continuation id="Tb_mwKcNqqDbE--8uXFTO1p2Q_cont1" continuedAt="Tb_mwKcNqqDbE--8uXFTO1p2Q_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;">payments on net sales of CNS disease products up to low-double digits, subject to certain standard reductions and offsets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:11pt 0pt 11pt 0pt;">We are responsible for performing and funding initial discovery and identification of CNS disease development candidates. Following candidate selection, Lilly will be responsible for performing and funding all future development and commercialization of the CNS disease development candidates. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:11pt 0pt 11pt 0pt;">Under the Lilly Agreement, we are responsible for <ix:nonFraction unitRef="Unit_Standard_pure_uVIKS5OYQEes3pxG5CV0tw" contextRef="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_R552Member_-FMAVRdgk0G_DrmYiygA5g" decimals="2" format="ixt:numdotdecimal" name="rigl:DevelopmentCostsCostSharingArrangementPercentage" scale="-2" id="Narr_SI1I3OTjY064BjRsI9tDuw">20</ix:nonFraction>% of development costs for R552 in the US, Europe, and Japan, up to a specified cap, and Lilly is responsible for funding the remainder of all development activities for R552 and other non-CNS disease development candidates. Pursuant to the terms of the Lilly Agreement, we have the right to opt-out of co-funding the R552 development activities at <ix:nonFraction unitRef="Unit_Standard_period_q1X9Nu1d1EeTbsf56ZdECg" contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" decimals="INF" format="ixt-sec:numwordsen" name="rigl:RightToOptOutOfAgreementNumberOfPeriods" scale="0" id="Narr_iyj81Ur7DkOswan_iaZGGw">two</ix:nonFraction> different specified times. If we exercise our first opt-out right (no later than September 30, 2023), we are required to fund our share of the R552 development activities up to a maximum funding commitment of $<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_srt_ProductOrServiceAxis_rigl_R552Member_srt_RangeAxis_srt_MaximumMember_nQDkYFvGfkGeTW-8GkyDkg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherCommitment" scale="6" id="Narr_dsgSkKrqsU2glebNwxSYkw">65.0</ix:nonFraction> million through April 1, 2024. If we decide not to exercise our opt-out rights, we will be required to share in global development costs of up to certain amounts at a specified cap, as provided for in the Lilly Agreement. Given our rights to opt-out from the development of R552, we believe at the minimum, we have a commitment to fund the development costs up to $<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_srt_ProductOrServiceAxis_rigl_R552Member_srt_RangeAxis_srt_MaximumMember_nQDkYFvGfkGeTW-8GkyDkg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherCommitment" scale="6" id="Narr_bKHwbWNhPkqXdS-HczVwEA">65.0</ix:nonFraction> million as discussed above. We considered this commitment to fund the development costs as a significant financing component of the contract, which we accounted for as a reduction of the upfront fee to derive the transaction price. This financing component was recorded as a liability at its net present value of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_srt_ProductOrServiceAxis_rigl_R552Member_JPs0ePqXlEKj9VOt8HSlUw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProductLiabilityAccrualComponentAmount" scale="6" id="Narr_GcibVPWKMk6J9l2rAlH-6w">57.9</ix:nonFraction> million using a <ix:nonFraction unitRef="Unit_Standard_pure_uVIKS5OYQEes3pxG5CV0tw" contextRef="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_R552Member_-FMAVRdgk0G_DrmYiygA5g" decimals="3" format="ixt:numdotdecimal" name="rigl:FinancingLiabilityInterestAccretionDiscountRate" scale="-2" id="Narr_CQ8_T2abwEC3EE2sTegktQ">6.4</ix:nonFraction>% discount rate. Interest expense is accreted on such liability over the expected commitment period, adjusted for timing of expected cost share payments. <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_R552Member_nAWV78-1SEKxOb73Me78JA" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:AccretionExpense" scale="6" id="Narr_GvJJvk3ml0ytWZYEyFD3_A">No</ix:nonFraction> interest was accreted during the six months ended June 30, 2023, and $<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_rigl_R552Member_6cuFgoRx00e-zcShKPySYQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccretionExpense" scale="6" id="Narr_UjbUjA-UqEqydrQRXjQrZQ">0.7</ix:nonFraction> million of interest was accreted during the six months ended June 30, 2022. Through June 30, 2023, Lilly billed us $<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_srt_ProductOrServiceAxis_rigl_R552Member_JPs0ePqXlEKj9VOt8HSlUw" decimals="-5" format="ixt:numdotdecimal" name="rigl:DueToCollaborationPartner" scale="6" id="Narr_EgMX7bwExECdyJr82cbrug">16.9</ix:nonFraction> million for our share of development costs under this agreement, and the amount was fully paid as of June 30, 2023. As of June 30, 2023 and December 31, 2022, the outstanding financing liability to Lilly was $<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_srt_ProductOrServiceAxis_rigl_R552Member_JPs0ePqXlEKj9VOt8HSlUw" decimals="-5" format="ixt:numdotdecimal" name="rigl:FinancingLiabilityIncludingInterestExpenseAccretion" scale="6" id="Narr_IOlXAKGPSEeuoeRgmXjzzg">44.5</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_srt_ProductOrServiceAxis_rigl_R552Member_0YBAFpZ08UOLKeVes5ohFA" decimals="-5" format="ixt:numdotdecimal" name="rigl:FinancingLiabilityIncludingInterestExpenseAccretion" scale="6" id="Narr_gSwJMmKY10-DtnPNokLsuQ">46.2</ix:nonFraction> million, respectively, and included within other long-term liabilities, current portion, and other long-term liabilities in the condensed balance sheet.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:11pt 0pt 11pt 0pt;">We accounted for this agreement under ASC 606 and identified the following distinct performance obligations at inception of the agreement: (a) granting of the license rights over the non-CNS penetrant intellectual property (IP), and (b) granting of the license rights over the CNS penetrant IP which will be delivered to Lilly upon completion of the additional research and development efforts specified in the agreement. We concluded each of these performance obligations is distinct. We based our assessment on the assumption that Lilly can benefit from each of the licenses on its own by developing and commercializing the underlying product using its own resources. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:11pt 0pt 11pt 0pt;">We allocated the net transaction price of $<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_srt_ProductOrServiceAxis_rigl_R552Member_JPs0ePqXlEKj9VOt8HSlUw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="Narr_oXjlq_qIl0G-cifjePpbQQ">67.1</ix:nonFraction>&#160;million to each performance obligation based on our best estimate of its relative standalone selling price using the adjusted market assessment approach. The transaction price allocated to the non-CNS penetrant IP of $<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2021_To_3_31_2021_srt_ProductOrServiceAxis_rigl_NonCentralNervousSystemPenetrantIntellectualPropertyMember_AzcLeTjz60Ckk-4IZ7Z2Yg" decimals="-5" format="ixt:numdotdecimal" name="rigl:CollaborativeArrangementRevenueRecognized" scale="6" id="Narr_b8QlRQ-lzkGGiKmmlOexog">60.4</ix:nonFraction> million was recognized as revenue upon delivery of the non-CNS penetrant IP to Lilly during the first quarter of 2021. The transaction price allocated to the CNS penetrant IP of $<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2022_rigl_AchievementOfMilestoneAxis_rigl_LicensedRightsMember_srt_ProductOrServiceAxis_rigl_CentralNervousSystemPenetrantIntellectualPropertyMember_nqY09VTQhkCP6kuB8E26vw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="Narr_smwZ9pcVCECmY0IxNDUy6Q">6.7</ix:nonFraction> million was recognized as revenue from the effective date of the Lilly Agreement through the eventual acceptance by Lilly using the input method, since we were required to perform additional research and development efforts before the final acceptance of the license by Lilly. In June 2022, Lilly provided notice of continuance pursuant to the terms of the Lilly Agreement, whereby Lilly elected its option to lead the identification and selection of CNS penetrant lead candidate. As such, we recognized the remaining outstanding deferred revenue in the second quarter of 2022. For the three and six months ended June 30, 2022, we recognized $<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_rigl_CentralNervousSystemPenetrantIntellectualPropertyMember_D23iXamso06lFysd2JS4lQ" decimals="-5" format="ixt:numdotdecimal" name="rigl:CollaborativeArrangementRevenueRecognized" scale="6" id="Narr_Tf3oXg68bUCwgEDw9KVTtg">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_rigl_CentralNervousSystemPenetrantIntellectualPropertyMember_sJI61AX-gkq7zwYyHj0Hgw" decimals="-5" format="ixt:numdotdecimal" name="rigl:CollaborativeArrangementRevenueRecognized" scale="6" id="Narr_w-qL1kpDBUaCqUoJqdiAyw">0.5</ix:nonFraction> million, respectively, of revenue associated with the delivery of CNS penetrant IP. <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_CentralNervousSystemPenetrantIntellectualPropertyMember_abvwS7ZRYkCRPqpRi8kUzA" decimals="-5" format="ixt-sec:numwordsen" name="rigl:CollaborativeArrangementRevenueRecognized" scale="6" id="Narr_kgUDVvjOfUuK0tWjmUWfLQ"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_CentralNervousSystemPenetrantIntellectualPropertyMember_u9CM64l4x06mzHqJqirPew" decimals="-5" format="ixt-sec:numwordsen" name="rigl:CollaborativeArrangementRevenueRecognized" scale="6" id="Narr_Tq_70k18wUyp_Rao7H5Q9g">No</ix:nonFraction></ix:nonFraction><span style="white-space:pre-wrap;"> such revenue was recognized in the three and six months ended June 30, 2023.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The remaining future variable consideration related to future milestone payments as discussed above were fully constrained because we cannot conclude that it is probable that a significant reversal of the amount of cumulative revenue recognized will not occur, given the inherent uncertainty of success with these future milestones. For sales-based milestones and royalties, we determined that the license is the predominant item to which the royalties or sales-based milestones relate. Accordingly, we will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). We will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur. </p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk6831824"></a><a id="_Hlk117064427"></a><ix:continuation id="Tb_mwKcNqqDbE--8uXFTO1p2Q_cont2" continuedAt="Tb_mwKcNqqDbE--8uXFTO1p2Q_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">Grifols License Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">We have an exclusive commercialization license agreement with Grifols entered in January 2019 with exclusive rights to commercialize fostamatinib for human diseases, including chronic ITP and AIHA, and non-exclusive rights to develop fostamatinib in Grifols territory. Under the agreement, we received an upfront payment of $<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2019_To_1_31_2019_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_-3boqmgcW0u1hhv3nltpLw" decimals="-5" format="ixt:numdotdecimal" name="rigl:CollaborativeArrangementUpfrontFeeReceived" scale="6" id="Narr_wDJgIk60K0K2Id1CZh43vQ">30.0</ix:nonFraction> million, with the potential for $<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2019_To_1_31_2019_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_rigl_AchievementOfMilestoneAxis_rigl_SpecifiedCommercialMilestonesMember_7nbfSECgx0WYA153JYabJQ" decimals="-5" format="ixt:numdotdecimal" name="rigl:ContingentPaymentsUnderAgreement" scale="6" id="Narr_HN8ahXxMdkmsOsYGgt6S2A">297.5</ix:nonFraction> million in total regulatory and commercial milestones. We are also entitled to receive stepped double-digit royalty payments based on tiered net sales which may reach <ix:nonFraction unitRef="Unit_Standard_pure_uVIKS5OYQEes3pxG5CV0tw" contextRef="Duration_1_1_2019_To_1_31_2019_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_srt_RangeAxis_srt_MaximumMember_G1KtN3XbpUSoL3F_Q5ONNQ" decimals="2" format="ixt:numdotdecimal" name="rigl:RoyaltyPaymentAsPercentageOfNetSales" scale="-2" id="Narr_RwPNXF6SfkWDr3E-C0oOVg">30</ix:nonFraction>% of net sales. The agreement also required us to continue to conduct our long-term open-label extension study on patients with ITP through European Medicines Agency (EMA) approval of ITP in Europe or until the study ends as well as conduct the Phase 3 trial of fostamatinib in AIHA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">In January 2020, the European Commission (EC) granted a centralized Marketing Authorization (MA) for fostamatinib valid throughout the European Union (EU) and in the UK after the departure of the UK from the EU for the treatment of chronic ITP in adult patients who are refractory to other treatments. With this approval, in February 2020, we received $<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_2_1_2020_To_2_29_2020_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember__7PyRX4jPECYeFKd4E3SHA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromCollaborators" scale="6" id="Narr_MnBXoBkwsUaStKIwKYa5RQ">20.0</ix:nonFraction> million non-refundable payment, composed of a $<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_2_1_2020_To_2_29_2020_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_rigl_AchievementOfMilestoneAxis_rigl_EuropeanMedicinesAgencyApprovalOfFostamatinibForTreatmentOfChronicImmuneThrombocytopenicPurpuraMember_srt_ProductOrServiceAxis_rigl_FostamatinibMember_jRYJphbQ30m9xYIoKA1dgg" decimals="-5" format="ixt:numdotdecimal" name="rigl:ContingentPaymentsUnderAgreement" scale="6" id="Narr_7yLv47rSmki0o_pXrXvHhg">17.5</ix:nonFraction> million payment due upon Marketing Authorization Application (MAA) approval by the EMA of fostamatinib for the first indication and a $<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_2_1_2020_To_2_29_2020_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_rigl_AchievementOfMilestoneAxis_rigl_CreditableAdvanceRoyaltyPaymentMember_srt_ProductOrServiceAxis_rigl_FostamatinibMember_aO7fdyjeKkKh-8rHnFGcDQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromCollaborators" scale="6" id="Narr_pmwUCupaS0OmiaDL9pMq2A">2.5</ix:nonFraction>&#160;million creditable advance royalty payment, based on the terms of our collaboration agreement with Grifols. The above milestone payment was allocated to the distinct performance obligations in the collaboration agreement with Grifols. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We accounted for this agreement under ASC 606 and identified the following distinct performance obligations at inception of the agreement: (a) granting of the license, (b) performance of research and regulatory services related to our long-term open-label extension study on patients with ITP, and (c) performance of research services related to our Phase 3 study in AIHA. We allocated the transaction price to the distinct performance obligations in our collaboration agreement based on our best estimate of the relative standalone selling price, and recognized the corresponding revenue in the periods we satisfied the performance obligations. During the three and six months ended June 30, 2022, we recognized $<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2022_To_6_30_2022_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_rigl_AchievementOfMilestoneAxis_rigl_ResearchActivitiesMember_bcLtqW_sUUGWAZXyYhABiQ" decimals="-5" format="ixt:numdotdecimal" name="rigl:CollaborativeArrangementRevenueRecognized" scale="6" id="Narr_w1bMb0t9L0m8vn7sbNTpag">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_rigl_AchievementOfMilestoneAxis_rigl_ResearchActivitiesMember_15-zZAIzYESjPJ56lMgsMg" decimals="-5" format="ixt:numdotdecimal" name="rigl:CollaborativeArrangementRevenueRecognized" scale="6" id="Narr_9M_a7xw-Vk2eewExRJiOQg">0.5</ix:nonFraction> million, respectively, of revenue associated with the remaining performance obligation to perform research services. <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_rigl_AchievementOfMilestoneAxis_rigl_ResearchActivitiesMember_86cJ5cqEH0CUdyuPMTHCqg" decimals="-5" format="ixt-sec:numwordsen" name="rigl:CollaborativeArrangementRevenueRecognized" scale="6" id="Narr_omG0Z8X4W0WWat93xquwbg"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_rigl_AchievementOfMilestoneAxis_rigl_ResearchActivitiesMember_wKD8r5wj8UWbEX-iqfwrAA" decimals="-5" format="ixt-sec:numwordsen" name="rigl:CollaborativeArrangementRevenueRecognized" scale="6" id="Narr_H7qsUMZheUeXuEV21WW8uA">No</ix:nonFraction></ix:nonFraction> such revenue was recognized during the three and six months ended June 30, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The remaining variable consideration related to future regulatory and commercial milestones were fully constrained because we cannot conclude that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur, given the inherent uncertainty of success with these future milestones. We are recognizing revenues related to the research and regulatory services throughout the term of the respective clinical programs using the input method. For sales-based milestones and royalties, we determined that the license is the predominant item to which the royalties or sales-based milestones relate. Accordingly, we will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). We will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We entered into a Commercial Supply Agreement with Grifols in October 2020 to supply and sell our drug product priced at a certain markup specified in the agreement, in quantities Grifols order from us pursuant to and in accordance with the agreement. Prior to the Commercial Supply Agreement, we had a Drug Product Purchase Agreement with Grifols entered in December 2019. During the three and six months ended June 30, 2023, we recognized $<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_rigl_AchievementOfMilestoneAxis_rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember_ahEiLx0SUk2_jcyttC4ctw" decimals="-5" format="ixt:numdotdecimal" name="rigl:CollaborativeArrangementRevenueRecognized" scale="6" id="Narr_-8sBLSHf302eXWpdwhglnA">1.2</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_rigl_AchievementOfMilestoneAxis_rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember_6EJQsZyI7Ei65WKe6vURdw" decimals="-5" format="ixt:numdotdecimal" name="rigl:CollaborativeArrangementRevenueRecognized" scale="6" id="Narr_Fz3-xEP0w0e2qL3bB55rmQ">2.8</ix:nonFraction> million, respectively, of revenue related to delivery of drug supply to Grifols. D<span style="background:#ffffff;">uring the three and six months ended June 30, 2022, we recognized </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_rigl_AchievementOfMilestoneAxis_rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember_2kS72QqQ3EiGnNpkGNQiwg" decimals="-5" format="ixt:numdotdecimal" name="rigl:CollaborativeArrangementRevenueRecognized" scale="6" id="Narr_6HKPfCKnlEi2b58jlz5ezA"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2022_To_6_30_2022_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_rigl_AchievementOfMilestoneAxis_rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember__2GzLf2h9Uy8zugKcIpR5Q" decimals="-5" format="ixt:numdotdecimal" name="rigl:CollaborativeArrangementRevenueRecognized" scale="6" id="Narr_odjvuafwl0a-Dta2HjPyvA">1.2</ix:nonFraction></ix:nonFraction></span><span style="background:#ffffff;">&#160;million of revenue </span>related to delivery of drug supply to Grifols<span style="background:#ffffff;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">We began recognizing royalty revenue from Grifols beginning in the third quarter of 2022. For the three and six months ended June 30, 2023, we recognized </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_YoqQXBJjBkuRMnl_Is2ryA" decimals="-5" format="ixt:numdotdecimal" name="rigl:CollaborativeArrangementRevenueRecognized" scale="6" id="Narr_yN4Y1B9aCk6ATfyTkVrYHg">0.8</ix:nonFraction></span><span style="background:#ffffff;">&#160;million and </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_BiD0k0-zyUKpI2kOTEgwHQ" decimals="-5" format="ixt:numdotdecimal" name="rigl:CollaborativeArrangementRevenueRecognized" scale="6" id="Narr_hY-njWu4ZUeM4Q9DYeWP7Q">1.5</ix:nonFraction></span><span style="background:#ffffff;"> million, respectively, of royalty revenue from Grifols, and such amount was included within contract revenues from collaboration.&#160;</span><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_8nDIYOyABEq7e05lMjmqPw" decimals="-5" format="ixt-sec:numwordsen" name="rigl:CollaborativeArrangementRevenueRecognized" scale="6" id="Narr_X48FQI2Y8Emryy1PwGQYNg"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2022_To_6_30_2022_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_UY3l2klaxkutbshAAhD9Eg" decimals="-5" format="ixt-sec:numwordsen" name="rigl:CollaborativeArrangementRevenueRecognized" scale="6" id="Narr_TPLTcfFZxUmUKhu7bE9wzw">No</ix:nonFraction></ix:nonFraction><span style="background:#ffffff;">&#160;such revenue was recognized for the three and six months ended June 30, 2022.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk1408655"></a><a id="_7b88d4a2_72bf_4bcd_9b77_81890ea0d572"></a><a id="_7b88d4a2_72bf_4bcd_9b77_81890ea0d572_2"></a><a id="_7b88d4a2_72bf_4bcd_9b77_81890ea0d572_3"></a><ix:continuation id="Tb_mwKcNqqDbE--8uXFTO1p2Q_cont3" continuedAt="Tb_mwKcNqqDbE--8uXFTO1p2Q_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">Kissei License Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We have an exclusive license and supply agreement with Kissei entered in October 2018, to develop and commercialize fostamatinib in all current and potential indications in Kissei&#8217;s territory. Kissei is responsible for performing and funding all development activities for fostamatinib in the above-mentioned territories. We received an upfront cash payment of $<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_10_1_2018_To_10_31_2018_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_PZS9u-OE1EmIeqOd2HsFnw" decimals="-5" format="ixt:numdotdecimal" name="rigl:CollaborativeArrangementUpfrontFeeReceived" scale="6" id="Narr_5HG7r7eQEkq68SUEqqu1_Q">33.0</ix:nonFraction>&#160;million, with the potential for up to an additional $<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_10_1_2018_To_10_31_2018_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_PZS9u-OE1EmIeqOd2HsFnw" decimals="-5" format="ixt:numdotdecimal" name="rigl:ContingentPaymentsUnderAgreement" scale="6" id="Narr_u5yfHHgeJU2ab_TaBanMwg">147.0</ix:nonFraction>&#160;million <span style="white-space:pre-wrap;">in development, regulatory and commercial milestone payments, and will receive mid- to upper twenty percent, tiered, escalated net sales-based payments for the supply of fostamatinib. Under the agreement, we granted Kissei the license rights to fostamatinib in Kissei&#8217;s territory and are obligated to supply Kissei with drug product for use in clinical trials and pre-commercialization activities. We are also responsible for the manufacture and supply of fostamatinib for all future development and commercialization activities under the agreement.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;">We accounted for this agreement under ASC 606 and identified the following distinct performance obligations at inception of the agreement: (a) granting of the license, (b) supply of fostamatinib for clinical use and (c) material right associated with discounted fostamatinib that is supplied for use other than clinical or commercial. In addition, we will provide commercial product supply if the product is approved in the licensed territory. We concluded that each of these performance obligations is distinct. We determined that the upfront fee of $<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_VOQGD0Imek29F_UrLGFn-w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="Narr_iZU-IoiZwEW5-aje3QTGWA">33.0</ix:nonFraction>&#160;million represented the transaction price and was allocated to the performance obligations based on our best estimate of the relative standalone selling price and recognized the corresponding revenue in the period we satisfied the performance obligations. As of June 30, 2023 and December 31, 2022, the remaining deferred revenue was related to the material right associated with discounted fostamatinib supply which amounted to $<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_dWMxniyFJ06ygU7yM53x1w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenue" scale="6" id="Narr__RjNdbAtEUKwAfKu7VPvvw"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_p5hH6L8EpUKDvP9iizwvIA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenue" scale="6" id="Narr_SL5H_kU94EmjbGnC7q--yQ">1.4</ix:nonFraction></ix:nonFraction>&#160;million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;">For the three and six months ended June 30, 2022, we recognized $<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2022_To_6_30_2022_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_rigl_AchievementOfMilestoneAxis_rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember_srt_ProductOrServiceAxis_rigl_FostamatinibMember_X1jrjFNaUUi-0RSb2kWr2A" decimals="-5" format="ixt:numdotdecimal" name="rigl:CollaborativeArrangementRevenueRecognized" scale="6" id="Narr_dFs4JkyaHEynUJUGuDqGGg">2.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_rigl_AchievementOfMilestoneAxis_rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember_srt_ProductOrServiceAxis_rigl_FostamatinibMember_ijWIH4IdnkaOE9hajv0lhw" decimals="-5" format="ixt:numdotdecimal" name="rigl:CollaborativeArrangementRevenueRecognized" scale="6" id="Narr_VfXkfGQd_USZjaKb58IQYw">2.6</ix:nonFraction>&#160;million, respectively, of revenue related to the delivery of fostamatinib supply to Kissei mainly for commercial use.&#160;<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_rigl_AchievementOfMilestoneAxis_rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember_srt_ProductOrServiceAxis_rigl_FostamatinibMember_knn1moXg0kCR1PGoGmvEkA" decimals="-5" format="ixt-sec:numwordsen" name="rigl:CollaborativeArrangementRevenueRecognized" scale="6" id="Narr_YWeps4QBgUWeRg_MnUXghQ"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_rigl_AchievementOfMilestoneAxis_rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember_srt_ProductOrServiceAxis_rigl_FostamatinibMember_iOGTC4JHqEqAcLNDtBnr0Q" decimals="-5" format="ixt-sec:numwordsen" name="rigl:CollaborativeArrangementRevenueRecognized" scale="6" id="Narr_eFJ63gdgXEySWrp-1ppuLg">No</ix:nonFraction></ix:nonFraction>&#160;such revenue was recognized during the three and six months ended June 30, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;">In April 2022, Kissei announced that an NDA was submitted to Japan&#8217;s Pharmaceuticals and Medical Devices Agency (PMDA) for fostamatinib in chronic ITP. With this milestone event, we received&#160;</span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_VJof-y5NIUmbhtjjV8-ZnQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromCollaborators" scale="6" id="Narr_bysHMpiptE2zu-7xYLJppQ"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2022_To_6_30_2022_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_AqH_Lz4Dqk2ULht1ffcBfQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromCollaborators" scale="6" id="Narr_-DWLvX7ANkyp3X0ZdRBg0Q">5.0</ix:nonFraction></ix:nonFraction></span><span style="font-size:10pt;">&#160;million non-refundable and non-creditable payment from Kissei pursuant to the terms of our collaboration agreement, and such amount was recognized as revenue in the three and six months ended </span><span style="font-size:10pt;">June 30, 2022</span><span style="font-size:10pt;">. In December 2022, Kissei announced that Japan&#8217;s PMDA approved the NDA for fostamatinib in chronic ITP. With this milestone event, we were entitled to receive </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_p5hH6L8EpUKDvP9iizwvIA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="Narr_qXdMXMRrOkmLdcUmLTIlaw">20.0</ix:nonFraction></span><span style="font-size:10pt;"> million non-refundable and non-creditable payment from Kissei pursuant to the terms of our collaboration agreement, which we recognized as revenue in the fourth quarter of </span><span style="-sec-ix-hidden:Hidden_sIEQoBwV_0WCfNDnOrc4Wg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2022</span></span><span style="font-size:10pt;white-space:pre-wrap;">. The amount was subsequently collected in January 2023.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The remaining variable consideration related to future development and regulatory milestones was fully constrained because we cannot conclude that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur, given the inherent uncertainty of success with these future milestones. For sales-based milestones and tiered, escalated net sales-based payments for the supply of fostamatinib, we determined that the license is the predominant item to which the sales-based milestones relate to. Accordingly, we will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the allocated costs for the tiered, escalated net sales-based payments has been satisfied (or partially satisfied). We will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 0pt 0pt;"><i style="font-style:italic;">Medison Commercial and License Agreements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 0pt 0pt;">We have <ix:nonFraction unitRef="Unit_Standard_agreement_KRHA7hMTtE2mxosuhHYaSA" contextRef="Duration_10_1_2019_To_10_31_2019_dei_LegalEntityAxis_rigl_MedisonPharmaLtd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_us-gaap_TypeOfArrangementAxis_rigl_CommercialAndLicenseAgreementMember_zpx7xwCeskCPVInu1YwLlw" decimals="INF" format="ixt-sec:numwordsen" name="rigl:NumberOfAgreements" scale="0" id="Narr_GBzC1MwiJk-rFrDdk0vQgw">two</ix:nonFraction> exclusive commercial and license agreements with Medison entered in October 2019 for the commercialization of fostamatinib for chronic ITP in Medison territory, pursuant to which, we received a $<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_10_1_2019_To_10_31_2019_dei_LegalEntityAxis_rigl_MedisonPharmaLtd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_us-gaap_TypeOfArrangementAxis_rigl_CommercialAndLicenseAgreementMember_zpx7xwCeskCPVInu1YwLlw" decimals="-5" format="ixt:numdotdecimal" name="rigl:CollaborativeArrangementUpfrontFeeReceived" scale="6" id="Narr_R2QH3LniM0u0t7ZYYeOD7A">5.0</ix:nonFraction> million upfront payment with respect to the agreement in Canada. We accounted for this agreement under ASC 606 and identified the following combined performance obligations at inception of the agreement: (a) granting of the license and (b) obtaining regulatory approval in Canada of fostamatinib in ITP. We determined that the non-refundable upfront fee of $<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_10_1_2019_To_10_31_2019_dei_LegalEntityAxis_rigl_MedisonPharmaLtd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ProductFinancingArrangementMember_RZVg4VgmR0iEhiVJHe0OGA" decimals="-5" format="ixt:numdotdecimal" name="rigl:CollaborativeArrangementUpfrontFeeReceived" scale="6" id="Narr_R7yatImc9ki-d5B-vAm3NA">5.0</ix:nonFraction>&#160;million represented the transaction price. However, under the agreement, we have the option to buy back all rights to the product in Canada within six months from obtaining regulatory approval for the treatment of AIHA in Canada. The buyback option precludes us from transferring control of the license to Medison under ASC 606. We believed that the buyback provision, if exercised, will require us to repurchase the license at an amount equal to or more than the upfront $<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_10_1_2019_To_10_31_2019_dei_LegalEntityAxis_rigl_MedisonPharmaLtd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ProductFinancingArrangementMember_RZVg4VgmR0iEhiVJHe0OGA" decimals="-5" format="ixt:numdotdecimal" name="rigl:CollaborativeArrangementUpfrontFeeReceived" scale="6" id="Narr_3R45iy3Pv0GKUNCYp04wew">5.0</ix:nonFraction> million. As such, this arrangement was accounted for as a financing arrangement. Interest expense </p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk108704489"></a><a id="_Hlk140153230"></a><ix:continuation id="Tb_mwKcNqqDbE--8uXFTO1p2Q_cont4" continuedAt="Tb_mwKcNqqDbE--8uXFTO1p2Q_cont5"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">was accreted on such liability over the expected buyback period. We also billed Medison for the delivery of fostamatinib supplies for clinical use which we previously deferred and included within the outstanding financing liability considering the buy-back provision.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 0pt 0pt;">The decision to exercise the buyback option is dependent of many factors including management&#8217;s cost and benefit assessments and the success of obtaining regulatory approval for the treatment of AIHA in Canada. In June 2022, we reported the top-line results from our Phase 3 trial of fostamatinib in warm autoimmune hemolytic anemia (wAIHA) which showed that the trial did not demonstrate statistical significance in the primary efficacy endpoint in the overall study population. We also announced in early October 2022 that we will not file a supplemental new drug application (sNDA) for wAIHA indication considering the top-line data results and the guidance received from the FDA. With these developments, we assessed our options path forward, including our buyback option right with regards to the Medison license agreement. Based on management&#8217;s assessment, the likelihood of exercising the buy-back option right was remote. As such, during the fourth quarter of 2022, we relieved the outstanding financing liability to Medison amounting to $<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_10_1_2022_To_12_31_2022_dei_LegalEntityAxis_rigl_MedisonPharmaLtd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ProductFinancingArrangementMember_FDUx_RGlykuMMywGpuGo3Q" decimals="-5" format="ixt:numdotdecimal" name="rigl:CollaborativeArrangementRevenueRecognized" scale="6" id="Narr_XKPx11nCIUucDpxYIr3STQ">5.7</ix:nonFraction> million and recognized such amount as collaboration revenue in accordance with ASC 606. There was <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_dei_LegalEntityAxis_rigl_MedisonPharmaLtd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ProductFinancingArrangementMember_BIXtwMz280OZBubIreCp6g" decimals="-5" format="ixt-sec:numwordsen" name="rigl:FinancingLiabilityIncludingInterestExpenseAccretion" scale="6" id="Narr_D4joo6DXKEeVjHV_zzTTVg"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_rigl_MedisonPharmaLtd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ProductFinancingArrangementMember_10kT5pgvQESOoSV7Z9NRdg" decimals="-5" format="ixt-sec:numwordsen" name="rigl:FinancingLiabilityIncludingInterestExpenseAccretion" scale="6" id="Narr_E1Uk663YHUOQfsPHKWIh2w">no</ix:nonFraction></ix:nonFraction> outstanding financing liability to Medison as of June 30, 2023 and December 31, 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 0pt 0pt;"><i style="font-style:italic;">Knight Commercial License and Supply Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">We have a commercial license and supply agreements with Knight entered in May 2022 for the commercialization of fostamatinib for approved indications in Knight territory. Pursuant to such commercial license agreement, we received a $<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_KnightTherapeuticsInternationalSaMember_us-gaap_TypeOfArrangementAxis_rigl_CommercialAndLicenseAgreementMember_lvwZmBPza0monsr9dfDiMw" decimals="-5" format="ixt:numdotdecimal" name="rigl:CollaborativeArrangementUpfrontFeeReceived" scale="6" id="Narr_DvyYyQbpDk6CXP7tEQwMaw">2.0</ix:nonFraction> million one-time, non-refundable, and non-creditable upfront payment, with potential for up to an additional $<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_KnightTherapeuticsInternationalSaMember_rigl_AchievementOfMilestoneAxis_rigl_SpecifiedCommercialMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_rigl_CommercialAndLicenseAgreementMember_w0GRfq66bE20v4GiBSs-dQ" decimals="-5" format="ixt:numdotdecimal" name="rigl:ContingentPaymentsUnderAgreement" scale="6" id="Narr_ufyAh5fAA0GcBLjVHuHvZg">20.0</ix:nonFraction> million in regulatory and sales-based commercial milestone payments, and will receive twenty- to mid-thirty percent, tiered, escalated net-sales based royalty payments for products sold in the Knight territory. We accounted for this agreement under ASC 606 and identified that the upfront payment was a consideration for granting Knight the license to commercialize fostamatinib for approved indication in the Knight territory, and no further material deliverables associated to such upfront payment. As such, we recognized the upfront payment as revenue during the three and six months ended June 30, 2022. Variable consideration related to future regulatory milestones was fully constrained because we cannot conclude that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur, given the inherent uncertainty of success with these future milestones. For sales-based milestones and royalties, we determined that the license is the predominant item to which the royalties or sales-based milestones relate to. Accordingly, we will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all the royalty has been allocated has been satisfied (or partially satisfied). We will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur. We are also responsible for the exclusive manufacture and supply of fostamatinib for all future development and commercialization activities under agreement.&#160; </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Government Contract - US Department of Defense&#8217;s JPEO-CBRND </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">In January 2021, we were awarded up to $<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2021_To_1_31_2021_srt_ProductOrServiceAxis_rigl_FostamatinibMember_CbO6IlzEuE-DlB2_dwCYvQ" decimals="-5" format="ixt:numdotdecimal" name="rigl:GovernmentAward" scale="6" id="Narr_6twm79SEc0yEZjO2hKC7Qw">16.5</ix:nonFraction>&#160;million by the US Department of Defense to support our ongoing Phase 3 clinical trial to evaluate the safety and efficacy of fostamatinib for the treatment of hospitalized high-risk patients with COVID-19. The amount of award we will receive from the US Department of Defense is subject to submission of proper documentation as evidence of completion of certain clinical trial events or milestones as specified in the agreement, and approval by the US Department of Defense that such events or milestones have been met. We record government contract revenue in the statement of operations in the period when it is probable that we will receive the award, which is when we comply with the conditions associated with the award and obtain approval from the US Department of Defense that such conditions have been met. For the three and six months ended June 30, 2023, we recognized $<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_FostamatinibMember_FfcxPSwT3UW6Q9F1eb4nlg" decimals="-5" format="ixt:numdotdecimal" name="rigl:CollaborativeArrangementRevenueRecognized" scale="6" id="Narr_eIQpVfRPAkmlOXv-h0SkMQ"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_FostamatinibMember_lBFcNSb6mkeW8CR2ORtSjg" decimals="-5" format="ixt:numdotdecimal" name="rigl:CollaborativeArrangementRevenueRecognized" scale="6" id="Narr_cyLsPxcG8Ei477KZbQ1zlA">1.0</ix:nonFraction></ix:nonFraction> million of revenue related to this grant upon achievement of certain milestones. Through June 30, 2023, we received $<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2021_To_3_31_2023_srt_ProductOrServiceAxis_rigl_FostamatinibMember_khHoF3cNM0WfiX7y2atpOw" decimals="-5" format="ixt:numdotdecimal" name="rigl:CollaborativeArrangementRevenueRecognized" scale="6" id="Narr_gbRNBVk09Ua1oivH_KfkOQ">16.0</ix:nonFraction> million of the awards which we recognized as revenue in the respective periods, with remaining $<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_FostamatinibMember_FfcxPSwT3UW6Q9F1eb4nlg" decimals="-5" format="ixt:numdotdecimal" name="rigl:GovernmentAwardExpectedToBeReceivedInSucceedingPeriods" scale="6" id="Narr_a9hibl9lQEmxK87BHaiNYw">0.5</ix:nonFraction> million available, subject to us meeting certain milestone and approval by the US Department of Defense that such milestone has been met, as specified in the agreement.</p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk140154763"></a><ix:continuation id="Tb_mwKcNqqDbE--8uXFTO1p2Q_cont5" continuedAt="Tb_mwKcNqqDbE--8uXFTO1p2Q_cont6"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">License and Transition Services Agreement with Forma (now Novo Nordisk) </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We have a license and transition services agreement with Forma (now Novo Nordisk) entered in July 2022, for an exclusive license to develop, manufacture and commercialize olutasidenib, a proprietary inhibitor of mutated IDH1 (mIDH1), for any uses worldwide, including for the treatment of AML and other malignancies. Forma became a wholly owned subsidiary of Novo Nordisk following the closing of its acquisition by Novo Nordisk in October 2022. Pursuant to the terms of the license and transition services agreement, we paid an upfront fee of $<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_7_1_2022_To_7_27_2022_dei_LegalEntityAxis_rigl_FormaTherapeuticsHoldingsIncMember_bDfSL0BJhEWrP72tbRoIWQ" decimals="-5" format="ixt:numdotdecimal" name="rigl:CollaborativeArrangementUpfrontPayment" scale="6" id="Narr_6sWDPRuIxEeOHej3g4XpKw">2.0</ix:nonFraction> million, with the potential to pay up to $<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_7_1_2022_To_7_27_2022_dei_LegalEntityAxis_rigl_FormaTherapeuticsHoldingsIncMember_rigl_AchievementOfMilestoneAxis_rigl_DevelopmentAndRegulatoryMilestonesMember_7OkGU0Mcw06DYh7peGdg4g" decimals="-5" format="ixt:numdotdecimal" name="rigl:CollaborativeArrangementPotentialPayments" scale="6" id="Narr_3zHT-oDbOUanK2QjwthnLg">67.5</ix:nonFraction> million of additional payments upon achievement of specified development and regulatory milestones and up to $<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_7_1_2022_To_7_27_2022_dei_LegalEntityAxis_rigl_FormaTherapeuticsHoldingsIncMember_rigl_AchievementOfMilestoneAxis_rigl_SpecifiedCommercialMilestonesMember_puSiFDremkCXvb9X1_0EfA" decimals="-5" format="ixt:numdotdecimal" name="rigl:CollaborativeArrangementPotentialPayments" scale="6" id="Narr_l53LtWy6wUWhUjpb4j0tYQ">165.5</ix:nonFraction> million of additional payments upon achievement of certain commercial milestones. <span style="background:#ffffff;">In addition, subject to the terms and conditions of the license and transition services agreement, Forma (now Novo Nordisk) would be entitled to tiered royalty payments on net sales of licensed products at percentages ranging from low-teens to mid-thirties, as well as certain portion of our sublicensing revenue, subject to certain standard reductions and offsets.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">The transaction was accounted for as an acquisition of asset under ASC 730, <i style="font-style:italic;">Research and Development</i>. In accordance with the guidance, in a transaction accounted for as an asset acquisition, any acquired IPR&amp;D that does not have alternative future use is charged to expense at the acquisition date. <span style="background:#ffffff;">At the acquisition date, the acquired license asset was accounted for as IPR&amp;D, and we anticipated no other economic benefit to be derived from such acquired licensed asset other than the primary indications. As such, we accounted for the upfront fee of </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_7_1_2022_To_9_30_2022_dei_LegalEntityAxis_rigl_FormaTherapeuticsHoldingsIncMember_gN0UrgqHwke5fJiA75tT0w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="Narr_SwWrC6OqHEuq6SCY5MBFqw">2.0</ix:nonFraction></span><span style="background:#ffffff;"> million </span>as IPR&amp;D and recorded such cost within research and development expense in the condensed statements of operations in the third quarter of 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"><span style="font-size:10pt;">Under the accounting guidance, we account for contingent </span><span style="font-size:10pt;background:#ffffff;">cash payments when it is probable that a liability is incurred and the amount can be reasonably estimated.&#160;We account for m</span><span style="font-size:10pt;white-space:pre-wrap;">ilestone payment obligations incurred at development stage and prior to a regulatory approval of an indication associated with the acquired licensed asset as research and development expense when the event requiring payment of the milestone occurs. Milestone payment obligations incurred upon and after a regulatory approval of an indication associated with the acquired licensed asset, and at the commercial stage, are recorded as intangible asset when the event requiring payment of the milestones occurs. The amount recorded as intangible asset is amortized over the estimated useful life of the acquired licensed asset. Royalty payments related to the acquired licensed asset is recorded as cost of sales when incurred. Prior to the FDA approval of REZLIDHIA in December 2022, we achieved certain regulatory milestone which entitled Forma (now Novo Nordisk) to receive a  </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_10_1_2022_To_12_31_2022_dei_LegalEntityAxis_rigl_FormaTherapeuticsHoldingsIncMember_rigl_AchievementOfMilestoneAxis_rigl_AchievementOfCertainNearTermRegulatoryMilestoneMember_mYsvlxGBhUyABmwFOCLmig" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="Narr_eSBme8CXL0KF02X7t7f6OQ">2.5</ix:nonFraction></span><span style="font-size:10pt;"> million milestone payment. Because such milestone payment obligation was incurred prior to a regulatory approval of an indication associated with the acquired licensed asset, we recorded such amount as research and development expense in the fourth quarter of 2022. On December 1, 2022, the FDA approved REZLIDHIA capsules for the treatment of adult patients with R/R AML with susceptible IDH1 mutations as detected by an FDA-approved test. Following the FDA approval, we launched REZLIDHIA and made first shipments of the product to our customers in December 2022. With this FDA approval and first commercial sale of the product, Forma (now Novo Nordisk) was entitled to receive a total of </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_rigl_FormaTherapeuticsHoldingsIncMember_rigl_AchievementOfMilestoneAxis_rigl_FdaApprovalAndFirstCommercialSaleOfProductMember_srt_ProductOrServiceAxis_rigl_RezlidhiaMember_0GWFqUYggk2HSLP63Ny2Tg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" scale="6" id="Narr_7kd3kbkDg0aLYXe2PB1m1A">15.0</ix:nonFraction></span><span style="font-size:10pt;"> million milestone payments. Since such milestone payment obligations were incurred upon and after regulatory approval of the product, we recorded such amount as intangible asset on our condensed balance sheet in the fourth quarter of 2022. The </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_rigl_FormaTherapeuticsHoldingsIncMember_rigl_AchievementOfMilestoneAxis_rigl_FdaApprovalAndFirstCommercialSaleOfProductMember_srt_ProductOrServiceAxis_rigl_RezlidhiaMember_0GWFqUYggk2HSLP63Ny2Tg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="6" id="Narr_4ZD3qjMoSkeFqVGeAIXXnA">15.0</ix:nonFraction></span><span style="font-size:10pt;"> million milestone payment obligation was outstanding as of December 31, 2022 and included within accounts payable in our condensed balance sheet. Such amount was paid in the first quarter of </span><span style="-sec-ix-hidden:Hidden_Muf8QwRdCECWl-UXgvN83Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2023</span></span><span style="font-size:10pt;">. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">During the three and six months ended June 30, 2023, we recognized $<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_FormaTherapeuticsHoldingsIncMember_srt_ProductOrServiceAxis_rigl_RezlidhiaMember_Ggj-m6AMbkSlsqSSg-Oh4Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="Narr_ERCEMoftP0uDUdYcl0FjtQ">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_FormaTherapeuticsHoldingsIncMember_srt_ProductOrServiceAxis_rigl_RezlidhiaMember_u5JNB-NKCE6uQDuM-ogIPw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="Narr_rkpSfjvfXEypn5bC46CqKw">0.5</ix:nonFraction> million, respectively, of amortization of intangible asset, and $<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_FormaTherapeuticsHoldingsIncMember_srt_ProductOrServiceAxis_rigl_RezlidhiaMember_Ggj-m6AMbkSlsqSSg-Oh4Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RoyaltyExpense" scale="6" id="Narr_0UPns-sQQkmcMKBb-k0VqA">0.4</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_FormaTherapeuticsHoldingsIncMember_srt_ProductOrServiceAxis_rigl_RezlidhiaMember_u5JNB-NKCE6uQDuM-ogIPw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RoyaltyExpense" scale="6" id="Narr_vHSLLV37PE6VG5f9asMM7Q">0.6</ix:nonFraction> million, respectively, of royalty expense related to the license and transition services agreement as discussed above. Such costs were included within cost of sales in our condensed statements of operations. <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022_dei_LegalEntityAxis_rigl_FormaTherapeuticsHoldingsIncMember_srt_ProductOrServiceAxis_rigl_RezlidhiaMember_yxVUJk2G5k2qwTfZTVvH9Q" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:RoyaltyExpense" scale="6" id="Narr_UYedS4shxEeSVDgk_EX-fg"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2022_To_6_30_2022_dei_LegalEntityAxis_rigl_FormaTherapeuticsHoldingsIncMember_srt_ProductOrServiceAxis_rigl_RezlidhiaMember_holN4_ByhUmtcYY2H349MA" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:RoyaltyExpense" scale="6" id="Narr_ygWOwC7_hkyX6DM6pkQVsg">No</ix:nonFraction></ix:nonFraction> such expenses were recognized during the three and six months ended June 30, 2022. </p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_mwKcNqqDbE--8uXFTO1p2Q_cont6"></ix:continuation><a id="_33a71a7e_7449_444e_a361_7c0368a38251"></a><a id="Tc_N_QTjZcqEEmaD3HT7hMUCQ_1_2"></a><a id="Tc_ReQRa18zP0Ce1KC7fI3zhA_1_8"></a><a id="Tc_0HsDakEHyk-YoG8DHqKwlw_2_2"></a><a id="Tc_Ha1VrOO3Rky5YtfKPr3X_Q_2_5"></a><a id="Tc_qEuI2gRWrEuxoGmP34lFPQ_2_8"></a><a id="Tc_sWUT-A8cXEGRGTnMiN0b8Q_2_11"></a><a id="Tc_E7qtf5g0dEijWC2cTYBwrQ_3_0"></a><a id="Tc_havZcW8P6k2UavmDckqbBA_3_2"></a><a id="Tc_bhOFX1jN6U-1zAhy8LC6yg_3_5"></a><a id="Tc_xETLnUM9bEWXlOzvLUofFA_3_8"></a><a id="Tc_Fc4AhoQS_0GDFA9Eow0sGg_3_11"></a><a id="Tc_JjjmbsddA0mCqDZ85eEBjw_4_0"></a><a id="Tc_BjM1XvthdkyhWX18Rz_tew_5_0"></a><a id="Tc_QcUvaVC2lk6PuUz2NFYfeQ_5_2"></a><a id="Tc_0NGckXu_LEqvEQLq6bkAtw_5_5"></a><a id="Tc_iarcaQS0dEeu8X55WYjtIw_5_8"></a><a id="Tc_qqr8w4ERMUK57N5OqVRbFQ_5_11"></a><a id="_Hlk77201288"></a><a id="Tc_68auaatmH0CSYuph8klZPw_1_2"></a><a id="Tc_-AsrISFu1UG2A7e0suwAQw_1_7"></a><a id="Tc_SzReV4SdmUGabMPRVUnWyQ_2_2"></a><a id="Tc_0GE7iSRoX0Sfs6dMLOVjaA_2_4"></a><a id="Tc_mvJv-rl49UKbuNwnpCe1dQ_2_7"></a><a id="Tc_6LVZLmJ2I0iOFGXkLPDEvQ_2_9"></a><a id="Tc_9WW9Dg9j0E6mPK64t8WJig_3_0"></a><a id="Tc_gwVjwy39EEmGkCk3aGLZUg_3_3"></a><a id="Tc_GMout9VJVEGI9th5UBSDWQ_3_5"></a><a id="Tc_qLHsL6MRNk6WmtCFVgw4SA_3_8"></a><a id="Tc_tekUCso0ekO6gFwjKoTOmA_3_10"></a><a id="Tc_Jk4NGNzSl0aN-UnV9Tt3lA_4_0"></a><a id="Tc_CqWburImf0iy926T445dsg_5_0"></a><a id="Tc_3R_lHyk87kq2B3euRpwqXg_5_3"></a><a id="Tc_0KmEU4ofvECpAIBlttYkpg_5_5"></a><a id="Tc_Y2kdY0qsekauodWNK_maNw_5_8"></a><a id="Tc_6di5ZlRVDkKL-nxQ0fhz0Q_5_10"></a><a id="Tc_ixUdkeaUY0mchm5FlzeAHA_6_0"></a><a id="Tc_eDMbXStmoECurinkYayNAA_6_3"></a><a id="Tc_Ldr0pjm-P0e0HpadcXj4CA_6_5"></a><a id="Tc_vTkHjcabh0q1J0Y7d_YUXQ_6_8"></a><a id="Tc_s7u0UA-hnkujhTfBYfPGBw_6_10"></a><a id="_Hlk77202049"></a><a id="_Hlk77202164"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Tb_qs1905oiV0KYM8T6_7l9Ug" continuedAt="Tb_qs1905oiV0KYM8T6_7l9Ug_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-size:10pt;font-weight:bold;">5.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-size:10pt;font-weight:bold;">Stock-Based Compensation</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="Tb_Uz7CopETnEy3zbOL61-5xw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Stock-based compensation for the periods presented was as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:97.21%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:20.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Selling, general and administrative</p></td><td style="vertical-align:bottom;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_OA1zy6euuUWd92D01bHyQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_quaV6tQahEOQolC-XMXVoA_3_3">1,796</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_5BqaR0t6HUmn3zbRET6b7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_f-1qizkXQUq4_Ee9W3TkzA_3_6">1,933</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_YYP3i7dwZkyEj_jUho867Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_yKVHGUEwT06qgDzE8doFiA_3_9">3,531</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_qUKc9ZeBcEiFN-VeeuFO_A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_XDHFOjQYTUK1_mmhkfmt4Q_3_12">4,672</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:54.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_cNvDS3J20E2jpHrHJN-GXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_wLuwBeq5h0aSqrpltsV6ww_4_3">376</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_NPerFx0HTUiasJQZFwYc_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_tp9_q4RsikGwEhFogvo-Vw_4_6">458</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_9G6CsmCnIE25iWXSTMDwUA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_2i2geBANzE-NjVMLKx4W-g_4_9">1,399</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_WWdgQCoeWk-M5rmywXJFrQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_rKfuVDqSEUyaahpH1CUt3g_4_12">926</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:54.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total stock-based compensation expense</p></td><td style="vertical-align:bottom;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_kLi-FM2G10i2se46_eRPHQ_5_3">2,172</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2022_To_6_30_2022_ICCkO9pPUUSORAn1kecZBA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_iJX7a2mlLUa_qsxPrmuWcA_5_6">2,391</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_f0V8pwERjEa-JjeMG1FpYA_5_9">4,930</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_p4nX8VRvm0CDb8sJduks-Q_5_12">5,598</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Stock-based compensation expense within research and development in the six months ended June 30, 2023 include an incremental charge of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" scale="6" id="Narr_zQW5Lq5BAUOsDOVHHf6WFQ">0.5</ix:nonFraction> million from stock option modifications recorded in the first quarter of 2023 related to the acceleration of vesting and extension of exercise period of vested stock option grants made to a former officer whose employment ended in March 2023. Stock-based compensation expense within selling, general and administrative in the six months ended June 30, 2022 include an incremental charge of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" scale="6" id="Narr_DuyLc3qrvUy39c7fbgNgkA">0.8</ix:nonFraction> million from stock option modifications recorded in the first quarter of 2022 related to the extension of the exercise period of the stock option grants made to our two former Board of Directors whose terms expired in May 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">During the six months ended June 30, 2023, we granted stock options to purchase <ix:nonFraction unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nQp2Q6A6Z0qf5xAVDXOnBg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_iZn4aPEkLk2Z_ytZmirs0A">2,938,600</ix:nonFraction> shares of common stock with weighted-average grant-date fair value of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Xu_N--yaaU6K7FdyMhFNnQ" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nQp2Q6A6Z0qf5xAVDXOnBg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_TDFhJdrw8kqaXxp2ybERCA">1.37</ix:nonFraction> per share, and <ix:nonFraction unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nQp2Q6A6Z0qf5xAVDXOnBg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Narr_M8m6AX5grk2_lLzlcKBpqw">15,557</ix:nonFraction> stock options were exercised. As of June 30, 2023, there were <ix:nonFraction unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA" contextRef="As_Of_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_gbdA-1ad4EqysI7py3ChOA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Narr_y5FA5VBEjUiQY3CHR9jN-A">35,244,121</ix:nonFraction> stock options outstanding, of which, <ix:nonFraction unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA" contextRef="As_Of_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_bC736RZBjkmPBtBhrfONyg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Narr_fDiyPKM1Pku5h55qRCUIXw">2,870,000</ix:nonFraction> are outstanding performance-based stock options wherein the achievement of the corresponding corporate-based milestones were not considered probable as of June 30, 2023. Accordingly, none of the $<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_bC736RZBjkmPBtBhrfONyg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="Narr_ll_a7o2oSk-g3HQOo_RmgA">5.3</ix:nonFraction> million grant date fair value for these awards has been recognized as stock-based compensation expense as of June 30, 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">The fair value of each option award is estimated on the date of grant using the Black-Scholes option pricing model. The following table summarizes the weighted-average assumptions relating to options granted pursuant to our Equity Incentive Plans (2018 Equity Incentive Plan and Inducement Plan) for the periods presented:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nQp2Q6A6Z0qf5xAVDXOnBg" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_gedDdMDWw0mGaC1Q6GhRwg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:92.03%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td><td colspan="4" style="vertical-align:bottom;width:24.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_uVIKS5OYQEes3pxG5CV0tw" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_DF-ET0UVsU-4JFbzSJC6wg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_aiF38RB2fkS1K7uzANOJ3Q_3_2">3.7</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_uVIKS5OYQEes3pxG5CV0tw" contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_om_Pkmw3FEmnJzDD0iVbRQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_yPYjybR77021TdVBS56wGw_3_4">2.9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_uVIKS5OYQEes3pxG5CV0tw" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nQp2Q6A6Z0qf5xAVDXOnBg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_yO6WzP1Clk6xqDdxnI9Ntw_3_7">3.7</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_uVIKS5OYQEes3pxG5CV0tw" contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_tNXptyV-B0yupU7uhJiuDg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_cHGNjFUTOEq295RfS6en2w_3_9">1.9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:46.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_DF-ET0UVsU-4JFbzSJC6wg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_VD13a-DdM0-hzUNBeD0Bhg_4_2"><span style="font-size:10pt;">6.7</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_om_Pkmw3FEmnJzDD0iVbRQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_CsI-uHNPnU6k50rOcddtpQ_4_4"><span style="font-size:10pt;">6.5</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nQp2Q6A6Z0qf5xAVDXOnBg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_pD1rpoYf5ki-l0frwKhRtQ_4_7"><span style="font-size:10pt;">7.0</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_tNXptyV-B0yupU7uhJiuDg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc__9UQkd0veU6F-2LT4yCWQA_4_9"><span style="font-size:10pt;">6.5</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dividend yield</p></td><td style="vertical-align:bottom;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_uVIKS5OYQEes3pxG5CV0tw" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_DF-ET0UVsU-4JFbzSJC6wg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_mQ79O_KB70CJHEBsq5btSA_5_2">0.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_uVIKS5OYQEes3pxG5CV0tw" contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_om_Pkmw3FEmnJzDD0iVbRQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_CB4GlDkImEqBq3GrZNAW4g_5_4">0.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_uVIKS5OYQEes3pxG5CV0tw" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nQp2Q6A6Z0qf5xAVDXOnBg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_YM2S4OHXDEu8K7WqrZWblA_5_7">0.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_uVIKS5OYQEes3pxG5CV0tw" contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_tNXptyV-B0yupU7uhJiuDg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_eOsnog3gbkWRYi6OENosMw_5_9">0.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:46.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_uVIKS5OYQEes3pxG5CV0tw" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_DF-ET0UVsU-4JFbzSJC6wg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_4_avoptZYUuVKV4jHTwopg_6_2">86.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_uVIKS5OYQEes3pxG5CV0tw" contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_om_Pkmw3FEmnJzDD0iVbRQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_tFVH0f0UKUOVWPvAFddTTw_6_4">70.3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_uVIKS5OYQEes3pxG5CV0tw" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nQp2Q6A6Z0qf5xAVDXOnBg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_zUqrNfA9PEOAwOCDrK5hfw_6_7">83.1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_uVIKS5OYQEes3pxG5CV0tw" contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_tNXptyV-B0yupU7uhJiuDg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_ZSZvs2okEkeDRoXUmL8FyA_6_9">70.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"><span style="font-size:10pt;">During the six months ended June 30, 2023, we granted </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_PpvU5eYgTEyg2sveoUrODg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_-uU_YxYVXUWJpwRXpXu0VQ">1,387,600</ix:nonFraction></span><span style="font-size:10pt;"> </span><span style="font-size:10pt;background:#ffffff;">RSUs </span><span style="font-size:10pt;">with a grant-date weighted-average fair value of </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_Xu_N--yaaU6K7FdyMhFNnQ" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_PpvU5eYgTEyg2sveoUrODg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_y7OgFZ8rNUOg0m2fQQZ3zg">1.80</ix:nonFraction></span><span style="font-size:10pt;"> per share, and </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_PpvU5eYgTEyg2sveoUrODg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="Narr_LYXLQP2Oy0KMnXKeX7ukQw">435,006</ix:nonFraction></span><span style="font-size:10pt;"> RSUs were released. The RSUs granted generally vest over </span><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_PpvU5eYgTEyg2sveoUrODg" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_MDJtTxm9KEy5XkhgSeTYQQ"><span style="font-size:10pt;">4 years</span></ix:nonNumeric><span style="font-size:10pt;">. As of June 30, 2023, there were </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA" contextRef="As_Of_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_phK8_7NtIEStEjkLueCcDw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Narr_xtEsv5DhYEig-MROz7kOJg">1,963,487</ix:nonFraction></span><span style="font-size:10pt;"> RSUs outstanding.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-bottom:12pt;text-indent:36pt;margin:12pt 0pt 0pt 0pt;"><span style="font-size:10pt;">As of June 30, 2023, there was approximately </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_us-gaap_AwardTypeAxis_rigl_ShareBasedCompensationOptionsAndRsusMember_eHSX5niPTk2ia4BsC8uknQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="Narr_bzPDgzZM1EesMiPMLrPVvQ">14.6</ix:nonFraction></span><span style="font-size:10pt;"> million </span><span style="font-size:10pt;">of unrecognized stock-based compensation cost which is expected to be recognized over a remaining weighted-average period of </span><span style="-sec-ix-hidden:Hidden_gNM8FB3j1EmiM03O-NFNhA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.68</span></span><span style="font-size:10pt;"> years, related to time-based stock options, performance-based stock options wherein achievement of the corresponding corporate-based milestones was considered as probable, and RSUs. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;">In April 2023, our Board of Directors approved additional <ix:nonFraction unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA" contextRef="Duration_4_1_2023_To_4_30_2023_qr7JWxKMEU6rcNt5QqihYw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="Narr_Z16rDw_pWE2RS28yDgmI5Q">108,600</ix:nonFraction> shares of common stock reserved for issuance under our Inducement Plan. In May 2023, our stockholders approved an amendment to our 2018 Plan, to, among other items, add an additional&#160;<ix:nonFraction unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA" contextRef="Duration_5_1_2023_To_5_31_2023_Q3DEP_Nkn0q2GbxII4v6Iw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="Narr_7_eoYU6P-UCY9mZ4m4YODQ">4,000,000</ix:nonFraction>&#160;shares&#160;to the number of shares of common stock authorized for issuance under our 2018 Plan. As of June 30, 2023, there were <ix:nonFraction unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA" contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Narr_BsNCfV8L-U2HaaXfWH6vVw">12,186,098</ix:nonFraction> shares of common stock available for future grant under our Equity Incentive Plans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_qs1905oiV0KYM8T6_7l9Ug_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Employee Stock Purchase Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;">Our Purchase Plan provides for a </span><span style="-sec-ix-hidden:Hidden_PQsDUEtR7km_2RPzqyzkJA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">24</span></span><span style="font-size:10pt;">-month offering period comprises </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_item_goOMrhYK4U2jGn5r_GJRhQ" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_sAWGlLehukGUN_F8wkmpLA" decimals="INF" format="ixt-sec:numwordsen" name="rigl:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriodsPerAwardOfferingPeriod" scale="0" id="Narr__JGjmGNCIU6kw1nme13WCQ">four</ix:nonFraction></span><span style="font-size:10pt;"> </span><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_sAWGlLehukGUN_F8wkmpLA" format="ixt-sec:durwordsen" name="rigl:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPurchasePeriod" id="Narr_NUF0HJQgjkW7MM8TyIWP5g"><span style="font-size:10pt;">six-month</span></ix:nonNumeric><span style="font-size:10pt;"> purchase periods with a look-back option. A look-back option is a provision in our Purchase Plan under which eligible employees can purchase shares of our common stock at a price per share equal to the lesser of </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_pure_uVIKS5OYQEes3pxG5CV0tw" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_sAWGlLehukGUN_F8wkmpLA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="Narr__qLmdYhn00aJAA6Fm7XTxA">85</ix:nonFraction>%</span><span style="font-size:10pt;"> of the fair market value on the first day of the offering period or </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_pure_uVIKS5OYQEes3pxG5CV0tw" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_sAWGlLehukGUN_F8wkmpLA" decimals="2" format="ixt:numdotdecimal" name="rigl:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentageOnFirstDayOfOfferingPeriod" scale="-2" id="Narr_kkQAZNyQFEa33W6thk0ilg">85</ix:nonFraction>%</span><span style="font-size:10pt;"> of the fair market value on the purchase date. </span><span style="font-size:10pt;">Our Purchase Plan also includes a feature that provides for a new offering period to begin when the fair market value of our common stock on any purchase date during an offering period falls below the fair market value of our common stock on the first day of such offering period. This feature is called a &#8220;reset.&#8221; Participants are automatically enrolled in the new offering period. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:12pt 0pt 0pt 0pt;"><span style="font-size:10pt;">Our previous </span><span style="-sec-ix-hidden:Hidden_zvVmLYm5wkGT80D-sHpXHw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">24</span></span><span style="font-size:10pt;">-month offering period under our Purchase Plan ended on June 30, 2022, and a new twenty-four-month offering period started on July 1, 2022. </span><span style="font-size:10pt;">The fair value of awards under our Purchase Plan is estimated on the date of our new offering period using the Black-Scholes option pricing model, which is being amortized over the requisite service periods. </span><span style="font-size:10pt;">As of June 30, 2023, unrecognized stock-based compensation cost related to our Purchase Plan amounted to </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_zHK5kte7M02N-LF9t66ILA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="Narr_qgKS4VwJwEuJ6-QgXVVAug">0.4</ix:nonFraction></span><span style="font-size:10pt;"> million, which is expected to be recognized over the remaining weighted average period of </span><span style="-sec-ix-hidden:Hidden_uq0rUsBH7E2jbRn6gMjYeg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">0.74</span></span><span style="font-size:10pt;"> years.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">During the six months ended June 30, 2023, there were <ix:nonFraction unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_sAWGlLehukGUN_F8wkmpLA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" scale="0" id="Narr_XVYJTpDMgEyqBNY1LyAMIw">509,190</ix:nonFraction> shares purchased under the Purchase Plan. As of June 30, 2023, there were <ix:nonFraction unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA" contextRef="As_Of_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_zHK5kte7M02N-LF9t66ILA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_FQ49285lUU-_VVrI4zo9oQ">2,928,443</ix:nonFraction> shares reserved for future issuance under the Purchase Plan.</p></ix:continuation><a id="_Hlk100222365"></a><a id="_28ae21c5_458a_4304_9602_02c0bdfc5534"></a><a id="Tc_THy31yITRk-9pjHo2XfGlg_2_2"></a><a id="Tc_fZbQXNPb80qZreonO29U2w_3_2"></a><a id="Tc_C8n0x3R5R0qvsZ99zvpbeA_3_5"></a><a id="Tc_UQ6-5BKZ00ed_IYgmiNhUA_4_0"></a><a id="Tc_33qtrY_nTESjtnM-qWP5TA_4_2"></a><a id="Tc_ytt6x4CDnUSGs_3d0neEAw_4_5"></a><a id="Tc_vA9fYgmVk0W3iivJwRzMLg_5_0"></a><a id="Tc_Lsi9GBIuKU-N7YCZ1nVf4g_6_0"></a><a id="Tc_wHq4luhm-E6e7AVuT0EAtw_7_0"></a><a id="Tc_WfM3w6GLzkG60ZZ96GuWAQ_7_2"></a><a id="Tc_61uJ4UZy0kiK2sPZ49LoLg_7_5"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" name="us-gaap:InventoryDisclosureTextBlock" id="Tb_nx9WXn68bEKpvVIlAXM6Eg" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:12pt;"><b style="font-size:10pt;font-weight:bold;">6.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:12pt;"><b style="font-size:10pt;font-weight:bold;">Inventories</b></p></td></tr></table><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="Tb_f3ag8OrepE6_i8onjCjrMA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Inventories for the periods presented consist of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:98.15%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="color:#0563c1;font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="color:#0563c1;font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:10.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="vertical-align:bottom;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterials" scale="3" id="Tc_WzoVg2nHiUa3yI9n9nTi5g_4_3">6,878</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterials" scale="3" id="Tc_IKWnDuTDiUuQklj9x7lcoQ_4_6">4,555</ix:nonFraction> </p></td></tr><tr><td style="vertical-align:bottom;width:74.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Work in process</p></td><td style="vertical-align:bottom;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcess" scale="3" id="Tc_8QvfvsSIc0euNpC_zVJjJQ_5_3">2,046</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcess" scale="3" id="Tc_lqeXQYtGNU6m2jWrx6bgng_5_6">2,659</ix:nonFraction> </p></td></tr><tr><td style="vertical-align:bottom;width:74.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="vertical-align:bottom;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoods" scale="3" id="Tc_28hFlLVRs0S5Hzb86elIsQ_6_3">1,858</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoods" scale="3" id="Tc_UtNDpbRDzEOVuomh3YJThQ_6_6">1,904</ix:nonFraction> </p></td></tr><tr><td style="vertical-align:bottom;width:74.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_sglA_hW0X0mC7ePmUQn_yQ_7_3">10,782</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_zNBhOcmKBUalp7DCUSnmPw_7_6">9,118</ix:nonFraction> </p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:12pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="font-size:10pt;">Inventories as of June 30, 2023 and December 31, 2022 include inventories acquired from Forma (now Novo Nordisk) pursuant to the license and transition agreement. As of June 30, 2023 and December 31, 2022, we have </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdvancesOnInventoryPurchases" scale="6" id="Narr_h6TvXRe5aEOkOuiQCponVg">0.7</ix:nonFraction></span><span style="font-size:10pt;"> million and </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdvancesOnInventoryPurchases" scale="6" id="Narr_9t6dvldMXEW-QYAOIX8Gxw">0.8</ix:nonFraction></span><span style="font-size:10pt;"> million, respectively, in advance payments to the manufacturer of our raw materials, which were included within prepaid and other current assets in the condensed balance sheet.</span></p></ix:nonNumeric><a id="_7d437357_134b_4c05_a4a8_8b008f4d3a2f"></a><a id="Tc_tJ5bljpkjECwvNtos706-A_1_2"></a><a id="Tc_ILo4kqCERUyBrAW2hmoD_g_2_2"></a><a id="Tc_TskYGnwUWkG6iiFGF-WQIA_2_5"></a><a id="Tc_jzSdu6Pj2E2WtJcfZbzBsw_3_0"></a><a id="Tc_l4RCxZHyIUS2vYyCwhdJLw_3_2"></a><a id="Tc_codwIrJZMUypBi3HMt9ftQ_3_5"></a><a id="Tc_9d89qT11g02ptYKuzcjtug_4_0"></a><a id="Tc_9GiaN_EdiEqWphTh1VdD_A_5_0"></a><a id="Tc_LfjrcxO7bEKjDjqzajz1GA_6_0"></a><a id="Tc_8TnKQ8TuZkCSRIjuyw9zUg_7_0"></a><a id="Tc_wFz1KZ6VVUGtGONYhKrF1Q_8_2"></a><a id="Tc_xIyf41mQ7ESvWL_hV091rQ_8_5"></a><a id="Tc_omqo5-Vr1E6sNPUshEQ4Fw_9_0"></a><a id="Tc_AhvSWQ2MEkKsenvkeIbIsQ_10_0"></a><a id="Tc_XEyli9c_T0a4qDhgVSQyJg_10_2"></a><a id="Tc_SOqk7EHuHEi6ovbdcNH9Og_10_5"></a><a id="Tc_K6O-iH0FpEKaRQV0jXRPqg_11_0"></a><a id="Tc_A0B0MmwD3Uy05jzDvyieAA_12_2"></a><a id="Tc_lawvlYs24k2IhqBaeTTiyA_12_5"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" name="us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock" id="Tb_z1QfhshyHE6aj4hxYvzGmA" continuedAt="Tb_z1QfhshyHE6aj4hxYvzGmA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">7.</b></span><b style="font-weight:bold;">Cash, Cash Equivalents and Short-Term Investments</b></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="Tb_YIPOgD46T0Wh9h0KRb1hsw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Cash, cash equivalents and short-term investments for the periods presented consist of the following (in thousands): </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:97.59%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.64%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash</p></td><td style="vertical-align:bottom;width:0.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CashMember_qUTZZY9s90OHjG7EZblg4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="3" id="Tc_U7NXR2piYUi9Dm6YYheMOw_3_3">8,794</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CashMember_FLsEIySBfEaeRVBihq2f2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="3" id="Tc_5rNGyVrFnk286I74HRL-1w_3_6">6,264</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Money market funds</p></td><td style="vertical-align:bottom;width:0.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_LfRnUUxRrEycHqB8YoPOOQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="3" id="Tc_6SwYISWp_0mixOUaJyzPsA_4_3">21,109</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_1pcJHoW0nkC8Ko2b5ADUog" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="3" id="Tc_qRVnPlpuBUq083Q1HBNq2Q_4_6">4,155</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">US treasury bills</p></td><td style="vertical-align:bottom;width:0.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryBillSecuritiesMember_ASiSMIactUqwVwnqPY3_ew" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="3" id="Tc_7aylijixWEW7tv0PMP8oBg_5_3">8,953</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryBillSecuritiesMember_sKjXaDQa5EiL5o0NsgoBFA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="3" id="Tc_-N5i-dKwpUeZzw9p4ciNwA_5_6">5,225</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Government-sponsored enterprise securities</p></td><td style="vertical-align:bottom;width:0.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_KL0hZTH2e063PXe0IU6-1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="3" id="Tc_O2zgl20gMUSedlD6BLAG7Q_6_3">15,584</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_M3axIPlo5k2k9b5gQJC25g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="3" id="Tc_Gr3uec7D5kGP9c33fkBkuA_6_6">15,796</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate bonds and commercial paper</p></td><td style="vertical-align:bottom;width:0.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_us-gaap_InvestmentTypeAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_1RwephmFh0WgSWKn57-wDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="3" id="Tc_N1IlrjsA_k-oiY9u2VHRBw_7_3">9,917</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_us-gaap_InvestmentTypeAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_BtwQ3KLKc02gIILPkP43sw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="3" id="Tc_eWApw8Fm4EOdA6lVpx37tA_7_6">26,766</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="3" id="Tc_qc1uCsJ4uU6GfRSTgwSuCg_8_3">64,357</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="3" id="Tc_8SWH14PCEUKG6ukDRbpn5w_8_6">58,206</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Reported as:</p></td><td style="vertical-align:bottom;width:0.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;width:0.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_aAkpBM95kk2PzRT6AgpQAg_10_3">48,812</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_YU917ozWLE2E6Vwj1G3Uww_10_6">24,459</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term investments</p></td><td style="vertical-align:bottom;width:0.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_VwK_RJmeMkOT66IzW99Ung_11_3">15,545</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_FOIS2cw310CumLymGEYa3w_11_6">33,747</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="3" id="Tc_0S82H3zyWUKpkBU2Ko12zA_12_3">64,357</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="3" id="Tc_BHUQZXUeEEycdqJC2nYR5w_12_6">58,206</ix:nonFraction> </p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_25e74ed7_67c5_4a30_99d2_d478b1b91b89"></a><a id="Tc_76s31x-IoEOS_wJXq2t54w_1_5"></a><a id="Tc_bydFCB5XUU2TvKwTm4I1qQ_1_8"></a><a id="Tc_QzizIsCsMk6R8dw29FwxSA_2_2"></a><a id="Tc_5oSTEiRl7kmAih3B6m8lDQ_2_5"></a><a id="Tc_NlCYOwpMw0SsST1y8CQHEw_2_8"></a><a id="Tc__jOCf_RdbkSzJWTs_d8G6Q_3_0"></a><a id="Tc_zSc_xRu70kqzdIRfuTKoVg_3_2"></a><a id="Tc_0rmi-yQsc0GA_4znBZS86w_3_5"></a><a id="Tc_VLynqrFgpk23fawn5-c16w_3_8"></a><a id="Tc_cqKQi9qikES3MxUrmYvFTw_3_11"></a><a id="Tc_zAGUbNU-WkmFg_epX06O0w_4_0"></a><a id="Tc_cGEy1pZ4p02G0lAMpdNjoQ_4_2"></a><a id="Tc_lfyOhcDJpECKrdACbXV2Sw_4_5"></a><a id="Tc_9a6dJ_7zVUSWtlZwi0l7JQ_4_8"></a><a id="Tc_F_ufpTyO20SmqKQu0bEnEw_4_9"></a><a id="Tc_zrExg41VQUePkMxDgRO7Cg_4_11"></a><a id="Tc_QUT0TzcMR02vSrigmt7qHQ_5_0"></a><a id="Tc_YQCIu19OE0i8h5oJSLxasg_5_11"></a><a id="Tc_-x-z4yeN-kqW2T703PhNGw_6_0"></a><a id="Tc_eDtGpAXU1EClI8HY1xyPjw_6_6"></a><a id="Tc_fwqLdysT8Um4K8DLmeqkgw_7_0"></a><a id="Tc_X0KjieI54k6HGivcOAKvpg_7_2"></a><a id="Tc_OpraHObgcEaCRaHrFc8iCw_7_5"></a><a id="Tc_zDfja11msEG65Vxbv8GtmQ_7_8"></a><a id="Tc_1qp4HCu-PE-DsQbMKbzSsQ_7_11"></a><a id="_876ddf36_b66a_45f2_84f5_bfe6af1f2cb7"></a><a id="Tc_A0j3ntd5EESCSqfxMYygRw_1_5"></a><a id="Tc___WK3OzAMEq8ZSYlemXyRA_1_8"></a><a id="Tc_MesudmJWkkCvgnrPZ8xeuQ_2_2"></a><a id="Tc_F7bW9SzgD0miOODsJ62dJQ_2_5"></a><a id="Tc_NDGyH67f00uhln0dSjkZ-A_2_8"></a><a id="Tc_jOkMHATewkaBfrAmQEBr2A_3_0"></a><a id="Tc_f93ymM8e5UWlj9fr7nZOKg_3_2"></a><a id="Tc_nARoXF1BFEa9sXCBeMThaw_3_5"></a><a id="Tc_hyUJbSfM0kCD2z3Zl7UGEw_3_8"></a><a id="Tc_e1ijuSTllk2afTnjCtIfAQ_3_11"></a><a id="Tc_n9b9kbcXJEOKNdr-jMp9wg_4_0"></a><a id="Tc_dIoCHk4v3U-EDhNF3QhyXg_4_2"></a><a id="Tc_XVa-FEVfL0iSYaWQckEpyA_4_5"></a><a id="Tc_zVC1UpqB-E-HLDXBGCwK_A_4_6"></a><a id="Tc_i3RuViFn1UGysU-WLpVlOg_4_8"></a><a id="Tc_NcPQa52b30qJKAjmTz_oGA_4_11"></a><a id="Tc_YYBQrWu_tkSo9ocQ--bSqA_5_0"></a><a id="Tc_9yJWiQdWxEm7XXp1UAGr8A_6_0"></a><a id="Tc_q0OfiEpJuESmPDXswIyOEw_6_6"></a><a id="Tc_WRjU6w6hlkuOldDG5ohI5w_7_0"></a><a id="Tc_kla5bPArU0KTyq2DbhRWog_7_2"></a><a id="Tc_feOnZTdjWEurCIO_sdlPwg_7_5"></a><a id="Tc_CBtf0E2QBUazOI0Bx9cLng_7_8"></a><a id="Tc_AzFgbizrgk2uIEHjesJmUA_7_11"></a><a id="_b0abda64_b2c5_4a90_8845_a7ad1462c837"></a><a id="Tc_-kK36jIJ40-m7O4wNTtrIg_1_0"></a><a id="Tc_YazKEJXXvkutW2D3AKhFIw_1_2"></a><a id="Tc_vPV1w4Jllkq-zWdvdyPUVQ_1_5"></a><a id="Tc_pFsNJIyfQUuAUFAIBc6AFw_2_0"></a><a id="Tc_V0ux3DVY-0CbNf6xMoFdNQ_2_2"></a><a id="Tc_CllhwGuyI0WO8BCMfD1iaw_2_5"></a><a id="Tc_vo5OUsw-XUqN8RvJxtCVWw_3_0"></a><a id="Tc_QJ0Bckr9CUKymEeeRItfrg_4_0"></a><a id="Tc_-bN787yaOkyVe5eKC_DNMA_4_2"></a><a id="Tc_uznUSYjz906ELyvV7QA1VQ_4_5"></a><ix:continuation id="Tb_z1QfhshyHE6aj4hxYvzGmA_cont1"><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" name="us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock" id="Tb_q0yQQh43P0mCMpK1pKgE9w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Cash equivalents and short-term investments include the following securities with gross unrealized gains and losses (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:97.7%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">As of June 30, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">US treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember_9b5OdbmUeUi1NDAMA8H9Vg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="Tc_Np9_NS3UhkKiGw4ToTs8JQ_4_3">8,951</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_ld4nogTT4UKONA-CGQuvUQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1" scale="3" id="Tc_4PkkfmosjUu6Gd5AUFRNkg_4_6">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember_9b5OdbmUeUi1NDAMA8H9Vg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_G_ZOOcneyUG7MjEx1z_XSw_4_12">8,953</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Government-sponsored enterprise securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_ReLJS_8Ua0iY--Vx8HxzUQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="Tc_CMhYJa7r4EK5CtnqrJEd7A_5_3">15,607</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_Z6JnOF8Gmkqq3XJoCK4JhA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1" scale="3" id="Tc__tec-VpyukOnt1iWd-V76g_5_6">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaap_StatementEquityComponentsAxis_rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember_M4prG97dGEaaceW_5B5zCw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1" sign="-" scale="3" id="Tc_rIcjhElT4EW_2DxVwXKEag_5_9">25</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_ReLJS_8Ua0iY--Vx8HxzUQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_V0Z0pIsDHk-pg-Y8Xhy1mg_5_12">15,584</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate bonds and commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_us-gaap_FinancialInstrumentAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_EovRXwcsBU6PVsykL7sTEQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="Tc_npamOTPxIE-kGNmu25ZZeA_6_3">9,921</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_us-gaap_FinancialInstrumentAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_us-gaap_StatementEquityComponentsAxis_rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember_qfBk03iVXEW6w48gjbjf7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1" sign="-" scale="3" id="Tc_C9SVfowMj0qERjzWVUC1RA_6_9">4</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_us-gaap_FinancialInstrumentAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_EovRXwcsBU6PVsykL7sTEQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_PgMThwG-kE6CK0hJt3A7WA_6_12">9,917</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="Tc_ZGvjFTlG1U-2QRZul6dwrg_7_3">34,479</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_8i-ahQp_70mFJFvxxl02wA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1" scale="3" id="Tc_LzWITpWjh0u7QlugZuSAhg_7_6">4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember_P5cNTt7IlEa-Rhtic4nyvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1" sign="-" scale="3" id="Tc_813sVG248kOh78fhYRMX4g_7_9">29</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_L1wYSbF0iEuGVbVmZ4Sv8A_7_12">34,454</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:98.34%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">As of December 31, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">US treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember_afYkc85gT0m66xklaugfbw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="Tc_8ocsswoTTEOC6G3WnTyE6Q_4_3">5,251</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember_us-gaap_StatementEquityComponentsAxis_rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember_C6IhUCU3BkGDHmqFolJgdQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1" sign="-" scale="3" id="Tc_B-WVOlH3NkyV75J8YKokDg_4_9">26</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember_afYkc85gT0m66xklaugfbw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_UI5Pc0-vGUGAn6Jqq0vN7w_4_12">5,225</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Government-sponsored enterprise securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_go32t6mGGEqSyKBPofyDEA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="Tc_ioQxBfzszkuyUViAj8uGNA_5_3">15,882</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_O0JjjXe-ZE-RH42gPIxthQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1" scale="3" id="Tc_kQArOmHthki5ZLRTMXPEAA_5_6">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaap_StatementEquityComponentsAxis_rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember_8aUcC__wTUGDPKa_b54-SQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1" sign="-" scale="3" id="Tc_HoLVoSDCs0WAxG_5NM5LLA_5_9">87</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_go32t6mGGEqSyKBPofyDEA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_0-l8QU1M-kGk-o17ptUFeA_5_12">15,796</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate bonds and commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_FuBEs4QimEqUM83PeYRZcw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="Tc_aH8t0GtPvkWQtyoCnj_UBQ_6_3">26,807</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_us-gaap_StatementEquityComponentsAxis_rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember_qoI-MShlREydakWlPmH8IA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1" sign="-" scale="3" id="Tc_Tld7HO_yHUaW648nPVc8dQ_6_9">41</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_FuBEs4QimEqUM83PeYRZcw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_Uaf-CKcsZE-vcGwn0kMtoQ_6_12">26,766</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="Tc_-BAAzCTtUkWj0NB2hjL4Qg_7_3">47,940</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_dT29_JlvC0m0JlLh8k3msw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1" scale="3" id="Tc_3Rk80dyPJk-yP4jZXg3Aug_7_6">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember_fV_8kfGMb0aVZbFHW8RnkA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1" sign="-" scale="3" id="Tc_S4R0L3sBgUmDei8__eat9w_7_9">154</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_tTEahOcawEqNUeRRZNgYKg_7_12">47,787</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"><span style="font-size:10pt;">As of June 30, 2023 and December 31, 2022, our cash equivalents and short-term investments had a weighted-average time to maturity of approximately </span><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" format="ixt-sec:durwordsen" name="rigl:CashEquivalentsAndAvailableForSaleSecuritiesWeightedAverageMaturityPeriod" id="Narr_FdzJ5b1BxkOq5GVmDRcFjA"><span style="font-size:10pt;">72 days</span></ix:nonNumeric><span style="font-size:10pt;"> and </span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_4hZ--7i_V0a3K3Xee2PShA" format="ixt-sec:durwordsen" name="rigl:CashEquivalentsAndAvailableForSaleSecuritiesWeightedAverageMaturityPeriod" id="Narr_dkEfPTOHRk2WuOCxTreNiw"><span style="font-size:10pt;">89 days</span></ix:nonNumeric><span style="font-size:10pt;">, respectively. </span><span style="font-size:10pt;background:#ffffff;">Our short-term investments are classified as available-for-sale securities. Accordingly, we have classified certain securities as short-term investments on our condensed balance sheets as they are available for use in the current operations. </span><span style="font-size:10pt;">As of </span><span style="font-size:10pt;">June 30, 2023, we had </span><span style="-sec-ix-hidden:Hidden_ut8FmrekU0qEihlZMrnsbQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">no</span></span><span style="font-size:10pt;"> investments that had been in a continuous unrealized loss position for more than 12 months. As of June 30, 2023, a total of </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_position_WoI3E1kTlEyL4Mc6Z0-iIg" contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="Narr_1ZBOwaZvq0eZzcJVCz0djA">19</ix:nonFraction></span><span style="font-size:10pt;"> individual securities had been in an unrealized loss position for 12 months or less, and the losses were determined to be temporary. No significant facts or circumstances have arisen to indicate that there has been any significant deterioration in the creditworthiness of the issuers of the securities held by us. Based on our review of these securities, including the assessment of the duration and severity of the unrealized losses, we have </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld" scale="6" id="Narr_zaF1Q_AfYU2qr4LH8641GQ"><ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld" scale="6" id="Narr_hTDQjAVKAkSy_xUxrMkHvQ">no</ix:nonFraction></ix:nonFraction></span><span style="font-size:10pt;">t recognized any credit losses on these securities as of June 30, 2023 and December 31, 2022.</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" name="us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" id="Tb_X9xcLSkrq0Kf_Z8nPR7Dyg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table shows the fair value and gross unrealized losses of our investments in individual securities that are in an unrealized loss position, aggregated by investment category (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:91.47%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">As of June 30, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:8.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Government-sponsored enterprise securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_KL0hZTH2e063PXe0IU6-1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" id="Tc_Z_phQwa7ckWkhtBdwSJ41g_2_3">10,576</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_KL0hZTH2e063PXe0IU6-1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="Tc_4qE0qLoWCUauD7NVUwxi7A_2_6">26</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate bonds and commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_us-gaap_InvestmentTypeAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_1RwephmFh0WgSWKn57-wDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" id="Tc_XD3BMmI2S0OTrerjvUNhsg_3_3">7,950</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_us-gaap_InvestmentTypeAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_1RwephmFh0WgSWKn57-wDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="Tc_89QsHqegWUWTQ22ehG5DlA_3_6">3</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" id="Tc_2lRw36d3xUmkTAkit8yMKw_4_3">18,526</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="Tc_pNiNBbH6oE2hm1FkxmanPw_4_6">29</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_e1f831c8_b4b3_47e8_b27d_a32df83534b6"></a><a id="Tc_QKyP_-y4aESI7QD927qMYQ_1_2"></a><a id="Tc_Hlzcd5t_dkCR_HCgbSi_QQ_2_2"></a><a id="Tc_fA6eVR-oc0ee80VBjTRmbw_2_5"></a><a id="Tc_Rc7wZtZbbkiIC9071ARBug_2_8"></a><a id="Tc_xppgyc8WHUGtsyNzUI4ZPA_2_11"></a><a id="Tc_hP6snLVb7UyWSUhl1FYsuw_3_0"></a><a id="Tc_qEVcN5Czr0mVUgVtevrgUQ_3_2"></a><a id="Tc_b2DypmX_s0GBdFvbdkUN_Q_3_5"></a><a id="Tc_CWdKnNp9rEyz2AkA_9-Mug_3_6"></a><a id="Tc_ogZ7Mh3-bk-MOvqrvdseIQ_3_8"></a><a id="Tc_jnScOxcJUkqB-uaumHoLAQ_3_9"></a><a id="Tc_nQqzlqOIwEWhGgUB9Vv1JA_3_11"></a><a id="Tc_JRilcvvjO0KPO10M0dlPmw_4_0"></a><a id="Tc_UVIwAqqJS0-2voKDK2huog_4_3"></a><a id="Tc_x54nl37lX0eTxZ23Pk79eA_4_9"></a><a id="Tc_L0wdPBsB-kadUm1Y9WapRA_5_0"></a><a id="Tc_NwiHCxAvR0eOgwdSKku6-g_5_3"></a><a id="Tc_207n1Ga4SE6fSn8wa_LsxA_5_9"></a><a id="Tc_uSbd0wEJvkeLxADQ6r2j0g_6_0"></a><a id="Tc_VGc-Xhe0YEWGpt9AEmIzow_6_3"></a><a id="Tc_jKNCgV1GrkSMWspMxl897A_6_9"></a><a id="Tc_KyVNKmIQLk-AKxScF2xYIQ_7_0"></a><a id="Tc_g3siHUz3UEOOXAuGf1IVrw_7_2"></a><a id="Tc_bRT4uUQwX0yBbyzDTBhKhw_7_5"></a><a id="Tc_sA0CVRjq_kWWkoPexWX5nQ_7_8"></a><a id="Tc_6pHFh83msEmnMgzo6TreFA_7_9"></a><a id="Tc_0CJ219hpbkaLda1iW8Fz-w_7_11"></a><a id="_068722dd_d51c_4e3a_9cd4_8b0c2bc0d80a"></a><a id="Tc_j4ZNkrlH2kOLC6UR6zv9tg_1_2"></a><a id="Tc_B9_NtaQiAkyT9V_0FKKQzQ_2_2"></a><a id="Tc_9mnRs1AHB0Kjjus0Mh6iyg_2_5"></a><a id="Tc_QeaZpuH1tkuT88JOhGWqgA_2_8"></a><a id="Tc_6_M9a6KhUEuHQqKFGmlLnQ_2_11"></a><a id="Tc__FrIXap9JUyYVJVfTNQ91A_3_0"></a><a id="Tc_dOKtjZ7OdEGxqND5oHZDUg_3_2"></a><a id="Tc_fwFDEDkNT0Ci3e3EPfLjWA_3_5"></a><a id="Tc_NEQfb1aHyEWOjHXKfW0Jdg_3_6"></a><a id="Tc_z5y7-LQteEaM6U0PVNRdmQ_3_8"></a><a id="Tc_BQB9-Tfh9EKDKDnHi7vnJA_3_9"></a><a id="Tc_iQVgGWcVg0KQ1bg8k_QjCg_3_11"></a><a id="Tc_UrXoXwMlG0KTOtQhBkOngw_4_0"></a><a id="Tc_fNeOgVJvBUC5HZc8yhj0tA_4_3"></a><a id="Tc_Z1Bj2hfmF0ObiW2XfqnNug_4_9"></a><a id="Tc_dABdkIjiyUW-h1ovkeZKbA_5_0"></a><a id="Tc_ZuwyfSz4MUq9x-sjprcYxA_5_3"></a><a id="Tc_SJj6b_wRKESNL6vQiyW1pg_5_9"></a><a id="Tc_UKrXdCBkAUiegBaH3zWsoQ_6_0"></a><a id="Tc_jRY-ceGoHESdaGyYieY7wg_6_3"></a><a id="Tc_yuWMEtDXMEa4xq82QeDr5w_6_9"></a><a id="Tc_CLPnaS9DUkyvAdAS71Ypqg_7_0"></a><a id="Tc_zibWsC9V4ky0hCfiT4rD-Q_7_2"></a><a id="Tc_-OLkMVtqaU67jVQvyEIuSA_7_5"></a><a id="Tc_cmVT0HM32UKG7HPnIB_Xew_7_8"></a><a id="Tc_T0EmmlzQAEuk5FfobHshCA_7_9"></a><a id="Tc_ykRHXX1u30aofnDDwzR_9w_7_11"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_d7Mct0kyqkeRft1iG6JvNA" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-size:10pt;font-weight:bold;">8.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-size:10pt;font-weight:bold;">Fair Value</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="Tb_GWHZWcfqMEiC6dCaQ3RufQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The table below summarizes the fair value of our cash equivalents and short-term investments measured at fair value on a recurring basis, and are categorized based upon the lowest level of significant input to the valuations (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:98.74%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Assets&#160;at&#160;Fair&#160;Value&#160;as&#160;of&#160;June 30, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_E0z-Tucd60Gr3PRXDlh0xw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_gcOUtKtlwUm7YJrS2jXVYg_3_3">21,109</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_wFvchknSJ0iAyfGzH6qAww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_y58YFvP4d0inRcMSFh720A_3_12">21,109</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:49.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">US treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryBillSecuritiesMember_9EFna87LuU6O4O7rLXT8_Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_p0K2NbA6k0WcQVuHxt820A_4_6">8,953</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryBillSecuritiesMember_W5abtcgj4EewIThyL6s9KQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_grLJscKmI0m31A7NXByX8A_4_12">8,953</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:49.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Government-sponsored enterprise securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_-mpWze0ew0qh9kNZ1GgxZg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_f5q2k53aIUSaDCZmNcEjvw_5_6">15,584</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_89OSD-Eh70S-lOaWIkx8jg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_Js8Eozaf-0iw1LOt3m6Nkg_5_12">15,584</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:49.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate bonds and commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_6LWYDoMSGEuqSbON9szqUA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_eRqvjTdT602rlF5z-wf02g_6_6">9,917</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_j804o1Qq5kW9BN0Wq8qKAw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_NWI6STnxiEG9f8gMQOCNfQ_6_12">9,917</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:49.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_aESIeqNLDEGTjQh7l8feaA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_FJjl-ymQdEuuD8uqqLI3vw_7_3">21,109</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_5w8Rm76YAUeQeOz8g-y38Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_qmZIYg8tQkOeUpZx72bg6A_7_6">34,454</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_QW_rs_VEA0KU4-yd8SrPbw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_XUVIJlqFGUqBs2xyZQt4Gw_7_12">55,563</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Assets&#160;at&#160;Fair&#160;Value&#160;as&#160;of December 31, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_u-RkEtQ-w0Oqm41OpKcIhw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_kI1-ZS89L0OdPI6ybJGREA_3_3">4,155</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_rIYz9iBffUO8TYWENsIDrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_XhBEpbsy2Ee1HtD_r_9ABQ_3_12">4,155</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">US treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryBillSecuritiesMember_I8wfKfL5DU-wQrbo5YC4Eg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_N4TTu9qh5Eq_0fbd-zTNNA_4_6">5,225</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryBillSecuritiesMember_Ttzv--YhbkeAEe271vcCHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_dQfsWDzGCkueUjLwCDhJtw_4_12">5,225</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Government-sponsored enterprise securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_DV0JpqqeFEG2yWKut9HiFw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_oYN5I9mrU0KO6JzsXaho8Q_5_6">15,796</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_wWiomWDuy0icYfW_HOwFgA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_VS7VJKr6vkyJoJz653Z_iA_5_12">15,796</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate bonds and commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_la2B--bWDkagQFiSFOzkrA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_5BlE62kbv0Wv68DLpWeXtg_6_6">26,766</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_5M7Ca4BjDU6p5rg68gEwqQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_GoRP-izSWkeojvj1quV1AA_6_12">26,766</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_d-_85Kk8g0mwIwHaIhvvxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_OlHJkxVHIEmvGZO8YKqqzg_7_3">4,155</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_D1RS1iCAi0Cf-ba1jen3jA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_8zCZG2DhVEC7Slnofcumjg_7_6">47,787</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_fPNOItXmGU6NPrDN3d1kDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_g-yQhiuMVkGknz_yK3yy6w_7_12">51,942</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="_Hlk85547516"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" name="us-gaap:DebtDisclosureTextBlock" id="Tb_g8HsBjxtJE-BB1KsDuqjfw" continuedAt="Tb_g8HsBjxtJE-BB1KsDuqjfw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">9.</b></span><b style="font-weight:bold;">Debt</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">We have a Credit and Security Agreement (Credit Agreement) with MidCap Financial Trust (MidCap) entered on September 27, 2019 (Closing Date) and amended on March 29, 2021 (First Amendment), February 11, 2022 (Second Amendment) and July 27, 2022 (Third Amendment). The Credit Agreement provides for a $<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_lZzWZsARrUq--he7HLPz4w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="Narr_5hH_NI3hUEWI74EKUlHSuw">60.0</ix:nonFraction>&#160;million term loan credit facility. At the Closing Date, $<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_DebtInstrumentAxis_rigl_CreditAgreementTrancheOneMember_NdmHGNjm80GwagBp6p25SQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding" scale="6" id="Narr_WwE_bikKEkOrKeXt5EpJBA">10.0</ix:nonFraction> million was funded (Tranche 1), in May 2020, an additional $<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_5_31_2020_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_DebtInstrumentAxis_rigl_CreditAgreementTrancheTwoMember_Pt33AwlsAE-LZCXlY1xdSw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding" scale="6" id="Narr_8_tXwlvOgUKf0gDdF4YHRg">10.0</ix:nonFraction> million was funded (Tranche 2), at the Second Amendment, an additional $<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_5_31_2022_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_DebtInstrumentAxis_rigl_CreditAgreementTrancheThreeMember_xE8L3bekvEKDIR_7sMJqCw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding" scale="6" id="Narr_Vf1c4ZxLx0WiYUIrm5TavQ">10.0</ix:nonFraction> million was funded (Tranche 3), at the Third Amendment, an additional $<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_5_31_2022_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_DebtInstrumentAxis_rigl_CreditAgreementTrancheFourMember_YfMR144_eUWzw-ApIaAstA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding" scale="6" id="Narr_T3NtQNqH7UOT8RdIl8OduA">10.0</ix:nonFraction> million was funded (Tranche 4), and in March 2023, an additional $<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_3_28_2023_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_DebtInstrumentAxis_rigl_CreditAgreementTrancheFiveMember_QUesi71yDkqy9WA84-x-ug" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding" scale="6" id="Narr_gptzRRCQl0mNanis--IpEg">20.0</ix:nonFraction> million was funded (Tranche 5). As of June 30, 2023, the outstanding principal balance of the loan was $<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_lZzWZsARrUq--he7HLPz4w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding" scale="6" id="Narr_AhBZmSoFYkmDcT87ntd-Iw">60.0</ix:nonFraction> million, and <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_lZzWZsARrUq--he7HLPz4w" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" scale="6" id="Narr_BS4C8YuHqUG1Qk8C_tUQ4g">no</ix:nonFraction> remaining funds are available for draw under the term loan credit facility. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">The First Amendment to the Credit Agreement extended the period through which Tranche 3 was available to us. The Second Amendment to the Credit Agreement, among other things, amended the applicable funding conditions, applicable commitments and certain other terms relating to available credit facilities (Tranches 3 and 4), added additional term loan credit facility (Tranche 5), and revised certain terms related to the financial covenants. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"><span style="font-size:10pt;">Following the Third Amendment, the maturity date for the term loans is on September 1, 2026, and the interest-only period is through October 1, 2024. </span><span style="font-size:10pt;background:#ffffff;">The interest rate applicable to the term loans under the amended Credit Agreement is the sum of one-month </span><span style="font-size:10pt;">Secured Overnight Financing Rate (SOFR)</span><span style="font-size:10pt;background:#ffffff;">, plus an adjustment of </span><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_srt_StatementScenarioAxis_rigl_FollowingThirdAmendmentMember_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_VariableRateAxis_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_4EMQf1c4MEiugud-VG7qaw" name="us-gaap:DebtInstrumentInterestRateBasisForEffectiveRate" id="Narr_Peh2HMX3oE2ng3e3aVSsHA"><span style="font-size:10pt;background:#ffffff;">0.11448%</span></ix:nonNumeric><span style="font-size:10pt;background:#ffffff;">, subject to </span><span style="font-size:10pt;background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_pure_uVIKS5OYQEes3pxG5CV0tw" contextRef="As_Of_6_30_2023_srt_StatementScenarioAxis_rigl_FollowingThirdAmendmentMember_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_VariableRateAxis_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_ShXm5jIvgkOs-ZS0wM0CGA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_cGcgBUiPQ0SSz63cFYtx6w">1.50</ix:nonFraction>%</span><span style="font-size:10pt;background:#ffffff;"> applicable floor, plus applicable margin of&#160;</span><span style="font-size:10pt;background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_pure_uVIKS5OYQEes3pxG5CV0tw" contextRef="Duration_1_1_2023_To_6_30_2023_srt_StatementScenarioAxis_rigl_FollowingThirdAmendmentMember_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_VariableRateAxis_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_4EMQf1c4MEiugud-VG7qaw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="Narr_v4r6bpXwgUGYPfn6-bl5iA">5.65</ix:nonFraction>%</span><span style="font-size:10pt;background:#ffffff;">. A</span><span style="font-size:10pt;"> final payment fee of </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_pure_uVIKS5OYQEes3pxG5CV0tw" contextRef="Duration_1_1_2023_To_6_30_2023_srt_StatementScenarioAxis_rigl_FollowingThirdAmendmentMember_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_LJSahnttvEiJdFf1pAqMfg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" scale="-2" id="Narr_mS1nZzdpik-vPF2pwCwqvA">2.5</ix:nonFraction>%</span><span style="font-size:10pt;"> of principal is due at maturity date of the term loans. Prior to the Third Amendment, the outstanding principal balance of the loan bore interest at an annual rate of one-month London Interbank Offered Rate (LIBOR), </span><span style="font-size:10pt;background:#ffffff;">or a comparable applicable index rate, </span><span style="font-size:10pt;">plus applicable margin of </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_pure_uVIKS5OYQEes3pxG5CV0tw" contextRef="Duration_1_1_2023_To_6_30_2023_srt_StatementScenarioAxis_rigl_PriorToThirdAmendmentMember_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_VariableRateAxis_rigl_LondonInterBankOfferedRateMember_2WmOu592Mkqf1Hwsj0OZug" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="Narr_IkvsiuL-4UGrjYvJVSnktg">5.65</ix:nonFraction>%</span><span style="font-size:10pt;">, subject to a LIBOR floor of </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_pure_uVIKS5OYQEes3pxG5CV0tw" contextRef="As_Of_6_30_2023_srt_StatementScenarioAxis_rigl_PriorToThirdAmendmentMember_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_VariableRateAxis_rigl_LondonInterBankOfferedRateMember_PMVwcFXhgUW15_EzDLiLAw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_r776z3z9gUqXOyl3FCzwzg">1.50</ix:nonFraction>%</span><span style="font-size:10pt;"> and is payable monthly in arrears. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"><span style="background:#ffffff;">We </span>may make voluntary prepayments, in whole or in part, subject to certain prepayment premiums and additional interest payments. The Credit Agreement also contains certain provisions, such as event of default and change in control provisions, which, if triggered, would require us to make mandatory prepayments on the term loan, which are subject to certain prepayment premiums and additional interest payments. The obligations under the amended Credit Agreement are secured by a perfected security interest in all of our assets including our intellectual property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Debt issuance costs are recorded as a direct deduction from the outstanding principal balance of the term loan. As of June 30, 2023 and December 31, 2022, the unamortized issuance costs and debt discounts amounted to $<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_lZzWZsARrUq--he7HLPz4w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="6" id="Narr_zJ0rqDyi-Ua2LU9AULawvw">0.4</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="6" id="Narr_gMZ59euYA0KQ6_vFQI2NKw">0.6</ix:nonFraction> million, respectively. </p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_ff4b3004_4239_4fed_a0c5_6c2acc4f0dac"></a><a id="Tc_4qdqxQM0SkOX9UkecjloGA_1_0"></a><a id="Tc_G_S94P9azUyOS9X2x9eBig_1_2"></a><a id="Tc_ZtBXLIjEskKGLRjSiO-Mig_1_3"></a><a id="Tc_yzrDzOJ7i0OKgDeZ8Vp9lQ_2_0"></a><a id="Tc_6M8Of7HeLUGkY76SJBMlBA_3_0"></a><a id="Tc_smVmg8nXh0O2EhDZoIUW9g_4_0"></a><a id="Tc_nkQZ1JuGhU6FWSH7fhKREw_5_0"></a><a id="Tc_DIjCnRyVcEiz6nizBTwpbQ_5_2"></a><ix:continuation id="Tb_g8HsBjxtJE-BB1KsDuqjfw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Interest expense, including amortization of the debt discount and accretion of the final fees related to the Credit Agreement for the three months ended June 30, 2023 and 2022 was $<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_BJeMNksUxkWrPx4dQB6u3A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="6" id="Narr_9H95SugY80KUGXSwBoMiGg">1.9</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_vq2GZ_j7vkilnhfg4of5cw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="6" id="Narr_CpDcO81V0kGOTO9BSB-oGQ">0.6</ix:nonFraction> million, respectively, and for the six months ended June 30, 2023 and 2022 was $<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_ePrDC_3ewk2JsGsYLAl0ZQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="6" id="Narr_tZIhfrEEM0SrVJAZrAkcog">3.1</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_CJn5TKw-Sk6p8v3y1c6mVA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="6" id="Narr_E2XLQ0ErAECroh2mGcTSQw">1.1</ix:nonFraction> million, respectively. Accrued interest of $<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_ePrDC_3ewk2JsGsYLAl0ZQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityIncreaseAccruedInterest" scale="6" id="Narr_B9DuxTTe5E2iBebJi_qZ1A">1.2</ix:nonFraction> million was included within other accrued liabilities in the condensed balance sheet as of June 30, 2023. </p><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" name="us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock" id="Tb_-DuwI-FISUy2RfLonwAIPA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">The following table presents the future minimum principal payments of the outstanding loan as of June 30, 2023 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:72.33%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:61.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:27.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Remainder of 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="3" id="Tc_Bt9CxmNSQUGo4GxzgQgeYQ_2_3">7,500</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="3" id="Tc_j_IBs-D4GUmKhNOQcojttA_3_3">30,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="3" id="Tc_bOngXPUc4EuY5h1BhFtcIQ_4_3">22,500</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Principal amount (Tranches 1, 2, 3 and 4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="Tc_7mK62tX5MUqGF8yMM5eSeQ_5_3">60,000</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The amended Credit Agreement contains certain covenants which, among others, require us to deliver financial reports at designated times of the year and maintain minimum unrestricted cash and trailing net revenues. As of June 30, 2023, we were not in violation of any covenants.</p></ix:continuation><a id="_a0e07898_4ae6_4028_a635_da1caef30a6f"></a><a id="Tc_0rLsMus0HEaWPW9s4amkrw_1_2"></a><a id="Tc_fyznGZdDjk2_GCqWPmSLWw_1_8"></a><a id="Tc_aezWHYmmAkqpa8-6ETFcAA_2_2"></a><a id="Tc_56n5Af3KzECJZ5dgUNG26A_2_5"></a><a id="Tc_gHfdk0izfkO5q4MsgF2XaQ_2_8"></a><a id="Tc_k8ExcF2wl0ydtM-CPueRDQ_2_11"></a><a id="Tc_PIAjHJxJ40OXFC6ssVdjRg_3_0"></a><a id="Tc_9HGncGdvw0WNZ_z2y17yYg_3_2"></a><a id="Tc_voNZrWfjjkOz4MR2RibYnA_3_5"></a><a id="Tc_me0-VTpsj0-_tUzAfDcX2g_3_8"></a><a id="Tc_oQ17cRLAo0mpQlWu-5o_2w_3_11"></a><a id="Tc_m9Lt5WbBj06Yawmlljiwtw_4_0"></a><a id="Tc_CSzgnMPk5kCtxXrCdQ_6zg_5_0"></a><a id="Tc_Hqnl8BmMZEy9rHjbhPKKJQ_5_2"></a><a id="Tc_G8K1ykS_Uky6ZFVAviTt-w_5_5"></a><a id="Tc_rK71SUdp6UyxEdCs5qdobA_5_8"></a><a id="Tc_XMypXnd_O0KhwI5FnNQwxQ_5_11"></a><a id="_afba53c4_5509_4a91_943c_d8ed1b065c77"></a><a id="Tc_FiZK3tjjGkG_irbNaju1xg_1_2"></a><a id="Tc_QNSmWC00OUC3Ov2ZKdxdQQ_1_8"></a><a id="Tc_FrB1safcpEqeFndjjmz5Fg_2_2"></a><a id="Tc_jcVOlhjQWUm1kPPrriSAew_2_5"></a><a id="Tc_epeQcxEqh0CRTzHCKudbXw_2_8"></a><a id="Tc_oR8-4K7YEEuhP-nn_D-mBQ_2_11"></a><a id="Tc_vuNPhHg3mUK9-AMqswbcuA_3_0"></a><a id="Tc_9jLdqm0G4kGw_blGONAKFg_3_2"></a><a id="Tc_xwBFosiRQUKm6BWepSXIeQ_3_5"></a><a id="Tc_6T6JqpcnRES_rbMTSGvUeg_3_8"></a><a id="Tc_x5S6H5dHokOMWnULh4TItQ_3_11"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" name="rigl:LeaseDisclosureTextBlock" id="Tb_L1PBzuvroUiw2FpM1QTCnQ" continuedAt="Tb_L1PBzuvroUiw2FpM1QTCnQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">10.</b></span><b style="font-weight:bold;">Leases</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"><span style="font-size:10pt;background:#ffffff;">We have a sublease agreement with Atara Biotherapeutics, Inc. (Atara) entered in October 2022 to sublease an office space located in South San Francisco, California. Subject to the terms of the sublease agreement, the lease term commenced in November 2022 and shall expire in May 2025. This leased facility is currently held as our new headquarters following the expiration of our previously leased facility in January 2023. At lease measurement date in the fourth quarter of 2022, we recognized the operating lease right-of-use asset and lease </span><span style="-sec-ix-hidden:Hidden_WC8UdES80kWQ1oTf-c3WYQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">liability</span></span><span style="font-size:10pt;background:#ffffff;"> of approximately </span><span style="font-size:10pt;background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_rigl_HeadquartersOfficeSpaceSubleaseSouthSanFranciscoCaliforniaMember_RzRVSQYro0qfZzFsimZvQA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="Narr_O6RsmCTaUk-GZL6mqjIohQ">1.3</ix:nonFraction></span><span style="font-size:10pt;background:#ffffff;"> million. </span><span style="font-size:10pt;">As of June 30, 2023, we recorded </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_rigl_HeadquartersOfficeSpaceSubleaseSouthSanFranciscoCaliforniaMember_Q7wBI-TD_USrGUm0m_WO2A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncentiveToLessee" scale="6" id="Narr_0bBOd50gP0yz_rwMIjUxiw">0.2</ix:nonFraction></span><span style="font-size:10pt;"> million of lease incentives from our sublease with Atara, which we recorded as a reduction to operating lease right-of-use asset and lease liability until the lease ends and the asset is transferred. The weighted average remaining term of our leases as of June 30, 2023 was </span><span style="-sec-ix-hidden:Hidden_V6j-ReLR3UOlKbpOTUVtAQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.92</span></span><span style="font-size:10pt;"> years. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">We had a lease agreement with Healthpeak Properties, Inc. (formerly known as HCP BTC, LLC), to occupy research and office space located in South San Francisco, California and a sublease agreement with an unrelated third-party to sublet a portion of the leased facility. Both leases expired in January 2023.  </span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" name="us-gaap:LeaseCostTableTextBlock" id="Tb_Gkb8_zKMpkSh9eBmHV2wFw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">The components of our operating lease expense were as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:94.39%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:41.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:27.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fixed operating lease expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_dmK9F74c-E2-kcnfXIHQ5w_3_3">166</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2022_To_6_30_2022_ICCkO9pPUUSORAn1kecZBA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_g43em5QHjEW4-xGf7z1Tkg_3_6">1,340</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_RbUt0Ky1IkyReA4Ws61ZPw_3_9">778</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_DLHZJElm3EqsEzpbwDGHbw_3_12">2,680</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Variable operating lease expense (net credit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ" decimals="-3" format="ixt:numdotdecimal" name="rigl:VariableLeaseExpenseNetCredit" sign="-" scale="3" id="Tc_0OZJBrfT4kiUYY5UsvUtCQ_4_3">42</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2022_To_6_30_2022_ICCkO9pPUUSORAn1kecZBA" decimals="-3" format="ixt:numdotdecimal" name="rigl:VariableLeaseExpenseNetCredit" scale="3" id="Tc_z0cTiWn8eEqglEx7RDc26A_4_6">125</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" decimals="-3" format="ixt:numdotdecimal" name="rigl:VariableLeaseExpenseNetCredit" scale="3" id="Tc_7WsukTfb5ECY_bhxHl1BmQ_4_9">30</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g" decimals="-3" format="ixt:numdotdecimal" name="rigl:VariableLeaseExpenseNetCredit" scale="3" id="Tc_gfaGwFjti0-znXvSUQOsIg_4_12">391</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total operating lease expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="Tc_LaGil1yJCkmcqC4LGCdZYg_5_3">124</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2022_To_6_30_2022_ICCkO9pPUUSORAn1kecZBA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="Tc_-QMlBd6JBke2TP3iQilt-A_5_6">1,465</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="Tc_56w7o_R00Uu-1X3dK8ywTA_5_9">808</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="Tc_8fuHzMZJP0KpkWzb-kVp6A_5_12">3,071</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" name="rigl:CashFlowInformationRelatedToOperatingLeaseTableTextBlock" id="Tb_KyU4KeV6IE-66Z3TVu3v1Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Supplemental information related to our operating lease were as follow (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:94.58%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:41.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:28.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash payments included in the measurement of operating lease liabilities</p></td><td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="Tc_suRqxRTkkUeIYSH0CA39jQ_3_3">178</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2022_To_6_30_2022_ICCkO9pPUUSORAn1kecZBA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="Tc_48p5OL7xlE-TZFOmEfL2HQ_3_6">2,630</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="Tc_66i7O02ERUmnCG8X_JEbmg_3_9">1,174</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="Tc_2sPtaBlVQ0qsOgAdPz3Irw_3_12">5,226</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_e447c6e4_4408_4e0f_9d60_ce142055cd14"></a><a id="Tc_tv9DZZcP3Em4rJNi1c17og_1_2"></a><a id="Tc_DbhMijiRd0-mtbxYviO6gQ_1_8"></a><a id="Tc_6u07r5k5wkqLC2SYNZg3lw_2_2"></a><a id="Tc_3Ll0xXyG-U-eDe31VzWsvQ_2_5"></a><a id="Tc_cBiNBsrFXUaEjVfn33ik8Q_2_8"></a><a id="Tc_cYJSRbE2wEWnwCWHJ8p8Mw_2_11"></a><a id="Tc_6o_VvDS3R0ynmK4CUD7VIA_3_0"></a><a id="Tc_zIeP5YIumEKdrtz3WQ2Elw_3_2"></a><a id="Tc_nthf9x0FM0mLCWth0eVLiQ_3_3"></a><a id="Tc_GVVsRXaMNEiOUsx5NYwZ0g_3_5"></a><a id="Tc_o547U6Zkv0KKreXcO21nDQ_3_8"></a><a id="Tc_CCu1K4gZQ0ezGxEwsHijNg_3_11"></a><a id="Tc_TV3Wx5D2c0quJYUjlqyIQQ_4_0"></a><a id="Tc_mJn9R9C_-UyyAWrBFv0CeA_4_3"></a><a id="Tc_zMdXBJtLXEu_Bxkn1G-YRA_5_0"></a><a id="Tc_kmbTTAV2b06-fEfmoiDViA_5_3"></a><a id="Tc_RD9u5yEFQ0u-IZbmzeKc5g_6_0"></a><a id="Tc_qhHKqoeA7EqUQQAWMLEosQ_6_2"></a><a id="Tc_hrnnnTzJUEafk1WLlRNXYQ_6_5"></a><a id="Tc_sMSIOoBFAESV05qXI9eS8w_6_8"></a><a id="Tc_nsbhpny8rk6_Nqy0juiWCA_6_11"></a><a id="_a1a60fa9_1a8c_4a0f_8f81_f25df7ee92f5"></a><a id="Tc_vS3aKFq4lEatCjhpxSYSQA_1_0"></a><a id="Tc_07luINj4Ukuyjj_0DcPerA_1_2"></a><a id="Tc_dcruGX-1GUu5Q6Rs-fPTDQ_2_0"></a><a id="Tc_2Xu5QMuAL0WeIeIgGI1Iqw_3_0"></a><a id="Tc_UDITOy0vt0mIgWrKvF9tHA_4_0"></a><a id="Tc_EHRgHDolXE6IhYorREmVoA_4_2"></a><ix:continuation id="Tb_L1PBzuvroUiw2FpM1QTCnQ_cont1"><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" name="us-gaap:OperatingLeaseLeaseIncomeTableTextBlock" id="Tb_wgk_qmEAUEam0bwAEKe40g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Supplemental information related to our operating sublease was as follow (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:94.15%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:41.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:27.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fixed sublease expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2022_To_6_30_2022_ICCkO9pPUUSORAn1kecZBA" decimals="-3" format="ixt:numdotdecimal" name="rigl:FixedSubleaseExpense" scale="3" id="Tc_AFuTUMeTCEWD9MP9g0tlfQ_3_6">1,095</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" decimals="-3" format="ixt:numdotdecimal" name="rigl:FixedSubleaseExpense" scale="3" id="Tc_80n8njQmn0KsIr_qbrcb9g_3_9">365</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g" decimals="-3" format="ixt:numdotdecimal" name="rigl:FixedSubleaseExpense" scale="3" id="Tc_NM85qXFNc0yf8CtxYW78yQ_3_12">2,190</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Variable sublease expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2022_To_6_30_2022_ICCkO9pPUUSORAn1kecZBA" decimals="-3" format="ixt:numdotdecimal" name="rigl:VariableSubleaseExpense" scale="3" id="Tc_n9I-NEjFQEq0PkwK7AZTIQ_4_6">206</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" decimals="-3" format="ixt:numdotdecimal" name="rigl:VariableSubleaseExpense" scale="3" id="Tc_kv8bLgIHk0ahasniRAVh0Q_4_9">77</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g" decimals="-3" format="ixt:numdotdecimal" name="rigl:VariableSubleaseExpense" scale="3" id="Tc_sSQfwQqgikuJOmT-R8WF4w_4_12">450</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sublease income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_4_1_2022_To_6_30_2022_ICCkO9pPUUSORAn1kecZBA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SubleaseIncome" scale="3" id="Tc_uWY3rh6o1EqLnINS2PLRSA_5_6">1,301</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SubleaseIncome" scale="3" id="Tc_u61E_yS2Jka8LHNLh77EZw_5_9">442</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SubleaseIncome" scale="3" id="Tc_CgAwS4etqkavN42uottv-A_5_12">2,640</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_if_nK6gayEetouowdVil5w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_v_fUsNyOv0y60ttHM-hoPg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_n4oiXcFrkUefbhZElnx3QQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_RzHufXubkkibtQabd8gePg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="Tb_-ej8DpmrME2G-5-0HmjGmA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table presents the future lease payments as of June 30, 2023 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:63.06%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:73.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Remainder of 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="Tc_BeuW9WT6E0GwXV_2iztjSw_1_3">360</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc_eBanHj3SyU-JcF0jbRhooQ_2_3">739</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="Tc_o7amubdcZ0WUciIMvtb-lw_3_3">301</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total minimum payments required</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA" contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="Tc_NRW0IF8eNUKdGBOknaCtUg_4_3">1,400</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_6e240971_1044_4412_9c25_53e9c722649e"></a><a id="Item2_ManagementsDiscussionAndAna_120616"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item 2.</b></span><b style="font-weight:bold;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;"><i style="font-style:italic;">This discussion and analysis should be read in conjunction with our financial statements and the accompanying notes included in this report and the audited financial statements and accompanying notes included in our Annual Report on Form&#160;10-K for the year ended December 31, 2022 filed with the SEC on March 7, 2023. Our financial results for the three and six months ended June 30, 2023 are not necessarily indicative of results that may occur in future interim periods or for the full fiscal year.</i></p><a id="_cp_text_1_12"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;"><i style="font-style:italic;">This Quarterly Report on Form&#160;10-Q contains statements indicating expectations about future performance and other forward-looking statements within the meaning of Section&#160;27A of the Securities Act of 1933, as amended (Securities Act) and Section&#160;21E of the Securities Exchange Act of 1934, as amended (Exchange Act), that involve risks and uncertainties. </i><i style="font-style:italic;">We usually use words such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;might,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;intend,&#8221; or the negative of these terms or similar expressions to identify these forward-looking statements.</i><i style="font-style:italic;"> </i><i style="font-style:italic;">These statements appear throughout this Quarterly Report on Form&#160;10-Q and are statements regarding our current expectations, beliefs or intent, primarily with respect to our operations and related industry developments. Examples of these statements include, but are not limited to:</i><i style="font-style:italic;"> our </i><i style="font-style:italic;">expectations regarding the impact of the global pandemic; our </i><i style="font-style:italic;">business and scientific strategies;</i><i style="font-style:italic;"> risks and uncertainties associated with the commercialization and marketing of our products in the US and outside the US; risks that the FDA, EMA or other regulatory authorities may make adverse decisions regarding our products; </i><i style="font-style:italic;">the progress of our and our collaborators&#8217; product development programs, including clinical testing, and the timing of results thereof; our corporate collaborations and revenues that may be received from our collaborations and the timing of those potential payments; our expectations with respect to regulatory submissions and approvals;&#160;our drug discovery technologies; our research and development expense; protection of our intellectual property and our intention to vigorously enforce our intellectual property rights; sufficiency of our cash and capital resources and the need for additional capital; and our operations and legal risks. You should not place undue reliance on these forward-looking statements. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including as a result of the risks and uncertainties discussed under the heading &#8220;Risk Factors&#8221; in Item 1A of Part&#160;II of this Quarterly Report on Form&#160;10-Q. Any forward-looking statement speaks only as of the date on which it is made, and we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events, except as required by applicable law. New factors emerge from time to time, and it is not possible for us to predict which factors will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements</i>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">We are a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. We focus on products that address signaling pathways that are critical to disease mechanisms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Our first product approved by the FDA is TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only approved oral SYK inhibitor for the treatment of adult patients with chronic ITP who have had an insufficient response to a previous treatment. The product is also commercially available in Europe and the UK (as TAVLESSE), and in Canada, Israel and Japan (as TAVALISSE) for the treatment of chronic ITP in adult patients. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Our second FDA approved product is REZLIDHIA<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#160;</sup><span style="color:#222222;background:#ffffff;">(olutasidenib) capsules for the treatment of adult patients with R/R AML with a susceptible IDH1 mutation as detected by an FDA-approved test. We began our commercialization of REZLIDHIA in December 2022. W</span>e in-licensed <span style="color:#222222;background:#ffffff;">olutasidenib</span> from Forma (now Novo Nordisk), with exclusive, worldwide rights for its development, manufacturing and commercialization. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">We continue to advance the development of our IRAK 1/4 inhibitor program, in an open-label, Phase 1b trial to determine the tolerability and preliminary efficacy of the drug in patients with lower-risk <span style="color:#222222;background:#ffffff;">MDS</span> who are refractory or resistant to prior therapies. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 0pt 0pt;">Our other ongoing clinical programs include a fostamatinib Phase 2/3 trial, the ACTIV-4 Host Tissue Trial, for the treatment <span style="background:#ffffff;">of hospitalized high-risk patients with COVID-19</span> being conducted and sponsored by the NIH/ NHLBI, and </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;">a RIPK1 inhibitor program in clinical development with our partner Lilly. We also have product candidates in clinical development with partners BerGenBio and Daiichi. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><b style="font-weight:bold;">Business Updates </b></p><a id="_Hlk77251980"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">TAVALISSE IN ITP</span></p><a id="_Hlk94800903"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">For the six months ended June 30, 2023, net product sales of TAVALISSE were $43.6 million, a 26% increase compared to the same period in 2022. The increase in our net product sales was primarily driven by the increase in quantities sold as well as the increase in price per bottle of TAVALISSE. Our first quarter net sales are typically impacted by the first quarter reimbursement issues such as the resetting of co-pays and the Medicare donut hole.</p><a id="_Hlk128487678"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="color:#222222;font-style:italic;font-weight:bold;background:#ffffff;">REZLIDHIA</span><span style="font-style:italic;font-weight:bold;"> in R/R AML with mIDHI</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="color:#222222;background:#ffffff;">For the six months ended June 30, 2023, we recognized $4.0 million of net product sales of REZLIDHIA. We began the commercialization of REZLIDHIA in December 2022 following the FDA approval. On December 1, 2022, the FDA approved REZLIDHIA capsules for the treatment of adult patients with R/R AML with a susceptible IDH1 mutation as detected by an FDA-approved test.</span><span style="background:#ffffff;"> Our commercial efforts focus on targeting healthcare professionals (HCPs) who manage&#160;patients with R/R AML.&#160;</span><span style="color:#222222;background:#ffffff;">For further discussions and other updates including recent publications on REZLIDHIA, refer to &#8220;Commercial Products &#8211; REZLIDHIA in R/R AML with mIDH1&#8221; section below.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="color:#222222;background:#ffffff;">W</span>e in-licensed <span style="color:#222222;background:#ffffff;">olutasidenib</span> from Forma (now Novo Nordisk), with exclusive, worldwide rights for development, manufacturing and commercialization of olutasidenib for any uses, including for the treatment of AML and other malignancies. In accordance with the terms of the license and transition services agreement, we paid an upfront fee of $2.0 million, with the potential to pay up to $67.5 million additional payments upon achievement of specified development and regulatory milestones and up to $165.5 million additional payments upon achievement of certain commercial milestones. <span style="background:#ffffff;">In addition, subject to the terms and conditions of the license and transition services agreement, Forma (now Novo Nordisk) would be entitled to tiered royalty payments on net sales of licensed products at percentages ranging from low-teens to mid-thirties, as well as certain portions of our sublicensing revenue, subject to certain standard reductions and offsets.</span> During the year ended December 31, 2022, certain milestones were met which entitled Forma (now Novo Nordisk) to receive a $17.5 million milestone payments. No new milestone was met during the six months ended June 30, 2023. For further discussions, see &#8220;Note 4 - Sponsored Research and License Agreements and Government Contract&#8221; <span style="background:#ffffff;">to our&#160;&#8220;Notes to Condensed Financial Statements&#8221;&#160;contained in Part I, Item&#160;1 of this Quarterly Report on Form 10-Q.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">R289, an Oral IRAK1/4 Inhibitor for Hematology-Oncology, Autoimmune, and Inflammatory Diseases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We continue to advance the development of our IRAK 1/4 inhibitor program, completing the evaluation of a new pro-drug formulation of R835, R289, in single-ascending and multiple ascending dose studies with positive safety results in 2021.&#160;In January 2022, we received clearance from the FDA on our clinical trial design to explore R289 in lower-risk <span style="color:#222222;background:#ffffff;">MDS</span>. The open-label, Phase 1b trial will determine the tolerability and preliminary efficacy of R289 in patients with lower-risk MDS who are refractory or resistant to prior therapies. In December 2022, we <span style="color:#222222;background:#ffffff;">announced that we dosed the first patient in our Phase 1b trial of R289.</span> The <span style="color:#222222;background:#ffffff;">Phase 1b trial of R289 is expected to enroll approximately 22 patients. The primary objective of the trial is safety, with secondary and exploratory objectives to assess preliminary efficacy and characterize the pharmacokinetic and pharmacodynamic profile of R289. The safety and efficacy data from this Phase 1b trial, along with the safety and pharmacokinetic/pharmacodynamic data from the completed first-in-human study in heathy volunteers, are intended to be used to determine the recommended Phase 2 dose for future clinical development of R289 targeting lower-risk MDS. To date, target enrollment in the second cohort of the trial has been completed and we expect to begin enrollment in the third cohort in the near future.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="color:#222222;font-size:10pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Global Strategic Partnership with Lilly</span></p><a id="_Hlk101965566"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:36pt;background:#ffffff;margin:12pt 0pt 0pt 0pt;">Lilly is continuing to advance R552, an investigational, potent and selective RIPK1 inhibitor. Lilly has initiated the Phase 2a trial studying R552 in adult patients with moderately to severely active rheumatoid arthritis. The trial plans to enroll 100 patients globally. RIPK1 is implicated in a broad range of key inflammatory cellular processes and plays a key role in tumor necrosis factor signaling, especially in the induction of pro-inflammatory necroptosis. The program </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">also includes RIPK1 compounds that cross the blood-brain barrier (CNS-penetrants) to address neurodegenerative diseases such as Alzheimer&#8217;s disease and amyotrophic lateral sclerosis. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:12.0pt;background:#ffffff;margin:0pt 0pt 9pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="font-size:10pt;">Under the Lilly Agreement, we are responsible for 20% of the development costs for R552 in the US, Europe, and Japan, up to a specified cap. Lilly is responsible for funding the remainder of all development activities for R552 and other non-CNS disease development candidates. Under the Lilly Agreement, we have the right to opt-out of co-funding the R552 development activities in the US, Europe and Japan at two different specified times. If we exercise our first opt-out right (no later than September 30, 2023), we are required to fund our share of the R552 development activities in the US, Europe, and Japan up to a maximum funding commitment of $65.0 million through April 1, 2024. Through June 30, 2023, Lilly billed us $16.9 million of the funding development costs and the amounts were fully paid as of June 30, 2023. </span></p><a id="_Hlk132270242"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:3pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Fostamatinib in Hospitalized COVID-19 patients</span></p><a id="_Hlk94800977"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">We previously announced in November 2022 the top-line results from the FOCUS Phase 3 clinical trial to evaluate the safety and efficacy of fostamatinib in hospitalized COVID-19 patients without respiratory failure that have certain high-risk prognostic factors did not meet statistical significance in the primary efficacy endpoint of the number of days on oxygen through Day 29. Upon further analysis, we discovered an error by the contract research organization (CRO) in the application of a statistical stratification factor. The contracted programming CRO misinterpreted receipt of prior COVID-19 treatment of interest 14 days before randomization (regardless of continuation post randomization), as those medications taken 14 days before the date of randomization and ended prior to the day of randomization. After correcting for this statistical error, the primary endpoint of the study was met; those who received fostamatinib had lower mean days on oxygen than those who received placebo (4.8 vs. 7.6 days, p=0.0136). Further, fostamatinib showed significance or trend towards significance in all secondary endpoints of reducing mortality and morbidity compared to placebo after correcting for the error. These results, which we intend to publish, have been accepted for oral presentation at IDWeek 2023. During our continued analysis regarding fostamatinib in hospitalized COVID-19 patients, we provided the updated analysis to the FDA and our partner, the US Department of Defense. Given </span>the end of the federal COVID-19 Public Health Emergency (PHE) in May 2023<span style="background:#ffffff;">, and based on feedback from the FDA, US Department of Defense and other advisors regarding the program&#8217;s regulatory requirements, costs, timeline and potential for success, we decided not to submit an Emergency Use Authorization (EUA) or sNDA.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The ACTIV-4 Host Tissue Trial, initiated and funded by NHLBI, is a randomized, placebo-controlled trial of therapies, including fostamatinib, targeting the host response to COVID-19 in hospitalized patients. The ACTIV-4 Host Tissue Trial is evaluating fostamatinib in a targeted population of approximately 600 hospitalized patients with COVID-19, 300 fostamatinib versus 300 placebo. An interim analysis of the trial was completed by the Data and Safety Monitoring Board with a recommendation for the trial to continue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Update on Current and Potential Future Impact of COVID-19 on our Business</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">The COVID-19 pandemic has adversely impacted our business and operations. Although the World Health Organization declared end of COVID-19 global public health emergency in May 2023, the degree to which another global pandemic may affect our business and operations and financial condition in the future will depend on developments that are highly uncertain and beyond our knowledge or control. <span style="background:#ffffff;">As such, we cannot ascertain the full extent of the future impacts it may have on our business. See also &#8220;Part I, Item 1A, Risk Factors&#8221; of this Quarterly Report on Form 10-Q for additional information on risks and uncertainties related to the COVID-19 pandemic.</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;min-height:205.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;"><b style="font-weight:bold;">Our Product Portfolio</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;</span></span>The following&#160;table summarizes our portfolio:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="rigl-20230630x10q004.jpg" alt="Graphic" style="display:inline-block;height:204.8pt;left:0%;padding-bottom:0.7pt;position:relative;top:0pt;width:477.5pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Commercial Products</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">TAVALISSE/Fostamatinib in ITP</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Chronic ITP affects an estimated 81,300 adult patients in the US. In patients with ITP, the immune system attacks and destroys the body&#8217;s own blood platelets, which play an active role in blood clotting and healing. ITP patients can suffer extraordinary bruising, bleeding and fatigue as a result of low platelet counts. Current therapies for ITP include steroids, blood platelet production boosters that imitate thrombopoietin (TPO) and splenectomy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Taken in tablet form, fostamatinib blocks the activation of SYK inside immune cells. ITP is typically characterized by the body producing antibodies that attach to healthy platelets in the blood stream. Immune cells recognize these antibodies and affix to them, which activates the SYK enzyme inside the immune cell, and triggers the destruction of the antibody and the attached platelet. When SYK is inhibited by fostamatinib, it interrupts this immune cell function and allows the platelets to escape destruction. The results of our Phase&#160;2 clinical trial, in which fostamatinib was orally administered to 16 adults with chronic ITP, published in <i style="font-style:italic;">Blood</i>, showed that fostamatinib significantly increased the platelet counts of certain ITP patients, including those who had failed other currently available agents.</p><a id="_Hlk511203532"></a><a id="_cp_text_1_7"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">Our Fostamatinib for Immune Thrombocytopenia (FIT) Phase 3 clinical program had a total of 150 ITP patients which were randomized into two identical multi-center, double-blind, placebo-controlled clinical trials. The patients were diagnosed with persistent or chronic ITP, and had blood platelet counts consistently below 30,000 per microliter of blood. Two-thirds of the subjects received fostamatinib orally at 100 mg twice daily (bid) and the other third received placebo on the same schedule. Subjects were expected to remain on treatment for up to 24 weeks. At week four of treatment, subjects who failed to meet certain platelet counts and met certain tolerability thresholds could have their dosage of fostamatinib (or corresponding placebo) increased to 150 mg bid. The primary efficacy endpoint of this program was a stable platelet response by week 24 with platelet counts at or above 50,000 per microliter of blood for at least four of the final six qualifying blood draws. In August 2016, we announced the results of the first FIT study, reporting that fostamatinib met the study&#8217;s primary efficacy endpoint. The study showed that 18% of patients receiving fostamatinib achieved a stable platelet response compared to none receiving a placebo control. In October 2016, we announced the results of the second FIT study, reporting that the response rate (16% in the treatment group, versus 4% in the placebo group) was consistent with the first study, although the difference was not statistically significant. In the ITP double-blind studies, the most commonly reported adverse reactions occurring in at least 5% of patients treated with TAVALISSE were diarrhea, hypertension, nausea, dizziness, increased alanine aminotransferase, increased aspartate aminotransferase, respiratory infection, rash, abdominal pain, fatigue, chest pain, and neutropenia. Serious adverse drug </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">reactions occurring in at least 1% of patients treated with TAVALISSE in the ITP double-blind studies were febrile neutropenia, diarrhea, pneumonia, and hypertensive crisis. A post-hoc analysis from our Phase 3 clinical program in adult patients with chronic ITP, highlighting the potential benefit of using TAVALISSE in earlier lines of therapy, was published in the British Journal of Haematology in July 2020. In addition, a report describing the long-term safety and durable efficacy of TAVALISSE with up to 5 years of treatment was published in Therapeutic Advances in Hematology in 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">TAVALISSE was approved by the FDA in April 2018 for the treatment of ITP in adult patients who have had an insufficient response to a previous treatment, and successfully launched in the US in May 2018. The FDA granted orphan drug designation for fostamatinib for the treatment of ITP in August 2015.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">In January 2020, the EC granted a centralized MA for fostamatinib (TAVLESSE) valid throughout the European Union (EU) and in the UK after the departure of the UK from the EU for the treatment of chronic ITP in adult patients who are refractory to other treatments. In December 2022, Japan&#8217;s PMDA approved the NDA for fostamatinib in chronic ITP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:12.0pt;margin:9pt 0pt 9pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><i style="font-size:10pt;font-style:italic;">Competitive landscape for TAVALISSE</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Our industry is intensely competitive and subject to rapid and significant technological change. TAVALISSE is competing with other existing therapies. In addition, a number of companies are pursuing the development of pharmaceuticals that target the same diseases and conditions that we are targeting. For example, there are existing therapies and drug candidates in development for the treatment of ITP that may be alternative therapies to TAVALISSE. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Currently, corticosteroids remain the most common first line therapy for ITP, occasionally in conjunction with intravenous immunoglobulin (IVIg) or anti-Rh(D) to help further augment platelet count recovery, particularly in emergency situations. However, it has been estimated that frontline agents lead to durable remissions in only a small percentage of newly diagnosed adults with ITP. Moreover, concerns with steroid-related side effects often restrict therapy to approximately four weeks. As such, many patients progress to persistent or chronic ITP, requiring other forms of therapeutic intervention. In long-term treatment of chronic ITP, patients are often cycled through several therapies over time in order to maintain a sufficient response to the disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Other approaches to treat ITP are varied in their mechanism of action, and there is no consensus about the sequence of their use. Options include splenectomy, thrombopoietin receptor agonists (TPO-RAs) and various immunosuppressants (such as rituximab). The response rate criteria of the above-mentioned options vary, precluding a comparison of response rates for individual therapies. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Even with the above treatment options, a significant number of patients remain severely thrombocytopenic for long durations and are subject to risk of spontaneous or trauma-induced hemorrhage. The addition of fostamatinib to the currently available treatment options could be beneficial because it has a different mechanism of action than any of the therapies that are currently available. Fostamatinib is a potent and relatively selective SYK inhibitor, and its inhibition of Fc receptors and B-cell receptors of signaling pathways make it a potentially broad immunomodulatory agent. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Other products in the US that are approved by the FDA to increase platelet production through binding to TPO receptors on megakaryocyte precursors include PROMACTA<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (Novartis International AG (Novartis)), Nplate<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (Amgen, Inc.) and DOPTELET<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (Swedish Orphan Biovitrum AB). In the longer term, we may eventually face competition from potential manufacturers of generic versions of our marketed products, including the proposed generic version of TAVALISSE that is the subject of an Abbreviated New Drug Application (ANDA) submitted to the FDA by Annora Pharma Private Limited (Annora), which, if approved and allowed to enter the market, it could result in significant decreases in the revenue derived from sale of TAVALISSE and thereby materially harm our business and financial condition. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;"><i style="font-style:italic;">Commercial activities, including sales and marketing</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:36pt;margin:9pt 0pt 0pt 0pt;">Our marketing and sales efforts are focused on hematologists and hematologist-oncologists in the US who manage chronic adult ITP patients.&#160;We have a fully integrated commercial team consisting of sales, marketing, market access, and commercial operations functions. Our sales team promotes our products in the US using customary </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 9pt 0pt;">pharmaceutical company practices, and we concentrate our efforts on hematologists and hematologist-oncologists. Our products are sold initially through third-party wholesale distribution and specialty pharmacy channels and group purchasing organizations before being ultimately prescribed to patients. To facilitate our commercial activities in the US, we also enter into arrangements with various third parties, including advertising agencies, market research firms and other sales-support-related services as needed. We believe that our commercial team and distribution practices are adequate to ensure that our marketing efforts reach relevant customers and deliver our products to patients in a timely and compliant fashion. Also, to help ensure that all eligible patients in the US have appropriate access to our products, we have established a reimbursement and patient support program called Rigel OneCare (ROC). Through ROC, we provide co-pay assistance to qualified, commercially insured patients to help minimize out-of-pocket costs and provide free product to uninsured or under-insured patients who meet certain established clinical and financial eligibility criteria. In addition, ROC is designed to provide reimbursement support, such as information related to prior authorizations, benefits investigations and appeals. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">We have entered into various license and commercial agreements to commercialize fostamatinib globally, but we retain the global rights to fostamatinib outside of the&#160;respective&#160;territories under such license and commercial agreements. Our collaborative partner Grifols has launched TAVLESSE in the UK and certain countries in Europe including Germany, France, Italy and Spain, and continues a phased rollout across the rest of Europe. Our collaborative partner Medison has also launched TAVALISSE in Canada and Israel. Further, our collaborative partner Kissei has also recently launched TAVALISSE in Japan. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:9pt 0pt 9pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><i style="font-size:10pt;font-style:italic;">Fostamatinib in Europe/Turkey</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">We have a commercialization license agreement with Grifols entered in January 2019, for an exclusive rights to commercialize fostamatinib for human diseases, including chronic ITP and AIHA, and non-exclusive rights to develop, fostamatinib in their territory. Grifols territory includes Europe, the UK, Turkey, the Middle East, North Africa and Russia (including Commonwealth of Independent States). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">We are responsible for performing and funding certain development activities for fostamatinib for ITP and AIHA and Grifols is responsible for all other development activities for fostamatinib in such territories. We remain responsible for the manufacturing and supply of fostamatinib for all development and commercialization activities under the agreement. Under the terms of the agreement, we received an upfront cash payment of $30.0 million and will be eligible to receive regulatory and commercial milestones of up to $297.5 million. In January 2020, the EC granted a MA for fostamatinib for the treatment of chronic ITP in adult patients who are refractory to other treatments. With this approval, we received a $20.0 million non-refundable milestone payment, consisted of a $17.5 million payment due upon MAA approval by the EMA of fostamatinib for the first indication and a $2.5&#160;million creditable advance royalty payment due upon EMA approval of fostamatinib in the first indication. <span style="background:#ffffff;">We are also entitled to receive stepped double-digit royalty payments based on tiered net sales which may reach&#160;30% of net sales.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-indent:36pt;margin:9pt 0pt 0pt 0pt;"><i style="font-style:italic;">Fostamatinib in Japan/Asia </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-indent:36pt;background:#ffffff;margin:0pt;">We have an exclusive license and supply agreement with Kissei entered in October 2018, to develop and commercialize fostamatinib in all current and potential indications in Kissei&#8217;s territory which includes Japan, China, Taiwan and the Republic of Korea. Kissei is a&#160;Japan-based pharmaceutical company addressing patients&#8217; unmet medical needs through its research, development and commercialization efforts, as well as through collaborations with partners. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-indent:36pt;background:#ffffff;margin:0pt;">Under the terms of the agreement, we received an upfront cash payment of&#160;$33.0 million, with the potential for an additional&#160;$147.0 million&#160;in development and commercial milestone payments, and will receive product transfer price payments in the mid to upper twenty percent range based on tiered net sales for the exclusive supply of fostamatinib. Kissei receives exclusive rights to fostamatinib in ITP and all future indications in&#160;Kissei&#8217;s territory. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;">In September 2019, Kissei initiated a Phase 3 trial in Japan of fostamatinib in adult Japanese patients with chronic ITP. The efficacy and safety of orally administered fostamatinib was assessed by comparing it with placebo in a randomized, double-blind study.&#160;Japan&#160;has the third highest prevalence of chronic ITP in the world behind the US and Europe. In February 2020, Kissei was granted orphan drug designation from the Japanese Ministry of Health, Labor and Welfare for R788 (fostamatinib) in chronic ITP. In December 2021, Kissei reported positive top-line results for a Phase 3 clinical trial, meeting its primary endpoint. The Phase 3 clinical trial showed that patients receiving fostamatinib </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">achieved a stable platelet response significantly higher than&#160;patients receiving a placebo control. Based on the positive Phase 3 results, in April 2022, Kissei submitted an NDA to Japan&#8217;s PMDA for fostamatinib in chronic ITP. With this milestone event, we received $5.0 million non-refundable and non-creditable payment from Kissei and recognized the amount as revenue in the second quarter of 2022. In December 2022, Japan&#8217;s PMDA approved TAVALISSE for the treatment of chronic ITP. With this milestone event, we were entitled to receive $20.0 million non-refundable and non-creditable payment from Kissei based on the terms of our collaboration agreement, and such amount was recognized as revenue in the fourth quarter of 2022. The amount was subsequently collected in January 2023. In April 2023, Kissei announced the commercial launch of TAVALISSE for chronic ITP in Japan. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:12pt;text-indent:36pt;background:#ffffff;margin:0pt;">&#160;<i style="font-style:italic;">Fostamatinib in Canada/Israel </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;">We have two exclusive commercial and license agreements with Medison entered in October 2019,&#160;to commercialize fostamatinib in all potential indications in Canada and Israel. Under the terms of the agreements, we received an upfront payment of $5.0 million with the potential for approximately $35.0 million in regulatory and commercial milestones. In addition, we will receive royalty payments beginning at 30%&#160;of net sales.&#160;Under our agreement with Medison for the Canada territory, we have the option to buy back all rights to the product upon regulatory approval in Canada for the indication of AIHA. The buyback provision, if exercised, would require both parties to mutually agree on commercially reasonable terms for us to purchase back the rights, taking into account Medison&#8217;s investment and the value of the rights, among others. Pursuant to this exclusive commercialization license agreement, in August 2020, we entered into a commercial supply agreement with Medison. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;">In November 2020, Health Canada approved the New Drug Submission for TAVALISSE for the treatment of thrombocytopenia in adult patients with chronic ITP who have had an insufficient response to other treatments. In August 2021, Medison Israel received the licenses for registrational approval from the Ministry of Health, which event entitled us to receive $0.1 million of non-refundable milestone payment. In November 2022, Medison Israel made its first commercial sale of TAVALISSE. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:12pt;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Fostamatinib in Latin America</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In May 2022, we entered into commercial license agreement with Knight for the commercialization of fostamatinib for approved indications in Latin America, consisting of Mexico, Central and South America, and the Caribbean (Knight territory). Pursuant to such commercial license agreement, we received a $2.0 million one-time, non-refundable, and non-creditable upfront payment, with potential for up to an additional $20.0 million in regulatory and sales-based commercial milestone payments, and will receive twenty- to mid-thirty percent, tiered, escalated net-sales based royalty payments for products sold in the Knight territory. We are also responsible for the exclusive manufacture and supply of fostamatinib for all future development and commercialization activities under a Commercial and Supply Agreement.&#160; </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">REZLIDHIA in R/R AML with mIDH1</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:9pt 0pt 0pt 0pt;">mIDH1 alterations are seen in AML, glioma, chondrosarcoma, and intrahepatic cholangiocarcinoma. It is estimated that there are approximately 1,000 adult patients, a well-identified patient population, with mIDH1 R/R AML, part of an AML market estimated to have an incidence of 20,000 cases in the US and estimated 120,000 cases globally. Despite having approved treatment options for R/R AML patients who are mIDH1 positive, an unmet need remains. Olutasidenib may represent a treatment option with durable remissions, reduced QTc potential, and a stable pharmacokinetics profile that enables a consistent drug exposure over time. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:9pt;text-indent:36pt;background:#ffffff;margin:0pt;">Olutasidenib is an oral, small molecule drug designed to selectively bind to and inhibit mIDH1. This targeted agent has the potential to provide therapeutic benefit by reducing 2-hydroxyglutarate levels and restoring normal cellular differentiation. IDH1 is a natural enzyme that is part of the normal metabolism of all cells. When mutated, IDH1 activity can promote blood malignancies and solid tumors.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#222222;background:#ffffff;">REZLIDHIA (olutasidenib) is an oral, small molecule, inhibitor of mIDH1 designed to bind to and inhibit mIDH1 to reduce 2-hydroxyglutarate levels and restore normal cellular differentiation of myeloid cells. REZLIDHIA is a novel, non-intensive monotherapy treatment in the R/R AML setting demonstrating a CR+CRh rate of 35% in patients with over 90% of those responders in complete remission. </span>The safety of REZLIDHIA 150 mg administered twice daily was evaluated in 153 adults with relapsed or refractory AML with an IDH1 mutation. <span style="background:#ffffff;">Olutasidenib was designated by the FDA as an orphan drug for the treatment of AML, which provides orphan drug market exclusivity from the time of marketing approval on December 1, 2022. </span></p><a id="_Hlk140159639"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:36pt;margin:12pt 0pt 0pt 0pt;"><span style="background:#ffffff;">On December 1, 2022, the FDA has approved REZLIDHIA capsules for the treatment of adult patients with R/R AML with IDH1 mutation as detected by an FDA approved test. On December 22, 2022, </span>we began the commercialization of REZLIDHIA and made it available to patients. <span style="color:#222222;background:#ffffff;">The recommended dosage of REZLIDHIA is 150 mg taken orally twice daily until disease progression or unacceptable toxicity. The FDA approval was based on the </span>NDA <span style="background:#ffffff;">for olutasidenib for the treatment of m1DH1 R/R AML submitted by </span><span style="background:#ffffff;">Forma (now Novo Nordisk)</span><span style="background:#ffffff;">, that had a PDUFA action date for the application of February 15, 2023.</span> The NDA application was supported with a Phase 2 registrational trial for olutasidenib in mIDH1 R/R AML. Interim results from the Phase 2 registrational trial were reported at the American Society of Clinical Oncology (ASCO) annual meeting in June 2021. The interim results of this trial of 153 patients showed that olutasidenib demonstrated a favorable tolerability profile as a monotherapy in patients with R/R AML who have a susceptible mIDH1, and achieved a complete remission (CR) plus CR with partial hematologic recovery (CRh) rate of 33.3% (30% CR and 3% CRh), the primary efficacy endpoint. While a median duration of CR/CRh was not yet reached, a sensitivity analysis (with a hematopoietic stem cell transplant, or HCST, as the end of a response) indicated the median duration of CR/CRh was 13.8 months<b style="font-weight:bold;">.</b> The overall response rate, comprised CR, CRh, CRi, partial response, and morphologic leukemia-free state (MLFS), was 46% and the median duration of overall response rate (ORR) was 11.7 months. The median overall survival was 10.5 months. For patients with CR/CRh, the median overall survival was not reached, but the estimated 18-month survival was 87%. The most frequently reported treatment emergent adverse events were nausea, constipation, increased white blood cell count, decreased RBC count, pyrexia, febrile neutropenia, and fatigue. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;">In November 2022, we announced the presentation of five posters highlighting data from our commercial and clinical hematology-oncology portfolio at the 64<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup> American Society of Hematology (ASH) Annual Meeting and Exposition which was held in December 2022. An updated interim analysis from the Phase 2 registrational trial of olutasidenib in patients with R/R AML demonstrated robust efficacy and safety results. The registrational cohort of the Phase 2 trial enrolled 153 patients with mIDH1 R/R AML who received olutasidenib monotherapy 150 mg twice daily. The efficacy evaluable population was 147 patients who received their first dose at least six months prior to the interim analysis cutoff date of June 18, 2021. The primary endpoint was a CR/CRh defined as less than 5% blasts in the bone marrow, no evidence of disease, and partial recovery of peripheral blood counts (platelets &gt;50,000/microliter and absolute neutrophil count &gt;500/microliter). The results from the updated interim analysis of patients with mIDH1 R/R AML demonstrated a 35% CR+CRh rate with a median duration of 25.9 months. The ORR a secondary end point, was 48%, and was defined as the rate of CR, CRh, CR with incomplete blood count recovery (CRi), partial remission (which required recovery of neutrophil and platelet counts consistent with a CR), or MLFS. Olutasidenib was effective in a broad range of patients including those with prior high-intensity chemotherapy and/or post-venetoclax. The abstract concluded that the observed activity is clinically meaningful and represents a therapeutic advance in the treatment of this patient population. In this pivotal cohort, olutasidenib was well tolerated with an adverse event profile largely characteristic of symptoms or conditions experienced by patients undergoing treatment for AML or of the underlying disease itself.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;">In November 2022, we announced the publication of data in <i style="font-style:italic;">The Lancet Haematology, </i>which summarizes the Phase 1 results of the Phase 1/2 trial of olutasidenib<span style="color:#222222;">. The objectives of the first phase of the multi-center, open-label Phase 1/2 trial were to assess the safety, pharmacokinetic and pharmacodynamic profile, and clinical activity of olutasidenib, both as monotherapy and in combination with azacitidine, in patients with treatment-na&#239;ve or R/R AML or MDS harboring IDH1 mutations. The published data suggest that olutasidenib, with or without azacitidine, was well-tolerated and was associated with improvements in clinical efficacy endpoints in patients with mIDH1 AML. This trial showed that olutasidenib has the potential to provide an additional treatment option for mIDH1 AML.</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In January 2023, we announced that REZLIDHIA has been added by the National Comprehensive Cancer Network (NCCN) to the latest NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for AML. REZLIDHIA is now included as a recommended targeted therapy for adult patients with R/R AML with IDH1 mutation. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">In February 2023, we announced peer-reviewed publication data in <i style="font-style:italic;">Blood Advances</i>, which summarize clinical results from the Phase 2 registrational trial of REZLIDHIA in patients with mIDH1 R/R AML. The published data demonstrate that REZLIDHIA induced durable remissions and transfusion independence with a well-characterized safety profile. The observed efficacy is clinically meaningful and represents a therapeutic advance in this poor prognosis patient population with limited treatment options.&#160;REZLIDHIA demonstrated both a high rate of response and an extended median duration of complete response of 28.1 months, which is more than a year longer than what is reported with the Standard of Care (SoC). In June 2023, we announced the second REZLIDHIA publication in <i style="font-style:italic;">Blood Advances</i>, a review article examining the preclinical and clinical development, and the positioning of olutasidenib in the mIDH1 AML treatment landscape. The review concluded that the approval of REZLIDHIA is a critical addition to the mIDH1 AML treatment landscape. Further, the available data support the use of REZLIDHIA as monotheraphy in R/R AML patients who have failed intensive chemotheraphy or venetoclax plus <span style="background:#ffffff;">hypomethylating agents</span> (HMA) combination therapy. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:13.5pt;text-indent:36pt;background:#ffffff;margin:1.5pt 0pt 0pt 0pt;"><span style="color:#222222;">In June 2023, we announced presentation of data from an analysis from the Phase 2 study of REZLIDHIA in 17 patients with mIDH1 AML who were previously treated with venetoclax. Data was featured in a poster presentation at the European Hematology Association 2023 Hybrid Congress. The data support olutasidenib induced durable remissions in patients with mIDH1 AML in this poor-prognosis patient population who were relapsed or refractory to venetoclax-based treatment.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">We plan to pursue strategic actions to further develop olutasidenib for the treatment of other malignancies and expansion of commercialization. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;padding-bottom:9pt;text-indent:36pt;margin:9pt 0pt 0pt 0pt;"><i style="font-style:italic;">Competitive landscape for REZLIDHIA</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;background:#ffffff;margin:0pt 0pt 11.25pt 0pt;"><span style="font-weight:normal;">There is currently one other product approved in the US for patients with IDH1 mutation. The FDA granted approval to TIBSOVO</span><sup style="font-size:7.5pt;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="font-weight:normal;"> (ivosidenib), an oral targeted IDH1 mutation inhibitor, (i) in July 2018, for adult patients with R/R AML with a susceptible IDH1 mutation, (ii) in May 2019, for newly diagnosed AML with a susceptible IDH1 mutation who are at least 75 years old or who have comorbidities that preclude use of intensive induction chemotherapy, (iii) in August 2021, for adult patients with previously treated, locally advanced or metastatic cholangiocarcinoma with an IDH1 mutation as detected by an FDA-approved test, and (iv) in May 2022, </span><span style="font-weight:normal;">in combination with azacitidine (azacitidine for injection)&#160;for newly diagnosed AML with a susceptible IDH1 mutation, as detected by an FDA-approved test in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. In addition, some clinicians may utilize non-targeted treatments for patients with mIDH1 R/R AML, including use of venetoclax combinations, hypomethylating agents, other chemotherapy regimens, or investigational agents that may be available to them.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;"><i style="font-style:italic;">Commercial activities, including sales and marketing</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="color:#222222;background:#ffffff;">REZLIDHIA</span><span style="background:#ffffff;"> is highly synergistic with our existing hematology-oncology focused commercial and medical affairs infrastructure. Our commercial efforts will focus on targeting HCPs</span> who manage <span style="background:#ffffff;">patients with R/R AML with mIDH1.</span> We plan to enter collaborations with third parties to commercialize REZLIDHIA outside of US.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Clinical Stage Programs</b></p><a id="_Hlk94686962"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="font-style:italic;font-weight:bold;">R289, an Oral IRAK 1/4 Inhibitor for Hematology-Oncology, Autoimmune, and Inflammatory Diseases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">During the second quarter of 2018, we selected R835, the active metabolite of R289, a proprietary molecule from our IRAK 1/4 inhibitor program for human clinical trials. This investigational candidate is an orally administered, potent and selective inhibitor of IRAK1 and IRAK4 that blocks inflammatory cytokine production in response to toll-like receptor (TLR) and the interleukin-1 receptor (IL-1R) family signaling. TLRs and IL-1Rs play a critical role in the innate immune response and dysregulation of these pathways can lead to a variety of inflammatory conditions. R835 </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">prevents cytokine release in response to TLR and IL-1R activation in vitro. R835 is active in multiple rodent models of inflammatory disease including psoriasis, arthritis, lupus, multiple sclerosis and gout. Preclinical studies show that R835 inhibits both the IRAK1 and IRAK4 signaling pathways, which play a key role in inflammation and immune responses to tissue damage. Dual inhibition of IRAK1 and IRAK4 allows for more complete suppression of pro-inflammatory cytokine release than inhibition of either one individually.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">In October 2019, we announced results from a Phase 1 clinical trial of R835 in healthy subjects to assess safety, tolerability, pharmacokinetics (PK) and pharmacodynamics. The Phase 1 trial was a randomized, placebo-controlled, double-blind trial in 91 healthy subjects, ages 18 to 55. The Phase 1 trial showed positive tolerability and PK data as well as established proof-of-mechanism by demonstrating the inhibition of inflammatory cytokine production in response to a lipopolysaccharide (LPS) challenge. </p><a id="_Hlk95377027"></a><a id="_Hlk96088072"></a><a id="_Hlk95377069"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We continue to advance the development of our IRAK 1/4 inhibitor program, completing the evaluation of a new pro-drug formulation of R835, R289, in single-ascending and multiple ascending dose studies with positive safety results in 2021.&#160;In January 2022, we received clearance from the FDA on our clinical trial design to explore R289 in lower-risk MDS. The open-label, Phase 1b trial will determine the tolerability and preliminary efficacy of R289 in patients with lower-risk MDS who are refractory or resistant to prior therapies. In December 2022, we <span style="color:#222222;background:#ffffff;">announced that we dosed the first patient in our Phase 1b trial of R289.</span> The <span style="color:#222222;background:#ffffff;">Phase 1b trial of R289 is expected to enroll approximately 22 patients. The primary objective of the trial is safety, with secondary and exploratory objectives to assess preliminary efficacy and characterize the pharmacokinetic and pharmacodynamic profile of R289. The safety and efficacy data from this Phase 1b trial, along with the safety and pharmacokinetic/pharmacodynamic data from the completed first-in-human study in heathy volunteers, are intended to be used to determine the recommended Phase 2 dose for future clinical development of R289 targeting lower-risk MDS. To date, target enrollment in the second cohort of the trial has been completed and we expect to begin enrollment in the third cohort in the near future.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Fostamatinib in Hospitalized COVID-19 Patients</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_Hlk55465880"></a><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="font-size:10pt;">COVID-19 is the infectious disease caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). SARS-CoV-2 primarily infects the upper and lower respiratory tract and can lead to acute respiratory distress syndrome (ARDS). Additionally, some patients develop other organ dysfunction including myocardial injury, acute kidney injury, shock resulting in endothelial dysfunction and subsequently micro and macrovascular thrombosis. Much of the underlying pathology of SARS-CoV-2 is thought to be secondary to a hyperinflammatory immune response associated with increased risk of thrombosis. SYK is involved in the intracellular signaling pathways of many different immune cells. Therefore, SYK inhibition may improve outcomes in patients with COVID-19 via inhibition of key Fc gamma receptor and c-type lectin receptor mediated drivers of pathology, such as inflammatory cytokine release by monocytes and macrophages, production of NETs by neutrophils, and platelet aggregation. Furthermore, SYK inhibition in neutrophils and platelets may lead to decreased thromboinflammation, alleviating organ dysfunction in critically ill patients with COVID-19.</span></p><a id="_Hlk70931211"></a><a id="_Hlk95376935"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 0pt 0pt;"><i style="font-style:italic;">Rigel-led Phase 3 Trial.</i><span style="font-style:italic;font-weight:bold;"> </span>In November 2020, we launched our FOCUS Phase 3 clinical trial to evaluate the safety and efficacy of fostamatinib in hospitalized COVID-19 patients without respiratory failure that have certain high-risk prognostic factors. In January 2021, we were awarded $16.5 million from the US Department of Defense&#8217;s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to support&#160;this&#160;Phase 3 clinical trial. This multi-center, double-blind, placebo-controlled, adaptive design study randomly assigns either fostamatinib plus SoC or matched placebo plus SoC (1:1) to targeted evaluable patients. Treatment is administered orally twice daily for 14 days with follow up to day 60. <span style="color:#222222;">In December 2021, we </span><span style="color:#222222;">expanded the inclusion criteria to include patients with more severe disease (NIAID Ordinal Scale 6) to more accurately reflect the clinically predominant patient population hospitalized with COVID-19 and help speed enrollment</span><span style="color:#222222;">. </span>In collaboration with the FDA and Department of Defense, we <span style="color:#222222;">also updated the primary endpoint for the trial from progression to severe disease within 29 days, to the number of days</span> on oxygen<span style="color:#222222;"> through day </span>29.<span style="color:#222222;"> </span>This endpoint allows for closer comparison of the results with earlier results from the NIH/NHLBI Phase 2 clinical trial with fostamatinib and various other NIH-sponsored trials, such as the ACTIV-4 Host Tissue Trial, which uses a similar outcome measure as a primary endpoint. <span style="background:#ffffff;">In July 2022, we completed enrollment with 280 patients. The trial had originally targeted a total of 308 patients; however, we determined the trial would be sufficiently powered with 280 patients to potentially provide a clinically meaningful result and determine the efficacy and safety of fostamatinib in hospitalized COVID-19 patients. We previously announced in November 2022 the top-line results from the FOCUS Phase 3 clinical trial to evaluate the safety and efficacy of </span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">fostamatinib in hospitalized COVID-19 patients without respiratory failure that have certain high-risk prognostic factors did not meet statistical significance in the primary efficacy endpoint of the number of days on oxygen through Day 29. Upon further analysis, we discovered an error by the CRO in the application of a statistical stratification factor. The contracted programming CRO misinterpreted receipt of prior COVID-19 treatment of interest 14 days before randomization (regardless of continuation post randomization), as those medications taken 14 days before the date of randomization and ended prior to the day of randomization. After correcting for this statistical error, the primary endpoint of the study was met; those who received fostamatinib had lower mean days on oxygen than those who received placebo (4.8 vs. 7.6 days, p=0.0136). Further, fostamatinib showed significance or trend towards significance in all secondary endpoints of reducing mortality and morbidity compared to placebo after correcting for the error. These results, which we intend to publish, have been accepted for oral presentation at IDWeek 2023. During our continued analysis regarding fostamatinib in hospitalized COVID-19 patients, we provided the updated analysis to the FDA and our partner, the US Department of Defense. Given </span>the end of the federal COVID-19 PHE in May 2023<span style="background:#ffffff;">, and based on feedback from the FDA, US Department of Defense and other advisors regarding the program&#8217;s regulatory requirements, costs, timeline and potential for success, we decided not to submit an EUA or sNDA.</span><i style="font-style:italic;"> </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:36pt;margin:12pt 0pt 0pt 0pt;"><i style="font-style:italic;">NIH/NHLBI-sponsored Phase 2 Trial.</i><b style="font-weight:bold;"> </b>In September 2020, we announced a Phase 2 clinical trial sponsored by the NIH/NHLBI to evaluate the safety of fostamatinib for the treatment of hospitalized COVID-19 patients. This multi-center, double-blind, placebo-controlled trial randomly assigned fostamatinib or matched placebo (1:1) to 59 evaluable patients. Treatment was administered orally twice daily for 14 days, and a follow-up period to day 60. <span style="background:#ffffff;">The primary endpoint of this trial was cumulative incidence of </span><span style="color:#222222;background:#ffffff;">Serious Adverse Events (SAEs)</span><span style="background:#ffffff;"> through day 29. The trial also included multiple secondary endpoints designed to assess the early efficacy and clinically relevant endpoints of disease course. The trial completed the enrollment in March 2021. In April 2021, w</span>e announced that the Phase 2 clinical trial met its primary endpoint of safety. <span style="color:#222222;background:#ffffff;">Fostamatinib reduced the incidence of SAEs by half.&#160;By day 29, there were three SAEs&#160;in the fostamatinib plus&#160;SoC group of thirty patients compared to six SAEs in the placebo plus SoC group of twenty-nine patients&#160;(p=0.23). Of these, there was a reduction for the disease related SAE of hypoxia in the fostamatinib group compared to placebo&#160;(1 vs 3, respectively; p=0.29). </span>The data from the NIH/NHLBI-Sponsored Phase 2 trial was published in Clinical Infectious Diseases, an official publication of the Infectious Disease Society of America in September 2021. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">In May 2021, the NIH/NHLBI Phase 2 clinical data were submitted as part of a request for an EUA from the FDA for fostamatinib as a treatment for hospitalized patients with COVID-19. In August 2021, the FDA informed us that the clinical data submitted from the NIH/NHLBI-sponsored Phase 2 trial of fostamatinib to treat hospitalized patients suffering from COVID-19 was insufficient for an EUA. </p><a id="_Hlk125718524"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">ACTIV-4 Host Tissue Phase 2/3 Trial.</i><b style="font-weight:bold;"> </b> In June 2021, we announced that fostamatinib had been selected for the NIH ACTIV-4 Host Tissue Trial in hospitalized patients with COVID-19. The ACTIV-4 Host Tissue Trial, initiated and funded by NHLBI, is a randomized, placebo-controlled trial of therapies, including fostamatinib, targeting the host response to COVID-19 in hospitalized patients. The master protocol for this trial was designed to be flexible in the number of study arms, the use of a single placebo group, and the stopping and adding of new therapies. Eligible participants include patients hospitalized for COVID-19 with laboratory-confirmed SARS-CoV-2 infection and a new need for oxygen therapy. The primary outcome is oxygen-free days through day 28. Secondary outcomes include 28-day hospital mortality, use of mechanical ventilation, and severity of disease as measured by World Health Organization (WHO) scale scores.&#160;The ACTIV-4 Host Tissue Trial is evaluating fostamatinib in a targeted population of approximately 600 hospitalized patients with COVID-19, 300 fostamatinib versus 300 placebo. An interim analysis of the trial was completed by the Data and Safety Monitoring Board with a recommendation for the trial to continue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 0pt 0pt;"><i style="font-style:italic;">Imperial College of London Phase 2 Trial. </i>In July 2020, we announced a Phase 2 clinical trial sponsored by Imperial College of London to evaluate the efficacy of fostamatinib for the treatment of COVID-19 pneumonia. <span style="background:#ffffff;">This is a two-stage, open label, controlled clinical trial with patients randomized (1:1:1) to fostamatinib plus SoC, ruxolitinib plus SoC, or SoC alone. Treatment was administered twice daily for 14 days and patients receive a follow-up assessment at day 14 and day 28 after the first dose. The primary endpoint of this trial is progression from mild to severe COVID-19 pneumonia within 14 days in hospitalized patients (WHO COVID-19 Severity Scale 3-4). In April 2022, Imperial College of London completed a pre-planned interim analysis of the primary endpoint, patients progressing from mild or moderate (modified WHO COVID-19 scale 3-4) to severe disease (modified WHO COVID-19 scale &#8805;5) within 14 days, in the Phase 2 MATIS trial. The independent data monitoring committee determined that the fostamatinib plus SoC arm </span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:0pt;"><span style="background:#ffffff;">did not meet the prespecified criteria for continuation to the next stage of the trial.&#160;No safety concerns were identified. The trial remains blinded and Imperial College of London plans to share results with us and scientific community once the trial is complete. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:36pt;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Other Publications. </i>Researchers at MIT and Harvard led a screen to identify FDA-approved compounds that reduce MUC1 protein abundance. MUC1 is a biomarker used to predict the development of ALI and ARDS and correlates with poor clinical outcomes. In June 2020, the results were presented, and of the 3,713 compounds that were screened, fostamatinib was the only compound identified which both decreased expression of MUC1 and is FDA approved. Fostamatinib demonstrated preferential depletion of MUC1 from epithelial cells without affecting cell viability. The research was focused on drug repurposing for the much lower risk of toxicity and the ability of FDA-approved treatments to be delivered on a shortened timescale, which is critical for patients afflicted with lung disease resulting from COVID-19.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;padding-top:12pt;text-indent:36pt;margin:0pt;">In addition, the in vitro studies led by the Amsterdam University Medical Center at the University of Amsterdam, showed that R406, the active metabolite of fostamatinib, blocked macrophage hyperinflammatory responses to a combination of immune complexes formed by anti-Spike IgG in serum from severe COVID-19 patients. Anti-Spike IgG levels are known to correlate with the severity of COVID-19. These results, presented in July 2020, suggest that by inhibiting anti-Spike IgG-mediated hyperinflammation, R406 could potentially play a role in the prevention of cytokine storms as well as pulmonary edema and thrombosis associated with severe COVID-19.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:36pt;background:#ffffff;margin:0pt;">In December 2020, the Journal of Infectious Diseases published research from NIH which demonstrated that R406, the active metabolite of fostamatinib, was able to inhibit NETosis ex vivo in donor plasma from patients with COVID-19. NETosis is a unique type of cell death resulting in the release of NETs. NETs contribute to thromboinflammation and have been associated with mortality in COVID-19. These data provide insights for how fostamatinib may mitigate neutrophil-associated mechanisms contributing to COVID-19 immunopathogenesis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:12.0pt;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_Hlk95820557"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="font-style:italic;font-weight:bold;">Fostamatinib in wAIHA</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">A<span style="color:#202124;background:#ffffff;">utoimmune hemolytic anemia </span>is a rare, serious blood disorder where the immune system produces antibodies that result in the destruction of the body&#8217;s own red blood cells. Symptoms can include fatigue, shortness of breath, rapid heartbeat, jaundice or enlarged spleen. While no medical treatments are currently approved for AIHA, physicians generally treat acute and chronic cases of the disorder with corticosteroids, other immuno-suppressants, or splenectomy. Research has shown that inhibiting SYK with fostamatinib may reduce the destruction of red blood cells. AIHA affects an estimated 45,000 Americans, and approximately 36,000 of those patients have wAIHA, where no approved treatment options currently exist.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">We completed our Phase 2 clinical trial, also known as the SOAR study, in patients with wAIHA. This trial was an open-label, multi-center, two-stage study that evaluated the efficacy and safety of fostamatinib in patients with wAIHA who had previously received treatment for the disorder but have relapsed. The primary efficacy endpoint of this study was to achieve increased hemoglobin levels by week 12 of greater than 10 g/dL, and greater than or equal to 2 g/dL higher than baseline. In November 2019, we announced updated data that in a Phase 2 open-label study of fostamatinib in patients with wAIHA, data showed that 44% (11/25) of evaluable patients met the primary efficacy endpoint of a hemoglobin level &gt;10 g/dL with an increase of &#8805;2 g/dL from baseline by week 24. Including one late responder at week 30, the overall response rate was 48% (12/25). Adverse events were manageable and consistent with those previously reported with fostamatinib. In February 2022, the American Journal of Hematology published the data from our Phase 2 clinical trial of fostamatinib in adults with wAIHA who have failed at least one prior treatment. <span style="color:#222222;background:#ffffff;">The published data demonstrate that fostamatinib rapidly and durably increased hemoglobin levels, with clinically meaningful hemoglobin responses observed in nearly half of the patients, and a safety and tolerability profile consistent with the existing fostamatinib safety database of patients across multiple disease programs studied. &#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">In January 2021, we announced that the FDA had granted Fast Track designation to fostamatinib for the treatment of wAIHA. The FDA granted orphan drug designation for fostamatinib for the treatment of wAIHA in January 2018.</p><a id="_Hlk33628875"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">In March 2019, we initiated our wAIHA pivotal Phase 3 clinical trial of fostamatinib, known as the </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk71026428"></a><a id="_Hlk71026243"></a><a id="_Hlk85727631"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">FORWARD study. The clinical trial protocol calls for a placebo-controlled study of 90 patients with primary or secondary wAIHA who have failed at least one prior treatment. The primary endpoint is a durable hemoglobin response, defined as hemoglobin &gt;10 g/dL and &gt;2 g/dL increase from baseline and durability measure, with the response not being attributed to rescue therapy. In November 2020, we reached an agreement with the FDA on the durable response measure for the primary efficacy endpoint of the trial as well as the inclusion of additional secondary endpoints.&#160;In November 2021, we completed the enrollment of this study. <span style="background:#ffffff;">In April 2022, we completed the treatment period for the last patient under the trial</span>. I<span style="background:#ffffff;">n June 2022, we announced top-line efficacy and safety data from the FORWARD study with 90 patients. Patients were randomized 1:1 to receive fostamatinib or matching placebo twice daily for 24 weeks. The primary efficacy endpoint of hemoglobin response was defined as achieving a hemoglobin &#8805;10 g/dL with an increase from baseline &#8805;2 g/dL on three consecutive available visits during the 24-week treatment period.&#160;The trial did not demonstrate statistical significance in the primary efficacy endpoint of durable hemoglobin response in the overall study population. The trial also included key secondary endpoints, including hemoglobin response on at least one visit, change in hemoglobin from baseline of &#8805;2 g/dL, use of permitted rescue therapy after week 4, change in hemoglobin from baseline to end of treatment and change from baseline to week 24 in Functional Assessment of Chronic Illness Therapy &#8211; Fatigue scale. Across the trial&#8217;s overall patient population, fostamatinib was generally well-tolerated.&#160;The safety profile of the product was consistent with prior clinical experience and no new safety issues were discovered. The most common adverse events (&#8805;10%) with fostamatinib and placebo were diarrhea, hypertension, fatigue, pyrexia, nausea, and dyspnea. Treatment-related SAEs were 6.7% (3/45) for fostamatinib and 4.4% (2/45) for placebo. There were five deaths on the trial (2 with fostamatinib and 3 with placebo), all of which were determined to be unrelated to study drug.&#160;The safety results were consistent with the overall safety profile data collected to date, which includes more than 5,000 patients across multiple diseases. We conducted an in-depth analysis of these data to better understand differences in patient characteristics and outcomes and submitted these findings to the FDA. In October 2022, we announced that we received guidance from the FDA&#8217;s review of these findings. Based on the result of the trial and the guidance from the FDA, we did not file an sNDA for this indication. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;"><span style="background:#ffffff;">Of the 90 patients that completed the FORWARD study, 71 (79%) enrolled in the open-label extension study. We plan on closing this study in 2023. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><b style="font-weight:bold;">Partnered Clinical Programs </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:9pt 0pt 9pt 36pt;"><span style="font-style:italic;font-weight:bold;">BGB324 &#8211; BerGenBio </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">We have an exclusive, worldwide research, development and commercialization agreement with BerGenBio for our investigational AXL receptor tyrosine kinase inhibitor, BGB324/R428 (now referred to as bemcentinib). In October 2022, BerGenBio announced the initiation of a Phase 1b/2a trial evaluating bemcentinib in combination with the current SoC, checkpoint inhibitor pembrolizumab and doublet chemotheraphy, for the treatment of first line non-small cell lung cancer (NSCLC) patients harboring serine/threonine kinase 11 mutations. In February 2023, BerGenBio also announced positive data from Phase 2 trial of bemcentinib in combination with pembrolizumab in patients with second-line NSCLC. The treatment with bemcentinib in combination with pembrolizumab demonstrated long survival benefit and sustained disease control, particularly in patients with AXL TPS &gt; 5, substantiating the relevance of AXL as a target and bemcentinib&#8217;s selective inhibition capabilities in NSCLC.<i style="font-style:italic;"> </i>In March 2023, BerGenBio announced its first patient dosed in Phase 1B/2A trial evaluating bemcentinib in first-line NSCLC patients harboring STK11 mutations. The product is also being investigated in Phase 2 clinical trials in patients with AML and COVID-19. Bemcentinib is being studied in over 600 patients, demonstrating its safety as a monotherapy and in combination with chemotheraphy and immune checkpoint inhibition. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:9pt 0pt 9pt 36pt;"><span style="font-style:italic;font-weight:bold;">DS-3032 - Daiichi</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">DS-3032 is an investigational oral selective inhibitor of the MDM2 protein investigated by Daiichi in three Phase 1 clinical trials for solid and hematological malignancies including AML, acute lymphocytic leukemia, chronic myeloid leukemia in blast phase, lymphoma and MDS. Preliminary safety and efficacy data from a Phase 1 trial of DS-3032 suggests that DS-3032 may be a promising treatment for hematological malignancies including R/R AML and high-risk MDS. In September 2020, worldwide rights to DS-3032 (milademetan) were out-licensed from Daiichi to Rain Oncology Inc., formerly Rain Therapeutics Inc. (Rain). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">In July 2021, Rain announced that it initiated a Phase 3 trial to evaluate the efficacy and safety of milademetan </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">(RAIN-32) for the treatment of patients with unresectable or metastatic dedifferentiated liposarcoma, a rare cancer originating from fat cells located in the soft tissues of the body, and announced the completion of enrollment in August 2022. In May 2023, Rain announced that the trial did not meet its primary endpoint of progression free survival by blinded independent central review compared to the standard of care. Based on the topline results, Rain does not expect to pursue further development of milademetan in dedifferentiated liposarcoma.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-indent:36pt;margin:0pt;">In late 2021, Rain commenced its second clinical trial of milademetan in patients with MDM2-amplified solid tumors. In November 2022, Rain provided an interim analysis of the trial which showed that the drug safety profile of milademetan is preliminarily consistent with its prior Phase 1 trial. In May 2023, Rain announced its plan to suspend the enrollment of its Phase 2 trial of milademetan in patients with MDM2-amplified solid tumors, and terminate its plans to initiate the Phase 1/2 study evaluating the safety and efficacy of milademetan in patients with CDKN2A loss/ TP53&#160;wild type advanced solid tumors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Research, Preclinical and Clinical Development Programs</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We have retained a selected team of experts in drug discovery and preclinical development to leverage our existing proprietary collection of inhibitors, small-molecule compound libraries and large database of associated phenotypic and biochemical assay results of therapeutic interest. We maintain leading expertise on specific areas of operation such as inhibition of SYK, IRAK 1/4, RIPK1 and mIDH1 kinases to assist clinical development and commercial affairs, as well as to expand and explore additional opportunities for such inhibitors in the clinical space. &#160;Our preclinical operations involve collaborations with clinical research organizations, leading investigators from universities and research organizations around the world, and strategic collaborations with other pharmaceutical companies. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have assembled a team of experts in drug development to design and implement clinical trials and to analyze the data derived from these trials. The clinical development group possesses expertise in project management and regulatory affairs. We work with external clinical research organizations with expertise in managing clinical trials, drug formulation, and the manufacture of clinical trial supplies to support our drug development efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Commercialization and Sponsored Research and License Agreements </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">For a discussion of our Sponsored Research and License Agreements and Government Contract, see &#8220;Note 4 - Sponsored Research and License Agreements and Government Contract&#8221; to our&#160;&#8220;Notes to Condensed Financial Statements&#8221;&#160;contained in Part I, Item&#160;1 of this Quarterly Report on Form 10-Q.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_26183957_7570_4b92_937c_ad23d7b87842"></a><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Revenues</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:34.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:34.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:21.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:34.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr><td style="vertical-align:bottom;width:34.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Product sales, net</p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 23,881</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 18,550</span></p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,331</span></p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 47,626</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 34,747</span></p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 12,879</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contract revenues from collaborations</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,005</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 11,269</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (9,264)</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,330</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 11,807</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (7,477)</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Government contract</p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,000</span></p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,000</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total revenues</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 26,886</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 29,819</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2,933)</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 52,956</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 46,554</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,402</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table summarizes the percentages of revenues from each of our customers who individually accounted for 10% or more of the total net product sales and revenues from collaborations:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:86.8%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:48.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">McKesson Specialty Care Distribution Corporation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">44%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">34%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">45%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">36%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cardinal Healthcare</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">28%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">16%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">26%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">20%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ASD Healthcare and Oncology Supply</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">19%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">12%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">21%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">19%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Kissei</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">25%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">16%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Net product sales pertained to sales of our products in the US, net of chargebacks, discounts and fees, government and other rebates and returns. For the three and six months ended June 30, 2023, net product sales increased by 29% and 37%, respectively, compared to the same periods in 2022. The increase was primarily driven by increased TAVALISSE net product sales and the current period net product sales from REZLIDHIA. TAVALISSE net product sales increased by $2.8 million or 15% in the three months ended June 30, 2023, and $8.9 million or 26% in the six months ended June 30, 2023, compared to the same periods in 2022, primarily as a result of increased quantities sold and higher price per bottle. In the three and six months ended June 30, 2023, we recognized $2.6 million and $4.0 million, respectively, of net product sales from REZLIDHA. We began our commercialization of REZLIDHIA in December 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Contract revenues from collaborations in the three and six months ended June 30, 2023 consisted primarily of revenue from Grifols related to the delivery of drug supplies of $1.2 million and $2.8 million, respectively, and royalty revenue of $0.8 million and $1.5 million, respectively. <span style="background:#ffffff;">Contract revenues from collaborations in the three and six months ended June 30, 2022 were consisted primarily of $7.5 million and $7.6 million, respectively, in revenue from Kissei related to a milestone payment and delivery of fostamatinib supply, $2.0 million for each of the periods in revenue related to our license agreement with Knight, $1.4 million and $1.7 million, respectively, in revenue from Grifols related delivery of fostamatinib supply and research and development services, and $0.3 million and $0.5 million, respectively, in revenue from Lilly related to delivery of CNS penetrant IP. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Government contract revenue in the three and six months ended June 30, 2023 was related to the income we recognized upon achievement of certain milestones from the $16.5 million government award granted to us, pursuant to the agreement we entered in January 2021 with the US Department of Defense to support our ongoing Phase 3 clinical trial to evaluate the safety and efficacy of fostamatinib in hospitalized COVID-19 patients. Through June 30, 2023, we received $16.0 million of the awards which we recognized as revenue in the respective periods, with remaining $0.5 million available, subject to us meeting certain milestone and approval by the US Department of Defense as specified in the agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">Our potential future revenues may include product sales, payments from our collaboration partners and from <span style="background:#ffffff;">new collaboration partners with whom we enter into agreements in the future, if any, and from</span> existing government grants and any future grants we may be entitled to, if any, the timing and amount of which is unknown at this time. Our net product sales may be impacted by changes to the government program rebates and new private payer rebate contracts we entered or may enter in the future. As of June 30, 2023, we had deferred revenues of $1.4 million, which we will recognize as revenue upon satisfaction of our remaining performance obligations under our collaboration agreement with Kissei. </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cost of Product Sales</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.08757782%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:21.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:33.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr><td style="vertical-align:bottom;width:33.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:33.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cost of product sales</p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,075</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,036</span></p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 39</span></p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,052</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,157</span></p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 895</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 9pt 0pt;">The cost of product sales includes the cost of inventories sold to specialty distributors and to our collaborative partners. Inventories sold for the periods presented include inventory quantities acquired or produced prior to the FDA approval of the product, and do not reflect the full cost of the inventories sold, since such costs incurred prior to FDA approval were previously expensed and charged to research and development expense. As such, we recognize lower cost of product sales in the periods where we sell inventory quantities acquired or produced prior to the FDA approval of the product. As we acquire or produce more FDA approved inventory quantities in the future, our inventory cost in the balance sheet and cost of product sales will reflect the full cost of acquiring or producing such products. Further, following the approval of REZLIDHIA, we recognize amortization expense from capitalized intangible asset and royalty expense on REZLIDHIA sales within cost of sales. </p><a id="_Hlk140161225"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Cost of product sales in the three and six months ended June 30, 2023 increased compared to the same periods in 2022 primarily due to amortization of capitalized intangible asset recorded in the three and six months ended June 30, 2023 of $0.3 million and $0.5 million, respectively, and royalty expense of $0.4 million and $0.6 million, respectively. No such expenses were incurred in the same periods in 2022. These increases were partly offset by the decrease in cost of product sales due to the timing of delivery of drug supplies pursuant to our supply agreements with our collaborative partners. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;"><b style="font-weight:bold;">Research and Development Expense</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:98.81%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:31.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:31.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td><td style="vertical-align:bottom;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:21.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:31.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr><td style="vertical-align:bottom;width:31.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td><td style="vertical-align:bottom;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td><td style="vertical-align:bottom;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development expense</p></td><td style="vertical-align:bottom;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,772</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 14,767</span></p></td><td style="vertical-align:bottom;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (9,995)</span></p></td><td style="vertical-align:bottom;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 14,861</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 30,241</span></p></td><td style="vertical-align:bottom;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (15,380)</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock-based compensation expense included in research and development expense</p></td><td style="vertical-align:bottom;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 376</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 458</span></p></td><td style="vertical-align:bottom;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (82)</span></p></td><td style="vertical-align:bottom;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,399</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 926</span></p></td><td style="vertical-align:bottom;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 473</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Stock-based compensation expense in the six months ended June 30, 2023 above include an incremental charge of approximately $0.5 million from stock option modifications recorded in the first quarter of 2023 related to the acceleration of vesting and extension of exercise period of vested stock option grants made to a former officer whose employment ended in March 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">The decrease in research and development expense in three months ended June 30, 2023 compared to the same period in 2022 was mainly due to <span style="background:#ffffff;">timing of activities related to our IRAK 1/4 inhibitor program of $2.6 million, and timing of trial completion activities of </span>our <span style="background:#ffffff;">Phase 3 clinical trials of fostamatinib for the treatment of hospitalized high-risk patients with COVID-19 of $1.3 million and </span>for the treatment of w<span style="background:#ffffff;">AIHA of $1.8 million. In addition, personnel-related costs decreased by $0.7 million, consultants and third party services decreased by $0.7 million, and other research and development expense including allocated facilities and laboratory costs decreased by $2.9 million. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">The decrease in research and development expense in six months ended June 30, 2023 compared to the same period in 2022 was mainly due to <span style="background:#ffffff;">timing of activities related to our IRAK 1/4 inhibitor program of $4.0 million, and timing of trial completion activities of </span>our <span style="background:#ffffff;">Phase 3 clinical trials of fostamatinib for the treatment of hospitalized high-risk patients with COVID-19 of $3.7 million and </span>for the treatment of w<span style="background:#ffffff;">AIHA of $3.1 million. In addition, personnel-related costs decreased by $1.1 million, consultants and third party services decreased by $0.7 million, and other research and development expense including allocated facilities and laboratory costs decreased by $3.3 million. These decreases were partially offset by the increase in stock-based compensation expense of $0.5 million mainly due to stock option modification as discussed above. </span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our research and development expenditures include costs related to preclinical and clinical trials, scientific personnel, supplies, equipment, consultants, sponsored research, stock-based compensation, allocated facility costs, and upfront payment related to our in-licensed agreement with Forma (now Novo Nordisk). W<span style="background:#ffffff;">e expect to continue to incur significant research and development expense as we continue our activities in our clinical studies including our IRAK 1/4 inhibitor program and any other clinical programs we may pursue in the future.</span> <span style="color:#222222;background:#ffffff;">In July 2022, we completed the enrollment </span><span style="background:#ffffff;">of the FOCUS Phase 3 clinical trial of fostamatinib for the treatment of hospitalized high-risk patients with COVID-19. </span><span style="background:#ffffff;">We previously announced in November 2022 the top-line results did not meet statistical significance in the primary efficacy endpoint of the number of days on oxygen through Day 29. Upon further analysis, we discovered an error by the CRO in the application of a statistical stratification factor. After correcting for this statistical error, the primary endpoint of the study was met. Given the end of the federal COVID-19 PHE in May 2023, and based on feedback from the FDA, US Department of Defense and other advisors regarding the program&#8217;s regulatory requirements, costs, timeline and potential for success, we decided not to submit an EUA or sNDA. </span><span style="background:#ffffff;">Our Phase 3 clinical trial for hospitalized COVID-19 patients is partially funded by the award granted to us by the US Department of Defense as discussed above. Our P</span>hase 3 wAIHA study completed enrollment in November 2021, and <span style="color:#222222;background:#ffffff;">in June 2022, we announced that the top-line results did not demonstrate statistical significance in the primary efficacy endpoint. In October 2022, we announced that we received guidance from the FDA&#8217;s further review of these findings. Based on the result of the trial and the guidance from FDA, we did not file an sNDA for this indication. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">We do not track fully burdened research and development costs separately for each of our drug candidates. We review our research and development expense by focusing on three categories: research, development, and other. Our research team is focused on identifying and evaluating product candidates in our focused range of therapeutic indications that can be developed into small molecule therapeutics in our own proprietary programs or with potential collaborative partners. &#8220;Research&#8221; expenses relate primarily to personnel expenses, lab supplies, fees to third party research consultants and compounds. Our development group leads the implementation of our clinical and regulatory strategies and prioritizes disease indications in which our compounds may be studied in clinical trials. &#8220;Development&#8221; expenses relate primarily to clinical trials, personnel expenses, costs related to our regulatory filings, lab supplies and fees to third party research consultants. &#8220;Other&#8221; expenses primarily consist of allocated facilities costs and allocated stock-based compensation expense relating to personnel in research and development groups. &#8220;Other&#8221; expenses also include the upfront payment to Forma (now Novo Nordisk) and pre-regulatory approval milestone recorded as research and development expense in 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">In addition to reviewing the three categories of research and development expense described in the preceding paragraph, we principally consider qualitative factors in making decisions regarding our research and development programs, which include enrollment in clinical trials and the results thereof, the clinical and commercial potential for our drug candidates and competitive dynamics. We also make our research and development decisions in the context of our overall business strategy, which includes the evaluation of potential collaborations for the development of our drug candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We do not have reliable estimates regarding the timing of our clinical trials. Preclinical testing and clinical development are long, expensive and uncertain processes. In general, biopharmaceutical development involves a series of steps, beginning with identification of a potential target and including, among others, proof of concept in animals and Phase 1, 2 and 3 clinical trials in humans. Significant delays in clinical testing could materially impact our product development costs and timing of completion of the clinical trials. We do not know whether planned clinical trials will begin on time, will need to be halted or revamped or will be completed on schedule, or at all. Clinical trials can be delayed for a variety of reasons, including delays in obtaining regulatory approval to commence a trial, delays from scale up, delays in reaching agreement on acceptable clinical trial agreement terms with prospective clinical sites, delays in obtaining institutional review board approval to conduct a clinical trial at a prospective clinical site or delays in recruiting subjects to participate in a clinical trial. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We currently do not have reliable estimates of total costs for a particular drug candidate to reach the market. Our potential products are subject to a lengthy and uncertain regulatory process that may involve unanticipated additional clinical trials and may not result in receipt of the necessary regulatory approvals. Failure to receive the necessary regulatory approvals would prevent us from commercializing the product candidates affected. In addition, clinical trials of our potential products may fail to demonstrate safety and efficacy, which could prevent or significantly delay regulatory approval.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table presents our total research and development expense by category (In thousands).</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:90.88%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:32.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:32.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:20.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six&#160;Months&#160;Ended&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">From&#160;January&#160;1,&#160;2007*</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:32.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">to June 30, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:32.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Categories:</b></p></td><td style="vertical-align:bottom;width:0.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research</p></td><td style="vertical-align:bottom;width:0.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 454</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 881</span></p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 957</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,915</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 268,240</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Development</p></td><td style="vertical-align:bottom;width:0.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,823</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 12,413</span></p></td><td style="vertical-align:bottom;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 11,763</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 25,128</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 554,583</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;width:0.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 495</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,473</span></p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,141</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,198</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 276,297</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,772</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 14,767</span></p></td><td style="vertical-align:bottom;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 14,861</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 30,241</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,099,120</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">*</span></span>We started tracking research and development expense by category on January&#160;1, 2007.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">&#8220;Other&#8221; expenses for the three months ended June 30, 2023 and 2022 consisted of allocated facilities costs of $0.1 million and $1.0 million, respectively, and stock-based compensation expense of $0.4 million and $0.5 million, respectively. <span style="white-space:pre-wrap;background:#ffffff;">For the six months ended June 30, 2023 and 2022, allocated facilities costs was $0.8 million and $2.3 million, respectively, and allocated stock-based compensation expense was $1.4 million and $0.9 million, respectively. For the three and six months ended June 30, 2023, a major portion of our total research and development expense was associated with our IRAK 1/4 program. For the three  and six months ended June 30, 2022, a major portion of our total research and development expense was associated with our COVID-19, AIHA and IRAK 1/4 inhibitor program.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Selling, General and Administrative Expense</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:21.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:33.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr><td style="vertical-align:bottom;width:33.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:33.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Selling, general and administrative expense</p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 26,306</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 26,981</span></p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (675)</span></p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 54,035</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 54,382</span></p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (347)</span></p></td></tr><tr><td style="vertical-align:bottom;width:33.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock-based compensation expense included in selling, general and administrative expense</p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,796</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,933</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (137)</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,531</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,672</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,141)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_Hlk70346410"></a><a id="_Hlk96511060"></a><a id="_Hlk528599932"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">Stock-based compensation expense in the six months ended June 30, 2022 above include an incremental charge of approximately $0.8 million from stock option modifications  recorded in the first quarter of 2022 related to the extension of the exercise period of the stock option grants made to our two former Board of Directors whose terms expired in May 2022.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The decrease in selling, general and administrative expense in the three months ended June 30, 2023 compared to the same period in 2022 was mainly due to decreased expenses on consulting and third party services of $1.5 million, partially offset by increased commercial related expenses of $0.7 million and increased other various sales, general and administrative costs of $0.1 million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">The decrease in selling, general and administrative expense in the six months ended June 30, 2023 compared to the same period in 2022 was mainly due to decreased stock-based compensation expense of $1.1 million, partly due to stock option modification as discussed above, and decreased other various sales, general and administrative costs of $0.3 million. These decreases we partially offset by the increase in commercial related expenses of $1.0 million.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><a id="_Hlk140162226"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">We expect to incur significant selling, general and administrative expenses, as we expect our commercial related expenses to increase as we continue to expand our commercial activities of our products. </span><span style="background:#ffffff;">We expect some cost savings on our general and administrative costs in the future because of reduction in workforce in our administrative group in October 2022. We continue to deploy resources to enable our field-based employees to engage with healthcare providers. </span>These engagements have enabled our field team to cover existing prescribers, as well as develop relationships with new prescribers to identify appropriate patients for our products. </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Interest Income and Interest Expense</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:35.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:35.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:35.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr><td style="vertical-align:bottom;width:35.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest income</p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 529</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 42</span></p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 487</span></p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 922</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 63</span></p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 859</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest expense</p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,862)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (569)</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,293)</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (3,066)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,774)</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,292)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Interest income is related to our interest-bearing cash and investment balances. The increase interest income in the three and six months ended June 30, 2023, compared to the same periods in 2022, was primarily driven by higher interest rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:12pt 0pt 0pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="font-size:10pt;">Interest expense comprised primarily of interest on the outstanding term loan with MidCap. The increase in interest expense in the three and six months ended June 30, 2023, compared to the same periods in 2022, was primarily due to higher interest expense on our term loan with Midcap of $1.3 million and $2.0 million, respectively, driven by higher outstanding term loan balance, as well as higher interest rates. The increase interest expense in the six months ended June 30, 2023 compared to the same period of 2022 was partly offset by the interest expense recognized in first quarter of 2022 related to the accretion of financing liability with Lilly of $0.7 million. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><b style="font-weight:bold;">Critical Accounting Policies and Use of Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Our discussion and analysis of our financial condition and results of operations is based upon our financial statements, which have been prepared in accordance with US GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;"><span style="background:#ffffff;">Our critical accounting estimates are described in &#8220;Item 7 </span>&#8211;<span style="background:#ffffff;"> Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations - Critical Accounting Estimates&#8221; in our Annual Report on Form 10-K. There had been no material changes to these accounting policies. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">Our significant accounting policies are described in &#8220;Note 1 &#8211; Description of Business and Summary of Significant Accounting Policies&#8221; to our&#160;&#8220;Notes to Financial Statements&#8221;&#160;contained in &#8220;Part II, Item&#160;8, Financial Statements and Supplementary Data&#8221; of our Annual Report on Form 10-K for the year ended December 31, 2022. There have been no material changes to these accounting policies.</p><a id="_Hlk70506876"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:9pt 0pt 9pt 0pt;"><b style="font-weight:bold;">Recent Accounting Pronouncements </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">No new accounting guidance was adopted during the period. Recently issued accounting guidance is not applicable or did not have, or is not expected to have, a material impact to us.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;"><b style="font-weight:bold;">Liquidity and Capital Resources</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">Liquidity </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">As of June 30, 2023 and December 31, 2022, we had approximately $64.4 million and $58.2 million, respectively, in cash, cash equivalents and short-term investments. We continue to maintain investment portfolios primarily in money market funds, US treasury bills, government-sponsored enterprise securities, and corporate bonds and commercial paper. Cash in excess of immediate requirements is invested with regard to liquidity and capital preservation. <span style="background:#ffffff;">We view our investments portfolio as available-for-sale and are available for use in current operations.&#160;</span>Wherever possible, we seek to minimize the potential effects of concentration and degrees of risk. We continue to monitor the impact of the changes in the conditions of the credit and financial markets to our investment portfolio and assess if future changes in our investment strategy are necessary. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Following summarizes our cash flow activity for the periods presented:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:90.3%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:33.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="8" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:63.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td><td style="vertical-align:bottom;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net cash provided by (used in):</p></td><td style="vertical-align:bottom;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating activities</p></td><td style="vertical-align:bottom;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,856</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (38,548)</span></p></td><td style="vertical-align:bottom;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Investing activities</p></td><td style="vertical-align:bottom;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,747</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 43,724</span></p></td><td style="vertical-align:bottom;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Financing activities</p></td><td style="vertical-align:bottom;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 18,750</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,135</span></p></td><td style="vertical-align:bottom;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net increase in cash and cash equivalents</p></td><td style="vertical-align:bottom;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 24,353</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,311</span></p></td><td style="vertical-align:bottom;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Net cash provided in operating activities for the six months ended June 30, 2023 was primarily due <span style="background:#ffffff;">the proceeds from sales of our products (TAVALISSE and REZLIDHIA), cash receipt from our collaboration partners, including the $20.0 million regulatory milestone payment from Kissei received in January 2023, and cash received from the awards granted by the US Department of Defense, partially offset by the</span> payments of our <span style="background:#ffffff;">operating expenses. Net cash used in operating activities for the six months ended June 30, 2022 was primarily due to payments for our operating expenses, partially offset by the proceeds from sales of our product (TAVALISSE), and cash received from collaboration partners.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Net cash provided by investing activities for the six months ended June 30, 2023 comprises net maturities of short-term investments of $18.6 million and proceeds from sale of property and equipment of $0.1 million, partially offset by the payment of milestone obligations to Forma (now Novo Nordisk) recorded as intangible assets of $15.0 million. <span style="background:#ffffff;">Net cash provided by investing activities for the six months ended June 30, 2022 comprises net maturities of short-term investments of $43.6 million and proceeds from sale of property and equipment of $0.3 million, partially offset by purchases of property and equipment of $0.2 million.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Net cash provided by financing activities for the six months ended June 30, 2023 was primarily due to the net cash proceeds from term loan financing (Tranche 5) of $20.0 million and proceeds from exercise of stock options and participation in the Purchase Plan of $0.6 million, partially offset by our cost share payments to Lilly of $1.8 million. <span style="background:#ffffff;">Net cash provided by financing activities for the six months ended June 30, 2022 was primarily due to the net cash proceeds from term loan financing (Tranche 3) of $9.9 million and proceeds from exercise of stock options and participation in the Purchase Plan of $1.5 million, partially offset by our payment of cost share to Lilly of $8.3 million.&#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We believe that our existing capital resources will be sufficient to support our current and projected funding requirements, including the continued commercialization of our products, through at least the next 12 months from the Form 10-Q filing date. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. Because of the numerous risks and uncertainties associated with commercializing a product, the development of our product candidates and other research and development activities, we are unable to estimate with certainty our future product revenues, our revenues from our current and future collaborative partners, the amounts of increased capital outlays and operating expenditures associated with our current and anticipated clinical trials and other research and development activities. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Capital Resources</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Since inception, we have financed our operations primarily through sales of equity securities, debt financing, from sales of our products, and contract payments under our collaboration agreements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Under our existing collaboration agreements that we entered in the ordinary course of business, we received or may be entitled to receive upfront cash payments, payments contingent upon specified events achieved by such partners and royalties on any net sales of products sold by such partners under the agreements. As of June 30, 2023, total future contingent payments to us under our existing agreements, excluding terminated agreements, could exceed $1.3 billion if all potential product candidates achieved all of the payment triggering events under all of our current agreements. This estimated future contingent amount does not include any estimated royalties that could be due to us if the partners successfully commercialize any of the licensed products. Future events that may trigger payments to us under the agreements are based solely on our partners&#8217; future efforts and achievements of specified development, regulatory and/or commercial events. See further discussion in &#8220;Note 4 &#8211; Sponsored Research and License Agreements and Government Contract&#8221; to our&#160;&#8220;Notes to Condensed Financial Statements&#8221;&#160;contained in Part I, Item&#160;1 of this Quarterly Report on Form 10-Q.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">In January 2021, we were awarded $16.5 million by the US Department of Defense to support our ongoing Phase 3 clinical trial to evaluate the safety and efficacy of fostamatinib in hospitalized COVID-19 patients. Under the agreement with the US Department of Defense, we are entitled to receive such award based on the agreed-upon payment schedule, subject to submission of proper documentation as evidence of completion of certain clinical trial events or milestones as specified in the agreement, and approval by the US Department of Defense that such events or milestones have been met. Through June 30, 2023, we received $16.0 million of the awards which we recognized as revenue in the respective periods, with remaining $0.5 million available, subject to us meeting certain milestone and approval by the US Department of Defense that such milestone has been met, as specified in the agreement. </p><a id="_Hlk132271680"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 0pt 0pt;"><span style="background:#ffffff;">In August 2020, we entered into an Open Market Sale Agreement</span><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;white-space:pre-wrap;background:#ffffff;">  </sup><span style="background:#ffffff;">with Jefferies LLC (Jefferies), as a sole agent, pursuant to which we may sell from time to time, through Jefferies, shares of our common stock in sales deemed to be &#8220;at-the-market offerings&#8221; as defined in Rule 415 under the Securities Act, subject to conditions specified in the Open Market Sale Agreement, including maintaining an effective registration statement covering the sale of shares under the Open Market Sale Agreement. We have a shelf registration statement filed with the SEC that was declared effective on May 3, 2022, which registered, among other securities, </span>a base prospectus which covers the offering, issuance, and sale by us of up to $250.0 million in the aggregate of the securities identified from time to time in one or more offerings, which include the $100.0 million of shares of our common stock that may be offered, issued and sold under the Open Market Sale Agreement.<span style="white-space:pre-wrap;background:#ffffff;"> As of June 30, 2023, we have not sold any shares of common stock under such Open Market Sale Agreement.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 0pt 0pt;"><span style="background:#ffffff;">We have a Credit Agreement with MidCap entered in September 2019, and subsequently amended in March 2021 (First Amendment), in February 2022 (Second Amendment) and in July 2022 (Third Amendment). The Credit Agreement provides for $60.0 million term&#160;loan&#160;credit facility, which was fully funded as of June 30, 2023. To date, no remaining funds are available for draw under the term loan credit facility with Midcap.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">Our operations will require significant additional funding in the foreseeable future. Unless and until we can generate sufficient cash from our operating activities, we may choose to raise additional funds through public and/or private offerings of equity securities, debt financings, or from other sources. However, certain external factors such as global pandemics, conflicts in Russia and Ukraine, political and economic legislations, and other factors may continue to rapidly evolve which could significantly disrupt the global financial markets. Our ability to raise additional funds may be adversely impacted by potential worsening of global economic conditions and volatility in the credit and financial markets in the US and worldwide. We could experience an inability to access additional funds, which could in the future negatively affect our capacity for certain corporate development transactions or our ability to make important, opportunistic investments.<span style="background:#ffffff;"> To the extent that we raise additional funds through the sale of equity, our shareholders&#8217; ownership interest may experience substantial dilution</span>. Our current credit facility with MidCap and any debt financing that we can obtain in the future may involve operating covenants that may restrict our business. To the extent that we raise additional funds through collaboration and licensing arrangements, we may be required to relinquish some of our rights to our technologies or product candidates or grant licenses on terms that are not favorable to us. </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">Our future funding requirements will depend upon many factors, including, but not limited to:</p><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ongoing costs to commercialize our products, or any other future product candidates, if any such candidate receives regulatory approval for commercial sale;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:6pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to generate expected revenue from our commercialization efforts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:6pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the progress and success of our clinical trials and preclinical activities (including studies and manufacture of materials) of our product candidates conducted by us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:6pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to meet operating covenants under our current and future credit facilities, if any;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:6pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to enter into partnering opportunities across our pipeline within and outside the US;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:6pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of regulatory filings and approvals by us and our collaborators; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:6pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the progress of research and development programs carried out by us and our collaborative partners;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:6pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any changes in the breadth of our research and development programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:6pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ability to achieve the events identified in our collaborative agreements that may trigger payments to us from our collaboration partners;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:6pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to acquire or license other technologies or compounds that we may seek to pursue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:6pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to manage our growth;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:6pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">competing technological and market developments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:6pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of obtaining, enforcing and defending our patent and other intellectual property rights, including regulatory rights such as regulatory data exclusivities; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expenses associated with any unforeseen litigation, including any arbitration and securities class action lawsuits.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Insufficient funds may require us to delay, scale back or eliminate some or all of our commercial efforts and/or research or development programs, to lose rights under existing licenses or to relinquish greater or all rights to product candidates at an earlier stage of development or on less favorable terms than we would otherwise choose or may adversely affect our ability to operate as a going concern. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Material Cash Requirements </span></p><a id="_Hlk70404843"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We conduct our commercial activities and research and development programs internally and through third parties that include, among others, arrangements with vendors, consultants, contract research organizations (CROs) and universities. We have contractual arrangements with these parties, however our contracts with them are cancelable generally on reasonable notice within one year and our obligations under these contracts are primarily based on services performed. We do not have any purchase commitments under any collaboration arrangements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We have agreements with certain clinical research organizations to conduct our clinical trials and with third parties relative to our commercialization of our products. The timing of payments for any amounts owed under the respective agreements will depend on various factors including, but not limited to, patient enrollment and other progress of the clinical trial and various activities related to commercial launch. We expect we will continue to enter into contracts in the normal course of business with various third parties who support our clinical trials, support our preclinical research studies, and provide other services related to our operating purposes as well as our commercialization of our products. We can terminate these agreements at any time, and if terminated, we would not be liable for the full amount of the respective agreements. Instead, we will be liable for services provided through the termination date plus certain cancellation charges, if any, as defined in each of the respective agreements. In addition, these agreements may, from time to time, be subjected to amendments as a result of any change orders executed by the parties. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><a id="_Hlk97202121"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">As discussed in detail in &#8220;Note 4 &#8211; Sponsored Research and License Agreements and Government Contract&#8221; of our&#160;&#8220;Notes to Condensed Financial Statements&#8221;&#160;contained in Part I, Item&#160;1 of this Quarterly Report on Form 10-Q, </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">pursuant to our global exclusive license agreement and strategic collaboration agreement with Lilly, we are responsible for funding the development costs for R552 in the US, Europe, and Japan, up to $65.0 million through April 1, 2024. Through June 30, 2023, Lilly billed us $16.9 million of the funding development costs and the amounts were fully paid as of June 30, 2023. We have the right to opt-out of co-funding of development costs at two different specified times. If we decide not to exercise our opt-out rights, we will be required to share in global development costs up to certain amounts at a specified cap, as set forth in the agreement.&#160; </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Additionally, as discussed in detail in &#8220;Note 4 &#8211; Sponsored Research and License Agreements and Government Contract&#8221; of our&#160;&#8220;Notes to Condensed Financial Statements&#8221;&#160;contained in Part I, Item&#160;1 of this Quarterly Report on Form 10-Q, pursuant to our license and transition services agreement, Forma (now Novo Nordisk) is entitled to potential development and regulatory milestone payments of up to $67.5 million, commercial milestone payments of up to $165.5 million, and tiered royalty payments. As of December 31, 2022, certain milestones were met which entitled Forma (now Novo Nordisk) to receive $17.5 million milestone payments, of which, $2.5 million was paid in the fourth quarter of 2022 and $15.0 million was paid in the first quarter of 2023. No new milestone was met during the six months ended June 30, 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">As of June 30, 2023, we have a contractual commitment related to our leased facilities of $1.4 million, with approximately $0.7 million payable within 12 months. See &#8220;Note 10 &#8211; Leases&#8221; to our&#160;&#8220;Notes to Condensed Financial Statements&#8221;&#160;contained in Part I, Item&#160;1 of this Quarterly Report on Form 10-Q for further discussions of our leases. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">As discussed above, we have a contractual commitment with respect to our credit facility with MidCap. Under the amended Credit Agreement, the term loans mature on September 1, 2026, and the interest-only period is through October 1, 2024. <span style="background:#ffffff;">The interest rate applicable to the term loans under the amended Credit Agreement is the sum of one-month SOFR, plus an adjustment of 0.11448%, subject to 1.50% applicable floor, plus applicable margin of&#160;5.65%. A</span> final payment fee of 2.5% of principal is due at maturity date of the term loans. As of June 30, 2023, the outstanding principal amount of the loan was $60.0 million, and no principal payments are due within 12 months. We are also obligated to pay annual administrative fees. As of June 30, 2023, future interest calculated using the base interest rate as per the Credit Agreement, and the final fee payments associated with the credit facility amounted to $11.7 million, with approximately $4.4 million payable within 12 months. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 0pt 0pt;"><span style="white-space:pre-wrap;">We are also subject to claims related to the patent protection of certain of our technologies, as well as purported securities class action lawsuit, other litigations, and other contractual agreements. We are required to assess the likelihood of any adverse judgments or outcomes to these matters as well as potential ranges of probable losses. A determination of the amount of reserves required, if any, for these contingencies is made after careful analysis of each individual matter.  We do not have other material contractual commitments with respect to matters discussed above. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_077a6fb9_2bbd_4505_8989_c88eadce1eac"></a><a id="Item3_QuantitativeandQualitative_065227"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:34.65pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item 3.</b></span><b style="font-weight:bold;">Quantitative and Qualitative Disclosures About Market Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">We are exposed to market risks in the ordinary course of our business. These risks primarily include interest rate sensitivities related to our short-term investments and outstanding loans. There were no material changes to our quantitative and qualitative disclosures about market risk related to our investment activities during the six months ended June 30, 2023 as disclosed in &#8220;Item 7A. Quantitative and Qualitative Disclosures About Market Risks&#8221; of our Annual Report on Form 10-K for the year ended December 31, 2022. </p><a id="_3cfa3659_0263_4aef_9e78_e31d920dbbf3"></a><a id="Item4_ControlsandProcedures_065229"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:34.65pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item 4.</b></span><b style="font-weight:bold;">Controls and Procedures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;"><i style="font-style:italic;">Evaluation of Disclosure Controls and Procedures. </i>Based on the evaluation of our disclosure controls and procedures (as defined in Rules&#160;13a-15(e)&#160;and 15d-15(e)&#160;under the Exchange Act), our chief executive officer (who serves as our principal executive officer) and our chief financial officer (who serves as our principal financial officer) have concluded that, as of the end of the period covered by this report, our disclosure controls and procedures were effective.</p><a id="_Hlk511985372"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;"><i style="font-style:italic;">Changes in Internal Controls. </i>There were no changes in our internal control over financial reporting that occurred during the quarter ended June 30, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 9pt 0pt;"><i style="font-style:italic;">Limitations on the Effectiveness of Controls. </i>A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the controls are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, if any, within a company have been detected. Accordingly, our disclosure controls and procedures are designed to provide reasonable, not absolute, assurance that the objectives of our disclosure control system are met and, as set forth above, our chief executive officer and chief financial officer have concluded, based on their evaluation as of the end of the period covered by this report, that our disclosure controls and procedures were sufficiently effective to provide reasonable assurance that the objectives of our disclosure control system were met.</p><a id="_63005913_c334_44e3_86c7_c79a47fee6f3"></a><a id="PARTII_OTHERINFORMATION_065230"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><b style="font-weight:bold;">PART&#160;II. OTHER INFORMATION</b></p><a id="Item1_LegalProceedings_065231"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><b style="font-weight:bold;">Item 1. Legal Proceedings</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-indent:36pt;margin:9pt 0pt 0pt 0pt;">From time to time, we may be a party or subject to legal proceedings and claims, either asserted or unasserted, which arise in the ordinary course of business. Some of these proceedings that we may be involved in the future, are claims that are subject to substantial uncertainties and unascertainable damages or other remedies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:36pt;background:#ffffff;margin:0pt 0pt 9pt 0pt;">In June 2022, we received a notice letter regarding an ANDA submitted to the FDA by Annora, requesting approval to market a generic version of TAVALISSE. In July 2022, we filed a lawsuit in the United States District Court for the District of New Jersey against Annora and its subsidiaries for infringement of certain of our US patents. In September 2022, Annora and its affiliates answered and counterclaimed for declaratory judgment of non-infringement and invalidity of certain patents. We served an answer to Annora&#8217;s counterclaims in October 2022. Annora served invalidity and non-infringement contentions in December 2022. We served an answer to Annora&#8217;s invalidity and non-infringement contentions in March 2023. Litigation continues with preparation for Markman hearing expected later this year. We intend to vigorously enforce and defend our intellectual property related to TAVALISSE. For a more detailed discussion of this litigation matter, see Part I, Item 3, &#8220;Legal Proceedings&#8221; of our Annual Report on Form 10-K as of December 31, 2022.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_9ebca11f_5225_42f2_b4ad_f2d674a56158"></a><a id="Item1A_RiskFactors_065233"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item&#160;1A.</b></span><b style="font-weight:bold;">Risk Factors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;"><i style="font-style:italic;">In evaluating our business, you should carefully consider the following risks, as well as the other information contained in this Quarterly Report on Form&#160;10-Q. These risk factors could cause our actual results to differ materially from those contained in forward-looking statements we have made in this Quarterly Report on Form&#160;10-Q and those we may make from time to time. If any of the following risks actually occurs, our business, financial condition and operating results could be harmed. The risks and uncertainties described below are not the only ones facing us. Additional risks and uncertainties not presently known to us, or that we currently see as immaterial, may also harm our business.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;"><i style="font-style:italic;">We have marked with an asterisk (*) those risk factors below that reflect a substantive change from the risk factors included in our Annual Report on Form&#160;10-K for the year ended December 31, 2022 filed with the SEC on March 7, 2023, if any.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><b style="font-weight:bold;">Risk Factor Summary</b></p><div style="margin-top:9pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:13.7pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our prospects are highly dependent on our commercial products, TAVALISSE</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> (fostamatinib disodium hexahydrate) and REZLIDHIA</span><span style="color:#222222;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">&#8482;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> (olutasidenib). To the extent that the commercial success of our products in the US and respective territories outside of the US is diminished or halted, our business, financial condition and results of operations may be adversely affected, and the price of our common stock may decline.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:13.7pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may not be able to successfully develop or commercialize our product candidates if problems arise in the clinical testing and/or approval process. There is a high risk that drug discovery and development efforts might not generate successful product candidates. If the results of our clinical trials do not meet the primary efficacy endpoints, or if the top-line data from the results of our clinical trials may not ultimately meet the requirements for an NDA approval by the FDA and other regulatory authorities, the commercial prospects of our business may be harmed, and our ability to generate product revenues may be delayed or eliminated.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:13.7pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Even if we, or any of our collaborative partners, are able to continue to commercialize our products or any product candidate that we, or they, develop, the product may become subject to unfavorable pricing regulations, unfavorable </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">health technology assessments (HTA)</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, third-party payor reimbursement practices or labeling restrictions, all of which may vary from country to country and any of which could harm our business.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:13.7pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If we are unable to successfully market and distribute our products and retain experienced commercial personnel, our business will be substantially harmed.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:13.7pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are subject to stringent and evolving healthcare regulatory, privacy and information security laws, regulations, rules, policies and contractual obligations, and changes in such laws, regulations, rules, policies, contractual obligations and our actual or perceived failure to comply with such requirements could subject us to significant investigations, audits, fines, penalties, and claims, any of which may have a material adverse effect on our business, financial condition, results of operations or prospects.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:13.7pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If manufacturers obtain approval for generic versions of our products, or of products with which we compete, our business may be harmed.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:13.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Unforeseen safety issues could emerge with our products that could require us to change the prescribing information to add warnings, limit use of the product, and/or result in litigation. Any of these events could have a negative impact on our business.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:13.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We rely and may continue to rely on third party distribution facilities for the sale of our products and potential sale of any of our product candidates. If any or all of them become subject to adverse findings from inspections or face other difficulties to operate, then the distribution of our products may be interrupted or otherwise adversely affected.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:13.7pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We lack the capability to manufacture compounds for clinical development and we intend to rely on third parties for commercial supply, manufacturing and distribution, if any, of our product candidates which receive regulatory approval and we may be unable to obtain required material or product in a timely manner, at an acceptable cost or at a quality level required to receive regulatory approval. </span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:13.7pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Any product for which we have obtained regulatory approval, or for which we obtain approval in the future, is subject to, or will be subject to, extensive ongoing regulatory requirements by the FDA, EMA and other comparable regulatory authorities, and if we fail to comply with regulatory requirements or if we experience unanticipated problems with our products, we may be subject to penalties, we may be unable to generate revenue from the sale of such products, our potential for generating positive cash flow may be diminished, and the capital necessary to fund our operations will be increased.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:13.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If our corporate collaborations or license agreements are unsuccessful, or if we fail to form new corporate collaborations or license agreements, our research and development efforts could be delayed.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 31.5pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:13.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our success is dependent on intellectual property and data exclusivity and similar regulatory rights held by us and third parties, and our interest in such rights is complex and uncertain.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 13.5pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:13.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If a dispute arises regarding the infringement or misappropriation of the proprietary rights of others, such dispute could be costly and result in delays in our research and development activities, partnering and commercialization activities.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 31.5pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:13.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If our competitors develop technologies that are more effective than ours, our commercial opportunity will be reduced or eliminated.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:13.7pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If product liability lawsuits are successfully brought against us, we may incur substantial liabilities and may be required to limit commercialization of our products.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 9pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;background:#ffffff;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;"><b style="font-weight:bold;background:#ffffff;">Risks Related to Our Business and Our Industry</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">If the market opportunities for our products and product candidates are smaller than we believe they are, our revenues may be adversely affected, and our business may suffer.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27.8pt;margin:9pt 0pt 9pt 0pt;">Certain of the diseases that our products and our other product candidates being developed to address are in underserved and underdiagnosed populations. Our projections of both the number of people who have these diseases, as well as the subset of people with these diseases who will seek treatment utilizing our products or product candidates, may not be accurate. If our estimates of the prevalence or number of patients potentially on therapy prove to be inaccurate, the market opportunities for fostamatinib and our other product candidates may be smaller than what we believe they are, our prospects for generating expected revenue may be adversely affected and our business may suffer. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may need to continue to increase the size of our organization and we may encounter difficulties with managing our growth, which could adversely affect our business and results of operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27.8pt;margin:9pt 0pt 9pt 0pt;">While we have substantially increased the size of our organization particularly in our sales force in the third quarter of 2021, we also implemented two separate reductions in workforce in November 2021 and October 2022, and may need to add additional qualified personnel and resources to support our commercial activities and expected growth. Our current infrastructure may be inadequate to support our development and commercialization efforts and expected growth. Future growth will impose significant added responsibilities on members of management, including the need to identify, recruit, maintain and integrate additional employees, and may take time away from running other aspects of our business, including commercialization of our products and development of our other product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27.8pt;margin:6pt 0pt 6pt 0pt;">Our future financial performance and our ability to sustain successful commercialization of our products and our ability to commercialize other product candidates that may receive regulatory approval will depend, in part, on our ability to manage any future growth effectively. In particular, as we continue to commercialize our products, we will need to support the training and ongoing activities of our sales force and will likely need to continue to expand the size of our employee base for managerial, operational, financial and other resources. To that end, we must be able to successfully:</p><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manage our development efforts effectively;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:6pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">integrate additional management, administrative and manufacturing personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:6pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">further develop our marketing and sales organization; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintain sufficient administrative, accounting and management information systems and controls.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27.8pt;margin:9pt 0pt 9pt 0pt;">We may not be able to accomplish these tasks or successfully manage our operations and, accordingly, may not achieve our research, development, and commercialization goals. Our failure to accomplish any of these goals, including as a result of business or other interruptions resulting from, if any, potential future impacts of a pandemic or global economic slowdown, could adversely affect our business and operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">There is a high risk that drug discovery and development efforts might not generate successful product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">At the present time, a significant portion of our operations are focused on various stages of drug identification and development. We currently have various product candidates in the clinical testing stage. In our industry, it is statistically unlikely that the limited number of compounds that we have identified as potential product candidates will actually lead to successful product development efforts. We have invested a significant portion of our efforts and financial resources into the development of fostamatinib. Our ability to generate product revenue, which will not occur until after regulatory approval, if ever, will depend on the successful development, regulatory approval and eventual commercialization of one of our product candidates. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 0pt 0pt;">Our compounds in clinical trials and our future leads for potential drug compounds are subject to the risks and failures inherent in the development of pharmaceutical products. These risks include, but are not limited to, the inherent difficulty in selecting the right drug and drug target and avoiding unwanted side effects, as well as unanticipated problems relating to product development, testing, enrollment, obtaining regulatory approvals, obtaining and maintaining reimbursement in national markets and positive recommendation from HTA bodies, maintaining regulatory compliance, manufacturing, competition and costs and expenses that may exceed current estimates. In future clinical </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;">trials, we or our partners may discover additional side effects and/or a higher frequency of side effects than those observed in previously completed clinical trials. The results of preliminary and mid-stage clinical trials do not necessarily predict clinical or commercial success, and larger later-stage clinical trials may fail to confirm the results observed in the previous clinical trials. Similarly, a clinical trial may show that a product candidate is safe and effective for certain patient populations in a particular indication, but other clinical trials may fail to confirm those results in a subset of that population or in a different patient population, which may limit the potential market for that product candidate. With respect to our own compounds in development, we have established anticipated timelines with respect to the initiation of clinical trials based on existing knowledge of the compounds. However, we cannot provide assurance that we will meet any of these timelines for clinical development. Additionally, the initial results of a completed earlier clinical trial of a product candidate do not necessarily predict final results and the results may not be repeated in later clinical trials.</p><a id="_Hlk109905702"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Because of the uncertainty of whether the accumulated preclinical evidence (PK, pharmacodynamic, safety and/or other factors) or early clinical results will be observed in later clinical trials, we can make no assurances regarding the likely results from our future clinical trials or the impact of those results on our business. For example, we initiated our FORWARD study,<span style="color:#222222;background:#ffffff;"> a Phase 3 pivotal trial of fostamatinib in patients with wAIHA</span> in March 2019, completed the enrollment in November 2021 and completed the treatment period for the last patient under the trial in April 2022. In June 2022, we announced top-line efficacy and safety data results of our FORWARD study, and the <span style="color:#222222;background:#ffffff;">results of the trial did not demonstrate statistical significance in the primary efficacy endpoint of durable hemoglobin response in the overall study population</span>. <span style="color:#222222;white-space:pre-wrap;background:#ffffff;">We conducted an in-depth analysis of these data to better understand differences in patient characteristics and outcomes and submitted these findings to the FDA. In October 2022, we announced that we received guidance from the FDA&#8217;s review of these findings. Based on the result of the trial and the guidance from the FDA, we did not file an sNDA for this indication. Further, we may experience errors in the analysis of our clinical trial results.  For example, we conducted our Phase 3 clinical trial to evaluate safety and efficacy of fostamatinib in hospitalized COVID-19 patients which we launched in November 2020 and completed the enrollment on this trial in July 2022. </span><span style="background:#ffffff;">We previously announced in November 2022 the top-line results did not meet statistical significance in the primary efficacy endpoint. Upon further analysis, we discovered an error by the CRO in the application of a statistical stratification factor. After correcting for this statistical error, the primary endpoint of the study was met. However, given the end of the federal COVID-19 PHE in May 2023, and based on feedback from the FDA, US Department of Defense and other advisors regarding the program&#8217;s regulatory requirements, costs, timeline and potential for success, we decided not to submit an EUA or sNDA.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">If the results of our clinical trials fail to meet the primary efficacy endpoints, or otherwise do not ultimately meet the requirements for an NDA approval by the FDA, the commercial prospects of our business may be harmed, our ability to generate product revenues may be delayed or eliminated or we may be forced to undertake other strategic alternatives that are in our shareholders&#8217; best interests, including cost reduction measures. If we are unable to obtain adequate financing or engage in a strategic transaction on commercially reasonable terms or at all, we may be required to implement further cost reduction strategies which could significantly impact activities related to our commercial efforts and/or research and development of our future product candidates, and could significantly harm our business, financial condition and results of operations. In addition, these cost reduction strategies could cause us to further curtail our operations or take other actions that would adversely impact our shareholders. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">We are subject to federal and state healthcare fraud and abuse laws, false claims laws and other federal and state healthcare laws, and the failure to comply with such laws could result in substantial penalties. Our employees, independent contractors, consultants, principal investigators, CROs, commercial partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 0pt 0pt;">Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors and customers, may expose us to broadly applicable federal, state and foreign fraud and abuse and other healthcare laws and regulations including anti-kickback and false claims laws, data privacy and security laws, and transparency reporting laws. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute any product for which we have obtained regulatory approval, or for which we obtain regulatory approval in the future. In particular, the promotion, sales and marketing of healthcare items and services, as well as certain business arrangements in the healthcare industry, are subject to extensive laws and regulations intended to prevent fraud, misconduct, bribery kickbacks, self-dealing and other abusive or inappropriate practices. These laws and regulations may restrict or prohibit </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;">a wide range of pricing, discounting, marketing and promotion, including promoting off-label uses of our products, commission compensation, certain customer incentive programs, certain patient support offerings, and other business arrangements generally. Activities subject to these laws also involve the improper use or misrepresentation of information obtained in the course of patient recruitment for clinical trials, creating fraudulent data in our preclinical studies or clinical trials or illegal misappropriation of drug product, which could result in regulatory sanctions and cause serious harm to our reputation. See &#8220;Part I, Item 1, Business &#8211; Government Regulation &#8211; <span style="background:#ffffff;">Healthcare and Privacy Law and Regulation and Healthcare Reform&#8221; of our Annual Report on Form 10-K for the year ended December 31, 2022, for more information on the healthcare laws and regulations that may affect our ability to operate</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">We are also exposed to the risk of fraud, misconduct or other illegal activity by our employees, independent contractors, consultants, principal investigators, CROs, commercial partners and vendors. Misconduct by these parties could include intentional, reckless and/or negligent conduct that fails to: comply with the laws of the FDA and other similar foreign regulatory bodies; provide true, complete and accurate information to the FDA and other similar foreign regulatory bodies; comply with manufacturing standards we have established; comply with federal and state data privacy, security, fraud and abuse and other healthcare laws and regulations in the US and similar foreign fraudulent misconduct laws; or report financial information or data accurately or to disclose unauthorized activities to us. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent inappropriate conduct may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:9pt 0pt 9pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="font-size:10pt;">We are also subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. Efforts to ensure that our business arrangements will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental and enforcement authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative penalties, damages, disgorgement, monetary fines, imprisonment, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">We are subject to stringent and evolving privacy and information security laws, regulations, rules, policies, and contractual obligations, and changes in such laws, regulations, rules, policies, contractual obligations and our actual or perceived failure to comply with such requirements could subject us to significant investigations, fines, penalties and claims, any of which may have a material adverse effect on our business, financial condition, results of operations or prospects.*</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 0pt 0pt;">We are subject to, or affected by, various federal, state and foreign laws, rules, directives, and regulations, as well as regulatory guidance, policies and contractual obligations relating to privacy and information security, governing the acquisition, collection, access, use, disclosure, processing, modification, retention, storage, transfer, destruction, protection, and security (collectively, &#8220;processing&#8221;) of personal information and other sensitive information about individuals. The global privacy and information security landscape is evolving rapidly, and implementation standards and enforcement practices are likely to continue to develop for the foreseeable future and may result in conflicting or inconsistent compliance obligations. Legislators and regulators are increasingly adopting or amending privacy and information security laws, rules, directives, and regulations that may create uncertainty in our business, affect our or our collaborators&#8217;, service providers&#8217; and contractors&#8217; ability to operate in certain jurisdictions or to process personal information, transfer data internationally, necessitate the acceptance of more onerous obligations in our contracts, result in enforcement actions, litigation or other liability or impose additional costs on us. The cost of compliance with these laws, regulations and standards is high and is likely to increase in the future. Any failure or perceived failure by us or our collaborators, service providers and contractors to comply with federal, state or foreign laws or regulations, our internal policies and procedures or our contracts governing the processing of personal information could result in negative publicity, diversion of management time and effort and proceedings against us by governmental entities or others. In many jurisdictions, enforcement actions, litigation, and other consequences for noncompliance with privacy and </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;">information security laws and regulations are rising. Compliance with applicable privacy and information security laws and regulations, as well as regulatory guidance, policies and contractual obligations, is a rigorous and time-intensive process, and we may be required to put in place additional mechanisms to ensure compliance with the new privacy and information security requirements. If we fail to comply with any such obligations, we may face significant investigations, fines, penalties and claims that could materially and adversely affect our business, financial condition, results of operations, ability to process personal information and income from certain business initiatives. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">In the US, these obligations include various federal, state, and local statutes, rules, and regulations relating to privacy and data security. The Federal Trade Commission (FTC) has authority under Section 5 of the FTC Act to regulate unfair or deceptive or practices, and has used this authority to initiate enforcement actions against companies that implement inadequate controls around privacy and information security in violation of their externally facing policies. The US federal government has also enacted statutes to address privacy and information security issues impacting particular industries or activities, including the following laws and regulations: the Electronic Communications Privacy Act, the Computer Fraud and Abuse Act, the Health Insurance Portability and Accountability Act, the Health Information Technology for Economic and Clinical Health Act, the Telephone Consumer Protection Act, the CAN-SPAM Act, and other laws and regulations. In addition, state legislatures have enacted statutes to address privacy and information security issues, including the California Consumer Privacy Act of 2018 (the CCPA), and similar state laws such as Virginia&#8217;s Consumer Data Protection Act and the Colorado Privacy Act. For example, the CCPA establishes a privacy framework applicable to for-profit entities that are doing business in California, including an expansive definition of personal information and data privacy rights for California residents, and authorizes potentially severe statutory damages and creates a private right of action for certain data security breaches. The CCPA also requires businesses subject to the law to provide new disclosures to California residents and to provide them with expanded rights with respect to their personal information, including the right to opt out of the sale of such information. Although there are limited exemptions for clinical trial and other research-related data under the CCPA, the CCPA and other similar laws could impact our business depending on how it will be interpreted by the new California Privacy Protection Agency. As we expand our operations, the CCPA may increase our compliance costs and potential liability. In addition, California voters approved the California Privacy Rights Act of 2020 (CPRA), which goes into effect on January 1, 2023. The CPRA will, among other things, give California residents the ability to limit the use of their sensitive information, opt out of certain types of profiling and automated processing activities, provide for penalties for CPRA violations concerning California residents under the age of 16, and establish a new California Privacy Protection Agency to implement and enforce the law. Additionally, Colorado and Virginia both signed privacy legislation, each of which go into effect in 2023, and multiple other states and the federal government are considering enacting similar legislation. Many states also have in place data security laws requiring companies to maintain certain safeguards with respect to the processing of personal information, and all states require companies to notify individuals or government regulators in the event of a data breach impacting such information. New privacy laws add additional complexity, requirements, restrictions and potential legal risk. Accordingly, compliance programs may require additional investment in resources, and could impact availability of previously useful data. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 0pt 0pt;">Internationally, our operations abroad may also be subject to increased scrutiny or attention from foreign data protection authorities. For example, our clinical trial programs and research collaborations outside the US may implicate foreign data protection laws, including in the European Economic Area, Switzerland, and/or the UK (collectively, Europe). Many jurisdictions have established or are in the process of establishing privacy and data security legal frameworks with which we, our collaborators, service providers, including our CROs, and contractors must comply. For example, European data protection laws, including, without limitation, the General Data Protection Regulation (the EU GDPR), impose strict requirements for processing personal information (i.e., data which identifies an individual or from which an individual is identifiable), including clinical trial data and grant individuals&#8217; various data protection rights (e.g., the right to erasure of personal information). In turn, the EU GDPR and similar laws increase our obligations with respect to clinical trials conducted in Europe by expanding the definition of personal information to also include coded data and requiring (i) changes to informed consent practices and more detailed notices for clinical trial participants and investigators; (ii) consideration of data protection as any new products or services are developed, including to limit the amount of personal information processed; and (iii) implementation of appropriate technical and organizational measures to safeguard personal information and to report certain personal data breaches to the relevant supervisory authority without undue delay (for the EU GDPR no later than 72 hours where feasible). In the event of non-compliance, the EU GDPR provides for robust regulatory enforcement and fines of up to &#8364;20 million or 4% of the annual global revenue, whichever is greater. In addition, the EU GDPR confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies and obtain compensation for </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;">damages resulting from violations of the EU GDPR.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">European data protection laws, including the EU GDPR, generally also restrict the transfer of personal information from Europe to the US and most other countries that are not recognized as having &#8220;adequate&#8221; data protection laws unless the parties to the transfer have implemented specific safeguards to protect the transferred personal information. One of the primary safeguards allowing US companies to import personal information from Europe has been certification to the EU-US Privacy Shield and Swiss-US Privacy Shield frameworks administered by the US Department of Commerce. However, the Court of Justice of the European Union (CJEU) issued a decision in July 2020 invalidating the EU-US Privacy Shield framework as a data transfer mechanism (<i style="font-style:italic;">Schrems II</i><span style="white-space:pre-wrap;">) and imposing further restrictions on the use of standard contractual clauses (SCCs). The SCCs were subsequently updated by the EC and these now place a contractual obligation on the parties, to carry out a transfer privacy impact assessment, which, among other things, assesses laws governing access to personal information in the recipient country and considers whether supplementary measures that provide privacy protections additional to those provided under the SCCs will need to be implemented to ensure an essentially equivalent level of data protection to that afforded in Europe. Following that decision, the Swiss Federal Data Protection and Information Commissioner (FDPIC) took a similar view and considered that data transfers based on the Swiss-US Privacy Shield framework are no longer lawful. On October 7, 2022, the US President introduced an Executive Order to facilitate a new Trans-Atlantic Data Privacy Framework (DPF) and  on July 10, 2023, the EC also adopted its adequacy decision to reflect its view that the new Executive Order and DPF, is able to meet the concerns raised in </span><i style="font-style:italic;">Schrems II</i>. In turn, entities relying on SCCs for transfers to the US are able to rely on the analysis in the EC&#8217;s adequacy decision as support for their transfer impact assessments.&#160;Importantly, the US Department of Commerce has also announced that companies will also immediately be able to self-certify to the UK and Swiss extensions of the DPF, but that the UK component will not be live until the finalization of the separate and ongoing UK-U.S. adequacy process. Given the above, any transfers by us or our third-party vendors, collaborators or others of personal information from Europe to the US or elsewhere may not comply with European data protection laws, may increase our exposure to European data protection laws&#8217; heightened sanctions for cross-border data transfer restrictions may restrict our clinical trial activities in Europe and may limit our ability to collaborate with CROs, service providers, contractors and other companies subject to European data protection laws. Loss of our ability to transfer personal information from Europe may also require us to increase our data processing capabilities in those jurisdictions at significant expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Following the UK&#8217;s departure from the EU (Brexit), the EU GDPR&#8217;s data protection obligations continue to apply to the UK in substantially unvaried form under the so-called &#8220;UK GDPR&#8221; (i.e., the EU GDPR as it continues to form part of law in the UK by virtue of section 3 of the European Union (Withdrawal) Act 2018, as amended (including by the various Data Protection, Privacy and Electronic Communications (Amendments etc.) (EU Exit) Regulations)). The UK GDPR exists alongside the UK Data Protection Act 2018 that implements certain derogations in the UK GDPR into UK law. Under the UK GDPR, companies not established in the UK but that process personal information either in relation to the offering of goods or services to individuals in the UK, or to monitor their behavior will be subject to the UK GDPR, the requirements of which are (at this time) largely aligned with those under the EU GDPR, and as such, may lead to similar compliance and operational costs with potential fines of up to &#163;17.5 million or 4% of global turnover. As a result, we are potentially exposed to two parallel data protection regimes, each of which authorizes fines and the potential for divergent enforcement actions. It should also be noted that the UK Government published its own form of EU SCCs, known as the International Data Transfer Agreement (IDTA) and International Data Transfer Addendum (UK&#160;<span style="white-space:pre-wrap;">Addendum) to the new EU SCCs. The UK Information Commissioner&#8217;s Office (ICO) has also published its version of the transfer impact assessment and revised guidance on international transfers, although entities may choose to adopt either the EU or UK style transfer impact assessment. In terms of international data transfers between the UK and US, as outlined above, there is an ongoing UK-US adequacy process which, once finalized, will extend the DPF to apply also to transfers from the UK.    </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Additionally, other countries outside of Europe have enacted or are considering enacting similar cross-border data transfer restrictions and laws requiring local data residency, with strict requirements and limitations for processing personal information, which could increase the cost and complexity of delivering our services and operating our business. For example, Brazil enacted the General Data Protection Law, New Zealand enacted the New Zealand Privacy Act, China released its Personal Information Protection Law, which went into effect November 1, 2021, and Canada introduced the Digital Charter Implementation Act. As with the EU GDPR, these laws are broad and may increase our compliance burdens, including by mandating potentially burdensome documentation requirements and granting certain rights to individuals to control how we collect, use, disclose, retain, and process personal information about them.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">We publish privacy policies and other documentation regarding our collection, processing, use and disclosure of personal information and/or other confidential information. Although we endeavor to comply with our published policies and other documentation, we may at times fail to do so or may be perceived to have failed to do so. Moreover, despite our efforts, we may not be successful in achieving compliance if our employees, collaborators, contractors, service providers or vendors fail to act in accordance with our published policies and documentation. Such failures can subject us to potential foreign, local, state and federal action if they are found to be deceptive, unfair, or misrepresentative of our actual practices. Moreover, trial participants or research subjects about whom we or our partners obtain information, as well as the providers who share this information with us, may contractually limit our ability to use and disclose the information or exercise their right to do so under applicable privacy legislation. Claims that we have violated individuals&#8217; privacy rights or failed to comply with data protection laws or applicable privacy policies and documentation, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business.</p><a id="_cp_text_1_235"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In addition to data privacy requirements, many jurisdictions impose mandatory clinical trial information obligations on sponsors. In the EU, such obligations arise under the Transparency Regulation No 1049/ 2001, EMA Policy 0043, EMA Policy 0070 and the Clinical Trials Regulation No 536/2014, all of which impose on sponsors the obligation to make publicly available certain information stemming from clinical studies. In the EU, the transparency framework provides EU-based parties the right to submit an access to documents request to the EMA for information included in the MAA dossier for approved medicinal products. Only very limited information is exempted from disclosure, i.e., commercially confidential information (which is construed increasingly narrowly) and protected personal data. It is possible for competitors to access and use this data in their own research and development programs anywhere in the world, once this data is in the public domain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">On May 3, 2022, the EC published a proposal for a regulation on the European Health Data Space (EHDS), which aims to further enable exchange of electronic health data both for primary use (among national EU healthcare systems for patient care) and secondary use (among private companies and regulators to enable scientific research). Whilst the regulation is currently under discussions among the EU legislators, the text is expected to be finalized by the end of 2023 and for the EHDS to become applicable in 2025. This will impose new obligations, but also create opportunities, for entities engaged in health-related research to share and access health data on a scale much larger than what is foreseen under current applicable transparency provisions.</p><a id="move15"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.8pt;padding-bottom:9pt;background:#ffffff;margin:9pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our business could be materially and adversely affected by pandemics as a result of their potential impacts on our sales force and commercialization efforts, supply chain, regulatory, clinical development and corporate development activities and other business operations, in addition to the impact of a global economic slowdown.</span><span style="font-style:italic;font-weight:bold;">*</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.8pt;padding-top:5pt;text-indent:36pt;background:#ffffff;margin:0pt;">Pandemics may result in extended travel and other restrictions in order to reduce the spread of diseases. Government measures taken in response to pandemics could have a significant impact, both direct and indirect, on our business and commerce, as significant reductions in business related activities may occur, supply chains may be disrupted, and manufacturing and clinical development activities may be curtailed or suspended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.8pt;text-indent:36pt;margin:14pt 0pt 0pt 0pt;"><span style="background:#ffffff;">For example, due to the effects of the COVID-19 pandemic, we have observed reduced patient-doctor interactions and our representatives have had fewer visits with health care providers, which has negatively affected our product sales and may continue to negatively affect our product sales in the future. Physicians with practices severely impacted by the COVID-19 pandemic, and who currently prescribe our products, may eventually decide to close their independent practices and join a larger medical organization with a practice that does not prescribe our products. Additionally, commercial-related activities, such as our marketing programs, speaker bureaus, and market access initiatives were conducted virtually, delayed or cancelled as a result of the COVID-19 pandemic. </span><span style="background:#ffffff;">We had to deploy resources&#160;to enable our field-based employees to continue to engage with&#160;health care providers in hybrid virtual and in-person interactions.&#160; </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.8pt;text-indent:36pt;margin:14pt 0pt 0pt 0pt;"><span style="background:#ffffff;">With respect to clinical development, in response to the COVID-19 pandemic, we had taken, and may continue to take, measures to implement remote and virtual approaches, including remote patient monitoring where possible and working with our investigators for appropriate care of these patients in a safe manner. Due to the effects of COVID-19 pandemic, we had experienced a number of our clinical trial investigators either paused, postponed or delayed new patient enrollment and restricted site visits of existing patients enrolled. In the event that a global pandemic occurs in the </span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="move83"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.8pt;margin:0pt;"><span style="background:#ffffff;">future, we may need to make decisions&#160;on a country-by-country&#160;basis to minimize risk to the patients and clinical trial sites. We may also rely heavily on our clinical trial investigators to inform us of the best course of action with respect to resuming enrollment/screening, considering the ability of sites to ensure patient safety or data integrity. We experienced slower than anticipated enrollment in some of our clinical trials due to adverse effects of COVID-19 pandemic, and in the future, we may experience adverse impact of a global pandemic on our clinical trials, including the timing thereof, or our ability to continue to treat patients enrolled in our trials, enroll and assess new patients, supply study drugs and obtain complete data points in accordance with study protocol. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:14pt 0pt 0pt 0pt;">Pandemics may cause significant disruption in the supply chain for our commercial products. We currently rely on third parties to, among other things, manufacture and ship our commercial product, raw materials and product supply for our clinical trials, perform quality testing and supply other goods and services to help manage our commercial activities, our clinical trials and our operations in the ordinary course of business. While we have engaged actively with various elements of our supply chain and distribution channel, including our customers, contract manufacturers, and logistics and transportation provider to meet demand for our products and to remain informed of any challenges within our supply chain, we may face disruptions to our supply chain and operations, and associated delays in the manufacturing and supply of our products. Such supply disruptions would adversely impact our ability to generate sales of and revenues from our products and our business, financial condition, results of operations and growth prospects could be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">Pandemics may affect</span> our collaboration and licensing partners for the commercialization of fostamatinib globally, as well as our ability to advance our various clinical stage programs. We cannot predict the impact of s<span style="background:#ffffff;">uch disruptions on our partners&#8217; ability to advance commercialization of fostamatinib in the market and the timing of enrollment and completion of various clinical trials being conducted by our collaboration partners.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Health regulatory agencies globally may experience prolonged disruptions in their operations as a result of pandemics.&#160;For example, in response to the COVID-19 pandemic, the FDA delayed inspections and evaluations of certain drug manufacturing facilities and clinical research sites We cannot predict whether, and when, health regulatory agencies will decide to pause or resume inspections due to pandemics. Any&#160;de-prioritization&#160;of our clinical trials or delay in regulatory review resulting from such disruptions could materially affect the completion of our clinical trials. </p><a id="move86"></a><a id="move54"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">In addition, as seen in the COVID-19 pandemic, pandemics could result in a significant disruption of global financial markets. We could experience an inability to access</span> additional capital or <span style="background:#ffffff;">an impact on liquidity, which could in the future negatively affect our capacity for certain corporate development transactions or our ability to make other important, opportunistic investments,</span> or <span style="background:#ffffff;">we may not be able to meet the requirements under our Credit Agreement with MidCap. While we expect </span>pandemics to <span style="background:#ffffff;">adversely affect</span> our <span style="background:#ffffff;">business, financial condition, results of operations and growth prospects in the future periods, the extent of the impact on our ability to generate sales of and revenues from our approved products, our ability to continue to secure new collaborations and support existing collaboration efforts with our partners, our clinical development and regulatory efforts, our corporate development objectives and the value of and market for our common stock,</span> will depend on future circumstances<span style="background:#ffffff;"> that are highly uncertain and</span> cannot be predicted <span style="background:#ffffff;">with confidence at this time, such as the ultimate duration and severity of pandemics, travel restrictions, quarantines, social distancing and business closure requirements in the US and other countries, and the effectiveness of actions taken globally to contain and treat diseases. </span>To the extent pandemics adversely affect our business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties described elsewhere in this &#8220;Risk Factors&#8221; section. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">Enhanced governmental and public scrutiny over, or investigations or litigation involving, pharmaceutical manufacturer donations to patient assistance programs may require us to modify our programs and could negatively impact our business practices, harm our reputation, divert the attention of management and increase our expenses.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">To help patients afford our products, we have a manufacturer-sponsored patient assistance program that helps financially needy patients in the US. This type of program has become the subject of enforcement scrutiny in recent years. For example, some pharmaceutical manufacturers have been named in class action lawsuits challenging the legality of their patient assistance programs under a variety of federal and state laws. In addition, certain state and federal enforcement authorities have pursued investigations and settlements and members of Congress have initiated inquiries about manufacturer-sponsored patient support programs, including, for example, manufacturer-sponsored patient </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">assistance programs, co-payment assistance programs, and manufacturer contributions to independent charitable patient assistance programs. Moreover, the Department of Health and Human Services, Office of the Inspector General continues to publish advisory opinions and other agency guidance on the topic of patient assistance, which reflects the government&#8217;s continued scrutiny of manufacturer sponsored or supported patient assistance programs. Numerous organizations, including pharmaceutical manufacturers, have been subject to ongoing litigation, enforcement activities and settlements related to their patient support programs and certain of these organizations have entered into, or have otherwise agreed to, significant civil settlements with applicable enforcement authorities. It is possible that future legislation may be proposed that would establish requirements or restrictions with respect to these programs and/or support that would affect pharmaceutical manufacturers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Our patient assistance program could become the target of similar inquiries, litigation, enforcement, and/or legislative proposals. If we are deemed not to have complied with laws or regulations in the operation of, or our interactions with, these programs, we could be subject to damages, fines, penalties or other criminal, civil or administrative sanctions or enforcement actions. We cannot ensure that our compliance controls, policies and procedures will be sufficient to protect against acts of our employees, business partners or vendors that may violate the laws or regulations of the jurisdictions in which we operate. A government investigation could negatively impact our business practices, harm our reputation, divert the attention of management and increase our expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">If manufacturers obtain approval for generic versions of our products, or of products with which we compete, our business may be harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Under the FDCA, the FDA can approve an ANDA for a generic version of a branded drug without the ANDA applicant undertaking the clinical testing necessary to obtain approval to market a new drug. Generally, in place of such clinical studies, an ANDA applicant usually needs only to submit data demonstrating that its product has the same active ingredient(s), strength, dosage form and route of administration&#160;and that it is bioequivalent to the branded product. In September 2019, the FDA published product-specific bioequivalence guidance on fostamatinib disodium to let potential ANDA applicants understand the data FDA would expect to see for approval of a generic version of our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">The FDCA requires that an applicant for approval of a generic form of a branded drug certify either that its generic product does not infringe any of the patents listed by the owner of the branded drug in the <span style="background:#ffffff;">FDA&#8217;s Approved Drug Products with Therapeutic Equivalence Evaluations (referred to as the &#8220;Orange Book&#8221;)</span> or that those patents are not enforceable. This process is known as a paragraph&#160;IV challenge. Upon notice of a paragraph&#160;IV challenge, a patent owner has 45&#160;days to bring a patent infringement suit in federal district court against the company seeking ANDA approval of a product covered by one of the owner&#8217;s patents. If this type of suit is commenced, the FDCA provides a 30-month stay on the FDA&#8217;s approval of the competitor&#8217;s application. If the litigation is resolved in favor of the ANDA applicant or the challenged patent expires during the 30-month stay period, the stay is lifted, and the FDA may thereafter approve the application based on the standards for approval of ANDAs. Once an ANDA is approved by the FDA, the generic manufacturer may market and sell the generic form of the branded drug in competition with the branded medicine.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">The ANDA process can result in generic competition if the patents at issue are not upheld or if the generic competitor is found not to infringe the owner&#8217;s patents. If this were to occur with respect to our products or products with which it competes, our business would be harmed. We have a number of patents listed in the Orange Book, the last of which is expected to expire in July 2032.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 0pt 0pt;">In June 2022, we received a notice letter regarding an ANDA submitted to the FDA by Annora, requesting approval to market a generic version of TAVALISSE. The notice letter included a Paragraph IV certification with respect to our US Patent Nos. 7,449,458; 8,263,122; 8,652,492; 8,771,648 and 8,951,504, which are listed in the Orange Book. The notice letter asserts that these patents will not be infringed by Annora&#8217;s proposed product, are invalid and/or are unenforceable. Annora&#8217;s notice letter does not provide a Paragraph IV certification against our other patents listed in the Orange Book. On <span style="background:#ffffff;">July 25, 2022, we filed a lawsuit in the US District Court for the District of New Jersey against Annora and its affiliates, Hetero Labs Ltd., and Hetero USA, Inc., for infringement of our US patents identified in Annora&#8217;s Paragraph IV certification. On September 21, 2022, Annora and its affiliates answered and counterclaimed for declaratory judgment of non-infringement and invalidity of the &#8217;458, &#8217;122, &#8217;492, &#8217;648, and &#8217;504 patents. We filed an answer to Annora&#8217;s counterclaims on October 12, 2022. Annora served invalidity and non-infringement contentions on </span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;"><span style="background:#ffffff;">December 31, 2022. We filed an answer to Annora&#8217;s invalidity and non-infringement contentions in March 2023. </span>We intend to vigorously enforce and defend our intellectual property related to TAVALISSE. We cannot be assured that such lawsuit will prevent the introduction of a generic version of TAVALISSE for any particular length of time, or at all. If an ANDA from Annora or any other generic manufacturer is approved, and a generic version of TAVALISSE is introduced, whether following the expiration of our patents, the invalidation of our patents as a result of any litigation, or the determination that the proposed generic product does not infringe on our patents, our sales of TAVALISSE would be adversely affected. In addition, we cannot predict what additional ANDAs could be filed by Annora or other potential generic competitors requesting approval to market generic forms of fostamatinib, which would require us to incur significant additional expense and result in distraction for our management team, and if approved, result in significant decreases in the revenue derived from sales of our marketed products and thereby materially harm our business and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">Unforeseen safety issues could emerge with our products that could require us to change the prescribing information to add warnings, limit use of the product, and/or result in litigation. Any of these events could have a negative impact on our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Discovery of unforeseen safety problems or increased focus on a known problem could impact our ability to commercialize our products and could result in restrictions on its permissible uses, including withdrawal of the medicine from the market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">If we or others identify additional undesirable side effects caused by our products after approval:</p><div style="margin-top:9pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may require the addition of labeling statements, specific warnings, contraindications, or field alerts to physicians and pharmacies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may withdraw their approval of the product and require us to take our approved drugs off the market or suspend their commercialization until the identified issues have been satisfactorily addressed;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be required to change the way the product is administered, conduct additional clinical trials, change the labeling of the product, or implement a Risk Evaluation and Mitigation Strategy (REMS);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may have additional limitations on how we promote our drugs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">third-party payors may limit coverage or reimbursement for our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sales of our products may decrease significantly;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be subject to litigation or product liability claims; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our reputation may suffer.</span></td></tr></table><div style="margin-top:9pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Any of these events could prevent us from achieving or maintaining market acceptance of our products and could substantially increase our operating costs and expenses, which in turn could delay or prevent us from generating significant revenue from sale of our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Side effects and toxicities associated with our products, as well as the warnings, precautions and requirements listed in the prescribing information for our products, could affect the willingness of physicians to prescribe, and patients to utilize, our products and thus harm commercial sales of our products. The FDA approved label for REZLIDHIA contains a boxed warning describing the risk of differentiation syndrome, which can be fatal, in patients receiving REZLIDHIA.&#160;This and other restrictions could limit the commercial success of REZLIDHIA.&#160;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">If a safety issue emerges post-approval, we may become subject to costly product liability litigation by our customers, their patients or payors. Product liability claims could divert management&#8217;s attention from our core business, be expensive to defend, and result in sizable damage awards against us that may not be covered by insurance. If we cannot successfully defend ourselves against claims that our products caused injuries, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">decreased demand for any product candidates or products that we may develop;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the inability to commercialize any products that we may develop;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injury to our reputation and significant negative media attention;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">withdrawal of patients from clinical studies or cancellation of studies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">significant costs to defend the related litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">substantial monetary awards to patients; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">loss of revenue.</span></td></tr></table><div style="margin-top:9pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">We currently hold $10.0&#160;million in product liability insurance coverage, which may not be adequate to cover all liabilities that we may incur. Insurance coverage is increasingly expensive. We may not be able to obtain insurance coverage at a reasonable cost or in amounts adequate to satisfy any liability or associated costs that may arise in the future. These events could harm our business and results of operations and cause our stock price to decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we fail to comply with our reporting and payment obligations under the Medicaid Drug Rebate Program or other governmental pricing programs in the US, we could be subject to additional rebate or discount requirements, fines, sanctions and exposure under other laws which could have an adverse effect on our business, results of operations and financial condition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">We participate in the Medicaid Drug Rebate Program, as administered by the <span style="background:#ffffff;">Centers for Medicare and Medicaid Services (CMS)</span>, the 340B Drug Pricing Program, and other federal and state government drug pricing programs in the US, and we may participate in additional government pricing programs in the future. These programs generally require us to pay rebates or otherwise provide discounts to government payors in connection with drugs that are dispensed to beneficiaries/recipients of these programs. In some cases, such as with the Medicaid Drug Rebate Program, the rebates are based on pricing metrics that we report on a monthly and quarterly basis to the government agencies that administer the programs. Pricing requirements and rebate/discount calculations are complex, vary among products and programs, and are often subject to interpretation by governmental or regulatory agencies and the courts. The requirements of these programs, including, by way of example, their respective terms and scope, change frequently. Responding to current and future changes may increase our costs, and the complexity of compliance will be time consuming. Invoicing for rebates is provided in arrears, and there is frequently a time lag of up to several months between the sales to which rebate notices relate and our receipt of those notices, which further complicates our ability to accurately estimate and accrue for rebates related to the Medicaid program as implemented by individual states. Thus, there can be no assurance that we will be able to identify all factors that may cause our discount and rebate payment obligations to vary from period to period, and our actual results may differ significantly from our estimated allowances for discounts and rebates. Changes in estimates and assumptions may have an adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">In addition, the Office of Inspector General of Human and Health Services (HHS) and other Congressional enforcement and administrative bodies have increased their focus on pricing requirements for products, including, but not limited to the methodologies used by manufacturers to calculate average manufacturer price and best price for compliance with reporting requirements under the Medicaid Drug Rebate Program. We are liable for errors associated with our submission of pricing data and for any overcharging of government payors. Failure to make necessary disclosures and/or to identify overpayments could result in allegations against us under the federal False Claims Act and other laws and regulations. Any required refunds to the US government or response to a government investigation or enforcement action would be expensive and time consuming and could have an adverse effect on our business, results of operations and financial condition. In addition, in the event that CMS were to terminate our rebate agreement, no federal payments would be available under Medicaid for our covered outpatient drugs or under Medicare Part B for any of our products that may be reimbursed under Part B.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">Even for those product candidates that have or may receive regulatory approval, they may fail to achieve the degree of market acceptance by physicians, patients, healthcare payors and others in the medical community necessary for commercial success, in which case we may not generate significant revenues or become profitable.*</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">For our product candidates that have or may receive regulatory approval, they may nonetheless fail to gain sufficient market acceptance by physicians, hospital administrators, patients, healthcare payors and others in the medical community. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including the following: </p><div style="margin-top:9pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">relative convenience and ease of administration;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the willingness of physicians to change their current treatment practices;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any additional support that may be required to administer the treatment to patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the willingness of hospitals and hospital systems to include our product candidates as treatment options;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">demonstration of efficacy and safety in clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the prevalence and severity of any side effects;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ability to offer product candidates for sale at competitive prices;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the price we charge for our product candidates; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the strength of marketing and distribution support; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability of third-party coverage and adequate reimbursement and the willingness of patients to pay out-of-pocket in the absence of such coverage and adequate reimbursement.</span></td></tr></table><div style="margin-top:9pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Efforts to educate the physicians, patients, healthcare payors and others in the medical community on the benefits of our product candidates may require significant resources and may not be successful. If any of our product candidates are approved, but do not achieve an adequate level of acceptance, we may not generate significant product revenue and we may not become profitable on a sustained basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">We will need additional capital in the future to sufficiently fund our operations and research.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">We have consumed substantial amounts of capital to date as we continue our research and development activities, including preclinical studies and clinical trials and for the commercialization of our products. We may seek another collaborator or licensee in the future for further clinical development and commercialization of fostamatinib, as well as our other clinical programs, which we may not be able to obtain on commercially reasonable terms or at all. We believe that our existing capital resources will be sufficient to support our current and projected funding requirements, including the continued commercialization of our products through at least the next 12 months. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. Because of the numerous risks and uncertainties associated with commercial launch, the development of our product candidates and other research and development activities, we are unable to estimate with certainty our future product revenues, our revenues from our current and future collaborative partners, the amounts of increased capital outlays and operating expenditures associated with our current and anticipated clinical trials and other research and development activities. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 0pt 0pt;">We will continue to need additional capital and the amount of future capital needed will depend largely on the success of our commercialization of our products, and the success of our internally developed programs as they proceed in later and more expensive clinical trials, including any additional clinical trials that we may decide to conduct with respect to fostamatinib. While we intend to opportunistically seek access to additional funds through public or private equity offerings or debt financings, we do not know whether additional financing will be available when needed, or that, </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;"><span style="white-space:pre-wrap;">if available, we will obtain financing on reasonable terms. Our ability to raise additional capital, including our ability to secure new collaborations and continue to support existing collaboration efforts with our partners, may also be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, the credit and financial markets in the US and worldwide resulting from the COVID-19 pandemic and the conflict in Russia and Ukraine. Unless and until we are able to generate a sufficient amount of product, royalty or milestone revenue, which may never occur, we expect to finance future cash needs through public and/or private offerings of equity securities, debt financings or collaboration and licensing arrangements, as well as through proceeds from the exercise of stock options and interest income earned on the investment of our cash balances and short-term investments. To the extent we raise additional capital by issuing equity securities in the future, our stockholders could at that time experience substantial dilution. In addition, we have a significant number of stock options outstanding. To the extent that outstanding stock options have been or may be exercised or other shares issued, our stockholders may experience further dilution. Further, we may choose to raise additional capital due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. Our credit facility with MidCap includes certain covenants that may restrict our business, and any other debt financing that we are able to obtain in the future may involve operating covenants that restrict our business. To the extent that we raise additional funds through any new collaboration and licensing arrangements, we may be required to refund certain payments made to us, relinquish some rights to our technologies or product candidates or grant licenses on terms that are not favorable to us.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have indebtedness in the form of a term loan pursuant to the Credit Agreement (as defined below) with MidCap, which could adversely affect our financial condition and our ability to respond to changes in our business. Further, if we are unable to satisfy certain conditions of the Credit Agreement, we will be unable to draw down the remainder of the facility.*</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We entered into the Credit Agreement with MidCap on September 27, 2019, amended on March 29, 2021, February 11, 2022, and July 27, 2022. The Credit Agreement provides for a $60.0&#160;million term loan credit facility. As of June 30, 2023, the outstanding principal balance of the loan was $60.0 million, and no remaining funds were available under the term loan credit facility. Under the Credit Agreement, we are required to repay amounts due when there is an event of default for the term loans that results in the principal, premium, if any, and interest, if any, becoming due prior to the maturity date for the term loans. The Credit Agreement also contains a number of other affirmative and restrictive covenants. <span style="background:#ffffff;">See &#8220;Note 9 &#8211; Debt&#8221; to our&#160;&#8220;Notes to Condensed Financial Statements&#8221;&#160;contained in Part I, Item&#160;1 of this Quarterly Report on Form 10-Q for additional details of the Credit Agreement. </span>These and other terms in the Credit Agreement have to be monitored closely for compliance and could restrict our ability to grow our business or enter into transactions that we believe would be beneficial to our business. Our business may not generate cash flow from operations in the future sufficient to service our debt and support our growth strategies. If we are unable to generate such cash flow, we may be required to adopt one or more alternatives, such as restructuring our debt or obtaining additional equity capital on terms that may be onerous or highly dilutive. Our ability to refinance our indebtedness will depend on the capital markets and our financial condition at such time. We may not be able to engage in any of these activities or engage in these activities on desirable terms, which could result in a default on our current debt obligations. In addition, we cannot be sure that additional financing will be available when required or, if available, will be on terms satisfactory to us. Further, even if we are able to obtain additional financing, we may be required to use such proceeds to repay a portion of our debt.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Our indebtedness may have other adverse effects, such as:</p><div style="margin-top:9pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our vulnerability to adverse general economic conditions and heightened competitive pressures;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">dedication of a portion of our cash flow from operations to interest payments, limiting the availability of cash for other operational purposes;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">limited flexibility in planning for, or reacting to, changes in our business and industry; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our inability to obtain additional financing in the future.</span></td></tr></table><div style="margin-top:9pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Our Credit Agreement with MidCap contains a mandatory prepayment provision that gives MidCap and/or its agent the right to demand payment of the outstanding principal and additional interest and fees in the event of default. We may not have enough available cash or be able to obtain financing at the time we are required to repay the term loan with additional interest and fees prior to maturity.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">We rely and may continue to rely on two distribution facilities for the sale of our products and potential sale of any of our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Our distribution operations for the sale of our products are currently concentrated in two distribution centers owned by a third-party logistics provider. Additionally, our distribution operations, if and when we launch any of our product candidates in the future, may also be concentrated in such distribution centers owned by a third-party logistics provider. Any errors in inventory level management and unforeseen inventory shortage could adversely affect our business. In addition, any significant disruption in the operation of the facility due to natural disaster or severe weather, or events such as fire, accidents, power outages, system failures, or other unforeseen causes, could devalue or damage a significant portion of our inventories and could adversely affect our product distribution and sales until such time as we could secure an alternative facility. <span style="background:#ffffff;">Further, climate change may increase both the frequency and severity of extreme weather conditions and natural disasters, which may affect our business operations.</span> If we encounter difficulties with any of our distribution facilities, whether due to the potential future impacts of a global pandemic (including as a result of disruptions of global shipping and the transport of products) or otherwise, or other problems or disasters arise, we cannot ensure that critical systems and operations will be restored in a timely manner or at all, and this would have an adverse effect on our business. In addition, growth could require us to further expand our current facility, which could affect us adversely in ways that we cannot predict.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">Forecasting potential sales for any of our product candidates will be difficult, and if our projections are inaccurate, our business may be harmed, and our stock price may be adversely affected.*</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:32.05pt;margin:9pt 0pt 9pt 0pt;">Our business planning requires us to&#160;forecast&#160;or make assumptions regarding product demand and revenues for any of our product candidates if they are approved despite numerous uncertainties. These uncertainties may be increased if we rely on our collaborators or other third parties to conduct commercial activities in certain geographies and provide us with accurate and timely information. Actual results may differ materially from projected results for various reasons, including the following, as well as risks identified in other risk factors:</p><div style="margin-top:9pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the efficacy and safety of any of our product candidates, including as relative to marketed products and product candidates in development by third parties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">pricing (including discounting or other promotions), reimbursement, product returns or recalls, competition, labeling, adverse events and other items that impact commercialization;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the rate of adoption in the particular market, including fluctuations in demand for various reasons;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential future impacts, if any, due to a global pandemic;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">lack of patient and physician familiarity with the drug;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">lack of patient use and physician prescribing history;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">lack of commercialization experience with the drug;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">actual sales to patients may significantly differ from expectations based on sales to wholesalers; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">uncertainty relating to when the drug may become commercially available to patients and rate of adoption in other territories.</span></td></tr></table><div style="margin-top:9pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:32.05pt;margin:9pt 0pt 9pt 0pt;">We expect that our revenues from sales of any of our products will continue to be based in part on estimates, judgment and accounting policies. Any incorrect estimates or disagreements with regulators or others regarding such estimates or accounting policies may result in changes to our guidance, projections or previously reported results. We make estimates for provisions for sales discounts, returns and allowances. Our estimates are based on available customer and payer data received from the specialty pharmacies and distributors, as well as third party market research data. In part, our estimates are dependent on our distribution channel and payer mix.<span style="background:#ffffff;"> If actual results in the future vary from our estimates, we adjust these estimates, which would affect our net product revenue and earnings in the period such variances become known. </span>Expected and actual product sales and quarterly and other results may greatly fluctuate, including in the near-term, and such fluctuations can adversely affect the price of our common stock, perceptions of our ability to&#160;forecast&#160;demand and revenues, and our ability to maintain and fund our operations.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">We do not and will not have access to all information regarding fostamatinib and product&#160;candidates we licensed to Lilly, Kissei, Grifols, Medison and Knight.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27.8pt;margin:9pt 0pt 9pt 0pt;">We do not and will not have access to all information regarding fostamatinib and other product candidates, including potentially material information about commercialization plans, medical information strategies, clinical trial design and execution, safety reports from clinical trials, safety reports, regulatory affairs, process development, manufacturing and other areas known by Lilly, Kissei, Grifols, Medison and Knight. In addition, we have confidentiality obligations under our respective agreements with Lilly, Kissei, Grifols, Medison and Knight. Thus, our ability to keep our shareholders informed about the status of fostamatinib and other product candidates will be limited by the degree to which Lilly, Kissei, Grifols, Medison and/or Knight keep us informed and allows us to disclose such information to the public. If Lilly, Kissei, Grifols, Medison and/or Knight fail to keep us informed about commercialization efforts related to fostamatinib, or the status of the clinical development or regulatory approval pathway of other product candidates licensed to them, we may make operational and/or investment decisions that we would not have made had we been fully informed, which may adversely affect our business and operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our future funding requirements will depend on many uncertain factors.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Our future funding requirements will depend upon many factors, many of which are beyond our control, including, but not limited to:</p><div style="margin-top:9pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs to commercialize our products in the US, or any other future product candidates, if any such candidate receives regulatory approval for commercial sale;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the progress and success of our clinical trials and preclinical activities (including studies and manufacture of materials) of our product candidates conducted by us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential future impacts, if any, of a global pandemic;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of regulatory filings and approvals by us and our collaborators; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the progress of research and development programs carried out by us and our collaborative partners;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any changes in the breadth of our research and development programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ability to achieve the events identified in our collaborative agreements that may trigger payments to us from our collaboration partners;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to acquire or license other technologies or compounds that we may seek to pursue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to manage our growth;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">competing technological and market developments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of obtaining, enforcing and defending our patent and other intellectual property rights; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expenses associated with any unforeseen litigation, including any arbitration and securities class action lawsuits.</span></td></tr></table><div style="margin-top:9pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Insufficient funds may require us to delay, scale back or eliminate some or all of our commercial efforts and/or research and development programs, to reduce personnel and operating expenses, to lose rights under existing licenses or to relinquish greater or all rights to product candidates at an earlier stage of development or on less favorable terms than we would otherwise choose or may adversely affect our ability to operate as a going concern.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our success as a company is uncertain due to our history of operating losses and the uncertainty of any future profitability.*</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">For the six months ended June 30, 2023, we recognized loss from operations of $18.0 million primarily due to higher operating and non-operating expenses, partly offset by our net product sales and collaboration revenues. We have historically incurred losses from operations each year since we were incorporated in June&#160;1996 other than in fiscal year 2010, due in large part to the significant research and development expenditures required to identify and validate new product candidates and pursue our development efforts, and the costs of our ongoing commercial efforts for our products. We expect to continue to incur losses from operations, at least in the next 12 months, and there can be no assurance that we will generate annual operating income in the foreseeable future. Currently, our potential sources of revenues are our sales of our products, upfront payments, research and development contingent payments and royalty payments pursuant to our collaboration arrangements, which may never materialize if our collaborators do not achieve certain events or generate net sales to which these contingent payments are dependent on. If our future drug candidates fail or do not gain regulatory approval, or if our drugs do not achieve sustainable market acceptance, we may not be profitable. As of June 30, 2023, we had an accumulated deficit of approximately $1.4&#160;billion. The extent of our future losses or profitability, if any, is highly uncertain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">If our corporate collaborations or license agreements are unsuccessful, or if we fail to form new corporate collaborations or license agreements, our research and development efforts could be delayed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Our strategy depends upon the formation and sustainability of multiple collaborative arrangements and license agreements with third parties now and in the future. We rely on these arrangements for not only financial resources, but also for expertise we need now and in the future relating to clinical trials, manufacturing, sales and marketing, and for licenses to technology rights. To date, we have entered into several such arrangements with corporate collaborators; however, we do not know if these collaborations or additional collaborations with third parties, if any, will dedicate sufficient resources or if any development or commercialization efforts by third parties will be successful. In addition, our corporate collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a drug candidate or development program. Should a collaborative partner fail to develop or commercialize a compound or product to which it has rights from us for any reason, including corporate restructuring, such failure might delay our ongoing research and development efforts, because we might not receive any future payments, and we would not receive any royalties associated with such compound or product. We may seek another collaborator or licensee in the future for clinical development and commercialization of fostamatinib, as well as our other clinical programs, which we may not be able to obtain on commercially reasonable terms or at all. If we are unable to form new collaborations or enter into new license agreements, our research and development efforts could be delayed. In addition, the continuation of some of our partnered drug discovery and development programs may be dependent on the periodic renewal of our corporate collaborations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">&#160;Each of our collaborations could be terminated by the other party at any time, and we may not be able to renew these collaborations on acceptable terms, if at all, or negotiate additional corporate collaborations on acceptable terms, if at all. If these collaborations terminate or are not renewed, any resultant loss of revenues from these collaborations or loss of the resources and expertise of our collaborative partners could adversely affect our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 0pt 0pt;"><span style="white-space:pre-wrap;">Conflicts also might arise with collaborative partners concerning proprietary rights to particular compounds. While our existing collaborative agreements typically provide that we retain milestone payments, royalty rights and/or revenue sharing with respect to drugs developed from certain compounds or derivative compounds, any such payments or royalty rights may be at reduced rates, and disputes may arise over the application of payment provisions or derivative payment provisions to such drugs, and we may not be successful in such disputes.  For example, in September 2018, BerGenBio served us with a notice of arbitration seeking declaratory relief related to the interpretation of provisions under our June 2011 license agreement, particularly as they relate to the rights and obligations of the parties in the event of the license or sale of a product in the program by BerGenBio and/or the sale of BerGenBio to a third party.&#160;The arbitration panel dismissed four of the six declarations sought by BerGenBio, and we thereafter consented to one of the remaining declarations requested by BerGenBio.&#160;On February 27, 2019, the arbitration panel issued a determination granting the declaration sought by BerGenBio on the remaining issue, and held that in the event of a sale of shares by BerGenBio&#8217;s shareholders where there is no monetary benefit to BerGenBio, we would not be entitled to a portion of the proceeds from such a sale.&#160; In this circumstance where the revenue share provision is not triggered, the milestone and royalty payment provisions remain in effect.&#160; While we do not believe that the determination will have an adverse effect on our operations, cash flows or financial condition, we can make no assurance regarding any such impact. Additionally, </span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;"><span style="white-space:pre-wrap;">the management teams of our collaborators may change for various reasons including due to being acquired. Different management teams or an acquiring company of our collaborators may have different priorities which may have adverse results on the collaboration with us.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">We are also a party to various license agreements that give us rights to use specified technologies in our research and development processes. The agreements pursuant to which we have in-licensed technology permit our licensors to terminate the agreements under certain circumstances. If we are not able to continue to license these and future technologies on commercially reasonable terms, our product development and research may be delayed or otherwise adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">If conflicts arise between our collaborators or advisors and us, any of them may act in their self-interest, which may be adverse to our stockholders&#8217; interests.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">If conflicts arise between us and our corporate collaborators or scientific advisors, the other party may act in its self-interest and not in the interest of our stockholders. Some of our corporate collaborators are conducting multiple product development efforts within each disease area that is the subject of the collaboration with us or may be acquired or merged with a company having a competing program. In some of our collaborations, we have agreed not to conduct, independently or with any third party, any research that is competitive with the research conducted under our collaborations. Our collaborators, however, may develop, either alone or with others, products in related fields that are competitive with the products or potential products that are the subject of these collaborations. Competing products, either developed by our collaborators or to which our collaborators have rights, may result in their withdrawal of support for our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">If any of our corporate collaborators were to breach or terminate its agreement with us or otherwise fail to conduct the collaborative activities successfully and in a timely manner, the preclinical or clinical development or commercialization of the affected product candidates or research programs could be delayed or terminated. We generally do not control the amount and timing of resources that our corporate collaborators devote to our programs or potential products. We do not know whether current or future collaborative partners, if any, might pursue alternative technologies or develop alternative products either on their own or in collaboration with others, including our competitors, as a means for developing treatments for the diseases targeted by collaborative arrangements with us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our success is dependent on intellectual property rights held by us and third parties, and our interest in such rights is complex and uncertain.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Our success will depend to a large part on our own, our licensees&#8217; and our licensors&#8217; ability to obtain and defend patents for each party&#8217;s respective technologies and the compounds and other products, if any, resulting from the application of such technologies. For example, fostamatinib is covered as a composition of matter in a US issued patent that has an expected expiration date of September 2031, after taking into account patent term adjustment and extension rules.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">In the future, our patent position might be highly uncertain and involve complex legal and factual questions. For example, we may be involved in post-grant proceedings before the US Patent and Trademark Office. Post-grant proceedings are complex and expensive legal proceedings and there is no assurance we will be successful in any such proceedings. A post-grant proceeding could result in our losing our patent rights and/or our freedom to operate and/or require us to pay significant royalties. Additionally, third parties may challenge the validity, enforceability or scope of our issued patents, which may result in such patents being narrowed, invalidated or held unenforceable through interference, opposition or invalidity proceedings before the US Patent and Trademark Office or non-US patent offices. Any successful opposition to our patents could deprive us of exclusive rights necessary for the successful commercialization of fostamatinib or our other product candidates. Oppositions could also be filed to complementary patents, such as formulations, methods of manufacture and methods of use, that are intended to extend the patent life of the overall portfolio beyond the patent life covering the composition of matter. A successful opposition to any such complementary patent could impact our ability to extend the life of the overall portfolio beyond that of the related composition of matter patent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 0pt 0pt;">An adverse outcome may allow third parties to use our intellectual property without a license and/or allow third parties to introduce generic and other competing products, any of which would negatively impact our business. For example, in June 2022, we received a notice letter from Annora advising that it has filed an ANDA with the FDA for a </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;">generic version of TAVALISSE and asserting that certain patents related to TAVALISSE that are listed in the Orange Book will not be infringed by Annora&#8217;s proposed product, are invalid and/or are unenforceable. In July 2022, we filed a lawsuit in the US District Court for the District of New Jersey against Annora and its subsidiaries for infringement of those US patents. In September 2022, Annora and its subsidiaries answered and counterclaimed for declaratory judgment of non-infringement and invalidity of those patents. We filed an answer to Annora&#8217;s counterclaims on October 12, 2022. <span style="background:#ffffff;">Annora served invalidity and non-infringement contentions on December 31, 2022.</span> We intend to vigorously enforce and defend our intellectual property rights related to TAVALISSE. Should Annora or any other third parties receive FDA approval of an ANDA for a generic version of fostamatinib or a 505(b)(2) NDA with respect to fostamatinib, and if our patents covering fostamatinib were held to be invalid (or if such competing generic versions of fostamatinib were found to not infringe our patents), then they could introduce generic versions of fostamatinib or other such 505(b)(2) products before our patents expire, and the resulting competition would negatively affect our business, financial condition and results of operations. Please also see the risk factor entitled, &#8220;If manufacturers obtain approval for generic versions of our products, or of products with which we compete, our business may be harmed.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Additional uncertainty may result because no consistent policy regarding the breadth of legal claims allowed in biotechnology patents has emerged to date. Accordingly, we cannot predict the breadth of claims allowed in our or other companies&#8217; patents. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Because the degree of future protection for our proprietary rights is uncertain, we cannot assure you that:</p><div style="margin-top:9pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we were the first to make the inventions covered by each of our pending patent applications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we were the first to file patent applications for these inventions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">others will not independently develop similar or alternative technologies or duplicate any of our technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any of our pending patent applications will result in issued patents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any patents issued to us or our collaborators will provide a basis for commercially viable products or will provide us with any competitive advantages or will not be challenged by third parties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we will develop additional proprietary technologies that are patentable; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we will obtain a supplemental protection certificate that will extend the protection afforded by the patent to the product with a marketing authorization; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the patents of others will not have a negative effect on our ability to do business.</span></td></tr></table><div style="margin-top:9pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">We rely on trade secrets to protect technology where we believe patent protection is not appropriate or obtainable; however, trade secrets are difficult to protect. While we require employees, collaborators and consultants to enter into confidentiality agreements, we may not be able to adequately protect our trade secrets or other proprietary information in the event of any unauthorized use or disclosure or the lawful development by others of such information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">We are a party to certain in-license agreements that are important to our business, and we generally do not control the prosecution of in-licensed technology. Accordingly, we are unable to exercise the same degree of control over this intellectual property as we exercise over our internally developed technology. Moreover, some of our academic institution licensors, research collaborators and scientific advisors have rights to publish data and information in which we have rights. If we cannot maintain the confidentiality of our technology and other confidential information in connection with our collaborations, our ability to receive patent protection or protect our proprietary information may otherwise be impaired. In addition, some of the technology we have licensed relies on patented inventions developed using US government resources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">The US government retains certain rights, as defined by law, in such patents, and may choose to exercise such rights. Certain of our in-licenses may be terminated if we fail to meet specified obligations. If we fail to meet such obligations and any of our licensors exercise their termination rights, we could lose our rights under those agreements. If we lose any of our rights, it may adversely affect the way we conduct our business. In addition, because certain of our licenses are sublicenses, the actions of our licensors may affect our rights under those licenses.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">If a dispute arises regarding the infringement or misappropriation of the proprietary rights of others, such dispute could be costly and result in delays in our research and development activities, partnering and commercialization activities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Our success will depend, in part, on our ability to operate without infringing or misappropriating the proprietary rights of others. There are many issued patents and patent applications filed by third parties relating to products or processes that are similar or identical to our licensors or ours, and others may be filed in the future. There may also be copyrights or trademarks that third parties hold. There can be no assurance that our activities, or those of our licensors, will not violate intellectual property rights of others. We believe that there may be significant litigation in the industry regarding patent and other intellectual property rights, and we do not know if our collaborators or we would be successful in any such litigation. Any legal action against our collaborators or us claiming damages or seeking to enjoin commercial activities relating to the affected products, our methods or processes could:</p><div style="margin-top:9pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">require our collaborators or us to obtain a license to continue to use, manufacture or market the affected products, methods or processes, which may not be available on commercially reasonable terms, if at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">prevent us from using the subject matter claimed in the patents held by others;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">subject us to potential liability for damages;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">consume a substantial portion of our managerial and financial resources; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">result in litigation or administrative proceedings that may be costly, whether we win or lose.</span></td></tr></table><div style="margin-top:9pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our effective tax rate may fluctuate, and we may incur obligations in tax jurisdictions in excess of accrued amounts.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">We are subject to taxation in numerous US states and territories. As a result, our effective tax rate is derived from a combination of applicable tax rates in the various places that we operate. In preparing our financial statements, we estimate the amount of tax that will become payable in each of such places. Nevertheless, our effective tax rate may be different than experienced in the past due to numerous factors, including passage of the newly enacted federal income tax law, changes in the mix of our profitability from state to state, the results of examinations and audits of our tax filings, our inability to secure or sustain acceptable agreements with tax authorities, changes in accounting for income taxes and changes in tax laws. Any of these factors could cause us to experience an effective tax rate significantly different from previous periods or our current expectations and may result in tax obligations in excess of amounts accrued in our financial statements.</p><a id="_Hlk101254585"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our ability to use net operating losses (NOLs) and certain other tax attributes is uncertain and may be limited.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:14pt 0pt 0pt 0pt;"><span style="white-space:pre-wrap;">Our ability to use our federal and state NOLs to offset potential future taxable income and related income taxes that would otherwise be due is dependent upon our generation of future taxable income before the expiration dates of the NOLs, and we cannot predict with certainty when, or whether, we will generate sufficient taxable income to use all of our NOLs. Federal NOLs generated prior to 2018 will continue to be governed by the NOL carryforward rules as they existed prior to the adoption of the Tax Cuts and Jobs Act (Tax Act), which means that generally they will expire 20 years after they were generated if not used prior thereto.  Many states have similar laws. Accordingly, our federal and state NOLs could expire unused and be unavailable to offset future income tax liabilities. Under the Tax Act as modified by the Coronavirus Aid, Relief, and Economic Security Act (CARES Act), federal NOLs incurred in tax years beginning after December 31, 2017 and before January 1, 2021 may be carried back to each of the five tax years preceding such loss, and NOLs arising in tax years beginning after December 31, 2020 may not be carried back. Moreover, federal NOLs generated in tax years ending after December 31, 2017 may be carried forward indefinitely, but the deductibility of such federal NOLs may be limited to 80% of current year taxable income for tax years beginning after January 1, 2021. Under A.B. 85, our California NOL carryforwards are suspended for tax years 2020, 2021, and 2022, but the period to use these carryovers was extended. Further, the Tax Act requires the taxpayers to capitalize Research and Experimental (R&amp;E) expenditures under Section 174 of the Internal Revenue Code, as amended (Code), effective for taxable years beginning after December 31, 2021, which will reduce our NOLs beginning in 2022. R&amp;E expenditures attributable to US-based research must be amortized over a period of 5 years and R&amp;E expenditures attributable to research conducted outside of the US must be amortized over a period of 15 years. </span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:14pt 0pt 0pt 0pt;">In addition, utilization of NOLs to offset potential future taxable income and related income taxes that would otherwise be due is subject to annual limitations under the &#8220;ownership change&#8221; provisions of Sections 382 and 383 of the Code and similar state provisions, which may result in the expiration of NOLs before future utilization. In general, under the Code, if a corporation undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50% change (by value) in its equity ownership over a three-year period, the corporation&#8217;s ability to use its pre-change NOLs and other pre-change tax attributes (such as research and development credit carryforwards) to offset its post-change taxable income or taxes may be limited. Our equity offerings and other changes in our stock ownership, some of which are outside of our control, may have resulted or could in the future result in an ownership change. Although we have completed studies to provide reasonable assurance that an ownership change limitation would not apply, we cannot be certain that a taxing authority would reach the same conclusion. If, after a review or audit, an ownership change limitation were to apply, utilization of our domestic NOLs and tax credit carryforwards could be limited in future periods and a portion of the carryforwards could expire before being available to reduce future income tax liabilities. Moreover, our ability to utilize our NOLs is conditioned upon us achieving profitability and generating US federal taxable income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Because we expect to be dependent upon collaborative and license agreements, we might not meet our strategic objectives.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our ability to generate revenue in the near term depends on the timing of recognition of certain upfront payments, achievement of certain payment triggering events with our existing collaboration agreements and our ability to enter into additional collaborative agreements with third parties. Our ability to enter into new collaborations and the revenue, if any, that may be recognized under these collaborations is highly uncertain. If we are unable to enter into one or more new collaborations, our business prospects could be harmed, which could have an immediate adverse effect on our ability to continue to develop our compounds and on the trading price of our stock. Our ability to enter into a collaboration may be dependent on many factors, such as the results of our clinical trials, competitive factors and the fit of one of our programs with another company&#8217;s risk tolerance, including toward regulatory issues, patent portfolio, clinical pipeline, the stage of the available data, particularly if it is early, overall corporate goals and financial position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">To date, a portion of our revenues have been related to the research or transition phase of each of our collaborative agreements. Such revenues are for specified periods, and the impact of such revenues on our results of operations is at least partially offset by corresponding research costs. Following the completion of the research or transition phase of each collaborative agreement, additional revenues may come only from payments triggered by milestones and/or the achievement of other contingent events, and royalties, which may not be paid, if at all, until certain conditions are met. This risk is heightened due to the fact that unsuccessful research efforts may preclude us from receiving any contingent payments under these agreements. Our receipt of revenues from collaborative arrangements is also significantly affected by the timing of efforts expended by us and our collaborators and the timing of lead compound identification. We have received payments from our current collaborations including Lilly, Grifols, Kissei, Medison, Knight, BerGenBio, and Daiichi. Under several agreements, future payments may not be earned until the collaborator has advanced product candidates into clinical testing, which may never occur or may not occur until sometime well into the future. If we are not able to generate revenue under our collaborations when and in accordance with our expectations or the expectations of industry analysts, this failure could harm our business and have an immediate adverse effect on the trading price of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our business requires us to generate meaningful revenue from royalties and licensing agreements. To date, we have not recognized material amount of revenue from royalties for the commercial sale of drugs, and we do not know when we will be able to generate such meaningful revenue in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Securities class action lawsuits or other litigation could result in substantial damages and may divert management&#8217;s time and attention from our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We have been subject to class action lawsuits in the past and we may be subject to lawsuits in the future, such as those that might occur if there was to be a change in our corporate strategy. These and other lawsuits are subject to inherent uncertainties, and the actual costs to be incurred relating to the lawsuit will depend upon many unknown factors. The outcome of litigation is necessarily uncertain, and we could be forced to expend significant resources in the defense of such suits, and we may not prevail. Monitoring and defending against legal actions is time-consuming for our management and detracts from our ability to fully focus our internal resources on our business activities. In addition, we </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;">may incur substantial legal fees and costs in connection with any such litigation. We have not established any reserves for any potential liability relating to any such potential lawsuits. It is possible that we could, in the future, incur judgments or enter into settlements of claims for monetary damages. A decision adverse to our interests on any such actions could result in the payment of substantial damages, or possibly fines, and could have an adverse effect on our cash flow, results of operations and financial position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">If our competitors develop technologies that are more effective than ours, our commercial opportunity will be reduced or eliminated.*</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 0pt 0pt;">The biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and significant technological change. Many of the drugs that we are attempting to discover will be competing with existing therapies. In addition, a number of companies are pursuing the development of pharmaceuticals that target the same diseases and conditions that we are targeting. For example, the commercialization of new pharmaceutical products is highly competitive, and we face substantial competition with respect to our products in which there are existing therapies and drug candidates in development for the treatment of <span style="color:#222222;background:#ffffff;">hematologic disorders and cancer</span> that may be alternative therapies to our products. Many of our competitors, including a number of large pharmaceutical companies that compete directly with us, have significantly greater financial resources and expertise commercializing approved products than we do. Also, many of our competitors are large pharmaceutical companies that will have a greater ability to reduce prices for their competing drugs in an effort to gain market share and undermine the value proposition that we might otherwise be able to offer to payers. We face, and will continue to face, intense competition from pharmaceutical and biotechnology companies, as well as from academic and research institutions and government agencies, both in the US and abroad. Some of these competitors are pursuing the development of pharmaceuticals that target the same diseases and conditions as our research programs. Our competitors including fully integrated pharmaceutical companies have extensive drug discovery efforts and are developing novel small-molecule pharmaceuticals. We also face significant competition from organizations that are pursuing the same or similar technologies, including the discovery of targets that are useful in compound screening, as the technologies used by us in our drug discovery efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">Competition may also arise from:</p><div style="margin-top:9pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">new or better methods of target identification or validation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">generic versions of our products or of products with which we compete;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other drug development technologies and methods of preventing or reducing the incidence of disease;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">new small molecules; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other classes of therapeutic agents.</span></td></tr></table><div style="margin-top:9pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Our competitors or their collaborative partners may utilize discovery technologies and techniques or partner with collaborators in order to develop products more rapidly or successfully than we or our collaborators are able to do. Many of our competitors, particularly large pharmaceutical companies, have substantially greater financial, technical and human resources and larger research and development staffs than we do. In addition, academic institutions, government agencies and other public and private organizations conducting research may seek patent protection with respect to potentially competitive products or technologies and may establish exclusive collaborative or licensing relationships with our competitors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">We believe that our ability to compete is dependent, in part, upon our ability to create, maintain and license scientifically-advanced technology and upon our and our collaborators&#8217; ability to develop and commercialize pharmaceutical products based on this technology, as well as our ability to attract and retain qualified personnel, obtain patent protection or otherwise develop proprietary technology or processes, secure effective market access by ensuring competitive pricing and reimbursement in territories of interest, and secure sufficient capital resources for the expected substantial time period between technological conception and commercial sales of products based upon our technology. The failure by any of our collaborators or us in any of those areas may prevent the successful commercialization of our potential drug targets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 0pt 0pt;">Many of our competitors, either alone or together with their collaborative partners, have significantly greater </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;">experience than we do in:</p><div style="margin-top:9pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">identifying and validating targets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">screening compounds against targets; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">undertaking preclinical testing and clinical trials.</span></td></tr></table><div style="margin-top:9pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Accordingly, our competitors may succeed in obtaining patent protection, identifying or validating new targets or discovering new drug compounds before we do.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Our competitors might develop technologies and drugs that are more effective or less costly than any that are being developed by us or that would render our technology and product candidates obsolete and noncompetitive. In addition, our competitors may succeed in obtaining the approval of the FDA or other regulatory agencies for product candidates more rapidly. Companies that complete clinical trials, obtain required regulatory agency approvals and commence commercial sale of their drugs before us may achieve a significant competitive advantage, including certain patent and FDA marketing exclusivity rights that would delay or prevent our ability to market certain products. Any drugs resulting from our research and development efforts, or from our joint efforts with our existing or future collaborative partners, might not be able to compete successfully with competitors&#8217; existing or future products or obtain regulatory approval in the US or elsewhere.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">We face and will continue to face intense competition from other companies for collaborative arrangements with pharmaceutical and biotechnology companies, for establishing relationships with academic and research institutions and for licenses to additional technologies. These competitors, either alone or with their collaborative partners, may succeed in developing technologies or products that are more effective than ours.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Our ability to compete successfully will depend, in part, on our ability to:</p><div style="margin-top:9pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">identify and validate targets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">discover candidate drug compounds that interact with the targets we identify in a safe and efficacious way;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">attract and retain scientific and product development personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">recruit subjects into our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain and maintain required regulatory approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain patent or other proprietary protection for our new drug compounds and technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain access to manufacturing resources of the sufficient standard and scale; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">enter commercialization agreements for our new drug compounds; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain and maintain appropriate reimbursement price and positive recommendations by HTA bodies.</span></td></tr></table><div style="margin-top:9pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our stock price may be volatile, and our stockholders&#8217; investment in our common stock could decline in value.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">The market prices for our common stock and the securities of other biotechnology companies have been highly volatile and may continue to be highly volatile in the future. The following factors, in addition to other risk factors described in this section, may have a significant impact on the market price of our common stock:</p><div style="margin-top:9pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the progress and success of our clinical trials and preclinical activities (including studies and manufacture of materials) of our product candidates conducted by us;</span></td></tr></table><div style="margin-top:9pt;"></div><div style="margin-top:9pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to continue to sell our products in the US;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to enter into partnering opportunities across our pipeline;</span></td></tr></table><div style="margin-top:9pt;"></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the receipt or failure to receive the additional funding necessary to conduct our business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">selling of our common stock by large stockholders;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">presentations of detailed clinical trial data at medical and scientific conferences and investor perception thereof;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements of technological innovations or new commercial products by our competitors or us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the announcement of regulatory applications, such as Annora&#8217;s ANDA, seeking approval of generic versions of our marketed products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developments concerning proprietary rights, including patents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developments concerning our collaborations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">publicity regarding actual or potential medical results relating to products under development by our competitors or us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory developments in the US and foreign countries; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in the structure of healthcare payment systems;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">litigation or arbitration;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">economic and other external factors or other disaster or crisis; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">period-to-period fluctuations in financial results.</span></td></tr></table><div style="margin-top:9pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">If we fail to continue to meet the&#160;listing standards&#160;of Nasdaq, our common stock may be delisted, which could have a material adverse effect on the liquidity of our common stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our common stock is currently listed on the Nasdaq Global Market. The Nasdaq Stock Market LLC has requirements that a company must meet in order to remain listed on Nasdaq. In particular, Nasdaq rules require us to maintain a minimum bid price of $1.00 per share of our common stock (the &#8220;Bid Price Requirement&#8221;). If the closing bid price of our common stock falls below $1.00 per share for 30 consecutive trading days or we do not meet other listing requirements, we would fail to be in compliance with Nasdaq listing standards. There can be no assurance that we will continue to meet the Bid Price Requirement, or any other requirement in the future. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:14pt 0pt 0pt 0pt;">On November 22, 2022, we received a deficiency letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC notifying us that, for the last 30 consecutive business days, the bid price for our common stock closed below the Bid Price Requirement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:14pt 0pt 0pt 0pt;">We were provided a period of 180 calendar days, or until May 22, 2023 (the &#8220;Compliance Date&#8221;), to regain compliance with the Bid Price Requirement. On January 5, 2023, we received notification from the Listing Qualifications Department of the Nasdaq Stock Market LLC that we have regained compliance with the Bid Price Requirement because the closing bid price of our common stock closed at $1.00 or more for over 10 consecutive business days from December 13, 2022 to January 4, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:14pt 0pt 0pt 0pt;">Although we have regained compliance, the Nasdaq Stock Market LLC may in the future initiate the delisting process with a notification letter if we were to again fall out of compliance. If we were to receive such a notification, we would be afforded a grace period of 180 calendar days to regain compliance with the minimum bid price requirement. In order to regain compliance, shares of our common stock would need to maintain a minimum closing bid price of at least $1.00 per share for a minimum of 10 consecutive trading days. In addition, we may be unable to meet other applicable Nasdaq listing requirements, including maintaining minimum levels of stockholders&#8217; equity or market values of our common stock in which case, our common stock could be delisted. If our common stock were to be delisted, the liquidity of our common stock would be adversely affected and the market price of our common stock could decrease.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">The withdrawal of the UK from the EU may adversely impact our ability to obtain regulatory approvals of our product candidates in the UK and the EU, result in restrictions or imposition of taxes and duties for importing our product candidates into the UK and the EU, and may require us to incur additional expenses in order to develop, manufacture and commercialize our product candidates in the UK and the EU.*</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Following the result of a referendum in 2016, the UK left the<span style="white-space:pre-wrap;"> EU on January 31, 2020, commonly referred to as Brexit.  Pursuant to the formal withdrawal arrangements agreed between the UK and the EU, the UK was subject to a transition period until December 31, 2020, or the Transition Period, during which EU rules continued to apply. A trade and cooperation agreement (Trade Agreement) that outlines the future trading relationship between the UK and the EU was agreed to in December 2020 and has been approved by each EU member state and the UK.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Since a significant proportion of the regulatory framework in the UK applicable to our business and our product candidates is derived from EU directives and regulations, Brexit has had, and will continue to have, a material impact upon the regulatory regime with respect to the development, manufacture, importation, approval and commercialization of our product candidates in the UK or the EU. Great Britain (made up of England, Scotland, and Wales) is no longer covered by the EEA&#8217;s procedures for the grant of marketing authorizations (Northern Ireland will be covered by such procedures). The UK Government and the EU recently adopted a new agreement, the &#8220;Windsor Framework&#8221; which will replace the Northern Ireland Protocol. Once the Windsor Framework becomes law, the Medicines and Healthcare Products Regulatory Agency (MHRA) rather than the EMA will approve all medicines placed on the market in Northern Ireland.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">A separate marketing authorization will be required to market drugs in Great Britain. It is currently unclear whether the MHRA in the UK is sufficiently prepared to handle the increased volume of marketing authorization applications that it is likely to receive. Any delay in obtaining, or an inability to obtain, any marketing approvals would delay or prevent us from commercializing our product candidates in the UK or the EU and restrict our ability to generate revenue and achieve and sustain profitability. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;"><span style="white-space:pre-wrap;">While the Trade Agreement provides for the tariff-free trade of medicinal products between the UK and the EU, there may be additional non-tariff costs to such trade which did not exist prior to the end of the Transition Period.  Further, should the UK diverge from the EU from a regulatory perspective in relation to medicinal products, tariffs could be put into place in the future.  We could therefore, both now and in the future, face significant additional expenses (when compared to the position prior to the end of the Transition Period) </span>to operate our business, which could significantly and materially harm or delay our ability to generate revenues or achieve profitability of our business. Any further changes in international trade, tariff and import/export regulations as a result of Brexit or otherwise may impose unexpected duty costs or other non-tariff barriers on us. These developments, or the perception that any of them could occur, may significantly reduce global trade and, in particular, trade between the impacted nations and the UK. It is also possible that Brexit may negatively affect our ability to attract and retain employees, particularly those from the EU.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Orphan designation in Great Britain following Brexit is granted on an essentially identical basis as in the EU but is based on the prevalence of the condition in Great Britain.&#160;It is therefore possible that conditions that are currently designated as orphan conditions in Great Britain will no longer be, and conditions that are not currently designated as orphan conditions in the EU will be designated as such in Great Britain. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">If product liability lawsuits are successfully brought against us, we may incur substantial liabilities and may be required to limit commercialization of our products.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 0pt 0pt;">The testing and marketing of medical products and the sale of any products for which we obtain marketing approval exposes us to the risk of product liability claims. Product liability claims might be brought against us by consumers, health care providers, pharmaceutical companies or others selling or otherwise coming into contact with our products. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our products. We carry product liability insurance that is limited in scope and amount and may not be adequate to fully protect us against product liability claims. If and when we obtain marketing approval for our product candidates, we intend to expand our insurance coverage to include the sale of commercial products; however, we may be unable to obtain product liability insurance on commercially reasonable terms or in adequate amounts. Our inability to obtain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of pharmaceutical products we </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;">develop, alone or with corporate collaborators. We, or our corporate collaborators, might not be able to obtain insurance at a reasonable cost, if at all. While under various circumstances we are entitled to be indemnified against losses by our corporate collaborators, indemnification may not be available or adequate should any claim arise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">We depend on various scientific consultants and advisors for the success and continuation of our research and development efforts.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">We work extensively with various scientific consultants and advisors. The potential success of our drug discovery and development programs depends, in part, on continued collaborations with certain of these consultants and advisors. We, and various members of our management and research staff, rely on certain of these consultants and advisors for expertise in our research, regulatory and clinical efforts. Our scientific advisors are not our employees and may have commitments to, or consulting or advisory contracts with, other entities that may limit their availability to us. We do not know if we will be able to maintain such consulting agreements or that such scientific advisors will not enter into consulting arrangements with competing pharmaceutical or biotechnology companies, any of which may have a detrimental impact on our research objectives and could have an adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">While we have a strong compliance process in place to ensure we are complying with all requirements of law, our consulting or advisory contracts with our scientific consultants and advisors may be scrutinized under the Anti-Kickback Statute, the UK Bribery Act 2010, and other similar national and state-level legislation, which prohibit, among other things, companies from offering or paying anything of value as remuneration for ordering, purchasing, or recommending the ordering or purchasing of pharmaceutical and biological products that may be paid for, in whole or in part, by Medicare, Medicaid, or another federal healthcare program. Although there are several statutory exceptions and regulatory safe harbors that may protect these arrangements from prosecution or regulatory sanctions, our consulting and advising contracts may be subject to scrutiny if they do not fit squarely within an available exception or safe harbor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we use biological and hazardous materials in a manner that causes injury or violates laws, we may be liable for damages, penalties or fines.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Our research and development activities involve the controlled use of potentially harmful biological materials as well as hazardous materials, chemicals, animals, and various radioactive compounds. We cannot completely eliminate the risk of accidental contamination or injury from the use, storage, handling or disposal of these animals and materials. In the event of contamination or injury, we could be held liable for damages that result or for penalties or fines that may be imposed, and such liability could exceed our resources. We are also subject to federal, state and local laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products. The cost of compliance with, or any potential violation of, these laws and regulations could be significant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our information technology systems, or those used by our CROs or other contractors or consultants, may fail or suffer other breakdowns, cyber-attacks, or information security breaches.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:36pt;margin:9pt 0pt 0pt 0pt;">We are increasingly dependent upon information technology systems, infrastructure, and data to operate our business, particularly during the COVID-19 pandemic. We also rely on third party vendors and their information technology systems. Despite the implementation of security measures, our recovery systems, security protocols, network protection mechanisms and other security measures and those of our CROs and other contractors and consultants are vulnerable to compromise from natural disasters; terrorism; war; telecommunication and electric failures; traditional computer hackers; malicious code (such as computer viruses or worms); employee error, theft or misuse; denial-of-service attacks; cyber-attacks by sophisticated nation-state and nation-state supported actors including ransomware; or other system disruptions. We receive, generate and store significant and increasing volumes of personal (including health), confidential and proprietary information. There can be no assurance that we, or our collaborators, CROs, third-party vendors, contractors and consultants will be successful in efforts to detect, prevent, protect against or fully recover systems or data from all breakdowns, service interruptions, attacks or breaches. Any breakdown, cyber-attack or information security breach could result in a disruption of our drug development programs or other aspects of our business. For example, the loss of clinical trial data from completed or ongoing clinical trials for a product candidate could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of or damage to our data or applications, or inappropriate disclosure of personal, confidential or proprietary information, we could incur liability, incur significant </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 9pt 0pt;">remediation or litigation costs, result in product development delays, disrupt key business operations, cause loss of revenue and divert attention of management and key information technology resources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Hackers and data thieves are increasingly sophisticated and operate large-scale and complex automated attacks, including on companies within the healthcare industry. As the cyber-threat landscape evolves, these threats are likely growing in frequency, sophistication and intensity and are increasingly difficult to detect. The costs of maintaining or upgrading our cyber-security systems at the level necessary to keep up with our expanding operations and prevent against potential attacks are increasing. Cyber threats may be generic, or they may be targeted against our information systems. Our network and storage applications and those of our contract manufacturing organizations, collaborators, contractors, CROs or vendors may be subject to unauthorized access or processing by hackers or breached due to operator or other human error, theft, malfeasance or other system disruptions. We may be unable to anticipate or immediately detect information security incidents and the damage caused by such incidents. These data breaches and any unauthorized access, processing or disclosure of our information or intellectual property could compromise our intellectual property and expose our sensitive business information. Such attacks, such as in the case of a ransomware attack, also may interfere with our ability to continue to operate and may result in delays and shortcomings due to an attack that may encrypt our or our service providers&#8217; or partners&#8217; systems unusable. Additionally, because our services involve the processing of personal information and other sensitive information about individuals we are subject to various laws, regulations, industry standards, and contractual requirements related to such processing. Any event that leads to unauthorized access, processing or disclosure of personal information, including personal information regarding our clinical trial participants or employees, could harm our reputation and business, compel us to comply with federal and/or state breach notification laws and foreign law equivalents, subject us to investigations and mandatory corrective action, and otherwise subject us to liability under laws, regulations or contracts that protect the privacy and security of personal information, which could disrupt our business, damage our reputation with our stakeholders, result in increased costs or loss of revenue, lead to negative publicity or result in significant financial exposure. The CCPA, in particular, includes a private right of action for California consumers whose personal information is impacted by a data security incident resulting from a company&#8217;s failure to maintain reasonable security procedures, and hence may result in civil litigation in the event of a security breach impacting such information. In addition, legislators and regulators in the US have enacted and are proposing new and more robust privacy and cybersecurity laws and regulations in response to increasing broad-based cyberattacks, including the CCPA and New York SHIELD Act. New data security laws add additional complexity, requirements, restrictions and potential legal risk, and compliance programs may require additional investment in resources, and could impact strategies and availability of previously useful data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">The costs to respond to a security breach and/or to mitigate any identified security vulnerabilities could be significant, our efforts to address these issues may not be successful, and these issues could result in interruptions, delays, negative publicity, loss of customer trust, and other harms to our business and competitive position. Remediation of any potential security breach may involve significant time, resources, and expenses. We could be required to fundamentally change our business activities and practices in response to a security breach and our systems or networks may be perceived as less desirable, which could negatively affect our business and damage our reputation. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">A security breach may cause us to breach our contracts with third parties. Our agreements with relevant stakeholders such as collaborators may require us to use legally required, industry-standard or reasonable measures to safeguard personal information. A security breach could lead to claims by relevant stakeholders that we have failed to comply with such contractual obligations, or require us to cooperate with these stakeholders in their own compliance efforts related to the security breach. In addition, any non-compliance with our data privacy obligations in our contracts or our inability to flow down such obligations from relevant stakeholders to our vendors may cause us to breach our contracts. As a result, we could be subject to legal action or the relevant stakeholders could end their relationships with us. There can be no assurance that the limitations of liability in our contracts would be enforceable or adequate or would otherwise protect us from liabilities or damages.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">We may not have adequate insurance coverage for security incidents or breaches. The successful assertion of one or more large claims against us that exceeds our available insurance coverage, or results in changes to our insurance policies (including premium increases or the imposition of large deductible or co-insurance requirements), could have an adverse effect on our business. In addition, we cannot be sure that our existing insurance coverage will continue to be available on acceptable terms or that our insurers will not deny coverage as to any future claim.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">Future equity issuances or a sale of a substantial number of shares of our common stock may cause the price of our common stock to decline.</span></p><a id="_cp_text_1_407"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Because we will continue to need additional capital in the future to continue to expand our business and our research and development activities, among other things, we may conduct additional equity offerings. For example, <span style="background:#ffffff;">on August 3, 2021, a new automatic shelf registration statement was filed by us as well-known seasoned issuer (WKSI). The automatic shelf registration statement was filed to register, among other securities, the sale of up to a maximum aggregate offering price of $100.0 million of shares of our common stock that may be issued and sold from time to time under our Open Market Sale Agreement with Jefferies, and </span><span style="letter-spacing:0.2pt;">a base prospectus which covers the offering, issuance, and sale by us of the securities identified above from time to time in one or more offerings</span><span style="background:#ffffff;">. On March 1, 2022, we filed a post-effective amendment to the automatic shelf registration statement immediately after filing our Annual Report Form 10-K for the year ended December 31, 2021 because we no longer qualified as a WKSI upon filing of such Annual Report. The post-effective amendment was declared effective on May 3, 2022. The post-effective amendment registers, among other securities, </span>a base prospectus which covers the offering, issuance, and sale by us of up to $250.0 million in the aggregate of the securities identified from time to time in one or more offerings, which include the $100.0 million of shares of our common stock that may be offered, issued and sold under the Open Market Sale Agreement.<span style="white-space:pre-wrap;background:#ffffff;">  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><a id="_cp_text_1_409"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We may also in the future enter into underwriting or sales agreements with financial institutions for the offer and sale of <span style="white-space:pre-wrap;">any combination of common stock, preferred stock, debt securities and warrants in one or more offerings.  If we or our stockholders sell, or if it is perceived that we or they will sell, substantial amounts of our common stock in the public market, the market price of our common stock could fall. A decline in the market price of our common stock could make it more difficult for us to sell equity or equity-related securities in the future at a time and price that we deem appropriate. In addition, future sales by us of our common stock may be dilutive to existing stockholders. Furthermore, if we obtain funds through a credit facility or through the issuance of debt or preferred securities, these securities would likely have rights senior to the rights of our common stockholders, which could impair the value of our common stock. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 9pt 0pt;"><b style="font-weight:bold;background:#ffffff;">Risks Related to Clinical Development and Regulatory Approval</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">Enacted or future legislation, and/or potentially unfavorable pricing regulations or other healthcare reform initiatives, may increase the difficulty and cost for us to obtain regulatory approval of our product candidates and/or commercialize fostamatinib or our product candidates, once approved, and affect the prices we may set or obtain.*</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;"><span style="white-space:pre-wrap;">The regulations that govern, among other things, regulatory approvals, coverage, pricing and reimbursement for new drug products vary widely from country to country. In the US and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay regulatory approval of our product candidates, restrict or regulate post-approval activities and affect our ability to successfully sell TAVALISSE, REZLIDHIA, or any product candidates for which we obtain regulatory approval in the future. In particular, in March 2010, the Affordable Care Act (ACA) was enacted, which substantially changed the way health care is financed by both governmental and private insurers, and continues to significantly impact the US pharmaceutical industry. On June 17, 2021, the US Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the law. Prior to the Supreme Court&#8217;s decision, President Biden issued an executive order that instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the Affordable Care Act. It is unclear how future actions before the Supreme Court, other such litigation, and the healthcare reform measures of the Biden administration will impact the Affordable Care Act and our business.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">There have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. We cannot predict the initiatives that may be adopted in the future. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce the costs of healthcare and/or impose price controls may adversely affect, for example:</p><div style="margin-top:9pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the demand for TAVALISSE, REZLIDHIA, or our product candidates, if we obtain regulatory approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to set a price that we believe is fair for our products;</span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to generate revenue and achieve or maintain profitability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the level of taxes that we are required to pay; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability of capital.</span></td></tr></table><div style="margin-top:9pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors, which may adversely affect our future profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">In the US, the EU and other potentially significant markets for our current and future products, government authorities and third-party payors are increasingly attempting to limit or regulate the price of medical products and services, particularly for new and innovative products and therapies, which has resulted in lower average selling prices. In the US, there have been several Congressional inquiries and federal legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer-sponsored patient assistance programs, and reform government program reimbursement methodologies for drugs<span style="background:#ffffff;">. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which, among other changes, eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug&#8217;s average manufacture price, for single source and innovator multiple source drugs, beginning January 1, 2024. The American Rescue Plan Act also temporarily increased premium tax credit assistance for individuals eligible for subsidies under the ACA for 2021 and 2022 and removed the 400% federal poverty level limit that otherwise applies for purposes of eligibility to receive premium tax credits. The Inflation Reduction Act of 2022 (IRA) extended this increased tax credit assistance and removal of the 400% federal poverty limit through 2025. Additionally, beginning in April 2013, the Budget Control Act of 2011 created an automatic reduction of Medicare payments to providers of up to 2%. As a result of the COVID-19 pandemic, this reduction was temporarily suspended from May 1, 2020 through March 31, 2022, with subsequent reductions to 1% from April 1, 2022 until June 30, 2022. The 2% reduction was then reinstated and has been in effect since June 30, 2022, and will remain in effect (with additional reductions of 2.25% in the first half of 2030 and 3% in the second half of 2030 to offset the COVID-19 suspension) until 2031, unless additional Congressional action is taken. Moreover, on June 16, 2022, the Federal Trade Commission issued a policy statement stating its intension to increase enforcement scrutiny of &#8220;exclusionary rebates&#8221; to PBMs and other intermediaries that &#8220;foreclose competition.&#8221; On August 16, 2022, President Biden signed into law the IRA, which, among other reforms, allows Medicare to: beginning in 2026, establish a &#8220;maximum fair price&#8221; for a fixed number of pharmaceutical and biological products covered under Medicare Parts B and D following a price negotiation with CMS; beginning in 2023, penalize drug companies that raise prices for products covered under Medicare Parts B and D faster than inflation; and beginning in 2025 impose new discounts obligations on pharmaceutical and biological manufacturers for products covered under Medicare Part D. On June 9, 2023, CMS released a list of 43 Medicare Part B products that had an adjusted coinsurance rate based on the inflationary rebate provisions of the IRA for the time period of July 1, 2023 to September 30, 2023. Additionally, on June 30, 2023, CMS issued guidance detailing the requirements and parameters of the first round of price negotiations for products subject to the &#8220;maximum fair price&#8221; provision. This negotiation process will occur during 2023 and 2024 and result in maximum prices that will be effective beginning in 2026. It is unclear how future regulatory actions to implement the IRA may affect our products and future profitability. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">   </span><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">The</span> Biden administration has also taken executive action to address drug pricing and other healthcare policy changes<span style="background:#ffffff;">. </span>For example, on September 12, 2022, President Biden issued an Executive Order to promote biotechnology and biomanufacturing innovation. The Order noted several methods through which the Biden Administration would support the advancement of biotechnology and biomanufacturing in healthcare, and instructed the Department of Health and Human Service to submit, within 180 days of the Order, a report assessing how to use biotechnology and biomanufacturing to achieve medical breakthroughs, reduce the overall burden of disease, and improve health outcomes. <span style="white-space:pre-wrap;background:#ffffff;">On October 14, 2022, President Biden issued an Executive Order on Lowering Prescription Drug Costs for Americans which instructed the Secretary of the Department of Health and Human Services to consider whether to select for testing by the CMS Innovation Center new health care payment and delivery models that would lower drug costs and promote access to innovative drug therapies for beneficiaries enrolled in the Medicare and Medicaid programs.  The Executive Order further directed the Secretary of the Department of Health and Human Services to submit, within 90 days after the date of the Executive Order, a report regarding any models that may lead to lower cost-sharing for commonly used drugs and support value-based payment that promotes high-quality care.</span> On February 14, 2023, the Department of Health and Human Services issued a report in response to the October 14, 2022, Executive Order, which, among other things, </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">75</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">selects three potential drug affordability and accessibility models to be tested by the CMS Innovation Center.  Specifically, the report addresses: (1) a model that would allow Part D Sponsors to establish a &#8220;high-value drug list&#8221; setting the maximum co-payment amount for certain common generic drugs at $2; (2) a Medicaid-focused model that would establish a partnership between CMS, manufacturers, and state Medicaid agencies that would result in multi-state outcomes-based agreements for certain cell and gene therapy drugs; and (3) a model that would adjust Medicare Part B payment amounts for Accelerated Approval Program drugs to advance the developments of novel treatments.  It remains to be seen how these drug pricing initiatives will affect the broader pharmaceutical industry.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing. Specifically, several U.S. states and localities have enacted legislation requiring pharmaceutical companies to establish marketing compliance programs, file periodic reports, and/or make periodic public disclosures on sales, marketing, pricing, clinical trials, and other activities. Other state laws prohibit certain marketing-related activities including the provision of gifts, meals or other items to certain healthcare providers, and restrict the ability of manufacturers to offer co-pay support to patients for certain prescription drugs. Several state laws require disclosures related to state agencies and/or commercial purchasers with respect to certain price increases that exceed a certain level as identified in the relevant statutes. Another emerging trend at the state level is the establishment of prescription drug affordability boards, some of which will prospectively permit certain states to establish upper payment limits for drugs that the state has determined to be &#8220;high-cost&#8221;. Some of these laws and regulations contain ambiguous requirements that government officials have not yet clarified. Given the lack of clarity in the laws and their implementation, our reporting actions could be subject to the penalty provisions of the pertinent federal and state laws and regulations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Furthermore, the increased emphasis on managed healthcare in the US and on country and regional pricing and reimbursement controls in the EU and the UK will put additional pressure on product pricing, reimbursement and usage, which may adversely affect our sales and results of operations. These pressures can arise from rules and practices of managed care groups, judicial decisions and governmental laws and regulations related to Medicare, Medicaid and healthcare reform, pharmaceutical reimbursement policies and pricing in general. Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;"><span style="white-space:pre-wrap;">We cannot predict the likelihood, nature, or extent of health reform initiatives that may arise from future legislation or administrative action. However, we expect these initiatives to increase pressure on drug pricing. Further, certain broader legislation that is not targeted to the health care industry may nonetheless adversely affect our profitability.  If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our product candidates may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;"><span style="background:#ffffff;">See &#8220;Part I, Item 1 &#8211; Business &#8211; Government Regulation &#8211; Healthcare Reform&#8221; of our Annual Report on Form 10-K for the year ended December 31, 202</span>2.</p><a id="_cp_text_4_434"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Regulatory approval for any approved product is limited by the FDA, the EC and other regulators to those specific indications and conditions for which clinical safety and efficacy have been demonstrated, and we may incur significant liability if it is determined that we are promoting the &#8220;off-label&#8221; use of our products or any of our future product candidates if approved.</span></p><a id="_cp_text_4_436"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:14pt 0pt 0pt 0pt;">Any regulatory approval is limited to those specific diseases, indications and patient populations for which a product is deemed to be safe and effective by the FDA, the EC and other regulators. For example, the FDA-approved label for TAVALISSE is only approved for use in adults with ITP who have had an insufficient response to other treatments and for REZLIDHIA is only approved for use in adult patients with R/R AML with a susceptible IDH1 mutation as detected by an FDA-approved test. In addition to the FDA approval required for new formulations, any new indication for an approved product also requires FDA approval. If we are not able to obtain FDA approval for any desired future indications for our products and product candidates, our ability to effectively market and sell our products may be reduced and our business may be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><a id="_cp_text_4_437"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">While physicians may choose to prescribe drugs for uses that are not described in the product&#8217;s labeling and for </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">76</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_cp_text_1_438"></a><a id="_cp_text_4_439"></a><a id="_cp_text_4_440"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">uses that differ from those tested in clinical studies and approved by the regulatory authorities, our ability to promote the products is limited to those indications and patient populations that are specifically approved by the FDA. These &#8220;off-label&#8221; uses are common across medical specialties and may constitute an appropriate treatment for some patients in varied circumstances. We have implemented compliance and monitoring policies and procedures, including a process for internal review of promotional materials, to deter the promotion of our products for off-label uses. We cannot guarantee that these compliance activities will prevent or timely detect off-label promotion by sales representatives or other personnel in their communications with health care professionals, patients and others, particularly if these activities are concealed from us. Regulatory authorities in the US generally do not regulate the behavior of physicians in their choice of treatments. Regulatory authorities do, however, restrict communications by pharmaceutical companies on the subject of off-label use. If our promotional activities fail to comply with the FDA&#8217;s or other competent national authority&#8217;s regulations or guidelines, we may be subject to warnings from, or enforcement action by, these regulatory authorities. In addition, our failure to follow FDA rules and guidelines relating to promotion and advertising may cause the FDA to issue warning letters or untitled letters, suspend or withdraw an approved product from the market, require a recall or institute fines, which could result in the disgorgement of money, operating restrictions, injunctions or civil or criminal enforcement, and other consequences, any of which could harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><a id="_cp_text_4_441"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">Notwithstanding the regulatory restrictions on off-label promotion, the FDA and other regulatory authorities allow companies to engage in truthful, non-misleading and non-promotional scientific exchange concerning their products. We engage in medical education activities and communicate with investigators and potential investigators regarding our clinical trials. If the FDA or other regulatory or enforcement authorities determine that our communications regarding our marketed product are not in compliance with the relevant regulatory requirements and that we have improperly promoted off-label uses, or that our communications regarding our investigational products are not in compliance with the relevant regulatory requirements and that we have improperly engaged in pre-approval promotion, we may be subject to significant liability, including civil and administrative remedies as well as criminal sanctions.  </span></p><a id="_Hlk70587505"></a><a id="_Hlk101337149"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">Delays in clinical testing could result in increased costs to us.*</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">We may not be able to initiate or continue clinical studies or trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these clinical trials as required by the FDA or other regulatory authorities, whether due to the impacts of a global pandemic, the Russian-Ukrainian conflict or otherwise. Even if we are able to enroll a sufficient number of patients in our clinical trials, if the pace of enrollment is slower than we expect, the development costs for our product candidates may increase and the completion of our clinical trials may be delayed, or our clinical trials could become too expensive to complete. Significant delays in clinical testing could negatively impact our product development costs and timing. Our estimates regarding timing are based on a number of assumptions, including assumptions based on past experience with our other clinical programs. If we are unable to enroll the patients in these trials at the projected rate, the completion of the clinical program could be delayed and the costs of conducting the program could increase, either of which could harm our business. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 0pt 0pt;">Clinical trials can be delayed for a variety of reasons, including delays in obtaining regulatory approval to commence a study, delays from scaling up of a study, delays in reaching agreement on acceptable clinical trial agreement terms with prospective clinical sites, delays in obtaining institutional review board approval to conduct a study at a prospective clinical site or delays in recruiting subjects to participate in a study. In addition, we typically rely on third-party clinical investigators to conduct our clinical trials and other third-party organizations to oversee the operations of such trials and to perform data collection and analysis. The clinical investigators are not our employees, and we cannot control the amount or timing of resources that they devote to our programs. Failure of the third-party organizations to meet their obligations, whether due to the potential future impacts of a global pandemic, the Russian-Ukrainian conflict or otherwise, could adversely affect clinical development of our products. As a result, we may face additional delaying factors outside our control if these parties do not perform their obligations in a timely fashion. For example, any number of those issues could arise with our clinical trials causing a delay. Delays of this sort could occur for the reasons identified above or other reasons. If we have delays in conducting the clinical trials or obtaining regulatory approvals, our product development costs will increase. For example, we may need to make additional payments to third-party investigators and organizations to retain their services or we may need to pay recruitment incentives. If the delays are significant, our financial results and the commercial prospects for our product candidates will be harmed, and our ability to become profitable will be delayed. Moreover, these third-party investigators and organizations may also have relationships with other commercial entities, some of which may compete with us. If these </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">77</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;">third-party investigators and organizations assist our competitors at our expense, it could harm our competitive position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;"><span style="white-space:pre-wrap;">Due to the effects of the COVID-19 pandemic, for several of our development programs, we had experienced disruption or delay in our ability to enroll and assess patients, maintain patient enrollment, supply study drug, report trial results, or interact with regulators, ethics committees or other important agencies due to limitations in employee resources or otherwise.  In addition, in the event that a global pandemic occurs in the future, some patients in our clinical trial may not be able or willing to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services.  Similarly, our ability to recruit and retain patients and principal investigators and site staff may be adversely affected if a global pandemic continues and persists for an extended period of time, and we may experience significant disruptions to our clinical development timelines, which would adversely affect our business, financial condition, results of operations and growth prospects in the future.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">We have conducted in the past and are currently conducting or may conduct in the future clinical trials in the US and outside US including Ukraine and Russia. Recent actions taken by the Russian Federation in Ukraine and surrounding areas have destabilized the region and caused the adoption of comprehensive sanctions by, among others, the EU, the US and the UK, which restrict a wide range of trade and financial dealings with Russia and Russian persons, as well as certain regions in Ukraine. Further, some patients may not be able to comply with clinical trial protocols if the conflict impedes patient movement or interrupts healthcare services. In addition, clinical trial site initiation and patient enrollment may be delayed, and we may not be able to access sites for initiation and monitoring in regions affected by the Russian-Ukrainian conflict including due to the prioritization of hospital resources away from clinical trials or as a result of government-imposed curfews, warfare, violence or other governmental actions or events that restrict movement. We could also experience disruptions in our supply chain or limits our ability to obtain sufficient materials for our drug products in certain regions.</p><a id="_cp_text_1_71"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">Public perception of the risk-benefit balance for our COVID-19 product candidates may be affected by adverse events in clinical trials involving our product candidate or other COVID-19 treatments.</span></p><a id="_cp_text_1_72"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Negative perception of the efficacy, safety, or tolerability of any investigational medicines that we develop, or of other products similar to products we are developing, such as fostamatinib for the treatment of COVID-19, could adversely affect our ability to conduct our business, advance our investigational medicines, or obtain regulatory approvals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Adverse events in clinical trials of our investigational medicines or in clinical trials of others developing similar products, including other COVID-19 treatments, could result in a decrease in the perceived benefit of one or more of our programs, increased regulatory scrutiny, decreased confidence by patients and clinical trial collaborators in our investigational medicines, and less demand for any product that we may develop. If and when they are used in clinical trials, our developmental candidates and investigational medicines could result in a greater quantity of reportable adverse events, including suspected unexpected serious adverse reactions, other reportable negative clinical outcomes, manufacturing reportable events or material clinical events that could lead to clinical delay or hold by the FDA or applicable regulatory authority or other clinical delays, any of which could negatively impact the perception of one or more of our programs, as well as our business as a whole. In addition, responses by US, state, or foreign governments to negative public perception may result in new legislation or regulations that could limit our ability to develop any investigational medicines or commercialize any approved products, obtain or maintain regulatory approval, or otherwise achieve profitability. More restrictive statutory regimes, government regulations, or negative public opinion would have an adverse effect on our business, financial condition, results of operations, and prospects and may delay or impair the development of our investigational medicines and commercialization of any approved products or demand for any products we may develop.</p><a id="_Hlk127458093"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">We lack the capability to manufacture compounds for clinical development, and we rely on and intend to continue relying on third parties for commercial supply, manufacturing and distribution if any of our product candidates which receive regulatory approval and we may be unable to obtain required material or product in a timely manner, at an acceptable cost or at a quality level required to receive regulatory approval.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 0pt 0pt;">We currently do not have the manufacturing capabilities or experience necessary to produce our products or any product candidates for clinical trials, including fostamatinib in our ongoing clinical trials for certain indications. We currently use one active pharmaceutical ingredient manufacturer and one finished goods manufacturer for each of our products. We do not currently have, nor do we plan to acquire the infrastructure or capability to supply, manufacture or </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">78</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;">distribute preclinical, clinical or commercial quantities of drug substances or products. For each clinical trial of our unpartnered product candidates, we rely on third-party manufacturers for the active pharmaceutical ingredients, as well as various manufacturers to manufacture starting components, excipients and formulated drug products. Our ability to develop our product candidates, and our ability to commercially supply our products will depend, in part, on our ability to successfully obtain the active pharmaceutical ingredients and other substances and materials used in our product candidates from third parties and to have finished products manufactured by third parties in accordance with regulatory requirements and in sufficient quantities for preclinical and clinical testing and commercialization. If we fail to develop and maintain supply relationships with these third parties, we may be unable to continue to develop or commercialize our product candidates. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">We rely and will continue to rely on certain third parties, including those located outside the US, as our limited source of the materials they supply or the finished products they manufacture. The drug substances and other materials used in our product candidates are currently available only from one or a limited number of suppliers or manufacturers and certain of our finished product candidates are manufactured by one or a limited number of contract manufacturers. Any of these existing suppliers or manufacturers may:</p><div style="margin-top:9pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fail to supply us with product on a timely basis or in the requested amount due to unexpected damage to or destruction of facilities or equipment or otherwise;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fail to increase manufacturing capacity and produce drug product and components in larger quantities and at higher yields in a timely or cost-effective manner, or at all, to sufficiently meet our commercial needs;</span></td></tr></table><div style="margin-top:9pt;"></div><div style="margin-top:9pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">be unable to meet our production demands due to issues related to their reliance on sole-source suppliers and manufacturers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">supply us with product that fails to meet regulatory requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">become unavailable through business interruption or financial insolvency;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">lose regulatory status as an approved source;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">be unable or unwilling to renew current supply agreements when such agreements expire on a timely basis, on acceptable terms or at all; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">discontinue production or manufacturing of necessary drug substances or products.</span></td></tr></table><div style="margin-top:9pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Our current and anticipated future dependence upon these third-party manufacturers may adversely affect our ability to develop and commercialize product candidates on a timely and competitive basis, which could have an adverse effect on sales, results of operations and financial condition. If we were required to transfer manufacturing processes to other third-party manufacturers and we were able to identify an alternative manufacturer, we would still need to satisfy various regulatory requirements. Satisfaction of these requirements could cause us to experience significant delays in receiving an adequate supply of our products and products in development and could be costly. Moreover, we may not be able to transfer processes that are proprietary to the manufacturer, if any. These manufacturers may not be able to produce material on a timely basis or manufacture material at the quality level or in the quantity required to meet our development timelines and applicable regulatory requirements and may also experience a shortage in qualified personnel. Our third-party manufacturers import certain materials from China to produce our products. The tensions between the US and China have led to a series of tariffs and sanctions being imposed by the US on imports from China mainland, as well as other business restrictions. Such tensions could adversely impact us and our third-party manufacturers.<span style="background:#ffffff;"> </span>We may not be able to maintain or renew our existing third-party manufacturing arrangements, or enter into new arrangements, on acceptable terms, or at all. Our third-party manufacturers could terminate or decline to renew our manufacturing arrangements based on their own business priorities, at a time that is costly or inconvenient for us. If we are unable to contract for the production of materials in sufficient quantity and of sufficient quality on acceptable terms, our planned clinical trials may be significantly delayed. Manufacturing delays could postpone the filing of our investigational new drug (IND) applications and/or the initiation or completion of clinical trials that we have currently planned or may plan in the future. </p><a id="_cp_text_4_467"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Drug manufacturers are subject to ongoing periodic unannounced inspection by the FDA, the Drug </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">79</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_cp_text_1_468"></a><a id="_cp_text_4_469"></a><a id="_cp_text_1_470"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Enforcement Administration, the European Medicines Agency, national competent authorities in the EU and UK and other federal and state government and regulatory agencies to ensure strict compliance with cGMP and other government regulations and corresponding foreign standards. We do not have control over third-party manufacturers&#8217; compliance with these regulations and standards and they may not be able to comply. Switching manufacturers may be difficult because the number of potential manufacturers is limited. It may be difficult or impossible for us to find a replacement manufacturer quickly on acceptable terms, or at all. Additionally, if we are required to enter into new supply arrangements, we may not be able to obtain approval from the FDA of any alternate supplier in a timely manner, or at all, which could delay or prevent the clinical development and commercialization of any related product candidates. Failure of our third-party manufacturers or us to comply with applicable regulations, whether due to the impacts of a global pandemic or otherwise, could result in sanctions being imposed on us, including fines, civil penalties, delays in or failure to grant marketing approval of our product candidates, injunctions, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of products and compounds, operating restrictions and criminal prosecutions, warning or similar letters or civil, criminal or administrative sanctions against us, any of which could adversely affect our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">Any product for which we have obtained regulatory approval, or for which we obtain approval in the future, is subject to, or will be subject to, extensive ongoing regulatory requirements by the FDA, EMA and other comparable regulatory authorities, and if we fail to comply with regulatory requirements or if we experience unanticipated problems with our products, we may be subject to penalties, we may be unable to generate revenue from the sale of such products, our potential for generating positive cash flow will be diminished, and the capital necessary to fund our operations will be increased.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">In April 2018, the FDA approved TAVALISSE for the treatment of adult patients with chronic ITP who have had insufficient response to previous treatment. In December 2022, the FDA approved REZLIDHIA for the treatment of adult patients with R/R AML with a susceptible IDH1 mutation as detected by an FDA-approved test. We commercialize TAVALISSE and REZLIDHIA in the US and we have entered into commercialization agreements with third parties to commercialize fostamatinib outside the US. Any product for which we have obtained regulatory approval, or for which we obtain regulatory approval in the future, along with the manufacturing processes and practices, post-approval clinical research, product labeling, advertising and promotional activities for such product, are subject to continual requirements of, and review by, the FDA, the EMA and other comparable international regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, cGMP requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians, import and export requirements and recordkeeping. If we or our suppliers encounter manufacturing, quality or compliance difficulties with respect to our products or any of our product candidates, when and if approved, whether due to the impacts of a global pandemic (including as a result of disruptions of global shipping and the transport of products) or otherwise, we may be unable to obtain or maintain regulatory approval or meet commercial demand for such products, which could adversely affect our business, financial conditions, results of operations and growth prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Promotional communications with respect to prescription drugs are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product&#8217;s approved labeling. Thus, we will not be able to promote any products we develop for indications or uses for which they are not approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">In addition, the FDA often requires post-marketing testing and surveillance to monitor the effects of products. The FDA, the EMA and other comparable international regulatory agencies may condition approval of our product candidates on the completion of such post-marketing clinical studies. These post-marketing studies may suggest that a product causes undesirable side effects or may present a risk to the patient. Additionally, the FDA may require REMS to help ensure that the benefits of the drug outweigh its risks. A REMS may be required to include various elements, such as a medication guide or patient package insert, a communication plan to educate healthcare providers of the drug&#8217;s risks, limitations on who may prescribe or dispense the drug, requirements that patients enroll in a registry or undergo certain health evaluations or other measures that the FDA deems necessary to ensure the safe use of the drug.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Discovery after approval of previously unknown problems with any of our products, manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in actions such as:</p><div style="margin-top:9pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on our ability to conduct clinical trials, including full or partial clinical holds on ongoing or planned trials&#894;</span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">80</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on product manufacturing processes;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on the marketing of a product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on product distribution;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">requirements to conduct post-marketing clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">untitled or warning letters or other adverse publicity;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">withdrawal of products from the market;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal to approve pending applications or supplements to approved applications that we submit;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">recall of products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal to permit the import or export of our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product seizure;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fines, restitution or disgorgement of profits or revenue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal to allow us to enter into supply contracts, including government contracts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injunctions; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">imposition of civil or criminal penalties.</span></td></tr></table><div style="margin-top:9pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">If such regulatory actions are taken, the value of our company and our operating results will be adversely affected. Additionally, if the FDA, the EMA or any other comparable international regulatory agency withdraws its approval of a product that is or may be approved, we will be unable to generate revenue from the sale of that product in the relevant jurisdiction, our potential for generating positive cash flow will be diminished and the capital necessary to fund our operations will be increased. Accordingly, we continue to expend significant time, money and effort in all areas of regulatory compliance, including manufacturing, production, product surveillance, post-marketing studies and quality control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">If any of our third-party contractors fail to perform their responsibilities to comply with FDA rules and regulations, the marketing and sales of our products could be delayed and we may be subject to enforcement action, which could decrease our revenues.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Conducting our business requires us to manage relationships with third-party contractors. As a result, our success depends partially on the success of these third parties in performing their responsibilities to comply with FDA rules and regulations. Although we pre-qualify our contractors and we believe that they are fully capable of performing their contractual obligations, we cannot directly control the adequacy and timeliness of the resources and expertise that they apply to these activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;"><span style="white-space:pre-wrap;">If any of our partners or contractors fail to perform their obligations in an adequate and timely manner, or fail to comply with the FDA&#8217;s rules and regulations, then the marketing and sales of our products could be delayed. The FDA may also take enforcement actions against us based on compliance issues identified with our contractors. If any of these events occur, we may incur significant liabilities, which could decrease our revenues.  For example, sales and medical science liaison or MSL personnel, including contractors, must comply with FDA requirements for the advertisement and promotion of products.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we are unable to obtain regulatory approval to market products in the US and foreign jurisdictions, we will not be permitted to commercialize products we or our collaborative partners may develop.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 0pt 0pt;">We cannot predict whether regulatory clearance will be obtained for any product that we, or our collaborative partners, hope to develop. Satisfaction of regulatory requirements typically takes many years, is dependent upon the type, complexity and novelty of the product and requires the expenditure of substantial resources. Of particular </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">81</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;">significance to us are the requirements relating to research and development and testing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Before commencing clinical trials in humans in the US, we, or our collaborative partners, will need to submit and receive approval from the FDA of an IND application. Clinical trials are subject to oversight by institutional review boards and the FDA and:</p><div style="margin-top:9pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">must be conducted in conformance with the FDA&#8217;s good clinical practices and other applicable regulations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">must meet requirements for institutional review board oversight;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">must meet requirements for informed consent;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">are subject to continuing FDA and regulatory oversight;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">may require large numbers of test subjects; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">may be suspended by us, our collaborators or the FDA at any time if it is believed that the subjects participating in these trials are being exposed to unacceptable health risks or if the FDA finds deficiencies in the IND or the conduct of these trials.</span></td></tr></table><div style="margin-top:9pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">While we have stated that we intend to file additional INDs for future product candidates, this is only a statement of intent, and we may not be able to do so because we may not be able to identify potential product candidates. In addition, the FDA may not approve any IND we or our collaborative partners may submit in a timely manner, or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Before receiving FDA approval to market a product, we must demonstrate with substantial clinical evidence that the product is safe and effective in the patient population and the indication that will be treated. Data obtained from preclinical and clinical activities are susceptible to varying interpretations that could delay, limit or prevent regulatory approvals. In addition, delays or rejections may be encountered based upon additional government regulation from future legislation or administrative action or changes in FDA policy during the period of product development, clinical trials and FDA regulatory review. Failure to comply with applicable FDA or other applicable regulatory requirements may result in criminal prosecution, civil penalties, recall or seizure of products, total or partial suspension of production or injunction, adverse publicity, as well as other regulatory action against our potential products or us. Additionally, we have limited experience in conducting and managing the clinical trials necessary to obtain regulatory approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">If regulatory approval of a product is granted, this approval will be limited to those indications or disease states and conditions for which the product is demonstrated through clinical trials to be safe and efficacious. We cannot assure you that any compound developed by us, alone or with others, will prove to be safe and efficacious in clinical trials and will meet all of the applicable regulatory requirements needed to receive marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:32.4pt;margin:9pt 0pt 9pt 0pt;">Outside the US, our ability, or that of our collaborative partners, to market a product is contingent upon receiving a marketing authorization from the appropriate regulatory authorities. This foreign regulatory approval process typically includes all of the risks and costs associated with FDA approval described above and may also include additional risks and costs, such as the risk that such foreign regulatory authorities, which often have different regulatory and clinical trial requirements, interpretations and guidance from the FDA, may require additional clinical trials or results for approval of a product candidate, any of which could result in delays, significant additional costs or failure to obtain such regulatory approval. There can be no assurance, however, that we or our collaborative partners will not have to provide additional information or analysis, or conduct additional clinical trials, before receiving approval to market product candidates.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">82</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may be unable to expand our product pipeline, which could limit our growth and revenue potential.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Our business is focused on the development and commercialization of novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. In this regard, we are pursuing internal drug discovery efforts with the goal of identifying new product candidates to advance into clinical trials. Internal discovery efforts to identify new product candidates require substantial technical, financial and human resources. These internal discovery efforts may initially show promise in identifying potential product candidates, yet ultimately fail to yield product candidates for clinical development for a number of reasons. For example, potential product candidates may, on later stage clinical trial, be shown to have inadequate efficacy, harmful side effects, suboptimal pharmaceutical profiles or other characteristics suggesting that they are unlikely to be commercially viable products. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Apart from our internal discovery efforts, our strategy to expand our development pipeline is also dependent on our ability to successfully identify and acquire or in-license relevant product candidates. In July 2022, we entered into a license and transition services agreement with Forma (now Novo Nordisk) for an exclusive license to develop, manufacture and commercialize olutasidenib, a proprietary inhibitor of mIDH1, for any uses worldwide, including for the treatment of AML and other malignancies. <span style="background:#ffffff;">On December 1, 2022, the FDA approved REZLIDHIA capsules for the treatment of adult patients with R/R AML with a susceptible IDH1 mutations as detected by and FDA-approved test. REZLIDHIA is our second commercial product and is highly synergistic with our existing hematology-oncology focused commercial and medical affairs infrastructure. </span>The in-licensing and acquisition of product candidates is a highly competitive area, and many other companies are pursuing the same or similar product candidates to those that we may consider attractive. In particular, larger companies with more well-established and diverse revenue streams may have a competitive advantage over us due to their size, financial resources and more extensive clinical development and commercialization capabilities. Furthermore, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We may also be unable to in-license or acquire additional relevant product candidates on acceptable terms that would allow us to realize an appropriate return on our investment. If we are unable to develop suitable product candidates through internal discovery efforts, whether due to the impacts of a global pandemic or otherwise, or if we are unable to successfully obtain rights to additional suitable product candidates, our business and prospects for growth could suffer. Even if we succeed in our efforts to obtain rights to suitable product candidates, the competitive business environment may result in higher acquisition or licensing costs, and our investment in these potential products will remain subject to the inherent risks associated with the development and commercialization of new medicines. In certain circumstances, we may also be reliant on the licensor for the continued development of the in-licensed technology and their efforts to safeguard their underlying intellectual property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">With respect to acquisitions, we may not be able to integrate the target company successfully into our existing business, maintain the key business relationships of the target, or retain key personnel of an acquired business. Furthermore, we could assume unknown or contingent liabilities or incur unanticipated expenses. Any acquisitions or investments made by us also could result in our spending significant amounts, issuing dilutive securities, assuming or incurring significant debt obligations and contingent liabilities, incurring large one-time expenses and acquiring intangible assets that could result in significant future amortization expense and significant write-offs, any of which could harm our operating results.</p><a id="_Hlk126159911"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have obtained orphan drug designation from the FDA for fostamatinib for the treatment of ITP and wAIHA, but we may not be able to obtain or maintain orphan drug designation or exclusivity for fostamatinib for the treatment of ITP, wAIHA or our other product candidates, or we may be unable to maintain the benefits associated with orphan drug designation, including the potential for market exclusivity.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 0pt 0pt;">We have obtained orphan drug designation in the US for fostamatinib for the treatment of ITP and wAIHA. We may seek orphan drug designation for other product candidates in the future. Under the Orphan Drug Act, the FDA may grant orphan drug designation to a drug or biologic intended to treat a rare disease or condition, which is defined as one occurring in a patient population of fewer than 200,000 in the US, or a patient population greater than 200,000 in the US where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the US. In the US, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. In addition, if a product that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications, including a full NDA, to </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">83</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;">market the same drug for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or where the manufacturer is unable to assure sufficient product quantity. At this time, we do not have nor will we seek to apply for orphan drug designation in the EU or the UK in the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">We cannot assure you that any future application for orphan drug designation with respect to any other product candidate will be granted. If we are unable to obtain orphan drug designation with respect to other product candidates in the US, we will not be eligible to obtain the period of market exclusivity that could result from orphan drug designation or be afforded the financial incentives associated with orphan drug designation. Even though we have received orphan drug designation for fostamatinib for the treatment of ITP and wAIHA in the US, we may not be the first to obtain marketing approval for the orphan-designated indication due to the uncertainties associated with developing pharmaceutical products or we might not maintain our orphan drug designation. In addition, exclusive marketing rights in the US for fostamatinib for the treatment of ITP, wAIHA or any future product candidate may be limited if we seek approval for an indication broader than the orphan-designated indication or may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. Further, even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs with different active moieties can be approved for the same condition. Even after an orphan product is approved, the FDA can subsequently approve the same drug with the same active moiety for the same condition if the FDA concludes that the later drug is safer, more effective, or makes a major contribution to patient care. Orphan drug designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">In addition, Congress is considering updates to the orphan drug provisions of the FDCA in response to a recent 11th Circuit decision. Any changes to the orphan drug provisions could change our opportunities for, or likelihood of success in obtaining, orphan drug exclusivity and would materially adversely affect our business, financial condition, results of operations, cash flows and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><b style="font-weight:bold;">Risks Related to Commercialization</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our prospects are highly dependent on our commercial products. To the extent that the commercial success of our products in the US is diminished or is not commercially successful, our business, financial condition and results of operations may be adversely affected, and the price of our common stock may decline. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:32.05pt;margin:9pt 0pt 9pt 0pt;">TAVALISSE is our first drug that has been approved for sale in the US and Europe for patients with chronic ITP. REZLIDHIA is our second drug product which was recently approved by the FDA for the treatment of adult patients with R/R AML with susceptible IDH1 mutations as detected by an FDA-approved test, and began its commercialization in December 2022. We are focusing a significant portion of our activities and resources on our products, and we believe our prospects are highly dependent on, and a significant portion of the value of our company relates to, our ability to sustain successful commercialization of our products in the US. We have also entered into exclusive commercialization agreements with third parties to commercialize fostamatinib outside the US, and we plan to further enter partnership with existing or other third parties to commercialize fostamatinib and olutasidenib outside the US in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Sustained successful commercialization of our products is subject to many risks and uncertainties, including the impact of a global pandemic on the successful commercialization in the US, as well as the successful commercialization efforts for our products through our collaborative partners. There are numerous examples of unsuccessful product launches and failures to meet high expectations of market potential, including by pharmaceutical companies with more experience and resources than us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:32.4pt;margin:9pt 0pt 0pt 0pt;">As we continue to build out our commercial team, there are many factors that could cause the commercialization of our products to be unsuccessful, including a number of factors that are outside our control. The commercial success of our products depends on the extent to which patients and physicians accept and adopt our products to treat the related diseases. We also do not know how physicians, patients and payors will respond to our future price increases of our products. Physicians may not prescribe our products and patients may be unwilling to use our products if coverage is not provided or reimbursement is inadequate to cover a significant portion of the cost. Our products compete, and may in the </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">84</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;">future compete, with currently existing therapies, including generic drugs, and products currently under development. Our competitors, particularly large pharmaceutical companies, may deploy more resources to market, sell and distribute their products. If our efforts are not appropriately resourced to adequately promote our products, the commercial potential of our sales may be diminished. Additionally, any negative development for fostamatinib in clinical development in additional indications, such as in the clinical trials of fostamatinib in COVID-19 patients, may adversely impact the commercial results and potential of fostamatinib. Thus, significant uncertainty remains regarding the commercial potential of fostamatinib.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Market acceptance of fostamatinib will depend on a number of factors, including: </p><div style="margin-top:9pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.25;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing of market introduction of the product as well as competitive products; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.25;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the clinical indications for which the product is approved; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.25;margin-bottom:0pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acceptance by physicians, the medical community and patients of the product as a safe and effective treatment; </span></td></tr></table><div style="margin-top:9pt;"></div><div style="margin-top:9pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential future impacts, if any, due to the effects of a global pandemic and the Russian-Ukrainian conflict;</span></td></tr></table><div style="margin-top:9pt;"></div><div style="margin-top:9pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.25;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ability to distinguish safety and efficacy from existing, less expensive generic alternative therapies, if any; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.25;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the convenience of prescribing, administrating and initiating patients on the product and the length of time the patient is on the product; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.25;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the potential and perceived value and advantages of the product over alternative treatments; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.25;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of treatment in relation to alternative treatments, including any similar generic treatments; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.25;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">pricing and the availability of coverage and adequate reimbursement by third-party payors and government authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.25;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a positive HTA concluding that the product is cost-effective and the HTA bodies issuing a positive recommendation for the use of the product as a first or second line of treatment for the granted therapeutic indication;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.25;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the prevalence and severity of adverse side effects; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.25;margin-bottom:0pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the effectiveness of sales and marketing efforts. </span></td></tr></table><div style="margin-top:9pt;"><a id="_DV_C11"></a></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">If we are unable to sustain anticipated level of sales growth from our products, or if we fail to achieve anticipated product royalties and collaboration milestones, we may need to reduce our operating expenses, access other sources of cash or otherwise modify our business plans, which could have a negative impact on our business, financial condition and results of operations. For example, during 2021, we experienced lower than anticipated sales of our products due to continuing impacts of <span style="background:#ffffff;">physician and patient access issues created by the COVID-19 pandemic.</span> From time to time, our net product sales are negatively impacted by the decrease in level of inventories remaining at our distribution channels. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 0pt 0pt;">We also may not be successful entering into arrangements with third parties to sell and market one or more of our product candidates or may be unable to do so on terms that are favorable to us. We likely will have little control over such third parties, including Kissei&#8217;s development and commercialization of fostamatinib in all indications in Japan, China, Taiwan, and the Republic of Korea, Grifols&#8217; commercialization of fostamatinib in Europe and Turkey, Medison for future commercialization of fostamatinib in Canada and Israel, and Knight for commercialization of fostamatinib in Latin America. As a consequence of our license agreements with Kissei, Grifols, Medison and Knight, we rely heavily upon their regulatory, commercial, medical affairs, market access and other expertise and resources for commercialization of fostamatinib in their respective territories outside of the US. We cannot control the amount of resources that our partners dedicate to the commercialization of fostamatinib, and our ability to generate revenues from </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">85</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;">the commercialization of fostamatinib by our partners depends on their ability to achieve market acceptance of fostamatinib in its approved indications in their respective territories.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Furthermore, foreign sales of fostamatinib by our partners could be adversely affected by the imposition of governmental controls, political and economic instability, outbreaks of pandemic diseases, such as the COVID-19 pandemic, trade restrictions or barriers and changes in tariffs and escalating global trade and political tensions. For example, the COVID-19 pandemic has resulted in increased travel restrictions and extended shutdowns of certain businesses in the US and around the world. If our collaborators are unable to successfully complete clinical trials, delay commercialization of fostamatinib or do not invest the resources necessary to successfully commercialize fostamatinib in international territories where it has been approved, this could reduce the amount of revenue we are due to receive under these license agreements, resulting in harm to our business and operations. If we do not establish and maintain sales and marketing capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">Even if we, or any of our collaborative partners, are able to continue to commercialize our products or any product candidate that we, or they, develop, the product may become subject to unfavorable pricing regulations, third-party payor reimbursement practices or labeling restrictions, all of which may vary from country to country and any of which could harm our business.</span></p><a id="_cp_text_4_79"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:32.05pt;margin:9pt 0pt 9pt 0pt;">The commercial success of any product for which we have obtained regulatory approval, or for which we obtain regulatory approval in the future will depend substantially on the extent to which the costs of our product or product candidates are or will be paid by third-party payors, including government health care programs and private health insurers. There is a significant trend in the health care industry by public and private payors to contain or reduce their costs, including by taking the following steps, among others: decreasing the portion of costs payors will cover, ceasing to provide full payment for certain products depending on outcomes, and/or not covering certain products at all. If payors implement any of the foregoing with respect to our products, it would have an adverse impact on our revenue and results of operations. If coverage is not available, or reimbursement is limited, we, or any of our collaborative partners, may not be able to successfully commercialize our products or any of our product candidates in some jurisdictions. Even if coverage is provided, the approved reimbursement amount may not be at a rate that covers our costs, including research, development, manufacture, sale and distribution. In the US, no uniform policy of coverage and reimbursement for products exists among third-party payors; therefore, coverage and reimbursement levels for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time consuming and costly process that may require us to provide scientific, clinical or other support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.</p><a id="_cp_text_4_82"></a><a id="_cp_text_4_83"></a><a id="_cp_text_4_84"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:32.4pt;margin:9pt 0pt 9pt 0pt;">There is significant uncertainty related to third-party payor coverage and reimbursement of newly approved drugs. Marketing approvals, pricing and reimbursement for new drug products vary widely from country to country. Some countries require approval of the sale price of a drug before it can be marketed, which could delay market entry (or, if pricing is not approved, we may be unable to sell at all in a country where we have received regulatory approval for a product. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some countries, the proposed pricing for a drug must be approved before it may be lawfully marketed<span style="white-space:pre-wrap;">). In addition, authorities in some countries impose additional obligations, such as HTAs, which assess the performance of a drug in comparison with its cost. The outcome of HTA assessments is judged on a national basis and some payors may not reimburse the use of our products or may reduce the rate of reimbursement for our products and as a result, revenue from such products may decrease.  </span> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:32.4pt;margin:9pt 0pt 0pt 0pt;">In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we, or any of our collaborative partners, might obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay commercial launch of the product, possibly for lengthy time periods, which may negatively impact the revenues we are able to generate from the sale of the product in that country. In particular, we cannot predict to what extent the effects of a global pandemic, depending on its scale and duration, may continue to disrupt global healthcare systems and access to our products or result in a widespread loss of individual health insurance coverage due to unemployment, a shift from commercial payor coverage to government payor coverage, or an increase in demand for patient assistance and/or free drug programs, any of which would adversely affect access to and demand for our products and our net sales. Adverse pricing limitations may also hinder our ability or the ability of any future collaborators to recoup our or their investment in one or more </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">86</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;">product candidates, even if our product candidates obtain marketing approval. Further, even if favorable coverage and reimbursement status is attained for one or more products for which we or our collaborative partners receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:32.4pt;margin:9pt 0pt 9pt 0pt;">Patients who are provided medical treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Therefore, our ability, and the ability of any of our collaborative partners, to successfully commercialize our products or any of our product candidates will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from third-party payors. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:32.05pt;margin:9pt 0pt 9pt 0pt;"><span style="white-space:pre-wrap;">Additionally, the labeling ultimately approved for any of our product candidates for which we have or may obtain regulatory approval may include restrictions on their uses and may be subject to ongoing FDA or international regulatory authority requirements governing the labeling, packaging, storage, distribution, safety surveillance, advertising, promotion, record-keeping and reporting of safety and other post-market information. If we or any of our collaborative partners do not timely obtain or comply with the labeling approval by the FDA or international regulatory authorities on any of our product candidates, it may delay or inhibit our ability to successfully commercialize our products and generate revenues.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we are unable to successfully market and distribute our products and retain experienced commercial personnel, our business will be substantially harmed.*</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">We currently have limited experience in marketing and selling pharmaceutical products. As a result, we will be required to expend significant time and resources to maintain a sales force that is credible and compliant with applicable laws in marketing our products. In addition, we must continually train our sales force to ensure that an appropriate and compliant message about our products is being delivered. If we are unable to effectively train our sales force and equip them with compliant and effective materials, including medical and sales literature to help them appropriately inform and educate health care providers regarding the potential benefits and proper administration of our products, our efforts to successfully commercialize our products could be put in jeopardy, which would negatively impact our ability to generate product revenues. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">We have established our distribution, sales, marketing and market access capabilities, all of which will be necessary to successfully commercialize our products. As a result, we will be required to expend significant time and resources to market, sell, and distribute our products to hematologists and hematologist-oncologists. There is no guarantee that the marketing strategies we have developed, or the distribution, sales, marketing and market access capabilities that we have developed will be successful. Particularly, we are dependent on third-party logistics, specialty pharmacies and distribution partners in the distribution of our products. If they are unable to perform effectively or if they do not provide efficient distribution of the medicine to patients, our business may be harmed. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Maintaining our sales, marketing, market access and product distribution capabilities requires significant resources, and there are numerous risks involved with managing our commercial team, including our potential inability to successfully train, retain and incentivize adequate numbers of qualified and effective sales and marketing personnel. We are also competing for talent with numerous commercial and pre-commercial-stage oncology-focused biotechnology companies seeking to build out their commercial organizations, as well as other large pharmaceutical organizations that have extensive, well-funded and more experienced sales and marketing operations, and we may be unable to maintain or adequately scale our commercial organization as a result of such competition. If we cannot maintain effective sales, marketing, market access and product distribution capabilities, whether as a result of a global pandemic or otherwise, we may be unable to realize the commercial potential of our products. Also, to the extent that the commercial opportunities for our products grow over time, we may not properly judge the requisite size and experience of our current commercialization teams or the level of distribution necessary to market and sell our products, which could have an adverse impact on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may not be able to successfully develop or commercialize our product candidates if problems arise in the clinical testing and approval process.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 0pt 0pt;">The activities associated with the research, development and commercialization of fostamatinib and other product candidates in our pipeline must undergo extensive clinical trials, which can take many years and require substantial expenditures, subject to extensive regulation by the FDA and other regulatory agencies in the US and by </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">87</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;">comparable authorities in other countries. The process of obtaining regulatory approvals in the US and other foreign jurisdictions is expensive, and lengthy, if approval is obtained at all. </p><a id="_Hlk128482170"></a><a id="_Hlk128488040"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Our clinical trials may fail to produce results satisfactory to the FDA or regulatory authorities in other jurisdictions. The regulatory process also requires preclinical testing, and data obtained from preclinical and clinical activities are susceptible to varying interpretations. The FDA has substantial discretion in the approval process and may refuse to approve any NDA or sNDA and decide that our data is insufficient for approval and require additional preclinical, clinical or other studies. Varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent regulatory approval of fostamatinib for any individual, additional indications. For example, in June 2022, we announced that the top-line results from our Phase 3 trial in wAIHA did not demonstrate statistical significance in the primary efficacy endpoint of durable hemoglobin response in the overall study population. While we conducted an in-depth analysis of these data to better understand differences in patient characteristics and outcomes and submitted these findings to the FDA, in October 2022, we announced that we received guidance from the FDA&#8217;s of these findings. <span style="color:#222222;background:#ffffff;">Based on the result of the trial and the guidance from the FDA</span>, we did not file an sNDA for wAIHA.<span style="background:#ffffff;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Due to the effects of a global pandemic, it is also possible that we could experience delays in the timing of our interactions with regulatory authorities due to absenteeism by governmental employees or the diversion of regulatory authority efforts and attention to approval of other therapeutics or other activities related to COVID-19 or other public health emergencies, which could delay or limit our ability to make planned regulatory submissions or develop and commercialize our product candidates on anticipated timelines.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">In addition, delays or rejections may be encountered based upon changes in regulatory policy for product approval during the period of product development and regulatory agency review, which may cause delays in the approval or rejection of an application for fostamatinib or for our other product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Commercialization of our product candidates depends upon successful completion of extensive preclinical studies and clinical trials to demonstrate their safety and efficacy for humans. Preclinical testing and clinical development are long, expensive and uncertain processes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">In connection with clinical trials of our product candidates, we may face the following risks among others:</p><div style="margin-top:9pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the product candidate may not prove to be effective;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the product candidate may cause harmful side effects;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the clinical results may not replicate the results of earlier, smaller trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we or third parties with whom we collaborate, may be significantly impacted by force majeure events;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we, or the FDA or similar foreign regulatory authorities, may delay, terminate or suspend the trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our results may not be statistically significant;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patient recruitment and enrollment may be slower than expected;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patients may drop out of the trials or otherwise not enroll; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory and clinical trial requirements, interpretations or guidance may change.</span></td></tr></table><div style="margin-top:9pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">We do not know whether we will be permitted to undertake clinical trials of potential products beyond the trials already concluded and the trials currently in process. It will take us or our collaborative partners several years to complete any such testing, and failure can occur at any stage of testing. Interim results of trials do not necessarily predict final results, and acceptable results in early trials may not be repeated in later trials. A number of companies in the pharmaceutical industry, including biotechnology companies, have suffered significant setbacks in advanced clinical trials, even after achieving promising results in earlier trials. </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">88</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;"><b style="font-weight:bold;">General Risk Factors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Global economic conditions could adversely impact our business.*</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Deterioration in the macroeconomic economy or financial services industry could lead to losses or defaults by our customers or suppliers, which in turn, could have a material adverse effect on our current and/or projected business operations and results of operations and financial condition. <span style="background:#ffffff;">The global credit and financial markets are currently, and have from time to time experienced extreme volatility and disruptions, including severely diminished liquidity and credit availability, rising interest and inflation rates, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. </span>More recently, the closures of Silicon Valley Bank (SVB) and Signature Bank and their placement into receivership with the Federal Deposit Insurance Corporation (FDIC) created bank-specific and broader financial institution liquidity risk and concerns. On March 12, 2023, federal regulators announced that the FDIC would complete its resolution of SVB in a manner that fully protects all depositors. On March 27, 2023, First Citizens Bank (FCB) announced that it has entered into an agreement with FDIC to purchase all of the asset and liabilities of SVB. Customers of SVB automatically become customers of FCB following the acquisition. We maintain a depository relationship with SVB/FCB. The amount of our cash held on deposit with SVB/FCB was not material with respect our total cash, cash equivalents and short-term investments. All of our cash deposits with SVB/FCB are accessible to us, and <span style="background:#ffffff;">we do not anticipate any losses with respect to such funds. </span>Since the March 2023 financial institution failure, there has been a heightened risk and greater focus on the potential failures of other banks in the future. If these banks fail in the future, we may not be able to immediately (or ever) recover our cash in excess of the FDIC insured limits which would adversely impact our operating liquidity and could negatively impact our operations, results of operations and financial performance. Although we believe our exposure is limited, if in the future any of the financial institutions that we maintain depository or lending relationships were to be placed into receivership, we may be unable to access such funds to meet our working capital requirements. In addition, if any of our customers, suppliers or other parties with whom we conduct business are unable to access funds, such parties&#8217; ability to pay their obligations to us or to enter into new commercial arrangements requiring additional payments to us could be adversely affected. Although we assess our banking and customer relationships as we believe necessary or appropriate, our access to funding sources and other credit arrangements in amounts adequate to finance or capitalize our current and projected future business operations could be significantly impacted by factors that affect us, the financial institutions with which we credit agreement or arrangements directly, or the financial services industry or economy in general. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;">In addition, any further deterioration in the US economy would likely affect the operation of our business and ability to raise capital. In addition, US debt ceiling and budget deficit concerns have increased the possibility of additional credit-rating downgrades and economic slowdowns, or a recession in the US. Although US lawmakers passed legislation to raise the federal debt ceiling on multiple occasions, ratings agencies have lowered or threatened to lower the long-term sovereign credit rating on the US. The impact of this or any further downgrades to the US government&#8217;s sovereign credit rating or its perceived creditworthiness could adversely affect the US and global financial markets and economic conditions. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">The financial markets and the global economy may also be adversely affected by the current or anticipated impact of military conflict, including the ongoing conflict between Russia and Ukraine, terrorism or other geopolitical events. Sanctions imposed by the US and other countries in response to such conflicts, including the one in Ukraine, may also adversely impact the financial markets and the global economy, and any economic countermeasures by the affected countries or others could exacerbate market and economic instability.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">The US government has indicated its intent to alter its approach to international trade policy and in some cases to renegotiate, or potentially terminate, certain existing bilateral or multi-lateral trade agreements and treaties with foreign countries. In addition, the US government has initiated or is considering imposing tariffs on certain foreign goods. Related to this action, certain foreign governments, including China, have instituted or are considering imposing tariffs on certain US goods. It remains unclear what the US Administration or foreign governments will or will not do with respect to tariffs or other international trade agreements and policies. A trade war or other governmental action related to tariffs or international trade agreements or policies has the potential to disrupt our research activities, affect our suppliers and/or the US economy or certain sectors thereof and, thus, could adversely impact our businesses.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">89</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">Shareholder activism could cause material disruption to our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Publicly traded companies have increasingly become subject to campaigns by our stakeholders, including investors, and more recently regulatory organizations advocating corporate actions such as actions related to environment, social and governance (ESG) matters, impacts of climate change, financial restructuring, increased borrowing, dividends, share repurchases and even sales of assets or the entire company. Responding to proxy contests and other actions by such activist investors or others in the future could be costly and time-consuming, disrupt our operations and divert the attention of our Board of Directors and senior management from the pursuit of our business strategies, which could adversely affect our results of operations and financial condition. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">Anti-takeover provisions in our charter documents and under Delaware law may make an acquisition of us, which may be beneficial to our stockholders, more difficult.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Provisions of our amended and restated certificate of incorporation and bylaws, as well as provisions of Delaware law, could make it more difficult for a third party to acquire us, even if doing so would benefit our stockholders. These provisions:</p><div style="margin-top:9pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establish that members of the board of directors may be removed only for cause upon the affirmative vote of stockholders owning a majority of our capital stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">authorize the issuance of &#8220;blank check&#8221; preferred stock that could be issued by our board of directors to increase the number of outstanding shares and thwart a takeover attempt;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">limit who may call a special meeting of stockholders;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">prohibit stockholder action by written consent, thereby requiring all stockholder actions to be taken at a meeting of our stockholders;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establish advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted upon at stockholder meetings;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">provide for a board of directors with staggered terms; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">provide that the authorized number of directors may be changed only by a resolution of our board of directors.</span></td></tr></table><div style="margin-top:9pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:9pt 0pt 9pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="font-size:10pt;">In addition, Section&#160;203 of the Delaware General Corporation Law (DGCL), which imposes certain restrictions relating to transactions with major stockholders, may discourage, delay or prevent a third party from acquiring us.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our bylaws designate a state or federal court located within the State of Delaware as the sole and exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our current or former directors, officers, stockholders, or other employees.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:9pt 0pt 9pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="font-size:10pt;">Our bylaws provide that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for (i) any derivative action or proceeding brought on behalf of us under Delaware law, (ii) any action asserting a claim of breach of a fiduciary duty owed by any current or former director, officer, or other employee of the Company to us or our stockholders, (iii) any action asserting a claim against us or any of our directors, officers, or other employees arising pursuant to any provision of the DGCL or our amended and restated certificate of incorporation and bylaws (as either may be amended from time to time), (iv) any action asserting a claim against us governed by the internal affairs doctrine, or (v) any other action asserting an &#8220;internal corporate claim,&#8221; as defined under Section 115 of the DGCL. The forgoing provisions do not apply to any claims arising under the Securities Act and, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States will be the sole and exclusive forum for resolving any action asserting a claim arising under the Securities Act.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:9pt 0pt 0pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="font-size:10pt;">These choice of forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our current or former directors, officers, or other employees, which may </span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">90</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 9pt 0pt;"><span style="font-size:10pt;">discourage lawsuits with respect to such claims. There is uncertainty as to whether a court would enforce such provisions, and the enforceability of similar choice of forum provisions in other companies&#8217; charter documents has been challenged in legal proceedings. It is possible that a court could find these types of provisions to be inapplicable or unenforceable, and if a court were to find the choice of forum provision to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, results of operations, and financial condition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">Increasing use of social media could give rise to liability and may harm our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">We and our employees are increasingly utilizing social media tools and our website as a means of communication. Despite our efforts to monitor evolving social media communication guidelines and comply with applicable laws, regulations and national and EU codes of conduct, there is risk that the unauthorized use of social media by us or our employees to communicate about our products or business, sharing of publications in unintended audiences in other jurisdictions, or any inadvertent promotional activity or disclosure of material, nonpublic information through these means, may cause us to be found in violation of applicable laws and regulations, which may give rise to liability and result in harm to our business. In addition, there is also risk of inappropriate disclosure of sensitive information, which could result in significant legal and financial exposure and reputational damages that could potentially have an adverse impact on our business, financial condition and results of operations. Furthermore, negative posts or comments about us or our products on social media could seriously damage our reputation, brand image and goodwill.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our research and development efforts will be seriously jeopardized if we are unable to attract and retain key employees and relationships.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Our success depends on the continued contributions of our principal management and scientific personnel and on our ability to develop and maintain important relationships with leading academic institutions, scientists and companies in the face of intense competition for such personnel. In particular, our research programs depend on our ability to attract and retain highly skilled chemists, other scientists, and development, regulatory and clinical personnel. If we lose the services of any of our key personnel, our research and development efforts could be seriously and adversely affected. Our employees can terminate their employment with us at any time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our facilities are located near known earthquake fault zones, and the occurrence of an earthquake or other catastrophic disaster could cause damage to our facilities and equipment, which could require us to cease or curtail operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Our facilities are located in the San Francisco Bay Area near known earthquake fault zones and are vulnerable to significant damage from earthquakes. We are also vulnerable to damage from other types of disasters, including fires, floods, power loss, communications failures and similar events. If any disaster were to occur, our ability to operate our business at our facilities would be seriously, or potentially completely, impaired, and our research could be lost or destroyed. In addition, the unique nature of our research activities and of much of our equipment could make it difficult for us to recover from a disaster. The insurance we maintain may not be adequate to cover our losses resulting from disasters or other business interruptions.</p><a id="_13b41e5e_c5c5_4334_80b9_4c783794158f"></a><a id="_cp_text_1_73"></a><a id="Item2UnregisteredSalesofEquitySecurities"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item 2.</b></span><b style="font-weight:bold;">Unregistered Sales of Equity Securities and Use of Proceeds</b><b style="font-weight:bold;"> </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">None.</p><a id="_f60223f1_99f6_4f9e_a7cd_8b9758a3a02a"></a><a id="_cp_text_1_75"></a><a id="Item3DefaultsUponSeniorSecurities"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item 3.</b></span><b style="font-weight:bold;">Defaults Upon Senior Securities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">None.</p><a id="_5439a133_088e_4b87_8cd9_4a6705cb536e"></a><a id="_cp_text_1_77"></a><a id="Item4MineSafetyDisclosures"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item 4.</b></span><b style="font-weight:bold;">Mine Safety Disclosures</b></p><a id="_cp_text_1_78"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">91</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;min-height:6.9pt;"><a id="_717777f0_2d99_4c6b_9b8e_fa377d52814e"></a><a id="_cp_text_1_79"></a><a id="Item5OtherInformation"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item 5.</b></span><b style="font-weight:bold;">Other Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Securities Trading Plans of Directors and Executive Officers</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;">During the three months ended June 30, 2023,&#160;none&#160;of our directors or executive officers </span><span style="-sec-ix-hidden:Hidden_QCL7E72EDUS0cbuyFXFOTg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adopted</span></span><span style="font-size:10pt;"> or </span><span style="-sec-ix-hidden:Hidden_k-kBHamybk-ItVew0754Ag;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">terminated</span></span><span style="font-size:10pt;"> </span><span style="-sec-ix-hidden:Hidden__T-axW871EyqhlqnUc5L-w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any</span></span><span style="font-size:10pt;"> </span><span style="-sec-ix-hidden:Hidden_GN8AxaIWvEm84zA14uJG0g;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">contract</span></span><span style="font-size:10pt;">, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any &#8220;non-Rule 10b5-1 trading arrangement.&#8221;</span></p><a id="_6ed4838c_8f5e_44b5_acf1_ab6793cee558"></a><a id="_Hlk77948760"></a><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;background:#ffff00;">&#8203;</span></p><a id="Item6_Exhibits_122646"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item 6.</b></span><b style="font-weight:bold;">Exhibits</b><b style="font-weight:bold;"> </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The exhibits listed on the accompanying index to exhibits are filed or incorporated by reference (as stated therein) as part of this Quarterly Report on Form 10-Q.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:9.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:87.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:9.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;width:2.14%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:87.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description of Document</b></p></td></tr><tr><td style="vertical-align:top;width:9.85%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:2pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:2pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.99%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:2pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="https://www.sec.gov/Archives/edgar/data/1034842/000110465912040165/a12-13153_1ex99d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Certificate of Incorporation. (1)</span></a></p></td></tr><tr style="height:3.15pt;"><td style="vertical-align:top;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:4pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:4pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:4pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:16.3pt;"><td style="vertical-align:top;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.2</p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="https://www.sec.gov/Archives/edgar/data/1034842/000110465922114413/tm2229578d1_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Bylaws. (2)</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.3</p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="https://www.sec.gov/Archives/edgar/data/1034842/000110465918034498/a18-13825_1ex3d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment to the Amended and Restated Certificate of Incorporation. (3)</span></a></p></td></tr><tr style="height:3.15pt;"><td style="vertical-align:top;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.1</p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="http://www.sec.gov/Archives/edgar/data/1034842/000091205700041537/a2025040zex-4_3.txt"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of warrant to purchase shares of common stock. (4)</span></a></p></td></tr><tr style="height:3.7pt;"><td style="vertical-align:top;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.2</p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="http://www.sec.gov/Archives/edgar/data/1034842/000110465903012978/j2357_ex4d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Specimen Common Stock Certificate. (5)</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:14.5pt;"><td style="vertical-align:top;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.3</p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="http://www.sec.gov/Archives/edgar/data/1034842/000110465909029353/a09-11065_1ex4d3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Warrant issued to HCP BTC, LLC for the purchase of shares of common stock. (6)</span></a></p></td></tr><tr style="height:14.05pt;"><td style="vertical-align:top;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1#</p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="color:#ff0000;font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="rigl-20230630xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Rigel Pharmaceuticals, Inc. 2018 Equity Incentive Plan, as amended.</span></a></p></td></tr><tr style="height:13.15pt;"><td style="vertical-align:top;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.2#</p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="color:#ff0000;font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="rigl-20230630xex10d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Rigel Pharmaceuticals, Inc. Inducement Plan, as amended.</span></a></p></td></tr><tr style="height:14.5pt;"><td style="vertical-align:top;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.3#<span style="background:#ffffff;">&#708;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="rigl-20230630xex10d3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendments 1, 2 and 3 to License and Transition Services Agreement with Forma Therapeutics, Inc.</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31.1#</p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="rigl-20230630xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification required by Rule 13a-14(a) or Rule 15d-14(a) of the Exchange Act.</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31.2#</p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="rigl-20230630xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification required by Rule 13a-14(a) or Rule 15d-14(a) of the Exchange Act.</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">32.1*#</p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="rigl-20230630xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification required by Rule 13a-14(b) or Rule 15d-14(b) of the Exchange Act and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. 1350).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.INS</p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</p></td></tr><tr><td style="vertical-align:top;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.SCH</p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Schema Document.</p></td></tr><tr><td style="vertical-align:top;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.CAL</p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</p></td></tr><tr><td style="vertical-align:top;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.LAB</p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Labels Linkbase Document.</p></td></tr><tr><td style="vertical-align:top;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.PRE</p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</p></td></tr><tr><td style="vertical-align:top;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.DEF</p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Definition Linkbase Document.</p></td></tr><tr><td style="vertical-align:top;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">104</p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:6.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:6pt;margin-top:6pt;"><span style="font-size:10pt;">#</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:6pt;margin-top:6pt;"><span style="font-size:10pt;">Filed herewith</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">&#708;</span></span><span style="background:#ffffff;">Certain marked information has been omitted from this exhibit because it is both not material and is the type that the registrant treats as private and confidential.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 12pt 0pt;"><i style="font-style:italic;white-space:pre-wrap;">*     The certifications attached as Exhibit&#160;32.1 accompany this Quarterly Report on Form&#160;10-Q pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed &#8220;filed&#8221; by the registrant for purposes of Section&#160;18 of the Exchange Act.</i></p><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Filed as an exhibit to Rigel&#8217;s Current Report on Form 8-K dated June 24, 2003, and incorporated herein by reference.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:6pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Filed as an exhibit to Rigel&#8217;s Current Report on Form 8-K dated November 3, 2022, and incorporated herein by reference.</span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">92</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:6pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Filed as an exhibit to Rigel&#8217;s Current Report on Form 8-K dated May 18, 2018, and incorporated herein by reference.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:6pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(4)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Filed as an exhibit to Rigel&#8217;s Registration Statement on Form S-1 (No. 333-45864), filed on September 15, 2000, as amended, and incorporated herein by reference.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:6pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(5)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Filed as an exhibit to Rigel&#8217;s Current Report on Form 10-K dated June 24, 2003, and incorporated herein by reference.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(6)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Filed as an exhibit to Rigel&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2009, and incorporated herein by reference. </span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">93</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_a9a12e8b_545d_461b_a760_0e11cb2904bc"></a><a id="Signatures_122812"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:24.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:5.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:44.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:24.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">RIGEL PHARMACEUTICALS, INC.</p></td></tr><tr><td style="vertical-align:top;width:24.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:24.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:44.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ RAUL R. RODRIGUEZ</p></td></tr><tr><td style="vertical-align:top;width:24.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.41%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raul R. Rodriguez</p></td></tr><tr style="height:27.55pt;"><td style="vertical-align:top;width:24.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Executive Officer)</p></td></tr><tr><td style="vertical-align:top;width:24.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:</p></td><td style="vertical-align:top;width:44.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">August 1, 2023</p></td></tr><tr><td style="vertical-align:top;width:24.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:24.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:24.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:44.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ DEAN L. SCHORNO</p></td></tr><tr><td style="vertical-align:top;width:24.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.41%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dean L. Schorno</p></td></tr><tr style="height:27.55pt;"><td style="vertical-align:top;width:24.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Financial Officer)</p></td></tr><tr><td style="vertical-align:top;width:24.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:</p></td><td style="vertical-align:top;width:44.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">August 1, 2023</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">94</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>rigl-20230630xex10d1.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 7/31/2023 08:05:49 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 10.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">Rigel Pharmaceuticals,&#160;Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">2018 Equity Incentive Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-variant:small-caps;font-weight:bold;">Adopted by the Board of Directors: February&#160;1, 2018</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-variant:small-caps;font-weight:bold;">Approved by the Stockholders: May&#160;16, 2018</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-variant:small-caps;font-weight:bold;">Amended January 23,2019</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-variant:small-caps;font-weight:bold;">Amended January 31, 2019</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-variant:small-caps;font-weight:bold;">Approved by the Stockholders: May 22, 2019</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-variant:small-caps;font-weight:bold;">Amended February 3, 2020</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-variant:small-caps;font-weight:bold;">Approved by the Stockholders: May 14, 2020</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-variant:small-caps;font-weight:bold;">Amended January 28, 2021</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-variant:small-caps;font-weight:bold;">Amended March 9, 2021</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-variant:small-caps;font-weight:bold;">Approved by the Stockholders: May 18, 2021</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-variant:small-caps;font-weight:bold;">Approved by the Stockholders: May 19, 2022</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-variant:small-caps;font-weight:bold;">Approved by the Stockholders: May 25, 2023</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;font-variant:small-caps;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;font-variant:small-caps;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;font-variant:small-caps;font-weight:bold;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:10pt;font-weight:bold;">1.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:10pt;font-variant:small-caps;font-weight:bold;">General.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(a)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Successor to and Continuation of Prior Plans.</b><font style="white-space:pre-wrap;">  The Plan is intended as the successor to and continuation of the Rigel Pharmaceuticals,&#160;Inc. 2011 Equity Incentive Plan (the &#8220;</font><font style="font-style:italic;font-weight:bold;">2011 Plan</font>&#8221;), the Rigel Pharmaceuticals,&#160;Inc. 2000 Equity Incentive Plan, as amended and restated (the &#8220;<font style="font-style:italic;font-weight:bold;">2000 Plan</font>&#8221;), and the Rigel Pharmaceuticals,&#160;Inc. 2000 Non-Employee Directors&#8217; Stock Option Plan (the &#8220;<font style="font-style:italic;font-weight:bold;">2000 Non-Employee Directors&#8217; Plan</font>&#8221;, and together with the 2011 Plan, and the 2000 Plan, the &#8220;<font style="font-style:italic;font-weight:bold;">Prior Plans</font>&#8221;). Following the Effective Date, no additional stock awards may be granted under the Prior Plans. Any unallocated shares remaining available for grant under the Prior Plans as of 12:01&#160;a.m., Pacific Time on the Effective Date (the &#8220;<font style="font-style:italic;font-weight:bold;">Prior Plans&#8217; Available Reserve</font>&#8221;) will cease to be available under such Prior Plans at such time and will be added to the Share Reserve (as further described in Section&#160;3(a) below) and be then immediately available for grant and issuance pursuant to Stock Awards granted under the Plan. In addition, from and after 12:01&#160;a.m., Pacific Time on the Effective Date, all outstanding stock awards granted under the Prior Plans will remain subject to the terms of such Prior Plans, as applicable; <i style="font-style:italic;">provided, however</i>, that any shares subject to outstanding stock awards granted under the Prior Plans that (i)&#160;expire or terminate for any reason prior to exercise or settlement, (ii)&#160;are forfeited, cancelled or otherwise returned to the Company because of the failure to meet a contingency or condition required for the vesting of such shares, or (iii)&#160;other than with respect to outstanding options and stock appreciation rights granted under the Prior Plans, with respect to which the exercise or strike price is at least one hundred percent (100%) of the Fair Market Value of the Common Stock subject to the option or stock appreciation right on the date of grant (the &#8220;<font style="font-style:italic;font-weight:bold;">Prior Plans&#8217; Appreciation Awards</font>&#8221;), are reacquired or withheld (or not issued) by the Company to satisfy a tax withholding obligation in connection with a stock award(collectively, the &#8220;<font style="font-style:italic;font-weight:bold;">Prior Plans&#8217; Returning Shares</font>&#8221;) will immediately be added to the Share Reserve (as further described in Section&#160;3(a) below) as and when such shares become Prior Plans&#8217; Returning Shares and become available for issuance pursuant to Awards granted hereunder. All Stock Awards granted on or after 12:01&#160;a.m., Pacific Time on the Effective Date will be subject to the terms of this Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(b)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Eligible Award Recipients.</b><font style="white-space:pre-wrap;">  Employees, Directors and Consultants are eligible to receive Stock Awards.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(c)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Available Stock Awards.</b><font style="white-space:pre-wrap;">  The Plan provides for the grant of the following types of Stock Awards: (i)&#160;Incentive Stock Options, (ii)&#160;Nonstatutory Stock Options, (iii)&#160;Stock Appreciation Rights, (iv)&#160;Restricted Stock Awards, (v)&#160;Restricted Stock Unit Awards, (vi)&#160;Performance Stock Awards, and (vii)&#160;Other Stock Awards.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">(d)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Purpose.</b><font style="white-space:pre-wrap;">  The Plan, through the granting of Stock Awards, is intended to help the Company and any Affiliate secure and retain the services of eligible award recipients, provide incentives for such persons to exert </font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;">1</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">maximum efforts for the success of the Company and any Affiliate and provide a means by which the eligible recipients may benefit from increases in value of the Common Stock.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:10pt;font-weight:bold;">2.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:10pt;font-variant:small-caps;font-weight:bold;">Administration.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(a)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Administration by Board.</b><font style="white-space:pre-wrap;">  The Board will administer the Plan. The Board may delegate administration of the Plan to a Committee or Committees, as provided in Section&#160;2(c).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(b)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Powers of Board.</b><font style="white-space:pre-wrap;">  The Board will have the power, subject to, and within the limitations of, the express provisions of the Plan:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(i)</b></font>To determine (A)&#160;who will be granted Stock Awards; (B)&#160;when and how each Stock Award will be granted; (C)&#160;what type of Stock Award will be granted; (D)&#160;the provisions of each Stock Award (which need not be identical), including when a person will be permitted to exercise or otherwise receive cash or Common Stock under the Stock Award; (E)&#160;the number of shares of Common Stock subject to, or the cash value of, a Stock Award; and (F)&#160;the Fair Market Value applicable to a Stock Award.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(ii)</b></font>To construe and interpret the Plan and Stock Awards granted under it, and to establish, amend and revoke rules and regulations for administration of the Plan and Stock Awards. The Board, in the exercise of these powers, may correct any defect, omission or inconsistency in the Plan or in any Stock Award Agreement, in a manner and to the extent it will deem necessary or expedient to make the Plan or Stock Award fully effective.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(iii)</b></font>To settle all controversies regarding the Plan and Stock Awards granted under it.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(iv)</b></font>To accelerate, in whole or in part, the time at which a Stock Award may be exercised or vest (or the time at which cash or shares of Common Stock may be issued in settlement thereof).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(v)</b></font>To suspend or terminate the Plan at any time. Except as otherwise provided in the Plan or a Stock Award Agreement, suspension or termination of the Plan will not materially impair a Participant&#8217;s rights under his or her then-outstanding Stock Award without his or her written consent except as provided in subsection&#160;(viii) below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(vi)</b></font>To amend the Plan in any respect the Board deems necessary or advisable, including, without limitation, by adopting amendments relating to Incentive Stock Options and certain nonqualified deferred compensation under Section&#160;409A of the Code and/or to make the Plan or Stock Awards granted under the Plan compliant with the requirements for Incentive Stock Options or exempt from or compliant with the requirements for nonqualified deferred compensation under Section&#160;409A of the Code, subject to the limitations, if any, of applicable law. However, if required by applicable law or listing requirements, and except as provided in Section&#160;10(a) relating to Capitalization Adjustments, the Company will seek stockholder approval of any amendment of the Plan that (A)&#160;materially increases the number of shares of Common Stock available for issuance under the Plan, (B)&#160;materially expands the class of individuals eligible to receive Stock Awards under the Plan, (C)&#160;materially increases the benefits accruing to Participants under the Plan, (D)&#160;materially reduces the price at which shares of Common Stock may be issued or purchased under the Plan, or (E)&#160;materially expands the types of Stock Awards available for issuance under the Plan. Except as provided in the Plan (including Section&#160;2(b)(viii)) or a Stock Award Agreement, no amendment of the Plan will materially impair a Participant&#8217;s rights under an outstanding Stock Award without the Participant&#8217;s written consent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(vii)</b></font>To submit any amendment to the Plan for stockholder approval, including, but not limited to, amendments to the Plan intended to satisfy the requirements of (A)&#160;Section&#160;422 of the Code regarding incentive stock options or (B)&#160;Rule&#160;16b-3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 0pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(viii)</b></font>To approve forms of Stock Award Agreements for use under the Plan and to amend the terms of any one or more Stock Awards, including, but not limited to, amendments to provide terms more </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;">2</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 36pt;">favorable to the Participant than previously provided in the Stock Award Agreement, subject to any specified limits in the Plan that are not subject to Board discretion; <i style="font-style:italic;">provided, however,</i> that a Participant&#8217;s rights under any Stock Award will not be impaired by any such amendment unless (A)&#160;the Company requests the consent of the affected Participant, and (B)&#160;such Participant consents in writing. Notwithstanding the foregoing, (1)&#160;a Participant&#8217;s rights will not be deemed to have been impaired by any such amendment if the Board, in its sole discretion, determines that the amendment, taken as a whole, does not materially impair the Participant&#8217;s rights, and (2)&#160;subject to the limitations of applicable law, if any, the Board may amend the terms of any one or more Stock Awards without the affected Participant&#8217;s consent (A)&#160;to maintain the qualified status of the Stock Award as an Incentive Stock Option under Section&#160;422 of the Code; (B)&#160;to change the terms of an Incentive Stock Option, if such change results in impairment of the Stock Award solely because it impairs the qualified status of the Stock Award as an Incentive Stock Option under Section&#160;422 of the Code; (C)&#160;to clarify the manner of exemption from, or to bring the Stock Award into compliance with, Section&#160;409A of the Code; or (D)&#160;to comply with other applicable laws or listing requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(ix)</b></font>Generally, to exercise such powers and to perform such acts as the Board deems necessary or expedient to promote the best interests of the Company and that are not in conflict with the provisions of the Plan or Stock Awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(x)</b></font>To adopt such procedures and sub-plans as are necessary or appropriate to permit participation in the Plan by Employees, Directors or Consultants who are foreign nationals or employed outside the United States (provided that Board approval will not be necessary for immaterial modifications to the Plan or any Stock Award Agreement that are required for compliance with the laws of the relevant foreign jurisdiction).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(c)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Delegation to Committee.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(i)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">General.</b><font style="white-space:pre-wrap;">  The Board may delegate some or all of the administration of the Plan to a Committee or Committees. If administration of the Plan is delegated to a Committee, the Committee will have, in connection with the administration of the Plan, the powers theretofore possessed by the Board that have been delegated to the Committee, including the power to delegate to a subcommittee of the Committee any of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Board will thereafter be to the Committee or subcommittee, as applicable). Any delegation of administrative powers will be reflected in resolutions, not inconsistent with the provisions of the Plan, adopted from time to time by the Board or Committee (as applicable). The Committee may, at any time, abolish the subcommittee and/or revest in the Committee any powers delegated to the subcommittee. The Board may retain the authority to concurrently administer the Plan with the Committee and may, at any time, revest in the Board some or all of the powers previously delegated.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><b style="font-weight:bold;">(ii)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Rule&#160;16b-3 Compliance.</b><font style="white-space:pre-wrap;">  The Committee may consist solely of two or more Non-Employee Directors, in accordance with Rule&#160;16b-3.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(d)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Delegation to an Officer.</b><font style="white-space:pre-wrap;">  The Board may delegate to one or more Officers the authority to do one or both of the following (i)&#160;designate Employees who are not Officers to be recipients of Options and SARs (and, to the extent permitted by applicable law, other Stock Awards) and, to the extent permitted by applicable law, the terms of such Stock Awards, and (ii)&#160;determine the number of shares of Common Stock to be subject to such Stock Awards granted to such Employees; </font><i style="font-style:italic;">provided, however</i>, that the Board resolutions regarding such delegation will specify the total number of shares of Common Stock that may be subject to the Stock Awards granted by such Officer and that such Officer may not grant a Stock Award to himself or herself. Any such Stock Awards will be granted on the form of Stock Award Agreement most recently approved for use by the Committee or the Board, unless otherwise provided in the resolutions approving the delegation authority. The Board may not delegate authority to an Officer who is acting solely in the capacity of an Officer (and not also as a Director) to determine the Fair Market Value pursuant to Section&#160;13(u)(iii) below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(e)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Effect of Board&#8217;s Decision.</b><font style="white-space:pre-wrap;">  All determinations, interpretations and constructions made by the Board in good faith will not be subject to review by any person and will be final, binding and conclusive on all persons.</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;">3</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(f)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Repricing; Cancellation and Re-Grant of Stock Awards.</b><font style="white-space:pre-wrap;">  Neither the Board nor any Committee will have the authority to (i)&#160;reduce the exercise, purchase or strike price of any outstanding Option or SAR under the Plan, or (ii)&#160;cancel any outstanding Option or SAR that has an exercise price or strike price greater than the then-current Fair Market Value of the Common Stock in exchange for cash or other Stock Awards under the Plan, unless the stockholders of the Company have approved such an action within 12&#160;months prior to such an event.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(g)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Dividends and Dividend Equivalents.</b><font style="white-space:pre-wrap;">  Dividends or dividend equivalents may be paid or credited, as applicable, with respect to any shares of Common Stock subject to a Stock Award (other than an Option or SAR), as determined by the Board and contained in the applicable Stock Award Agreement; </font><i style="font-style:italic;">provided, however</i>, that (i)&#160;no dividends or dividend equivalents may be paid with respect to any such shares before the date such shares have vested under the terms of such Stock Award Agreement, (ii)&#160;any dividends or dividend equivalents that are credited with respect to any such shares will be subject to all of the terms and conditions applicable to such shares under the terms of such Stock Award Agreement (including, but not limited to, any vesting conditions), and (iii)&#160;any dividends or dividend equivalents that are credited with respect to any such shares will be forfeited to the Company on the date, if any, such shares are forfeited to or repurchased by the Company due to a failure to meet any vesting conditions under the terms of such Stock Award Agreement.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:10pt;font-weight:bold;">3.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:10pt;font-variant:small-caps;font-weight:bold;">Shares Subject to the Plan.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(a)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Share Reserve.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(i)</b></font>Subject to Section 10(a) relating to Capitalization Adjustments, the aggregate number of shares of&#160;Common Stock that may be issued pursuant to Stock Awards from and after the Effective Date will&#160;not exceed (A) 31,657,133 shares (which number is the sum of (i)&#160;the number of shares (10,032,133)&#160;subject to the Prior Plans&#8217; Available Reserve and (ii)&#160;an additional 5,000,000 new shares, plus&#160;4,000,000 shares of Common Stock approved by the Board in January 2019, and subsequently&#160;approved by the Company&#8217;s stockholders, plus 2,800,000 shares of Common Stock approved by&#160;the Board in February 2020, and subsequently approved by the Company&#8217;s stockholders, plus&#160;825,000 shares of Common Stock approved by the Board in January 2021, and subsequently&#160;approved by the Company&#8217;s stockholders, plus 5,000,000 shares of Common Stock approved by&#160;the Board in March 2022, and subsequently approved by the Company&#8217;s stockholders),&#160;plus 4,000,000 shares of Common Stock approved by the Board in February 2023, and subsequently approved by the Company&#8217;s stockholders<font style="font-family:'Arial','Helvetica','sans-serif';"> </font>and&#160;(B) the&#160;Prior Plans&#8217; Returning Shares, if any, which become available for grant under this Plan from time to&#160;time (such aggregate number of shares described in (A) and (B) above, the &#8220;<b style="font-weight:bold;">Share Reserve</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(ii)</b></font>For clarity, the Share Reserve in this Section&#160;3(a) is a limitation on the number of shares of Common Stock that may be issued pursuant to the Plan. Accordingly, this Section&#160;3(a) does not limit the granting of Stock Awards except as provided in Section&#160;8(a). Shares may be issued in connection with a merger or acquisition as permitted by NASDAQ Listing Rule&#160;5635(c) or, if applicable, NYSE Listed Company Manual Section&#160;303A.08, AMEX Company Guide Section&#160;711 or other applicable rule, and such issuance will not reduce the number of shares available for issuance under the Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(iii)</b></font>Subject to Section&#160;3(b), the number of shares of Common Stock available for issuance under the Plan will be reduced by: (A)&#160;one share for each share of Common Stock issued pursuant to an Option or SAR with respect to which the exercise or strike price is at least 100% of the Fair Market Value of the Common Stock subject to the Option or SAR on the date of grant; and (B)&#160;one and forty four hundredths (1.44) shares for each share of Common Stock issued pursuant to a Full Value Award.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(b)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Reversion of Shares to the Share Reserve.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 0pt 36pt;"><b style="font-weight:bold;">(i)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Shares Available For Subsequent Issuance.</b><font style="white-space:pre-wrap;">  If (A)&#160;any shares of Common Stock subject to a Stock Award are not issued because such Stock Award or any portion thereof expires or otherwise terminates without all of the shares covered by such Stock Award having been issued or is settled in cash (</font><i style="font-style:italic;">i.e.</i>, the Participant receives cash rather than stock), (B)&#160;any shares of Common Stock issued pursuant to a Stock Award are forfeited back to or repurchased by the Company because of the failure to meet a contingency or condition required for the vesting of such shares, or (C)&#160;with respect to a Full Value Award, </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;">4</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 36pt;">any shares of Common Stock are reacquired or withheld (or not issued) by the Company to satisfy a tax withholding obligation in connection with such Full Value Award, such shares will again become available for issuance under the Plan (collectively, the &#8220;<font style="font-style:italic;font-weight:bold;">2018 Plan Returning Shares</font>&#8221;). For each (1)&#160;2018 Plan Returning Share subject to a Full Value Award or (2)&#160;Prior Plans&#8217; Returning Share subject to a stock award other than a Prior Plans&#8217; Appreciation Award, the number of shares of Common Stock available for issuance under the Plan will increase by one and forty-four hundredths (1.44) shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><b style="font-weight:bold;">(ii)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Shares Not Available For Subsequent Issuance.</b><font style="white-space:pre-wrap;">  Any shares of Common Stock reacquired or withheld (or not issued) by the Company to satisfy the exercise or purchase price of a Stock Award will no longer be available for issuance under the Plan, including any shares subject to a Stock Award that are not delivered to a Participant because such Stock Award is exercised through a reduction of shares subject to such Stock Award (</font><i style="font-style:italic;">i.e</i>., &#8220;net exercised&#8221;). In addition, any shares reacquired or withheld (or not issued) by the Company to satisfy a tax withholding obligation in connection with an Option or Stock Appreciation Right or a Prior Plans&#8217; Appreciation Award, or any shares repurchased by the Company on the open market with the proceeds of the exercise or strike price of an Option or Stock Appreciation Right or a Prior Plans&#8217; Appreciation Award will no longer be available for issuance under the Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(c)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Incentive Stock Option Limit.</b><font style="white-space:pre-wrap;">  Subject to the Share Reserve and Section&#160;10(a) relating to Capitalization Adjustments, the aggregate maximum number of shares of Common Stock that may be issued pursuant to the exercise of Incentive Stock Options will be 39,070,403 shares of Common Stock.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(d)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Source of Shares.</b><font style="white-space:pre-wrap;">  The stock issuable under the Plan will be shares of authorized but unissued or reacquired Common Stock, including shares repurchased by the Company on the open market or otherwise.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:10pt;font-weight:bold;">4.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:10pt;font-variant:small-caps;font-weight:bold;">Eligibility.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(a)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Eligibility for Specific Stock Awards.</b><font style="white-space:pre-wrap;">  Incentive Stock Options may be granted only to employees of the Company or a &#8220;parent corporation&#8221; or &#8220;subsidiary corporation&#8221; thereof (as such terms are defined in Sections&#160;424(e) and 424(f) of the Code). Stock Awards other than Incentive Stock Options may be granted to Employees, Directors and Consultants; provided, however, that Stock Awards may not be granted to Employees, Directors and Consultants who are providing Continuous Service only to any &#8220;parent&#8221; of the Company, as such term is defined in Rule&#160;405, unless (i)&#160;the stock underlying such Stock Awards is treated as &#8220;service recipient stock&#8221; under Section&#160;409A of the Code (for example, because the Stock Awards are granted pursuant to a corporate transaction such as a spin off transaction) or (ii)&#160;the Company, in consultation with its legal counsel, has determined that such Stock Awards are otherwise exempt from or alternatively comply with the distribution requirements of Section&#160;409A of the Code.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(b)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Ten Percent Stockholders.</b><font style="white-space:pre-wrap;">  A Ten Percent Stockholder will not be granted an Incentive Stock Option unless the exercise price of such Option is at least 110% of the Fair Market Value on the date of grant and the Option is not exercisable after the expiration of five years from the date of grant.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:10pt;font-weight:bold;">5.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:10pt;font-variant:small-caps;font-weight:bold;">Non-Employee Directors Compensation Limits</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Non-Employee Director Compensation Limit</b>. The aggregate value of all compensation granted or paid, as applicable, to any individual for service as a Non-Employee Director with respect to any period commencing on the date of the Company&#8217;s Annual Meeting of Stockholders for a particular year and ending on the day immediately prior to the date of the Company&#8217;s Annual Meeting of Stockholders for the next subsequent year (the &#8220;Annual Period&#8221;), including Awards granted and cash fees paid by the Company to such Non-Employee Director, will not exceed (i) $1,000,000 in total value or (ii) in the event such Non-Employee Director is first appointed or elected to the Board during such Annual Period, $1,500,000 in total value, in each case calculating the value of any equity awards based on the grant date fair value of such equity awards for financial reporting purposes. The limitations in this Section 5 shall apply commencing on the date of the 2021 Annual Meeting of Stockholders.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;">5</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:10pt;font-weight:bold;">6.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:10pt;font-variant:small-caps;font-weight:bold;">Provisions Relating to Options and Stock Appreciation Rights.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Each Option or SAR will be in such form and will contain such terms and conditions as the Board deems appropriate. All Options will be separately designated Incentive Stock Options or Nonstatutory Stock Options at the time of grant, and, if certificates are issued, a separate certificate or certificates will be issued for shares of Common Stock purchased on exercise of each type of Option. If an Option is not specifically designated as an Incentive Stock Option, or if an Option is designated as an Incentive Stock Option but some portion or all of the Option fails to qualify as an Incentive Stock Option under the applicable rules, then the Option (or portion thereof) will be a Nonstatutory Stock Option. The provisions of separate Options or SARs need not be identical; <i style="font-style:italic;">provided, however</i>, that each Stock Award Agreement will conform to (through incorporation of provisions hereof by reference in the applicable Stock Award Agreement or otherwise) the substance of each of the following provisions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(a)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Term.</b><font style="white-space:pre-wrap;">  Subject to the provisions of Section&#160;4(b) regarding Ten Percent Stockholders, no Option or SAR will be exercisable after the expiration of ten years from the date of its grant, or such shorter period specified in the Stock Award Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(b)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Exercise Price.</b><font style="white-space:pre-wrap;">  Subject to the provisions of Section&#160;4(b) regarding Ten Percent Stockholders, the exercise or strike price of each Option or SAR will be not less than 100% of the Fair Market Value of the Common Stock subject to the Option or SAR on the date the Stock Award is granted. Notwithstanding the foregoing, an Option or SAR may be granted with an exercise or strike price lower than 100% of the Fair Market Value of the Common Stock subject to the Stock Award if such Stock Award is granted pursuant to an assumption of or substitution for another option or stock appreciation right pursuant to a Corporate Transaction and in a manner consistent with the provisions of Section&#160;409A of the Code and, if applicable, Section&#160;424(a) of the Code. Each SAR will be denominated in shares of Common Stock equivalents.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(c)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Purchase Price for Options.</b><font style="white-space:pre-wrap;">  The purchase price of Common Stock acquired pursuant to the exercise of an Option may be paid, to the extent permitted by applicable law and as determined by the Board in its sole discretion, by any combination of the methods of payment set forth below. The Board will have the authority to grant Options that do not permit all of the following methods of payment (or that otherwise restrict the ability to use certain methods) and to grant Options that require the consent of the Company to use a particular method of payment. The permitted methods of payment are as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(i)</b></font>by cash, check, bank draft or money order payable to the Company;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(ii)</b></font>pursuant to a program developed under Regulation&#160;T as promulgated by the Federal Reserve Board that, prior to the issuance of the Common Stock subject to the Option, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to pay the aggregate exercise price to the Company from the sales proceeds;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(iii)</b></font>by delivery to the Company (either by actual delivery or attestation) of shares of Common Stock;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(iv)</b></font>if an Option is a Nonstatutory Stock Option, by a &#8220;net exercise&#8221; arrangement pursuant to which the Company will reduce the number of shares of Common Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price; <i style="font-style:italic;">provided, however</i>, that the Company will accept a cash or other payment from the Participant to the extent of any remaining balance of the aggregate exercise price not satisfied by such reduction in the number of whole shares to be issued. Shares of Common Stock will no longer be subject to an Option and will not be exercisable thereafter to the extent that (A)&#160;shares issuable upon exercise are used to pay the exercise price pursuant to the &#8220;net exercise,&#8221; (B)&#160;shares are delivered to the Participant as a result of such exercise, and (C)&#160;shares are withheld to satisfy tax withholding obligations; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(v)</b></font>in any other form of legal consideration that may be acceptable to the Board and specified in the applicable Stock Award Agreement.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;">6</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(d)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Exercise and Payment of a SAR.</b><font style="white-space:pre-wrap;">  To exercise any outstanding SAR, the Participant must provide written notice of exercise to the Company in compliance with the provisions of the Stock Award Agreement evidencing such SAR. The appreciation distribution payable on the exercise of a SAR will be not greater than an amount equal to the excess of (A)&#160;the aggregate Fair Market Value (on the date of the exercise of the SAR) of a number of shares of Common Stock equal to the number of Common Stock equivalents in which the Participant is vested under such SAR, and with respect to which the Participant is exercising the SAR on such date, over (B)&#160;the aggregate strike price of the number of Common Stock equivalents with respect to which the Participant is exercising the SAR on such date. The appreciation distribution may be paid in Common Stock, in cash, in any combination of the two or in any other form of consideration, as determined by the Board and contained in the Stock Award Agreement evidencing such SAR.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(e)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Transferability of Options and SARs.</b><font style="white-space:pre-wrap;">  The Board may, in its sole discretion, impose such limitations on the transferability of Options and SARs as the Board will determine. In the absence of such a determination by the Board to the contrary, the restrictions set forth in this Section&#160;6(e) on the transferability of Options and SARs will apply. Notwithstanding the foregoing or anything in the Plan or a Stock Award Agreement to the contrary, no Option or SAR may be transferred to any financial institution without prior stockholder approval.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><b style="font-weight:bold;">(i)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Restrictions on Transfer.</b><font style="white-space:pre-wrap;">  An Option or SAR will not be transferable except by will or by the laws of descent and distribution (and pursuant to Sections&#160;6(e)(ii) and 6(e)(iii) below) and will be exercisable during the lifetime of the Participant only by the Participant. Subject to the foregoing paragraph, the Board may permit transfer of the Option or SAR in a manner that is not prohibited by applicable tax and securities laws. Except as explicitly provided in the Plan, neither an Option nor a SAR may be transferred for consideration.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><b style="font-weight:bold;">(ii)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Domestic Relations Orders.</b><font style="white-space:pre-wrap;">  Subject to the approval of the Board or a duly authorized Officer, an Option or SAR may be transferred pursuant to the terms of a domestic relations order, official marital settlement agreement or other divorce or separation instrument as permitted by Treasury Regulations Section&#160;1.421-1(b)(2). If an Option is an Incentive Stock Option, such Option may be deemed to be a Nonstatutory Stock Option as a result of such transfer.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><b style="font-weight:bold;">(iii)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Beneficiary Designation.</b><font style="white-space:pre-wrap;">  Subject to the approval of the Board or a duly authorized Officer, a Participant may, by delivering written notice to the Company, in a form approved by the Company (or the designated broker), designate a third party who, upon the death of the Participant, will thereafter be entitled to exercise the Option or SAR and receive the Common Stock or other consideration resulting from such exercise. In the absence of such a designation, upon the death of the Participant, the executor or administrator of the Participant&#8217;s estate will be entitled to exercise the Option or SAR and receive the Common Stock or other consideration resulting from such exercise. However, the Company may prohibit designation of a beneficiary at any time, including due to any conclusion by the Company that such designation would be inconsistent with the provisions of applicable laws.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(f)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Vesting Generally.</b><font style="white-space:pre-wrap;">  The total number of shares of Common Stock subject to an Option or SAR may vest and become exercisable in periodic installments that may or may not be equal. The Option or SAR may be subject to such other terms and conditions on the time or times when it may or may not be exercised (which may be based on the satisfaction of Performance Goals or other criteria) as the Board may deem appropriate. The vesting provisions of individual Options or SARs may vary.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(g)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Termination of Continuous Service.</b><font style="white-space:pre-wrap;">  Except as otherwise provided in the applicable Stock Award Agreement or other agreement between the Participant and the Company or an Affiliate, if a Participant&#8217;s Continuous Service terminates (other than for Cause and other than upon the Participant&#8217;s death or Disability), the Participant may exercise his or her Option or SAR (to the extent that the Participant was entitled to exercise such Option or SAR as of the date of termination of Continuous Service), but only within such period of time ending on the earlier of (i)&#160;the date three months following such termination of Continuous Service (or such longer or shorter period specified in the Stock Award Agreement), and (ii)&#160;the expiration of the term of the Option or SAR as set forth in the Stock Award Agreement. If, after termination of Continuous Service, the Participant does not exercise his or her Option or SAR (as applicable) within the applicable time frame, the Option or SAR (as applicable) will terminate.</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;">7</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(h)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Extension of Termination Date.</b><font style="white-space:pre-wrap;">  Except as otherwise provided in the applicable Stock Award Agreement or other agreement between the Participant and the Company or an Affiliate, if the exercise of an Option or SAR following the termination of the Participant&#8217;s Continuous Service (other than for Cause and other than upon the Participant&#8217;s death or Disability) would be prohibited at any time solely because the issuance of shares of Common Stock would violate the registration requirements under the Securities Act, then the Option or SAR will terminate on the earlier of (i)&#160;the expiration of a total period of time (that need not be consecutive) equal to the applicable post-termination exercise period after the termination of the Participant&#8217;s Continuous Service during which the exercise of the Option or SAR would not be in violation of such registration requirements, or (ii)&#160;the expiration of the term of the Option or SAR as set forth in the applicable Stock Award Agreement. In addition, unless otherwise provided in a Participant&#8217;s Stock Award Agreement, if the sale of any Common Stock received upon exercise of an Option or SAR following the termination of the Participant&#8217;s Continuous Service (other than for Cause) would violate the Company&#8217;s insider trading policy, then the Option or SAR will terminate on the earlier of (i)&#160;the expiration of a period of time (that need not be consecutive) equal to the applicable post-termination exercise period after the termination of the Participant&#8217;s Continuous Service during which the sale of the Common Stock received upon exercise of the Option or SAR would not be in violation of the Company&#8217;s insider trading policy, or (ii)&#160;the expiration of the term of the Option or SAR as set forth in the applicable Stock Award Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(i)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Disability of Participant.</b><font style="white-space:pre-wrap;">  Except as otherwise provided in the applicable Stock Award Agreement or other agreement between the Participant and the Company or an Affiliate, if a Participant&#8217;s Continuous Service terminates as a result of the Participant&#8217;s Disability, the Participant may exercise his or her Option or SAR (to the extent that the Participant was entitled to exercise such Option or SAR as of the date of termination of Continuous Service), but only within such period of time ending on the earlier of (i)&#160;the date 12&#160;months following such termination of Continuous Service (or such longer or shorter period specified in the Stock Award Agreement), and (ii)&#160;the expiration of the term of the Option or SAR as set forth in the Stock Award Agreement. If, after termination of Continuous Service, the Participant does not exercise his or her Option or SAR (as applicable) within the applicable time frame, the Option or SAR (as applicable) will terminate.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(j)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Death of Participant.</b><font style="white-space:pre-wrap;">  Except as otherwise provided in the applicable Stock Award Agreement or other agreement between the Participant and the Company or an Affiliate, if (i)&#160;a Participant&#8217;s Continuous Service terminates as a result of the Participant&#8217;s death, or (ii)&#160;the Participant dies within the period (if any) specified in the Stock Award Agreement for exercisability after the termination of the Participant&#8217;s Continuous Service (for a reason other than death), then the Participant&#8217;s Option or SAR may be exercised (to the extent that the Participant was entitled to exercise such Option or SAR as of the date of death) by the Participant&#8217;s estate, by a person who acquired the right to exercise the Option or SAR by bequest or inheritance or by a person designated to exercise the Option or SAR upon the Participant&#8217;s death, but only within such period of time ending on the earlier of (i)&#160;the date 18&#160;months following the date of death (or such longer or shorter period specified in the Stock Award Agreement), and (ii)&#160;the expiration of the term of such Option or SAR as set forth in the Stock Award Agreement. If, after the Participant&#8217;s death, the Option or SAR (as applicable) is not exercised within the applicable time frame, the Option or SAR (as applicable) will terminate.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(k)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Termination for Cause.</b><font style="white-space:pre-wrap;">  Except as explicitly provided otherwise in a Participant&#8217;s Stock Award Agreement or other individual written agreement between the Participant and the Company or an Affiliate, if a Participant&#8217;s Continuous Service is terminated for Cause, the Participant&#8217;s Option or SAR will terminate immediately upon such termination of Continuous Service, and the Participant will be prohibited from exercising his or her Option or SAR from and after the time of such termination of Continuous Service.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">(l)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Non-Exempt Employees.</b><font style="white-space:pre-wrap;">  If an Option or SAR is granted to an Employee who is a non-exempt employee for purposes of the Fair Labor Standards Act of 1938, as amended, the Option or SAR will not be first exercisable for any shares of Common Stock until at least six months following the date of grant of the Option or SAR (although the Stock Award may vest prior to such date). Consistent with the provisions of the Worker Economic Opportunity Act, (i)&#160;if such non-exempt employee dies or suffers a Disability, (ii)&#160;upon a Corporate Transaction in which such Option or SAR is not assumed, continued, or substituted, (iii)&#160;upon a Change in Control, or (iv)&#160;upon the Participant&#8217;s retirement (as such term may be defined in the Participant&#8217;s Stock Award Agreement, in another agreement between the Participant and the Company or an Affiliate, or, if no such definition, in accordance with the Company&#8217;s or Affiliate&#8217;s then current employment policies and guidelines), the vested portion of any Options and SARs may be exercised earlier than six months following the date of grant. The foregoing </font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;">8</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">provision is intended to operate so that any income derived by a non-exempt employee in connection with the exercise or vesting of an Option or SAR will be exempt from his or her regular rate of pay. To the extent permitted and/or required for compliance with the Worker Economic Opportunity Act to ensure that any income derived by a non-exempt employee in connection with the exercise, vesting or issuance of any shares under any other Stock Award will be exempt from the employee&#8217;s regular rate of pay, the provisions of this Section&#160;6(l) will apply to all Stock Awards and are hereby incorporated by reference into such Stock Award Agreements.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:10pt;font-weight:bold;">7.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:10pt;font-variant:small-caps;font-weight:bold;">Provisions of Stock Awards Other than Options and SARs.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(a)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Restricted Stock Awards.</b><font style="white-space:pre-wrap;">  Each Restricted Stock Award Agreement will be in such form and will contain such terms and conditions as the Board deems appropriate. To the extent consistent with the Company&#8217;s bylaws, at the Board&#8217;s election, shares of Common Stock underlying a Restricted Stock Award may be (i)&#160;held in book entry form subject to the Company&#8217;s instructions until any restrictions relating to the Restricted Stock Award lapse, or (ii)&#160;evidenced by a certificate, which certificate will be held in such form and manner as determined by the Board. The terms and conditions of Restricted Stock Award Agreements may change from time to time, and the terms and conditions of separate Restricted Stock Award Agreements need not be identical. Each Restricted Stock Award Agreement will conform to (through incorporation of the provisions hereof by reference in the agreement or otherwise) the substance of each of the following provisions:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><b style="font-weight:bold;">(i)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Consideration.</b><font style="white-space:pre-wrap;">  A Restricted Stock Award may be awarded in consideration for (A)&#160;cash, check, bank draft or money order payable to the Company, (B)&#160;past services to the Company or an Affiliate, or (C)&#160;any other form of legal consideration (including future services) that may be acceptable to the Board, in its sole discretion, and permissible under applicable law.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><b style="font-weight:bold;">(ii)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Vesting.</b><font style="white-space:pre-wrap;">  Shares of Common Stock awarded under the Restricted Stock Award Agreement may be subject to forfeiture to the Company in accordance with a vesting schedule to be determined by the Board.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><b style="font-weight:bold;">(iii)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Termination of Participant&#8217;s Continuous Service.</b><font style="white-space:pre-wrap;">  If a Participant&#8217;s Continuous Service terminates, the Company may receive through a forfeiture condition or a repurchase right any or all of the shares of Common Stock held by the Participant as of the date of termination of Continuous Service under the terms of the Restricted Stock Award Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 9pt 36pt;"><b style="font-weight:bold;">(iv)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Transferability.</b><font style="white-space:pre-wrap;">  Rights to acquire shares of Common Stock under the Restricted Stock Award Agreement will be transferable by the Participant only upon such terms and conditions as are set forth in the Restricted Stock Award Agreement, as the Board will determine in its sole discretion, so long as Common Stock awarded under the Restricted Stock Award Agreement remains subject to the terms of the Restricted Stock Award Agreement. Notwithstanding the foregoing or anything in the Plan or a Restricted Stock Award Agreement to the contrary, no Restricted Stock Award may be transferred to any financial institution without prior stockholder approval.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 9pt 0pt;"><b style="font-weight:bold;">(b)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Restricted Stock Unit Awards.</b><font style="white-space:pre-wrap;">  Each Restricted Stock Unit Award Agreement will be in such form and will contain such terms and conditions as the Board deems appropriate. The terms and conditions of Restricted Stock Unit Award Agreements may change from time to time, and the terms and conditions of separate Restricted Stock Unit Award Agreements need not be identical. Each Restricted Stock Unit Award Agreement will conform to (through incorporation of the provisions hereof by reference in the Agreement or otherwise) the substance of each of the following provisions:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 9pt 36pt;"><b style="font-weight:bold;">(i)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Consideration.</b><font style="white-space:pre-wrap;">  At the time of grant of a Restricted Stock Unit Award, the Board will determine the consideration, if any, to be paid by the Participant upon delivery of each share of Common Stock subject to the Restricted Stock Unit Award. The consideration to be paid (if any) by the Participant for each share of Common Stock subject to a Restricted Stock Unit Award may be paid in any form of legal consideration that may be acceptable to the Board, in its sole discretion, and permissible under applicable law.</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;">9</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 9pt 36pt;"><b style="font-weight:bold;">(ii)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Vesting.</b><font style="white-space:pre-wrap;">  At the time of the grant of a Restricted Stock Unit Award, the Board may impose such restrictions on or conditions to the vesting of the Restricted Stock Unit Award as it, in its sole discretion, deems appropriate.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 9pt 36pt;"><b style="font-weight:bold;">(iii)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Payment.</b><font style="white-space:pre-wrap;">  A Restricted Stock Unit Award may be settled by the delivery of shares of Common Stock, their cash equivalent, any combination thereof or in any other form of consideration, as determined by the Board and contained in the Restricted Stock Unit Award Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 9pt 36pt;"><b style="font-weight:bold;">(iv)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Additional Restrictions.</b><font style="white-space:pre-wrap;">  At the time of the grant of a Restricted Stock Unit Award, the Board, as it deems appropriate, may impose such restrictions or conditions that delay the delivery of the shares of Common Stock (or their cash equivalent) subject to a Restricted Stock Unit Award to a time after the vesting of such Restricted Stock Unit Award.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 9pt 36pt;"><b style="font-weight:bold;">(v)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Termination of Participant&#8217;s Continuous Service.</b><font style="white-space:pre-wrap;">  Except as otherwise provided in the applicable Restricted Stock Unit Award Agreement, such portion of the Restricted Stock Unit Award that has not vested will be forfeited upon the Participant&#8217;s termination of Continuous Service.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 9pt 0pt;"><b style="font-weight:bold;">(c)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Performance Stock Awards.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 9pt 36pt;"><b style="font-weight:bold;">(i)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Performance Stock Awards.</b><font style="white-space:pre-wrap;">  A Performance Stock Award is a Stock Award that is payable (including that may be granted, vest or be exercised) contingent upon the attainment during a Performance Period of certain Performance Goals. A Performance Stock Award may, but need not, require the Participant&#8217;s completion of a specified period of Continuous Service. The length of any Performance Period, the Performance Goals to be achieved during the Performance Period, and the measure of whether and to what degree such Performance Goals have been attained will be conclusively determined by the Board, in its sole discretion. In addition, to the extent permitted by applicable law and the applicable Stock Award Agreement, the Board may determine that cash may be used in payment of Performance Stock Awards.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 9pt 36pt;"><b style="font-weight:bold;">(ii)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Discretion.</b><font style="white-space:pre-wrap;">  The Board retains the discretion to reduce or eliminate the compensation or economic benefit due upon the attainment of any Performance Goals and to define the manner of calculating the Performance Criteria it selects to use for a Performance Period.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 9pt 0pt;"><b style="font-weight:bold;">(d)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Other Stock Awards.</b><font style="white-space:pre-wrap;">  Other forms of Stock Awards valued in whole or in part by reference to, or otherwise based on, Common Stock, including the appreciation in value thereof (</font><i style="font-style:italic;">e.g</i>., options or stock appreciation rights with an exercise price or strike price less than 100% of the Fair Market Value of the Common Stock at the time of grant) may be granted either alone or in addition to Stock Awards granted under Section&#160;6 and this Section&#160;7. Subject to the provisions of the Plan (including, but not limited to, Section&#160;2(g)), the Board will have sole and complete authority to determine the persons to whom and the time or times at which such Other Stock Awards will be granted, the number of shares of Common Stock (or the cash equivalent thereof) to be granted pursuant to such Other Stock Awards and all other terms and conditions of such Other Stock Awards.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:10pt;font-weight:bold;">8.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:10pt;font-variant:small-caps;font-weight:bold;">Covenants of the Company.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(a)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Availability of Shares.</b><font style="white-space:pre-wrap;">  The Company will keep available at all times the number of shares of Common Stock reasonably required to satisfy then-outstanding Stock Awards.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">(b)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Securities Law Compliance.</b><font style="white-space:pre-wrap;">  The Company will seek to obtain from each regulatory commission or agency having jurisdiction over the Plan the authority required to grant Stock Awards and to issue and sell shares of Common Stock upon exercise of the Stock Awards; </font><i style="font-style:italic;">provided, however</i>, that this undertaking will not require the Company to register under the Securities Act the Plan, any Stock Award or any Common Stock issued or issuable pursuant to any such Stock Award. If, after reasonable efforts and at a reasonable cost, the Company is unable to obtain from any such regulatory commission or agency the authority that counsel for the Company deems necessary for the lawful issuance and sale of Common Stock under the Plan, the Company will be relieved from any liability for failure to issue and sell Common Stock upon exercise of such Stock Awards unless and until such authority is obtained. A Participant will not be eligible for the grant of a Stock Award or the subsequent issuance of cash or Common Stock pursuant to the Stock Award if such grant or issuance would be in violation of any applicable securities law.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;">10</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">(c)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">No Obligation to Notify or Minimize Taxes.</b><font style="white-space:pre-wrap;">  The Company will have no duty or obligation to any Participant to advise such holder as to the time or manner of exercising a Stock Award. Furthermore, the Company will have no duty or obligation to warn or otherwise advise such holder of a pending termination or expiration of a Stock Award or a possible period in which the Stock Award may not be exercised. The Company has no duty or obligation to minimize the tax consequences of a Stock Award to the holder of such Stock Award.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;"><b style="font-size:10pt;font-weight:bold;">9.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;"><b style="font-size:10pt;font-variant:small-caps;font-weight:bold;">Miscellaneous.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">(a)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Use of Proceeds from Sales of Common Stock.</b><font style="white-space:pre-wrap;">  Proceeds from the sale of shares of Common Stock issued pursuant to Stock Awards will constitute general funds of the Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">(b)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Corporate Action Constituting Grant of Stock Awards.</b><font style="white-space:pre-wrap;">  Corporate action constituting a grant by the Company of a Stock Award to any Participant will be deemed completed as of the date of such corporate action, unless otherwise determined by the Board, regardless of when the instrument, certificate, or letter evidencing the Stock Award is communicated to, or actually received or accepted by, the Participant. In the event that the corporate records (</font><i style="font-style:italic;">e.g</i>., Board consents, resolutions or minutes) documenting the corporate action constituting the grant contain terms (<i style="font-style:italic;">e.g</i>., exercise price, vesting schedule or number of shares) that are inconsistent with those in the Stock Award Agreement or related grant documents as a result of a clerical error in the preparation of the Stock Award Agreement or related grant documents, the corporate records will control and the Participant will have no legally binding right to the incorrect terms in the Stock Award Agreement or related grant documents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">(c)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Stockholder Rights.</b><font style="white-space:pre-wrap;">  No Participant will be deemed to be the holder of, or to have any of the rights of a holder with respect to, any shares of Common Stock subject to a Stock Award unless and until (i)&#160;such Participant has satisfied all requirements for exercise of, or the issuance of shares of Common Stock under, the Stock Award pursuant to its terms, and (ii)&#160;the issuance of the Common Stock subject to such Stock Award has been entered into the books and records of the Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">(d)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">No Employment or Other Service Rights.</b><font style="white-space:pre-wrap;">  Nothing in the Plan, any Stock Award Agreement or any other instrument executed thereunder or in connection with any Stock Award granted pursuant thereto will confer upon any Participant any right to continue to serve the Company or an Affiliate in the capacity in effect at the time the Stock Award was granted or will affect the right of the Company or an Affiliate to terminate (i)&#160;the employment of an Employee with or without notice and with or without cause, (ii)&#160;the service of a Consultant pursuant to the terms of such Consultant&#8217;s agreement with the Company or an Affiliate, or (iii)&#160;the service of a Director pursuant to the bylaws of the Company or an Affiliate, and any applicable provisions of the corporate law of the state in which the Company or the Affiliate is incorporated, as the case may be.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">(e)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Change in Time Commitment.</b><font style="white-space:pre-wrap;">  In the event a Participant&#8217;s regular level of time commitment in the performance of his or her services for the Company or any Affiliate is reduced (for example, and without limitation, if the Participant is an Employee of the Company and the Employee has a change in status from a full-time Employee to a part-time Employee) after the date of grant of any Stock Award to the Participant, the Board has the right in its sole discretion to (x)&#160;make a corresponding reduction in the number of shares or cash amount subject to any portion of such Stock Award that is scheduled to vest or become payable after the date of such change in time commitment, and (y)&#160;in lieu of or in combination with such a reduction, extend the vesting or payment schedule applicable to such Stock Award. In the event of any such reduction, the Participant will have no right with respect to any portion of the Stock Award that is so reduced or extended.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">(f)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Incentive Stock Option Limitations.</b><font style="white-space:pre-wrap;">  To the extent that the aggregate Fair Market Value (determined at the time of grant) of Common Stock with respect to which Incentive Stock Options are exercisable for the first time by any Optionholder during any calendar year (under all plans of the Company and any Affiliates) exceeds $100,000 (or such other limit established in the Code) or otherwise does not comply with the rules governing Incentive Stock Options, the Options or portions thereof that exceed such limit (according to the order in which they were granted) or otherwise do not comply with such rules will be treated as Nonstatutory Stock Options, notwithstanding any contrary provision of the applicable Option Agreement(s).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">(g)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Investment Assurances.</b><font style="white-space:pre-wrap;">  The Company may require a Participant, as a condition of exercising or acquiring Common Stock under any Stock Award, (i)&#160;to give written assurances satisfactory to the Company as to the Participant&#8217;s knowledge and experience in financial and business matters and/or to employ a purchaser representative reasonably satisfactory to the Company who is knowledgeable and experienced in financial and </font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;">11</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><font style="white-space:pre-wrap;">business matters and that he or she is capable of evaluating, alone or together with the purchaser representative, the merits and risks of exercising the Stock Award; and (ii)&#160;to give written assurances satisfactory to the Company stating that the Participant is acquiring Common Stock subject to the Stock Award for the Participant&#8217;s own account and not with any present intention of selling or otherwise distributing the Common Stock. The foregoing requirements, and any assurances given pursuant to such requirements, will be inoperative if (A)&#160;the issuance of the shares upon the exercise or acquisition of Common Stock under the Stock Award has been registered under a then currently effective registration statement under the Securities Act, or (B)&#160;as to any particular requirement, a determination is made by counsel for the Company that such requirement need not be met in the circumstances under the then applicable securities laws. The Company may, upon advice of counsel to the Company, place legends on stock certificates issued under the Plan as such counsel deems necessary or appropriate in order to comply with applicable securities laws, including, but not limited to, legends restricting the transfer of the Common Stock.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">(h)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Withholding Obligations.</b><font style="white-space:pre-wrap;">  Unless prohibited by the terms of a Stock Award Agreement, the Company may, in its sole discretion, satisfy any federal, state or local tax withholding obligation relating to a Stock Award by any of the following means or by a combination of such means: (i)&#160;causing the Participant to tender a cash payment; (ii)&#160;withholding shares of Common Stock from the shares of Common Stock issued or otherwise issuable to the Participant in connection with the Stock Award; </font><i style="font-style:italic;">provided, however,</i> that no shares of Common Stock are withheld with a value exceeding the maximum amount of tax that may be required to be withheld by law (or such other amount as may be permitted while still avoiding classification of the Stock Award as a liability for financial accounting purposes); (iii)&#160;withholding cash from a Stock Award settled in cash; (iv)&#160;withholding payment from any amounts otherwise payable to the Participant; or (v)&#160;by such other method as may be set forth in the Stock Award Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">(i)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Electronic Delivery.</b><font style="white-space:pre-wrap;">  Any reference herein to a &#8220;written&#8221; agreement or document will include any agreement or document delivered electronically, filed publicly at www.sec.gov (or any successor website thereto) or posted on the Company&#8217;s intranet (or other shared electronic medium controlled by the Company to which the Participant has access).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">(j)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Deferrals.</b><font style="white-space:pre-wrap;">  To the extent permitted by applicable law, the Board, in its sole discretion, may determine that the delivery of Common Stock or the payment of cash, upon the exercise, vesting or settlement of all or a portion of any Stock Award may be deferred and may establish programs and procedures for deferral elections to be made by Participants. Deferrals by Participants will be made in accordance with Section&#160;409A of the Code. Consistent with Section&#160;409A of the Code, the Board may provide for distributions while a Participant is still an employee or otherwise providing services to the Company or an Affiliate. The Board is authorized to make deferrals of Stock Awards and determine when, and in what annual percentages, Participants may receive payments, including lump sum payments, following the Participant&#8217;s termination of Continuous Service, and implement such other terms and conditions consistent with the provisions of the Plan and in accordance with applicable law.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">(k)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Compliance with Section&#160;409A of the Code.</b><font style="white-space:pre-wrap;">  Unless otherwise expressly provided for in a Stock Award Agreement, the Plan and Stock Award Agreements will be interpreted to the greatest extent possible in a manner that makes the Plan and the Stock Awards granted hereunder exempt from Section&#160;409A of the Code, and, to the extent not so exempt, in compliance with Section&#160;409A of the Code. To the extent that the Board determines that any Stock Award granted hereunder is not exempt from and is therefore subject to Section&#160;409A of the Code, the Stock Award Agreement evidencing such Stock Award will incorporate the terms and conditions necessary to avoid the consequences specified in Section&#160;409A(a)(1) of the Code, and, to the extent applicable, the Plan and Stock Award Agreements will be interpreted in accordance with the requirements of Section&#160;409A of the Code. Notwithstanding anything to the contrary in this Plan (and unless the Stock Award Agreement specifically provides otherwise), if the shares of Common Stock are publicly traded and a Participant holding a Stock Award that constitutes &#8220;deferred compensation&#8221; under Section&#160;409A of the Code is a &#8220;specified employee&#8221; for purposes of Section&#160;409A of the Code, no distribution or payment of any amount will be made upon a &#8220;separation from service&#8221; before a date that is six months following the date of such Participant&#8217;s &#8220;separation from service&#8221; (as defined in Section&#160;409A of the Code without regard to alternative definitions thereunder) or, if earlier, the date of the Participant&#8217;s death.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">(l)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Clawback/Recovery.</b><font style="white-space:pre-wrap;">  All Stock Awards granted under the Plan will be subject to recoupment in accordance with the clawback policy adopted by the Compensation Committee in January 2019 and then ratified by the Board of Directors, or any successor to such policy.  This clawback policy complies with the listing standards of any national securities exchange or association on which the Company&#8217;s securities are listed or as is otherwise </font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;">12</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other applicable law. In addition, the Plan Administrator may impose such other clawback, recovery or recoupment provisions in a Stock Award Agreement as the Plan Administrator determines necessary or appropriate, including but not limited to a reacquisition right in respect of previously acquired shares of Common Stock or other cash or property upon the occurrence of Cause. No recovery of compensation under such a clawback policy will be an event giving rise to a right to resign for &#8220;good reason&#8221; or &#8220;constructive termination&#8221; (or similar term) under any agreement with the Company or an Affiliate.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:10pt;font-weight:bold;">10.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:10pt;font-variant:small-caps;font-weight:bold;">Adjustments upon Changes in Common Stock; Other Corporate Events.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(a)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Capitalization Adjustments.</b><font style="white-space:pre-wrap;">  In the event of a Capitalization Adjustment, the Board will appropriately and proportionately adjust: (i)&#160;the class(es) and maximum number of securities subject to the Plan pursuant to Section&#160;3(a), (ii)&#160;the class(es) and maximum number of securities that may be issued pursuant to the exercise of Incentive Stock Options pursuant to Section&#160;3(c), and (iii)&#160; the class(es) and number of securities and price per share of stock subject to outstanding Stock Awards. The Board will make such adjustments, and its determination will be final, binding and conclusive.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(b)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Dissolution or Liquidation.</b><font style="white-space:pre-wrap;">  Except as otherwise provided in the Stock Award Agreement, in the event of a dissolution or liquidation of the Company, all outstanding Stock Awards (other than Stock Awards consisting of vested and outstanding shares of Common Stock not subject to a forfeiture condition or the Company&#8217;s right of repurchase) will terminate immediately prior to the completion of such dissolution or liquidation, and the shares of Common Stock subject to the Company&#8217;s repurchase rights or subject to a forfeiture condition may be repurchased or reacquired by the Company notwithstanding the fact that the holder of such Stock Award is providing Continuous Service, </font><i style="font-style:italic;">provided, however</i>, that the Board may, in its sole discretion, cause some or all Stock Awards to become fully vested, exercisable and/or no longer subject to repurchase or forfeiture (to the extent such Stock Awards have not previously expired or terminated) before the dissolution or liquidation is completed but contingent on its completion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(c)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Corporate Transaction.</b><font style="white-space:pre-wrap;">  The provisions of this Section&#160;10(c) will apply to Stock Awards in the event of a Corporate Transaction unless otherwise provided in the instrument evidencing the Stock Award or any other written agreement between the Company or any Affiliate and the Participant or in any director compensation policy of the Company or unless otherwise expressly provided by the Board at the time of grant of a Stock Award.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><b style="font-weight:bold;">(i)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Stock Awards May Be Assumed.</b><font style="white-space:pre-wrap;">  In the event of a Corporate Transaction, any surviving corporation or acquiring corporation (or the surviving or acquiring corporation&#8217;s parent company) may assume or continue any or all Stock Awards outstanding under the Plan or may substitute similar stock awards for Stock Awards outstanding under the Plan (including but not limited to, awards to acquire the same consideration paid to the stockholders of the Company pursuant to the Corporate Transaction), and any reacquisition or repurchase rights held by the Company in respect of Common Stock issued pursuant to Stock Awards may be assigned by the Company to the successor of the Company (or the successor&#8217;s parent company, if any), in connection with such Corporate Transaction. A surviving corporation or acquiring corporation (or its parent) may choose to assume or continue only a portion of a Stock Award or substitute a similar stock award for only a portion of a Stock Award, or may choose to assume or continue the Stock Awards held by some, but not all Participants. The terms of any assumption, continuation or substitution will be set by the Board.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 0pt 36pt;"><b style="font-weight:bold;">(ii)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Stock Awards Held by Current Participants.</b><font style="white-space:pre-wrap;">  In the event of a Corporate Transaction in which the surviving corporation or acquiring corporation (or its parent company) does not assume or continue such outstanding Stock Awards or substitute similar stock awards for such outstanding Stock Awards, then with respect to Stock Awards that have not been assumed, continued or substituted and that are held by Participants whose Continuous Service has not terminated prior to the effective time of the Corporate Transaction (referred to as the &#8220;Current Participants&#8221;), the vesting of such Stock Awards (and, with respect to Options and Stock Appreciation Rights, the time when such Stock Awards may be exercised) will be accelerated in full to a date prior to the effective time of such Corporate Transaction (contingent upon the effectiveness of the Corporate Transaction) as the Board will determine (or, if the Board does not determine such a date, to the date that is five days prior to the effective time of the </font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;">13</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 36pt;"><font style="white-space:pre-wrap;">Corporate Transaction), and such Stock Awards will terminate if not exercised (if applicable) at or prior to the effective time of the Corporate Transaction, and any reacquisition or repurchase rights held by the Company with respect to such Stock Awards will lapse (contingent upon the effectiveness of the Corporate Transaction).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><b style="font-weight:bold;">(iii)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Stock Awards Held by Persons other than Current Participants.</b><font style="white-space:pre-wrap;">  In the event of a Corporate Transaction in which the surviving corporation or acquiring corporation (or its parent company) does not assume or continue such outstanding Stock Awards or substitute similar stock awards for such outstanding Stock Awards, then with respect to Stock Awards that have not been assumed, continued or substituted and that are held by persons other than Current Participants, such Stock Awards will terminate if not exercised (if applicable) prior to the effective time of the Corporate Transaction; </font><i style="font-style:italic;">provided</i>, <i style="font-style:italic;">however</i>, that any reacquisition or repurchase rights held by the Company with respect to such Stock Awards will not terminate and may continue to be exercised notwithstanding the Corporate Transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><b style="font-weight:bold;">(iv)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Payment for Stock Awards in Lieu of Exercise.</b><font style="white-space:pre-wrap;">  Notwithstanding the foregoing, in the event a Stock Award will terminate if not exercised prior to the effective time of a Corporate Transaction, the Board may provide, in its sole discretion, that the holder of such Stock Award may not exercise such Stock Award but instead will receive a payment, in such form as may be determined by the Board, equal in value to the excess, if any, of (A)&#160;the value of the property the Participant would have received upon the exercise of the Stock Award immediately prior to the effective time of the Corporate Transaction (including, at the discretion of the Board, any unvested portion of such Stock Award), over (B)&#160;any exercise price payable by such holder in connection with such exercise. For clarity, this payment may be zero if the value of the property is equal to or less than the exercise price. Payments under this provision may be delayed to the same extent that payment of consideration to the holders of the Company&#8217;s Common Stock in connection with the Corporate Transaction is delayed as a result of escrows, earn outs, holdbacks or any other contingencies.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(d)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Change in Control.</b><font style="white-space:pre-wrap;">  A Stock Award may be subject to additional acceleration of vesting and exercisability upon or after a Change in Control as may be provided in the Stock Award Agreement for such Stock Award or as may be provided in any other written agreement between the Company or any Affiliate and the Participant, but in the absence of such provision, no such acceleration will occur. Notwithstanding the foregoing, upon a Change in Control, all Stock Awards held by each Director who is not an Employee and whose Continuous Service has not terminated immediately prior to the Change in Control shall become fully vested and exercisable immediately prior to the effectiveness of such Change in Control.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:10pt;font-weight:bold;">11.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:10pt;font-variant:small-caps;font-weight:bold;">Termination or Suspension of the Plan.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(a)</b></font>The Board may suspend or terminate the Plan at any time. No Incentive Stock Option will be granted after the tenth anniversary of the earlier of (i)&#160;the date the Plan is adopted by the Board, or (ii)&#160;the date the Plan is approved by the stockholders of the Company. No Stock Awards may be granted under the Plan while the Plan is suspended or after it is terminated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(b)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">No Impairment of Rights.</b><font style="white-space:pre-wrap;">  Suspension or termination of the Plan will not materially impair rights and obligations under any Stock Award granted while the Plan is in effect except with the written consent of the affected Participant or as otherwise permitted in the Plan.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:10pt;font-weight:bold;">12.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:10pt;font-variant:small-caps;font-weight:bold;">Effective Date of Plan.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This Plan will become effective on the Effective Date.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:10pt;font-weight:bold;">13.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:10pt;font-variant:small-caps;font-weight:bold;">Choice of Law.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The laws of the State of Delaware will govern all questions concerning the construction, validity and interpretation of this Plan, without regard to that state&#8217;s conflict of laws rules.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;">14</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:10pt;font-weight:bold;">14.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:10pt;font-variant:small-caps;font-weight:bold;">Definitions.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As used in the Plan, the following definitions will apply to the capitalized terms indicated below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(a)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Affiliate</font>&#8221; means, at the time of determination, any &#8220;parent&#8221; or &#8220;subsidiary&#8221; of the Company as such terms are defined in Rule&#160;405. The Board will have the authority to determine the time or times at which &#8220;parent&#8221; or &#8220;subsidiary&#8221; status is determined within the foregoing definition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(b)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Annual Meeting</font>&#8221; means the annual meeting of the stockholders of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(c)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Board</font>&#8221; means the Board of Directors of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(d)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Capitalization Adjustment</font>&#8221; means any change that is made in, or other events that occur with respect to, the Common Stock subject to the Plan or subject to any Stock Award after the Effective Date without the receipt of consideration by the Company through merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, reverse stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or any similar equity restructuring transaction, as that term is used in Statement of Financial Accounting Standards Board Accounting Standards Codification Topic 718 (or any successor thereto). Notwithstanding the foregoing, the conversion of any convertible securities of the Company will not be treated as a Capitalization Adjustment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(e)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Cause</font>&#8221; will have the meaning ascribed to such term in any written agreement between the Participant and the Company or an Affiliate defining such term and, in the absence of such agreement, such term will mean, with respect to a Participant, the occurrence of any of the following events: (i)&#160;such Participant&#8217;s conviction of, or plea of no contest with respect to, any crime involving fraud, dishonesty or moral turpitude; (ii)&#160;such Participant&#8217;s attempted commission of or participation in a fraud or act of dishonesty against the Company or an Affiliate that results in (or might have reasonably resulted in) material harm to the business of the Company or an Affiliate; (iii)&#160;such Participant&#8217;s intentional, material violation of any contract or agreement between the Participant and the Company or an Affiliate, or any statutory duty the Participant owes to the Company or an Affiliate; or (iv)&#160;such Participant&#8217;s conduct that constitutes gross misconduct, insubordination, incompetence or habitual neglect of duties and that results in (or might have reasonably resulted in) material harm to the business of the Company or an Affiliate. The determination that a termination of the Participant&#8217;s Continuous Service is either for Cause or without Cause will be made by the Company, in its sole discretion. Any determination by the Company that the Continuous Service of a Participant was terminated with or without Cause for the purposes of outstanding Stock Awards held by such Participant will have no effect upon any determination of the rights or obligations of the Company or an Affiliate or such Participant for any other purpose.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(f)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Change in Control</font>&#8221; will be deemed to have occurred upon the first to occur of an event set forth in any one of the following paragraphs:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(i)</b></font>the acquisition (other than from the Company, by any person (as such term is defined in Section&#160;13(c) or 14(d) of the Exchange Act) of beneficial ownership (within the meaning of Rule&#160;13d 3 promulgated under the Exchange Act) of fifty percent (50%) or more of the combined voting power of the Company&#8217;s then outstanding voting securities;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(ii)</b></font>the individuals who, as of the effective date of the Plan, are members of the Board (the &#8220;<font style="font-style:italic;font-weight:bold;">Incumbent Board</font>&#8221;), cease for any reason to constitute at least a majority of the Board, unless the election, or nomination for election by the Company&#8217;s stockholders, of any new director was approved by a vote of at least a majority of the Incumbent Board, and such new director shall, for purposes of this Plan, be considered as a member of the Incumbent Board; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(iii)</b></font>the closing of:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 0pt 72pt;"><b style="font-weight:bold;">(1)</b><font style="display:inline-block;width:24.34pt;"></font>a merger or consolidation involving the Company if the stockholders of the Company, immediately before such merger or consolidation, do not, as a result of such merger or </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;">15</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 72pt;">consolidation, own, directly or indirectly, more than fifty percent (50%) of the combined voting power of the then outstanding voting securities of the corporation resulting from such merger or consolidation in substantially the same proportion as their ownership of the combined voting power of the voting securities of the Company outstanding immediately before such merger or consolidation; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 72pt;"><b style="font-weight:bold;">(2)</b><font style="display:inline-block;width:24.34pt;"></font>a complete liquidation or dissolution of the Company or an agreement for the sale or other disposition of all or substantially all of the assets of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Notwithstanding the foregoing, a Change in Control shall not be deemed to occur solely because fifty percent (50%) or more of the combined voting power of the Company&#8217;s then outstanding securities is acquired by (i)&#160;a trustee or other fiduciary holding securities under one or more employee benefit plans maintained by the Company or any of its subsidiaries or (ii)&#160;any corporation which, immediately prior to such acquisition, is owned directly or indirectly by the stockholders of the Company in the same proportion as their ownership of stock in the Company immediately prior to such acquisition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the avoidance of doubt, the term Change in Control shall not include a sale of assets, merger or other transaction effected exclusively for the purpose of changing the domicile of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Notwithstanding the foregoing or any other provision of this Plan, the definition of Change in Control (or any analogous term) in an individual written agreement between the Company or any Affiliate and the Participant shall supersede the foregoing definition with respect to Stock Awards subject to such agreement; provided, however, that if no definition of Change in Control or any analogous term is set forth in such an individual written agreement, the foregoing definition shall apply.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(g)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Code</font>&#8221; means the Internal Revenue Code of 1986, as amended, including any applicable regulations and guidance thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(h)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Committee</font>&#8221; means a committee of one or more Directors to whom authority has been delegated by the Board in accordance with Section&#160;2(c).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(i)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Common Stock</font>&#8221; means the common stock of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(j)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Company</font>&#8221; means Rigel Pharmaceuticals,&#160;Inc., a Delaware corporation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(k)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Consultant</font>&#8221; means any person, including an advisor, who is (i)&#160;engaged by the Company or an Affiliate to render consulting or advisory services and is compensated for such services, or (ii)&#160;serving as a member of the board of directors of an Affiliate and is compensated for such services. However, service solely as a Director, or payment of a fee for such service, will not cause a Director to be considered a &#8220;Consultant&#8221; for purposes of the Plan. Notwithstanding the foregoing, a person is treated as a Consultant under this Plan only if a Form&#160;S-8 Registration Statement under the Securities Act is available to register either the offer or the sale of the Company&#8217;s securities to such person.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(l)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Continuous Service</font>&#8221; means that the Participant&#8217;s service with the Company or an Affiliate, whether as an Employee, Director or Consultant, is not interrupted or terminated. A change in the capacity in which the Participant renders service to the Company or an Affiliate as an Employee, Director or Consultant or a change in the Entity for which the Participant renders such service, provided that there is no interruption or termination of the Participant&#8217;s service with the Company or an Affiliate, will not terminate a Participant&#8217;s Continuous Service; <i style="font-style:italic;">provided, however,</i> that if the Entity for which a Participant is rendering services ceases to qualify as an Affiliate, as determined by the Board, in its sole discretion, such Participant&#8217;s Continuous Service will be considered to have terminated on the date such Entity ceases to qualify as an Affiliate. For example, a change in status from an Employee of the Company to a Consultant of an Affiliate or to a Director will not constitute an interruption of Continuous Service. To the extent permitted by law, the Board or the chief executive officer of the Company, in that party&#8217;s sole discretion, may determine whether Continuous Service will be considered interrupted in the case of (i)&#160;any leave of absence approved by the Board or chief executive officer, including sick leave, military leave or any </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;">16</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">other personal leave, or (ii)&#160;transfers between the Company, an Affiliate, or their successors. Notwithstanding the foregoing, a leave of absence will be treated as Continuous Service for purposes of vesting in a Stock Award only to such extent as may be provided in the Company&#8217;s or Affiliate&#8217;s leave of absence policy, in the written terms of any leave of absence agreement or policy applicable to the Participant, or as otherwise required by law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(m)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Corporate Transaction</font>&#8221; means the consummation, in a single transaction or in a series of related transactions, of any one or more of the following events:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(i)</b></font>a sale, lease or other disposition of all or substantially all of the assets of the Company;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(ii)</b></font>a sale or other disposition of at least ninety percent (90%) of the outstanding securities of the Company;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(iii)</b></font>a merger, consolidation or similar transaction in which the Company is not the surviving corporation; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(iv)</b></font>a reverse merger, consolidation or similar transaction in which the Company is the surviving corporation but the shares of Common Stock outstanding immediately preceding the merger, consolidation or similar transaction are converted by virtue of the merger, consolidation or similar transaction into other property, whether in the form of securities, cash or otherwise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Notwithstanding the foregoing definition or any other provision of this Plan, the term Corporate Transaction will not include a sale of assets, merger or other transaction effected exclusively for the purpose of changing the domicile of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(n)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Director</font>&#8221; means a member of the Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(o)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Disability</font>&#8221; means, with respect to a Participant, the inability of such Participant to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment that can be expected to result in death or that has lasted or can be expected to last for a continuous period of not less than 12&#160;months, as provided in Sections&#160;22(e)(3) and 409A(a)(2)(c)(i) of the Code, and will be determined by the Board on the basis of such medical evidence as the Board deems warranted under the circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(p)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Effective Date</font>&#8221; means the effective date of this Plan document, which is the date of the annual meeting of stockholders of the Company held in 2018, provided this Plan is approved by the Company&#8217;s stockholders at such meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(q)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Employee</font>&#8221; means any person employed by the Company or an Affiliate. However, service solely as a Director, or payment of a fee for such services, will not cause a Director to be considered an &#8220;Employee&#8221; for purposes of the Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(r)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Entity</font>&#8221; means a corporation, partnership, limited liability company or other entity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(s)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Exchange Act</font>&#8221; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(t)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Fair Market Value</font>&#8221; means, as of any date, the value of the Common Stock determined as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(i)</b></font>If the Common Stock is listed on any established stock exchange or traded on any established market, the Fair Market Value of a share of Common Stock will be, unless otherwise determined by the Board, the closing sales price for such stock as quoted on such exchange or market (or the exchange or market with the greatest volume of trading in the Common Stock) on the date of determination, as reported in a source the Board deems reliable.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;">17</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(ii)</b></font>Unless otherwise provided by the Board, if there is no closing sales price for the Common Stock on the date of determination, then the Fair Market Value will be the closing selling price on the last preceding date for which such quotation exists.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(iii)</b></font>In the absence of such markets for the Common Stock, the Fair Market Value will be determined by the Board in good faith and in a manner that complies with Sections&#160;409A and 422 of the Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(u)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Full Value Award</font>&#8221; means a Stock Award that is not an Option or SAR with respect to which the exercise or strike price is at least 100% of the Fair Market Value of the Common Stock subject to the Option or SAR on the date of grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(v)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Incentive Stock Option</font>&#8221; means an option granted pursuant to Section&#160;6 that is intended to be, and that qualifies as, an &#8220;incentive stock option&#8221; within the meaning of Section&#160;422 of the Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(w)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Non-Employee Director</font>&#8221; means a Director who either (i)&#160;is not a current employee or officer of the Company or an Affiliate, does not receive compensation, either directly or indirectly, from the Company or an Affiliate for services rendered as a consultant or in any capacity other than as a Director (except for an amount as to which disclosure would not be required under Item&#160;404(a) of Regulation&#160;S-K promulgated pursuant to the Securities Act (&#8220;<font style="font-style:italic;font-weight:bold;">Regulation&#160;S-K</font>&#8221;)), does not possess an interest in any other transaction for which disclosure would be required under Item&#160;404(a) of Regulation&#160;S-K, and is not engaged in a business relationship for which disclosure would be required pursuant to Item&#160;404(b) of Regulation&#160;S-K; or (ii)&#160;is otherwise considered a &#8220;non-employee director&#8221; for purposes of Rule&#160;16b-3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(x)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Nonstatutory Stock Option</font>&#8221; means any option granted pursuant to Section&#160;6 that does not qualify as an Incentive Stock Option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(y)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Officer</font>&#8221; means a person who is an officer of the Company within the meaning of Section&#160;16 of the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(z)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Option</font>&#8221; means an Incentive Stock Option or a Nonstatutory Stock Option to purchase shares of Common Stock granted pursuant to the Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(aa)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Option Agreement</font>&#8221; means a written agreement between the Company and an Optionholder evidencing the terms and conditions of an Option grant. Each Option Agreement will be subject to the terms and conditions of the Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(bb)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Optionholder</font>&#8221; means a person to whom an Option is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(cc)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Other Stock Award</font>&#8221; means an award based in whole or in part by reference to the Common Stock which is granted pursuant to the terms and conditions of Section&#160;7(d).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(dd)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Other Stock Award Agreement</font>&#8221; means a written agreement between the Company and a holder of an Other Stock Award evidencing the terms and conditions of an Other Stock Award grant. Each Other Stock Award Agreement will be subject to the terms and conditions of the Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(ee)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Own,</font>&#8221; &#8220;<font style="font-style:italic;font-weight:bold;">Owned,</font>&#8221; &#8220;<font style="font-style:italic;font-weight:bold;">Owner,</font>&#8221; &#8220;<font style="font-style:italic;font-weight:bold;">Ownership</font>&#8221; A person or Entity will be deemed to &#8220;Own,&#8221; to have &#8220;Owned,&#8221; to be the &#8220;Owner&#8221; of, or to have acquired &#8220;Ownership&#8221; of securities if such person or Entity, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise, has or shares voting power, which includes the power to vote or to direct the voting, with respect to such securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(ff)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Participant</font>&#8221; means a person to whom a Stock Award is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Stock Award.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;">18</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(gg)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Performance Criteria</font>&#8221; means the one or more criteria that the Board shall select for purposes of establishing the Performance Goals for a Performance Period. The Performance Criteria that shall be used to establish such Performance Goals may be based on any one of, or combination of, the following: (i)&#160;earnings per share; (ii)&#160;earnings before interest, taxes and depreciation; (iii)&#160;earnings before interest, taxes, depreciation and amortization (EBITDA); (iv)&#160;net earnings; (v)&#160;total stockholder return; (vi)&#160;return on equity; (vii)&#160;return on assets, investment, or capital employed; (viii)&#160;operating margin; (ix)&#160;gross margin; (x)&#160;operating income; (xi)&#160;net income (before or after taxes); (xii)&#160;net operating income; (xiii)&#160;net operating income after tax; (xiv)&#160;pre- and after-tax income; (xv)&#160;pre-tax profit; (xvi)&#160;operating cash flow; (xvii)&#160;sales or revenue targets; (xviii)&#160;increases in revenue or product revenue; (xix)&#160;expenses and cost reduction goals; (xx)&#160;improvement in or attainment of expense levels; (xxi)&#160;improvement in or attainment of working capital levels; (xxii)&#160;economic value added (or an equivalent metric); (xxiii)&#160;market share; (xxiv)&#160;cash flow; (xxv)&#160;cash flow per share; (xxvi)&#160;share price performance; (xxvii)&#160;debt reduction; (xxviii)&#160;implementation or completion of projects or processes; (xxix)&#160;customer satisfaction; (xxx)&#160;total stockholder return; (xxxi)&#160;stockholders&#8217; equity; and (xxxii)&#160;other measures of performance selected by the Board. Partial achievement of the specified criteria may result in the payment or vesting corresponding to the degree of achievement as specified in the Stock Award Agreement. The Board shall, in its sole discretion, define the manner of calculating the Performance Criteria it selects to use for such Performance Period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(hh)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Performance Goals</font>&#8221; means, for a Performance Period, the one or more goals established by the Board for the Performance Period based upon the Performance Criteria. Performance Goals may be based on a Company-wide basis, with respect to one or more business units, divisions, Affiliates, or business segments, and in either absolute terms or relative to the performance of one or more comparable companies or the performance of one or more relevant indices. The Board is authorized at any time in its sole discretion, to adjust or modify the calculation of a Performance Goal for such Performance Period in order to prevent the dilution or enlargement of the rights of Participants, (a)&#160;in the event of, or in anticipation of, any unusual or extraordinary corporate item, transaction, event or development; (b)&#160;in recognition of, or in anticipation of, any other unusual or nonrecurring events affecting the Company, or the financial statements of the Company in response to, or in anticipation of, changes in applicable laws, regulations, accounting principles, or business conditions; or (c)&#160;in view of the Board&#8217;s assessment of the business strategy of the Company, performance of comparable organizations, economic and business conditions, and any other circumstances deemed relevant. Specifically, the Board is authorized to make adjustment in the method of calculating attainment of Performance Goals and objectives for a Performance Period as follows: (i)&#160;to exclude the dilutive effects of acquisitions or joint ventures; (ii)&#160;to assume that any business divested by the Company achieved performance objectives at targeted levels during the balance of a Performance Period following such divestiture; and (iii)&#160;to exclude the effect of any change in the outstanding shares of common stock of the Company by reason of any stock dividend or split, stock repurchase, reorganization, recapitalization, merger, consolidation, spin-off, combination or exchange of shares or other similar corporate change, or any distributions to common stockholders other than regular cash dividends. In addition, the Board is authorized to make adjustment in the method of calculating attainment of Performance Goals and objectives for a Performance Period as follows: (i)&#160;to exclude restructuring and/or other nonrecurring charges; (ii)&#160;to exclude exchange rate effects, as applicable, for non-U.S. dollar denominated net sales growth and operating earnings; (iii)&#160;to exclude the effects of changes to generally accepted accounting standards required by the Financial Accounting Standards Board; (iv)&#160;to exclude the effects of any items that are &#8220;unusual&#8221; in nature or occur &#8220;infrequently&#8221; as determined under generally accepted accounting principles; (v)&#160;to exclude the effects to any statutory adjustments to corporate tax rates; and (vi)&#160;to make other appropriate adjustments selected by the Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(ii)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Performance Period</font>&#8221; means the period of time selected by the Board over which the attainment of one or more Performance Goals will be measured for the purpose of determining a Participant&#8217;s right to and the payment of a Performance Stock Award. Performance Periods may be of varying and overlapping duration, at the sole discretion of the Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(jj)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Performance Stock Award</font>&#8221; means a Stock Award granted under the terms and conditions of Section&#160;7(c)(i).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(kk)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Plan</font>&#8221; means this Rigel Pharmaceuticals,&#160;Inc. 2018 Equity Incentive Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(ll)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Restricted Stock Award</font>&#8221; means an award of shares of Common Stock which is granted pursuant to the terms and conditions of Section&#160;7(a).</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;">19</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(mm)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Restricted Stock Award Agreement</font>&#8221; means a written agreement between the Company and a holder of a Restricted Stock Award evidencing the terms and conditions of a Restricted Stock Award grant. Each Restricted Stock Award Agreement will be subject to the terms and conditions of the Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(nn)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Restricted Stock Unit Award</font>&#8221; means a right to receive shares of Common Stock which is granted pursuant to the terms and conditions of Section&#160;7(b).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(oo)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Restricted Stock Unit Award Agreement</font>&#8221; means a written agreement between the Company and a holder of a Restricted Stock Unit Award evidencing the terms and conditions of a Restricted Stock Unit Award grant. Each Restricted Stock Unit Award Agreement will be subject to the terms and conditions of the Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(pp)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Rule&#160;16b-3</font>&#8221; means Rule&#160;16b-3 promulgated under the Exchange Act or any successor to Rule&#160;16b-3, as in effect from time to time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(qq)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Rule&#160;405</font>&#8221; means Rule&#160;405 promulgated under the Securities Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(rr)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Securities Act</font>&#8221; means the Securities Act of 1933, as amended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(ss)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Stock Appreciation Right</font>&#8221; or &#8220;<font style="font-style:italic;font-weight:bold;">SAR</font>&#8221; means a right to receive the appreciation on Common Stock that is granted pursuant to the terms and conditions of Section&#160;6.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(tt)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Stock Appreciation Right Agreement</font>&#8221; means a written agreement between the Company and a holder of a Stock Appreciation Right evidencing the terms and conditions of a Stock Appreciation Right grant. Each Stock Appreciation Right Agreement will be subject to the terms and conditions of the Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(uu)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Stock Award</font>&#8221; means any right to receive Common Stock granted under the Plan, including an Incentive Stock Option, a Nonstatutory Stock Option, a Stock Appreciation Right, a Restricted Stock Award, a Restricted Stock Unit Award, a Performance Stock Award or any Other Stock Award.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(vv)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Stock Award Agreement</font>&#8221; means a written agreement between the Company and a Participant evidencing the terms and conditions of a Stock Award grant. Each Stock Award Agreement will be subject to the terms and conditions of the Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(ww)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Subsidiary</font>&#8221; means, with respect to the Company, (i)&#160;any corporation of which more than 50% of the outstanding capital stock having ordinary voting power to elect a majority of the board of directors of such corporation (irrespective of whether, at the time, stock of any other class or classes of such corporation will have or might have voting power by reason of the happening of any contingency) is at the time, directly or indirectly, Owned by the Company, and (ii)&#160;any partnership, limited liability company or other entity in which the Company has a direct or indirect interest (whether in the form of voting or participation in profits or capital contribution) of more than 50%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(xx)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Ten Percent Stockholder</font>&#8221; means a person who Owns (or is deemed to Own pursuant to Section&#160;424(d) of the Code) stock possessing more than 10% of the total combined voting power of all classes of stock of the Company or any Affiliate. </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;">20</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>rigl-20230630xex10d2.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 7/31/2023 08:05:49 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 10.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;"><a name="OLE_LINK4"></a><a name="OLE_LINK3"></a></font><b style="font-variant:small-caps;font-weight:bold;">Rigel Pharmaceuticals, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">Inducement Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">Adopted by the Compensation Committee: October 10, 2016</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">Amended by the Compensation Committee: January 3, 2017</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">Amended by the Compensation Committee: August 16, 2017</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">Amended by the Compensation Committee: November 7, 2017</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">Amended by the Compensation Committee: December 23, 2017</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">Amended by the Compensation Committee: January 24, 2018</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">Amended by the Compensation Committee: August 19, 2020 </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">Amended by the Compensation Committee: September 30, 2021</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">Amended by the Compensation Committee: January 4, 2022</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">Amended by the Compensation Committee: </b><b style="font-family:'Times New Roman Bold';font-variant:small-caps;font-weight:bold;">April 4, 2022</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">Amended by the Compensation Committee: </b><b style="font-family:'Times New Roman Bold';font-variant:small-caps;font-weight:bold;">December 8, 2022</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">Amended by the Compensation Committee: </b><b style="font-family:'Times New Roman Bold';font-variant:small-caps;font-weight:bold;">April 4, 2023</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">Amended by the Compensation Committee: </b><b style="font-family:'Times New Roman Bold';font-variant:small-caps;font-weight:bold;">July 6, 2023</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt 0pt 6pt 0pt;"><font style="font-size:10pt;font-variant:small-caps;font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><a name="_Ref92447064"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-variant:small-caps;font-weight:bold;">General.</b></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><a name="_DV_M7"></a><a name="_Ref98825084"></a><a name="_Ref92447068"></a><b style="font-weight:bold;">Eligible Stock Award Recipients.</b> The only persons eligible to receive grants of Stock Awards under this Plan are individuals who satisfy the standards for inducement grants under NASDAQ Marketplace Rule 5635(c)(4) and the related guidance under NASDAQ IM 5635-1. A person who previously served as an Employee or Director will not be eligible to receive Stock Awards under the Plan, other than following a <i style="font-style:italic;">bona fide</i> period of non-employment. Persons eligible to receive grants of Stock Awards under this Plan are referred to in this Plan as &#8220;<font style="font-style:italic;font-weight:bold;">Eligible Employees</font>&#8221;. These Stock Awards must be approved by either a majority of the Company&#39;s &#8220;<font style="font-style:italic;font-weight:bold;">Independent Directors</font>&#8221; (as such term is defined in NASDAQ Listing Rule 5605(a)(2)) or the Company&#8217;s compensation committee, provided such committee is comprised solely of Independent Directors (the &#8220;<font style="font-style:italic;font-weight:bold;">Independent Compensation Committee</font>&#8221;) in order to comply with the exemption from the stockholder approval requirement for &#8220;inducement grants&#8221; provided under Rule 5635(c)(4) of the NASDAQ Listing Rules. NASDAQ Marketplace Rule 5635(c)(4) and the related guidance under NASDAQ IM 5635-1 are referred to in this Plan as the &#8220;<font style="font-style:italic;font-weight:bold;">Inducement Award Rules</font>&#8221;.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><b style="font-weight:bold;">Available Awards.</b> The Plan provides for the grant of Options and&#160;Restricted Stock Unit Awards<a name="_DV_M8"></a>. All Options will be Nonstatutory Stock Options. Awards intended to qualify as stockholder-approved performance based compensation for purposes of Section 162(m) of the Code may not be granted under this Plan. </div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font><b style="font-weight:bold;">Purpose.</b> This Plan, through the granting of Stock Awards, is intended to provide (i) an inducement material for certain individuals to enter into employment with the Company within the meaning of Rule 5635(c)(4) of the NASDAQ Listing Rules, (ii) incentives for such persons to exert maximum efforts for the success of the Company and any Affiliate and (iii) a means by which Eligible Employees may be given an opportunity to benefit from increases in value of the Common Stock through the granting of Stock Awards.</div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><a name="_Ref92447603"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Administration.</b></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><b style="font-weight:bold;">Administration by Board.</b> The Board will administer the Plan, provided, however, that Stock Awards may only be granted by either (i) a majority of the Company&#39;s Independent Directors or (ii) the Independent </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;">1</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;">Compensation Committee. Subject to those constraints and the other constraints of the Inducement Award Rules, the Board may delegate some of its powers of administration of the Plan to a Committee, as provided in Section 2(c). </div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><b style="font-weight:bold;">Powers of Board.</b> The Board will have the power, subject to, and within the limitations of, the express provisions of the Plan and the Inducement Award Rules:</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(i)</font>To determine: (A)&#160;who will be granted Stock Awards; (B)&#160;when and how each Stock Award will be granted; (C)&#160;what type of Stock Award will be granted; (D)&#160;the provisions of each Stock Award (which need not be identical), including when a person will be permitted to exercise or otherwise receive cash or Common Stock under the Stock Award; (E)&#160;the number of shares of Common Stock subject to, or the cash value of, a Stock Award; and (F) the Fair Market Value applicable to a Stock Award; provided, however, that Stock Awards may only be granted by either (i) a majority of the Company&#39;s Independent Directors or (ii) the Independent Compensation Committee.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(ii)</font>To construe and interpret the Plan and Stock Awards granted under it, and to establish, amend and revoke rules and regulations for administration of the Plan and Stock Awards. The Board, in the exercise of these powers, may correct any defect, omission or inconsistency in the Plan or in any Stock Award Agreement, in a manner and to the extent it will deem necessary or expedient to make the Plan or Stock Award fully effective.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(iii)</font>To settle all controversies regarding the Plan and Stock Awards granted under it.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(iv)</font>To accelerate, in whole or in part, the time at which a Stock Award may be exercised or vest (or at which cash or shares of Common Stock may be issued). </div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(v)</font>To suspend or terminate the Plan at any time. Except as otherwise provided in the Plan or a Stock Award Agreement, suspension or termination of the Plan will not materially impair a Participant&#8217;s rights under his or her then-outstanding Stock Award without his or her written consent except as provided in subsection (viii) below.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(vi)</font>To amend the Plan in any respect the Board deems necessary or advisable, including, without limitation, adopting amendments relating to nonqualified deferred compensation under Section 409A of the Code and/or making the Plan or Stock Awards granted under the Plan exempt from or compliant with the requirements for nonqualified deferred compensation under Section 409A of the Code, subject to the limitations, if any, of applicable law. If required by applicable law or listing requirements, and except as provided in Section&#160;9(a) relating to Capitalization Adjustments, the Company will seek stockholder approval of any amendment of the Plan that (A)&#160;materially increases the number of shares of Common Stock available for issuance under the Plan, (B)&#160;materially expands the class of individuals eligible to receive Stock Awards under the Plan, (C)&#160;materially increases the benefits accruing to Participants under the Plan, (D)&#160;materially reduces the price at which shares of Common Stock may be issued or purchased under the Plan, (E)&#160;materially extends the term of the Plan, or (F)&#160;materially expands the types of Stock Awards available for issuance under the Plan. Except as otherwise provided in the Plan (including subsection (viii) below) or a Stock Award Agreement, no amendment of the Plan will materially impair a Participant&#8217;s rights under an outstanding Stock Award without the Participant&#8217;s written consent. </div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(vii)</font>To submit any amendment to the Plan for stockholder approval, including, but not limited to, amendments to the Plan intended to satisfy the requirements of Rule 16b-3 of Exchange Act or any successor rule.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(viii)</font>To approve forms of Stock Award Agreements for use under the Plan and to amend the terms of any one or more outstanding Stock Awards, including, but not limited to, amendments to provide terms more favorable to the Participant than previously provided in the Stock Award Agreement, subject to any specified limits in the Plan that are not subject to Board discretion. A Participant&#8217;s rights under any Stock Award will not be impaired by any such amendment unless the Company requests the consent of the affected Participant, and the Participant consents in writing. However, a Participant&#8217;s rights will not be deemed to have been impaired by any such amendment if the Board, in its sole discretion, determines that the amendment, taken as a whole, does not materially impair the Participant&#8217;s rights. In addition, subject to the limitations of applicable law, if any, the Board may amend the terms of any one or more Stock Awards without the affected Participant&#8217;s consent (A)&#160;to clarify the manner of exemption from, </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;">2</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;">or to bring the Stock Award into compliance with, Section 409A of the Code, or (B)&#160;to comply with other applicable laws or listing requirements.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(ix)</font>Generally, to exercise such powers and to perform such acts as the Board deems necessary or expedient to promote the best interests of the Company and that are not in conflict with the provisions of the Plan and/or Stock Award Agreements.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(x)</font>To adopt such procedures and sub-plans as are necessary or appropriate (A) to permit participation in the Plan by individuals who are foreign nationals or employed outside the United States or (B) allow Stock Awards to qualify for special tax treatment in a foreign jurisdiction; <i style="font-style:italic;">provided</i> that Board approval will not be necessary for immaterial modifications to the Plan or any Stock Award Agreement that are required for compliance with the laws of the relevant foreign jurisdiction.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font><a name="_Ref92447106"></a><b style="font-weight:bold;">Delegation to Committee.</b> </div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(i)</font><b style="font-weight:bold;">General. </b>The Board may delegate some or all of the administration of the Plan to a Committee or Committees. If administration of the Plan is delegated to a Committee, the Committee will have, in connection with the administration of the Plan, the powers theretofore possessed by the Board that have been delegated to the Committee, including the power to delegate to a subcommittee of the Committee any of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Board will thereafter be to the Committee or subcommittee). Any delegation of administrative powers will be reflected in resolutions, not inconsistent with the provisions of the Plan, adopted from time to time by the Board or Committee (as applicable). The Committee may, at any time, abolish the subcommittee and/or revest in the Committee any powers delegated to the subcommittee. The Board may retain the authority to concurrently administer the Plan with the Committee and may, at any time, revest in the Board some or all of the powers previously delegated.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(ii)</font><b style="font-weight:bold;">Rule 16b-3 Compliance.</b> The Committee may consist solely of two or more Non-Employee Directors, in accordance with Rule 16b-3 of the Exchange Act.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(d)</font><a name="_DV_M77"></a><a name="_DV_M78"></a><a name="_DV_M79"></a><a name="_DV_M80"></a><b style="font-weight:bold;">Effect of Board&#8217;s Decision.</b> All determinations, interpretations and constructions made by the Board in good faith will not be subject to review by any person and will be final, binding and conclusive on all persons.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(e)</font><b style="font-weight:bold;">Cancellation and Re-Grant of Stock Awards</b>. &#160;Neither the Board nor any Committee will have the authority to: (i) reduce the exercise, purchase or strike price of any outstanding Option, or (ii) cancel any outstanding Option that has an exercise price or strike price greater than the current Fair Market Value of the Common Stock in exchange for cash or other Stock Awards under the Plan, unless the stockholders of the Company have approved such an action within twelve (12) months prior to such an event.</div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Shares Subject to the Plan.</b></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><a name="_Ref126996582"></a><a name="_Ref38179407"></a><b style="font-weight:bold;">Share Reserve</b>. <a name="OLE_LINK7"></a><a name="OLE_LINK8"></a></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(i)</font>Subject to Section 9(a) relating to Capitalization Adjustments, the aggregate number of shares of Common Stock that may be issued pursuant to Stock Awards will not exceed 4,784,000 shares (the &#8220;<font style="font-style:italic;font-weight:bold;">Share Reserve</font>&#8221;). &#160;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(ii)</font>Shares may be issued under the terms of this Plan in connection with a merger or acquisition as permitted by NASDAQ Listing Rule 5635(c), NYSE Listed Company Manual Section 303A.08, AMEX Company Guide Section 711 or other applicable rule, and such issuance will not reduce the number of shares available for issuance under the Plan.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><a name="_Ref134435282"></a><a name="_Ref126997548"></a><b style="font-weight:bold;">Reversion of Shares to the Share Reserve</b>. &#160;If a Stock Award or any portion of a Stock Award (i)&#160;expires or otherwise terminates without all of the shares covered by the Stock Award having been issued or (ii)&#160;is settled in cash (<i style="font-style:italic;">i.e.</i>, the Participant receives cash rather than stock), such expiration, termination or settlement will nevertheless reduce (or otherwise offset) the number of shares of Common Stock that are available for issuance under </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;">3</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;">the Plan. If any shares of Common Stock issued under a Stock Award are forfeited back to or repurchased by the Company because of the failure to meet a contingency or condition required to vest such shares in the Participant, then the shares that are forfeited or repurchased will not revert to and again become available for issuance under the Plan. Any shares reacquired by the Company in satisfaction of tax withholding obligations on a Stock Award or as consideration for the exercise or purchase price of a Stock Award will not again become available for issuance under the Plan. </div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font><b style="font-weight:bold;">Source of Shares.</b> The stock issuable under the Plan will be shares of authorized but unissued or reacquired Common Stock, including shares repurchased by the Company on the open market or otherwise.</div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Eligibility.</b></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><b style="font-weight:bold;">Eligibility for Specific Stock Awards.</b> Stock Awards may only be granted to persons who are Eligible Employees described in Section 1(a) of the Plan, where the Stock Award is an inducement material to the individual&#8217;s entering into employment with the Company or an Affiliate within the meaning of Rule 5635(c)(4) of the NASDAQ Listing Rules, <i style="font-style:italic;">provided however</i>, that Stock Awards may not be granted to Eligible Employees who are providing Continuous Service only to any &#8220;parent&#8221; of the Company, as such term is defined in Rule&#160;405 of the Securities Act, unless (i) the stock underlying such Stock Awards is treated as &#8220;service recipient stock&#8221; under Section 409A of the Code (for example, because the Stock Awards are granted pursuant to a corporate transaction such as a spin off transaction), or (ii) the Company, in consultation with its legal counsel, has determined that such Stock Awards are otherwise exempt from or comply with the distribution requirements of Section 409A of the Code. </div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><a name="_DV_M89"></a><a name="_Ref92447500"></a><b style="font-weight:bold;">Approval Requirements.</b> All Stock Awards must be granted either by a majority of the Company&#8217;s independent directors or the Independent Compensation Committee. </div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">5.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><a name="_Ref92447517"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Provisions Relating to Options.</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Each Option will be in such form and will contain such terms and conditions as the Board deems appropriate. All Options will be Nonstatutory Stock Options. The provisions of separate Options need not be identical; <i style="font-style:italic;">provided, however</i>, that each Option Agreement will conform to (through incorporation of provisions hereof by reference in the applicable Option Agreement or otherwise) the substance of each of the following provisions:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><b style="font-weight:bold;">Term.</b> No Option will be exercisable after the expiration of 10 years from the date of its grant or such shorter period specified in the Option Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><b style="font-weight:bold;">Exercise Price.</b> The exercise or strike price of each Option will be not less than 100% of the Fair Market Value of the Common Stock subject to the Option on the date the Option is granted. Notwithstanding the foregoing, an Option may be granted with an exercise price lower than 100% of the Fair Market Value of the Common Stock subject to the Option if such Option is granted pursuant to an assumption of or substitution for another option or stock appreciation right pursuant to a Corporate Transaction and in a manner consistent with the provisions of Section 409A of the Code. </div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font><a name="_Ref92447428"></a><b style="font-weight:bold;">Purchase Price for Options.</b> The purchase price of Common Stock acquired pursuant to the exercise of an Option may be paid, to the extent permitted by applicable law and as determined by the Board in its sole discretion, by any combination of the methods of payment set forth below. The Board will have the authority to grant Options that do not permit all of the following methods of payment (or otherwise restrict the ability to use certain methods) and to grant Options that require the consent of the Company to use a particular method of payment. The permitted methods of payment are as follows:</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(i)</font>by cash, check, bank draft or money order payable to the Company;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(ii)</font>pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the issuance of the stock subject to the Option, results in either the receipt of cash (or </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;">4</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;">check) by the Company or the receipt of irrevocable instructions to pay the aggregate exercise price to the Company from the sales proceeds;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(iii)</font>by delivery to the Company (either by actual delivery or attestation) of shares of Common Stock;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(iv)</font>by a &#8220;net exercise&#8221; arrangement pursuant to which the Company will reduce the number of shares of Common Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price; <i style="font-style:italic;">provided, however</i>, that the Company will accept a cash or other payment from the Participant to the extent of any remaining balance of the aggregate exercise price not satisfied by such reduction in the number of whole shares to be issued. Shares of Common Stock will no longer be subject to an Option and will not be exercisable thereafter to the extent that (A) shares issuable upon exercise are used to pay the exercise price pursuant to the &#8220;net exercise,&#8221; (B) shares are delivered to the Participant as a result of such exercise, and (C) shares are withheld to satisfy tax withholding obligations; or</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(v)</font>in any other form of legal consideration that may be acceptable to the Board and specified in the applicable Option Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(d)</font><b style="font-weight:bold;">Transferability of Options.</b> The Board may, in its sole discretion, impose such limitations on the transferability of Options as the Board will determine. In the absence of such a determination by the Board to the contrary, the following restrictions on the transferability of Options will apply:</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(i)</font><b style="font-weight:bold;">Restrictions on Transfer.</b> An Option will not be transferable except by will or by the laws of descent and distribution (or pursuant to subsections (ii) and (iii) below), and will be exercisable during the lifetime of the Participant only by the Participant. The Board may permit transfer of the Option in a manner that is not prohibited by applicable tax and securities laws. Except as explicitly provided in the Plan, an Option may not be transferred for consideration. </div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(ii)</font><b style="font-weight:bold;">Domestic Relations Orders.</b> Subject to the approval of the Board or a duly authorized Officer, an Option may be transferred pursuant to the terms of a domestic relations order, official marital settlement agreement <a name="_DV_C240"></a>or other divorce or separation instrument. </div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(iii)</font><b style="font-weight:bold;">Beneficiary Designation.</b> Subject to the approval of the Board or a duly authorized Officer, a Participant may, by delivering written notice to the Company, in a form approved by the Company (or the designated broker), designate a third party who, on the death of the Participant, will thereafter be entitled to exercise the Option and receive the Common Stock or other consideration resulting from such exercise. In the absence of such a designation, the executor or administrator of the Participant&#8217;s estate will be entitled to exercise the Option and receive the Common Stock or other consideration resulting from such exercise. However, the Company may prohibit designation of a beneficiary at any time, including due to any conclusion by the Company that such designation would be inconsistent with the provisions of applicable laws.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(e)</font><a name="_Ref92447444"></a><b style="font-weight:bold;">Vesting Generally.</b> The total number of shares of Common Stock subject to an Option may vest and therefore become exercisable in periodic installments that may or may not be equal. The Option may be subject to such other terms and conditions on the time or times when it may or may not be exercised (which may be based on the satisfaction of performance goals or other criteria) as the Board may deem appropriate. The vesting provisions of individual Options may vary. The provisions of this Section 5(e) are subject to any Option provisions governing the minimum number of shares of Common Stock as to which an Option may be exercised.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(f)</font><b style="font-weight:bold;">Termination of Continuous Service.</b> Except as otherwise provided in the applicable Option Agreement or other agreement between the Participant and the Company, if a Participant&#8217;s Continuous Service terminates (other than for Cause and other than upon the Participant&#8217;s death or Disability), the Participant may exercise his or her Option (to the extent that the Participant was entitled to exercise such Option as of the date of termination of Continuous Service) within the period of time ending on the earlier of (i) the date which occurs 3 months following the termination of the Participant&#8217;s Continuous Service<a name="_DV_C248"></a>, and (ii) the expiration of the term of the Option as set forth in </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;">5</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;">the Option Agreement. If, after termination of Continuous Service, the Participant does not exercise his or her Option within the applicable time frame, the Option will terminate.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(g)</font><a name="_DV_M102"></a><b style="font-weight:bold;">Extension of Termination Date.</b> Except as otherwise provided in the applicable Stock Award Agreement, if the exercise of an Option following the termination of the Participant&#8217;s Continuous Service (other than for Cause and other than upon the Participant&#8217;s death or Disability) would be prohibited at any time solely because the issuance of shares of Common Stock would violate the registration requirements under the Securities Act, then the Option will terminate on the earlier of (i) the expiration of a total period of time (that need not be consecutive) equal to the applicable post-termination exercise period after the termination of the Participant&#8217;s Continuous Service during which the exercise of the Option would not be in violation of such registration requirements, and (ii) the expiration of the term of the Option as set forth in the applicable Option Agreement.<a name="OLE_LINK5"></a><a name="OLE_LINK6"></a> In addition, unless otherwise provided in a Participant&#8217;s Option Agreement, if the sale of any Common Stock received upon exercise of an Option following the termination of the Participant&#8217;s Continuous Service (other than for Cause) would violate the Company&#8217;s insider trading policy, then the Option will terminate on the earlier of (i) the expiration of a period of days or months (that need not be consecutive) equal to the applicable post-termination exercise period after the termination of the Participant&#8217;s Continuous Service during which the sale of the Common Stock received upon exercise of the Option would not be in violation of the Company&#8217;s insider trading policy, or (ii) the expiration of the term of the Option as set forth in the applicable Option Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(h)</font><a name="_DV_M103"></a><b style="font-weight:bold;">Disability of Participant.</b> Except as otherwise provided in the applicable Option Agreement or other agreement between the Participant and the Company, if a Participant&#8217;s Continuous Service terminates as a result of the Participant&#8217;s Disability, the Participant may exercise his or her Option (to the extent that the Participant was entitled to exercise such Option as of the date of termination of Continuous Service), but only within such period of time ending on the earlier of (i) the date 12 months following such te<a name="_DV_C268"></a>rmination of Continuous Service<font style="color:#ff0000;"> </font>and (ii) the expiration of the term of the Option as set forth in the Option Agreement. If, after termination of Continuous Service, the Participant does not exercise his or her Option within the applicable time frame, the Option will terminate.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(i)</font><a name="_DV_M104"></a><b style="font-weight:bold;">Death of Participant.</b><a name="_DV_M105"></a> Except as otherwise provided in the applicable Option Agreement or other agreement between the Participant and the Company, if (i) a Participant&#8217;s Continuous Service terminates as a result of the Participant&#8217;s death, or (ii) the Participant dies within the period (if any) specified in the Option Agreement for exercisability after the termination of the Participant&#8217;s Continuous Service for a reason other than death, then the Option may be exercised (to the extent the Participant was entitled to exercise such Option as of the date of death) by the Participant&#8217;s estate, by a person who acquired the right to exercise the Option by bequest or inheritance or by a person designated to exercise the Option upon the Participant&#8217;s death, but only within the period ending on the earlier of (i) the date 18 months following the date of death<a name="_DV_C274"></a><font style="color:#ff0000;">,</font> and (ii) the expiration of the term of such Option as set forth in the Option Agreement. If, after the Participant&#8217;s death, the Option is not exercised within the applicable time frame, the Option will terminate.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(j)</font><a name="_DV_M106"></a><a name="_DV_M107"></a><b style="font-weight:bold;">Termination for Cause. </b>Except as explicitly provided otherwise in a Participant&#8217;s Stock Award Agreement or other individual written agreement between the Company or any Affiliate and the Participant, if a Participant&#8217;s Continuous Service is terminated for Cause, the Option will terminate upon the date on which the event giving rise to the termination for Cause first occurred, and the Participant will be prohibited from exercising his or her Option from and after the date on which the event giving rise to the termination for Cause first occurred (or, if required by applicable law, the date of termination of Continuous Service). If a Participant&#8217;s Continuous Service is suspended pending an investigation of the existence of Cause, all of the Participant&#8217;s rights under the Option will also be suspended during the investigation period, except to the extent prohibited by applicable law.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(k)</font><b style="font-weight:bold;">Non-Exempt Employees</b>. If an Option is granted to an Employee who is a non-exempt employee for purposes of the Fair Labor Standards Act of 1938, as amended, the Option will not be first exercisable for any shares of Common Stock until at least 6 months following the date of grant of the Option (although the Option may vest prior to such date). Consistent with the provisions of the Worker Economic Opportunity Act, (i) if such non-exempt Employee dies or suffers a Disability, (ii) upon a Corporate Transaction in which such Option is not assumed, continued, or substituted, or (iii) upon the non-exempt Employee&#8217;s retirement (as such term may be defined in the non-exempt Employee&#8217;s Option Agreement in another agreement between the non-exempt Employee and the Company, or, if no such definition, in accordance with the Company&#39;s then current employment policies and guidelines), the vested portion of any Options may be exercised earlier than 6 months following the date of grant. The </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;">6</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;">foregoing provision is intended to operate so that any income derived by a non-exempt employee in connection with the exercise or vesting of an Option will be exempt from his or her regular rate of pay. To the extent permitted and/or required for compliance with the Worker Economic Opportunity Act to ensure that any income derived by a non-exempt Employee in connection with the exercise, vesting or issuance of any shares under any other Option will be exempt from such Employee&#8217;s regular rate of pay, the provisions of this paragraph will apply to all Options and are hereby incorporated by reference into such Option Agreements.</div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">6.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Provisions Relating to Restricted Stock Unit Awards.</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><a name="_DV_M115"></a><a name="_Ref92447212"></a>Each Restricted Stock Unit Award Agreement will be in such form and will contain such terms and conditions as the Board deems appropriate. The terms and conditions of Restricted Stock Unit Award Agreements may change from time to time, and the terms and conditions of separate Restricted Stock Unit Award Agreements need not be identical. Each Restricted Stock Unit Award Agreement will conform to (through incorporation of the provisions hereof by reference in the Agreement or otherwise) the substance of each of the following provisions:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><a name="_DV_M116"></a><b style="font-weight:bold;">Consideration.</b> At the time of grant of a Restricted Stock Unit Award, the Board will determine the consideration, if any, to be paid by the Participant upon delivery of each share of Common Stock subject to the Restricted Stock Unit Award. The consideration to be paid (if any) by the Participant for each share of Common Stock subject to a Restricted Stock Unit Award may be paid in any form of legal consideration that may be acceptable to the Board, in its sole discretion, and permissible under applicable law.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><a name="_DV_M117"></a><a name="_Ref168993349"></a><b style="font-weight:bold;">Vesting. </b>At the time of the grant of a Restricted Stock Unit Award, the Board may impose such restrictions on or conditions to the vesting of the Restricted Stock Unit Award as it, in its sole discretion, deems appropriate.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font><a name="_DV_M118"></a><b style="font-weight:bold;">Payment</b>. A Restricted Stock Unit Award may be settled by the delivery of shares of Common Stock, their cash equivalent, any combination thereof or in any other form of consideration, as determined by the Board and contained in the Restricted Stock Unit Award Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(d)</font><a name="_DV_M119"></a><b style="font-weight:bold;">Additional Restrictions. </b>At the time of the grant of a Restricted Stock Unit Award, the Board, as it deems appropriate, may impose such restrictions or conditions that delay the delivery of the shares of Common Stock (or their cash equivalent) subject to a Restricted Stock Unit Award to a time after the vesting of such Restricted Stock Unit Award. </div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(e)</font><a name="_DV_M120"></a><b style="font-weight:bold;">Dividend Equivalents. </b>Dividend equivalents may be credited in respect of shares of Common Stock covered by a Restricted Stock Unit Award, as determined by the Board and contained in the Restricted Stock Unit Award Agreement. At the sole discretion of the Board, such dividend equivalents may be converted into additional shares of Common Stock covered by the Restricted Stock Unit Award in such manner as determined by the Board. Any additional shares covered by the Restricted Stock Unit Award credited by reason of such dividend equivalents will be subject to all of the same terms and conditions of the underlying Restricted Stock Unit Award Agreement to which they relate.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(f)</font><a name="_DV_M121"></a><b style="font-weight:bold;">Termination of Participant&#8217;s Continuous Service. </b>Except as otherwise provided in the applicable Restricted Stock Unit Award Agreement, such portion of the Restricted Stock Unit Award that has not vested will be forfeited upon the Participant&#8217;s termination of Continuous Service.<b style="font-weight:bold;"> </b></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">7.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><a name="_DV_M128"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Covenants of the Company.</b></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><a name="_Ref147744725"></a><b style="font-weight:bold;">Availability of Shares.</b> The Company will keep available at all times the number of shares of Common Stock reasonably required to satisfy then-outstanding Stock Awards.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><b style="font-weight:bold;">Securities Law Compliance.</b> The Company will seek to obtain from each regulatory commission or agency having jurisdiction over the Plan such authority as may be required to grant Stock Awards and to issue and sell shares of Common Stock upon exercise of the Stock Awards; <i style="font-style:italic;">provided, however,</i> that this undertaking will not require the Company to register under the Securities Act the Plan, any Stock Award or any Common Stock issued or </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;">7</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;">issuable pursuant to any such Stock Award. If, after reasonable efforts and at a reasonable cost, the Company is unable to obtain from any such regulatory commission or agency the authority that counsel for the Company deems necessary for the lawful issuance and sale of Common Stock under the Plan, the Company will be relieved from any liability for failure to issue and sell Common Stock upon exercise of such Stock Awards unless and until such authority is obtained. A Participant will not be eligible for the grant of a Stock Award or the subsequent issuance of cash or Common Stock pursuant to the Stock Award if such grant or issuance would be in violation of any applicable securities law. </div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font><b style="font-weight:bold;">No Obligation to Notify or Minimize Taxes. </b>The Company will have no duty or obligation to any Participant to advise such holder as to the time or manner of exercising such Stock Award. Furthermore, the Company will have no duty or obligation to warn or otherwise advise such holder of a pending termination or expiration of a Stock Award or a possible period in which the Stock Award may not be exercised. The Company has no duty or obligation to minimize the tax consequences of a Stock Award to the holder of such Stock Award.</div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">8.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Miscellaneous.</b></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><b style="font-weight:bold;">Use of Proceeds from Sales of Common Stock. </b>Proceeds from the sale of shares of Common Stock pursuant to Stock Awards will constitute general funds of the Company.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><b style="font-weight:bold;">Corporate Action Constituting Grant of Stock Awards.</b> Corporate action constituting a grant by the Company of a Stock Award to any Participant will be deemed completed as of the date of such corporate action, unless otherwise determined by the Board, regardless of when the instrument, certificate, or letter evidencing the Stock Award is communicated to, or actually received or accepted by, the Participant. In the event that the corporate records (<i style="font-style:italic;">e.g.</i>, Board consents, resolutions or minutes) documenting the corporate action constituting the grant contain terms (<i style="font-style:italic;">e.g.</i>, exercise price, vesting schedule or number of shares) that are inconsistent with those in the Stock Award Agreement as a result of a clerical error in the papering of the Stock Award Agreement, the corporate records will control and the Participant will have no legally binding right to the incorrect term in the Stock Award Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font><b style="font-weight:bold;">Stockholder Rights.</b> No Participant will be deemed to be the holder of, or to have any of the rights of a holder with respect to, any shares of Common Stock subject to a Stock Award unless and until (i)&#160;such Participant has satisfied all requirements for exercise of, or the issuance of shares of Common Stock under, the Stock Award pursuant to its terms, and (ii)&#160;the issuance of the Common Stock subject to such Stock Award has been entered into the books and records of the Company.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(d)</font><b style="font-weight:bold;">No Employment or Other Service Rights.</b> Nothing in the Plan, any Stock Award Agreement or any other instrument executed thereunder or in connection with any Stock Award granted pursuant thereto will confer upon any Participant any right to continue to serve the Company or an Affiliate in the capacity in effect at the time the Stock Award was granted or will affect the right of the Company or an Affiliate to terminate (i)&#160;the employment of an Employee with or without notice and with or without cause, including, but not limited to, Cause, (ii)&#160;the service of a Consultant pursuant to the terms of such Consultant&#8217;s agreement with the Company or an Affiliate, or (iii)&#160;the service of a Director pursuant to the bylaws of the Company or an Affiliate, and any applicable provisions of the corporate law of the state in which the Company or the Affiliate is incorporated, as the case may be.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(e)</font><b style="font-weight:bold;">Change in Time Commitment</b>. In the event a Participant&#8217;s regular level of time commitment in the performance of his or her services for the Company and any Affiliates is reduced (for example, and without limitation, if the Participant is an Employee of the Company and the Employee has a change in status from a full-time Employee to a part-time Employee or takes an extended leave of absence) after the date of grant of any Stock Award to the Participant, the Board has the right in its sole discretion to (i) make a corresponding reduction in the number of shares or cash amount subject to any portion of such Stock Award that is scheduled to vest or become payable after the date of such change in time commitment, and (ii) in lieu of or in combination with such a reduction, extend the vesting or payment schedule applicable to such Stock Award. In the event of any such reduction, the Participant will have no right with respect to any portion of the Stock Award that is so reduced or extended.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(f)</font><b style="font-weight:bold;">Investment Assurances.</b> The Company may require a Participant, as a condition of exercising or acquiring Common Stock under any Stock Award, (i)&#160;to give written assurances satisfactory to the Company as to the Participant&#8217;s knowledge and experience in financial and business matters and/or to employ a purchaser representative reasonably satisfactory to the Company who is knowledgeable and experienced in financial and business matters and </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;">8</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;">that he or she is capable of evaluating, alone or together with the purchaser representative, the merits and risks of exercising the Stock Award, and (ii)&#160;to give written assurances satisfactory to the Company stating that the Participant is acquiring Common Stock subject to the Stock Award for the Participant&#8217;s own account and not with any present intention of selling or otherwise distributing the Common Stock. The foregoing requirements, and any assurances given pursuant to such requirements, will be inoperative if (i)&#160;the issuance of the shares upon the exercise of a Stock Award or acquisition of Common Stock under the Stock Award has been registered under a then currently effective registration statement under the Securities Act, or (ii)&#160;as to any particular requirement, a determination is made by counsel for the Company that such requirement need not be met in the circumstances under the then applicable securities laws. The Company may, upon advice of counsel to the Company, place legends on stock certificates issued under the Plan as such counsel deems necessary or appropriate in order to comply with applicable securities laws, including, but not limited to, legends restricting the transfer of the Common Stock. </div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(g)</font><a name="_Ref147744804"></a><b style="font-weight:bold;">Withholding Obligations.</b> Unless prohibited by the terms of a Stock Award Agreement, the Company may, in its sole discretion, satisfy any U.S. federal, state, local, foreign or other tax withholding obligation relating to a Stock Award by any of the following means or by a combination of such means: (i)&#160;causing the Participant to tender a cash payment; (ii)&#160;withholding shares of Common Stock from the shares of Common Stock issued or otherwise issuable to the Participant in connection with the Stock Award; <i style="font-style:italic;">provided, however</i>, that no shares of Common Stock are withheld with a value exceeding the minimum amount of tax required to be withheld by law (or such other amount as may be necessary to avoid classification of the Stock Award as a liability for financial accounting purposes); (iii)&#160;withholding cash from a Stock Award settled in cash; (iv) withholding payment from any amounts otherwise payable to the Participant, including proceeds from the sale of shares of Common Stock issued pursuant to a Stock Award; or (v)&#160;by such other method as may be set forth in the Stock Award Agreement. </div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(h)</font><b style="font-weight:bold;">Electronic Delivery</b>. Any reference herein to a &#8220;written&#8221; agreement or document will include any agreement or document delivered electronically, filed publicly at www.sec.gov (or any successor website thereto), or posted on the Company&#8217;s intranet (or other shared electronic medium controlled by the Company to which the Participant has access).</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(i)</font><b style="font-weight:bold;">Deferrals.</b> To the extent permitted by applicable law, the Board, in its sole discretion, may determine that the delivery of Common Stock or the payment of cash, upon the exercise, vesting or settlement of all or a portion of any Stock Award may be deferred and may establish programs and procedures for deferral elections to be made by Participants. Deferrals by Participants will be made in accordance with Section 409A of the Code (to the extent applicable to a Participant). Consistent with Section 409A of the Code, the Board may provide for distributions while a Participant is still an employee or otherwise providing services to the Company. The Board is authorized to make deferrals of Stock Awards and determine when, and in what annual percentages, Participants may receive payments, including lump sum payments, following the Participant&#8217;s termination of Continuous Service, and implement such other terms and conditions consistent with the provisions of the Plan and in accordance with applicable law.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(j)</font><b style="font-weight:bold;">Compliance with Section 409A. </b>Unless otherwise expressly provided for in a Stock Award Agreement and the Plan will be interpreted to the greatest extent possible in a manner that makes the Plan and the Stock Awards granted hereunder exempt from Section 409A of the Code, and, to the extent not so exempt, in compliance with Section 409A of the Code. If the Board determines that any Stock Award granted hereunder is not exempt from and is therefore subject to Section 409A of the Code, the Stock Award Agreement evidencing such Stock Award will incorporate the terms and conditions necessary to avoid the consequences specified in Section 409A(a)(1) of the Code, and to the extent a Stock Award Agreement is silent on terms necessary for compliance, such terms are hereby incorporated by reference into the Stock Award Agreement. Notwithstanding anything to the contrary in this Plan (and unless the Stock Award Agreement specifically provides otherwise), if the shares of Common Stock are publicly traded, and if a Participant holding a Stock Award that constitutes &#8220;deferred compensation&#8221; under Section 409A of the Code is a &#8220;specified employee&#8221; for purposes of Section 409A of the Code, no distribution or payment of any amount that is due because of a &#8220;separation from service&#8221; (as defined in Section 409A of the Code) will be issued or paid before the date that is six (6) months following the date of such Participant&#8217;s &#8220;separation from service&#8221; or, if earlier, the date of the Participant&#8217;s death, unless such distribution or payment can be made in a manner that complies with Section 409A of the Code, and any amounts so deferred will be paid in a lump sum on the day after such six (6) month period elapses, with the balance paid thereafter on the original schedule.</div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;">9</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(k)</font><b style="font-weight:bold;">Clawback/Recovery.</b> All Stock Awards granted under the Plan will be subject to recoupment in accordance with any clawback policy that the Company is required to adopt pursuant to the listing standards of any national securities exchange or association on which the Company&#8217;s securities are listed or as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other applicable law. In addition, the Board may impose such other clawback, recovery or recoupment provisions in a Stock Award Agreement as the Board determines necessary or appropriate, including, but not limited to, a reacquisition right in respect of previously acquired shares of Common Stock or other cash or property upon the occurrence of an event constituting Cause. No recovery of compensation under such a clawback policy will be an event giving rise to a right to resign for &#8220;good reason&#8221; or &#8220;constructive termination&#8221; (or similar term) under any agreement with the Company or an Affiliate.</div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">9.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Adjustments upon Changes in Common Stock; Other Corporate Events.</b></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><a name="_Ref92447089"></a><b style="font-weight:bold;">Capitalization Adjustments</b>. In the event of a Capitalization Adjustment, the Board will appropriately and proportionately adjust: (i)&#160;the class(es) and maximum number of securities subject to the Plan pursuant to Section&#160;3(a) and (ii)&#160;the class(es) and number of securities and price per share of stock subject to outstanding Stock Awards. The Board will make such adjustments, and its determination will be final, binding and conclusive. </div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><b style="font-weight:bold;">Dissolution or Liquidation.</b>&#160; In the event of a dissolution or liquidation of the Company, then all outstanding Stock Awards shall terminate immediately prior to such event.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font><b style="font-weight:bold;">Corporate Transaction.</b>&#160; In the event of (i)&#160;a sale, lease or other disposition of all or substantially all of the securities or assets of the Company, (ii)&#160;a merger or consolidation in which the Company is not the surviving corporation or (iii)&#160;a reverse merger in which the Company is the surviving corporation but the shares of Common Stock outstanding immediately preceding the merger are converted by virtue of the merger into other property, whether in the form of securities, cash or otherwise (a &#8220;<font style="font-style:italic;font-weight:bold;">Corporate Transaction</font>&#8221;), then any surviving corporation or acquiring corporation may assume any Stock Awards outstanding under the Plan or may substitute similar stock awards (including an award to acquire the same consideration paid to the stockholders in such Corporate Transaction) for those outstanding under the Plan. In the event any surviving corporation or acquiring corporation does not assume such Stock Awards or substitute similar stock awards for those outstanding under the Plan, then with respect to Stock Awards held by Participants whose Continuous Service has not terminated, the vesting of such Stock Awards (and, if applicable, the time during which such Stock Awards may be exercised) shall be accelerated in full, and the Stock Awards shall terminate if not exercised (if applicable) at or prior to such event. With respect to any other Stock Awards outstanding under the Plan, such Stock Awards shall terminate if not exercised (if applicable) prior to such event.<sup style="font-size:7.5pt;font-variant:small-caps;font-weight:bold;vertical-align:top;"> </sup></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">10.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><a name="_Ref92447246"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Termination or Suspension of the Plan.</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;width:36pt;"></font>The Board may suspend or terminate the Plan at any time. No Stock Awards may be granted under the Plan while the Plan is suspended or after it is terminated.</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">11.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><a name="_Ref92447127"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Effective Date of Plan; Timing of First Grant or Exercise.</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Plan will come into existence on the Effective Date. No Stock Award may be granted prior to the Effective Date.</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">12.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Choice of Law.</b></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.27;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The laws of the</font><b style="color:#0070c0;font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">State of Delaware will govern all questions concerning the construction, validity and interpretation of this Plan, without regard to that state&#8217;s conflict of laws rules.</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">13.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Definitions. &#160;</b><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">As used in the Plan, the following definitions will apply to the capitalized terms indicated below: </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(a)</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">&#8220;Affiliate&#8221; </b><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">means, at the time of determination, any &#8220;parent&#8221; or &#8220;subsidiary&#8221; of the Company, as such terms are defined in Rule&#160;405 of the Securities Act. The Board will have the authority to determine the time or times at which &#8220;parent&#8221; or &#8220;subsidiary&#8221; status is determined within the foregoing definition. </font></td></tr></table></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;">10</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Board</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Board of Directors of the Company.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(c)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Capitalization Adjustment</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any change that is made in, or other events that occur with respect to, the Common Stock subject to the Plan or subject to any Stock Award after the Effective Date without the receipt of consideration by the Company through merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, reverse stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or other similar equity restructuring transaction, as that term is used in Financial Accounting Standards Board Accounting Standards Codification Topic 718 (or any successor thereto). Notwithstanding the foregoing, the conversion of any convertible securities of the Company will not be treated as a Capitalization Adjustment.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(d)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Cause</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">will have the meaning ascribed to such term in any written agreement between the Participant and the Company or any Affiliate defining such term and, in the absence of such agreement, such term means, with respect to a Participant, the occurrence of any of the following events: (i) such Participant&#8217;s conviction of any felony or any crime involving moral turpitude or dishonesty, (ii) such Participant&#8217;s participation in a fraud or act of dishonesty against the Company, (iii) such Participant&#8217;s conduct that, based upon a good faith and reasonable factual investigation and determination by the Board, demonstrates the Participant&#8217;s gross unfitness to serve, or (iv) such Participant&#8217;s intentional, material violation of any contract between the Company and the Participant or any statutory duty that the Participant has to the Company that the Participant does not correct within 30 days after written notice to the Participant thereof. The determination as to whether a Participant is being terminated for Cause will be made in good faith by the Company and will be final and binding on the Participant. Any determination by the Company that the Continuous Service of a Participant was terminated with or without Cause for the purposes of outstanding Stock Awards held by such Participant will have no effect upon any determination of the rights or obligations of the Company, any Affiliate or such Participant for any other purpose. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(e)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Code</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the U.S. Internal Revenue Code of 1986, as amended, including any applicable regulations and guidance thereunder.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(f)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Committee</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a committee of one (1) or more Independent Directors to whom authority has been delegated by the Board in accordance with Section </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2(c)</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(g)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Common Stock</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the common stock of the Company.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(h)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Company</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means Rigel Pharmaceuticals, Inc., a Delaware corporation.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(i)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Consultant</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any person, including an advisor, who is (i)&#160;engaged by the Company or an Affiliate to render consulting or advisory services and is compensated for such services, or (ii)&#160;serving as a member of the board of directors of an Affiliate and is compensated for such services. However, service solely as a Director, or payment of a fee for such service, will not cause a Director to be considered a &#8220;Consultant&#8221; for purposes of the Plan. Notwithstanding the foregoing, a person is treated as a Consultant under this Plan only if a Form S-8 Registration Statement under the Securities Act is available to register either the offer or the sale of the Company&#8217;s securities to such person.</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;"> </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(j)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Continuous Service</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means that the Participant&#8217;s service with the Company or an Affiliate, whether as an Employee, Director or Consultant, is not interrupted or terminated. A change in the capacity in which the Participant renders service to the Company or an Affiliate as an Employee, Consultant or Director or a change in the Entity for which the Participant renders such service, provided that there is no interruption or termination of the Participant&#8217;s service with the Company or an Affiliate, will not terminate a Participant&#8217;s Continuous Service. For example, a change in status from an Employee of the Company to a Consultant of an Affiliate or to a Director will not constitute an interruption of Continuous Service. If the Entity for which a Participant is rendering services ceases to qualify as an Affiliate, as determined by the Board in its sole discretion, such Participant&#8217;s Continuous Service will be considered to have terminated on the date such Entity ceases to qualify as an Affiliate. To the extent permitted by law, the </font></td></tr></table></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;">11</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Board or the chief executive officer of the Company, in that party&#8217;s sole discretion, may determine whether Continuous Service will be considered interrupted in the case of (i)&#160;any leave of absence approved by the Board or chief executive officer, including sick leave, military leave or any other personal leave, or (ii)&#160;transfers between the Company, an Affiliate, or their successors. In addition, if required for exemption from or compliance with Section 409A of the Code, the determination of whether there has been a termination of Continuous Service will be made, and such term will be construed, in a manner that is consistent with the definition of &#8220;separation from service&#8221; as defined under Treasury Regulation Section 1.409A-1(h). A leave of absence will be treated as Continuous Service for purposes of vesting in a Stock Award only to such extent as may be provided in the Company&#8217;s leave of absence policy, in the written terms of any leave of absence agreement or policy applicable to the Participant, or as otherwise required by law. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(k)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Director</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a member of the Board. Directors are not eligible to receive Stock Awards under the Plan with respect to their service in such capacity.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(l)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Disability</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the permanent and total disability of a person within the meaning of Section&#160;22(e)(3)&#160;of the Code. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(m)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Effective Date</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means October 10, 2016.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(n)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Employee</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any person employed by the Company or an Affiliate. However, service solely as a Director, or payment of a fee for such services, will not cause a Director to be considered an &#8220;Employee&#8221; for purposes of the Plan. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(o)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Entity</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a corporation, partnership, limited liability company or other entity.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(p)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Exchange Act</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><a name="_Ref147744671"></a></font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(q)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Fair Market Value</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">means, as of any date, the value of the Common Stock determined as follows:</font></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(i)</font>If the Common Stock is listed on any established stock exchange or traded on any established market, the Fair Market Value of a share of Common Stock will be, unless otherwise determined by the Board, the closing sales price for such stock as quoted on such exchange or market (or the exchange or market with the greatest volume of trading in the Common Stock) on the last market trading day prior to the date of determination, as reported in a source the Board deems reliable.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(ii)</font>Unless otherwise provided by the Board, if there is no closing sales price for the Common Stock on the date of determination, then the Fair Market Value will be the closing selling price on the last preceding date for which such quotation exists.<a name="_Ref92447285"></a></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(iii)</font>In the absence of such markets for the Common Stock, the Fair Market Value will be determined by the Board in good faith and in a manner that complies with Section 409A of the Code.</div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(r)</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">&#8220;Independent Director&#8221;</b><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> has the meaning set forth in Section 1(a) above.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(s)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Non-Employee Director</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a Director who either (i)&#160;is not a current employee or officer of the Company or an Affiliate, does not receive compensation, either directly or indirectly, from the Company or an Affiliate for services rendered as a consultant or in any capacity other than as a Director (except for an amount as to which disclosure would not be required under Item 404(a) of Regulation S-K promulgated pursuant to the Securities Act (&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Regulation S-K</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;)), does not possess an interest in any other transaction for which disclosure would be required under Item 404(a) of Regulation S-K, and is not engaged in a business relationship for which disclosure would be required pursuant to Item&#160;404(b) of Regulation S-K; or (ii)&#160;is otherwise considered a &#8220;non-employee director&#8221; for purposes of Rule 16b-3 of the Exchange Act.</font></td></tr></table></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;">12</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(t)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Nonstatutory Stock Option</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any option granted pursuant to Section </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4(b)</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> of the Plan that does not qualify as an &#8220;incentive stock option&#8221; within the meaning of Section 422 of the Code.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(u)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Officer</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a person who is an officer of the Company within the meaning of Section 16 of the Exchange Act. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(v)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Option</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a Nonstatutory Stock Option to purchase shares of Common Stock granted pursuant to the Plan.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(w)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Option Agreement</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a written agreement between the Company and an Optionholder evidencing the terms and conditions of an Option grant. Each Option Agreement will be subject to the terms and conditions of the Plan.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(x)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Optionholder</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a person to whom an Option is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Option.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(y)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Participant</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a person to whom a Stock Award is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Stock Award.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(z)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Plan</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means this</font><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Rigel Pharmaceuticals, Inc. Inducement Plan, as it may be amended.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(aa)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Restricted Stock Unit Award</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">means a right to receive shares of Common Stock which is granted pursuant to the terms and conditions of Section&#160;6(b).</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><a name="_DV_M55"></a></font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(bb)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Restricted Stock Unit Award Agreement</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">means a written agreement between the Company and a holder of a Restricted Stock Unit Award evidencing the terms and conditions of a Restricted Stock Unit Award grant. Each Restricted Stock Unit Award Agreement will be subject to the terms and conditions of the Plan. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(cc)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">&#8220;Rule 16b-3</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means Rule 16b-3 promulgated under the Exchange Act or any successor to Rule 16b-3, as in effect from time to time.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(dd)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Securities Act</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Securities Act of 1933, as amended.</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><a name="_DV_M64"></a></font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(ee)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">&#8220;Stock Award&#8221; </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">means any right to receive Common Stock granted under the Plan, including an Option or a Restricted Stock Unit Award. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(ff)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Stock Award Agreement</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a written agreement between the Company and a Participant evidencing the terms and conditions of a Stock Award grant. Each Stock Award Agreement will be subject to the terms and conditions of the Plan.</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><a name="_DV_M65"></a></font></td></tr></table></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;">13</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>rigl-20230630xex10d3.htm
<DESCRIPTION>EX-10.3
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 7/31/2023 08:05:48 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 10.3</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:justify;margin:0pt;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;text-transform:uppercase;margin:12pt 0pt 12pt 0pt;"><b style="font-weight:bold;">AMendment 1 to LICENSE AND TRANSITION SERVICES AGREEMENT </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This AMENDMENT 1 to the License and Transition Services Agreement by and between Rigel Pharmaceuticals, Inc. (the &#8220;Company&#8221;) and Forma Therapeutics, Inc. (&#8220;Forma&#8221;) dated July 27, 2022 (the &#8220;Agreement&#8221;) is made and entered into this 22<sup style="font-size:7.5pt;vertical-align:top;">nd</sup> day of December 2022 (the &#8220;Amendment&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">WHEREAS Forma and the Company wish to amend the Agreement upon the terms and conditions contained in this Amendment. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">NOW THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt and legal sufficiency of which are hereby acknowledged, accepted and agreed to, Forma and the Company hereby agree as follows:</p><div style="font-family:'Calibri Light';font-size:16pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;margin-top:12pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;text-transform:uppercase;white-space:nowrap;">1.</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:normal;">AMENDMENTS.</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:normal;white-space:pre-wrap;">  </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-right:0pt;visibility:hidden;">&#8203;</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:36pt;margin-top:0pt;padding-left:18pt;text-align:justify;text-indent:-18pt;"><font style="display:inline-block;font-size:10pt;min-width:18pt;text-indent:0pt;white-space:nowrap;">a)</font><font style="font-size:10pt;">That Schedule 1.38 (Existing Inventory) to the Agreement be deleted in its entirety and replaced with Revised Schedule 1.38 (Existing Inventory) attached hereto. </font></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">That Schedule 2.1 (Transition Plan) to the Agreement be deleted in its entirety and replaced with Revised Schedule 2.1 (Transition Plan) attached hereto.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 54pt;"><font style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">c)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">That a new section, &#8220;Section 2.12 Additional Supply of Licensed Product&#8221; shall be added to the Agreement as follows:</font></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;line-height:1.19;text-indent:0pt;margin:12pt 0pt 3pt 108pt;"><font style="font-family:'Times New Roman','Times','serif';font-weight:normal;">&#8220;2.12</font><font style="display:inline-block;width:14.06pt;"></font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Additional Supply of Licensed Product. </b><font style="font-family:'Times New Roman','Times','serif';font-weight:normal;">Forma may have in its possession research grade supply of Licensed Product </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">(&#8220;Research Supply&#8221;)</b><font style="font-family:'Times New Roman','Times','serif';font-weight:normal;white-space:pre-wrap;"> which is not Existing Inventory.  Forma in its sole discretion and subject to the terms set forth in this Section 2.12 may make Research Supply available to Company, upon Company&#8217;s prior written request.  Notwithstanding anything to the contrary contained in this Agreement, any Research Supply provided by Forma to Company shall be subject to the following:</font></p><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:13pt;font-style:italic;font-weight:bold;line-height:1.19;margin-bottom:3pt;margin-left:144pt;margin-top:12pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(i)</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">Research Supply shall be provided to Company free of charge with respect to the costs incurred by Forma for the manufacture of the Research Supply.  Company shall be responsible for all costs associated with the transfer of the Research Supply from Forma or its designee to Company or its designee, including, shipping and permit fees, taxes and insurance coverage of such transfer.  </font></div><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:13pt;font-style:italic;font-weight:bold;line-height:1.19;margin-bottom:3pt;margin-left:144pt;margin-top:12pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(ii)</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Company is under no obligation to use any Research Supply supplied under this Section 2.12; however, Company agrees that any Research Supply that it decides to use shall be sued by Company or any of its designees solely for in vitro and in vivo laboratory animal studies only. </font></div><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:13pt;font-style:italic;font-weight:bold;line-height:1.19;margin-bottom:3pt;margin-left:144pt;margin-top:12pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(iii)</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">FORMA MAKES NO REPRESENTATIONS NOR EXTENDS ANY WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED, TO COMPANY WITH RESPECT TO THE RESEARCH SUPPLY AND HEREBY DISCLAIMS ALL IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NON-INFRINGEMENT WITH RESPECT TO ANY AND ALL OF THE RESEARCH SUPPLY.  The representations, warranties and covenants set forth in Section 11 of the Agreement by Forma to Company shall not apply to any Research Supply. </font></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:13pt;font-style:italic;font-weight:bold;line-height:1.19;margin-bottom:3pt;margin-left:144pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(iv)</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">Forma&#8217;s indemnification obligations under Section 12 of the Agreement shall not extend to the Research Supply.  Further, Company&#8217;s indemnification obligations under Section 12.1 shall extend to any uses of the Research Supply.</font></div><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:13pt;font-style:italic;font-weight:bold;line-height:1.19;margin-bottom:3pt;margin-left:144pt;margin-top:12pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(v)</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">This Section 2.12 shall survive expiration or termination of the Agreement.&#8221;   </font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 54pt;"><font style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Calibri Light';font-size:16pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;margin-top:12pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;text-transform:uppercase;white-space:nowrap;">2.</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:normal;">EFFECT OF AMENDMENTS.</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:normal;white-space:pre-wrap;">  </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-right:0pt;visibility:hidden;">&#8203;</font></div><div style="font-family:'Calibri Light';font-size:16pt;font-weight:bold;line-height:1.19;margin-bottom:3pt;margin-left:0pt;margin-top:12pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;min-width:36pt;text-decoration-line:none;text-indent:0pt;text-transform:uppercase;white-space:nowrap;">3.</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:normal;white-space:pre-wrap;">Except as forth herein, the Agreement shall remain in full force and effect in accordance with the terms set forth therein.                               </font></div><div style="font-family:'Calibri Light';font-size:16pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;margin-top:12pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;min-width:42pt;text-decoration-line:none;text-indent:0pt;text-transform:uppercase;white-space:nowrap;">4.</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:normal;">COUNTERPARTS.</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:normal;white-space:pre-wrap;">  </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-right:0pt;visibility:hidden;">&#8203;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This Amendment may be executed in two or more counterparts, each of which shall be deemed an original and all of which shall together constitute one and the same instrument. &#160;Counterparts may be delivered via electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">[Signature Page Follows]</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">EXECUTED as of the date first above written.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 216pt;">RIGEL PHARMACEUTICALS, INC.<br><br><br>By: <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">/s/ James J. Diehl</u><br>Name: James J. Diehl</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 216pt;">Title: VP, Legal</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 216pt;"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><font style="margin-left:0pt;visibility:hidden;">&#8203;</font><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 216pt;">FORMA THERAPEUTICS, INC.<br><br><br>By: <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">/s/ Agustin Melian</u><br>Name: Agustin Melian</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 216pt;">Title: Head of R&amp;D</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 216pt;"><font style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><a name="Schedule21"></a><a name="_9kR3WTr8E845EhJfifw5q8J"></a><font style="line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Re-Revised Schedule 1.38 </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Existing Inventory</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="margin-left:-27pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:110.91%;"><tr style="height:1pt;"><td style="vertical-align:top;width:7.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 7.85pt 0pt 8.35pt;"><font style="font-size:9pt;font-weight:bold;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="font-size:1pt;line-height:1.19;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:8.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0pt 8.55pt;"><font style="font-size:9pt;font-weight:bold;line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="font-size:1pt;line-height:1.19;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:10.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:10.3pt;text-align:center;margin:0.25pt 6.95pt 0pt 7.65pt;"><b style="font-weight:bold;vertical-align:super;">2</b></p></div></div></td><td style="vertical-align:top;width:8.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 4.85pt 0pt 0pt;"><font style="font-size:9pt;font-weight:bold;line-height:1.19;margin-right:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="font-size:1pt;line-height:1.19;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:9.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:8.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 6.7pt 0pt 7.25pt;"><font style="font-size:9pt;font-weight:bold;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="font-size:1pt;line-height:1.19;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:8.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:9.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 13.15pt 0pt 0pt;"><font style="font-size:9pt;font-weight:bold;line-height:1.19;margin-right:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="font-size:1pt;line-height:1.19;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:8.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:10.3pt;padding-left:8.05pt;text-indent:-8.05pt;margin:0.25pt 8.55pt 0pt 10.45pt;"><font style="font-size:10.3pt;font-weight:bold;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:14.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 6.35pt 0pt 7.1pt;"><font style="font-size:9pt;font-weight:bold;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="font-size:1pt;line-height:1.19;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:13.75pt;"><td colspan="11" style="vertical-align:top;width:100%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:12.8pt;text-align:center;margin:0pt 230.1pt 0pt 230.7pt;"><font style="font-size:12.8pt;font-weight:bold;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:21.1pt;"><td style="vertical-align:top;width:7.32%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 7.85pt 0pt 8.35pt;"><font style="font-size:9pt;font-weight:bold;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.18%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-indent:5.85pt;margin:5.25pt 5.9pt 0pt 7.55pt;"><font style="font-size:9pt;font-weight:bold;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0pt 8.55pt;"><font style="font-size:9pt;font-weight:bold;line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:10.36%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:10.3pt;text-align:center;margin:0.25pt 6.95pt 0pt 7.65pt;"><font style="font-size:10.3pt;font-weight:bold;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.19%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 4.85pt 0pt 0pt;"><font style="font-size:9pt;font-weight:bold;line-height:1.19;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.3%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-indent:18.8pt;margin:5.25pt 4.9pt 0pt 6.55pt;"><font style="font-size:9pt;font-weight:bold;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.43%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 6.7pt 0pt 7.25pt;"><font style="font-size:9pt;font-weight:bold;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.66%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;padding-left:4.35pt;text-indent:-4.35pt;margin:5.25pt 3.85pt 0pt 5.45pt;"><font style="font-size:9pt;font-weight:bold;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.01%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 13.15pt 0pt 0pt;"><font style="font-size:9pt;font-weight:bold;line-height:1.19;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.21%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:10.3pt;padding-left:8.05pt;text-indent:-8.05pt;margin:0.25pt 8.55pt 0pt 10.45pt;"><font style="font-size:10.3pt;font-weight:bold;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:14.03%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 6.35pt 0pt 7.1pt;"><font style="font-size:9pt;font-weight:bold;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:21.1pt;"><td style="vertical-align:top;width:7.32%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:8.85pt 7.85pt 0pt 8.15pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.18%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:8.85pt 0pt 0pt 8.05pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:8.85pt 0pt 0pt 7pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:10.36%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:8.85pt 0pt 0pt 11.6pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.19%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:8.85pt 8.05pt 0pt 0pt;"><font style="font-size:9pt;line-height:1.19;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.3%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:8.85pt 0pt 0pt 20.25pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.43%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:8.85pt 6.7pt 0pt 7.5pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.66%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:8.85pt 0pt 0pt 18.65pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.01%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:8.85pt 12.5pt 0pt 0pt;"><font style="font-size:9pt;line-height:1.19;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.21%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:8.85pt 11.5pt 0pt 0pt;"><font style="font-size:9pt;line-height:1.19;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:14.03%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:10.3pt;text-align:center;margin:0pt 6.2pt 0pt 7.35pt;"><font style="font-size:10.3pt;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:22.9pt;"><td style="vertical-align:top;width:7.32%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 7.85pt 0pt 8.15pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.18%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0pt 8.05pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0pt 7pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:10.36%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0pt 11.6pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.19%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 8.05pt 0pt 0pt;"><font style="font-size:9pt;line-height:1.19;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.3%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0pt 20.25pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.43%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 6.7pt 0pt 7.4pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.66%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0pt 16.4pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.01%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 12.5pt 0pt 0pt;"><font style="font-size:9pt;line-height:1.19;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.21%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 9.25pt 0pt 0pt;"><font style="font-size:9pt;line-height:1.19;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:14.03%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:9.65pt;margin:0pt 0pt 0pt 32.45pt;"><font style="font-size:9.65pt;line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:22pt;"><td style="vertical-align:top;width:7.32%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:7.8pt 7.85pt 0pt 8.15pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.18%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:7.8pt 0pt 0pt 8.05pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:7.8pt 0pt 0pt 7pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:10.36%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:7.8pt 0pt 0pt 11.6pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.19%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:7.8pt 8.05pt 0pt 0pt;"><font style="font-size:9pt;line-height:1.19;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.3%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:7.8pt 0pt 0pt 20.25pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.43%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:7.8pt 6.7pt 0pt 7.5pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.66%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:7.8pt 0pt 0pt 16.4pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.01%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:7.8pt 12.5pt 0pt 0pt;"><font style="font-size:9pt;line-height:1.19;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.21%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:7.8pt 9.25pt 0pt 0pt;"><font style="font-size:9pt;line-height:1.19;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:14.03%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:9.6pt;text-align:center;margin:0pt 6.2pt 0pt 7.35pt;"><font style="font-size:9.6pt;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:26.5pt;"><td style="vertical-align:top;width:7.32%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 7.85pt 0pt 8.15pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.18%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0pt 8.05pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0pt 9.15pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:10.36%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0pt 13.15pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.19%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 7.3pt 0pt 0pt;"><font style="font-size:9pt;line-height:1.19;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.3%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0pt 20.25pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.43%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 6.7pt 0pt 7.4pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.66%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0pt 18.65pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.01%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 12.5pt 0pt 0pt;"><font style="font-size:9pt;line-height:1.19;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.21%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 9.25pt 0pt 0pt;"><font style="font-size:9pt;line-height:1.19;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:14.03%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;min-height:10.5pt;text-align:center;margin:0pt 6.3pt 0pt 7.35pt;"><font style="font-size:9pt;font-weight:bold;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:26.5pt;"><td style="vertical-align:top;width:7.32%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0.05pt 7.85pt 0pt 8.15pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.18%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0.05pt 0pt 0pt 8.05pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0.05pt 0pt 0pt 9.15pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:10.36%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0.05pt 0pt 0pt 13.15pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.19%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0.05pt 7.3pt 0pt 0pt;"><font style="font-size:9pt;line-height:1.19;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.3%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0.05pt 0pt 0pt 20.25pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.43%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0.05pt 6.7pt 0pt 7.4pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.66%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0.05pt 0pt 0pt 18.65pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.01%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0.05pt 12.5pt 0pt 0pt;"><font style="font-size:9pt;line-height:1.19;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.21%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0.05pt 9.25pt 0pt 0pt;"><font style="font-size:9pt;line-height:1.19;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:14.03%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:10.3pt;text-align:center;margin:0.1pt 6.3pt 0pt 7.35pt;"><font style="font-size:10.3pt;font-weight:bold;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:26.5pt;"><td style="vertical-align:top;width:7.32%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 7.85pt 0pt 8.15pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.18%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0pt 8.85pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0pt 18.15pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:10.36%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0pt 10.6pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.19%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 8.05pt 0pt 0pt;"><font style="font-size:9pt;line-height:1.19;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.3%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:10.35pt;text-align:center;margin:0pt 11.5pt 0pt 12.3pt;"><font style="font-size:10.35pt;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.43%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 6.6pt 0pt 7.5pt;"><font style="font-size:6pt;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.66%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:10.45pt;text-align:center;margin:0pt 11.15pt 0pt 11.85pt;"><font style="font-size:10.45pt;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.01%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 4.7pt 0pt 6.35pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.21%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 7.6pt 0pt 0pt;"><font style="font-size:6pt;line-height:1.19;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:14.03%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:10.3pt;text-align:center;margin:0pt 5.5pt 0pt 6.5pt;"><font style="font-size:10.3pt;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:31pt;"><td style="vertical-align:top;width:7.32%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0.05pt 7.85pt 0pt 8.15pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.18%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0.05pt 0pt 0pt 8.85pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0.05pt 0pt 0pt 18.15pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:10.36%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0.05pt 0pt 0pt 10.6pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.19%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0.05pt 8.05pt 0pt 0pt;"><font style="font-size:9pt;line-height:1.19;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.3%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:10.35pt;text-align:center;margin:0pt 11.5pt 0pt 12.3pt;"><font style="font-size:10.35pt;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.43%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 6.6pt 0pt 7.5pt;"><font style="font-size:6pt;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.66%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:10.45pt;text-align:center;margin:0pt 11.15pt 0pt 11.85pt;"><font style="font-size:10.45pt;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.01%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 4.7pt 0pt 6.35pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.21%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 7.6pt 0pt 0pt;"><font style="font-size:6pt;line-height:1.19;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:14.03%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:10.3pt;text-align:center;margin:0pt 5.5pt 0pt 6.5pt;"><font style="font-size:10.3pt;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Revised Schedule 2.1</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">Transition Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-7.6923065%;padding-left:2.9pt;padding-right:2.9pt;table-layout:auto;width:115.38%;" align="center"><tr><td style="vertical-align:top;width:14.96%;background:#bfbfbf;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:10pt;line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:22.5%;background:#bfbfbf;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;text-align:center;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:19.17%;background:#bfbfbf;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;text-align:center;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:21.67%;background:#bfbfbf;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;text-align:center;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:21.67%;background:#bfbfbf;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:10pt;font-weight:bold;line-height:1.19;visibility:hidden;">&#8203;</font></p></td></tr><tr><td rowspan="2" style="vertical-align:top;width:14.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:10pt;line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:22.5%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;text-align:center;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:19.17%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;text-align:center;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:21.67%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;text-align:center;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:21.67%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:10pt;line-height:1.19;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="display:none;vertical-align:middle;width:14.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"></td><td style="vertical-align:top;width:22.5%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:10pt;line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:19.17%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;text-align:center;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:21.67%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;text-align:center;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:21.67%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:10pt;line-height:1.19;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:14.96%;background:#bfbfbf;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:10pt;font-weight:bold;line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:22.5%;background:#bfbfbf;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;text-align:center;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:19.17%;background:#bfbfbf;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;text-align:center;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:21.67%;background:#bfbfbf;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;text-align:center;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:21.67%;background:#bfbfbf;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:10pt;font-weight:bold;line-height:1.19;visibility:hidden;">&#8203;</font></p></td></tr><tr><td rowspan="3" style="vertical-align:top;width:14.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:10pt;line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:22.5%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;text-align:center;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:19.17%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;text-align:center;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:21.67%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;text-align:center;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:21.67%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:10pt;line-height:1.19;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="display:none;vertical-align:middle;width:14.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"></td><td style="vertical-align:top;width:22.5%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:10pt;line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:19.17%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;text-align:center;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:21.67%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;text-align:center;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:21.67%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:10pt;line-height:1.19;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="display:none;vertical-align:middle;width:14.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"></td><td style="vertical-align:top;width:22.5%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:10pt;line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:19.17%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;text-align:center;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:21.67%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;text-align:center;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:21.67%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:10pt;line-height:1.19;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:14.96%;background:#bfbfbf;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:10pt;line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:22.5%;background:#bfbfbf;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;text-align:center;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:19.17%;background:#bfbfbf;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;text-align:center;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:21.67%;background:#bfbfbf;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;text-align:center;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:21.67%;background:#bfbfbf;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:10pt;font-weight:bold;line-height:1.19;visibility:hidden;">&#8203;</font></p></td></tr><tr><td rowspan="3" style="vertical-align:top;width:14.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:10pt;line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:22.5%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;text-align:center;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:19.17%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;text-align:center;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:21.67%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;text-align:center;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:21.67%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:10pt;line-height:1.19;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="display:none;vertical-align:middle;width:14.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"></td><td style="vertical-align:top;width:22.5%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:10pt;line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:19.17%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;text-align:center;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:21.67%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;text-align:center;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:21.67%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:10pt;line-height:1.19;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="display:none;vertical-align:middle;width:14.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"></td><td style="vertical-align:top;width:22.5%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:10pt;line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:19.17%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;text-align:center;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:21.67%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;text-align:center;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:21.67%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:10pt;line-height:1.19;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:14.96%;background:#bfbfbf;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:10pt;line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:22.5%;background:#bfbfbf;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;text-align:center;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:19.17%;background:#bfbfbf;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;text-align:center;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:21.67%;background:#bfbfbf;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;text-align:center;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:21.67%;background:#bfbfbf;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:10pt;font-weight:bold;line-height:1.19;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri Light';font-size:10pt;font-weight:bold;line-height:1.19;text-align:center;text-indent:0pt;margin:4.5pt 0pt 3pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">AMENDMENT 2 TO LICENSE AND TRANSITION SERVICES AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt;">This AMENDMENT 2 to the License and Transition Services Agreement by and between Rigel Pharmaceuticals, Inc. (the &#8220;Company&#8221;) and Forma Therapeutics, Inc. (&#8220;Forma&#8221;) dated July 27, 2022 (the &#8220;Agreement&#8221;) is made and entered into this 18th day of May 2023 (the &#8220;Amendment&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0.05pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0.05pt 0pt 0pt 0pt;">WHEREAS Forma and the Company wish to amend the Agreement upon the terms and conditions contained in this Amendment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt;">NOW THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt and legal sufficiency of which are hereby acknowledged, accepted and agreed to, Forma and the Company hereby agree as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:35.95pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">1.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a name="1._AMENDMENTS."></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">AMENDMENTS.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">That Revised Schedule 1.38 (Existing Inventory) to the Agreement be deleted in its entirety and replaced with Re-Revised Schedule 1.38 (Existing Inventory) attached</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">hereto.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:10.85pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:35.95pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">2.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a name="2._EFFECT_OF_AMENDMENTS."></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">EFFECT OF</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">AMENDMENTS.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0.55pt 0pt 12pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-size:10pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">3.</font><a name="3._Except_as_set_forth_herein,_the_Agree"></a><font style="font-size:10pt;">Except</font><font style="font-size:10pt;letter-spacing:-0.65pt;"> </font><font style="font-size:10pt;">as</font><font style="font-size:10pt;letter-spacing:-0.65pt;"> </font><font style="font-size:10pt;">set</font><font style="font-size:10pt;letter-spacing:-0.65pt;"> </font><font style="font-size:10pt;">forth</font><font style="font-size:10pt;letter-spacing:-0.65pt;"> </font><font style="font-size:10pt;">herein,</font><font style="font-size:10pt;letter-spacing:-0.55pt;"> </font><font style="font-size:10pt;">the</font><font style="font-size:10pt;letter-spacing:-0.65pt;"> </font><font style="font-size:10pt;">Agreement</font><font style="font-size:10pt;letter-spacing:-0.6pt;"> </font><font style="font-size:10pt;">shall</font><font style="font-size:10pt;letter-spacing:-0.65pt;"> </font><font style="font-size:10pt;">remain</font><font style="font-size:10pt;letter-spacing:-0.65pt;"> </font><font style="font-size:10pt;">in</font><font style="font-size:10pt;letter-spacing:-0.65pt;"> </font><font style="font-size:10pt;">full</font><font style="font-size:10pt;letter-spacing:-0.6pt;"> </font><font style="font-size:10pt;">force</font><font style="font-size:10pt;letter-spacing:-0.7pt;"> </font><font style="font-size:10pt;">and</font><font style="font-size:10pt;letter-spacing:-0.55pt;"> </font><font style="font-size:10pt;">effect</font><font style="font-size:10pt;letter-spacing:-0.55pt;"> </font><font style="font-size:10pt;">in</font><font style="font-size:10pt;letter-spacing:-0.65pt;"> </font><font style="font-size:10pt;">accordance</font><font style="font-size:10pt;letter-spacing:-0.65pt;"> </font><font style="font-size:10pt;">with</font><font style="font-size:10pt;letter-spacing:-0.65pt;"> </font><font style="font-size:10pt;">the</font><font style="font-size:10pt;letter-spacing:-0.7pt;"> </font><font style="font-size:10pt;">terms</font><font style="font-size:10pt;letter-spacing:-0.65pt;"> </font><font style="font-size:10pt;">set</font><font style="font-size:10pt;letter-spacing:-0.65pt;"> </font><font style="font-size:10pt;">forth</font><font style="font-size:10pt;letter-spacing:-0.6pt;"> </font><font style="font-size:10pt;">therein. </font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-size:10pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">4.</font><font style="font-size:10pt;">COUNTERPARTS.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt;">This<font style="letter-spacing:-0.3pt;"> </font>Amendment<font style="letter-spacing:-0.3pt;"> </font>may<font style="letter-spacing:-0.6pt;"> </font>be<font style="letter-spacing:-0.25pt;"> </font>executed<font style="letter-spacing:-0.35pt;"> </font>in<font style="letter-spacing:-0.25pt;"> </font>two<font style="letter-spacing:-0.3pt;"> </font>or<font style="letter-spacing:-0.35pt;"> </font>more<font style="letter-spacing:-0.45pt;"> </font>counterparts,<font style="letter-spacing:-0.3pt;"> </font>each<font style="letter-spacing:-0.25pt;"> </font>of<font style="letter-spacing:-0.35pt;"> </font>which<font style="letter-spacing:-0.3pt;"> </font>shall<font style="letter-spacing:-0.05pt;"> </font>be<font style="letter-spacing:-0.35pt;"> </font>deemed<font style="letter-spacing:-0.35pt;"> </font>an<font style="letter-spacing:-0.25pt;"> </font>original<font style="letter-spacing:-0.3pt;"> </font>and<font style="letter-spacing:-0.3pt;"> </font>all<font style="letter-spacing:-0.25pt;"> </font>of<font style="letter-spacing:-0.35pt;"> </font>which<font style="letter-spacing:-0.3pt;"> </font>shall together constitute one and the same instrument. Counterparts may be delivered via electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all<font style="letter-spacing:-0.55pt;"> </font>purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:7.94pt 0pt 0pt 0pt;">[Signature Page Follows]</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">EXECUTED as of the date first above written.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0.5pt 0pt 12pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 216pt;">RIGEL PHARMACEUTICALS, INC.<br><br><br>By: <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">/s/ Raymond Furey</u><br>Name: Raymond Furey</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 216pt;">Title: EVP, General Counsel and Corporate Secretary </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 216pt;"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><font style="margin-left:0pt;visibility:hidden;">&#8203;</font><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 216pt;">FORMA THERAPEUTICS, INC.<br><br><br>By: <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">/s/ Agustin Melian</u><br>Name: Agustin Melian</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 216pt;">Title: EVP, Head of R&amp;D Forma Therapeutics</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Re-Revised Schedule 1.38 </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Existing Inventory</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="margin-left:-27pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:110.91%;"><tr style="height:1pt;"><td style="vertical-align:top;width:7.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 7.85pt 0pt 8.35pt;"><font style="font-size:9pt;font-weight:bold;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="font-size:1pt;line-height:1.19;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:8.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0pt 8.55pt;"><font style="font-size:9pt;font-weight:bold;line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="font-size:1pt;line-height:1.19;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:10.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:10.3pt;text-align:center;margin:0.25pt 6.95pt 0pt 7.65pt;"><b style="font-weight:bold;vertical-align:super;">2</b></p></div></div></td><td style="vertical-align:top;width:8.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 4.85pt 0pt 0pt;"><font style="font-size:9pt;font-weight:bold;line-height:1.19;margin-right:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="font-size:1pt;line-height:1.19;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:9.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:8.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 6.7pt 0pt 7.25pt;"><font style="font-size:9pt;font-weight:bold;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="font-size:1pt;line-height:1.19;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:8.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:9.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 13.15pt 0pt 0pt;"><font style="font-size:9pt;font-weight:bold;line-height:1.19;margin-right:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="font-size:1pt;line-height:1.19;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:8.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:10.3pt;padding-left:8.05pt;text-indent:-8.05pt;margin:0.25pt 8.55pt 0pt 10.45pt;"><font style="font-size:10.3pt;font-weight:bold;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:14.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 6.35pt 0pt 7.1pt;"><font style="font-size:9pt;font-weight:bold;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="font-size:1pt;line-height:1.19;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:13.75pt;"><td colspan="11" style="vertical-align:top;width:100%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:12.8pt;text-align:center;margin:0pt 230.1pt 0pt 230.7pt;"><font style="font-size:12.8pt;font-weight:bold;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:21.1pt;"><td style="vertical-align:top;width:7.32%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 7.85pt 0pt 8.35pt;"><font style="font-size:9pt;font-weight:bold;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.18%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-indent:5.85pt;margin:5.25pt 5.9pt 0pt 7.55pt;"><font style="font-size:9pt;font-weight:bold;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0pt 8.55pt;"><font style="font-size:9pt;font-weight:bold;line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:10.36%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:10.3pt;text-align:center;margin:0.25pt 6.95pt 0pt 7.65pt;"><font style="font-size:10.3pt;font-weight:bold;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.19%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 4.85pt 0pt 0pt;"><font style="font-size:9pt;font-weight:bold;line-height:1.19;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.3%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-indent:18.8pt;margin:5.25pt 4.9pt 0pt 6.55pt;"><font style="font-size:9pt;font-weight:bold;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.43%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 6.7pt 0pt 7.25pt;"><font style="font-size:9pt;font-weight:bold;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.66%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;padding-left:4.35pt;text-indent:-4.35pt;margin:5.25pt 3.85pt 0pt 5.45pt;"><font style="font-size:9pt;font-weight:bold;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.01%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 13.15pt 0pt 0pt;"><font style="font-size:9pt;font-weight:bold;line-height:1.19;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.21%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:10.3pt;padding-left:8.05pt;text-indent:-8.05pt;margin:0.25pt 8.55pt 0pt 10.45pt;"><font style="font-size:10.3pt;font-weight:bold;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:14.03%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 6.35pt 0pt 7.1pt;"><font style="font-size:9pt;font-weight:bold;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:21.1pt;"><td style="vertical-align:top;width:7.32%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:8.85pt 7.85pt 0pt 8.15pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.18%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:8.85pt 0pt 0pt 8.05pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:8.85pt 0pt 0pt 7pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:10.36%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:8.85pt 0pt 0pt 11.6pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.19%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:8.85pt 8.05pt 0pt 0pt;"><font style="font-size:9pt;line-height:1.19;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.3%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:8.85pt 0pt 0pt 20.25pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.43%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:8.85pt 6.7pt 0pt 7.5pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.66%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:8.85pt 0pt 0pt 18.65pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.01%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:8.85pt 12.5pt 0pt 0pt;"><font style="font-size:9pt;line-height:1.19;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.21%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:8.85pt 11.5pt 0pt 0pt;"><font style="font-size:9pt;line-height:1.19;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:14.03%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:10.3pt;text-align:center;margin:0pt 6.2pt 0pt 7.35pt;"><font style="font-size:10.3pt;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:22.9pt;"><td style="vertical-align:top;width:7.32%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 7.85pt 0pt 8.15pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.18%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0pt 8.05pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0pt 7pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:10.36%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0pt 11.6pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.19%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 8.05pt 0pt 0pt;"><font style="font-size:9pt;line-height:1.19;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.3%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0pt 20.25pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.43%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 6.7pt 0pt 7.4pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.66%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0pt 16.4pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.01%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 12.5pt 0pt 0pt;"><font style="font-size:9pt;line-height:1.19;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.21%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 9.25pt 0pt 0pt;"><font style="font-size:9pt;line-height:1.19;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:14.03%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:9.65pt;margin:0pt 0pt 0pt 32.45pt;"><font style="font-size:9.65pt;line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:22pt;"><td style="vertical-align:top;width:7.32%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:7.8pt 7.85pt 0pt 8.15pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.18%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:7.8pt 0pt 0pt 8.05pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:7.8pt 0pt 0pt 7pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:10.36%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:7.8pt 0pt 0pt 11.6pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.19%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:7.8pt 8.05pt 0pt 0pt;"><font style="font-size:9pt;line-height:1.19;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.3%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:7.8pt 0pt 0pt 20.25pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.43%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:7.8pt 6.7pt 0pt 7.5pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.66%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:7.8pt 0pt 0pt 16.4pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.01%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:7.8pt 12.5pt 0pt 0pt;"><font style="font-size:9pt;line-height:1.19;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.21%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:7.8pt 9.25pt 0pt 0pt;"><font style="font-size:9pt;line-height:1.19;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:14.03%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:9.6pt;text-align:center;margin:0pt 6.2pt 0pt 7.35pt;"><font style="font-size:9.6pt;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:26.5pt;"><td style="vertical-align:top;width:7.32%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 7.85pt 0pt 8.15pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.18%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0pt 8.05pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0pt 9.15pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:10.36%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0pt 13.15pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.19%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 7.3pt 0pt 0pt;"><font style="font-size:9pt;line-height:1.19;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.3%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0pt 20.25pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.43%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 6.7pt 0pt 7.4pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.66%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0pt 18.65pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.01%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 12.5pt 0pt 0pt;"><font style="font-size:9pt;line-height:1.19;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.21%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 9.25pt 0pt 0pt;"><font style="font-size:9pt;line-height:1.19;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:14.03%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;min-height:10.5pt;text-align:center;margin:0pt 6.3pt 0pt 7.35pt;"><font style="font-size:9pt;font-weight:bold;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:26.5pt;"><td style="vertical-align:top;width:7.32%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0.05pt 7.85pt 0pt 8.15pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.18%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0.05pt 0pt 0pt 8.05pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0.05pt 0pt 0pt 9.15pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:10.36%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0.05pt 0pt 0pt 13.15pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.19%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0.05pt 7.3pt 0pt 0pt;"><font style="font-size:9pt;line-height:1.19;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.3%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0.05pt 0pt 0pt 20.25pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.43%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0.05pt 6.7pt 0pt 7.4pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.66%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0.05pt 0pt 0pt 18.65pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.01%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0.05pt 12.5pt 0pt 0pt;"><font style="font-size:9pt;line-height:1.19;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.21%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0.05pt 9.25pt 0pt 0pt;"><font style="font-size:9pt;line-height:1.19;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:14.03%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:10.3pt;text-align:center;margin:0.1pt 6.3pt 0pt 7.35pt;"><font style="font-size:10.3pt;font-weight:bold;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:26.5pt;"><td style="vertical-align:top;width:7.32%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 7.85pt 0pt 8.15pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.18%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0pt 8.85pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0pt 18.15pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:10.36%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0pt 10.6pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.19%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 8.05pt 0pt 0pt;"><font style="font-size:9pt;line-height:1.19;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.3%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:10.35pt;text-align:center;margin:0pt 11.5pt 0pt 12.3pt;"><font style="font-size:10.35pt;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.43%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 6.6pt 0pt 7.5pt;"><font style="font-size:6pt;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.66%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:10.45pt;text-align:center;margin:0pt 11.15pt 0pt 11.85pt;"><font style="font-size:10.45pt;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.01%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 4.7pt 0pt 6.35pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.21%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 7.6pt 0pt 0pt;"><font style="font-size:6pt;line-height:1.19;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:14.03%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:10.3pt;text-align:center;margin:0pt 5.5pt 0pt 6.5pt;"><font style="font-size:10.3pt;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:31pt;"><td style="vertical-align:top;width:7.32%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0.05pt 7.85pt 0pt 8.15pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.18%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0.05pt 0pt 0pt 8.85pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0.05pt 0pt 0pt 18.15pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:10.36%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0.05pt 0pt 0pt 10.6pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.19%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0.05pt 8.05pt 0pt 0pt;"><font style="font-size:9pt;line-height:1.19;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.3%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:10.35pt;text-align:center;margin:0pt 11.5pt 0pt 12.3pt;"><font style="font-size:10.35pt;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.43%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 6.6pt 0pt 7.5pt;"><font style="font-size:6pt;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.66%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:10.45pt;text-align:center;margin:0pt 11.15pt 0pt 11.85pt;"><font style="font-size:10.45pt;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.01%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 4.7pt 0pt 6.35pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.21%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 7.6pt 0pt 0pt;"><font style="font-size:6pt;line-height:1.19;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:14.03%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:10.3pt;text-align:center;margin:0pt 5.5pt 0pt 6.5pt;"><font style="font-size:10.3pt;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><font style="line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">AMENDMENT 3 TO LICENSE AND TRANSITION SERVICES AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">This AMENDMENT 3 to the License and Transition Services Agreement by and between Rigel Pharmaceuticals, Inc. (the &#8220;Company&#8221;) and Forma Therapeutics, Inc. (&#8220;Forma&#8221;) dated July 27, 2022, as amended December 22, 2022 by Amendment 1 and May 18, 2023 by Amendment 2 (the &#8220;Agreement&#8221;) is made and entered into this 30th day of June 2023 (the &#8220;Amendment&#8221;). </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">WHEREAS Forma and the Company wish to amend the Agreement upon the terms and conditions contained in this Amendment. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">WHEREAS Forma and the Company agree this Amendment shall apply only to the France Expanded Access Authorization Program (&#8220;France EAP Program&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">NOW THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt and legal sufficiency of which are hereby acknowledged, accepted and agreed to, Forma and the Company hereby agree as follows: </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">1. AMENDMENTS. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;"><a name="_Hlk138688102"></a><font style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;">Section 10 (Financial Terms; Royalty Reports; Payments and Audits) of the Agreement is hereby revised to include the addition of Section 10.15 as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;">&#8220;10.15 France EAP Program. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Forma shall lead the operational efforts and bear any and all costs related to the preparation and filing of the dossier (as detailed in Statement of Work 1 between Forma and Pharma Blue [</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> (SOW1)) and the set-up of the France EAP Program (as detailed in Statement of Work 1 between Forma, Rigel and Pharma Blue [</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;"> (SOW2)), including any amendments to SOW1 and SOW2. Notwithstanding the foregoing, the Company shall collaborate with Forma in the preparation and set-up process of the France EAP Program.  The Parties mutually agree to target a dossier submission date of </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, and a France EAP Program opening date of </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. </font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Forma, the Company and Pharma Blue S.A.S., having its principal place of business at 1800 route des Cr&#234;tes Les 2 Arcs-B&#226;t A, CS 60327, 06906 Sophia Antipolis Cedex, France (&#8220;Pharma Blue&#8221;), shall enter into a tripartite agreement, and shall make best efforts to do so by </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> (&#8220;3-Way Agreement&#8221;). Such 3-Way Agreement shall stipulate that, upon the latest to occur of the following events: &#160;(a) EAP granted by the French authorities, Agence nationale de s&#233;curit&#233; du m&#233;dicament et des produits de sant&#233;&#160; (ANSM); and (b) completion of all work under SOWs 1 and 2, and any other related SOWs, all rights and obligations of Forma under the 3-Way Agreement shall transfer immediately to Company, except for Forma&#8217;s obligation of payment by Forma to Pharma Blue under any outstanding SOWs, which shall remain with Forma as Forma&#8217;s sole obligation under the 3-Way Agreement until such payment is received by Pharma Blue, upon which time Forma shall immediately terminate as a party to the 3-Way Agreement, thereby leaving the Company and Pharma Blue as the only two parties in such 3-Way Agreement.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">c)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">Forma remains responsible for all France EAP Program costs, fees and expenses prior to the Company assuming responsibility for the France EAP Program. After assuming responsibility for the France EAP Program, the Company may off-set its France EAP Program-related out-of-pocket costs, less any reimbursement that it received for product costs from the French authorities (after deducting Company&#8217;s COGs if the French authorities do not provide Company reimbursement for any new patients), against royalty or milestone payments due to Forma (&#8220;Off-Set&#8221;). The length of term for such Off-Set is the earlier of  </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">[***] </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">from the time that Company assumed responsibility of the France EAP Program or </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">[***] </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">after Company&#8217;s partner executes a definitive agreement for rights to the France territory. Such allowable costs include any and all out-of-pocket costs associated with the France EAP Program, including but not limited to Pharma Blue fees and France EAP-specific packaging or labeling costs. The Off-Set expenses shall be calculated on a </font></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">quarterly </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">basis. Any Off-Set expenses not off-set in any specific </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">quarter </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">will, subject to Forma&#8217;s finance review, roll over on a </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">quarterly </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">basis.  For clarity, Company shall bear all responsibility for any money due back to the French authorities (if the cost of product during the EAP France Program reimbursed by the French authorities is lower than the commercial reimbursed price).   </font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">2. EFFECT OF AMENDMENTS. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;">Except as set forth herein, the Agreement and all related amendments shall remain in full force and effect in accordance with the terms set forth therein. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">3. COUNTERPARTS. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;">This Amendment may be executed in two or more counterparts, each of which shall be deemed an original and all of which shall together constitute one and the same instrument. Counterparts may be delivered via electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">[Signature Page Follows]</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">EXECUTED as of the date first above written. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 180pt;">RIGEL PHARMACEUTICALS, INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 180pt;"><font style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 180pt;">By: <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">/s/ Ray Furey</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 180pt;">Name: Ray Furey</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 180pt;">Title: EVP, GC</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 180pt;"><font style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 180pt;">FORMA THERAPEUTICS, INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 180pt;"><font style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 180pt;">By: <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">/s/ Agustin Melian</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 180pt;">Name: Agustin Melian</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 180pt;">Title: CPVP Rare Diseases NN and Advanced Therapies, EVP R&amp;D</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>rigl-20230630xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 7/31/2023 08:05:48 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">I, Raul R. Rodriguez, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:34.55pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.</font></font>I have reviewed this quarterly report on Form 10-Q of Rigel Pharmaceuticals, Inc.;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:34.55pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.</font></font>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:34.55pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.</font></font>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:34.55pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.</font></font>The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">c)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">d)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:34.55pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.</font></font>The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Date: August 1, 2023</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">/s/ RAUL R. RODRIGUEZ</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Raul R. Rodriguez</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Chief Executive Officer</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:avoid;width:79.41%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>rigl-20230630xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 7/31/2023 08:06:06 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">I, Dean L. Schorno, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:10pt;">1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:10pt;">I have reviewed this quarterly report on Form 10-Q of Rigel Pharmaceuticals, Inc.;</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:10pt;">2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:10pt;">3.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:10pt;">4.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">c)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">d)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:10pt;">5.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Date: August 1, 2023</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">/s/ DEAN L. SCHORNO</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Dean L. Schorno</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Chief Financial Officer</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:avoid;width:79.41%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>rigl-20230630xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 7/31/2023 08:06:09 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 32.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">18 U.S.C. SECTION 1350,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">AS ADOPTED PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350), Raul R. Rodriguez, Chief Executive Officer of Rigel Pharmaceuticals, Inc. (the &#8220;Company&#8221;), and Dean L. Schorno, Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:34.55pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.</font></font>The Company&#8217;s Quarterly Report on Form 10-Q for the period ended June 30, 2023, to which this Certification is attached as Exhibit 32.1 (the &#8220;Periodic Report&#8221;), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act, and</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:34.55pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.</font></font>The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">In Witness Whereof, the undersigned have set their hands hereto as of August 1, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:47.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:4.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:47.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:47.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">/s/ RAUL R. RODRIGUEZ</p></td><td style="vertical-align:top;width:4.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:47.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">/s/ DEAN L. SCHORNO</p></td></tr><tr><td style="vertical-align:top;width:47.92%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Raul R. Rodriguez</p></td><td style="vertical-align:top;width:4.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:47.92%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Dean L. Schorno</p></td></tr><tr><td style="vertical-align:top;width:47.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Chief Executive Officer</p></td><td style="vertical-align:top;width:4.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:47.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Chief Financial Officer</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Rigel Pharmaceuticals, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:avoid;width:79.41%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>rigl-20230630x10q004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 rigl-20230630x10q004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &; [T# 2(  A$! Q$!_\0
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MM[>-IIY7$<<:#+,Q. ![DU7^KV#[R^]?Y"_M*KV1^SG_  ]#^ W_ $&M8_\
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M$4%M",O(YZ*!ZU3X>P:5VY?>O\A?VE5?1'[*?\/0_@-_T&M8_P#!)<?X4?\
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M8K2U3?(^T%FP/8 G\*I\/8)*[<OO7^0EF-9Z)(_8[_AZ'\!O^@UK'_@DN/\
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MVUK NZ2:1B%5%'<DD #WJGP]@UJW+[U_D+^TJKZ(_93_ (>A_ ;_ *#6L?\
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M6)=SL$7U8X%1_;;?_GO%_P!]BOCSV":BH?MMO_SWB_[[%'VVW_Y[Q?\ ?8H
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M']JNT\*6OQ;ED\'+I2:5=:?:7,D>BLAM4N'B!E5%0E4PW\ Z5X_6_P#\*_\
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M% #_ #Y?^>LG_?9H\^7_ )ZR?]]FF44 /\^7_GK)_P!]FCSY?^>LG_?9IE%
M#_/E_P">LG_?9H\^7_GK)_WV:910 _SY?^>LG_?9H\^7_GK)_P!]FF44 /\
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M7_GK)_WV://E_P">LG_?9IE% #_/E_YZR?\ ?9H\^7_GK)_WV:910 _SY?\
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M+_SUD_[[-,HH ?Y\O_/63_OLT>?+_P ]9/\ OLTRB@!_GR_\]9/^^S1Y\O\
MSUD_[[-,HH ?Y\O_ #UD_P"^S6KIK,]MEF+')Y8YK'K7TO\ X]?^!&@!=3.+
M4D<'(_G7SQXF_8L^#GBSQ!>ZQ?>$3'<7TOGWEO8ZA<VMI=R9R6E@C<1L2>O'
M-?1T\"7$923.WKP2/Y55&D6I[/\ ]_&_QK6G5J47>G)KT=B91C+XE<\9\?\
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M4-,\&Z4VD6%]=&\F@-Q),OFE0N5WDE1@#@5Z;_8]M_=?_OXW^-']CVW]U_\
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MM_=?_OXW^-']CVW]U_\ OXW^- &316M_8]M_=?\ [^-_C1_8]M_=?_OXW^-
M&316M_8]M_=?_OXW^-']CVW]U_\ OXW^- &316M_8]M_=?\ [^-_C1_8]M_=
M?_OXW^- &316M_8]M_=?_OXW^-']CVW]U_\ OXW^- &316M_8]M_=?\ [^-_
MC1_8]M_=?_OXW^- &316M_8]M_=?_OXW^-']CVW]U_\ OXW^- &316M_8]M_
M=?\ [^-_C1_8]M_=?_OXW^- &316M_8]M_=?_OXW^-']CVW]U_\ OXW^- &3
M16M_8]M_=?\ [^-_C1_8]M_=?_OXW^- &316M_8]M_=?_OXW^-']CVW]U_\
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MD^S#ZS0_G7WHZNBN4_X79\)_^B@>'/\ P=1?_%T?\+L^$_\ T4#PY_X.HO\
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MVL*]Q':QW:3?9I1=>1&(U9V:$L&91\Q4CDDC% 'DUEKNOMX+\+>(M>UC7/\
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M )"+_P#QJCZS1_F0?V3CO^?,ON/F#%&*^H?^'='Q8_YZ^'/_  8O_P#&J/\
MAW1\6/\ GKX<_P#!B_\ \:H^LT?YD']DX[_GS+[CY>Q1BOJ'_AW1\6/^>OAS
M_P &+_\ QJC_ (=T?%C_ )Z^'/\ P8O_ /&J/K-'^9!_9.._Y\R^X^7L48KZ
MA_X=T?%C_GKX<_\ !B__ ,:H_P"'='Q8_P">OAS_ ,&+_P#QJCZS1_F0?V3C
MO^?,ON/E[%&*^H?^'='Q8_YZ^'/_  8O_P#&J/\ AW1\6/\ GKX<_P#!B_\
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M (,7_P#C5'UFC_,@_LG'?\^9?<?+V*,5]0_\.Z/BQ_SU\.?^#%__ (U39/\
M@G9\5XHV<R^'<*,G_B8O_P#&J/K-'^9!_9.._P"?,ON/F#%&*^H?^'='Q8_Y
MZ^'/_!B__P :H_X=T?%C_GKX<_\ !B__ ,:H^LT?YD']DX[_ )\R^X^7L48K
MZA_X=T?%C_GKX<_\&+__ !JC_AW1\6/^>OAS_P &+_\ QJCZS1_F0?V3CO\
MGS+[CY>Q1BOJ'_AW1\6/^>OAS_P8O_\ &J/^'='Q8_YZ^'/_  8O_P#&J/K-
M'^9!_9.._P"?,ON/E[%&*^H?^'='Q8_YZ^'/_!B__P :H_X=T?%C_GKX<_\
M!B__ ,:H^LT?YD']DX[_ )\R^X^7L48KZA_X=T?%C_GKX<_\&+__ !JC_AW1
M\6/^>OAS_P &+_\ QJCZS1_F0?V3CO\ GS+[CY=8?*?I7[9_!_\ Y)+X)_[
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M=A72Z\M[\-/$/AR:SUC4;_2M6U%=,NM.U*Y-SM+HYCEBD?+J59!E<E2K'@$
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MN?\ "Q]4US2OB'/I\[6/]B[39/<Z<\4B_NMY#QRA2<GN0.* /4?L(_Y[3_\
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MC^SH_P P?ZU5O^?2^]G[/_\ "Z/AM_T43P__ .#R#_XNC_A='PV_Z*)X?_\
M!Y!_\77XP;5_NC\J-J_W1^5']G1_F#_6JM_SZ7WL_9__ (71\-O^BB>'_P#P
M>0?_ !=0S_&?X;^9#CXA^'R-W/\ Q.X../\ ?K\9MJ_W1^5&U?[H_*C^SH_S
M!_K56_Y]+[V?L_\ \+H^&W_11/#_ /X/(/\ XNC_ (71\-O^BB>'_P#P>0?_
M !=?C!M7^Z/RHVK_ '1^5']G1_F#_6JM_P ^E][/V?\ ^%T?#;_HHGA__P '
MD'_Q='_"Z/AM_P!%$\/_ /@\@_\ BZ_&#:O]T?E1M7^Z/RH_LZ/\P?ZU5O\
MGTOO9^S_ /PNCX;?]%$\/_\ @\@_^+H_X71\-O\ HHGA_P#\'D'_ ,77XP;5
M_NC\J-J_W1^5']G1_F#_ %JK?\^E][/V?_X71\-O^BB>'_\ P>0?_%T?\+H^
M&W_11/#_ /X/(/\ XNOQ@VK_ '1^5&U?[H_*C^SH_P P?ZU5O^?2^]G[/_\
M"Z/AM_T43P__ .#R#_XNH;KXS_#<B/'Q#\/GYQG_ (G</_Q=?C-M7^Z/RHVK
M_='Y4?V='^8/]:JW_/I?>S]G_P#A='PV_P"BB>'_ /P>0?\ Q='_  NCX;?]
M%$\/_P#@\@_^+K\8-J_W1^5&U?[H_*C^SH_S!_K56_Y]+[V?L_\ \+H^&W_1
M1/#_ /X/(/\ XNC_ (71\-O^BB>'_P#P>0?_ !=?C!M7^Z/RHVK_ '1^5']G
M1_F#_6JM_P ^E][/V?\ ^%T?#;_HHGA__P 'D'_Q='_"Z/AM_P!%$\/_ /@\
M@_\ BZ_&#:O]T?E1M7^Z/RH_LZ/\P?ZU5O\ GTOO9^S_ /PNCX;?]%$\/_\
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M^+G]S0/_  9'_P"-U^DOGS_\_,OYC_"CSY_^?F7\Q_A1]?K>0?ZM8'^]]_\
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MC_"CZ_6\@_U:P/\ >^__ (!^;7_#O#XN?W- _P#!D?\ XW1_P[P^+G]S0/\
MP9'_ .-U^DOGS_\ /S+^8_PH\^?_ )^9?S'^%'U^MY!_JU@?[WW_ / /S:_X
M=X?%S^YH'_@R/_QNC_AWA\7/[F@?^#(__&Z_27SY_P#GYE_,?X4>?/\ \_,O
MYC_"CZ_6\@_U:P/][[_^ ?FU_P .\/BY_<T#_P &1_\ C='_  [P^+G]S0/_
M  9'_P"-U^DOGS_\_,OYC_"CSY_^?F7\Q_A1]?K>0?ZM8'^]]_\ P#\V'_X)
MX_%L(?DT#I_T$S_\;K])_AWH]QX=\ >&=*O-GVNQTRUM9O+;<N](E5L'N,@\
MTV2>?RV_TF7H>X_PHAFG\F/%Q*/E'<>GTKGK8B=9)2Z'IX'*\/E\I2HWU[LZ
M.H[B1HH)'5#(RJ2$'5CZ5A>?/_S\R_F/\*//G_Y^9?S'^%<Q[!P%[\3?&%W9
MW-JW@'4DD>-H]UK,5==R?*ZETVX#,%.<D%6."!SY]JG@*5-+\-PP>'?$7V"V
MTE-(N$ANF5;F#SP[&<>3O8/Y WXVL1,1@9)KZ \^?_GYE_,?X4>?/_S\R_F/
M\*[8XE0^&-OFS-PONSQ'P9>:[\.K_5;W3/ 5\DVOW#ZKJK7+237!F95$:E@@
M4!$'EJBC_EF!D Y/L?PZOM8UK2#JNM0W6GW=U@-IEP@46Q7@[>,X;[W4XR.>
MM6_/G_Y^9?S'^%'GS_\ /S+^8_PK.I651?#KW'&-NIT-%<]Y\_\ S\R_F/\
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M_8L7_/:;_OH?X5HT4 9W]BQ?\]IO^^A_A1_8L7_/:;_OH?X5HT4 9W]BQ?\
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MQ$_$?] L?_ G_D'^HU#_ )_O[E_F?9O]J^'?^A@M?_ V+_&C^U?#O_0P6O\
MX&Q?XU\9;5_NC\J-J_W1^5'_ !$_$?\ 0+'_ ,"?^0?ZC4/^?[^Y?YGV;_:O
MAW_H8+7_ ,#8O\:/[5\._P#0P6O_ (&Q?XU\9;5_NC\J-J_W1^5'_$3\1_T"
MQ_\  G_D'^HU#_G^_N7^9]F_VKX=_P"A@M?_  -B_P :AFU7P^)(=NO6I&[G
M_3(^./K7QQM7^Z/RHVK_ '1^5'_$3\1_T"Q_\"?^0?ZC4/\ G^_N7^9]F_VK
MX=_Z&"U_\#8O\:/[5\._]#!:_P#@;%_C7QEM7^Z/RHVK_='Y4?\ $3\1_P!
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MT5-N\LJ,68')1> !BM7[;=?\_#?]\K_A1]MNO^?AO^^5_P * +7ACPU8>#]
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M,F_FJ?\ @2_^1#_73,OY8?<_\SYQ_P"&?O&7_/I:?^!2T?\ #/WC+_GTM/\
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M^^5_PH WJKZA_P >-Q_N'^59/VVZ_P"?AO\ OE?\*BN[RY-K*#<,1M/&U?\
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M.E@A@^S."4\L$G;@!5P2>,MS6<(8!_$[*_=W^+TVY=>]QR==;?IV_P SIO\
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MH DHHHH **** "BBB@ HHHH *CN/]4?JO\Q4E1W'^J/U7^8H DHHHH ****
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M?\*/[%'_ #\2?DO^%:5<7#XZFN9?&,1CBM!H;!8YV5I0V8M^YD!4G'H#SZT
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MJX3XR?$F;X6>$H]9@TTZL[7D%L;99-C%7;#,.#DJ 3CVH ZG^Q1_S\2?DO\
MA1_8H_Y^)/R7_"N+\5?&&WT3Q1X*TFQM1J,?B&91)<B3:MM$RDHYXYW'@"L#
M3OBKXO;PU=>+)](TFZ\/VT\J36EK-*MW'$CE3("P*.0!DK\O'0T >I_V*/\
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MVKU:6"E7IQFG;_ASDG75.3BT?;_]C+_S\R?DO^%']C+_ ,_,GY+_ (5\0?\
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M &,O_/S)^2_X4?V,O_/S)^2_X5\0?\+5\9_]#5J__@6U'_"U?&?_ $-6K_\
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M22!G!'2^%]&U%_B1XCUJ_MC;Q_8[/3X9 ,+<%-\DCJ,DA<R #//!KIO-N?\
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M_/<?]^Q_C1R,.=&I167YMS_SW'_?L?XT>;<_\]Q_W['^-'(PYT:E%9?FW/\
MSW'_ '['^-'FW/\ SW'_ '['^-'(PYT:E%9?FW/_ #W'_?L?XT>;<_\ /<?]
M^Q_C1R,.=&I7+^-?!7_"8W.@L]VL%MIM^E])"T6_S]H("9R,=>O-:GFW/_/<
M?]^Q_C1YMS_SW'_?L?XT<C#G1YII?[/B:5:31KKLEQ,-6AO[6::V!-M!$28[
M88;D#<WS>_3BDLO@_P")XO#L_A>7Q+IZ>'+BXDDF:UTZ1;R2)W+&/>TQ1<YP
M6"=.@%>F>;<_\]Q_W['^-'FW/_/<?]^Q_C1R,.='E^I_LZQWEE=1VFO2Z9<S
MZHUX)[>#.VU951[7!;D,BA2WZ5:USX.:U#8Z_:>%?$5MH<.LW44LPELWD:.%
M8PC1HR2H5+ ??Z@=.>:]&\VY_P">X_[]C_&CS;G_ )[C_OV/\:.1ASHI^!/#
M\_A7PS::5,FGQK:KY<4>F0/#"J=@%=W.?4D\FN@K+\VY_P">X_[]C_&CS;G_
M )[C_OV/\:.1ASH\3_:ITF^UH>&[?3[*XOKC?,WE6T32-C:.<*"<5X)_PKSQ
M5_T+.L?^ $O_ ,37V#JTLX\>>'AYFZ0P7.'"?=X7MWKI]]W_ ,]C_P!^A7JT
ML7.A3C!1O_PYR3IQJ2<FSX7_ .%>>*O^A9UC_P  )?\ XFC_ (5YXJ_Z%G6/
M_ "7_P")K[HWW?\ SV/_ 'Z%&^[_ .>Q_P"_0K3^T:G\J(^KP[GPO_PKSQ5_
MT+.L?^ $O_Q-'_"O/%7_ $+.L?\ @!+_ /$U]T;[O_GL?^_0HWW?_/8_]^A1
M_:-3^5!]7AW/A?\ X5YXJ_Z%G6/_   E_P#B:/\ A7GBK_H6=8_\ )?_ (FO
MNC?=_P#/8_\ ?H4;[O\ Y['_ +]"C^T:G\J#ZO#N?"__  KSQ5_T+.L?^ $O
M_P 31_PKSQ5_T+.L?^ $O_Q-?=&^[_Y['_OT*-]W_P ]C_WZ%']HU/Y4'U>'
M<^%_^%>>*O\ H6=8_P# "7_XFHY?A[XI#19\-:N/F_Y\)?3_ ':^[-]W_P ]
MC_WZ%0SO=&2#,Q^]_P \AZ4?VC4_E0?5X=SX=_X5YXJ_Z%G6/_ "7_XFC_A7
MGBK_ *%G6/\ P E_^)K[HWW?_/8_]^A1ON_^>Q_[]"C^T:G\J#ZO#N?"_P#P
MKSQ5_P!"SK'_ ( 2_P#Q-'_"O/%7_0LZQ_X 2_\ Q-?=&^[_ .>Q_P"_0HWW
M?_/8_P#?H4?VC4_E0?5X=SX7_P"%>>*O^A9UC_P E_\ B:/^%>>*O^A9UC_P
M E_^)K[HWW?_ #V/_?H4;[O_ )['_OT*/[1J?RH/J\.Y\+_\*\\5?]"SK'_@
M!+_\31_PKSQ5_P!"SK'_ ( 2_P#Q-?=&^[_Y['_OT*-]W_SV/_?H4?VC4_E0
M?5X=SX7_ .%>>*O^A9UC_P  )?\ XFHYOA[XI 3/AK5Q\X_Y<)?_ (FONS?=
M_P#/8_\ ?H5#<M=$1YF/WQ_RR'O1_:-3^5!]7AW/AW_A7GBK_H6=8_\  "7_
M .)H_P"%>>*O^A9UC_P E_\ B:^Z-]W_ ,]C_P!^A1ON_P#GL?\ OT*/[1J?
MRH/J\.Y\+_\ "O/%7_0LZQ_X 2__ !-'_"O/%7_0LZQ_X 2__$U]T;[O_GL?
M^_0HWW?_ #V/_?H4?VC4_E0?5X=SX7_X5YXJ_P"A9UC_ , )?_B:/^%>>*O^
MA9UC_P  )?\ XFONC?=_\]C_ -^A1ON_^>Q_[]"C^T:G\J#ZO#N?"_\ PKSQ
M5_T+.L?^ $O_ ,31_P *\\5?]"SK'_@!+_\ $U]T;[O_ )['_OT*-]W_ ,]C
M_P!^A1_:-3^5!]7AW/A?_A7GBK_H6=8_\ )?_B:9/\/?%(BY\-:N.5_Y<)?4
M?[-?=>^[_P">Q_[]"HKI[OR>9B?F7_ED/[PH_M&I_*@^KP[GPY_PKSQ5_P!"
MSK'_ ( 2_P#Q-'_"O/%7_0LZQ_X 2_\ Q-?=&^[_ .>Q_P"_0HWW?_/8_P#?
MH4?VC4_E0?5X=SX7_P"%>>*O^A9UC_P E_\ B:/^%>>*O^A9UC_P E_^)K[H
MWW?_ #V/_?H4;[O_ )['_OT*/[1J?RH/J\.Y\+_\*\\5?]"SK'_@!+_\31_P
MKSQ5_P!"SK'_ ( 2_P#Q-?=&^[_Y['_OT*3S;K_GX'_?L?XT_P"T:G\J#ZO#
MN?#'_"O/%7_0LZQ_X 2__$T?\*\\5?\ 0LZQ_P" $O\ \37W/YMU_P _ _[]
MC_&CS;K_ )^!_P!^Q_C1_:-3^5!]7AW/AC_A7GBK_H6=8_\  "7_ .)J*[^'
MGBH6LV?#6L?</_+A+Z?[M?=GFW7_ #\#_OV/\:AO)KG[)-FXXV'_ )9CT^M'
M]HU/Y4'U>'<;X&MY;7P3X?AGC>&:/3[='CD4JRL(U!!!Z$&MRLLR7.?^/@?]
M^Q_C1YMS_P ]Q_W['^->,XMML[5))6-2BLOS;G_GN/\ OV/\:/-N?^>X_P"_
M8_QI<C'SHU**R_-N?^>X_P"_8_QH\VY_Y[C_ +]C_&CD8<Z-2BLOS;G_ )[C
M_OV/\:/-N?\ GN/^_8_QHY&'.C4HK+\VY_Y[C_OV/\:/-N?^>X_[]C_&CD8<
MZ-"?_4O_ +IKPSXY^"?%EOKWASXA>!X'O]9TFU>SN]/B*^9<6SE6R@8A6967
M[A(W!C@Y KV&66Y\I\SCH?\ EF/\:+62X,4/[\;<+QY8KHP]2>'J*I%)^3V:
M>Z9S8BE3Q5)TIMI/MHT]TT^Z9\X61^)G[07B#1;#Q!X>N_"WA'3[R&^OWO;4
MVK7)B8.D2(S%V)91D\*HR>3BO7/$WPMU76O$?B.]L_$$6G6>OZ?;Z==1BQ\R
M>)(S+EHI/,"AF$Q'S*<8!YZ5-\1OCYX'^%&J6VG>)=8-C?7$7GI"EM)*=F<;
MCL4XY!Z^AKDO^&SOA-_T,<O_ (+[C_XBMJN,G-KV<5%+HEIO?KUNE]QEAL%#
M#P<7)S;=VY.[[>73H30_L\746O079\2A["R,,5C:-9G-O;Q30R)#N\S&!Y.W
M(4$[LMDU-H_P$O\ 1M N]!B\1POI-T]I<RB33\S">%85)5_,QL80K\I!().#
MCBG:/^UK\,=>NVM;'7I9[D123"(6,X9PBEF"@IR< X Y..*],\*>*]*\;^'K
M'7-$O8]0TJ]C$L%Q'G#K]#R#D$$'D$5+Q6(<;MZ>BWW['1[*ES6Z^IQ6@?!2
MUTW4-3N+[4)+]+N7SDCB\RW,;_:;B<$E)!O'^D8P>#MSCGCG->_9^U?7;_6-
M1'BFTTV_U:%+2_\ L&EF*&\B42#?*HFW&7]X/F# 87:05)%>W45"Q=:,G)2U
M?DBW1@U:QX=JW[-$6KZ4EE=Z\WD RF7R;4HS*\ENY (?((^SXS_M>W-?0?A7
M=>+;R?7(M7N%N+::QDM+V^TUH5N+FV;]Y,T#%6VNJQ(>1DH2N!BO>:BN2RPL
M4;8WKC-6L;6:LW^7^74GV%-:V,7P1X43P;H0L%F^T2/<3W4TH78&DED:1]JY
M.!EC@9/'K6_67YMS_P ]Q_W['^-7;1G:'YVWMGKC%<D^:3<I=36+6R,WQC?S
M:5X5U>]M]OVBVLYIX]PR-RQLRY'<9 KS;P?\2;6+PA;ZQJ'B&;Q!<W%O:#[#
M;6"1R?:)@-L<055W%F) R< +DD $UZ;XITPZUX=U+3Q((3=VTMN)"N0N]"N<
M=\9SBN4U'P(U_P"#=$TA=0:"^T?[++9WPCW!)X% 5S&3RK88%<]&/(.#1&Y,
MK=2CJGQ<L/#MIJKZ[IE_H]UI]F+\VLWE2&:'>$WQNCE#AV56RPV[@3P<U#JW
MCO6[?Q5X)LH=#GM[;5Y+I;N*>6W+H$B++AA(1C@/E2<KQUXJR_@G6+_4KC6-
M1O\ 2[K518MI]G;_ &)S911.ZM-O1G+2%]B@\@    \YJ>%?A.WAL^&,:@C1
MZ-<WUP+:.%EA5;A640P@L2D<>["@D\#'';34C0CUOXW6.B^')_$?]@:S>^&X
MY!&FJ6R1%)<OL#JAD#^66. Y4 ]>G-3:M\9;#1KCQ$9]&U9M,\/W*VNI:FD<
M9AA+(C[E7?OD $B[MJDCTK)USX1:_?> YO!5AXFM;+0-HB@EEL&DNTMPX80,
MWF!2 !MW[0VW'?FMW5_AI)JGA_QKIHU%8F\1WANUE,)/V?,<*;2-WS?ZG.>/
MO>U&H:$TWQ3L-..H)JVGZAH]Q:V\5TEM.B227$<DGEQB,1LV7,F$V'!!8>N:
MC'Q/:+Q/IWA^]\-:OIVJ:C;W%Q:B8P-$XB0,RF1)"%;D#:?7/3FE\7_#,>+/
M$$^IG4GLG-C%! 8HPSPSQ7*W$<V2<, RC*D<\\\U%'X(\1:AXYT'Q#K&NV$D
M.E17,:Z?86+Q)*TJ!/,+/(Q!&.G3!/?FC4-#D/#OQKO8?#.E:[XBCN(!_9&H
M:E<V5K:PO]H6"1%WJXDRI ; 3'S'))'&>HUSXG^3H>JF6QU+PW>+I,^JVDMW
M;PS-)%& 681B3&]=R$QN5/S#GKC(N/@7+/X9L=)&M1J;;1K[2?-^S'#&XD1Q
M)C=P%VXQWSU%=#\0/AM)XWO!,FHK9 :/J&E%6A+Y-R(P)/O#[OE].^>HHU#0
MS=(^)NI2:]XKLSHNH:W!I,\&);&&*/9&]K%*1\[CS'+,YVKD@8'IGLO^$JT^
M?PD?$5K-]HTTV9O8Y%!&Z,(6Z'D' Z'H:Y:U\ ^)-%UCQ#=:3XALH[?67A<Q
M7=@TC6K);QP[XR) &)V9PPQT]\[?_"%0Z=\.9/"]A(YC33GLHI9CEF)0C<V.
MY))/UH5PT.>UCQYK&A_"72M3;[)/XLU:&"*RAD CA:[G **1G[B!LL?[J$TZ
M#XGW&I>!-#O["V@?7=4NUTH02L?)M[P,RS;RO)5"CM@<D  8S2:%X!/B6#P?
MJ/B*V0P:7I"0KH=Y;!A%=E%1Y7W$@D*I51CC<QSS4LWPAMDNM7_L^\&DVEU<
M6^HV4-I J_8+Z,8,R#[I5P$#)C!PW/S&EJ&AL0:1XLL[RV?_ (2&UU*U<E;J
M.XT]8&0$'YX2A/(./E<,".XKB9?%OB71=*\57DNM+J#Z9K5OI<"2V,*+L<VY
M9FV $MB5QZ=#C(KN+/2O%4VHV<FHZ[8QV=NV^2#3+%HVNCC #M([[%[D(,G'
MW@*S-2^&<FH:7XAM!J*1G5M7AU0.82?*">1\F,\Y\GKQ][IQ18+F=<_$R]\-
MZ3XUBU=8Y]9T2YQ:QQIL%W%.?]$P.Y+$QGU*$]Z[O16N[?1[*/5KF";4T@3[
M7)$ B&3;\Y5<\+G./:N<\3?#"R\2^/= \3RW,D3Z86,EHH_=W6#NAW_]<W^<
M>]6-1^$_@W5=5OM4N/#6G-JU]$\%SJ,</EW4B,NQE,JX?E>.#TIJXM#(^'?Q
M-G\?>+_$EM%:"#0[**!]/N6'SW:LTBO,/]@E,+Z@$]"*7_A9]MI?C/Q1I6K7
M\-M%8I;/:)Y+%CO1RV2H.>0.N*O>$_A?8^#_ !7J.K6,]P+:YLK>RBLY+F>5
M85B+?WY&!&&  Q\N..M:>E^%7TWQ%XCU/[7O75A !$%(\KRT9>3GG.[/;I1J
M-6N<QX/^*DVL>'-!S8SZYKU_:->2P:>L<2QQ"1E#L9&55!P !G).>.N+H^+V
MFW$^EVMEI]_>:E?2SP_8!Y44L#PX\U7WN%+ $'"DY!R,CFJF@_"_4/",>FW&
MCZM;?VC;V1L+DWEL[P7,?F-(APKAE92QQR003GMBMJ_P>N-4\.2Z6VH6,TU[
M=O?WNH7-DQG2X;;MEMBKCRB@4!<YZ#)/.5J&AM>$/%NK:WXX\6Z5>6)@L=-D
M@6VFW1\AD).=K$G/49' %9.IZOK]EX\U6R_X2!TTVVTA]36(:? [*V_;MS@%
M@!SU!/K75Z!X5;1/$&OZDUW]H&J/ P0IAH_+C*<G/.<YZ"JNI^"7U'Q'J6J"
M\6,7FDMI@B,9)0E]V_.>?I^M.SL%U<Q="^+MG>6$S-;7UY%INGPW=_J CBC"
MEX!*,PB0L-P_N@J"<9.":U=(^(]OJA\/B33+RR.MES:>8\,BE%B\P.6C=A@K
MTQSGK6);?"S4+;4]"O%O],CGT:Q6S@N([!UFN%$/E^7.?,P\6[Y]O7..1UJ/
M2?A#=:''#=6.H6-IJ=OJ4FH00PV;BQB\R/RY(ECW[E5AEB0P^8YQZFH:&W?_
M !3TNRGN;5;:ZN+^/4/[-BM$V*]Q*(UD)4LP4*%;)9B,8-97B'XIM'H&HW5C
M";+4](N+<WMA=[)&,+N!E61F4AEW88'@CI3+OX._;HXKZXN[&[UY=1DU%I+N
MP$MF[/&(VB,1;.S8  =V[(S[55UWX>ZC!X3O]-BBL[FZUB]MT=-)TY+2WM(0
MXW'CYF &26=B<] *&V"L.\;>%/$/BWQW:VMW%+%X7E@N;0S6%^T;Q*T1!D=1
M'@.3@+\Q_6NR\ ^";/X=^$[#0+"YN[RULTV)-?2^9*WU( _("NB)RQ/O25HI
M-1Y;Z$-*]PKD3XFUG7-3U"V\/V5B;6PE^SS7FI32*LDV 2D:(I.!D98GO@ U
MUU<DWA;6-&U._N?#^H645O?R^?-9ZC;O(B2X +QLCJ1D 94Y'&1BH92(KCQA
MK27%AH\>CVR^([F-YI(GNRUK!$A ,ID5=S D@!=H.3SCK535/'NLZ FH6E[I
M%M-J\%JU];K:SL8;N)2!(%RNY74'.T@@^M7)_!^LM+8:HNMP-XBMD>)[A[+;
M;3Q,03$T2ON ! PP;=QSGD5;TCPM=G7)-9UN\@OK_P @VL,-K"8X((R<L &+
M,S-@98GIP *6H]#%\1?%9+%+=]'M(]4C;2WU>9VE*". */+Z \LQ QVY]*AT
M?Q[XE\2'49M,TG2W@L1"3!/=2K+,7B$A"L%*KUP,@^^*71_@[;Z'X>\4:;!J
M,DKZR72*:=-WV2$YV0J,\JI9SV^][4ND> ?$7ALZC%I>LZ;'#>K"#+<6<KRQ
M%(A&2H$@4],C/XYI:AH=CX<UZ+Q/H%KJEK%)''<(3Y<HP48$JRMCN&!''I7'
MGXFWD'A2\U&>PM%O(=5.EJOVAEMP=P42.Y7*K\W/':M_P]\/]%\.QV+0VBS7
MMHFP7LO^M8DDLQQQDDD].]5;/P3<Z?X<U[3H+Z SZE<SW"336V](O,QP4)^;
M&/H:>HM"SX+\53^(QJD%W#;QW>FW1M99+*4RP2':&!1B >AY!Z5TM8O@_P )
MV'@CP[::/IL2Q6UNIR54*9')RSG'&6.36U5+S$PHHHIB"BBB@ HHHH ****
M"BBB@##\;>(9O"OAJ]U2"R:^DMU#>4"0 ,X+-@$[5')P"<"N9O\ XF7OAWP]
M8:_K%E8'0G<B[U'3+MKB..,C]W,@VY*,>"#R#CK78>(+'4-0TYH],U(Z7>AE
M=)S$)5.#RKJ>JGH<$'T-<I;_  RDC\#ZUH9O;>&;5)GN&:UMREO S,&(CCW9
M"\>O4YJ7<I6,J7XPZE:W^BZ?-X=SJFMVTMSI]A%.3(P5L+YA*X0;<,Q[ X&3
M7I.G-=M8P&^2&.\*@RI;L6C5NX4L 2/<BN.\4_"V#Q5JFGWL]Z]M+8V?D6\T
M"XF@FR"LR/GC&.1W'!KK='AO[?38(]3N8;N]1<23P1&))#_>VDG&?3-"OU!V
MZ%VBBBJ)/$/VDK^YTZ;PW+:7,UK+NG&^&0HV,#C(->.?\);KG_0:U'_P+D_^
M*KV3]I#3;O5)_#<-E:S7<VZ=O+@C+MC YP*\>_X0KQ#_ - +4O\ P$D_PKZ#
M"<OL5?\ K4X:M^=V&?\ "6ZY_P!!K4?_  +D_P#BJ/\ A+=<_P"@UJ/_ (%R
M?_%4_P#X0KQ#_P! +4O_  $D_P */^$*\0_] +4O_ 23_"NN]/R,O>&?\);K
MG_0:U'_P+D_^*H_X2W7/^@UJ/_@7)_\ %4__ (0KQ#_T M2_\!)/\*/^$*\0
M_P#0"U+_ ,!)/\*+T_(/>&?\);KG_0:U'_P+D_\ BJ/^$MUS_H-:C_X%R?\
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M?_PA7B'_ * 6I?\ @))_A1_PA7B'_H!:E_X"2?X47I^0>\,_X2W7/^@UJ/\
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MK^T+K_GZN/\ O\W^-']H77_/U<?]_F_QH_LV7\_X?\$/K*_E/N7[!-_S]?\
MD/\ ^O1]@F_Y^O\ R'_]>OAK^T+K_GZN/^_S?XT?VA=?\_5Q_P!_F_QH_LV7
M\_X?\$/K*_E/N7[!-_S]?^0__KT?8)O^?K_R'_\ 7KX:_M"Z_P"?JX_[_-_C
M1_:%U_S]7'_?YO\ &C^S9?S_ (?\$/K*_E/N7[!-_P _7_D/_P"O4,]E,)(/
M](S\W_//V^M?$']H77_/U<?]_F_QH^WW7_/U/_W];_&C^S9?S_A_P1_65_*?
M<OV";_GZ_P#(?_UZ/L$W_/U_Y#_^O7PU_:%U_P _5Q_W^;_&C^T+K_GZN/\
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M2;>/D_[HKBQ.&EADGS7N=%*HJK>@_P"P3_\ /U_Y#_\ KT?8)_\ GZ_\A_\
MUZOT5P<S.CE10^P3_P#/U_Y#_P#KU%=V,RP9-SGYE_@_VA[UJ57OO^/?_@2_
M^A"CF8<J(/L$_P#S]?\ D/\ ^O1]@G_Y^O\ R'_]>K]%',PY44/L$_\ S]?^
M0_\ Z]'V"?\ Y^O_ "'_ /7J_11S,.5%#^SYO^?K_P A_P#UZ/[/F_Y^1_W[
M'^-7Z*.9ARHH?V?-_P _(_[]C_&C^SYO^?D?]^Q_C5^BCF8<J*']GS?\_(_[
M]C_&H;VPE6SG)N 0$/'ECT^M:M5]0_X\;C_</\J.9ARH@_L^;_GY'_?L?XT?
MV?-_S\C_ +]C_&K]%',PY44/[/F_Y^1_W['^-']GS?\ /R/^_8_QJ_11S,.5
M%#^SYO\ GY'_ '['^-']GS?\_(_[]C_&K]%',PY44/[/F_Y^1_W['^-']GS?
M\_(_[]C_ !J_11S,.5%#^SYO^?D?]^Q_C1_9\W_/R/\ OV/\:OT4<S#E1FS:
M?,(G_P!('0_\LQ_C26]A,8(B+@#Y1_RS'I]:OS_ZE_\ =-5;G4(-)T9[VY;9
M;V\!ED8#.%5<DX^@I<S74:A=V2'&WN1UO,?]LQ_C6%H/B_3/$U]=V>F:Y'=7
M-KGS46$C@,5)4D ,-P(RN1FOF!_BMX/N/%Y^/?\ PD^OGPTK?V ?#WV3YS,4
M)'_+39Y94^9ZY'KQ7I7A'XA>$?#OQ8\/^$3K.I:IJ%YI0;1D>S5(+6VE_>+&
MSC#,Q6-0"1P$&>22>*.*4GNO^'V^\^EJY+4HP;<9-J-W[K5FOB3NM>72[NEK
MI?8]R^S77_/Y_P"0Q_C1]ENO^?S_ ,AC_&O ?%/[1>O>'?B?JFB^5I TBPU:
MSL&2>VN5E:*9$+RFY!\F/;N/#8SC'<5T%M^UCX/OYH[>SL]8OKNXE2.TMK6W
MCDDN5;?M=0)/E4F,\/M89!( .:T6)IW:N<<LGQBC&:A=-)Z=FKZ_+^M&>O?9
MKK_G\_\ (8_QH^S77_/Y_P"0Q_C7A&E_M%:JM[IFMZW)X?TKPEJD]U';64TD
MJZBD4!=3,6Y1V+(08P 0",$\UKP?M9>%+R+%KIFMWEYL>4V5M!#)*L:QB7S"
M1*5 *9.-V0000#Q36(IOJ*63XR+LH7].G1W]&M>A[!]FNO\ G\_\AC_&AK2Y
M88-WD?\ 7,?XU\Q+^U;KM]J-S);?V.ND27MQ:V[/870ECB6 RQS-(6$3D\#R
M@0QS@5ZSX"^.ND>+KW2=-\F^\Z]0Q1:FUJ([.ZN4B$DT<?SE@0,G##'RD G%
M*&)A-V3*Q&3XO#1YIPTM?T_K^M#T'^SYO^?D?]^Q_C5JWB:&/:S[SGKC%2T5
MTMMGBI)%#7M-.LZ)J%@)!$;JWD@\PC.W<I7.._6O*8/@5>^(-&T_2_%6I6<M
MIIV@3:# -+@9'D2:*.-Y':1FZ")2J 8W<G.!7L<@<KA&"MZD9J'R[G_GM'_W
M[/\ C2&>:>'OA%>6.JVMS=_\(U;I9P21J^D:#';S74C(4$LCDDQX!)VQXR3]
M['RG1TCX7S:99_#6 ZC'(?"5MY$C"$C[2?L9M\CGY>3NYSZ>]=UY=S_SVC_[
M]G_&CR[G_GM'_P!^S_C0!YI#\(+_ $K69M=TS6(8]:35;V^@\^W9H&@N5C$D
M$BA@>L*,'4C!4<$9!F\3?##5_&]G8W.N7^D76JZ=??;;*!M,\VR0>4T312([
MEI RNWSY4J<$#C!]%\NY_P">T?\ W[/^-'EW/_/:/_OV?\: /,K7X.7)LI/-
MGT?3[B35+"_$&D:2EM!%';3K+Y8(^=V;:<LYP"1A1@YM^,_A+<>*M3\974>J
M1VR:_H,6CI&T);R61ICYA^8;@?. QQ]WKS7H7EW/_/:/_OV?\:/+N?\ GM'_
M -^S_C0!YQJOP>GU'QP=?&J1)&;[3;SR# 2<6J3*5W;OXO-'..,=\U'J_P &
M;C4_&][KPU:-(I]2TV_%N8"2HMDD5ESNZMO'..,=Z]+\NY_Y[1_]^S_C1Y=S
M_P ]H_\ OV?\: /)-(^#?B2U\$+X*OO$EE<^'97D^T316+1W;0/*TC6ZG>5
M(;9O(R!GC.#7L2J%  X J#R[G_GM'_W[/^-'EW/_ #VC_P"_9_QH L457\NY
M_P">T?\ W[/^-&RY_P">T?\ W[/^- %BBJ_EW/\ SVC_ ._9_P :/+N?^>T?
M_?L_XT 6**K^7<_\]H_^_9_QH\NY_P">T?\ W[/^- %BBJ_EW/\ SVC_ ._9
M_P :/+N?^>T?_?L_XT 6**K^7<_\]H_^_9_QH\NY_P">T?\ W[/^- %BBJ_E
MW/\ SVC_ ._9_P :/+N?^>T?_?L_XT 6**K^7<_\]H_^_9_QH\NY_P">T?\
MW[/^- %BBJ_EW/\ SVC_ ._9_P :/+N?^>T?_?L_XT 6**K^7<_\]H_^_9_Q
MH\NY_P">T?\ W[/^- %BO.M8^#=GXCF\5?VC=$KK$D,UO+;J8Y[*2-"JR(^?
MO G(/'IS7>^7<_\ /:/_ +]G_&CR[G_GM'_W[/\ C0!Y/-\%M9D\.Z/X=DU^
MUO=(LHK=1)<V.+FWEB.?/@=6&UV[[L@'IQQ710^#O$?A:[OU\,ZCIPTR]F:Y
M%KJ=O(YMI6^^49&&Y2>=K#@YYYKMO+N?^>T?_?L_XT>7<_\ /:/_ +]G_&@#
M@SX,\56?B>QUR'5M,O[P6!L;LW-I)"'S('WHJ.=O3&#GZU):^#_$_A9KNW\.
M:IIO]FW,KSI!J=M([6CN<L$9'&Y223M;!!)YQT[CR[G_ )[1_P#?L_XT>7<_
M\]H_^_9_QH Q=3T#5=3\%7&DR:T8]6FMS$=4MX/+PY_B$88X';&[/O7GO@KX
M-^(_"?C"WUB#7[+3M*+?Z5X<TJWEBLI3MP9SN=F,IZG^$]P3S7KGEW/_ #VC
M_P"_9_QH\NY_Y[1_]^S_ (T <MK_ (/U)?$J^(?#U[;VFHM!]FN;>]A:2"YC
M!RN=I#*RGH1GJ015.]\$:_XBL1-J^M6D6L6MREWITVGV16.T901M8.Y,JMT.
M=O'3%=KY=S_SVC_[]G_&CR[G_GM'_P!^S_C0!QT/A#7=>UK3KWQ-J%B]MILG
MGV]EID#HLDP'$DC.Q/'4*._4FH]%^$]KHWQ*U3Q6MY))'=Q_N=/9?W=M*W$L
MJGU<!0?I7:^7<_\ /:/_ +]G_&CR[G_GM'_W[/\ C0!YCI'PP\0^$KVPN]'U
M'2[B6"VN;=Q?02@'S9S*"-C=NF#U]JW-!^%5A;H]WK936-9GNC>S781H4$A
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M[C_GK'_WZ/\ C7J4L;.A3C"*_JYR3H*I)R;/C?\ X55XP_Z%O4/^_7_UZ/\
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MYZQ_]^C_ (T?VG4_E0?58]SXW_X55XP_Z%O4/^_7_P!>C_A57C#_ *%O4/\
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M_P">L?\ WZ/^-'EW'_/6/_OT?\:/[3J?RH/JL>Y\;_\ "JO&'_0MZA_WZ_\
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M_P#OV?\ &CR[G_GM'_W[/^-)4::U40GF.,JIQG5;3\RQ15?R[G_GM'_W[/\
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M=?\ ?]_\:W?^%8>+O^A;U+_OP:/^%8>+O^A;U+_OP:/:4^Z#EEV9A?VK??\
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MS%&V*S;9 K$ \<&HM.^+^E:@^F2OI^J66E:K*(=/U6ZMPEM=,W^KVX8NH?\
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MUG;\/=-E:73[*U#I=QJH4VL+2DD%+=\LAZG9"&SM.[V7%UZP_D:,77K#^1H
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M**KXNO6'\C1BZ]8?R- %BBJ^+KUA_(T8NO6'\C0!8HJOBZ]8?R-&+KUA_(T
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% "&OFG7/C_XJT_6M0M8OL'E07,L2;K<
MDX5R!GYO05]+'FO&M3_9LL=2U*[NVUNZC-Q,\Q40(0NYB<=?>O@N+,+G6)IT
MEDTFFF^:TE'32V[1];P_7RRA.H\R2::5KIOUV1ZCX6U*75O#&E7]QM\^YM(I
MI-@P-S*"<#\:Y9/&OB36=5U)]"T2QO-'TZ[>RD-S?-#<W+I@2F-=A10I) WL
M-Q4_=&">PT/2UT31;'3DD,J6L"0!V&"P50,D?A7-ZC\+=,O]8NKU+W5;&&\E
M6>]L;*^>&WNI   [*O()"J#L*[MHW9K[K!IPHP5?XK*_76VI\MB&I59.E\-W
M;TZ&;J?QV\,:1%J-Q<_VB+*T65DO(["1XKLQ,$E6 @$R,K'& .<-MW $B*3X
M^>'+6"]FO+;5[&.R%PMR9].D'E30Q&9X.,YD,0W@+D,,8.3BK5W\%/#U[-=>
M<U_):2L[PV1NV$%JTD@DE:)?X2[#)Y. 6"[0Q!9XX^#>E^+/#>MZ?#++9W6H
M37%VMP9&(CN);5K8O@$' 1ON@CGD$&N]?5]$[G*_:>1(OQFT802K+9:O;:F'
MB2+29]/=+R?S YC*1GJ"(Y#G(V[&W;<5G0?M"^&;B;REM=:#1*[W9?2Y4%DB
M3-"[3$@;0'5O7(!897FM$_!G1Y$GEEU#6)]5:6*6+5I;]FN[?RPPC6-R,!0)
M) 00=WF-NW9I--^"?AS3M,U:R!U"Y758)(+N6ZO7EDD#R/(QW'H2TC=.@P!@
M "C_ &?K</WAHI\4_#ADMXY=0CM'F21O],(@",DOE%&+D .7W +U.UL<"N6T
M7XX[X)SJVDS+?/J;Z;;Z7I4<MU>)*J/(4GC**(SY:;P^XHRL"&Q@GK/#G@&S
MT75_$FI3)#/<ZU>+<2;8R%1$1410"3SPS$C&6<FN9OO@392ZEIMY::WK%M/:
MW)E-T;UWN5B6&>.*%)#T1#.YPX?()!SQ@C[#5,'[32QI3?&SPY'%;R1C4+A#
M&9KHPV,C&P19&C9K@8S'AT=2#D_(QQA2:IS?M >%[>+4)Y4U.*TM6N(UN9;!
MTBN9(9/+D2)C@-AN_"D9(. <6W^"?A\V]O!%+J5O&(S#>"*^<'44+M(PN3UD
MW.[DG@_.PR 2*MZA\)=$OM/M[5'O+3[.]U)#+;W!5T:X9FDZ@@@[F !! !QC
M%+_9_,/WGD1W'QAT.TOQ;S0ZE%&NQ)[E[&00V\SH'6"1B/ED(9?E[%E!(+#.
M/8_M'>#+VXTB%KNXM)-2BAG1+R'R'B29B(&D1B'7S,9'!('+;16C%\$O#L M
MH8FU"+3H4C!TY;Q_L\LD:!(Y73^)PJKSG!*J2"0*G3X/:!!?V%S!]LMUMH;>
M!X(KDB.Y6 8A,HZL5]B-W1MPXI_[/YA^\\BK:_&*RU7Q=HNCZ?I][+:ZE+<Q
MQZE- \<$GDQNS&)B/G&Y-O.W/)7<!6)?_&N_\.7VM6NL:=;/-%>RV.G1Z:+B
M8S,EN+@O,?+Q$@1AD\\@XSD ]-I'PAT;1O$5CJT%SJ;#3VF:QL9+UVM;4R@B
M39'[[CC<3MSA<#BK6I?"[0M5OKF[GBG,UQ+-,Y6=@"TL @?C_<4?0\T<U!/;
M2WXA:I;<YJ_^/NE6.E).+&]N9701+<06TC61NC$)/)\[;QUQN*@9X^]Q74?#
M_P"(=C\0;*>:RAN(S;%$F:2)A'YA0,RHY^]M)P>AZ'&""<*X^ WAVX>.,W&K
M)IZ2+.-.COW6V\X)L\PH.I('(SMS\V-W-=!X/^'FF>"KN_N;&2ZEFO$AB=KJ
M<R;8XE(C1>!P-S=<GGK@ !3]AR>Y>X1]I?78ZBBBBN0V"LN]_P"/E_P_E6I6
M5>G_ $E_PK2GN9SV(:*,TAP00>AK<P/-+?XU6NG6NM77B..TTA+*_%A%9I.Q
MO#(6(19(Y%11O4!U8,5()Y^4U%)^T-X7A+7#S@Z:\,36TR.OFS3.\B-%M)"@
MKY9).['7MUUW^#>@2/<RO-J<EW(Z/#=RWI>:UV,S*L3,#A06;AMW!QTXI;CX
M.>'IDB*MJ$-W"B+'?1WA,Z%6=MP9@1DF1\Y&"#C  %==Z'9F7ODMC\6]"U@6
M;:4FHZS'<1+.TFG6+S+;HS%092/N_,K# R?E/&!FJ$?Q9=_!-[X@?19[7[-J
M;:>;>Z;86"S"/S 1GL<X]L5JQ?#+2[2ZM9[*]U;3GBA2"7[)J#I]J12643$Y
M+$$L<@@_,1G!Q5NX\ :-=:!<:-)%,;&>Z:\=1,0WF&3S"0WIN[5%Z2>S'[QD
MZ'\9/#VO/;B-=2LX[HK]FDO[%X%F1GV!US_#NPN3CEAQ@YJM<?'GP;:ZO;Z=
M+J3)-*0"S(%6/<Y1"P+;L,5." >!DX%:MS\+O#MYIRV,UO-);#3SI@4W# ^0
M6#=1SNRHPW44V;X6Z%)J=O>Q?:[3RHXHVM[6Y,<4PB&(C( ,DKZ@C/?-->Q\
MP]\Y?7/CY:6UO97&E:1=W=I=)=L+R\B>"!# I))(#$J2",@$C!X[5LO\;/#=
MO+$+D:C;VLWFB'47T^3[).T:EI!'+CG&U@,@9(XS3S\&?#DEO<1W'V^[>XDG
MDEFGNR9',J!'R0 /N@ <=N<FN=L?@0\NM1_VQK+:AX>M6N&M=,C>6-5\Y6!!
M7=M7&XD%<\\C;S6G^SM=43[YIWWQOLH+VULXM"UM;EKRWM[F*]L&MS;QS9VR
MY8X884]#QT.*M3_'#PY;11N\.K_OW1+15TR0M>AW"!X1_&NXC)XP"#TYJU8?
M"31;2[>[N;O5M7NWDAD:?4[]IF/E9\M<8  &XY '/?)I;'X2Z#97UK=%]0N7
MLY$>S2YO&=+15?>(XQCA-P&0<G  SCBH_<]F5[Y5U7XJ16_B/2K.Q_LZYTNZ
M21I-0>\)4NGWX(S&KJ9@,G8S G&!3[#XT^'+W3S>2)J=A$\ NK9;[3Y(9+N,
MD &%#RYR0-O!Y'&.:O\ BCX:Z5XIF$TTEU 0O_'O#.4MI''*.\0X)4\@C!]2
M:R-"^"ND:?HUO9ZC>ZCK%Q#9I:1W%S>.QM@N"3!GF,E@#DEB, 9QQ0O8N*O>
MX/GOH23_ !MT"VFAMFM-:-\RR-+9KICF6V$>-YF&<( &!ZG(/&:GC^,GAZZC
MG:S&H7Y2X6UA2ULF=KJ0J&VQ#^+ ()SC YZ5:L/A=HEBUQ*S7MY=W,$MO<W=
MU=%Y9UD(W%C@#/R@#   ' JE%\&M!@EDGBN=5BO<1+#>K?'S[98UVHL;;>!C
M((8-G)I?N?,/?*UY\?/"5BEP\LM^L<$<;22M9,D:R2,52$NY4"4E2-A/&.2!
MS3Y_C?X>DT1;_2UO=99K>6Y,-C:M,T*IPQEVY"C=@<9)SP"*NCX1>'$TZ>UB
MCNXC*\4OVE;EC,LL9)656.?GRQ))!SGI3+[X0Z)>6<4"WFKV;"![::XL]0>*
M:YB<Y997 Y!//&".Q XI_N/,7OE36?B/JEE:>$;ZVL-/^PZS#YUPUS--OMQY
M/FG8$0[^,CG'-5]'^.6G:J;AUTW4F#%#96<%E*U[/&4+F1H6"[% &<[CD>^!
M75W7@;2+O3M)LI(YC;Z7'Y5L!,057R_+Y/\ %\OKWYK(N/A#H3R)/:S:EIMX
MBHB7EE>F.946/R]H.",%>""/?@\T)T6K-#M.Y:\!?$2U^(#ZE+8V\D5E;&+R
MI)T:.20,&SNC8 H05(P:ZVN=\&^ ](\!VLT&E"Y"3;?,:ZN&G=MN<$LW)/S'
M)[UT6:PGR\SY-BHWMJ%:EG_Q[K67FM2S_P"/=:YY[&T-R>BBBL3<**** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "FE
M%)Y /X4ZB@!NQ?[H_*C8O]T?E3J* &[%_NC\J-B_W1^5.HH ;L7^Z/RHV+_=
M'Y4ZB@!NQ?[H_*C8O]T?E3J* &[%_NC\J-B_W1^5.HH ;L7^Z/RHV+_='Y4Z
MB@!NQ?[H_*C8O]T?E3J* &[%_NC\J-B_W1^5.HH ;L7^Z/RHV+_='Y4ZB@!N
MQ?[H_*C8O]T?E3J* &[%_NC\J-B_W1^5.HH ;L7^Z/RI0 .G%+10 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 (:X#7_ !QK&C^ M*U0Q0Q:G=7=M:R_Z%-,J>9*$9E@5O,8XY"@
MY^M=Y<3?9X))=CR;%+;(QEFP,X [FN"\1>,K>?P*=?O/#MS=I87:RFS^T1!D
M>.3Y9%??L;#8Z'KD=J ,>/XT7.AOY'B+3_*NI(H/LT$$9ADG9WN?G99&_=+Y
M<"OM<Y7=M))Q6M<?&:Q_LJ34;'1-7U.UM[-;Z\\B*-'M8V+8#+(ZEF^1R0N<
M 9[C-2T\0>"O&^I7R:@!INN6\C03AKMH9HFMM^=LT;#:0LDA^5@2CDD;34K^
M'_AWXKT"XNRD+:586GV>YVW$UN@MT&\"90R[T )8%P1R2.IH +_XYZ3I\;B3
M3K\7)O9;.*V;RU=S$,NQ!?Y!C;@/M8[T(!# UO:C\1+*QT[P_>QV=[<P:U)&
MD!$8B\O>NX>9YA4*>P4_,3P 37)FY^%]S8->?VE&!<7D:K=+?W*7#RR(5C5'
M#"38Z[@JJ=C#( /-;-]JG@'7[-[:>_LVL]# D:%;AXH41& &0"%D0,H&/F7<
M .M &?!^T#X<GM=1NA!?"UM8S)%*(0PN0)5B 7!^4LS+@/M)!ST!QHS_ !0^
MV?#G7_$>E:=-)=Z9#,?L=SM4&1$W#YMVUEP0<JWJ.HQ65X<G^'WB&\UVPM(@
M5 994GN)=NW"32>2C-F$*SHQ"A/FVGL#6I%K7@:TTNXT%+Z*XMKZ!I9HWGEG
M>X62/<=\I)9G9,$ MN*XP,8H HZ=\9/LYU&37M)N--LK:[GMEO5V-$#%!YQ4
M@.68[0_S*-N1@5M^$/B'!X\T_4&TZWN-/NK=%(%]"&4;P2C?*V&Z'*A@1C!Q
MD&L--<\&WGA?0=:FT]$TC6)9+\273A!$[6TF]W5F!;*!DVJ&^]TQS6YID_A/
MP7X>74;>Z$.GWNP+//<2W$DO&$12Y9S@ X0=.>!S0!R-Q\9+_0O!>A:EJ9T^
MXU+4)7E>*""6)%MHV_>[1ND)? PN2 6=1P,UTD_C^Z^W3:;;QV\U_<7%O_9S
M -Y<MM*N[S3SD[0DI./[J],U0\-^,O -K?K'I<]M%&88;6WNTD+1RJ\DW[M.
M21M='W9 QQD\<;'AY?!M]K,=OI36DVHZ3!+;1"-V+Q1,X$BH3U4,H4XSM/''
M2@#F+_XVF/4/%-M:):3?V?!))8D^9F5H2!,'Z#&6&W:>0KGM6CXW^(.LZ#K5
M[:V4-I'86B6TMQ?3P23_ &=)/.R[HCJ2@:- 6'W0Q8@@58U&3P!J]A)X;NKB
MS-GID;DP^>\:Q!%*OB0$9(#$-AB1DYK'U"X^%TUG;7-]J*2&<M"DUQ?W)N&"
M ET9BWF;0LI+*W&UN>,4 &M_$[7-,NM3A865M*EU;16L'V">X=X)98T%PFQ_
M](!W-\J!2I"@YR"=CQ-XUU31M"\/2PRH]SJ-Y]FEG?1;HE5VR-D6@?S0?D Y
M/J>E8]U)\*TAEG:\MHTFN D?V>[G4K(,3#R%1LH#Y8?,0 ;9G)Q6]!XF\$S:
M?;S)JL5]!I$R20S/<RW$@=PRHRL2S2[@S@$;@>0.G !7UOXL0Z=X4GO[>WEE
MO%DN+6/SH?+1IH86D)9=VY5.P\9R,X-4]3^)6K1^$]#U"WB@BNM0U*:S?;8S
M7@54>8 K%&P<D^6.^!DFC4)OAI<:C>375W9R3W%JUY/$;F4IY<@\HR>6#M5F
M *9 #G!7KD58M?$_@N'[+%&(8].T_-];W!EX29Y&4J(\^9O+.W!7^+B@"G'\
M<$TVR*ZUH5_9W\30V\@4(L4EQ(F_RTW/D83YFW8"],DU?7XV:0RHYL-12)K,
MW>]XE4G#E-BJ6#.=RXRH*C<I) 8&L?4?&O@#5=2:V"-<PWTRW$NIVL[1+%,@
M9,[U97C91'M.W&._>NBNO"W@A8+J2ZCMVMM-@,$XN+J1H8%9226#-M#%6)+_
M 'CNY/- %'Q3\5;[1+)HO^$;U"RU)K>:Y!NA#+##'&%+.Y2;D?,!A3G/YU0/
MQCO8/"SWM]I$NFW,IN([6[EB5[::2-Y !L67S!E4R-VT'L>E7M"3X>:VMS;6
MEW'?R>5+;SK=WD\DP1E4NC&5MX^55.#S@9'%9-R/A=H_FPHUO<27"2-%9M>R
MM&SS NRQ!W\M)'#$G&TX;T- &U;?&BQEA66;1M5MEGWBR#I$6O727RBJ*)"0
M2Q&-^T$<\5-?_$V9?#OB&ZBTBXT_4M'9$EMM0V%6+ ,"K1N0PP>N1S7+ZEJG
M@/6_!T0N9U\,JBS10/*V]H%+!I'X+#9N(RQ(]F'%5_".K^"K#0O$-G=7S:M=
M7D\CW<<I8-=-&@P$)D<DE0" TA8CGI0!M:S\:I_[!N;G2] O([MU=K+^T/*"
M3A)A$[867( )R Q7(K0OOC':Z3837=UHNJ/:H)4AN(HXMMU+'D.D:^9D'*L!
MNP#M.#TS)IT7@?7I++3$A@-PEN3%:LS@H),3,F<X+=&(R2.O2LB:[^'7]MZA
M;ZI'!97SSRQ&VGNV=2/DWRK&CE8@2P#-A3S\W7D T8?C(MQ<^0GA?61(99;=
M QMP'DB3?( ?-P %S\QX)! YQF<?%^UN8X;BQT75+[3Y)8;<WL:Q*D<L@4JK
M!I V!O7<0"!FH->O-$\.^);+38-#6XN)%FOS.UXD*1[\1R-\[@L2&Z 55U*P
M^&6D'2K^[GM;6.1H9+-1>2K%*\;!(F$8;:[ [5!()Z"@"OX<^,FH:A-Y5YHT
MDE[*-MOIEDJ&5F$DRDF1I=FT+%GMC!ZY K6C^,MA-=^7'H^J&VB$7VJ[9(EC
MMFD=D","^XL&1@0H/KS5&\?X8I#?F:[L[9;3#33I=2PM'B1CE9%8'AY&!*G@
MM@^E78IOA_!H+R1&V6PE>*W:-/,WEHLLBE/OY&XL>,\Y/K0!Z$#FEK(U+Q9H
M^CZ5#J5UJ$$5E-CRI0VX29Z;0,EB?09K(M/BWX/OKFV@M_$-C-+<8*+')G@L
M5R>/E&X$<XYXZT ==17*I\2M!N/$MKH=K>)>7\\LD16$Y"%%+-DG@XQ@[<X/
M7%9+?&_PU#K,VGW$\MJ8IY;=II8R$W1JI; QDC#=0,<'.* /0**Q(O&NB3ZM
M'IL>I027DBAD1"2&R,@!L;<D<XSG':L^_P#B)9:?)?H]M<,;.[ALW*[?F:0<
M$<]!WH ZNBN7\&^/+?QO9&_L;.YCTS9E;R8*$D;)#*O.3MP<MTSP">:HZ?\
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M .1WQ0!UU%<39?&7PC>0PLVL0V\LD2R>1*&$BEE#*A&/OE2"%ZD= :U5\?\
MAYYK&)=5MW:]19("I)5E;A23C"Y/ W$9/ H Z&BN&O\ XT>$[72KJ_@U2/4(
MK9D5UM 7)W2"/*\?, QY(SC'K6]K/C31?#WV4:EJ,-FUUS$LI()'&6/HHR,L
M< 9&30!MT5S.A^/M.UR;Q!L)MK71KAK>>ZG8*A*J&9LGHHSU-11?%3PI-;W4
MRZW;8MF1)8SN$BLX)0;"-Q+ $@ <@$]* .KHKE=!^)>@>(+"\O(+^)(+61D=
MG<8VB5HE?C^%F4X_I47@[XFZ7XUOYK.SCN(;B&UBNW69, +(6 &>A(V\X/>@
M#KZ*XG5/C%X7TP(?[2CN%-RELS1'A2VX!@3C>N5VY3.20!UJXOQ3\)LVT:[9
ME_LPNRF\[EC+; 2,9&6!4 \D@C&>* .JHKE)/BGX4A^Q[]<M%-V"T2ECN*A]
MC$C&5"M\I+8VG@XHB^)FA)Y:WMY%8327$L"122*Y.R4Q;R4+!5++P6(]#@@B
M@#JZ*Y;7/B-H_AG5WL=5G6Q7RHGBFD=3YS/YF$1%)<G$3G[N" <9P<1O\6/"
M*6LEQ_;]FT"/''O1RP=I,[ F!\^[:P&W.2I'44 =;17-:=\2?#&K2K'::W:7
M#,8PFQ^'+G"A3T/((XZ$8.#27GQ+\,6&I1V$^MVD=X[L@AWDL")#$2<#Y0'4
MKDX&1C- '345CV'BW2-3U:YTVUOHIKVWW;XES_"<-@XPVTD X)P3@XKE9/CE
MX8MM9N-/NKB2S\B>YMGGF0A-\(B+X'4C$H.0, *Q.!C(!Z%17*3_ !3\*6[7
M:MKEJ6M)A;S*C%RLA7?LP <D+\Q S@<G I;KXI^$[.]>TDUZR\]$5RB/NSN0
M.@! (+,I#*HY8= : .JHKBK7XP>&+G5WL/[1CC^2WDBN&/[J59AF,AA]T$_+
MEL9/ R:UT\=^'Y-0O;(:O:BXLT=YPTFU45/]8=QX.S(W8/R]\4 ;U%<]IGQ
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M=*@\UX[J5%8/)*%5F<9(.=KDD#<,<C1\/^ M6U/X8QZ>MK%I$[ZJU[':RR2
M10^=N51N7<..@(&/0=* -*T^&N@> ]>MM8N+Q C7"F%&LD:9[ET$?^L"ER"!
MG Q@]\<5JR?"BSDNM?G-_<;M7ADA?Y%_=ARN=O'^P.M<Q!\#WM7T:*WATZ*S
MM%LY)4.YB;B)6#S#*\L=WWB<GO56#X+ZE=BT@N[73;>UADA-X(KJ63^TV20,
M9Y05'S'!X.[.X@G % ';>)/APNO:Y8:DEU CVUL;4QW5C'< J64Y4L04;Y>H
MK*3X2VNGRV5YJ&M7$]KI#%[16B1!%%OWLK$#+= -W! 'KS6':_ J2UL'"16"
MWGV&9%D$C_\ 'V9M\<Q..JKD!NJ]!Q4=S\(=4U35D>ZT_1K@K/<R7&K274C3
MW:21NJQO'LQA2P&"Q "Y !H GG^'D?B72'AT#Q"URMBZK9*T*H+59&64G<5/
MF':>,C&#SD\ULZI\%X-;D-]?ZB+S66G,K74]E&\6"A3:(CP,*3@YSGOCBN?7
MX/:O9VL4+6NEZM:1QK%%I]Q<R10P-Y,:><F$/S*5; P.&R"#6GIGPKU#0+Q-
M7B-O>ZVE\L\EVTS"6> 0*ACW-TRRD[>G.3S0!OZGX6L;>+P[HMAJ;Z7JFG*9
M;"1+=7!"KM?<FT)@ACP-O7BJ>F_!RWLM*U2UFU>[NY=1VF:X>*-6R)&<X"@#
M&6(QZ 4WX@_#[4O'LVC-*;>*VC0?;;4W$@5LLC,H*CYAP1SC-94OPLO[/4,C
M3-*UG2$FF^S:5=7+PPVBN4*R(!&P####  QNX(YH V/#'@B%]7L;ZS\1S7VE
M:1<W MK 01@1R/N#J\F-S;2QQT]\TNM^'=#\-:K+JVI:Q+;/>/<*BLF>9$4,
M%P"> F:YZ+X7>);+^TK:"2Q-MJN4EE^U2!K4;]P95V?.<9XRO0<U0UCX.Z_?
MWD)AM])@N8I;B236C>RBYO-X8(&4)QMR!RQP!QB@#J]"^"FF:#KMIJ$,XD2!
MDFV26D1E:54";O-(W 8 .T=^^.*G\6>"[&UN;_6KW69K'1R\=Y=V_DJP,D8P
MK!L%@.1E0#G Z5Q^J_"B_P##.@036-I'<NL<G]I6]H\C/?[IMX5R!N9=O!ZD
M#@ CBK7ACP;J.K>!O&5M;:3'H*ZK/NL;,22PHBA5'&Y%:,$@]$'J!0!UGPY\
M,Z9IFBG^P=6FNM&FB,?V=TPJ2@_,X! *$]TP!GG [QZ9\.)O[*L8[J]>TN[6
MVGLPUMA@4D<G=R.N,?K7+_\ "J=;.GQ)/9Z=J* S>78WM_*_V5G((G\[9F60
M8/) .#@'BEU/X1>(;RSOD2^M]US$D859V7;MQO.61AF;'S?*<<=><@'6#X3^
M'M*@NET^!-)LY[,VUS';1JHD Y60\?>7J#]:RCH&EVD.B3Z=XG6TA33YHC)/
M LOVJ'[TLF3C#9!)/Z5C1_"76(-'M89++3]7B43@:5?WK"&V9P LB,D(7*X/
M C7&3C!K<N_AKJMQX%\-:0ES:PWVGE([AM[M&T1^655)&3E20,_C0!AV/@;1
MIO"[V4/BNR.F"!;N22WTV"-7M^2'D;N>X?@@C.#4'B3PWX=^T6\]_P"+FG>^
MBBFLI9[!;E&@1@RF8JNV1<D -)C /6MJU^$VJ16VJ:>VHQ0:?>WB!7MCB6*R
M096(!E*Y+$@Y!&,=:S=1^#.N2WMH(M6:XT[3PZ102W;1?;(FD#F&<1HHVCG!
M7VXH W/#ATO1+R]U:ZU?3)-/6)-+62S41IY@)+J47(0]./QK$E\):1J%ANC\
M;)+HNGN\$%J]I!*D#3#(60D;F/S97[O4=>M+??!/4VM9'L+ZULKBXOVN+NW^
M8PW$?\!R!E9%Z;L'(X-(?@EJ8L"UO?6MGJ,ES"UP4W-'<P*J JW (8%25;M]
M.* -+4(/"GB2WT?PW<>(YKBYL9Q$+A\D73 8> R%=C%AP5#;N*==? ;39[:V
M47SS7,32@W%Y;17!:.0\J%88&T8"GL!SFK.G^%_&%BFG:3%=6EGI]E<%S?6\
MBL9XBQ;:T#PMAN<9#CU]J](H XS0/A=I_A_4[VZBN)I([J!K<P,JJJH0!QM
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M/B"YU*:R\M8(S;11(J(" #M&2>>3GZ 5Z#10!YG<?!C%G>6ECX@NK&WOP%O
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MP00");KX=7:>!?$6E+J;:CJ>J2377VBYC2)?-;:0N%& @V =SCJ2>3WM% '
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MUN)+BXEN-Z,L2JWR+$[C)S@Y<XZ\]*V_$OQ-N])M_#EU;VMGY&IVXF99YB9
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MHRW\<$TCM>)DC<[;5W  9Z''H:P]'^,>H?V3-J.J:;:K:6\J1336LZ2<R+E
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MEW!/[H.,X]NE6J* *T^FVEU"\4UM#+$Z"-D>,,I4= 01T]J=;6-O9J!!!%"
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M(E4JOH"!P/:K=% $7V6'C]TG!)'RCJ>IJ.VTRTLXEB@M888U8N$CC50&/4@
M=?>K-% %5]+LY+M+IK2!KE,[9C&I=?HV,BE33K6.2XD2VA5[C_7,(P#)QCYC
MCGCUJS10!6M].M;6)(H;:&&)%*JD<:JJ@]0 !P*5["VDE@D>WB:2#_5.4!,?
M;Y3V_"K%% %#^PM-,,L/V"U\J5B\D?D+M<GJ2,<FITT^UCC$:6\2H%"A1&
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
*4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>rigl-20230630.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.3.0.9 -->
<!--Based on XBRL 2.1-->
<!--Created on: 7/31/2023 8:06:11 PM-->
<!--Modified on: 7/31/2023 8:06:11 PM-->
<xsd:schema xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsd="http://www.w3.org/2001/XMLSchema" targetNamespace="http://www.rigel.com/20230630" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:rigl="http://www.rigel.com/20230630" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:srt-roles="http://fasb.org/srt-roles/2023" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2023">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/StatementCondensedBalanceSheets" id="StatementCondensedBalanceSheets">
        <link:definition>00100 - Statement - CONDENSED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/StatementCondensedStatementsOfOperations" id="StatementCondensedStatementsOfOperations">
        <link:definition>00200 - Statement - CONDENSED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/StatementCondensedStatementsOfComprehensiveLoss" id="StatementCondensedStatementsOfComprehensiveLoss">
        <link:definition>00300 - Statement - CONDENSED STATEMENTS OF COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows" id="StatementCondensedStatementsOfCashFlows">
        <link:definition>00500 - Statement - CONDENSED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureInventoriesDetails" id="DisclosureInventoriesDetails">
        <link:definition>40601 - Disclosure - INVENTORIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails" id="DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails">
        <link:definition>40701 - Disclosure - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureDebtFutureMinimumPaymentsDetails" id="DisclosureDebtFutureMinimumPaymentsDetails">
        <link:definition>40902 - Disclosure - DEBT - Future Minimum Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureLeasesLeaseExpenseDetails" id="DisclosureLeasesLeaseExpenseDetails">
        <link:definition>41002 - Disclosure - LEASES - Lease Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureLeasesSubleaseInformationDetails" id="DisclosureLeasesSubleaseInformationDetails">
        <link:definition>41004 - Disclosure - LEASES - Sublease Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails" id="DisclosureLeasesFutureMinimumLeasePaymentsDetails">
        <link:definition>41005 - Disclosure - LEASES - Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - DOCUMENT AND ENTITY INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/StatementCondensedStatementsOfStockholdersDeficitEquity" id="StatementCondensedStatementsOfStockholdersDeficitEquity">
        <link:definition>00400 - Statement - CONDENSED STATEMENTS OF STOCKHOLDERS' (DEFICIT) EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies" id="DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies">
        <link:definition>10101 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureNetLossPerShare" id="DisclosureNetLossPerShare">
        <link:definition>10201 - Disclosure - NET LOSS PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureRevenues" id="DisclosureRevenues">
        <link:definition>10301 - Disclosure - REVENUES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContract" id="DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContract">
        <link:definition>10401 - Disclosure - SPONSORED RESEARCH AND LICENSE AGREEMENTS AND GOVERNMENT CONTRACT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureStockBasedCompensation" id="DisclosureStockBasedCompensation">
        <link:definition>10501 - Disclosure - STOCK-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureInventories" id="DisclosureInventories">
        <link:definition>10601 - Disclosure - INVENTORIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestments" id="DisclosureCashCashEquivalentsAndShortTermInvestments">
        <link:definition>10701 - Disclosure - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureFairValue" id="DisclosureFairValue">
        <link:definition>10801 - Disclosure - FAIR VALUE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureDebt" id="DisclosureDebt">
        <link:definition>10901 - Disclosure - DEBT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureLeases" id="DisclosureLeases">
        <link:definition>11001 - Disclosure - LEASES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>20102 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureNetLossPerShareTables" id="DisclosureNetLossPerShareTables">
        <link:definition>30203 - Disclosure - NET LOSS PER SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureRevenuesTables" id="DisclosureRevenuesTables">
        <link:definition>30303 - Disclosure - REVENUES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureStockBasedCompensationTables" id="DisclosureStockBasedCompensationTables">
        <link:definition>30503 - Disclosure - STOCK-BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureInventoriesTables" id="DisclosureInventoriesTables">
        <link:definition>30603 - Disclosure - INVENTORIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsTables" id="DisclosureCashCashEquivalentsAndShortTermInvestmentsTables">
        <link:definition>30703 - Disclosure - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureFairValueTables" id="DisclosureFairValueTables">
        <link:definition>30803 - Disclosure - FAIR VALUE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureDebtTables" id="DisclosureDebtTables">
        <link:definition>30903 - Disclosure - DEBT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureLeasesTables" id="DisclosureLeasesTables">
        <link:definition>31003 - Disclosure - LEASES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndLiquidityDetails" id="DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndLiquidityDetails">
        <link:definition>40101 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Basis of Presentation and Liquidity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureNetLossPerShareDetails" id="DisclosureNetLossPerShareDetails">
        <link:definition>40201 - Disclosure - NET LOSS PER SHARE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureRevenuesDisaggregatedDetails" id="DisclosureRevenuesDisaggregatedDetails">
        <link:definition>40301 - Disclosure - REVENUES - Disaggregated (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureRevenuesActivityDetails" id="DisclosureRevenuesActivityDetails">
        <link:definition>40302 - Disclosure - REVENUES - Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureRevenuesPercentageByCustomerDetails" id="DisclosureRevenuesPercentageByCustomerDetails">
        <link:definition>40303 - Disclosure - REVENUES - Percentage by Customer (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails" id="DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails">
        <link:definition>40401 - Disclosure - SPONSORED RESEARCH AND LICENSE AGREEMENTS AND GOVERNMENT CONTRACT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureStockBasedCompensationDetails" id="DisclosureStockBasedCompensationDetails">
        <link:definition>40501 - Disclosure - STOCK-BASED COMPENSATION (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureStockBasedCompensationOptionsAndRsusDetails" id="DisclosureStockBasedCompensationOptionsAndRsusDetails">
        <link:definition>40502 - Disclosure - STOCK-BASED COMPENSATION - Options and RSUs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureStockBasedCompensationAssumptionsDetails" id="DisclosureStockBasedCompensationAssumptionsDetails">
        <link:definition>40503 - Disclosure - STOCK-BASED COMPENSATION - Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureStockBasedCompensationPurchasePlanDetails" id="DisclosureStockBasedCompensationPurchasePlanDetails">
        <link:definition>40504 - Disclosure - STOCK-BASED COMPENSATION - Purchase Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsGrossUnrealizedGainsAndLossesDetails" id="DisclosureCashCashEquivalentsAndShortTermInvestmentsGrossUnrealizedGainsAndLossesDetails">
        <link:definition>40702 - Disclosure - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS - Gross Unrealized Gains and Losses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsUnrealizedLossPositionDetails" id="DisclosureCashCashEquivalentsAndShortTermInvestmentsUnrealizedLossPositionDetails">
        <link:definition>40703 - Disclosure - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS - Unrealized Loss Position (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureFairValueDetails" id="DisclosureFairValueDetails">
        <link:definition>40801 - Disclosure - FAIR VALUE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureDebtDetails" id="DisclosureDebtDetails">
        <link:definition>40901 - Disclosure - DEBT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureLeasesDetails" id="DisclosureLeasesDetails">
        <link:definition>41001 - Disclosure - LEASES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureLeasesCashFlowInformationDetails" id="DisclosureLeasesCashFlowInformationDetails">
        <link:definition>41003 - Disclosure - LEASES - Cash Flow Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="rigl-20230630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="rigl-20230630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="rigl-20230630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="rigl-20230630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/ecd/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/ecd-sub/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd" />
  <xsd:element id="rigl_SpecifiedProductLaunchEventsMember" name="SpecifiedProductLaunchEventsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentageOnFirstDayOfOfferingPeriod" id="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentageOnFirstDayOfOfferingPeriod" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardOfferingPeriod" id="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardOfferingPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriodsPerAwardOfferingPeriod" id="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriodsPerAwardOfferingPeriod" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPurchasePeriod" id="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPurchasePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AchievementOfMilestoneAxis" id="rigl_AchievementOfMilestoneAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AchievementOfMilestoneDomain" id="rigl_AchievementOfMilestoneDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CollaborativeArrangementUpfrontFeeReceived" id="rigl_CollaborativeArrangementUpfrontFeeReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="rigl_CollaborativeArrangementRevenueRecognized" name="CollaborativeArrangementRevenueRecognized" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element name="CorporateBondSecuritiesAndCommercialPaperMember" id="rigl_CorporateBondSecuritiesAndCommercialPaperMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element id="rigl_CashEquivalentsAndAvailableForSaleSecuritiesWeightedAverageMaturityPeriod" name="CashEquivalentsAndAvailableForSaleSecuritiesWeightedAverageMaturityPeriod" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element name="ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable" id="rigl_ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element id="rigl_CashAndCashEquivalentsAndAvailableForSaleSecuritiesLineItems" name="CashAndCashEquivalentsAndAvailableForSaleSecuritiesLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="CashEquivalentsAndAvailableForSaleSecuritiesAbstract" id="rigl_CashEquivalentsAndAvailableForSaleSecuritiesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element id="rigl_SpecifiedDevelopmentEventsMember" name="SpecifiedDevelopmentEventsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rigl_SpecifiedRegulatoryEventsMember" name="SpecifiedRegulatoryEventsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="AccruedResearchAndDevelopmentLiabilityCurrent" id="rigl_AccruedResearchAndDevelopmentLiabilityCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="IncreaseDecreaseInAccruedResearchAndDevelopmentLiability" id="rigl_IncreaseDecreaseInAccruedResearchAndDevelopmentLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="rigl_ContingentPaymentsUnderAgreement" name="ContingentPaymentsUnderAgreement" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="rigl_ResearchActivitiesMember" name="ResearchActivitiesMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rigl_SubleaseAgreementAbstract" name="SubleaseAgreementAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rigl_CorporateCollaborationsDisclosureAbstract" name="CorporateCollaborationsDisclosureAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rigl_ChargebacksDiscountsAndFeesMember" name="ChargebacksDiscountsAndFeesMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rigl_GovernmentAndOtherRebatesMember" name="GovernmentAndOtherRebatesMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rigl_ContractRevenuesFromCollaborationsMember" name="ContractRevenuesFromCollaborationsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rigl_AsdHealthcareAndOncologySupplyMember" name="AsdHealthcareAndOncologySupplyMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rigl_MckessonSpecialtyCareDistributionCorporationMember" name="MckessonSpecialtyCareDistributionCorporationMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rigl_CardinalHealthcareMember" name="CardinalHealthcareMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rigl_DevelopmentMilestonesMember" name="DevelopmentMilestonesMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rigl_GrossProductMember" name="GrossProductMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rigl_DiscountsAndAllowancesMember" name="DiscountsAndAllowancesMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rigl_GrifolsS.a.Member" name="GrifolsS.a.Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rigl_FostamatinibMember" name="FostamatinibMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rigl_RoyaltyPaymentAsPercentageOfNetSales" name="RoyaltyPaymentAsPercentageOfNetSales" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="rigl_KisseiPharmaceuticalCo.Ltd.Member" name="KisseiPharmaceuticalCo.Ltd.Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rigl_SpecifiedCommercialMilestonesMember" name="SpecifiedCommercialMilestonesMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rigl_EuropeanMedicinesAgencyApprovalOfFostamatinibForTreatmentOfChronicImmuneThrombocytopenicPurpuraMember" name="EuropeanMedicinesAgencyApprovalOfFostamatinibForTreatmentOfChronicImmuneThrombocytopenicPurpuraMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rigl_AccountsReceivableAndPrepaidAndOtherCurrentAssetsMember" name="AccountsReceivableAndPrepaidAndOtherCurrentAssetsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rigl_CashFlowInformationRelatedToOperatingLeaseTableTextBlock" name="CashFlowInformationRelatedToOperatingLeaseTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="rigl_FixedSubleaseExpense" name="FixedSubleaseExpense" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="rigl_VariableSubleaseExpense" name="VariableSubleaseExpense" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="rigl_NetSubleaseIncomeExpense" name="NetSubleaseIncomeExpense" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="rigl_DisaggregationOfRevenueByCustomerTableTextBlock" name="DisaggregationOfRevenueByCustomerTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="rigl_LeaseDisclosureTextBlock" name="LeaseDisclosureTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember" name="AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rigl_CreditAgreementTrancheOneMember" name="CreditAgreementTrancheOneMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rigl_CreditAgreementTrancheTwoMember" name="CreditAgreementTrancheTwoMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rigl_CreditAgreementTrancheThreeMember" name="CreditAgreementTrancheThreeMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rigl_CreditAgreementTrancheFourMember" name="CreditAgreementTrancheFourMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rigl_SalesDiscountsAndAllowances" name="SalesDiscountsAndAllowances" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="rigl_MedisonPharmaLtd.Member" name="MedisonPharmaLtd.Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rigl_CreditableAdvanceRoyaltyPaymentMember" name="CreditableAdvanceRoyaltyPaymentMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rigl_NumberOfAgreements" name="NumberOfAgreements" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="rigl_CommercialAndLicenseAgreementMember" name="CommercialAndLicenseAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rigl_LicensedRightsMember" name="LicensedRightsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember" name="OneTimeDeliveryOfDrugSupplyForCommercializationMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rigl_DevelopmentCostsCostSharingArrangementPercentage" name="DevelopmentCostsCostSharingArrangementPercentage" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="rigl_IncreaseDecreaseRightOfUseAssets" name="IncreaseDecreaseRightOfUseAssets" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="rigl_R552Member" name="R552Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rigl_DevelopmentAndRegulatoryMilestonesByNonCentralNervousSystemDiseaseProductsMember" name="DevelopmentAndRegulatoryMilestonesByNonCentralNervousSystemDiseaseProductsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rigl_DevelopmentAndRegulatoryMilestonesByCentralNervousSystemDiseaseProductsMember" name="DevelopmentAndRegulatoryMilestonesByCentralNervousSystemDiseaseProductsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rigl_MilestonePaymentsOnProductByProductBasisMember" name="MilestonePaymentsOnProductByProductBasisMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rigl_NoncashInterestExpense" name="NoncashInterestExpense" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="rigl_NonCentralNervousSystemPenetrantIntellectualPropertyMember" name="NonCentralNervousSystemPenetrantIntellectualPropertyMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rigl_CentralNervousSystemPenetrantIntellectualPropertyMember" name="CentralNervousSystemPenetrantIntellectualPropertyMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rigl_ShareBasedCompensationOptionsAndRsusMember" name="ShareBasedCompensationOptionsAndRsusMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rigl_GovernmentAward" name="GovernmentAward" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="rigl_GovernmentAwardExpectedToBeReceivedInSucceedingPeriods" name="GovernmentAwardExpectedToBeReceivedInSucceedingPeriods" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="rigl_FinancingLiabilityIncludingInterestExpenseAccretion" name="FinancingLiabilityIncludingInterestExpenseAccretion" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="rigl_FinancingLiabilityInterestAccretionDiscountRate" name="FinancingLiabilityInterestAccretionDiscountRate" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="rigl_PaymentOfCostShareToCollaborationPartner" name="PaymentOfCostShareToCollaborationPartner" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" abstract="false" />
  <xsd:element name="CreditAgreementTrancheFiveMember" id="rigl_CreditAgreementTrancheFiveMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="LiquidityAndCapitalResourcesPolicyPolicyTextBlock" id="rigl_LiquidityAndCapitalResourcesPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="DueToCollaborationPartner" id="rigl_DueToCollaborationPartner" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="KnightTherapeuticsInternationalSaMember" id="rigl_KnightTherapeuticsInternationalSaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DevelopmentAndRegulatoryMilestonesMember" id="rigl_DevelopmentAndRegulatoryMilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="FormaTherapeuticsHoldingsIncMember" id="rigl_FormaTherapeuticsHoldingsIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CollaborativeArrangementUpfrontPayment" id="rigl_CollaborativeArrangementUpfrontPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="CollaborativeArrangementPotentialPayments" id="rigl_CollaborativeArrangementPotentialPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="PriorToThirdAmendmentMember" id="rigl_PriorToThirdAmendmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="FollowingThirdAmendmentMember" id="rigl_FollowingThirdAmendmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="RevenueReservesAndRefundLiability" id="rigl_RevenueReservesAndRefundLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="RezlidhiaMember" id="rigl_RezlidhiaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="HeadquartersOfficeSpaceSubleaseSouthSanFranciscoCaliforniaMember" id="rigl_HeadquartersOfficeSpaceSubleaseSouthSanFranciscoCaliforniaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AchievementOfCertainNearTermRegulatoryMilestoneMember" id="rigl_AchievementOfCertainNearTermRegulatoryMilestoneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="FdaApprovalAndFirstCommercialSaleOfProductMember" id="rigl_FdaApprovalAndFirstCommercialSaleOfProductMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="RoyaltyDeliveryOfDrugSuppliesAndOthersMember" id="rigl_RoyaltyDeliveryOfDrugSuppliesAndOthersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PaymentsOfMilestonePaymentObligations" id="rigl_PaymentsOfMilestonePaymentObligations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="LondonInterBankOfferedRateMember" id="rigl_LondonInterBankOfferedRateMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="VariableLeaseExpenseNetCredit" id="rigl_VariableLeaseExpenseNetCredit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="RightToOptOutOfAgreementNumberOfPeriods" id="rigl_RightToOptOutOfAgreementNumberOfPeriods" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>rigl-20230630_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.3.0.9 -->
<!--Based on XBRL 2.1-->
<!--Created on: 7/31/2023 8:06:11 PM-->
<!--Modified on: 7/31/2023 8:06:11 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="rigl-20230630.xsd#StatementCondensedBalanceSheets" roleURI="http://www.rigel.com/role/StatementCondensedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20230630.xsd#StatementCondensedStatementsOfOperations" roleURI="http://www.rigel.com/role/StatementCondensedStatementsOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20230630.xsd#StatementCondensedStatementsOfComprehensiveLoss" roleURI="http://www.rigel.com/role/StatementCondensedStatementsOfComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20230630.xsd#StatementCondensedStatementsOfCashFlows" roleURI="http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20230630.xsd#DisclosureInventoriesDetails" roleURI="http://www.rigel.com/role/DisclosureInventoriesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20230630.xsd#DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails" roleURI="http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20230630.xsd#DisclosureDebtFutureMinimumPaymentsDetails" roleURI="http://www.rigel.com/role/DisclosureDebtFutureMinimumPaymentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20230630.xsd#DisclosureLeasesLeaseExpenseDetails" roleURI="http://www.rigel.com/role/DisclosureLeasesLeaseExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20230630.xsd#DisclosureLeasesSubleaseInformationDetails" roleURI="http://www.rigel.com/role/DisclosureLeasesSubleaseInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20230630.xsd#DisclosureLeasesFutureMinimumLeasePaymentsDetails" roleURI="http://www.rigel.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <calculationLink xlink:role="http://www.rigel.com/role/StatementCondensedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONDENSED BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638264307686403595" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_638264307686403595" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638264307686413607" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638264307686403595" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638264307686413607" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments_638264307686413607" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638264307686403595" xlink:to="us-gaap_ShortTermInvestments_638264307686413607" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_638264307686413607" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638264307686403595" xlink:to="us-gaap_AccountsReceivableNetCurrent_638264307686413607" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638264307686413607" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638264307686403595" xlink:to="us-gaap_InventoryNet_638264307686413607" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638264307686413607" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638264307686403595" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638264307686413607" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638264307686413607" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638264307686413607" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetIncludingGoodwill_638264307686413607" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_IntangibleAssetsNetIncludingGoodwill_638264307686413607" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638264307686413607" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638264307686413607" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_638264307686423594" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent_638264307686423594" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638264307686423594" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_638264307686423594" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638264307686423594" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638264307686423594" xlink:to="us-gaap_LiabilitiesCurrent_638264307686423594" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638264307686423594" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638264307686423594" xlink:to="us-gaap_AccountsPayableCurrent_638264307686423594" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638264307686423594" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638264307686423594" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638264307686423594" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_AccruedResearchAndDevelopmentLiabilityCurrent" xlink:label="rigl_AccruedResearchAndDevelopmentLiabilityCurrent_638264307686423594" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638264307686423594" xlink:to="rigl_AccruedResearchAndDevelopmentLiabilityCurrent_638264307686423594" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerRefundLiabilityCurrent_638264307686423594" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638264307686423594" xlink:to="us-gaap_ContractWithCustomerRefundLiabilityCurrent_638264307686423594" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_638264307686433604" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638264307686423594" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_638264307686433604" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638264307686433604" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638264307686423594" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638264307686433604" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_638264307686433604" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638264307686423594" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_638264307686433604" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_638264307686433604" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638264307686423594" xlink:to="us-gaap_OtherLiabilitiesCurrent_638264307686433604" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638264307686433604" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638264307686423594" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638264307686433604" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermLoansPayable" xlink:label="us-gaap_LongTermLoansPayable_638264307686433604" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638264307686423594" xlink:to="us-gaap_LongTermLoansPayable_638264307686433604" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_638264307686433604" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638264307686423594" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_638264307686433604" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638264307686443597" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_638264307686443597" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638264307686443597" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638264307686443597" xlink:to="us-gaap_PreferredStockValue_638264307686443597" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638264307686443597" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638264307686443597" xlink:to="us-gaap_CommonStockValue_638264307686443597" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_638264307686443597" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638264307686443597" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_638264307686443597" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638264307686443597" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638264307686443597" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638264307686443597" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638264307686443597" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638264307686443597" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638264307686443597" order="5" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.rigel.com/role/StatementCondensedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - CONDENSED STATEMENTS OF OPERATIONS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638264307686453599" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_638264307686453599" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638264307686453599" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638264307686453599" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638264307686453599" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses_638264307686453599" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638264307686453599" xlink:to="us-gaap_CostsAndExpenses_638264307686453599" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold_638264307686453599" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses_638264307686453599" xlink:to="us-gaap_CostOfGoodsAndServicesSold_638264307686453599" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_638264307686453599" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses_638264307686453599" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_638264307686453599" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_638264307686463611" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses_638264307686453599" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_638264307686463611" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_638264307686463611" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InvestmentIncomeInterest_638264307686463611" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_638264307686463611" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestExpense_638264307686463611" order="3" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.rigel.com/role/StatementCondensedStatementsOfComprehensiveLoss" xlink:type="extended" xlink:title="00300 - Statement - CONDENSED STATEMENTS OF COMPREHENSIVE LOSS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638264307686463611" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638264307686463611" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_638264307686463611" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_638264307686463611" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows" xlink:type="extended" xlink:title="00500 - Statement - CONDENSED STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638264307686463611" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638264307686463611" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638264307686473606" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638264307686463611" xlink:to="us-gaap_ProfitLoss_638264307686473606" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_638264307686473606" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638264307686463611" xlink:to="us-gaap_DepreciationDepletionAndAmortization_638264307686473606" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_NoncashInterestExpense" xlink:label="rigl_NoncashInterestExpense_638264307686473606" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638264307686463611" xlink:to="rigl_NoncashInterestExpense_638264307686473606" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_638264307686473606" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638264307686463611" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_638264307686473606" order="4" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_638264307686473606" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638264307686463611" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_638264307686473606" order="5" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_638264307686473606" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638264307686463611" xlink:to="us-gaap_IncreaseDecreaseInInventories_638264307686473606" order="6" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638264307686473606" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638264307686463611" xlink:to="us-gaap_ShareBasedCompensation_638264307686473606" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_638264307686483612" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638264307686463611" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_638264307686483612" order="8" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638264307686483612" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638264307686463611" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638264307686483612" order="9" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_638264307686483612" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638264307686463611" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_638264307686483612" order="10" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_IncreaseDecreaseRightOfUseAssets" xlink:label="rigl_IncreaseDecreaseRightOfUseAssets_638264307686483612" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638264307686463611" xlink:to="rigl_IncreaseDecreaseRightOfUseAssets_638264307686483612" order="11" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_638264307686483612" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638264307686463611" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_638264307686483612" order="12" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_638264307686483612" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638264307686463611" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_638264307686483612" order="13" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_IncreaseDecreaseInAccruedResearchAndDevelopmentLiability" xlink:label="rigl_IncreaseDecreaseInAccruedResearchAndDevelopmentLiability_638264307686493620" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638264307686463611" xlink:to="rigl_IncreaseDecreaseInAccruedResearchAndDevelopmentLiability_638264307686493620" order="14" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_RevenueReservesAndRefundLiability" xlink:label="rigl_RevenueReservesAndRefundLiability_638264307686493620" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638264307686463611" xlink:to="rigl_RevenueReservesAndRefundLiability_638264307686493620" order="15" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_638264307686493620" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638264307686463611" xlink:to="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_638264307686493620" order="16" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_638264307686493620" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638264307686463611" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_638264307686493620" order="17" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638264307686493620" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638264307686463611" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638264307686493620" order="18" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638264307686493620" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638264307686463611" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638264307686493620" order="19" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638264307686493620" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638264307686493620" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_638264307686503601" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638264307686493620" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments_638264307686503601" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_638264307686503601" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638264307686493620" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_638264307686503601" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_638264307686503601" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638264307686493620" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_638264307686503601" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638264307686503601" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638264307686493620" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638264307686503601" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638264307686513607" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638264307686493620" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638264307686513607" order="5" use="optional" weight="-1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638264307686513607" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638264307686513607" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_PaymentOfCostShareToCollaborationPartner" xlink:label="rigl_PaymentOfCostShareToCollaborationPartner_638264307686513607" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638264307686513607" xlink:to="rigl_PaymentOfCostShareToCollaborationPartner_638264307686513607" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:label="us-gaap_ProceedsFromLongTermLinesOfCredit_638264307686513607" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638264307686513607" xlink:to="us-gaap_ProceedsFromLongTermLinesOfCredit_638264307686513607" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_638264307686513607" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638264307686513607" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_638264307686513607" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.rigel.com/role/DisclosureInventoriesDetails" xlink:type="extended" xlink:title="40601 - Disclosure - INVENTORIES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods_638264307686523604" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryFinishedGoods_638264307686523604" order="1" use="optional" weight="1" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess_638264307686523604" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryWorkInProcess_638264307686523604" order="2" use="optional" weight="1" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials_638264307686523604" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryRawMaterials_638264307686523604" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails" xlink:type="extended" xlink:title="40701 - Disclosure - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638264307686523604" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638264307686523604" order="1" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments_638264307686533617" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_638264307686533617" order="2" use="optional" weight="1" priority="3" />
  </calculationLink>
  <calculationLink xlink:role="http://www.rigel.com/role/DisclosureDebtFutureMinimumPaymentsDetails" xlink:type="extended" xlink:title="40902 - Disclosure - DEBT - Future Minimum Payments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_638264307686533617" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_638264307686533617" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_638264307686533617" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_638264307686533617" order="2" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_638264307686533617" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_638264307686533617" order="3" use="optional" weight="1" priority="3" />
  </calculationLink>
  <calculationLink xlink:role="http://www.rigel.com/role/DisclosureLeasesLeaseExpenseDetails" xlink:type="extended" xlink:title="41002 - Disclosure - LEASES - Lease Expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost_638264307686533617" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost_638264307686533617" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_VariableLeaseExpenseNetCredit" xlink:label="rigl_VariableLeaseExpenseNetCredit_638264307686543615" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="rigl_VariableLeaseExpenseNetCredit_638264307686543615" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.rigel.com/role/DisclosureLeasesSubleaseInformationDetails" xlink:type="extended" xlink:title="41004 - Disclosure - LEASES - Sublease Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_NetSubleaseIncomeExpense" xlink:label="rigl_NetSubleaseIncomeExpense" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_FixedSubleaseExpense" xlink:label="rigl_FixedSubleaseExpense_638264307686543615" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="rigl_NetSubleaseIncomeExpense" xlink:to="rigl_FixedSubleaseExpense_638264307686543615" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_VariableSubleaseExpense" xlink:label="rigl_VariableSubleaseExpense_638264307686543615" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="rigl_NetSubleaseIncomeExpense" xlink:to="rigl_VariableSubleaseExpense_638264307686543615" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome_638264307686543615" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="rigl_NetSubleaseIncomeExpense" xlink:to="us-gaap_SubleaseIncome_638264307686543615" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.rigel.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails" xlink:type="extended" xlink:title="41005 - Disclosure - LEASES - Future Minimum Lease Payments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_638264307686543615" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_638264307686543615" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638264307686543615" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638264307686543615" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638264307686553612" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638264307686553612" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>rigl-20230630_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.3.0.9 -->
<!--Based on XBRL 2.1-->
<!--Created on: 7/31/2023 8:06:11 PM-->
<!--Modified on: 7/31/2023 8:06:11 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="rigl-20230630.xsd#StatementCondensedStatementsOfOperations" roleURI="http://www.rigel.com/role/StatementCondensedStatementsOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20230630.xsd#StatementCondensedStatementsOfStockholdersDeficitEquity" roleURI="http://www.rigel.com/role/StatementCondensedStatementsOfStockholdersDeficitEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20230630.xsd#DisclosureStockBasedCompensationTables" roleURI="http://www.rigel.com/role/DisclosureStockBasedCompensationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20230630.xsd#DisclosureNetLossPerShareDetails" roleURI="http://www.rigel.com/role/DisclosureNetLossPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20230630.xsd#DisclosureRevenuesDisaggregatedDetails" roleURI="http://www.rigel.com/role/DisclosureRevenuesDisaggregatedDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20230630.xsd#DisclosureRevenuesActivityDetails" roleURI="http://www.rigel.com/role/DisclosureRevenuesActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20230630.xsd#DisclosureRevenuesPercentageByCustomerDetails" roleURI="http://www.rigel.com/role/DisclosureRevenuesPercentageByCustomerDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20230630.xsd#DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails" roleURI="http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20230630.xsd#DisclosureStockBasedCompensationDetails" roleURI="http://www.rigel.com/role/DisclosureStockBasedCompensationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20230630.xsd#DisclosureStockBasedCompensationOptionsAndRsusDetails" roleURI="http://www.rigel.com/role/DisclosureStockBasedCompensationOptionsAndRsusDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20230630.xsd#DisclosureStockBasedCompensationAssumptionsDetails" roleURI="http://www.rigel.com/role/DisclosureStockBasedCompensationAssumptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20230630.xsd#DisclosureStockBasedCompensationPurchasePlanDetails" roleURI="http://www.rigel.com/role/DisclosureStockBasedCompensationPurchasePlanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20230630.xsd#DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails" roleURI="http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20230630.xsd#DisclosureCashCashEquivalentsAndShortTermInvestmentsGrossUnrealizedGainsAndLossesDetails" roleURI="http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsGrossUnrealizedGainsAndLossesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20230630.xsd#DisclosureCashCashEquivalentsAndShortTermInvestmentsUnrealizedLossPositionDetails" roleURI="http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsUnrealizedLossPositionDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20230630.xsd#DisclosureFairValueDetails" roleURI="http://www.rigel.com/role/DisclosureFairValueDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20230630.xsd#DisclosureDebtDetails" roleURI="http://www.rigel.com/role/DisclosureDebtDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20230630.xsd#DisclosureLeasesDetails" roleURI="http://www.rigel.com/role/DisclosureLeasesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:roleRef roleURI="http://www.rigel.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="rigl-20230630.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <roleRef xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="Extensible Enumeration Domain Members" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:definitionLink xlink:role="http://www.rigel.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_1" xlink:title="dei_LegalEntityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_1" xlink:title="dei_EntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_LegalEntityAxis_1" xlink:to="dei_EntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_LegalEntityAxis_1 To dei_EntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_1" xlink:title="srt_StatementScenarioAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_1" xlink:title="srt_ScenarioUnspecifiedDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementScenarioAxis_1" xlink:to="srt_ScenarioUnspecifiedDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementScenarioAxis_1 To srt_ScenarioUnspecifiedDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_1" xlink:title="srt_ProductOrServiceAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_1" xlink:title="srt_ProductsAndServicesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ProductOrServiceAxis_1" xlink:to="srt_ProductsAndServicesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ProductOrServiceAxis_1 To srt_ProductsAndServicesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_1" xlink:title="us-gaap_StatementEquityComponentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1" xlink:title="us-gaap_EquityComponentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementEquityComponentsAxis_1" xlink:to="us-gaap_EquityComponentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementEquityComponentsAxis_1 To us-gaap_EquityComponentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_1" xlink:title="us-gaap_AwardTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AwardTypeAxis_1" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AwardTypeAxis_1 To us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_1" xlink:title="srt_TitleOfIndividualAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:title="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_TitleOfIndividualAxis_1" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_TitleOfIndividualAxis_1 To srt_TitleOfIndividualWithRelationshipToEntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_1" xlink:title="us-gaap_ConcentrationRiskByBenchmarkAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_1" xlink:title="us-gaap_ConcentrationRiskBenchmarkDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis_1" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ConcentrationRiskByBenchmarkAxis_1 To us-gaap_ConcentrationRiskBenchmarkDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_1" xlink:title="us-gaap_ConcentrationRiskByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_1" xlink:title="us-gaap_ConcentrationRiskTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ConcentrationRiskByTypeAxis_1" xlink:to="us-gaap_ConcentrationRiskTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ConcentrationRiskByTypeAxis_1 To us-gaap_ConcentrationRiskTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis_1" xlink:title="srt_MajorCustomersAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_1" xlink:title="srt_NameOfMajorCustomerDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_MajorCustomersAxis_1" xlink:to="srt_NameOfMajorCustomerDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_MajorCustomersAxis_1 To srt_NameOfMajorCustomerDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_1" xlink:title="srt_RangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1" xlink:title="srt_RangeMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RangeAxis_1" xlink:to="srt_RangeMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RangeAxis_1 To srt_RangeMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis_1" xlink:title="srt_CumulativeEffectPeriodOfAdoptionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain_1" xlink:title="srt_CumulativeEffectPeriodOfAdoptionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis_1" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CumulativeEffectPeriodOfAdoptionAxis_1 To srt_CumulativeEffectPeriodOfAdoptionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:title="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_1" xlink:title="us-gaap_TypeOfAdoptionMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:to="us-gaap_TypeOfAdoptionMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1 To us-gaap_TypeOfAdoptionMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1 To us-gaap_AntidilutiveSecuritiesNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:label="us-gaap_ChangeInAccountingEstimateByTypeAxis_1" xlink:title="us-gaap_ChangeInAccountingEstimateByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:label="us-gaap_ChangeInAccountingEstimateTypeDomain_1" xlink:title="us-gaap_ChangeInAccountingEstimateTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ChangeInAccountingEstimateByTypeAxis_1" xlink:to="us-gaap_ChangeInAccountingEstimateTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ChangeInAccountingEstimateByTypeAxis_1 To us-gaap_ChangeInAccountingEstimateTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis_1" xlink:title="us-gaap_ValuationAllowancesAndReservesTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain_1" xlink:title="us-gaap_ValuationAllowancesAndReservesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis_1" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ValuationAllowancesAndReservesTypeAxis_1 To us-gaap_ValuationAllowancesAndReservesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_1" xlink:title="us-gaap_BalanceSheetLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_1" xlink:title="us-gaap_BalanceSheetLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_BalanceSheetLocationAxis_1" xlink:to="us-gaap_BalanceSheetLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_BalanceSheetLocationAxis_1 To us-gaap_BalanceSheetLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_1" xlink:title="us-gaap_SubsequentEventTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_1" xlink:title="us-gaap_SubsequentEventTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsequentEventTypeAxis_1" xlink:to="us-gaap_SubsequentEventTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsequentEventTypeAxis_1 To us-gaap_SubsequentEventTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_AchievementOfMilestoneAxis" xlink:label="rigl_AchievementOfMilestoneAxis_1" xlink:title="rigl_AchievementOfMilestoneAxis_1" />
    <link:loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_AchievementOfMilestoneDomain" xlink:label="rigl_AchievementOfMilestoneDomain_1" xlink:title="rigl_AchievementOfMilestoneDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="rigl_AchievementOfMilestoneAxis_1" xlink:to="rigl_AchievementOfMilestoneDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:rigl_AchievementOfMilestoneAxis_1 To rigl_AchievementOfMilestoneDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_1" xlink:title="us-gaap_TypeOfArrangementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TypeOfArrangementAxis_1" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TypeOfArrangementAxis_1 To us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis_1" xlink:title="us-gaap_ShortTermDebtTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain_1" xlink:title="us-gaap_ShortTermDebtTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ShortTermDebtTypeAxis_1" xlink:to="us-gaap_ShortTermDebtTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ShortTermDebtTypeAxis_1 To us-gaap_ShortTermDebtTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_1" xlink:title="us-gaap_IncomeStatementLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_1" xlink:title="us-gaap_IncomeStatementLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementLocationAxis_1" xlink:to="us-gaap_IncomeStatementLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeStatementLocationAxis_1 To us-gaap_IncomeStatementLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_1" xlink:title="us-gaap_PlanNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1" xlink:title="us-gaap_PlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PlanNameAxis_1" xlink:to="us-gaap_PlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PlanNameAxis_1 To us-gaap_PlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_1" xlink:title="us-gaap_VestingAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_1" xlink:title="us-gaap_VestingDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_VestingAxis_1" xlink:to="us-gaap_VestingDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_VestingAxis_1 To us-gaap_VestingDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:title="us-gaap_SubsidiarySaleOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsidiarySaleOfStockAxis_1 To us-gaap_SaleOfStockNameOfTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1 To us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis_1" xlink:title="us-gaap_CashAndCashEquivalentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" xlink:title="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_CashAndCashEquivalentsAxis_1" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_CashAndCashEquivalentsAxis_1 To us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis_1" xlink:title="us-gaap_InvestmentTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_1" xlink:title="us-gaap_InvestmentTypeCategorizationMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_InvestmentTypeAxis_1" xlink:to="us-gaap_InvestmentTypeCategorizationMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_InvestmentTypeAxis_1 To us-gaap_InvestmentTypeCategorizationMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_1" xlink:title="us-gaap_FairValueByMeasurementFrequencyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_1" xlink:title="us-gaap_FairValueMeasurementFrequencyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_1" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByMeasurementFrequencyAxis_1 To us-gaap_FairValueMeasurementFrequencyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByFairValueHierarchyLevelAxis_1 To us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis_1" xlink:title="us-gaap_FairValueByMeasurementBasisAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_1" xlink:title="us-gaap_PortionAtFairValueFairValueDisclosureMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByMeasurementBasisAxis_1" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByMeasurementBasisAxis_1 To us-gaap_PortionAtFairValueFairValueDisclosureMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PropertyPlantAndEquipmentByTypeAxis_1 To us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis_1" xlink:title="us-gaap_CreditFacilityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain_1" xlink:title="us-gaap_CreditFacilityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_CreditFacilityAxis_1" xlink:to="us-gaap_CreditFacilityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_CreditFacilityAxis_1 To us-gaap_CreditFacilityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_1" xlink:title="us-gaap_DebtInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_1" xlink:title="us-gaap_DebtInstrumentNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DebtInstrumentAxis_1" xlink:to="us-gaap_DebtInstrumentNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DebtInstrumentAxis_1 To us-gaap_DebtInstrumentNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis_1" xlink:title="us-gaap_VariableRateAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain_1" xlink:title="us-gaap_VariableRateDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_VariableRateAxis_1" xlink:to="us-gaap_VariableRateDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_VariableRateAxis_1 To us-gaap_VariableRateDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_1" xlink:title="us-gaap_IncomeTaxAuthorityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_1" xlink:title="us-gaap_IncomeTaxAuthorityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="us-gaap_IncomeTaxAuthorityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeTaxAuthorityAxis_1 To us-gaap_IncomeTaxAuthorityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis_1" xlink:title="us-gaap_TaxPeriodAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain_1" xlink:title="us-gaap_TaxPeriodDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TaxPeriodAxis_1" xlink:to="us-gaap_TaxPeriodDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TaxPeriodAxis_1 To us-gaap_TaxPeriodDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis_1" xlink:title="us-gaap_TaxCreditCarryforwardAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_1" xlink:title="us-gaap_TaxCreditCarryforwardNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TaxCreditCarryforwardAxis_1" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TaxCreditCarryforwardAxis_1 To us-gaap_TaxCreditCarryforwardNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis_1" xlink:title="us-gaap_RestructuringCostAndReserveAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain_1" xlink:title="us-gaap_TypeOfRestructuringDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RestructuringCostAndReserveAxis_1" xlink:to="us-gaap_TypeOfRestructuringDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RestructuringCostAndReserveAxis_1 To us-gaap_TypeOfRestructuringDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:title="us-gaap_ClassOfWarrantOrRightAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1" xlink:title="us-gaap_ClassOfWarrantOrRightDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ClassOfWarrantOrRightAxis_1 To us-gaap_ClassOfWarrantOrRightDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_1" xlink:title="us-gaap_FinancialInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:title="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FinancialInstrumentAxis_1" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FinancialInstrumentAxis_1 To us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_1" xlink:title="srt_CounterpartyNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_1" xlink:title="srt_RepurchaseAgreementCounterpartyNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CounterpartyNameAxis_1" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CounterpartyNameAxis_1 To srt_RepurchaseAgreementCounterpartyNameDomain_1" order="1" />
  </link:definitionLink>
  <definitionLink xlink:role="http://www.rigel.com/role/StatementCondensedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - CONDENSED STATEMENTS OF OPERATIONS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_ContractRevenuesFromCollaborationsMember" xlink:label="rigl_ContractRevenuesFromCollaborationsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="rigl_ContractRevenuesFromCollaborationsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentContractMember" xlink:label="us-gaap_GovernmentContractMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_GovernmentContractMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostsAndExpensesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSold" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InvestmentIncomeInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.rigel.com/role/StatementCondensedStatementsOfStockholdersDeficitEquity" xlink:type="extended" xlink:title="00400 - Statement - CONDENSED STATEMENTS OF STOCKHOLDERS' (DEFICIT) EQUITY" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_SharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.rigel.com/role/DisclosureStockBasedCompensationTables" xlink:type="extended" xlink:title="30503 - Disclosure - STOCK-BASED COMPENSATION (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.rigel.com/role/DisclosureNetLossPerShareDetails" xlink:type="extended" xlink:title="40201 - Disclosure - NET LOSS PER SHARE (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.rigel.com/role/DisclosureRevenuesDisaggregatedDetails" xlink:type="extended" xlink:title="40301 - Disclosure - REVENUES - Disaggregated (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_GrossProductMember" xlink:label="rigl_GrossProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="rigl_GrossProductMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_DiscountsAndAllowancesMember" xlink:label="rigl_DiscountsAndAllowancesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="rigl_DiscountsAndAllowancesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_DevelopmentMilestonesMember" xlink:label="rigl_DevelopmentMilestonesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="srt_ProductsAndServicesDomain" xlink:to="rigl_DevelopmentMilestonesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_RoyaltyDeliveryOfDrugSuppliesAndOthersMember" xlink:label="rigl_RoyaltyDeliveryOfDrugSuppliesAndOthersMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="srt_ProductsAndServicesDomain" xlink:to="rigl_RoyaltyDeliveryOfDrugSuppliesAndOthersMember" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_ContractRevenuesFromCollaborationsMember" xlink:label="rigl_ContractRevenuesFromCollaborationsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="srt_ProductsAndServicesDomain" xlink:to="rigl_ContractRevenuesFromCollaborationsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentContractMember" xlink:label="us-gaap_GovernmentContractMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_GovernmentContractMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.rigel.com/role/DisclosureRevenuesActivityDetails" xlink:type="extended" xlink:title="40302 - Disclosure - REVENUES - Activity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="srt_ValuationAndQualifyingAccountsDisclosureTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_ChargebacksDiscountsAndFeesMember" xlink:label="rigl_ChargebacksDiscountsAndFeesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="rigl_ChargebacksDiscountsAndFeesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_GovernmentAndOtherRebatesMember" xlink:label="rigl_GovernmentAndOtherRebatesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="rigl_GovernmentAndOtherRebatesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesReturnsAndAllowancesMember" xlink:label="us-gaap_SalesReturnsAndAllowancesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="us-gaap_SalesReturnsAndAllowancesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="us-gaap_BalanceSheetLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_AccountsReceivableAndPrepaidAndOtherCurrentAssetsMember" xlink:label="rigl_AccountsReceivableAndPrepaidAndOtherCurrentAssetsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="rigl_AccountsReceivableAndPrepaidAndOtherCurrentAssetsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="srt_ValuationAndQualifyingAccountsDisclosureLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="srt_ValuationAndQualifyingAccountsDisclosureTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesBalance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesDeductions" xlink:label="us-gaap_ValuationAllowancesAndReservesDeductions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesDeductions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_SalesDiscountsAndAllowances" xlink:label="rigl_SalesDiscountsAndAllowances" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="rigl_SalesDiscountsAndAllowances" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.rigel.com/role/DisclosureRevenuesPercentageByCustomerDetails" xlink:type="extended" xlink:title="40303 - Disclosure - REVENUES - Percentage by Customer (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesMember" xlink:label="us-gaap_SalesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_MajorCustomersAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_MckessonSpecialtyCareDistributionCorporationMember" xlink:label="rigl_MckessonSpecialtyCareDistributionCorporationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="rigl_MckessonSpecialtyCareDistributionCorporationMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_KisseiPharmaceuticalCo.Ltd.Member" xlink:label="rigl_KisseiPharmaceuticalCo.Ltd.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="rigl_KisseiPharmaceuticalCo.Ltd.Member" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_CardinalHealthcareMember" xlink:label="rigl_CardinalHealthcareMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="rigl_CardinalHealthcareMember" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_AsdHealthcareAndOncologySupplyMember" xlink:label="rigl_AsdHealthcareAndOncologySupplyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="rigl_AsdHealthcareAndOncologySupplyMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails" xlink:type="extended" xlink:title="40401 - Disclosure - SPONSORED RESEARCH AND LICENSE AGREEMENTS AND GOVERNMENT CONTRACT (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_FostamatinibMember" xlink:label="rigl_FostamatinibMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="rigl_FostamatinibMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_R552Member" xlink:label="rigl_R552Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="rigl_R552Member" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_NonCentralNervousSystemPenetrantIntellectualPropertyMember" xlink:label="rigl_NonCentralNervousSystemPenetrantIntellectualPropertyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_ProductsAndServicesDomain" xlink:to="rigl_NonCentralNervousSystemPenetrantIntellectualPropertyMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_CentralNervousSystemPenetrantIntellectualPropertyMember" xlink:label="rigl_CentralNervousSystemPenetrantIntellectualPropertyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_ProductsAndServicesDomain" xlink:to="rigl_CentralNervousSystemPenetrantIntellectualPropertyMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_RezlidhiaMember" xlink:label="rigl_RezlidhiaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="srt_ProductsAndServicesDomain" xlink:to="rigl_RezlidhiaMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_GrifolsS.a.Member" xlink:label="rigl_GrifolsS.a.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="rigl_GrifolsS.a.Member" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_KisseiPharmaceuticalCo.Ltd.Member" xlink:label="rigl_KisseiPharmaceuticalCo.Ltd.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="dei_EntityDomain" xlink:to="rigl_KisseiPharmaceuticalCo.Ltd.Member" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_MedisonPharmaLtd.Member" xlink:label="rigl_MedisonPharmaLtd.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="dei_EntityDomain" xlink:to="rigl_MedisonPharmaLtd.Member" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_KnightTherapeuticsInternationalSaMember" xlink:label="rigl_KnightTherapeuticsInternationalSaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="dei_EntityDomain" xlink:to="rigl_KnightTherapeuticsInternationalSaMember" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_FormaTherapeuticsHoldingsIncMember" xlink:label="rigl_FormaTherapeuticsHoldingsIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="dei_EntityDomain" xlink:to="rigl_FormaTherapeuticsHoldingsIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_AchievementOfMilestoneAxis" xlink:label="rigl_AchievementOfMilestoneAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="rigl_AchievementOfMilestoneAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_AchievementOfMilestoneDomain" xlink:label="rigl_AchievementOfMilestoneDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="rigl_AchievementOfMilestoneAxis" xlink:to="rigl_AchievementOfMilestoneDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_SpecifiedDevelopmentEventsMember" xlink:label="rigl_SpecifiedDevelopmentEventsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="rigl_AchievementOfMilestoneDomain" xlink:to="rigl_SpecifiedDevelopmentEventsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_SpecifiedRegulatoryEventsMember" xlink:label="rigl_SpecifiedRegulatoryEventsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="rigl_AchievementOfMilestoneDomain" xlink:to="rigl_SpecifiedRegulatoryEventsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_SpecifiedProductLaunchEventsMember" xlink:label="rigl_SpecifiedProductLaunchEventsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="rigl_AchievementOfMilestoneDomain" xlink:to="rigl_SpecifiedProductLaunchEventsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_LicensedRightsMember" xlink:label="rigl_LicensedRightsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="rigl_AchievementOfMilestoneDomain" xlink:to="rigl_LicensedRightsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_ResearchActivitiesMember" xlink:label="rigl_ResearchActivitiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="rigl_AchievementOfMilestoneDomain" xlink:to="rigl_ResearchActivitiesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_DevelopmentAndRegulatoryMilestonesByNonCentralNervousSystemDiseaseProductsMember" xlink:label="rigl_DevelopmentAndRegulatoryMilestonesByNonCentralNervousSystemDiseaseProductsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="rigl_AchievementOfMilestoneDomain" xlink:to="rigl_DevelopmentAndRegulatoryMilestonesByNonCentralNervousSystemDiseaseProductsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_DevelopmentAndRegulatoryMilestonesByCentralNervousSystemDiseaseProductsMember" xlink:label="rigl_DevelopmentAndRegulatoryMilestonesByCentralNervousSystemDiseaseProductsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="rigl_AchievementOfMilestoneDomain" xlink:to="rigl_DevelopmentAndRegulatoryMilestonesByCentralNervousSystemDiseaseProductsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember" xlink:label="rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="rigl_AchievementOfMilestoneDomain" xlink:to="rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_SpecifiedCommercialMilestonesMember" xlink:label="rigl_SpecifiedCommercialMilestonesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="rigl_AchievementOfMilestoneDomain" xlink:to="rigl_SpecifiedCommercialMilestonesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_EuropeanMedicinesAgencyApprovalOfFostamatinibForTreatmentOfChronicImmuneThrombocytopenicPurpuraMember" xlink:label="rigl_EuropeanMedicinesAgencyApprovalOfFostamatinibForTreatmentOfChronicImmuneThrombocytopenicPurpuraMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="rigl_AchievementOfMilestoneDomain" xlink:to="rigl_EuropeanMedicinesAgencyApprovalOfFostamatinibForTreatmentOfChronicImmuneThrombocytopenicPurpuraMember" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_CreditableAdvanceRoyaltyPaymentMember" xlink:label="rigl_CreditableAdvanceRoyaltyPaymentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="rigl_AchievementOfMilestoneDomain" xlink:to="rigl_CreditableAdvanceRoyaltyPaymentMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_DevelopmentAndRegulatoryMilestonesMember" xlink:label="rigl_DevelopmentAndRegulatoryMilestonesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="rigl_AchievementOfMilestoneDomain" xlink:to="rigl_DevelopmentAndRegulatoryMilestonesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_AchievementOfCertainNearTermRegulatoryMilestoneMember" xlink:label="rigl_AchievementOfCertainNearTermRegulatoryMilestoneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="rigl_DevelopmentAndRegulatoryMilestonesMember" xlink:to="rigl_AchievementOfCertainNearTermRegulatoryMilestoneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_FdaApprovalAndFirstCommercialSaleOfProductMember" xlink:label="rigl_FdaApprovalAndFirstCommercialSaleOfProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="rigl_AchievementOfMilestoneDomain" xlink:to="rigl_FdaApprovalAndFirstCommercialSaleOfProductMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_CommercialAndLicenseAgreementMember" xlink:label="rigl_CommercialAndLicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="rigl_CommercialAndLicenseAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_MilestonePaymentsOnProductByProductBasisMember" xlink:label="rigl_MilestonePaymentsOnProductByProductBasisMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="rigl_MilestonePaymentsOnProductByProductBasisMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="7" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductFinancingArrangementMember" xlink:label="us-gaap_ProductFinancingArrangementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ProductFinancingArrangementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_ContingentPaymentsUnderAgreement" xlink:label="rigl_ContingentPaymentsUnderAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rigl_ContingentPaymentsUnderAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_DevelopmentCostsCostSharingArrangementPercentage" xlink:label="rigl_DevelopmentCostsCostSharingArrangementPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rigl_DevelopmentCostsCostSharingArrangementPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_RightToOptOutOfAgreementNumberOfPeriods" xlink:label="rigl_RightToOptOutOfAgreementNumberOfPeriods" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rigl_RightToOptOutOfAgreementNumberOfPeriods" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitment" xlink:label="us-gaap_OtherCommitment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_OtherCommitment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_CollaborativeArrangementUpfrontFeeReceived" xlink:label="rigl_CollaborativeArrangementUpfrontFeeReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rigl_CollaborativeArrangementUpfrontFeeReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductLiabilityAccrualComponentAmount" xlink:label="us-gaap_ProductLiabilityAccrualComponentAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProductLiabilityAccrualComponentAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_FinancingLiabilityInterestAccretionDiscountRate" xlink:label="rigl_FinancingLiabilityInterestAccretionDiscountRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rigl_FinancingLiabilityInterestAccretionDiscountRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_FinancingLiabilityIncludingInterestExpenseAccretion" xlink:label="rigl_FinancingLiabilityIncludingInterestExpenseAccretion" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rigl_FinancingLiabilityIncludingInterestExpenseAccretion" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionExpense" xlink:label="us-gaap_AccretionExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccretionExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_DueToCollaborationPartner" xlink:label="rigl_DueToCollaborationPartner" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rigl_DueToCollaborationPartner" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_PaymentOfCostShareToCollaborationPartner" xlink:label="rigl_PaymentOfCostShareToCollaborationPartner" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rigl_PaymentOfCostShareToCollaborationPartner" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_CollaborativeArrangementRevenueRecognized" xlink:label="rigl_CollaborativeArrangementRevenueRecognized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rigl_CollaborativeArrangementRevenueRecognized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_GovernmentAward" xlink:label="rigl_GovernmentAward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rigl_GovernmentAward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="us-gaap_ProceedsFromCollaborators" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromCollaborators" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_RoyaltyPaymentAsPercentageOfNetSales" xlink:label="rigl_RoyaltyPaymentAsPercentageOfNetSales" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rigl_RoyaltyPaymentAsPercentageOfNetSales" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccountsReceivableNetCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_GovernmentAwardExpectedToBeReceivedInSucceedingPeriods" xlink:label="rigl_GovernmentAwardExpectedToBeReceivedInSucceedingPeriods" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rigl_GovernmentAwardExpectedToBeReceivedInSucceedingPeriods" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_NumberOfAgreements" xlink:label="rigl_NumberOfAgreements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rigl_NumberOfAgreements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_CollaborativeArrangementUpfrontPayment" xlink:label="rigl_CollaborativeArrangementUpfrontPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rigl_CollaborativeArrangementUpfrontPayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_CollaborativeArrangementPotentialPayments" xlink:label="rigl_CollaborativeArrangementPotentialPayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rigl_CollaborativeArrangementPotentialPayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetIncludingGoodwill" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="25" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_IntangibleAssetsNetIncludingGoodwill" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="26" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccountsPayableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_PaymentsOfMilestonePaymentObligations" xlink:label="rigl_PaymentsOfMilestonePaymentObligations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="27" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rigl_PaymentsOfMilestonePaymentObligations" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="28" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="29" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RoyaltyExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.rigel.com/role/DisclosureStockBasedCompensationDetails" xlink:type="extended" xlink:title="40501 - Disclosure - STOCK-BASED COMPENSATION (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.rigel.com/role/DisclosureStockBasedCompensationOptionsAndRsusDetails" xlink:type="extended" xlink:title="40502 - Disclosure - STOCK-BASED COMPENSATION - Options and RSUs (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_ShareBasedCompensationOptionsAndRsusMember" xlink:label="rigl_ShareBasedCompensationOptionsAndRsusMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="rigl_ShareBasedCompensationOptionsAndRsusMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.rigel.com/role/DisclosureStockBasedCompensationAssumptionsDetails" xlink:type="extended" xlink:title="40503 - Disclosure - STOCK-BASED COMPENSATION - Assumptions (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.rigel.com/role/DisclosureStockBasedCompensationPurchasePlanDetails" xlink:type="extended" xlink:title="40504 - Disclosure - STOCK-BASED COMPENSATION - Purchase Plan (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardOfferingPeriod" xlink:label="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardOfferingPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardOfferingPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentageOnFirstDayOfOfferingPeriod" xlink:label="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentageOnFirstDayOfOfferingPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentageOnFirstDayOfOfferingPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriodsPerAwardOfferingPeriod" xlink:label="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriodsPerAwardOfferingPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriodsPerAwardOfferingPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPurchasePeriod" xlink:label="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPurchasePeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPurchasePeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails" xlink:type="extended" xlink:title="40701 - Disclosure - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable" xlink:label="rigl_ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="rigl_ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CashMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="rigl_ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable" xlink:to="us-gaap_InvestmentTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasuryBillSecuritiesMember" xlink:label="us-gaap_USTreasuryBillSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USTreasuryBillSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_CorporateBondSecuritiesAndCommercialPaperMember" xlink:label="rigl_CorporateBondSecuritiesAndCommercialPaperMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="rigl_CorporateBondSecuritiesAndCommercialPaperMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="rigl_ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ShortTermInvestments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsGrossUnrealizedGainsAndLossesDetails" xlink:type="extended" xlink:title="40702 - Disclosure - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS - Gross Unrealized Gains and Losses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable" xlink:label="rigl_ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="rigl_ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasuryBillSecuritiesMember" xlink:label="us-gaap_USTreasuryBillSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasuryBillSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_CorporateBondSecuritiesAndCommercialPaperMember" xlink:label="rigl_CorporateBondSecuritiesAndCommercialPaperMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="rigl_CorporateBondSecuritiesAndCommercialPaperMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="rigl_ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:label="us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:label="rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_CashAndCashEquivalentsAndAvailableForSaleSecuritiesLineItems" xlink:label="rigl_CashAndCashEquivalentsAndAvailableForSaleSecuritiesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="rigl_CashAndCashEquivalentsAndAvailableForSaleSecuritiesLineItems" xlink:to="rigl_ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_CashEquivalentsAndAvailableForSaleSecuritiesAbstract" xlink:label="rigl_CashEquivalentsAndAvailableForSaleSecuritiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="rigl_CashAndCashEquivalentsAndAvailableForSaleSecuritiesLineItems" xlink:to="rigl_CashEquivalentsAndAvailableForSaleSecuritiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="rigl_CashEquivalentsAndAvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="rigl_CashEquivalentsAndAvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="rigl_CashEquivalentsAndAvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_InvestmentsFairValueDisclosure" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsUnrealizedLossPositionDetails" xlink:type="extended" xlink:title="40703 - Disclosure - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS - Unrealized Loss Position (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable" xlink:label="rigl_ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="rigl_ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable" xlink:to="us-gaap_InvestmentTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_CorporateBondSecuritiesAndCommercialPaperMember" xlink:label="rigl_CorporateBondSecuritiesAndCommercialPaperMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="rigl_CorporateBondSecuritiesAndCommercialPaperMember" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_CashAndCashEquivalentsAndAvailableForSaleSecuritiesLineItems" xlink:label="rigl_CashAndCashEquivalentsAndAvailableForSaleSecuritiesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="rigl_CashAndCashEquivalentsAndAvailableForSaleSecuritiesLineItems" xlink:to="rigl_ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="rigl_CashAndCashEquivalentsAndAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_CashEquivalentsAndAvailableForSaleSecuritiesWeightedAverageMaturityPeriod" xlink:label="rigl_CashEquivalentsAndAvailableForSaleSecuritiesWeightedAverageMaturityPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:to="rigl_CashEquivalentsAndAvailableForSaleSecuritiesWeightedAverageMaturityPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld" xlink:label="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:to="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.rigel.com/role/DisclosureFairValueDetails" xlink:type="extended" xlink:title="40801 - Disclosure - FAIR VALUE (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasuryBillSecuritiesMember" xlink:label="us-gaap_USTreasuryBillSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USTreasuryBillSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_CorporateBondSecuritiesAndCommercialPaperMember" xlink:label="rigl_CorporateBondSecuritiesAndCommercialPaperMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="rigl_CorporateBondSecuritiesAndCommercialPaperMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementBasisAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_InvestmentsFairValueDisclosure" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.rigel.com/role/DisclosureDebtDetails" xlink:type="extended" xlink:title="40901 - Disclosure - DEBT (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_CreditFacilityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditMember" xlink:label="us-gaap_LineOfCreditMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_LineOfCreditMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_CreditAgreementTrancheOneMember" xlink:label="rigl_CreditAgreementTrancheOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="rigl_CreditAgreementTrancheOneMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_CreditAgreementTrancheTwoMember" xlink:label="rigl_CreditAgreementTrancheTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="rigl_CreditAgreementTrancheTwoMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_CreditAgreementTrancheThreeMember" xlink:label="rigl_CreditAgreementTrancheThreeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="rigl_CreditAgreementTrancheThreeMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_CreditAgreementTrancheFourMember" xlink:label="rigl_CreditAgreementTrancheFourMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="rigl_CreditAgreementTrancheFourMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_CreditAgreementTrancheFiveMember" xlink:label="rigl_CreditAgreementTrancheFiveMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="rigl_CreditAgreementTrancheFiveMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_VariableRateAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:label="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_LondonInterBankOfferedRateMember" xlink:label="rigl_LondonInterBankOfferedRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_VariableRateDomain" xlink:to="rigl_LondonInterBankOfferedRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_PriorToThirdAmendmentMember" xlink:label="rigl_PriorToThirdAmendmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="rigl_PriorToThirdAmendmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_FollowingThirdAmendmentMember" xlink:label="rigl_FollowingThirdAmendmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="rigl_FollowingThirdAmendmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" xlink:label="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:label="us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityIncreaseAccruedInterest" xlink:label="us-gaap_LineOfCreditFacilityIncreaseAccruedInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityIncreaseAccruedInterest" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.rigel.com/role/DisclosureLeasesDetails" xlink:type="extended" xlink:title="41001 - Disclosure - LEASES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_HeadquartersOfficeSpaceSubleaseSouthSanFranciscoCaliforniaMember" xlink:label="rigl_HeadquartersOfficeSpaceSubleaseSouthSanFranciscoCaliforniaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BuildingMember" xlink:to="rigl_HeadquartersOfficeSpaceSubleaseSouthSanFranciscoCaliforniaMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_SubleaseAgreementAbstract" xlink:label="rigl_SubleaseAgreementAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="rigl_SubleaseAgreementAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="rigl_SubleaseAgreementAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="rigl_SubleaseAgreementAbstract" xlink:to="us-gaap_OperatingLeaseLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="rigl_SubleaseAgreementAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncentiveToLessee" xlink:label="us-gaap_IncentiveToLessee" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="rigl_SubleaseAgreementAbstract" xlink:to="us-gaap_IncentiveToLessee" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>rigl-20230630_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.3.0.9 -->
<!--Based on XBRL 2.1-->
<!--Created on: 7/31/2023 8:06:11 PM-->
<!--Modified on: 7/31/2023 8:06:11 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">DOCUMENT AND ENTITY INFORMATION</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Quarterly Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONDENSED BALANCE SHEETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term investments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivable, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetIncludingGoodwill" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetIncludingGoodwill_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetIncludingGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible Assets, Net (Including Goodwill)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsNetIncludingGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible asset, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IntangibleAssetsNetIncludingGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible asset</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-use assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease right-of-use asset</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and stockholders' (deficit) equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee-related Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued compensation</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_AccruedResearchAndDevelopmentLiabilityCurrent" xlink:label="rigl_AccruedResearchAndDevelopmentLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_AccruedResearchAndDevelopmentLiabilityCurrent" xlink:to="rigl_AccruedResearchAndDevelopmentLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_AccruedResearchAndDevelopmentLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the carrying value as of the balance sheet date of research and development costs that are incurred but not billed to the entity as of the end of the period. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_AccruedResearchAndDevelopmentLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Research and Development Liability Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rigl_AccruedResearchAndDevelopmentLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerRefundLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerRefundLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerRefundLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract with Customer, Refund Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ContractWithCustomerRefundLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue reserves and refund liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other accrued liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liabilities, current portion</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract with Customer, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other long-term liabilities, current portion</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term portion of lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermLoansPayable" xlink:label="us-gaap_LongTermLoansPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermLoansPayable" xlink:to="us-gaap_LongTermLoansPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermLoansPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loans Payable, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermLoansPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loans payable, net of discount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other long-term liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' deficit:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid in Capital, Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated other comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stockholders' deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities and stockholders' deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONDENSED STATEMENTS OF OPERATIONS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product and Service [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product and Service [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product sales, net</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_ContractRevenuesFromCollaborationsMember" xlink:label="rigl_ContractRevenuesFromCollaborationsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_ContractRevenuesFromCollaborationsMember" xlink:to="rigl_ContractRevenuesFromCollaborationsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_ContractRevenuesFromCollaborationsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents contract revenues from collaborations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_ContractRevenuesFromCollaborationsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract revenues from collaborations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentContractMember" xlink:label="us-gaap_GovernmentContractMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentContractMember" xlink:to="us-gaap_GovernmentContractMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GovernmentContractMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Government contract</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total revenues</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Costs and Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Costs and expenses:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of Goods and Services Sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of product sales</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense (Excluding Acquired in Process Cost)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling, General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling, general and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Costs and Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total costs and expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment Income, Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share, basic (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share, diluted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average common shares outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average shares used in computing net loss per share, basic (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average shares outstanding and common stock equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average shares used in computing net loss per share, diluted (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONDENSED STATEMENTS OF COMPREHENSIVE LOSS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Available to Common Stockholders, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive gain (loss):</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net unrealized gain (loss) on short-term investments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONDENSED STATEMENTS OF STOCKHOLDERS' (DEFICIT) EQUITY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-in Capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Stockholders' Equity [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock upon exercise of options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock upon exercise of options (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock upon vesting of restricted stock units (RSUs)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock upon vesting of restricted stock units (RSUs) (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONDENSED STATEMENTS OF CASH FLOWS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets1" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (Loss) on Disposition of Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss (gain) on sale and disposal of fixed assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation, Depletion and Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation and amortization</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_NoncashInterestExpense" xlink:label="rigl_NoncashInterestExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_NoncashInterestExpense" xlink:to="rigl_NoncashInterestExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_NoncashInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Noncash interest expense during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_NoncashInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Noncash Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rigl_NoncashInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash interest expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment Income, Net, Amortization of Discount and Premium</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net amortization and accretion of discount on short-term investments and term loan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivable, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventories</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Other Noncurrent Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other assets</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_IncreaseDecreaseRightOfUseAssets" xlink:label="rigl_IncreaseDecreaseRightOfUseAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_IncreaseDecreaseRightOfUseAssets" xlink:to="rigl_IncreaseDecreaseRightOfUseAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_IncreaseDecreaseRightOfUseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of increase or decrease in right-of-use assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_IncreaseDecreaseRightOfUseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase Decrease Right Of Use Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rigl_IncreaseDecreaseRightOfUseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Employee Related Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued compensation</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_IncreaseDecreaseInAccruedResearchAndDevelopmentLiability" xlink:label="rigl_IncreaseDecreaseInAccruedResearchAndDevelopmentLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_IncreaseDecreaseInAccruedResearchAndDevelopmentLiability" xlink:to="rigl_IncreaseDecreaseInAccruedResearchAndDevelopmentLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_IncreaseDecreaseInAccruedResearchAndDevelopmentLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the increase (decrease) during the reporting period in the aggregate amount of research and development expenses incurred but not yet paid.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_IncreaseDecreaseInAccruedResearchAndDevelopmentLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accrued Research and Development Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rigl_IncreaseDecreaseInAccruedResearchAndDevelopmentLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued research and development</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_RevenueReservesAndRefundLiability" xlink:label="rigl_RevenueReservesAndRefundLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_RevenueReservesAndRefundLiability" xlink:to="rigl_RevenueReservesAndRefundLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_RevenueReservesAndRefundLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the increase (decrease) during the reporting period in the aggregate amount of revenue reserves and refund liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_RevenueReservesAndRefundLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Reserves And Refund Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rigl_RevenueReservesAndRefundLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue reserves and refund liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Other Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other accrued liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase Decrease In Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Contract with Customer, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Other Operating Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other current and long-term liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by (used in) operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Short-term Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of short-term investments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Maturities, Prepayments and Calls of Short-term Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maturities of short-term investments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of intangible asset</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Sale of Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from sale of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities, Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing activities</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_PaymentOfCostShareToCollaborationPartner" xlink:label="rigl_PaymentOfCostShareToCollaborationPartner" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_PaymentOfCostShareToCollaborationPartner" xlink:to="rigl_PaymentOfCostShareToCollaborationPartner_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_PaymentOfCostShareToCollaborationPartner_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment of cost share to collaboration partner.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_PaymentOfCostShareToCollaborationPartner_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment Of Cost Share To Collaboration Partner</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="rigl_PaymentOfCostShareToCollaborationPartner_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost share payments to a collaboration partner</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rigl_PaymentOfCostShareToCollaborationPartner_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment of cost share to collaboration partner</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Including Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net proceeds from issuances of common stock upon exercise of options and participation in Purchase Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:label="us-gaap_ProceedsFromLongTermLinesOfCredit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:to="us-gaap_ProceedsFromLongTermLinesOfCredit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromLongTermLinesOfCredit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Long-term Lines of Credit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromLongTermLinesOfCredit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net proceeds from term loan financing</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities, Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net increase in cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents at beginning of period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental Cash Flow Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental disclosure of cash flow information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest paid</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Description and Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NET LOSS PER SHARE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NET LOSS PER SHARE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">REVENUES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenues:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Contract with Customer [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">REVENUES</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_CorporateCollaborationsDisclosureAbstract" xlink:label="rigl_CorporateCollaborationsDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_CorporateCollaborationsDisclosureAbstract" xlink:to="rigl_CorporateCollaborationsDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_CorporateCollaborationsDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Corporate Collaborations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_CorporateCollaborationsDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SPONSORED RESEARCH AND LICENSE AGREEMENTS AND GOVERNMENT CONTRACT</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SPONSORED RESEARCH AND LICENSE AGREEMENTS AND GOVERNMENT CONTRACT</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">STOCK-BASED COMPENSATION</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">STOCK-BASED COMPENSATION</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">INVENTORIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">INVENTORIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, and Short-term Investments [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">FAIR VALUE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">FAIR VALUE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">DEBT</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">DEBT</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">LEASES</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_LeaseDisclosureTextBlock" xlink:label="rigl_LeaseDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_LeaseDisclosureTextBlock" xlink:to="rigl_LeaseDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_LeaseDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure of information about leases.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_LeaseDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rigl_LeaseDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">LEASES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_LiquidityAndCapitalResourcesPolicyPolicyTextBlock" xlink:label="rigl_LiquidityAndCapitalResourcesPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_LiquidityAndCapitalResourcesPolicyPolicyTextBlock" xlink:to="rigl_LiquidityAndCapitalResourcesPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_LiquidityAndCapitalResourcesPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for liquidity and capital resources.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_LiquidityAndCapitalResourcesPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liquidity And Capital Resources Policy Policy Text Block</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rigl_LiquidityAndCapitalResourcesPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liquidity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recently Issued Accounting Standards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of antidilutive securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disaggregation of Revenue [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of revenues disaggregated by category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:label="srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:to="srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of product revenue allowance and reserve categories</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_DisaggregationOfRevenueByCustomerTableTextBlock" xlink:label="rigl_DisaggregationOfRevenueByCustomerTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_DisaggregationOfRevenueByCustomerTableTextBlock" xlink:to="rigl_DisaggregationOfRevenueByCustomerTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_DisaggregationOfRevenueByCustomerTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of disaggregation of revenue by customer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_DisaggregationOfRevenueByCustomerTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disaggregation Of Revenue By Customer [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rigl_DisaggregationOfRevenueByCustomerTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of revenues from product sales disaggregated by customers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of weighted-average assumptions relating to options granted pursuant to equity incentive plans</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Inventory, Current [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Inventories</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents and Investments [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of cash, cash equivalents and short-term investments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:label="us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:to="us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized Gain (Loss) on Investments [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of cash equivalents and short-term investments including securities with unrealized gains and losses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Unrealized Loss on Investments [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of fair value and gross unrealized losses of investments in unrealized loss position</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of financial assets measured at fair value on a recurring basis</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:label="us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:to="us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Line of Credit Facilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of future minimum payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, Cost [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of components of operating lease expense</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_CashFlowInformationRelatedToOperatingLeaseTableTextBlock" xlink:label="rigl_CashFlowInformationRelatedToOperatingLeaseTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_CashFlowInformationRelatedToOperatingLeaseTableTextBlock" xlink:to="rigl_CashFlowInformationRelatedToOperatingLeaseTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_CashFlowInformationRelatedToOperatingLeaseTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of supplemental cash flow information related to operating lease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_CashFlowInformationRelatedToOperatingLeaseTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Flow Information Related To Operating Lease [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rigl_CashFlowInformationRelatedToOperatingLeaseTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of supplemental information related to operating lease</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:label="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:to="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Lease Income [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of operating sublease information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of future minimum lease payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, and Short-term Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents and short-term investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents and short-term investments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RSUs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive securities excluded from the computation of diluted net loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disaggregation of Revenue [Table]</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_GrossProductMember" xlink:label="rigl_GrossProductMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_GrossProductMember" xlink:to="rigl_GrossProductMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_GrossProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents gross product.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_GrossProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross product sales</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_DiscountsAndAllowancesMember" xlink:label="rigl_DiscountsAndAllowancesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_DiscountsAndAllowancesMember" xlink:to="rigl_DiscountsAndAllowancesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_DiscountsAndAllowancesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents discounts and allowances.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_DiscountsAndAllowancesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Discounts and allowances</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseMember" xlink:to="us-gaap_LicenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License revenues</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_DevelopmentMilestonesMember" xlink:label="rigl_DevelopmentMilestonesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_DevelopmentMilestonesMember" xlink:to="rigl_DevelopmentMilestonesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_DevelopmentMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents development milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_DevelopmentMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Development milestones</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_RoyaltyDeliveryOfDrugSuppliesAndOthersMember" xlink:label="rigl_RoyaltyDeliveryOfDrugSuppliesAndOthersMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_RoyaltyDeliveryOfDrugSuppliesAndOthersMember" xlink:to="rigl_RoyaltyDeliveryOfDrugSuppliesAndOthersMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_RoyaltyDeliveryOfDrugSuppliesAndOthersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents royalty, delivery of drug supplies and others.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_RoyaltyDeliveryOfDrugSuppliesAndOthersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty, delivery of drug supplies and others</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disaggregation of Revenue [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="srt_ValuationAndQualifyingAccountsDisclosureTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="srt_ValuationAndQualifyingAccountsDisclosureTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ValuationAndQualifyingAccountsDisclosureTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_ChargebacksDiscountsAndFeesMember" xlink:label="rigl_ChargebacksDiscountsAndFeesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_ChargebacksDiscountsAndFeesMember" xlink:to="rigl_ChargebacksDiscountsAndFeesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_ChargebacksDiscountsAndFeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents chargebacks, discounts and fees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_ChargebacksDiscountsAndFeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Chargebacks, Discounts and Fees</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_GovernmentAndOtherRebatesMember" xlink:label="rigl_GovernmentAndOtherRebatesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_GovernmentAndOtherRebatesMember" xlink:to="rigl_GovernmentAndOtherRebatesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_GovernmentAndOtherRebatesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents government and other rebates.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_GovernmentAndOtherRebatesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Government and Other Rebates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesReturnsAndAllowancesMember" xlink:label="us-gaap_SalesReturnsAndAllowancesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesReturnsAndAllowancesMember" xlink:to="us-gaap_SalesReturnsAndAllowancesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesReturnsAndAllowancesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Returns</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance Sheet Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance Sheet Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_AccountsReceivableAndPrepaidAndOtherCurrentAssetsMember" xlink:label="rigl_AccountsReceivableAndPrepaidAndOtherCurrentAssetsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_AccountsReceivableAndPrepaidAndOtherCurrentAssetsMember" xlink:to="rigl_AccountsReceivableAndPrepaidAndOtherCurrentAssetsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_AccountsReceivableAndPrepaidAndOtherCurrentAssetsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Primary financial statement caption encompassing accounts receivable and prepaid and other current assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_AccountsReceivableAndPrepaidAndOtherCurrentAssetsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivable and prepaid and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="srt_ValuationAndQualifyingAccountsDisclosureLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="srt_ValuationAndQualifyingAccountsDisclosureLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ValuationAndQualifyingAccountsDisclosureLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="us-gaap_ValuationAllowancesAndReservesBalance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation Allowances and Reserves, Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:to="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation Allowances and Reserves, Additions for Charges to Cost and Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provision related to current period sales</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesDeductions" xlink:label="us-gaap_ValuationAllowancesAndReservesDeductions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesDeductions" xlink:to="us-gaap_ValuationAllowancesAndReservesDeductions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowancesAndReservesDeductions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation Allowances and Reserves, Deductions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ValuationAllowancesAndReservesDeductions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Credit or payments made during the period</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_SalesDiscountsAndAllowances" xlink:label="rigl_SalesDiscountsAndAllowances" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_SalesDiscountsAndAllowances" xlink:to="rigl_SalesDiscountsAndAllowances_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_SalesDiscountsAndAllowances_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of sales discounts and allowances during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_SalesDiscountsAndAllowances_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales Discounts And Allowances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rigl_SalesDiscountsAndAllowances_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Discounts and allowances</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Benchmark [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Benchmark [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesMember" xlink:label="us-gaap_SalesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesMember" xlink:to="us-gaap_SalesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer Concentration Risk</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MajorCustomersAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Name Of Major Customer [Domain]</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_MckessonSpecialtyCareDistributionCorporationMember" xlink:label="rigl_MckessonSpecialtyCareDistributionCorporationMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_MckessonSpecialtyCareDistributionCorporationMember" xlink:to="rigl_MckessonSpecialtyCareDistributionCorporationMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_MckessonSpecialtyCareDistributionCorporationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents McKesson Specialty Care Distribution Corporation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_MckessonSpecialtyCareDistributionCorporationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">McKesson Specialty Care Distribution Corporation</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_KisseiPharmaceuticalCo.Ltd.Member" xlink:label="rigl_KisseiPharmaceuticalCo.Ltd.Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_KisseiPharmaceuticalCo.Ltd.Member" xlink:to="rigl_KisseiPharmaceuticalCo.Ltd.Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_KisseiPharmaceuticalCo.Ltd.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents Kissei Pharmaceutical Co., Ltd.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_KisseiPharmaceuticalCo.Ltd.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Kissei</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_CardinalHealthcareMember" xlink:label="rigl_CardinalHealthcareMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_CardinalHealthcareMember" xlink:to="rigl_CardinalHealthcareMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_CardinalHealthcareMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents Cardinal Healthcare.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_CardinalHealthcareMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cardinal Healthcare</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_AsdHealthcareAndOncologySupplyMember" xlink:label="rigl_AsdHealthcareAndOncologySupplyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_AsdHealthcareAndOncologySupplyMember" xlink:to="rigl_AsdHealthcareAndOncologySupplyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_AsdHealthcareAndOncologySupplyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents ASD Healthcare and Oncology Supply.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_AsdHealthcareAndOncologySupplyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ASD Healthcare and Oncology Supply</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_FostamatinibMember" xlink:label="rigl_FostamatinibMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_FostamatinibMember" xlink:to="rigl_FostamatinibMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_FostamatinibMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents fostamatinib.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_FostamatinibMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">fostamatinib</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_R552Member" xlink:label="rigl_R552Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_R552Member" xlink:to="rigl_R552Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_R552Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for the treatment of non-central nervous system (non-CNS) diseases.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_R552Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">R552</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_NonCentralNervousSystemPenetrantIntellectualPropertyMember" xlink:label="rigl_NonCentralNervousSystemPenetrantIntellectualPropertyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_NonCentralNervousSystemPenetrantIntellectualPropertyMember" xlink:to="rigl_NonCentralNervousSystemPenetrantIntellectualPropertyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_NonCentralNervousSystemPenetrantIntellectualPropertyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents non-central nervous system penetrant intellectual property.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_NonCentralNervousSystemPenetrantIntellectualPropertyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-CNS penetrant IP</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_CentralNervousSystemPenetrantIntellectualPropertyMember" xlink:label="rigl_CentralNervousSystemPenetrantIntellectualPropertyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_CentralNervousSystemPenetrantIntellectualPropertyMember" xlink:to="rigl_CentralNervousSystemPenetrantIntellectualPropertyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_CentralNervousSystemPenetrantIntellectualPropertyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents central nervous system penetrant intellectual property.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_CentralNervousSystemPenetrantIntellectualPropertyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CNS penetrant IP</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyMember" xlink:to="us-gaap_RoyaltyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_RezlidhiaMember" xlink:label="rigl_RezlidhiaMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_RezlidhiaMember" xlink:to="rigl_RezlidhiaMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_RezlidhiaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents REZLIDHIA product.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_RezlidhiaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">REZLIDHIA</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Legal Entity [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity [Domain]</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_GrifolsS.a.Member" xlink:label="rigl_GrifolsS.a.Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_GrifolsS.a.Member" xlink:to="rigl_GrifolsS.a.Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_GrifolsS.a.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents Grifols, S.A.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_GrifolsS.a.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grifols</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_MedisonPharmaLtd.Member" xlink:label="rigl_MedisonPharmaLtd.Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_MedisonPharmaLtd.Member" xlink:to="rigl_MedisonPharmaLtd.Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_MedisonPharmaLtd.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents Medison Pharma Ltd.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_MedisonPharmaLtd.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Medison</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_KnightTherapeuticsInternationalSaMember" xlink:label="rigl_KnightTherapeuticsInternationalSaMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_KnightTherapeuticsInternationalSaMember" xlink:to="rigl_KnightTherapeuticsInternationalSaMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_KnightTherapeuticsInternationalSaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents Knight Therapeutics International SA.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_KnightTherapeuticsInternationalSaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Knight</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_FormaTherapeuticsHoldingsIncMember" xlink:label="rigl_FormaTherapeuticsHoldingsIncMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_FormaTherapeuticsHoldingsIncMember" xlink:to="rigl_FormaTherapeuticsHoldingsIncMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_FormaTherapeuticsHoldingsIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents Forma Therapeutics Holdings, Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_FormaTherapeuticsHoldingsIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forma</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_AchievementOfMilestoneAxis" xlink:label="rigl_AchievementOfMilestoneAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_AchievementOfMilestoneAxis" xlink:to="rigl_AchievementOfMilestoneAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_AchievementOfMilestoneAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information by categories of milestones achieved.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_AchievementOfMilestoneAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Achievement of Milestone [Axis]</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_AchievementOfMilestoneDomain" xlink:label="rigl_AchievementOfMilestoneDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_AchievementOfMilestoneDomain" xlink:to="rigl_AchievementOfMilestoneDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_AchievementOfMilestoneDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Different categories of achievement of milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_AchievementOfMilestoneDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Achievement Of Milestone [Domain]</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_SpecifiedDevelopmentEventsMember" xlink:label="rigl_SpecifiedDevelopmentEventsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_SpecifiedDevelopmentEventsMember" xlink:to="rigl_SpecifiedDevelopmentEventsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_SpecifiedDevelopmentEventsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents specified development events.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_SpecifiedDevelopmentEventsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Specified Development Events [Member]</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_SpecifiedRegulatoryEventsMember" xlink:label="rigl_SpecifiedRegulatoryEventsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_SpecifiedRegulatoryEventsMember" xlink:to="rigl_SpecifiedRegulatoryEventsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_SpecifiedRegulatoryEventsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents specified regulatory events.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_SpecifiedRegulatoryEventsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Specified Regulatory Events [Member]</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_SpecifiedProductLaunchEventsMember" xlink:label="rigl_SpecifiedProductLaunchEventsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_SpecifiedProductLaunchEventsMember" xlink:to="rigl_SpecifiedProductLaunchEventsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_SpecifiedProductLaunchEventsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents specified product launch events.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_SpecifiedProductLaunchEventsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Specified Product Launch Events [Member]</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_LicensedRightsMember" xlink:label="rigl_LicensedRightsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_LicensedRightsMember" xlink:to="rigl_LicensedRightsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_LicensedRightsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents licensed rights.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_LicensedRightsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Licensed Rights</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_ResearchActivitiesMember" xlink:label="rigl_ResearchActivitiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_ResearchActivitiesMember" xlink:to="rigl_ResearchActivitiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_ResearchActivitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents research services.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_ResearchActivitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research Services</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_DevelopmentAndRegulatoryMilestonesByNonCentralNervousSystemDiseaseProductsMember" xlink:label="rigl_DevelopmentAndRegulatoryMilestonesByNonCentralNervousSystemDiseaseProductsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_DevelopmentAndRegulatoryMilestonesByNonCentralNervousSystemDiseaseProductsMember" xlink:to="rigl_DevelopmentAndRegulatoryMilestonesByNonCentralNervousSystemDiseaseProductsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_DevelopmentAndRegulatoryMilestonesByNonCentralNervousSystemDiseaseProductsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents development and regulatory milestones by non-central nervous system disease products.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_DevelopmentAndRegulatoryMilestonesByNonCentralNervousSystemDiseaseProductsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Development and regulatory milestones by non-CNS disease products</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_DevelopmentAndRegulatoryMilestonesByCentralNervousSystemDiseaseProductsMember" xlink:label="rigl_DevelopmentAndRegulatoryMilestonesByCentralNervousSystemDiseaseProductsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_DevelopmentAndRegulatoryMilestonesByCentralNervousSystemDiseaseProductsMember" xlink:to="rigl_DevelopmentAndRegulatoryMilestonesByCentralNervousSystemDiseaseProductsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_DevelopmentAndRegulatoryMilestonesByCentralNervousSystemDiseaseProductsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents development and regulatory milestones by central nervous system disease products.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_DevelopmentAndRegulatoryMilestonesByCentralNervousSystemDiseaseProductsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Development and regulatory milestones by CNS disease products</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember" xlink:label="rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember" xlink:to="rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents a one-time delivery of drug supply for commercialization.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Delivery of drug supply for commercialization</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_SpecifiedCommercialMilestonesMember" xlink:label="rigl_SpecifiedCommercialMilestonesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_SpecifiedCommercialMilestonesMember" xlink:to="rigl_SpecifiedCommercialMilestonesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_SpecifiedCommercialMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents specified commercial milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_SpecifiedCommercialMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial milestones</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_EuropeanMedicinesAgencyApprovalOfFostamatinibForTreatmentOfChronicImmuneThrombocytopenicPurpuraMember" xlink:label="rigl_EuropeanMedicinesAgencyApprovalOfFostamatinibForTreatmentOfChronicImmuneThrombocytopenicPurpuraMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_EuropeanMedicinesAgencyApprovalOfFostamatinibForTreatmentOfChronicImmuneThrombocytopenicPurpuraMember" xlink:to="rigl_EuropeanMedicinesAgencyApprovalOfFostamatinibForTreatmentOfChronicImmuneThrombocytopenicPurpuraMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_EuropeanMedicinesAgencyApprovalOfFostamatinibForTreatmentOfChronicImmuneThrombocytopenicPurpuraMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents European Medicines Agency approval of fostamatinib for treatment of chronic immune thrombocytopenic purpura.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_EuropeanMedicinesAgencyApprovalOfFostamatinibForTreatmentOfChronicImmuneThrombocytopenicPurpuraMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upon EMA approval of fostamatinib for treatment of chronic ITP</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_CreditableAdvanceRoyaltyPaymentMember" xlink:label="rigl_CreditableAdvanceRoyaltyPaymentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_CreditableAdvanceRoyaltyPaymentMember" xlink:to="rigl_CreditableAdvanceRoyaltyPaymentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_CreditableAdvanceRoyaltyPaymentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents creditable advance royalty payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_CreditableAdvanceRoyaltyPaymentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Creditable advance royalty payment</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_DevelopmentAndRegulatoryMilestonesMember" xlink:label="rigl_DevelopmentAndRegulatoryMilestonesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_DevelopmentAndRegulatoryMilestonesMember" xlink:to="rigl_DevelopmentAndRegulatoryMilestonesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_DevelopmentAndRegulatoryMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents development and regulatory milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_DevelopmentAndRegulatoryMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Development and regulatory milestones</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_AchievementOfCertainNearTermRegulatoryMilestoneMember" xlink:label="rigl_AchievementOfCertainNearTermRegulatoryMilestoneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_AchievementOfCertainNearTermRegulatoryMilestoneMember" xlink:to="rigl_AchievementOfCertainNearTermRegulatoryMilestoneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_AchievementOfCertainNearTermRegulatoryMilestoneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents achievement of a certain near-term regulatory milestone.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_AchievementOfCertainNearTermRegulatoryMilestoneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Achievement of certain near-term regulatory milestone.</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_FdaApprovalAndFirstCommercialSaleOfProductMember" xlink:label="rigl_FdaApprovalAndFirstCommercialSaleOfProductMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_FdaApprovalAndFirstCommercialSaleOfProductMember" xlink:to="rigl_FdaApprovalAndFirstCommercialSaleOfProductMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_FdaApprovalAndFirstCommercialSaleOfProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents FDA approval and first commercial sale of the product.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_FdaApprovalAndFirstCommercialSaleOfProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">FDA approval and first commercial sale of product</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Arrangements And Nonarrangement Transactions [Member]</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_CommercialAndLicenseAgreementMember" xlink:label="rigl_CommercialAndLicenseAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_CommercialAndLicenseAgreementMember" xlink:to="rigl_CommercialAndLicenseAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_CommercialAndLicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents commercial and license agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_CommercialAndLicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial and license agreements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Domain]</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_MilestonePaymentsOnProductByProductBasisMember" xlink:label="rigl_MilestonePaymentsOnProductByProductBasisMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_MilestonePaymentsOnProductByProductBasisMember" xlink:to="rigl_MilestonePaymentsOnProductByProductBasisMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_MilestonePaymentsOnProductByProductBasisMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents milestone payments made on a product-by-product basis.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_MilestonePaymentsOnProductByProductBasisMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone payments on a product-by-product basis</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term Debt, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ShortTermDebtTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term Debt, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductFinancingArrangementMember" xlink:label="us-gaap_ProductFinancingArrangementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductFinancingArrangementMember" xlink:to="us-gaap_ProductFinancingArrangementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductFinancingArrangementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing arrangement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborations</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_ContingentPaymentsUnderAgreement" xlink:label="rigl_ContingentPaymentsUnderAgreement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_ContingentPaymentsUnderAgreement" xlink:to="rigl_ContingentPaymentsUnderAgreement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_ContingentPaymentsUnderAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents additional contingent payments by entities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_ContingentPaymentsUnderAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent Payments Under Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rigl_ContingentPaymentsUnderAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent payments</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_DevelopmentCostsCostSharingArrangementPercentage" xlink:label="rigl_DevelopmentCostsCostSharingArrangementPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_DevelopmentCostsCostSharingArrangementPercentage" xlink:to="rigl_DevelopmentCostsCostSharingArrangementPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_DevelopmentCostsCostSharingArrangementPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of development costs in cost sharing arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_DevelopmentCostsCostSharingArrangementPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Development Costs Cost Sharing Arrangement Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rigl_DevelopmentCostsCostSharingArrangementPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Company's percentage of development costs</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_RightToOptOutOfAgreementNumberOfPeriods" xlink:label="rigl_RightToOptOutOfAgreementNumberOfPeriods" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_RightToOptOutOfAgreementNumberOfPeriods" xlink:to="rigl_RightToOptOutOfAgreementNumberOfPeriods_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_RightToOptOutOfAgreementNumberOfPeriods_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of periods with right to opt out of agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_RightToOptOutOfAgreementNumberOfPeriods_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right To Opt Out Of Agreement Number Of Periods</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rigl_RightToOptOutOfAgreementNumberOfPeriods_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right to opt out of agreement, different specified times</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitment" xlink:label="us-gaap_OtherCommitment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitment" xlink:to="us-gaap_OtherCommitment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Commitment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherCommitment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Funding commitment</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_CollaborativeArrangementUpfrontFeeReceived" xlink:label="rigl_CollaborativeArrangementUpfrontFeeReceived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_CollaborativeArrangementUpfrontFeeReceived" xlink:to="rigl_CollaborativeArrangementUpfrontFeeReceived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_CollaborativeArrangementUpfrontFeeReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of upfront fees received during the period under the terms of collaborative and licensing agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_CollaborativeArrangementUpfrontFeeReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement Upfront Fee Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rigl_CollaborativeArrangementUpfrontFeeReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront payment received</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductLiabilityAccrualComponentAmount" xlink:label="us-gaap_ProductLiabilityAccrualComponentAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductLiabilityAccrualComponentAmount" xlink:to="us-gaap_ProductLiabilityAccrualComponentAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductLiabilityAccrualComponentAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product Liability Accrual, Component Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProductLiabilityAccrualComponentAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing component liability</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_FinancingLiabilityInterestAccretionDiscountRate" xlink:label="rigl_FinancingLiabilityInterestAccretionDiscountRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_FinancingLiabilityInterestAccretionDiscountRate" xlink:to="rigl_FinancingLiabilityInterestAccretionDiscountRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_FinancingLiabilityInterestAccretionDiscountRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rate applied to the undiscounted amount of financing liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_FinancingLiabilityInterestAccretionDiscountRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing Liability Interest Accretion Discount Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rigl_FinancingLiabilityInterestAccretionDiscountRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing liability interest accretion discount rate</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_FinancingLiabilityIncludingInterestExpenseAccretion" xlink:label="rigl_FinancingLiabilityIncludingInterestExpenseAccretion" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_FinancingLiabilityIncludingInterestExpenseAccretion" xlink:to="rigl_FinancingLiabilityIncludingInterestExpenseAccretion_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_FinancingLiabilityIncludingInterestExpenseAccretion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of financing liability including interest expense accretion.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_FinancingLiabilityIncludingInterestExpenseAccretion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing Liability Including Interest Expense Accretion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rigl_FinancingLiabilityIncludingInterestExpenseAccretion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing liability with accreted interest expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionExpense" xlink:label="us-gaap_AccretionExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionExpense" xlink:to="us-gaap_AccretionExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccretionExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accretion Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccretionExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accretion expense</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_DueToCollaborationPartner" xlink:label="rigl_DueToCollaborationPartner" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_DueToCollaborationPartner" xlink:to="rigl_DueToCollaborationPartner_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_DueToCollaborationPartner_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount due to collaboration partner.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_DueToCollaborationPartner_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Due To Collaboration Partner</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rigl_DueToCollaborationPartner_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Development costs due to collaboration partner</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligation" xlink:to="us-gaap_RevenueRemainingPerformanceObligation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue, Remaining Performance Obligation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue, remaining performance obligation</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_CollaborativeArrangementRevenueRecognized" xlink:label="rigl_CollaborativeArrangementRevenueRecognized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_CollaborativeArrangementRevenueRecognized" xlink:to="rigl_CollaborativeArrangementRevenueRecognized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_CollaborativeArrangementRevenueRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the revenue recognized during the period under the terms of sponsored research and license agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_CollaborativeArrangementRevenueRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement Revenue Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rigl_CollaborativeArrangementRevenueRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue recognized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred revenue</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_GovernmentAward" xlink:label="rigl_GovernmentAward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_GovernmentAward" xlink:to="rigl_GovernmentAward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_GovernmentAward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of award from the government.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_GovernmentAward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Government Award</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rigl_GovernmentAward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Government contract</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="us-gaap_ProceedsFromCollaborators" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromCollaborators" xlink:to="us-gaap_ProceedsFromCollaborators_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromCollaborators_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Collaborators</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromCollaborators_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative payment received</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_RoyaltyPaymentAsPercentageOfNetSales" xlink:label="rigl_RoyaltyPaymentAsPercentageOfNetSales" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_RoyaltyPaymentAsPercentageOfNetSales" xlink:to="rigl_RoyaltyPaymentAsPercentageOfNetSales_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_RoyaltyPaymentAsPercentageOfNetSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents royalty payment as a percentage of net sales.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_RoyaltyPaymentAsPercentageOfNetSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty Payment As Percentage Of Net Sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rigl_RoyaltyPaymentAsPercentageOfNetSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty payment as a percentage of net sales</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_GovernmentAwardExpectedToBeReceivedInSucceedingPeriods" xlink:label="rigl_GovernmentAwardExpectedToBeReceivedInSucceedingPeriods" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_GovernmentAwardExpectedToBeReceivedInSucceedingPeriods" xlink:to="rigl_GovernmentAwardExpectedToBeReceivedInSucceedingPeriods_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_GovernmentAwardExpectedToBeReceivedInSucceedingPeriods_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The remaining amount of government award expected to be received in the succeeding periods.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_GovernmentAwardExpectedToBeReceivedInSucceedingPeriods_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Government Award Expected To Be Received In Succeeding Periods</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rigl_GovernmentAwardExpectedToBeReceivedInSucceedingPeriods_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remaining amount of government award expected to be received in succeeding periods</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_NumberOfAgreements" xlink:label="rigl_NumberOfAgreements" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_NumberOfAgreements" xlink:to="rigl_NumberOfAgreements_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_NumberOfAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_NumberOfAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rigl_NumberOfAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of agreements</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_CollaborativeArrangementUpfrontPayment" xlink:label="rigl_CollaborativeArrangementUpfrontPayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_CollaborativeArrangementUpfrontPayment" xlink:to="rigl_CollaborativeArrangementUpfrontPayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_CollaborativeArrangementUpfrontPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of collaborative arrangement upfront payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_CollaborativeArrangementUpfrontPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement Upfront Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rigl_CollaborativeArrangementUpfrontPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront fee</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_CollaborativeArrangementPotentialPayments" xlink:label="rigl_CollaborativeArrangementPotentialPayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_CollaborativeArrangementPotentialPayments" xlink:to="rigl_CollaborativeArrangementPotentialPayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_CollaborativeArrangementPotentialPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum amount of contingent payments under collaborative arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_CollaborativeArrangementPotentialPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement Potential Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rigl_CollaborativeArrangementPotentialPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Potential payments</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_PaymentsOfMilestonePaymentObligations" xlink:label="rigl_PaymentsOfMilestonePaymentObligations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_PaymentsOfMilestonePaymentObligations" xlink:to="rigl_PaymentsOfMilestonePaymentObligations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_PaymentsOfMilestonePaymentObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of payments of milestone payment obligations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_PaymentsOfMilestonePaymentObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments Of Milestone Payment Obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rigl_PaymentsOfMilestonePaymentObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of milestone payment obligations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of intangible assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RoyaltyExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling, general and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense related to stock-based awards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allocated Share-based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Incremental Compensation Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Incremental stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_ShareBasedCompensationOptionsAndRsusMember" xlink:label="rigl_ShareBasedCompensationOptionsAndRsusMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_ShareBasedCompensationOptionsAndRsusMember" xlink:to="rigl_ShareBasedCompensationOptionsAndRsusMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_ShareBasedCompensationOptionsAndRsusMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents share based compensation options and RSUs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_ShareBasedCompensationOptionsAndRsusMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee stock options and Restricted Stock Units</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting upon achievement of corporate performance-based milestones</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, end of period (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, beginning of period (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised/Released (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, end of period (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, beginning of period (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-Average Grant Date Fair Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional disclosures</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total unrecognized compensation cost related to performance-based stock options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total unrecognized compensation costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average recognition period of unrecognized compensation cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average assumptions relating to options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average assumptions relating to Purchase Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected term (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividend yield (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected volatility (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant-date weighted-average fair value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase Plan</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardOfferingPeriod" xlink:label="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardOfferingPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardOfferingPeriod" xlink:to="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardOfferingPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardOfferingPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the offering period for awards under the equity-based compensation plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardOfferingPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement by Share Based Payment Award, Award Offering Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardOfferingPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award offering period</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentageOnFirstDayOfOfferingPeriod" xlink:label="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentageOnFirstDayOfOfferingPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentageOnFirstDayOfOfferingPeriod" xlink:to="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentageOnFirstDayOfOfferingPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentageOnFirstDayOfOfferingPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the purchase price expressed as a percentage of the fair market value of common stock on the first day of the offering period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentageOnFirstDayOfOfferingPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement by Share Based Payment Award Purchase Price of Common Stock Percentage on First Day of Offering Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentageOnFirstDayOfOfferingPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase price expressed as a percentage of fair market value of common stock on the first day of the offering period</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriodsPerAwardOfferingPeriod" xlink:label="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriodsPerAwardOfferingPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriodsPerAwardOfferingPeriod" xlink:to="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriodsPerAwardOfferingPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriodsPerAwardOfferingPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of purchase periods per award offering period under the equity-based compensation plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriodsPerAwardOfferingPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement by Share Based Payment Award Number of Purchase Periods Per Award Offering Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriodsPerAwardOfferingPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of purchase periods per award offering period</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPurchasePeriod" xlink:label="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPurchasePeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPurchasePeriod" xlink:to="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPurchasePeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPurchasePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the purchase period for awards under the equity-based compensation plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPurchasePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement by Share Based Payment Award, Award Purchase Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPurchasePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award purchase period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase price expressed as a percentage of fair market value of common stock on the purchase date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional shares approved</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares of common stock available for grant</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Shares Purchased for Award</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares purchased</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares reserved for future issuance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized compensation cost related to purchase plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterials_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Raw Materials, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryRawMaterials_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Raw Materials</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcess" xlink:to="us-gaap_InventoryWorkInProcess_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Work in Process, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Work in process</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Finished Goods, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finished goods</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvancesOnInventoryPurchases" xlink:label="us-gaap_AdvancesOnInventoryPurchases" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvancesOnInventoryPurchases" xlink:to="us-gaap_AdvancesOnInventoryPurchases_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvancesOnInventoryPurchases_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Advances on Inventory Purchases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdvancesOnInventoryPurchases_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Advance payments for raw materials</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable" xlink:label="rigl_ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable" xlink:to="rigl_ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of cash and cash equivalent balances, excluding any restricted cash balances, and available-for-sale securities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Cash and Cash Equivalents and Available For Sale Securities [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashMember" xlink:to="us-gaap_CashMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment Type Categorization [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Money market funds</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasuryBillSecuritiesMember" xlink:label="us-gaap_USTreasuryBillSecuritiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasuryBillSecuritiesMember" xlink:to="us-gaap_USTreasuryBillSecuritiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_USTreasuryBillSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">US treasury bills</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Government-sponsored enterprise securities</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_CorporateBondSecuritiesAndCommercialPaperMember" xlink:label="rigl_CorporateBondSecuritiesAndCommercialPaperMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_CorporateBondSecuritiesAndCommercialPaperMember" xlink:to="rigl_CorporateBondSecuritiesAndCommercialPaperMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_CorporateBondSecuritiesAndCommercialPaperMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount) and unsecured promissory note (generally negotiable) that provides institutions with short-term funds.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_CorporateBondSecuritiesAndCommercialPaperMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Corporate bonds and commercial paper</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalent and short term investments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instruments [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:label="us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross Unrealized Gains</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:label="rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), including portion attributable to noncontrolling interest.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross Unrealized Losses</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_CashAndCashEquivalentsAndAvailableForSaleSecuritiesLineItems" xlink:label="rigl_CashAndCashEquivalentsAndAvailableForSaleSecuritiesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_CashAndCashEquivalentsAndAvailableForSaleSecuritiesLineItems" xlink:to="rigl_CashAndCashEquivalentsAndAvailableForSaleSecuritiesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_CashAndCashEquivalentsAndAvailableForSaleSecuritiesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_CashAndCashEquivalentsAndAvailableForSaleSecuritiesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents and Available For Sale Securities [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rigl_CashAndCashEquivalentsAndAvailableForSaleSecuritiesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents and short-term investments</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_CashEquivalentsAndAvailableForSaleSecuritiesAbstract" xlink:label="rigl_CashEquivalentsAndAvailableForSaleSecuritiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_CashEquivalentsAndAvailableForSaleSecuritiesAbstract" xlink:to="rigl_CashEquivalentsAndAvailableForSaleSecuritiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_CashEquivalentsAndAvailableForSaleSecuritiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Equivalents and Available For Sale Securities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rigl_CashEquivalentsAndAvailableForSaleSecuritiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash equivalents and available-for-sale securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale, Amortized Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortized Cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">AOCI Including Portion Attributable to Noncontrolling Interest, before Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross Unrealized Gains (Losses)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsFairValueDisclosure" xlink:to="us-gaap_InvestmentsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investments, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investments at fair value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Available-for-sale Securities, Continuous Unrealized Loss Position [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value and gross unrealized losses of investments in individual securities in unrealized loss position</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_CashEquivalentsAndAvailableForSaleSecuritiesWeightedAverageMaturityPeriod" xlink:label="rigl_CashEquivalentsAndAvailableForSaleSecuritiesWeightedAverageMaturityPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_CashEquivalentsAndAvailableForSaleSecuritiesWeightedAverageMaturityPeriod" xlink:to="rigl_CashEquivalentsAndAvailableForSaleSecuritiesWeightedAverageMaturityPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_CashEquivalentsAndAvailableForSaleSecuritiesWeightedAverageMaturityPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the weighted-average period of maturity of cash equivalents and available-for-sale debt securities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_CashEquivalentsAndAvailableForSaleSecuritiesWeightedAverageMaturityPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Equivalents and Available For Sale Securities, Weighted Average Maturity Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rigl_CashEquivalentsAndAvailableForSaleSecuritiesWeightedAverageMaturityPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average time to maturity of cash equivalents and available-for-sale securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of investments in continuous unrealized loss position for more than 12 months</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of individual securities in unrealized loss position for 12 months or less</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld" xlink:label="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld" xlink:to="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other than Temporary Impairment, Credit Losses Recognized in Earnings, Credit Losses on Debt Securities Held</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Credit losses recognized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Available For Sale Securities Continuous Unrealized Loss Position Less than 12 Months Accumulated Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized Losses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Frequency [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement Frequency [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements Recurring</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Hierarchy [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements Fair Value Hierarchy [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 1</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 2</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_FairValueByMeasurementBasisAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementBasisAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Basis [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Portion at Fair Value Measurement [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimate Of Fair Value Fair Value Disclosure</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Long-term Debt Instruments [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditFacilityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Credit Facility [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditFacilityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Credit Facility [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditMember" xlink:label="us-gaap_LineOfCreditMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditMember" xlink:to="us-gaap_LineOfCreditMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Credit Facility with MidCap</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_CreditAgreementTrancheOneMember" xlink:label="rigl_CreditAgreementTrancheOneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_CreditAgreementTrancheOneMember" xlink:to="rigl_CreditAgreementTrancheOneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_CreditAgreementTrancheOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche one representing borrowing capacity under terms of the credit agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_CreditAgreementTrancheOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche 1</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_CreditAgreementTrancheTwoMember" xlink:label="rigl_CreditAgreementTrancheTwoMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_CreditAgreementTrancheTwoMember" xlink:to="rigl_CreditAgreementTrancheTwoMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_CreditAgreementTrancheTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche two representing borrowing capacity under terms of the credit agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_CreditAgreementTrancheTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche 2</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_CreditAgreementTrancheThreeMember" xlink:label="rigl_CreditAgreementTrancheThreeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_CreditAgreementTrancheThreeMember" xlink:to="rigl_CreditAgreementTrancheThreeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_CreditAgreementTrancheThreeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche three representing borrowing capacity under terms of the credit agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_CreditAgreementTrancheThreeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche 3</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_CreditAgreementTrancheFourMember" xlink:label="rigl_CreditAgreementTrancheFourMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_CreditAgreementTrancheFourMember" xlink:to="rigl_CreditAgreementTrancheFourMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_CreditAgreementTrancheFourMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche four representing borrowing capacity under terms of the credit agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_CreditAgreementTrancheFourMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche 4</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_CreditAgreementTrancheFiveMember" xlink:label="rigl_CreditAgreementTrancheFiveMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_CreditAgreementTrancheFiveMember" xlink:to="rigl_CreditAgreementTrancheFiveMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_CreditAgreementTrancheFiveMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche five representing borrowing capacity under terms of the credit agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_CreditAgreementTrancheFiveMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche 5</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableRateAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Variable Rate [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_VariableRateDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableRateDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Variable Rate [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:label="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:to="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SOFR</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_LondonInterBankOfferedRateMember" xlink:label="rigl_LondonInterBankOfferedRateMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_LondonInterBankOfferedRateMember" xlink:to="rigl_LondonInterBankOfferedRateMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_LondonInterBankOfferedRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest rate at which a bank borrows funds from other banks in the London interbank market.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_LondonInterBankOfferedRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">LIBOR</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_PriorToThirdAmendmentMember" xlink:label="rigl_PriorToThirdAmendmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_PriorToThirdAmendmentMember" xlink:to="rigl_PriorToThirdAmendmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_PriorToThirdAmendmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period of time prior to third amendment of credit agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_PriorToThirdAmendmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prior to Third Amendment</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_FollowingThirdAmendmentMember" xlink:label="rigl_FollowingThirdAmendmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_FollowingThirdAmendmentMember" xlink:to="rigl_FollowingThirdAmendmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_FollowingThirdAmendmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period of time following third amendment of credit agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_FollowingThirdAmendmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Following Third Amendment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line of Credit Facility, Maximum Borrowing Capacity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum borrowing capacity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line of Credit Facility, Remaining Borrowing Capacity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remaining borrowing capacity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" xlink:label="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" xlink:to="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Interest Rate, Basis for Effective Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rate adjustment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Basis Spread on Variable Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis spread on variable rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Interest Rate, Stated Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Floor rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Final payment fee, percentage of principal</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:label="us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:to="us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line of Credit Facility, Fair Value of Amount Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding balance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unamortized issuance costs and debt discounts</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityIncreaseAccruedInterest" xlink:label="us-gaap_LineOfCreditFacilityIncreaseAccruedInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityIncreaseAccruedInterest" xlink:to="us-gaap_LineOfCreditFacilityIncreaseAccruedInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityIncreaseAccruedInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line of Credit Facility, Increase, Accrued Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityIncreaseAccruedInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:label="us-gaap_MaturitiesOfLongTermDebtAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:to="us-gaap_MaturitiesOfLongTermDebtAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MaturitiesOfLongTermDebtAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maturities of Long-term Debt [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MaturitiesOfLongTermDebtAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Future minimum payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt, Maturities, Repayments of Principal in Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2025</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt, Maturities, Repayments of Principal in Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2026</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Principal amount (Tranches 1, 2, 3 and 4)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Description [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property Plant And Equipment Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingMember" xlink:to="us-gaap_BuildingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BuildingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Building</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_HeadquartersOfficeSpaceSubleaseSouthSanFranciscoCaliforniaMember" xlink:label="rigl_HeadquartersOfficeSpaceSubleaseSouthSanFranciscoCaliforniaMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_HeadquartersOfficeSpaceSubleaseSouthSanFranciscoCaliforniaMember" xlink:to="rigl_HeadquartersOfficeSpaceSubleaseSouthSanFranciscoCaliforniaMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_HeadquartersOfficeSpaceSubleaseSouthSanFranciscoCaliforniaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents Headquarters office space sublease in South San Francisco, California.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_HeadquartersOfficeSpaceSubleaseSouthSanFranciscoCaliforniaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Headquarters office space sublease, South San Francisco, California</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Description [Line Items]</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_SubleaseAgreementAbstract" xlink:label="rigl_SubleaseAgreementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_SubleaseAgreementAbstract" xlink:to="rigl_SubleaseAgreementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_SubleaseAgreementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_SubleaseAgreementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sublease Agreement Abstract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rigl_SubleaseAgreementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sublease Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rigl_SubleaseAgreementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating sublease information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Weighted Average Remaining Lease Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average remaining lease term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncentiveToLessee" xlink:label="us-gaap_IncentiveToLessee" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncentiveToLessee" xlink:to="us-gaap_IncentiveToLessee_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncentiveToLessee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Incentive to Lessee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncentiveToLessee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leasehold improvement incentives from landlord</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed operating lease expense</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_VariableLeaseExpenseNetCredit" xlink:label="rigl_VariableLeaseExpenseNetCredit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_VariableLeaseExpenseNetCredit" xlink:to="rigl_VariableLeaseExpenseNetCredit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_VariableLeaseExpenseNetCredit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of variable lease expense (net credit).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_VariableLeaseExpenseNetCredit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Variable Lease Expense Net Credit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rigl_VariableLeaseExpenseNetCredit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Variable operating lease expense (net credit)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating lease expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash payments included in the measurement of operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_FixedSubleaseExpense" xlink:label="rigl_FixedSubleaseExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_FixedSubleaseExpense" xlink:to="rigl_FixedSubleaseExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_FixedSubleaseExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of fixed sublease expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_FixedSubleaseExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed Sublease Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rigl_FixedSubleaseExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed sublease expense</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_VariableSubleaseExpense" xlink:label="rigl_VariableSubleaseExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_VariableSubleaseExpense" xlink:to="rigl_VariableSubleaseExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_VariableSubleaseExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of variable sublease expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_VariableSubleaseExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Variable Sublease Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rigl_VariableSubleaseExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Variable sublease expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubleaseIncome" xlink:to="us-gaap_SubleaseIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubleaseIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sublease income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SubleaseIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sublease income</label>
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_NetSubleaseIncomeExpense" xlink:label="rigl_NetSubleaseIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_NetSubleaseIncomeExpense" xlink:to="rigl_NetSubleaseIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_NetSubleaseIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of net sublease income (expense).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_NetSubleaseIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Sublease Income Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="rigl_NetSubleaseIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease Liabilities, Payments Due [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remainder of 2023</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Payments, Due Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2025</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Payments, Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total minimum payments required</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>rigl-20230630_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.3.0.9 -->
<!--Based on XBRL 2.1-->
<!--Created on: 7/31/2023 8:06:11 PM-->
<!--Modified on: 7/31/2023 8:06:11 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="rigl-20230630.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.rigel.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20230630.xsd#StatementCondensedBalanceSheets" roleURI="http://www.rigel.com/role/StatementCondensedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20230630.xsd#StatementCondensedStatementsOfOperations" roleURI="http://www.rigel.com/role/StatementCondensedStatementsOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20230630.xsd#StatementCondensedStatementsOfComprehensiveLoss" roleURI="http://www.rigel.com/role/StatementCondensedStatementsOfComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20230630.xsd#StatementCondensedStatementsOfStockholdersDeficitEquity" roleURI="http://www.rigel.com/role/StatementCondensedStatementsOfStockholdersDeficitEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20230630.xsd#StatementCondensedStatementsOfCashFlows" roleURI="http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20230630.xsd#DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies" roleURI="http://www.rigel.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20230630.xsd#DisclosureNetLossPerShare" roleURI="http://www.rigel.com/role/DisclosureNetLossPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20230630.xsd#DisclosureRevenues" roleURI="http://www.rigel.com/role/DisclosureRevenues" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20230630.xsd#DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContract" roleURI="http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContract" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20230630.xsd#DisclosureStockBasedCompensation" roleURI="http://www.rigel.com/role/DisclosureStockBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20230630.xsd#DisclosureInventories" roleURI="http://www.rigel.com/role/DisclosureInventories" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20230630.xsd#DisclosureCashCashEquivalentsAndShortTermInvestments" roleURI="http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20230630.xsd#DisclosureFairValue" roleURI="http://www.rigel.com/role/DisclosureFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20230630.xsd#DisclosureDebt" roleURI="http://www.rigel.com/role/DisclosureDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20230630.xsd#DisclosureLeases" roleURI="http://www.rigel.com/role/DisclosureLeases" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20230630.xsd#DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.rigel.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20230630.xsd#DisclosureNetLossPerShareTables" roleURI="http://www.rigel.com/role/DisclosureNetLossPerShareTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20230630.xsd#DisclosureRevenuesTables" roleURI="http://www.rigel.com/role/DisclosureRevenuesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20230630.xsd#DisclosureStockBasedCompensationTables" roleURI="http://www.rigel.com/role/DisclosureStockBasedCompensationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20230630.xsd#DisclosureInventoriesTables" roleURI="http://www.rigel.com/role/DisclosureInventoriesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20230630.xsd#DisclosureCashCashEquivalentsAndShortTermInvestmentsTables" roleURI="http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20230630.xsd#DisclosureFairValueTables" roleURI="http://www.rigel.com/role/DisclosureFairValueTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20230630.xsd#DisclosureDebtTables" roleURI="http://www.rigel.com/role/DisclosureDebtTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20230630.xsd#DisclosureLeasesTables" roleURI="http://www.rigel.com/role/DisclosureLeasesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20230630.xsd#DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndLiquidityDetails" roleURI="http://www.rigel.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndLiquidityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20230630.xsd#DisclosureNetLossPerShareDetails" roleURI="http://www.rigel.com/role/DisclosureNetLossPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20230630.xsd#DisclosureRevenuesDisaggregatedDetails" roleURI="http://www.rigel.com/role/DisclosureRevenuesDisaggregatedDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20230630.xsd#DisclosureRevenuesActivityDetails" roleURI="http://www.rigel.com/role/DisclosureRevenuesActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20230630.xsd#DisclosureRevenuesPercentageByCustomerDetails" roleURI="http://www.rigel.com/role/DisclosureRevenuesPercentageByCustomerDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20230630.xsd#DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails" roleURI="http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20230630.xsd#DisclosureStockBasedCompensationDetails" roleURI="http://www.rigel.com/role/DisclosureStockBasedCompensationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20230630.xsd#DisclosureStockBasedCompensationOptionsAndRsusDetails" roleURI="http://www.rigel.com/role/DisclosureStockBasedCompensationOptionsAndRsusDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20230630.xsd#DisclosureStockBasedCompensationAssumptionsDetails" roleURI="http://www.rigel.com/role/DisclosureStockBasedCompensationAssumptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20230630.xsd#DisclosureStockBasedCompensationPurchasePlanDetails" roleURI="http://www.rigel.com/role/DisclosureStockBasedCompensationPurchasePlanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20230630.xsd#DisclosureInventoriesDetails" roleURI="http://www.rigel.com/role/DisclosureInventoriesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20230630.xsd#DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails" roleURI="http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20230630.xsd#DisclosureCashCashEquivalentsAndShortTermInvestmentsGrossUnrealizedGainsAndLossesDetails" roleURI="http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsGrossUnrealizedGainsAndLossesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20230630.xsd#DisclosureCashCashEquivalentsAndShortTermInvestmentsUnrealizedLossPositionDetails" roleURI="http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsUnrealizedLossPositionDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20230630.xsd#DisclosureFairValueDetails" roleURI="http://www.rigel.com/role/DisclosureFairValueDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20230630.xsd#DisclosureDebtDetails" roleURI="http://www.rigel.com/role/DisclosureDebtDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20230630.xsd#DisclosureDebtFutureMinimumPaymentsDetails" roleURI="http://www.rigel.com/role/DisclosureDebtFutureMinimumPaymentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20230630.xsd#DisclosureLeasesDetails" roleURI="http://www.rigel.com/role/DisclosureLeasesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20230630.xsd#DisclosureLeasesLeaseExpenseDetails" roleURI="http://www.rigel.com/role/DisclosureLeasesLeaseExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20230630.xsd#DisclosureLeasesCashFlowInformationDetails" roleURI="http://www.rigel.com/role/DisclosureLeasesCashFlowInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20230630.xsd#DisclosureLeasesSubleaseInformationDetails" roleURI="http://www.rigel.com/role/DisclosureLeasesSubleaseInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20230630.xsd#DisclosureLeasesFutureMinimumLeasePaymentsDetails" roleURI="http://www.rigel.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingArrangements" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.rigel.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - DOCUMENT AND ENTITY INFORMATION" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638264307687463688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_638264307687463688" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport_638264307687463688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentQuarterlyReport_638264307687463688" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_638264307687463688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_638264307687463688" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_638264307687463688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_638264307687463688" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638264307687463688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638264307687463688" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_638264307687463688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport_638264307687463688" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638264307687463688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_638264307687463688" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638264307687463688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_638264307687463688" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638264307687463688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638264307687463688" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638264307687463688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638264307687463688" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638264307687463688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638264307687463688" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638264307687473713" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638264307687473713" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638264307687473713" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638264307687473713" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638264307687473713" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638264307687473713" order="14" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638264307687473713" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_638264307687473713" order="15" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638264307687473713" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_638264307687473713" order="16" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638264307687473713" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_638264307687473713" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638264307687473713" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_638264307687473713" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638264307687483666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_638264307687483666" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_638264307687483666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_638264307687483666" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_638264307687483666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_638264307687483666" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_638264307687483666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory_638264307687483666" order="22" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_638264307687483666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness_638264307687483666" order="23" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638264307687483666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638264307687483666" order="24" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_638264307687483666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany_638264307687483666" order="25" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638264307687483666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638264307687483666" order="26" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638264307687493666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_638264307687493666" order="27" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_638264307687493666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_638264307687493666" order="28" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_638264307687493666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_638264307687493666" order="29" use="optional" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/StatementCondensedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONDENSED BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_638264307687493666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract_638264307687493666" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_638264307687493666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638264307687493666" xlink:to="us-gaap_AssetsCurrentAbstract_638264307687493666" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638264307687503670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638264307687493666" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638264307687503670" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments_638264307687503670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638264307687493666" xlink:to="us-gaap_ShortTermInvestments_638264307687503670" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_638264307687503670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638264307687493666" xlink:to="us-gaap_AccountsReceivableNetCurrent_638264307687503670" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638264307687503670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638264307687493666" xlink:to="us-gaap_InventoryNet_638264307687503670" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638264307687503670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638264307687493666" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638264307687503670" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638264307687503670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638264307687493666" xlink:to="us-gaap_AssetsCurrent_638264307687503670" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638264307687503670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638264307687493666" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638264307687503670" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetIncludingGoodwill_638264307687503670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638264307687493666" xlink:to="us-gaap_IntangibleAssetsNetIncludingGoodwill_638264307687503670" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638264307687503670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638264307687493666" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638264307687503670" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_638264307687503670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638264307687493666" xlink:to="us-gaap_OtherAssetsNoncurrent_638264307687503670" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_638264307687503670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638264307687493666" xlink:to="us-gaap_Assets_638264307687503670" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638264307687513664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638264307687513664" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_638264307687513664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638264307687513664" xlink:to="us-gaap_LiabilitiesCurrentAbstract_638264307687513664" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638264307687513664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638264307687513664" xlink:to="us-gaap_AccountsPayableCurrent_638264307687513664" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638264307687513664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638264307687513664" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638264307687513664" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_AccruedResearchAndDevelopmentLiabilityCurrent" xlink:label="rigl_AccruedResearchAndDevelopmentLiabilityCurrent_638264307687513664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638264307687513664" xlink:to="rigl_AccruedResearchAndDevelopmentLiabilityCurrent_638264307687513664" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerRefundLiabilityCurrent_638264307687513664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638264307687513664" xlink:to="us-gaap_ContractWithCustomerRefundLiabilityCurrent_638264307687513664" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_638264307687513664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638264307687513664" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_638264307687513664" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638264307687513664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638264307687513664" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638264307687513664" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_638264307687513664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638264307687513664" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_638264307687513664" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_638264307687523665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638264307687513664" xlink:to="us-gaap_OtherLiabilitiesCurrent_638264307687523665" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638264307687523665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638264307687513664" xlink:to="us-gaap_LiabilitiesCurrent_638264307687523665" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638264307687523665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638264307687513664" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638264307687523665" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermLoansPayable" xlink:label="us-gaap_LongTermLoansPayable_638264307687523665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638264307687513664" xlink:to="us-gaap_LongTermLoansPayable_638264307687523665" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_638264307687523665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638264307687513664" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_638264307687523665" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638264307687523665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638264307687513664" xlink:to="us-gaap_Liabilities_638264307687523665" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638264307687523665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638264307687513664" xlink:to="us-gaap_CommitmentsAndContingencies_638264307687523665" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_638264307687533666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638264307687513664" xlink:to="us-gaap_StockholdersEquityAbstract_638264307687533666" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638264307687533666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638264307687533666" xlink:to="us-gaap_PreferredStockValue_638264307687533666" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638264307687533666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638264307687533666" xlink:to="us-gaap_CommonStockValue_638264307687533666" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_638264307687533666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638264307687533666" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_638264307687533666" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638264307687533666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638264307687533666" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638264307687533666" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638264307687533666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638264307687533666" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638264307687533666" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638264307687533666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638264307687533666" xlink:to="us-gaap_StockholdersEquity_638264307687533666" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_638264307687543664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638264307687513664" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_638264307687543664" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/StatementCondensedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - CONDENSED STATEMENTS OF OPERATIONS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638264307687543664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable_638264307687543664" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638264307687543664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638264307687543664" xlink:to="srt_ProductOrServiceAxis_638264307687543664" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638264307687543664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638264307687543664" xlink:to="srt_ProductsAndServicesDomain_638264307687543664" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember_638264307687543664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638264307687543664" xlink:to="us-gaap_ProductMember_638264307687543664" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_ContractRevenuesFromCollaborationsMember" xlink:label="rigl_ContractRevenuesFromCollaborationsMember_638264307687543664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638264307687543664" xlink:to="rigl_ContractRevenuesFromCollaborationsMember_638264307687543664" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentContractMember" xlink:label="us-gaap_GovernmentContractMember_638264307687543664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638264307687543664" xlink:to="us-gaap_GovernmentContractMember_638264307687543664" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638264307687553676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638264307687543664" xlink:to="us-gaap_StatementLineItems_638264307687553676" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638264307687553676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638264307687553676" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638264307687553676" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract_638264307687553676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638264307687553676" xlink:to="us-gaap_CostsAndExpensesAbstract_638264307687553676" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold_638264307687553676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_638264307687553676" xlink:to="us-gaap_CostOfGoodsAndServicesSold_638264307687553676" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_638264307687553676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_638264307687553676" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_638264307687553676" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_638264307687553676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_638264307687553676" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_638264307687553676" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses_638264307687553676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_638264307687553676" xlink:to="us-gaap_CostsAndExpenses_638264307687553676" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638264307687553676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638264307687553676" xlink:to="us-gaap_OperatingIncomeLoss_638264307687553676" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_638264307687553676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638264307687553676" xlink:to="us-gaap_InvestmentIncomeInterest_638264307687553676" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_638264307687553676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638264307687553676" xlink:to="us-gaap_InterestExpense_638264307687553676" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638264307687563667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638264307687553676" xlink:to="us-gaap_NetIncomeLoss_638264307687563667" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638264307687563667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638264307687553676" xlink:to="us-gaap_EarningsPerShareBasic_638264307687563667" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638264307687563667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638264307687553676" xlink:to="us-gaap_EarningsPerShareDiluted_638264307687563667" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638264307687563667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638264307687553676" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638264307687563667" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638264307687563667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638264307687553676" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638264307687563667" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/StatementCondensedStatementsOfComprehensiveLoss" xlink:type="extended" xlink:title="00300 - Statement - CONDENSED STATEMENTS OF COMPREHENSIVE LOSS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638264307687563667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638264307687563667" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_638264307687563667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_638264307687563667" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_638264307687563667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_638264307687563667" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_638264307687563667" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_638264307687573671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_638264307687573671" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/StatementCondensedStatementsOfStockholdersDeficitEquity" xlink:type="extended" xlink:title="00400 - Statement - CONDENSED STATEMENTS OF STOCKHOLDERS' (DEFICIT) EQUITY" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638264307687573671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_638264307687573671" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638264307687573671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638264307687573671" xlink:to="us-gaap_StatementEquityComponentsAxis_638264307687573671" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638264307687573671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638264307687573671" xlink:to="us-gaap_CommonStockMember_638264307687573671" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_638264307687573671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638264307687573671" xlink:to="us-gaap_AdditionalPaidInCapitalMember_638264307687573671" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_638264307687573671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638264307687573671" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_638264307687573671" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_638264307687573671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638264307687573671" xlink:to="us-gaap_RetainedEarningsMember_638264307687573671" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638264307687573671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638264307687573671" xlink:to="us-gaap_EquityComponentDomain_638264307687573671" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638264307687573671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638264307687573671" xlink:to="us-gaap_StatementLineItems_638264307687573671" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638264307687573671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638264307687573671" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638264307687573671" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638264307687573671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638264307687573671" xlink:to="us-gaap_StockholdersEquity_638264307687573671" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued_638264307687584127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638264307687573671" xlink:to="us-gaap_SharesIssued_638264307687584127" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638264307687584127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638264307687573671" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638264307687584127" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_638264307687584127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638264307687573671" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_638264307687584127" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_638264307687584127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638264307687573671" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_638264307687584127" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_638264307687584127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_638264307687584127" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_638264307687584127" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_638264307687584127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638264307687573671" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_638264307687584127" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_638264307687584127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_638264307687584127" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_638264307687584127" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638264307687584127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638264307687573671" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638264307687584127" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638264307687593673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638264307687573671" xlink:to="us-gaap_StockholdersEquity_638264307687593673" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued_638264307687593673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638264307687573671" xlink:to="us-gaap_SharesIssued_638264307687593673" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows" xlink:type="extended" xlink:title="00500 - Statement - CONDENSED STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638264307687593673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638264307687593673" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638264307687593673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638264307687593673" xlink:to="us-gaap_ProfitLoss_638264307687593673" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638264307687593673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638264307687593673" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638264307687593673" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638264307687593673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638264307687593673" xlink:to="us-gaap_ShareBasedCompensation_638264307687593673" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_638264307687593673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638264307687593673" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_638264307687593673" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_638264307687593673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638264307687593673" xlink:to="us-gaap_DepreciationDepletionAndAmortization_638264307687593673" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_NoncashInterestExpense" xlink:label="rigl_NoncashInterestExpense_638264307687603681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638264307687593673" xlink:to="rigl_NoncashInterestExpense_638264307687603681" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_638264307687603681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638264307687593673" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_638264307687603681" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638264307687603681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638264307687593673" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638264307687603681" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_638264307687603681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638264307687603681" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_638264307687603681" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_638264307687603681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638264307687603681" xlink:to="us-gaap_IncreaseDecreaseInInventories_638264307687603681" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638264307687603681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638264307687603681" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638264307687603681" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_638264307687603681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638264307687603681" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_638264307687603681" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_IncreaseDecreaseRightOfUseAssets" xlink:label="rigl_IncreaseDecreaseRightOfUseAssets_638264307687603681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638264307687603681" xlink:to="rigl_IncreaseDecreaseRightOfUseAssets_638264307687603681" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_638264307687603681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638264307687603681" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_638264307687603681" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_638264307687613673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638264307687603681" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_638264307687613673" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_IncreaseDecreaseInAccruedResearchAndDevelopmentLiability" xlink:label="rigl_IncreaseDecreaseInAccruedResearchAndDevelopmentLiability_638264307687613673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638264307687603681" xlink:to="rigl_IncreaseDecreaseInAccruedResearchAndDevelopmentLiability_638264307687613673" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_RevenueReservesAndRefundLiability" xlink:label="rigl_RevenueReservesAndRefundLiability_638264307687613673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638264307687603681" xlink:to="rigl_RevenueReservesAndRefundLiability_638264307687613673" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_638264307687613673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638264307687603681" xlink:to="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_638264307687613673" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638264307687613673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638264307687603681" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638264307687613673" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638264307687613673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638264307687603681" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638264307687613673" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_638264307687613673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638264307687603681" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_638264307687613673" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638264307687623689" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638264307687593673" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638264307687623689" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638264307687623689" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638264307687623689" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_638264307687623689" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638264307687623689" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments_638264307687623689" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_638264307687623689" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638264307687623689" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_638264307687623689" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_638264307687623689" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638264307687623689" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_638264307687623689" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638264307687623689" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638264307687623689" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638264307687623689" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638264307687623689" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638264307687623689" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638264307687623689" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638264307687633704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638264307687623689" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638264307687633704" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638264307687633704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638264307687633704" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_PaymentOfCostShareToCollaborationPartner" xlink:label="rigl_PaymentOfCostShareToCollaborationPartner_638264307687633704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638264307687633704" xlink:to="rigl_PaymentOfCostShareToCollaborationPartner_638264307687633704" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_638264307687633704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638264307687633704" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_638264307687633704" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:label="us-gaap_ProceedsFromLongTermLinesOfCredit_638264307687633704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638264307687633704" xlink:to="us-gaap_ProceedsFromLongTermLinesOfCredit_638264307687633704" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638264307687633704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638264307687633704" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638264307687633704" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_638264307687643673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_638264307687643673" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638264307687643673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638264307687643673" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6382643076876436731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6382643076876436731" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_638264307687643673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_638264307687643673" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet_638264307687643673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638264307687643673" xlink:to="us-gaap_InterestPaidNet_638264307687643673" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="10101 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_638264307687653675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_638264307687653675" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureNetLossPerShare" xlink:type="extended" xlink:title="10201 - Disclosure - NET LOSS PER SHARE" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_638264307687653675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock_638264307687653675" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureRevenues" xlink:type="extended" xlink:title="10301 - Disclosure - REVENUES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_638264307687653675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_638264307687653675" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContract" xlink:type="extended" xlink:title="10401 - Disclosure - SPONSORED RESEARCH AND LICENSE AGREEMENTS AND GOVERNMENT CONTRACT" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_CorporateCollaborationsDisclosureAbstract" xlink:label="rigl_CorporateCollaborationsDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_638264307687653675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_CorporateCollaborationsDisclosureAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_638264307687653675" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureStockBasedCompensation" xlink:type="extended" xlink:title="10501 - Disclosure - STOCK-BASED COMPENSATION" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638264307687663811" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638264307687663811" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureInventories" xlink:type="extended" xlink:title="10601 - Disclosure - INVENTORIES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock_638264307687663811" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock_638264307687663811" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestments" xlink:type="extended" xlink:title="10701 - Disclosure - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_638264307687663811" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_638264307687663811" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureFairValue" xlink:type="extended" xlink:title="10801 - Disclosure - FAIR VALUE" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_638264307687663811" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock_638264307687663811" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureDebt" xlink:type="extended" xlink:title="10901 - Disclosure - DEBT" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock_638264307687673694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock_638264307687673694" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureLeases" xlink:type="extended" xlink:title="11001 - Disclosure - LEASES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_LeaseDisclosureTextBlock" xlink:label="rigl_LeaseDisclosureTextBlock_638264307687673694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="rigl_LeaseDisclosureTextBlock_638264307687673694" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20102 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638264307687673694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638264307687673694" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_638264307687673694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_638264307687673694" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_LiquidityAndCapitalResourcesPolicyPolicyTextBlock" xlink:label="rigl_LiquidityAndCapitalResourcesPolicyPolicyTextBlock_638264307687673694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="rigl_LiquidityAndCapitalResourcesPolicyPolicyTextBlock_638264307687673694" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638264307687673694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638264307687673694" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureNetLossPerShareTables" xlink:type="extended" xlink:title="30203 - Disclosure - NET LOSS PER SHARE (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638264307687683679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638264307687683679" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureRevenuesTables" xlink:type="extended" xlink:title="30303 - Disclosure - REVENUES (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_638264307687683679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_638264307687683679" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:label="srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_638264307687683679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_638264307687683679" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_DisaggregationOfRevenueByCustomerTableTextBlock" xlink:label="rigl_DisaggregationOfRevenueByCustomerTableTextBlock_638264307687683679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="rigl_DisaggregationOfRevenueByCustomerTableTextBlock_638264307687683679" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureStockBasedCompensationTables" xlink:type="extended" xlink:title="30503 - Disclosure - STOCK-BASED COMPENSATION (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638264307687683679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638264307687683679" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638264307687693704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638264307687683679" xlink:to="us-gaap_AwardTypeAxis_638264307687693704" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638264307687693704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638264307687693704" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638264307687693704" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638264307687693704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638264307687693704" xlink:to="us-gaap_EmployeeStockOptionMember_638264307687693704" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638264307687693704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638264307687683679" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638264307687693704" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638264307687693704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638264307687693704" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638264307687693704" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638264307687693704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638264307687693704" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638264307687693704" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureInventoriesTables" xlink:type="extended" xlink:title="30603 - Disclosure - INVENTORIES (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract_636675324950241405" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_638264307687693704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract_636675324950241405" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_638264307687693704" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsTables" xlink:type="extended" xlink:title="30703 - Disclosure - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_638264307687693704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:to="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_638264307687693704" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:label="us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_638264307687703676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:to="us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_638264307687703676" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_638264307687703676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:to="us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_638264307687703676" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureFairValueTables" xlink:type="extended" xlink:title="30803 - Disclosure - FAIR VALUE (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_638264307687703676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_638264307687703676" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureDebtTables" xlink:type="extended" xlink:title="30903 - Disclosure - DEBT (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_637067339432329346" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:label="us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_638264307687703676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_637067339432329346" xlink:to="us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_638264307687703676" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureLeasesTables" xlink:type="extended" xlink:title="31003 - Disclosure - LEASES (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract_636915213672463198" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock_638264307687703676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_636915213672463198" xlink:to="us-gaap_LeaseCostTableTextBlock_638264307687703676" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_CashFlowInformationRelatedToOperatingLeaseTableTextBlock" xlink:label="rigl_CashFlowInformationRelatedToOperatingLeaseTableTextBlock_638264307687703676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_636915213672463198" xlink:to="rigl_CashFlowInformationRelatedToOperatingLeaseTableTextBlock_638264307687703676" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:label="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock_638264307687703676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_636915213672463198" xlink:to="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock_638264307687703676" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_638264307687713672" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_636915213672463198" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_638264307687713672" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndLiquidityDetails" xlink:type="extended" xlink:title="40101 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Basis of Presentation and Liquidity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_638264307687713672" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_638264307687713672" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureNetLossPerShareDetails" xlink:type="extended" xlink:title="40201 - Disclosure - NET LOSS PER SHARE (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638264307687713672" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638264307687713672" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638264307687713672" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638264307687713672" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638264307687713672" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_638264307687713672" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638264307687713672" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_638264307687713672" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638264307687713672" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638264307687713672" xlink:to="us-gaap_EmployeeStockOptionMember_638264307687713672" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638264307687713672" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638264307687713672" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638264307687713672" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638264307687713672" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638264307687713672" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638264307687713672" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638264307687723674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638264307687713672" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638264307687723674" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureRevenuesDisaggregatedDetails" xlink:type="extended" xlink:title="40301 - Disclosure - REVENUES - Disaggregated (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable_638264307687723674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable_638264307687723674" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638264307687723674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable_638264307687723674" xlink:to="srt_ProductOrServiceAxis_638264307687723674" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638264307687723674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638264307687723674" xlink:to="srt_ProductsAndServicesDomain_638264307687723674" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_GrossProductMember" xlink:label="rigl_GrossProductMember_638264307687723674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638264307687723674" xlink:to="rigl_GrossProductMember_638264307687723674" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_DiscountsAndAllowancesMember" xlink:label="rigl_DiscountsAndAllowancesMember_638264307687723674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638264307687723674" xlink:to="rigl_DiscountsAndAllowancesMember_638264307687723674" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember_638264307687723674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638264307687723674" xlink:to="us-gaap_ProductMember_638264307687723674" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember_638264307687723674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638264307687723674" xlink:to="us-gaap_LicenseMember_638264307687723674" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_DevelopmentMilestonesMember" xlink:label="rigl_DevelopmentMilestonesMember_638264307687723674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638264307687723674" xlink:to="rigl_DevelopmentMilestonesMember_638264307687723674" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_RoyaltyDeliveryOfDrugSuppliesAndOthersMember" xlink:label="rigl_RoyaltyDeliveryOfDrugSuppliesAndOthersMember_638264307687723674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638264307687723674" xlink:to="rigl_RoyaltyDeliveryOfDrugSuppliesAndOthersMember_638264307687723674" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_ContractRevenuesFromCollaborationsMember" xlink:label="rigl_ContractRevenuesFromCollaborationsMember_638264307687723674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638264307687723674" xlink:to="rigl_ContractRevenuesFromCollaborationsMember_638264307687723674" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentContractMember" xlink:label="us-gaap_GovernmentContractMember_638264307687733676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638264307687723674" xlink:to="us-gaap_GovernmentContractMember_638264307687733676" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_638264307687733676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable_638264307687723674" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_638264307687733676" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638264307687733676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems_638264307687733676" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638264307687733676" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureRevenuesActivityDetails" xlink:type="extended" xlink:title="40302 - Disclosure - REVENUES - Activity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="srt_ValuationAndQualifyingAccountsDisclosureTable_638264307687733676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="srt_ValuationAndQualifyingAccountsDisclosureTable_638264307687733676" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis_638264307687733676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureTable_638264307687733676" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis_638264307687733676" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain_638264307687733676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis_638264307687733676" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain_638264307687733676" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_ChargebacksDiscountsAndFeesMember" xlink:label="rigl_ChargebacksDiscountsAndFeesMember_638264307687733676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain_638264307687733676" xlink:to="rigl_ChargebacksDiscountsAndFeesMember_638264307687733676" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_GovernmentAndOtherRebatesMember" xlink:label="rigl_GovernmentAndOtherRebatesMember_638264307687733676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain_638264307687733676" xlink:to="rigl_GovernmentAndOtherRebatesMember_638264307687733676" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesReturnsAndAllowancesMember" xlink:label="us-gaap_SalesReturnsAndAllowancesMember_638264307687733676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain_638264307687733676" xlink:to="us-gaap_SalesReturnsAndAllowancesMember_638264307687733676" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_638264307687743672" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureTable_638264307687733676" xlink:to="us-gaap_BalanceSheetLocationAxis_638264307687743672" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_638264307687743672" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis_638264307687743672" xlink:to="us-gaap_BalanceSheetLocationDomain_638264307687743672" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_AccountsReceivableAndPrepaidAndOtherCurrentAssetsMember" xlink:label="rigl_AccountsReceivableAndPrepaidAndOtherCurrentAssetsMember_638264307687743672" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain_638264307687743672" xlink:to="rigl_AccountsReceivableAndPrepaidAndOtherCurrentAssetsMember_638264307687743672" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="srt_ValuationAndQualifyingAccountsDisclosureLineItems_638264307687743672" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureTable_638264307687733676" xlink:to="srt_ValuationAndQualifyingAccountsDisclosureLineItems_638264307687743672" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance_638264307687743672" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureLineItems_638264307687743672" xlink:to="us-gaap_ValuationAllowancesAndReservesBalance_638264307687743672" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_638264307687743672" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureLineItems_638264307687743672" xlink:to="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_638264307687743672" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesDeductions" xlink:label="us-gaap_ValuationAllowancesAndReservesDeductions_638264307687743672" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureLineItems_638264307687743672" xlink:to="us-gaap_ValuationAllowancesAndReservesDeductions_638264307687743672" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance_6382643076877436721" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureLineItems_638264307687743672" xlink:to="us-gaap_ValuationAllowancesAndReservesBalance_6382643076877436721" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_SalesDiscountsAndAllowances" xlink:label="rigl_SalesDiscountsAndAllowances_638264307687743672" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureLineItems_638264307687743672" xlink:to="rigl_SalesDiscountsAndAllowances_638264307687743672" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_638264307687743672" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureLineItems_638264307687743672" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_638264307687743672" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureRevenuesPercentageByCustomerDetails" xlink:type="extended" xlink:title="40303 - Disclosure - REVENUES - Percentage by Customer (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable_638264307687753674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable_638264307687753674" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_638264307687753674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable_638264307687753674" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_638264307687753674" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_638264307687753674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis_638264307687753674" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_638264307687753674" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesMember" xlink:label="us-gaap_SalesMember_638264307687753674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain_638264307687753674" xlink:to="us-gaap_SalesMember_638264307687753674" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_638264307687753674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable_638264307687753674" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_638264307687753674" order="2" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_638264307687753674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis_638264307687753674" xlink:to="us-gaap_ConcentrationRiskTypeDomain_638264307687753674" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember_638264307687753674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain_638264307687753674" xlink:to="us-gaap_CustomerConcentrationRiskMember_638264307687753674" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis_638264307687753674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable_638264307687753674" xlink:to="srt_MajorCustomersAxis_638264307687753674" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_638264307687753674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis_638264307687753674" xlink:to="srt_NameOfMajorCustomerDomain_638264307687753674" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_MckessonSpecialtyCareDistributionCorporationMember" xlink:label="rigl_MckessonSpecialtyCareDistributionCorporationMember_638264307687753674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_638264307687753674" xlink:to="rigl_MckessonSpecialtyCareDistributionCorporationMember_638264307687753674" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_KisseiPharmaceuticalCo.Ltd.Member" xlink:label="rigl_KisseiPharmaceuticalCo.Ltd.Member_638264307687763772" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_638264307687753674" xlink:to="rigl_KisseiPharmaceuticalCo.Ltd.Member_638264307687763772" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_CardinalHealthcareMember" xlink:label="rigl_CardinalHealthcareMember_638264307687763772" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_638264307687753674" xlink:to="rigl_CardinalHealthcareMember_638264307687763772" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_AsdHealthcareAndOncologySupplyMember" xlink:label="rigl_AsdHealthcareAndOncologySupplyMember_638264307687763772" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_638264307687753674" xlink:to="rigl_AsdHealthcareAndOncologySupplyMember_638264307687763772" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_638264307687763772" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable_638264307687753674" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_638264307687763772" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1_638264307687763772" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems_638264307687763772" xlink:to="us-gaap_ConcentrationRiskPercentage1_638264307687763772" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails" xlink:type="extended" xlink:title="40401 - Disclosure - SPONSORED RESEARCH AND LICENSE AGREEMENTS AND GOVERNMENT CONTRACT (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_CorporateCollaborationsDisclosureAbstract" xlink:label="rigl_CorporateCollaborationsDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638264307687773681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_CorporateCollaborationsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638264307687773681" order="1" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638264307687843687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638264307687773681" xlink:to="srt_ProductOrServiceAxis_638264307687843687" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638264307687853707" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638264307687843687" xlink:to="srt_ProductsAndServicesDomain_638264307687853707" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_FostamatinibMember" xlink:label="rigl_FostamatinibMember_638264307687853707" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638264307687853707" xlink:to="rigl_FostamatinibMember_638264307687853707" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_R552Member" xlink:label="rigl_R552Member_638264307687853707" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638264307687853707" xlink:to="rigl_R552Member_638264307687853707" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_NonCentralNervousSystemPenetrantIntellectualPropertyMember" xlink:label="rigl_NonCentralNervousSystemPenetrantIntellectualPropertyMember_638264307687853707" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638264307687853707" xlink:to="rigl_NonCentralNervousSystemPenetrantIntellectualPropertyMember_638264307687853707" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_CentralNervousSystemPenetrantIntellectualPropertyMember" xlink:label="rigl_CentralNervousSystemPenetrantIntellectualPropertyMember_638264307687853707" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638264307687853707" xlink:to="rigl_CentralNervousSystemPenetrantIntellectualPropertyMember_638264307687853707" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember_638264307687853707" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638264307687853707" xlink:to="us-gaap_RoyaltyMember_638264307687853707" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_RezlidhiaMember" xlink:label="rigl_RezlidhiaMember_638264307687853707" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638264307687853707" xlink:to="rigl_RezlidhiaMember_638264307687853707" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638264307687853707" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638264307687773681" xlink:to="dei_LegalEntityAxis_638264307687853707" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638264307687853707" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638264307687853707" xlink:to="dei_EntityDomain_638264307687853707" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_GrifolsS.a.Member" xlink:label="rigl_GrifolsS.a.Member_638264307687853707" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638264307687853707" xlink:to="rigl_GrifolsS.a.Member_638264307687853707" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_KisseiPharmaceuticalCo.Ltd.Member" xlink:label="rigl_KisseiPharmaceuticalCo.Ltd.Member_638264307687853707" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638264307687853707" xlink:to="rigl_KisseiPharmaceuticalCo.Ltd.Member_638264307687853707" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_MedisonPharmaLtd.Member" xlink:label="rigl_MedisonPharmaLtd.Member_638264307687863690" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638264307687853707" xlink:to="rigl_MedisonPharmaLtd.Member_638264307687863690" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_KnightTherapeuticsInternationalSaMember" xlink:label="rigl_KnightTherapeuticsInternationalSaMember_638264307687863690" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638264307687853707" xlink:to="rigl_KnightTherapeuticsInternationalSaMember_638264307687863690" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_FormaTherapeuticsHoldingsIncMember" xlink:label="rigl_FormaTherapeuticsHoldingsIncMember_638264307687863690" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638264307687853707" xlink:to="rigl_FormaTherapeuticsHoldingsIncMember_638264307687863690" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638264307687863690" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638264307687773681" xlink:to="srt_RangeAxis_638264307687863690" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638264307687863690" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638264307687863690" xlink:to="srt_RangeMember_638264307687863690" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638264307687863690" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638264307687863690" xlink:to="srt_MaximumMember_638264307687863690" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_AchievementOfMilestoneAxis" xlink:label="rigl_AchievementOfMilestoneAxis_638264307687863690" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638264307687773681" xlink:to="rigl_AchievementOfMilestoneAxis_638264307687863690" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_AchievementOfMilestoneDomain" xlink:label="rigl_AchievementOfMilestoneDomain_638264307687863690" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_AchievementOfMilestoneAxis_638264307687863690" xlink:to="rigl_AchievementOfMilestoneDomain_638264307687863690" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_SpecifiedDevelopmentEventsMember" xlink:label="rigl_SpecifiedDevelopmentEventsMember_638264307687863690" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_AchievementOfMilestoneDomain_638264307687863690" xlink:to="rigl_SpecifiedDevelopmentEventsMember_638264307687863690" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_SpecifiedRegulatoryEventsMember" xlink:label="rigl_SpecifiedRegulatoryEventsMember_638264307687873689" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_AchievementOfMilestoneDomain_638264307687863690" xlink:to="rigl_SpecifiedRegulatoryEventsMember_638264307687873689" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_SpecifiedProductLaunchEventsMember" xlink:label="rigl_SpecifiedProductLaunchEventsMember_638264307687873689" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_AchievementOfMilestoneDomain_638264307687863690" xlink:to="rigl_SpecifiedProductLaunchEventsMember_638264307687873689" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_LicensedRightsMember" xlink:label="rigl_LicensedRightsMember_638264307687873689" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_AchievementOfMilestoneDomain_638264307687863690" xlink:to="rigl_LicensedRightsMember_638264307687873689" order="4" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_ResearchActivitiesMember" xlink:label="rigl_ResearchActivitiesMember_638264307687873689" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_AchievementOfMilestoneDomain_638264307687863690" xlink:to="rigl_ResearchActivitiesMember_638264307687873689" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_DevelopmentAndRegulatoryMilestonesByNonCentralNervousSystemDiseaseProductsMember" xlink:label="rigl_DevelopmentAndRegulatoryMilestonesByNonCentralNervousSystemDiseaseProductsMember_638264307687873689" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_AchievementOfMilestoneDomain_638264307687863690" xlink:to="rigl_DevelopmentAndRegulatoryMilestonesByNonCentralNervousSystemDiseaseProductsMember_638264307687873689" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_DevelopmentAndRegulatoryMilestonesByCentralNervousSystemDiseaseProductsMember" xlink:label="rigl_DevelopmentAndRegulatoryMilestonesByCentralNervousSystemDiseaseProductsMember_638264307687873689" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_AchievementOfMilestoneDomain_638264307687863690" xlink:to="rigl_DevelopmentAndRegulatoryMilestonesByCentralNervousSystemDiseaseProductsMember_638264307687873689" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember" xlink:label="rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember_638264307687873689" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_AchievementOfMilestoneDomain_638264307687863690" xlink:to="rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember_638264307687873689" order="8" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_SpecifiedCommercialMilestonesMember" xlink:label="rigl_SpecifiedCommercialMilestonesMember_638264307687883687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_AchievementOfMilestoneDomain_638264307687863690" xlink:to="rigl_SpecifiedCommercialMilestonesMember_638264307687883687" order="9" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_EuropeanMedicinesAgencyApprovalOfFostamatinibForTreatmentOfChronicImmuneThrombocytopenicPurpuraMember" xlink:label="rigl_EuropeanMedicinesAgencyApprovalOfFostamatinibForTreatmentOfChronicImmuneThrombocytopenicPurpuraMember_638264307687883687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_AchievementOfMilestoneDomain_638264307687863690" xlink:to="rigl_EuropeanMedicinesAgencyApprovalOfFostamatinibForTreatmentOfChronicImmuneThrombocytopenicPurpuraMember_638264307687883687" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_CreditableAdvanceRoyaltyPaymentMember" xlink:label="rigl_CreditableAdvanceRoyaltyPaymentMember_638264307687883687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_AchievementOfMilestoneDomain_638264307687863690" xlink:to="rigl_CreditableAdvanceRoyaltyPaymentMember_638264307687883687" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_DevelopmentAndRegulatoryMilestonesMember" xlink:label="rigl_DevelopmentAndRegulatoryMilestonesMember_638264307687883687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_AchievementOfMilestoneDomain_638264307687863690" xlink:to="rigl_DevelopmentAndRegulatoryMilestonesMember_638264307687883687" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_AchievementOfCertainNearTermRegulatoryMilestoneMember" xlink:label="rigl_AchievementOfCertainNearTermRegulatoryMilestoneMember_638264307687883687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_DevelopmentAndRegulatoryMilestonesMember_638264307687883687" xlink:to="rigl_AchievementOfCertainNearTermRegulatoryMilestoneMember_638264307687883687" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_FdaApprovalAndFirstCommercialSaleOfProductMember" xlink:label="rigl_FdaApprovalAndFirstCommercialSaleOfProductMember_638264307687883687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_AchievementOfMilestoneDomain_638264307687863690" xlink:to="rigl_FdaApprovalAndFirstCommercialSaleOfProductMember_638264307687883687" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638264307687893708" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638264307687773681" xlink:to="us-gaap_TypeOfArrangementAxis_638264307687893708" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638264307687893708" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638264307687893708" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638264307687893708" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_CommercialAndLicenseAgreementMember" xlink:label="rigl_CommercialAndLicenseAgreementMember_638264307687893708" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638264307687893708" xlink:to="rigl_CommercialAndLicenseAgreementMember_638264307687893708" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638264307687893708" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638264307687773681" xlink:to="srt_StatementScenarioAxis_638264307687893708" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638264307687893708" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638264307687893708" xlink:to="srt_ScenarioUnspecifiedDomain_638264307687893708" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_MilestonePaymentsOnProductByProductBasisMember" xlink:label="rigl_MilestonePaymentsOnProductByProductBasisMember_638264307687893708" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638264307687893708" xlink:to="rigl_MilestonePaymentsOnProductByProductBasisMember_638264307687893708" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis_638264307687903695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638264307687773681" xlink:to="us-gaap_ShortTermDebtTypeAxis_638264307687903695" order="7" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain_638264307687903695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis_638264307687903695" xlink:to="us-gaap_ShortTermDebtTypeDomain_638264307687903695" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductFinancingArrangementMember" xlink:label="us-gaap_ProductFinancingArrangementMember_638264307687903695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeDomain_638264307687903695" xlink:to="us-gaap_ProductFinancingArrangementMember_638264307687903695" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638264307687903695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638264307687773681" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638264307687903695" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_ContingentPaymentsUnderAgreement" xlink:label="rigl_ContingentPaymentsUnderAgreement_638264307687903695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638264307687903695" xlink:to="rigl_ContingentPaymentsUnderAgreement_638264307687903695" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_DevelopmentCostsCostSharingArrangementPercentage" xlink:label="rigl_DevelopmentCostsCostSharingArrangementPercentage_638264307687903695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638264307687903695" xlink:to="rigl_DevelopmentCostsCostSharingArrangementPercentage_638264307687903695" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_RightToOptOutOfAgreementNumberOfPeriods" xlink:label="rigl_RightToOptOutOfAgreementNumberOfPeriods_638264307687913685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638264307687903695" xlink:to="rigl_RightToOptOutOfAgreementNumberOfPeriods_638264307687913685" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitment" xlink:label="us-gaap_OtherCommitment_638264307687913685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638264307687903695" xlink:to="us-gaap_OtherCommitment_638264307687913685" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_CollaborativeArrangementUpfrontFeeReceived" xlink:label="rigl_CollaborativeArrangementUpfrontFeeReceived_638264307687913685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638264307687903695" xlink:to="rigl_CollaborativeArrangementUpfrontFeeReceived_638264307687913685" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductLiabilityAccrualComponentAmount" xlink:label="us-gaap_ProductLiabilityAccrualComponentAmount_638264307687913685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638264307687903695" xlink:to="us-gaap_ProductLiabilityAccrualComponentAmount_638264307687913685" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_FinancingLiabilityInterestAccretionDiscountRate" xlink:label="rigl_FinancingLiabilityInterestAccretionDiscountRate_638264307687913685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638264307687903695" xlink:to="rigl_FinancingLiabilityInterestAccretionDiscountRate_638264307687913685" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_FinancingLiabilityIncludingInterestExpenseAccretion" xlink:label="rigl_FinancingLiabilityIncludingInterestExpenseAccretion_638264307687923686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638264307687903695" xlink:to="rigl_FinancingLiabilityIncludingInterestExpenseAccretion_638264307687923686" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionExpense" xlink:label="us-gaap_AccretionExpense_638264307687923686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638264307687903695" xlink:to="us-gaap_AccretionExpense_638264307687923686" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_DueToCollaborationPartner" xlink:label="rigl_DueToCollaborationPartner_638264307687923686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638264307687903695" xlink:to="rigl_DueToCollaborationPartner_638264307687923686" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_PaymentOfCostShareToCollaborationPartner" xlink:label="rigl_PaymentOfCostShareToCollaborationPartner_638264307687923686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638264307687903695" xlink:to="rigl_PaymentOfCostShareToCollaborationPartner_638264307687923686" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_638264307687933686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638264307687903695" xlink:to="us-gaap_RevenueRemainingPerformanceObligation_638264307687933686" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_CollaborativeArrangementRevenueRecognized" xlink:label="rigl_CollaborativeArrangementRevenueRecognized_638264307687933686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638264307687903695" xlink:to="rigl_CollaborativeArrangementRevenueRecognized_638264307687933686" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue_638264307687933686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638264307687903695" xlink:to="us-gaap_DeferredRevenue_638264307687933686" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_GovernmentAward" xlink:label="rigl_GovernmentAward_638264307687933686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638264307687903695" xlink:to="rigl_GovernmentAward_638264307687933686" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="us-gaap_ProceedsFromCollaborators_638264307687943706" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638264307687903695" xlink:to="us-gaap_ProceedsFromCollaborators_638264307687943706" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_RoyaltyPaymentAsPercentageOfNetSales" xlink:label="rigl_RoyaltyPaymentAsPercentageOfNetSales_638264307687943706" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638264307687903695" xlink:to="rigl_RoyaltyPaymentAsPercentageOfNetSales_638264307687943706" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_638264307687943706" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638264307687903695" xlink:to="us-gaap_AccountsReceivableNetCurrent_638264307687943706" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_GovernmentAwardExpectedToBeReceivedInSucceedingPeriods" xlink:label="rigl_GovernmentAwardExpectedToBeReceivedInSucceedingPeriods_638264307687943706" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638264307687903695" xlink:to="rigl_GovernmentAwardExpectedToBeReceivedInSucceedingPeriods_638264307687943706" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_NumberOfAgreements" xlink:label="rigl_NumberOfAgreements_638264307687953691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638264307687903695" xlink:to="rigl_NumberOfAgreements_638264307687953691" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_CollaborativeArrangementUpfrontPayment" xlink:label="rigl_CollaborativeArrangementUpfrontPayment_638264307687953691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638264307687903695" xlink:to="rigl_CollaborativeArrangementUpfrontPayment_638264307687953691" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_CollaborativeArrangementPotentialPayments" xlink:label="rigl_CollaborativeArrangementPotentialPayments_638264307687953691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638264307687903695" xlink:to="rigl_CollaborativeArrangementPotentialPayments_638264307687953691" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_638264307687953691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638264307687903695" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_638264307687953691" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetIncludingGoodwill_638264307687953691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638264307687903695" xlink:to="us-gaap_IntangibleAssetsNetIncludingGoodwill_638264307687953691" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638264307687963689" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638264307687903695" xlink:to="us-gaap_AccountsPayableCurrent_638264307687963689" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_PaymentsOfMilestonePaymentObligations" xlink:label="rigl_PaymentsOfMilestonePaymentObligations_638264307687963689" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638264307687903695" xlink:to="rigl_PaymentsOfMilestonePaymentObligations_638264307687963689" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets_638264307687963689" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638264307687903695" xlink:to="us-gaap_AmortizationOfIntangibleAssets_638264307687963689" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense_638264307687963689" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638264307687903695" xlink:to="us-gaap_RoyaltyExpense_638264307687963689" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureStockBasedCompensationDetails" xlink:type="extended" xlink:title="40501 - Disclosure - STOCK-BASED COMPENSATION (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638264307687973688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638264307687973688" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638264307687973688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638264307687973688" xlink:to="us-gaap_IncomeStatementLocationAxis_638264307687973688" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638264307687973688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638264307687973688" xlink:to="us-gaap_IncomeStatementLocationDomain_638264307687973688" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_638264307687973688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638264307687973688" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_638264307687973688" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_638264307687973688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638264307687973688" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_638264307687973688" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638264307687983701" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638264307687973688" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638264307687983701" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638264307687983701" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638264307687983701" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638264307687983701" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_638264307687983701" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638264307687983701" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_638264307687983701" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureStockBasedCompensationOptionsAndRsusDetails" xlink:type="extended" xlink:title="40502 - Disclosure - STOCK-BASED COMPENSATION - Options and RSUs (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_635972700703720791" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638264307687983701" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_635972700703720791" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638264307687983701" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638264307687983701" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638264307687983701" xlink:to="us-gaap_AwardTypeAxis_638264307687983701" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638264307687983701" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638264307687983701" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638264307687983701" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_ShareBasedCompensationOptionsAndRsusMember" xlink:label="rigl_ShareBasedCompensationOptionsAndRsusMember_638264307687983701" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638264307687983701" xlink:to="rigl_ShareBasedCompensationOptionsAndRsusMember_638264307687983701" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638264307687983701" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638264307687983701" xlink:to="us-gaap_EmployeeStockOptionMember_638264307687983701" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638264307687993713" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638264307687983701" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638264307687993713" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_638264307687993713" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638264307687983701" xlink:to="us-gaap_VestingAxis_638264307687993713" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_638264307687993713" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis_638264307687993713" xlink:to="us-gaap_VestingDomain_638264307687993713" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_638264307687993713" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638264307687993713" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_638264307687993713" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638264307687993713" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638264307687983701" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638264307687993713" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638264307687993713" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638264307687993713" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638264307687993713" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638264307687993713" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638264307687993713" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638264307687993713" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638264307687993713" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638264307687993713" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638264307687993713" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638264307687993713" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638264307687993713" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638264307687993713" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6382643076879937131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638264307687993713" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6382643076879937131" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638264307687993713" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638264307687993713" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638264307687993713" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638264307688003697" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638264307687993713" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638264307688003697" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638264307688003697" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638264307687993713" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638264307688003697" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_638264307688003697" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638264307687993713" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_638264307688003697" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6382643076880036971" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638264307687993713" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6382643076880036971" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638264307688003697" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638264307687993713" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638264307688003697" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638264307688003697" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638264307688003697" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638264307688003697" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638264307688003697" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638264307687993713" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638264307688003697" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_638264307688003697" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638264307688003697" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_638264307688003697" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638264307688003697" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638264307688003697" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638264307688003697" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638264307688013695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638264307688003697" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638264307688013695" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureStockBasedCompensationAssumptionsDetails" xlink:type="extended" xlink:title="40503 - Disclosure - STOCK-BASED COMPENSATION - Assumptions (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637779241883707043" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638264307688013695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637779241883707043" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638264307688013695" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638264307688013695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638264307688013695" xlink:to="us-gaap_AwardTypeAxis_638264307688013695" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638264307688013695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638264307688013695" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638264307688013695" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638264307688013695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638264307688013695" xlink:to="us-gaap_EmployeeStockOptionMember_638264307688013695" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_638264307688013695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638264307688013695" xlink:to="us-gaap_VestingAxis_638264307688013695" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_638264307688013695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis_638264307688013695" xlink:to="us-gaap_VestingDomain_638264307688013695" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_638264307688013695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638264307688013695" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_638264307688013695" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638264307688023705" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638264307688013695" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638264307688023705" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638264307688023705" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638264307688023705" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638264307688023705" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638264307688023705" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638264307688023705" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638264307688023705" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638264307688023705" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638264307688023705" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638264307688023705" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638264307688023705" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638264307688023705" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638264307688023705" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638264307688023705" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638264307688023705" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638264307688023705" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638264307688023705" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638264307688023705" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638264307688023705" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638264307688023705" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638264307688023705" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638264307688023705" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_638264307688023705" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638264307688023705" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_638264307688023705" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638264307688023705" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638264307688023705" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638264307688023705" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureStockBasedCompensationPurchasePlanDetails" xlink:type="extended" xlink:title="40504 - Disclosure - STOCK-BASED COMPENSATION - Purchase Plan (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638264307688033697" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638264307688033697" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638264307688033697" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638264307688033697" xlink:to="us-gaap_AwardTypeAxis_638264307688033697" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638264307688033697" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638264307688033697" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638264307688033697" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember_638264307688033697" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638264307688033697" xlink:to="us-gaap_EmployeeStockMember_638264307688033697" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638264307688033697" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638264307688033697" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638264307688033697" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638264307688033697" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638264307688033697" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638264307688033697" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardOfferingPeriod" xlink:label="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardOfferingPeriod_638264307688033697" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638264307688033697" xlink:to="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardOfferingPeriod_638264307688033697" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentageOnFirstDayOfOfferingPeriod" xlink:label="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentageOnFirstDayOfOfferingPeriod_638264307688043704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638264307688033697" xlink:to="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentageOnFirstDayOfOfferingPeriod_638264307688043704" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriodsPerAwardOfferingPeriod" xlink:label="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriodsPerAwardOfferingPeriod_638264307688043704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638264307688033697" xlink:to="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriodsPerAwardOfferingPeriod_638264307688043704" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPurchasePeriod" xlink:label="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPurchasePeriod_638264307688043704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638264307688033697" xlink:to="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPurchasePeriod_638264307688043704" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_638264307688043704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638264307688033697" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_638264307688043704" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_638264307688043704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638264307688033697" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_638264307688043704" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638264307688043704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638264307688033697" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638264307688043704" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_638264307688043704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638264307688033697" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_638264307688043704" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638264307688043704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638264307688033697" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638264307688043704" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_638264307688043704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638264307688033697" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_638264307688043704" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638264307688043704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638264307688033697" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638264307688043704" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638264307688053699" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638264307688033697" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638264307688053699" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638264307688053699" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638264307688053699" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638264307688053699" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638264307688053699" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638264307688053699" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638264307688053699" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638264307688053699" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638264307688053699" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638264307688053699" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638264307688053699" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638264307688053699" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638264307688053699" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureInventoriesDetails" xlink:type="extended" xlink:title="40601 - Disclosure - INVENTORIES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract_636675325439140266" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials_638264307688063707" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract_636675325439140266" xlink:to="us-gaap_InventoryRawMaterials_638264307688063707" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess_638264307688063707" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract_636675325439140266" xlink:to="us-gaap_InventoryWorkInProcess_638264307688063707" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods_638264307688063707" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract_636675325439140266" xlink:to="us-gaap_InventoryFinishedGoods_638264307688063707" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638264307688063707" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract_636675325439140266" xlink:to="us-gaap_InventoryNet_638264307688063707" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvancesOnInventoryPurchases" xlink:label="us-gaap_AdvancesOnInventoryPurchases_638264307688063707" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract_636675325439140266" xlink:to="us-gaap_AdvancesOnInventoryPurchases_638264307688063707" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails" xlink:type="extended" xlink:title="40701 - Disclosure - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable" xlink:label="rigl_ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable_638264307688063707" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:to="rigl_ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable_638264307688063707" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis_638264307688063707" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable_638264307688063707" xlink:to="us-gaap_CashAndCashEquivalentsAxis_638264307688063707" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638264307688063707" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis_638264307688063707" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638264307688063707" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember_638264307688063707" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638264307688063707" xlink:to="us-gaap_CashMember_638264307688063707" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis_638264307688063707" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable_638264307688063707" xlink:to="us-gaap_InvestmentTypeAxis_638264307688063707" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_638264307688073736" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis_638264307688063707" xlink:to="us-gaap_InvestmentTypeCategorizationMember_638264307688073736" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember_638264307688073736" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember_638264307688073736" xlink:to="us-gaap_MoneyMarketFundsMember_638264307688073736" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasuryBillSecuritiesMember" xlink:label="us-gaap_USTreasuryBillSecuritiesMember_638264307688073736" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember_638264307688073736" xlink:to="us-gaap_USTreasuryBillSecuritiesMember_638264307688073736" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_638264307688073736" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember_638264307688073736" xlink:to="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_638264307688073736" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_CorporateBondSecuritiesAndCommercialPaperMember" xlink:label="rigl_CorporateBondSecuritiesAndCommercialPaperMember_638264307688073736" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember_638264307688073736" xlink:to="rigl_CorporateBondSecuritiesAndCommercialPaperMember_638264307688073736" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_638264307688073736" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable_638264307688063707" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_638264307688073736" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638264307688073736" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_638264307688073736" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638264307688073736" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments_638264307688073736" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_638264307688073736" xlink:to="us-gaap_ShortTermInvestments_638264307688073736" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_638264307688073736" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_638264307688073736" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_638264307688073736" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsGrossUnrealizedGainsAndLossesDetails" xlink:type="extended" xlink:title="40702 - Disclosure - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS - Gross Unrealized Gains and Losses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_635495982422198217" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable" xlink:label="rigl_ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable_638264307688083709" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_635495982422198217" xlink:to="rigl_ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable_638264307688083709" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_638264307688083709" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable_638264307688083709" xlink:to="us-gaap_FinancialInstrumentAxis_638264307688083709" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638264307688083709" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis_638264307688083709" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638264307688083709" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasuryBillSecuritiesMember" xlink:label="us-gaap_USTreasuryBillSecuritiesMember_638264307688083709" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638264307688083709" xlink:to="us-gaap_USTreasuryBillSecuritiesMember_638264307688083709" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_638264307688083709" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638264307688083709" xlink:to="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_638264307688083709" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_CorporateBondSecuritiesAndCommercialPaperMember" xlink:label="rigl_CorporateBondSecuritiesAndCommercialPaperMember_638264307688083709" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638264307688083709" xlink:to="rigl_CorporateBondSecuritiesAndCommercialPaperMember_638264307688083709" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638264307688083709" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable_638264307688083709" xlink:to="us-gaap_StatementEquityComponentsAxis_638264307688083709" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638264307688083709" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638264307688083709" xlink:to="us-gaap_EquityComponentDomain_638264307688083709" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:label="us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_638264307688093717" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_638264307688083709" xlink:to="us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_638264307688093717" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:label="rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember_638264307688093717" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_638264307688083709" xlink:to="rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember_638264307688093717" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_CashAndCashEquivalentsAndAvailableForSaleSecuritiesLineItems" xlink:label="rigl_CashAndCashEquivalentsAndAvailableForSaleSecuritiesLineItems_638264307688093717" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable_638264307688083709" xlink:to="rigl_CashAndCashEquivalentsAndAvailableForSaleSecuritiesLineItems_638264307688093717" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_CashEquivalentsAndAvailableForSaleSecuritiesAbstract" xlink:label="rigl_CashEquivalentsAndAvailableForSaleSecuritiesAbstract_638264307688093717" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_CashAndCashEquivalentsAndAvailableForSaleSecuritiesLineItems_638264307688093717" xlink:to="rigl_CashEquivalentsAndAvailableForSaleSecuritiesAbstract_638264307688093717" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_638264307688093717" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_CashEquivalentsAndAvailableForSaleSecuritiesAbstract_638264307688093717" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_638264307688093717" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1_638264307688093717" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_CashEquivalentsAndAvailableForSaleSecuritiesAbstract_638264307688093717" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1_638264307688093717" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure_638264307688093717" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_CashEquivalentsAndAvailableForSaleSecuritiesAbstract_638264307688093717" xlink:to="us-gaap_InvestmentsFairValueDisclosure_638264307688093717" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsUnrealizedLossPositionDetails" xlink:type="extended" xlink:title="40703 - Disclosure - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS - Unrealized Loss Position (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_635495973119372251" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable" xlink:label="rigl_ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable_638264307688103727" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_635495973119372251" xlink:to="rigl_ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable_638264307688103727" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis_638264307688103727" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable_638264307688103727" xlink:to="us-gaap_InvestmentTypeAxis_638264307688103727" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_638264307688103727" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis_638264307688103727" xlink:to="us-gaap_InvestmentTypeCategorizationMember_638264307688103727" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_638264307688103727" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember_638264307688103727" xlink:to="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_638264307688103727" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_CorporateBondSecuritiesAndCommercialPaperMember" xlink:label="rigl_CorporateBondSecuritiesAndCommercialPaperMember_638264307688103727" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember_638264307688103727" xlink:to="rigl_CorporateBondSecuritiesAndCommercialPaperMember_638264307688103727" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_CashAndCashEquivalentsAndAvailableForSaleSecuritiesLineItems" xlink:label="rigl_CashAndCashEquivalentsAndAvailableForSaleSecuritiesLineItems_638264307688103727" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable_638264307688103727" xlink:to="rigl_CashAndCashEquivalentsAndAvailableForSaleSecuritiesLineItems_638264307688103727" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_638264307688103727" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_CashAndCashEquivalentsAndAvailableForSaleSecuritiesLineItems_638264307688103727" xlink:to="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_638264307688103727" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_CashEquivalentsAndAvailableForSaleSecuritiesWeightedAverageMaturityPeriod" xlink:label="rigl_CashEquivalentsAndAvailableForSaleSecuritiesWeightedAverageMaturityPeriod_638264307688103727" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_638264307688103727" xlink:to="rigl_CashEquivalentsAndAvailableForSaleSecuritiesWeightedAverageMaturityPeriod_638264307688103727" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_638264307688103727" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_638264307688103727" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_638264307688103727" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_638264307688103727" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_638264307688103727" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_638264307688103727" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld" xlink:label="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld_638264307688103727" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_638264307688103727" xlink:to="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld_638264307688103727" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_638264307688113710" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_638264307688103727" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_638264307688113710" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_638264307688113710" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_638264307688103727" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_638264307688113710" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureFairValueDetails" xlink:type="extended" xlink:title="40801 - Disclosure - FAIR VALUE (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638264307688113710" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638264307688113710" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_638264307688113710" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638264307688113710" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_638264307688113710" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_638264307688113710" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_638264307688113710" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_638264307688113710" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_638264307688113710" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain_638264307688113710" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_638264307688113710" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_638264307688113710" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638264307688113710" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_638264307688113710" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638264307688113710" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_638264307688113710" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638264307688113710" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member_638264307688123713" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638264307688113710" xlink:to="us-gaap_FairValueInputsLevel1Member_638264307688123713" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member_638264307688123713" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638264307688113710" xlink:to="us-gaap_FairValueInputsLevel2Member_638264307688123713" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis_638264307688123713" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638264307688113710" xlink:to="us-gaap_InvestmentTypeAxis_638264307688123713" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_638264307688123713" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis_638264307688123713" xlink:to="us-gaap_InvestmentTypeCategorizationMember_638264307688123713" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember_638264307688123713" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember_638264307688123713" xlink:to="us-gaap_MoneyMarketFundsMember_638264307688123713" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasuryBillSecuritiesMember" xlink:label="us-gaap_USTreasuryBillSecuritiesMember_638264307688123713" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember_638264307688123713" xlink:to="us-gaap_USTreasuryBillSecuritiesMember_638264307688123713" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_638264307688123713" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember_638264307688123713" xlink:to="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_638264307688123713" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_CorporateBondSecuritiesAndCommercialPaperMember" xlink:label="rigl_CorporateBondSecuritiesAndCommercialPaperMember_638264307688123713" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember_638264307688123713" xlink:to="rigl_CorporateBondSecuritiesAndCommercialPaperMember_638264307688123713" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis_638264307688123713" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638264307688113710" xlink:to="us-gaap_FairValueByMeasurementBasisAxis_638264307688123713" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_638264307688123713" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementBasisAxis_638264307688123713" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember_638264307688123713" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember_638264307688133705" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember_638264307688123713" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember_638264307688133705" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638264307688133705" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638264307688113710" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638264307688133705" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure_638264307688133705" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638264307688133705" xlink:to="us-gaap_InvestmentsFairValueDisclosure_638264307688133705" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureDebtDetails" xlink:type="extended" xlink:title="40901 - Disclosure - DEBT (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_637067369541427086" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_638264307688133705" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_637067369541427086" xlink:to="us-gaap_DebtInstrumentTable_638264307688133705" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis_638264307688133705" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638264307688133705" xlink:to="us-gaap_CreditFacilityAxis_638264307688133705" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain_638264307688133705" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis_638264307688133705" xlink:to="us-gaap_CreditFacilityDomain_638264307688133705" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditMember" xlink:label="us-gaap_LineOfCreditMember_638264307688133705" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain_638264307688133705" xlink:to="us-gaap_LineOfCreditMember_638264307688133705" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638264307688143715" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638264307688133705" xlink:to="us-gaap_DebtInstrumentAxis_638264307688143715" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638264307688143715" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638264307688143715" xlink:to="us-gaap_DebtInstrumentNameDomain_638264307688143715" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_CreditAgreementTrancheOneMember" xlink:label="rigl_CreditAgreementTrancheOneMember_638264307688143715" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638264307688143715" xlink:to="rigl_CreditAgreementTrancheOneMember_638264307688143715" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_CreditAgreementTrancheTwoMember" xlink:label="rigl_CreditAgreementTrancheTwoMember_638264307688143715" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638264307688143715" xlink:to="rigl_CreditAgreementTrancheTwoMember_638264307688143715" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_CreditAgreementTrancheThreeMember" xlink:label="rigl_CreditAgreementTrancheThreeMember_638264307688143715" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638264307688143715" xlink:to="rigl_CreditAgreementTrancheThreeMember_638264307688143715" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_CreditAgreementTrancheFourMember" xlink:label="rigl_CreditAgreementTrancheFourMember_638264307688143715" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638264307688143715" xlink:to="rigl_CreditAgreementTrancheFourMember_638264307688143715" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_CreditAgreementTrancheFiveMember" xlink:label="rigl_CreditAgreementTrancheFiveMember_638264307688143715" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638264307688143715" xlink:to="rigl_CreditAgreementTrancheFiveMember_638264307688143715" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis_638264307688143715" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638264307688133705" xlink:to="us-gaap_VariableRateAxis_638264307688143715" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain_638264307688143715" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis_638264307688143715" xlink:to="us-gaap_VariableRateDomain_638264307688143715" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:label="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_638264307688143715" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateDomain_638264307688143715" xlink:to="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_638264307688143715" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_LondonInterBankOfferedRateMember" xlink:label="rigl_LondonInterBankOfferedRateMember_638264307688143715" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateDomain_638264307688143715" xlink:to="rigl_LondonInterBankOfferedRateMember_638264307688143715" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638264307688153703" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638264307688133705" xlink:to="srt_StatementScenarioAxis_638264307688153703" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638264307688153703" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638264307688153703" xlink:to="srt_ScenarioUnspecifiedDomain_638264307688153703" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_PriorToThirdAmendmentMember" xlink:label="rigl_PriorToThirdAmendmentMember_638264307688153703" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638264307688153703" xlink:to="rigl_PriorToThirdAmendmentMember_638264307688153703" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_FollowingThirdAmendmentMember" xlink:label="rigl_FollowingThirdAmendmentMember_638264307688153703" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638264307688153703" xlink:to="rigl_FollowingThirdAmendmentMember_638264307688153703" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_638264307688153703" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638264307688133705" xlink:to="us-gaap_DebtInstrumentLineItems_638264307688153703" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_638264307688153703" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638264307688153703" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_638264307688153703" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_638264307688153703" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638264307688153703" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_638264307688153703" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" xlink:label="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate_638264307688153703" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638264307688153703" xlink:to="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate_638264307688153703" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_638264307688163704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638264307688153703" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_638264307688163704" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_638264307688163704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638264307688153703" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_638264307688163704" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_638264307688163704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638264307688153703" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_638264307688163704" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:label="us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_638264307688163704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638264307688153703" xlink:to="us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_638264307688163704" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_638264307688163704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638264307688153703" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_638264307688163704" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_638264307688163704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638264307688153703" xlink:to="us-gaap_InterestExpense_638264307688163704" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityIncreaseAccruedInterest" xlink:label="us-gaap_LineOfCreditFacilityIncreaseAccruedInterest_638264307688163704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638264307688153703" xlink:to="us-gaap_LineOfCreditFacilityIncreaseAccruedInterest_638264307688163704" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureDebtFutureMinimumPaymentsDetails" xlink:type="extended" xlink:title="40902 - Disclosure - DEBT - Future Minimum Payments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_637069051856462272" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:label="us-gaap_MaturitiesOfLongTermDebtAbstract_638264307688173705" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_637069051856462272" xlink:to="us-gaap_MaturitiesOfLongTermDebtAbstract_638264307688173705" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_638264307688173705" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MaturitiesOfLongTermDebtAbstract_638264307688173705" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_638264307688173705" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_638264307688173705" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MaturitiesOfLongTermDebtAbstract_638264307688173705" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_638264307688173705" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_638264307688173705" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MaturitiesOfLongTermDebtAbstract_638264307688173705" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_638264307688173705" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt_638264307688173705" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MaturitiesOfLongTermDebtAbstract_638264307688173705" xlink:to="us-gaap_LongTermDebt_638264307688173705" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="8" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureLeasesDetails" xlink:type="extended" xlink:title="41001 - Disclosure - LEASES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable_638264307688173705" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable_638264307688173705" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638264307688183720" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638264307688173705" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638264307688183720" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638264307688183720" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638264307688183720" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638264307688183720" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember_638264307688183720" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638264307688183720" xlink:to="us-gaap_BuildingMember_638264307688183720" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_HeadquartersOfficeSpaceSubleaseSouthSanFranciscoCaliforniaMember" xlink:label="rigl_HeadquartersOfficeSpaceSubleaseSouthSanFranciscoCaliforniaMember_638264307688183720" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BuildingMember_638264307688183720" xlink:to="rigl_HeadquartersOfficeSpaceSubleaseSouthSanFranciscoCaliforniaMember_638264307688183720" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_638264307688183720" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638264307688173705" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_638264307688183720" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_SubleaseAgreementAbstract" xlink:label="rigl_SubleaseAgreementAbstract_638264307688200556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638264307688183720" xlink:to="rigl_SubleaseAgreementAbstract_638264307688200556" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638264307688200556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_SubleaseAgreementAbstract_638264307688200556" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638264307688200556" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638264307688200556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_SubleaseAgreementAbstract_638264307688200556" xlink:to="us-gaap_OperatingLeaseLiability_638264307688200556" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_638264307688203723" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_SubleaseAgreementAbstract_638264307688200556" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_638264307688203723" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncentiveToLessee" xlink:label="us-gaap_IncentiveToLessee_638264307688203723" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_SubleaseAgreementAbstract_638264307688200556" xlink:to="us-gaap_IncentiveToLessee_638264307688203723" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureLeasesLeaseExpenseDetails" xlink:type="extended" xlink:title="41002 - Disclosure - LEASES - Lease Expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract_636915211722771774" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost_638264307688203723" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_636915211722771774" xlink:to="us-gaap_OperatingLeaseCost_638264307688203723" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_VariableLeaseExpenseNetCredit" xlink:label="rigl_VariableLeaseExpenseNetCredit_638264307688203723" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_636915211722771774" xlink:to="rigl_VariableLeaseExpenseNetCredit_638264307688203723" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost_638264307688203723" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_636915211722771774" xlink:to="us-gaap_LeaseCost_638264307688203723" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureLeasesCashFlowInformationDetails" xlink:type="extended" xlink:title="41003 - Disclosure - LEASES - Cash Flow Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract_636915251773897105" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments_638264307688203723" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_636915251773897105" xlink:to="us-gaap_OperatingLeasePayments_638264307688203723" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureLeasesSubleaseInformationDetails" xlink:type="extended" xlink:title="41004 - Disclosure - LEASES - Sublease Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract_637073416785770995" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_SubleaseAgreementAbstract" xlink:label="rigl_SubleaseAgreementAbstract_638264307688213724" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_637073416785770995" xlink:to="rigl_SubleaseAgreementAbstract_638264307688213724" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_FixedSubleaseExpense" xlink:label="rigl_FixedSubleaseExpense_638264307688213724" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_SubleaseAgreementAbstract_638264307688213724" xlink:to="rigl_FixedSubleaseExpense_638264307688213724" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_VariableSubleaseExpense" xlink:label="rigl_VariableSubleaseExpense_638264307688213724" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_SubleaseAgreementAbstract_638264307688213724" xlink:to="rigl_VariableSubleaseExpense_638264307688213724" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome_638264307688213724" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_SubleaseAgreementAbstract_638264307688213724" xlink:to="us-gaap_SubleaseIncome_638264307688213724" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="rigl-20230630.xsd#rigl_NetSubleaseIncomeExpense" xlink:label="rigl_NetSubleaseIncomeExpense_638264307688213724" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_SubleaseAgreementAbstract_638264307688213724" xlink:to="rigl_NetSubleaseIncomeExpense_638264307688213724" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails" xlink:type="extended" xlink:title="41005 - Disclosure - LEASES - Future Minimum Lease Payments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract_637073417401946655" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638264307688213724" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_637073417401946655" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638264307688213724" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_638264307688213724" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638264307688213724" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_638264307688213724" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638264307688213724" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638264307688213724" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638264307688213724" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638264307688213724" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638264307688213724" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638264307688213724" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638264307688223720" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638264307688213724" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638264307688223720" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended" xlink:title="995445 - Disclosure - Insider Trading Arrangements" xmlns="http://www.xbrl.org/2003/linkbase" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140108311088704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DOCUMENT AND ENTITY INFORMATION - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jul. 27, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>DOCUMENT AND ENTITY INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-29889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">RIGEL PHARMACEUTICALS INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">94-3248524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">611 Gateway Boulevard, Suite 900,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South San Francisco<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">624-1100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">RIGL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001034842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174,364,286<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140108312710912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 48,812<span></span>
</td>
<td class="nump">$ 24,459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">15,545<span></span>
</td>
<td class="nump">33,747<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">20,819<span></span>
</td>
<td class="nump">40,320<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">10,782<span></span>
</td>
<td class="nump">9,118<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="nump">4,967<span></span>
</td>
<td class="nump">8,259<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">100,925<span></span>
</td>
<td class="nump">115,903<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">215<span></span>
</td>
<td class="nump">857<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Intangible asset, net</a></td>
<td class="nump">14,413<span></span>
</td>
<td class="nump">14,949<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">997<span></span>
</td>
<td class="nump">1,930<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">541<span></span>
</td>
<td class="nump">640<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">117,091<span></span>
</td>
<td class="nump">134,279<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">5,240<span></span>
</td>
<td class="nump">22,508<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">6,739<span></span>
</td>
<td class="nump">8,866<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_AccruedResearchAndDevelopmentLiabilityCurrent', window );">Accrued research and development</a></td>
<td class="nump">5,826<span></span>
</td>
<td class="nump">7,708<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerRefundLiabilityCurrent', window );">Revenue reserves and refund liability</a></td>
<td class="nump">13,684<span></span>
</td>
<td class="nump">12,145<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">5,013<span></span>
</td>
<td class="nump">6,485<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities, current portion</a></td>
<td class="nump">466<span></span>
</td>
<td class="nump">1,133<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">1,355<span></span>
</td>
<td class="nump">1,369<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other long-term liabilities, current portion</a></td>
<td class="nump">5,700<span></span>
</td>
<td class="nump">4,997<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">44,023<span></span>
</td>
<td class="nump">65,211<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term portion of lease liabilities</a></td>
<td class="nump">628<span></span>
</td>
<td class="nump">972<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermLoansPayable', window );">Loans payable, net of discount</a></td>
<td class="nump">59,574<span></span>
</td>
<td class="nump">39,448<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">40,981<span></span>
</td>
<td class="nump">42,264<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">145,206<span></span>
</td>
<td class="nump">147,895<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">175<span></span>
</td>
<td class="nump">174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">1,374,330<span></span>
</td>
<td class="nump">1,368,822<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(25)<span></span>
</td>
<td class="num">(153)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,402,595)<span></span>
</td>
<td class="num">(1,382,459)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' deficit</a></td>
<td class="num">(28,115)<span></span>
</td>
<td class="num">(13,616)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' deficit</a></td>
<td class="nump">$ 117,091<span></span>
</td>
<td class="nump">$ 134,279<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_AccruedResearchAndDevelopmentLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the carrying value as of the balance sheet date of research and development costs that are incurred but not billed to the entity as of the end of the period. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_AccruedResearchAndDevelopmentLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerRefundLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerRefundLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140108311605344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 26,886<span></span>
</td>
<td class="nump">$ 29,819<span></span>
</td>
<td class="nump">$ 52,956<span></span>
</td>
<td class="nump">$ 46,554<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of product sales</a></td>
<td class="nump">1,075<span></span>
</td>
<td class="nump">1,036<span></span>
</td>
<td class="nump">2,052<span></span>
</td>
<td class="nump">1,157<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">4,772<span></span>
</td>
<td class="nump">14,767<span></span>
</td>
<td class="nump">14,861<span></span>
</td>
<td class="nump">30,241<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">26,306<span></span>
</td>
<td class="nump">26,981<span></span>
</td>
<td class="nump">54,035<span></span>
</td>
<td class="nump">54,382<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
<td class="nump">32,153<span></span>
</td>
<td class="nump">42,784<span></span>
</td>
<td class="nump">70,948<span></span>
</td>
<td class="nump">85,780<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(5,267)<span></span>
</td>
<td class="num">(12,965)<span></span>
</td>
<td class="num">(17,992)<span></span>
</td>
<td class="num">(39,226)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">529<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="nump">922<span></span>
</td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(1,862)<span></span>
</td>
<td class="num">(569)<span></span>
</td>
<td class="num">(3,066)<span></span>
</td>
<td class="num">(1,774)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (6,600)<span></span>
</td>
<td class="num">$ (13,492)<span></span>
</td>
<td class="num">$ (20,136)<span></span>
</td>
<td class="num">$ (40,937)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (in dollars per share)</a></td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="num">$ (0.08)<span></span>
</td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="num">$ (0.24)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in dollars per share)</a></td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="num">$ (0.08)<span></span>
</td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="num">$ (0.24)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares used in computing net loss per share, basic (in shares)</a></td>
<td class="nump">173,748<span></span>
</td>
<td class="nump">172,147<span></span>
</td>
<td class="nump">173,659<span></span>
</td>
<td class="nump">171,961<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares used in computing net loss per share, diluted (in shares)</a></td>
<td class="nump">173,748<span></span>
</td>
<td class="nump">172,147<span></span>
</td>
<td class="nump">173,659<span></span>
</td>
<td class="nump">171,961<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 23,881<span></span>
</td>
<td class="nump">$ 18,550<span></span>
</td>
<td class="nump">$ 47,626<span></span>
</td>
<td class="nump">$ 34,747<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rigl_ContractRevenuesFromCollaborationsMember', window );">Contract revenues from collaborations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">2,005<span></span>
</td>
<td class="nump">$ 11,269<span></span>
</td>
<td class="nump">4,330<span></span>
</td>
<td class="nump">$ 11,807<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GovernmentContractMember', window );">Government contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rigl_ContractRevenuesFromCollaborationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rigl_ContractRevenuesFromCollaborationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GovernmentContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GovernmentContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140108312684016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>CONDENSED STATEMENTS OF COMPREHENSIVE LOSS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td>
<td class="num">$ (6,600)<span></span>
</td>
<td class="num">$ (13,492)<span></span>
</td>
<td class="num">$ (20,136)<span></span>
</td>
<td class="num">$ (40,937)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive gain (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Net unrealized gain (loss) on short-term investments</a></td>
<td class="nump">2<span></span>
</td>
<td class="num">(22)<span></span>
</td>
<td class="nump">128<span></span>
</td>
<td class="num">(336)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (6,598)<span></span>
</td>
<td class="num">$ (13,514)<span></span>
</td>
<td class="num">$ (20,008)<span></span>
</td>
<td class="num">$ (41,273)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140108308715376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF STOCKHOLDERS' (DEFICIT) EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 172<span></span>
</td>
<td class="nump">$ 1,354,190<span></span>
</td>
<td class="num">$ (102)<span></span>
</td>
<td class="num">$ (1,323,886)<span></span>
</td>
<td class="nump">$ 30,374<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">171,602,226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27,445)<span></span>
</td>
<td class="num">(27,445)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Net unrealized gain (loss) on short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(314)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(314)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock upon exercise of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock upon exercise of options (in shares)</a></td>
<td class="nump">420,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock upon vesting of restricted stock units (RSUs) (in shares)</a></td>
<td class="nump">22,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,243<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2022</a></td>
<td class="nump">$ 172<span></span>
</td>
<td class="nump">1,358,373<span></span>
</td>
<td class="num">(416)<span></span>
</td>
<td class="num">(1,351,331)<span></span>
</td>
<td class="nump">6,798<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Mar. 31, 2022</a></td>
<td class="nump">172,045,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 172<span></span>
</td>
<td class="nump">1,354,190<span></span>
</td>
<td class="num">(102)<span></span>
</td>
<td class="num">(1,323,886)<span></span>
</td>
<td class="nump">30,374<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">171,602,226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(40,937)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Net unrealized gain (loss) on short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(336)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2022</a></td>
<td class="nump">$ 173<span></span>
</td>
<td class="nump">1,361,411<span></span>
</td>
<td class="num">(438)<span></span>
</td>
<td class="num">(1,364,823)<span></span>
</td>
<td class="num">(3,677)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Jun. 30, 2022</a></td>
<td class="nump">172,836,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2022</a></td>
<td class="nump">$ 172<span></span>
</td>
<td class="nump">1,358,373<span></span>
</td>
<td class="num">(416)<span></span>
</td>
<td class="num">(1,351,331)<span></span>
</td>
<td class="nump">6,798<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Mar. 31, 2022</a></td>
<td class="nump">172,045,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,492)<span></span>
</td>
<td class="num">(13,492)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Net unrealized gain (loss) on short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock upon exercise of options</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">599<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock upon exercise of options (in shares)</a></td>
<td class="nump">609,839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock upon vesting of restricted stock units (RSUs) (in shares)</a></td>
<td class="nump">181,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,440<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2022</a></td>
<td class="nump">$ 173<span></span>
</td>
<td class="nump">1,361,411<span></span>
</td>
<td class="num">(438)<span></span>
</td>
<td class="num">(1,364,823)<span></span>
</td>
<td class="num">(3,677)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Jun. 30, 2022</a></td>
<td class="nump">172,836,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 174<span></span>
</td>
<td class="nump">1,368,822<span></span>
</td>
<td class="num">(153)<span></span>
</td>
<td class="num">(1,382,459)<span></span>
</td>
<td class="num">(13,616)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">173,398,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,536)<span></span>
</td>
<td class="num">(13,536)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Net unrealized gain (loss) on short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock upon exercise of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock upon exercise of options (in shares)</a></td>
<td class="nump">952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock upon vesting of restricted stock units (RSUs) (in shares)</a></td>
<td class="nump">266,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,768<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2023</a></td>
<td class="nump">$ 174<span></span>
</td>
<td class="nump">1,371,591<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="num">(1,395,995)<span></span>
</td>
<td class="num">(24,257)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Mar. 31, 2023</a></td>
<td class="nump">173,665,853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 174<span></span>
</td>
<td class="nump">1,368,822<span></span>
</td>
<td class="num">(153)<span></span>
</td>
<td class="num">(1,382,459)<span></span>
</td>
<td class="num">(13,616)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">173,398,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,136)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Net unrealized gain (loss) on short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2023</a></td>
<td class="nump">$ 175<span></span>
</td>
<td class="nump">1,374,330<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="num">(1,402,595)<span></span>
</td>
<td class="num">(28,115)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Jun. 30, 2023</a></td>
<td class="nump">174,358,398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2023</a></td>
<td class="nump">$ 174<span></span>
</td>
<td class="nump">1,371,591<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="num">(1,395,995)<span></span>
</td>
<td class="num">(24,257)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Mar. 31, 2023</a></td>
<td class="nump">173,665,853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,600)<span></span>
</td>
<td class="num">(6,600)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Net unrealized gain (loss) on short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock upon exercise of options</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">554<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock upon exercise of options (in shares)</a></td>
<td class="nump">523,795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock upon vesting of restricted stock units (RSUs) (in shares)</a></td>
<td class="nump">168,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,186<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2023</a></td>
<td class="nump">$ 175<span></span>
</td>
<td class="nump">$ 1,374,330<span></span>
</td>
<td class="num">$ (25)<span></span>
</td>
<td class="num">$ (1,402,595)<span></span>
</td>
<td class="num">$ (28,115)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Jun. 30, 2023</a></td>
<td class="nump">174,358,398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140108308659600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (20,136)<span></span>
</td>
<td class="num">$ (40,937)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">4,930<span></span>
</td>
<td class="nump">5,598<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss (gain) on sale and disposal of fixed assets</a></td>
<td class="nump">398<span></span>
</td>
<td class="num">(253)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">653<span></span>
</td>
<td class="nump">474<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_NoncashInterestExpense', window );">Non-cash interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">682<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium', window );">Net amortization and accretion of discount on short-term investments and term loan</a></td>
<td class="num">(114)<span></span>
</td>
<td class="nump">107<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="nump">19,501<span></span>
</td>
<td class="num">(1,726)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(1,640)<span></span>
</td>
<td class="nump">483<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid and other current assets</a></td>
<td class="nump">3,292<span></span>
</td>
<td class="num">(527)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="nump">99<span></span>
</td>
<td class="nump">571<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_IncreaseDecreaseRightOfUseAssets', window );">Right-of-use assets</a></td>
<td class="nump">933<span></span>
</td>
<td class="nump">4,458<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(2,268)<span></span>
</td>
<td class="num">(1,585)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation</a></td>
<td class="num">(2,127)<span></span>
</td>
<td class="num">(3,165)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_IncreaseDecreaseInAccruedResearchAndDevelopmentLiability', window );">Accrued research and development</a></td>
<td class="num">(1,882)<span></span>
</td>
<td class="num">(1,171)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_RevenueReservesAndRefundLiability', window );">Revenue reserves and refund liability</a></td>
<td class="nump">1,539<span></span>
</td>
<td class="nump">2,316<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities', window );">Other accrued liabilities</a></td>
<td class="num">(1,472)<span></span>
</td>
<td class="nump">1,878<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Lease liability</a></td>
<td class="num">(1,011)<span></span>
</td>
<td class="num">(4,840)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(14)<span></span>
</td>
<td class="num">(1,053)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other current and long-term liabilities</a></td>
<td class="nump">1,175<span></span>
</td>
<td class="nump">142<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="nump">1,856<span></span>
</td>
<td class="num">(38,548)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchases of short-term investments</a></td>
<td class="num">(8,780)<span></span>
</td>
<td class="num">(6,997)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments', window );">Maturities of short-term investments</a></td>
<td class="nump">27,400<span></span>
</td>
<td class="nump">50,645<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Purchases of intangible asset</a></td>
<td class="num">(15,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property and equipment</a></td>
<td class="nump">127<span></span>
</td>
<td class="nump">264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(188)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">3,747<span></span>
</td>
<td class="nump">43,724<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_PaymentOfCostShareToCollaborationPartner', window );">Cost share payments to a collaboration partner</a></td>
<td class="num">(1,754)<span></span>
</td>
<td class="num">(8,346)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Net proceeds from issuances of common stock upon exercise of options and participation in Purchase Plan</a></td>
<td class="nump">554<span></span>
</td>
<td class="nump">1,539<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLongTermLinesOfCredit', window );">Net proceeds from term loan financing</a></td>
<td class="nump">19,950<span></span>
</td>
<td class="nump">9,942<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">18,750<span></span>
</td>
<td class="nump">3,135<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">24,353<span></span>
</td>
<td class="nump">8,311<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">24,459<span></span>
</td>
<td class="nump">18,890<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">48,812<span></span>
</td>
<td class="nump">27,201<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">$ 2,485<span></span>
</td>
<td class="nump">$ 951<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_IncreaseDecreaseInAccruedResearchAndDevelopmentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the increase (decrease) during the reporting period in the aggregate amount of research and development expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_IncreaseDecreaseInAccruedResearchAndDevelopmentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_IncreaseDecreaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase or decrease in right-of-use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_IncreaseDecreaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_NoncashInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash interest expense during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_NoncashInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_PaymentOfCostShareToCollaborationPartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of cost share to collaboration partner.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_PaymentOfCostShareToCollaborationPartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_RevenueReservesAndRefundLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the increase (decrease) during the reporting period in the aggregate amount of revenue reserves and refund liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_RevenueReservesAndRefundLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482312/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140108313929232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock', window );">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;"><b style="font-size:10pt;font-weight:bold;">1.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;"><b style="font-size:10pt;font-weight:bold;">Organization and Summary of Significant Accounting Policies</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">Description of Business</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">We are a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. We focus on products that address signaling pathways that are critical to disease mechanisms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Our first product approved by the US Food and Drug Administration (FDA) is TAVALISSE<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (fostamatinib disodium hexahydrate) tablets, the only approved oral spleen tyrosine kinase (SYK) inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. The product is also commercially available in Europe and the United Kingdom (UK) (as TAVLESSE), and in Canada, Israel and Japan (as TAVALISSE) for the treatment of chronic ITP in adult patients. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Our second FDA approved product is REZLIDHIA<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;&#160;</sup><span style="color:#222222;background:#ffffff;">(olutasidenib) capsules for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. We began our commercialization of REZLIDHIA in December 2022. W</span>e in-licensed <span style="color:#222222;background:#ffffff;">olutasidenib</span> from Forma Therapeutics, Inc. (now Novo Nordisk), with exclusive, worldwide rights for its development, manufacturing and commercialization. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">We continue to advance the development of our interleukin receptor-associated kinase (IRAK) 1/4 inhibitor program, in an open-label, Phase 1b trial to determine the tolerability and preliminary efficacy of the drug in patients with lower-risk <span style="color:#222222;background:#ffffff;">myelodysplastic syndrome (MDS)</span> who are refractory or resistant to prior therapies. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Our other ongoing clinical programs include a fostamatinib Phase 2/3 trial, the Accelerating COVID-19 Therapeutic Inventions and Vaccines Phase 2/3 trial (ACTIV-4 Host Tissue Trial), for the treatment <span style="background:#ffffff;">of hospitalized high-risk patients with COVID-19</span> being conducted and sponsored by the National Institute of Health (NIH)/National Heart, Lung, and Blood Institute (NHLBI), and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with our partner Eli Lilly and Company (Lilly). We also have product candidates in clinical development with partners BerGenBio ASA (BerGenBio) and Daiichi Sankyo (Daiichi). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:9pt 0pt 9pt 18pt;"><span style="font-style:italic;font-weight:bold;">Basis of Presentation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Our accompanying unaudited condensed financial statements have been prepared in accordance with United States generally accepted accounting principles (US GAAP), for interim financial information and pursuant to the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities Act of 1933, as amended (Securities Act). Accordingly, they do not include all the information and notes required by US GAAP for complete financial statements. These unaudited condensed financial statements include only normal and recurring adjustments that we believe are necessary to fairly state our financial position and the results of our operations and cash flows. Interim-period results are not necessarily indicative of results of operations or cash flows for a full-year or any subsequent interim period. The balance sheet as of December 31, 2022 has been derived from audited financial statements at that date but does not include all disclosures required by US GAAP for complete financial statements. Because certain disclosures required by US GAAP for complete financial statements are not included herein, these interim unaudited condensed financial statements and the notes accompanying them should be read in conjunction with our audited financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC on March 7, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-indent:36pt;margin:9pt 0pt 0pt 0pt;">The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results could differ from these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Significant Accounting Policies</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-indent:36pt;background:#ffffff;margin:0pt;">Our significant accounting policies are described in &#8220;Note 1 &#8211; Description of Business and Summary of Significant Accounting Policies&#8221; to our&#160;&#8220;Notes to Financial Statements&#8221;&#160;contained in &#8220;Part II, Item&#160;8, Financial Statements and Supplementary Data&#8221; of our Annual Report on Form 10-K for the year ended December 31, 2022. There have been no material changes to these accounting policies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Liquidity</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-indent:36pt;background:#ffffff;margin:0pt;">As of June 30, 2023, we had approximately $64.4 million in cash, cash equivalents and short-term investments. Since inception, we have financed our operations primarily through sales of equity securities, debt financing, contract payments under our collaboration agreements and from product sales. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-indent:36pt;background:#ffffff;margin:0pt;">Based on our current operating plan, we believe that our existing cash, cash equivalents, and short-term investments will be sufficient to fund our expenses and capital expenditure requirements for at least the next 12 months from the date of issuance of this Form 10-Q.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Recently Issued Accounting Standards </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt 0pt 9pt 0pt;">Recently issued accounting guidance is either not applicable or did not have, or is not expected to have, a material impact to us. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and accounting policies concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140108314067296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>NET LOSS PER SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">NET LOSS PER SHARE</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;"><b style="font-size:10pt;font-weight:bold;">2.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;"><b style="font-size:10pt;font-weight:bold;">Net Loss Per Share</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period and the number of additional shares of common stock that would have been outstanding if potentially dilutive securities had been issued. Potentially dilutive securities include stock options, RSUs and shares issuable under our Employee Stock Purchase Plan (Purchase Plan). The dilutive effect of these potentially dilutive securities is reflected in diluted earnings per share using the treasury stock method. Under the treasury stock method, an increase in the fair market value of our common stock can result in a greater dilutive effect from potentially dilutive securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The potential shares of common stock that were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive are as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:93.39%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:23.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:21.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding stock options</p></td><td style="vertical-align:bottom;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">35,244 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">33,081 </p></td><td style="vertical-align:bottom;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">35,244 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">33,081 </p></td></tr><tr><td style="vertical-align:bottom;width:51.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">RSUs</p></td><td style="vertical-align:bottom;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">1,963 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">1,191 </p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">1,963 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">1,191 </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">37,207 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">34,272 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">37,207 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">34,272 </p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140108313969952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>REVENUES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">REVENUES</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-size:10pt;font-weight:bold;">3.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-size:10pt;font-weight:bold;">Revenues</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Revenues disaggregated by category were as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:41.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:41.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:26.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Product sales:</p></td><td style="vertical-align:bottom;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Gross product sales</p></td><td style="vertical-align:bottom;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">33,456 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">26,427 </p></td><td style="vertical-align:bottom;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">66,654 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">49,045 </p></td></tr><tr><td style="vertical-align:bottom;width:41.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Discounts and allowances</p></td><td style="vertical-align:bottom;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(9,575)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(7,877)</p></td><td style="vertical-align:bottom;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(19,028)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(14,298)</p></td></tr><tr><td style="vertical-align:bottom;width:41.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total product sales, net</p></td><td style="vertical-align:bottom;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 23,881</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 18,550</p></td><td style="vertical-align:bottom;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 47,626</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 34,747</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Revenues from collaborations:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">License revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,337</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">2,545 </p></td></tr><tr><td style="vertical-align:bottom;width:41.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Development milestones</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,000</p></td></tr><tr><td style="vertical-align:bottom;width:41.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Royalty, delivery of drug supplies and others</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">2,005 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">3,932 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">4,330 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">4,262 </p></td></tr><tr><td style="vertical-align:bottom;width:41.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total revenues from collaborations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,005</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 11,269</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,330</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 11,807</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Government contract</p></td><td style="vertical-align:bottom;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Total revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 26,886</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 29,819</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 52,956</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 46,554</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Revenue from product sales are related to sales of our commercial products, TAVALISSE and REZLIDHIA, to our specialty distributors. For detailed discussions of our revenues from collaboration and government contract, see &#8220;Note 4 &#8211; Sponsored Research and License Agreements and Government Contract&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Our net product sales include gross product sales, net of chargebacks, discounts and fees, government and other rebates and returns. Of the total discounts and allowances from gross product sales for the six months ended June 30, 2023 and 2022, $18.6 million and $13.0 million, respectively, was accounted for as additions to revenue reserves and refund liability, and $0.4 million and $1.3 million, respectively, as reductions in accounts receivable (as it relates to allowance for prompt pay discount) and prepaid and other current assets (as it relates to certain chargebacks and other fees that were prepaid) in the condensed balance sheet. The following tables summarize the activities in chargebacks, discounts and fees, government and other rebates and returns that were accounted for within revenue reserves and refund liability, for each of the periods presented (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:38.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Chargebacks,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Government</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Discounts&#160;and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">and Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fees</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Rebates</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Returns</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance as of January 1, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 6,213</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,636</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,296</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 12,145</p></td></tr><tr><td style="vertical-align:bottom;width:38.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Provision related to current period sales</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 14,439</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,725</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 395</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 18,559</p></td></tr><tr><td style="vertical-align:bottom;width:38.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Credit or payments made during the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (13,139)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,765)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (116)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (17,020)</p></td></tr><tr><td style="vertical-align:bottom;width:38.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance as of June 30, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 7,513</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,596</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,575</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 13,684</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:38.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Chargebacks,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Government</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Discounts&#160;and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">and Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fees</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Rebates</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Returns</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance as of January 1, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,404</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,494</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,017</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 7,915</p></td></tr><tr><td style="vertical-align:bottom;width:38.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Provision related to current period sales</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 9,680</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,711</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 613</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 13,004</p></td></tr><tr><td style="vertical-align:bottom;width:38.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Credit or payments made during the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7,748)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,901)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (39)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (10,688)</p></td></tr><tr><td style="vertical-align:bottom;width:38.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance as of June 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,336</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,304</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,591</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 10,231</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 6pt 0pt;">The following table summarizes the percentages of revenues from each of our customers who individually accounted for 10% or more of the total net product sales and revenues from collaborations:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:96.98%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:43.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:24.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">McKesson Specialty Care Distribution Corporation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">44%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">34%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">45%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">36%</p></td></tr><tr><td style="vertical-align:bottom;width:43.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cardinal Healthcare</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">28%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">16%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">26%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">20%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ASD Healthcare and Oncology Supply</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">19%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">12%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">21%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">19%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Kissei</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">25%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">16%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-15<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140108311085520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SPONSORED RESEARCH AND LICENSE AGREEMENTS AND GOVERNMENT CONTRACT<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_CorporateCollaborationsDisclosureAbstract', window );"><strong>SPONSORED RESEARCH AND LICENSE AGREEMENTS AND GOVERNMENT CONTRACT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">SPONSORED RESEARCH AND LICENSE AGREEMENTS AND GOVERNMENT CONTRACT</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:10pt;font-weight:bold;">4.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:10pt;font-weight:bold;">Sponsored Research and License Agreements and Government Contract</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Sponsored Research and License Agreements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">We conduct research and development programs independently and in connection with our corporate collaborators. As of June 30, 2023, we are a party to collaboration agreements with Lilly to develop and commercialize R552, a RIPK1 inhibitor, for the treatment of non-central nervous system (non-CNS) diseases and collaboration aimed at developing additional RIPK1 inhibitors for the treatment of central nervous system (CNS) diseases; with Grifols S.A. (Grifols) to commercialize fostamatinib for human diseases in all indications, including chronic ITP and <span style="color:#202124;background:#ffffff;">autoimmune hemolytic anemia</span> (AIHA), in Grifols territory which includes Europe, the UK, Turkey, the Middle East, North Africa and Russia (including Commonwealth of Independent States); with Kissei Pharmaceutical Co., Ltd. (Kissei) to develop and commercialize fostamatinib in Kissei territory which includes Japan, China, Taiwan and the Republic of Korea; with Medison Pharma Trading AG (Medison Canada) and Medison Pharma Ltd. (Medison Israel and, together with Medison Canada, Medison) to commercialize fostamatinib in all indications, including chronic ITP and AIHA, in Medison territory which includes Canada and Israel; and with Knight Therapeutics International SA (Knight) to commercialize fostamatinib in all indications, including chronic ITP and AIHA, in Knight territory which includes Latin America, consisting of Mexico, Central and South America, and the Caribbean (Knight territory).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Further, we are also a party to collaboration agreements, but do not have ongoing performance obligations with BerGenBio for the development and commercialization of <span style="background:#ffffff;">AXL receptor tyrosine kinase (</span>AXL) inhibitors in oncology, and with Daiichi to pursue research related to <span style="background:#ffffff;">murine double minute 2&#160;(</span>MDM2) inhibitors, a novel class of drug targets called ligases. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Under the above existing agreements that we entered into in the ordinary course of business, we received or may be entitled to receive upfront cash payments, payments contingent upon specified events achieved by such partners and royalties on any net sales of products sold by such partners under the agreements. As of June 30, 2023, total future contingent payments to us under all of the above existing agreements, excluding terminated agreements, could exceed $1.3 billion if all potential product candidates achieved all of the payment triggering events under all of our current agreements. Of this amount, $279.5&#160;million relates to the achievement of development events, $263.1 million relates to the achievement of regulatory events and $796.0&#160;million relates to the achievement of certain commercial events. This estimated future contingent amount does not include any estimated royalties that could be due to us if the partners successfully commercialize any of the licensed products. Future events that may trigger payments to us under the agreements are based solely on our partners&#8217; future efforts and achievements of specified development, regulatory and/or commercial events. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:11pt 0pt 11pt 0pt;"><i style="font-style:italic;">Global Exclusive License Agreement with Lilly </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:11pt 0pt 11pt 0pt;">We have a global exclusive license agreement and strategic collaboration with Lilly (Lilly Agreement) entered in February 2021, which became effective on March 27, 2021, upon clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, to develop and commercialize R552 for the treatment of non-CNS diseases. In addition, the collaboration is aimed at developing additional RIPK1 inhibitors for the treatment of CNS diseases. Pursuant to the terms of the license agreement, we granted to Lilly exclusive rights to develop and commercialize R552 and related RIPK1 inhibitors in all indications worldwide. The parties&#8217; collaboration is governed through a joint governance committee and appropriate subcommittees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:11pt 0pt 0pt 0pt;">Under the terms of the Lilly Agreement, we were entitled to receive a non-refundable and non-creditable upfront cash payment amounting to $125.0 million, which we received in April 2021. We are also entitled to additional milestone payments for non-CNS disease products consisting of up to $330.0 million in milestone payments upon the achievement of specified development, regulatory and commercial milestones, and up to $100.0 million in sales milestone payments on a product-by-product basis. In addition, depending on the extent of our co-funding of R552 development activities, we would be entitled to receive tiered royalty payments on net sales of non-CNS disease products at percentages ranging from the mid-single digits to high-teens, subject to certain standard reductions and offsets. We are also eligible to receive milestone payments for CNS disease products consisting of up to $255.0 million in milestone payments upon the achievement of specified development, regulatory and commercial milestones, and up to $150.0 million in sales milestone payments on a product-by-product basis. We would be entitled to receive tiered royalty </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;">payments on net sales of CNS disease products up to low-double digits, subject to certain standard reductions and offsets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:11pt 0pt 11pt 0pt;">We are responsible for performing and funding initial discovery and identification of CNS disease development candidates. Following candidate selection, Lilly will be responsible for performing and funding all future development and commercialization of the CNS disease development candidates. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:11pt 0pt 11pt 0pt;">Under the Lilly Agreement, we are responsible for 20% of development costs for R552 in the US, Europe, and Japan, up to a specified cap, and Lilly is responsible for funding the remainder of all development activities for R552 and other non-CNS disease development candidates. Pursuant to the terms of the Lilly Agreement, we have the right to opt-out of co-funding the R552 development activities at two different specified times. If we exercise our first opt-out right (no later than September 30, 2023), we are required to fund our share of the R552 development activities up to a maximum funding commitment of $65.0 million through April 1, 2024. If we decide not to exercise our opt-out rights, we will be required to share in global development costs of up to certain amounts at a specified cap, as provided for in the Lilly Agreement. Given our rights to opt-out from the development of R552, we believe at the minimum, we have a commitment to fund the development costs up to $65.0 million as discussed above. We considered this commitment to fund the development costs as a significant financing component of the contract, which we accounted for as a reduction of the upfront fee to derive the transaction price. This financing component was recorded as a liability at its net present value of approximately $57.9 million using a 6.4% discount rate. Interest expense is accreted on such liability over the expected commitment period, adjusted for timing of expected cost share payments. No interest was accreted during the six months ended June 30, 2023, and $0.7 million of interest was accreted during the six months ended June 30, 2022. Through June 30, 2023, Lilly billed us $16.9 million for our share of development costs under this agreement, and the amount was fully paid as of June 30, 2023. As of June 30, 2023 and December 31, 2022, the outstanding financing liability to Lilly was $44.5 million and $46.2 million, respectively, and included within other long-term liabilities, current portion, and other long-term liabilities in the condensed balance sheet.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:11pt 0pt 11pt 0pt;">We accounted for this agreement under ASC 606 and identified the following distinct performance obligations at inception of the agreement: (a) granting of the license rights over the non-CNS penetrant intellectual property (IP), and (b) granting of the license rights over the CNS penetrant IP which will be delivered to Lilly upon completion of the additional research and development efforts specified in the agreement. We concluded each of these performance obligations is distinct. We based our assessment on the assumption that Lilly can benefit from each of the licenses on its own by developing and commercializing the underlying product using its own resources. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:11pt 0pt 11pt 0pt;">We allocated the net transaction price of $67.1&#160;million to each performance obligation based on our best estimate of its relative standalone selling price using the adjusted market assessment approach. The transaction price allocated to the non-CNS penetrant IP of $60.4 million was recognized as revenue upon delivery of the non-CNS penetrant IP to Lilly during the first quarter of 2021. The transaction price allocated to the CNS penetrant IP of $6.7 million was recognized as revenue from the effective date of the Lilly Agreement through the eventual acceptance by Lilly using the input method, since we were required to perform additional research and development efforts before the final acceptance of the license by Lilly. In June 2022, Lilly provided notice of continuance pursuant to the terms of the Lilly Agreement, whereby Lilly elected its option to lead the identification and selection of CNS penetrant lead candidate. As such, we recognized the remaining outstanding deferred revenue in the second quarter of 2022. For the three and six months ended June 30, 2022, we recognized $0.3 million and $0.5 million, respectively, of revenue associated with the delivery of CNS penetrant IP. No<span style="white-space:pre-wrap;"> such revenue was recognized in the three and six months ended June 30, 2023.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The remaining future variable consideration related to future milestone payments as discussed above were fully constrained because we cannot conclude that it is probable that a significant reversal of the amount of cumulative revenue recognized will not occur, given the inherent uncertainty of success with these future milestones. For sales-based milestones and royalties, we determined that the license is the predominant item to which the royalties or sales-based milestones relate. Accordingly, we will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). We will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">Grifols License Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">We have an exclusive commercialization license agreement with Grifols entered in January 2019 with exclusive rights to commercialize fostamatinib for human diseases, including chronic ITP and AIHA, and non-exclusive rights to develop fostamatinib in Grifols territory. Under the agreement, we received an upfront payment of $30.0 million, with the potential for $297.5 million in total regulatory and commercial milestones. We are also entitled to receive stepped double-digit royalty payments based on tiered net sales which may reach 30% of net sales. The agreement also required us to continue to conduct our long-term open-label extension study on patients with ITP through European Medicines Agency (EMA) approval of ITP in Europe or until the study ends as well as conduct the Phase 3 trial of fostamatinib in AIHA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">In January 2020, the European Commission (EC) granted a centralized Marketing Authorization (MA) for fostamatinib valid throughout the European Union (EU) and in the UK after the departure of the UK from the EU for the treatment of chronic ITP in adult patients who are refractory to other treatments. With this approval, in February 2020, we received $20.0 million non-refundable payment, composed of a $17.5 million payment due upon Marketing Authorization Application (MAA) approval by the EMA of fostamatinib for the first indication and a $2.5&#160;million creditable advance royalty payment, based on the terms of our collaboration agreement with Grifols. The above milestone payment was allocated to the distinct performance obligations in the collaboration agreement with Grifols. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We accounted for this agreement under ASC 606 and identified the following distinct performance obligations at inception of the agreement: (a) granting of the license, (b) performance of research and regulatory services related to our long-term open-label extension study on patients with ITP, and (c) performance of research services related to our Phase 3 study in AIHA. We allocated the transaction price to the distinct performance obligations in our collaboration agreement based on our best estimate of the relative standalone selling price, and recognized the corresponding revenue in the periods we satisfied the performance obligations. During the three and six months ended June 30, 2022, we recognized $0.2 million and $0.5 million, respectively, of revenue associated with the remaining performance obligation to perform research services. No such revenue was recognized during the three and six months ended June 30, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The remaining variable consideration related to future regulatory and commercial milestones were fully constrained because we cannot conclude that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur, given the inherent uncertainty of success with these future milestones. We are recognizing revenues related to the research and regulatory services throughout the term of the respective clinical programs using the input method. For sales-based milestones and royalties, we determined that the license is the predominant item to which the royalties or sales-based milestones relate. Accordingly, we will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). We will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We entered into a Commercial Supply Agreement with Grifols in October 2020 to supply and sell our drug product priced at a certain markup specified in the agreement, in quantities Grifols order from us pursuant to and in accordance with the agreement. Prior to the Commercial Supply Agreement, we had a Drug Product Purchase Agreement with Grifols entered in December 2019. During the three and six months ended June 30, 2023, we recognized $1.2 million and $2.8 million, respectively, of revenue related to delivery of drug supply to Grifols. D<span style="background:#ffffff;">uring the three and six months ended June 30, 2022, we recognized </span><span style="background:#ffffff;">$1.2</span><span style="background:#ffffff;">&#160;million of revenue </span>related to delivery of drug supply to Grifols<span style="background:#ffffff;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">We began recognizing royalty revenue from Grifols beginning in the third quarter of 2022. For the three and six months ended June 30, 2023, we recognized </span><span style="background:#ffffff;">$0.8</span><span style="background:#ffffff;">&#160;million and </span><span style="background:#ffffff;">$1.5</span><span style="background:#ffffff;"> million, respectively, of royalty revenue from Grifols, and such amount was included within contract revenues from collaboration.&#160;</span>No<span style="background:#ffffff;">&#160;such revenue was recognized for the three and six months ended June 30, 2022.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">Kissei License Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We have an exclusive license and supply agreement with Kissei entered in October 2018, to develop and commercialize fostamatinib in all current and potential indications in Kissei&#8217;s territory. Kissei is responsible for performing and funding all development activities for fostamatinib in the above-mentioned territories. We received an upfront cash payment of $33.0&#160;million, with the potential for up to an additional $147.0&#160;million <span style="white-space:pre-wrap;">in development, regulatory and commercial milestone payments, and will receive mid- to upper twenty percent, tiered, escalated net sales-based payments for the supply of fostamatinib. Under the agreement, we granted Kissei the license rights to fostamatinib in Kissei&#8217;s territory and are obligated to supply Kissei with drug product for use in clinical trials and pre-commercialization activities. We are also responsible for the manufacture and supply of fostamatinib for all future development and commercialization activities under the agreement.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;">We accounted for this agreement under ASC 606 and identified the following distinct performance obligations at inception of the agreement: (a) granting of the license, (b) supply of fostamatinib for clinical use and (c) material right associated with discounted fostamatinib that is supplied for use other than clinical or commercial. In addition, we will provide commercial product supply if the product is approved in the licensed territory. We concluded that each of these performance obligations is distinct. We determined that the upfront fee of $33.0&#160;million represented the transaction price and was allocated to the performance obligations based on our best estimate of the relative standalone selling price and recognized the corresponding revenue in the period we satisfied the performance obligations. As of June 30, 2023 and December 31, 2022, the remaining deferred revenue was related to the material right associated with discounted fostamatinib supply which amounted to $1.4&#160;million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;">For the three and six months ended June 30, 2022, we recognized $2.5&#160;million and $2.6&#160;million, respectively, of revenue related to the delivery of fostamatinib supply to Kissei mainly for commercial use.&#160;No&#160;such revenue was recognized during the three and six months ended June 30, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;">In April 2022, Kissei announced that an NDA was submitted to Japan&#8217;s Pharmaceuticals and Medical Devices Agency (PMDA) for fostamatinib in chronic ITP. With this milestone event, we received&#160;</span><span style="font-size:10pt;">$5.0</span><span style="font-size:10pt;">&#160;million non-refundable and non-creditable payment from Kissei pursuant to the terms of our collaboration agreement, and such amount was recognized as revenue in the three and six months ended </span><span style="font-size:10pt;">June 30, 2022</span><span style="font-size:10pt;">. In December 2022, Kissei announced that Japan&#8217;s PMDA approved the NDA for fostamatinib in chronic ITP. With this milestone event, we were entitled to receive </span><span style="font-size:10pt;">$20.0</span><span style="font-size:10pt;"> million non-refundable and non-creditable payment from Kissei pursuant to the terms of our collaboration agreement, which we recognized as revenue in the fourth quarter of </span><span style="-sec-ix-hidden:Hidden_sIEQoBwV_0WCfNDnOrc4Wg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2022</span></span><span style="font-size:10pt;white-space:pre-wrap;">. The amount was subsequently collected in January 2023.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The remaining variable consideration related to future development and regulatory milestones was fully constrained because we cannot conclude that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur, given the inherent uncertainty of success with these future milestones. For sales-based milestones and tiered, escalated net sales-based payments for the supply of fostamatinib, we determined that the license is the predominant item to which the sales-based milestones relate to. Accordingly, we will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the allocated costs for the tiered, escalated net sales-based payments has been satisfied (or partially satisfied). We will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 0pt 0pt;"><i style="font-style:italic;">Medison Commercial and License Agreements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 0pt 0pt;">We have two exclusive commercial and license agreements with Medison entered in October 2019 for the commercialization of fostamatinib for chronic ITP in Medison territory, pursuant to which, we received a $5.0 million upfront payment with respect to the agreement in Canada. We accounted for this agreement under ASC 606 and identified the following combined performance obligations at inception of the agreement: (a) granting of the license and (b) obtaining regulatory approval in Canada of fostamatinib in ITP. We determined that the non-refundable upfront fee of $5.0&#160;million represented the transaction price. However, under the agreement, we have the option to buy back all rights to the product in Canada within six months from obtaining regulatory approval for the treatment of AIHA in Canada. The buyback option precludes us from transferring control of the license to Medison under ASC 606. We believed that the buyback provision, if exercised, will require us to repurchase the license at an amount equal to or more than the upfront $5.0 million. As such, this arrangement was accounted for as a financing arrangement. Interest expense </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">was accreted on such liability over the expected buyback period. We also billed Medison for the delivery of fostamatinib supplies for clinical use which we previously deferred and included within the outstanding financing liability considering the buy-back provision.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 0pt 0pt;">The decision to exercise the buyback option is dependent of many factors including management&#8217;s cost and benefit assessments and the success of obtaining regulatory approval for the treatment of AIHA in Canada. In June 2022, we reported the top-line results from our Phase 3 trial of fostamatinib in warm autoimmune hemolytic anemia (wAIHA) which showed that the trial did not demonstrate statistical significance in the primary efficacy endpoint in the overall study population. We also announced in early October 2022 that we will not file a supplemental new drug application (sNDA) for wAIHA indication considering the top-line data results and the guidance received from the FDA. With these developments, we assessed our options path forward, including our buyback option right with regards to the Medison license agreement. Based on management&#8217;s assessment, the likelihood of exercising the buy-back option right was remote. As such, during the fourth quarter of 2022, we relieved the outstanding financing liability to Medison amounting to $5.7 million and recognized such amount as collaboration revenue in accordance with ASC 606. There was no outstanding financing liability to Medison as of June 30, 2023 and December 31, 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 0pt 0pt;"><i style="font-style:italic;">Knight Commercial License and Supply Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">We have a commercial license and supply agreements with Knight entered in May 2022 for the commercialization of fostamatinib for approved indications in Knight territory. Pursuant to such commercial license agreement, we received a $2.0 million one-time, non-refundable, and non-creditable upfront payment, with potential for up to an additional $20.0 million in regulatory and sales-based commercial milestone payments, and will receive twenty- to mid-thirty percent, tiered, escalated net-sales based royalty payments for products sold in the Knight territory. We accounted for this agreement under ASC 606 and identified that the upfront payment was a consideration for granting Knight the license to commercialize fostamatinib for approved indication in the Knight territory, and no further material deliverables associated to such upfront payment. As such, we recognized the upfront payment as revenue during the three and six months ended June 30, 2022. Variable consideration related to future regulatory milestones was fully constrained because we cannot conclude that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur, given the inherent uncertainty of success with these future milestones. For sales-based milestones and royalties, we determined that the license is the predominant item to which the royalties or sales-based milestones relate to. Accordingly, we will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all the royalty has been allocated has been satisfied (or partially satisfied). We will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur. We are also responsible for the exclusive manufacture and supply of fostamatinib for all future development and commercialization activities under agreement.&#160; </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Government Contract - US Department of Defense&#8217;s JPEO-CBRND </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">In January 2021, we were awarded up to $16.5&#160;million by the US Department of Defense to support our ongoing Phase 3 clinical trial to evaluate the safety and efficacy of fostamatinib for the treatment of hospitalized high-risk patients with COVID-19. The amount of award we will receive from the US Department of Defense is subject to submission of proper documentation as evidence of completion of certain clinical trial events or milestones as specified in the agreement, and approval by the US Department of Defense that such events or milestones have been met. We record government contract revenue in the statement of operations in the period when it is probable that we will receive the award, which is when we comply with the conditions associated with the award and obtain approval from the US Department of Defense that such conditions have been met. For the three and six months ended June 30, 2023, we recognized $1.0 million of revenue related to this grant upon achievement of certain milestones. Through June 30, 2023, we received $16.0 million of the awards which we recognized as revenue in the respective periods, with remaining $0.5 million available, subject to us meeting certain milestone and approval by the US Department of Defense that such milestone has been met, as specified in the agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">License and Transition Services Agreement with Forma (now Novo Nordisk) </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We have a license and transition services agreement with Forma (now Novo Nordisk) entered in July 2022, for an exclusive license to develop, manufacture and commercialize olutasidenib, a proprietary inhibitor of mutated IDH1 (mIDH1), for any uses worldwide, including for the treatment of AML and other malignancies. Forma became a wholly owned subsidiary of Novo Nordisk following the closing of its acquisition by Novo Nordisk in October 2022. Pursuant to the terms of the license and transition services agreement, we paid an upfront fee of $2.0 million, with the potential to pay up to $67.5 million of additional payments upon achievement of specified development and regulatory milestones and up to $165.5 million of additional payments upon achievement of certain commercial milestones. <span style="background:#ffffff;">In addition, subject to the terms and conditions of the license and transition services agreement, Forma (now Novo Nordisk) would be entitled to tiered royalty payments on net sales of licensed products at percentages ranging from low-teens to mid-thirties, as well as certain portion of our sublicensing revenue, subject to certain standard reductions and offsets.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">The transaction was accounted for as an acquisition of asset under ASC 730, <i style="font-style:italic;">Research and Development</i>. In accordance with the guidance, in a transaction accounted for as an asset acquisition, any acquired IPR&amp;D that does not have alternative future use is charged to expense at the acquisition date. <span style="background:#ffffff;">At the acquisition date, the acquired license asset was accounted for as IPR&amp;D, and we anticipated no other economic benefit to be derived from such acquired licensed asset other than the primary indications. As such, we accounted for the upfront fee of </span><span style="background:#ffffff;">$2.0</span><span style="background:#ffffff;"> million </span>as IPR&amp;D and recorded such cost within research and development expense in the condensed statements of operations in the third quarter of 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"><span style="font-size:10pt;">Under the accounting guidance, we account for contingent </span><span style="font-size:10pt;background:#ffffff;">cash payments when it is probable that a liability is incurred and the amount can be reasonably estimated.&#160;We account for m</span><span style="font-size:10pt;white-space:pre-wrap;">ilestone payment obligations incurred at development stage and prior to a regulatory approval of an indication associated with the acquired licensed asset as research and development expense when the event requiring payment of the milestone occurs. Milestone payment obligations incurred upon and after a regulatory approval of an indication associated with the acquired licensed asset, and at the commercial stage, are recorded as intangible asset when the event requiring payment of the milestones occurs. The amount recorded as intangible asset is amortized over the estimated useful life of the acquired licensed asset. Royalty payments related to the acquired licensed asset is recorded as cost of sales when incurred. Prior to the FDA approval of REZLIDHIA in December 2022, we achieved certain regulatory milestone which entitled Forma (now Novo Nordisk) to receive a  </span><span style="font-size:10pt;">$2.5</span><span style="font-size:10pt;"> million milestone payment. Because such milestone payment obligation was incurred prior to a regulatory approval of an indication associated with the acquired licensed asset, we recorded such amount as research and development expense in the fourth quarter of 2022. On December 1, 2022, the FDA approved REZLIDHIA capsules for the treatment of adult patients with R/R AML with susceptible IDH1 mutations as detected by an FDA-approved test. Following the FDA approval, we launched REZLIDHIA and made first shipments of the product to our customers in December 2022. With this FDA approval and first commercial sale of the product, Forma (now Novo Nordisk) was entitled to receive a total of </span><span style="font-size:10pt;">$15.0</span><span style="font-size:10pt;"> million milestone payments. Since such milestone payment obligations were incurred upon and after regulatory approval of the product, we recorded such amount as intangible asset on our condensed balance sheet in the fourth quarter of 2022. The </span><span style="font-size:10pt;">$15.0</span><span style="font-size:10pt;"> million milestone payment obligation was outstanding as of December 31, 2022 and included within accounts payable in our condensed balance sheet. Such amount was paid in the first quarter of </span><span style="-sec-ix-hidden:Hidden_Muf8QwRdCECWl-UXgvN83Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2023</span></span><span style="font-size:10pt;">. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">During the three and six months ended June 30, 2023, we recognized $0.3 million and $0.5 million, respectively, of amortization of intangible asset, and $0.4 million and $0.6 million, respectively, of royalty expense related to the license and transition services agreement as discussed above. Such costs were included within cost of sales in our condensed statements of operations. No such expenses were recognized during the three and six months ended June 30, 2022. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_CorporateCollaborationsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Corporate Collaborations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_CorporateCollaborationsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140108316830576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>STOCK-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-size:10pt;font-weight:bold;">5.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-size:10pt;font-weight:bold;">Stock-Based Compensation</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Stock-based compensation for the periods presented was as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:97.21%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:20.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Selling, general and administrative</p></td><td style="vertical-align:bottom;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,796</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,933</p></td><td style="vertical-align:bottom;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,531</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,672</p></td></tr><tr><td style="vertical-align:bottom;width:54.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 376</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 458</p></td><td style="vertical-align:bottom;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,399</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 926</p></td></tr><tr><td style="vertical-align:bottom;width:54.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total stock-based compensation expense</p></td><td style="vertical-align:bottom;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,172</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,391</p></td><td style="vertical-align:bottom;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,930</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,598</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Stock-based compensation expense within research and development in the six months ended June 30, 2023 include an incremental charge of approximately $0.5 million from stock option modifications recorded in the first quarter of 2023 related to the acceleration of vesting and extension of exercise period of vested stock option grants made to a former officer whose employment ended in March 2023. Stock-based compensation expense within selling, general and administrative in the six months ended June 30, 2022 include an incremental charge of approximately $0.8 million from stock option modifications recorded in the first quarter of 2022 related to the extension of the exercise period of the stock option grants made to our two former Board of Directors whose terms expired in May 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">During the six months ended June 30, 2023, we granted stock options to purchase 2,938,600 shares of common stock with weighted-average grant-date fair value of $1.37 per share, and 15,557 stock options were exercised. As of June 30, 2023, there were 35,244,121 stock options outstanding, of which, 2,870,000 are outstanding performance-based stock options wherein the achievement of the corresponding corporate-based milestones were not considered probable as of June 30, 2023. Accordingly, none of the $5.3 million grant date fair value for these awards has been recognized as stock-based compensation expense as of June 30, 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">The fair value of each option award is estimated on the date of grant using the Black-Scholes option pricing model. The following table summarizes the weighted-average assumptions relating to options granted pursuant to our Equity Incentive Plans (2018 Equity Incentive Plan and Inducement Plan) for the periods presented:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:92.03%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td><td colspan="4" style="vertical-align:bottom;width:24.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">3.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">2.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">3.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">1.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:46.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="font-size:10pt;">6.7</span></p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="font-size:10pt;">6.5</span></p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="font-size:10pt;">7.0</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="font-size:10pt;">6.5</span></p></td><td style="vertical-align:bottom;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dividend yield</p></td><td style="vertical-align:bottom;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:46.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">86.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">70.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">83.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">70.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"><span style="font-size:10pt;">During the six months ended June 30, 2023, we granted </span><span style="font-size:10pt;">1,387,600</span><span style="font-size:10pt;"> </span><span style="font-size:10pt;background:#ffffff;">RSUs </span><span style="font-size:10pt;">with a grant-date weighted-average fair value of </span><span style="font-size:10pt;">$1.80</span><span style="font-size:10pt;"> per share, and </span><span style="font-size:10pt;">435,006</span><span style="font-size:10pt;"> RSUs were released. The RSUs granted generally vest over </span><span style="font-size:10pt;">4 years</span><span style="font-size:10pt;">. As of June 30, 2023, there were </span><span style="font-size:10pt;">1,963,487</span><span style="font-size:10pt;"> RSUs outstanding.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-bottom:12pt;text-indent:36pt;margin:12pt 0pt 0pt 0pt;"><span style="font-size:10pt;">As of June 30, 2023, there was approximately </span><span style="font-size:10pt;">$14.6</span><span style="font-size:10pt;"> million </span><span style="font-size:10pt;">of unrecognized stock-based compensation cost which is expected to be recognized over a remaining weighted-average period of </span><span style="-sec-ix-hidden:Hidden_gNM8FB3j1EmiM03O-NFNhA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.68</span></span><span style="font-size:10pt;"> years, related to time-based stock options, performance-based stock options wherein achievement of the corresponding corporate-based milestones was considered as probable, and RSUs. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;">In April 2023, our Board of Directors approved additional 108,600 shares of common stock reserved for issuance under our Inducement Plan. In May 2023, our stockholders approved an amendment to our 2018 Plan, to, among other items, add an additional&#160;4,000,000&#160;shares&#160;to the number of shares of common stock authorized for issuance under our 2018 Plan. As of June 30, 2023, there were 12,186,098 shares of common stock available for future grant under our Equity Incentive Plans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Employee Stock Purchase Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;">Our Purchase Plan provides for a </span><span style="-sec-ix-hidden:Hidden_PQsDUEtR7km_2RPzqyzkJA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">24</span></span><span style="font-size:10pt;">-month offering period comprises </span><span style="font-size:10pt;">four</span><span style="font-size:10pt;"> </span><span style="font-size:10pt;">six-month</span><span style="font-size:10pt;"> purchase periods with a look-back option. A look-back option is a provision in our Purchase Plan under which eligible employees can purchase shares of our common stock at a price per share equal to the lesser of </span><span style="font-size:10pt;">85%</span><span style="font-size:10pt;"> of the fair market value on the first day of the offering period or </span><span style="font-size:10pt;">85%</span><span style="font-size:10pt;"> of the fair market value on the purchase date. </span><span style="font-size:10pt;">Our Purchase Plan also includes a feature that provides for a new offering period to begin when the fair market value of our common stock on any purchase date during an offering period falls below the fair market value of our common stock on the first day of such offering period. This feature is called a &#8220;reset.&#8221; Participants are automatically enrolled in the new offering period. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:12pt 0pt 0pt 0pt;"><span style="font-size:10pt;">Our previous </span><span style="-sec-ix-hidden:Hidden_zvVmLYm5wkGT80D-sHpXHw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">24</span></span><span style="font-size:10pt;">-month offering period under our Purchase Plan ended on June 30, 2022, and a new twenty-four-month offering period started on July 1, 2022. </span><span style="font-size:10pt;">The fair value of awards under our Purchase Plan is estimated on the date of our new offering period using the Black-Scholes option pricing model, which is being amortized over the requisite service periods. </span><span style="font-size:10pt;">As of June 30, 2023, unrecognized stock-based compensation cost related to our Purchase Plan amounted to </span><span style="font-size:10pt;">$0.4</span><span style="font-size:10pt;"> million, which is expected to be recognized over the remaining weighted average period of </span><span style="-sec-ix-hidden:Hidden_uq0rUsBH7E2jbRn6gMjYeg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">0.74</span></span><span style="font-size:10pt;"> years.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">During the six months ended June 30, 2023, there were 509,190 shares purchased under the Purchase Plan. As of June 30, 2023, there were 2,928,443 shares reserved for future issuance under the Purchase Plan.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140108314079808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:12pt;"><b style="font-size:10pt;font-weight:bold;">6.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:12pt;"><b style="font-size:10pt;font-weight:bold;">Inventories</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Inventories for the periods presented consist of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:98.15%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="color:#0563c1;font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="color:#0563c1;font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:10.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="vertical-align:bottom;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">6,878 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">4,555 </p></td></tr><tr><td style="vertical-align:bottom;width:74.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Work in process</p></td><td style="vertical-align:bottom;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">2,046 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">2,659 </p></td></tr><tr><td style="vertical-align:bottom;width:74.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="vertical-align:bottom;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">1,858 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">1,904 </p></td></tr><tr><td style="vertical-align:bottom;width:74.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">10,782 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">9,118 </p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:12pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="font-size:10pt;">Inventories as of June 30, 2023 and December 31, 2022 include inventories acquired from Forma (now Novo Nordisk) pursuant to the license and transition agreement. As of June 30, 2023 and December 31, 2022, we have </span><span style="font-size:10pt;">$0.7</span><span style="font-size:10pt;"> million and </span><span style="font-size:10pt;">$0.8</span><span style="font-size:10pt;"> million, respectively, in advance payments to the manufacturer of our raw materials, which were included within prepaid and other current assets in the condensed balance sheet.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140108311113632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock', window );">CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">7.</b></span><b style="font-weight:bold;">Cash, Cash Equivalents and Short-Term Investments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Cash, cash equivalents and short-term investments for the periods presented consist of the following (in thousands): </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:97.59%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.64%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash</p></td><td style="vertical-align:bottom;width:0.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">8,794 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 6,264</p></td></tr><tr><td style="vertical-align:bottom;width:73.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Money market funds</p></td><td style="vertical-align:bottom;width:0.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">21,109 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,155</p></td></tr><tr><td style="vertical-align:bottom;width:73.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">US treasury bills</p></td><td style="vertical-align:bottom;width:0.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 8,953</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,225</p></td></tr><tr><td style="vertical-align:bottom;width:73.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Government-sponsored enterprise securities</p></td><td style="vertical-align:bottom;width:0.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">15,584 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 15,796</p></td></tr><tr><td style="vertical-align:bottom;width:73.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate bonds and commercial paper</p></td><td style="vertical-align:bottom;width:0.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">9,917 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 26,766</p></td></tr><tr><td style="vertical-align:bottom;width:73.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">64,357 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 58,206</p></td></tr><tr><td style="vertical-align:bottom;width:73.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Reported as:</p></td><td style="vertical-align:bottom;width:0.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;width:0.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">48,812 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 24,459</p></td></tr><tr><td style="vertical-align:bottom;width:73.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term investments</p></td><td style="vertical-align:bottom;width:0.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">15,545 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 33,747</p></td></tr><tr><td style="vertical-align:bottom;width:73.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">64,357 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">58,206 </p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Cash equivalents and short-term investments include the following securities with gross unrealized gains and losses (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:97.7%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">As of June 30, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">US treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 8,951</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 8,953</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Government-sponsored enterprise securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 15,607</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (25)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 15,584</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate bonds and commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 9,921</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 9,917</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 34,479</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (29)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 34,454</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:98.34%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">As of December 31, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">US treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,251</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (26)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,225</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Government-sponsored enterprise securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 15,882</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (87)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 15,796</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate bonds and commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 26,807</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (41)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 26,766</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 47,940</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (154)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 47,787</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"><span style="font-size:10pt;">As of June 30, 2023 and December 31, 2022, our cash equivalents and short-term investments had a weighted-average time to maturity of approximately </span><span style="font-size:10pt;">72 days</span><span style="font-size:10pt;"> and </span><span style="font-size:10pt;">89 days</span><span style="font-size:10pt;">, respectively. </span><span style="font-size:10pt;background:#ffffff;">Our short-term investments are classified as available-for-sale securities. Accordingly, we have classified certain securities as short-term investments on our condensed balance sheets as they are available for use in the current operations. </span><span style="font-size:10pt;">As of </span><span style="font-size:10pt;">June 30, 2023, we had </span><span style="-sec-ix-hidden:Hidden_ut8FmrekU0qEihlZMrnsbQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">no</span></span><span style="font-size:10pt;"> investments that had been in a continuous unrealized loss position for more than 12 months. As of June 30, 2023, a total of </span><span style="font-size:10pt;">19</span><span style="font-size:10pt;"> individual securities had been in an unrealized loss position for 12 months or less, and the losses were determined to be temporary. No significant facts or circumstances have arisen to indicate that there has been any significant deterioration in the creditworthiness of the issuers of the securities held by us. Based on our review of these securities, including the assessment of the duration and severity of the unrealized losses, we have </span><span style="font-size:10pt;">no</span><span style="font-size:10pt;">t recognized any credit losses on these securities as of June 30, 2023 and December 31, 2022.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table shows the fair value and gross unrealized losses of our investments in individual securities that are in an unrealized loss position, aggregated by investment category (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:91.47%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">As of June 30, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:8.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Government-sponsored enterprise securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,576</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (26)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate bonds and commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,950</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,526</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (29)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the components of cash, cash equivalents, and short-term investments. Short-term investments may include current marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140108310935056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-size:10pt;font-weight:bold;">8.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-size:10pt;font-weight:bold;">Fair Value</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The table below summarizes the fair value of our cash equivalents and short-term investments measured at fair value on a recurring basis, and are categorized based upon the lowest level of significant input to the valuations (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:98.74%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Assets&#160;at&#160;Fair&#160;Value&#160;as&#160;of&#160;June 30, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 21,109</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 21,109</p></td></tr><tr><td style="vertical-align:bottom;width:49.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">US treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 8,953</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 8,953</p></td></tr><tr><td style="vertical-align:bottom;width:49.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Government-sponsored enterprise securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 15,584</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 15,584</p></td></tr><tr><td style="vertical-align:bottom;width:49.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate bonds and commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 9,917</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 9,917</p></td></tr><tr><td style="vertical-align:bottom;width:49.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 21,109</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 34,454</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 55,563</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Assets&#160;at&#160;Fair&#160;Value&#160;as&#160;of December 31, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,155</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,155</p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">US treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,225</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,225</p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Government-sponsored enterprise securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 15,796</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 15,796</p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate bonds and commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 26,766</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 26,766</p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,155</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 47,787</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 51,942</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140108395091808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>DEBT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">DEBT</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">9.</b></span><b style="font-weight:bold;">Debt</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">We have a Credit and Security Agreement (Credit Agreement) with MidCap Financial Trust (MidCap) entered on September 27, 2019 (Closing Date) and amended on March 29, 2021 (First Amendment), February 11, 2022 (Second Amendment) and July 27, 2022 (Third Amendment). The Credit Agreement provides for a $60.0&#160;million term loan credit facility. At the Closing Date, $10.0 million was funded (Tranche 1), in May 2020, an additional $10.0 million was funded (Tranche 2), at the Second Amendment, an additional $10.0 million was funded (Tranche 3), at the Third Amendment, an additional $10.0 million was funded (Tranche 4), and in March 2023, an additional $20.0 million was funded (Tranche 5). As of June 30, 2023, the outstanding principal balance of the loan was $60.0 million, and no remaining funds are available for draw under the term loan credit facility. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">The First Amendment to the Credit Agreement extended the period through which Tranche 3 was available to us. The Second Amendment to the Credit Agreement, among other things, amended the applicable funding conditions, applicable commitments and certain other terms relating to available credit facilities (Tranches 3 and 4), added additional term loan credit facility (Tranche 5), and revised certain terms related to the financial covenants. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"><span style="font-size:10pt;">Following the Third Amendment, the maturity date for the term loans is on September 1, 2026, and the interest-only period is through October 1, 2024. </span><span style="font-size:10pt;background:#ffffff;">The interest rate applicable to the term loans under the amended Credit Agreement is the sum of one-month </span><span style="font-size:10pt;">Secured Overnight Financing Rate (SOFR)</span><span style="font-size:10pt;background:#ffffff;">, plus an adjustment of </span><span style="font-size:10pt;background:#ffffff;">0.11448%</span><span style="font-size:10pt;background:#ffffff;">, subject to </span><span style="font-size:10pt;background:#ffffff;">1.50%</span><span style="font-size:10pt;background:#ffffff;"> applicable floor, plus applicable margin of&#160;</span><span style="font-size:10pt;background:#ffffff;">5.65%</span><span style="font-size:10pt;background:#ffffff;">. A</span><span style="font-size:10pt;"> final payment fee of </span><span style="font-size:10pt;">2.5%</span><span style="font-size:10pt;"> of principal is due at maturity date of the term loans. Prior to the Third Amendment, the outstanding principal balance of the loan bore interest at an annual rate of one-month London Interbank Offered Rate (LIBOR), </span><span style="font-size:10pt;background:#ffffff;">or a comparable applicable index rate, </span><span style="font-size:10pt;">plus applicable margin of </span><span style="font-size:10pt;">5.65%</span><span style="font-size:10pt;">, subject to a LIBOR floor of </span><span style="font-size:10pt;">1.50%</span><span style="font-size:10pt;"> and is payable monthly in arrears. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"><span style="background:#ffffff;">We </span>may make voluntary prepayments, in whole or in part, subject to certain prepayment premiums and additional interest payments. The Credit Agreement also contains certain provisions, such as event of default and change in control provisions, which, if triggered, would require us to make mandatory prepayments on the term loan, which are subject to certain prepayment premiums and additional interest payments. The obligations under the amended Credit Agreement are secured by a perfected security interest in all of our assets including our intellectual property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Debt issuance costs are recorded as a direct deduction from the outstanding principal balance of the term loan. As of June 30, 2023 and December 31, 2022, the unamortized issuance costs and debt discounts amounted to $0.4 million and $0.6 million, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Interest expense, including amortization of the debt discount and accretion of the final fees related to the Credit Agreement for the three months ended June 30, 2023 and 2022 was $1.9 million and $0.6 million, respectively, and for the six months ended June 30, 2023 and 2022 was $3.1 million and $1.1 million, respectively. Accrued interest of $1.2 million was included within other accrued liabilities in the condensed balance sheet as of June 30, 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">The following table presents the future minimum principal payments of the outstanding loan as of June 30, 2023 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:72.33%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:61.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:27.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Remainder of 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 7,500</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 30,000</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 22,500</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Principal amount (Tranches 1, 2, 3 and 4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 60,000</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The amended Credit Agreement contains certain covenants which, among others, require us to deliver financial reports at designated times of the year and maintain minimum unrestricted cash and trailing net revenues. As of June 30, 2023, we were not in violation of any covenants.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140108313863168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>LEASES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_LeaseDisclosureTextBlock', window );">LEASES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">10.</b></span><b style="font-weight:bold;">Leases</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"><span style="font-size:10pt;background:#ffffff;">We have a sublease agreement with Atara Biotherapeutics, Inc. (Atara) entered in October 2022 to sublease an office space located in South San Francisco, California. Subject to the terms of the sublease agreement, the lease term commenced in November 2022 and shall expire in May 2025. This leased facility is currently held as our new headquarters following the expiration of our previously leased facility in January 2023. At lease measurement date in the fourth quarter of 2022, we recognized the operating lease right-of-use asset and lease </span><span style="-sec-ix-hidden:Hidden_WC8UdES80kWQ1oTf-c3WYQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">liability</span></span><span style="font-size:10pt;background:#ffffff;"> of approximately </span><span style="font-size:10pt;background:#ffffff;">$1.3</span><span style="font-size:10pt;background:#ffffff;"> million. </span><span style="font-size:10pt;">As of June 30, 2023, we recorded </span><span style="font-size:10pt;">$0.2</span><span style="font-size:10pt;"> million of lease incentives from our sublease with Atara, which we recorded as a reduction to operating lease right-of-use asset and lease liability until the lease ends and the asset is transferred. The weighted average remaining term of our leases as of June 30, 2023 was </span><span style="-sec-ix-hidden:Hidden_V6j-ReLR3UOlKbpOTUVtAQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.92</span></span><span style="font-size:10pt;"> years. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">We had a lease agreement with Healthpeak Properties, Inc. (formerly known as HCP BTC, LLC), to occupy research and office space located in South San Francisco, California and a sublease agreement with an unrelated third-party to sublet a portion of the leased facility. Both leases expired in January 2023.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">The components of our operating lease expense were as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:94.39%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:41.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:27.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fixed operating lease expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 166</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,340</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 778</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,680</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Variable operating lease expense (net credit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (42)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 125</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 30</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 391</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total operating lease expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 124</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,465</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 808</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,071</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Supplemental information related to our operating lease were as follow (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:94.58%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:41.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:28.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash payments included in the measurement of operating lease liabilities</p></td><td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 178</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,630</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,174</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,226</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Supplemental information related to our operating sublease was as follow (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:94.15%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:41.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:27.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fixed sublease expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,095</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 365</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,190</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Variable sublease expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 206</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 77</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 450</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sublease income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,301)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (442)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,640)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_if_nK6gayEetouowdVil5w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_v_fUsNyOv0y60ttHM-hoPg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_n4oiXcFrkUefbhZElnx3QQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_RzHufXubkkibtQabd8gePg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table presents the future lease payments as of June 30, 2023 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:63.06%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:73.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Remainder of 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 360</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 739</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 301</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total minimum payments required</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,400</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_LeaseDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of information about leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_LeaseDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140108311059136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:9pt 0pt 9pt 18pt;"><span style="font-style:italic;font-weight:bold;">Basis of Presentation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Our accompanying unaudited condensed financial statements have been prepared in accordance with United States generally accepted accounting principles (US GAAP), for interim financial information and pursuant to the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities Act of 1933, as amended (Securities Act). Accordingly, they do not include all the information and notes required by US GAAP for complete financial statements. These unaudited condensed financial statements include only normal and recurring adjustments that we believe are necessary to fairly state our financial position and the results of our operations and cash flows. Interim-period results are not necessarily indicative of results of operations or cash flows for a full-year or any subsequent interim period. The balance sheet as of December 31, 2022 has been derived from audited financial statements at that date but does not include all disclosures required by US GAAP for complete financial statements. Because certain disclosures required by US GAAP for complete financial statements are not included herein, these interim unaudited condensed financial statements and the notes accompanying them should be read in conjunction with our audited financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC on March 7, 2023.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-indent:36pt;margin:9pt 0pt 0pt 0pt;">The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results could differ from these estimates.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_LiquidityAndCapitalResourcesPolicyPolicyTextBlock', window );">Liquidity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Liquidity</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-indent:36pt;background:#ffffff;margin:0pt;">As of June 30, 2023, we had approximately $64.4 million in cash, cash equivalents and short-term investments. Since inception, we have financed our operations primarily through sales of equity securities, debt financing, contract payments under our collaboration agreements and from product sales. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-indent:36pt;background:#ffffff;margin:0pt;">Based on our current operating plan, we believe that our existing cash, cash equivalents, and short-term investments will be sufficient to fund our expenses and capital expenditure requirements for at least the next 12 months from the date of issuance of this Form 10-Q.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Standards</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Recently Issued Accounting Standards </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt 0pt 9pt 0pt;">Recently issued accounting guidance is either not applicable or did not have, or is not expected to have, a material impact to us. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_LiquidityAndCapitalResourcesPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for liquidity and capital resources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_LiquidityAndCapitalResourcesPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140108316830576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>NET LOSS PER SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of antidilutive securities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:93.39%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:23.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:21.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding stock options</p></td><td style="vertical-align:bottom;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">35,244 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">33,081 </p></td><td style="vertical-align:bottom;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">35,244 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">33,081 </p></td></tr><tr><td style="vertical-align:bottom;width:51.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">RSUs</p></td><td style="vertical-align:bottom;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">1,963 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">1,191 </p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">1,963 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">1,191 </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">37,207 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">34,272 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">37,207 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">34,272 </p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140108310929392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>REVENUES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of revenues disaggregated by category</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Revenues disaggregated by category were as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:41.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:41.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:26.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Product sales:</p></td><td style="vertical-align:bottom;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Gross product sales</p></td><td style="vertical-align:bottom;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">33,456 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">26,427 </p></td><td style="vertical-align:bottom;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">66,654 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">49,045 </p></td></tr><tr><td style="vertical-align:bottom;width:41.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Discounts and allowances</p></td><td style="vertical-align:bottom;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(9,575)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(7,877)</p></td><td style="vertical-align:bottom;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(19,028)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(14,298)</p></td></tr><tr><td style="vertical-align:bottom;width:41.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total product sales, net</p></td><td style="vertical-align:bottom;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 23,881</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 18,550</p></td><td style="vertical-align:bottom;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 47,626</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 34,747</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Revenues from collaborations:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">License revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,337</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">2,545 </p></td></tr><tr><td style="vertical-align:bottom;width:41.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Development milestones</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,000</p></td></tr><tr><td style="vertical-align:bottom;width:41.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Royalty, delivery of drug supplies and others</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">2,005 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">3,932 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">4,330 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">4,262 </p></td></tr><tr><td style="vertical-align:bottom;width:41.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total revenues from collaborations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,005</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 11,269</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,330</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 11,807</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Government contract</p></td><td style="vertical-align:bottom;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Total revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 26,886</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 29,819</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 52,956</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 46,554</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock', window );">Schedule of product revenue allowance and reserve categories</a></td>
<td class="text"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:38.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Chargebacks,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Government</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Discounts&#160;and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">and Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fees</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Rebates</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Returns</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance as of January 1, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 6,213</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,636</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,296</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 12,145</p></td></tr><tr><td style="vertical-align:bottom;width:38.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Provision related to current period sales</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 14,439</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,725</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 395</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 18,559</p></td></tr><tr><td style="vertical-align:bottom;width:38.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Credit or payments made during the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (13,139)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,765)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (116)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (17,020)</p></td></tr><tr><td style="vertical-align:bottom;width:38.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance as of June 30, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 7,513</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,596</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,575</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 13,684</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:38.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Chargebacks,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Government</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Discounts&#160;and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">and Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fees</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Rebates</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Returns</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance as of January 1, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,404</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,494</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,017</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 7,915</p></td></tr><tr><td style="vertical-align:bottom;width:38.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Provision related to current period sales</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 9,680</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,711</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 613</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 13,004</p></td></tr><tr><td style="vertical-align:bottom;width:38.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Credit or payments made during the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7,748)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,901)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (39)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (10,688)</p></td></tr><tr><td style="vertical-align:bottom;width:38.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance as of June 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,336</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,304</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,591</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 10,231</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_DisaggregationOfRevenueByCustomerTableTextBlock', window );">Schedule of revenues from product sales disaggregated by customers</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 6pt 0pt;">The following table summarizes the percentages of revenues from each of our customers who individually accounted for 10% or more of the total net product sales and revenues from collaborations:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:96.98%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:43.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:24.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">McKesson Specialty Care Distribution Corporation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">44%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">34%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">45%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">36%</p></td></tr><tr><td style="vertical-align:bottom;width:43.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cardinal Healthcare</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">28%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">16%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">26%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">20%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ASD Healthcare and Oncology Supply</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">19%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">12%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">21%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">19%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Kissei</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">25%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">16%</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_DisaggregationOfRevenueByCustomerTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue by customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_DisaggregationOfRevenueByCustomerTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 09<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140108311284672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of stock-based compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Stock-based compensation for the periods presented was as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:97.21%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:20.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Selling, general and administrative</p></td><td style="vertical-align:bottom;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,796</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,933</p></td><td style="vertical-align:bottom;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,531</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,672</p></td></tr><tr><td style="vertical-align:bottom;width:54.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 376</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 458</p></td><td style="vertical-align:bottom;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,399</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 926</p></td></tr><tr><td style="vertical-align:bottom;width:54.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total stock-based compensation expense</p></td><td style="vertical-align:bottom;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,172</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,391</p></td><td style="vertical-align:bottom;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,930</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,598</p></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of weighted-average assumptions relating to options granted pursuant to equity incentive plans</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:92.03%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td><td colspan="4" style="vertical-align:bottom;width:24.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">3.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">2.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">3.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">1.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:46.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="font-size:10pt;">6.7</span></p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="font-size:10pt;">6.5</span></p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="font-size:10pt;">7.0</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="font-size:10pt;">6.5</span></p></td><td style="vertical-align:bottom;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dividend yield</p></td><td style="vertical-align:bottom;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:46.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">86.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">70.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">83.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">70.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140108314093056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventories</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Inventories for the periods presented consist of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:98.15%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="color:#0563c1;font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="color:#0563c1;font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:10.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="vertical-align:bottom;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">6,878 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">4,555 </p></td></tr><tr><td style="vertical-align:bottom;width:74.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Work in process</p></td><td style="vertical-align:bottom;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">2,046 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">2,659 </p></td></tr><tr><td style="vertical-align:bottom;width:74.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="vertical-align:bottom;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">1,858 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">1,904 </p></td></tr><tr><td style="vertical-align:bottom;width:74.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">10,782 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">9,118 </p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140108311106016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Schedule of cash, cash equivalents and short-term investments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Cash, cash equivalents and short-term investments for the periods presented consist of the following (in thousands): </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:97.59%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.64%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash</p></td><td style="vertical-align:bottom;width:0.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">8,794 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 6,264</p></td></tr><tr><td style="vertical-align:bottom;width:73.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Money market funds</p></td><td style="vertical-align:bottom;width:0.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">21,109 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,155</p></td></tr><tr><td style="vertical-align:bottom;width:73.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">US treasury bills</p></td><td style="vertical-align:bottom;width:0.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 8,953</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,225</p></td></tr><tr><td style="vertical-align:bottom;width:73.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Government-sponsored enterprise securities</p></td><td style="vertical-align:bottom;width:0.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">15,584 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 15,796</p></td></tr><tr><td style="vertical-align:bottom;width:73.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate bonds and commercial paper</p></td><td style="vertical-align:bottom;width:0.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">9,917 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 26,766</p></td></tr><tr><td style="vertical-align:bottom;width:73.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">64,357 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 58,206</p></td></tr><tr><td style="vertical-align:bottom;width:73.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Reported as:</p></td><td style="vertical-align:bottom;width:0.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;width:0.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">48,812 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 24,459</p></td></tr><tr><td style="vertical-align:bottom;width:73.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term investments</p></td><td style="vertical-align:bottom;width:0.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">15,545 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 33,747</p></td></tr><tr><td style="vertical-align:bottom;width:73.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">64,357 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">58,206 </p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock', window );">Schedule of cash equivalents and short-term investments including securities with unrealized gains and losses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Cash equivalents and short-term investments include the following securities with gross unrealized gains and losses (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:97.7%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">As of June 30, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">US treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 8,951</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 8,953</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Government-sponsored enterprise securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 15,607</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (25)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 15,584</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate bonds and commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 9,921</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 9,917</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 34,479</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (29)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 34,454</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:98.34%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">As of December 31, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">US treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,251</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (26)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,225</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Government-sponsored enterprise securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 15,882</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (87)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 15,796</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate bonds and commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 26,807</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (41)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 26,766</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 47,940</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (154)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 47,787</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock', window );">Schedule of fair value and gross unrealized losses of investments in unrealized loss position</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table shows the fair value and gross unrealized losses of our investments in individual securities that are in an unrealized loss position, aggregated by investment category (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:91.47%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">As of June 30, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:8.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Government-sponsored enterprise securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,576</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (26)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate bonds and commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,950</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,526</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (29)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For all investments in an unrealized loss position, including those for which other-than-temporary impairments have not been recognized in earnings (including investments for which a portion of an other-than-temporary impairment has been recognized in other comprehensive income), a tabular disclosure of the aggregate related fair value of investments with unrealized losses and the aggregate amount of unrealized losses (that is, the amount by which amortized cost basis exceeds fair value).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of unrealized gains and losses on investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140108313851072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of financial assets measured at fair value on a recurring basis</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The table below summarizes the fair value of our cash equivalents and short-term investments measured at fair value on a recurring basis, and are categorized based upon the lowest level of significant input to the valuations (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:98.74%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Assets&#160;at&#160;Fair&#160;Value&#160;as&#160;of&#160;June 30, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 21,109</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 21,109</p></td></tr><tr><td style="vertical-align:bottom;width:49.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">US treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 8,953</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 8,953</p></td></tr><tr><td style="vertical-align:bottom;width:49.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Government-sponsored enterprise securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 15,584</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 15,584</p></td></tr><tr><td style="vertical-align:bottom;width:49.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate bonds and commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 9,917</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 9,917</p></td></tr><tr><td style="vertical-align:bottom;width:49.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 21,109</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 34,454</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 55,563</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Assets&#160;at&#160;Fair&#160;Value&#160;as&#160;of December 31, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,155</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,155</p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">US treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,225</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,225</p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Government-sponsored enterprise securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 15,796</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 15,796</p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate bonds and commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 26,766</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 26,766</p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,155</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 47,787</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 51,942</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140108313863168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>DEBT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock', window );">Schedule of future minimum payments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">The following table presents the future minimum principal payments of the outstanding loan as of June 30, 2023 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:72.33%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:61.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:27.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Remainder of 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 7,500</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 30,000</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 22,500</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Principal amount (Tranches 1, 2, 3 and 4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 60,000</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140108311555888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>LEASES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of components of operating lease expense</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">The components of our operating lease expense were as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:94.39%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:41.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:27.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fixed operating lease expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 166</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,340</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 778</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,680</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Variable operating lease expense (net credit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (42)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 125</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 30</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 391</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total operating lease expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 124</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,465</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 808</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,071</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_CashFlowInformationRelatedToOperatingLeaseTableTextBlock', window );">Schedule of supplemental information related to operating lease</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Supplemental information related to our operating lease were as follow (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:94.58%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:41.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:28.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash payments included in the measurement of operating lease liabilities</p></td><td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 178</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,630</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,174</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,226</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock', window );">Schedule of operating sublease information</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Supplemental information related to our operating sublease was as follow (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:94.15%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:41.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:27.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fixed sublease expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,095</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 365</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,190</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Variable sublease expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 206</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 77</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 450</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sublease income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,301)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (442)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,640)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_if_nK6gayEetouowdVil5w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_v_fUsNyOv0y60ttHM-hoPg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_n4oiXcFrkUefbhZElnx3QQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_RzHufXubkkibtQabd8gePg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of future minimum lease payments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table presents the future lease payments as of June 30, 2023 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:63.06%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:73.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Remainder of 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 360</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 739</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 301</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total minimum payments required</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,400</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_CashFlowInformationRelatedToOperatingLeaseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information related to operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_CashFlowInformationRelatedToOperatingLeaseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of components of income from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482964/270-10-50-6A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLeaseIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140108314056640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Basis of Presentation and Liquidity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents and short-term investments</a></td>
<td class="nump">$ 64,357<span></span>
</td>
<td class="nump">$ 58,206<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140108403986416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive securities excluded from the computation of diluted net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">37,207<span></span>
</td>
<td class="nump">34,272<span></span>
</td>
<td class="nump">37,207<span></span>
</td>
<td class="nump">34,272<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive securities excluded from the computation of diluted net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">35,244<span></span>
</td>
<td class="nump">33,081<span></span>
</td>
<td class="nump">35,244<span></span>
</td>
<td class="nump">33,081<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive securities excluded from the computation of diluted net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">1,963<span></span>
</td>
<td class="nump">1,191<span></span>
</td>
<td class="nump">1,963<span></span>
</td>
<td class="nump">1,191<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140108312091376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES - Disaggregated (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 26,886<span></span>
</td>
<td class="nump">$ 29,819<span></span>
</td>
<td class="nump">$ 52,956<span></span>
</td>
<td class="nump">$ 46,554<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rigl_GrossProductMember', window );">Gross product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">33,456<span></span>
</td>
<td class="nump">26,427<span></span>
</td>
<td class="nump">66,654<span></span>
</td>
<td class="nump">49,045<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rigl_DiscountsAndAllowancesMember', window );">Discounts and allowances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="num">(9,575)<span></span>
</td>
<td class="num">(7,877)<span></span>
</td>
<td class="num">(19,028)<span></span>
</td>
<td class="num">(14,298)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">23,881<span></span>
</td>
<td class="nump">18,550<span></span>
</td>
<td class="nump">47,626<span></span>
</td>
<td class="nump">34,747<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,545<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rigl_DevelopmentMilestonesMember', window );">Development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rigl_RoyaltyDeliveryOfDrugSuppliesAndOthersMember', window );">Royalty, delivery of drug supplies and others</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">2,005<span></span>
</td>
<td class="nump">3,932<span></span>
</td>
<td class="nump">4,330<span></span>
</td>
<td class="nump">4,262<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rigl_ContractRevenuesFromCollaborationsMember', window );">Contract revenues from collaborations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">2,005<span></span>
</td>
<td class="nump">$ 11,269<span></span>
</td>
<td class="nump">4,330<span></span>
</td>
<td class="nump">$ 11,807<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GovernmentContractMember', window );">Government contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rigl_GrossProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rigl_GrossProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rigl_DiscountsAndAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rigl_DiscountsAndAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rigl_DevelopmentMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rigl_DevelopmentMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rigl_RoyaltyDeliveryOfDrugSuppliesAndOthersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rigl_RoyaltyDeliveryOfDrugSuppliesAndOthersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rigl_ContractRevenuesFromCollaborationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rigl_ContractRevenuesFromCollaborationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GovernmentContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GovernmentContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140108310178128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES - Activity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance</a></td>
<td class="nump">$ 12,145<span></span>
</td>
<td class="nump">$ 7,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Provision related to current period sales</a></td>
<td class="nump">18,559<span></span>
</td>
<td class="nump">13,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Credit or payments made during the period</a></td>
<td class="num">(17,020)<span></span>
</td>
<td class="num">(10,688)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance</a></td>
<td class="nump">13,684<span></span>
</td>
<td class="nump">10,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_SalesDiscountsAndAllowances', window );">Discounts and allowances</a></td>
<td class="nump">18,600<span></span>
</td>
<td class="nump">13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">5,013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,485<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=rigl_AccountsReceivableAndPrepaidAndOtherCurrentAssetsMember', window );">Accounts receivable and prepaid and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_SalesDiscountsAndAllowances', window );">Discounts and allowances</a></td>
<td class="nump">400<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=rigl_ChargebacksDiscountsAndFeesMember', window );">Chargebacks, Discounts and Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance</a></td>
<td class="nump">6,213<span></span>
</td>
<td class="nump">3,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Provision related to current period sales</a></td>
<td class="nump">14,439<span></span>
</td>
<td class="nump">9,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Credit or payments made during the period</a></td>
<td class="num">(13,139)<span></span>
</td>
<td class="num">(7,748)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance</a></td>
<td class="nump">7,513<span></span>
</td>
<td class="nump">5,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=rigl_GovernmentAndOtherRebatesMember', window );">Government and Other Rebates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance</a></td>
<td class="nump">2,636<span></span>
</td>
<td class="nump">2,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Provision related to current period sales</a></td>
<td class="nump">3,725<span></span>
</td>
<td class="nump">2,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Credit or payments made during the period</a></td>
<td class="num">(3,765)<span></span>
</td>
<td class="num">(2,901)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance</a></td>
<td class="nump">2,596<span></span>
</td>
<td class="nump">2,304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember', window );">Returns</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance</a></td>
<td class="nump">3,296<span></span>
</td>
<td class="nump">2,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Provision related to current period sales</a></td>
<td class="nump">395<span></span>
</td>
<td class="nump">613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Credit or payments made during the period</a></td>
<td class="num">(116)<span></span>
</td>
<td class="num">(39)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance</a></td>
<td class="nump">$ 3,575<span></span>
</td>
<td class="nump">$ 2,591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_SalesDiscountsAndAllowances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sales discounts and allowances during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_SalesDiscountsAndAllowances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 09<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C(1)))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C(2)))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ValuationAndQualifyingAccountsDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=rigl_AccountsReceivableAndPrepaidAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=rigl_AccountsReceivableAndPrepaidAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=rigl_ChargebacksDiscountsAndFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=rigl_ChargebacksDiscountsAndFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=rigl_GovernmentAndOtherRebatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=rigl_GovernmentAndOtherRebatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140108310168336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES - Percentage by Customer (Details) - Sales - Customer Concentration Risk<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesMember', window );">McKesson Specialty Care Distribution Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage</a></td>
<td class="nump">44.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="nump">36.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesMember', window );">Kissei</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesMember', window );">Cardinal Healthcare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage</a></td>
<td class="nump">28.00%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesMember', window );">ASD Healthcare and Oncology Supply</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage</a></td>
<td class="nump">19.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=rigl_MckessonSpecialtyCareDistributionCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=rigl_MckessonSpecialtyCareDistributionCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=rigl_KisseiPharmaceuticalCo.Ltd.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=rigl_KisseiPharmaceuticalCo.Ltd.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=rigl_CardinalHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=rigl_CardinalHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=rigl_AsdHealthcareAndOncologySupplyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=rigl_AsdHealthcareAndOncologySupplyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140108298085456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SPONSORED RESEARCH AND LICENSE AGREEMENTS AND GOVERNMENT CONTRACT (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="7">1 Months Ended</th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">27 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 27, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 29, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2019 </div>
<div>USD ($) </div>
<div>agreement</div>
</th>
<th class="th">
<div>Jan. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>period</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_ContingentPaymentsUnderAgreement', window );">Contingent payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_RightToOptOutOfAgreementNumberOfPeriods', window );">Right to opt out of agreement, different specified times | period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_CollaborativeArrangementUpfrontFeeReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_PaymentOfCostShareToCollaborationPartner', window );">Payment of cost share to collaboration partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,754<span></span>
</td>
<td class="nump">$ 8,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_CollaborativeArrangementRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,861<span></span>
</td>
<td class="nump">30,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Intangible asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_AchievementOfMilestoneAxis=rigl_SpecifiedDevelopmentEventsMember', window );">Specified Development Events [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_ContingentPaymentsUnderAgreement', window );">Contingent payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">279,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_AchievementOfMilestoneAxis=rigl_SpecifiedRegulatoryEventsMember', window );">Specified Regulatory Events [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_ContingentPaymentsUnderAgreement', window );">Contingent payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">263,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_AchievementOfMilestoneAxis=rigl_SpecifiedProductLaunchEventsMember', window );">Specified Product Launch Events [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_ContingentPaymentsUnderAgreement', window );">Contingent payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">796,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_AchievementOfMilestoneAxis=rigl_DevelopmentAndRegulatoryMilestonesByNonCentralNervousSystemDiseaseProductsMember', window );">Development and regulatory milestones by non-CNS disease products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_ContingentPaymentsUnderAgreement', window );">Contingent payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">330,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_AchievementOfMilestoneAxis=rigl_DevelopmentAndRegulatoryMilestonesByNonCentralNervousSystemDiseaseProductsMember', window );">Development and regulatory milestones by non-CNS disease products | Milestone payments on a product-by-product basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_ContingentPaymentsUnderAgreement', window );">Contingent payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_AchievementOfMilestoneAxis=rigl_DevelopmentAndRegulatoryMilestonesByCentralNervousSystemDiseaseProductsMember', window );">Development and regulatory milestones by CNS disease products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_ContingentPaymentsUnderAgreement', window );">Contingent payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">255,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_AchievementOfMilestoneAxis=rigl_DevelopmentAndRegulatoryMilestonesByCentralNervousSystemDiseaseProductsMember', window );">Development and regulatory milestones by CNS disease products | Milestone payments on a product-by-product basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_ContingentPaymentsUnderAgreement', window );">Contingent payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=rigl_GrifolsS.a.Member', window );">Grifols</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_CollaborativeArrangementUpfrontFeeReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=rigl_GrifolsS.a.Member', window );">Grifols | Research Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_CollaborativeArrangementRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=rigl_GrifolsS.a.Member', window );">Grifols | Delivery of drug supply for commercialization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_CollaborativeArrangementRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=rigl_GrifolsS.a.Member', window );">Grifols | Commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_ContingentPaymentsUnderAgreement', window );">Contingent payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 297,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=rigl_KisseiPharmaceuticalCo.Ltd.Member', window );">Kissei</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_ContingentPaymentsUnderAgreement', window );">Contingent payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 147,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_CollaborativeArrangementUpfrontFeeReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=rigl_KnightTherapeuticsInternationalSaMember', window );">Knight | Commercial and license agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_CollaborativeArrangementUpfrontFeeReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=rigl_KnightTherapeuticsInternationalSaMember', window );">Knight | Maximum | Commercial milestones | Commercial and license agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_ContingentPaymentsUnderAgreement', window );">Contingent payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=rigl_FormaTherapeuticsHoldingsIncMember', window );">Forma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_CollaborativeArrangementUpfrontPayment', window );">Upfront fee</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=rigl_FormaTherapeuticsHoldingsIncMember', window );">Forma | Commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_CollaborativeArrangementPotentialPayments', window );">Potential payments</a></td>
<td class="nump">165,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=rigl_FormaTherapeuticsHoldingsIncMember', window );">Forma | Development and regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_CollaborativeArrangementPotentialPayments', window );">Potential payments</a></td>
<td class="nump">$ 67,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=rigl_FormaTherapeuticsHoldingsIncMember', window );">Forma | Achievement of certain near-term regulatory milestone.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rigl_FostamatinibMember', window );">fostamatinib</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_CollaborativeArrangementRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_GovernmentAward', window );">Government contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_GovernmentAwardExpectedToBeReceivedInSucceedingPeriods', window );">Remaining amount of government award expected to be received in succeeding periods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rigl_FostamatinibMember', window );">fostamatinib | Grifols</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Collaborative payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rigl_FostamatinibMember', window );">fostamatinib | Grifols | Upon EMA approval of fostamatinib for treatment of chronic ITP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_ContingentPaymentsUnderAgreement', window );">Contingent payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rigl_FostamatinibMember', window );">fostamatinib | Grifols | Creditable advance royalty payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Collaborative payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rigl_FostamatinibMember', window );">fostamatinib | Grifols | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_RoyaltyPaymentAsPercentageOfNetSales', window );">Royalty payment as a percentage of net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rigl_FostamatinibMember', window );">fostamatinib | Kissei</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_CollaborativeArrangementRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Collaborative payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rigl_FostamatinibMember', window );">fostamatinib | Kissei | Delivery of drug supply for commercialization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_CollaborativeArrangementRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rigl_FostamatinibMember', window );">fostamatinib | Medison | Financing arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_CollaborativeArrangementUpfrontFeeReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_FinancingLiabilityIncludingInterestExpenseAccretion', window );">Financing liability with accreted interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_CollaborativeArrangementRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rigl_FostamatinibMember', window );">fostamatinib | Medison | Commercial and license agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_CollaborativeArrangementUpfrontFeeReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_NumberOfAgreements', window );">Number of agreements | agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rigl_R552Member', window );">R552</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_DevelopmentCostsCostSharingArrangementPercentage', window );">Company's percentage of development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityAccrualComponentAmount', window );">Financing component liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_FinancingLiabilityInterestAccretionDiscountRate', window );">Financing liability interest accretion discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_FinancingLiabilityIncludingInterestExpenseAccretion', window );">Financing liability with accreted interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionExpense', window );">Accretion expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_DueToCollaborationPartner', window );">Development costs due to collaboration partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rigl_R552Member', window );">R552 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Funding commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rigl_NonCentralNervousSystemPenetrantIntellectualPropertyMember', window );">Non-CNS penetrant IP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_CollaborativeArrangementRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rigl_CentralNervousSystemPenetrantIntellectualPropertyMember', window );">CNS penetrant IP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_CollaborativeArrangementRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rigl_CentralNervousSystemPenetrantIntellectualPropertyMember', window );">CNS penetrant IP | Licensed Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty | Grifols</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_CollaborativeArrangementRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rigl_RezlidhiaMember', window );">REZLIDHIA | Forma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rigl_RezlidhiaMember', window );">REZLIDHIA | Forma | FDA approval and first commercial sale of product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Intangible asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_PaymentsOfMilestonePaymentObligations', window );">Payments of milestone payment obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_CollaborativeArrangementPotentialPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of contingent payments under collaborative arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_CollaborativeArrangementPotentialPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_CollaborativeArrangementRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the revenue recognized during the period under the terms of sponsored research and license agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_CollaborativeArrangementRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_CollaborativeArrangementUpfrontFeeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of upfront fees received during the period under the terms of collaborative and licensing agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_CollaborativeArrangementUpfrontFeeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_CollaborativeArrangementUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of collaborative arrangement upfront payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_CollaborativeArrangementUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_ContingentPaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents additional contingent payments by entities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_ContingentPaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_DevelopmentCostsCostSharingArrangementPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of development costs in cost sharing arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_DevelopmentCostsCostSharingArrangementPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_DueToCollaborationPartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due to collaboration partner.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_DueToCollaborationPartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_FinancingLiabilityIncludingInterestExpenseAccretion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financing liability including interest expense accretion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_FinancingLiabilityIncludingInterestExpenseAccretion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_FinancingLiabilityInterestAccretionDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate applied to the undiscounted amount of financing liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_FinancingLiabilityInterestAccretionDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_GovernmentAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of award from the government.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_GovernmentAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_GovernmentAwardExpectedToBeReceivedInSucceedingPeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The remaining amount of government award expected to be received in the succeeding periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_GovernmentAwardExpectedToBeReceivedInSucceedingPeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_NumberOfAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_NumberOfAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_PaymentOfCostShareToCollaborationPartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of cost share to collaboration partner.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_PaymentOfCostShareToCollaborationPartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_PaymentsOfMilestonePaymentObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payments of milestone payment obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_PaymentsOfMilestonePaymentObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_RightToOptOutOfAgreementNumberOfPeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of periods with right to opt out of agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_RightToOptOutOfAgreementNumberOfPeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_RoyaltyPaymentAsPercentageOfNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents royalty payment as a percentage of net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_RoyaltyPaymentAsPercentageOfNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481639/420-10-35-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received from collaborators during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductLiabilityAccrualComponentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recorded amount of the accrual for a material component of a product liability contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.Y.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480102/450-20-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductLiabilityAccrualComponentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_AchievementOfMilestoneAxis=rigl_SpecifiedDevelopmentEventsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_AchievementOfMilestoneAxis=rigl_SpecifiedDevelopmentEventsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_AchievementOfMilestoneAxis=rigl_SpecifiedRegulatoryEventsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_AchievementOfMilestoneAxis=rigl_SpecifiedRegulatoryEventsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_AchievementOfMilestoneAxis=rigl_SpecifiedProductLaunchEventsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_AchievementOfMilestoneAxis=rigl_SpecifiedProductLaunchEventsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_AchievementOfMilestoneAxis=rigl_DevelopmentAndRegulatoryMilestonesByNonCentralNervousSystemDiseaseProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_AchievementOfMilestoneAxis=rigl_DevelopmentAndRegulatoryMilestonesByNonCentralNervousSystemDiseaseProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=rigl_MilestonePaymentsOnProductByProductBasisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=rigl_MilestonePaymentsOnProductByProductBasisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_AchievementOfMilestoneAxis=rigl_DevelopmentAndRegulatoryMilestonesByCentralNervousSystemDiseaseProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_AchievementOfMilestoneAxis=rigl_DevelopmentAndRegulatoryMilestonesByCentralNervousSystemDiseaseProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=rigl_GrifolsS.a.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=rigl_GrifolsS.a.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_AchievementOfMilestoneAxis=rigl_ResearchActivitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_AchievementOfMilestoneAxis=rigl_ResearchActivitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_AchievementOfMilestoneAxis=rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_AchievementOfMilestoneAxis=rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_AchievementOfMilestoneAxis=rigl_SpecifiedCommercialMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_AchievementOfMilestoneAxis=rigl_SpecifiedCommercialMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=rigl_KisseiPharmaceuticalCo.Ltd.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=rigl_KisseiPharmaceuticalCo.Ltd.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=rigl_KnightTherapeuticsInternationalSaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=rigl_KnightTherapeuticsInternationalSaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rigl_CommercialAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rigl_CommercialAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=rigl_FormaTherapeuticsHoldingsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=rigl_FormaTherapeuticsHoldingsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_AchievementOfMilestoneAxis=rigl_DevelopmentAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_AchievementOfMilestoneAxis=rigl_DevelopmentAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_AchievementOfMilestoneAxis=rigl_AchievementOfCertainNearTermRegulatoryMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_AchievementOfMilestoneAxis=rigl_AchievementOfCertainNearTermRegulatoryMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rigl_FostamatinibMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rigl_FostamatinibMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_AchievementOfMilestoneAxis=rigl_EuropeanMedicinesAgencyApprovalOfFostamatinibForTreatmentOfChronicImmuneThrombocytopenicPurpuraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_AchievementOfMilestoneAxis=rigl_EuropeanMedicinesAgencyApprovalOfFostamatinibForTreatmentOfChronicImmuneThrombocytopenicPurpuraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_AchievementOfMilestoneAxis=rigl_CreditableAdvanceRoyaltyPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_AchievementOfMilestoneAxis=rigl_CreditableAdvanceRoyaltyPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=rigl_MedisonPharmaLtd.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=rigl_MedisonPharmaLtd.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ProductFinancingArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ProductFinancingArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rigl_R552Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rigl_R552Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rigl_NonCentralNervousSystemPenetrantIntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rigl_NonCentralNervousSystemPenetrantIntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rigl_CentralNervousSystemPenetrantIntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rigl_CentralNervousSystemPenetrantIntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_AchievementOfMilestoneAxis=rigl_LicensedRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_AchievementOfMilestoneAxis=rigl_LicensedRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rigl_RezlidhiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rigl_RezlidhiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_AchievementOfMilestoneAxis=rigl_FdaApprovalAndFirstCommercialSaleOfProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_AchievementOfMilestoneAxis=rigl_FdaApprovalAndFirstCommercialSaleOfProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140108311615648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation expense related to stock-based awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 2,172<span></span>
</td>
<td class="nump">$ 2,391<span></span>
</td>
<td class="nump">$ 4,930<span></span>
</td>
<td class="nump">$ 5,598<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost', window );">Incremental stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="nump">800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation expense related to stock-based awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">1,796<span></span>
</td>
<td class="nump">1,933<span></span>
</td>
<td class="nump">3,531<span></span>
</td>
<td class="nump">4,672<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation expense related to stock-based awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 376<span></span>
</td>
<td class="nump">$ 458<span></span>
</td>
<td class="nump">$ 1,399<span></span>
</td>
<td class="nump">$ 926<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>An excess of the fair value of the modified award over the fair value of the award immediately before the modification.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140108311908496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Options and RSUs (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=rigl_ShareBasedCompensationOptionsAndRsusMember', window );">Employee stock options and Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Additional disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Total unrecognized compensation costs | $</a></td>
<td class="nump">$ 14.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average recognition period of unrecognized compensation cost</a></td>
<td class="text">2 years 7 months 24 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">2,938,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised/Released (in shares)</a></td>
<td class="nump">15,557<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, end of period (in shares)</a></td>
<td class="nump">35,244,121<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member] | Vesting upon achievement of corporate performance-based milestones</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, end of period (in shares)</a></td>
<td class="nump">2,870,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Additional disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Total unrecognized compensation costs | $</a></td>
<td class="nump">$ 5.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">1,387,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="nump">435,006<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, end of period (in shares)</a></td>
<td class="nump">1,963,487<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Additional disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=rigl_ShareBasedCompensationOptionsAndRsusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=rigl_ShareBasedCompensationOptionsAndRsusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140108312725056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Assumptions (Details) - Employee Stock Option [Member] - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted-average assumptions relating to options granted</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (as a percent)</a></td>
<td class="nump">3.70%<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="nump">3.70%<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 8 months 12 days<span></span>
</td>
<td class="text">6 years 6 months<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">6 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield (as a percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (as a percent)</a></td>
<td class="nump">86.00%<span></span>
</td>
<td class="nump">70.30%<span></span>
</td>
<td class="nump">83.10%<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Additional disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Grant-date weighted-average fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Vesting upon achievement of corporate performance-based milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Additional disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Total unrecognized compensation costs</a></td>
<td class="nump">$ 5.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140108404016544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Purchase Plan (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>May 31, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>item </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Additional disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional shares approved</a></td>
<td class="nump">4,000,000<span></span>
</td>
<td class="nump">108,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares of common stock available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,186,098<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Additional disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardOfferingPeriod', window );">Award offering period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentageOnFirstDayOfOfferingPeriod', window );">Purchase price expressed as a percentage of fair market value of common stock on the first day of the offering period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriodsPerAwardOfferingPeriod', window );">Number of purchase periods per award offering period | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPurchasePeriod', window );">Award purchase period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price expressed as a percentage of fair market value of common stock on the purchase date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward', window );">Shares purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">509,190<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,928,443<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation cost related to purchase plan | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average recognition period of unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 months 26 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the offering period for awards under the equity-based compensation plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPurchasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the purchase period for awards under the equity-based compensation plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPurchasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriodsPerAwardOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of purchase periods per award offering period under the equity-based compensation plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriodsPerAwardOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentageOnFirstDayOfOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the purchase price expressed as a percentage of the fair market value of common stock on the first day of the offering period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentageOnFirstDayOfOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares purchased for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140108310986160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVENTORIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw Materials</a></td>
<td class="nump">$ 6,878<span></span>
</td>
<td class="nump">$ 4,555<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">2,046<span></span>
</td>
<td class="nump">2,659<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">1,858<span></span>
</td>
<td class="nump">1,904<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total</a></td>
<td class="nump">10,782<span></span>
</td>
<td class="nump">9,118<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvancesOnInventoryPurchases', window );">Advance payments for raw materials</a></td>
<td class="nump">$ 700<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvancesOnInventoryPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of capitalized payments made in advance for inventory that is expected to be received within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvancesOnInventoryPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140108311129952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Cash, cash equivalent and short term investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 48,812<span></span>
</td>
<td class="nump">$ 24,459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">15,545<span></span>
</td>
<td class="nump">33,747<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents and short-term investments</a></td>
<td class="nump">64,357<span></span>
</td>
<td class="nump">58,206<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Cash, cash equivalent and short term investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents and short-term investments</a></td>
<td class="nump">21,109<span></span>
</td>
<td class="nump">4,155<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryBillSecuritiesMember', window );">US treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Cash, cash equivalent and short term investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents and short-term investments</a></td>
<td class="nump">8,953<span></span>
</td>
<td class="nump">5,225<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">Government-sponsored enterprise securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Cash, cash equivalent and short term investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents and short-term investments</a></td>
<td class="nump">15,584<span></span>
</td>
<td class="nump">15,796<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=rigl_CorporateBondSecuritiesAndCommercialPaperMember', window );">Corporate bonds and commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Cash, cash equivalent and short term investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents and short-term investments</a></td>
<td class="nump">9,917<span></span>
</td>
<td class="nump">26,766<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Cash, cash equivalent and short term investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents and short-term investments</a></td>
<td class="nump">$ 8,794<span></span>
</td>
<td class="nump">$ 6,264<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryBillSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryBillSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=rigl_CorporateBondSecuritiesAndCommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=rigl_CorporateBondSecuritiesAndCommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140108311958528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS - Gross Unrealized Gains and Losses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_CashEquivalentsAndAvailableForSaleSecuritiesAbstract', window );"><strong>Cash equivalents and available-for-sale securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 34,479<span></span>
</td>
<td class="nump">$ 47,940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">34,454<span></span>
</td>
<td class="nump">47,787<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_CashEquivalentsAndAvailableForSaleSecuritiesAbstract', window );"><strong>Cash equivalents and available-for-sale securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1', window );">Gross Unrealized Gains (Losses)</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_CashEquivalentsAndAvailableForSaleSecuritiesAbstract', window );"><strong>Cash equivalents and available-for-sale securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1', window );">Gross Unrealized Gains (Losses)</a></td>
<td class="num">(29)<span></span>
</td>
<td class="num">(154)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember', window );">US treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_CashEquivalentsAndAvailableForSaleSecuritiesAbstract', window );"><strong>Cash equivalents and available-for-sale securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">8,951<span></span>
</td>
<td class="nump">5,251<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">8,953<span></span>
</td>
<td class="nump">5,225<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember', window );">US treasury bills | Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_CashEquivalentsAndAvailableForSaleSecuritiesAbstract', window );"><strong>Cash equivalents and available-for-sale securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1', window );">Gross Unrealized Gains (Losses)</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember', window );">US treasury bills | Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_CashEquivalentsAndAvailableForSaleSecuritiesAbstract', window );"><strong>Cash equivalents and available-for-sale securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1', window );">Gross Unrealized Gains (Losses)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">Government-sponsored enterprise securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_CashEquivalentsAndAvailableForSaleSecuritiesAbstract', window );"><strong>Cash equivalents and available-for-sale securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">15,607<span></span>
</td>
<td class="nump">15,882<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">15,584<span></span>
</td>
<td class="nump">15,796<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">Government-sponsored enterprise securities | Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_CashEquivalentsAndAvailableForSaleSecuritiesAbstract', window );"><strong>Cash equivalents and available-for-sale securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1', window );">Gross Unrealized Gains (Losses)</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">Government-sponsored enterprise securities | Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_CashEquivalentsAndAvailableForSaleSecuritiesAbstract', window );"><strong>Cash equivalents and available-for-sale securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1', window );">Gross Unrealized Gains (Losses)</a></td>
<td class="num">(25)<span></span>
</td>
<td class="num">(87)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=rigl_CorporateBondSecuritiesAndCommercialPaperMember', window );">Corporate bonds and commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_CashEquivalentsAndAvailableForSaleSecuritiesAbstract', window );"><strong>Cash equivalents and available-for-sale securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">9,921<span></span>
</td>
<td class="nump">26,807<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">9,917<span></span>
</td>
<td class="nump">26,766<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=rigl_CorporateBondSecuritiesAndCommercialPaperMember', window );">Corporate bonds and commercial paper | Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_CashEquivalentsAndAvailableForSaleSecuritiesAbstract', window );"><strong>Cash equivalents and available-for-sale securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1', window );">Gross Unrealized Gains (Losses)</a></td>
<td class="num">$ (4)<span></span>
</td>
<td class="num">$ (41)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_CashEquivalentsAndAvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_CashEquivalentsAndAvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of increase (decrease) in accumulated equity from transactions and other events and circumstances from non-owner sources, including portion attributable to noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners (distributions to owners).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=rigl_CorporateBondSecuritiesAndCommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=rigl_CorporateBondSecuritiesAndCommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140108308759088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS - Unrealized Loss Position (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>position</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Fair value and gross unrealized losses of investments in individual securities in unrealized loss position</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_CashEquivalentsAndAvailableForSaleSecuritiesWeightedAverageMaturityPeriod', window );">Weighted-average time to maturity of cash equivalents and available-for-sale securities</a></td>
<td class="text">72 days<span></span>
</td>
<td class="text">89 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions', window );">Number of investments in continuous unrealized loss position for more than 12 months | position</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions', window );">Number of individual securities in unrealized loss position for 12 months or less | position</a></td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld', window );">Credit losses recognized</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Fair Value</a></td>
<td class="nump">18,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized Losses</a></td>
<td class="num">(29)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">Government-sponsored enterprise securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Fair value and gross unrealized losses of investments in individual securities in unrealized loss position</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Fair Value</a></td>
<td class="nump">10,576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized Losses</a></td>
<td class="num">(26)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=rigl_CorporateBondSecuritiesAndCommercialPaperMember', window );">Corporate bonds and commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Fair value and gross unrealized losses of investments in individual securities in unrealized loss position</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Fair Value</a></td>
<td class="nump">7,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized Losses</a></td>
<td class="num">$ (3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_CashEquivalentsAndAvailableForSaleSecuritiesWeightedAverageMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the weighted-average period of maturity of cash equivalents and available-for-sale debt securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_CashEquivalentsAndAvailableForSaleSecuritiesWeightedAverageMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of credit losses recognized in earnings related to debt securities held for which a portion of an other than temporary impairment (OTTI) was recognized in other comprehensive income (a component of shareholders' equity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-8B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-8B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=rigl_CorporateBondSecuritiesAndCommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=rigl_CorporateBondSecuritiesAndCommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140108311938880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments at fair value</a></td>
<td class="nump">$ 34,454<span></span>
</td>
<td class="nump">$ 47,787<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements Recurring | Estimate Of Fair Value Fair Value Disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments at fair value</a></td>
<td class="nump">55,563<span></span>
</td>
<td class="nump">51,942<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements Recurring | Money market funds | Estimate Of Fair Value Fair Value Disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments at fair value</a></td>
<td class="nump">21,109<span></span>
</td>
<td class="nump">4,155<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements Recurring | US treasury bills | Estimate Of Fair Value Fair Value Disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments at fair value</a></td>
<td class="nump">8,953<span></span>
</td>
<td class="nump">5,225<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements Recurring | Government-sponsored enterprise securities | Estimate Of Fair Value Fair Value Disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments at fair value</a></td>
<td class="nump">15,584<span></span>
</td>
<td class="nump">15,796<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements Recurring | Corporate bonds and commercial paper | Estimate Of Fair Value Fair Value Disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments at fair value</a></td>
<td class="nump">9,917<span></span>
</td>
<td class="nump">26,766<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments at fair value</a></td>
<td class="nump">21,109<span></span>
</td>
<td class="nump">4,155<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements Recurring | Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments at fair value</a></td>
<td class="nump">21,109<span></span>
</td>
<td class="nump">4,155<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments at fair value</a></td>
<td class="nump">34,454<span></span>
</td>
<td class="nump">47,787<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements Recurring | Level 2 | US treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments at fair value</a></td>
<td class="nump">8,953<span></span>
</td>
<td class="nump">5,225<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements Recurring | Level 2 | Government-sponsored enterprise securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments at fair value</a></td>
<td class="nump">15,584<span></span>
</td>
<td class="nump">15,796<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements Recurring | Level 2 | Corporate bonds and commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments at fair value</a></td>
<td class="nump">$ 9,917<span></span>
</td>
<td class="nump">$ 26,766<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryBillSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryBillSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=rigl_CorporateBondSecuritiesAndCommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=rigl_CorporateBondSecuritiesAndCommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140108309571328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 28, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>May 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized issuance costs and debt discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">$ 1,862<span></span>
</td>
<td class="nump">$ 569<span></span>
</td>
<td class="nump">$ 3,066<span></span>
</td>
<td class="nump">$ 1,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Credit Facility with MidCap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Remaining borrowing capacity</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding', window );">Outstanding balance</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized issuance costs and debt discounts</a></td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">$ 1,900<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">3,100<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityIncreaseAccruedInterest', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Credit Facility with MidCap | Following Third Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Final payment fee, percentage of principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Credit Facility with MidCap | SOFR | Following Third Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate', window );">Rate adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">0.11448%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Floor rate</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Credit Facility with MidCap | LIBOR | Prior to Third Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Floor rate</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Credit Facility with MidCap | Tranche 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding', window );">Outstanding balance</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Credit Facility with MidCap | Tranche 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding', window );">Outstanding balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Credit Facility with MidCap | Tranche 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding', window );">Outstanding balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Credit Facility with MidCap | Tranche 4</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding', window );">Outstanding balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Credit Facility with MidCap | Tranche 5</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding', window );">Outstanding balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of any adjustments made to the stated rate to determine the effective rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of principal amount of debt redeemed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of the amount outstanding under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityIncreaseAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase for accrued, but unpaid interest on the credit facility for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityIncreaseAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=rigl_FollowingThirdAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=rigl_FollowingThirdAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=rigl_LondonInterBankOfferedRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=rigl_LondonInterBankOfferedRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=rigl_PriorToThirdAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=rigl_PriorToThirdAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rigl_CreditAgreementTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rigl_CreditAgreementTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rigl_CreditAgreementTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rigl_CreditAgreementTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rigl_CreditAgreementTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rigl_CreditAgreementTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rigl_CreditAgreementTrancheFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rigl_CreditAgreementTrancheFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rigl_CreditAgreementTrancheFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rigl_CreditAgreementTrancheFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140108310929136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DEBT - Future Minimum Payments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MaturitiesOfLongTermDebtAbstract', window );"><strong>Future minimum payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 7,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2025</a></td>
<td class="nump">30,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2026</a></td>
<td class="nump">22,500<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Principal amount (Tranches 1, 2, 3 and 4)</a></td>
<td class="nump">$ 60,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MaturitiesOfLongTermDebtAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MaturitiesOfLongTermDebtAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140108316120944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_SubleaseAgreementAbstract', window );"><strong>Sublease Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">$ 997<span></span>
</td>
<td class="nump">$ 1,930<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=rigl_HeadquartersOfficeSpaceSubleaseSouthSanFranciscoCaliforniaMember', window );">Headquarters office space sublease, South San Francisco, California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_SubleaseAgreementAbstract', window );"><strong>Sublease Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">1 year 11 months 1 day<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncentiveToLessee', window );">Leasehold improvement incentives from landlord</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_SubleaseAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_SubleaseAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncentiveToLessee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of incentive granted by lessor to lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481178/840-20-25-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481178/840-20-25-7<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 5<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479924/842-10-30-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncentiveToLessee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=rigl_HeadquartersOfficeSpaceSubleaseSouthSanFranciscoCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=rigl_HeadquartersOfficeSpaceSubleaseSouthSanFranciscoCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140108311620640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Lease Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>LEASES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Fixed operating lease expense</a></td>
<td class="nump">$ 166<span></span>
</td>
<td class="nump">$ 1,340<span></span>
</td>
<td class="nump">$ 778<span></span>
</td>
<td class="nump">$ 2,680<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_VariableLeaseExpenseNetCredit', window );">Variable operating lease expense (net credit)</a></td>
<td class="num">(42)<span></span>
</td>
<td class="nump">125<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="nump">391<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total operating lease expense</a></td>
<td class="nump">$ 124<span></span>
</td>
<td class="nump">$ 1,465<span></span>
</td>
<td class="nump">$ 808<span></span>
</td>
<td class="nump">$ 3,071<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_VariableLeaseExpenseNetCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease expense (net credit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_VariableLeaseExpenseNetCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140108315927984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Cash Flow Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>LEASES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash payments included in the measurement of operating lease liabilities</a></td>
<td class="nump">$ 178<span></span>
</td>
<td class="nump">$ 2,630<span></span>
</td>
<td class="nump">$ 1,174<span></span>
</td>
<td class="nump">$ 5,226<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140108312072304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Sublease Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_SubleaseAgreementAbstract', window );"><strong>Operating sublease information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_FixedSubleaseExpense', window );">Fixed sublease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,095<span></span>
</td>
<td class="nump">$ 365<span></span>
</td>
<td class="nump">$ 2,190<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_VariableSubleaseExpense', window );">Variable sublease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">206<span></span>
</td>
<td class="nump">77<span></span>
</td>
<td class="nump">450<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,301)<span></span>
</td>
<td class="num">(442)<span></span>
</td>
<td class="num">(2,640)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_NetSubleaseIncomeExpense', window );">Net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_FixedSubleaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of fixed sublease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_FixedSubleaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_NetSubleaseIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net sublease income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_NetSubleaseIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_SubleaseAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_SubleaseAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_VariableSubleaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable sublease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_VariableSubleaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140108312052384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES - Future Minimum Lease Payments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Lease</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Remainder of 2023</a></td>
<td class="nump">$ 360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">739<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">301<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum payments required</a></td>
<td class="nump">$ 1,400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140108311296368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (6,600)<span></span>
</td>
<td class="num">$ (13,492)<span></span>
</td>
<td class="num">$ (20,136)<span></span>
</td>
<td class="num">$ (40,937)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140108312562032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>rigl-20230630x10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:rigl="http://www.rigel.com/20230630"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="rigl-20230630.xsd" xlink:type="simple"/>
    <context id="Duration_1_1_2023_To_6_30_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember_5hmOTOINYUi1yMKOyqV_Tg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_GovernmentAndOtherRebatesMember_6P-es-h0okS3mUsko2UktA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">rigl:GovernmentAndOtherRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_ChargebacksDiscountsAndFeesMember_Fj8Wggl3gkGVVa1f_QMscg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">rigl:ChargebacksDiscountsAndFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember_ioiPIbSN6U6AmT1ftZXQ6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_GovernmentAndOtherRebatesMember_OChMZBgap0qvP6EMKEatOg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">rigl:GovernmentAndOtherRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_ChargebacksDiscountsAndFeesMember_t4iNGTcP0UaLBEDeXCMGOw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">rigl:ChargebacksDiscountsAndFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember_-dSzQZXVFEuMJw8h2iIHxw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_GovernmentAndOtherRebatesMember_jVuu0q4VHEWON15mELkW8g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">rigl:GovernmentAndOtherRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_ChargebacksDiscountsAndFeesMember_DfMT0NHFbUOWySs4XQGnsg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">rigl:ChargebacksDiscountsAndFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember_acq92gncQkKXH4cm6zevsA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_GovernmentAndOtherRebatesMember__X6NqDu8YU-SnfKyNeY8HA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">rigl:GovernmentAndOtherRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_ChargebacksDiscountsAndFeesMember_PB_xsJ2Rnka8evD4QKOfWg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">rigl:ChargebacksDiscountsAndFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember_jBU6vZXXI0qTA8tjSyNMHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_GovernmentAndOtherRebatesMember_bsvDCX99AUmyaU2yXJOh2w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">rigl:GovernmentAndOtherRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_ChargebacksDiscountsAndFeesMember_nboH8Ly9PkqdAPD6SogU6Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">rigl:ChargebacksDiscountsAndFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember_2U4Oj50ug0SqZPXE5_VdHg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_GovernmentAndOtherRebatesMember_eCxe-sGTfE-EJIbGHCs0Rw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">rigl:GovernmentAndOtherRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_ChargebacksDiscountsAndFeesMember_Pp0Xy4dvykCBp639HzD29g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">rigl:ChargebacksDiscountsAndFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2mIl79LxpkuN5mgFsNHdfg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1ylsF_WCdkeufVQaI9L5Qg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_X0BNnHhQVkGCCdDEwUQPOQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_h87Ta8IYBkSUtMHbuewiIg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_6WAzHoGFsEyRh9-_I-EgwA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_GsGkBqFtIEeF4t6uDl64RA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_uWcj3WWP8EKEJxuUNUBsng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_zZnbux6ITEas3Z5CntDoJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_OfzaBWn7ikCSgv7BTwXlfQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4ofcdRQIYUqAzW1HPzZ5vA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_BgUu_xw-pEOX64_3oVKFUQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_7r-CKjYwcEWPEVrhWmkNzw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_H75YemqVnEyPwV--MIGWGw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_lUJBYmkmN0mPdtrXTwmLYw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_SgCZ7AQnVkal8VnKIFXBDg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_8FRPOicKCUukQ6L7AAUMNw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_JNCe4Z95dE6Iw1LvI3RQ4g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_mUlMkH6yV0ev7oy48pw70w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_HUMQpp-hhUmkBPR7Q8NCIw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_DP28xveaSEKwPEHlfm8Vvg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2022_BK3VScSjz0OWZFv-nNNaXA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_j5agreqUq0C05wMxAlbdRg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_2EWYq3VBqUSwnhTDnAcB0w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_n7Oc0ne_BUqW0jhEW7x51g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NXFVM5fZJUmDlMyyzE1ttg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0zb7z7FwO0GI2RAEVAHXQw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xvjnxqS-hkCiR6PhUg5rig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8sjAYkMEXkWQKgqr3XNtXg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4k30MtA2pUm5iDpAhJLPrg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Mal6s5t5Z0qQ9EIsFrTGuQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_gbdA-1ad4EqysI7py3ChOA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="Duration_5_1_2023_To_5_31_2023_Q3DEP_Nkn0q2GbxII4v6Iw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_4_30_2023_qr7JWxKMEU6rcNt5QqihYw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-04-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_DF-ET0UVsU-4JFbzSJC6wg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_om_Pkmw3FEmnJzDD0iVbRQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_tNXptyV-B0yupU7uhJiuDg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_phK8_7NtIEStEjkLueCcDw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_PpvU5eYgTEyg2sveoUrODg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nQp2Q6A6Z0qf5xAVDXOnBg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_dei_LegalEntityAxis_rigl_FormaTherapeuticsHoldingsIncMember_srt_ProductOrServiceAxis_rigl_RezlidhiaMember_holN4_ByhUmtcYY2H349MA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:RezlidhiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:FormaTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_dei_LegalEntityAxis_rigl_FormaTherapeuticsHoldingsIncMember_srt_ProductOrServiceAxis_rigl_RezlidhiaMember_yxVUJk2G5k2qwTfZTVvH9Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:RezlidhiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:FormaTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2023_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_VOQGD0Imek29F_UrLGFn-w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:KisseiPharmaceuticalCo.Ltd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_rigl_AchievementOfMilestoneAxis_rigl_LicensedRightsMember_srt_ProductOrServiceAxis_rigl_CentralNervousSystemPenetrantIntellectualPropertyMember_nqY09VTQhkCP6kuB8E26vw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:CentralNervousSystemPenetrantIntellectualPropertyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:LicensedRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_v4jyMWOILkimNDJi27bJNA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_GovernmentContractMember_WN0BoWdZGU-KXqAccwJ68A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GovernmentContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_RoyaltyDeliveryOfDrugSuppliesAndOthersMember_jqRyjOlFGUu5mu87xpyztg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:RoyaltyDeliveryOfDrugSuppliesAndOthersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_GrossProductMember_ene2KCce8kCbyUMQexHEMg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:GrossProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_DiscountsAndAllowancesMember_uHoWbEnKdU2tg1UhL6Vz-g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:DiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_ContractRevenuesFromCollaborationsMember_yU4TzCXKCkSEqjOPYCD5ig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:ContractRevenuesFromCollaborationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_C2EWGpiFxUGr9E995bXhCQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_GovernmentContractMember_9xcr5RYkM0WkIqJKKgDS8A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GovernmentContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_RoyaltyDeliveryOfDrugSuppliesAndOthersMember_V9FmeTwnFU20hq0tJetk3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:RoyaltyDeliveryOfDrugSuppliesAndOthersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_GrossProductMember_ufxFI3eqlEur3o5rbubmLA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:GrossProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_DiscountsAndAllowancesMember_POb1Otc_IkOne8fdyW38vA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:DiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_ContractRevenuesFromCollaborationsMember_TmFkSqljNUiYYmkDnr-3ag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:ContractRevenuesFromCollaborationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_Zl3JCD-6OEeEiUA808bVig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_LicenseMember_dRyVOn5NcEee-uU6cPlByQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_rigl_RoyaltyDeliveryOfDrugSuppliesAndOthersMember_v1BBxfjOM0iXxMM8ZntPkg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:RoyaltyDeliveryOfDrugSuppliesAndOthersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_rigl_GrossProductMember_95E_EFQSok-CYS8j9cMXTA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:GrossProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_rigl_DiscountsAndAllowancesMember_OH1BW4gyzU6mjxq6VfcyGg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:DiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_rigl_DevelopmentMilestonesMember_8XRCe7N2D0q0_dL4LzLrSw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:DevelopmentMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_rigl_ContractRevenuesFromCollaborationsMember_B3F0S8vRz0eWxrI-zbC5eQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:ContractRevenuesFromCollaborationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_I08rIoA1_0itpE8QmmW4zw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_LicenseMember_aC5yN2D_3U6wto3RbpNFkQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_rigl_RoyaltyDeliveryOfDrugSuppliesAndOthersMember_ClPsUsxGhkStEb_3uR8ZgA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:RoyaltyDeliveryOfDrugSuppliesAndOthersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_rigl_GrossProductMember_rXnbhU9tKUyNBTlYxDeWHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:GrossProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_rigl_DiscountsAndAllowancesMember_rYICJn1GSUmzENKUTvY70A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:DiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_rigl_DevelopmentMilestonesMember_HoBUCB_cmEGo56InBGrucg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:DevelopmentMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_rigl_ContractRevenuesFromCollaborationsMember_LOIZvjtJ4kefhhUMq6-K0Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:ContractRevenuesFromCollaborationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_12_31_2022_dei_LegalEntityAxis_rigl_FormaTherapeuticsHoldingsIncMember_rigl_AchievementOfMilestoneAxis_rigl_AchievementOfCertainNearTermRegulatoryMilestoneMember_mYsvlxGBhUyABmwFOCLmig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:AchievementOfCertainNearTermRegulatoryMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:FormaTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_dei_LegalEntityAxis_rigl_FormaTherapeuticsHoldingsIncMember_gN0UrgqHwke5fJiA75tT0w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:FormaTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_2_1_2020_To_2_29_2020_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_rigl_AchievementOfMilestoneAxis_rigl_CreditableAdvanceRoyaltyPaymentMember_srt_ProductOrServiceAxis_rigl_FostamatinibMember_aO7fdyjeKkKh-8rHnFGcDQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:CreditableAdvanceRoyaltyPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:GrifolsS.a.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="Duration_2_1_2020_To_2_29_2020_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember__7PyRX4jPECYeFKd4E3SHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:GrifolsS.a.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_QxrzwDPl-02u7MxFvVCYNQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_hHQBvZ1Mi06kiRDiBIcvOg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3JpqoXaqL0SrqUrpHTj6kg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_n9loXyMYREivaHgcSKMHMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2023_srt_ProductOrServiceAxis_rigl_R552Member_srt_RangeAxis_srt_MaximumMember_nQDkYFvGfkGeTW-8GkyDkg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:R552Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_rigl_HeadquartersOfficeSpaceSubleaseSouthSanFranciscoCaliforniaMember_RzRVSQYro0qfZzFsimZvQA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rigl:HeadquartersOfficeSpaceSubleaseSouthSanFranciscoCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_BC0bgoovFkSFc26FtpY0vA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_lxmvkD9RK0qU7ZM5gMSIQw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_aR01SJIgMUW3MS43CRdmBw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_egDPK9MhIkOXkH42vVRrWw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_DebtInstrumentAxis_rigl_CreditAgreementTrancheOneMember_NdmHGNjm80GwagBp6p25SQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rigl:CreditAgreementTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_28_2023_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_DebtInstrumentAxis_rigl_CreditAgreementTrancheFiveMember_QUesi71yDkqy9WA84-x-ug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rigl:CreditAgreementTrancheFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-28</instant>
        </period>
    </context>
    <context id="As_Of_5_31_2022_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_DebtInstrumentAxis_rigl_CreditAgreementTrancheThreeMember_xE8L3bekvEKDIR_7sMJqCw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rigl:CreditAgreementTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="As_Of_5_31_2022_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_DebtInstrumentAxis_rigl_CreditAgreementTrancheFourMember_YfMR144_eUWzw-ApIaAstA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rigl:CreditAgreementTrancheFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="As_Of_5_31_2020_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_DebtInstrumentAxis_rigl_CreditAgreementTrancheTwoMember_Pt33AwlsAE-LZCXlY1xdSw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rigl:CreditAgreementTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryBillSecuritiesMember_9EFna87LuU6O4O7rLXT8_Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_-mpWze0ew0qh9kNZ1GgxZg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_6LWYDoMSGEuqSbON9szqUA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">rigl:CorporateBondSecuritiesAndCommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_E0z-Tucd60Gr3PRXDlh0xw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryBillSecuritiesMember_W5abtcgj4EewIThyL6s9KQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_89OSD-Eh70S-lOaWIkx8jg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_wFvchknSJ0iAyfGzH6qAww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_j804o1Qq5kW9BN0Wq8qKAw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">rigl:CorporateBondSecuritiesAndCommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_5w8Rm76YAUeQeOz8g-y38Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_aESIeqNLDEGTjQh7l8feaA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_QW_rs_VEA0KU4-yd8SrPbw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryBillSecuritiesMember_I8wfKfL5DU-wQrbo5YC4Eg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_DV0JpqqeFEG2yWKut9HiFw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_la2B--bWDkagQFiSFOzkrA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">rigl:CorporateBondSecuritiesAndCommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_u-RkEtQ-w0Oqm41OpKcIhw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryBillSecuritiesMember_Ttzv--YhbkeAEe271vcCHQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_wWiomWDuy0icYfW_HOwFgA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_rIYz9iBffUO8TYWENsIDrg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_5M7Ca4BjDU6p5rg68gEwqQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">rigl:CorporateBondSecuritiesAndCommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_D1RS1iCAi0Cf-ba1jen3jA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_d-_85Kk8g0mwIwHaIhvvxA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_fPNOItXmGU6NPrDN3d1kDg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_BJeMNksUxkWrPx4dQB6u3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_ePrDC_3ewk2JsGsYLAl0ZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_vq2GZ_j7vkilnhfg4of5cw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_CJn5TKw-Sk6p8v3y1c6mVA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_rigl_HeadquartersOfficeSpaceSubleaseSouthSanFranciscoCaliforniaMember_Q7wBI-TD_USrGUm0m_WO2A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rigl:HeadquartersOfficeSpaceSubleaseSouthSanFranciscoCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_bC736RZBjkmPBtBhrfONyg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_AwardTypeAxis_rigl_ShareBasedCompensationOptionsAndRsusMember_eHSX5niPTk2ia4BsC8uknQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rigl:ShareBasedCompensationOptionsAndRsusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_rigl_ShareBasedCompensationOptionsAndRsusMember__foVAAxJ0UaZLSEd-5d-Tw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rigl:ShareBasedCompensationOptionsAndRsusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2023_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_dWMxniyFJ06ygU7yM53x1w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:KisseiPharmaceuticalCo.Ltd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_lZzWZsARrUq--he7HLPz4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_srt_StatementScenarioAxis_rigl_FollowingThirdAmendmentMember_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_LJSahnttvEiJdFf1pAqMfg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">rigl:FollowingThirdAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2023_srt_StatementScenarioAxis_rigl_PriorToThirdAmendmentMember_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_VariableRateAxis_rigl_LondonInterBankOfferedRateMember_PMVwcFXhgUW15_EzDLiLAw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">rigl:PriorToThirdAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">rigl:LondonInterBankOfferedRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_srt_StatementScenarioAxis_rigl_FollowingThirdAmendmentMember_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_VariableRateAxis_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_ShXm5jIvgkOs-ZS0wM0CGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">rigl:FollowingThirdAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_srt_StatementScenarioAxis_rigl_PriorToThirdAmendmentMember_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_VariableRateAxis_rigl_LondonInterBankOfferedRateMember_2WmOu592Mkqf1Hwsj0OZug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">rigl:PriorToThirdAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">rigl:LondonInterBankOfferedRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_srt_StatementScenarioAxis_rigl_FollowingThirdAmendmentMember_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_VariableRateAxis_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_4EMQf1c4MEiugud-VG7qaw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">rigl:FollowingThirdAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_srt_MajorCustomersAxis_rigl_MckessonSpecialtyCareDistributionCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_NFFFR5Op6EGibKqyThuK6g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rigl:MckessonSpecialtyCareDistributionCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_srt_MajorCustomersAxis_rigl_CardinalHealthcareMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_ZvGiZXP9CEeNn157o58OQQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rigl:CardinalHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_srt_MajorCustomersAxis_rigl_AsdHealthcareAndOncologySupplyMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_ezDA2vAhCkWEvWvApmdHcA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rigl:AsdHealthcareAndOncologySupplyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_srt_MajorCustomersAxis_rigl_MckessonSpecialtyCareDistributionCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_ijLIVbFhwE2dv-2rbK1hJw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rigl:MckessonSpecialtyCareDistributionCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_srt_MajorCustomersAxis_rigl_CardinalHealthcareMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_7kgMzAici0eIlntate3Qlw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rigl:CardinalHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_srt_MajorCustomersAxis_rigl_AsdHealthcareAndOncologySupplyMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_L3diTTLKsk23XOOP9fvJUg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rigl:AsdHealthcareAndOncologySupplyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_srt_MajorCustomersAxis_rigl_MckessonSpecialtyCareDistributionCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_Xm7pTW7phEG80_TFGMPzwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rigl:MckessonSpecialtyCareDistributionCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_srt_MajorCustomersAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_KKDtN8IagE6J4I_uAnU00A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rigl:KisseiPharmaceuticalCo.Ltd.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_srt_MajorCustomersAxis_rigl_CardinalHealthcareMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_crG-CxphyUmLeRthseHyVQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rigl:CardinalHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_srt_MajorCustomersAxis_rigl_AsdHealthcareAndOncologySupplyMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_sEWKR2JD6EG-XvczwGJTDg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rigl:AsdHealthcareAndOncologySupplyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_srt_MajorCustomersAxis_rigl_MckessonSpecialtyCareDistributionCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_hMd2onJOT0a7o-jJSOOdJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rigl:MckessonSpecialtyCareDistributionCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_srt_MajorCustomersAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_r58vna9bwkWOHGAEZRVhtg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rigl:KisseiPharmaceuticalCo.Ltd.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_srt_MajorCustomersAxis_rigl_CardinalHealthcareMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_XwGmaHgDQE6DlBxIrLRYjw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rigl:CardinalHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_srt_MajorCustomersAxis_rigl_AsdHealthcareAndOncologySupplyMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_Z_7YFCzct0KfoaZgxA9q_Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rigl:AsdHealthcareAndOncologySupplyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_zHK5kte7M02N-LF9t66ILA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_X6KPuRq2uEa6dhukywoGKw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_LY4sWUaA_UOIKxqqgZ5UAQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryBillSecuritiesMember_ASiSMIactUqwVwnqPY3_ew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_KL0hZTH2e063PXe0IU6-1g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_LfRnUUxRrEycHqB8YoPOOQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CashMember_qUTZZY9s90OHjG7EZblg4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_InvestmentTypeAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_1RwephmFh0WgSWKn57-wDg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">rigl:CorporateBondSecuritiesAndCommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryBillSecuritiesMember_sKjXaDQa5EiL5o0NsgoBFA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_M3axIPlo5k2k9b5gQJC25g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_1pcJHoW0nkC8Ko2b5ADUog">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CashMember_FLsEIySBfEaeRVBihq2f2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_InvestmentTypeAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_BtwQ3KLKc02gIILPkP43sw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">rigl:CorporateBondSecuritiesAndCommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember_9b5OdbmUeUi1NDAMA8H9Vg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_ReLJS_8Ua0iY--Vx8HxzUQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_FinancialInstrumentAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_EovRXwcsBU6PVsykL7sTEQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rigl:CorporateBondSecuritiesAndCommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember_afYkc85gT0m66xklaugfbw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_go32t6mGGEqSyKBPofyDEA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_FuBEs4QimEqUM83PeYRZcw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rigl:CorporateBondSecuritiesAndCommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_kUrHXkhzkEmFf7R8bUu2kA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_mJfwLdIwJE2PuCZyxHa0nA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_3tETexLm0UCBsN9ftHBwtg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_eLmQDXheSkOcwdRhfkuNbw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_FPUuaR2SyUSRDy3fSQcDRQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_3BL6mb7WlEWnOeX6FOCPaw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_WHRK7Ydr8Euv9ScMKMDa3Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_2SVbQAbboUOHtAeVDBUKZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_FormaTherapeuticsHoldingsIncMember_srt_ProductOrServiceAxis_rigl_RezlidhiaMember_Ggj-m6AMbkSlsqSSg-Oh4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:RezlidhiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:FormaTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_FormaTherapeuticsHoldingsIncMember_srt_ProductOrServiceAxis_rigl_RezlidhiaMember_u5JNB-NKCE6uQDuM-ogIPw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:RezlidhiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:FormaTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_OA1zy6euuUWd92D01bHyQA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_cNvDS3J20E2jpHrHJN-GXQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_YYP3i7dwZkyEj_jUho867Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_9G6CsmCnIE25iWXSTMDwUA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_5BqaR0t6HUmn3zbRET6b7A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_NPerFx0HTUiasJQZFwYc_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_qUKc9ZeBcEiFN-VeeuFO_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_WWdgQCoeWk-M5rmywXJFrQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_OPWXZu-4xESxTw7UEzGEfw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_pug8RCBYIkeZTp1-6vn_VQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_qfQwkxMZLU6ffGWe8LPnaQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_jRjTsJgDwE65v_ICJzPELw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_q29chwJC8UWqOM6gViWQCA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_NyURkj24PU2gRd22NkwY9w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_ld4nogTT4UKONA-CGQuvUQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_Z6JnOF8Gmkqq3XJoCK4JhA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaap_StatementEquityComponentsAxis_rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember_M4prG97dGEaaceW_5B5zCw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rigl:AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_FinancialInstrumentAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_us-gaap_StatementEquityComponentsAxis_rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember_qfBk03iVXEW6w48gjbjf7A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rigl:CorporateBondSecuritiesAndCommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rigl:AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_8i-ahQp_70mFJFvxxl02wA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember_P5cNTt7IlEa-Rhtic4nyvA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rigl:AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember_us-gaap_StatementEquityComponentsAxis_rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember_C6IhUCU3BkGDHmqFolJgdQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rigl:AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_O0JjjXe-ZE-RH42gPIxthQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaap_StatementEquityComponentsAxis_rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember_8aUcC__wTUGDPKa_b54-SQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rigl:AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_us-gaap_StatementEquityComponentsAxis_rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember_qoI-MShlREydakWlPmH8IA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rigl:CorporateBondSecuritiesAndCommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rigl:AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_dT29_JlvC0m0JlLh8k3msw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember_fV_8kfGMb0aVZbFHW8RnkA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rigl:AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_R552Member_nAWV78-1SEKxOb73Me78JA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:R552Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_rigl_R552Member_6cuFgoRx00e-zcShKPySYQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:R552Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_p5hH6L8EpUKDvP9iizwvIA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:KisseiPharmaceuticalCo.Ltd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_dei_LegalEntityAxis_rigl_FormaTherapeuticsHoldingsIncMember_rigl_AchievementOfMilestoneAxis_rigl_FdaApprovalAndFirstCommercialSaleOfProductMember_srt_ProductOrServiceAxis_rigl_RezlidhiaMember_0GWFqUYggk2HSLP63Ny2Tg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:RezlidhiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:FdaApprovalAndFirstCommercialSaleOfProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:FormaTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_sAWGlLehukGUN_F8wkmpLA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_us-gaap_BalanceSheetLocationAxis_rigl_AccountsReceivableAndPrepaidAndOtherCurrentAssetsMember__I6hFO6Y_0yiZKdPOpgk-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">rigl:AccountsReceivableAndPrepaidAndOtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_us-gaap_BalanceSheetLocationAxis_rigl_AccountsReceivableAndPrepaidAndOtherCurrentAssetsMember_EmK1_sfXdkCE9z-LmqaUnw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">rigl:AccountsReceivableAndPrepaidAndOtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_1_31_2019_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_srt_RangeAxis_srt_MaximumMember_G1KtN3XbpUSoL3F_Q5ONNQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:GrifolsS.a.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_dei_LegalEntityAxis_rigl_FormaTherapeuticsHoldingsIncMember_rigl_AchievementOfMilestoneAxis_rigl_FdaApprovalAndFirstCommercialSaleOfProductMember_srt_ProductOrServiceAxis_rigl_RezlidhiaMember_Q2ZF2zilOEO-sSwctjZDng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:RezlidhiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:FdaApprovalAndFirstCommercialSaleOfProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:FormaTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_1_31_2021_srt_ProductOrServiceAxis_rigl_FostamatinibMember_CbO6IlzEuE-DlB2_dwCYvQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_ICCkO9pPUUSORAn1kecZBA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2023_dei_LegalEntityAxis_rigl_MedisonPharmaLtd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ProductFinancingArrangementMember_BIXtwMz280OZBubIreCp6g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ProductFinancingArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:MedisonPharmaLtd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_dei_LegalEntityAxis_rigl_MedisonPharmaLtd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ProductFinancingArrangementMember_10kT5pgvQESOoSV7Z9NRdg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ProductFinancingArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:MedisonPharmaLtd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_ProductOrServiceAxis_rigl_R552Member_0YBAFpZ08UOLKeVes5ohFA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:R552Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_srt_ProductOrServiceAxis_rigl_R552Member_JPs0ePqXlEKj9VOt8HSlUw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:R552Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_R552Member_-FMAVRdgk0G_DrmYiygA5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:R552Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_KnightTherapeuticsInternationalSaMember_rigl_AchievementOfMilestoneAxis_rigl_SpecifiedCommercialMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_rigl_CommercialAndLicenseAgreementMember_w0GRfq66bE20v4GiBSs-dQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rigl:CommercialAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:SpecifiedCommercialMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:KnightTherapeuticsInternationalSaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_rigl_AchievementOfMilestoneAxis_rigl_DevelopmentAndRegulatoryMilestonesByNonCentralNervousSystemDiseaseProductsMember_srt_StatementScenarioAxis_rigl_MilestonePaymentsOnProductByProductBasisMember_437LgKAaEUCSP1qghK8PUg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">rigl:MilestonePaymentsOnProductByProductBasisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:DevelopmentAndRegulatoryMilestonesByNonCentralNervousSystemDiseaseProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_rigl_AchievementOfMilestoneAxis_rigl_DevelopmentAndRegulatoryMilestonesByCentralNervousSystemDiseaseProductsMember_srt_StatementScenarioAxis_rigl_MilestonePaymentsOnProductByProductBasisMember_GdhaCtbSb0a6DDLJ7JX1QA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">rigl:MilestonePaymentsOnProductByProductBasisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:DevelopmentAndRegulatoryMilestonesByCentralNervousSystemDiseaseProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_rigl_AchievementOfMilestoneAxis_rigl_SpecifiedRegulatoryEventsMember_zr3FrB7HG0yHHKE65ZlQ0g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:SpecifiedRegulatoryEventsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_rigl_AchievementOfMilestoneAxis_rigl_SpecifiedProductLaunchEventsMember_kqeKijsRnkOOsVnTduINrw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:SpecifiedProductLaunchEventsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_rigl_AchievementOfMilestoneAxis_rigl_SpecifiedDevelopmentEventsMember_sRR_821DCEKRn49CXFeLEw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:SpecifiedDevelopmentEventsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_rigl_AchievementOfMilestoneAxis_rigl_DevelopmentAndRegulatoryMilestonesByNonCentralNervousSystemDiseaseProductsMember_qhsapuJyEU-hSuSu6wuzRA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:DevelopmentAndRegulatoryMilestonesByNonCentralNervousSystemDiseaseProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_rigl_AchievementOfMilestoneAxis_rigl_DevelopmentAndRegulatoryMilestonesByCentralNervousSystemDiseaseProductsMember_Rs41QnjvWk6gGclD-ADolA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:DevelopmentAndRegulatoryMilestonesByCentralNervousSystemDiseaseProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_2_1_2020_To_2_29_2020_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_rigl_AchievementOfMilestoneAxis_rigl_EuropeanMedicinesAgencyApprovalOfFostamatinibForTreatmentOfChronicImmuneThrombocytopenicPurpuraMember_srt_ProductOrServiceAxis_rigl_FostamatinibMember_jRYJphbQ30m9xYIoKA1dgg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:EuropeanMedicinesAgencyApprovalOfFostamatinibForTreatmentOfChronicImmuneThrombocytopenicPurpuraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:GrifolsS.a.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_1_31_2019_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_rigl_AchievementOfMilestoneAxis_rigl_SpecifiedCommercialMilestonesMember_7nbfSECgx0WYA153JYabJQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:SpecifiedCommercialMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:GrifolsS.a.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_7_27_2022_dei_LegalEntityAxis_rigl_FormaTherapeuticsHoldingsIncMember_bDfSL0BJhEWrP72tbRoIWQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:FormaTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-27</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_KnightTherapeuticsInternationalSaMember_us-gaap_TypeOfArrangementAxis_rigl_CommercialAndLicenseAgreementMember_lvwZmBPza0monsr9dfDiMw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rigl:CommercialAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:KnightTherapeuticsInternationalSaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_4_30_2021_JKmOcc6NLUygXEbnIz_jXg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2019_To_10_31_2019_dei_LegalEntityAxis_rigl_MedisonPharmaLtd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ProductFinancingArrangementMember_RZVg4VgmR0iEhiVJHe0OGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ProductFinancingArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:MedisonPharmaLtd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2019_To_10_31_2019_dei_LegalEntityAxis_rigl_MedisonPharmaLtd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_us-gaap_TypeOfArrangementAxis_rigl_CommercialAndLicenseAgreementMember_zpx7xwCeskCPVInu1YwLlw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rigl:CommercialAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:MedisonPharmaLtd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_1_31_2019_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_-3boqmgcW0u1hhv3nltpLw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:GrifolsS.a.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2018_To_10_31_2018_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_PZS9u-OE1EmIeqOd2HsFnw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:KisseiPharmaceuticalCo.Ltd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_rigl_AchievementOfMilestoneAxis_rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember_srt_ProductOrServiceAxis_rigl_FostamatinibMember_iOGTC4JHqEqAcLNDtBnr0Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:OneTimeDeliveryOfDrugSupplyForCommercializationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:KisseiPharmaceuticalCo.Ltd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_YoqQXBJjBkuRMnl_Is2ryA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:GrifolsS.a.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_rigl_AchievementOfMilestoneAxis_rigl_ResearchActivitiesMember_wKD8r5wj8UWbEX-iqfwrAA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:ResearchActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:GrifolsS.a.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_rigl_AchievementOfMilestoneAxis_rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember_ahEiLx0SUk2_jcyttC4ctw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:OneTimeDeliveryOfDrugSupplyForCommercializationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:GrifolsS.a.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_FostamatinibMember_lBFcNSb6mkeW8CR2ORtSjg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_CentralNervousSystemPenetrantIntellectualPropertyMember_u9CM64l4x06mzHqJqirPew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:CentralNervousSystemPenetrantIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_rigl_AchievementOfMilestoneAxis_rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember_srt_ProductOrServiceAxis_rigl_FostamatinibMember_knn1moXg0kCR1PGoGmvEkA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:OneTimeDeliveryOfDrugSupplyForCommercializationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:KisseiPharmaceuticalCo.Ltd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_BiD0k0-zyUKpI2kOTEgwHQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:GrifolsS.a.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_rigl_AchievementOfMilestoneAxis_rigl_ResearchActivitiesMember_86cJ5cqEH0CUdyuPMTHCqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:ResearchActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:GrifolsS.a.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_rigl_AchievementOfMilestoneAxis_rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember_6EJQsZyI7Ei65WKe6vURdw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:OneTimeDeliveryOfDrugSupplyForCommercializationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:GrifolsS.a.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_FostamatinibMember_FfcxPSwT3UW6Q9F1eb4nlg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_CentralNervousSystemPenetrantIntellectualPropertyMember_abvwS7ZRYkCRPqpRi8kUzA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:CentralNervousSystemPenetrantIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_12_31_2022_dei_LegalEntityAxis_rigl_MedisonPharmaLtd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ProductFinancingArrangementMember_FDUx_RGlykuMMywGpuGo3Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ProductFinancingArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:MedisonPharmaLtd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_12_31_2022_FhmwYe6SJ0ePT2UUdm49MA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_rigl_AchievementOfMilestoneAxis_rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember_srt_ProductOrServiceAxis_rigl_FostamatinibMember_X1jrjFNaUUi-0RSb2kWr2A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:OneTimeDeliveryOfDrugSupplyForCommercializationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:KisseiPharmaceuticalCo.Ltd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_AqH_Lz4Dqk2ULht1ffcBfQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:KisseiPharmaceuticalCo.Ltd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_UY3l2klaxkutbshAAhD9Eg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:GrifolsS.a.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_rigl_AchievementOfMilestoneAxis_rigl_ResearchActivitiesMember_bcLtqW_sUUGWAZXyYhABiQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:ResearchActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:GrifolsS.a.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_rigl_AchievementOfMilestoneAxis_rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember__2GzLf2h9Uy8zugKcIpR5Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:OneTimeDeliveryOfDrugSupplyForCommercializationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:GrifolsS.a.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_rigl_CentralNervousSystemPenetrantIntellectualPropertyMember_D23iXamso06lFysd2JS4lQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:CentralNervousSystemPenetrantIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_rigl_AchievementOfMilestoneAxis_rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember_srt_ProductOrServiceAxis_rigl_FostamatinibMember_ijWIH4IdnkaOE9hajv0lhw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:OneTimeDeliveryOfDrugSupplyForCommercializationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:KisseiPharmaceuticalCo.Ltd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_VJof-y5NIUmbhtjjV8-ZnQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:KisseiPharmaceuticalCo.Ltd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_8nDIYOyABEq7e05lMjmqPw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:GrifolsS.a.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_rigl_AchievementOfMilestoneAxis_rigl_ResearchActivitiesMember_15-zZAIzYESjPJ56lMgsMg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:ResearchActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:GrifolsS.a.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_rigl_AchievementOfMilestoneAxis_rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember_2kS72QqQ3EiGnNpkGNQiwg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:OneTimeDeliveryOfDrugSupplyForCommercializationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:GrifolsS.a.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_rigl_CentralNervousSystemPenetrantIntellectualPropertyMember_sJI61AX-gkq7zwYyHj0Hgw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:CentralNervousSystemPenetrantIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2023_srt_ProductOrServiceAxis_rigl_FostamatinibMember_khHoF3cNM0WfiX7y2atpOw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_srt_ProductOrServiceAxis_rigl_NonCentralNervousSystemPenetrantIntellectualPropertyMember_AzcLeTjz60Ckk-4IZ7Z2Yg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:NonCentralNervousSystemPenetrantIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_7_27_2022_dei_LegalEntityAxis_rigl_FormaTherapeuticsHoldingsIncMember_rigl_AchievementOfMilestoneAxis_rigl_SpecifiedCommercialMilestonesMember_puSiFDremkCXvb9X1_0EfA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:SpecifiedCommercialMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:FormaTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-27</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_7_27_2022_dei_LegalEntityAxis_rigl_FormaTherapeuticsHoldingsIncMember_rigl_AchievementOfMilestoneAxis_rigl_DevelopmentAndRegulatoryMilestonesMember_7OkGU0Mcw06DYh7peGdg4g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:DevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:FormaTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-27</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_4hZ--7i_V0a3K3Xee2PShA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_7_27_2023_fIa718F-RUSNkmUlyUHJ_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
        </entity>
        <period>
            <instant>2023-07-27</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_pure_uVIKS5OYQEes3pxG5CV0tw">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_agreement_KRHA7hMTtE2mxosuhHYaSA">
        <measure>rigl:agreement</measure>
    </unit>
    <unit id="Unit_Standard_period_q1X9Nu1d1EeTbsf56ZdECg">
        <measure>rigl:period</measure>
    </unit>
    <unit id="Unit_Standard_item_goOMrhYK4U2jGn5r_GJRhQ">
        <measure>rigl:item</measure>
    </unit>
    <unit id="Unit_Standard_position_WoI3E1kTlEyL4Mc6Z0-iIg">
        <measure>rigl:position</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_Xu_N--yaaU6K7FdyMhFNnQ">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww"
      id="Hidden_CZR7a5zKkEuoZzzA22JcKg"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A"
      id="Hidden_OAAck4EWKEOUhEAsCJb8iw"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww"
      id="Hidden_AbxTGvx4Q0CPiiy6Tx7JJg"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A"
      id="Hidden_Yl_yqQR19EOEkaV4777NXA"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA"
      xsi:nil="true"/>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww"
      decimals="INF"
      id="Hidden_ut8FmrekU0qEihlZMrnsbQ"
      unitRef="Unit_Standard_position_WoI3E1kTlEyL4Mc6Z0-iIg">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <rigl:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardOfferingPeriod
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_sAWGlLehukGUN_F8wkmpLA"
      id="Hidden_PQsDUEtR7km_2RPzqyzkJA">P24M</rigl:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardOfferingPeriod>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ"
      decimals="2"
      id="Hidden_1vCSe6v77U-Pv5aEoT8NYw"
      unitRef="Unit_Divide_USD_shares_Xu_N--yaaU6K7FdyMhFNnQ">-0.04</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_4_1_2022_To_6_30_2022_ICCkO9pPUUSORAn1kecZBA"
      decimals="2"
      id="Hidden_rANeXql6ykWq9e5A-w2NuA"
      unitRef="Unit_Divide_USD_shares_Xu_N--yaaU6K7FdyMhFNnQ">-0.08</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      decimals="2"
      id="Hidden_L9LT0bCefkCJMaNCePj8fQ"
      unitRef="Unit_Divide_USD_shares_Xu_N--yaaU6K7FdyMhFNnQ">-0.12</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g"
      decimals="2"
      id="Hidden_WLazubqkGEyubmaVA5dzKw"
      unitRef="Unit_Divide_USD_shares_Xu_N--yaaU6K7FdyMhFNnQ">-0.24</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ"
      decimals="-3"
      id="Hidden_UyLeVOcoUUaabboWsjSswA"
      unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA">173748000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_4_1_2022_To_6_30_2022_ICCkO9pPUUSORAn1kecZBA"
      decimals="-3"
      id="Hidden_rxVm8W3E4E6qxzONFlRoZQ"
      unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA">172147000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      decimals="-3"
      id="Hidden_SQp-nWz5iEWvz4nR5H-ayw"
      unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA">173659000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g"
      decimals="-3"
      id="Hidden_2wnfhWvUgEWjiutudXGVNg"
      unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA">171961000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <rigl:NetSubleaseIncomeExpense
      contextRef="Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ"
      id="Hidden_if_nK6gayEetouowdVil5w"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA"
      xsi:nil="true"/>
    <rigl:NetSubleaseIncomeExpense
      contextRef="Duration_4_1_2022_To_6_30_2022_ICCkO9pPUUSORAn1kecZBA"
      id="Hidden_v_fUsNyOv0y60ttHM-hoPg"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA"
      xsi:nil="true"/>
    <rigl:NetSubleaseIncomeExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      id="Hidden_n4oiXcFrkUefbhZElnx3QQ"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA"
      xsi:nil="true"/>
    <rigl:NetSubleaseIncomeExpense
      contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g"
      id="Hidden_RzHufXubkkibtQabd8gePg"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA"
      xsi:nil="true"/>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      id="Hidden_ZClN4TxlXECXi30paBlJgA">RIGEL PHARMACEUTICALS INC</dei:EntityRegistrantName>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      id="Hidden_9W3VprSizE2GIycyz962gg">Accelerated Filer</dei:EntityFilerCategory>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      id="Tc_KaQnbPBX-kG6t4mnWtmamw_1_1">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      id="Tc_N1JIIWD_dkqnYGRA1SuNuA_2_1">0001034842</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      id="Tc_cx0vSkDxPUCCnC7bLpJFBA_3_1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      id="Tc_ufCvMqiuqUyhkklQbX1CxA_4_1">false</dei:AmendmentFlag>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      id="Tc_Xf9SiwJHW0yM2basTIH4pw_5_1">2023-06-30</dei:DocumentPeriodEndDate>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      id="Hidden_evwQgBeMCkK3vHVn6qdmTA">NASDAQ</dei:SecurityExchangeName>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_rigl_ShareBasedCompensationOptionsAndRsusMember__foVAAxJ0UaZLSEd-5d-Tw"
      id="Hidden_gNM8FB3j1EmiM03O-NFNhA">P2Y7M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <rigl:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardOfferingPeriod
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_sAWGlLehukGUN_F8wkmpLA"
      id="Hidden_zvVmLYm5wkGT80D-sHpXHw">P24M</rigl:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardOfferingPeriod>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_sAWGlLehukGUN_F8wkmpLA"
      id="Hidden_uq0rUsBH7E2jbRn6gMjYeg">P0Y8M26D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <rigl:CollaborativeArrangementRevenueRecognized
      contextRef="Duration_1_1_2022_To_6_30_2022_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_VJof-y5NIUmbhtjjV8-ZnQ"
      decimals="-5"
      id="Hidden__wXnWXc-L0ayd7KDHxLEEA"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">5000000</rigl:CollaborativeArrangementRevenueRecognized>
    <rigl:CollaborativeArrangementRevenueRecognized
      contextRef="Duration_4_1_2022_To_6_30_2022_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_AqH_Lz4Dqk2ULht1ffcBfQ"
      decimals="-5"
      id="Hidden_DbLhvPAx_0Cf0r70yTVP_Q"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">5000000</rigl:CollaborativeArrangementRevenueRecognized>
    <rigl:CollaborativeArrangementRevenueRecognized
      contextRef="Duration_10_1_2022_To_12_31_2022_FhmwYe6SJ0ePT2UUdm49MA"
      decimals="-5"
      id="Hidden_sIEQoBwV_0WCfNDnOrc4Wg"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">20000000</rigl:CollaborativeArrangementRevenueRecognized>
    <rigl:PaymentsOfMilestonePaymentObligations
      contextRef="Duration_1_1_2023_To_3_31_2023_dei_LegalEntityAxis_rigl_FormaTherapeuticsHoldingsIncMember_rigl_AchievementOfMilestoneAxis_rigl_FdaApprovalAndFirstCommercialSaleOfProductMember_srt_ProductOrServiceAxis_rigl_RezlidhiaMember_Q2ZF2zilOEO-sSwctjZDng"
      decimals="-5"
      id="Hidden_Muf8QwRdCECWl-UXgvN83Q"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">15000000</rigl:PaymentsOfMilestonePaymentObligations>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_rigl_HeadquartersOfficeSpaceSubleaseSouthSanFranciscoCaliforniaMember_RzRVSQYro0qfZzFsimZvQA"
      decimals="-5"
      id="Hidden_WC8UdES80kWQ1oTf-c3WYQ"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">1300000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_rigl_HeadquartersOfficeSpaceSubleaseSouthSanFranciscoCaliforniaMember_Q7wBI-TD_USrGUm0m_WO2A"
      id="Hidden_V6j-ReLR3UOlKbpOTUVtAQ">P1Y11M1D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ"
      id="Hidden_QCL7E72EDUS0cbuyFXFOTg">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ"
      id="Hidden_k-kBHamybk-ItVew0754Ag">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ"
      id="Hidden__T-axW871EyqhlqnUc5L-w">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ"
      id="Hidden_GN8AxaIWvEm84zA14uJG0g">false</ecd:NonRule10b51ArrTrmntdFlag>
    <dei:DocumentType
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      id="Narr_H2Qgw6preU-ZbdafRUAFng">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      id="Tc_3Q8gq7Pvv0G32lV-7EuzUw_1_0">true</dei:DocumentQuarterlyReport>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      id="Narr_5Gwn16cB1kCzuT_O_RvJqw">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      id="Tc_kf3ZNU9gekid-IYvP0gfQw_1_0">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      id="Narr_UjF5qDM7vU-N_Ide1yT-yw">0-29889</dei:EntityFileNumber>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      id="Tc_R1RkvsxCrkyY4_uodX1_vw_2_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      id="Tc_PrB9BXxdI0OJQbyuJ6emMQ_2_2">94-3248524</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      id="Tc_Zppv8ctPUEyQ0fr3Q7BV0w_2_0">611 Gateway Boulevard, Suite 900,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      id="Narr_ZcTkIoHLiUCp-Jw5XWcrWg">South San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      id="Narr_WyZaZD1Yeku-2DOPLx7WNw">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      id="Tc_5NFcNfhMKkqe6uq5aOcYaQ_3_2">94080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      id="Narr_Aoo2NMJREUufY_kJUOBMKA">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      id="Narr_NnLK472__kSuadk_oQvOzg">624-1100</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      id="Tc_1HdmmcLE8U6EOV702269YA_3_0">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      id="Tc__RlQR8vZ_kKs-x_QSu7ngw_3_2">RIGL</dei:TradingSymbol>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      id="Narr_jo811cwFrUynToMz7z3y0Q">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      id="Narr_zz4ubYedxkCouKbn1LMVxA">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      id="Narr_8hPpQeeVoEyP_fV_6SHYmg">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      id="Narr_iVsrfVn3SUOpaKOXhBvJXQ">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      id="Narr_vcWzkH8yjU2x6ZDvUqlIDg">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_7_27_2023_fIa718F-RUSNkmUlyUHJ_A"
      decimals="INF"
      id="Narr_aWDHvsSTJUah9eekU99pfQ"
      unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA">174364286</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww"
      decimals="-3"
      id="Tc_jSu8PRRNJUu-kkzKuxPKgg_6_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">48812000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A"
      decimals="-3"
      id="Tc_7aULfNOXV0Sj_zpprf3MHw_6_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">24459000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww"
      decimals="-3"
      id="Tc_0fwe7EJ8xEWsuHPyZWaY6Q_7_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">15545000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A"
      decimals="-3"
      id="Tc_dH3EI8QT_kCpnWkrIy4Fcw_7_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">33747000</us-gaap:ShortTermInvestments>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww"
      decimals="-3"
      id="Tc_Mvj0XWw8eE-z23AS_X-Asg_8_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">20819000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A"
      decimals="-3"
      id="Tc_rbZ6Wy4BVESGnmbhN1Ir4Q_8_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">40320000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww"
      decimals="-3"
      id="Tc_hR-941ee6EeTD1TAzNqTvA_9_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">10782000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A"
      decimals="-3"
      id="Tc_aaalVsEafUWZv7K--MYsiQ_9_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">9118000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww"
      decimals="-3"
      id="Tc_S73nBUob8UmppLls8W_Hwg_10_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">4967000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A"
      decimals="-3"
      id="Tc_UPBLo-IV2kWq72mIn_6lkQ_10_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">8259000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww"
      decimals="-3"
      id="Tc_M6BkMCovjEa0oXwCsHYw9A_11_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">100925000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A"
      decimals="-3"
      id="Tc_Nn7r0J4NyUWwPs7TbTSXsA_11_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">115903000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww"
      decimals="-3"
      id="Tc_AbJ81LH_WUG5mUitQWgGJw_12_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">215000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A"
      decimals="-3"
      id="Tc_OnSgtgK-UUm7m5ztFE9DFg_12_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">857000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww"
      decimals="-3"
      id="Tc_Lu7RwDI43E2TUof2PMNh2Q_13_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">14413000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A"
      decimals="-3"
      id="Tc_GP6twiNt_USvmrHueKxc2Q_13_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">14949000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww"
      decimals="-3"
      id="Tc_lQB12j3nmUuo2-QVr5Z-Fw_14_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">997000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A"
      decimals="-3"
      id="Tc_YsvhUGZRSkGuErMGRIi-FA_14_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">1930000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww"
      decimals="-3"
      id="Tc_N9_E217oBUCe4cOi9O4XEw_15_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">541000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A"
      decimals="-3"
      id="Tc_Y34k5E-qGUCf6f9bUuIbDw_15_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">640000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww"
      decimals="-3"
      id="Tc_i-hqAc8jNkuwIv84auBrPQ_16_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">117091000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A"
      decimals="-3"
      id="Tc_SwnvJVXmdUeyRVffiEjlhw_16_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">134279000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww"
      decimals="-3"
      id="Tc_HN87il0WuE2bGkEcUdPY6g_19_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">5240000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A"
      decimals="-3"
      id="Tc_mhQVyEAzN0exMJzvwROAHA_19_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">22508000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww"
      decimals="-3"
      id="Tc_t538cbm6nE68w5Idp_dDTA_20_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">6739000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A"
      decimals="-3"
      id="Tc_T301qmyAEU6gLd1TmTX9cQ_20_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">8866000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <rigl:AccruedResearchAndDevelopmentLiabilityCurrent
      contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww"
      decimals="-3"
      id="Tc_DkHbQH9TikCMVa3plX03qw_21_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">5826000</rigl:AccruedResearchAndDevelopmentLiabilityCurrent>
    <rigl:AccruedResearchAndDevelopmentLiabilityCurrent
      contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A"
      decimals="-3"
      id="Tc_F9EBNLVOdU6z8M2cG7UBqw_21_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">7708000</rigl:AccruedResearchAndDevelopmentLiabilityCurrent>
    <us-gaap:ContractWithCustomerRefundLiabilityCurrent
      contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww"
      decimals="-3"
      id="Tc_AJqprIedvU2n4lq-KaNFAw_22_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">13684000</us-gaap:ContractWithCustomerRefundLiabilityCurrent>
    <us-gaap:ContractWithCustomerRefundLiabilityCurrent
      contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A"
      decimals="-3"
      id="Tc_G2p9MkZME0yVWvyZKBpsAA_22_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">12145000</us-gaap:ContractWithCustomerRefundLiabilityCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww"
      decimals="-3"
      id="Tc_uIttbhHfmUiSuMpEdbaLtQ_23_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">5013000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A"
      decimals="-3"
      id="Tc_N6S5SzpfV0Sl3SuCQdBXCg_23_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">6485000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww"
      decimals="-3"
      id="Tc_ds-d2jYnFUiEAHrtzvCjag_24_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">466000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A"
      decimals="-3"
      id="Tc_p507IcdKE0u39YxTLilCaA_24_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">1133000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww"
      decimals="-3"
      id="Tc_x1BtFuqafUy5OtgfqqUwAw_25_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">1355000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A"
      decimals="-3"
      id="Tc_Zw3DU4340kifwlCqx09CeQ_25_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">1369000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww"
      decimals="-3"
      id="Tc_2lO3pQN9q0GXAxvxrHa5MA_26_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">5700000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A"
      decimals="-3"
      id="Tc_uJIyAw0cx0GTT958aT_BWQ_26_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">4997000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww"
      decimals="-3"
      id="Tc_J0ee9C9GDUmVtgzOBt4DGw_27_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">44023000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A"
      decimals="-3"
      id="Tc_ObPFkSbTkEqkCthYipA-GA_27_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">65211000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww"
      decimals="-3"
      id="Tc_MMaCY97U3kOY5pqmNIfFFA_28_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">628000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A"
      decimals="-3"
      id="Tc_6PPgfdKBvEWpu0LdWLMECw_28_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">972000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LongTermLoansPayable
      contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww"
      decimals="-3"
      id="Tc_cswCv0r8HE2zLNd5ybEqiA_29_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">59574000</us-gaap:LongTermLoansPayable>
    <us-gaap:LongTermLoansPayable
      contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A"
      decimals="-3"
      id="Tc_DcNUELMVekmnVvEabI1ywg_29_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">39448000</us-gaap:LongTermLoansPayable>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww"
      decimals="-3"
      id="Tc_WraFcgzxI0eSoO0_-07Ixw_30_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">40981000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A"
      decimals="-3"
      id="Tc_cZSBHk0r3Eqa1HbmU0M8hg_30_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">42264000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww"
      decimals="-3"
      id="Tc_qmzUVq7GhkuJehWJ8dl10w_31_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">145206000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A"
      decimals="-3"
      id="Tc_2d5ZZ1_xB06bCl_U9sOHiA_31_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">147895000</us-gaap:Liabilities>
    <us-gaap:CommonStockValue
      contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww"
      decimals="-3"
      id="Tc_-e6MfQOzmUifyTEhu1ntNw_37_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">175000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A"
      decimals="-3"
      id="Tc_wtlGTTLNa0iBamhCu-UPZA_37_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">174000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww"
      decimals="-3"
      id="Tc_BDOC9Irtd0OSIWObotgDnQ_38_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">1374330000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A"
      decimals="-3"
      id="Tc_aNmETaucNUuNEJm9s9Ag-g_38_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">1368822000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww"
      decimals="-3"
      id="Tc_MLEyM-z53kC891Z75LATVA_39_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-25000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A"
      decimals="-3"
      id="Tc_Q7OlZ7npCkakiGnRXEvolA_39_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-153000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww"
      decimals="-3"
      id="Tc_9-CXquhw4UKeX9E0myePDQ_40_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-1402595000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A"
      decimals="-3"
      id="Tc_IJSB9j8VCk6bnwxP5YDDDQ_40_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-1382459000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww"
      decimals="-3"
      id="Tc_jC-BbyH7ekay44Vt-h5v3A_41_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-28115000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A"
      decimals="-3"
      id="Tc_PP7n2efzr0eyGn8WgZX-UA_41_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-13616000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww"
      decimals="-3"
      id="Tc_14gvs43i4UWkSOA9qoyg-Q_42_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">117091000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A"
      decimals="-3"
      id="Tc_UAy2XGC0M0W3hxE1lDORVQ_42_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">134279000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_v4jyMWOILkimNDJi27bJNA"
      decimals="-3"
      id="Tc_AYR1u19h10GkURi7LSBdyg_4_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">23881000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_4_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_Zl3JCD-6OEeEiUA808bVig"
      decimals="-3"
      id="Tc_cFBiMaKO_0yrDrUhYwKNog_4_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">18550000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_C2EWGpiFxUGr9E995bXhCQ"
      decimals="-3"
      id="Tc_IVGjji-Mj0Gz5w2C8P9HNw_4_9"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">47626000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_I08rIoA1_0itpE8QmmW4zw"
      decimals="-3"
      id="Tc_uyMTW8nPIUC2bCPv51ITBw_4_12"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">34747000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_ContractRevenuesFromCollaborationsMember_yU4TzCXKCkSEqjOPYCD5ig"
      decimals="-3"
      id="Tc_g1skwfyR1kyKIAWHLXKQrg_5_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">2005000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_4_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_rigl_ContractRevenuesFromCollaborationsMember_B3F0S8vRz0eWxrI-zbC5eQ"
      decimals="-3"
      id="Tc_kaW5Jpto3U69-G7SVSvDhg_5_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">11269000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_ContractRevenuesFromCollaborationsMember_TmFkSqljNUiYYmkDnr-3ag"
      decimals="-3"
      id="Tc_pzW-twG2MkWkeNrjM51nBw_5_9"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">4330000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_rigl_ContractRevenuesFromCollaborationsMember_LOIZvjtJ4kefhhUMq6-K0Q"
      decimals="-3"
      id="Tc_4zPp_yZI8EG7U-D8frGshg_5_12"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">11807000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_GovernmentContractMember_WN0BoWdZGU-KXqAccwJ68A"
      decimals="-3"
      id="Tc__GyOGKM3ikK-NjMY67EPPw_6_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">1000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_GovernmentContractMember_9xcr5RYkM0WkIqJKKgDS8A"
      decimals="-3"
      id="Tc_9blN2CRkp0WRP1ar2J6O0Q_6_9"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">1000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ"
      decimals="-3"
      id="Tc_ZI3Qc0DCGk6Ib4IqPWJsgA_7_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">26886000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_4_1_2022_To_6_30_2022_ICCkO9pPUUSORAn1kecZBA"
      decimals="-3"
      id="Tc_MQbkJMur2kuvrzj7thF76Q_7_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">29819000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      decimals="-3"
      id="Tc_XIvCZTN3fkWHLyyr5s-vow_7_9"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">52956000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g"
      decimals="-3"
      id="Tc_TIEZLSeo50qq2pAy2P4hCA_7_12"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">46554000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ"
      decimals="-3"
      id="Tc_54XkK_D0F0evbpD2wddr1Q_9_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">1075000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="Duration_4_1_2022_To_6_30_2022_ICCkO9pPUUSORAn1kecZBA"
      decimals="-3"
      id="Tc_b3CdDAqhN0KvCMkkQO7-GA_9_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">1036000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      decimals="-3"
      id="Tc_vL9KNhrwlEmer2-k8k2EUg_9_9"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">2052000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g"
      decimals="-3"
      id="Tc_rzPxjlSOeEeBD8vsFOenvg_9_12"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">1157000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ"
      decimals="-3"
      id="Tc_2Vk4y4IeSkG44LHiqplz6Q_10_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">4772000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_4_1_2022_To_6_30_2022_ICCkO9pPUUSORAn1kecZBA"
      decimals="-3"
      id="Tc_27aLj4qVt0KPpOyiCAl_Mw_10_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">14767000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      decimals="-3"
      id="Tc_pRgG-FisYUinBt76A9x2_A_10_9"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">14861000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g"
      decimals="-3"
      id="Tc_Z-epsfwgXky5riFBszGLSg_10_12"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">30241000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ"
      decimals="-3"
      id="Tc_yEuQ7iCSzUGP7pIsTWtETw_11_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">26306000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_4_1_2022_To_6_30_2022_ICCkO9pPUUSORAn1kecZBA"
      decimals="-3"
      id="Tc_PS94dv1nCU-IwyR1h-zjxQ_11_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">26981000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      decimals="-3"
      id="Tc_sogkdc9mA06M34BD4fqaIg_11_9"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">54035000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g"
      decimals="-3"
      id="Tc_9dFNIxc_PU6mgo9-zrY7mQ_11_12"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">54382000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ"
      decimals="-3"
      id="Tc_Jyp0by236kufzSD5XowOJg_12_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">32153000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="Duration_4_1_2022_To_6_30_2022_ICCkO9pPUUSORAn1kecZBA"
      decimals="-3"
      id="Tc_T-ttd5_npUKMRWWsPNRjnQ_12_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">42784000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      decimals="-3"
      id="Tc_ApDp64aWM0ym_Y7zUbBYAQ_12_9"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">70948000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g"
      decimals="-3"
      id="Tc_foKObuF7xkO8kHFoDkXUHg_12_12"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">85780000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ"
      decimals="-3"
      id="Tc_6GU6cHyq8EGmkipN0S9Jvg_13_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-5267000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_4_1_2022_To_6_30_2022_ICCkO9pPUUSORAn1kecZBA"
      decimals="-3"
      id="Tc_SoZZwI3AQEuGGFDI7U9SlA_13_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-12965000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      decimals="-3"
      id="Tc_yr8u39e6hUSv_GJgx6AYHQ_13_9"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-17992000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g"
      decimals="-3"
      id="Tc_oblCfl7ej0C1mSgHUJyvqw_13_12"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-39226000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ"
      decimals="-3"
      id="Tc_6G3usvialESGceYyUfpmWg_14_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">529000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_4_1_2022_To_6_30_2022_ICCkO9pPUUSORAn1kecZBA"
      decimals="-3"
      id="Tc_HqrvFXXEQUaIWIriVxSGcw_14_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">42000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      decimals="-3"
      id="Tc_YKIP_yuP7kWASDDhntCBDw_14_9"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">922000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g"
      decimals="-3"
      id="Tc_d0t3KAlmwEywHf9PlUJH4A_14_12"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">63000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ"
      decimals="-3"
      id="Tc_jjxoT-DOZkOfBnZfJVjOxA_15_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">1862000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="Duration_4_1_2022_To_6_30_2022_ICCkO9pPUUSORAn1kecZBA"
      decimals="-3"
      id="Tc_5LWT2cWiJka6sAdO3x5NoQ_15_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">569000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      decimals="-3"
      id="Tc_Sj9K6nZ8jkCu24uKMPn_Lg_15_9"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">3066000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g"
      decimals="-3"
      id="Tc_Vx2ktfg57E6qUn31LzaNuQ_15_12"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">1774000</us-gaap:InterestExpense>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ"
      decimals="-3"
      id="Tc_zqnjPA5HOkm9G-Bmyj1U3w_16_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-6600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2022_To_6_30_2022_ICCkO9pPUUSORAn1kecZBA"
      decimals="-3"
      id="Tc_WtOWZw6GokmVko9UaeJlBA_16_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-13492000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      decimals="-3"
      id="Tc_1I7Lzj8rWkScniC54J_2fQ_16_9"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-20136000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g"
      decimals="-3"
      id="Tc_fOM0P11ID0eM25Wekyy2dw_16_12"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-40937000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ"
      decimals="2"
      id="Tc_2Pfn2326pkiZvQovL-BxVw_18_3"
      unitRef="Unit_Divide_USD_shares_Xu_N--yaaU6K7FdyMhFNnQ">-0.04</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_4_1_2022_To_6_30_2022_ICCkO9pPUUSORAn1kecZBA"
      decimals="2"
      id="Tc_PARv9DNHRUKXDTmGoU8qfw_18_6"
      unitRef="Unit_Divide_USD_shares_Xu_N--yaaU6K7FdyMhFNnQ">-0.08</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      decimals="2"
      id="Tc_jhVgRMmfSkSYUHj8FSwexA_18_9"
      unitRef="Unit_Divide_USD_shares_Xu_N--yaaU6K7FdyMhFNnQ">-0.12</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g"
      decimals="2"
      id="Tc_64ajk4oDeEOVPiORoqPMKA_18_12"
      unitRef="Unit_Divide_USD_shares_Xu_N--yaaU6K7FdyMhFNnQ">-0.24</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ"
      decimals="-3"
      id="Tc_VDNvISXPGEyrBomADsILVA_20_3"
      unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA">173748000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_4_1_2022_To_6_30_2022_ICCkO9pPUUSORAn1kecZBA"
      decimals="-3"
      id="Tc_CypmmOM2LUe4F1JNYoAK2w_20_6"
      unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA">172147000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      decimals="-3"
      id="Tc_1AsAU20LOUO1lMDIevdOyw_20_9"
      unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA">173659000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g"
      decimals="-3"
      id="Tc_Q9nMi9n1YkSF64FknV1XDA_20_12"
      unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA">171961000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ"
      decimals="-3"
      id="Tc_aJbpZrDx4UOSgWJgG3nBrg_3_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-6600000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_4_1_2022_To_6_30_2022_ICCkO9pPUUSORAn1kecZBA"
      decimals="-3"
      id="Tc_l84q1Q0Av0ipsqgT9oK2eg_3_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-13492000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      decimals="-3"
      id="Tc_5pLbk6NCIU-xP_vWkP026w_3_9"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-20136000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g"
      decimals="-3"
      id="Tc_pIWP2_0ewk2d8ChV3tkyfA_3_12"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-40937000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ"
      decimals="-3"
      id="Tc_rDawXEz0nEKtkEpguKwhtQ_5_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">2000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_4_1_2022_To_6_30_2022_ICCkO9pPUUSORAn1kecZBA"
      decimals="-3"
      id="Tc_ImgVBkfx60-PrUE0KijI9A_5_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-22000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      decimals="-3"
      id="Tc_CMmeF9OmYk2_1oqhuk_Iug_5_9"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">128000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g"
      decimals="-3"
      id="Tc_4MKZeBRy6USuYISk-8zkkw_5_12"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-336000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ"
      decimals="-3"
      id="Tc_9DhexomIZ0yRHckqe1pn9A_6_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-6598000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_4_1_2022_To_6_30_2022_ICCkO9pPUUSORAn1kecZBA"
      decimals="-3"
      id="Tc_alWsbYQkkESMcxxsJL_kJg_6_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-13514000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      decimals="-3"
      id="Tc_eVIjV1qg4UisJf8E7k1AfQ_6_9"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-20008000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g"
      decimals="-3"
      id="Tc_cyXvG7Uf1UqeDwKqAP6eJg_6_12"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-41273000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesIssued
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xvjnxqS-hkCiR6PhUg5rig"
      decimals="INF"
      id="Tc_JwfiQK7BNE64a7u4CS057Q_5_2"
      unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA">173398645</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xvjnxqS-hkCiR6PhUg5rig"
      decimals="-3"
      id="Tc_ueNtVZ2OPEWA9FoYaeQczQ_5_5"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">174000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_H75YemqVnEyPwV--MIGWGw"
      decimals="-3"
      id="Tc_qhkCoLDXWki_T9qP5KPc_Q_5_8"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">1368822000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_lUJBYmkmN0mPdtrXTwmLYw"
      decimals="-3"
      id="Tc_-mheQl8DOkOJJ67ZaOBENA_5_11"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-153000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_7r-CKjYwcEWPEVrhWmkNzw"
      decimals="-3"
      id="Tc_gJiRf3oUi02JMVv-4sFC7A_5_14"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-1382459000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A"
      decimals="-3"
      id="Tc_vKX1l1lh2k6_ZsypxObT9A_5_17"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-13616000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_lxmvkD9RK0qU7ZM5gMSIQw"
      decimals="-3"
      id="Tc_mYF0xxicrkO_T7Exj5_tHw_6_14"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-13536000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2023_To_3_31_2023_qfQwkxMZLU6ffGWe8LPnaQ"
      decimals="-3"
      id="Tc_qwI8mdLj7E-Ek14O49UCEA_6_17"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-13536000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_hHQBvZ1Mi06kiRDiBIcvOg"
      decimals="-3"
      id="Tc_msD9ZTGpbEyTu7D3m00xkg_7_11"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">126000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2023_To_3_31_2023_qfQwkxMZLU6ffGWe8LPnaQ"
      decimals="-3"
      id="Tc_VVTTIRmNu0GXk6Y4UYiQQg_7_17"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">126000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1ylsF_WCdkeufVQaI9L5Qg"
      decimals="INF"
      id="Tc_jwbJ8SxvS0i86p8pv9PtSw_8_2"
      unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA">952</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_pug8RCBYIkeZTp1-6vn_VQ"
      decimals="-3"
      id="Tc_5X0IqEbAJUG7jXBpwAlWAw_8_8"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2023_To_3_31_2023_qfQwkxMZLU6ffGWe8LPnaQ"
      decimals="-3"
      id="Tc_aCUIjFCUUEqYpTe-fY3siA_8_17"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1ylsF_WCdkeufVQaI9L5Qg"
      decimals="INF"
      id="Tc_Eq8NS4__qU6jo4AqaQJhxg_9_2"
      unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA">266256</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_pug8RCBYIkeZTp1-6vn_VQ"
      decimals="-3"
      id="Tc_quRM8UO-aE-uf9_OJ2p-9g_10_8"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">2768000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2023_To_3_31_2023_qfQwkxMZLU6ffGWe8LPnaQ"
      decimals="-3"
      id="Tc_D1OqN_YNtE6IMB_SyasYJA_10_17"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">2768000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:SharesIssued
      contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0zb7z7FwO0GI2RAEVAHXQw"
      decimals="INF"
      id="Tc_T6cvZ--nvUSqmCQzpwlCLg_11_2"
      unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA">173665853</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0zb7z7FwO0GI2RAEVAHXQw"
      decimals="-3"
      id="Tc_u5WAMVqPc0uOpZg9ASoq-A_11_5"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">174000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_OfzaBWn7ikCSgv7BTwXlfQ"
      decimals="-3"
      id="Tc_iqe6r69m_UONp2oot7FN6Q_11_8"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">1371591000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4ofcdRQIYUqAzW1HPzZ5vA"
      decimals="-3"
      id="Tc_VIsQZ5DRRUGuJqoHhgsBgQ_11_11"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-27000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_zZnbux6ITEas3Z5CntDoJA"
      decimals="-3"
      id="Tc_5umZPAHW-EWqNgs1isT-Yw_11_14"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-1395995000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2023_BgUu_xw-pEOX64_3oVKFUQ"
      decimals="-3"
      id="Tc_kq2HMy-7IkiLks0tea-y4w_11_17"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-24257000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_BC0bgoovFkSFc26FtpY0vA"
      decimals="-3"
      id="Tc_LObPwnJd3ku2VXZfJGs0_g_12_14"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-6600000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ"
      decimals="-3"
      id="Tc_u3zdg3RxDEOSZRFIpS7LpQ_12_17"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-6600000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_QxrzwDPl-02u7MxFvVCYNQ"
      decimals="-3"
      id="Tc_pLdRAopxMkGZizUv8BwKow_13_11"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">2000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ"
      decimals="-3"
      id="Tc_CvZ3Y8w2l0y231zOzX0-PA_13_17"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">2000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2mIl79LxpkuN5mgFsNHdfg"
      decimals="INF"
      id="Tc_RigDEjXgG0mHzvrIdUoIDQ_14_2"
      unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA">523795</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2mIl79LxpkuN5mgFsNHdfg"
      decimals="-3"
      id="Tc_moBZMR4lLE-R3W4gJxlJBw_14_5"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_OPWXZu-4xESxTw7UEzGEfw"
      decimals="-3"
      id="Tc_oT7rh2ehm02VoSNOAOwq7g_14_8"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">553000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ"
      decimals="-3"
      id="Tc_P0pTmw4yekKkpiCuLSGxbg_14_17"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">554000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2mIl79LxpkuN5mgFsNHdfg"
      decimals="INF"
      id="Tc_bklHtHdq5UWMTREPp1nirw_15_2"
      unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA">168750</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_OPWXZu-4xESxTw7UEzGEfw"
      decimals="-3"
      id="Tc_u-rJn-Fb0kSvt37rq1WBpA_16_8"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">2186000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ"
      decimals="-3"
      id="Tc_lUXCqGeZO0ugoKOx_kPcug_16_17"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">2186000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:SharesIssued
      contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NXFVM5fZJUmDlMyyzE1ttg"
      decimals="INF"
      id="Tc_YQX8SDjrW0ayPLkrE1D8mA_17_2"
      unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA">174358398</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NXFVM5fZJUmDlMyyzE1ttg"
      decimals="-3"
      id="Tc_WV6wTmm9MUy6msu9fpFJ0Q_17_5"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">175000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_GsGkBqFtIEeF4t6uDl64RA"
      decimals="-3"
      id="Tc_9g9ZkuqDTkqe3ORi9rKspA_17_8"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">1374330000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_uWcj3WWP8EKEJxuUNUBsng"
      decimals="-3"
      id="Tc_3Cr5--3bFEuy1ySTRLhAOg_17_11"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-25000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_6WAzHoGFsEyRh9-_I-EgwA"
      decimals="-3"
      id="Tc_zDGHfU8VBEu1GXsVUlq00A_17_14"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-1402595000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww"
      decimals="-3"
      id="Tc_9otVWMH_70CJIBQ__eYLdg_17_17"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-28115000</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Mal6s5t5Z0qQ9EIsFrTGuQ"
      decimals="INF"
      id="Tc_9630uB8pm0eu8yrUab_FXw_5_2"
      unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA">171602226</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Mal6s5t5Z0qQ9EIsFrTGuQ"
      decimals="-3"
      id="Tc_9w-moQH0mEOMF3lMNdp7aA_5_5"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">172000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_2EWYq3VBqUSwnhTDnAcB0w"
      decimals="-3"
      id="Tc_umK9uqWS4UqMv7J2IPaK-A_5_8"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">1354190000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_n7Oc0ne_BUqW0jhEW7x51g"
      decimals="-3"
      id="Tc_XoBKpEu2DEi52PHtaXYXrw_5_11"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-102000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_j5agreqUq0C05wMxAlbdRg"
      decimals="-3"
      id="Tc_XKJ9onduHkuMu13cTAQmlA_5_14"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-1323886000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_LY4sWUaA_UOIKxqqgZ5UAQ"
      decimals="-3"
      id="Tc_aKPgsf-zq0iLiYGbLxXyhg_5_17"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">30374000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_egDPK9MhIkOXkH42vVRrWw"
      decimals="-3"
      id="Tc_Qp1k46t3S0qXqu8Pls812A_6_14"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-27445000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2022_To_3_31_2022_NyURkj24PU2gRd22NkwY9w"
      decimals="-3"
      id="Tc_zqbBUdwjgEKWZLHJ5hbPWg_6_17"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-27445000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_n9loXyMYREivaHgcSKMHMA"
      decimals="-3"
      id="Tc_1W1o91sItke2BWpNCH7K1g_7_11"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-314000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2022_To_3_31_2022_NyURkj24PU2gRd22NkwY9w"
      decimals="-3"
      id="Tc_dRQC73AETEuJhm-vyM7uGw_7_17"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-314000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_h87Ta8IYBkSUtMHbuewiIg"
      decimals="INF"
      id="Tc_4G5-1bAMp0OordgwR0OiuQ_8_2"
      unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA">420521</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_q29chwJC8UWqOM6gViWQCA"
      decimals="-3"
      id="Tc_7YzP15-M_UuhACsMs2VoMA_8_8"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">940000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2022_To_3_31_2022_NyURkj24PU2gRd22NkwY9w"
      decimals="-3"
      id="Tc_H-rguhRj8kGMiFf18o7cKA_8_17"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">940000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_h87Ta8IYBkSUtMHbuewiIg"
      decimals="INF"
      id="Tc_snYb7AveaEWB6eVhmWXRcw_9_2"
      unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA">22500</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_q29chwJC8UWqOM6gViWQCA"
      decimals="-3"
      id="Tc_PjxE4CcEAkuOL8M27qvVOw_10_8"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">3243000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2022_To_3_31_2022_NyURkj24PU2gRd22NkwY9w"
      decimals="-3"
      id="Tc_Pz9QszP7YkWgSmSXQQtJMA_10_17"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">3243000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:SharesIssued
      contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4k30MtA2pUm5iDpAhJLPrg"
      decimals="INF"
      id="Tc_UOnkW_bFsEW7qZRyasE_HQ_11_2"
      unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA">172045247</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4k30MtA2pUm5iDpAhJLPrg"
      decimals="-3"
      id="Tc_u4rTx_blik-tqzH379a7kg_11_5"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">172000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_HUMQpp-hhUmkBPR7Q8NCIw"
      decimals="-3"
      id="Tc_jmFvzzJpI0CvWmuxW0DW1g_11_8"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">1358373000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_DP28xveaSEKwPEHlfm8Vvg"
      decimals="-3"
      id="Tc_J8T2Jq7VtkO0ozKRTgq8Fw_11_11"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-416000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_mUlMkH6yV0ev7oy48pw70w"
      decimals="-3"
      id="Tc_o7wOu5KhLUau0W5cNy-1NQ_11_14"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-1351331000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2022_BK3VScSjz0OWZFv-nNNaXA"
      decimals="-3"
      id="Tc_b4KTYJHWBUOOrQi5rW2EOQ_11_17"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">6798000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_aR01SJIgMUW3MS43CRdmBw"
      decimals="-3"
      id="Tc_ehHEDul5sEWHWqPJAyNylA_12_14"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-13492000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_4_1_2022_To_6_30_2022_ICCkO9pPUUSORAn1kecZBA"
      decimals="-3"
      id="Tc_OC7GP5CChkCPTh4KwGWVmQ_12_17"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-13492000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3JpqoXaqL0SrqUrpHTj6kg"
      decimals="-3"
      id="Tc_ry6oOFxT006Pn2Fnchtq9A_13_11"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-22000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_4_1_2022_To_6_30_2022_ICCkO9pPUUSORAn1kecZBA"
      decimals="-3"
      id="Tc_CkXdx2h250u4aJLo-mDWGA_13_17"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-22000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_X0BNnHhQVkGCCdDEwUQPOQ"
      decimals="INF"
      id="Tc_FH_HfewjU0Gfq1awTrmVjw_14_2"
      unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA">609839</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_X0BNnHhQVkGCCdDEwUQPOQ"
      decimals="-3"
      id="Tc_A9l4HYicsU2D3Z6cQB9X_A_14_5"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_jRjTsJgDwE65v_ICJzPELw"
      decimals="-3"
      id="Tc_S44w--rqmku6NBjpuCDOvg_14_8"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">598000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_4_1_2022_To_6_30_2022_ICCkO9pPUUSORAn1kecZBA"
      decimals="-3"
      id="Tc_FL8Ja8JHxE-8_sFG-508kg_14_17"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">599000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_X0BNnHhQVkGCCdDEwUQPOQ"
      decimals="INF"
      id="Tc_vLt95NLFc06L387u1tcGlw_15_2"
      unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA">181250</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_jRjTsJgDwE65v_ICJzPELw"
      decimals="-3"
      id="Tc_SgPa9MskD0-LVkdeOZV6NA_16_8"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">2440000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_4_1_2022_To_6_30_2022_ICCkO9pPUUSORAn1kecZBA"
      decimals="-3"
      id="Tc_bmH6pTEHy0ipVH80kcdBow_16_17"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">2440000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:SharesIssued
      contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8sjAYkMEXkWQKgqr3XNtXg"
      decimals="INF"
      id="Tc_Lhy4m4NvZUiCAUU_bhQeTA_17_2"
      unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA">172836336</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8sjAYkMEXkWQKgqr3XNtXg"
      decimals="-3"
      id="Tc_5AEPm9y6WEqiChTC_URUsw_17_5"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">173000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_8FRPOicKCUukQ6L7AAUMNw"
      decimals="-3"
      id="Tc_mcDDSX6SxU-WpL-PWZgP6A_17_8"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">1361411000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_JNCe4Z95dE6Iw1LvI3RQ4g"
      decimals="-3"
      id="Tc_XEfNbS7o70-S0vm_bI88uQ_17_11"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-438000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_SgCZ7AQnVkal8VnKIFXBDg"
      decimals="-3"
      id="Tc_yLFsJn6-dkeHrSC3aeU7kA_17_14"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-1364823000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2022_X6KPuRq2uEa6dhukywoGKw"
      decimals="-3"
      id="Tc_is4BJMo8VkWh_Fm6HIEhog_17_17"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-3677000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      decimals="-3"
      id="Tc_sQ4fc-YV9kqIKYj2V0sdfw_4_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-20136000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g"
      decimals="-3"
      id="Tc_KsOK0rm2bUKz8JcAKwPqBg_4_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-40937000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      decimals="-3"
      id="Tc_I5ie7dwVTEWrCjvuflNS4w_6_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">4930000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g"
      decimals="-3"
      id="Tc_NGSIRKkmaUuM1_1R1rBF4Q_6_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">5598000</us-gaap:ShareBasedCompensation>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      decimals="-3"
      id="Tc_c8zg9Pve9kO82UoGmE45cA_7_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-398000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g"
      decimals="-3"
      id="Tc_fWlO1EQInk2U1U1NIEcWjw_7_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">253000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      decimals="-3"
      id="Tc_Q6xqSJUbyEeTsUfMloTSag_8_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">653000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g"
      decimals="-3"
      id="Tc_x_5y2aLaVU2K_CV-XLjOCA_8_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">474000</us-gaap:DepreciationDepletionAndAmortization>
    <rigl:NoncashInterestExpense
      contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g"
      decimals="-3"
      id="Tc_uIW070NAz0am0p7dX69VkQ_9_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">682000</rigl:NoncashInterestExpense>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      decimals="-3"
      id="Tc_RqoEhhJFXEyGrMB8UeYPag_10_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">114000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g"
      decimals="-3"
      id="Tc_wgiW8gbEt0-i78Y_M_bAEg_10_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-107000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      decimals="-3"
      id="Tc_xxLCHvcmTkeqYUu7VQntVg_12_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-19501000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g"
      decimals="-3"
      id="Tc_xV97d7QBok-WIOYsKBkKLA_12_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">1726000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      decimals="-3"
      id="Tc_v6Ll9k0I5EeyB5BF-kfW7g_13_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">1640000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g"
      decimals="-3"
      id="Tc_7cuzvsx5t0C5c251dO3qFg_13_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-483000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      decimals="-3"
      id="Tc_6M7c0zhg_k-uQ3-YKT8Ljg_14_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-3292000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g"
      decimals="-3"
      id="Tc_9x6FX2A5ekuq7lfl0qRjmg_14_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">527000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      decimals="-3"
      id="Tc_PLeQg27vuEyahQ-gJhAxZQ_15_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-99000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g"
      decimals="-3"
      id="Tc_Khu7_F_A_0KkdE4eu0Ls-w_15_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-571000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <rigl:IncreaseDecreaseRightOfUseAssets
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      decimals="-3"
      id="Tc_KAEFJEAasUywUsQS4DQjwQ_16_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">933000</rigl:IncreaseDecreaseRightOfUseAssets>
    <rigl:IncreaseDecreaseRightOfUseAssets
      contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g"
      decimals="-3"
      id="Tc_Id-CMQMKLEiyEBc4PcYR4A_16_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">4458000</rigl:IncreaseDecreaseRightOfUseAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      decimals="-3"
      id="Tc_XRdgUQdBb0eGBfepFpf4qg_17_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-2268000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g"
      decimals="-3"
      id="Tc_LWQKs_BQPkm-Yo9dJM6r4A_17_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-1585000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      decimals="-3"
      id="Tc__tL6liO5NUWiO1p6SEj7Jg_18_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-2127000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g"
      decimals="-3"
      id="Tc_19g4Hv0OIkGvKzTUEurCAw_18_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-3165000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <rigl:IncreaseDecreaseInAccruedResearchAndDevelopmentLiability
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      decimals="-3"
      id="Tc_H3hvx-g2XUWBUofagX_rpg_19_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-1882000</rigl:IncreaseDecreaseInAccruedResearchAndDevelopmentLiability>
    <rigl:IncreaseDecreaseInAccruedResearchAndDevelopmentLiability
      contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g"
      decimals="-3"
      id="Tc_VUY5rb8uVkWev4uH27jfHg_19_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-1171000</rigl:IncreaseDecreaseInAccruedResearchAndDevelopmentLiability>
    <rigl:RevenueReservesAndRefundLiability
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      decimals="-3"
      id="Tc_iH-GCwyFe0aTLQ10u1YZFA_20_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">1539000</rigl:RevenueReservesAndRefundLiability>
    <rigl:RevenueReservesAndRefundLiability
      contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g"
      decimals="-3"
      id="Tc_aHr2SnwpYE-8Rk6h5tVkSQ_20_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">2316000</rigl:RevenueReservesAndRefundLiability>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      decimals="-3"
      id="Tc_kSFQUphowUahXO1HSfyvkg_21_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-1472000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g"
      decimals="-3"
      id="Tc_IYVubVA8hEmRdZHCZj6Rmg_21_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">1878000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      decimals="-3"
      id="Tc_-kvqxRae3EiCC1tO6IB2hg_22_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-1011000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g"
      decimals="-3"
      id="Tc_7yiN-KW-G0ag9KCOiiQ-Yg_22_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-4840000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      decimals="-3"
      id="Tc_ZX23pqvET0WQjasre79BKw_23_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-14000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g"
      decimals="-3"
      id="Tc_VjLm2PDSHkqmV1afZAEvNA_23_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-1053000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      decimals="-3"
      id="Tc_-TdMnFsRJUCKdHzxPBeQRg_24_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">1175000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g"
      decimals="-3"
      id="Tc_aRk-e-ILz0ShUGkyzKxFyw_24_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">142000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      decimals="-3"
      id="Tc_8tp93Ctfuk-ie4WwyNnZgg_25_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">1856000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g"
      decimals="-3"
      id="Tc_ReiKUZKM8UKU1mrHJIQlLw_25_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-38548000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      decimals="-3"
      id="Tc_376EaXZKmkGa0eNeExapqA_27_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">8780000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g"
      decimals="-3"
      id="Tc_PSRho2B5VEq1Pil597U-og_27_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">6997000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      decimals="-3"
      id="Tc_ThBnYkOdukudC9kLa1olqA_28_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">27400000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
      contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g"
      decimals="-3"
      id="Tc_wHalOnwgo0akh-7IMcNdVw_28_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">50645000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      decimals="-3"
      id="Tc_CQoWl3TQ5UmsZ7v2Ol-BZQ_29_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">15000000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      decimals="-3"
      id="Tc_VUfw1k5_tkGTsL8AHPrrKw_30_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">127000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g"
      decimals="-3"
      id="Tc_N9urej_AFkmk-ANlqA6VFw_30_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">264000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g"
      decimals="-3"
      id="Tc_FhltASC2a0SDEhZSbKBXrw_31_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">188000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      decimals="-3"
      id="Tc_T7BAvF2tekCeo7pbjO4Gmg_32_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">3747000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g"
      decimals="-3"
      id="Tc_zuhmfSIGJUqR4_GbJpjQmA_32_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">43724000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <rigl:PaymentOfCostShareToCollaborationPartner
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      decimals="-3"
      id="Tc_8lKzXXFXj0mAi23V4vC7Ww_34_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">1754000</rigl:PaymentOfCostShareToCollaborationPartner>
    <rigl:PaymentOfCostShareToCollaborationPartner
      contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g"
      decimals="-3"
      id="Tc_ZkdWYTZVrECjIBSzMg72RA_34_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">8346000</rigl:PaymentOfCostShareToCollaborationPartner>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      decimals="-3"
      id="Tc_jIYUUDNNeUuWbOb_ljTprg_35_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">554000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g"
      decimals="-3"
      id="Tc_BaOd7o-yoUORECQoYvqz4A_35_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">1539000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      decimals="-3"
      id="Tc_q_F38_KffE6ieg_s_Yc4Eg_36_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">19950000</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g"
      decimals="-3"
      id="Tc_bdrOHroyhUC0Q4pGpUmuIQ_36_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">9942000</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      decimals="-3"
      id="Tc_9p6sh8w8NEePh756sNbBCg_37_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">18750000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g"
      decimals="-3"
      id="Tc_M5nxbjTKUEqNDu_o6y_nQw_37_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">3135000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      decimals="-3"
      id="Tc_4GU3ljYhNkW99yjqtvETgQ_38_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">24353000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g"
      decimals="-3"
      id="Tc_Eb-hHKrOUE20TSHaBMdkEA_38_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">8311000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A"
      decimals="-3"
      id="Tc_V6d8KC6JDUOBpDajC6lVyA_39_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">24459000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_LY4sWUaA_UOIKxqqgZ5UAQ"
      decimals="-3"
      id="Tc_Fh2pqaxGpESrvCn0q-oeTA_39_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">18890000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww"
      decimals="-3"
      id="Tc_NTaaoq3Dt0yNdr8WmHAcvw_40_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">48812000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_6_30_2022_X6KPuRq2uEa6dhukywoGKw"
      decimals="-3"
      id="Tc_vsxxM8nUIkW1N3hyqyKETg_40_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">27201000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      decimals="-3"
      id="Tc_A0rOfg28JkWbjeTIhgcpCA_42_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">2485000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g"
      decimals="-3"
      id="Tc_gmJHk-Khs0uHbam4f-dQOg_42_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">951000</us-gaap:InterestPaidNet>
    <us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      id="Tb_pHNbC0_rC0ahLFUdpI4IoQ">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;"&gt;&lt;b style="font-size:10pt;font-weight:bold;"&gt;1.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;"&gt;&lt;b style="font-size:10pt;font-weight:bold;"&gt;Organization and Summary of Significant Accounting Policies&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Description of Business&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;"&gt;We are a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. We focus on products that address signaling pathways that are critical to disease mechanisms.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;"&gt;Our first product approved by the US Food and Drug Administration (FDA) is TAVALISSE&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; (fostamatinib disodium hexahydrate) tablets, the only approved oral spleen tyrosine kinase (SYK) inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. The product is also commercially available in Europe and the United Kingdom (UK) (as TAVLESSE), and in Canada, Israel and Japan (as TAVALISSE) for the treatment of chronic ITP in adult patients. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;"&gt;Our second FDA approved product is REZLIDHIA&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&#160;&lt;/sup&gt;&lt;span style="color:#222222;background:#ffffff;"&gt;(olutasidenib) capsules for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. We began our commercialization of REZLIDHIA in December 2022. W&lt;/span&gt;e in-licensed &lt;span style="color:#222222;background:#ffffff;"&gt;olutasidenib&lt;/span&gt; from Forma Therapeutics, Inc. (now Novo Nordisk), with exclusive, worldwide rights for its development, manufacturing and commercialization. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;"&gt;We continue to advance the development of our interleukin receptor-associated kinase (IRAK) 1/4 inhibitor program, in an open-label, Phase 1b trial to determine the tolerability and preliminary efficacy of the drug in patients with lower-risk &lt;span style="color:#222222;background:#ffffff;"&gt;myelodysplastic syndrome (MDS)&lt;/span&gt; who are refractory or resistant to prior therapies. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;"&gt;Our other ongoing clinical programs include a fostamatinib Phase 2/3 trial, the Accelerating COVID-19 Therapeutic Inventions and Vaccines Phase 2/3 trial (ACTIV-4 Host Tissue Trial), for the treatment &lt;span style="background:#ffffff;"&gt;of hospitalized high-risk patients with COVID-19&lt;/span&gt; being conducted and sponsored by the National Institute of Health (NIH)/National Heart, Lung, and Blood Institute (NHLBI), and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with our partner Eli Lilly and Company (Lilly). We also have product candidates in clinical development with partners BerGenBio ASA (BerGenBio) and Daiichi Sankyo (Daiichi). &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:9pt 0pt 9pt 18pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;"&gt;Our accompanying unaudited condensed financial statements have been prepared in accordance with United States generally accepted accounting principles (US GAAP), for interim financial information and pursuant to the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities Act of 1933, as amended (Securities Act). Accordingly, they do not include all the information and notes required by US GAAP for complete financial statements. These unaudited condensed financial statements include only normal and recurring adjustments that we believe are necessary to fairly state our financial position and the results of our operations and cash flows. Interim-period results are not necessarily indicative of results of operations or cash flows for a full-year or any subsequent interim period. The balance sheet as of December 31, 2022 has been derived from audited financial statements at that date but does not include all disclosures required by US GAAP for complete financial statements. Because certain disclosures required by US GAAP for complete financial statements are not included herein, these interim unaudited condensed financial statements and the notes accompanying them should be read in conjunction with our audited financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC on March 7, 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 9pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-indent:36pt;margin:9pt 0pt 0pt 0pt;"&gt;The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results could differ from these estimates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Significant Accounting Policies&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;Our significant accounting policies are described in &#x201c;Note 1 &#x2013; Description of Business and Summary of Significant Accounting Policies&#x201d; to our&#160;&#x201c;Notes to Financial Statements&#x201d;&#160;contained in &#x201c;Part II, Item&#160;8, Financial Statements and Supplementary Data&#x201d; of our Annual Report on Form 10-K for the year ended December 31, 2022. There have been no material changes to these accounting policies.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Liquidity&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;As of June 30, 2023, we had approximately $64.4 million in cash, cash equivalents and short-term investments. Since inception, we have financed our operations primarily through sales of equity securities, debt financing, contract payments under our collaboration agreements and from product sales. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;Based on our current operating plan, we believe that our existing cash, cash equivalents, and short-term investments will be sufficient to fund our expenses and capital expenditure requirements for at least the next 12 months from the date of issuance of this Form 10-Q.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Recently Issued Accounting Standards &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt 0pt 9pt 0pt;"&gt;Recently issued accounting guidance is either not applicable or did not have, or is not expected to have, a material impact to us. &lt;/p&gt;</us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      id="Tb_hPFwR685F0OJyCS2qOP41A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:9pt 0pt 9pt 18pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;"&gt;Our accompanying unaudited condensed financial statements have been prepared in accordance with United States generally accepted accounting principles (US GAAP), for interim financial information and pursuant to the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities Act of 1933, as amended (Securities Act). Accordingly, they do not include all the information and notes required by US GAAP for complete financial statements. These unaudited condensed financial statements include only normal and recurring adjustments that we believe are necessary to fairly state our financial position and the results of our operations and cash flows. Interim-period results are not necessarily indicative of results of operations or cash flows for a full-year or any subsequent interim period. The balance sheet as of December 31, 2022 has been derived from audited financial statements at that date but does not include all disclosures required by US GAAP for complete financial statements. Because certain disclosures required by US GAAP for complete financial statements are not included herein, these interim unaudited condensed financial statements and the notes accompanying them should be read in conjunction with our audited financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC on March 7, 2023.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      id="Tb_GkKGYiIZEk6g62ZIy7X77w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 9pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-indent:36pt;margin:9pt 0pt 0pt 0pt;"&gt;The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results could differ from these estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <rigl:LiquidityAndCapitalResourcesPolicyPolicyTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      id="Tb_-7iJAurwVEKUbTUErTvlOA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Liquidity&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;As of June 30, 2023, we had approximately $64.4 million in cash, cash equivalents and short-term investments. Since inception, we have financed our operations primarily through sales of equity securities, debt financing, contract payments under our collaboration agreements and from product sales. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;Based on our current operating plan, we believe that our existing cash, cash equivalents, and short-term investments will be sufficient to fund our expenses and capital expenditure requirements for at least the next 12 months from the date of issuance of this Form 10-Q.&lt;/p&gt;</rigl:LiquidityAndCapitalResourcesPolicyPolicyTextBlock>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww"
      decimals="-5"
      id="Narr_gQzQAPLYMkOOp1ewbatTpw"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">64400000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      id="Tb_4X0ahPd2i0SxuF0BH5V2UA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Recently Issued Accounting Standards &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt 0pt 9pt 0pt;"&gt;Recently issued accounting guidance is either not applicable or did not have, or is not expected to have, a material impact to us. &lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      id="Tb_63D7Zi8QjU2iAMUYRFPZSQ">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;"&gt;&lt;b style="font-size:10pt;font-weight:bold;"&gt;2.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;"&gt;&lt;b style="font-size:10pt;font-weight:bold;"&gt;Net Loss Per Share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;"&gt;Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period and the number of additional shares of common stock that would have been outstanding if potentially dilutive securities had been issued. Potentially dilutive securities include stock options, RSUs and shares issuable under our Employee Stock Purchase Plan (Purchase Plan). The dilutive effect of these potentially dilutive securities is reflected in diluted earnings per share using the treasury stock method. Under the treasury stock method, an increase in the fair market value of our common stock can result in a greater dilutive effect from potentially dilutive securities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The potential shares of common stock that were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive are as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:93.39%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:51.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:23.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:21.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;35,244 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;33,081 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;35,244 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;33,081 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;RSUs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;1,963 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;1,191 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;1,963 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;1,191 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;37,207 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;34,272 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;37,207 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;34,272 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      id="Tb_UHW8epxnl0i5EC9_8eqLzw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:93.39%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:51.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:23.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:21.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;35,244 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;33,081 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;35,244 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;33,081 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;RSUs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;1,963 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;1,191 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;1,963 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;1,191 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;37,207 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;34,272 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;37,207 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;34,272 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_mJfwLdIwJE2PuCZyxHa0nA"
      decimals="-3"
      id="Tc_72CaDYJTaEKIGD-VYUAGhA_3_3"
      unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA">35244000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_3BL6mb7WlEWnOeX6FOCPaw"
      decimals="-3"
      id="Tc_RjtoEqE0NkyeeaWn4GH-vA_3_6"
      unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA">33081000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_eLmQDXheSkOcwdRhfkuNbw"
      decimals="-3"
      id="Tc_o9E54pq50kaO2luPulZHHw_3_9"
      unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA">35244000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_2SVbQAbboUOHtAeVDBUKZA"
      decimals="-3"
      id="Tc_KjMokNKTxEy5BN6pg2Hgug_3_12"
      unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA">33081000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_kUrHXkhzkEmFf7R8bUu2kA"
      decimals="-3"
      id="Tc_8kexN_Dyz0K88N2mb80Wbg_4_3"
      unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA">1963000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_FPUuaR2SyUSRDy3fSQcDRQ"
      decimals="-3"
      id="Tc_Wxjj0KhNDUWaS5Ivs4X7zQ_4_6"
      unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA">1191000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_3tETexLm0UCBsN9ftHBwtg"
      decimals="-3"
      id="Tc_nGt-ziIZAkesciIsGVAosA_4_9"
      unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA">1963000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_WHRK7Ydr8Euv9ScMKMDa3Q"
      decimals="-3"
      id="Tc_0-i23OEuLUCsJ5lVKSrdVA_4_12"
      unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA">1191000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ"
      decimals="-3"
      id="Tc_TKly2VVf80i5X40PNSdKWA_5_3"
      unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA">37207000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_4_1_2022_To_6_30_2022_ICCkO9pPUUSORAn1kecZBA"
      decimals="-3"
      id="Tc_mzLTglFNNEewMD-f0BOX0w_5_6"
      unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA">34272000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      decimals="-3"
      id="Tc_HTIamhsSqkyIo1OxJfA0aQ_5_9"
      unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA">37207000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g"
      decimals="-3"
      id="Tc_Cz_EXLW77k2fqodS7nJG7g_5_12"
      unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA">34272000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      id="Tb_GU3iqFDY5E6-EIlXVsRv7Q">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"&gt;&lt;b style="font-size:10pt;font-weight:bold;"&gt;3.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"&gt;&lt;b style="font-size:10pt;font-weight:bold;"&gt;Revenues&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Revenues disaggregated by category were as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:41.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:26.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Product sales:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Gross product sales&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;33,456 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;26,427 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;66,654 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;49,045 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Discounts and allowances&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;(9,575)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;(7,877)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;(19,028)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;(14,298)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total product sales, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 23,881&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 18,550&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 47,626&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 34,747&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Revenues from collaborations:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;License revenues&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,337&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;2,545 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Development milestones&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Royalty, delivery of drug supplies and others&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;2,005 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;3,932 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;4,330 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;4,262 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total revenues from collaborations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,005&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 11,269&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4,330&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 11,807&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Government contract&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;Total revenues&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 26,886&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 29,819&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 52,956&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 46,554&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;"&gt;Revenue from product sales are related to sales of our commercial products, TAVALISSE and REZLIDHIA, to our specialty distributors. For detailed discussions of our revenues from collaboration and government contract, see &#x201c;Note 4 &#x2013; Sponsored Research and License Agreements and Government Contract&#x201d;.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;"&gt;Our net product sales include gross product sales, net of chargebacks, discounts and fees, government and other rebates and returns. Of the total discounts and allowances from gross product sales for the six months ended June 30, 2023 and 2022, $18.6 million and $13.0 million, respectively, was accounted for as additions to revenue reserves and refund liability, and $0.4 million and $1.3 million, respectively, as reductions in accounts receivable (as it relates to allowance for prompt pay discount) and prepaid and other current assets (as it relates to certain chargebacks and other fees that were prepaid) in the condensed balance sheet. The following tables summarize the activities in chargebacks, discounts and fees, government and other rebates and returns that were accounted for within revenue reserves and refund liability, for each of the periods presented (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:38.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Chargebacks,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Government&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Discounts&#160;and&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;and Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fees&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Rebates&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Returns&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance as of January 1, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 6,213&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,636&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,296&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 12,145&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Provision related to current period sales&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 14,439&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,725&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 395&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 18,559&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Credit or payments made during the period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (13,139)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,765)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (116)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (17,020)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance as of June 30, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 7,513&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,596&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,575&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 13,684&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:38.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Chargebacks,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Government&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Discounts&#160;and&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;and Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fees&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Rebates&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Returns&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance as of January 1, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,404&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,494&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,017&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 7,915&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Provision related to current period sales&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 9,680&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,711&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 613&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 13,004&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Credit or payments made during the period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (7,748)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,901)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (39)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (10,688)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance as of June 30, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5,336&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,304&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,591&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 10,231&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 6pt 0pt;"&gt;The following table summarizes the percentages of revenues from each of our customers who individually accounted for 10% or more of the total net product sales and revenues from collaborations:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:96.98%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:24.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;McKesson Specialty Care Distribution Corporation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;44%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;34%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;45%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;36%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cardinal Healthcare&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;28%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;16%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;26%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;20%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;ASD Healthcare and Oncology Supply&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;19%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;12%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;21%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;19%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Kissei&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;25%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;16%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      id="Tb_ijgLq9LSZkuLf20lbgO0rg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Revenues disaggregated by category were as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:41.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:26.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Product sales:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Gross product sales&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;33,456 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;26,427 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;66,654 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;49,045 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Discounts and allowances&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;(9,575)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;(7,877)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;(19,028)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;(14,298)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total product sales, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 23,881&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 18,550&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 47,626&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 34,747&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Revenues from collaborations:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;License revenues&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,337&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;2,545 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Development milestones&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Royalty, delivery of drug supplies and others&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;2,005 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;3,932 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;4,330 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;4,262 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total revenues from collaborations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,005&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 11,269&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4,330&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 11,807&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Government contract&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;Total revenues&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 26,886&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 29,819&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 52,956&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 46,554&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_GrossProductMember_ene2KCce8kCbyUMQexHEMg"
      decimals="-3"
      id="Tc_hnA9vQ9wN0CJDkzxttV6iA_4_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">33456000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_4_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_rigl_GrossProductMember_95E_EFQSok-CYS8j9cMXTA"
      decimals="-3"
      id="Tc_IKiftc063EWbcctw1mJC-Q_4_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">26427000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_GrossProductMember_ufxFI3eqlEur3o5rbubmLA"
      decimals="-3"
      id="Tc_dXMlfbUn-EmC6-uDy3H5Ig_4_9"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">66654000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_rigl_GrossProductMember_rXnbhU9tKUyNBTlYxDeWHA"
      decimals="-3"
      id="Tc_B0PZw9bKrkiBWg1XJ31LKg_4_12"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">49045000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_DiscountsAndAllowancesMember_uHoWbEnKdU2tg1UhL6Vz-g"
      decimals="-3"
      id="Tc_dExZZmUF3kWtrcE-L79HLg_5_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-9575000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_4_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_rigl_DiscountsAndAllowancesMember_OH1BW4gyzU6mjxq6VfcyGg"
      decimals="-3"
      id="Tc_dDBsJky9ckKai0u34BHoGw_5_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-7877000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_DiscountsAndAllowancesMember_POb1Otc_IkOne8fdyW38vA"
      decimals="-3"
      id="Tc_mtb6N4VYVUuez5lzOu97eA_5_9"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-19028000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_rigl_DiscountsAndAllowancesMember_rYICJn1GSUmzENKUTvY70A"
      decimals="-3"
      id="Tc_nfEpx-7Xtk2bUcSdOyMBYQ_5_12"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-14298000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_v4jyMWOILkimNDJi27bJNA"
      decimals="-3"
      id="Tc_01b4mqvAREWk5EWyoqICGw_6_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">23881000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_4_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_Zl3JCD-6OEeEiUA808bVig"
      decimals="-3"
      id="Tc_OAHsRJ1NvU6qV8iXWmz_NQ_6_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">18550000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_C2EWGpiFxUGr9E995bXhCQ"
      decimals="-3"
      id="Tc_f_XjOSzELky4boa8FlmAlQ_6_9"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">47626000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_I08rIoA1_0itpE8QmmW4zw"
      decimals="-3"
      id="Tc_gyHx8WStZ0213Qvgk_XSig_6_12"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">34747000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_4_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_LicenseMember_dRyVOn5NcEee-uU6cPlByQ"
      decimals="-3"
      id="Tc_oQYwcyj5Q0alRODj0qf9Vg_8_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">2337000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_LicenseMember_aC5yN2D_3U6wto3RbpNFkQ"
      decimals="-3"
      id="Tc_6fEgd2Wje0OPxgAAiuVYlw_8_12"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">2545000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_4_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_rigl_DevelopmentMilestonesMember_8XRCe7N2D0q0_dL4LzLrSw"
      decimals="-3"
      id="Tc__hD0Pn76WU-TxRcJO7aRPw_9_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">5000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_rigl_DevelopmentMilestonesMember_HoBUCB_cmEGo56InBGrucg"
      decimals="-3"
      id="Tc_bxLIrVsMtU6mOVoAFZfmRg_9_12"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">5000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_RoyaltyDeliveryOfDrugSuppliesAndOthersMember_jqRyjOlFGUu5mu87xpyztg"
      decimals="-3"
      id="Tc_j7AN36tQS0KXqzIj8oKO1A_10_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">2005000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_4_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_rigl_RoyaltyDeliveryOfDrugSuppliesAndOthersMember_v1BBxfjOM0iXxMM8ZntPkg"
      decimals="-3"
      id="Tc_2HOcBcg4gUyulFBHcsxY-g_10_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">3932000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_RoyaltyDeliveryOfDrugSuppliesAndOthersMember_V9FmeTwnFU20hq0tJetk3A"
      decimals="-3"
      id="Tc_5CCn-aplgUyV7D3FzToPog_10_9"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">4330000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_rigl_RoyaltyDeliveryOfDrugSuppliesAndOthersMember_ClPsUsxGhkStEb_3uR8ZgA"
      decimals="-3"
      id="Tc_LoYCZrHTTUyqZip6QcWv_w_10_12"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">4262000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_ContractRevenuesFromCollaborationsMember_yU4TzCXKCkSEqjOPYCD5ig"
      decimals="-3"
      id="Tc_oUGJXqlIEU-lF3dbseYV_w_11_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">2005000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_4_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_rigl_ContractRevenuesFromCollaborationsMember_B3F0S8vRz0eWxrI-zbC5eQ"
      decimals="-3"
      id="Tc_HM8QX56ASESyEYIvnuY_bw_11_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">11269000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_ContractRevenuesFromCollaborationsMember_TmFkSqljNUiYYmkDnr-3ag"
      decimals="-3"
      id="Tc_NVwNNL6olkq8RBvmRYs9bg_11_9"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">4330000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_rigl_ContractRevenuesFromCollaborationsMember_LOIZvjtJ4kefhhUMq6-K0Q"
      decimals="-3"
      id="Tc_k5KIVVcqaE6v-lZIBqiSNA_11_12"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">11807000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_GovernmentContractMember_WN0BoWdZGU-KXqAccwJ68A"
      decimals="-3"
      id="Tc_DH38-MzEaUaYi4BEfU_uyA_12_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">1000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_GovernmentContractMember_9xcr5RYkM0WkIqJKKgDS8A"
      decimals="-3"
      id="Tc_kbkHm8GTDkKqaGZL7BlCgQ_12_9"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">1000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ"
      decimals="-3"
      id="Tc_rG4BZwwyFEa0tvc-wN5riQ_13_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">26886000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_4_1_2022_To_6_30_2022_ICCkO9pPUUSORAn1kecZBA"
      decimals="-3"
      id="Tc_MOqK6_JCE0uU_yasSQtJYQ_13_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">29819000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      decimals="-3"
      id="Tc_rXCKmw_NaEWBgZV5orVBYQ_13_9"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">52956000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g"
      decimals="-3"
      id="Tc_lQwWtm1c5kOlCorvUphdIQ_13_12"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">46554000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <rigl:SalesDiscountsAndAllowances
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      decimals="-5"
      id="Narr_tvCbA1l-Ykepi2cXWZoG5Q"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">18600000</rigl:SalesDiscountsAndAllowances>
    <rigl:SalesDiscountsAndAllowances
      contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g"
      decimals="-5"
      id="Narr_-eAAkLytZUytOqLdqvbnzw"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">13000000.0</rigl:SalesDiscountsAndAllowances>
    <rigl:SalesDiscountsAndAllowances
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_BalanceSheetLocationAxis_rigl_AccountsReceivableAndPrepaidAndOtherCurrentAssetsMember__I6hFO6Y_0yiZKdPOpgk-Q"
      decimals="-5"
      id="Narr_DtM7uejankuPhEk2pUIBRg"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">400000</rigl:SalesDiscountsAndAllowances>
    <rigl:SalesDiscountsAndAllowances
      contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_BalanceSheetLocationAxis_rigl_AccountsReceivableAndPrepaidAndOtherCurrentAssetsMember_EmK1_sfXdkCE9z-LmqaUnw"
      decimals="-5"
      id="Narr_ycfPZjcFEk2tB4codrM8dw"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">1300000</rigl:SalesDiscountsAndAllowances>
    <srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      id="Tb_RBPZQi6yFk65KWTW1V-Oug">&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:38.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Chargebacks,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Government&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Discounts&#160;and&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;and Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fees&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Rebates&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Returns&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance as of January 1, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 6,213&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,636&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,296&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 12,145&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Provision related to current period sales&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 14,439&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,725&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 395&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 18,559&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Credit or payments made during the period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (13,139)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,765)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (116)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (17,020)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance as of June 30, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 7,513&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,596&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,575&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 13,684&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:38.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Chargebacks,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Government&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Discounts&#160;and&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;and Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fees&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Rebates&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Returns&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance as of January 1, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,404&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,494&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,017&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 7,915&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Provision related to current period sales&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 9,680&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,711&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 613&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 13,004&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Credit or payments made during the period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (7,748)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,901)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (39)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (10,688)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance as of June 30, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5,336&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,304&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,591&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 10,231&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="As_Of_12_31_2022_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_ChargebacksDiscountsAndFeesMember_PB_xsJ2Rnka8evD4QKOfWg"
      decimals="-3"
      id="Tc_sFb1qOlSnUuSHLVZtarL0A_4_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">6213000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="As_Of_12_31_2022_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_GovernmentAndOtherRebatesMember__X6NqDu8YU-SnfKyNeY8HA"
      decimals="-3"
      id="Tc_xHWJBsN2Wkm_AVywDk39-A_4_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">2636000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="As_Of_12_31_2022_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember_acq92gncQkKXH4cm6zevsA"
      decimals="-3"
      id="Tc_sPITMmTvbEubXT2QPjs83A_4_9"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">3296000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A"
      decimals="-3"
      id="Tc_PmK8xFG1K0Si2SRLG6HGig_4_12"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">12145000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_ChargebacksDiscountsAndFeesMember_Fj8Wggl3gkGVVa1f_QMscg"
      decimals="-3"
      id="Tc_CfWcuW6PR0Cby6ZoT2_0tg_5_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">14439000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_GovernmentAndOtherRebatesMember_6P-es-h0okS3mUsko2UktA"
      decimals="-3"
      id="Tc_uZ_CORzsZEyUt6pGsjCOaQ_5_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">3725000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember_5hmOTOINYUi1yMKOyqV_Tg"
      decimals="-3"
      id="Tc_bo6dM6DFykG0gXLzSUnUfw_5_9"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">395000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      decimals="-3"
      id="Tc_2yDqcPPNNEO8bOQaPj5vzQ_5_12"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">18559000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_ChargebacksDiscountsAndFeesMember_Fj8Wggl3gkGVVa1f_QMscg"
      decimals="-3"
      id="Tc_OKttO_H2rUSmWr1DMbsUVA_6_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">13139000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_GovernmentAndOtherRebatesMember_6P-es-h0okS3mUsko2UktA"
      decimals="-3"
      id="Tc_KbLqZeu4SkuPKF-_xusQtw_6_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">3765000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember_5hmOTOINYUi1yMKOyqV_Tg"
      decimals="-3"
      id="Tc_uNKU2b5RXUSLFy43uwj7FA_6_9"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">116000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      decimals="-3"
      id="Tc_eVzI66W0jUGR10f_lmeU_Q_6_12"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">17020000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="As_Of_6_30_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_ChargebacksDiscountsAndFeesMember_DfMT0NHFbUOWySs4XQGnsg"
      decimals="-3"
      id="Tc_hJJkYrHlqUywrzL_5hNRRg_7_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">7513000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="As_Of_6_30_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_GovernmentAndOtherRebatesMember_jVuu0q4VHEWON15mELkW8g"
      decimals="-3"
      id="Tc_vDWorq33kUaz0wrkckILMg_7_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">2596000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="As_Of_6_30_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember_-dSzQZXVFEuMJw8h2iIHxw"
      decimals="-3"
      id="Tc_eu947VLQhkeAkxd8Y-0J9w_7_9"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">3575000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww"
      decimals="-3"
      id="Tc_H-UWPFMejUCuGcQ749A3iA_7_12"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">13684000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="As_Of_12_31_2021_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_ChargebacksDiscountsAndFeesMember_Pp0Xy4dvykCBp639HzD29g"
      decimals="-3"
      id="Tc_ZBYfPnc-XkWA3zdtpS-2Tg_4_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">3404000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="As_Of_12_31_2021_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_GovernmentAndOtherRebatesMember_eCxe-sGTfE-EJIbGHCs0Rw"
      decimals="-3"
      id="Tc_BRPHGl8S_EuUUYlqsm-R2Q_4_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">2494000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="As_Of_12_31_2021_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember_2U4Oj50ug0SqZPXE5_VdHg"
      decimals="-3"
      id="Tc_PkUbI-NB-EqovAAuFXcQ1w_4_9"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">2017000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="As_Of_12_31_2021_LY4sWUaA_UOIKxqqgZ5UAQ"
      decimals="-3"
      id="Tc_MWDNB97fdU2NC8kY-8nRXQ_4_12"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">7915000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_ChargebacksDiscountsAndFeesMember_t4iNGTcP0UaLBEDeXCMGOw"
      decimals="-3"
      id="Tc_y7Syt8G1UUqfE3AiXoaGVQ_5_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">9680000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_GovernmentAndOtherRebatesMember_OChMZBgap0qvP6EMKEatOg"
      decimals="-3"
      id="Tc_ZpsciorR_Uy29OnMuADvGg_5_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">2711000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember_ioiPIbSN6U6AmT1ftZXQ6w"
      decimals="-3"
      id="Tc_JnssMOOvTU-0_h1BTdVXzQ_5_9"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">613000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g"
      decimals="-3"
      id="Tc_aeGreS2PHkSEOo_15MDg4A_5_12"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">13004000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_ChargebacksDiscountsAndFeesMember_t4iNGTcP0UaLBEDeXCMGOw"
      decimals="-3"
      id="Tc_yoNDZPhhh02GTO2YxVOrQQ_6_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">7748000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_GovernmentAndOtherRebatesMember_OChMZBgap0qvP6EMKEatOg"
      decimals="-3"
      id="Tc_J1mV1rzACUmFAcDtzxKjGw_6_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">2901000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember_ioiPIbSN6U6AmT1ftZXQ6w"
      decimals="-3"
      id="Tc_hIQxxnoKu02Qsvg0bBiN2w_6_9"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">39000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g"
      decimals="-3"
      id="Tc_R1wp-e-ib0eVaFQs8Lx61w_6_12"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">10688000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="As_Of_6_30_2022_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_ChargebacksDiscountsAndFeesMember_nboH8Ly9PkqdAPD6SogU6Q"
      decimals="-3"
      id="Tc_eN_jqnrGZUaQbGqWUHBD2w_7_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">5336000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="As_Of_6_30_2022_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_GovernmentAndOtherRebatesMember_bsvDCX99AUmyaU2yXJOh2w"
      decimals="-3"
      id="Tc_e8bCAa9ky0mU2u9qiu6wIw_7_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">2304000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="As_Of_6_30_2022_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember_jBU6vZXXI0qTA8tjSyNMHA"
      decimals="-3"
      id="Tc_kXFTQikaHUeC9LFGdsT0kA_7_9"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">2591000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="As_Of_6_30_2022_X6KPuRq2uEa6dhukywoGKw"
      decimals="-3"
      id="Tc_582L0VgYI0yXRmWcqJicOA_7_12"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">10231000</us-gaap:ValuationAllowancesAndReservesBalance>
    <rigl:DisaggregationOfRevenueByCustomerTableTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      id="Tb_VpaO109tk0GzPQJELPtydA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 6pt 0pt;"&gt;The following table summarizes the percentages of revenues from each of our customers who individually accounted for 10% or more of the total net product sales and revenues from collaborations:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:96.98%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:24.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;McKesson Specialty Care Distribution Corporation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;44%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;34%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;45%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;36%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cardinal Healthcare&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;28%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;16%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;26%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;20%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;ASD Healthcare and Oncology Supply&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;19%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;12%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;21%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;19%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Kissei&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;25%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;16%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</rigl:DisaggregationOfRevenueByCustomerTableTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_4_1_2023_To_6_30_2023_srt_MajorCustomersAxis_rigl_MckessonSpecialtyCareDistributionCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_NFFFR5Op6EGibKqyThuK6g"
      decimals="2"
      id="Tc_PlW5HdNn6kW2RpOG5abFbQ_3_3"
      unitRef="Unit_Standard_pure_uVIKS5OYQEes3pxG5CV0tw">0.44</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_4_1_2022_To_6_30_2022_srt_MajorCustomersAxis_rigl_MckessonSpecialtyCareDistributionCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_Xm7pTW7phEG80_TFGMPzwQ"
      decimals="2"
      id="Tc_g8Z1Z2ptcE6zMmxsXV_Zqg_3_6"
      unitRef="Unit_Standard_pure_uVIKS5OYQEes3pxG5CV0tw">0.34</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2023_To_6_30_2023_srt_MajorCustomersAxis_rigl_MckessonSpecialtyCareDistributionCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_ijLIVbFhwE2dv-2rbK1hJw"
      decimals="2"
      id="Tc_rpY6W4AH3kKH-Y7apWqvUg_3_10"
      unitRef="Unit_Standard_pure_uVIKS5OYQEes3pxG5CV0tw">0.45</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_MajorCustomersAxis_rigl_MckessonSpecialtyCareDistributionCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_hMd2onJOT0a7o-jJSOOdJA"
      decimals="2"
      id="Tc_bx05ELwDmUGUGeTdfm6azw_3_13"
      unitRef="Unit_Standard_pure_uVIKS5OYQEes3pxG5CV0tw">0.36</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_4_1_2023_To_6_30_2023_srt_MajorCustomersAxis_rigl_CardinalHealthcareMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_ZvGiZXP9CEeNn157o58OQQ"
      decimals="2"
      id="Tc_SLSdDI_KhES8oMW_-4KA5g_4_3"
      unitRef="Unit_Standard_pure_uVIKS5OYQEes3pxG5CV0tw">0.28</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_4_1_2022_To_6_30_2022_srt_MajorCustomersAxis_rigl_CardinalHealthcareMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_crG-CxphyUmLeRthseHyVQ"
      decimals="2"
      id="Tc_TTv1RMndE0Ss1jXzGfdezA_4_6"
      unitRef="Unit_Standard_pure_uVIKS5OYQEes3pxG5CV0tw">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2023_To_6_30_2023_srt_MajorCustomersAxis_rigl_CardinalHealthcareMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_7kgMzAici0eIlntate3Qlw"
      decimals="2"
      id="Tc_lwfhSzFmVkGZwO8YMqPI4Q_4_10"
      unitRef="Unit_Standard_pure_uVIKS5OYQEes3pxG5CV0tw">0.26</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_MajorCustomersAxis_rigl_CardinalHealthcareMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_XwGmaHgDQE6DlBxIrLRYjw"
      decimals="2"
      id="Tc_P58gLCs_nEeGE8zSJpUywg_4_13"
      unitRef="Unit_Standard_pure_uVIKS5OYQEes3pxG5CV0tw">0.20</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_4_1_2023_To_6_30_2023_srt_MajorCustomersAxis_rigl_AsdHealthcareAndOncologySupplyMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_ezDA2vAhCkWEvWvApmdHcA"
      decimals="2"
      id="Tc_fwSV7eAXtUK8p-EMw1_CuQ_5_3"
      unitRef="Unit_Standard_pure_uVIKS5OYQEes3pxG5CV0tw">0.19</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_4_1_2022_To_6_30_2022_srt_MajorCustomersAxis_rigl_AsdHealthcareAndOncologySupplyMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_sEWKR2JD6EG-XvczwGJTDg"
      decimals="2"
      id="Tc_-Os1sZBO9EW_mXrN3bZq3w_5_6"
      unitRef="Unit_Standard_pure_uVIKS5OYQEes3pxG5CV0tw">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2023_To_6_30_2023_srt_MajorCustomersAxis_rigl_AsdHealthcareAndOncologySupplyMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_L3diTTLKsk23XOOP9fvJUg"
      decimals="2"
      id="Tc_vBSraoislk6aGAcqRrSBkA_5_10"
      unitRef="Unit_Standard_pure_uVIKS5OYQEes3pxG5CV0tw">0.21</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_MajorCustomersAxis_rigl_AsdHealthcareAndOncologySupplyMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_Z_7YFCzct0KfoaZgxA9q_Q"
      decimals="2"
      id="Tc_Rsz3ub__Q0Sv1o33mZkpnw_5_13"
      unitRef="Unit_Standard_pure_uVIKS5OYQEes3pxG5CV0tw">0.19</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_4_1_2022_To_6_30_2022_srt_MajorCustomersAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_KKDtN8IagE6J4I_uAnU00A"
      decimals="2"
      id="Tc_LdsdoLcg10yFSjgGz2Uovg_6_6"
      unitRef="Unit_Standard_pure_uVIKS5OYQEes3pxG5CV0tw">0.25</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_MajorCustomersAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_r58vna9bwkWOHGAEZRVhtg"
      decimals="2"
      id="Tc_QSFQ-mISNE6lQ2ueYVMmYg_6_13"
      unitRef="Unit_Standard_pure_uVIKS5OYQEes3pxG5CV0tw">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      id="Tb_mwKcNqqDbE--8uXFTO1p2Q">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-size:10pt;font-weight:bold;"&gt;4.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-size:10pt;font-weight:bold;"&gt;Sponsored Research and License Agreements and Government Contract&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Sponsored Research and License Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;We conduct research and development programs independently and in connection with our corporate collaborators. As of June 30, 2023, we are a party to collaboration agreements with Lilly to develop and commercialize R552, a RIPK1 inhibitor, for the treatment of non-central nervous system (non-CNS) diseases and collaboration aimed at developing additional RIPK1 inhibitors for the treatment of central nervous system (CNS) diseases; with Grifols S.A. (Grifols) to commercialize fostamatinib for human diseases in all indications, including chronic ITP and &lt;span style="color:#202124;background:#ffffff;"&gt;autoimmune hemolytic anemia&lt;/span&gt; (AIHA), in Grifols territory which includes Europe, the UK, Turkey, the Middle East, North Africa and Russia (including Commonwealth of Independent States); with Kissei Pharmaceutical Co., Ltd. (Kissei) to develop and commercialize fostamatinib in Kissei territory which includes Japan, China, Taiwan and the Republic of Korea; with Medison Pharma Trading AG (Medison Canada) and Medison Pharma Ltd. (Medison Israel and, together with Medison Canada, Medison) to commercialize fostamatinib in all indications, including chronic ITP and AIHA, in Medison territory which includes Canada and Israel; and with Knight Therapeutics International SA (Knight) to commercialize fostamatinib in all indications, including chronic ITP and AIHA, in Knight territory which includes Latin America, consisting of Mexico, Central and South America, and the Caribbean (Knight territory).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;Further, we are also a party to collaboration agreements, but do not have ongoing performance obligations with BerGenBio for the development and commercialization of &lt;span style="background:#ffffff;"&gt;AXL receptor tyrosine kinase (&lt;/span&gt;AXL) inhibitors in oncology, and with Daiichi to pursue research related to &lt;span style="background:#ffffff;"&gt;murine double minute 2&#160;(&lt;/span&gt;MDM2) inhibitors, a novel class of drug targets called ligases. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;Under the above existing agreements that we entered into in the ordinary course of business, we received or may be entitled to receive upfront cash payments, payments contingent upon specified events achieved by such partners and royalties on any net sales of products sold by such partners under the agreements. As of June 30, 2023, total future contingent payments to us under all of the above existing agreements, excluding terminated agreements, could exceed $1.3 billion if all potential product candidates achieved all of the payment triggering events under all of our current agreements. Of this amount, $279.5&#160;million relates to the achievement of development events, $263.1 million relates to the achievement of regulatory events and $796.0&#160;million relates to the achievement of certain commercial events. This estimated future contingent amount does not include any estimated royalties that could be due to us if the partners successfully commercialize any of the licensed products. Future events that may trigger payments to us under the agreements are based solely on our partners&#x2019; future efforts and achievements of specified development, regulatory and/or commercial events. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:11pt 0pt 11pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Global Exclusive License Agreement with Lilly &lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:11pt 0pt 11pt 0pt;"&gt;We have a global exclusive license agreement and strategic collaboration with Lilly (Lilly Agreement) entered in February 2021, which became effective on March 27, 2021, upon clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, to develop and commercialize R552 for the treatment of non-CNS diseases. In addition, the collaboration is aimed at developing additional RIPK1 inhibitors for the treatment of CNS diseases. Pursuant to the terms of the license agreement, we granted to Lilly exclusive rights to develop and commercialize R552 and related RIPK1 inhibitors in all indications worldwide. The parties&#x2019; collaboration is governed through a joint governance committee and appropriate subcommittees.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:11pt 0pt 0pt 0pt;"&gt;Under the terms of the Lilly Agreement, we were entitled to receive a non-refundable and non-creditable upfront cash payment amounting to $125.0 million, which we received in April 2021. We are also entitled to additional milestone payments for non-CNS disease products consisting of up to $330.0 million in milestone payments upon the achievement of specified development, regulatory and commercial milestones, and up to $100.0 million in sales milestone payments on a product-by-product basis. In addition, depending on the extent of our co-funding of R552 development activities, we would be entitled to receive tiered royalty payments on net sales of non-CNS disease products at percentages ranging from the mid-single digits to high-teens, subject to certain standard reductions and offsets. We are also eligible to receive milestone payments for CNS disease products consisting of up to $255.0 million in milestone payments upon the achievement of specified development, regulatory and commercial milestones, and up to $150.0 million in sales milestone payments on a product-by-product basis. We would be entitled to receive tiered royalty &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;"&gt;payments on net sales of CNS disease products up to low-double digits, subject to certain standard reductions and offsets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:11pt 0pt 11pt 0pt;"&gt;We are responsible for performing and funding initial discovery and identification of CNS disease development candidates. Following candidate selection, Lilly will be responsible for performing and funding all future development and commercialization of the CNS disease development candidates. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:11pt 0pt 11pt 0pt;"&gt;Under the Lilly Agreement, we are responsible for 20% of development costs for R552 in the US, Europe, and Japan, up to a specified cap, and Lilly is responsible for funding the remainder of all development activities for R552 and other non-CNS disease development candidates. Pursuant to the terms of the Lilly Agreement, we have the right to opt-out of co-funding the R552 development activities at two different specified times. If we exercise our first opt-out right (no later than September 30, 2023), we are required to fund our share of the R552 development activities up to a maximum funding commitment of $65.0 million through April 1, 2024. If we decide not to exercise our opt-out rights, we will be required to share in global development costs of up to certain amounts at a specified cap, as provided for in the Lilly Agreement. Given our rights to opt-out from the development of R552, we believe at the minimum, we have a commitment to fund the development costs up to $65.0 million as discussed above. We considered this commitment to fund the development costs as a significant financing component of the contract, which we accounted for as a reduction of the upfront fee to derive the transaction price. This financing component was recorded as a liability at its net present value of approximately $57.9 million using a 6.4% discount rate. Interest expense is accreted on such liability over the expected commitment period, adjusted for timing of expected cost share payments. No interest was accreted during the six months ended June 30, 2023, and $0.7 million of interest was accreted during the six months ended June 30, 2022. Through June 30, 2023, Lilly billed us $16.9 million for our share of development costs under this agreement, and the amount was fully paid as of June 30, 2023. As of June 30, 2023 and December 31, 2022, the outstanding financing liability to Lilly was $44.5 million and $46.2 million, respectively, and included within other long-term liabilities, current portion, and other long-term liabilities in the condensed balance sheet.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:11pt 0pt 11pt 0pt;"&gt;We accounted for this agreement under ASC 606 and identified the following distinct performance obligations at inception of the agreement: (a) granting of the license rights over the non-CNS penetrant intellectual property (IP), and (b) granting of the license rights over the CNS penetrant IP which will be delivered to Lilly upon completion of the additional research and development efforts specified in the agreement. We concluded each of these performance obligations is distinct. We based our assessment on the assumption that Lilly can benefit from each of the licenses on its own by developing and commercializing the underlying product using its own resources. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:11pt 0pt 11pt 0pt;"&gt;We allocated the net transaction price of $67.1&#160;million to each performance obligation based on our best estimate of its relative standalone selling price using the adjusted market assessment approach. The transaction price allocated to the non-CNS penetrant IP of $60.4 million was recognized as revenue upon delivery of the non-CNS penetrant IP to Lilly during the first quarter of 2021. The transaction price allocated to the CNS penetrant IP of $6.7 million was recognized as revenue from the effective date of the Lilly Agreement through the eventual acceptance by Lilly using the input method, since we were required to perform additional research and development efforts before the final acceptance of the license by Lilly. In June 2022, Lilly provided notice of continuance pursuant to the terms of the Lilly Agreement, whereby Lilly elected its option to lead the identification and selection of CNS penetrant lead candidate. As such, we recognized the remaining outstanding deferred revenue in the second quarter of 2022. For the three and six months ended June 30, 2022, we recognized $0.3 million and $0.5 million, respectively, of revenue associated with the delivery of CNS penetrant IP. No&lt;span style="white-space:pre-wrap;"&gt; such revenue was recognized in the three and six months ended June 30, 2023.  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The remaining future variable consideration related to future milestone payments as discussed above were fully constrained because we cannot conclude that it is probable that a significant reversal of the amount of cumulative revenue recognized will not occur, given the inherent uncertainty of success with these future milestones. For sales-based milestones and royalties, we determined that the license is the predominant item to which the royalties or sales-based milestones relate. Accordingly, we will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). We will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Grifols License Agreement&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;"&gt;We have an exclusive commercialization license agreement with Grifols entered in January 2019 with exclusive rights to commercialize fostamatinib for human diseases, including chronic ITP and AIHA, and non-exclusive rights to develop fostamatinib in Grifols territory. Under the agreement, we received an upfront payment of $30.0 million, with the potential for $297.5 million in total regulatory and commercial milestones. We are also entitled to receive stepped double-digit royalty payments based on tiered net sales which may reach 30% of net sales. The agreement also required us to continue to conduct our long-term open-label extension study on patients with ITP through European Medicines Agency (EMA) approval of ITP in Europe or until the study ends as well as conduct the Phase 3 trial of fostamatinib in AIHA.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 0pt 0pt;"&gt;In January 2020, the European Commission (EC) granted a centralized Marketing Authorization (MA) for fostamatinib valid throughout the European Union (EU) and in the UK after the departure of the UK from the EU for the treatment of chronic ITP in adult patients who are refractory to other treatments. With this approval, in February 2020, we received $20.0 million non-refundable payment, composed of a $17.5 million payment due upon Marketing Authorization Application (MAA) approval by the EMA of fostamatinib for the first indication and a $2.5&#160;million creditable advance royalty payment, based on the terms of our collaboration agreement with Grifols. The above milestone payment was allocated to the distinct performance obligations in the collaboration agreement with Grifols. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;We accounted for this agreement under ASC 606 and identified the following distinct performance obligations at inception of the agreement: (a) granting of the license, (b) performance of research and regulatory services related to our long-term open-label extension study on patients with ITP, and (c) performance of research services related to our Phase 3 study in AIHA. We allocated the transaction price to the distinct performance obligations in our collaboration agreement based on our best estimate of the relative standalone selling price, and recognized the corresponding revenue in the periods we satisfied the performance obligations. During the three and six months ended June 30, 2022, we recognized $0.2 million and $0.5 million, respectively, of revenue associated with the remaining performance obligation to perform research services. No such revenue was recognized during the three and six months ended June 30, 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The remaining variable consideration related to future regulatory and commercial milestones were fully constrained because we cannot conclude that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur, given the inherent uncertainty of success with these future milestones. We are recognizing revenues related to the research and regulatory services throughout the term of the respective clinical programs using the input method. For sales-based milestones and royalties, we determined that the license is the predominant item to which the royalties or sales-based milestones relate. Accordingly, we will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). We will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;We entered into a Commercial Supply Agreement with Grifols in October 2020 to supply and sell our drug product priced at a certain markup specified in the agreement, in quantities Grifols order from us pursuant to and in accordance with the agreement. Prior to the Commercial Supply Agreement, we had a Drug Product Purchase Agreement with Grifols entered in December 2019. During the three and six months ended June 30, 2023, we recognized $1.2 million and $2.8 million, respectively, of revenue related to delivery of drug supply to Grifols. D&lt;span style="background:#ffffff;"&gt;uring the three and six months ended June 30, 2022, we recognized &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$1.2&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;million of revenue &lt;/span&gt;related to delivery of drug supply to Grifols&lt;span style="background:#ffffff;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="background:#ffffff;"&gt;We began recognizing royalty revenue from Grifols beginning in the third quarter of 2022. For the three and six months ended June 30, 2023, we recognized &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$0.8&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;million and &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$1.5&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; million, respectively, of royalty revenue from Grifols, and such amount was included within contract revenues from collaboration.&#160;&lt;/span&gt;No&lt;span style="background:#ffffff;"&gt;&#160;such revenue was recognized for the three and six months ended June 30, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Kissei License Agreement&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;We have an exclusive license and supply agreement with Kissei entered in October 2018, to develop and commercialize fostamatinib in all current and potential indications in Kissei&#x2019;s territory. Kissei is responsible for performing and funding all development activities for fostamatinib in the above-mentioned territories. We received an upfront cash payment of $33.0&#160;million, with the potential for up to an additional $147.0&#160;million &lt;span style="white-space:pre-wrap;"&gt;in development, regulatory and commercial milestone payments, and will receive mid- to upper twenty percent, tiered, escalated net sales-based payments for the supply of fostamatinib. Under the agreement, we granted Kissei the license rights to fostamatinib in Kissei&#x2019;s territory and are obligated to supply Kissei with drug product for use in clinical trials and pre-commercialization activities. We are also responsible for the manufacture and supply of fostamatinib for all future development and commercialization activities under the agreement.  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;We accounted for this agreement under ASC 606 and identified the following distinct performance obligations at inception of the agreement: (a) granting of the license, (b) supply of fostamatinib for clinical use and (c) material right associated with discounted fostamatinib that is supplied for use other than clinical or commercial. In addition, we will provide commercial product supply if the product is approved in the licensed territory. We concluded that each of these performance obligations is distinct. We determined that the upfront fee of $33.0&#160;million represented the transaction price and was allocated to the performance obligations based on our best estimate of the relative standalone selling price and recognized the corresponding revenue in the period we satisfied the performance obligations. As of June 30, 2023 and December 31, 2022, the remaining deferred revenue was related to the material right associated with discounted fostamatinib supply which amounted to $1.4&#160;million. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;For the three and six months ended June 30, 2022, we recognized $2.5&#160;million and $2.6&#160;million, respectively, of revenue related to the delivery of fostamatinib supply to Kissei mainly for commercial use.&#160;No&#160;such revenue was recognized during the three and six months ended June 30, 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;"&gt;In April 2022, Kissei announced that an NDA was submitted to Japan&#x2019;s Pharmaceuticals and Medical Devices Agency (PMDA) for fostamatinib in chronic ITP. With this milestone event, we received&#160;&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$5.0&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;&#160;million non-refundable and non-creditable payment from Kissei pursuant to the terms of our collaboration agreement, and such amount was recognized as revenue in the three and six months ended &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;June 30, 2022&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;. In December 2022, Kissei announced that Japan&#x2019;s PMDA approved the NDA for fostamatinib in chronic ITP. With this milestone event, we were entitled to receive &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$20.0&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; million non-refundable and non-creditable payment from Kissei pursuant to the terms of our collaboration agreement, which we recognized as revenue in the fourth quarter of &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_sIEQoBwV_0WCfNDnOrc4Wg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;white-space:pre-wrap;"&gt;. The amount was subsequently collected in January 2023.  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The remaining variable consideration related to future development and regulatory milestones was fully constrained because we cannot conclude that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur, given the inherent uncertainty of success with these future milestones. For sales-based milestones and tiered, escalated net sales-based payments for the supply of fostamatinib, we determined that the license is the predominant item to which the sales-based milestones relate to. Accordingly, we will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the allocated costs for the tiered, escalated net sales-based payments has been satisfied (or partially satisfied). We will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 0pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Medison Commercial and License Agreements&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 0pt 0pt;"&gt;We have two exclusive commercial and license agreements with Medison entered in October 2019 for the commercialization of fostamatinib for chronic ITP in Medison territory, pursuant to which, we received a $5.0 million upfront payment with respect to the agreement in Canada. We accounted for this agreement under ASC 606 and identified the following combined performance obligations at inception of the agreement: (a) granting of the license and (b) obtaining regulatory approval in Canada of fostamatinib in ITP. We determined that the non-refundable upfront fee of $5.0&#160;million represented the transaction price. However, under the agreement, we have the option to buy back all rights to the product in Canada within six months from obtaining regulatory approval for the treatment of AIHA in Canada. The buyback option precludes us from transferring control of the license to Medison under ASC 606. We believed that the buyback provision, if exercised, will require us to repurchase the license at an amount equal to or more than the upfront $5.0 million. As such, this arrangement was accounted for as a financing arrangement. Interest expense &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;was accreted on such liability over the expected buyback period. We also billed Medison for the delivery of fostamatinib supplies for clinical use which we previously deferred and included within the outstanding financing liability considering the buy-back provision.  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 0pt 0pt;"&gt;The decision to exercise the buyback option is dependent of many factors including management&#x2019;s cost and benefit assessments and the success of obtaining regulatory approval for the treatment of AIHA in Canada. In June 2022, we reported the top-line results from our Phase 3 trial of fostamatinib in warm autoimmune hemolytic anemia (wAIHA) which showed that the trial did not demonstrate statistical significance in the primary efficacy endpoint in the overall study population. We also announced in early October 2022 that we will not file a supplemental new drug application (sNDA) for wAIHA indication considering the top-line data results and the guidance received from the FDA. With these developments, we assessed our options path forward, including our buyback option right with regards to the Medison license agreement. Based on management&#x2019;s assessment, the likelihood of exercising the buy-back option right was remote. As such, during the fourth quarter of 2022, we relieved the outstanding financing liability to Medison amounting to $5.7 million and recognized such amount as collaboration revenue in accordance with ASC 606. There was no outstanding financing liability to Medison as of June 30, 2023 and December 31, 2022. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 0pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Knight Commercial License and Supply Agreement&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;We have a commercial license and supply agreements with Knight entered in May 2022 for the commercialization of fostamatinib for approved indications in Knight territory. Pursuant to such commercial license agreement, we received a $2.0 million one-time, non-refundable, and non-creditable upfront payment, with potential for up to an additional $20.0 million in regulatory and sales-based commercial milestone payments, and will receive twenty- to mid-thirty percent, tiered, escalated net-sales based royalty payments for products sold in the Knight territory. We accounted for this agreement under ASC 606 and identified that the upfront payment was a consideration for granting Knight the license to commercialize fostamatinib for approved indication in the Knight territory, and no further material deliverables associated to such upfront payment. As such, we recognized the upfront payment as revenue during the three and six months ended June 30, 2022. Variable consideration related to future regulatory milestones was fully constrained because we cannot conclude that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur, given the inherent uncertainty of success with these future milestones. For sales-based milestones and royalties, we determined that the license is the predominant item to which the royalties or sales-based milestones relate to. Accordingly, we will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all the royalty has been allocated has been satisfied (or partially satisfied). We will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur. We are also responsible for the exclusive manufacture and supply of fostamatinib for all future development and commercialization activities under agreement.&#160; &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Government Contract - US Department of Defense&#x2019;s JPEO-CBRND &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;In January 2021, we were awarded up to $16.5&#160;million by the US Department of Defense to support our ongoing Phase 3 clinical trial to evaluate the safety and efficacy of fostamatinib for the treatment of hospitalized high-risk patients with COVID-19. The amount of award we will receive from the US Department of Defense is subject to submission of proper documentation as evidence of completion of certain clinical trial events or milestones as specified in the agreement, and approval by the US Department of Defense that such events or milestones have been met. We record government contract revenue in the statement of operations in the period when it is probable that we will receive the award, which is when we comply with the conditions associated with the award and obtain approval from the US Department of Defense that such conditions have been met. For the three and six months ended June 30, 2023, we recognized $1.0 million of revenue related to this grant upon achievement of certain milestones. Through June 30, 2023, we received $16.0 million of the awards which we recognized as revenue in the respective periods, with remaining $0.5 million available, subject to us meeting certain milestone and approval by the US Department of Defense that such milestone has been met, as specified in the agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;License and Transition Services Agreement with Forma (now Novo Nordisk) &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;We have a license and transition services agreement with Forma (now Novo Nordisk) entered in July 2022, for an exclusive license to develop, manufacture and commercialize olutasidenib, a proprietary inhibitor of mutated IDH1 (mIDH1), for any uses worldwide, including for the treatment of AML and other malignancies. Forma became a wholly owned subsidiary of Novo Nordisk following the closing of its acquisition by Novo Nordisk in October 2022. Pursuant to the terms of the license and transition services agreement, we paid an upfront fee of $2.0 million, with the potential to pay up to $67.5 million of additional payments upon achievement of specified development and regulatory milestones and up to $165.5 million of additional payments upon achievement of certain commercial milestones. &lt;span style="background:#ffffff;"&gt;In addition, subject to the terms and conditions of the license and transition services agreement, Forma (now Novo Nordisk) would be entitled to tiered royalty payments on net sales of licensed products at percentages ranging from low-teens to mid-thirties, as well as certain portion of our sublicensing revenue, subject to certain standard reductions and offsets.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;The transaction was accounted for as an acquisition of asset under ASC 730, &lt;i style="font-style:italic;"&gt;Research and Development&lt;/i&gt;. In accordance with the guidance, in a transaction accounted for as an asset acquisition, any acquired IPR&amp;amp;D that does not have alternative future use is charged to expense at the acquisition date. &lt;span style="background:#ffffff;"&gt;At the acquisition date, the acquired license asset was accounted for as IPR&amp;amp;D, and we anticipated no other economic benefit to be derived from such acquired licensed asset other than the primary indications. As such, we accounted for the upfront fee of &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$2.0&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; million &lt;/span&gt;as IPR&amp;amp;D and recorded such cost within research and development expense in the condensed statements of operations in the third quarter of 2022. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;Under the accounting guidance, we account for contingent &lt;/span&gt;&lt;span style="font-size:10pt;background:#ffffff;"&gt;cash payments when it is probable that a liability is incurred and the amount can be reasonably estimated.&#160;We account for m&lt;/span&gt;&lt;span style="font-size:10pt;white-space:pre-wrap;"&gt;ilestone payment obligations incurred at development stage and prior to a regulatory approval of an indication associated with the acquired licensed asset as research and development expense when the event requiring payment of the milestone occurs. Milestone payment obligations incurred upon and after a regulatory approval of an indication associated with the acquired licensed asset, and at the commercial stage, are recorded as intangible asset when the event requiring payment of the milestones occurs. The amount recorded as intangible asset is amortized over the estimated useful life of the acquired licensed asset. Royalty payments related to the acquired licensed asset is recorded as cost of sales when incurred. Prior to the FDA approval of REZLIDHIA in December 2022, we achieved certain regulatory milestone which entitled Forma (now Novo Nordisk) to receive a  &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$2.5&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; million milestone payment. Because such milestone payment obligation was incurred prior to a regulatory approval of an indication associated with the acquired licensed asset, we recorded such amount as research and development expense in the fourth quarter of 2022. On December 1, 2022, the FDA approved REZLIDHIA capsules for the treatment of adult patients with R/R AML with susceptible IDH1 mutations as detected by an FDA-approved test. Following the FDA approval, we launched REZLIDHIA and made first shipments of the product to our customers in December 2022. With this FDA approval and first commercial sale of the product, Forma (now Novo Nordisk) was entitled to receive a total of &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$15.0&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; million milestone payments. Since such milestone payment obligations were incurred upon and after regulatory approval of the product, we recorded such amount as intangible asset on our condensed balance sheet in the fourth quarter of 2022. The &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$15.0&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; million milestone payment obligation was outstanding as of December 31, 2022 and included within accounts payable in our condensed balance sheet. Such amount was paid in the first quarter of &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_Muf8QwRdCECWl-UXgvN83Q;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;During the three and six months ended June 30, 2023, we recognized $0.3 million and $0.5 million, respectively, of amortization of intangible asset, and $0.4 million and $0.6 million, respectively, of royalty expense related to the license and transition services agreement as discussed above. Such costs were included within cost of sales in our condensed statements of operations. No such expenses were recognized during the three and six months ended June 30, 2022. &lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <rigl:ContingentPaymentsUnderAgreement
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      decimals="-8"
      id="Narr__A8pDX1TFk2g-aZXP7H0dA"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">1300000000</rigl:ContingentPaymentsUnderAgreement>
    <rigl:ContingentPaymentsUnderAgreement
      contextRef="Duration_1_1_2023_To_6_30_2023_rigl_AchievementOfMilestoneAxis_rigl_SpecifiedDevelopmentEventsMember_sRR_821DCEKRn49CXFeLEw"
      decimals="-5"
      id="Narr_F-Nzc6P33kaiDpU97yL_Mg"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">279500000</rigl:ContingentPaymentsUnderAgreement>
    <rigl:ContingentPaymentsUnderAgreement
      contextRef="Duration_1_1_2023_To_6_30_2023_rigl_AchievementOfMilestoneAxis_rigl_SpecifiedRegulatoryEventsMember_zr3FrB7HG0yHHKE65ZlQ0g"
      decimals="-5"
      id="Narr_wMpSSGueA0OEY0uOMBecFQ"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">263100000</rigl:ContingentPaymentsUnderAgreement>
    <rigl:ContingentPaymentsUnderAgreement
      contextRef="Duration_1_1_2023_To_6_30_2023_rigl_AchievementOfMilestoneAxis_rigl_SpecifiedProductLaunchEventsMember_kqeKijsRnkOOsVnTduINrw"
      decimals="-5"
      id="Narr_eSck76dcTU-lxYzMncNnXQ"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">796000000.0</rigl:ContingentPaymentsUnderAgreement>
    <rigl:CollaborativeArrangementUpfrontFeeReceived
      contextRef="Duration_4_1_2021_To_4_30_2021_JKmOcc6NLUygXEbnIz_jXg"
      decimals="-5"
      id="Narr_d-wkqLHIAE2Y6H7Bb86TJA"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">125000000.0</rigl:CollaborativeArrangementUpfrontFeeReceived>
    <rigl:ContingentPaymentsUnderAgreement
      contextRef="Duration_1_1_2023_To_6_30_2023_rigl_AchievementOfMilestoneAxis_rigl_DevelopmentAndRegulatoryMilestonesByNonCentralNervousSystemDiseaseProductsMember_qhsapuJyEU-hSuSu6wuzRA"
      decimals="-5"
      id="Narr__QJ209mIBEmWLEHGhhJwFg"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">330000000.0</rigl:ContingentPaymentsUnderAgreement>
    <rigl:ContingentPaymentsUnderAgreement
      contextRef="Duration_1_1_2023_To_6_30_2023_rigl_AchievementOfMilestoneAxis_rigl_DevelopmentAndRegulatoryMilestonesByNonCentralNervousSystemDiseaseProductsMember_srt_StatementScenarioAxis_rigl_MilestonePaymentsOnProductByProductBasisMember_437LgKAaEUCSP1qghK8PUg"
      decimals="-5"
      id="Narr_m92PYVZ7pUiav8fjdO__Gw"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">100000000.0</rigl:ContingentPaymentsUnderAgreement>
    <rigl:ContingentPaymentsUnderAgreement
      contextRef="Duration_1_1_2023_To_6_30_2023_rigl_AchievementOfMilestoneAxis_rigl_DevelopmentAndRegulatoryMilestonesByCentralNervousSystemDiseaseProductsMember_Rs41QnjvWk6gGclD-ADolA"
      decimals="-5"
      id="Narr_24MlmSH6PE6U0hqNE7-LZA"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">255000000.0</rigl:ContingentPaymentsUnderAgreement>
    <rigl:ContingentPaymentsUnderAgreement
      contextRef="Duration_1_1_2023_To_6_30_2023_rigl_AchievementOfMilestoneAxis_rigl_DevelopmentAndRegulatoryMilestonesByCentralNervousSystemDiseaseProductsMember_srt_StatementScenarioAxis_rigl_MilestonePaymentsOnProductByProductBasisMember_GdhaCtbSb0a6DDLJ7JX1QA"
      decimals="-5"
      id="Narr_6HiKX46zikmC60s8YolK2g"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">150000000.0</rigl:ContingentPaymentsUnderAgreement>
    <rigl:DevelopmentCostsCostSharingArrangementPercentage
      contextRef="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_R552Member_-FMAVRdgk0G_DrmYiygA5g"
      decimals="2"
      id="Narr_SI1I3OTjY064BjRsI9tDuw"
      unitRef="Unit_Standard_pure_uVIKS5OYQEes3pxG5CV0tw">0.20</rigl:DevelopmentCostsCostSharingArrangementPercentage>
    <rigl:RightToOptOutOfAgreementNumberOfPeriods
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      decimals="INF"
      id="Narr_iyj81Ur7DkOswan_iaZGGw"
      unitRef="Unit_Standard_period_q1X9Nu1d1EeTbsf56ZdECg">2</rigl:RightToOptOutOfAgreementNumberOfPeriods>
    <us-gaap:OtherCommitment
      contextRef="As_Of_6_30_2023_srt_ProductOrServiceAxis_rigl_R552Member_srt_RangeAxis_srt_MaximumMember_nQDkYFvGfkGeTW-8GkyDkg"
      decimals="-5"
      id="Narr_dsgSkKrqsU2glebNwxSYkw"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">65000000.0</us-gaap:OtherCommitment>
    <us-gaap:OtherCommitment
      contextRef="As_Of_6_30_2023_srt_ProductOrServiceAxis_rigl_R552Member_srt_RangeAxis_srt_MaximumMember_nQDkYFvGfkGeTW-8GkyDkg"
      decimals="-5"
      id="Narr_bKHwbWNhPkqXdS-HczVwEA"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">65000000.0</us-gaap:OtherCommitment>
    <us-gaap:ProductLiabilityAccrualComponentAmount
      contextRef="As_Of_6_30_2023_srt_ProductOrServiceAxis_rigl_R552Member_JPs0ePqXlEKj9VOt8HSlUw"
      decimals="-5"
      id="Narr_GcibVPWKMk6J9l2rAlH-6w"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">57900000</us-gaap:ProductLiabilityAccrualComponentAmount>
    <rigl:FinancingLiabilityInterestAccretionDiscountRate
      contextRef="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_R552Member_-FMAVRdgk0G_DrmYiygA5g"
      decimals="3"
      id="Narr_CQ8_T2abwEC3EE2sTegktQ"
      unitRef="Unit_Standard_pure_uVIKS5OYQEes3pxG5CV0tw">0.064</rigl:FinancingLiabilityInterestAccretionDiscountRate>
    <us-gaap:AccretionExpense
      contextRef="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_R552Member_nAWV78-1SEKxOb73Me78JA"
      decimals="-5"
      id="Narr_GvJJvk3ml0ytWZYEyFD3_A"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">0</us-gaap:AccretionExpense>
    <us-gaap:AccretionExpense
      contextRef="Duration_4_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_rigl_R552Member_6cuFgoRx00e-zcShKPySYQ"
      decimals="-5"
      id="Narr_UjbUjA-UqEqydrQRXjQrZQ"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">700000</us-gaap:AccretionExpense>
    <rigl:DueToCollaborationPartner
      contextRef="As_Of_6_30_2023_srt_ProductOrServiceAxis_rigl_R552Member_JPs0ePqXlEKj9VOt8HSlUw"
      decimals="-5"
      id="Narr_EgMX7bwExECdyJr82cbrug"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">16900000</rigl:DueToCollaborationPartner>
    <rigl:FinancingLiabilityIncludingInterestExpenseAccretion
      contextRef="As_Of_6_30_2023_srt_ProductOrServiceAxis_rigl_R552Member_JPs0ePqXlEKj9VOt8HSlUw"
      decimals="-5"
      id="Narr_IOlXAKGPSEeuoeRgmXjzzg"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">44500000</rigl:FinancingLiabilityIncludingInterestExpenseAccretion>
    <rigl:FinancingLiabilityIncludingInterestExpenseAccretion
      contextRef="As_Of_12_31_2022_srt_ProductOrServiceAxis_rigl_R552Member_0YBAFpZ08UOLKeVes5ohFA"
      decimals="-5"
      id="Narr_gSwJMmKY10-DtnPNokLsuQ"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">46200000</rigl:FinancingLiabilityIncludingInterestExpenseAccretion>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="As_Of_6_30_2023_srt_ProductOrServiceAxis_rigl_R552Member_JPs0ePqXlEKj9VOt8HSlUw"
      decimals="-5"
      id="Narr_oXjlq_qIl0G-cifjePpbQQ"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">67100000</us-gaap:RevenueRemainingPerformanceObligation>
    <rigl:CollaborativeArrangementRevenueRecognized
      contextRef="Duration_1_1_2021_To_3_31_2021_srt_ProductOrServiceAxis_rigl_NonCentralNervousSystemPenetrantIntellectualPropertyMember_AzcLeTjz60Ckk-4IZ7Z2Yg"
      decimals="-5"
      id="Narr_b8QlRQ-lzkGGiKmmlOexog"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">60400000</rigl:CollaborativeArrangementRevenueRecognized>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="As_Of_6_30_2022_rigl_AchievementOfMilestoneAxis_rigl_LicensedRightsMember_srt_ProductOrServiceAxis_rigl_CentralNervousSystemPenetrantIntellectualPropertyMember_nqY09VTQhkCP6kuB8E26vw"
      decimals="-5"
      id="Narr_smwZ9pcVCECmY0IxNDUy6Q"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">6700000</us-gaap:RevenueRemainingPerformanceObligation>
    <rigl:CollaborativeArrangementRevenueRecognized
      contextRef="Duration_4_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_rigl_CentralNervousSystemPenetrantIntellectualPropertyMember_D23iXamso06lFysd2JS4lQ"
      decimals="-5"
      id="Narr_Tf3oXg68bUCwgEDw9KVTtg"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">300000</rigl:CollaborativeArrangementRevenueRecognized>
    <rigl:CollaborativeArrangementRevenueRecognized
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_ProductOrServiceAxis_rigl_CentralNervousSystemPenetrantIntellectualPropertyMember_sJI61AX-gkq7zwYyHj0Hgw"
      decimals="-5"
      id="Narr_w-qL1kpDBUaCqUoJqdiAyw"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">500000</rigl:CollaborativeArrangementRevenueRecognized>
    <rigl:CollaborativeArrangementRevenueRecognized
      contextRef="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_CentralNervousSystemPenetrantIntellectualPropertyMember_abvwS7ZRYkCRPqpRi8kUzA"
      decimals="-5"
      id="Narr_kgUDVvjOfUuK0tWjmUWfLQ"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">0</rigl:CollaborativeArrangementRevenueRecognized>
    <rigl:CollaborativeArrangementRevenueRecognized
      contextRef="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_CentralNervousSystemPenetrantIntellectualPropertyMember_u9CM64l4x06mzHqJqirPew"
      decimals="-5"
      id="Narr_Tq_70k18wUyp_Rao7H5Q9g"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">0</rigl:CollaborativeArrangementRevenueRecognized>
    <rigl:CollaborativeArrangementUpfrontFeeReceived
      contextRef="Duration_1_1_2019_To_1_31_2019_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_-3boqmgcW0u1hhv3nltpLw"
      decimals="-5"
      id="Narr_wDJgIk60K0K2Id1CZh43vQ"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">30000000.0</rigl:CollaborativeArrangementUpfrontFeeReceived>
    <rigl:ContingentPaymentsUnderAgreement
      contextRef="Duration_1_1_2019_To_1_31_2019_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_rigl_AchievementOfMilestoneAxis_rigl_SpecifiedCommercialMilestonesMember_7nbfSECgx0WYA153JYabJQ"
      decimals="-5"
      id="Narr_HN8ahXxMdkmsOsYGgt6S2A"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">297500000</rigl:ContingentPaymentsUnderAgreement>
    <rigl:RoyaltyPaymentAsPercentageOfNetSales
      contextRef="Duration_1_1_2019_To_1_31_2019_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_srt_RangeAxis_srt_MaximumMember_G1KtN3XbpUSoL3F_Q5ONNQ"
      decimals="2"
      id="Narr_RwPNXF6SfkWDr3E-C0oOVg"
      unitRef="Unit_Standard_pure_uVIKS5OYQEes3pxG5CV0tw">0.30</rigl:RoyaltyPaymentAsPercentageOfNetSales>
    <us-gaap:ProceedsFromCollaborators
      contextRef="Duration_2_1_2020_To_2_29_2020_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember__7PyRX4jPECYeFKd4E3SHA"
      decimals="-5"
      id="Narr_MnBXoBkwsUaStKIwKYa5RQ"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">20000000.0</us-gaap:ProceedsFromCollaborators>
    <rigl:ContingentPaymentsUnderAgreement
      contextRef="Duration_2_1_2020_To_2_29_2020_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_rigl_AchievementOfMilestoneAxis_rigl_EuropeanMedicinesAgencyApprovalOfFostamatinibForTreatmentOfChronicImmuneThrombocytopenicPurpuraMember_srt_ProductOrServiceAxis_rigl_FostamatinibMember_jRYJphbQ30m9xYIoKA1dgg"
      decimals="-5"
      id="Narr_7yLv47rSmki0o_pXrXvHhg"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">17500000</rigl:ContingentPaymentsUnderAgreement>
    <us-gaap:ProceedsFromCollaborators
      contextRef="Duration_2_1_2020_To_2_29_2020_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_rigl_AchievementOfMilestoneAxis_rigl_CreditableAdvanceRoyaltyPaymentMember_srt_ProductOrServiceAxis_rigl_FostamatinibMember_aO7fdyjeKkKh-8rHnFGcDQ"
      decimals="-5"
      id="Narr_pmwUCupaS0OmiaDL9pMq2A"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">2500000</us-gaap:ProceedsFromCollaborators>
    <rigl:CollaborativeArrangementRevenueRecognized
      contextRef="Duration_4_1_2022_To_6_30_2022_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_rigl_AchievementOfMilestoneAxis_rigl_ResearchActivitiesMember_bcLtqW_sUUGWAZXyYhABiQ"
      decimals="-5"
      id="Narr_w1bMb0t9L0m8vn7sbNTpag"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">200000</rigl:CollaborativeArrangementRevenueRecognized>
    <rigl:CollaborativeArrangementRevenueRecognized
      contextRef="Duration_1_1_2022_To_6_30_2022_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_rigl_AchievementOfMilestoneAxis_rigl_ResearchActivitiesMember_15-zZAIzYESjPJ56lMgsMg"
      decimals="-5"
      id="Narr_9M_a7xw-Vk2eewExRJiOQg"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">500000</rigl:CollaborativeArrangementRevenueRecognized>
    <rigl:CollaborativeArrangementRevenueRecognized
      contextRef="Duration_1_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_rigl_AchievementOfMilestoneAxis_rigl_ResearchActivitiesMember_86cJ5cqEH0CUdyuPMTHCqg"
      decimals="-5"
      id="Narr_omG0Z8X4W0WWat93xquwbg"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">0</rigl:CollaborativeArrangementRevenueRecognized>
    <rigl:CollaborativeArrangementRevenueRecognized
      contextRef="Duration_4_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_rigl_AchievementOfMilestoneAxis_rigl_ResearchActivitiesMember_wKD8r5wj8UWbEX-iqfwrAA"
      decimals="-5"
      id="Narr_H7qsUMZheUeXuEV21WW8uA"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">0</rigl:CollaborativeArrangementRevenueRecognized>
    <rigl:CollaborativeArrangementRevenueRecognized
      contextRef="Duration_4_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_rigl_AchievementOfMilestoneAxis_rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember_ahEiLx0SUk2_jcyttC4ctw"
      decimals="-5"
      id="Narr_-8sBLSHf302eXWpdwhglnA"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">1200000</rigl:CollaborativeArrangementRevenueRecognized>
    <rigl:CollaborativeArrangementRevenueRecognized
      contextRef="Duration_1_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_rigl_AchievementOfMilestoneAxis_rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember_6EJQsZyI7Ei65WKe6vURdw"
      decimals="-5"
      id="Narr_Fz3-xEP0w0e2qL3bB55rmQ"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">2800000</rigl:CollaborativeArrangementRevenueRecognized>
    <rigl:CollaborativeArrangementRevenueRecognized
      contextRef="Duration_1_1_2022_To_6_30_2022_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_rigl_AchievementOfMilestoneAxis_rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember_2kS72QqQ3EiGnNpkGNQiwg"
      decimals="-5"
      id="Narr_6HKPfCKnlEi2b58jlz5ezA"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">1200000</rigl:CollaborativeArrangementRevenueRecognized>
    <rigl:CollaborativeArrangementRevenueRecognized
      contextRef="Duration_4_1_2022_To_6_30_2022_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_rigl_AchievementOfMilestoneAxis_rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember__2GzLf2h9Uy8zugKcIpR5Q"
      decimals="-5"
      id="Narr_odjvuafwl0a-Dta2HjPyvA"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">1200000</rigl:CollaborativeArrangementRevenueRecognized>
    <rigl:CollaborativeArrangementRevenueRecognized
      contextRef="Duration_4_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_YoqQXBJjBkuRMnl_Is2ryA"
      decimals="-5"
      id="Narr_yN4Y1B9aCk6ATfyTkVrYHg"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">800000</rigl:CollaborativeArrangementRevenueRecognized>
    <rigl:CollaborativeArrangementRevenueRecognized
      contextRef="Duration_1_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_BiD0k0-zyUKpI2kOTEgwHQ"
      decimals="-5"
      id="Narr_hY-njWu4ZUeM4Q9DYeWP7Q"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">1500000</rigl:CollaborativeArrangementRevenueRecognized>
    <rigl:CollaborativeArrangementRevenueRecognized
      contextRef="Duration_1_1_2022_To_6_30_2022_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_8nDIYOyABEq7e05lMjmqPw"
      decimals="-5"
      id="Narr_X48FQI2Y8Emryy1PwGQYNg"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">0</rigl:CollaborativeArrangementRevenueRecognized>
    <rigl:CollaborativeArrangementRevenueRecognized
      contextRef="Duration_4_1_2022_To_6_30_2022_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_UY3l2klaxkutbshAAhD9Eg"
      decimals="-5"
      id="Narr_TPLTcfFZxUmUKhu7bE9wzw"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">0</rigl:CollaborativeArrangementRevenueRecognized>
    <rigl:CollaborativeArrangementUpfrontFeeReceived
      contextRef="Duration_10_1_2018_To_10_31_2018_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_PZS9u-OE1EmIeqOd2HsFnw"
      decimals="-5"
      id="Narr_5HG7r7eQEkq68SUEqqu1_Q"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">33000000.0</rigl:CollaborativeArrangementUpfrontFeeReceived>
    <rigl:ContingentPaymentsUnderAgreement
      contextRef="Duration_10_1_2018_To_10_31_2018_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_PZS9u-OE1EmIeqOd2HsFnw"
      decimals="-5"
      id="Narr_u5yfHHgeJU2ab_TaBanMwg"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">147000000.0</rigl:ContingentPaymentsUnderAgreement>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="As_Of_6_30_2023_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_VOQGD0Imek29F_UrLGFn-w"
      decimals="-5"
      id="Narr_iZU-IoiZwEW5-aje3QTGWA"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">33000000.0</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:DeferredRevenue
      contextRef="As_Of_6_30_2023_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_dWMxniyFJ06ygU7yM53x1w"
      decimals="-5"
      id="Narr__RjNdbAtEUKwAfKu7VPvvw"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">1400000</us-gaap:DeferredRevenue>
    <us-gaap:DeferredRevenue
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_p5hH6L8EpUKDvP9iizwvIA"
      decimals="-5"
      id="Narr_SL5H_kU94EmjbGnC7q--yQ"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">1400000</us-gaap:DeferredRevenue>
    <rigl:CollaborativeArrangementRevenueRecognized
      contextRef="Duration_4_1_2022_To_6_30_2022_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_rigl_AchievementOfMilestoneAxis_rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember_srt_ProductOrServiceAxis_rigl_FostamatinibMember_X1jrjFNaUUi-0RSb2kWr2A"
      decimals="-5"
      id="Narr_dFs4JkyaHEynUJUGuDqGGg"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">2500000</rigl:CollaborativeArrangementRevenueRecognized>
    <rigl:CollaborativeArrangementRevenueRecognized
      contextRef="Duration_1_1_2022_To_6_30_2022_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_rigl_AchievementOfMilestoneAxis_rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember_srt_ProductOrServiceAxis_rigl_FostamatinibMember_ijWIH4IdnkaOE9hajv0lhw"
      decimals="-5"
      id="Narr_VfXkfGQd_USZjaKb58IQYw"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">2600000</rigl:CollaborativeArrangementRevenueRecognized>
    <rigl:CollaborativeArrangementRevenueRecognized
      contextRef="Duration_1_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_rigl_AchievementOfMilestoneAxis_rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember_srt_ProductOrServiceAxis_rigl_FostamatinibMember_knn1moXg0kCR1PGoGmvEkA"
      decimals="-5"
      id="Narr_YWeps4QBgUWeRg_MnUXghQ"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">0</rigl:CollaborativeArrangementRevenueRecognized>
    <rigl:CollaborativeArrangementRevenueRecognized
      contextRef="Duration_4_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_rigl_AchievementOfMilestoneAxis_rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember_srt_ProductOrServiceAxis_rigl_FostamatinibMember_iOGTC4JHqEqAcLNDtBnr0Q"
      decimals="-5"
      id="Narr_eFJ63gdgXEySWrp-1ppuLg"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">0</rigl:CollaborativeArrangementRevenueRecognized>
    <us-gaap:ProceedsFromCollaborators
      contextRef="Duration_1_1_2022_To_6_30_2022_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_VJof-y5NIUmbhtjjV8-ZnQ"
      decimals="-5"
      id="Narr_bysHMpiptE2zu-7xYLJppQ"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">5000000.0</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ProceedsFromCollaborators
      contextRef="Duration_4_1_2022_To_6_30_2022_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_AqH_Lz4Dqk2ULht1ffcBfQ"
      decimals="-5"
      id="Narr_-DWLvX7ANkyp3X0ZdRBg0Q"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">5000000.0</us-gaap:ProceedsFromCollaborators>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_p5hH6L8EpUKDvP9iizwvIA"
      decimals="-5"
      id="Narr_qXdMXMRrOkmLdcUmLTIlaw"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">20000000.0</us-gaap:AccountsReceivableNetCurrent>
    <rigl:NumberOfAgreements
      contextRef="Duration_10_1_2019_To_10_31_2019_dei_LegalEntityAxis_rigl_MedisonPharmaLtd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_us-gaap_TypeOfArrangementAxis_rigl_CommercialAndLicenseAgreementMember_zpx7xwCeskCPVInu1YwLlw"
      decimals="INF"
      id="Narr_GBzC1MwiJk-rFrDdk0vQgw"
      unitRef="Unit_Standard_agreement_KRHA7hMTtE2mxosuhHYaSA">2</rigl:NumberOfAgreements>
    <rigl:CollaborativeArrangementUpfrontFeeReceived
      contextRef="Duration_10_1_2019_To_10_31_2019_dei_LegalEntityAxis_rigl_MedisonPharmaLtd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_us-gaap_TypeOfArrangementAxis_rigl_CommercialAndLicenseAgreementMember_zpx7xwCeskCPVInu1YwLlw"
      decimals="-5"
      id="Narr_R2QH3LniM0u0t7ZYYeOD7A"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">5000000.0</rigl:CollaborativeArrangementUpfrontFeeReceived>
    <rigl:CollaborativeArrangementUpfrontFeeReceived
      contextRef="Duration_10_1_2019_To_10_31_2019_dei_LegalEntityAxis_rigl_MedisonPharmaLtd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ProductFinancingArrangementMember_RZVg4VgmR0iEhiVJHe0OGA"
      decimals="-5"
      id="Narr_R7yatImc9ki-d5B-vAm3NA"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">5000000.0</rigl:CollaborativeArrangementUpfrontFeeReceived>
    <rigl:CollaborativeArrangementUpfrontFeeReceived
      contextRef="Duration_10_1_2019_To_10_31_2019_dei_LegalEntityAxis_rigl_MedisonPharmaLtd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ProductFinancingArrangementMember_RZVg4VgmR0iEhiVJHe0OGA"
      decimals="-5"
      id="Narr_3R45iy3Pv0GKUNCYp04wew"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">5000000.0</rigl:CollaborativeArrangementUpfrontFeeReceived>
    <rigl:CollaborativeArrangementRevenueRecognized
      contextRef="Duration_10_1_2022_To_12_31_2022_dei_LegalEntityAxis_rigl_MedisonPharmaLtd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ProductFinancingArrangementMember_FDUx_RGlykuMMywGpuGo3Q"
      decimals="-5"
      id="Narr_XKPx11nCIUucDpxYIr3STQ"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">5700000</rigl:CollaborativeArrangementRevenueRecognized>
    <rigl:FinancingLiabilityIncludingInterestExpenseAccretion
      contextRef="As_Of_6_30_2023_dei_LegalEntityAxis_rigl_MedisonPharmaLtd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ProductFinancingArrangementMember_BIXtwMz280OZBubIreCp6g"
      decimals="-5"
      id="Narr_D4joo6DXKEeVjHV_zzTTVg"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">0</rigl:FinancingLiabilityIncludingInterestExpenseAccretion>
    <rigl:FinancingLiabilityIncludingInterestExpenseAccretion
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_rigl_MedisonPharmaLtd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ProductFinancingArrangementMember_10kT5pgvQESOoSV7Z9NRdg"
      decimals="-5"
      id="Narr_E1Uk663YHUOQfsPHKWIh2w"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">0</rigl:FinancingLiabilityIncludingInterestExpenseAccretion>
    <rigl:CollaborativeArrangementUpfrontFeeReceived
      contextRef="Duration_1_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_KnightTherapeuticsInternationalSaMember_us-gaap_TypeOfArrangementAxis_rigl_CommercialAndLicenseAgreementMember_lvwZmBPza0monsr9dfDiMw"
      decimals="-5"
      id="Narr_DvyYyQbpDk6CXP7tEQwMaw"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">2000000.0</rigl:CollaborativeArrangementUpfrontFeeReceived>
    <rigl:ContingentPaymentsUnderAgreement
      contextRef="Duration_1_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_KnightTherapeuticsInternationalSaMember_rigl_AchievementOfMilestoneAxis_rigl_SpecifiedCommercialMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_rigl_CommercialAndLicenseAgreementMember_w0GRfq66bE20v4GiBSs-dQ"
      decimals="-5"
      id="Narr_ufyAh5fAA0GcBLjVHuHvZg"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">20000000.0</rigl:ContingentPaymentsUnderAgreement>
    <rigl:GovernmentAward
      contextRef="Duration_1_1_2021_To_1_31_2021_srt_ProductOrServiceAxis_rigl_FostamatinibMember_CbO6IlzEuE-DlB2_dwCYvQ"
      decimals="-5"
      id="Narr_6twm79SEc0yEZjO2hKC7Qw"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">16500000</rigl:GovernmentAward>
    <rigl:CollaborativeArrangementRevenueRecognized
      contextRef="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_FostamatinibMember_FfcxPSwT3UW6Q9F1eb4nlg"
      decimals="-5"
      id="Narr_eIQpVfRPAkmlOXv-h0SkMQ"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">1000000.0</rigl:CollaborativeArrangementRevenueRecognized>
    <rigl:CollaborativeArrangementRevenueRecognized
      contextRef="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_FostamatinibMember_lBFcNSb6mkeW8CR2ORtSjg"
      decimals="-5"
      id="Narr_cyLsPxcG8Ei477KZbQ1zlA"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">1000000.0</rigl:CollaborativeArrangementRevenueRecognized>
    <rigl:CollaborativeArrangementRevenueRecognized
      contextRef="Duration_1_1_2021_To_3_31_2023_srt_ProductOrServiceAxis_rigl_FostamatinibMember_khHoF3cNM0WfiX7y2atpOw"
      decimals="-5"
      id="Narr_gbRNBVk09Ua1oivH_KfkOQ"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">16000000.0</rigl:CollaborativeArrangementRevenueRecognized>
    <rigl:GovernmentAwardExpectedToBeReceivedInSucceedingPeriods
      contextRef="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_FostamatinibMember_FfcxPSwT3UW6Q9F1eb4nlg"
      decimals="-5"
      id="Narr_a9hibl9lQEmxK87BHaiNYw"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">500000</rigl:GovernmentAwardExpectedToBeReceivedInSucceedingPeriods>
    <rigl:CollaborativeArrangementUpfrontPayment
      contextRef="Duration_7_1_2022_To_7_27_2022_dei_LegalEntityAxis_rigl_FormaTherapeuticsHoldingsIncMember_bDfSL0BJhEWrP72tbRoIWQ"
      decimals="-5"
      id="Narr_6sWDPRuIxEeOHej3g4XpKw"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">2000000.0</rigl:CollaborativeArrangementUpfrontPayment>
    <rigl:CollaborativeArrangementPotentialPayments
      contextRef="Duration_7_1_2022_To_7_27_2022_dei_LegalEntityAxis_rigl_FormaTherapeuticsHoldingsIncMember_rigl_AchievementOfMilestoneAxis_rigl_DevelopmentAndRegulatoryMilestonesMember_7OkGU0Mcw06DYh7peGdg4g"
      decimals="-5"
      id="Narr_3zHT-oDbOUanK2QjwthnLg"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">67500000</rigl:CollaborativeArrangementPotentialPayments>
    <rigl:CollaborativeArrangementPotentialPayments
      contextRef="Duration_7_1_2022_To_7_27_2022_dei_LegalEntityAxis_rigl_FormaTherapeuticsHoldingsIncMember_rigl_AchievementOfMilestoneAxis_rigl_SpecifiedCommercialMilestonesMember_puSiFDremkCXvb9X1_0EfA"
      decimals="-5"
      id="Narr_l53LtWy6wUWhUjpb4j0tYQ"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">165500000</rigl:CollaborativeArrangementPotentialPayments>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_7_1_2022_To_9_30_2022_dei_LegalEntityAxis_rigl_FormaTherapeuticsHoldingsIncMember_gN0UrgqHwke5fJiA75tT0w"
      decimals="-5"
      id="Narr_SwWrC6OqHEuq6SCY5MBFqw"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">2000000.0</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_10_1_2022_To_12_31_2022_dei_LegalEntityAxis_rigl_FormaTherapeuticsHoldingsIncMember_rigl_AchievementOfMilestoneAxis_rigl_AchievementOfCertainNearTermRegulatoryMilestoneMember_mYsvlxGBhUyABmwFOCLmig"
      decimals="-5"
      id="Narr_eSBme8CXL0KF02X7t7f6OQ"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">2500000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_rigl_FormaTherapeuticsHoldingsIncMember_rigl_AchievementOfMilestoneAxis_rigl_FdaApprovalAndFirstCommercialSaleOfProductMember_srt_ProductOrServiceAxis_rigl_RezlidhiaMember_0GWFqUYggk2HSLP63Ny2Tg"
      decimals="-5"
      id="Narr_7kd3kbkDg0aLYXe2PB1m1A"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">15000000.0</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_rigl_FormaTherapeuticsHoldingsIncMember_rigl_AchievementOfMilestoneAxis_rigl_FdaApprovalAndFirstCommercialSaleOfProductMember_srt_ProductOrServiceAxis_rigl_RezlidhiaMember_0GWFqUYggk2HSLP63Ny2Tg"
      decimals="-5"
      id="Narr_4ZD3qjMoSkeFqVGeAIXXnA"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">15000000.0</us-gaap:AccountsPayableCurrent>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Duration_4_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_FormaTherapeuticsHoldingsIncMember_srt_ProductOrServiceAxis_rigl_RezlidhiaMember_Ggj-m6AMbkSlsqSSg-Oh4Q"
      decimals="-5"
      id="Narr_ERCEMoftP0uDUdYcl0FjtQ"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">300000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Duration_1_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_FormaTherapeuticsHoldingsIncMember_srt_ProductOrServiceAxis_rigl_RezlidhiaMember_u5JNB-NKCE6uQDuM-ogIPw"
      decimals="-5"
      id="Narr_rkpSfjvfXEypn5bC46CqKw"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">500000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:RoyaltyExpense
      contextRef="Duration_4_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_FormaTherapeuticsHoldingsIncMember_srt_ProductOrServiceAxis_rigl_RezlidhiaMember_Ggj-m6AMbkSlsqSSg-Oh4Q"
      decimals="-5"
      id="Narr_0UPns-sQQkmcMKBb-k0VqA"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">400000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_FormaTherapeuticsHoldingsIncMember_srt_ProductOrServiceAxis_rigl_RezlidhiaMember_u5JNB-NKCE6uQDuM-ogIPw"
      decimals="-5"
      id="Narr_vHSLLV37PE6VG5f9asMM7Q"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">600000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="Duration_1_1_2022_To_6_30_2022_dei_LegalEntityAxis_rigl_FormaTherapeuticsHoldingsIncMember_srt_ProductOrServiceAxis_rigl_RezlidhiaMember_yxVUJk2G5k2qwTfZTVvH9Q"
      decimals="-5"
      id="Narr_UYedS4shxEeSVDgk_EX-fg"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">0</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="Duration_4_1_2022_To_6_30_2022_dei_LegalEntityAxis_rigl_FormaTherapeuticsHoldingsIncMember_srt_ProductOrServiceAxis_rigl_RezlidhiaMember_holN4_ByhUmtcYY2H349MA"
      decimals="-5"
      id="Narr_ygWOwC7_hkyX6DM6pkQVsg"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">0</us-gaap:RoyaltyExpense>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      id="Tb_qs1905oiV0KYM8T6_7l9Ug">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"&gt;&lt;b style="font-size:10pt;font-weight:bold;"&gt;5.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"&gt;&lt;b style="font-size:10pt;font-weight:bold;"&gt;Stock-Based Compensation&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Stock-based compensation for the periods presented was as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:97.21%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:54.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:20.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Selling, general and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,796&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,933&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,531&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4,672&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 376&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 458&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,399&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 926&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total stock-based compensation expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,172&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,391&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4,930&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5,598&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;Stock-based compensation expense within research and development in the six months ended June 30, 2023 include an incremental charge of approximately $0.5 million from stock option modifications recorded in the first quarter of 2023 related to the acceleration of vesting and extension of exercise period of vested stock option grants made to a former officer whose employment ended in March 2023. Stock-based compensation expense within selling, general and administrative in the six months ended June 30, 2022 include an incremental charge of approximately $0.8 million from stock option modifications recorded in the first quarter of 2022 related to the extension of the exercise period of the stock option grants made to our two former Board of Directors whose terms expired in May 2022. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;During the six months ended June 30, 2023, we granted stock options to purchase 2,938,600 shares of common stock with weighted-average grant-date fair value of $1.37 per share, and 15,557 stock options were exercised. As of June 30, 2023, there were 35,244,121 stock options outstanding, of which, 2,870,000 are outstanding performance-based stock options wherein the achievement of the corresponding corporate-based milestones were not considered probable as of June 30, 2023. Accordingly, none of the $5.3 million grant date fair value for these awards has been recognized as stock-based compensation expense as of June 30, 2023. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;The fair value of each option award is estimated on the date of grant using the Black-Scholes option pricing model. The following table summarizes the weighted-average assumptions relating to options granted pursuant to our Equity Incentive Plans (2018 Equity Incentive Plan and Inducement Plan) for the periods presented:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:92.03%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:46.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;width:24.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;3.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;2.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;3.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;1.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;6.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;6.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;7.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;6.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;0.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;0.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;0.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;0.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;86.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;70.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;83.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;70.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;During the six months ended June 30, 2023, we granted &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;1,387,600&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;background:#ffffff;"&gt;RSUs &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;with a grant-date weighted-average fair value of &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$1.80&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; per share, and &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;435,006&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; RSUs were released. The RSUs granted generally vest over &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;4 years&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;. As of June 30, 2023, there were &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;1,963,487&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; RSUs outstanding.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-bottom:12pt;text-indent:36pt;margin:12pt 0pt 0pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;As of June 30, 2023, there was approximately &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$14.6&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; million &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;of unrecognized stock-based compensation cost which is expected to be recognized over a remaining weighted-average period of &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_gNM8FB3j1EmiM03O-NFNhA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;2.68&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; years, related to time-based stock options, performance-based stock options wherein achievement of the corresponding corporate-based milestones was considered as probable, and RSUs. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;In April 2023, our Board of Directors approved additional 108,600 shares of common stock reserved for issuance under our Inducement Plan. In May 2023, our stockholders approved an amendment to our 2018 Plan, to, among other items, add an additional&#160;4,000,000&#160;shares&#160;to the number of shares of common stock authorized for issuance under our 2018 Plan. As of June 30, 2023, there were 12,186,098 shares of common stock available for future grant under our Equity Incentive Plans.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;"&gt;Our Purchase Plan provides for a &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_PQsDUEtR7km_2RPzqyzkJA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;24&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;-month offering period comprises &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;four&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;six-month&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; purchase periods with a look-back option. A look-back option is a provision in our Purchase Plan under which eligible employees can purchase shares of our common stock at a price per share equal to the lesser of &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;85%&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; of the fair market value on the first day of the offering period or &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;85%&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; of the fair market value on the purchase date. &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;Our Purchase Plan also includes a feature that provides for a new offering period to begin when the fair market value of our common stock on any purchase date during an offering period falls below the fair market value of our common stock on the first day of such offering period. This feature is called a &#x201c;reset.&#x201d; Participants are automatically enrolled in the new offering period. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:12pt 0pt 0pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;Our previous &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_zvVmLYm5wkGT80D-sHpXHw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;24&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;-month offering period under our Purchase Plan ended on June 30, 2022, and a new twenty-four-month offering period started on July 1, 2022. &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;The fair value of awards under our Purchase Plan is estimated on the date of our new offering period using the Black-Scholes option pricing model, which is being amortized over the requisite service periods. &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;As of June 30, 2023, unrecognized stock-based compensation cost related to our Purchase Plan amounted to &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$0.4&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; million, which is expected to be recognized over the remaining weighted average period of &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_uq0rUsBH7E2jbRn6gMjYeg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;0.74&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; years.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;During the six months ended June 30, 2023, there were 509,190 shares purchased under the Purchase Plan. As of June 30, 2023, there were 2,928,443 shares reserved for future issuance under the Purchase Plan.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      id="Tb_Uz7CopETnEy3zbOL61-5xw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Stock-based compensation for the periods presented was as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:97.21%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:54.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:20.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Selling, general and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,796&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,933&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,531&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4,672&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 376&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 458&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,399&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 926&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total stock-based compensation expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,172&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,391&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4,930&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5,598&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_OA1zy6euuUWd92D01bHyQA"
      decimals="-3"
      id="Tc_quaV6tQahEOQolC-XMXVoA_3_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">1796000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_5BqaR0t6HUmn3zbRET6b7A"
      decimals="-3"
      id="Tc_f-1qizkXQUq4_Ee9W3TkzA_3_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">1933000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_YYP3i7dwZkyEj_jUho867Q"
      decimals="-3"
      id="Tc_yKVHGUEwT06qgDzE8doFiA_3_9"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">3531000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_qUKc9ZeBcEiFN-VeeuFO_A"
      decimals="-3"
      id="Tc_XDHFOjQYTUK1_mmhkfmt4Q_3_12"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">4672000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_cNvDS3J20E2jpHrHJN-GXQ"
      decimals="-3"
      id="Tc_wLuwBeq5h0aSqrpltsV6ww_4_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">376000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_NPerFx0HTUiasJQZFwYc_w"
      decimals="-3"
      id="Tc_tp9_q4RsikGwEhFogvo-Vw_4_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">458000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_9G6CsmCnIE25iWXSTMDwUA"
      decimals="-3"
      id="Tc_2i2geBANzE-NjVMLKx4W-g_4_9"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">1399000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_WWdgQCoeWk-M5rmywXJFrQ"
      decimals="-3"
      id="Tc_rKfuVDqSEUyaahpH1CUt3g_4_12"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">926000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ"
      decimals="-3"
      id="Tc_kLi-FM2G10i2se46_eRPHQ_5_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">2172000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_4_1_2022_To_6_30_2022_ICCkO9pPUUSORAn1kecZBA"
      decimals="-3"
      id="Tc_iJX7a2mlLUa_qsxPrmuWcA_5_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">2391000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      decimals="-3"
      id="Tc_f0V8pwERjEa-JjeMG1FpYA_5_9"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">4930000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g"
      decimals="-3"
      id="Tc_p4nX8VRvm0CDb8sJduks-Q_5_12"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">5598000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      decimals="-5"
      id="Narr_zQW5Lq5BAUOsDOVHHf6WFQ"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
      contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g"
      decimals="-5"
      id="Narr_DuyLc3qrvUy39c7fbgNgkA"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nQp2Q6A6Z0qf5xAVDXOnBg"
      decimals="INF"
      id="Narr_iZn4aPEkLk2Z_ytZmirs0A"
      unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA">2938600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nQp2Q6A6Z0qf5xAVDXOnBg"
      decimals="2"
      id="Narr_TDFhJdrw8kqaXxp2ybERCA"
      unitRef="Unit_Divide_USD_shares_Xu_N--yaaU6K7FdyMhFNnQ">1.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nQp2Q6A6Z0qf5xAVDXOnBg"
      decimals="INF"
      id="Narr_M8m6AX5grk2_lLzlcKBpqw"
      unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA">15557</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_gbdA-1ad4EqysI7py3ChOA"
      decimals="INF"
      id="Narr_y5FA5VBEjUiQY3CHR9jN-A"
      unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA">35244121</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_bC736RZBjkmPBtBhrfONyg"
      decimals="INF"
      id="Narr_fDiyPKM1Pku5h55qRCUIXw"
      unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA">2870000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="As_Of_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_bC736RZBjkmPBtBhrfONyg"
      decimals="-5"
      id="Narr_ll_a7o2oSk-g3HQOo_RmgA"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">5300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nQp2Q6A6Z0qf5xAVDXOnBg"
      id="Tb_gedDdMDWw0mGaC1Q6GhRwg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:92.03%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:46.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;width:24.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;3.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;2.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;3.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;1.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;6.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;6.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;7.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;6.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;0.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;0.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;0.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;0.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;86.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;70.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;83.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;70.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_DF-ET0UVsU-4JFbzSJC6wg"
      decimals="3"
      id="Tc_aiF38RB2fkS1K7uzANOJ3Q_3_2"
      unitRef="Unit_Standard_pure_uVIKS5OYQEes3pxG5CV0tw">0.037</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_om_Pkmw3FEmnJzDD0iVbRQ"
      decimals="3"
      id="Tc_yPYjybR77021TdVBS56wGw_3_4"
      unitRef="Unit_Standard_pure_uVIKS5OYQEes3pxG5CV0tw">0.029</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nQp2Q6A6Z0qf5xAVDXOnBg"
      decimals="3"
      id="Tc_yO6WzP1Clk6xqDdxnI9Ntw_3_7"
      unitRef="Unit_Standard_pure_uVIKS5OYQEes3pxG5CV0tw">0.037</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_tNXptyV-B0yupU7uhJiuDg"
      decimals="3"
      id="Tc_cHGNjFUTOEq295RfS6en2w_3_9"
      unitRef="Unit_Standard_pure_uVIKS5OYQEes3pxG5CV0tw">0.019</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_DF-ET0UVsU-4JFbzSJC6wg"
      id="Tc_VD13a-DdM0-hzUNBeD0Bhg_4_2">P6Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_om_Pkmw3FEmnJzDD0iVbRQ"
      id="Tc_CsI-uHNPnU6k50rOcddtpQ_4_4">P6Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nQp2Q6A6Z0qf5xAVDXOnBg"
      id="Tc_pD1rpoYf5ki-l0frwKhRtQ_4_7">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_tNXptyV-B0yupU7uhJiuDg"
      id="Tc__9UQkd0veU6F-2LT4yCWQA_4_9">P6Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_DF-ET0UVsU-4JFbzSJC6wg"
      decimals="3"
      id="Tc_mQ79O_KB70CJHEBsq5btSA_5_2"
      unitRef="Unit_Standard_pure_uVIKS5OYQEes3pxG5CV0tw">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_om_Pkmw3FEmnJzDD0iVbRQ"
      decimals="3"
      id="Tc_CB4GlDkImEqBq3GrZNAW4g_5_4"
      unitRef="Unit_Standard_pure_uVIKS5OYQEes3pxG5CV0tw">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nQp2Q6A6Z0qf5xAVDXOnBg"
      decimals="3"
      id="Tc_YM2S4OHXDEu8K7WqrZWblA_5_7"
      unitRef="Unit_Standard_pure_uVIKS5OYQEes3pxG5CV0tw">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_tNXptyV-B0yupU7uhJiuDg"
      decimals="3"
      id="Tc_eOsnog3gbkWRYi6OENosMw_5_9"
      unitRef="Unit_Standard_pure_uVIKS5OYQEes3pxG5CV0tw">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_DF-ET0UVsU-4JFbzSJC6wg"
      decimals="3"
      id="Tc_4_avoptZYUuVKV4jHTwopg_6_2"
      unitRef="Unit_Standard_pure_uVIKS5OYQEes3pxG5CV0tw">0.860</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_om_Pkmw3FEmnJzDD0iVbRQ"
      decimals="3"
      id="Tc_tFVH0f0UKUOVWPvAFddTTw_6_4"
      unitRef="Unit_Standard_pure_uVIKS5OYQEes3pxG5CV0tw">0.703</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nQp2Q6A6Z0qf5xAVDXOnBg"
      decimals="3"
      id="Tc_zUqrNfA9PEOAwOCDrK5hfw_6_7"
      unitRef="Unit_Standard_pure_uVIKS5OYQEes3pxG5CV0tw">0.831</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_tNXptyV-B0yupU7uhJiuDg"
      decimals="3"
      id="Tc_ZSZvs2okEkeDRoXUmL8FyA_6_9"
      unitRef="Unit_Standard_pure_uVIKS5OYQEes3pxG5CV0tw">0.700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_PpvU5eYgTEyg2sveoUrODg"
      decimals="INF"
      id="Narr_-uU_YxYVXUWJpwRXpXu0VQ"
      unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA">1387600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_PpvU5eYgTEyg2sveoUrODg"
      decimals="2"
      id="Narr_y7OgFZ8rNUOg0m2fQQZ3zg"
      unitRef="Unit_Divide_USD_shares_Xu_N--yaaU6K7FdyMhFNnQ">1.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_PpvU5eYgTEyg2sveoUrODg"
      decimals="INF"
      id="Narr_LYXLQP2Oy0KMnXKeX7ukQw"
      unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA">435006</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_PpvU5eYgTEyg2sveoUrODg"
      id="Narr_MDJtTxm9KEy5XkhgSeTYQQ">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_phK8_7NtIEStEjkLueCcDw"
      decimals="INF"
      id="Narr_xtEsv5DhYEig-MROz7kOJg"
      unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA">1963487</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="As_Of_6_30_2023_us-gaap_AwardTypeAxis_rigl_ShareBasedCompensationOptionsAndRsusMember_eHSX5niPTk2ia4BsC8uknQ"
      decimals="-5"
      id="Narr_bzPDgzZM1EesMiPMLrPVvQ"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">14600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="Duration_4_1_2023_To_4_30_2023_qr7JWxKMEU6rcNt5QqihYw"
      decimals="INF"
      id="Narr_Z16rDw_pWE2RS28yDgmI5Q"
      unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA">108600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="Duration_5_1_2023_To_5_31_2023_Q3DEP_Nkn0q2GbxII4v6Iw"
      decimals="INF"
      id="Narr_7_eoYU6P-UCY9mZ4m4YODQ"
      unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA">4000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww"
      decimals="INF"
      id="Narr_BsNCfV8L-U2HaaXfWH6vVw"
      unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA">12186098</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <rigl:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriodsPerAwardOfferingPeriod
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_sAWGlLehukGUN_F8wkmpLA"
      decimals="INF"
      id="Narr__JGjmGNCIU6kw1nme13WCQ"
      unitRef="Unit_Standard_item_goOMrhYK4U2jGn5r_GJRhQ">4</rigl:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriodsPerAwardOfferingPeriod>
    <rigl:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPurchasePeriod
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_sAWGlLehukGUN_F8wkmpLA"
      id="Narr_NUF0HJQgjkW7MM8TyIWP5g">P6M</rigl:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPurchasePeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_sAWGlLehukGUN_F8wkmpLA"
      decimals="2"
      id="Narr__qLmdYhn00aJAA6Fm7XTxA"
      unitRef="Unit_Standard_pure_uVIKS5OYQEes3pxG5CV0tw">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <rigl:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentageOnFirstDayOfOfferingPeriod
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_sAWGlLehukGUN_F8wkmpLA"
      decimals="2"
      id="Narr_kkQAZNyQFEa33W6thk0ilg"
      unitRef="Unit_Standard_pure_uVIKS5OYQEes3pxG5CV0tw">0.85</rigl:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentageOnFirstDayOfOfferingPeriod>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="As_Of_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_zHK5kte7M02N-LF9t66ILA"
      decimals="-5"
      id="Narr_qgKS4VwJwEuJ6-QgXVVAug"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_sAWGlLehukGUN_F8wkmpLA"
      decimals="INF"
      id="Narr_XVYJTpDMgEyqBNY1LyAMIw"
      unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA">509190</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_zHK5kte7M02N-LF9t66ILA"
      decimals="INF"
      id="Narr_FQ49285lUU-_VVrI4zo9oQ"
      unitRef="Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA">2928443</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      id="Tb_nx9WXn68bEKpvVIlAXM6Eg">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:12pt;"&gt;&lt;b style="font-size:10pt;font-weight:bold;"&gt;6.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:12pt;"&gt;&lt;b style="font-size:10pt;font-weight:bold;"&gt;Inventories&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;Inventories for the periods presented consist of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:98.15%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="color:#0563c1;font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="color:#0563c1;font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:10.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;6,878 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;4,555 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Work in process&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;2,046 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;2,659 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;1,858 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;1,904 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;10,782 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;9,118 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:12pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;Inventories as of June 30, 2023 and December 31, 2022 include inventories acquired from Forma (now Novo Nordisk) pursuant to the license and transition agreement. As of June 30, 2023 and December 31, 2022, we have &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$0.7&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; million and &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$0.8&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; million, respectively, in advance payments to the manufacturer of our raw materials, which were included within prepaid and other current assets in the condensed balance sheet.&lt;/span&gt;&lt;/p&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      id="Tb_f3ag8OrepE6_i8onjCjrMA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;Inventories for the periods presented consist of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:98.15%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="color:#0563c1;font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="color:#0563c1;font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:10.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;6,878 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;4,555 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Work in process&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;2,046 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;2,659 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;1,858 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;1,904 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;10,782 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;9,118 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww"
      decimals="-3"
      id="Tc_WzoVg2nHiUa3yI9n9nTi5g_4_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">6878000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A"
      decimals="-3"
      id="Tc_IKWnDuTDiUuQklj9x7lcoQ_4_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">4555000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess
      contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww"
      decimals="-3"
      id="Tc_8QvfvsSIc0euNpC_zVJjJQ_5_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">2046000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A"
      decimals="-3"
      id="Tc_lqeXQYtGNU6m2jWrx6bgng_5_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">2659000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww"
      decimals="-3"
      id="Tc_28hFlLVRs0S5Hzb86elIsQ_6_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">1858000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A"
      decimals="-3"
      id="Tc_UtNDpbRDzEOVuomh3YJThQ_6_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">1904000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryNet
      contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww"
      decimals="-3"
      id="Tc_sglA_hW0X0mC7ePmUQn_yQ_7_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">10782000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A"
      decimals="-3"
      id="Tc_zNBhOcmKBUalp7DCUSnmPw_7_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">9118000</us-gaap:InventoryNet>
    <us-gaap:AdvancesOnInventoryPurchases
      contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww"
      decimals="-5"
      id="Narr_h6TvXRe5aEOkOuiQCponVg"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">700000</us-gaap:AdvancesOnInventoryPurchases>
    <us-gaap:AdvancesOnInventoryPurchases
      contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A"
      decimals="-5"
      id="Narr_9t6dvldMXEW-QYAOIX8Gxw"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">800000</us-gaap:AdvancesOnInventoryPurchases>
    <us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      id="Tb_z1QfhshyHE6aj4hxYvzGmA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;7.&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Cash, Cash Equivalents and Short-Term Investments&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;Cash, cash equivalents and short-term investments for the periods presented consist of the following (in thousands): &lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:97.59%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.64%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;8,794 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 6,264&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;21,109 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4,155&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;US treasury bills&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 8,953&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5,225&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Government-sponsored enterprise securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;15,584 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 15,796&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Corporate bonds and commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;9,917 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 26,766&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;64,357 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 58,206&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Reported as:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;48,812 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 24,459&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term investments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;15,545 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 33,747&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;64,357 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;58,206 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Cash equivalents and short-term investments include the following securities with gross unrealized gains and losses (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:97.7%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:60.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of June 30, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gains&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;US treasury bills&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 8,951&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 8,953&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Government-sponsored enterprise securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 15,607&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (25)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 15,584&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Corporate bonds and commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 9,921&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 9,917&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 34,479&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (29)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 34,454&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:98.34%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:60.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December 31, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gains&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;US treasury bills&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5,251&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (26)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5,225&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Government-sponsored enterprise securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 15,882&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (87)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 15,796&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Corporate bonds and commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 26,807&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (41)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 26,766&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 47,940&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (154)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 47,787&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;As of June 30, 2023 and December 31, 2022, our cash equivalents and short-term investments had a weighted-average time to maturity of approximately &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;72 days&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;89 days&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;, respectively. &lt;/span&gt;&lt;span style="font-size:10pt;background:#ffffff;"&gt;Our short-term investments are classified as available-for-sale securities. Accordingly, we have classified certain securities as short-term investments on our condensed balance sheets as they are available for use in the current operations. &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;June 30, 2023, we had &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_ut8FmrekU0qEihlZMrnsbQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; investments that had been in a continuous unrealized loss position for more than 12 months. As of June 30, 2023, a total of &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;19&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; individual securities had been in an unrealized loss position for 12 months or less, and the losses were determined to be temporary. No significant facts or circumstances have arisen to indicate that there has been any significant deterioration in the creditworthiness of the issuers of the securities held by us. Based on our review of these securities, including the assessment of the duration and severity of the unrealized losses, we have &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;no&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;t recognized any credit losses on these securities as of June 30, 2023 and December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The following table shows the fair value and gross unrealized losses of our investments in individual securities that are in an unrealized loss position, aggregated by investment category (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:91.47%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of June 30, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:8.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Government-sponsored enterprise securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,576&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (26)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Corporate bonds and commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,950&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18,526&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (29)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      id="Tb_YIPOgD46T0Wh9h0KRb1hsw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;Cash, cash equivalents and short-term investments for the periods presented consist of the following (in thousands): &lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:97.59%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.64%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;8,794 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 6,264&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;21,109 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4,155&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;US treasury bills&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 8,953&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5,225&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Government-sponsored enterprise securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;15,584 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 15,796&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Corporate bonds and commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;9,917 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 26,766&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;64,357 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 58,206&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Reported as:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;48,812 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 24,459&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term investments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;15,545 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 33,747&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;64,357 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;58,206 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="As_Of_6_30_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CashMember_qUTZZY9s90OHjG7EZblg4w"
      decimals="-3"
      id="Tc_U7NXR2piYUi9Dm6YYheMOw_3_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">8794000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CashMember_FLsEIySBfEaeRVBihq2f2g"
      decimals="-3"
      id="Tc_5rNGyVrFnk286I74HRL-1w_3_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">6264000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="As_Of_6_30_2023_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_LfRnUUxRrEycHqB8YoPOOQ"
      decimals="-3"
      id="Tc_6SwYISWp_0mixOUaJyzPsA_4_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">21109000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="As_Of_12_31_2022_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_1pcJHoW0nkC8Ko2b5ADUog"
      decimals="-3"
      id="Tc_qRVnPlpuBUq083Q1HBNq2Q_4_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">4155000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="As_Of_6_30_2023_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryBillSecuritiesMember_ASiSMIactUqwVwnqPY3_ew"
      decimals="-3"
      id="Tc_7aylijixWEW7tv0PMP8oBg_5_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">8953000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="As_Of_12_31_2022_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryBillSecuritiesMember_sKjXaDQa5EiL5o0NsgoBFA"
      decimals="-3"
      id="Tc_-N5i-dKwpUeZzw9p4ciNwA_5_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">5225000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="As_Of_6_30_2023_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_KL0hZTH2e063PXe0IU6-1g"
      decimals="-3"
      id="Tc_O2zgl20gMUSedlD6BLAG7Q_6_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">15584000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="As_Of_12_31_2022_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_M3axIPlo5k2k9b5gQJC25g"
      decimals="-3"
      id="Tc_Gr3uec7D5kGP9c33fkBkuA_6_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">15796000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="As_Of_6_30_2023_us-gaap_InvestmentTypeAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_1RwephmFh0WgSWKn57-wDg"
      decimals="-3"
      id="Tc_N1IlrjsA_k-oiY9u2VHRBw_7_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">9917000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="As_Of_12_31_2022_us-gaap_InvestmentTypeAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_BtwQ3KLKc02gIILPkP43sw"
      decimals="-3"
      id="Tc_eWApw8Fm4EOdA6lVpx37tA_7_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">26766000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww"
      decimals="-3"
      id="Tc_qc1uCsJ4uU6GfRSTgwSuCg_8_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">64357000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A"
      decimals="-3"
      id="Tc_8SWH14PCEUKG6ukDRbpn5w_8_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">58206000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww"
      decimals="-3"
      id="Tc_aAkpBM95kk2PzRT6AgpQAg_10_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">48812000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A"
      decimals="-3"
      id="Tc_YU917ozWLE2E6Vwj1G3Uww_10_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">24459000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww"
      decimals="-3"
      id="Tc_VwK_RJmeMkOT66IzW99Ung_11_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">15545000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A"
      decimals="-3"
      id="Tc_FOIS2cw310CumLymGEYa3w_11_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">33747000</us-gaap:ShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww"
      decimals="-3"
      id="Tc_0S82H3zyWUKpkBU2Ko12zA_12_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">64357000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A"
      decimals="-3"
      id="Tc_BHUQZXUeEEycdqJC2nYR5w_12_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">58206000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      id="Tb_q0yQQh43P0mCMpK1pKgE9w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Cash equivalents and short-term investments include the following securities with gross unrealized gains and losses (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:97.7%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:60.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of June 30, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gains&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;US treasury bills&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 8,951&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 8,953&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Government-sponsored enterprise securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 15,607&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (25)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 15,584&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Corporate bonds and commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 9,921&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 9,917&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 34,479&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (29)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 34,454&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:98.34%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:60.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December 31, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gains&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;US treasury bills&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5,251&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (26)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5,225&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Government-sponsored enterprise securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 15,882&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (87)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 15,796&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Corporate bonds and commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 26,807&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (41)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 26,766&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 47,940&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (154)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 47,787&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_6_30_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember_9b5OdbmUeUi1NDAMA8H9Vg"
      decimals="-3"
      id="Tc_Np9_NS3UhkKiGw4ToTs8JQ_4_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">8951000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1
      contextRef="As_Of_6_30_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_ld4nogTT4UKONA-CGQuvUQ"
      decimals="-3"
      id="Tc_4PkkfmosjUu6Gd5AUFRNkg_4_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">2000</us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_6_30_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember_9b5OdbmUeUi1NDAMA8H9Vg"
      decimals="-3"
      id="Tc_G_ZOOcneyUG7MjEx1z_XSw_4_12"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">8953000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_6_30_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_ReLJS_8Ua0iY--Vx8HxzUQ"
      decimals="-3"
      id="Tc_CMhYJa7r4EK5CtnqrJEd7A_5_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">15607000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1
      contextRef="As_Of_6_30_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_Z6JnOF8Gmkqq3XJoCK4JhA"
      decimals="-3"
      id="Tc__tec-VpyukOnt1iWd-V76g_5_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">2000</us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1
      contextRef="As_Of_6_30_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaap_StatementEquityComponentsAxis_rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember_M4prG97dGEaaceW_5B5zCw"
      decimals="-3"
      id="Tc_rIcjhElT4EW_2DxVwXKEag_5_9"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-25000</us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_6_30_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_ReLJS_8Ua0iY--Vx8HxzUQ"
      decimals="-3"
      id="Tc_V0Z0pIsDHk-pg-Y8Xhy1mg_5_12"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">15584000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_6_30_2023_us-gaap_FinancialInstrumentAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_EovRXwcsBU6PVsykL7sTEQ"
      decimals="-3"
      id="Tc_npamOTPxIE-kGNmu25ZZeA_6_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">9921000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1
      contextRef="As_Of_6_30_2023_us-gaap_FinancialInstrumentAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_us-gaap_StatementEquityComponentsAxis_rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember_qfBk03iVXEW6w48gjbjf7A"
      decimals="-3"
      id="Tc_C9SVfowMj0qERjzWVUC1RA_6_9"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-4000</us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_6_30_2023_us-gaap_FinancialInstrumentAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_EovRXwcsBU6PVsykL7sTEQ"
      decimals="-3"
      id="Tc_PgMThwG-kE6CK0hJt3A7WA_6_12"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">9917000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww"
      decimals="-3"
      id="Tc_ZGvjFTlG1U-2QRZul6dwrg_7_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">34479000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1
      contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_8i-ahQp_70mFJFvxxl02wA"
      decimals="-3"
      id="Tc_LzWITpWjh0u7QlugZuSAhg_7_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">4000</us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1
      contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember_P5cNTt7IlEa-Rhtic4nyvA"
      decimals="-3"
      id="Tc_813sVG248kOh78fhYRMX4g_7_9"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-29000</us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww"
      decimals="-3"
      id="Tc_L1wYSbF0iEuGVbVmZ4Sv8A_7_12"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">34454000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember_afYkc85gT0m66xklaugfbw"
      decimals="-3"
      id="Tc_8ocsswoTTEOC6G3WnTyE6Q_4_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">5251000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember_us-gaap_StatementEquityComponentsAxis_rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember_C6IhUCU3BkGDHmqFolJgdQ"
      decimals="-3"
      id="Tc_B-WVOlH3NkyV75J8YKokDg_4_9"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-26000</us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember_afYkc85gT0m66xklaugfbw"
      decimals="-3"
      id="Tc_UI5Pc0-vGUGAn6Jqq0vN7w_4_12"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">5225000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_go32t6mGGEqSyKBPofyDEA"
      decimals="-3"
      id="Tc_ioQxBfzszkuyUViAj8uGNA_5_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">15882000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_O0JjjXe-ZE-RH42gPIxthQ"
      decimals="-3"
      id="Tc_kQArOmHthki5ZLRTMXPEAA_5_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">1000</us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaap_StatementEquityComponentsAxis_rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember_8aUcC__wTUGDPKa_b54-SQ"
      decimals="-3"
      id="Tc_HoLVoSDCs0WAxG_5NM5LLA_5_9"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-87000</us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_go32t6mGGEqSyKBPofyDEA"
      decimals="-3"
      id="Tc_0-l8QU1M-kGk-o17ptUFeA_5_12"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">15796000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_FuBEs4QimEqUM83PeYRZcw"
      decimals="-3"
      id="Tc_aH8t0GtPvkWQtyoCnj_UBQ_6_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">26807000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_us-gaap_StatementEquityComponentsAxis_rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember_qoI-MShlREydakWlPmH8IA"
      decimals="-3"
      id="Tc_Tld7HO_yHUaW648nPVc8dQ_6_9"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-41000</us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_FuBEs4QimEqUM83PeYRZcw"
      decimals="-3"
      id="Tc_Uaf-CKcsZE-vcGwn0kMtoQ_6_12"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">26766000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A"
      decimals="-3"
      id="Tc_-BAAzCTtUkWj0NB2hjL4Qg_7_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">47940000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_dT29_JlvC0m0JlLh8k3msw"
      decimals="-3"
      id="Tc_3Rk80dyPJk-yP4jZXg3Aug_7_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">1000</us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember_fV_8kfGMb0aVZbFHW8RnkA"
      decimals="-3"
      id="Tc_S4R0L3sBgUmDei8__eat9w_7_9"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-154000</us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A"
      decimals="-3"
      id="Tc_tTEahOcawEqNUeRRZNgYKg_7_12"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">47787000</us-gaap:InvestmentsFairValueDisclosure>
    <rigl:CashEquivalentsAndAvailableForSaleSecuritiesWeightedAverageMaturityPeriod
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      id="Narr_FdzJ5b1BxkOq5GVmDRcFjA">P72D</rigl:CashEquivalentsAndAvailableForSaleSecuritiesWeightedAverageMaturityPeriod>
    <rigl:CashEquivalentsAndAvailableForSaleSecuritiesWeightedAverageMaturityPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_4hZ--7i_V0a3K3Xee2PShA"
      id="Narr_dkEfPTOHRk2WuOCxTreNiw">P89D</rigl:CashEquivalentsAndAvailableForSaleSecuritiesWeightedAverageMaturityPeriod>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww"
      decimals="INF"
      id="Narr_1ZBOwaZvq0eZzcJVCz0djA"
      unitRef="Unit_Standard_position_WoI3E1kTlEyL4Mc6Z0-iIg">19</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld
      contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww"
      decimals="-5"
      id="Narr_zaF1Q_AfYU2qr4LH8641GQ"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">0</us-gaap:OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld>
    <us-gaap:OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld
      contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A"
      decimals="-5"
      id="Narr_hTDQjAVKAkSy_xUxrMkHvQ"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">0</us-gaap:OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld>
    <us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      id="Tb_X9xcLSkrq0Kf_Z8nPR7Dyg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The following table shows the fair value and gross unrealized losses of our investments in individual securities that are in an unrealized loss position, aggregated by investment category (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:91.47%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of June 30, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:8.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Government-sponsored enterprise securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,576&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (26)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Corporate bonds and commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,950&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18,526&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (29)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="As_Of_6_30_2023_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_KL0hZTH2e063PXe0IU6-1g"
      decimals="-3"
      id="Tc_Z_phQwa7ckWkhtBdwSJ41g_2_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">10576000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="As_Of_6_30_2023_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_KL0hZTH2e063PXe0IU6-1g"
      decimals="-3"
      id="Tc_4qE0qLoWCUauD7NVUwxi7A_2_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">26000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="As_Of_6_30_2023_us-gaap_InvestmentTypeAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_1RwephmFh0WgSWKn57-wDg"
      decimals="-3"
      id="Tc_XD3BMmI2S0OTrerjvUNhsg_3_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">7950000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="As_Of_6_30_2023_us-gaap_InvestmentTypeAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_1RwephmFh0WgSWKn57-wDg"
      decimals="-3"
      id="Tc_89QsHqegWUWTQ22ehG5DlA_3_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">3000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww"
      decimals="-3"
      id="Tc_2lRw36d3xUmkTAkit8yMKw_4_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">18526000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww"
      decimals="-3"
      id="Tc_pNiNBbH6oE2hm1FkxmanPw_4_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">29000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      id="Tb_d7Mct0kyqkeRft1iG6JvNA">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"&gt;&lt;b style="font-size:10pt;font-weight:bold;"&gt;8.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"&gt;&lt;b style="font-size:10pt;font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The table below summarizes the fair value of our cash equivalents and short-term investments measured at fair value on a recurring basis, and are categorized based upon the lowest level of significant input to the valuations (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:98.74%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:49.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets&#160;at&#160;Fair&#160;Value&#160;as&#160;of&#160;June 30, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 21,109&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 21,109&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;US treasury bills&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 8,953&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 8,953&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Government-sponsored enterprise securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 15,584&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 15,584&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Corporate bonds and commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 9,917&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 9,917&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 21,109&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 34,454&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 55,563&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets&#160;at&#160;Fair&#160;Value&#160;as&#160;of December 31, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4,155&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4,155&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;US treasury bills&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5,225&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5,225&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Government-sponsored enterprise securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 15,796&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 15,796&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Corporate bonds and commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 26,766&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 26,766&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4,155&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 47,787&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 51,942&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      id="Tb_GWHZWcfqMEiC6dCaQ3RufQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The table below summarizes the fair value of our cash equivalents and short-term investments measured at fair value on a recurring basis, and are categorized based upon the lowest level of significant input to the valuations (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:98.74%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:49.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets&#160;at&#160;Fair&#160;Value&#160;as&#160;of&#160;June 30, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 21,109&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 21,109&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;US treasury bills&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 8,953&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 8,953&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Government-sponsored enterprise securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 15,584&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 15,584&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Corporate bonds and commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 9,917&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 9,917&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 21,109&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 34,454&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 55,563&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets&#160;at&#160;Fair&#160;Value&#160;as&#160;of December 31, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4,155&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4,155&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;US treasury bills&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5,225&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5,225&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Government-sponsored enterprise securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 15,796&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 15,796&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Corporate bonds and commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 26,766&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 26,766&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4,155&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 47,787&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 51,942&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_6_30_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_E0z-Tucd60Gr3PRXDlh0xw"
      decimals="-3"
      id="Tc_gcOUtKtlwUm7YJrS2jXVYg_3_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">21109000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_6_30_2023_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_wFvchknSJ0iAyfGzH6qAww"
      decimals="-3"
      id="Tc_y58YFvP4d0inRcMSFh720A_3_12"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">21109000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_6_30_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryBillSecuritiesMember_9EFna87LuU6O4O7rLXT8_Q"
      decimals="-3"
      id="Tc_p0K2NbA6k0WcQVuHxt820A_4_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">8953000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_6_30_2023_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryBillSecuritiesMember_W5abtcgj4EewIThyL6s9KQ"
      decimals="-3"
      id="Tc_grLJscKmI0m31A7NXByX8A_4_12"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">8953000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_6_30_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_-mpWze0ew0qh9kNZ1GgxZg"
      decimals="-3"
      id="Tc_f5q2k53aIUSaDCZmNcEjvw_5_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">15584000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_6_30_2023_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_89OSD-Eh70S-lOaWIkx8jg"
      decimals="-3"
      id="Tc_Js8Eozaf-0iw1LOt3m6Nkg_5_12"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">15584000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_6_30_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_6LWYDoMSGEuqSbON9szqUA"
      decimals="-3"
      id="Tc_eRqvjTdT602rlF5z-wf02g_6_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">9917000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_6_30_2023_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_j804o1Qq5kW9BN0Wq8qKAw"
      decimals="-3"
      id="Tc_NWI6STnxiEG9f8gMQOCNfQ_6_12"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">9917000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_6_30_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_aESIeqNLDEGTjQh7l8feaA"
      decimals="-3"
      id="Tc_FJjl-ymQdEuuD8uqqLI3vw_7_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">21109000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_6_30_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_5w8Rm76YAUeQeOz8g-y38Q"
      decimals="-3"
      id="Tc_qmZIYg8tQkOeUpZx72bg6A_7_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">34454000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_6_30_2023_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_QW_rs_VEA0KU4-yd8SrPbw"
      decimals="-3"
      id="Tc_XUVIJlqFGUqBs2xyZQt4Gw_7_12"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">55563000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_u-RkEtQ-w0Oqm41OpKcIhw"
      decimals="-3"
      id="Tc_kI1-ZS89L0OdPI6ybJGREA_3_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">4155000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_rIYz9iBffUO8TYWENsIDrg"
      decimals="-3"
      id="Tc_XhBEpbsy2Ee1HtD_r_9ABQ_3_12"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">4155000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryBillSecuritiesMember_I8wfKfL5DU-wQrbo5YC4Eg"
      decimals="-3"
      id="Tc_N4TTu9qh5Eq_0fbd-zTNNA_4_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">5225000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryBillSecuritiesMember_Ttzv--YhbkeAEe271vcCHQ"
      decimals="-3"
      id="Tc_dQfsWDzGCkueUjLwCDhJtw_4_12"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">5225000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_DV0JpqqeFEG2yWKut9HiFw"
      decimals="-3"
      id="Tc_oYN5I9mrU0KO6JzsXaho8Q_5_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">15796000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_wWiomWDuy0icYfW_HOwFgA"
      decimals="-3"
      id="Tc_VS7VJKr6vkyJoJz653Z_iA_5_12"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">15796000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_la2B--bWDkagQFiSFOzkrA"
      decimals="-3"
      id="Tc_5BlE62kbv0Wv68DLpWeXtg_6_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">26766000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_5M7Ca4BjDU6p5rg68gEwqQ"
      decimals="-3"
      id="Tc_GoRP-izSWkeojvj1quV1AA_6_12"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">26766000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_d-_85Kk8g0mwIwHaIhvvxA"
      decimals="-3"
      id="Tc_OlHJkxVHIEmvGZO8YKqqzg_7_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">4155000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_D1RS1iCAi0Cf-ba1jen3jA"
      decimals="-3"
      id="Tc_8zCZG2DhVEC7Slnofcumjg_7_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">47787000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_fPNOItXmGU6NPrDN3d1kDg"
      decimals="-3"
      id="Tc_g-yQhiuMVkGknz_yK3yy6w_7_12"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">51942000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      id="Tb_g8HsBjxtJE-BB1KsDuqjfw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;9.&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Debt&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;We have a Credit and Security Agreement (Credit Agreement) with MidCap Financial Trust (MidCap) entered on September 27, 2019 (Closing Date) and amended on March 29, 2021 (First Amendment), February 11, 2022 (Second Amendment) and July 27, 2022 (Third Amendment). The Credit Agreement provides for a $60.0&#160;million term loan credit facility. At the Closing Date, $10.0 million was funded (Tranche 1), in May 2020, an additional $10.0 million was funded (Tranche 2), at the Second Amendment, an additional $10.0 million was funded (Tranche 3), at the Third Amendment, an additional $10.0 million was funded (Tranche 4), and in March 2023, an additional $20.0 million was funded (Tranche 5). As of June 30, 2023, the outstanding principal balance of the loan was $60.0 million, and no remaining funds are available for draw under the term loan credit facility. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;The First Amendment to the Credit Agreement extended the period through which Tranche 3 was available to us. The Second Amendment to the Credit Agreement, among other things, amended the applicable funding conditions, applicable commitments and certain other terms relating to available credit facilities (Tranches 3 and 4), added additional term loan credit facility (Tranche 5), and revised certain terms related to the financial covenants. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;Following the Third Amendment, the maturity date for the term loans is on September 1, 2026, and the interest-only period is through October 1, 2024. &lt;/span&gt;&lt;span style="font-size:10pt;background:#ffffff;"&gt;The interest rate applicable to the term loans under the amended Credit Agreement is the sum of one-month &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;Secured Overnight Financing Rate (SOFR)&lt;/span&gt;&lt;span style="font-size:10pt;background:#ffffff;"&gt;, plus an adjustment of &lt;/span&gt;&lt;span style="font-size:10pt;background:#ffffff;"&gt;0.11448%&lt;/span&gt;&lt;span style="font-size:10pt;background:#ffffff;"&gt;, subject to &lt;/span&gt;&lt;span style="font-size:10pt;background:#ffffff;"&gt;1.50%&lt;/span&gt;&lt;span style="font-size:10pt;background:#ffffff;"&gt; applicable floor, plus applicable margin of&#160;&lt;/span&gt;&lt;span style="font-size:10pt;background:#ffffff;"&gt;5.65%&lt;/span&gt;&lt;span style="font-size:10pt;background:#ffffff;"&gt;. A&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; final payment fee of &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;2.5%&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; of principal is due at maturity date of the term loans. Prior to the Third Amendment, the outstanding principal balance of the loan bore interest at an annual rate of one-month London Interbank Offered Rate (LIBOR), &lt;/span&gt;&lt;span style="font-size:10pt;background:#ffffff;"&gt;or a comparable applicable index rate, &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;plus applicable margin of &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;5.65%&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;, subject to a LIBOR floor of &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;1.50%&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; and is payable monthly in arrears. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;We &lt;/span&gt;may make voluntary prepayments, in whole or in part, subject to certain prepayment premiums and additional interest payments. The Credit Agreement also contains certain provisions, such as event of default and change in control provisions, which, if triggered, would require us to make mandatory prepayments on the term loan, which are subject to certain prepayment premiums and additional interest payments. The obligations under the amended Credit Agreement are secured by a perfected security interest in all of our assets including our intellectual property.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;Debt issuance costs are recorded as a direct deduction from the outstanding principal balance of the term loan. As of June 30, 2023 and December 31, 2022, the unamortized issuance costs and debt discounts amounted to $0.4 million and $0.6 million, respectively. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Interest expense, including amortization of the debt discount and accretion of the final fees related to the Credit Agreement for the three months ended June 30, 2023 and 2022 was $1.9 million and $0.6 million, respectively, and for the six months ended June 30, 2023 and 2022 was $3.1 million and $1.1 million, respectively. Accrued interest of $1.2 million was included within other accrued liabilities in the condensed balance sheet as of June 30, 2023. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;The following table presents the future minimum principal payments of the outstanding loan as of June 30, 2023 (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:72.33%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Remainder of 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 7,500&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 30,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 22,500&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Principal amount (Tranches 1, 2, 3 and 4)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 60,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The amended Credit Agreement contains certain covenants which, among others, require us to deliver financial reports at designated times of the year and maintain minimum unrestricted cash and trailing net revenues. As of June 30, 2023, we were not in violation of any covenants.&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="As_Of_6_30_2023_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_lZzWZsARrUq--he7HLPz4w"
      decimals="-5"
      id="Narr_5hH_NI3hUEWI74EKUlHSuw"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">60000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding
      contextRef="As_Of_6_30_2023_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_DebtInstrumentAxis_rigl_CreditAgreementTrancheOneMember_NdmHGNjm80GwagBp6p25SQ"
      decimals="-5"
      id="Narr_WwE_bikKEkOrKeXt5EpJBA"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">10000000.0</us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding>
    <us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding
      contextRef="As_Of_5_31_2020_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_DebtInstrumentAxis_rigl_CreditAgreementTrancheTwoMember_Pt33AwlsAE-LZCXlY1xdSw"
      decimals="-5"
      id="Narr_8_tXwlvOgUKf0gDdF4YHRg"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">10000000.0</us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding>
    <us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding
      contextRef="As_Of_5_31_2022_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_DebtInstrumentAxis_rigl_CreditAgreementTrancheThreeMember_xE8L3bekvEKDIR_7sMJqCw"
      decimals="-5"
      id="Narr_Vf1c4ZxLx0WiYUIrm5TavQ"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">10000000.0</us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding>
    <us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding
      contextRef="As_Of_5_31_2022_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_DebtInstrumentAxis_rigl_CreditAgreementTrancheFourMember_YfMR144_eUWzw-ApIaAstA"
      decimals="-5"
      id="Narr_T3NtQNqH7UOT8RdIl8OduA"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">10000000.0</us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding>
    <us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding
      contextRef="As_Of_3_28_2023_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_DebtInstrumentAxis_rigl_CreditAgreementTrancheFiveMember_QUesi71yDkqy9WA84-x-ug"
      decimals="-5"
      id="Narr_gptzRRCQl0mNanis--IpEg"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">20000000.0</us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding>
    <us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding
      contextRef="As_Of_6_30_2023_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_lZzWZsARrUq--he7HLPz4w"
      decimals="-5"
      id="Narr_AhBZmSoFYkmDcT87ntd-Iw"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">60000000.0</us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="As_Of_6_30_2023_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_lZzWZsARrUq--he7HLPz4w"
      decimals="-5"
      id="Narr_BS4C8YuHqUG1Qk8C_tUQ4g"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">0</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:DebtInstrumentInterestRateBasisForEffectiveRate
      contextRef="Duration_1_1_2023_To_6_30_2023_srt_StatementScenarioAxis_rigl_FollowingThirdAmendmentMember_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_VariableRateAxis_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_4EMQf1c4MEiugud-VG7qaw"
      id="Narr_Peh2HMX3oE2ng3e3aVSsHA">0.11448%</us-gaap:DebtInstrumentInterestRateBasisForEffectiveRate>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_6_30_2023_srt_StatementScenarioAxis_rigl_FollowingThirdAmendmentMember_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_VariableRateAxis_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_ShXm5jIvgkOs-ZS0wM0CGA"
      decimals="4"
      id="Narr_cGcgBUiPQ0SSz63cFYtx6w"
      unitRef="Unit_Standard_pure_uVIKS5OYQEes3pxG5CV0tw">0.0150</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="Duration_1_1_2023_To_6_30_2023_srt_StatementScenarioAxis_rigl_FollowingThirdAmendmentMember_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_VariableRateAxis_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_4EMQf1c4MEiugud-VG7qaw"
      decimals="4"
      id="Narr_v4r6bpXwgUGYPfn6-bl5iA"
      unitRef="Unit_Standard_pure_uVIKS5OYQEes3pxG5CV0tw">0.0565</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="Duration_1_1_2023_To_6_30_2023_srt_StatementScenarioAxis_rigl_FollowingThirdAmendmentMember_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_LJSahnttvEiJdFf1pAqMfg"
      decimals="3"
      id="Narr_mS1nZzdpik-vPF2pwCwqvA"
      unitRef="Unit_Standard_pure_uVIKS5OYQEes3pxG5CV0tw">0.025</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="Duration_1_1_2023_To_6_30_2023_srt_StatementScenarioAxis_rigl_PriorToThirdAmendmentMember_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_VariableRateAxis_rigl_LondonInterBankOfferedRateMember_2WmOu592Mkqf1Hwsj0OZug"
      decimals="4"
      id="Narr_IkvsiuL-4UGrjYvJVSnktg"
      unitRef="Unit_Standard_pure_uVIKS5OYQEes3pxG5CV0tw">0.0565</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_6_30_2023_srt_StatementScenarioAxis_rigl_PriorToThirdAmendmentMember_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_VariableRateAxis_rigl_LondonInterBankOfferedRateMember_PMVwcFXhgUW15_EzDLiLAw"
      decimals="4"
      id="Narr_r776z3z9gUqXOyl3FCzwzg"
      unitRef="Unit_Standard_pure_uVIKS5OYQEes3pxG5CV0tw">0.0150</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="As_Of_6_30_2023_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_lZzWZsARrUq--he7HLPz4w"
      decimals="-5"
      id="Narr_zJ0rqDyi-Ua2LU9AULawvw"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">400000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A"
      decimals="-5"
      id="Narr_gMZ59euYA0KQ6_vFQI2NKw"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">600000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:InterestExpense
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_BJeMNksUxkWrPx4dQB6u3A"
      decimals="-5"
      id="Narr_9H95SugY80KUGXSwBoMiGg"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">1900000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_vq2GZ_j7vkilnhfg4of5cw"
      decimals="-5"
      id="Narr_CpDcO81V0kGOTO9BSB-oGQ"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">600000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_ePrDC_3ewk2JsGsYLAl0ZQ"
      decimals="-5"
      id="Narr_tZIhfrEEM0SrVJAZrAkcog"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">3100000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_CJn5TKw-Sk6p8v3y1c6mVA"
      decimals="-5"
      id="Narr_E2XLQ0ErAECroh2mGcTSQw"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">1100000</us-gaap:InterestExpense>
    <us-gaap:LineOfCreditFacilityIncreaseAccruedInterest
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_ePrDC_3ewk2JsGsYLAl0ZQ"
      decimals="-5"
      id="Narr_B9DuxTTe5E2iBebJi_qZ1A"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">1200000</us-gaap:LineOfCreditFacilityIncreaseAccruedInterest>
    <us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      id="Tb_-DuwI-FISUy2RfLonwAIPA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;The following table presents the future minimum principal payments of the outstanding loan as of June 30, 2023 (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:72.33%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Remainder of 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 7,500&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 30,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 22,500&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Principal amount (Tranches 1, 2, 3 and 4)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 60,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww"
      decimals="-3"
      id="Tc_Bt9CxmNSQUGo4GxzgQgeYQ_2_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">7500000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww"
      decimals="-3"
      id="Tc_j_IBs-D4GUmKhNOQcojttA_3_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">30000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww"
      decimals="-3"
      id="Tc_bOngXPUc4EuY5h1BhFtcIQ_4_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">22500000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebt
      contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww"
      decimals="-3"
      id="Tc_7mK62tX5MUqGF8yMM5eSeQ_5_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">60000000</us-gaap:LongTermDebt>
    <rigl:LeaseDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      id="Tb_L1PBzuvroUiw2FpM1QTCnQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;10.&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Leases&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;&lt;span style="font-size:10pt;background:#ffffff;"&gt;We have a sublease agreement with Atara Biotherapeutics, Inc. (Atara) entered in October 2022 to sublease an office space located in South San Francisco, California. Subject to the terms of the sublease agreement, the lease term commenced in November 2022 and shall expire in May 2025. This leased facility is currently held as our new headquarters following the expiration of our previously leased facility in January 2023. At lease measurement date in the fourth quarter of 2022, we recognized the operating lease right-of-use asset and lease &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_WC8UdES80kWQ1oTf-c3WYQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"&gt;liability&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;background:#ffffff;"&gt; of approximately &lt;/span&gt;&lt;span style="font-size:10pt;background:#ffffff;"&gt;$1.3&lt;/span&gt;&lt;span style="font-size:10pt;background:#ffffff;"&gt; million. &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;As of June 30, 2023, we recorded &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$0.2&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; million of lease incentives from our sublease with Atara, which we recorded as a reduction to operating lease right-of-use asset and lease liability until the lease ends and the asset is transferred. The weighted average remaining term of our leases as of June 30, 2023 was &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_V6j-ReLR3UOlKbpOTUVtAQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;1.92&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; years. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;We had a lease agreement with Healthpeak Properties, Inc. (formerly known as HCP BTC, LLC), to occupy research and office space located in South San Francisco, California and a sublease agreement with an unrelated third-party to sublet a portion of the leased facility. Both leases expired in January 2023.  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;The components of our operating lease expense were as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:94.39%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:27.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Fixed operating lease expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 166&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,340&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 778&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,680&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Variable operating lease expense (net credit)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (42)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 125&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 30&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 391&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total operating lease expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 124&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,465&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 808&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,071&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;Supplemental information related to our operating lease were as follow (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:94.58%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:41.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:28.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash payments included in the measurement of operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 178&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,630&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,174&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5,226&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Supplemental information related to our operating sublease was as follow (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:94.15%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:27.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Fixed sublease expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,095&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 365&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,190&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Variable sublease expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 206&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 77&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 450&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Sublease income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,301)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (442)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,640)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_if_nK6gayEetouowdVil5w;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_v_fUsNyOv0y60ttHM-hoPg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_n4oiXcFrkUefbhZElnx3QQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_RzHufXubkkibtQabd8gePg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The following table presents the future lease payments as of June 30, 2023 (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:63.06%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Remainder of 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 360&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 739&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 301&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total minimum payments required&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,400&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</rigl:LeaseDisclosureTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_rigl_HeadquartersOfficeSpaceSubleaseSouthSanFranciscoCaliforniaMember_RzRVSQYro0qfZzFsimZvQA"
      decimals="-5"
      id="Narr_O6RsmCTaUk-GZL6mqjIohQ"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">1300000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IncentiveToLessee
      contextRef="As_Of_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_rigl_HeadquartersOfficeSpaceSubleaseSouthSanFranciscoCaliforniaMember_Q7wBI-TD_USrGUm0m_WO2A"
      decimals="-5"
      id="Narr_0bBOd50gP0yz_rwMIjUxiw"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">200000</us-gaap:IncentiveToLessee>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      id="Tb_Gkb8_zKMpkSh9eBmHV2wFw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;The components of our operating lease expense were as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:94.39%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:27.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Fixed operating lease expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 166&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,340&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 778&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,680&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Variable operating lease expense (net credit)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (42)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 125&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 30&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 391&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total operating lease expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 124&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,465&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 808&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,071&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ"
      decimals="-3"
      id="Tc_dmK9F74c-E2-kcnfXIHQ5w_3_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">166000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_4_1_2022_To_6_30_2022_ICCkO9pPUUSORAn1kecZBA"
      decimals="-3"
      id="Tc_g43em5QHjEW4-xGf7z1Tkg_3_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">1340000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      decimals="-3"
      id="Tc_RbUt0Ky1IkyReA4Ws61ZPw_3_9"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">778000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g"
      decimals="-3"
      id="Tc_DLHZJElm3EqsEzpbwDGHbw_3_12"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">2680000</us-gaap:OperatingLeaseCost>
    <rigl:VariableLeaseExpenseNetCredit
      contextRef="Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ"
      decimals="-3"
      id="Tc_0OZJBrfT4kiUYY5UsvUtCQ_4_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">-42000</rigl:VariableLeaseExpenseNetCredit>
    <rigl:VariableLeaseExpenseNetCredit
      contextRef="Duration_4_1_2022_To_6_30_2022_ICCkO9pPUUSORAn1kecZBA"
      decimals="-3"
      id="Tc_z0cTiWn8eEqglEx7RDc26A_4_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">125000</rigl:VariableLeaseExpenseNetCredit>
    <rigl:VariableLeaseExpenseNetCredit
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      decimals="-3"
      id="Tc_7WsukTfb5ECY_bhxHl1BmQ_4_9"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">30000</rigl:VariableLeaseExpenseNetCredit>
    <rigl:VariableLeaseExpenseNetCredit
      contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g"
      decimals="-3"
      id="Tc_gfaGwFjti0-znXvSUQOsIg_4_12"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">391000</rigl:VariableLeaseExpenseNetCredit>
    <us-gaap:LeaseCost
      contextRef="Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ"
      decimals="-3"
      id="Tc_LaGil1yJCkmcqC4LGCdZYg_5_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">124000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="Duration_4_1_2022_To_6_30_2022_ICCkO9pPUUSORAn1kecZBA"
      decimals="-3"
      id="Tc_-QMlBd6JBke2TP3iQilt-A_5_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">1465000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      decimals="-3"
      id="Tc_56w7o_R00Uu-1X3dK8ywTA_5_9"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">808000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g"
      decimals="-3"
      id="Tc_8fuHzMZJP0KpkWzb-kVp6A_5_12"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">3071000</us-gaap:LeaseCost>
    <rigl:CashFlowInformationRelatedToOperatingLeaseTableTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      id="Tb_KyU4KeV6IE-66Z3TVu3v1Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;Supplemental information related to our operating lease were as follow (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:94.58%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:41.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:28.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash payments included in the measurement of operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 178&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,630&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,174&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5,226&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</rigl:CashFlowInformationRelatedToOperatingLeaseTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ"
      decimals="-3"
      id="Tc_suRqxRTkkUeIYSH0CA39jQ_3_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">178000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_4_1_2022_To_6_30_2022_ICCkO9pPUUSORAn1kecZBA"
      decimals="-3"
      id="Tc_48p5OL7xlE-TZFOmEfL2HQ_3_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">2630000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      decimals="-3"
      id="Tc_66i7O02ERUmnCG8X_JEbmg_3_9"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">1174000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g"
      decimals="-3"
      id="Tc_2sPtaBlVQ0qsOgAdPz3Irw_3_12"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">5226000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseLeaseIncomeTableTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      id="Tb_wgk_qmEAUEam0bwAEKe40g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Supplemental information related to our operating sublease was as follow (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:94.15%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:27.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Fixed sublease expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,095&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 365&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,190&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Variable sublease expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 206&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 77&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 450&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Sublease income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,301)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (442)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,640)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_if_nK6gayEetouowdVil5w;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_v_fUsNyOv0y60ttHM-hoPg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_n4oiXcFrkUefbhZElnx3QQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_RzHufXubkkibtQabd8gePg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:OperatingLeaseLeaseIncomeTableTextBlock>
    <rigl:FixedSubleaseExpense
      contextRef="Duration_4_1_2022_To_6_30_2022_ICCkO9pPUUSORAn1kecZBA"
      decimals="-3"
      id="Tc_AFuTUMeTCEWD9MP9g0tlfQ_3_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">1095000</rigl:FixedSubleaseExpense>
    <rigl:FixedSubleaseExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      decimals="-3"
      id="Tc_80n8njQmn0KsIr_qbrcb9g_3_9"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">365000</rigl:FixedSubleaseExpense>
    <rigl:FixedSubleaseExpense
      contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g"
      decimals="-3"
      id="Tc_NM85qXFNc0yf8CtxYW78yQ_3_12"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">2190000</rigl:FixedSubleaseExpense>
    <rigl:VariableSubleaseExpense
      contextRef="Duration_4_1_2022_To_6_30_2022_ICCkO9pPUUSORAn1kecZBA"
      decimals="-3"
      id="Tc_n9I-NEjFQEq0PkwK7AZTIQ_4_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">206000</rigl:VariableSubleaseExpense>
    <rigl:VariableSubleaseExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      decimals="-3"
      id="Tc_kv8bLgIHk0ahasniRAVh0Q_4_9"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">77000</rigl:VariableSubleaseExpense>
    <rigl:VariableSubleaseExpense
      contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g"
      decimals="-3"
      id="Tc_sSQfwQqgikuJOmT-R8WF4w_4_12"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">450000</rigl:VariableSubleaseExpense>
    <us-gaap:SubleaseIncome
      contextRef="Duration_4_1_2022_To_6_30_2022_ICCkO9pPUUSORAn1kecZBA"
      decimals="-3"
      id="Tc_uWY3rh6o1EqLnINS2PLRSA_5_6"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">1301000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      decimals="-3"
      id="Tc_u61E_yS2Jka8LHNLh77EZw_5_9"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">442000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="Duration_1_1_2022_To_6_30_2022__dqA6SkfZ0ezs5z8EFTK4g"
      decimals="-3"
      id="Tc_CgAwS4etqkavN42uottv-A_5_12"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">2640000</us-gaap:SubleaseIncome>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw"
      id="Tb_-ej8DpmrME2G-5-0HmjGmA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The following table presents the future lease payments as of June 30, 2023 (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:63.06%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Remainder of 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 360&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 739&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 301&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total minimum payments required&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,400&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww"
      decimals="-3"
      id="Tc_BeuW9WT6E0GwXV_2iztjSw_1_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">360000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww"
      decimals="-3"
      id="Tc_eBanHj3SyU-JcF0jbRhooQ_2_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">739000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww"
      decimals="-3"
      id="Tc_o7amubdcZ0WUciIMvtb-lw_3_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">301000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww"
      decimals="-3"
      id="Tc_NRW0IF8eNUKdGBOknaCtUg_4_3"
      unitRef="Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA">1400000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>64
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MR@J4[4NG]D+P??/>YHX+P?/FZXY1J5L9R/]O.1=/%^I54/_J;_D?4$L#!!0
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M*UMT+K;#\>BW!=2\+3BA^(8NG>#!WL#<S)M3?$J;T;G:;%(WWCN'R%FYJ@^
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M\6ZDZ,I^X3Y9QTPLJ.YP$Z[A'+*'S8SPF5JK1$D&$4TP @2N1LJ5/@CZ E\
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MEY71Z]*H\891$XPQ8C$% 8I@).'[A_G. ;[* U!'P=A'X=HX*/@M1^? U+X
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M;VV@O[_)\^K[A_H'$ Z_P7'Q/U!+ P04    " "R@ %71!8V"=('  !I(@
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M=MQJ-][48<19&D\#4UB6-*&B90:B%X92<[/A"[J9=_HG4$L#!!0    ( +*
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M,R_U$GPQGP6AF[\JI3^TVL7/W_YR=3'$UK%WD;FA]8:;BORG@]B]:Z4:MKN
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MUI3R7DU->GEU\>-ALKO ?_8L!7B?@@PN.@T3#MUYJ]>O@@MJ%D#*C")? ]*
M!^8R7(&'YA!'E*N"0N\)T*H$IQE#%@5E #(.>:E-%E_1C=^_-<KP'K0I>C'N
MSQYO>ZWL0P*E3<=W#15K^?SQ ^V*>,)%W+L+O<*#>NC-?'@97R.YS162&\K#
MX:V1IR>?-F?'?=BA?8JZNP)CX/G,*NJL[N/9WKN'.F^OW/;6RK7;LC=>68H7
M6=+%I%%L3I%%>)#6\,K<V60[$X M/%O0</5I%V&^:X'K[A)"$6T/E+6&UX,
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MU=.>BF$-_1VWH(M<B.VMZL>#>W-CO]PH>1NP/VK]?1EV&WIQI6*IFUSV?#]
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M_E*72_K:R$E9@^VB'^<23%Z%#\#?IR4$MN87G,!]C^CS_P!02P,$%     @
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MURI'<!!AZ*TW462ABN87E9[))<(ZJQ6?I7"0F$IMQ5)F)8?E53?LC<@EE;Z
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M)"UIJ@DBAJIN='("J%]B4^8V[8@V$X48I30LX90=#F0D]<!2XV ]8'KLV$0
MKV!7RCMK&F:Z)2W(%@/K@&(F#"6.T%[E<#AP\\XU_#XU>6[TM0'UQ%:4^4,U
MSQTQ3)9X,[6<(T=,:^&\H!KPOC,>!A'>88X=MY0ZXR9&ITU+7UK5],7VQ,-]
M*&RIYI8G=3 PC^3BKIGCN",U0I^A:/L)N1SIX_AH*>*^.&.6HO< 9>NAB&J
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MG8..L-5'DNK&FP5_F'@P'A7-EW,E@94$\'QJC&]NZ(#V2]75?P!02P,$%
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M:#88+5\\RV;IZR/4)CVUR;'HOZ-V'#P;P97:H'+:"+1/YG1/P54(#1JAN85
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M1W#6P-S1H.;0.'_]A]OKO#DP ;^<@'](^_\S@<,F^BUVQ?74L4]V_347<YY
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M*? 8% W _V,IS;I!!LH+S_-_ 5!+ P04    " "R@ %7G7K;;H$#  #+"@
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M,F?;4=>:!^(L FR[</=2QX&+N!?;KBEW73?,.3NSB>6P^;=&1<&,PSF14HX
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MH#<>=JIAL5XX7?AK[EP[O#3[GS3:<T,*^'RAM:L7M$'SO\?D=U!+ P04
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M<!@@(-UNHEZ&Q*W4;;)0RBYL@1]*;+REIM_TQ$1Q'O@G1KS1=+M,.V#P1>O
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MX_02;!4OI%,;<+V-CP5Z,3G>@.\S"^)M7EA!^Q^*HW\ 4$L#!!0    ( +*
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M,<(#C')8TIJ;F5S?PK:><\>72:[]%ZT;;-3#**NUD>4VV"HHF6A&NMG^A[V
M0?A* -D&$*^[2>15?J*&)D,EUT@YM&5S$U^JC[;BF'";DAIE5YF-,\FWR1Q]
M?4A3-)W,4'I[/9N@#W.ZX* _#@-C$SA8D&W)Q@T9>86LA^ZE,(5&$Y%#_C(^
ML,):=62G;DQ.$GZIQ1F*P@XB(8E.\$5MM9'GB_ZYVF-%-ASQ<0YW2RYU13,8
M87L--*AGP,G[=]U>>'5"8=PJC$^Q)ZF]=7G- <DEHL*PG/':G5ND(:L5,PST
M,<DG25^3/"!A=(7^US@O%,"+ X/L=H/?[ATF99N_(':C.R#N0XYX'FJC#14Y
M$RMD+U3VA&3E6H(^8(G..R2.#]U1)QQTWXB>I8^'";J=BUYTQ-N].*0_A9U+
M0_EAYGZ'A/U#=]PA??)&]+&S'.SUF1+4RG=3C3)9"].TG-;;-NSKID_]@3?=
M_IZJ%;,[P&%I0\.S_CE&JNF@C6%DY;O60AK; _VTL(\.* >PZTLIS<YP"=IG
M+/D-4$L#!!0    ( +*  5= ^)> Q04  ,45   9    >&PO=V]R:W-H965T
M<R]S:&5E=#$Y+GAM;-58;7/3.!#^*YIP,'1&0VSYO;29H:7 P7'7:0KW6;&5
M6(-C&4ENR/WZ6_FM3FW<=AB.N2]QM))V5_OVK'2R$_*+2AG3Z-LVR]7I+-6Z
M.)[/59RR+54O1,%RF%D+N:4:AG(S5X5D-*DV;;,YL2Q_OJ4\GRU.*MJE7)R(
M4F<\9Y<2J7*[I7)_QC*Q.YW9LY9PQ3>I-H3YXJ2@&[9D^E-Q*6$T[[@D?,MR
MQ46.)%N?SE[9QV>^65\M^,S93O7^(W.2E1!?S.#WY'1F&858QF)M.%#XW+!S
MEF6&$:CQM>$YZT2:C?W_+?<WU=GA+"NJV+G(_N:)3D]GX0PE;$W+3%^)W3O6
MG,<S_&*1J>H7[>JU?C!#<:FTV#:;08,MS^LO_=;8H;<AM+ZS@30;2*5W+:C2
M\C75='$BQ0Y)LQJXF3_54:O=H!S/C5.66L(LAWUZ<77Q^>+/3Q=+]/R:KC*F
MCD[F&MB:R7G<L#BK69#OL/#11Y'K5*&+/&')X?XYJ-/I1%J=SL@DP_=E_@(Y
M%D;$(LX$/Z<[HU/Q<^XYX]C1ZIWN^$Z3$<>JH#$[G4'(*R9OV&SQ[(GM6R\G
M]'([O=PI[HLE9%A29@R)-<3W#<M+IE#"%=UL)-M0S1*TVJ,8_FR$W(]I/\W_
MZEZ>:,<D0U2AM<@@/15ZSG.D4U$JFB?JZ!@]>Q(2RWGYR[[7J63L(+X01 >K
MHJ-=L^3?[EG1?DT\F1\R0KF4(BECC12%+/CY!W\KA5*HZ OMYGY#CH-=S^\1
MB(]=$O0(OH]]SQVP=2-LN1YZS54LREPK!'Y$U/B6YG%/1/M]'F$O\(Z&] "'
M03!"MT$ "<<F7$PBF+@6FF:'!\,H!W09.,/!86@/R':(/<\:'BS /O$'9,?%
M@1N@+M+74FP1U,2,KH2DIN[_![[\@\> 4NPVA\<6VF2XD6#'"1ZQVC.N!2&9
M*  7-> !6%>+_!$B/6Q90^M.K[X2>YKI/0:TRP!"H6Q P4IDN0$H+XJ,LSK,
MA$Z9'&I"@(<W=!R.'#*@NF"0$=]CXI,FL.2$IQ\HVK:!7_1 V; XM +T5L"Y
M\\KH,90:"<W$<.FC3#N]^LYA#PI!&!Y4A@B'=M0C> 1'![7#]2&CW F\\CJ\
M\AZ,5VV"-RK>UI@J%!JL;'$&(F0,O::E_2K(.4^IW+ 5C;^H6P3I^?^Q_ YK
M<4LU__\R"?-H?F]8+R"N0%%],-:E[&5"'4=G-*M=HXSKWM.\A/X;(K"&/P 3
M3&RG'U/8=_H1Y$!I[X]M@FTH10"9-[SISK.JM= ">E8IC9D*)KE([B!;%_PN
M=IUA"CHX(".E(AK)88,2$3J7+.$:"8D*NC?>4= ;)PPEI>3Y!CH9UNHQQ"L'
MVTXT F2@A#^&B+;MCU$#P$/KZ*Z)VPZD,7" O3L&]J)# P,*]PWL8#\<HOO_
M/15^=FK\Y%0AE:=<Z]8QQI-N=#BV['Z?%N#(_I%,B2 0AC!!<& /6R>_%V-=
MHCB ,^Z/)$H '=98PP<P8]EC^3.65+8%YPBGTL08UP,(/L V[-PQMA?9O3%P
M)8X]@6Q^AVS^XV]B58=QV*$/+U+5#1W:GC%\FY9Y#3:OKUV5!\SMNWD:X?^
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M.#\"F'( G(RM8:OU(H#^5]:/AO5 BZ)ZJ%L)#=E<_4T95&EI%L#\6@C=#HR
M[N5V\2]02P,$%     @ LH !5U6G*YOL P  B@L  !D   !X;"]W;W)K<VAE
M971S+W-H965T,C N>&ULS591;^,V#/XKA&]WN )I[-B-G?22 &FOP[JMUZ+I
MMH?#'A2;L87:ED^2D^;?CY(3-UG3=!@PW ##EBCR$S^)I#E:"?FH,D0-3T5>
MJK&3:5V=NZZ*,RR8ZHH*2UI9"%DP35.9NJJ2R!)K5.2N[WFA6S!>.I.1E=W)
MR4C4.N<EWDE0=5$PN;[ 7*S&3L_9"NYYFFDC<">CBJ4X0_U;=2=IYK8H"2^P
M5%R4('$Q=J:]\XO(Z%N%WSFNU,X8#).Y$(]F<IV,'<\XA#G&VB P^BSQ$O/<
M )$;WS:83KNE,=P=;]%_M-R)RYPIO!3Y'SS1V=@9.)#@@M6YOA>KGW##IV_P
M8I$K^X;51M=S(*Z5%L7&F#PH>-E\V=/F'/Z)@;\Q\*W?S4;6R\],L\E(BA5(
MHTUH9F"I6FMRCI?F4F9:TBHG.SV9/=Q>_G)Z,9U=?8;+VYN[JR^SZ</U[1?X
M^,#F.:J3D:MI&Z/LQAO(BP;2?P4RA!M1ZDS!59E@LF_ODGNMC_[6QPO_*.#/
M==F%P.N [_G!$;R@Y1Q8O. USAF3>&KN,H%+45!\*V9#9"HE*U.DF-,P7\.N
MWAU;6_%TQ60"7W\E2+C66*@_#QU0L__9X?U-GIVKBL4X=BB1%,HE.I,/[WJA
M]^D(N[.6W=DQ],F,\C:I<P2Q  J?^''#(-YA>LCG-U!?00*J"Z SA HE%XD"
MRZC4I+9B"NA9B)PR7\%'7I*BJ!4K$W5R#A_>#7PO^/3=O@^91-P+5:! 0QMH
M6YT9?WI#8_LUH6E>_@')C&H.+],.I%BB9#G0"0!+*)NYTI*9LM1:_0"]3C0,
M]^;#(-B9!YU^T-N9GW7"R(=[.G4FX\QB)[BD:EO9@/V[HT$4OI"=]0<O9+U.
M,!R^D []$!Z$)@ZOA1;@DQGO,O([O<C?FP?#?0;#P-N9]SO]X>!()O3;3.@?
MC=FKHLK%FB[9!B_<5M:_KS=8S%$>S-NC>/\R;\/6V_ [5Z7P/V 7M>RBX_6C
M^>F;HK2R?TI,3MF2LB%%*A+4$MC+4?2?SXEUF8(6(#:RE/B;@E+54M4T-&OX
MK>9Z#;R,B;])H"IGI3K$^KA?_Z>J\W:U>:XISZ-[KAY/%P:5TRG1S6F@FO*<
M?T$W@O?@=X?TWI?UK.R*\C4VQTO&A:W2:ZHDZJ15#DGY>=Q_02GJ>@?7/_,E
M3Y#*T9ICGK1BC]3?;]Z'9*T_2V%"(3?7O-4;A%8E\KK!CO4@Z/8:*2T>BE5W
MIS\J4*:V"U14MNI2-ZU2*VT;S6G37SVK-UWJ#9,IIYC,<4&F7C>BDB&;SJ^9
M:%'9;FLN-/5N=IA1LXS2*-#Z0@B]G9@-VO9[\A=02P,$%     @ LH !5X!P
MI\BF @  :@8  !D   !X;"]W;W)K<VAE971S+W-H965T,C$N>&ULQ55M3]LP
M$/XKIVQ"(%7DI6D)I8U$>=$Z"89:!I_=Y-I8.'9F.Y3]^]E.FV6L=!_W)?:=
M[WG\G.,[CS="OJ@"4<-;R;B:>(76U<CW559@2=2IJ)";E960)='&E&M?51))
M[D E\Z,@&/HEH=Q+Q\[W(-.QJ#6C'!\DJ+HLB?PY128V$R_T=HXY71?:.OQT
M7)$U+E!_KQZDL?R6):<E<D4%!XFKB7<9CJ:QC7<!3Q0WJC,'F\E2B!=KS/*)
M%UA!R##3EH&8X16OD#%+9&3\V')Z[986V)WOV&]=[B:7)5%X)=@SS74Q\1(/
M<ER1FNFYV'S!;3X#RY<)IMP7-DUL%'N0U4J+<@LV"DK*FY&\;<^A TB"#P#1
M%A YW<U&3N4UT20=2[$!::,-FYVX5!W:B*/<_I2%EF:5&IQ.9_=/-_>/W^:S
MFP4</Y(E0W4R]K5AMNM^MF69-BS1!RQ#N!-<%PIN>([YGWC?*&IE13M9T^@@
MX=>:GT(_Z$$41/T#?/TVS;[CZ_\[S7W9->!X/]C6Q4A5),.)9RZ^0OF*7GKT
M*1P&%P>DQ:VT^!![NC!UEM<,0:Q@QE^1:R$IJGTR#Q+ME]EA!%/"H N$"B45
MN0(7Q37FD E394I;"39@)9@I5LK7<$RY\8A:$9ZKDQ$<?4JBH'_QW\9+936^
M]YK;@NUM@6O,L%RBA'[H/!',R<;4C#9I$Z9:U&<8]I*SI&/'O<%@ ,^FC8#)
MNY(B0Z7^VBWJ!?%PCW<X.(=;RJDIQAS6PI[P^Z"PEPR2/=[S((9'H0GKB F#
MWED2=1SGO3!,8-^-\SOU7Z)<NRZGS%^MN6Y:0>MM&^EETS]^AS==^([(->4*
M&*X,-#@]&W@@F\[6&%I4KILLA3:]R4T+\QB@M %F?26$WAEV@_9Y27\!4$L#
M!!0    ( +*  5=#LT'E!P4  "@2   9    >&PO=V]R:W-H965T<R]S:&5E
M=#(R+GAM;,58;7/:.!#^*QK:Z<",6_QNDR;,)&G:]*;)Y0+)?1;V IK:%I5D
M:.[7W\H&(U["A?8Z_6)9\FKWV=4^N[9/%UQ\E5, 1;[G62'/6E.E9B?=KDRF
MD%/YCL^@P"=C+G*J<"HF73D30--J4YYU7=L.NSEE1:M_6JW=B?XI+U7&"K@3
M1)9Y3L73!61\<=9R6JN%>S:9*KW0[9_.Z 0&H!YF=P)GW49+RG(H).,%$3 ^
M:YT[)Q>AEJ\$'ADLI'%/M"<CSK_JR>?TK&5K0)!!HK0&BL,<+B'+M"*$\6VI
ML]68U!O-^Y7VCY7OZ,N(2KCDV=\L5=.S5MPB*8QIF:E[OKB&I3^!UI?P3%97
MLEC*VBV2E%+Q?+D9$>2LJ$?Z?1F'EVQPEQO<"G=MJ$+Y@2K:/Q5\08261FWZ
MIG*UVHW@6*$/9: $/F6X3_4OSP?7%M%7<O77P^?'\R]7M\,!.;_]0 ;7?]X/
MWPZO[F_(Y]O'J\'PIGK4'M)1!K)SVE5H7VOI)DM;%[4M]QE;(;GAA9I*<E6D
MD&[N[R+N!KR[ G_A'E3X1UF\(YYM$==VO0/ZO"887J7/^[^"L2\&M0E_OPG-
ML1,YHPF<M9!$$L0<6OTWKYS0?G_  ;]QP#^DO3] SJ9E!H2/24+EU*JN!+Z5
M;$XS*)0DM$B)G'*AWBH0.6'%'*3*]:-]SAPTM]^9RV/M$BPM1$V!S$ PGDI2
MZ2H4I"3AR'ZIM#M:8,PS+"*LF) V*W"%EQ+5RLX)>?,J=FWO_4^/YU+;VE[%
M/(,FS\@'2" ?@2">4ZVX1+O<"+\FL17U?&,>6F[HZ]R')Z2N^(JE=EPB[D;$
M=2S'[C53WW*"@#P,B,(R*TOQ1$8LR];BL=4+O&866*X;D$]\#J+0\7PK9Q@U
M+C!\.HAB)I@$(B$I!5,,UFJ<P IBWYQ&O9!<<C'C@BH@(ZXQZG-+>)Z#2!C-
MR(SB*35[>E;/B=9NA%84ACO1PP#XEA=$QD(06ZX=DGM 4_J<J3S^"*N@5^BV
M4VUMQX^MV'&-!=>W_*!'!OL3T8R,'S13S[,B/SK"KP-,#AHF!T<Q^:5<8D62
ME:FFB''B"Z:FI"PPFS+V#X9[@LVZUI)Q*6$O\P_#NSP:$FPQ>!O>1""40R!_
M&>=_=OQ4(:^O_UE?<@Q1Y=YJY6'M\8&E_75JLRXUQ.!8,1MP5117LR]U)%?3
MCY0)\DBS$@Y4F]=5O7%,$AGW^LYQWV])K\'\0%TR6!C:N[1S=U;:;M Q &S5
MM6,+FNML&#"=:_L=4](H?4.N4-<:@X=U)NH9"V8_:+N]SI9LX#][U+][_'WI
MO=MH?UF*8Q/=2/'=M&Z[86=S@[ON$#^7Y7&\F]/.SDH[CCK[=NNF_4.YCNTZ
MWN+79K(['5/6;.W;Z>Y'5L^W30Z:D7,"O[,I',6-W0.],FQZ9?CB7CG6YSVO
MSEL[O]-5EKT$)3=;U+8,F7')]'?COMYX&,YPH\\I_;6D6^-"UAWPQ0!Y*;9!
MLB)E<Y:6&'PCI=24*D(%: GZO"<6H9.)@ G5;URC)T,WOF$HF'#DQ:]]K][L
M5R8UUY"7_/T!1F'6V580A6;JF:0]BARK$1,[L'>YZ'6>Y8(36X&["6)=[O=E
M>]?X>D<PD^H?A41H9:'J#_EFM?D-<EY__:_%ZW\H-U1,=#',8(Q;[7<1OL6)
M^K]$/5%\5OT+&'&E>%[=3H&F(+0 /A]SKE83;:#Y.=3_%U!+ P04    " "R
M@ %7O5T(OID#  #T"@  &0   'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6S-
M5MMNVS@0_96!NBA:0(VLFR^);<!)FVZ+%@ARVV=:&ME$)%(E*;O9K^^0DK7>
MPG&0W6*Q+^9E9@[/< [EF6ZE>M!K1 /?JU+HF;<VICX- IVML6+Z1-8HR%)(
M53%#2[4*=*V0Y2ZH*H-H,!@&%>/"FT_=WI6:3V5C2B[P2H%NJHJIQW,LY7;F
MA=YNXYJOUL9N!/-IS59X@^:NOE*T"GJ4G%<H-)<"%!8S;Q&>GB?6WSG<<]SJ
MO3G83)92/MC%IWSF#2PA+#$S%H'1L,$++$L+1#2^=9A>?Z0-W)_OT"]=[I3+
MDFF\D.4?/#?KF3?V(,>"-:6YEMO?L<LGM7B9++7[A6WK.XH]R!IM9-4%$X.*
MBW9DW[M[V L8#YX(B+J R/%N#W(LWS/#YE,EMZ"L-Z'9B4O511,Y+FQ1;HPB
M*Z<X,[]<?+J&^\67NP_PYI8M2]1OIX$A8&L.L@[DO 6)G@ 9PE<IS%K#!Y%C
M_O?X@ CUK*(=J_/H*.#G1IQ // A&D3Q$;RXSS)V>/&S61Y*KHU-#L?:5W&J
M:Y;AS"/9:U0;].:O7X7#P=D19DG/+#F&/K^A5Y8W)8(LH.""B8RS$IC6:#14
MR'2C, =FH&!<P8:5#;F2F.E!9(U27*RL*+D^E-?QDV_7",96');V:7;/DO^)
M&@R9]L\K0#8*,J;7@-\:3KLHB!X3.>BU5.:=054!%QO4IG*F%S#W'0Y32 <8
M7$E+(7<O+8>FI@C+A@@2-I2XP=+RT7PE>,$S)@R=6S<&C'2.]AQFW[N&-]S&
MRD83OGY["J]?C:-!?/:?CXNVF'03E_8F[MU-,&W3()UCK_,^X(O+,NS&J!MC
MN)6&M$%/#1_I$Z >Z)-=-)1;'_@;1*$?#B9[&W861F='=[J@NQLPRM7M$9:\
M+/7!C/9#=^/8GZ3Q"[T_R@TJ8=7R3E.5M;1JH16J6G&-H*U*N.&HGP0,4S\=
M)\^9+Z2JI2)IP5+:R[)JRV15H7)/K68UJB<Q)OXD'#UC;<MRI 9QXB=I<K0$
M*7$='K["_XE4WV.&U9*N*@Z=7*-?(=?$#]/TA6IM8_ZY6%,_BM(7>O\:L8XF
MP^?,_TJLT= ?#9\^HC/_+->?:Y",_-%X=+0$:>A/DNC0OU^PUXD0Z97KMS2E
MT C3-B7];M_2+=I.YB_WMA_\RM2*TV>\Q()"!R>CU /5]ECMPLC:]35+::A+
M<M,UM:6HK /9"RG-;F$/Z!O=^0]02P,$%     @ LH !5XJ;YL.( @  T@4
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M"J/O<SB!*R*H +:"*4>!I23-U90IW-&GFJ94OL#A&"6AN3A2_LOY& X/CN
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MF8]TQVR:LA_XNMV^QGQ-J$ YK)0IYV2BMLKK#K8>2%::%NV.2=7PF=M,=?W
M]0+U?,68W ZT@?9_A/ [4$L#!!0    ( +*  5<"K7FRF 4  ,TI   9
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ML;P(4-^O.)?/!\4 S0[.Q;]02P,$%     @ LX !5ZN]8]'/!0  7R,  !D
M  !X;"]W;W)K<VAE971S+W-H965T,CDN>&ULQ5I=;]LV%/TKA%<,+9#4(B5+
M5N88:*QTZ[!N6;)T#\,>&(NQB4JB2U).\^]'?42R1(9K%05YB?5Q[^&]A^3E
M$</%'>.?Q980";ZF229.)ULI=R?3J5AO28K%6[8CF7ISRWB*I;KEFZG8<8+C
MTBE-ILAQ_&F*:399+LIG%WRY8+E,:$8N.!!YFF)^?T82=G<Z@9.'!Y=TLY7%
M@^ERL<,;<D7D]>Z"J[MI@Q+3E&2"L@QP<GLZ>0=/(M<I'$J+3Y3<B8-K4*1R
MP]CGXN9#?#IQBHA(0M:R@,#J9T]6)$D*)!7'EQITTK19.!Y>/Z"_+Y-7R=Q@
M058L^9O&<GLZF4] 3&YQGLA+=O<+J1.:%7AKEHCR+[BK;(-P M:YD"RMG54$
M*<VJ7_RU)N+ 0>&8'5#M@/H.WB,.;NW@?JN#5SMX)3-5*B4/$99XN>#L#O#"
M6J$5%R69I;=*GV9%OU])KMY2Y2>7E^>?SG^_/K\"Q^!=T054WH/7$9&8)N*-
M>GA]%8'7K]Z 5X!FX*\MRP7.8K&82M5V@3!=U^V<5>V@1]KQP4>6R:T YUE,
MXJ[_5,7<!(X> C]#5L!?\^PM<)TC@!SD&N)9?;L[,KA'=O>(K)4[-+EWLG&;
M;G!+//<1O*OS%;A2<SK.$W($(#IVPB/P"2<YKF9'%H,_<YS0VWN:;51/K5F>
M20$B*M8)$SDGX)_?%"3X($DJ_C5U3]6^9VZ_J"XG8H?7Y'2BRH<@?$\FRQ]_
M@+[SDXG;,<&BD< ZO'L-[YX-?7F&$YRMB8FPRM$O'8OJN5]"!+W98KH_9$*W
M"D+8,XJL,0S,<-9D.+-F>,'9GM95.L&2Q$ R55@X)YD$.\(IBX' "3'.Z0IZ
M=LC!?#8+>QP8K%S'\7HD6,,<2(+?D.!;25AQ$E,)& <[?*]6+35U4AP3$.>\
MF$]R2VHJ3"3X6GK','"0TV/!9.;X\WF/!FN@ VD(&AJ"H:,],/2A/^_UX<I@
MI:HO[*5H#6)@BO,FQ;DUQ:(B5K6QJ)DX4;JF2-DXNN>&T>T[_7XU6*G1W;.*
MK%$-S#EL<@ZM.?^AQB]7"FK-<S6]$XIO:$(E-2<=:NG,'.CV<K:V][WU/=1*
MI._-VQ+921DZK6YQK$DW:R G:T+W^"8A99>KB':8QN4U*XEY*'98""+-TL7:
MU/<NCJ.B16.A=6D^D(?PA85)'<!8Y(^)%HV%UB4?M>2CT8I9#74XL3VMEAF,
MBF+6JV7VJ(9FW4IA:%5\R]46\PVYP>O/X@AT*7A/'DE^5'4[*EHT%EJ7S5;@
M0N^E)_!(\K8F?TRT:"RT+OFM]H9V\6T17%!7S3[2%F*#E>MITMH>Q= L6W$-
M[>KZ29\84-?-T//<_C>&P2STYUKE>@YU#5MY#>WZ^DF?&5 7U\?0A3H3!KL@
M\/K?&?90AU+1RG!HU^&VD:\KZF"FCWS=:N:Z?C_+Y]#=L!7>T*Z\?V9[PK.T
M5)>JD%9"_%*M7?*1P3ZFL%Z-BA:-A=;=S6OU/')>>)U"HZK\4=&BL="ZY+<J
M'UF%K&VVUIZ'\Q#Y_7FX,EEY87^=LD<Q-,M63B.[G'[2.H5TZ>P&J+\=:+!"
M >QOD-CC',I#*[#1_PCLIRQ3-79G^7$#7R/"8(9"1V/B.<0Q:L4Q&KS]6WMV
M>G(6:N/>8.5J^LP>Q= L6Q6*["KTDLB<9^91/9)RK-D8$RT:"ZW+6JMJD?_2
M"])(:K4F?TRT:"RT+OFMDD:#=ZJ1KG]=I$],W0HY,.A/S.<0R:@5R<@NDI^V
M(.D"V0VU,JP;^7VI'=FC',I"*Z*1740_;3G2][./(=1&@\&J_V$5V<,<2(/;
M"F#7OJ%M&?*UY^$6NCL+^GUML%(K5G_%M4?QO5E.#TX>I(1ORA,< I2UL/I?
M?O.T.27RKCP;T7M^!D]6U5F/%J8Z>O(1\PW-!$C(K8)TW@:J%WEUFJ.ZD6Q7
MGF^X85*RM+S<$C6 >&&@WM\R)A]NB@::,S7+_P!02P,$%     @ LX !5]RG
M9-;A P  !Q8  !D   !X;"]W;W)K<VAE971S+W-H965T,S N>&ULM5C;;N,V
M$/T50@6*%FBCJQTGM0TDEHK=;M,&-G;[4/2!D<:V$(E42=K>_'U)2I$M@=8F
M#?-B2=2<,YPYY%B<Z8&R1[X%$.AK61 ^<[9"5->NR],ME)A?T J(?+.FK,1"
M/K*-RRL&.-.@LG #SQN[)<Z),Y_JL7LVG]*=*'("]PSQ75EB]G0+!3W,'-]Y
M'ECFFZU0 ^Y\6N$-K$!\KNZ9?');EBPO@?"<$L1@/7-N_.O$CQ1 6WS)X<!/
M[I$*Y8'21_7P,9LYGIH1%) *18'E90\+* K%).?Q;T/JM#X5\/3^F?U7';P,
MY@%S6-#BKSP3VYDS<5 &:[PKQ)(>/D 3T$CQI;3@^A<=&EO/0>F."UHV8#F#
M,B?U%7]M$G$"D#QF0-  @CX@.@,(&T#X4@]1 XA>ZF'4 '3H;AV[3ER,!9Y/
M&3T@IJPEF[K1V==HF:^<J(6R$DR^S25.S)?)E^2/S\D*_8SN@:5 A%P>Z.$)
M+;1O8.B'& 3."_ZC-%GA KB\MB\7E"@,PUKU9<X?IZZ0TU+D;MI,X;:>0G!F
M"B&ZHT1L.4I(!ID!'P_CQP-X5Z:CS4GPG)/;8)#PMQVY0*'W$PJ\(#3,9_%R
M>& *YVW>D__MO9.,L%T@H>:+SO#=I9^ <RGNJH(TQX602P,S0''.!<L?=EKX
M!645K1>!2?]!#ZH47O,*IS!S9*WCP/;@S+__SA][OYB2;Y,LMDF66"+KR!2U
M,D6:/3PCDY0#;S8,-O5.I&NTA#V0':"_?Y>FZ*. DO]C$B>R*8Y-LM@F66*)
MK"/.J!5G-+B'CI75)$"-G6BL^E_?S[V+*)JZ^]/$FHS"GE%L9!IUC1(CT[@U
MZ@0X;@,<#P;X*><<<E-P@[C7KBZ;9+%-LL0262?YEVWR+]]IZU_:%,<F66R3
M++%$UA%GTHHS></6'\2^5H")86,'O=T?V_28F#SZ9TK)59NPJ\&$R8^++">X
M0!] ?FQL4_FM8<K<(,EK,V>3++9)EE@BZRCA>\>S@?=.E:4AMJ2/5;;8*EMB
MBZTKT<GQS7]#?6G O9HPZ7U;&*U.]G&3-B-7SRHQ6YE+@A\<HPP&H[Q9Q2?U
M &&2H3^)//K2S1-:[:JJ>#)&/TCZZD5HDRVVRI;88NO*<SPB^N%[U0FK1T.K
M;+%5ML066U>BX_'0'SS@?*M.1*8*<-6O$T:KH%\G3%:!WZ\3W_!8A^F>-+9*
M8!O=4>0HI3LBZA9&.]IV+6]TKZXW?NM?+WS#>*RZG+J1=J2O6Z1WF&URPE$!
M:^G*N[B4YR96=QWK!T$KW59[H$+04M]N 6? E(%\OZ94/#\H!VWO=_X?4$L#
M!!0    ( +.  5<+-,<$+R0  )7! @ 9    >&PO=V]R:W-H965T<R]S:&5E
M=#,Q+GAM;+7=<6_;2(+FX:]"Y!9WN\!TQY)LV>Y+!TB'5621K"HRZ=X#[G!_
M,!+M$".)6DI.VHW^\"<YDBE*=%D:_6Z F9;=YE.R.'G#(OFRWGVOZG\NOA;%
MTOMS.IDM?GWS=;F<__+V[6+TM9CFBY^K>3%;_9N[JI[FR]67]?W;Q;PN\O'3
M1M/)V_[%Q?#M-"]G;]Z_>_I>6K]_5STL)^6L2&MO\3"=YO7C;\6D^O[KF]Z;
M[3<^E?=?E^MOO'W_;I[?%Y^+Y1_SM%Y]]?99&9?38K8HJYE7%W>_OOG0^R7K
M#:[76SS]R'^6Q??%SFMO_;M\J:I_KK]0XU_?7*S?4C$I1LNUD:_^\:WX6$PF
M:VKU1OYKH[YY'G2]X>[KK2Z??OO5;_,E7Q0?J\G_*L?+K[^^N7GCC8N[_&&R
M_%1]#XO-;W2U]D;59/'TO][WS<]>O/%&#XME-=ULO'H'TW+VXY_YGYM/8F>#
M?O^%#?J;#?K';C#8;# X=H/+S0:7QVYPM=G@:F^#P4L;##<;#(\=X7JSP?6Q
M&]QL-K@Y=H/;S0:WQV[0N]CNN8NC-WG>V4?O[=YV=_>.WM^][0[O';W'>]M=
MWCO8Y[<O;;+=Z;W]O?[R*-O=WCMZO_>V.[[WM.??_OAS]?2'TL^7^?MW=?7=
MJ]<_O_+6+Y[^9#]MO_JS6,[6*?1Y6:_^;;G:;OG^<VK-9_M)^-XG\5E\^/0Q
M]#X8WTO41V$^"^]#\$D(+<SOGY^^'=C_%)_,^FOOHS6_?_KP\7?OW_UBF9>3
MQ7]X_^:5,^_WK]7#(I^-%^_>+E?O;SW*V]'FO?SVX[WT7W@O/4]7L^77A2=F
MXV+<L;UR;S]X;7OKWG[XVO:9>_O^M0-XN]HQSWNGO]T[O_6=8O0P^=GK7__#
MZU_T^]X?GWWOW__M/SK>V$<W\V%>_^P-+IZ8GH/Q7WDW^6S%]%YEA)N1Q9?5
M+W7[Q%PX&.EF[&BY?3>]VRWCY?=U4:S^EEQV@,'1OUX#=C#A\>_KQL&HUW;]
M['F?#1Q,Y&9T7C_O,Q<3NQF_&#TSKO\C)F[F<S%__J5<C#[^LW$QYOC/QO7_
M9_LO["EO7M1EU14B*?.[96?O]U8B#9[_OA@\N8,7W-7!WB3_4M7Y^A"R,^-_
M;'_9O?WZH/J7Q3P?%;^^61TU+XKZ6_'F_7__;[WAQ?_LRC42\TE,D)@DL8#$
M0A)3)!:16$QB"8EI$C,D9DDL);$,PEH!>?D<D)<N?160LV4YNU\=@7CS_'%]
M)-*9DD[DU)0D,9_$!(E)$@M(+"0Q16(1B<4DEI"8)C%#8O8'-GS"UJ<$O[WO
M#2[6_WGW]MMN )*#9A#6"L"KYP"\<@;@TXE,;UEYU7SI50^K_]XUL[)_>./R
M[JZHU_&XF!>C\JXLQMZRG!8+[^^7CYE_<PYY:ER2F$]B@L0DB04D%I*8(K&(
MQ&(22TA,DY@A,?L#N]J)R_Y>4)+#91#6"LKA<U .G4'YQ_RNKIK#1*\N1D7Y
MK?/$XV].Z=3\&Q[^E=2_.O@;R2?'%"0F22P@L9#$%(E%)!:36$)BFL0,B5D2
M2TDL@[!6"%X_A^"U,P333?BM#A)'U6)U4/@UKXOUT>-H]T3C*B/KY:RHNZ+1
MZ9\:C23FDY@@,4EB 8F%)*9(+"*QF,02$M,D9DC,7A\>MEQ?7>X='1[^T,W@
M<MC^H0QZ6ZW NWD.O!OW]+CX5LP>BO717G4_*__J/MYS&J>&&HGY)"9(3))8
M0&(AB2D2BT@LOCGXL]<_/-&5D$-J$C,D9DDL);$,PEKI=_N<?K?.]/LP&E4/
ML^5B,]G-OTR*KOAS(J?&'XGY)"9(3))80&(AB:G;CI"YZ=VV0R8BAXQO#\Y)
M75X,^ONY1@ZI2<R0F#W\,#H^_Y0<,H.P5F#U+IX3:WW?JO. ;5'D]>BKE\_&
MWGAU]#:IYB_<8/:;FSHUN%#-1S6!:A+5 E0+44UMM%:87%_OG>..T#%C5$M0
M36^TUJSN\GIXW?Y ##JH[=@)O<N;86\OQ#I^;'#1O]S[L8QZ;^U\VKF!N^?,
M)S5;YK/[<G4DY>6+1=&=2T[BY%PB-1_5!*I)5 M0+40UM=':?R0N>X/]8"('
MC3L'O;W<.YA(T$$UJAE4L\?MA10=-*.T=G[UF_SJ'S<EG.>/+\T'W<3)^45J
M/JH)5).H%J!:B&IJH^W^R;GJ7U[LQQ<Y9MPQ9K]_=7&S'U_DH!K5#*K9HW9"
MBHZ945H[O9HZ1,]Y,_'[S\\WL?G-U- 3W];W_7K_1Q?3+T7]?SLC#>U)H)J/
M:@+5)*H%J!:BFD*U"-5B5$M03:.:036+:BFJ99363M*F-['N5"_.:99M "HR
M2<U'-8%J$M4"5 M13:%:A&HQJB6HIE'-H)I%M135,DIK1V;3M.BYJQ9'=LW<
MRLFYB=8G4$V@FD2U -5"5%.H%J%:C&H)JFE4,ZAF>QU5BNO;JX/B&3IJ1FGM
M1&PJ%3UWIZ*9CG\J[A\F^;*J'X^:C:,%"U3S44V@FD2U -5"5%.H%J%:C&H)
MJFE4,ZAF42U%M8S2VD':U#)ZU^?.QM'B!:KYJ"903:):@&HAJBE4BU M1K4$
MU32J&52SJ):B6D9I[<ALBAT]=[/CV-DXVNU -1_5!*I)5 M0+40UA6H1JL6H
MEJ":1C6#:G:CM6;CPT'O<#:.5CTHK9V(3=FCYVY[-+/QM*[&#Z.EE^0/L]'7
MHV;D: <$U7Q4$Z@F42U M1#5%*I%J!:C6H)J&M4,JEE42U$MH[3VDZ";'DK_
MXLP9>1]MGZ":CVH"U22J!:@6HII"M0C58E1+4$VCFD$UBVHIJF64UH[,IAK3
M=U=CCIR1NY63<Q-MQZ":0#6):@&JA:BF4"U"M1C5$E33J&90S?8/NS;7M\/#
M![.BHV:4UD[$?I.([K+-[DWJZSYSW5PEGY:38K&L9L7"^_+HS:K93Q_-9V]<
M+HI\47CS'Q/X[OQ$VSFHYJ.:0#6):@&JA:BF4"U"M1C5$E33J&90S:):BFH9
MI;53MBD%]<]=)*6/MG]0S4<U@6H2U0)4"U%-H5J$:C&J):BF4<V@FD6U%-4R
M2FM'9M/^6;TDINI.Y>3<)#4?U02J250+4"U$-85J$:K%J):@FD8U@VIVH[4>
MQ#/H6$,%'36CM'8B-N6>OKO<<_94W?O;T]L?? Y5;[WP\_9'?OKR^-/FY7HE
MY[([<M'V$*KYJ"903:):@&HAJBE4BU M1K4$U32J&52SJ):B6D9I[6!N.D;]
MX;FS>[1-A&H^J@E4DZ@6H%J(:@K5(E2+42U!-8UJ!M4LJJ6HEE%:.S*;-E'?
MO<K+L;-[M%*$:CZJ"523J!:@6HAJ"M4B5(M1+4$UC6H&U>Q&:SWTLFN%5'34
MC-+:B=B4A?KNLM#1L_NC+\*CM2)4\U%-H)I$M0#50E13J!:A6HQJ":II5#.H
M9E$M1;6,TMH)VY2/^K?G3M/1BA&J^:@F4$VB6H!J(:HI5(M0+4:U!-4TJAE4
MLZB6HEI&::W('#05HX%[J9LCI^ENY=3<1#4?U02J250+4"U$-85J$:K%J):@
MFD8U@VIV<+@:3O_J<-GX%!TUH[1V(C8-HH&[0736-!VZ .]^BR?'+5I/0C6!
M:A+5 E0+44VA6H1J,:HEJ*91S:":1;44U3)*:X=ROPGE_IDS^P':2$(U']4$
MJDE4"U M1#6%:A&JQ:B6H)I&-8-J%M525,LHK1V932-IX%ZFZ-B9/5I+0C4?
MU02J250+4"U$-85J$:K%J):@FD8U@VIVH[4NP%]U7(!'1\THK9V(3>%H]=*5
MB$%=WE63[A1T;GER"I*:CVH"U22J!:@6HII"M0C58E1+4$VCFD$UBVHIJF64
MUL[*IHHTN#IWPHV6A%#-1S6!:A+5 E0+44VA6H1J,:HEJ*91S:":1;44U3)*
M:T=F4Q(:N!<B^F-^5U?-;-NKBU%1?BO&G>&)UH50S4<U@6H2U8*--MR9!75T
MC$-T4(5J$:K%J):@FD8U@VH6U5)4RRBMG8I-#VC@[@%M)MW>W]ZGE9[7HZ_>
MY]4@Y:CH/JI$^T"HYJ.:0#6):@&JA:BF4"U"M1C5$E33J&90S:):BFH9I;7S
MLVD-#6[.G8BC-2!4\U%-H)I$M0#50E13J!:A6HQJ":II5#.H9E$M1;6,TMJ1
MV=2 !NXUB#X5WXK90[&>@%?WL_*O%Z;@:!4(U7Q4$Z@F42U M1#5U$;;O4BZ
M=VH@0@>,42U!-=WQ8?3WSY08=$C[^N>?=OS(P7+G&?6N6G%TV51L+MT5FV8&
M[!>3\EM1/WK5G3>N'^Z]Q<-\/GGT[JK:&U73:5&/RGQ2_O5TK->56>Z13LTL
M5/-13:":1+4 U4)44Z@6H5J,:@FJ:50SJ&91+46UC-+:V=J4=2Y[9\Z.+]$J
M#:KYJ"903:):@&HAJBE4BU M1K4$U32J&52SJ):B6D9I[<CL-Y'I7@_HN-FQ
M&SDY-M$Z#:H)5).H%J!:B&IJH[5N(3Z8$4;HF#&J):BFC_H\##JF[1BS?W-P
M$_=1[RRCWED[EIJZRJ6[KM+,DC\^SX1W"M>=&8565U#-1S6!:A+5 E0+44VA
M6H1J,:HEJ*91S:":1;44U3)*:V=H4W!9O3QS-GR)1B:I^:@F4$VB6H!J(:HI
M5(M0+4:U!-4TJAE4LZB6HEI&:>W(;'HNE^XE=XYL2;N5DW,3+;N@FD UB6K!
M1MN]7[M_>WUPP2]$1U6H%J%:C&H)JFE4,ZAF42U%M8S2VHG8U%@NW366N%PL
MBK(S!-'2"JKYJ"903:):@&HAJBE4BU M1K4$U32J&52SJ):B6D9I[:ALNBV7
MU^?.M]$Z"ZKYJ"903:):@&HAJBE4BU M1K4$U32J&52SJ):B6D9I[<ALZBR7
M[D5PCIUOHYT65/-13:":1+4 U<*-MCM[[UU>']2M%3IJA&HQJB6HIE'-H)I%
MM135,DIK)V+35KETMU5.>6R$FSHY%M'."JH)5).H%J!:N-%:#Z$8=*0BNBX-
MJL6HEJ":1C6#:A;54E3+**V5BE=-:>;*79K9W*7XCU4<3O-RMCID].9%?5?5
MTWPV*KSJRZ2\?[$FX[9/C4E4\U%-H)I$M0#50E135X<KFW2$;H0.&J-:@FH:
MU0RJV>-V5HH.FE%:._^:8LN5>Q6:>%;>?UVV[X9<KT8S*4?%;%%X^7U=%"].
MG]WXR0&(EEY03:":1+4 U4)44Z@6H5J,:@FJ:50SJ&91+46UC-+:<=IOXO3<
M]6.NT,(+JOFH)E!-HEJ :B&J*52+4"U&M035-*H95+.HEJ):1FGMR&P*.5?N
M0LXIYR7=U,GAB39Q4$V@FD2U -5"5%.H%J%:C&H)JFE4,ZAFKPX7D>EW3,O1
MA@VEM4.Q:=BL7AXU+=?YG^7T8?I27?%?GK@[AS\Y2$G-1S6!:A+5 E0+44VA
M6H1J,:HEJ*91S:":1;44U3)*:P=NT\^Y.G<=FBNTFH-J/JH)5).H%J!:B&H*
MU2)4BU$M036-:@;5+*JEJ)916CLRFP+/E;O <^0MEF[EY-Q$VSRH)E!-HEJ
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MJ)8>]1MDU)BMF+MM*CNW[LJ.7]P5=5V,5SGWE'==(><F3@TY5/-13:":1+4
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MP2C[6]>G3K*X(O/;V;+Z&3W%3%N83D*#)J'!:$)78L/.\>8CV"",J,BJT'D
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M#&X%DNLTQ6(W!<JW(\=W7@;NR'*ES( ['F9X"7-0#]FMT#VW1$E("DP2SI"
MQ<B9^%>1'Q@%*_&%P%;NM9%QY9'S)]/YE(P<S\P(*,3*0&#]MX$94&J0]#S^
M*4"=TJ91W&^_H/]JG=?./&(),TZ_DD2M1L[ 00DL\)JJ.[[]'0J'N@8OYE3:
M7[0M9#T'Q6NI>%HHZQFDA.7_^+D(Q)Y"T'U#(2@4@B,%O_^&0J=0Z!PKO&7A
MHE"X.-5"MU"PKKNY[S9P(59X/!1\BX21UFBF8:-OM76\"#.),E="?R5:3XWG
M]S>S/UO3R3P*T>SF^C;Z/)_<?[KYC%IH(G7V9(9.B<Y"4)A0>:['HS2C? >
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MR)7BJ6VN "<@C(#^ON!<O72,@?*U;/P?4$L#!!0    ( +.  5?C5^CDF00
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M7>'+H6FHA#SB.80UWSI'JI0II:]J<#OO:X9B!!',A((@\F<%0X@BA21Y_"Q
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M7!"Q.#Q9#!3/S/G#B"O%$W,Y!1J!T"_@\S'G:CG0$Y1'6/W_ %!+ P04
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M !_!P_T5>/_N W@'LA+\N28;ALHEF_I<?*5,]!<-_*<]/#P"__NF/ -1\ N
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MQ0+Z[T]IJM[N% 7VESZ;_0]02P,$%     @ LX !5W\/S6]' @  >P4  !D
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MNRV;&_BH'FW-4>'^E)51=I5:G"D6/^8/\ 5N&M,HA#LJ*&\X+,FK/7BC8;1
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MVJS=<8#+-;0E27.V[B,;MHWA$9F&.(9:25L9B*%@?2.T&/3YGX4X[>"G_YW
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MKKIJ;WCY(B@[DBU-R9LQJ0JH:6;J$05< ]3\G#&YZ^@ ];,L^@-02P,$%
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M$_D=2D$8<$4$1Q+68^]J.)JD-M\E_"+0J(,YLDZ60CS;X'LQ]@(K""BLM$7
M9MC"-5!J@8R,EQVFUU':PL/Y'OW6>3=>EEC!M:"_2:'+L??%0P6L<4WU7#1W
ML/.36+R5H,I]4=/FIK&'5K72@NV*C0)&>#OBU]TY'!2$X9&"<%<0.MTMD5,Y
MQ1KGF10-DC;;H-F)L^JJC3C"[4]9:&EVB:G3^?W-U>)F@3ZCVUK7$M #X835
M#-V#L8IF^,W\ *W0^10T)E1=H#-$.'HL1:TP+U3F:R/"0OFK'>&D)0R/$/ZH
M^0!%P2<4!F&$GA93='YV\3>,;SQT1L+.2.APHR.X/RN06!.^::7W"6L!XGX
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MVF6AARP($Z#WEYRKK6$$^K&=_ 502P,$%     @ LX !5UB-)I5$ @  B@8
M !D   !X;"]W;W)K<VAE971S+W-H965T-#DN>&ULG95=;YLP%$#_BL6D/;6!
M0#ZV#)"2;M-2J5.4=MNS@R]@U=C,-DG[[V<;PK(IH5)>P#;W'I]KQ"4^"/FL
M2@"-7BK&5>*56M<+WU=9"156(U$#-T]R(2NLS506OJHE8.*2*N:'03#S*TRY
ME\9N;2/36#2:40X;B51355B^KH")0^*-O>/"EA:EM@M^&M>X@$?0/^J--#._
MIQ!: 5=4<"0A3[SE>+&:VW@7\)/"09V,D:UD)\2SG:Q)X@56"!ADVA*PN>WA
M#ABS(*/QNV-Z_98V\71\I']UM9M:=EC!G6"_*-%EXGWP$($<-TQOQ>$;=/5,
M+2\33+DK.K2QT4</98W2HNJ2C4%%>7O'+]TYG"08SOF$L$L(G7>[D;/\C#5.
M8RD.2-IH0[,#5ZK+-G*4VY?RJ*5Y2DV>3M?F> E(]"0QH;Q 2RDQ+\ <NU:Q
MK\T.-L[/.MJJI847:!%Z$%R7"GWA!,B_^;XQZ_7"H]XJ' 3>-WR$HN &A4$8
M#?"BOMS(\:(+O'-EWJ#=*UIS0O>4-)B=J[J%3LY#[7>S4#7.(/',AZ% [L%+
MW[\;SX)/ \J37GDR1$^W#0,T#G;3V_&I-EH24>O_#[G5'0;FF"D8$)OV8M-!
MSG?!;Z^0&X:^)3?KY697G=H32/,5X0MNP\RWW.:]V_SJ@QOV&^9>]/-/^D,%
MLG!=4*%,-%RWK:)?[1OMLNTO?\/;+OV 94&Y0@QRDQJ,YN9URK;SM1,M:M=M
M=D*;WN6&I?E9@+0!YGDNA#Y.[ ;][R?] U!+ P04    " "S@ %7JI+]0BD#
M  !&$@  #0   'AL+W-T>6QE<RYX;6S=6%UKVS 4_2M&74<+HT[BQ8W7)+ %
M"H-M%-J'O14EEA.!+'FRTB7[]=.5'.>CNJ7KP];,(;5TC\ZY1])U93*LS5JP
MVP5C)EJ50M8CLC"F^A#']6S!2EI?J(I)BQ1*E]38KI['=:49S6L@E2+N=3II
M7%(NR7@HE^5U:>IHII;2C$B_#47^]CD?D6[ZGD1>;J)R-B+W9V]_+)6Y>A/Y
M^\F[DY/._?G58?S, ><D#HKVGR%ZT<%U+89)I_O2;OBI%?+$4XQV&:#9+%LF
M=##RX%G3>6(V3CAN-F0\+)3<[DM"?,!FIB6+'J@8D0D5?*HYL I:<K'VX1X$
M9DHH'1E;$-9*%R+U+P]W?0]JI=$IN53:Y?89_-]I,_P V/3 (!>B-=@C/C >
M5M08IN6U[;C!+O@(BIKVW;JR#N>:KKN]/MD2W,TFF2J=,]VFZ9)-:#P4K  [
MFL\7<#>JB@$T1I6VD7,Z5Y(Z#QM&T["R,R;$+3Q(WXL][56QLZ<=V%'9-JVA
MINEE? ?T=]6\]J[LRW2CBC\H\VEIIR-='VJ%W6A6\)7KKXK6 *;>Q=5I58GU
M1\'GLF1^\L]..![2#2]:*,U_V6Q0*C,;8)I$#TP;/MN-_-2TNF,KLRFG58%[
M[AVAY[^[SG,FF:9BU[2M_=>\RB]VG%S^*\ONO\JAX:#'YG1\[2;[QV R/0:3
M1U&3@U=I,F[.QIT#>._X;:,1O.:,R#=XH1+;I-%TR87ALNDM>)XS^>@4MO*&
M3NU+\IZ^'9^S@BZ%N6O!$=FVO[*<+\NL'74#"]&,VK:_P/2Z:?N.97-QF;,5
MRR=-5\^GKAG9ALW:7$ X1*[=%48PCL?""&!8'LP!QO$L+,__-)\!.A^/8=X&
M062 <@8HQ[-"R,1]L#QA3F:O\$RS+$G2%%O1R23H8(*M6YK"-ZR&>0,&E@<R
M_=E:X[N-5\C3=8#MZ5,5@LT4KT1LIOA: Q)>-V!D67BWL3S P'8!JQW('\X#
M-17F) GL*N8->X)Q),LP!&HQ7*-IBJQ."I_P_F!/29)D61@!+.P@23 $GD8<
MP1R !PQ)$G<.'IQ'\>:<BK>_'(U_ U!+ P04    " "S@ %7EXJ[',     3
M @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/
MV!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"
MKM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O@*\Z3'%"
M:4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0
MT^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    ( +.  5=H
MZWPP;00  &,@   /    >&PO=V]R:V)O;VLN>&ULQ9E=;YLZ&(#_BL75)IV<
MA(]V6[5,HH0T: GD *FT<W/D@)-8XR.R3;ONUQ\#S>9L]-5NG%Y1#'4>7OR^
MCVT^/M;LZ[:NOZ)O95'QJ7$0XG@S'O/L0$K,_ZZ/I))7=C4KL9"G;#_F1T9P
MS@^$B+(86Y/)];C$M#(^?3SUM69C]:06)!.TKF1CVW!/R2/_>;T]10^4TRTM
MJ'B:&MW?!3%022M:TN\DGQH3 _%#_;BH&?U>5P(72<;JHI@:9G_AGC!!L]^:
MDQ8RQ5O>M0B\C;$$F1K7$]GACC(NNCNZ_K%D?"#RYOZL$?6<%H*P&1;DCM7-
MD5;[MAOY%&/E,;HXG(Y]$&_8GX2QWNUH1F9UUI2D$GT<&2E:P(H?Z)$;J,(E
MF1JSR-NL_#!%;CA#\ABD7U 0SJ-XY:9!%+9/*G\ZR/NG%A)7B2&[H?(""_(.
M7!^D%X4S/TS\&;IUEV[H^2A9^'Z:*'060&==BBY)W=1OHYF@:(ZBM1_+("J0
M-@!IOPZD%ZW6L;]0(!T TGD=R"2-O,^+2(&\ B"O7BF2;K) \Z4">0U 7NN%
MC.([-PS^[7*X2^UDLUJY\9<NFL&= OD.@'RG%S+T4[2,D@3)1)$9[<:^PO4>
MX'JOEROV[_UPXZOEY0- \T$O3;*.PB2*Y7B+_<1W8V_1O=!EX+6C$*D5>@*5
MZ(EFS#9'1[=NFQAM49%POQD$5(AFAP2A?*EI% =G[]6$O&'J%H>L&'_U=</_
M9Q/<N\NNEG3INHAB%1,RAZE9'7,WB)&$VZCI:4*:,#5[8N;?IBH+9 -3LPZ6
MOASR9T,**OOF:];]_RP5$RK\YL4K/WHC)\<%X6]51,@!YH4D, @&Z<#4[8,7
M"NTSJ#HGAGQ@:?:!4F^'0FA!+K!TKR>@PGN6)1:XKM#LAY^%=S""D!,LS4YH
M*_ @%*0%2[,6^E(\B 49PM)L"+@FVRHFI Y+LSJ&:O*,"$R+\U!"WK T>^-'
M41ZA&>5XOV=D+U'R9U(5$W*'=2EWC)#;;OQ0\30<2\@CEF:/*)!KPC)Y,]X3
MM'U"7L-%7:K;%I!';-WK"FCY<U:K;4@IMF:EO&SE7T>F#2G%UJR4%S%'*#J*
M,TQPLTJS7@!,E_-&Q82$8VL6#H"Y;EBF8D("LC4+Z&PJ-E"&;$@[MF;MP',Q
MU8XV9!Y;LWE@3$?%A,QC:S8/C'FE8D+NL36[1YW9#@Q(!Q*.HUDX_=1VB KR
MBZ/9+QW5",T;T3""5NW'JZ9$:_S4_A]7=P$=R"^.9K^<IN!#X8.$XF@6RC/7
M""T)Y@3YWV1?\GCB5#'![Q^76<&,D(?Y <V+^A$%5=^3O/7L+4-"<2ZRYR4Q
MDT;^<!M0E?*-B@FIQ=&LEA^8OV1-/P;6*B:D%D>S6F02HP?>3L*[?Z\RTBYN
MLJ+F$EJ%A,3B:!9+4'&:$X92AG-:[9'+&*[VI*L^*B-D%:>SROCT43LG.UJ1
M/)3]<]F>X2);,]0>^IUYYZK=9]LU1>')MJA:UC@_?2,_?=__]#]02P,$%
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M;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ LH !5S?&S(WM    *P(  !$
M             ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @
MLH !5YE<G",0!@  G"<  !,              ( !RP$  'AL+W1H96UE+W1H
M96UE,2YX;6Q02P$"% ,4    " "R@ %7RR"4D? %   ('P  &
M    @($,"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @
MLH !5T</<AU0!@  !AP  !@              ("!,@X  'AL+W=O<FMS:&5E
M=',O<VAE970R+GAM;%!+ 0(4 Q0    ( +*  5<SHB"_Q@4  +8;   8
M          " @;@4  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M    " "R@ %7'V^5L2\#  !@"P  &               @(&T&@  >&PO=V]R
M:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ LH !5]6YG-VY"@  CV,
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M965T.2YX;6Q02P$"% ,4    " "R@ %7X V@<((=  !3=   &0
M    @(%"1@  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    (
M +*  5?3&V3.PP@  +4:   9              " @?MC  !X;"]W;W)K<VAE
M971S+W-H965T,3$N>&UL4$L! A0#%     @ LH !5\I4 8=3 P  \P<  !D
M             ("!]6P  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"
M% ,4    " "R@ %7<"@5;8L&  #\%   &0              @(%_<   >&PO
M=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( +*  5>=>MMN@0,
M ,L*   9              " @4%W  !X;"]W;W)K<VAE971S+W-H965T,30N
M>&UL4$L! A0#%     @ LH !5_BM2>S,!@  RA$  !D              ("!
M^7H  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " "R@ %7
MTR9R0J8%   #$0  &0              @('\@0  >&PO=V]R:W-H965T<R]S
M:&5E=#$V+GAM;%!+ 0(4 Q0    ( +*  5>)O;'CH 8  *T0   9
M      " @=F'  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%
M  @ LH !5PVG!+Y[ @  T@8  !D              ("!L(X  'AL+W=O<FMS
M:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " "R@ %70/B7@,4%  #%%0
M&0              @(%BD0  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+
M 0(4 Q0    ( +*  5=5IRN;[ ,  (H+   9              " @5Z7  !X
M;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ LH !5X!PI\BF
M @  :@8  !D              ("!@9L  'AL+W=O<FMS:&5E=',O<VAE970R
M,2YX;6Q02P$"% ,4    " "R@ %70[-!Y0<%   H$@  &0
M@(%>G@  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( +*
M 5>]70B^F0,  /0*   9              " @9RC  !X;"]W;W)K<VAE971S
M+W-H965T,C,N>&UL4$L! A0#%     @ LH !5XJ;YL.( @  T@4  !D
M         ("!;*<  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4
M    " "R@ %7V0BM/? #   Y#@  &0              @($KJ@  >&PO=V]R
M:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( +*  5>1O^4S<0(  (D%
M   9              " @5*N  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL
M4$L! A0#%     @ LH !5WW2V0AE P  4Q   !D              ("!^K
M 'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " "R@ %7 JUY
MLI@%  #-*0  &0              @(&6M   >&PO=V]R:W-H965T<R]S:&5E
M=#(X+GAM;%!+ 0(4 Q0    ( +.  5>KO6/1SP4  %\C   9
M  " @66Z  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @
MLX !5]RG9-;A P  !Q8  !D              ("!:\   'AL+W=O<FMS:&5E
M=',O<VAE970S,"YX;6Q02P$"% ,4    " "S@ %7"S3'!"\D  "5P0( &0
M            @(&#Q   >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4
M Q0    ( +.  5?F\"B3K ,  -X1   9              " @>GH  !X;"]W
M;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ LX !5Q@'"H2$!
M+A(  !D              ("!S.P  'AL+W=O<FMS:&5E=',O<VAE970S,RYX
M;6Q02P$"% ,4    " "S@ %7IB.(I'($   Y$P  &0              @(&'
M\0  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( +.  5?C
M5^CDF00  #$6   9              " @3#V  !X;"]W;W)K<VAE971S+W-H
M965T,S4N>&UL4$L! A0#%     @ LX !5_15B$2< @  5 <  !D
M     ("! /L  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( +.  5<JVR5>N @   9M   9              "
M@4,1 0!X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ LX !
M5W\/S6]' @  >P4  !D              ("!,AH! 'AL+W=O<FMS:&5E=',O
M<VAE970T,BYX;6Q02P$"% ,4    " "S@ %7]W 6)0X#  !>"@  &0
M        @(&P' $ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0
M   ( +.  5=FOFJCY0(  *()   9              " @?4? 0!X;"]W;W)K
M<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ LX !5_VO;J"J @  Y0<
M !D              ("!$2,! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q0
M2P$"% ,4    " "S@ %7&"P*G@(#  !\"P  &0              @('R)0$
M>&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( +.  5<KZTL:
M3@(  '@%   9              " @2LI 0!X;"]W;W)K<VAE971S+W-H965T
M-#<N>&UL4$L! A0#%     @ LX !5T,P$3F% @  P@<  !D
M ("!L"L! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4    " "S
M@ %76(TFE40"  "*!@  &0              @(%L+@$ >&PO=V]R:W-H965T
M<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( +.  5>JDOU"*0,  $82   -
M          "  ><P 0!X;"]S='EL97,N>&UL4$L! A0#%     @ LX !5Y>*
MNQS     $P(   L              ( !.S0! %]R96QS+RYR96QS4$L! A0#
M%     @ LX !5VCK?#!M!   8R    \              ( !)#4! 'AL+W=O
M<FMB;V]K+GAM;%!+ 0(4 Q0    ( +.  5>.83CZO0$  'H=   :
M      "  ;XY 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0
M   ( +.  5><*],/O0$  '<=   3              "  ;,[ 0!;0V]N=&5N
B=%]4>7!E<UTN>&UL4$L%!@     Y #D A@\  *$] 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>282</ContextCount>
  <ElementCount>247</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>85</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="rigl-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - DOCUMENT AND ENTITY INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>DOCUMENT AND ENTITY INFORMATION</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="rigl-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - CONDENSED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/StatementCondensedBalanceSheets</Role>
      <ShortName>CONDENSED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="rigl-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00200 - Statement - CONDENSED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/StatementCondensedStatementsOfOperations</Role>
      <ShortName>CONDENSED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="rigl-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00300 - Statement - CONDENSED STATEMENTS OF COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/StatementCondensedStatementsOfComprehensiveLoss</Role>
      <ShortName>CONDENSED STATEMENTS OF COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="rigl-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00400 - Statement - CONDENSED STATEMENTS OF STOCKHOLDERS' (DEFICIT) EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/StatementCondensedStatementsOfStockholdersDeficitEquity</Role>
      <ShortName>CONDENSED STATEMENTS OF STOCKHOLDERS' (DEFICIT) EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="rigl-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00500 - Statement - CONDENSED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows</Role>
      <ShortName>CONDENSED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="rigl-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>10101 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="rigl-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10201 - Disclosure - NET LOSS PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureNetLossPerShare</Role>
      <ShortName>NET LOSS PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="rigl-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10301 - Disclosure - REVENUES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureRevenues</Role>
      <ShortName>REVENUES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="rigl-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10401 - Disclosure - SPONSORED RESEARCH AND LICENSE AGREEMENTS AND GOVERNMENT CONTRACT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContract</Role>
      <ShortName>SPONSORED RESEARCH AND LICENSE AGREEMENTS AND GOVERNMENT CONTRACT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="rigl-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10501 - Disclosure - STOCK-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureStockBasedCompensation</Role>
      <ShortName>STOCK-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="rigl-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10601 - Disclosure - INVENTORIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureInventories</Role>
      <ShortName>INVENTORIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="rigl-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10701 - Disclosure - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestments</Role>
      <ShortName>CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="rigl-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10801 - Disclosure - FAIR VALUE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureFairValue</Role>
      <ShortName>FAIR VALUE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="rigl-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10901 - Disclosure - DEBT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureDebt</Role>
      <ShortName>DEBT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="rigl-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>11001 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureLeases</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="rigl-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>20102 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="rigl-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>30203 - Disclosure - NET LOSS PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureNetLossPerShareTables</Role>
      <ShortName>NET LOSS PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.rigel.com/role/DisclosureNetLossPerShare</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="rigl-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>30303 - Disclosure - REVENUES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureRevenuesTables</Role>
      <ShortName>REVENUES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.rigel.com/role/DisclosureRevenues</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="rigl-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>30503 - Disclosure - STOCK-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureStockBasedCompensationTables</Role>
      <ShortName>STOCK-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.rigel.com/role/DisclosureStockBasedCompensation</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="rigl-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>30603 - Disclosure - INVENTORIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureInventoriesTables</Role>
      <ShortName>INVENTORIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.rigel.com/role/DisclosureInventories</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="rigl-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>30703 - Disclosure - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsTables</Role>
      <ShortName>CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestments</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="rigl-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>30803 - Disclosure - FAIR VALUE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureFairValueTables</Role>
      <ShortName>FAIR VALUE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.rigel.com/role/DisclosureFairValue</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="rigl-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>30903 - Disclosure - DEBT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureDebtTables</Role>
      <ShortName>DEBT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.rigel.com/role/DisclosureDebt</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="rigl-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>31003 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureLeasesTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.rigel.com/role/DisclosureLeases</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="rigl-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>40101 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Basis of Presentation and Liquidity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndLiquidityDetails</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Basis of Presentation and Liquidity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="rigl-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>40201 - Disclosure - NET LOSS PER SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureNetLossPerShareDetails</Role>
      <ShortName>NET LOSS PER SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.rigel.com/role/DisclosureNetLossPerShareTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="rigl-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>40301 - Disclosure - REVENUES - Disaggregated (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureRevenuesDisaggregatedDetails</Role>
      <ShortName>REVENUES - Disaggregated (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="rigl-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>40302 - Disclosure - REVENUES - Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureRevenuesActivityDetails</Role>
      <ShortName>REVENUES - Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="rigl-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>40303 - Disclosure - REVENUES - Percentage by Customer (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureRevenuesPercentageByCustomerDetails</Role>
      <ShortName>REVENUES - Percentage by Customer (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="rigl-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>40401 - Disclosure - SPONSORED RESEARCH AND LICENSE AGREEMENTS AND GOVERNMENT CONTRACT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails</Role>
      <ShortName>SPONSORED RESEARCH AND LICENSE AGREEMENTS AND GOVERNMENT CONTRACT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContract</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="rigl-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>40501 - Disclosure - STOCK-BASED COMPENSATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureStockBasedCompensationDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.rigel.com/role/DisclosureStockBasedCompensationTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="rigl-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>40502 - Disclosure - STOCK-BASED COMPENSATION - Options and RSUs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureStockBasedCompensationOptionsAndRsusDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Options and RSUs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="rigl-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>40503 - Disclosure - STOCK-BASED COMPENSATION - Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureStockBasedCompensationAssumptionsDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="rigl-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>40504 - Disclosure - STOCK-BASED COMPENSATION - Purchase Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureStockBasedCompensationPurchasePlanDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Purchase Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="rigl-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>40601 - Disclosure - INVENTORIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureInventoriesDetails</Role>
      <ShortName>INVENTORIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.rigel.com/role/DisclosureInventoriesTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="rigl-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>40701 - Disclosure - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails</Role>
      <ShortName>CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="rigl-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>40702 - Disclosure - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS - Gross Unrealized Gains and Losses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsGrossUnrealizedGainsAndLossesDetails</Role>
      <ShortName>CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS - Gross Unrealized Gains and Losses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="rigl-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>40703 - Disclosure - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS - Unrealized Loss Position (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsUnrealizedLossPositionDetails</Role>
      <ShortName>CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS - Unrealized Loss Position (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="rigl-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>40801 - Disclosure - FAIR VALUE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureFairValueDetails</Role>
      <ShortName>FAIR VALUE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.rigel.com/role/DisclosureFairValueTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="rigl-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>40901 - Disclosure - DEBT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureDebtDetails</Role>
      <ShortName>DEBT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.rigel.com/role/DisclosureDebtTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="rigl-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>40902 - Disclosure - DEBT - Future Minimum Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureDebtFutureMinimumPaymentsDetails</Role>
      <ShortName>DEBT - Future Minimum Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="rigl-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>41001 - Disclosure - LEASES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureLeasesDetails</Role>
      <ShortName>LEASES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.rigel.com/role/DisclosureLeasesTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="rigl-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>41002 - Disclosure - LEASES - Lease Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureLeasesLeaseExpenseDetails</Role>
      <ShortName>LEASES - Lease Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="rigl-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>41003 - Disclosure - LEASES - Cash Flow Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureLeasesCashFlowInformationDetails</Role>
      <ShortName>LEASES - Cash Flow Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="rigl-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>41004 - Disclosure - LEASES - Sublease Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureLeasesSubleaseInformationDetails</Role>
      <ShortName>LEASES - Sublease Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="rigl-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>41005 - Disclosure - LEASES - Future Minimum Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails</Role>
      <ShortName>LEASES - Future Minimum Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="rigl-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="rigl-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 27 fact(s) appearing in ix:hidden were eligible for transformation: dei:DocumentPeriodEndDate, dei:EntityFilerCategory, dei:EntityRegistrantName, dei:SecurityExchangeName, ecd:NonRule10b51ArrAdoptedFlag, ecd:NonRule10b51ArrTrmntdFlag, ecd:Rule10b51ArrAdoptedFlag, ecd:Rule10b51ArrTrmntdFlag, rigl:CollaborativeArrangementRevenueRecognized, rigl:PaymentsOfMilestonePaymentObligations, rigl:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardOfferingPeriod, us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions, us-gaap:EarningsPerShareDiluted, us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1, us-gaap:OperatingLeaseLiability, us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1, us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding -  rigl-20230630x10q.htm 9</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Not-Referenced] WARN: 2 fact(s) appearing in ix:hidden were not referenced by any -sec-ix-hidden style property: us-gaap:CommitmentsAndContingencies -  rigl-20230630x10q.htm 9</Log>
    <Log type="Warning">[dq-0712-Presentation-Base-Set-Order] Role '41005 - Disclosure - LEASES - Future Minimum Lease Payments (Details)', a level 4, Detail role, appears before '995410 - Disclosure - Pay vs Performance Disclosure', a level 1, Note role. https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd 30, rigl-20230630.xsd 69</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="rigl-20230630x10q.htm">rigl-20230630x10q.htm</File>
    <File>rigl-20230630.xsd</File>
    <File>rigl-20230630_cal.xml</File>
    <File>rigl-20230630_def.xml</File>
    <File>rigl-20230630_lab.xml</File>
    <File>rigl-20230630_pre.xml</File>
    <File>rigl-20230630xex10d1.htm</File>
    <File>rigl-20230630xex10d2.htm</File>
    <File>rigl-20230630xex10d3.htm</File>
    <File>rigl-20230630xex31d1.htm</File>
    <File>rigl-20230630xex31d2.htm</File>
    <File>rigl-20230630xex32d1.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>rigl-20230630x10q004.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2023</BaseTaxonomy>
    <BaseTaxonomy items="596">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>70
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "rigl-20230630x10q.htm": {
   "axisCustom": 1,
   "axisStandard": 26,
   "baseTaxonomies": {
    "http://fasb.org/srt/2023": 1,
    "http://fasb.org/us-gaap/2023": 596,
    "http://xbrl.sec.gov/dei/2023": 29,
    "http://xbrl.sec.gov/ecd/2023": 4
   },
   "contextCount": 282,
   "dts": {
    "calculationLink": {
     "local": [
      "rigl-20230630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "rigl-20230630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "rigl-20230630x10q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "rigl-20230630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "rigl-20230630_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "rigl-20230630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd"
     ]
    }
   },
   "elementCount": 530,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2023": 17,
    "http://www.rigel.com/20230630": 10,
    "http://xbrl.sec.gov/dei/2023": 8,
    "http://xbrl.sec.gov/ecd/2023": 4,
    "total": 39
   },
   "keyCustom": 35,
   "keyStandard": 212,
   "memberCustom": 49,
   "memberStandard": 30,
   "nsprefix": "rigl",
   "nsuri": "http://www.rigel.com/20230630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - DOCUMENT AND ENTITY INFORMATION",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.rigel.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "DOCUMENT AND ENTITY INFORMATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10401 - Disclosure - SPONSORED RESEARCH AND LICENSE AGREEMENTS AND GOVERNMENT CONTRACT",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContract",
     "shortName": "SPONSORED RESEARCH AND LICENSE AGREEMENTS AND GOVERNMENT CONTRACT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10501 - Disclosure - STOCK-BASED COMPENSATION",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.rigel.com/role/DisclosureStockBasedCompensation",
     "shortName": "STOCK-BASED COMPENSATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10601 - Disclosure - INVENTORIES",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.rigel.com/role/DisclosureInventories",
     "shortName": "INVENTORIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10701 - Disclosure - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestments",
     "shortName": "CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10801 - Disclosure - FAIR VALUE",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.rigel.com/role/DisclosureFairValue",
     "shortName": "FAIR VALUE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10901 - Disclosure - DEBT",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.rigel.com/role/DisclosureDebt",
     "shortName": "DEBT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "rigl:LeaseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11001 - Disclosure - LEASES",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.rigel.com/role/DisclosureLeases",
     "shortName": "LEASES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "rigl:LeaseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "20102 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "menuCat": "Policies",
     "order": "17",
     "role": "http://www.rigel.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30203 - Disclosure - NET LOSS PER SHARE (Tables)",
     "menuCat": "Tables",
     "order": "18",
     "role": "http://www.rigel.com/role/DisclosureNetLossPerShareTables",
     "shortName": "NET LOSS PER SHARE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30303 - Disclosure - REVENUES (Tables)",
     "menuCat": "Tables",
     "order": "19",
     "role": "http://www.rigel.com/role/DisclosureRevenuesTables",
     "shortName": "REVENUES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00100 - Statement - CONDENSED BALANCE SHEETS",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.rigel.com/role/StatementCondensedBalanceSheets",
     "shortName": "CONDENSED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30503 - Disclosure - STOCK-BASED COMPENSATION (Tables)",
     "menuCat": "Tables",
     "order": "20",
     "role": "http://www.rigel.com/role/DisclosureStockBasedCompensationTables",
     "shortName": "STOCK-BASED COMPENSATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30603 - Disclosure - INVENTORIES (Tables)",
     "menuCat": "Tables",
     "order": "21",
     "role": "http://www.rigel.com/role/DisclosureInventoriesTables",
     "shortName": "INVENTORIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30703 - Disclosure - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsTables",
     "shortName": "CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30803 - Disclosure - FAIR VALUE (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://www.rigel.com/role/DisclosureFairValueTables",
     "shortName": "FAIR VALUE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30903 - Disclosure - DEBT (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://www.rigel.com/role/DisclosureDebtTables",
     "shortName": "DEBT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "rigl:LeaseDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31003 - Disclosure - LEASES (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://www.rigel.com/role/DisclosureLeasesTables",
     "shortName": "LEASES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "rigl:LeaseDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40101 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Basis of Presentation and Liquidity (Details)",
     "menuCat": "Details",
     "order": "26",
     "role": "http://www.rigel.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndLiquidityDetails",
     "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Basis of Presentation and Liquidity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40201 - Disclosure - NET LOSS PER SHARE (Details)",
     "menuCat": "Details",
     "order": "27",
     "role": "http://www.rigel.com/role/DisclosureNetLossPerShareDetails",
     "shortName": "NET LOSS PER SHARE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40301 - Disclosure - REVENUES - Disaggregated (Details)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://www.rigel.com/role/DisclosureRevenuesDisaggregatedDetails",
     "shortName": "REVENUES - Disaggregated (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_GrossProductMember_ene2KCce8kCbyUMQexHEMg",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40302 - Disclosure - REVENUES - Activity (Details)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://www.rigel.com/role/DisclosureRevenuesActivityDetails",
     "shortName": "REVENUES - Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00200 - Statement - CONDENSED STATEMENTS OF OPERATIONS",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.rigel.com/role/StatementCondensedStatementsOfOperations",
     "shortName": "CONDENSED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "rigl:DisaggregationOfRevenueByCustomerTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "Duration_4_1_2023_To_6_30_2023_srt_MajorCustomersAxis_rigl_MckessonSpecialtyCareDistributionCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_NFFFR5Op6EGibKqyThuK6g",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_uVIKS5OYQEes3pxG5CV0tw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40303 - Disclosure - REVENUES - Percentage by Customer (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://www.rigel.com/role/DisclosureRevenuesPercentageByCustomerDetails",
     "shortName": "REVENUES - Percentage by Customer (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "rigl:DisaggregationOfRevenueByCustomerTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "Duration_4_1_2023_To_6_30_2023_srt_MajorCustomersAxis_rigl_MckessonSpecialtyCareDistributionCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_NFFFR5Op6EGibKqyThuK6g",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_uVIKS5OYQEes3pxG5CV0tw",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw",
      "decimals": "-8",
      "first": true,
      "lang": null,
      "name": "rigl:ContingentPaymentsUnderAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40401 - Disclosure - SPONSORED RESEARCH AND LICENSE AGREEMENTS AND GOVERNMENT CONTRACT (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails",
     "shortName": "SPONSORED RESEARCH AND LICENSE AGREEMENTS AND GOVERNMENT CONTRACT (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw",
      "decimals": "-8",
      "first": true,
      "lang": null,
      "name": "rigl:ContingentPaymentsUnderAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40501 - Disclosure - STOCK-BASED COMPENSATION (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://www.rigel.com/role/DisclosureStockBasedCompensationDetails",
     "shortName": "STOCK-BASED COMPENSATION (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "As_Of_6_30_2023_us-gaap_AwardTypeAxis_rigl_ShareBasedCompensationOptionsAndRsusMember_eHSX5niPTk2ia4BsC8uknQ",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40502 - Disclosure - STOCK-BASED COMPENSATION - Options and RSUs (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://www.rigel.com/role/DisclosureStockBasedCompensationOptionsAndRsusDetails",
     "shortName": "STOCK-BASED COMPENSATION - Options and RSUs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "As_Of_6_30_2023_us-gaap_AwardTypeAxis_rigl_ShareBasedCompensationOptionsAndRsusMember_eHSX5niPTk2ia4BsC8uknQ",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "Duration_4_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_DF-ET0UVsU-4JFbzSJC6wg",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_uVIKS5OYQEes3pxG5CV0tw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40503 - Disclosure - STOCK-BASED COMPENSATION - Assumptions (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.rigel.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
     "shortName": "STOCK-BASED COMPENSATION - Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "Duration_4_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_DF-ET0UVsU-4JFbzSJC6wg",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_uVIKS5OYQEes3pxG5CV0tw",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "Duration_5_1_2023_To_5_31_2023_Q3DEP_Nkn0q2GbxII4v6Iw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40504 - Disclosure - STOCK-BASED COMPENSATION - Purchase Plan (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.rigel.com/role/DisclosureStockBasedCompensationPurchasePlanDetails",
     "shortName": "STOCK-BASED COMPENSATION - Purchase Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "Duration_5_1_2023_To_5_31_2023_Q3DEP_Nkn0q2GbxII4v6Iw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_Xh88GcG7X0WC8aZpYUb8zA",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40601 - Disclosure - INVENTORIES (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.rigel.com/role/DisclosureInventoriesDetails",
     "shortName": "INVENTORIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40701 - Disclosure - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails",
     "shortName": "CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "As_Of_6_30_2023_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_LfRnUUxRrEycHqB8YoPOOQ",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40702 - Disclosure - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS - Gross Unrealized Gains and Losses (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsGrossUnrealizedGainsAndLossesDetails",
     "shortName": "CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS - Gross Unrealized Gains and Losses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "rigl:CashEquivalentsAndAvailableForSaleSecuritiesWeightedAverageMaturityPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40703 - Disclosure - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS - Unrealized Loss Position (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsUnrealizedLossPositionDetails",
     "shortName": "CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS - Unrealized Loss Position (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "rigl:CashEquivalentsAndAvailableForSaleSecuritiesWeightedAverageMaturityPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00300 - Statement - CONDENSED STATEMENTS OF COMPREHENSIVE LOSS",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.rigel.com/role/StatementCondensedStatementsOfComprehensiveLoss",
     "shortName": "CONDENSED STATEMENTS OF COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ComprehensiveIncomeNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InvestmentsFairValueDisclosure",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40801 - Disclosure - FAIR VALUE (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.rigel.com/role/DisclosureFairValueDetails",
     "shortName": "FAIR VALUE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "As_Of_6_30_2023_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_QW_rs_VEA0KU4-yd8SrPbw",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:InvestmentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40901 - Disclosure - DEBT (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.rigel.com/role/DisclosureDebtDetails",
     "shortName": "DEBT (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "As_Of_12_31_2022_eJ6FWzr7ckS4sgKxQNf_2A",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40902 - Disclosure - DEBT - Future Minimum Payments (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.rigel.com/role/DisclosureDebtFutureMinimumPaymentsDetails",
     "shortName": "DEBT - Future Minimum Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41001 - Disclosure - LEASES (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.rigel.com/role/DisclosureLeasesDetails",
     "shortName": "LEASES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "rigl:LeaseDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_rigl_HeadquartersOfficeSpaceSubleaseSouthSanFranciscoCaliforniaMember_RzRVSQYro0qfZzFsimZvQA",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "rigl:LeaseDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41002 - Disclosure - LEASES - Lease Expense (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.rigel.com/role/DisclosureLeasesLeaseExpenseDetails",
     "shortName": "LEASES - Lease Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "rigl:LeaseDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "rigl:CashFlowInformationRelatedToOperatingLeaseTableTextBlock",
       "rigl:LeaseDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41003 - Disclosure - LEASES - Cash Flow Information (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.rigel.com/role/DisclosureLeasesCashFlowInformationDetails",
     "shortName": "LEASES - Cash Flow Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "rigl:CashFlowInformationRelatedToOperatingLeaseTableTextBlock",
       "rigl:LeaseDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "Duration_4_1_2022_To_6_30_2022_ICCkO9pPUUSORAn1kecZBA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "rigl:FixedSubleaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41004 - Disclosure - LEASES - Sublease Information (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.rigel.com/role/DisclosureLeasesSubleaseInformationDetails",
     "shortName": "LEASES - Sublease Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "Duration_4_1_2022_To_6_30_2022_ICCkO9pPUUSORAn1kecZBA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "rigl:FixedSubleaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41005 - Disclosure - LEASES - Future Minimum Lease Payments (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.rigel.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails",
     "shortName": "LEASES - Future Minimum Lease Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "As_Of_6_30_2023_5M5Z00y1gka_8oKxuvPxww",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "Duration_4_1_2023_To_6_30_2023_BXRDYbKXDkuJ4GqgG5jcsQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "menuCat": "Uncategorized",
     "order": "48",
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "shortName": "Pay vs Performance Disclosure",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R49": {
     "firstAnchor": null,
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "menuCat": "Cover",
     "order": "49",
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "shortName": "Insider Trading Arrangements",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Mal6s5t5Z0qQ9EIsFrTGuQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00400 - Statement - CONDENSED STATEMENTS OF STOCKHOLDERS' (DEFICIT) EQUITY",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.rigel.com/role/StatementCondensedStatementsOfStockholdersDeficitEquity",
     "shortName": "CONDENSED STATEMENTS OF STOCKHOLDERS' (DEFICIT) EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_egDPK9MhIkOXkH42vVRrWw",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00500 - Statement - CONDENSED STATEMENTS OF CASH FLOWS",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows",
     "shortName": "CONDENSED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_UQB-p0I0Nk6yp9HRQS7TgA",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10101 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://www.rigel.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies",
     "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10201 - Disclosure - NET LOSS PER SHARE",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.rigel.com/role/DisclosureNetLossPerShare",
     "shortName": "NET LOSS PER SHARE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10301 - Disclosure - REVENUES",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.rigel.com/role/DisclosureRevenues",
     "shortName": "REVENUES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rigl-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_iDUSAUyEjkOMF_iEqHhlxw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 85,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.rigel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.rigel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "DOCUMENT AND ENTITY INFORMATION"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.rigel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.rigel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.rigel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.rigel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.rigel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r645"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.rigel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.rigel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.rigel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.rigel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.rigel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.rigel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.rigel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.rigel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.rigel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.rigel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.rigel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.rigel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.rigel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r684"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.rigel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.rigel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.rigel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.rigel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.rigel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.rigel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.rigel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.rigel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.rigel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "auth_ref": [
      "r646"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "localname": "Additional402vDisclosureTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_AdjToCompAmt": {
     "auth_ref": [
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "localname": "AdjToCompAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_AdjToCompAxis": {
     "auth_ref": [
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "localname": "AdjToCompAxis",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "auth_ref": [
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "auth_ref": [
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "localname": "AdjToPeoCompFnTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_AggtErrCompAmt": {
     "auth_ref": [
      "r617",
      "r628",
      "r638",
      "r663"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "localname": "AggtErrCompAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "auth_ref": [
      "r620",
      "r631",
      "r641",
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_AllAdjToCompMember": {
     "auth_ref": [
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "localname": "AllAdjToCompMember",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "domainItemType"
    },
    "ecd_AllExecutiveCategoriesMember": {
     "auth_ref": [
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "localname": "AllExecutiveCategoriesMember",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "domainItemType"
    },
    "ecd_AllIndividualsMember": {
     "auth_ref": [
      "r624",
      "r632",
      "r642",
      "r659",
      "r667",
      "r671",
      "r679"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "localname": "AllIndividualsMember",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "domainItemType"
    },
    "ecd_AllTradingArrangementsMember": {
     "auth_ref": [
      "r677"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "localname": "AllTradingArrangementsMember",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "xbrltype": "domainItemType"
    },
    "ecd_AwardExrcPrice": {
     "auth_ref": [
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "localname": "AwardExrcPrice",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "xbrltype": "perShareItemType"
    },
    "ecd_AwardGrantDateFairValue": {
     "auth_ref": [
      "r675"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "localname": "AwardGrantDateFairValue",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_AwardTmgDiscLineItems": {
     "auth_ref": [
      "r670"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "localname": "AwardTmgDiscLineItems",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "xbrltype": "stringItemType"
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "auth_ref": [
      "r670"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_AwardTmgMethodTextBlock": {
     "auth_ref": [
      "r670"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "localname": "AwardTmgMethodTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "auth_ref": [
      "r670"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "xbrltype": "booleanItemType"
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "auth_ref": [
      "r670"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "localname": "AwardTmgMnpiDiscTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "auth_ref": [
      "r670"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "localname": "AwardTmgPredtrmndFlag",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "xbrltype": "booleanItemType"
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "auth_ref": [
      "r673"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "localname": "AwardUndrlygSecuritiesAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "xbrltype": "decimalItemType"
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "auth_ref": [
      "r672"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "localname": "AwardsCloseToMnpiDiscIndName",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "auth_ref": [
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "localname": "AwardsCloseToMnpiDiscTable",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "auth_ref": [
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "auth_ref": [
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "localname": "ChangedPeerGroupFnTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_CoSelectedMeasureAmt": {
     "auth_ref": [
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "localname": "CoSelectedMeasureAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "decimalItemType"
    },
    "ecd_CoSelectedMeasureName": {
     "auth_ref": [
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "localname": "CoSelectedMeasureName",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "auth_ref": [
      "r656"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "auth_ref": [
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "auth_ref": [
      "r657"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "auth_ref": [
      "r654"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "auth_ref": [
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "auth_ref": [
      "r617",
      "r628",
      "r638",
      "r663"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "localname": "ErrCompAnalysisTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_ErrCompRecoveryTable": {
     "auth_ref": [
      "r614",
      "r625",
      "r635",
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "localname": "ErrCompRecoveryTable",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_ExecutiveCategoryAxis": {
     "auth_ref": [
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "localname": "ExecutiveCategoryAxis",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "auth_ref": [
      "r621",
      "r632",
      "r642",
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "auth_ref": [
      "r621",
      "r632",
      "r642",
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "auth_ref": [
      "r621",
      "r632",
      "r642",
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "auth_ref": [
      "r621",
      "r632",
      "r642",
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_ForgoneRecoveryIndName": {
     "auth_ref": [
      "r621",
      "r632",
      "r642",
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "localname": "ForgoneRecoveryIndName",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_IndividualAxis": {
     "auth_ref": [
      "r624",
      "r632",
      "r642",
      "r659",
      "r667",
      "r671",
      "r679"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "localname": "IndividualAxis",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_InsiderTradingArrLineItems": {
     "auth_ref": [
      "r677"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "localname": "InsiderTradingArrLineItems",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "xbrltype": "stringItemType"
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "auth_ref": [
      "r613",
      "r683"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "localname": "InsiderTradingPoliciesProcLineItems",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "xbrltype": "stringItemType"
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "auth_ref": [
      "r613",
      "r683"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "xbrltype": "booleanItemType"
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "auth_ref": [
      "r613",
      "r683"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_MeasureAxis": {
     "auth_ref": [
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "localname": "MeasureAxis",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_MeasureName": {
     "auth_ref": [
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "localname": "MeasureName",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "auth_ref": [
      "r670"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "localname": "MnpiDiscTimedForCompValFlag",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "xbrltype": "booleanItemType"
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "auth_ref": [
      "r678"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "auth_ref": [
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "auth_ref": [
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_NonNeosMember": {
     "auth_ref": [
      "r621",
      "r632",
      "r642",
      "r659",
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "localname": "NonNeosMember",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "domainItemType"
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "auth_ref": [
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "auth_ref": [
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_NonPeoNeoMember": {
     "auth_ref": [
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "localname": "NonPeoNeoMember",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "domainItemType"
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "auth_ref": [
      "r678"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "localname": "NonRule10b51ArrAdoptedFlag",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "xbrltype": "booleanItemType"
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "auth_ref": [
      "r678"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "localname": "NonRule10b51ArrTrmntdFlag",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "xbrltype": "booleanItemType"
    },
    "ecd_OtherPerfMeasureAmt": {
     "auth_ref": [
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "localname": "OtherPerfMeasureAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "decimalItemType"
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "auth_ref": [
      "r619",
      "r630",
      "r640",
      "r665"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "localname": "OutstandingAggtErrCompAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "auth_ref": [
      "r622",
      "r633",
      "r643",
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "localname": "OutstandingRecoveryCompAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_OutstandingRecoveryIndName": {
     "auth_ref": [
      "r622",
      "r633",
      "r643",
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "localname": "OutstandingRecoveryIndName",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "auth_ref": [
      "r647"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "localname": "PayVsPerformanceDisclosureLineItems",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "xbrltype": "stringItemType"
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "auth_ref": [
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "localname": "PeerGroupIssuersFnTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "auth_ref": [
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "auth_ref": [
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "localname": "PeoActuallyPaidCompAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_PeoMember": {
     "auth_ref": [
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "localname": "PeoMember",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "domainItemType"
    },
    "ecd_PeoName": {
     "auth_ref": [
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "localname": "PeoName",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "ecd_PeoTotalCompAmt": {
     "auth_ref": [
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "localname": "PeoTotalCompAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_PvpTable": {
     "auth_ref": [
      "r647"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "localname": "PvpTable",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_PvpTableTextBlock": {
     "auth_ref": [
      "r647"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "localname": "PvpTableTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "auth_ref": [
      "r614",
      "r625",
      "r635",
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "xbrltype": "stringItemType"
    },
    "ecd_RestatementDateAxis": {
     "auth_ref": [
      "r615",
      "r626",
      "r636",
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "localname": "RestatementDateAxis",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_RestatementDeterminationDate": {
     "auth_ref": [
      "r616",
      "r627",
      "r637",
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "localname": "RestatementDeterminationDate",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "dateItemType"
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "auth_ref": [
      "r623",
      "r634",
      "r644",
      "r669"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "auth_ref": [
      "r678"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "localname": "Rule10b51ArrAdoptedFlag",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "xbrltype": "booleanItemType"
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "auth_ref": [
      "r678"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "localname": "Rule10b51ArrTrmntdFlag",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "xbrltype": "booleanItemType"
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "auth_ref": [
      "r618",
      "r629",
      "r639",
      "r664"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_TabularListTableTextBlock": {
     "auth_ref": [
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "localname": "TabularListTableTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_TotalShareholderRtnAmt": {
     "auth_ref": [
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "localname": "TotalShareholderRtnAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "auth_ref": [
      "r657"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_TradingArrAxis": {
     "auth_ref": [
      "r677"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "localname": "TradingArrAxis",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_TradingArrByIndTable": {
     "auth_ref": [
      "r679"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "localname": "TradingArrByIndTable",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_TrdArrAdoptionDate": {
     "auth_ref": [
      "r680"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "localname": "TrdArrAdoptionDate",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_TrdArrDuration": {
     "auth_ref": [
      "r681"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "localname": "TrdArrDuration",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "xbrltype": "durationItemType"
    },
    "ecd_TrdArrIndName": {
     "auth_ref": [
      "r679"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "localname": "TrdArrIndName",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_TrdArrIndTitle": {
     "auth_ref": [
      "r679"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "localname": "TrdArrIndTitle",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "auth_ref": [
      "r682"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "xbrltype": "sharesItemType"
    },
    "ecd_TrdArrTerminationDate": {
     "auth_ref": [
      "r680"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "localname": "TrdArrTerminationDate",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "auth_ref": [
      "r676"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "localname": "UndrlygSecurityMktPriceChngPct",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "xbrltype": "pureItemType"
    },
    "rigl_AccountsReceivableAndPrepaidAndOtherCurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing accounts receivable and prepaid and other current assets.",
        "label": "Accounts receivable and prepaid and other current assets"
       }
      }
     },
     "localname": "AccountsReceivableAndPrepaidAndOtherCurrentAssetsMember",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rigl_AccruedResearchAndDevelopmentLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the carrying value as of the balance sheet date of research and development costs that are incurred but not billed to the entity as of the end of the period. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Research and Development Liability Current",
        "terseLabel": "Accrued research and development"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentLiabilityCurrent",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), including portion attributable to noncontrolling interest.",
        "label": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsGrossUnrealizedGainsAndLossesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rigl_AchievementOfCertainNearTermRegulatoryMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents achievement of a certain near-term regulatory milestone.",
        "label": "Achievement of certain near-term regulatory milestone."
       }
      }
     },
     "localname": "AchievementOfCertainNearTermRegulatoryMilestoneMember",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rigl_AchievementOfMilestoneAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by categories of milestones achieved.",
        "label": "Achievement of Milestone [Axis]"
       }
      }
     },
     "localname": "AchievementOfMilestoneAxis",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "rigl_AchievementOfMilestoneDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different categories of achievement of milestones.",
        "label": "Achievement Of Milestone [Domain]"
       }
      }
     },
     "localname": "AchievementOfMilestoneDomain",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rigl_AsdHealthcareAndOncologySupplyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents ASD Healthcare and Oncology Supply.",
        "label": "ASD Healthcare and Oncology Supply"
       }
      }
     },
     "localname": "AsdHealthcareAndOncologySupplyMember",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesPercentageByCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rigl_CardinalHealthcareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Cardinal Healthcare.",
        "label": "Cardinal Healthcare"
       }
      }
     },
     "localname": "CardinalHealthcareMember",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesPercentageByCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rigl_CashAndCashEquivalentsAndAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Cash and Cash Equivalents and Available For Sale Securities [Line Items]",
        "terseLabel": "Cash, cash equivalents and short-term investments"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAndAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsGrossUnrealizedGainsAndLossesDetails",
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsUnrealizedLossPositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "rigl_CashEquivalentsAndAvailableForSaleSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Equivalents and Available For Sale Securities [Abstract]",
        "terseLabel": "Cash equivalents and available-for-sale securities"
       }
      }
     },
     "localname": "CashEquivalentsAndAvailableForSaleSecuritiesAbstract",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsGrossUnrealizedGainsAndLossesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "rigl_CashEquivalentsAndAvailableForSaleSecuritiesWeightedAverageMaturityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the weighted-average period of maturity of cash equivalents and available-for-sale debt securities.",
        "label": "Cash Equivalents and Available For Sale Securities, Weighted Average Maturity Period",
        "terseLabel": "Weighted-average time to maturity of cash equivalents and available-for-sale securities"
       }
      }
     },
     "localname": "CashEquivalentsAndAvailableForSaleSecuritiesWeightedAverageMaturityPeriod",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsUnrealizedLossPositionDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "rigl_CashFlowInformationRelatedToOperatingLeaseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of supplemental cash flow information related to operating lease.",
        "label": "Cash Flow Information Related To Operating Lease [Table Text Block]",
        "terseLabel": "Schedule of supplemental information related to operating lease"
       }
      }
     },
     "localname": "CashFlowInformationRelatedToOperatingLeaseTableTextBlock",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "rigl_CentralNervousSystemPenetrantIntellectualPropertyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents central nervous system penetrant intellectual property.",
        "label": "CNS penetrant IP"
       }
      }
     },
     "localname": "CentralNervousSystemPenetrantIntellectualPropertyMember",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rigl_ChargebacksDiscountsAndFeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents chargebacks, discounts and fees.",
        "label": "Chargebacks, Discounts and Fees"
       }
      }
     },
     "localname": "ChargebacksDiscountsAndFeesMember",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rigl_CollaborativeArrangementPotentialPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount of contingent payments under collaborative arrangement.",
        "label": "Collaborative Arrangement Potential Payments",
        "terseLabel": "Potential payments"
       }
      }
     },
     "localname": "CollaborativeArrangementPotentialPayments",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rigl_CollaborativeArrangementRevenueRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the revenue recognized during the period under the terms of sponsored research and license agreements.",
        "label": "Collaborative Arrangement Revenue Recognized",
        "terseLabel": "Revenue recognized"
       }
      }
     },
     "localname": "CollaborativeArrangementRevenueRecognized",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rigl_CollaborativeArrangementUpfrontFeeReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of upfront fees received during the period under the terms of collaborative and licensing agreement.",
        "label": "Collaborative Arrangement Upfront Fee Received",
        "terseLabel": "Upfront payment received"
       }
      }
     },
     "localname": "CollaborativeArrangementUpfrontFeeReceived",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rigl_CollaborativeArrangementUpfrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of collaborative arrangement upfront payment.",
        "label": "Collaborative Arrangement Upfront Payment",
        "terseLabel": "Upfront fee"
       }
      }
     },
     "localname": "CollaborativeArrangementUpfrontPayment",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rigl_CommercialAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents commercial and license agreements.",
        "label": "Commercial and license agreements"
       }
      }
     },
     "localname": "CommercialAndLicenseAgreementMember",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rigl_ContingentPaymentsUnderAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents additional contingent payments by entities.",
        "label": "Contingent Payments Under Agreement",
        "terseLabel": "Contingent payments"
       }
      }
     },
     "localname": "ContingentPaymentsUnderAgreement",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rigl_ContractRevenuesFromCollaborationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents contract revenues from collaborations.",
        "label": "Contract revenues from collaborations"
       }
      }
     },
     "localname": "ContractRevenuesFromCollaborationsMember",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesDisaggregatedDetails",
      "http://www.rigel.com/role/StatementCondensedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "rigl_CorporateBondSecuritiesAndCommercialPaperMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount) and unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Corporate bonds and commercial paper"
       }
      }
     },
     "localname": "CorporateBondSecuritiesAndCommercialPaperMember",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails",
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsGrossUnrealizedGainsAndLossesDetails",
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsUnrealizedLossPositionDetails",
      "http://www.rigel.com/role/DisclosureFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rigl_CorporateCollaborationsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate Collaborations",
        "label": "SPONSORED RESEARCH AND LICENSE AGREEMENTS AND GOVERNMENT CONTRACT"
       }
      }
     },
     "localname": "CorporateCollaborationsDisclosureAbstract",
     "nsuri": "http://www.rigel.com/20230630",
     "xbrltype": "stringItemType"
    },
    "rigl_CreditAgreementTrancheFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche five representing borrowing capacity under terms of the credit agreement.",
        "label": "Tranche 5"
       }
      }
     },
     "localname": "CreditAgreementTrancheFiveMember",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rigl_CreditAgreementTrancheFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche four representing borrowing capacity under terms of the credit agreement.",
        "label": "Tranche 4"
       }
      }
     },
     "localname": "CreditAgreementTrancheFourMember",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rigl_CreditAgreementTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche one representing borrowing capacity under terms of the credit agreement.",
        "label": "Tranche 1"
       }
      }
     },
     "localname": "CreditAgreementTrancheOneMember",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rigl_CreditAgreementTrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche three representing borrowing capacity under terms of the credit agreement.",
        "label": "Tranche 3"
       }
      }
     },
     "localname": "CreditAgreementTrancheThreeMember",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rigl_CreditAgreementTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche two representing borrowing capacity under terms of the credit agreement.",
        "label": "Tranche 2"
       }
      }
     },
     "localname": "CreditAgreementTrancheTwoMember",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rigl_CreditableAdvanceRoyaltyPaymentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents creditable advance royalty payment.",
        "label": "Creditable advance royalty payment"
       }
      }
     },
     "localname": "CreditableAdvanceRoyaltyPaymentMember",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rigl_DevelopmentAndRegulatoryMilestonesByCentralNervousSystemDiseaseProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents development and regulatory milestones by central nervous system disease products.",
        "label": "Development and regulatory milestones by CNS disease products"
       }
      }
     },
     "localname": "DevelopmentAndRegulatoryMilestonesByCentralNervousSystemDiseaseProductsMember",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rigl_DevelopmentAndRegulatoryMilestonesByNonCentralNervousSystemDiseaseProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents development and regulatory milestones by non-central nervous system disease products.",
        "label": "Development and regulatory milestones by non-CNS disease products"
       }
      }
     },
     "localname": "DevelopmentAndRegulatoryMilestonesByNonCentralNervousSystemDiseaseProductsMember",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rigl_DevelopmentAndRegulatoryMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents development and regulatory milestones.",
        "label": "Development and regulatory milestones"
       }
      }
     },
     "localname": "DevelopmentAndRegulatoryMilestonesMember",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rigl_DevelopmentCostsCostSharingArrangementPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of development costs in cost sharing arrangement.",
        "label": "Development Costs Cost Sharing Arrangement Percentage",
        "terseLabel": "Company's percentage of development costs"
       }
      }
     },
     "localname": "DevelopmentCostsCostSharingArrangementPercentage",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "rigl_DevelopmentMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents development milestones.",
        "label": "Development milestones"
       }
      }
     },
     "localname": "DevelopmentMilestonesMember",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesDisaggregatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rigl_DisaggregationOfRevenueByCustomerTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue by customer.",
        "label": "Disaggregation Of Revenue By Customer [Table Text Block]",
        "terseLabel": "Schedule of revenues from product sales disaggregated by customers"
       }
      }
     },
     "localname": "DisaggregationOfRevenueByCustomerTableTextBlock",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "rigl_DiscountsAndAllowancesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents discounts and allowances.",
        "label": "Discounts and allowances"
       }
      }
     },
     "localname": "DiscountsAndAllowancesMember",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesDisaggregatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rigl_DueToCollaborationPartner": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due to collaboration partner.",
        "label": "Due To Collaboration Partner",
        "terseLabel": "Development costs due to collaboration partner"
       }
      }
     },
     "localname": "DueToCollaborationPartner",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rigl_EuropeanMedicinesAgencyApprovalOfFostamatinibForTreatmentOfChronicImmuneThrombocytopenicPurpuraMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents European Medicines Agency approval of fostamatinib for treatment of chronic immune thrombocytopenic purpura.",
        "label": "Upon EMA approval of fostamatinib for treatment of chronic ITP"
       }
      }
     },
     "localname": "EuropeanMedicinesAgencyApprovalOfFostamatinibForTreatmentOfChronicImmuneThrombocytopenicPurpuraMember",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rigl_FdaApprovalAndFirstCommercialSaleOfProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents FDA approval and first commercial sale of the product.",
        "label": "FDA approval and first commercial sale of product"
       }
      }
     },
     "localname": "FdaApprovalAndFirstCommercialSaleOfProductMember",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rigl_FinancingLiabilityIncludingInterestExpenseAccretion": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of financing liability including interest expense accretion.",
        "label": "Financing Liability Including Interest Expense Accretion",
        "terseLabel": "Financing liability with accreted interest expense"
       }
      }
     },
     "localname": "FinancingLiabilityIncludingInterestExpenseAccretion",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rigl_FinancingLiabilityInterestAccretionDiscountRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate applied to the undiscounted amount of financing liability.",
        "label": "Financing Liability Interest Accretion Discount Rate",
        "terseLabel": "Financing liability interest accretion discount rate"
       }
      }
     },
     "localname": "FinancingLiabilityInterestAccretionDiscountRate",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "rigl_FixedSubleaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.rigel.com/role/DisclosureLeasesSubleaseInformationDetails": {
       "order": 1.0,
       "parentTag": "rigl_NetSubleaseIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of fixed sublease expense.",
        "label": "Fixed Sublease Expense",
        "terseLabel": "Fixed sublease expense"
       }
      }
     },
     "localname": "FixedSubleaseExpense",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureLeasesSubleaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rigl_FollowingThirdAmendmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time following third amendment of credit agreement.",
        "label": "Following Third Amendment"
       }
      }
     },
     "localname": "FollowingThirdAmendmentMember",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rigl_FormaTherapeuticsHoldingsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Forma Therapeutics Holdings, Inc.",
        "label": "Forma"
       }
      }
     },
     "localname": "FormaTherapeuticsHoldingsIncMember",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rigl_FostamatinibMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents fostamatinib.",
        "label": "fostamatinib"
       }
      }
     },
     "localname": "FostamatinibMember",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rigl_GovernmentAndOtherRebatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents government and other rebates.",
        "label": "Government and Other Rebates"
       }
      }
     },
     "localname": "GovernmentAndOtherRebatesMember",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rigl_GovernmentAward": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of award from the government.",
        "label": "Government Award",
        "terseLabel": "Government contract"
       }
      }
     },
     "localname": "GovernmentAward",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rigl_GovernmentAwardExpectedToBeReceivedInSucceedingPeriods": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The remaining amount of government award expected to be received in the succeeding periods.",
        "label": "Government Award Expected To Be Received In Succeeding Periods",
        "terseLabel": "Remaining amount of government award expected to be received in succeeding periods"
       }
      }
     },
     "localname": "GovernmentAwardExpectedToBeReceivedInSucceedingPeriods",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rigl_GrifolsS.a.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Grifols, S.A.",
        "label": "Grifols"
       }
      }
     },
     "localname": "GrifolsS.a.Member",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rigl_GrossProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents gross product.",
        "label": "Gross product sales"
       }
      }
     },
     "localname": "GrossProductMember",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesDisaggregatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rigl_HeadquartersOfficeSpaceSubleaseSouthSanFranciscoCaliforniaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Headquarters office space sublease in South San Francisco, California.",
        "label": "Headquarters office space sublease, South San Francisco, California"
       }
      }
     },
     "localname": "HeadquartersOfficeSpaceSubleaseSouthSanFranciscoCaliforniaMember",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rigl_IncreaseDecreaseInAccruedResearchAndDevelopmentLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the increase (decrease) during the reporting period in the aggregate amount of research and development expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Research and Development Liability",
        "terseLabel": "Accrued research and development"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedResearchAndDevelopmentLiability",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rigl_IncreaseDecreaseRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase or decrease in right-of-use assets.",
        "label": "Increase Decrease Right Of Use Assets",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "IncreaseDecreaseRightOfUseAssets",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rigl_KisseiPharmaceuticalCo.Ltd.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Kissei Pharmaceutical Co., Ltd.",
        "label": "Kissei"
       }
      }
     },
     "localname": "KisseiPharmaceuticalCo.Ltd.Member",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesPercentageByCustomerDetails",
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rigl_KnightTherapeuticsInternationalSaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Knight Therapeutics International SA.",
        "label": "Knight"
       }
      }
     },
     "localname": "KnightTherapeuticsInternationalSaMember",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rigl_LeaseDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of information about leases.",
        "label": "Lease Disclosure [Text Block]",
        "verboseLabel": "LEASES"
       }
      }
     },
     "localname": "LeaseDisclosureTextBlock",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureLeases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "rigl_LicensedRightsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents licensed rights.",
        "label": "Licensed Rights"
       }
      }
     },
     "localname": "LicensedRightsMember",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rigl_LiquidityAndCapitalResourcesPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for liquidity and capital resources.",
        "label": "Liquidity And Capital Resources Policy Policy Text Block",
        "terseLabel": "Liquidity"
       }
      }
     },
     "localname": "LiquidityAndCapitalResourcesPolicyPolicyTextBlock",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "rigl_LondonInterBankOfferedRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "LIBOR"
       }
      }
     },
     "localname": "LondonInterBankOfferedRateMember",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rigl_MckessonSpecialtyCareDistributionCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents McKesson Specialty Care Distribution Corporation.",
        "label": "McKesson Specialty Care Distribution Corporation"
       }
      }
     },
     "localname": "MckessonSpecialtyCareDistributionCorporationMember",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesPercentageByCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rigl_MedisonPharmaLtd.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Medison Pharma Ltd.",
        "label": "Medison"
       }
      }
     },
     "localname": "MedisonPharmaLtd.Member",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rigl_MilestonePaymentsOnProductByProductBasisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents milestone payments made on a product-by-product basis.",
        "label": "Milestone payments on a product-by-product basis"
       }
      }
     },
     "localname": "MilestonePaymentsOnProductByProductBasisMember",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rigl_NetSubleaseIncomeExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.rigel.com/role/DisclosureLeasesSubleaseInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net sublease income (expense).",
        "label": "Net Sublease Income Expense",
        "totalLabel": "Net"
       }
      }
     },
     "localname": "NetSubleaseIncomeExpense",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureLeasesSubleaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rigl_NonCentralNervousSystemPenetrantIntellectualPropertyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents non-central nervous system penetrant intellectual property.",
        "label": "Non-CNS penetrant IP"
       }
      }
     },
     "localname": "NonCentralNervousSystemPenetrantIntellectualPropertyMember",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rigl_NoncashInterestExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash interest expense during the period.",
        "label": "Noncash Interest Expense",
        "terseLabel": "Non-cash interest expense"
       }
      }
     },
     "localname": "NoncashInterestExpense",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rigl_NumberOfAgreements": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of agreements.",
        "label": "Number Of Agreements",
        "terseLabel": "Number of agreements"
       }
      }
     },
     "localname": "NumberOfAgreements",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents a one-time delivery of drug supply for commercialization.",
        "label": "Delivery of drug supply for commercialization"
       }
      }
     },
     "localname": "OneTimeDeliveryOfDrugSupplyForCommercializationMember",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rigl_PaymentOfCostShareToCollaborationPartner": {
     "auth_ref": [],
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment of cost share to collaboration partner.",
        "label": "Payment Of Cost Share To Collaboration Partner",
        "negatedLabel": "Cost share payments to a collaboration partner",
        "terseLabel": "Payment of cost share to collaboration partner"
       }
      }
     },
     "localname": "PaymentOfCostShareToCollaborationPartner",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails",
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rigl_PaymentsOfMilestonePaymentObligations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payments of milestone payment obligations.",
        "label": "Payments Of Milestone Payment Obligations",
        "terseLabel": "Payments of milestone payment obligations"
       }
      }
     },
     "localname": "PaymentsOfMilestonePaymentObligations",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rigl_PriorToThirdAmendmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time prior to third amendment of credit agreement.",
        "label": "Prior to Third Amendment"
       }
      }
     },
     "localname": "PriorToThirdAmendmentMember",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rigl_R552Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for the treatment of non-central nervous system (non-CNS) diseases.",
        "label": "R552"
       }
      }
     },
     "localname": "R552Member",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rigl_ResearchActivitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents research services.",
        "label": "Research Services"
       }
      }
     },
     "localname": "ResearchActivitiesMember",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rigl_RevenueReservesAndRefundLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the increase (decrease) during the reporting period in the aggregate amount of revenue reserves and refund liability.",
        "label": "Revenue Reserves And Refund Liability",
        "terseLabel": "Revenue reserves and refund liability"
       }
      }
     },
     "localname": "RevenueReservesAndRefundLiability",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rigl_RezlidhiaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents REZLIDHIA product.",
        "label": "REZLIDHIA"
       }
      }
     },
     "localname": "RezlidhiaMember",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rigl_RightToOptOutOfAgreementNumberOfPeriods": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of periods with right to opt out of agreement.",
        "label": "Right To Opt Out Of Agreement Number Of Periods",
        "terseLabel": "Right to opt out of agreement, different specified times"
       }
      }
     },
     "localname": "RightToOptOutOfAgreementNumberOfPeriods",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "rigl_RoyaltyDeliveryOfDrugSuppliesAndOthersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents royalty, delivery of drug supplies and others.",
        "label": "Royalty, delivery of drug supplies and others"
       }
      }
     },
     "localname": "RoyaltyDeliveryOfDrugSuppliesAndOthersMember",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesDisaggregatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rigl_RoyaltyPaymentAsPercentageOfNetSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents royalty payment as a percentage of net sales.",
        "label": "Royalty Payment As Percentage Of Net Sales",
        "terseLabel": "Royalty payment as a percentage of net sales"
       }
      }
     },
     "localname": "RoyaltyPaymentAsPercentageOfNetSales",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "rigl_SalesDiscountsAndAllowances": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sales discounts and allowances during the period.",
        "label": "Sales Discounts And Allowances",
        "terseLabel": "Discounts and allowances"
       }
      }
     },
     "localname": "SalesDiscountsAndAllowances",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rigl_ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of cash and cash equivalent balances, excluding any restricted cash balances, and available-for-sale securities.",
        "label": "Schedule of Cash and Cash Equivalents and Available For Sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails",
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsGrossUnrealizedGainsAndLossesDetails",
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsUnrealizedLossPositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardOfferingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the offering period for awards under the equity-based compensation plan.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award, Award Offering Period",
        "terseLabel": "Award offering period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardOfferingPeriod",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationPurchasePlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPurchasePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the purchase period for awards under the equity-based compensation plan.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award, Award Purchase Period",
        "terseLabel": "Award purchase period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPurchasePeriod",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationPurchasePlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriodsPerAwardOfferingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of purchase periods per award offering period under the equity-based compensation plan.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Number of Purchase Periods Per Award Offering Period",
        "terseLabel": "Number of purchase periods per award offering period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriodsPerAwardOfferingPeriod",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationPurchasePlanDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentageOnFirstDayOfOfferingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the purchase price expressed as a percentage of the fair market value of common stock on the first day of the offering period.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Purchase Price of Common Stock Percentage on First Day of Offering Period",
        "verboseLabel": "Purchase price expressed as a percentage of fair market value of common stock on the first day of the offering period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentageOnFirstDayOfOfferingPeriod",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationPurchasePlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "rigl_ShareBasedCompensationOptionsAndRsusMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents share based compensation options and RSUs.",
        "label": "Employee stock options and Restricted Stock Units"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionsAndRsusMember",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationOptionsAndRsusDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rigl_SpecifiedCommercialMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents specified commercial milestones.",
        "label": "Commercial milestones"
       }
      }
     },
     "localname": "SpecifiedCommercialMilestonesMember",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rigl_SpecifiedDevelopmentEventsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents specified development events.",
        "label": "Specified Development Events [Member]"
       }
      }
     },
     "localname": "SpecifiedDevelopmentEventsMember",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rigl_SpecifiedProductLaunchEventsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents specified product launch events.",
        "label": "Specified Product Launch Events [Member]"
       }
      }
     },
     "localname": "SpecifiedProductLaunchEventsMember",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rigl_SpecifiedRegulatoryEventsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents specified regulatory events.",
        "label": "Specified Regulatory Events [Member]"
       }
      }
     },
     "localname": "SpecifiedRegulatoryEventsMember",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rigl_SubleaseAgreementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Sublease Agreement Abstract",
        "terseLabel": "Sublease Agreement",
        "verboseLabel": "Operating sublease information"
       }
      }
     },
     "localname": "SubleaseAgreementAbstract",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureLeasesDetails",
      "http://www.rigel.com/role/DisclosureLeasesSubleaseInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "rigl_VariableLeaseExpenseNetCredit": {
     "auth_ref": [],
     "calculation": {
      "http://www.rigel.com/role/DisclosureLeasesLeaseExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease expense (net credit).",
        "label": "Variable Lease Expense Net Credit",
        "terseLabel": "Variable operating lease expense (net credit)"
       }
      }
     },
     "localname": "VariableLeaseExpenseNetCredit",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureLeasesLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rigl_VariableSubleaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.rigel.com/role/DisclosureLeasesSubleaseInformationDetails": {
       "order": 2.0,
       "parentTag": "rigl_NetSubleaseIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable sublease expense.",
        "label": "Variable Sublease Expense",
        "terseLabel": "Variable sublease expense"
       }
      }
     },
     "localname": "VariableSubleaseExpense",
     "nsuri": "http://www.rigel.com/20230630",
     "presentation": [
      "http://www.rigel.com/role/DisclosureLeasesSubleaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r210",
      "r582",
      "r729",
      "r777",
      "r778"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name or description of a single external customer or a group of external customers.",
        "label": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesPercentageByCustomerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r259",
      "r260",
      "r261",
      "r262",
      "r324",
      "r447",
      "r474",
      "r492",
      "r493",
      "r545",
      "r547",
      "r549",
      "r550",
      "r555",
      "r562",
      "r563",
      "r570",
      "r579",
      "r590",
      "r597",
      "r728",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upper limit of the provided range.",
        "label": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r210",
      "r582",
      "r729",
      "r777",
      "r778"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Single external customer or group of external customers.",
        "label": "Name Of Major Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesPercentageByCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r208",
      "r449",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r564",
      "r580",
      "r596",
      "r690",
      "r724",
      "r725",
      "r729",
      "r777"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by product and service, or group of similar products and similar services.",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesDisaggregatedDetails",
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails",
      "http://www.rigel.com/role/StatementCondensedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r208",
      "r449",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r564",
      "r580",
      "r596",
      "r690",
      "r724",
      "r725",
      "r729",
      "r777"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product or service, or a group of similar products or similar services.",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesDisaggregatedDetails",
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails",
      "http://www.rigel.com/role/StatementCondensedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r259",
      "r260",
      "r261",
      "r262",
      "r317",
      "r324",
      "r353",
      "r354",
      "r355",
      "r423",
      "r447",
      "r474",
      "r492",
      "r493",
      "r545",
      "r547",
      "r549",
      "r550",
      "r555",
      "r562",
      "r563",
      "r570",
      "r579",
      "r590",
      "r597",
      "r600",
      "r722",
      "r728",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r259",
      "r260",
      "r261",
      "r262",
      "r317",
      "r324",
      "r353",
      "r354",
      "r355",
      "r423",
      "r447",
      "r474",
      "r492",
      "r493",
      "r545",
      "r547",
      "r549",
      "r550",
      "r555",
      "r562",
      "r563",
      "r570",
      "r579",
      "r590",
      "r597",
      "r600",
      "r722",
      "r728",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Range [Member]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r177",
      "r325",
      "r685",
      "r714"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.",
        "label": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebtDetails",
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock": {
     "auth_ref": [
      "r122",
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for valuation and qualifying accounts and reserves.",
        "label": "Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]",
        "verboseLabel": "Schedule of product revenue allowance and reserve categories"
       }
      }
     },
     "localname": "ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r177",
      "r325",
      "r685",
      "r686",
      "r714"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.",
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebtDetails",
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "auth_ref": [
      "r122",
      "r157",
      "r158",
      "r159",
      "r161",
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "auth_ref": [
      "r122",
      "r157",
      "r158",
      "r159",
      "r161",
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r16",
      "r595"
     ],
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails",
      "http://www.rigel.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r211",
      "r212"
     ],
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, Net, Current",
        "terseLabel": "Accounts receivable",
        "verboseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails",
      "http://www.rigel.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionExpense": {
     "auth_ref": [
      "r572",
      "r723"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations.",
        "label": "Accretion Expense",
        "terseLabel": "Accretion expense"
       }
      }
     },
     "localname": "AccretionExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r133",
      "r134",
      "r135",
      "r136",
      "r141",
      "r705",
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), including portion attributable to noncontrolling interest.",
        "label": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsGrossUnrealizedGainsAndLossesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of increase (decrease) in accumulated equity from transactions and other events and circumstances from non-owner sources, including portion attributable to noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners (distributions to owners).",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest, before Tax",
        "terseLabel": "Gross Unrealized Gains (Losses)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossBeforeTax1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsGrossUnrealizedGainsAndLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r28",
      "r29",
      "r74",
      "r130",
      "r459",
      "r479",
      "r480"
     ],
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r1",
      "r9",
      "r29",
      "r378",
      "r381",
      "r416",
      "r475",
      "r476",
      "r704",
      "r705",
      "r706",
      "r711",
      "r712",
      "r713"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r363",
      "r364",
      "r365",
      "r485",
      "r711",
      "r712",
      "r713",
      "r763",
      "r781"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r49",
      "r50",
      "r328"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvancesOnInventoryPurchases": {
     "auth_ref": [
      "r702"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of capitalized payments made in advance for inventory that is expected to be received within one year or the normal operating cycle, if longer.",
        "label": "Advances on Inventory Purchases",
        "terseLabel": "Advance payments for raw materials"
       }
      }
     },
     "localname": "AdvancesOnInventoryPurchases",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r357",
      "r366"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share-based Compensation Expense",
        "terseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r5",
      "r42",
      "r43"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "verboseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive securities excluded from the computation of diluted net loss per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements And Nonarrangement Transactions [Member]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r99",
      "r129",
      "r155",
      "r194",
      "r202",
      "r206",
      "r243",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r371",
      "r375",
      "r396",
      "r455",
      "r514",
      "r595",
      "r608",
      "r726",
      "r727",
      "r767"
     ],
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r125",
      "r132",
      "r155",
      "r243",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r371",
      "r375",
      "r396",
      "r595",
      "r726",
      "r727",
      "r767"
     ],
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r214",
      "r251",
      "r454"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "terseLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsGrossUnrealizedGainsAndLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Available-for-sale Securities, Continuous Unrealized Loss Position [Abstract]",
        "terseLabel": "Fair value and gross unrealized losses of investments in individual securities in unrealized loss position"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsUnrealizedLossPositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://www.rigel.com/role/DisclosureStockBasedCompensationOptionsAndRsusDetails",
      "http://www.rigel.com/role/DisclosureStockBasedCompensationPurchasePlanDetails",
      "http://www.rigel.com/role/DisclosureStockBasedCompensationTables",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r51",
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BuildingMember": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.",
        "label": "Building"
       }
      }
     },
     "localname": "BuildingMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r88",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and accounting policies concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Business Description and Accounting Policies [Text Block]",
        "terseLabel": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "BusinessDescriptionAndAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r34",
      "r127",
      "r565"
     ],
     "calculation": {
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsAndShortTermInvestments",
       "weight": 1.0
      },
      "http://www.rigel.com/role/StatementCondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails",
      "http://www.rigel.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r703"
     ],
     "calculation": {
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-term Investments",
        "terseLabel": "Cash, cash equivalents and short-term investments",
        "totalLabel": "Cash, cash equivalents and short-term investments"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails",
      "http://www.rigel.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndLiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock": {
     "auth_ref": [
      "r715"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of the components of cash, cash equivalents, and short-term investments. Short-term investments may include current marketable securities.",
        "label": "Cash, Cash Equivalents, and Short-term Investments [Text Block]",
        "verboseLabel": "CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r34",
      "r85",
      "r153"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r0",
      "r85"
     ],
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Net Cash Provided by (Used in) Continuing Operations",
        "totalLabel": "Net increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashMember": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.",
        "label": "Cash"
       }
      }
     },
     "localname": "CashMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r113",
      "r115",
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "SPONSORED RESEARCH AND LICENSE AGREEMENTS AND GOVERNMENT CONTRACT"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContract"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]",
        "terseLabel": "Collaborations"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r25",
      "r60",
      "r456",
      "r501"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Shares reserved for future issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationPurchasePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r598",
      "r599",
      "r600",
      "r602",
      "r603",
      "r604",
      "r605",
      "r711",
      "r712",
      "r763",
      "r779",
      "r781"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r65",
      "r458",
      "r595"
     ],
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r30",
      "r138",
      "r140",
      "r145",
      "r450",
      "r466"
     ],
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r36",
      "r38",
      "r54",
      "r55",
      "r210",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesPercentageByCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r36",
      "r38",
      "r54",
      "r55",
      "r210",
      "r481",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesPercentageByCustomerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r36",
      "r38",
      "r54",
      "r55",
      "r210",
      "r561",
      "r688"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesPercentageByCustomerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r36",
      "r38",
      "r54",
      "r55",
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "verboseLabel": "Percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesPercentageByCustomerDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r36",
      "r38",
      "r54",
      "r55",
      "r210",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesPercentageByCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r303",
      "r304",
      "r315"
     ],
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerRefundLiabilityCurrent": {
     "auth_ref": [
      "r730"
     ],
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer, classified as current.",
        "label": "Contract with Customer, Refund Liability, Current",
        "verboseLabel": "Revenue reserves and refund liability"
       }
      }
     },
     "localname": "ContractWithCustomerRefundLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r77",
      "r449"
     ],
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of product sales"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total costs and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Costs and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r37",
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesPercentageByCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "DEBT"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r92",
      "r154",
      "r272",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r288",
      "r295",
      "r296",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "DEBT"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r14",
      "r62",
      "r63",
      "r100",
      "r101",
      "r156",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r279",
      "r284",
      "r285",
      "r286",
      "r287",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r404",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r709"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Basis spread on variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate": {
     "auth_ref": [
      "r22",
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of any adjustments made to the stated rate to determine the effective rate.",
        "label": "Debt Instrument, Interest Rate, Basis for Effective Rate",
        "terseLabel": "Rate adjustment"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateBasisForEffectiveRate",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r22",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Floor rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [
      "r156",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r279",
      "r284",
      "r285",
      "r286",
      "r287",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r297",
      "r404",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r709"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r23",
      "r156",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r279",
      "r284",
      "r285",
      "r286",
      "r287",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r404",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r709"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of principal amount of debt redeemed.",
        "label": "Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed",
        "terseLabel": "Final payment fee, percentage of principal"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r23",
      "r44",
      "r45",
      "r56",
      "r57",
      "r59",
      "r61",
      "r93",
      "r94",
      "r156",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r279",
      "r284",
      "r285",
      "r286",
      "r287",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r297",
      "r404",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r709"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r58",
      "r284",
      "r299",
      "r575",
      "r576"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "terseLabel": "Unamortized issuance costs and debt discounts"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions": {
     "auth_ref": [
      "r721"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions",
        "terseLabel": "Number of investments in continuous unrealized loss position for more than 12 months"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsUnrealizedLossPositionDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "auth_ref": [
      "r108",
      "r253",
      "r571"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "auth_ref": [
      "r108",
      "r253"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Available For Sale Securities Continuous Unrealized Loss Position Less than 12 Months Accumulated Loss",
        "negatedLabel": "Unrealized Losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions": {
     "auth_ref": [
      "r721"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions",
        "terseLabel": "Number of individual securities in unrealized loss position for 12 months or less"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsUnrealizedLossPositionDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DeferredRevenue": {
     "auth_ref": [
      "r698"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Deferred Revenue",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r5",
      "r199"
     ],
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [
      "r314",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesDisaggregatedDetails",
      "http://www.rigel.com/role/DisclosureRevenuesPercentageByCustomerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r314",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesDisaggregatedDetails",
      "http://www.rigel.com/role/DisclosureRevenuesPercentageByCustomerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r729"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of revenues disaggregated by category"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r326",
      "r330",
      "r358",
      "r359",
      "r362",
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]",
        "terseLabel": "STOCK-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCK-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NET LOSS PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r146",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r179",
      "r182",
      "r185",
      "r186",
      "r187",
      "r191",
      "r385",
      "r386",
      "r451",
      "r467",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "verboseLabel": "Net loss per share, basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r146",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r182",
      "r185",
      "r186",
      "r187",
      "r191",
      "r385",
      "r386",
      "r451",
      "r467",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Net loss per share, diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r178",
      "r188",
      "r189",
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "NET LOSS PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureNetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]",
        "terseLabel": "Stock-based compensation expense related to stock-based awards"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted-average recognition period of unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://www.rigel.com/role/DisclosureStockBasedCompensationOptionsAndRsusDetails",
      "http://www.rigel.com/role/DisclosureStockBasedCompensationPurchasePlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r759"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options",
        "terseLabel": "Unrecognized compensation cost related to purchase plan"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationPurchasePlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r759"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Total unrecognized compensation cost related to performance-based stock options",
        "verboseLabel": "Total unrecognized compensation costs"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://www.rigel.com/role/DisclosureStockBasedCompensationOptionsAndRsusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Purchase Plan"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationPurchasePlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureNetLossPerShareDetails",
      "http://www.rigel.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://www.rigel.com/role/DisclosureStockBasedCompensationOptionsAndRsusDetails",
      "http://www.rigel.com/role/DisclosureStockBasedCompensationTables",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r10",
      "r123",
      "r141",
      "r142",
      "r143",
      "r164",
      "r165",
      "r166",
      "r168",
      "r174",
      "r176",
      "r193",
      "r244",
      "r245",
      "r302",
      "r363",
      "r364",
      "r365",
      "r367",
      "r368",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r384",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r416",
      "r475",
      "r476",
      "r477",
      "r485",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsGrossUnrealizedGainsAndLossesDetails",
      "http://www.rigel.com/role/StatementCondensedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r286",
      "r395",
      "r575",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate Of Fair Value Fair Value Disclosure"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [
      "r388",
      "r389",
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r388",
      "r389",
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r53",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of financial assets measured at fair value on a recurring basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureFairValueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r286",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r389",
      "r420",
      "r421",
      "r422",
      "r575",
      "r576",
      "r587",
      "r588",
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value, Hierarchy [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r13",
      "r53",
      "r286",
      "r575",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r388",
      "r389",
      "r390",
      "r391",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "FAIR VALUE"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureFairValue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r286",
      "r318",
      "r323",
      "r389",
      "r420",
      "r587",
      "r588",
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r286",
      "r318",
      "r323",
      "r389",
      "r421",
      "r575",
      "r576",
      "r587",
      "r588",
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Fair Value Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r286",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r420",
      "r421",
      "r422",
      "r575",
      "r576",
      "r587",
      "r588",
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Measurements Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r387",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value Measurements Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r252",
      "r254",
      "r255",
      "r297",
      "r301",
      "r383",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r465",
      "r571",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r716",
      "r717",
      "r718",
      "r719"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsGrossUnrealizedGainsAndLossesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "auth_ref": [
      "r708"
     ],
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.",
        "label": "Gain (Loss) on Disposition of Assets",
        "negatedLabel": "Loss (gain) on sale and disposal of fixed assets"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GovernmentContractMember": {
     "auth_ref": [
      "r731"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Formal agreement with government or its agency.",
        "label": "Government contract"
       }
      }
     },
     "localname": "GovernmentContractMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesDisaggregatedDetails",
      "http://www.rigel.com/role/StatementCondensedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncentiveToLessee": {
     "auth_ref": [
      "r111",
      "r112",
      "r687"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of incentive granted by lessor to lessee.",
        "label": "Incentive to Lessee",
        "terseLabel": "Leasehold improvement incentives from landlord"
       }
      }
     },
     "localname": "IncentiveToLessee",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED STATEMENTS OF OPERATIONS"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r257",
      "r258",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r258",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r4"
     ],
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r4"
     ],
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r448",
      "r707"
     ],
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r4"
     ],
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r4"
     ],
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r689",
      "r707"
     ],
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase Decrease In Operating Lease Liability",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherAccruedLiabilities": {
     "auth_ref": [
      "r4"
     ],
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in other expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Other Accrued Liabilities",
        "terseLabel": "Other accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r707"
     ],
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r4"
     ],
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Other current and long-term liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r4"
     ],
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsNetIncludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.",
        "label": "Intangible Assets, Net (Including Goodwill)",
        "terseLabel": "Intangible asset, net",
        "verboseLabel": "Intangible asset"
       }
      }
     },
     "localname": "IntangibleAssetsNetIncludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails",
      "http://www.rigel.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r58",
      "r106",
      "r144",
      "r198",
      "r403",
      "r526",
      "r606",
      "r780"
     ],
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebtDetails",
      "http://www.rigel.com/role/StatementCondensedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r148",
      "r151",
      "r152"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "INVENTORIES"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "verboseLabel": "INVENTORIES"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureInventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r699"
     ],
     "calculation": {
      "http://www.rigel.com/role/DisclosureInventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r131",
      "r566",
      "r595"
     ],
     "calculation": {
      "http://www.rigel.com/role/DisclosureInventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.rigel.com/role/StatementCondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureInventoriesDetails",
      "http://www.rigel.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r701"
     ],
     "calculation": {
      "http://www.rigel.com/role/DisclosureInventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Raw Materials"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r700"
     ],
     "calculation": {
      "http://www.rigel.com/role/DisclosureInventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r80",
      "r197"
     ],
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.",
        "label": "Investment Income, Net, Amortization of Discount and Premium",
        "negatedTerseLabel": "Net amortization and accretion of discount on short-term investments and term loan"
       }
      }
     },
     "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r544",
      "r546",
      "r548",
      "r551",
      "r552",
      "r553",
      "r554",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails",
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsUnrealizedLossPositionDetails",
      "http://www.rigel.com/role/DisclosureFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r544",
      "r546",
      "r548",
      "r551",
      "r552",
      "r553",
      "r554",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investment Type Categorization [Member]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails",
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsUnrealizedLossPositionDetails",
      "http://www.rigel.com/role/DisclosureFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r388"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Investments at fair value",
        "verboseLabel": "Fair Value"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsGrossUnrealizedGainsAndLossesDetails",
      "http://www.rigel.com/role/DisclosureFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r409",
      "r594"
     ],
     "calculation": {
      "http://www.rigel.com/role/DisclosureLeasesLeaseExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total operating lease expense"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureLeasesLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r765"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of components of operating lease expense"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LEASES"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r766"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of future minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r414"
     ],
     "calculation": {
      "http://www.rigel.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due",
        "totalLabel": "Total minimum payments required"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r414"
     ],
     "calculation": {
      "http://www.rigel.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r414"
     ],
     "calculation": {
      "http://www.rigel.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r766"
     ],
     "calculation": {
      "http://www.rigel.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year",
        "terseLabel": "Remainder of 2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r19",
      "r155",
      "r243",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r372",
      "r375",
      "r376",
      "r396",
      "r500",
      "r568",
      "r608",
      "r726",
      "r767",
      "r768"
     ],
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r70",
      "r102",
      "r461",
      "r595",
      "r710",
      "r720",
      "r764"
     ],
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' deficit"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders' (deficit) equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r21",
      "r126",
      "r155",
      "r243",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r372",
      "r375",
      "r376",
      "r396",
      "r595",
      "r726",
      "r767",
      "r768"
     ],
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r731"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License revenues"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesDisaggregatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding": {
     "auth_ref": [
      "r395"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of the amount outstanding under the credit facility.",
        "label": "Line of Credit Facility, Fair Value of Amount Outstanding",
        "terseLabel": "Outstanding balance"
       }
      }
     },
     "localname": "LineOfCreditFacilityFairValueOfAmountOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityIncreaseAccruedInterest": {
     "auth_ref": [
      "r709"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase for accrued, but unpaid interest on the credit facility for the period.",
        "label": "Line of Credit Facility, Increase, Accrued Interest",
        "terseLabel": "Accrued interest"
       }
      }
     },
     "localname": "LineOfCreditFacilityIncreaseAccruedInterest",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r17"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "auth_ref": [
      "r17"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).",
        "label": "Line of Credit Facility, Remaining Borrowing Capacity",
        "terseLabel": "Remaining borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Credit Facility with MidCap"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r14",
      "r101",
      "r285",
      "r300",
      "r575",
      "r576",
      "r776"
     ],
     "calculation": {
      "http://www.rigel.com/role/DisclosureDebtFutureMinimumPaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-term Debt",
        "totalLabel": "Principal amount (Tranches 1, 2, 3 and 4)"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebtFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r7",
      "r156",
      "r290"
     ],
     "calculation": {
      "http://www.rigel.com/role/DisclosureDebtFutureMinimumPaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebtFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r7",
      "r156",
      "r290"
     ],
     "calculation": {
      "http://www.rigel.com/role/DisclosureDebtFutureMinimumPaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Year Three",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebtFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r7",
      "r156",
      "r290"
     ],
     "calculation": {
      "http://www.rigel.com/role/DisclosureDebtFutureMinimumPaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Year Two",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebtFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermLoansPayable": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.",
        "label": "Loans Payable, Noncurrent",
        "terseLabel": "Loans payable, net of discount"
       }
      }
     },
     "localname": "LongTermLoansPayable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MaturitiesOfLongTermDebtAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturities of Long-term Debt [Abstract]",
        "terseLabel": "Future minimum payments"
       }
      }
     },
     "localname": "MaturitiesOfLongTermDebtAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebtFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r732"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails",
      "http://www.rigel.com/role/DisclosureFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r150"
     ],
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r150"
     ],
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations",
        "totalLabel": "Net cash provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r85",
      "r86",
      "r87"
     ],
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations",
        "totalLabel": "Net cash provided by (used in) operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r75",
      "r87",
      "r105",
      "r124",
      "r137",
      "r139",
      "r143",
      "r155",
      "r167",
      "r169",
      "r170",
      "r171",
      "r172",
      "r175",
      "r176",
      "r183",
      "r194",
      "r201",
      "r205",
      "r207",
      "r243",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r386",
      "r396",
      "r464",
      "r522",
      "r539",
      "r540",
      "r569",
      "r606",
      "r726"
     ],
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfOperations",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r147",
      "r169",
      "r170",
      "r171",
      "r172",
      "r179",
      "r180",
      "r184",
      "r187",
      "r194",
      "r201",
      "r205",
      "r207",
      "r569"
     ],
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfComprehensiveLoss",
      "http://www.rigel.com/role/StatementCondensedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Issued Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r194",
      "r201",
      "r205",
      "r207",
      "r569"
     ],
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r410",
      "r594"
     ],
     "calculation": {
      "http://www.rigel.com/role/DisclosureLeasesLeaseExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Fixed operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureLeasesLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLeaseIncomeTableTextBlock": {
     "auth_ref": [
      "r192",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of components of income from operating lease.",
        "label": "Operating Lease, Lease Income [Table Text Block]",
        "terseLabel": "Schedule of operating sublease information"
       }
      }
     },
     "localname": "OperatingLeaseLeaseIncomeTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Liabilities, Payments Due [Abstract]",
        "verboseLabel": "Operating Lease"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r406"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Total operating lease liabilities",
        "verboseLabel": "Lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r406"
     ],
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Lease liabilities, current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r406"
     ],
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term portion of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r407",
      "r412"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash payments included in the measurement of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureLeasesCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r405"
     ],
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets",
        "verboseLabel": "Operating lease right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureLeasesDetails",
      "http://www.rigel.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r413",
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesActivityDetails",
      "http://www.rigel.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r128"
     ],
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.",
        "label": "Other Commitment",
        "terseLabel": "Funding commitment"
       }
      }
     },
     "localname": "OtherCommitment",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r3",
      "r8",
      "r97"
     ],
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.",
        "label": "Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "verboseLabel": "Net unrealized gain (loss) on short-term investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfComprehensiveLoss",
      "http://www.rigel.com/role/StatementCondensedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent [Abstract]",
        "verboseLabel": "Other comprehensive gain (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r20",
      "r595"
     ],
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other long-term liabilities, current portion"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld": {
     "auth_ref": [
      "r109",
      "r110"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of credit losses recognized in earnings related to debt securities held for which a portion of an other than temporary impairment (OTTI) was recognized in other comprehensive income (a component of shareholders' equity).",
        "label": "Other than Temporary Impairment, Credit Losses Recognized in Earnings, Credit Losses on Debt Securities Held",
        "terseLabel": "Credit losses recognized"
       }
      }
     },
     "localname": "OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedLabel": "Purchases of intangible asset"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Payments to Acquire Short-term Investments",
        "negatedLabel": "Purchases of short-term investments"
       }
      }
     },
     "localname": "PaymentsToAcquireShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r64",
      "r457",
      "r595"
     ],
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r703"
     ],
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromCollaborators": {
     "auth_ref": [
      "r33"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received from collaborators during the current period.",
        "label": "Proceeds from Collaborators",
        "terseLabel": "Collaborative payment received"
       }
      }
     },
     "localname": "ProceedsFromCollaborators",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r2",
      "r11"
     ],
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Including Stock Options",
        "terseLabel": "Net proceeds from issuances of common stock upon exercise of options and participation in Purchase Plan"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLongTermLinesOfCredit": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.",
        "label": "Proceeds from Long-term Lines of Credit",
        "terseLabel": "Net proceeds from term loan financing"
       }
      }
     },
     "localname": "ProceedsFromLongTermLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments": {
     "auth_ref": [
      "r31",
      "r83"
     ],
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Proceeds from Maturities, Prepayments and Calls of Short-term Investments",
        "terseLabel": "Maturities of short-term investments"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds from sale of property and equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductFinancingArrangementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement that in form is a sale with full right of return but in substance is a financing in that the financier is not the end customer, is not at risk other than credit risk similar to any other form of lending arrangement, and typically is repaid from collections of sales made to actual customers including an amount that constitutes interest.",
        "label": "Financing arrangement"
       }
      }
     },
     "localname": "ProductFinancingArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProductLiabilityAccrualComponentAmount": {
     "auth_ref": [
      "r573"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recorded amount of the accrual for a material component of a product liability contingency.",
        "label": "Product Liability Accrual, Component Amount",
        "terseLabel": "Financing component liability"
       }
      }
     },
     "localname": "ProductLiabilityAccrualComponentAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product sales, net"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesDisaggregatedDetails",
      "http://www.rigel.com/role/StatementCondensedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r124",
      "r137",
      "r139",
      "r149",
      "r155",
      "r167",
      "r175",
      "r176",
      "r194",
      "r201",
      "r205",
      "r207",
      "r243",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r370",
      "r373",
      "r374",
      "r386",
      "r396",
      "r452",
      "r463",
      "r484",
      "r522",
      "r539",
      "r540",
      "r569",
      "r592",
      "r593",
      "r607",
      "r706",
      "r726"
     ],
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r6",
      "r453",
      "r462",
      "r595"
     ],
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property Plant And Equipment Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r761"
     ],
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails",
      "http://www.rigel.com/role/StatementCondensedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "RSUs"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureNetLossPerShareDetails",
      "http://www.rigel.com/role/DisclosureStockBasedCompensationOptionsAndRsusDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r67",
      "r95",
      "r460",
      "r478",
      "r480",
      "r483",
      "r503",
      "r595"
     ],
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated undistributed earnings (deficit).",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r123",
      "r164",
      "r165",
      "r166",
      "r168",
      "r174",
      "r176",
      "r244",
      "r245",
      "r363",
      "r364",
      "r365",
      "r367",
      "r368",
      "r377",
      "r379",
      "r380",
      "r382",
      "r384",
      "r475",
      "r477",
      "r485",
      "r781"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated undistributed earnings (deficit).",
        "label": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "REVENUES",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r195",
      "r196",
      "r200",
      "r203",
      "r204",
      "r208",
      "r209",
      "r210",
      "r313",
      "r314",
      "r449"
     ],
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue",
        "verboseLabel": "Total revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesDisaggregatedDetails",
      "http://www.rigel.com/role/StatementCondensedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r120",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "verboseLabel": "REVENUES"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenues"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r119"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation",
        "terseLabel": "Revenue, remaining performance obligation"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyExpense": {
     "auth_ref": [
      "r78"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.",
        "label": "Royalty Expense",
        "terseLabel": "Royalty expense"
       }
      }
     },
     "localname": "RoyaltyExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyMember": {
     "auth_ref": [
      "r731"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Money for usage-based right to asset.",
        "label": "Royalty"
       }
      }
     },
     "localname": "RoyaltyMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesMember": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing revenue from sale of goods and services rendered in the normal course of business.",
        "label": "Sales"
       }
      }
     },
     "localname": "SalesMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesPercentageByCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesReturnsAndAllowancesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A revision in the estimated reserve needed for product returns and price or other concessions granted to customers.",
        "label": "Returns"
       }
      }
     },
     "localname": "SalesReturnsAndAllowancesMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of antidilutive securities"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureNetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Cash, cash equivalent and short term investments"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.",
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "terseLabel": "Schedule of cash, cash equivalents and short-term investments"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]",
        "terseLabel": "Schedule of stock-based compensation"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r15",
      "r71",
      "r72",
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventories"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureInventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Schedule of Line of Credit Facilities [Table Text Block]",
        "terseLabel": "Schedule of future minimum payments"
       }
      }
     },
     "localname": "ScheduleOfLineOfCreditFacilitiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r327",
      "r329",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://www.rigel.com/role/DisclosureStockBasedCompensationOptionsAndRsusDetails",
      "http://www.rigel.com/role/DisclosureStockBasedCompensationPurchasePlanDetails",
      "http://www.rigel.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Summary of weighted-average assumptions relating to options granted pursuant to equity incentive plans"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For all investments in an unrealized loss position, including those for which other-than-temporary impairments have not been recognized in earnings (including investments for which a portion of an other-than-temporary impairment has been recognized in other comprehensive income), a tabular disclosure of the aggregate related fair value of investments with unrealized losses and the aggregate amount of unrealized losses (that is, the amount by which amortized cost basis exceeds fair value).",
        "label": "Schedule of Unrealized Loss on Investments [Table Text Block]",
        "terseLabel": "Schedule of fair value and gross unrealized losses of investments in unrealized loss position"
       }
      }
     },
     "localname": "ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember": {
     "auth_ref": [
      "r762"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap that has its variable-rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable-rate leg.",
        "label": "SOFR"
       }
      }
     },
     "localname": "SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r4"
     ],
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Compensation",
        "verboseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationOptionsAndRsusDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationOptionsAndRsusDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationOptionsAndRsusDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r342",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Outstanding, end of period (in shares)",
        "periodStartLabel": "Outstanding, beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationOptionsAndRsusDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationOptionsAndRsusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationOptionsAndRsusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "terseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationOptionsAndRsusDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]",
        "terseLabel": "Weighted-average assumptions relating to options granted",
        "verboseLabel": "Weighted-average assumptions relating to Purchase Plan"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://www.rigel.com/role/DisclosureStockBasedCompensationPurchasePlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://www.rigel.com/role/DisclosureStockBasedCompensationPurchasePlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://www.rigel.com/role/DisclosureStockBasedCompensationPurchasePlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://www.rigel.com/role/DisclosureStockBasedCompensationPurchasePlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [
      "r327",
      "r329",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "verboseLabel": "Stock Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://www.rigel.com/role/DisclosureStockBasedCompensationOptionsAndRsusDetails",
      "http://www.rigel.com/role/DisclosureStockBasedCompensationPurchasePlanDetails",
      "http://www.rigel.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Additional shares approved"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationPurchasePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares of common stock available for grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationPurchasePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Additional disclosures"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://www.rigel.com/role/DisclosureStockBasedCompensationOptionsAndRsusDetails",
      "http://www.rigel.com/role/DisclosureStockBasedCompensationPurchasePlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationOptionsAndRsusDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Grant-date weighted-average fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r334",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding, end of period (in shares)",
        "periodStartLabel": "Outstanding, beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationOptionsAndRsusDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "verboseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationOptionsAndRsusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost": {
     "auth_ref": [
      "r360"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An excess of the fair value of the modified award over the fair value of the award immediately before the modification.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Incremental Compensation Cost",
        "terseLabel": "Incremental stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward": {
     "auth_ref": [
      "r760"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares purchased for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Purchased for Award",
        "terseLabel": "Shares purchased"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationPurchasePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "All Award Types",
        "terseLabel": "All Award Types"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://www.rigel.com/role/DisclosureStockBasedCompensationOptionsAndRsusDetails",
      "http://www.rigel.com/role/DisclosureStockBasedCompensationPurchasePlanDetails",
      "http://www.rigel.com/role/DisclosureStockBasedCompensationTables",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Vesting upon achievement of corporate performance-based milestones"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://www.rigel.com/role/DisclosureStockBasedCompensationOptionsAndRsusDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://www.rigel.com/role/DisclosureStockBasedCompensationPurchasePlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent",
        "positiveLabel": "Purchase price expressed as a percentage of fair market value of common stock on the purchase date"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationPurchasePlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.",
        "label": "Short-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r103",
      "r104",
      "r702"
     ],
     "calculation": {
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsAndShortTermInvestments",
       "weight": 1.0
      },
      "http://www.rigel.com/role/StatementCondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-term Investments",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails",
      "http://www.rigel.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r10",
      "r27",
      "r123",
      "r141",
      "r142",
      "r143",
      "r164",
      "r165",
      "r166",
      "r168",
      "r174",
      "r176",
      "r193",
      "r244",
      "r245",
      "r302",
      "r363",
      "r364",
      "r365",
      "r367",
      "r368",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r384",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r416",
      "r475",
      "r476",
      "r477",
      "r485",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsGrossUnrealizedGainsAndLossesDetails",
      "http://www.rigel.com/role/StatementCondensedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [
      "r164",
      "r165",
      "r166",
      "r193",
      "r449",
      "r482",
      "r486",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r502",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r521",
      "r523",
      "r524",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r541",
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfOperations",
      "http://www.rigel.com/role/StatementCondensedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED STATEMENTS OF CASH FLOWS"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED BALANCE SHEETS"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED STATEMENTS OF COMPREHENSIVE LOSS"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED STATEMENTS OF STOCKHOLDERS' (DEFICIT) EQUITY"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r164",
      "r165",
      "r166",
      "r193",
      "r449",
      "r482",
      "r486",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r502",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r521",
      "r523",
      "r524",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r541",
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfOperations",
      "http://www.rigel.com/role/StatementCondensedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period.",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)"
       }
      }
     },
     "localname": "StockAppreciationRightsSARSMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r10",
      "r64",
      "r65",
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Issuance of common stock upon vesting of restricted stock units (RSUs) (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r10",
      "r64",
      "r65",
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures",
        "terseLabel": "Issuance of common stock upon exercise of options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r10",
      "r64",
      "r65",
      "r95",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "verboseLabel": "Exercised/Released (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationOptionsAndRsusDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r10",
      "r95"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Issuance of common stock upon vesting of restricted stock units (RSUs)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r47",
      "r64",
      "r65",
      "r95"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures",
        "terseLabel": "Issuance of common stock upon exercise of options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r65",
      "r68",
      "r69",
      "r90",
      "r504",
      "r520",
      "r542",
      "r543",
      "r595",
      "r608",
      "r710",
      "r720",
      "r764",
      "r781"
     ],
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders' deficit"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedBalanceSheets",
      "http://www.rigel.com/role/StatementCondensedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' deficit:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r411",
      "r594"
     ],
     "calculation": {
      "http://www.rigel.com/role/DisclosureLeasesSubleaseInformationDetails": {
       "order": 3.0,
       "parentTag": "rigl_NetSubleaseIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease income",
        "negatedLabel": "Sublease income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureLeasesSubleaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "verboseLabel": "Supplemental disclosure of cash flow information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r297",
      "r301",
      "r383",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r465",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r716",
      "r717",
      "r718",
      "r719"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsGrossUnrealizedGainsAndLossesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Type of Arrangement and Non-arrangement Transactions [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember": {
     "auth_ref": [
      "r732",
      "r775"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae).",
        "label": "Government-sponsored enterprise securities"
       }
      }
     },
     "localname": "USGovernmentSponsoredEnterprisesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails",
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsGrossUnrealizedGainsAndLossesDetails",
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsUnrealizedLossPositionDetails",
      "http://www.rigel.com/role/DisclosureFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasuryBillSecuritiesMember": {
     "auth_ref": [
      "r775"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one year or less, are interest bearing, and are backed by the full faith and credit of the United States government.",
        "label": "US treasury bills"
       }
      }
     },
     "localname": "USTreasuryBillSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails",
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsGrossUnrealizedGainsAndLossesDetails",
      "http://www.rigel.com/role/DisclosureFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of unrealized gains and losses on investments.",
        "label": "Unrealized Gain (Loss) on Investments [Table Text Block]",
        "terseLabel": "Schedule of cash equivalents and short-term investments including securities with unrealized gains and losses"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r39",
      "r40",
      "r41",
      "r114",
      "r116",
      "r117",
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "auth_ref": [
      "r157",
      "r162"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation and qualifying accounts and reserves.",
        "label": "Valuation Allowances and Reserves, Balance",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesBalance",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": {
     "auth_ref": [
      "r160"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.",
        "label": "Valuation Allowances and Reserves, Additions for Charges to Cost and Expense",
        "terseLabel": "Provision related to current period sales"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDeductions": {
     "auth_ref": [
      "r161"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.",
        "label": "Valuation Allowances and Reserves, Deductions",
        "negatedLabel": "Credit or payments made during the period"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDeductions",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [
      "r157",
      "r158",
      "r159",
      "r161",
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r157",
      "r158",
      "r159",
      "r161",
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://www.rigel.com/role/DisclosureStockBasedCompensationOptionsAndRsusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://www.rigel.com/role/DisclosureStockBasedCompensationOptionsAndRsusDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r181",
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted-average shares outstanding and common stock equivalents",
        "terseLabel": "Weighted average shares used in computing net loss per share, diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r179",
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted-average common shares outstanding, Basic",
        "terseLabel": "Weighted average shares used in computing net loss per share, basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 8
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-7",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-8B",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-8B",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "https://asc.fasb.org//1943274/2147481178/840-20-25-6",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "https://asc.fasb.org//1943274/2147481178/840-20-25-7",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org//606/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org//808/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r122": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "09",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.B)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09)",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org//260/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "https://asc.fasb.org//1943274/2147482964/270-10-50-6A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aaa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aaa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(3)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(4)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org//330/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org//718/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "808",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(iii)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(iv)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(i)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(b)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(c)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(c)(2)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(a)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(e)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(f)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(14))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(15))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(17))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(19))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(8))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-05(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-05(4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(b)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(9))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147481639/420-10-35-4",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(b)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(a)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r609": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r611": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r612": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r613": {
   "Name": "Form 20-F",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "16",
   "Subsection": "J",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r614": {
   "Name": "Form 20-F",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "6",
   "Subsection": "F",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r615": {
   "Name": "Form 20-F",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "6",
   "Subparagraph": "i",
   "Subsection": "F",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r616": {
   "Name": "Form 20-F",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "6",
   "Sentence": "A",
   "Subparagraph": "i",
   "Subsection": "F",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r617": {
   "Name": "Form 20-F",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "6",
   "Sentence": "B",
   "Subparagraph": "i",
   "Subsection": "F",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r618": {
   "Name": "Form 20-F",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "6",
   "Sentence": "C",
   "Subparagraph": "i",
   "Subsection": "F",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r619": {
   "Name": "Form 20-F",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "6",
   "Sentence": "D",
   "Subparagraph": "i",
   "Subsection": "F",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Form 20-F",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "6",
   "Sentence": "E",
   "Subparagraph": "i",
   "Subsection": "F",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r621": {
   "Name": "Form 20-F",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "6",
   "Subparagraph": "ii",
   "Subsection": "F",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r622": {
   "Name": "Form 20-F",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "6",
   "Subparagraph": "iii",
   "Subsection": "F",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r623": {
   "Name": "Form 20-F",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "6",
   "Subsection": "F",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r624": {
   "Name": "Form 20-F",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "6",
   "Subparagraph": "ii",
   "Subsection": "F",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r625": {
   "Name": "Form 40-F",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "19",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r626": {
   "Name": "Form 40-F",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "19",
   "Subparagraph": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r627": {
   "Name": "Form 40-F",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "19",
   "Sentence": "i",
   "Subparagraph": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r628": {
   "Name": "Form 40-F",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "19",
   "Sentence": "ii",
   "Subparagraph": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r629": {
   "Name": "Form 40-F",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "19",
   "Sentence": "iii",
   "Subparagraph": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Form 40-F",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "19",
   "Sentence": "iv",
   "Subparagraph": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r631": {
   "Name": "Form 40-F",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "19",
   "Sentence": "v",
   "Subparagraph": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r632": {
   "Name": "Form 40-F",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "19",
   "Subparagraph": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r633": {
   "Name": "Form 40-F",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "19",
   "Subparagraph": "3",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r634": {
   "Name": "Form 40-F",
   "Paragraph": "b",
   "Publisher": "SEC",
   "Section": "19",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r635": {
   "Name": "Form N-CSR",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "18",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r636": {
   "Name": "Form N-CSR",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "18",
   "Subparagraph": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r637": {
   "Name": "Form N-CSR",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "18",
   "Sentence": "i",
   "Subparagraph": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r638": {
   "Name": "Form N-CSR",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "18",
   "Sentence": "ii",
   "Subparagraph": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r639": {
   "Name": "Form N-CSR",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "18",
   "Sentence": "iii",
   "Subparagraph": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Form N-CSR",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "18",
   "Sentence": "iv",
   "Subparagraph": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r641": {
   "Name": "Form N-CSR",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "18",
   "Sentence": "v",
   "Subparagraph": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r642": {
   "Name": "Form N-CSR",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "18",
   "Subparagraph": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r643": {
   "Name": "Form N-CSR",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "18",
   "Subparagraph": "3",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r644": {
   "Name": "Form N-CSR",
   "Paragraph": "b",
   "Publisher": "SEC",
   "Section": "18",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r645": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r646": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Publisher": "SEC",
   "Section": "402",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r647": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "402",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r648": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "402",
   "Subparagraph": "ii",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r649": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "402",
   "Subparagraph": "iii",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "402",
   "Subparagraph": "iv",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r651": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "402",
   "Subparagraph": "vi",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r652": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "3",
   "Publisher": "SEC",
   "Section": "402",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r653": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "4",
   "Publisher": "SEC",
   "Section": "402",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r654": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "5",
   "Publisher": "SEC",
   "Section": "402",
   "Subparagraph": "i",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r655": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "5",
   "Publisher": "SEC",
   "Section": "402",
   "Subparagraph": "ii",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r656": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "5",
   "Publisher": "SEC",
   "Section": "402",
   "Subparagraph": "iii",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r657": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "5",
   "Publisher": "SEC",
   "Section": "402",
   "Subparagraph": "iv",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r658": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "6",
   "Publisher": "SEC",
   "Section": "402",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r659": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "6",
   "Publisher": "SEC",
   "Section": "402",
   "Subparagraph": "i",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "402",
   "Subsection": "w",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r661": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "402",
   "Subparagraph": "i",
   "Subsection": "w",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r662": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "402",
   "Sentence": "A",
   "Subparagraph": "i",
   "Subsection": "w",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r663": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "402",
   "Sentence": "B",
   "Subparagraph": "i",
   "Subsection": "w",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r664": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "402",
   "Sentence": "C",
   "Subparagraph": "i",
   "Subsection": "w",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r665": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "402",
   "Sentence": "D",
   "Subparagraph": "i",
   "Subsection": "w",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r666": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "402",
   "Sentence": "E",
   "Subparagraph": "i",
   "Subsection": "w",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r667": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "402",
   "Subparagraph": "ii",
   "Subsection": "w",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r668": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "402",
   "Subparagraph": "iii",
   "Subsection": "w",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r669": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "402",
   "Subsection": "w",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "402",
   "Subsection": "x",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r671": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "402",
   "Subsection": "x",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r672": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "402",
   "Sentence": "A",
   "Subparagraph": "ii",
   "Subsection": "x",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r673": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "402",
   "Sentence": "C",
   "Subparagraph": "ii",
   "Subsection": "x",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r674": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "402",
   "Sentence": "D",
   "Subparagraph": "ii",
   "Subsection": "x",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r675": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "402",
   "Sentence": "E",
   "Subparagraph": "ii",
   "Subsection": "x",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r676": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "402",
   "Sentence": "F",
   "Subparagraph": "ii",
   "Subsection": "x",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r677": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Publisher": "SEC",
   "Section": "408",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r678": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "408",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r679": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "408",
   "Subparagraph": "A",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "408",
   "Subparagraph": "B",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r681": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "408",
   "Subparagraph": "C",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r682": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "408",
   "Subparagraph": "D",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r683": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "408",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r684": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479924/842-10-30-5",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r691": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r692": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r693": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r694": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r695": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r696": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r697": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org//320/tableOfContent",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "27",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-27",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480682/815-20-25-6A",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r770": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r771": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r772": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r773": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r774": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r775": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r776": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r777": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r778": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r779": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r780": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(i)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r781": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org//235/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org//275/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org//470/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>71
<FILENAME>0001558370-23-012722-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-23-012722-xbrl.zip
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M=1W#7I+ %SA!^=SP&/(]]B__!U!+ P04    " "S@ %7? L^?:\R  #1)P,
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MD4"D31PP1&J)0TJ8.X>YB1?1N]Q)BF(%I[=R*P=2KW4EITR;57E=>1%%9K(
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MRO" S"]BG$"ISLU"%B'&64YK(8QF%52X]PH%L/;O%?)UI^"W /T.7#?W_A>
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M9_!,:TMM\FP>O77V^!8_)TRMH5$Y-O9K*!)EWU!N8OM8$4UCYX<Z75W[5P<
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M(LRJT-K9) X,QCT!MSZ*M>OK'?&+?8.]U1W<^"7VYJ?LG#(0L F77 E0;.S
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MVA9S3S4B'%+=;IG[C6OPJ4;$-ZK%VC4BNKC]-O#P@OZ?/BKU[$4T+9NP9;*
M**$;Q&UV^LRRM?5NP?U\<;E_"V[0GWS\K^S?WO"?GVX_]^^&#]-)K_]PW9M\
M'(VG9]/A^+YW^_!Y.)G>9S]U?1V.EZ6SS6&GG"'L.&10.?@S(=].@)\2V84
MLVZWM=:K8=\]&T_^!3=1 ^NWW5H6;<7K+J#;ZH8T)I,7A72Q8:/(_E9XO:E9
MEVY<8),K=EFZS2BV&WTC. FE609PP"?0AK[N3TPG!+';1R5WA%F UHO)=[AT
MLNAU2%(#8IG-:?Y19O )IY)*0S>6/[XR\B7#IL>JI.YA#-;W'OH"DILT#L3;
M%@_8@45/7>/*XN$19%4DGR93!#QB[Z^OPBC:37^A:&2-'/#[U1.1C##+HOH
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MA(3Q1#:H&_8N7XGXW'<B$DC7T=$L1TQHL;( ';!+1?I39CT+?>LIM4KO&K
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MJZ+<N@[]@9>=N\O+SE5XL.U"P<72\ZPC:\Y?(G_#RNZ)@GNLUB%[IL/CS)R
MZ;_UO[ G*YJL,$EH7^$#G1SX'&+HWP'FU0A#;[EG:\U_M8V[BEUAAWD?_:O!
MKM(/;LCWDE[7_:M,%JA@PT.@RLC*K'UR"W"U';G:*M%._%W 0_C[/_WX/0]C
M]LD_6?J'3N/;7SEO;PDS2!6T8S'9TLQN"'J1F[(U6!.*J@BMG3839.F2KOZR
M-O+$Z:?D&2-QV^W;,8*O"7FF4'?41]^[@&5D!2\:?U [10GR8L%%(=,J:+(7
MOF(W2L.$HND#P7L_W4LP6(\23*@R8)UZ@8+>9.#.-H8HHW\3/^>9)1CY6<Y%
M;>+!YM\Y:SX\9\Q'7(T\=E<LF-Y6+ M;G9F(J8KK$IQ;R<NM)*T;SOOP#X/(
MT9G;&,"ETUH/18(U.W35L0O3BP!T%.IKB_;J*++>D#&GMPZ&BWZ4>Q490]L;
M%1.:Y/*9]L,Q,X-(;7!X"'SGR0_L[2J<&V#I<EB+U]C%_@O;3E>V76/7N:&"
M7/]V/#CO-R<D:)'>, ;DG%#)RE*J<Q(K%.J2@N:"[3+""'8VM0HI(U]Z>ZVK
MS]S"NT'C]KBN=)A30#>);3B2*RS 1+!9M67Z68I6NK@Y.+YWA;>8$.QEJ12Z
MZN'%0\46C;*E%(G-+;[[V*@]\%4HS0D1>NEC&"HRWGD6DD]]1<5;JYN=EHR4
M6X-9(1*/1J:$O[5I;].S827$)&/96R%;3WB1]9X;GK1:H2-#T-1U3HC1KH#I
MW  /A)(;-&08QQA":^VPE^Q^GDJ_]G?/R6K[B2)94Q2K]H$9N[TT+O9&NSH
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M;[P"/"IG1PD^L--"]%_B%"D#%O:YL]L1GFY@QXFR%17))!<W'TK9\R.,[)
M3S-XZ"E-4!@EZ(@3Q'*&=E=8D]E>/EWC6+6N&K B0('<IT_)6%B536:KW"@R
MKS('YFM*-.1U9#%YP3%5:(VW:>BUHK9*)\#PK*QS@<.=/8 #KKK\$)&5R\YC
M@0G/8X%P\8NC5L=I,70*<PJE<Q:(\D""B4U G$[QUE\;QEI7;!\*I-99Z,K[
MP\1.;4LH;*F==Y[3^K9+A5&VU?(Y KR5[5CFR#;6,KT#J=ZVS^'?L7_+)E Z
M_6>'!^V64#R$7^\\*SSH4,'<YM5M]0 ^YV9I>C"],82VP.8$K( DNUKP=S]Y
MODSC)-ICTA\)NJC,#0^4K-*."JTDYH0-:HH8GC'D3-%GRA7E;!?@L&)<X^0G
M /,E)0S(X+.:$B1U%Q(2"G.#BDYK*"PFFKK/"2*ZE1AE05&92,!<4HQBDE7]
ML"Y+,T3A3ES\M;S$4"_\++%C+P*PD:*_+?1JJ</%"0T=[-=.'P4^HL0)VN!C
M8DOQDB6'JJ72W%)-E48!(8FHPF#@M89V0K-$%@7;*"!,"Y79(8V*+B,A3L%Z
MMJ\UC&F\TCJ67VMPCOES4.X?J4_PAM50>:0SJ;+<B_0A!\6^L+&DEP5JSS^H
M=(2+&/W$U[YCEW'ACZD)/FA3ENFIL+)TPV@B,U#)GQUVI"C:2LH467JKQ<78
MBV]H1'QTDI1P'.+W(H55EJ%WZ01!O-IRLR1JN#"8*G#$,&.UDZ=DAI $C#*&
M%-._XROX(_83HE*"!:K(P%,(7 H6GA/ D^K$Q+;U2I[ <.L4M&_#A&KH/P7-
M-RO[] ../:J:M\Y43CL!Q@]ET4W.4$HF=J\_3Z!]=6+BEVKSZX:VIR0;)\"K
M+?V$KA23XP-5D=66O*:6X"=J%4"SFP+P<.]O#=FTHJ,[8 C04,+,=(%Q8W&1
M\Z.3!L9QP><+!5/K,X-IC1)G1CED_+@QL,08=F8#O1&C#P'@@-';%JT3A3G"
M17\=3$X=)L2* ?.($6U2G5# P0CU%._@'#%XC.AO"[U=$[@8H:&#_5T22/NR
M8UGJ;%_6![)/(K'#C1\ZH6M@-[:=T"SQ1,$V"KC20F5V^**BRT@X4[">[6[L
MF,8KK3,(923W=;/9UVI[&<4)?YOS,;J, DH^$B9_<$@28G)BC[Y]88*$E@6*
M2[RJ'8'?Y>VMQL 5"9M[NY05BADOMCQQJ]S00;";]@;NY$98;1%CA3@O]!BA
M&C>4L9MX23:M*2Y+)SA4%JM.LS],?SD9:&#83GS?QG%*!R3,MO6HG/&GT,/D
MEGY A^L75@:Y^85GMIJ/:;,@]>A8QI]K7AWXF*Z011R#)\PA:5*+R]+QQAG"
MG0U/H[:9['8NGS@(P"1$*1,1%3+R7);LP7>>]*,3ZT)4Q&5%F;#6MPK@F9^M
M6PZUG\#/9(P%6._W[&4W;L7TP!^;Q\3U8_X+14((_I,PZ/9=_R!^!U;L/LM$
M\M_$-J+?1>&.'2J[\T,<T^&.8,]7V<"4]9L/LK9J+D/'QD[S0+AVT<V@U%UQ
MW8ES8:$@^%@'F'&T/P>)XCU'M,W7[K#3@H.3'>"#OK\M]-)_<&% 0P?[Z3Y(
MVPIC6>IL6V%K)N$W&#^8$=C_L_W7%R? _-&[."&^F] 9&/V"E^NJ?E!I^<#K
ML)U>O+W^DDW3Z!_\K<NUD^#K[19+MR0F%P(VCMGY3:I8.*T$</'4DAU&PF0X
MZ#M#NQ;%*>G"CJ,Y6_+Q/W IVNP0?(S?YW7CJW&X?*7H-WSG@-);"#BKD%V@
MDJ/XTN%%3NN?74M#THC11/W9Z[#UR)M]ZS5"%'(2A-E[@]NLC.YX!MHD#DEF
M:J(GO//#D V5,D-- NZ;]' (,-_:#9B\-T'T^3;<1F3/1^^.HS[JO6$#=D\K
M5*%9L2M<$.ZK@&XT5/D($&6<4(75R,=R7C!YBMKS?%9LX?FQ&T1Q2GC"GV/%
MEEG&+QG;J0F78&KFY,'Q/3H_E5CLO!7L2)=H5:_?5FL"-W)E@NI7[!#T$".X
M0,6"AT;KP:>>ZO^+3G_R1HO&@DN6"K.-9 ?V#HJ-T,M>4:.F?8@"W^T^<MO:
M 79 =NM:C4UY:[AAJB"S=IG ]8?E_>U_+1]O5_=H>7^%-I\^?ERN_X%6-VAS
M^^'^]N;V<GG_B):7EZM/]X^W]Q_0P^KN]O+V>F/#K]^G,=LTBZ]P[!*?[VS3
M"?BY?1[QE^0]%>%WB45UZ,". FW+5(.C-Q&X,:.OBFXHY1Q1A25?O)5,4<X5
M_<;X(L[8S@GRZ>TS,ZBY=@A;7+-<+C_PTS& MC2'#1Q=>E;Q0=86+@QT2JR=
M<+]^1'>KS08]7*_1YI?E^AJ"DW:->VWMY^6FK>.8M/%\'-4<[N:4$26=G?.W
M/OJ,IRV,N,R>^V*GO9IJ_W>,)>J]8<=L3RM4(UBQ*]QX[JN KK^OKW^]OO]T
M-D6:)HPG4U+PB7\&&,M=0VZ/[K..YM8!6;7O;./9W "6OQ3)C_ V/W S^OBM
ML-$QG3V: 6[ 7>/+B!S8939<NT477Q6[*)+AN7=GF/&L9X/BNK%R3^#WC?OK
MH7_!-.-4OUP[RE9'$X1-K.[F876_6:VOK]#Z>G.]7%_^PK,]=[>7U_>;:[3\
ML+Z^_GA]_[CA'W]8_7J]OF?_1I>K^\?U\O+1RA&UTBHO>$D(.Y['W*>T3]<X
MWX\"3&@88(W:83/U[G '?!TE]!&BP@M5F*&2F_U%^Y06F26(E(9@E_7+JZ%K
M'+!2!^S^?LS3'?Q2;%YPKB,9,)@H;*@Q8[,J^@RC"!>0#.FE'9&/J\N_7;Q?
M;FA,7JX^/M XY%LYH /M?=4472/X<*JO)-3:K:85:\TD7T&P=2BF&VU7M2-]
MM?()F0B\;D^\J)59*(JM6I\KV+8?)+1BA2!#2O;8F6%0ZP$;912TK9^5E#:'
MBPXJ0FN?';S_E<YC5VM+QQX:5.L:-SNZS,Y=6T>\MO:S<EAS6%L0GW*UJI"B
M'E=INV':<"^)5R8Z?Y>M8ZC1(@0[I/5MTW%CLH,*W/ ?H(MV2FNY^66!V'_1
M]7]^NOUU>5=D:S:_K-:/%X_7ZX^(1='FD2=R8$=19_97B])KB:/V;'!_,J\A
MD@QFAR77C$61O::'^"",OE8L-0?0N7%\\JL3I+B<EG0-TAU=8,.(BKY5O&AK
M#Q<8E*36KKV^O%TCZLV?K!QF;%*M:SSLZC,_EVT=XUH[S,MIS:$QHXXX^<K"
M$$!N<F2MK<;J%7Y*E-.,TL:PH[-=Q]KV1&-+N/'8(:_V9L+U>SO[X35U.K??
MI*WGY([MVV7-3>?BD :WMRA=4&=;1E/44NC=L4)P7<N*LT:P ZU9IVI\U5O
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MU ,UVEJ\ AX_4LXMIY:5.\,,%3T;5,<&M9[P@D13_I$BI&3.@R5GCQA_BZ>
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M*@/$.*""@<5]]'.]<Z%:=],5NLW-NYOU;O?N>I\Y>;=$\G&\VV(Q;#Y*=1_
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M[>]3MAA?;:EV?N0U/CNEWA4P2O;4ORR=JM8/.";VU<+ I(\=SPXY>7XP63!
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M_9,7#9$3L[*-M=NL(4[XPR03+]FGL42F?L8%+>/*#69VD8]R0IR5A:M\4QI
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ML(D-T/7K6[GNN(](XO^+"[#:WM*@"7?^4X"7<8S/IGG*G6"B7C^=:Q<C6WO
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M6*OT-HW6]13^&,J^8/(4656W_%TAK)C*Z=XE'5/\,(W2N 14!J0/_('7**S
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M Q'_@AFK:50[C0  !$:TA5 ]+E1_R54GYZI;GCUL$O9"WP.FM@X39]=_XM!
M8$YXH&(+M>G":>^Y8(*2#F--$@1#5'($  RC&N0FB.B," 8.K+&']P>VU?)
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MP-(QQHG,(4XYGK[9@PC^(_5)[0GG/W]7"GI'__KKO^6?9,3^^O\!4$L#!!0
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MJMA2$42PF7%(10PY1V(N =K;&X^AIHAB!#)X +H@*%D/O)$;@@GEH[*J@<T
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MK+*)LO/,^/S*=RS[AR-"L8-7@ %QL4$JWAH6< DH-9]^Y:Z16%3ZLN"H5(N
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M63?4 Q-T$0[ ?*?DJV"IJAK32L+-PA]&)93=3.:L]6N88X\5@4=[&WW(),;
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M@] (XJ,S.;9_E6'[B^GH[Q_OAOA=O='TZ059?+ W5W55<."X6";?7 UR2>%
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MFB?%+PZBKHT'H5@:ZOQ(*IX4L5];_+>(J9)+Q@C&FYIA)+@5\@Z-\JJI JL
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MI-"QQ(D23I#:!#DEBM!0T5./D^*3,'4)<D#4\Q8C0C>XTXN7O-X67_AU[)R
M5FH=50A5[>*>7R64P:>V[/A'G:>NP3/+J@)^<5C2T+(+JL@>?:CK_MH/'D5_
M!M[>C8&]<]@O-[%URS?PLSX.#+#P/&B^^AZF^\)Y=FS=L3VD8-2G59PBB;J.
MD??!I)IO^X->O1&Q[%Q(\ZAB+8DA(V&=0I)%*+TD?JD-O*I:/6+"PD@+7_[I
M^9$0ZE&Z/57(4<T*1HZZZKX23J$9JX"$ Y_"[2A%*^& 9Q!*B((:'T5R+'?2
M.S%<X['Y3YQIR?7N-)>XY^)M1CFV"6%#QJI*A%Z4>AE9Y/H_2$J/EQ40O ';
M-=\!6A0X:X"7!W=@Z4"PT'Z2<GERMW,RG!.BF':%1!V<EN^RP.T#3'+O3V55
M.A4Z%=""H.45*:/WA3)!3_O@(FQ1+\$[DH[-&^W4%Q'M=!#GA/O2B3MS#G)B
MB)@9]'L]Q-V+BRO>]ZN:'.34ZR*1Z[^7+P RN4%.L9X4<:"*NNY=(_PR4:+-
M8%0]* FOO.O>"E@_(S!YB#*+J@C"*L5H*,<"9C E1%Z(Y8F:011M %R8$D[S
MT*#U$[\<=34^D3!9\)%C>Z;M.SYA1WO@4L(_SMF'"?^.4NP5SJM\K[$<!=9]
M=B'@$.PW8*[>\*.-:-K75N!)\_ OMN'#C&5/QJB-JT+):BE3XAB-7YM2CSTJ
M?Z?\Z.3G2$]Y(/4NGE")-W<*'QU[!>"SC]<TTV7\>Y(+0/)73]T*ZE2SU .:
MAIG'(W!=_+AUK,EJS"/WJV?SJ$_-=8?XE+:(W8OM"[#&&UVXG:PWF@GQOGF$
MNF]ZX2WV_7O4$WNL0=NT5^[A[Z=V4OU?@76\-*KBDV=;J$G'$IXM:\T\4<FT
MD$2EUQ_TNB?)_ JT*NO1CX;2^PBO2MA^],TS^>M2<F0+UT5MX3:T!1NL@L]4
MG7EH'VO$%4USDW[NYF$XF76^#Q^_C=6/A<F(L,KSMM*K5)Q_Y>"%51 XA!Y-
M[14_JQH<N.%K^,"8VC-L"!"M:%"!9P<Q/OIG$ *;%?TBO'W5AB46W!/96J0J
M0I%S\IV0=]M()+Q(?H#@#Q_8^I:6V2>_IK(,D((HA4&<*E*-&UF=I]X,9JBI
M+#<XL:*@SBF\PJB[.Y.@1LJP5%46=TZTV'!GDEXUX.^VN[]^-0%$NGS;/H)W
M8+'-!I3*RH)?_83 JR5%GF3()'E:%N[9@=B&LI3AAY!QR.#2A&ICQ\3>^)X;
MZ*''-E>D:R0%O4""]M6 O#!*%.09Q5<8YPMNG"].&V>:^(H,\\+N/RB$:D5S
M/*-&%'DAH[*;$/43@1&8/$29155DR!;]\)UR2#(#DD:60UQ%T)2=P+9-Z!80
M6Y'I5ZG;2ZUBA"!EM/GANS8 +DP)BCQ\E^V=#M:FW$<TNUJJH:[&\0Q=/91(
MK]IRMNZ2^^T$RCCJI$X2'"TH2QH.$--4**L 15:'8]<SUVC FRX+4X&GB:0J
M^OU!]ZI6+I1%,<V+TMI0A!@BAM;'G(=5A7Y#-6K5-C=)4V;CXSAEYQMK">OH
M+*!YNY@U).N6JZRX1[S-XPMYO$V'/-Z/[Q;J!SL&HNZZG1/FF%WX7_B=Z.M!
M__KVZK)W>3'HWEQ7;>JX8_NW/6C1BQDE53-J#BVGK9-5/HI)UK9/":_6/&@Z
M'L!HH87I@BIBR )#&D!&V=3'CQKBD554-0P9D<B#D"*<(HM_O *8+L->4_=^
MZ8)J8T91?1HU1N$4P2PYP%#&RG3!I%B7:(?1U+&24385WU%*=OU96P/J>$DJ
MKC:61$3RH,P14&YNN& $&*X@"#R%^+4Y_0U,[6RW&$L5M4'*T?7QF4D!46N
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M[S6]N6/[P&N\PC*9S,]EB)==JT!67G\]O'#P^N4+M!RT&5Y]I)4V-@[NA#\
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MZ%OD@LT!1Y,/1IWSG;7B%C$1VXR[;>\183LND5Y >K:APJ67FOOX*VM.#3L
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M+H#14!VPAK4DFLU;#_9((3]UL*U5T1_U_*&N:T.O*0T5:@S>X^P9,='[?%&
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M^JMK^\[ZV[JR\=>69NLQ'1FOA!4UFTC+,.Q%6,FWCGN!"ZT:<%\$,J$U=%O
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M-ZB<B:#S+_1?K]'_"KZGN,(>?.\';[!W9R UE@W95/Q%G0'@IF0G94U2>:"
MQ1C8*1Q-IP+&3<W\7XP!,'V*M7T-5U,3VUJD7/_O94_5@CR'B6;ZS]%"#[;L
M@K#H>4HS%<-3_=]J9JJC38'Q>$9R4IQI>O[8#EA:MIOR]XB"_U('#PF*9*H!
M>8>/WP'93@$S>$;TK2::X7^^T=Q9.%8 BF?_.IOQ6V4FFU.0"LNP.TZP$_TE
M\+E_!5]7EVUEEJ+#!^%/7'7AZ7]XYL@(/Y[M;(]3;Y$Z\_6C_<FM#,77(&"_
M(8, 0(I3@MQEV=SY($HU+-?_,I]/<Y:O,*;CZT;A62N%9ZT\T>M^:J-\N?YC
MW[;X\,X9TNZ+#4DQ?$ $5L+L;U5SECX-_@Q5YA5OXJ]V/HQ^P$G_HS]N=+\]
M+*, PWA->;]9)D]/./.J8\2+93_,,GZ1Y?O4\KSX]__]?Q^R'EZLXM,"A;O%
M%&3&-I#UC#SQ9^&G;&SDG?,XY33[@/_:WY[>'0\==HB_NO^7>O%S($]$=Q;R
M-O-B^1[WG@/2'__LZ3/[8-T\?A@Q<'Z\>N[S!HVAP5'@I>81Z ,=U;RSQ%*I
M7P<0.36S@Z/#_W0MY2@RW]\;0U/'WPQSP4DDI(W'=9=_?][3RI(4KJ OW/P?
M _'K-3DVU0GAJD?3DIGXMNC$MT,G)* E8H*2DDPBM(0QF()/$'6BD$^FY?GW
MC$#4\6_?\E*P'_]TRD6^EFJ5N$Z=R_%BMYSC:D+ZL(3E1L[?H<<OA1.Z7)>O
M\XVNT"PT6WR'ZY:;#4'""8QEF=@(E6LV\GQ#X/.I7^^;:A92SV\<2O76$X1G
MN:\OS5]ET[?N+,_Q;3HGG0);!?@X7_IVH#.3;=\ 7?@$ZSK_BM,K>^:C67S*
MMSK'R?P1LRP8(]2$ !([84F)&).4Q.(X*JDTB1(JH#$,IW\[0'85J9#7$<)S
M2@X""&*ZF,DN42MO)%3"7H]L9%H%_\DUP*^:@[R(C=J*I08CF=<C.3FK]YU5
M9:%[O+EJE?5,QY#:$A9]9J<DUG,NKO)ZM8I4)\/ZO&VW.7\D^7KD/">"1F.=
M&>H>T9GF%M6L8BO!R,BWTQ-C971W^%3'",<RZS6K31/!2!1]/50E>;LZX3&)
M%QIKX*#8;BTQG(1+R.N1$T*?[[O#S@9IZJ7"7,_.MD9C(Q'1D:)GVAI++E6^
M20+=S+0;E=(T&!D1'I_D['%++0D(5F@7+'G+M6R4\T=&A,=R\]YT7]*&?+%@
M2HMJM3IM#Z;^R(CP>DL?T%S=)77-ZJH5L52G^T;PS*CP#?]IH#%<.4AUI&=)
M3Y473'<CD5&13$-?] ;* M$I997I(L1F[B^41$5'+AOKY:24J9-\M8/,:BI'
M[*5!,))Z/=*@NXL!EJ=4T9NMB@5.[.U7[6 D&IFG7K_2R.U$N:$+51;G>6J(
MT_.I1$>_'EGF^G-ZUUCK?:0K]B;M3M=8M"4F.G*$R=6%Z!F:+I?GN<4H.RN/
M,E.)C8XL-Y@N-Z#6C-AW*HC+&75/%7RU1Z)#<;(XTHN#'2;VM2VO+]1]LTFW
M_:F/#FW1TSPCS!9#4>LKQ5I/R8VY>COPCD:&[I=T/Z\W,5D7^G7,G-G%)F=/
M)?2(EC+(OB'QXSK&]]$M71HIS6%/Y"3TB)J:?'O/C!W,7]->PY5:_2:5V?DO
M<&3Y!W.OT"GAU:&88X;BO&T:TUS+GX$CZ\]4<ACKXF6<SV!NVZ48=[,/9H"*
M:G]=+^G.'F$J2*9O#)9J"]01/1P:47]U,-0<A=G7D$Q/ZJV7"M+,9\*A$?VW
M,A3 NKQOG?<YC)R*_;&.R>'0* "T[G*TV/>LDJ[5A=*>Z1;&MN"//:(NXUU-
M9\E-QD4$>M\3L[N-W+*F$O9+"3[A4SO0>V!@/QK7@?6H'.S3W\[M@5?QZ8.#
M*1]^\IO%_\)[_#@&>3;36?R!HO[OX$%[>K47'L\?'W5@D\@#AKZ5P_#"*'[Q
M?,M_YL2P-D];U]-_9P+_VL_#"6GCS]2[)Y,77L3GH?+8L0S/?>WTO>#^_ G'
M^<OSY<?C!N@#2\-9O_RLHU#7+S[K[ -+P%F_O*[3;^;*PUD_$\.\F1$(9QTR
MS*W,.K1A(,/<RZPS#PS4=6C#W/JLOY'@^69U*;@0%UH(]@&!ELX)%^*3-UW>
M]99=-KG[RSDKIS/RDB6P8AG!A__]0?[X(@ Q_.&Z5W:9;T8^NS,;@$/XO.[_
M=N8<?N:#!+[#CQ7/?!R (^FG7(DQU)P/:LY!31XOAB173P1M^STM@=1Z;8"P
M$7G?6O##&D;_C6#_&0K8AZ" ^L8CF6@H'!*0/\6 ?S:DWS[17%W6,VC!'^?B
MZB4!3J 86"RWQJLC_\_G%S;9YA/D@O-P ?* $DE7#.P4!M"UJRATP!J8'G!^
M?HW4;N4NY&<2"NY+YD.P[;YD/E#UO<F,WM#=9JC;D+?O6[</(<S[DOG.>/OM
M\-W=3\,A>':%:7B[#M])RW?$RN'Z^^'B=?6ZEFVIGN*F'-D 3CIE@D\79(M/
MB.&26'X[ASFF=9/>2]%+?BO!O&?+P7.""UF'NFA=ZT61-,=VI4>-;]H"L->:
M KBMYDB/-8Z>?ED/*VA(:V*^J_>;Y9JN+1KYBH;1XTKC.Y7/PU-]P;86P6WI
M0.2^YLYRGN.O&K#Y;5 %Q%\.SG& _S_UT#KG=4TE;MA!/92=H4A1%SL:71.R
MZBZXJQ94R\73#!,MLI8$/]F'4<Y<$.1G+BP*07X2D&,O08Y]%N0C Z_D\AFJ
MR0->$SD&8<8];7IED"N%K%:7JTT)V=EY6YP--]6&%8 \J)O&I$DRVF48[MLW
M"^GW$E]O"-+H*?;M',;WBTNML!6+-LNS+#D>S'+M*T.ZW"O.YUJF/D>*>W*#
MY9@66PION+,__B'H-(5%2V'#??L<>;(Q!?E[6:6W!_+O[=MEA+'+%H=*B.8N
M>::]6/2)_7?:EYT"Y-ZNWNTS9JLLYK!QKK4FT7(W&X \J+J $VF:H-] >0*#
ME:_]"4]SE[(?0YB'$HCA!?VQ=5C_3[?-OC/O^-M>A[N?AJO$AV+#G9]T;/@O
M:DA/H'Q**SB0W$M$/G+J3B2Z^]R@FM,%?C5OMH:Y/'GUL] 4=?3-9-=!]5VU
MS/5+M4&U;4\E,G1XI!$DVAWH9'933+%V81=(3&<!,DXLO2R?8YPL7D $9MW9
M(Z"_M<N9_3A'@FL?U72Y3U:6KH6+%)LITD)/6.=G >,$WA<TC5'1HO70I($$
M\UT'S[T2S"=]/I\CF.ZBH LK8]X0M>%PH>=-.X/+US9IEOM^QMT4L;K>UT'#
MGM=)U,P&I0$#7U :Q[_EW84F#4S#B&<:1MP8YSPF3:U9'JWG;H70P60V$^LK
M*E-%KFW2$/O64MJ-R@Q?I,5,GIG812<T:0+'E&_3,,CI'5/7\T(5@\OU9M#&
M(%S_0" 8'ONP@^F*#5/C-R>/9[_X-I&-K>OIR6W_"XQ/_/5(E/T&DK7ZZJ@H
M9JJ#%:<HFPK%7#N]1BKNFL5J'=?T:J8QKP\IFF^U-H&\/D^F_;6&4;I3GOP@
MUR2;:\).5=AGVG7?\^X*-?ZXXR-)&A\3+\B[NRN[56RR,]3K2%\OKRK5ZC0O
M7'UW9<=& \MU]"72[[10V<8J5!,)NA*P<'<]@Y<#<DW4Y9$DKHGLKC>0(=*U
M7-EX3@^!<9/3IH) R'\H<)LH%KCL>3X[Z.2'X^H@KWL5HKB:%LFYXES;?3DJ
MXVT%R>>*.E4>$^55JU]QIIQ$ASD@5)IASI@\&U.RN7X2".0:R#7?2R(IYW)Z
MDUVV1%%H=C@3U8$RRE[[C%)OC_5*W;,QW5O;^SGMS@HTU?:YAO*YADTS*,S^
M@-D?%\G^@,SQ1[^(EA<%3MSQ<[U9+T@:ORK-C.VUL_\'Y75NU&W@$[U?JNUV
M-NEDUM;&9P[VQS\DEF9):*5</J\#6BD?RON 7//'O!!)77&4H$]&"-@[Y)[A
M"]TJ<>T4LFZ9']4$8)'(:H4MN1W6(F:YX$04)'005)HDB00G=(0WB1S72?DK
MF0+;)3"=+U=#O"^ G[\T2?QD/G_)@_C)?)=!C7/?WH_?,M^R:M\S1]^=(I^_
MAD7\9+Y+CCYW\87X+?/Y*S><3>8;B"<'YX24-4DM7U8RA [9TX:5[VL:X'W?
MLX>% ]0V)T7+4AW.5!\3VQS!,M0CO@Z2&.A5*8\4$+ >+_/81E5MM"VQCSG9
M-*P  $,TD!$2'KS]%".,\9R:YU:S!E)=Y^JZWF[2F2+G,P(5,@+^K4 +M @@
M_N$%_4N'8#^%_W6-K39F]L;@%\#&,CJC8[PX]?'/AC6!2 Q:!/ "/;Q G^Q
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M?P"!I%G\S?O.B<C]N-Y>#N,R5R[>$+]IN,H5\ 1XC&&\X6H7IB%(X@82N&]
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MOGHSA[4$9!E<AI0^G6MP5E*B"'FN$U8>\,U>2VMVK%6K7@U)*4@Y0!ZP,]Q
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MR1)8L8S@P__^(']\1'@,>T"9U\E2%^U:RGPS6-:=V0 <@JIU_[<SY_ S;ZI
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MW^XR]^VZ._2)'9"7WTESZQ$^9#:8@>PP'-TW]P,DT^+"G91^>R=-5D[=I_N
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M:@F@+ DN@%*H&19(V'L3!GV+/FNJ-TT$*'^"82><$XS&]\]'9V!'#;,7F+W
M[ 5F+S![\:%6P<>9  \Y#\(I.&L][JLP&B_'\]HZ/KT/\<GHCM>]E??5)X\5
M"?(B(_Y-\R%A79WTRYI=)SRQ(FL 7E]W.U+/S<Q6P=BJM9DUZACTQ* C=ER+
M*X$9D7@J*_6FLL;$"/DR.GY9JN67=;R6;Q=;97.NRD$5]JQ%NND<TX0=X[[]
M8._8U'&.^=_1\:N0+1^U-]\@$_-R:A 7E_AKHAKVWPDHXAX4C@24ZP1*GN7
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M&+-!-Z<4-V-+Q6S>KD\V?W"PV.^87+FIY8OM#*42[:PT';9'Y73?A2975'1
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MV*&S%/Y=M"'>)QIO_,'A!'0_J(A[NTNTVO+!4PC[&IIVCZ0;,B:E^<)RM@!
MZP#]:0/ZW6'D5,-"@;K/?OP[.N!]>#^(J,<H$@"V>6M4X<6DL15MR>&Y:K3@
M8 ^D3Q8<T3J3AY L+W"W^Z'-@3]%PB(_L(8G&]Q%4=&/A=%"'E0U7+C_NR:4
M&FB&!^# LCQ;/TVU]YQC&*F1F*"8,. >#3MR7EX?\D>$X#\AH0^=>5TT$2$4
M!IGJAV/WD'P-]>N!P=9_KHP'XBG2$>0\AD$Z2#7W!^>1-#Z<1K]4!A5V\F&R
MPHL;R$NQPIB#O\*U<@(/2JWW]_>/",IJ:U.@!Q:HC\4G'7L,6I'V<X7*?V<>
M9ZD^?ML D L] 2PVMD48K)1)*0)85G:7.(*AWA20,]RM_S4[Y<FS42?VAYOH
M]$Z+S@</FVIXFJH&OG/X(CI*#;]Y=N+ZU+^*VA /QZ0I^IY._2NRB0Y=.T36
M1^/^M:P;+'G/OUHHZ\FAY)/GHYM$*%CF,&^'GY/(VOH>G5"OX4R]>3*\MSG"
M%Q^:JB,/Q96#LY\(_W+BA5^7C6?G^[^3[(1G\:Q_X*S_U"6X9QB\$#%8B-0]
M@7$H#@M!W5,"7H@8+ 2$IE<S5.*%^#AH>C6M(%Z("YE(K^:#P[/^83B$I3\.
MZR"$'A]>B*LO!'5/8 LI#@N!D2D>ZP"1"6_59UR(W\R]_R:']W&C%DZ="%ZB
M]L+K]-EM#5AS+/3E_WUCO_W*X"GZGN)>YL;^T"JR#]GY_C"+8&?J A!%"5?#
M8*SHLX2">:./*(XR^D03=X?[,J=/Q-_C0WQN.8FXS1N6D[:Q>9^48"#]FD!*
MO:4@/[4HB7OVJ)["3>D,.@#^3:C\4R;XZF,]7&!Y^>_1^,\B& Q[ZX)!X3WT
M_9*0NN=2MRX(YT.(UYF0JX_U Q$"RL5M6^7' /%GYM.U*\C6G\0</HL+_#/C
M*,X5_BY78NHH1.(*T_!*\:4XS$L4L7 %:7^U*-4]]R<EPJ/ 2:4_%82\EN?[
M1"\CJ,/%0!X)NY\5IF).QA[NHPN5=\84IK>G'R!N#._A'8<8WC"$MQXJ>36\
M"*S,2^-U12^N2Q+5"#+#[::@$K;XQ^6QWCD8,4Q0<**H%D]EU.R@U%&E<C&?
M378'LIB?HNLA]+<?-'M',2>N2)[-L,? %@988& ['>_PY8'M1<6]>  ;G:YP
M\Q'?LZ2>70=]+E?/--0_K^1Y*6!KS7Q'6DI$S82C4'LVDR\D5PC8. AL]!TA
M'-<+_!U@>^*88A2[OTX=]IB#6!0M\75![/3-D'B &*C,F]G^%+3-NK;66].Q
M&=1&\0,Q)R6QS&+)$J9:IZR@$5C#0F$-02QU8>N,P-89QK578RV^/*[%TCBC
MVMU14QR-'+E>\$70S:;E\C!^7F=Y5G7,6KFSD;9LNL8M)E1A$DP@KI'4KUAG
M\3M4/:( T?W?VST*_7!J[WJ<]2T@[I[GN^(DQ0A^KT_ZM8#GNP:Z2Q\",!J2
M!_5]#\&F[!;ZYG1G2O/<F&\)(SF@S/A!L&""34W);G=$61!JU'PD$+W1!,XN
M_>T'>9?BZ OR?E\.XJX;T'$C$$=CB(L-_?<ZQ.4:<J"VJ/96;K>R6WK<;FK9
M5C-V$-?;S&9$>5K+RCVUS197'M/G=RBA%8<@CDR=C0'\:GAV94V] 3C;<W\8
MSN)!!+X.9[0O=<"F,B?D3-JKI<9^(;WV)[&#,SOO)W=&<2B:P-.,HI?OBHXG
M0CA+7=9BNW" %4:X6T6XZP:;Q1#A8FNP]0JM,C_074$*5JFV5BU7LRH=/X.-
M2!H479>"BISQ2JS5+;==O8L0#M&";UILO\X*_DRF8Q(^V'%\U3H+C.'HP=>B
M!Y^#%PW!2W<"E&CMHR ^7O/TTVC"J\Y3C%#^-/.8[K>R@U&YGS6#$I-?3O+L
M3//BAZV=LK6ENMVQ0!ALGR$:M;9>[HD*&P;Z\7<4P>- ORL$^F$,^K7 /XQ!
MKU&#Q4S&K*<6#5ENUUNB39I &Z;C=^8PWU4Z$RM7JTE@7<TFQT2ZWB=0WG@4
MD\?<43QU$0S"87JOAK-@"/JUL#T,07^2\3EF$%3H%-7YU&LOS6W1(>N;TE@D
MU":$H-2%S2 <48<AZ-T1=AB"7N/;%'TI<FUS/"3 SF-W@I3KE)GX\?B9G2+U
M*SV>-ZGQTM';O%W*\Q.%C8+?WC2#GM4N.7_-U4MDE[J%3EZS$L!M]/(WX.\V
M)O.UFN>ZX2TL=?L]U+/]BQ]P-V1L'\O'4_P]?5P^_LESGSTLJ0'+^N?5H(*S
M%J#_Z85\BCDJJ)TZX^K]?+'^)"D=^O>__^M9SKV'[3%Y*&\?[8%/5O&P0.%V
M. ')**6?.H:S\%VUUNK6VT\YGWH\\OO^L(VBA4Z0!%S=?R6>?$;C.9(=5&;C
MR?(]*Z.Q_[/GE30.7[Z16G O>J@.%D7><\\ECT$4_Y'DG?M((A00[G%?5Q-3
M%VW'_]-QM)-ZB#Y#Q(?[K/4L7<K^JV\_.E']P'$BXX2%21ZK9ZO/GW=869:C
M-?(AF\:O*O'+-3DUU?NZ@B.:2-&:QBOZ>#12&)KC%('61@I@4O!;+<4S0NK;
MC^=E\,RTVQ%7.:M.U&LMLBZ 08KJK$_5%:PO9Z3(5KII*2BSIAG,5OS6FYRJ
M*YBU^\R(GF4[<GNCL4G#H]7"9GVJKJ \J,PI+>,DI0QH\ ..H(RFT#Q55]"S
M\NE1O2:N);7@>M-Y->EG\NM3=04[.Y7IM&K])C'OC:?$6AS)B_GINH*Z3-9G
MAB%UB*VQHTVYG]V,E.:INH(;30+N9#2BY*3,&,FEN=BIX\FINH+=^G+!S(;=
MH3E7.W90J0^ 5D(MCP:?+)M*)CENI\R>U=+$0@"--FD-6QX-'HC,BE 7!=BR
MH>R$:4ZE%DWTS*/!J[9?GXL4DS:WW&8F[8A"=V1.GE0U?"S4"-*I=4=6.*G,
ME[L[UA[G&TP36J)'+<>94G92JEII$_C#3C%7)#?!<*+PQRV9]F[$%G94A9BW
M1Z/*O+RIDI*H",<MB^75/+W5_;X,K,RNWUEV&=J=P);TRY9$E5BFA]Q:,=MZ
MI=@OS/U%>8*>>23*KB'7U^U4D3;5O&T0$R_G;QH3)77\=CXC=',3(=,QDQ7"
M2 ]W0I#LHI9';\\!4^]/[5U72NIY%TA]J5J'LY0Z?OMN,IAO6BO1(LHYJ[(;
MYT5_G105DCA^O<U6],K.ER4Y&(W,+NDRR;S<A/)YW)2V!L9,65I#V:BMMST[
MKZ1*#GPJ==S4;Q6RJPDT]:7>B)I5UT+*<S)KU)0[4I%M-D_ERO.%!.@E+_85
M3532X5/)(RF=;P(U:TR"$L&E:4&8@$8YH*':GU"29*X9>*GY0C/+ EL9KKL@
MGRHV4=.CIQ+;F;2EI+DOJXN.UEBV)4>MKE'3(^&7"I5%4QRD!&G+;K:5;*:4
M&7+A4X^DWZCYNVYSV,B:;9?T^7J972KCL*\O=%\I6"8+_2V"INCGLZ.0FL!K
M@LXI),L0"L/K8V4T@O_0U%A7U?&( M21E$C4O+-V*Q-6ZK%SGE7H4GZ:/ FB
MVU+/2%9K@XXT%_MJ/DL6*AL2@>C1L,ERD:STEXY &-EZW_,*0DYHGRS..O:-
M\3I?2,M$F^U[-:X(BKW6Y!2(=H!/-_U&I4WD"XI0L=I.<Y!&5S&/GJF9;'ZV
ML1<K,S_T4AFMMJ[M0F0\QJ;,@"'T[,XUZ]F6WVVD9&T.T#./5J<&;0=^9>=U
MB>O*H[;D%E9I*[PP=03,5BJUR*?34$+:?':NEV1[V"V=A%MRT;0FV2X3$""_
MG#.;$3W.CINGX':<2<KYD474"%4JI=;!QK*+D\DIN*VY@:J8N:$C]Z;)^83M
MN&19:YZ"VS*;=WP'%(9$O3*KN.MLJ;:C$80?#VG=+K!MGLXY<KEB]7;N2.$"
M>7T*F0%(C]*CQG9)])IC(EF9+UN+0#R%S%N2E5PIM\H25&XX+">K<WUBB:>0
MF5_UU6R.HC=RK]33FLO>-@5TA.%'TU1H)85QI5W*R<&T&Y!KLCRV"=3R:)I:
M(R]M9Y-:TNQ5"C1'#=5Y5T,MCZ9I&BQRA#\RH(P(@B6.G*)D;U _7ZHER7"D
MSNN,PFF4H#! I921(/ *(%55'Z<T%M#:D:@ZG7Y[)(BVO.PK\V&F,^S7UR>5
MK[/5T[E"$Y1EKI^TVJX[%@?=]2GE4^A=N>,M1V,3U/+=7JZ;K4UFS9,6C )4
M6BVK?7D95!?)?&?6&CLGE6^[8H<UVYFJQ+8J3'6I73#'T^8IY?/(IDHU:Y8L
M!:L^U]9+3@"VZU/*MYQL4X+?G,^)>8842L4AT.O-T\I77I=YM=^MF74ZG:T4
MJ_.:KJY/*M]6;&<&O< TS'PEJ\YV8TNE>B=K*)?91E-JTBO5+ =<=;5:^J.>
M<=+6(=(*K;4:E:K49EFA6.')3-<^J7RENK*K06AF3;68FE6S]L"=MTXJ'YGC
M!IMV=6S+R52FF5N;?-F=3DXJ7U-J+5LYCI EKF588[-53(U;XBGE:WAJA2CF
M>4VJNTE/4UV>W%1/*A];KVS-&JUDY>4\E]M18,(.J\U3RE?W3<8HIPL[HJ[6
MM[5:GBKD^)/*MR.)2:I0:"[E3(FP_66&4<W)^I3R&32I2,UM<2'/)Q6SDAVW
M^IW<^I3RE<K+17< -UHY24ND1LJE C0H3R@?KQ$JPXXIA0>4KC"4RBKJ6!,4
M?4236HKD. KH+Q_>;A4FE7YUIDI<?M4$RLCNB]" /Z%\AJ-.RC-*:TAM<EO/
MS39I.'5(^8XL*4,@-2HCJ4 ._++47G-]PLN<5+[%EA?F-5)KFM2T/:NW1YVN
M5CRI?#UOT=0HH]N4N(!1<LW6(!D,T3./WN[I4\D)ZDN6*/-;?NZ08TZW4,MC
MTVC4-QHKRLOXLM$?C4MN6],=]Z3[4.,[FUXZU:S)Y>9<'C1KFD>LUZ=4JEBR
M5C-IGMT0G&NO4WHOF>Z53QKP@2?F35>:5:5 GM<;PYDZV,$-Y82D%HAIGZA4
MZBY!@7HK/RD/QO,=DNEC8UO(MUL5NUDEYI4T.>@WE(+B(*> _*"JZ"VP G8
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M0)8 60)D^1QD$9_I?&^K)WBY'3.FY9=F;3*B;@\!C44Y^9(OD&6B+5'M5J5
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MDO>(SJN<UQ;T!&;7RZ99'Q4IG6TO>CJ9JXX-MIN&!P![^X;)$_ZJ7U\Y[!?
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M!7J6$N(5SD""6-"M:<@$-R@"V0IP30'OAZ<*9,-3Z$Y4PX*/X>L#M 'N'O
M9@B?&F#.@+ %5(5<$")40\"I@1.'W])0B2?@-!YH(@:R"\<6O#'#0)0(;Q)8
M/0+X8&C!V:$Q>HQD*OCLG3^'K.4$L+0)3L68 9*U'<IT?W+,GBDD+0NH>B$#
M=J.;2. A@.B06@ON683O&=LAP^)GB.Z!<,<*A*[90/9(X!0AZ:LV$/MFR(!^
M0KA@H'%!E<R 0S]./,#:'9%W)F=T*U,#&FIH8IG IO.OV=L'V++E/A$"''C$
MQ;,/@U^ZJ <.'Y >HEK_!\#!@U6#CXG@#_]SI6N7;>=&;#,361(EHB;3]C)5
M;#7;B<XT_:;LVG/V[\XE&DE>X1.%GF#H$'6.J^&<%J)-3W7WG*(I;"37.%T?
MC=+)9:Y/=O(R-8UPPWXC422$](]_R:?HD4<T- ::+'(33-#9+S7HO@#PY!(
MH#X@;P2HC^SHR7=+SBT"15*:3@'G@3MQJ&_O0I%*;NDZPD$?Q=3A4R3PZ 6
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M$0*^?P!V3HSW&!$]OY6K\^!8$N+S8P TH!ZU!HL2$'8Y*'H -T^A M!'<4K
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M*#O8]9+\X+O_2@(X)0F=>B)71#E,ZS'Q2=(HU95^NEQHM!G1TL36=-&?;[>
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M9_A".;A%/"8K""G@)C'5&G".U PN#%R<X!\7CLJ1]BD<U^<XKH\I^+QG;[D
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MA-WQ4$683 S1-#YXSO%;HX>=@SCVZ9I;=4_1@*1H@+7[<F42T$MY.0^T)1K
M H(I[2AWU8,LF/&)QR,=Y+'[BT_"*-%];Z4G5XF6Y5MK&"EQZ!>0@$J-UO_E
M%LM_<MAY(VC@7&&^!E9J%2?#;.TE85@XPL7/P %B2G2+BYUT!O^Q"!PL"7F=
MN]*GOQK>_18NU>,EM*63U^+MQLFQ@HP'8%1:XJ0IS=%"1<"HVD+BO6(OV,D
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MM64QO^H6Q'2IWU<_B0T.1;>_;!W7I1]5H9_LS>08@[#Y"]H?I-,+9 R8[V
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MJH4.(^$S_4F4^@M[5;5F;GO( W"A(;@0W+>2#V(_Y?TDI6A;T/52G*(]#I%
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M0C@)(>H*"5>ZOW/!/_UQN<1FDL04$V9J"24J2#E3GO GS>.KD8'P3_@@,.9
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MS?W=:U2,>4<<[^]X?&_\@Q^'@[\WMF4Q@^8*M?%4:S,E,"OX^7:5&K\'(C;
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MLC"!MLM5T9X(-3+C];GCM_.39:-=PTN"5K058ZDI^0&,<&+H\:4=P==5#B@
M*I&+]&3<:M3\PAA>>M321F6A,4+.S0DJ;2X'\K"<XRK!I4=-+=(51,VAF;E0
ME.JU%CKMU*L+<"EVHJUH$BW-O#0A^B@U7:>7OJKP/ 2RHP;HDK?4NS9.:GA^
MLDA*2K.I^L&E5ZJ-E9+L"?P?\FPM > !I.$-N3$Q+:>I6+-\4((T *#CRD-K
MK#::V!,_)]#2E)RLNLMU=K;!<-5P%9EWWKANPVESF3I%%_"S@D)<1VG-ERD=
MNLF29C8%M4+,?2N?&HKP(0%_)O8D&<!\($L$"C.Q)\U=OO75REE]0M-.%[KJ
MYJN5<9JDFVA[PDW08GV 36PO H6NPL$?PL%77@R^'0R^ P=??>[@&<IA):);
M#XMYI+ASU,,B'E$FKO;PPF_\1!SI:_6PT$<LKH=US5%_/9+'QNH?!4%PCT1<
MER\*@L >N5@.$9 #_HC'99BB( @,"T["QY*X54&L]US4^SJ4?@;O\+XZ?(9:
M%/0C\^-K4<16<-<=_GCQ@3?F(9Q\WPHVWP?5V>_)1"Y1NR+P96\U(!&L:_'J
M.!&/]%^L6F>N@Q$B\:T/I<!XZ-<@-:*YY-?,OV0C(,#S)&P1MSD?=?,4K6/^
M*&@0O"&_W/W8)Y."WVTXI!9BL]?K<C:'5G+3+"/T!OJ8_'IJYL?W74XEAC/E
M3AV?JUU1Y=(SNMN=**4*W/ F?OUA'QCNS<3P;TZ.T<2"JV5RAE&6OP$*-F&*
MB&/!1_GDOIR]]#4TR#S90MYO)$>"I-1;276RP$?X^#9H0%GEK-^R,H:&LW2>
M(7/U)P2#:$##PCHX?8HN-+J+RB-=+YF&XF]YKT= 3S]]H#8Z"\-KNRPWM.3=
M@N1L7DN48.E*+LJSX1_Q7 9F40JL(@.-8@-,3Z.Z(8JKNB7XP]PBR7;-:J52
MNPTPT0VOFV^TYWUTIJXJHE3PUU6;#RM^X=@#AKYY]/]2&U)_K5/REQC[N]LG
M?[$3\GE[Q^;#0LYLHX:68HLF/J#XM&C>R!%9U%M&59^[27&!LD0-RR7+"WQ7
M'PP[41_LWF,J8B/A6(IDNY:? %;^^?JB<8#EM@&6JSHPT>K?E5#N4TZ-V&AN
MS"D)K*FA#%U+=51E"W9\0VV4\J!UXL)K><:BVB7ZRHUB,(SDZ^I47;6%-N,L
MT6JIRIK)<5B=C'W@J&/V[C@$<^<AF.LZ0-'J8"1]HG?@PBY..U*Z)E&"^D29
M:-D>F\G,UX_B?@LND#*E(G+1FXM*;^UQ<W*HECT^K()&/>#X^7VCJSI"69BM
M9,#. XTV#=N$AU"#;;>YI=I*PM[))@[>Q,&;'Q^\$1O/!M/8VHNP,Q<[K0R<
M(S@K/J&37C.'*RA-5#L*FA=I!+O14J^"K\<ZCHY+8D.1]32=?.*SS+:T&?5
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M3JG1P\;BS"-!S7=D;1O:@;WG'CP,&2JZ_L];7L_YB M>V,-AC6"<?+:%C3U
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M$D\FOE@8-$8E5$NE\371TQDQ*YS$$P53IVZCJ>L:+HV:QC3EY$=\[22>&-R
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M]8=]X"CLC?*Y,42<X>S&WP 1X>&'&"+. 1';RT![' 7>#(M/.G[*G,U-(ZA
MN?\P?CAT9ZX.+I7+BO-<9F);>B(?U&< XUZ%6& :O.-8ZL -2BLTS;)IP!Y9
MIJZ#2_+0#0+W;QJBRZ1ACIM-4BQ6RCR2RM;<I5C[.E8]M[3B3!0+=LA2)HIA
MJTL%--.<*;#!204\46E**^P$6)%531O-3'LJNG16IG@Q4R]KX[ 8SS'Q4 Q4
M,5#=)5!! 6+X6;@+8OV-??%XHKV&+[Y7X@E&1(* 2%JUA[H)6G"*KRO;[U4J
M0T/QQ2Q3F@HK;-WO!#4M,3QTO8E+S&AA<"6BB'!I>M(KI.(=F7T6GM<RH%X
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MNN2.1X.;UNIBS:%M>V:S*512=)9H&TU?H&M]$M;JHAYPZE(EVV/4>/5XQM^
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ME=_;7_9;!1NQB4',I!42J+.Q;1>B*R/GM^0ZYO:#()(6?K()Y837[,5V-M?
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MR3,9+TK3'1[18!]?.XQR#ZV'2I(X<<CJ(!IUGI8?KNYV)V,V<1T$.SY)^/W
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MAA2%D0_ZCNUB*9[F#HM=G(,%IQE%$3..QUBA(_6B !X,5K_08?&72IN2 R>
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M;]7F$!="XX,":E:,3DD,@X%]*ZR(B:1/L3K&UXJK8^[=?,+D(K4K@2\1 ,O
MZ8?\R!F_%G$F&FT9?_$\#I+2NEA,0 7C? 1G0+L9R.Q ODU)#Q2BF:+,\:,I
M&9>4AJ>F@QXP2X4I3!20?%+QMF%P+;#,:6*BW"_EQTU'5,:Y:!J0"M%1&8/
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MVNKH^/[<Y)!7.@8:584IHK6=X,Q9TI)K(O1G!*"XMUZ%)P E.MN)X@\,TF<
M*BR@+O!&>3Q#1&1N8>5/J J0J;:4/(XZ'NI"=<^\H#$N_N/(#$0:$+IUL;"&
MZA]]1"J5"7 I#0P?IR[?H#J.;,$OS[JT,.DY@+W>8CU?4P#%5N-R'JV<D'G^
M:F_W:7-\VC&.,)DS]I"IT4O/F3/@X5S?.%E;7S=6]!U<36?BIQ/\2[GX+H@:
M6-6*<Q'D'M]Y#[9]CGR*_&BT<NE$E?0]J/AZV?1C]=++6&QV+'9]&8M=QF*7
ML=CG;]:C[:J> -"0A.4A.<)[ZO!%9_"T#-R&#:76D)(F>+!DF0K:7RL5Q.HL
MP;SC##,X@0.>0YE1N/58G9;F*8AU.DK-2^J>_ZG=[RV0_D7--I>J*<DV,6.>
M.2M@K/0&.Y3Z+9+1DKU6KSGD+E(?+OZYQ6JQW_PQ5\MC^\#A93)L_0?=*$_<
MF)Y.!\H02 4,T"<2FP6BC',D=W!F!OK>+FXH5G?  A<V]#0^!1P#J(K7 H14
M$N8X'$\GX;S&SA =C28KN?B$== 1S5S@D8QD7N$@63;R^J$-W4A#EIS=6^ Q
M;B"XV+.\&SP.]!>/ ;VF@^-%*_BXW>V?ZH=!/*W87M.CD' -%N(OPB21,;ML
M=TPC)Z*>#T9;A!_F7M]+1L#O,9,^N->FUWW7.K>]SXY/5&_]IZ)_A=SYCSNT
M4_'\&4O:[XLN2VQA[9(T"T')^I-O8<(KR3_BFX <+.4BDX<B^;'80&4R)UOJ
M\3H0:IX=S0WJIX+'$1OL(J6;O SD\M57+3V_\3G)MVI^9I@\1ELX(X2WT$LH
MBX%C]M@#U54/3,R9R*^FABL&ZBTR-8AJRB*1STZ+1H:>R/W [&O/Y:4N1!H$
M1\;3:'@Z%.-KI-@TK1&[=(PY[ 5F*5F\BE%LHA)Z/"]"N6GPZ]AX0]62R[&
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M)4 @/*N!:$K(/?>$H8_X-C% @BTRG(C$"-/ -4&08+(_[PL@ZY[E!<*IBM&
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M9BS<25TC$*V/@ OW;%'YR._HG6G!)0-V1@[RE(A1ERKOFO_O?\J5!FA]AA9
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MZ^OU1KW\)MGZW*>_GB+Z/'V2TM[P_V6OD.<77)?7&Z2S'*+.TCEI[AJEOZK
MD66)#;+6V"S+2[=M#L1TZ%'39!'0[+@#QYQ,..+ IFBK\;H,[B$GZD>/Q2>F
MN<E;0=R'T8>JX(R)$EG,D5ROU(2[AN>UR#I2[N<39VCPSE[P)S@ 57BK<@O5
MV<;E4[)A5]P.)8DP&XC0:5JV67#>-F5_Q65:*3SBG-[I.V[OG2C=PAF5..W
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M!<O/G4/VD(12=COEQBKYA9#!I?#)RF6]X;A6(Z1RM&4^MF"$,6.F8X@+640
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ME)19C%%=U2(YAGRZ%RQ4=9M(J#JQCJ/4F$TL6&@4C#/L]BB+NF2]()=^=D
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M*.K.5RLIVUV*WY(]HO@2]1&U\4J#.*PGT2YH$T>:&X/1HB85XU(29RPCQS!
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MP%$@2 $$,A+3V64-&J-9884I?)Y'##"""PUKRG>DSM8UT%>:G^PL.//ALV_
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M7]B;WVZ!;&!F8C""ULWO:!-.ZQ3\+3^LW16Q?K0)P/-R1;7!SD=P,!3-<+9
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M2IK_P@=W5WML'->!O,1CHW79ML(<&]6&5Q<L"E6,^#>QUY-/1.Q%@NVM+L^
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M@LHH2BJ- <[E'O@THRA4B(KS +3@O!G;Y"R1?]I,TQ*'FA8HMB/6^4"A$<M
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M]Z;PHX+"CZ)YZ(!YF$09HCN>RCX<JP^CCGNM/IEB#P9M<_=QJB*1LPO0L9I
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M3*A6$T88-.J:,,*@41L7Z1E0W;A(-6>$<9&J9<1CN_YWW6I>]!3-2VLS.3>
MK$&C-JBR!E76H%$?U9BT1HW^9<,E&E-A3$6E -3&"3/P@ : ^OS3C"X,2=0
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M$YTXILW=.T'&Z+^P-D]L7^HH"CG3,O:0#+BZ"9I79X$,AM-[&D=SL3>!IML
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MQAI%M>^ VD^B#'M(3Z7WQTI7UW&OE=NX=M?N] Y 6ZI52&JTY?RI\CKNM7J
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M2P.4N#-ODN$L]B0;_\MS1=)C//=9K%7R%&R)FQ%"$9]48'\P38:N &6!YHM
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M! V:+S?"]RVMCH)J(2;SLU'N;?0/8=D"95(+OH2X.XS+"3:%K%<FK1UM..%
M1+#.)O Q <.+H"VX0[!"&0D': UPYOMV3[\V4D;E#G%-4I4(SA=BX<F2,@?7
MY)&NZ$/",9N#7Y4+D=RH=':IN@$TLFC"MTBN<DO'XJE(*HFM%DXX7MF+L;O+
M@,J5OC3*D?$U.O*T!'2U\VT4ML"K(P._3>[.BP.Y%T"-T(LW#,1R7?2-&!I;
M#XYOO47*$$7M9FLD9#$;)]Z_,[Y]<.9\2^<348 ^Z$%:+]X3\/(U_A$?_Y)
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M.>J/6\1R3[0P)I@.;#GI[<'3^PZUGO+"#O."4GC7/4@A#M63339;"TIM.8\
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M4QLG3BLE"GMR*UQFS3LU[!IT/1&;FMI_XLI4*(]WGFK]K-],FS4_/O,?VLY
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M9OC0#!_Z@/ AW@&1SU?0C)!"L^B!A-P^Z>:W!:.@1\ >O[>&&FR]Q-$I^R9
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M<GZL=!Z#X%7809RQW-QT59>\,B8=>$[2]1; [)ZIZG@[Y,21O?QE= 5QZ9#
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MZGL4.^'3":\XO'#EB7KVP_?VZG>[C6; $:1D8T%]SC+DO)_&H BYU&73MI)
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M"?__A!1X(GAHJ4I$G !LS81/%;;UEA\R,9VBM6R"&BY5%P2F S,::5BRF/-
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M(:&XWZ#AY!>UEZ!*SEBXD'$N6GL7H<#E4:EY"H"TCGM_XA?I;3-4C9]'M.Q
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M^]?>OB/1R'"R>%MOE*N#!?8D"-40U/()I3^,I%#&E,S:YJ;<,)E(M-@8N<;
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MI@\;RX%$/CS M_:E22LB4\Q]&E4A-2%(^QA2&,82$V_!W?(DL1/6)1$4:$W
M1I%\-CKS39](9@&J1MNJWW(O7'U39)%3^BM*56!BZ/%SIDQ ?:_<]P"CH00R
M'L"!5XU#@%,22D$);V%Q]5>031)R E/XN0II0SJY WW7FQ 6E%-X]/"KOY'T
MZE/\Z_3TJ\7SZ-WP2?QOW@54"<B^C>TA'DU7S$/UTOS0&U.'EROP3^6!.(6'
M?O]7Q>)5_"9_?"KEZF[Q?XP;Z@=CCWI)OO7TX8/_P^:?]LQ5B!?='/1!)[J_
M,'-72N/RWB3O?/0&X..Y$K!MZFK?M,@)-W"^ QJ0Q 61[?[.]\9YO\YI",$]
M04E,=C1QY^S*I2M'^.!*J1J,Y6NC^W+RW-_[BX_*K@C>UW%OD=1[*BOF(<Z@
MLL/$+\S]0T$3HGY7[J''BLY0(T7*>[^:V#A2];?G%F(>RZ%PI5PUQ+M4<R,N
MY7?C$8[RPV3>CK$,D]T378L>US%(BCC/53O.V8F<,*Q<D$4G,@PJVU =)E[C
M,F[ZE(]&>$TDF,,40M"3(6>P730PZ(O%@5?NJJ=HW9\G]^X]/R(=:0YQ;X;Z
M IR=M5;QN2<M52#8P/1+XT]KTB.KVI0CR0,-1^EB[E,83324Y\E.M$_CTY7H
M2*%BV :E<;M[/MJ,HN&(Q&=_Y!?V%CDX0=?QC4:6%LVX$\M$E#\UI$.V244[
MO!P[;J>]: $>H%3VH GZD/"$NT>UWP\MTDBN9/O(J&K2DOK3W)0]0\NF4]%D
MT%?]AARY([@3.Q(6S(,I2$[#AYJK^PY '3KP3,T8ZMG27%L00>+4D8Z\ZN%0
M1MDX0=<F.8Z"R>$493($1_+%+ 5G%R/03=_N8K0WV^9LFXZ97I@&UT1V:B3M
MR&#60F9:, $=Q5J@52T.95OD++GJ8Q1[,T.Y9TL;[;>9T-B18'7 4?TOA:BF
M4/5HBLUE04C(CWF8=@BY4U8,C)@X7US0&5%_*R4Y@E$3]3(#!9'99DK_;<9^
MOSZ2#V, NTV][3.HD894K1KFG++S&R+P4'-NW\$'XQX$IJSAP22]X)*'CB+7
MP618GF##'!X=LB6J-$DUDR].XWT^?SCC?6:\SXSW^:CDBS]!;NS&>EH\XJ95
M4.IUDS?*27FADJ*)DL"/$.78!PQ:HU\YVB#S47LPOF<V]O2@[AAT_$%;#T>/
M<TC.KP7@N9J8OZ6H>S37->./RJR?C K"A&\UVO[V9'%F6\[FIE#:^*F!2OED
MQ;F^ZR!(]EO:D@:H$(^8&CX-DEK_]./$T0@A-P !M+]3!,(=3_&MEA>I;ZXG
M-NG0$=0C?1,P&<K#'BGAICQ^ED-E^H*$34GX+9T'F\YA\52A'37M[<# ="4(
M@0C906 G"B1*3H]2JIA%DS2UOJYH<LOE$K3?U-767--O>WH0RA>"!09\EY2_
M*1**Q4T!6ASB9_S<*R)IZ%G6I]RB*3#O!LN/^3I_UN-S>/+42K)7S10BI/?
M #++J%L?$EU/0'W4RI9*#*XH>7L!S7+,RPTW10B_5Z:805Z7WPYK5RC%B6.J
MB$N?.F/TI0PS:,/7V'GPVH0AN76FCDI*,_'N5#,%<HB*/03:"X)&=$OO@!LM
M#%@N]H6"J7E.*2,Q8K'C_(W $PT#>,]!\COHA*'40#&S@R<2:SW_L+NL=CMM
M@V8ZJ[+NN 9E2+_N?B:SXPPR?B%NJMSW9+/'^F&^2!'J5*-8$@)MZ<B.7$L)
MC4V+#Q1.-ZUHE<"X-M 9J'F9<9>5-CU4RKE^-[[X@2>02IL69[S4D +!PON=
M5I6T1*.&/ "1\ W[SF-,J;Q_DVJ/,BL[.IDM/V@5XP-"<5[&R8^G)P:19;MW
M=X"#WN\D^A9M&4AUWW[P<U!YL1:BWZ+F4N0+38I$)#07G+B)EX^3KPR=5UC]
MY@B71R</G]P61]B36!9+[*MC ^/8<BUSS?\"D/%=R+KHVG!1MG)L%H?,!VP&
M*&CKUZWOI5ISNX]O0*9BY:[:NTZYK#].9;GRICF9]M0IQA5 #1:Y92FU>2:A
M+@X*6"^,00[:!N3Z[EPQE;!0@HFZ"-2TM+O4;4OEOGKUL&)$)BF!M4>XL9)!
MG&<'17%H=VFYIY.%=:R_4K],<WL5/1LZ"0&!/TS G&&(N>U0)#XJ=FC2ZQ8_
M43+GN3HX9RN/$$],L;?==HC*^O-$!:NZ<IAD[@/,%-DF3@2^"1/*A6[YSO6;
MV4[-3E4QR<6@JAT&#)$+&K<-MK7[1<Y74KC>YACK,E2>ML;-!D<=J6Y3S!9W
M%@)5DZO54._*Q GY/A5S:5+0Q3'SN(EVMM_9?C,_VW)W$</D7"J Y4W[3=F*
M[_3.=;TAH%S"_$EH-A$QS/8VVUOREP=.]@GZ+&F T3%_-J/9C!)LHJ1V.",1
MXTA..;,6N#E)%VO#%ZA,VOYBMJ'9A@[:4"]@_F1'*M!!^]UE1:FYF]F"9@L:
M6="8I\:UU<X.:#:?:?,1N6H3$3=&3)#'98K5DK%#FHZ9!"3R9C(R8G!-4N1-
M_*_XK[:;,8"SQ646E]+9-Y(: Z+4.AWAHR3-#0Z'C/@O(<R\L2(9/W&"M)ZX
MMN*JZR<'([RMEO%38NU0+L.<<([7W&1*LAOSIITK=2 ZYKD'T53DB\7/_>HB
M29TO+86T:S;40">*U<2MT;8TIB1 +W5(!3MVRBTF(I.I#.%+*BA?9]>8N*=2
M($CGEN*.I5?PHJ]63,SJ:UMHY@]7E $ 623555-)0>"+[X*[M\BQ,^@RL>-W
MEDD#FP#GQC Y5'$ :PCWT*4K487'/*(#1/8Q=ML*O]NNO*%B,RF<BQ[G*C&<
M$!U;!7Z7'=7?RJ667:QZ#0W*C"U%4\,WRGIA='YT$Y1=Z6.N\N5CY98^ #SK
M<9&<IKL.&S?J;?7^Y'8$ :AX\ZI/WI1Y!656I4QT-DA(T-7//1-@=B'[B(E"
M?;V7?ER':=I=(G\!"XWFDN)R;%9L=90?8M(7\3+$+U=;6^T+K+FPDH6 Y]!;
ML%W0!_]M';T9CZ+5N"Y(*8@J6Y*G"CYY)8.JXRA!-U-((^KR,L]K+5-5/2%$
M$B6_HRFD'9@*M 4]*3$6*^8@[]N=*GU.%#53U=?AM:DCGA';]6J*T'<&VQX
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MC,<Q-=6D+]<*]Z,*UP%$+-Q;<=A)PFZB5D/D7#7AGC<5:2^"H ^TO1GN@TR
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M7 F\"U?]Q(3@9<L:![@#2Y4F!.D8%ME.)PXE!8_^G!T9%@G7'C:B@.W6#7M
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MPM@&09@)*YFIXV:^D2/Y?<,HW<L*#%K&Z:9[/^L.TT<AH\V"+.\0<<U,B/3
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M#TR.K\S]&O4@\O9\]>]2B#.7>1]ZZ"6<\R*K-:JX7"JGA*\SS=8S6X]9SXX
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M*JZG+S6%Y/>FFG@\R@]<#&NF.'7WDR8(?9MOL#$>.^4C?NDE%7GV9QPJHK-
MTV18,LD9[VE'OGF*DYJ^0%LS%TU#V>[W%5CAPA;:AC/Y[,\V?'T@>DU"BZ]&
MS,R/K:=V6SD^K'^PZ Y79<H%V3WCS/5;UYQJ)M^L(\Y''IBV OE0D/O%#[0-
M=(A$[N:.:^@.ZH]O(7EQ;\RD>!O^YY./_083)^JWY G;N[_5:<G+\^?\XKV-
MJZ*,DVWR.,UY?$N?W\W#.;D=%HLW.SOQZX0([AE43QSCG[W%8UP2=O3NT^/9
M#7#CI=V2<7&#EZRT'U4!8]N-LN]Z/T@92#P!3"(:>;"@^]"M@J.BW5[:8-@Z
M,3K@QX6)7GZPJB[W?C. ?PKSHIS53QK_^4+HOA0YX"1^0"+&4.&U,/7&RK&6
M!A7E@UB(_\ 'A,+]=$P." $@JOS"C<7'\3UE>-8@'KG0*%$O>,^_WI:O*GHL
M+$B$9=%KXVH</8W3-^)_G6G]T;N=Q'[ E */PY7[VFD0KH+A+!SL.JM<R!78
MS,P;'I4@K3>B$-7&PH9_@>?*9[L%62RS'PBS"[4@R"6#@H[:K\&2PF*L0Y"P
MD0?67Z*8(]Z:[@>&QDS*:H%I.-4G3ID+>P*C8Q$SRC+(O!K'+BL_G'A>ZZ#[
MU@2U]6K>8#QD/B6E^H;]HLNOR$?F"=9E\@4^EYKTVM_7_2MB-;=R]C-%>SSW
M@7ZP(<]\+G,(__.#R]_@J=[$^.&7TN7&& O,.>$8D :EGP\>FG5YT_*@%FT7
M5HA(,!W2XHO 3O"54M$16G8UL)O",\A#&,"PZ::6+CJ-A<;M?5P:YH20@-Q^
MJI^R#A<N*:!LZDMUI%-\?BV(E$2H@N,>::M9(MQKYM97S"2,FWQ8U97['%<_
M1*F'R.3*X[[3">J4(D_A*M)J"(QSJ+>7Q#F)';%&1_.6QXR,Y.&&\*ZW(0#<
M''0N*!P\G2#O\$^;O?[K2XG+MI6AF'X*[JI?U4J8P P.\%8L+^)*&V;/PN3N
M'D4KYSJ2!FU*_6'$=F4H9<%V"N=N1DS(--BO9:41;>$8(23"CQ(::8=YFH<Y
M8?_$>?C#Q=\NOG[Q\N67Q>+[+_^_KU\\_^K%11RL'F^8*8+5J8?)V,Y?Y& E
M2?>8X 2D*%"*A--X1HM(]"?O73R[>!])CV!M],QP(8DUW!GG>DLD.HYFM>XE
MGN/Z! C6KTQ5PZ8-&3"E1?\(-ZS!24XKE\Z&,0A%C"_C+8D@=5)M'4(@\_@3
MK:S(7[P<J,T2GC2\GSV!T;;A0)8GV));8XF/8,7$,T^5I^OPI%7#8V!8KF<7
MQC=+:%['2R+H>8)@RES]DGO2PT9@]L+Q8,%MJ; 9M '+6R*[=4=Y<K<&Z I1
M6L@,Z SX+I@GH\"^H/\7<Z40QJCJI6A8@;BUX2%JVDI"<Y6^$5(#J2L!Q]S4
M J:BR;N&OJ>33J?%2-;&PL<@?<183[!)":Z;9"YLBWJLE/-FV&E4.F.TOA+&
MA$?=TFI)12%8^$^5,A'?EC3]$8%-\H2<>@+RGN*F&"HE]\L>@N#V5".*.'\C
MC+=C#3>:/<@D;ZS$>';KDK1,["ZE=E?MD.OVUD)>P75=,HOXR :4P$OX)A2&
M9Q"AB9/=8 YB96PIY8J6VE8628?;6U,^(:^MGK_I;/FUH5S^8.$ED.!XH@-9
MG#IM^(0!)P8_OQQFA4?S"I175%Q9\(D%DP$,K(R.(X?$N7>BWBU.I6S:V\KH
M"91O(_Z%)V#9468A+\C%:TG91(6)LE/@!^&6">M!WZ40$#&)Z 2*Q+2-+8V'
MJE;LV)-!$(<;VY6'ENGV_(FL0'=ERJZ%7,G&=VU<)UVF#]I.]1XX\Q-JG#Y3
M*^3CMA V/M3>/X<]3C?</N- C%M,W(+6^B@<Y1FP1KN^^ES_\?0-M$RUS_Q9
M*B8)@T<'.40FX=3X?%W_7*U\ZT_;EWS7^R[\[\H"2'P,FX2>:+_RO_Q5FS!K
M96-/AOM]ZD/6ID7 *O?Z*=JQZ(7*S?Z/__CL]Y]\]C2_K_1#XZ3HE][R/;N4
M2&:JK:#NC\=@Q\+!)/.?B+YB88X>^P-Z81_@#3^\L7TV&]M;-K8\!:CV/"+@
MREB7U0:".S5@^EU.8M^?L*<9ZS+"NGPT8UUFK,N_%]9E/E7^S4^5D_*(U*72
MD:]$TVV.4V:+2H)B)CPPS76-3[B.$.=M0H[WE"SL'3*?1[/Y/+SYY"4/P>N=
M'[>3>Z3G;UTQN!$M1YULS=HEU Q14NO82XO%DWS(,G***7MX<O6PEQ+V::Z$
M<Q6E<,ST>:T#"8+4"U/-VP>IPUDKB&OLHN8K)2'7G/33?@PLZ"W=$85"GH:W
M)Q-Y5[? 0AQ@O19/*BCEIQ%/#+$#;7<H5YL<FF_F)-#92<T[K6%EM*+:/F.N
MFB:D_SP8F<GEA1V-&AJ_T&M0N)-E<)$.Y;^P?;B(K&)SW,%T;;9Q'TW[#B$$
MO:)!4AWC)5^MRZ/%2]<W%D%'>//I?N(EJI' <NR)HX/T;$DCG$#$W"A$/['0
M#H$,2-GHDPF<^L:C4Z(G &7X9$LGRB[\%=YKN'\6M[$]5$B-%C7L\1[+]N:V
M"H:Q BNVM,H@X'T? .3;JV$++;@!+A]K;RIOX^@;HD+\ECB PD-\7_7+$-U]
MMPG_IFI\,%8@( &O@I8"#"Q]I](P+2)A-X,'(XE^[+30N^VJ2Y YEKO"J8:B
M<$'9XZ/_8J Z?=:Z46J[[A6S_7)-%KLP?"/F>OU>H=B4B MV\;=X9T24$E8+
M]?$_A6M26X97ZB.N8Q]=$D#0:+.W7=G5CDAR9;-5(;I1@(ZSN358<B)G2EBM
MJUH9PJGC6:_(K)R.Q+,+_ YO@)Z)T)]BL-OV1M[=1[1@N@=W9,(T[,]J$2*W
M0C-/-J@'6B8QW]W0L5!F6'"^'8OXA1%VXIEDW.U%LY;-_KV=-]%DGBS>>_']
MQ?O,E+G"K=:]6ZKI);)G,RKQ(X\G#\;-L/!U'X]I</3M!O=W$2QE0[WH#_GT
M^&)8705K>\:U_GC7CQ]+MP[-S0@[C@=J^)B=S7:RLJ0A,_=$..R3_TI&0?5Y
M1MS0!2]-_ [JAWO[ZH=^QVO(L4&IEOHHM@.QU3^,X&H>];WLP7RVCQ?'S3[^
M+[X2+XO\4;"[??@O]+,_?.21QD_^*[\Y4LD,GK%!JXI!LW3BX,1@]EP*(,*>
M#*\TN2"[6_3-PFMFQ3+]^'NLX1(G']Q-T]LY?_+Q?UG#J>YZFMS<K/G%??@(
M%_[0/M!3,WF5?H*:K>LUN9GD/?#RTLGVOJQ!^'18E*'!J+V[H?00E.%=TF,N
M7U7-^>*;<-BT$.IL%1?P>WUL^L8_B!'_ ('N9R2NA&M9/YT;QP<'::=_P88!
M"=WS;3J^$)O0Y4^K^D=X8G*<3QX]K7Y>;@;<<'<0OPLFJ2>/G])EOOOB&]];
M \$#0/2=M:_E0M2J)+*D*M(SM*1*S9?ZUF9,XB,?.6[T),&2!!<Q>:+P@4RG
M,REP]W'/[=O/TZT=OBM\8]53O%_WA(R4&]:1$!2\<5+HS3*Y,!(VAQ*ZIS@-
M.O&F]F/W]5U)C<XO\&?/G7"X5N*;ZJK=UXYOZ-DW+Y^.GN1#41<AD!I.RLB7
MR,H19=T;\&S==J][6R!.ITN!#)^]]U-^U.Q./M:N*)!;I+G&L& W-D](B9-K
MYJ.Q^]_NXGG$U7Q6R*J$U<)X/(Z.,KA_;F!_]&'VMU]D*D+7)7ORU4_!-L'?
MY :8P9CE!=EM3>)F8<?>JQ,2FS6L.&##NQ HM"OZ]9^&C?KF#VE[O:QV>QDE
M80?X87Y,J:?0W_.CBD.X&NH5;G55[4L>*N$PV%&C 6]2AE"UVLOI$_TCHE!F
MR\EL,'L=CIB _OK.'62+0@=$<(#>NE6U"TZ^71*5M"@C8%4DC/E(CGI-7O6[
MQ+:Y,"34[''(9;3S3V!<?-LT'GTFEF"O$KEOS'B3O&HR_7V37"FO,;5Q!,BY
M6$P.D=VS>_36GV(R.PI!AMS4-&R(8@N.NNF@=: S.8(=SY'/'3W9D%/_XC-6
M<I;72-V2L<OPK7%S/WYR[,R+2+DO[::_9:0<8L9MNZ\R]4!QHBDKJB;^HI @
MUVA:'FS@%)V3TS@CP)6 B,6ZR+!8 *Z*? 0#BE8WY&VVPK%VK]M*,'><=AGX
MCZ[YO*)BAE[R*\:UT>>^ I'J2R&^!'3U<DLB=D(,_/C31XL5,6N*1\,3%XBF
M<</$L,%$CK3GA9WG'K=,MB)M"ZW"H-\IJP:$H(&&@+HC)S1TM((T2U'3P*L^
MZQ;0<(7KM0.Q?U)!Y1?.A85C[]OEOH5)??3Z)A5>ZM<*\Z*_6G8U2Q(\ITWQ
M#  H<ON:V?8V2)>\LI=5""VA%R!+?[]WJ-@K1G#>7E=<[L%8#CE7')D5 SHO
M#QR"AZ/NA5GVXAE/<E'$X1&^DF;)2/6FAH3-MET1/([/"1Y808E+HJ9^;YAN
M;+$(K70E-'S62F>XP<NJJ4C:GN/?JA&1-$DJ+-:@2UM)0TM)YPMLS?RMK'FD
M)R+Y?NT:9QOE,]DG//&Z9Z4*&[;,[L9MH(AN)R2X7T\(M0KC%*\J+>@9352"
M_['5J1TFW^.BCM0PQ9U@Q$<X#/7]*;LGO9!^<5U?79]AA)98@@F"J$= V 5_
MJ"X[KLA\I&'1ZRR2Y5/RJ!D'&]S):)^-5FHB+='BY<P",XV,^7A&QLS(F'\O
M9,R;7JQ[AOU\J"+8J[QD.LZT4F#U7,MEI 9HK^4GZNQ!F45G,L_.'#V2P\GV
MT@V:%)*%<AS&@7?5?[YX[_'[1,5!%_<',THXDMJ'ZZ I@R^?*-K@5.#Y4#P)
M)?J:=/;5?J\IL*:+R_;,P@-,+O/I)%,G,ELJ"@=Z3.T7__GDZ>*])W2S>HB?
MK=LECK+1W?N;5"IVWWX*"U:DE8["H?@M2(@S+_'2+ONE#H4(NFD4*:>G&UY/
M'@T:K.%[Z.$DB#GP$W)!Y[T/IU\&*B'CJDFRB!(F!IO9 /2SLC'6$%=R7XS7
M$HG7C; ,5I[P!G%[,"/Z=JJH;UF$@-)U+ORJ^?6TB CA69_ YV]^^@#% #=]
MR<,0W='9K(><&;G86_M+("^%:_SH#->XA7S%U660[8=7PNF-[ZI*TL$5C'SL
MUK5<=8KA?D5-7>_S;)=K8OG7\Y?G=M.-",9R=SSAR?9WRC4J-)G36W 53>\!
MN%5?CP3@I4E+3#%29T,[AEQ/;\/)8 :PWPH_023W1ZD2,_I%_!Z;6"UR\3E/
M4AR'+L\7W_)(%+]4XM)6X77;E'9Q(QU(])<]>;=5T&B?7-5KJ+16U!4TQ$<-
M.F!ZF7+Y5,*<VTW:OY;Q4:3Q$1^35F"Y_X%PGKQFS/U;[9"G/F;G<TAL^& A
M?@Z1ET$)8_V">\$&UJU4_S<:R%:->.9B!$DOV&C\DW/],C)6.K9,HD*03W'/
MLTQH921S\]2J^V'/HHJ\S&$OT3:^(C_5K'0RR^U=='B(?%Z-51.0T?ID!^]E
MR](6F%L.GY>Q6G)D2KG#7,W!=+?.C&2K)?LCO"J>?<*7H_WI  @+XWCE^[X&
MC1#U<FIQ")=5<L120B?G:GBG<G_[4W+*C.XLMY?UU0 =;U^$=M/CLCA(HC?B
M(&BJ[%#MB4*SPVLY7_PQ/'DCXZC+5RP860K!JDZI)H*XB<BMZMF2^?+DI-[F
MF&D7NPT:VX>)8CY)SX0UHL!A/((WL1(/ WY*:$&X4Z%]]&H;'&Q?P\?I_%PB
MJ.4GZ*' Q6/V\ES<RCP^O&_C<'(AP5WAFG\66QX2OCK:%2RITN0'3)%=G*XT
M]* /N .')D0^UC)@WA'3PU)U(_WN'D3(P9Y4/)B'AE-F=E-QDX%#2@9W8;O:
M3+8.0/,?)B/,DYO$.3V-KPH7 3:K\=ALD1^/Z0(E@\\Q*A(T]N9\\?5]ADTC
MFFM+C>=(89@2#(S:2G:JQ-7G\DWL?\O9AF92^B!1X?V=Y<"8'GG%;&]]W;:K
M@C6GF6Y9%%]M@'2"T216SYSEC3E5F$@[UN*MCW&^^*J]K0 @N*V@2L"WU&=S
MN*[[[S>;#YV-2:BP4T4#9G\G/,S>PT&;WIOXS(1D006;F#.[H=JN@",F-FO6
M+HN$551H3%CZE3RE:J[ N4R3O)0L$N=+5$A;E3N.!H27@R C2@V0&*TT93&<
M+*$5%9/SS^BN4JHLOCG,NJ=W1_=#2Z-WXG1M(H.(A:O%,0X:U%.IEUXVT\0@
M9C=QI_+LIV!K;B-9N1NYZ,,K&4U<O$V@X1V[;K+%\;*R0 2IYXLBI(35=O$8
M/WT<TOPOE%-5?_#'&%=\;][6?OM5=*G?8T=JN4#85E+>Q_"'KT7]*(OYY'R*
M N^COW_TX4=OE )/R:K&I=77YW7Z?L+0UK()E=/(K#7X ,24L1#TA^<7@K1^
MYO(A)Y8$-T%6K1PD2'&]W",AL.J(-A V,$VV2 M#5?\H7"15AVC_D9%#F9=D
M$XS%J9V.@=+>^=C7C9C(Z24IF)AAB%7/-N5EM5'#&:)&I8$!9-WDQREVW&_U
M< >ZMJ<XD,ER?O]6R!,G3.GBB!=R-C!^M]+W9/&^Y"TKN'K7[BP2BJ^[]"9&
M;'J6CM#[U[>O\([[F=Z$ZGSXDS,S:KS-=/!^@0!YXRR?><40()<K1)1(/E_\
M\!VII;$E"GJ(($-(:$0'S1I)TA2R^M9"!_YMRO_N[XVI-[[_^P^^7UQ\\S7_
M!W%U]Z1A )1PN.#CQ=9D GL1"!7=MB9= ZKJ)F2%>JR'3RWRD&]E0P;D0*-.
M(]18PD_C*Q</,G8@@&?(Y?KD2\[E_,\/4V$W2.Y'_1/DC2K#WWB3RT?7-2P=
MD[>E XQF99N#$D[RT 6AE/SUA.&$40"K$1U-9$!)(Q]L^']9-E=R2&^3E/W'
M:Q3TK@\]I5J-*.N$H)LWEE16+@6KKYM&(FRUI)5\R*H\\@YM9@".0/-:NL;<
MMYWNV_Y^[MO.?=M_K[[MF,[ZPT_% 4[XQL^._NJC1[]%!L K'ET>,:,2E@@D
MZ8C,I&U+K4"+J/?#RN@A]8"6F,H'?'&Z<71**E[*>=-^,C"\3Q1HSCIA*<SO
M+ 0 6KX[$9%S,BX-W7+9D;RDXO=P^9 %ZK.+D :S'U86KC"#<PS7>.R*:M\6
M@H75)-EJJ@C6W7+8\E02"T,B(K0R=)7(GN);VZ8.ZSOB*_1ZMXZ4T'#2:]%.
M[WCD!<..:"[$2MLVW+>TIJ"QHD O^\PH7T&4I,N(]?,,;R1!&#*G*FK#R5B'
M/DZL[$FWPMA-"? >M>GC5\1;(;)*U N[BHYQ+MG?5*ZQQ=J'3:4DHC6W@X;&
M+ K1;X(![-JU#MY@0%9>F*4'^=1LK>T,3YL*"PH/6&YTEHJ4\[Z?W!JN<B[5
M5GKL%H%',M1[607+J%N9(;& )C[:=2M3O[X1?N1+5VU!S7 N EK]-5N=L,)'
MFZHRR:#]#[(+;P8(QL52)@NY9;W)%2-EDUI49>^1!X'(,)CSGBXESQ)EH3-B
M:!IIH)BLBIHW:;OFMNP(X,_CZEQY=1-. OB^/"AO^;1?RVC:D;-'>6J>SD'F
M$?L"\<9DS)BQPM&NX557".#0ET]5D>AB5)@EY*$^PX*57'HN9P9OM$&3?,_:
M'#+5!RG%L,RKKKR=S*S$YRM-ONDT ]Y(+A553/-V:UE;1[T><28 :=3]5=M=
M&<P[^*V*!E&XF8*2:E1^)I?UT] L[?VQ,C?]H\.H[\:_'M\Y)P>,X4.1V3W$
M#JA*!7;;E.CS7SM_^NCQ6\R?[M/>^$N[)\."+&T<';+MD@A\XP@9^?(B5@S&
M99C4<3'(*P5W<%&?S*X+GX3$-&F[;NN>T,6:E]&/O#?J46=!T:GZ6:26X;4[
M93ZM.]==^K%R7Z01 >7N4B9)6;.C)Q5A618DIYDVU8./6+KT=Q$O#2J)%#,"
MOZJ+90[2K57NQ[S/UV+EPL0I,X>??C7[ 5][D7RX3O1WS7<;]B%Y^5FO+U$.
MQEQ#\ >;@P:$JRR:*!(MS9.W&U=1^\-:N/D-;YM- N$Q[0@K,#G3GCQ])NO*
M/FYC_\=G0=+"ZR!/7ID\&@2EU4?VI;C0C,Q8O,A7FU>?//KXTT\^?O1QFF>$
M7SQ^]/C##S]Y_-&;U=IY@_H1SZ$"GR0B.N8QUH]7U )/:&!JYV&U$IP.,!7U
MI#8I[581O15^YU&>15L NS\O2F8= 2E^QHXF >CV4OS&B DJO59BCC/)QA!A
M 2^P6A3GUCLFM-?H/?5'B[*/Q=V8:$VZIB0?U+F=U6"C$LS7W3,GQ]6FO:1]
MY+@+JL7W0PC-R^;LKZ\Z8IPN:4,WZXWH&1CSQ/GB2P+]Q!71]3B]"#X[FW"]
MA<3Z"SK_L&BX&BO"]>@GZ\RS==6+'*XJ!GGB/29B)0J!@=^J? :6OP>5_J%-
M0ITL92+*/J; )4+^AA4!0H.&_6\JB\8K4A]ZZ?S3ZJZ-UY#L&E>\A7/=/]OX
MZ?%4Y+&NSA??DOARN-@6#^^4,/![O#T;G?9:&R0[OMU9[&CI;OQQ_+M=V>_Q
MH"'C3I3>)8+4IXH#5B\F-I,8#UM M!3>%KH;5+$%Q/[AVZFO6$R\0OPD^]Z(
M*I.WZ%Z_<(J+;*<#=[H_5*LI%E6-![LS$'Z;D)E8!7Z6VR1KR>M#,VL"RB,,
M+NV@_)F\YFB24=5@$O#0,@ 4Q0;XTT.A?XQ\IR>$<?CC82>:M<E'@, @) 19
MENEKIHK?Z0YS'V,I<-B:0V$Z[UZC?33U*+57U-!:#5">V:.)B"O?-@N,'?TN
MTXR1YUIV ^O725@RY?/ERF,=]?UAIV(@M.U1#8C<9?:]:63K;GG*-\78WU\K
MI>>G?A[Z83(W:\@\4\%T%Z/GJ3J@IX)O+1=$UU@M8Y(=%O?0U\(R=.2>-7B$
M2'S8P>VA4DW5*">O*'B @G@\A$M8(L\9(A,P0D7\+%6V;E  ;=59BNOY@]0/
MQ$F<7(IMQ1PS=><),R8/UYAM:*_S39VVA;B7$43+5M2? %D!,6$NLEAY32>L
M@WK";#$2&FX9H@S#GL9_)2G@Q;=*G**JI(BF)C!:)S9P*32NR_X:T+BDY8_&
MM)TY4I&FTHN>I S LP-E=-R60\]56#S"^4*"6%R,@@;""O&5F,%"H4+B\\:B
MN2ZPPB?TK$)BXD[J]*#([\L$Q(XXSKZXXPAG@14Y<+)%4Q19Q75\#$UXW*YC
ML_+6/<Z01_9.H\Q6[S0I#BILI5^Y U\E'!R'9PVU)JDX;/FS+!6Z!C'6D1*>
MZ78J"-C%839-('[V9#"GS")T]"J^*.N$2"RFX+I-97\D!Z+G>Y)@XS56S;1,
M66#1$1O*V60E5GTP6BF.T=-Y NYVH!++?SG8:H9[FCO>TQWO3^:.]]SQ_O?J
M>/\FBQ4K*:_C_9CQ46N'8)/#!R6>0^Y+&F[[/$4R[KD;R",R"=W#0YV/5."?
MQSB/X6<V=C1! HENM$S7233FS_<X"WG+P,28.*^HI],-.QTN8 5*J99X")R4
M62C&!GN.)<R%X^^71GZLHA08%"0>2F0SA,@J=/J;DRLYCAE/3YZ7:@TRRZ>@
MS9#]!@M9]CC2ZOV^\AUAXIKK2.\QS@E*C S@08P+-=1WH7M:84HS(FEY<?>:
MX0AY3,T!7J8)78QQ >,P<E0X1">/F96S%FKVA^%=[MLEIJK6BW]P,QZ=Q[ .
MU<J^=T$<KUMIO&-=Z25/R9[1@#YS?X-3+GWM$G')2(]_R397U%!J.4JQ"!Y)
M"6J_#YG#<=PC0,^C98WBFOB.\#>U5MB@&RFLL)$[CP+^!.GM*D.^+!]MO=<L
M;3*C00+AFZ&WT^F0K[P4+L8T]'HQ/7/&7>.NO76%A,R,'G0(72$KDG(XE"25
MW> $" ]A],LN-<%(M?TD?:91SI)-&$H&&/XSEH4X4^6R*6>O!(!8QH:^4*AJ
MI5HR7"%,52)[?Y4^W#8%1%*++'M-M'H>A/FG\"SQA".W_LI!%5C]@!!MTZZZ
MEF*K-6H ,4B50WG\L?!/RV.0:F"&UR@A;+SHT+L$\(/F[@!"-?-:5:AP*>P;
M3^P6J!&4#-4T7$-)9KGXL7JW*F[@*W5=$]V-^WHFSJRDM,"NJ3_MF_IIYY3X
MY.P;X6%TO$U>U?@,&M71L[$H]W1"]84RGH"KDHL[G)9;27-FJ0E.%5E<N=/5
M<4A/-WS//TLUK.O@$JAKYHZJDL2+6>QZG/B7*55T'#<]8R;6%>W5=75+_JSL
MUA@NO:G;#1SDA$R$,13CZC@"E456[53?(6/#A*RE;[WG]=Y63D&)!I;7(K(I
MP^C9J2/P?M?1,12;9>:I(CA831+[GIRZ>OSW3WX#I 7GC<2-4J\/;[(]^AVS
M480%Q2!';#-T=?_JC/GF@OV6&Z.(IY6)\>%T)XKLW5FL'&KZEI.6D'KIFW9S
MHSWYT56C =DW.[3:">!+>!M/W@KN9?PN_B+MK8FUU8&R0J;,&*[0$IM-),>@
M(F(.3@" !*&8(@LDI.#.W5H1C$:<*XHKC!3CGTF'2OX08^^H@)=D^.%\(DKY
MIKZ,',(&2*4T49;_:/4VVV:^<!^C&"7EF<)?V",6L=PX66M\F+SJXDY3EN3H
M^*N#SY_\,YSD[LW8^XLR,-&[']T/^FZ\],ZJDM:P!EEDDS5@SK+%Z?L;UDIK
M.S]A*&E=!$>XEZ&,[H5] <8JUU1_7F)@+@GEL[,5.EB7;<?QO+CO$_8 <A^P
MZ$;M6MHEZBYT3Y 'DD5$J1&'\37S>1RX/=MGV'3MU6=I+=UD]&S,'WOLM8X7
M_0I:#1VE4%0<E:XD4DD*!E*OZ%\ML)=PGD/#B #PZ(8S?+"9=K08I7&CI7V[
MM+;6XP,J;9<G ^,JOOV1F#2B:SX*XY_[\YD?5!DX77)#:7U+)->;'-0!38\E
MOF4"V7%PF-WD:M/(S#%NP"S:O.Q)4W81:S(ZAQ#G-MQ^E<6$.E0);#/)$(&
M!0Y*)-)=8(.TSU[ ;G2^IJI8-+^8D2]X2+)?<-9L2OVKV.H=AT5":$3D_5-#
MUF1'EZI,/D4EH)ZW2&H:-O*?S?E3]R&".&^\V@Z%3S!%1\GC'AK7SQ>0_&&D
MA48V!>)\V4)R^#2_.%TN=!A"$F4=U#"K)E.KNQ$PYTYOK[!.77P+P"?? =?'
MIKQ;GWNV#*'W^,DG'WW\Z:///GQ7@7@_"I<2TK9RYXS8:R91\D>9LU!]351.
M++E2" &[92K8*+4<\'#T:YR334:;L4ZV@^0+N5\$FS/!)^O+@3/\M1^QGVK:
M29+-LD13L!*7%%YZB) %.0*(,_<;-1"2IG.XTP9<R7OL 0<J:7LDO"@D*GDQ
MDX1Y^<H3]_@ ):%'OB04ZSW2AL=.Y_$"_WK,@ 3HZ%+"IJ($F]B9+>JM)MD2
M)MYA8G.&W[-S.8F/)5YIFZL6=Y3%<YZISDVC<2YK3PDRAT;&@*HQ6^05,?]P
M=AJI\H0K"\,4=7]-2APM,>LGGZ'O)Q#2&#H1;D 6-]X'+3/!WSOZ5;#1':F)
MH5K!PQQ[EA_I2J9B'UCZ,=W&XXV$#\TMWND6[Z=SBW=N\<XMWC?8XK7S&L1C
MZI!=23<]^"4MJYEK#\4^DJ3CF5IW]BJA2[D<U:/%MPZ-4"]7TUP?+ECQ;>BQ
M !6J_W<<!6D"0X!7R@I'5*K>"X=GZHR\MFWX(M7/RWH7<W.E5A&]!/?PWTZG
M'--AT"18*2[ZYJ#UV>1$!G9I5=' 8<'DPMV^T' ^.6)0/5\/="$)F^ZU9@XE
MZMXQ!_E:]M6BP)'X3@8=$P(V#CD1H]A9[)A:[ U(/NS_MD;D1G2LABT_-4F4
MUJJ=Z;)0EEE[5F<1P/UD$J(80!VJC;GD*N9_\K8F$& .5*8/54R&MQ:1>^/)
M,]+I17\@=L8?9;\B8"?3](^@.UF#NVP%/(\RX3YYF"9V'KD]5VCQ09D+1/M5
M"L31*%&RTBW##F)L:?B0,S>&)N<>+6Z!>]M\VH(5>7,Z38@S"AM""BVE/4C$
MO>*N:QDP3OT3[%'63TG+LJ?*;R/?32>^&-!>J@LE7TJ4RJIG0R4#I6@\<9O!
ME#^' =Y#IITS,(V7$-R<H<"YZZO/]1]/WT"4IZ'Q9_$G=#.P< 2](?P-QO8Y
M!"1]M*(1%]\UJ=#O5X80PL>P*WXG.O7QE[]JUV71-S9AN-^G'I/4M$ DR;U^
MB@@2X9O<[/_XC\]^_\EG3_/[2C\TCHU^Z2W?,[!2ORF[<XA3&]SR<!G[)5,@
M=Y'O^Q\#$Z0([E]:M:[<NPJ)YA67!SH ![HH\1LLU.>^X:C8::_;ZG(Q<*-%
M^X!>]P>PCP<PU4>IJ7XVF^H#F:I-"(ZK*4O58M&2B8\"-8"0X)',>$-\O)V/
M1$JFIR<"]_"+0UUM5NFP1"M*79%142M94K/:; K>4!KH4+&+AE5TBELB=P+L
M]R<,_![N>O;H\S89;9,D;#7#DST %064Y@W]*3,]CEB=9TS"#Y@M@(0]VO "
M);J+H0;'V"[6>)?<]6>SNWY8.SP24: 92*X\3O$=21EG:YJMR7DUC(H%SV;Y
MFVKP6NO;()+2@XZ-T[H)'NRF:I:'V:AFHS*C@F" 1P)1=Y\A%(XDC,^]V7!F
MPYF(L4 [YR92NHK ,%)NTJS:Z0L"PL50Q?C#D"_7K"^2)MM%QK? M J69SP-
M_WR'K').D!_8*DD<3FN\+MY/*H+"RA#Q!:=:1K\J.7W;]6[J\.B^8XH+9?,P
MCGMNS@!@,>S:QE?_)[M91Z6R)L%KJZP;,%$#]CM<JQ$Z:BD[/F6M.880$Z7%
MXT-3$Z Q;97<5EV50&GV7=GTZRHW$R'/9:+!,3G)N!BNUS:&+R9P@'!"N0'[
MKA9,["_1;6$\7+^G+H7R&/3ALWWX6^T-'DD2SA<O\<%RZ;#I?97VGG@UF4AT
MZ$6<:W+NS7/$5/4-MYW"^H>K$8)?>Q@9$["31\ ?>VP=OV8A-Z+*T>;@60VF
MYVOLC;AWH$3/S++,PO8R&),N*(.\E.]Y;-'9=VFI+ *VIFJ^OA-KGQ3*IQ2D
M%0O$!AGVQF85B<DY0N75G@#:CKJ)1N_@7F:YZ*\)"LQ4E;@Q$(@8'3)W@H_;
M,4_).K51FZ>A1M&SZ["MCD&RN&&UIRDW#+>)>+$;9>,_QZ[>\&J40$1S\WY/
MPHUKF0F-,W(5IJAD/$D0R>%ZA.;#O2:W1BW/34D-:(\/QMZU-,F3DH;M ^(@
MO>E\($*PR4-O'?&C2W=^MS"5\C).$P):NQ;P80JC>%!=6ES37\S#B9@"E+D!
ML( 28CU<K04T.?O].*1RM=N[[(,7B,E$2R66HE9U%:,_)A ]=H>1FTU8>6Z;
M^&YTQ T8A+WLPX5*R+'[X!T6W'I(:&OE6!^.,+=9&U&1&3XP6#O[GNS-\RF%
M-JC_%4_W3*XC[8<-%<3S00F;J7+^=G-P1"_)@HDCYM4F"44JVDOC>",QS!1D
MF98?$<U[+_[R_'WU)'8L?B"+X,85N8GOZ.GRVT[H3V,?69]2YGB!-4P'DQ='
M2(Q__S9%8)[38F1'=9?0L2KVT[2=@_$T3=BY2W35F5"M;4;"4;CRC(N<QD5^
M-N,B9USDOQ<N<BSV\OOC8B^_/R+V$O[JD]]0[.5+1P]^X;BEE8;]RX'(K<.J
M?6.C+Q=$EG(HHOQ"5&284+(0Z>:__MD!E<:BUVYDJ$P%A8V:!50R/>,>59\B
MH>]>_O&;[]R73$\A2?;1\>R7P/]YU@N4]:2=[K'T2F8!4D&ZXO%(2,0GIFC%
M8U'5[L&^32D=#E,1(),FA)@T7(F91\?9"Q$4U!2,T.S99175(1R9L?$]9K&]
M:>R$6&D_OAH/2+5]#SIHCJJ@95%34D)3AIM2C">94@AYR?+5YEA$%"/+"R,"
MI F#2-'LTZ,L=-4"8A+!3N>,@B2-.G^J:8'Q11G5DBP\=G$G9W(<DL&7(VR,
M3+5J$GK%<=)[9%Y,.\U32$G' 'HRV5C8R_%$&^/$\2@GZ"D*T$F*SSCM>"PW
M"T\XI),V//'+=/:[JF'YI(3V-M%,N2*.(I$>0-:@K_+HO%8B'5+8O"G+GO02
MWJKR"5_(T5R&M2(.,"+9;9?B!?NJ_B?$W9&$$<UM+TI)L=1AXVW'%$WX4TK,
M3_.(U7+0=R&Z+<3$)8/A3L(%:U7$OVU',MYQ]<NKDLB"L>@3$[8G28C>Y-S]
M&QPOO' 375'?59,/TZL^-L^:_$GN#S+R+6)@M22@4%ZM5*JA8 XIL/9HFG"L
M(N/3@R^_\6HF$"SICLU-UPJWKQ,<M]_6Q[ZR565Q5P"BY"76?<.CAZ]5*FI?
MK#FB3>%VZ10*G%6J]M@R%979S<E20=9XF-TP,GUEI!\.=RR78 FSGDN_R[*_
M7JQ)W,7X3^NM0(F+2,!:,M=-,ANX'J0NX^J_>A%C.WA0CJP7S>)BUX6W^N31
MXT^=VHVV5Z-^\"19QY2 [_*Z:\.A,Q82/JHB3"<6RLAV;4S'FQ3YDT=/GDS<
M6]08OO>]O5EQX1^KK*D05PL\5E$#.2DTJL= -($T/AE@T0/9]R4Y=O/#'=F?
M5.GD:#H*P+CT-^RZ)@6T4R]6;H@]S/1LCC4PN$!//0(H95%!*>K56 1#2GIE
MM[PN[$%4W+9(5,FDW#^I[4;'FG,!15YMD09=N<E<V;J05(#Y[@]%6FPYZE%%
MU=#H\J>5VGX8]T0X3,&];>N^-Q[YJ!@O-#RT5C$FJ2F#VD:F+Z;>0"OJRI(I
M)CF1NJW_UH+3EN1&O!)<\OX**S5*1A)_0%(7G:E"I@D.RLA5P]!%XBJA^20V
M@56['.0^LELPZ0T6;XL3\U@2*@^R1(!I#Q;:*8# S,_XYZA#P=_]JJIVT/O@
M^JRP3T4893BW"#Z?]]_BTVJ)DK,LRU=8.A+G(XITCD\_&1$_$3T"C2"'KWJ>
MUP^7W_,:) G!FF<V([XU_D.:O]KI1F*G&E842^A"S?>S,/P$Z< =7!_X/;6=
M'/K:\5-D1_:]8\A)9HZ33=F<R?)AV)^^<ZYK2A/4F9-HA#.BCF7",W^6J)5L
MPC[:Y"6-46*P'?H]-T,;XBNEL]0<N'<O1P3'[814YTSN;>" #9'/N+\)N=V<
MAD0;]TQ?&)5V6Y%!CR>2,2[1E?7K'^;=)8P^,;D/BZC>I\\]MA^?#%[SI@IK
M!$="_I9Y&G/VY+2C^6L.(2UG*=5IS<?#G8FM:JRFK1G>J>GCY8IA>MAE'U,]
M,;J1?KBZ"HNB9,7QV_'>0T!=]34_&"(<6QCI]+#@+OFYNG]EW)0<!.9%'GU%
MS)?$-!3??_G-2TS<5IN=%OE4&T69S(S$&LVL$&LA3US0+^A;:0Z0KR,NT9>0
M]&17Y$2UT<-7*?)*$7'$ND*4%54=E9<NEZ^X@1ZLE2*8U$L8K08+0%:>CI1>
M:[A:E]Q^E*FE.R\2NFDB0[IN;5V#K[GDGFJ-"D9E%\E.;*R7!=Y"NHU2EL0A
M!T;FA7NY:JV;+VK'53"](>YV&2<-F1(*'_8JZ+VM*LH>DXS+WEB%8(G93^+3
M/HQ?>$[0KW!6T4%%D83?89K[$!B_>=50OSG-B\=!0L*P-IHJ36+K(BMBW2-Q
M+S+Z,*50%?.<IU5GA..1=M=(3W>:J/,4^]' 8LY(<GWR1X1_?$TI=+41R<"7
M"7[LLX].P,#G-GC>!O_TT=P&G]O@_UYM\(<^E&;8_4,?2II/' F8YD&BV7:.
MV@X7L35I1;5-S&DVF]EL[G0YOG0]&\QL,,Y@?/$D9DK'BFF<\<PF-)N0F=!
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MK!;RFYG.D_./3AG/MPDA?.&Y^0H.RLI]Q,=.=S4F3D#6/:3\^,IZX$Z<U2\
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MI5\Z^CY?N#IR>8UC? 5F7RVO\1U>%836 >@>CZQD>8+Z^!TP(KN6 8D^A!5
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M,NDKF2B6=H*;<^7(E 9A4PUIS,OU9(LD<>M7C?]"-PZ=<"$E0=.(K3*O1R.
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MEA5P8R R3J!B22L\U=Z:G'?>8*2V=8TF%)RX) !NZIX/T!DP/PV8_W@&S,^
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MY5&% @B*E$U1E(QYF+8D$J@C*S,KC^\#@UB)4B5*15%BB)D(ZL[2?!XFSI5
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MB4)E1 6S\0IH6<,SRHBA"[;@#O@4LPM]$Y-I((:#:"63,+U$V#- TP)6/(2
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M&9/2.29\B%R'U^"P@'L:E8V/LOV*6Q4[Y\.EV(<>A=)Y9;)2V#:%]P^9<_K
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MMP<MUVT->O:P/VCYW9[;[;><=F_\@H);_ U_,8"3-7 &73?WE]-$S)J?YQ%
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ME5Y]XGJU]8R$\;GHU"-@<;(^>I>K$OHOB0\:ZJZ\.)>PA_HM($;SY&]&4!7
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M2_Y6BL($2Y_D ^3DO"DJO2 F-O#;A2 ^7_@I$I=!G! N9R0\(.*,K4447 %
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M^%>YQCNCL<XE95-L$+P* ]6/7.@/U V !\-P="O_,TEFTU__'U!+ P04
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M/H%3Z:F09EXQM<AOO(L<UPE2L*+5Y1G1*9;=!)^?D& ]?7?;99O2WR9NN)$
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M[[UTEJTK7K"X0-<Y4!P!8/&,=99NX523&I8[O,_$5SGY=-Z'Y%%75"NF#:T
M_O1PFI@ZX,1]#J_LGV)A>+;>0_U=I?)2=BH"V9GJG5W#5 ^=)5+C.IAME?/.
MQ=<!'?=(1]F%&CSV#'S)EEON_8K'RO]?/.[=GDDM\?LJZX(YU8?XIDEDI=5*
M^+;CPFJ/'(+,-RF0NT0C4+F8AL?)_9WGZ-9#L_.\%TH"?@^EUZSQ\S"K7H9&
M4_L@9F1V0AM2<RT7>;6',L1OMFI(7@MNR:2TK1MC/'B]5$.8EXY48]&0/W55
M86RX05=G-J\UW>V-KY3(>]2GX@S5EC<\D*2  JUWPPS*$S+C*D7)[+8G-%57
MD9L_DX8ID</N?><P@>_>(9KRM3P1O/;#E.W%L#R1L<P7B-E-;'#Q2KQC3$<K
MIG3-2@"$U&.*XD'UK\E+2MFO6W.@?%V<U>9NI*VZ;G)_<9<YF8([FTQUOF1\
M]NT+Q188^U*6"LJJ>9H!:]>45BUW]K*TRL7JH*&(WJ8J+8JR[//SY8FGC14V
MG!8@1)V(HV&.T^]T^D%VLC^3726&^9I"X3O#8;T ;2=?E^ 8!_P)K,GL%>0N
M6@J.Y//4.)"[59471/X.#2W.<D$*!4UB)S\\U/K*X(?)A :>1HLVU:S;Z5>B
M#,.+S1TR,M]@QL3-1DL3E"N/I8:#9;BV#$K35KL"B<1.>_@S@TG\E.W$P3":
M "R9#$%^8@;SI/I;"8,!'*M=1V$K"%XS7Q'I8\LGS:3#;6:0 VOAE5]3Y1&8
M_<KZJ7M;T^ODBT=V+\\OVL,L4-"]4!7Y0H>QM"+11F?.F['-/CKY%K[ZLXT7
M*)\YGV+>[V)UX19FRJ:_H>AAE46D^T>^N1>(W.-DV@W#_'"**$YBDY78@Y87
M$X ?>'GG*W9#7"I_=V]S^H/XU@U<Q/WB59%"W\\-3[]\.^9./>'D^MNW3,)^
M#[9J$+TO;W/I4I:H(6JAK!BCQ<:GX):R "/[!KOQ9B;'"8/[:J]AOF>_/3<4
M?MBT:M96SR_6C8O]F7W$_DB+T$]OE)\3R75G"(Y>\U5&*C8R,?D&U:KL&1VP
M&2JU%N*K\%\%JCB=W!MU2T\#Y^A??%RA\$]/"#1!V<URQ@?J>,QIJ0B.!:?/
MCE.O5_+)?M8IZM1\O \]$S5><G*;E$,EG)N,+ 8+_C4</Q/U]\QD3=Q/\THB
M  ]_X'?+-O3-;MS:[J!K$0)']M&H<$A1;:&\"G658XH[I46)LZ'K"K$??YRP
M'MR)/%R7&E+HQX5]JXU/8;[C9Y ><7XZHLL$E96.DKTQ6'LO"D^-YG^;@3V\
M<;</ZIR0/1]61N(C%LW&UY UD#XA4VM==XP A$-F(0>_T,MOZ^ _G%,\12D)
MX3SX=)@XWKG/=!$;4(CUT#DJ# 0%Y"DM\[-'-O=T,HU+)273N2EH[%\:N\TT
M^_5\E]LTI]0, IL[._[")/=CU0N#C\D7<AXNK=A:<VO-A"K'O H6P+[:10U5
M0#:X?_'$;R+\2:R5.1NDJ',<EMF6G@[]0KN,H\/7$%NT][K=V]=@?ZQX%@*A
M@72SQO>'?+ >QKIC!HWQ8P_FA)_6"XB:5I='"@W<1DK9YBQ6&!*A*,C_QW0E
M@A4?#G4B !0I! #-GE\1Z:&F[:T6$SO7CY,Y2L'S.TSQ*E%T1TL1 /@#EQ)1
M_B#\"_*^ N5C6N3!CGN>#T)26P*8FF&<.&%L"-2W:KQE&A5CN:RD&AGA(NGE
MK)K#\_3;LSXTAZ?S5GC<$QON,<[SE'5L/SO^-T7\CPT(3,I82<K\L[>/"QX*
MP@K(EAH6I+YTJ< E?MQTQI%09OLH%+T.Y!J8 7.;\M'V:R'>5R;/:8V>:&E^
MYUZ4^7$[0H=>NX'=3JNOCGK,=[,ME":0\]WJND@6QIL W.^=K0@=:*5'O_KP
MU$0N!YLT^V F]-'Q&"SH3Y3Q$T;G!%!QJ^=W\%]^(*(NEU=^'0)5P55N6,'3
MM_@[7OO::*)AZY>@#OQD:(OTQDV:R4X5?<=TG@&]2Z[W1DQR$^X@;0T[:$/J
M[FCX4A;B1S+>(["I^<:C(MD"D9[.(M/:O>II,*="99.FIYH99CY>+.?H6V@^
MAU+X7<!"9L.&FY1Z#Y:_1X<-THA GU]&9MX+DON1+^OQ8JUO[B\&2$ :/GTY
M_F9VKK/FK$0>UH\ ""E!AO,6\<FZ?]'/S B08M.86'*UD5UW.=?@81X.Y2%=
MQ?40JD+2:O&O*LG#.4]/?$?,P+^*&'>_4R,'0LC$-F^L_*&X ]P4Z)&JM>.,
M<\T:/KSH-^SOZ6XL#'&,.'%RYF49I9?M:JM3OXK>G$!DU@54:EK8K 8*>E09
MV>C$V[XK[^3Q3B3_>"P^D:]UO5/P,@'XP.?N?D$>;?6G,OYS"_VS8G[)#;U/
M/PX4;P80 (N$2M/7YK75 AY.:1#ZUNBYC]9]>,8IK(&4W)69$2A,TAFV(1D_
M +(W*_3 //Y\[]H60Y-T'-3\A2Z6'\%6>TMMDX+/!<)DJIOKH#!T<*&R]%FW
MZ-A)N^1+^>"'0EN8&O9]9=<.$'&R)\9#S8.8CU_+LZW6_M'K66&SN8@D96?2
MEO\3_=OL<HU-#1_T=T,K-[VMX*F;[?[#S5V<C?S"1_DN<M,4JTI639G\?OIR
M V-8M6P'K_G M133=!K>CGIQ[QSW\WJFV95?<U]WY@2>[JM8A4J-W^S=N?
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M-Q#?5<C?K57OQR2"%:1M&8H3^;^C&8G:G'5)S''(V(M\_,3>_F3_J?+JC*$
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M7A(@WA#2@6GA"J9QL+2*K1LM6N5)[8Z1?%V)^%B=)=,@Q,CYF3;$9E9CAC[
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MD/QB,D,H]ZQHB\3Y\:KCR-WXZF>)5^&7$6?C>)SM:<%!T(KK;0OR^.5A$);
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M74_V6L>1 T<XN#/.5A#9DMBS5?O=E6=5E@!VB_9+P(**<S/"KTX,<0$^VMS
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M\4GO'1;=0 ^W%X-WR+H%3"('TK-47A$J58:MKAS=K*KCF%\-K&7+@/E\E\N
M-<B-%(AQ?2VIYZ,KP[-\;O:LG$[,ASR;!="'TZO;>UWZVR@8D2;8]SY,5ZMC
MU\&_Q)10XX?M)Y877R)\6AB;=F@92&A*R@INP]+:I0UN9YMEFA&ZVH/HE%J=
M(4]L@+$J/%2L-Q\P,&0+CZY_O$YUD!A41B<)9VOF>%(HX8Q__2SDN&+_1=Q.
MH9_$4WS%D&_",,N8I?4WD/GZ+[F3<B!PIIFF<"_?UF*U__$/Q$M: ,:##W[!
M@MAJF/(VD6$>OR2,?;?=6["&%LU9/^'L5)B]V9E<1FO-U/M.DOQ)*=G7C_8E
M/R2E_: 5'HVTAIJTL(FGZ4Y_TXQ>+U8@*(\4+GE;+Y[K1<A5HX+9*L4[G;G"
MV^OF>=V#2\7N]!!0'J?),$MI';.F__I.\LO"AD2L\F.RR)C1W@Y#8M"*K8T7
M6_QQI.*;_WI@I-/2I/PRAGB:@24KN^_<31&/BBL&?XP4Y#].&T%-B=*/B"8O
MJF]255D3^:[?YMRK \79NL!.S![7=LZ5'>0J+1V*[7O"C_?6X(/LD)%3)@JJ
M'81KJ_*Z)Z+,+P%H1S7 (/[^L%H>)Q.#;QVQ V*H^4T8W:;#.*CSCZ;Z&3>C
M,J>"MQY"D]*<]I[([-%^=MY.&9H=4G_NER#57Q,>=TNR@.K%QMZU/(B!K^+^
MTQUL/S>B-(/-,:1W]9IMID196S[_$*!^MAV"_989>:):(!]M6", 7P*\BL%^
M'HDN*=,ZFY.>62:ANGU\BA+X"Q7>?79M;)IN5G7ZEX#VAK8Z3=Y=?3E1B54Z
M*&)(7BX9!]S$EPL>0-;GEX ;AC\G\?A%8G,YTDZXVU5+L8F#$$)P-1RG(11:
M^C?>5T%/X+3Q%1<W"RX!4,*K67KP>K40WFJ7 !@& TQM6N WE:$5NH7((O[J
M5<*K0X6S:I+ Y\!)!2/H_JQ X,.*"(5'$TSXUG5K%D/FY3\]^/CG7^<CAFWZ
MU>GM$)<WJ;^.=8T/ZCD0O4T0LHA"?/CI#B[RPAFIP:B!T  A',X;MO_S1/'_
M$$RYNN!NJK,U8-Z_8$AR\BAOG7XA4^<1$R'Z;R6HZU?5\7]*&+$3=V 'L=Y9
MI@PHZ@5H_[>R8<Y9 -QY^FI>$^)_,0*=4<",C'V'IES5F(+QX9> NGKX^/J@
M+Q)7NSY>6)14_B?1>%/Z$C#2</XU"H(0^G()> MF"AI:'\C77S;XDLJ[DQ;Z
MTI[!%(67\X9Y[=02E6^MP6+'H?<"Z*U9H58GK:XF1J=E_#)!$Y[@B[X:!0$;
M_]VA.K1K4/K>JM L]M72TSOS#Q;(T4,<''(JX!PS0JJ9_?PXC07O^16"OI75
M:;744^WYIYE9OA[><?!+E(BN3-R*3+GIQ"1R0)R&R_:=O@0N=@YT?[FGYG>$
M1:NZYQCJQA(?V  2CW6HJE.)T7DPS5L6B$K%HG]*LF.Q;OF'<1;1&Z\F5T!3
MHY< O=%RX5 ;"7XN O6VNR_&2FGR3!RL@LP/5>7.^V='3L-5+^(%#;+G3)7#
M8<^W#SWX9]WT%V!)6UJ>1S'QTNGG)RRMG@Z@S^=1Z-G"!!KNLGO)064SV =M
M;+T+6,PJ0%,(Y\?)69E,D13UJ2=2;\)-L=5L.IG(^-J'BEMM.!7(3A\2$]#^
M(*=J*ZGE6'BOAV;J6"T<:@;2_SKI4Z357NG7R>)"%R5-%R4OS05\&6*<H"63
M7W/J"FYFG:BM3*K3YER'A!BQICEG=CM.Q<S,\:QZFG$OW;>*S?T92T,_PPR2
MZJ[T6Q IMS=8[W+O7 ),,@#"?_XX]#_^F$@>IX4&E[P.-S?3T^>.71Y1 5>(
M72R=D@K/X)R$+YOMUS?]T.G&_W6KZ8J'[R<G9(@A_K5Z;@^<149>S#&VT30R
M#O^]NHULFYP1$F%JXWQQMLAH_?=Z^+\D\>F]_K]-<'9D2S")O&CZL%8HYS&%
M.+XR\?5YA/YO^/G7FT&$@;!<A;$R#/7ZQA51.Q;IZNEH/]O;GM:B>C*4%FUE
MP(GB=N61_)TIK>J0:=D# EQJC*J@=CU7V&.6IE7U>/M8.?IXZ_@AI6$9J\&C
M6J >RQ?^<';IKS'YGX\F*-,60"]TM)I)52[:YH1_##U*'W_*P^[S%DBZ$MU6
M3S?FH"-]R'JO[4!R.'^V2\S.?6!ZNOKU"P,=/_Q'=%A;/ 1 ^]=)S6)#D.>#
MEO;+$5VQA70WQE\7JJ#0>1+T;@ Q[+LOWFP</7'0(K9^J+%K:5F01.:6#0 (
M,.VCWTW98JXQG8D__T;Z-NV6WF)Q@PXH>W_</T-5/J[9R5K>WRIS;ZJ9]+EF
M:&O_<6!QJ8;&$]K"R,4:MJ?2JC=OL+,7M0%6L2K>H@:FPTX7NM6?&->6CVX9
M%!-AV)H,IU.^&F@Q=N;M,V3#FG\LAOEZ>3%/!XX//=J"Z-KI=9HQ"S0;6HV+
MF@])T<6DZBT\;F:(]E)_/-!"Z+PT/QNWV(^UZ>K.WFWBD"5GXUAQ6X)&( BD
M.5Y_ ^T&V8X/WS*N19V'WO,=VP:S9:D&DE)]U%S6V )0=D 0S9#)\,P3A@.4
MCUT2KCZT$:NT5FTS%02):-L8"Y^#:C/*QGR?YY\8'58I:M#(#M3(2I&).%AK
M>ZD;N>3=AYI(1C+$ZHBI)ZN8O8EEU=0ZMJ@!LSP--;!]BH].AXKKY!):XVC&
M.>?C23Y<VJO90?%LQ4&=SF='*Q<2*XW2L<\V[7IOB$?>%_ :P(A,")MO+Q92
MD_'AO(8583K/!"0_T5D?-CVXT_GD@]+[")2XZ9M' EKD=U=*]<($YA,V)F6[
MW<\^KY>?Z<:05Z@%,:5U*#MW,8:<FM4*+X9\NV/Y.JFD.>E&R: #^)[Y2SJ.
MZ4VU]S;TXQVOGHL_5T07A/9(M6ETYAN?S\M]J([][&*6MTDX/#G]26ZPSJE*
M/99D*1@_XO Y1U5S0 <=^9Z/</.KQG,Y%C.YO9+FR%9K.@/%2C&2^+5F UHR
M5 U2;@OOD/8 265LA8YV8F7SA+E2-+_MQ1&&&"[>/%;-1:ZJV,8AYD_4T=V1
M- 9>XU;P1R0/YLFUP#Z>5-S'4/''&=;$(<W.-/5O'? ?#SVM$C*<WEE.PNEK
M?G"/:?8+-.YY_?#VMM(NJW#?B;(8:UVCFD2EL1F_SQV!CP!1 +D!?L,$O/DD
MZ;D3%;&]@,R>-2?_!Z7\EJ25+4/<J9XUBM>1@:>&U'$K6QJB#PK[A,*W*>:[
MIT)I"&LJ2Z.5@TD&GU#O4])]"O1.EZ"&]+1)HGIW@PC2B!J?8']G_1)4=J=T
M3?FI_4HMN*2;SO0>GPXPJ"GG(.%>CA3=W41A'%-<O7'MQN-NAW+_630?YBC:
M*O7;U.QAW]3&0V?(WBXFGP,_>AYTY%KL!7>K[#F^3UL_\]@JK_Y0P=:>+8?2
MCIHD:]7SYHVP317W085@S/2M-WIPBP;HRG&9Q3>SL7Y.M>+Q]<'UU$4#CH>5
ME4_8]O?NH>I']S]8X@,<3DHV49!)[!&$Y=WJ^]JL8!;?UB8#L=!ZR4@C%WF^
MPSLM/[WPEC=7,ZYI&T.EOJHFZ5$/Y%XO1TRB%RO+3;2EBU8JL5[RD?M3,I[4
MYK'3/PH0PNNJ_,KR+-961O9XK"V$0UR1U6SH@LD"UA0VE5DD2[LV.I+("CC0
M$8AKF1G?11;86_3\4WK0.T]]D9ZLU5T0 ]J7-1L?]*9*&-;"5$ 8ATTN?5(4
MRY)\V,785!]Z20\C?Q0:K8#=@8$3UX S<.''I_G<FO//)(\SXO>H@R8W[.C'
M%Y5IQ>??\O!H)[G. _ O ABJW-YY9!R-;S"F!B]SW^VNNP2$Q\&!,>:J*NN7
M &EP4VEF5<(Q=6K($#FNZ)J%'4HO*X)+<WVL>A02N%0Z=*\+KBYN'%U4RTY(
M32BU_$JI3L3A=:L40_*'$67/@5FB=V7-?=CQT):Q8=J"SYQ]^[3BI1$I!;'2
M D60"ATG&$^*U E[[61"G"V_((_M;%P\Q("#J:4'&Y_0BLP)C8(WHQ+&M[ >
M19.7)>9TEZ;=@V*!XXNJXS2)-PF]9)_$'=[O #6=-4=CW5/6\-8Z#'5"4 9]
MVK=VFWM]0V9C3]BGTM@4C6AWX%W-* PK@J^-LR3WC.8:>>H?>!"ZZ968@S(_
MNWT=5V=I C[%2VKG/6XU;X5VRY16ER5UG:@.)S$JHWMV9O%[9./'*K'QL8BR
MV-X!LI$TMFI50F^'.J1HFPZ)LQ4EK1=0/&_A^6AX@(ZU7E,FOLY00E5KN 8F
M$10J$*H,=6#FW0F^B)<Y)_(VEO#PA@";:S"BP]1M?./S;/96&\NKZ^H3'Z=W
M<J;?[/%6%>I3PK@Y5=@J?P?-._I_4/<607&P4;M@XQ L6'#7X.X0(&A(H\$]
M:-,T&ER"!'</UKC3G>!.<'>G<7</T 1"YOMG-34U=SWW+L[B[-[CSU-U3KTA
MQLWO<#ND?,MYXA9OU9R$;\LPQ/ (DPS%M"?/*OH\25>ZWASI.'H]U ;"YT83
M.! ;BWM#I+V,47'!>"E=!7$/$R)G 7V;$H$>N_NEC9WI@^DE9NL(,]95W+%A
M*/;K[I(45;P/*=C#Z'%T4OICSTY7ZQVUN,D5JXB)@RA/\KF])Y9SJHPD%5Z)
MP44T!IL$(<UWF $2K)W]WO0N[?[1["E&Y>UL*H(%*B, PC8 C=<A6^LJ?0@A
M;R/]_6 =(C(29KP-^S*\8;@0L&\I;[9J0!V-X3'%[")2_B1EIBW[6!YXW36*
MNVHBWL #<3:^V=@XX%K%;!:]GLBKVT^@L-)\/_0^IO'=$"&!B1)UA^2ORW7B
M&8./28U'WMAT1,_@EC@H/[:,1+4^/8ZPB7IS>VO[0J-_<PHE5:#&WS+K??LQ
M4TL YFX2ELP-R"F(^$C48+%9Z0XWLSZ9;H+7A7)V1N\A:I=B6PPER=T5,"E>
M\7?*SJ!+;R&(4\EE1X9S<NA)\E"]38T**'^)HW/\L!4W""^S%/020G4+T?R)
MG-L>6Y?>4,W.^Z8):&LR.9=5M6F/2T())^1UEUOMV7-+^(\[Q\A2'9N__0X4
MSM1Z_>OZ$F^?I\1M5*I?G%63(8Y>!\RL@.0J ?T1Z806^U><DK]>*2WQ)A=+
M&%SFQ>&W_SYB2:#VF1_3;0!WN:5Z8^OQLI#E'X#Z"RZHL D,=-@4')Y=@7\_
M,+&B$\N*< W&Q*H<EK8K3]QECX07Y]4,%@;I;$.LU$W8O-J2*B"UA#O=#+F[
M:-!TQ[YMK^C/2\3UYAMF:ST\G1/K"S.^]D;8:X9;>,\%>   S:M2\AX8)HX-
ME"M/GVM-\><&[/KV/$,$$4L-V;)FB,#/S;9HO24,@/E>W_;JOW6]&0NJ[:&!
ML,!L1JA&F,E4U5NU6%E5ES4I]D(F9+_&O]"E*IK\Y7'QS #[.G\4%84)*53V
M47KM<:R'#*I- 6+:9(E\W(2/SS\G7#!S#? A]/?CQKAMTM,-#P_'B-6P)(X_
M=B'?%YD;#:!N.-X[,?B#X-QW6#'@[[G[&09H29K2E@G]!&]?=L?-'W6-D(E5
M1L8^RG\0?9I/!/6$>:Y+0L"N-5]9T#(1P8N@Q)"(A0IRO]RQ;'L)./]=X+VM
M/48:S%_:%C>+Z@UNK1SEY&[R98B9V5)(0VRGE%I=BD1\5R9]NA-Z/YD%W]C>
M/P#YV.EF]G +\GVA=+1,#2(CQR<F*C/#H$PB_<T[/@=Q9@P?AL0@0F%VI6IA
M*8W]'R@!BHW(X#]I3:(W2K9.GV]*\J@D6/"HI8HM7[W^%$=U"LZ[<@G^G8B"
MF,!,XU4 -H^#JR/R5IU=U<58GH?8.[\8U;"/C3^*<HHU%1IG?+V^:,S,GJ__
MKR=[PGW/(/@C1T4Q_6O_7WMH_R?(VU)2J-R[<,D8@// R]%SQ?*O=?KT_QVU
M2CFT<M*&__5YQ/^/@DJU)?(/0 .F>A?< -,:P#/.6UAOK/EUI/NQ\N #49:E
M_BW%;E+!X:G9?O^F?:B:EW0.:=/PH-%/H6"I[*T.I5TNW^=7GD]3!&OKI>&(
M4:>7F=<V/GN/-@:;M3^7C_SVO KP?%Z$38]<]GQB-6_@)3&$]?+H=I3L]O[Y
M>1G*?V<?7;G./=+7&U+<C)?H*6N^UI7,.WT!6N@V-M>;G$XQ<<R<6W]>QJN3
MS'!)'L'-18'NBO!(RV_]H#XQ&*E *3O-N!$FB6AWL(N&-1\ZS?Q$*(PP/AH2
M)ZA1 S^\T".]=SI1=\Y*>$H-C0.AAY#^Q2.>:1=46[SV:51#<G1WU1,'P"_D
M8<GQ=4NJQB]RMGL3<5C.F(''Z[%:C!?Y^!;"QH3?#*^[%^^+KXE'AS2N_IYY
M>3?S@W64DX@H8L<VVB.S#LA>^6.\$Y & -WM#K<#)\+,OX*4,0;V')O5O[IG
M$G)'Z8NHX+$LG[9P5B[W,:!-.&TZ0E&6SC80_D^B]=/=R84FD3&DBI:8<HPV
M<J.8LK9K@%,YRJN@:5D:Z))VVVL+7!/#\>0/C'B\<NF?45R#=,;'@I_4L&10
M!N/^ 4AE5ZX.+:[ITLN!K!M9>$-GWE*?*(G$"'.\%DU?N\-.)./T#2+9D8$[
MU!->O;,,GS"-=/RCO<Y[@>PI<2O?N"0%7I$<(/S1C)/!YI@-LQ?"I%TQ.X@_
MF!D.&[[V_N$I,D,!)1GV-CV IIV6[D$.U(2\Z]2S0^U4\UEGX54N<.MYQIV7
ML-P 5NZGX/WOYX2W'*O)(29!KY&16(G"?^4;3OWC94_624,"L6VI>S@VN:S:
M:"HLE?G=DL#X(E.8&SX6\HME<S/"\9^-^/HS-5XKGD/8'CSM,.I"4ATCGM8%
M)IQ!J4C-GB Z,^6-H_?E&V>XT@_$:VI\%(HZ^[E;:-]H);8\Y&CBAP;5_^+V
M^+TIK<R3W=699_4UYV#(8#%Q6'UH5S[&"<#C5<7(4T$3F=7<??K1#"Q;'7(1
M^3LP\.O> [!AVC0+OQ2^36U@*=E]JIX3>=\7)'B%#_LS5#H%(;6C@$ N9A5F
M1G^P;+9KJ%&;T7O)#5%*N]5N[U]![NMIN](64QTE/Q*O*C)[\9%^W%*MT-3#
M*]00:K@>^@ XX'L1_7Y'2+IJS%JRN7*EQAHM:V?KH$J"=2200>T%56@]-Y85
M0X;5'$DNG,/21).7C5D;FLGG>OZ;R_9JTF?M19(I(<5RAH'3 U$,>O'*F@#'
M>V(?YY.=\97CY%;^QTNJ?J(/72SH-L']HA3)J=E#\[RRY$![B$=@14F$^W3)
M$OD#VW8HJAEEK&^.PJ@ZEUMCZRXI /R5I'%"\%0W/#R]H=(30E9#;PG=WL"Q
MC<?H=?KZ.]A;;#3DPW]ESI"72.*S]&FF@8]0':_B03+^<*4T[[=)D9[7\,J;
MD.?I(#D)V?)2ZW6U*QACAE='4SQ;"P[]RL6A3AW>1^EPY5&T_<AQ.<R5W%S]
MWW1L5Q\1@1TC50.!F,F":GA3'CS](6N"Q5S$$[Q;DRC4(7L$N0"#Q1?N]^4^
M.OY/_KZV'4:\/-:WA3<S91%ODC+,5M,U^@;=A<(^W;V+-FX((IF^P_4IB#G5
MFB^K#VP2,L?XY!O,1>I$D[J?@*1DBU=PB<BDBM];,O!RUW1S7$KM=[9]NS\L
M7<R>0;!@!RB3(W U@"L9-EZ_"]U^XM:.LIYK>-XT6:/T48,JZQ1)/^:,2;D:
M(%L*7KD]NP)%A^&-A18KF_W3J\.D3 .L_=&_QH!3R=\><[Q0?X^(! :)@O J
M#OJT5;/'UR]]TM7ZTI:K#(7RQN(J.,7>LF!BUM[14R'1].:SEYE-^P(%U]0K
M$9,SW+H,-I-WMCXKBOX::]:__([@'3Q;X:$GZA7GB%5@<(]X2UMR88B1&FN8
MZ/2 8<H_@,_%WJT<:8#NM?Z38IW#KVWJ>>Y&MN;L/>I"O)]]-%;J4FDYR;<H
MX1)3AY\(!Z66I;D?FA&*;9#QLATID];/!DW9JAMRF .9XY2?AM<;Z(9*S:=3
MMP^:FD47,]TV1_;57237-S19>B@_M0FD-R>F?]JZ#4D>L%E+#$>\RWDETMF?
MB<.L9+=4U^!TBWI6B_65A\6U/Q<B[O)>CEI_DXK;-MPV1WD!DA&X,RRI:'PW
M:\%1Q9&4I$X4_R1/<ZUK\0S,"I#:H:YHB(U_IS.S0FP">6^ESXV&"J-.ZL."
MJXB,G1B7!]_]PE+DM;? J^*>D;MIN@]1QTQ&<HLZ,W.KWEL-&%PE_-BJQL?M
M%_4VF*@V,]=D7A]Z:[D$I,)#9U-A20<$S[YAAJ:A--8\.^8_81X<JD_S,;=[
M>M6]3-^$:A!;D32],0W&&<8S8&K@ZQ) '(N2F*T[M!4C"M(96V+$F];5Z=Z7
M@ ]L:*I1V@'GXC)";'GD(7?'W W]$6BN&7L#CN-;!:DD@O;B/#-1(\P_/@QG
M7VXOW6\4NE2I8*3?3G$K(_R;/)GW-CD'$_09U $3X=+/Z[Z F<A=IC731YSM
M0!M5VXQU-&I7.M74@&!Z,0#&U+@/RVN)07MZ\G-GZXB=(:4%OH9'UHBUC<%:
M3A7ND _5F$FBF'=K<@QV!4L_A#4)D!ECP+#W)K'1;\"W4N8L;^F>59@#+G")
MJ0O(#'1^(FU+:#E?+OQ-#/<<;.JU?3D'N 9[F*PH(/#N<RU5]H*"5R\TR)$*
M1Q)?@VSA%/-1T=7CC \1^E8LHVK)I2L-W$;G<72MJ(W%R#$KD<U,NL0J:H=O
M%H[M-M'632#:)&;4IUA,970.V8X%ZB'DYZ3-+/C9><8<OO"Q)S</'8MU>K(A
M'9TR>N56$V&I68Q+Y)4#'XORBA.K#PPA?"N6$<L=HWNYY\SM,R4AVX!R)'>0
M42?"]\;ACVPZ0:EGA3Q9VO)-*7Z+&C1';N1S(":8:6YG,^P2#BEHOL:/FUVS
M+!IB\^$V8$],<T;W2/ YE:/U)!LM[X=A[O8WM='"=LPMIKB3R;[M,2IQK["'
MQ5F>3Q*:ZJL'N%S-2XXC OMO$-_+,];+,@1)OCB6_A1(X5^7&\(2+R"4*ZIE
MNH9'R\+H<NA*T3-3.&P462*&AU%JFUD\X@YIJV7_ 798,_)9_\@T]E%+M3BM
MP3>S2FB(IN0W@B7;N#*O7!)YGEUL7,Z<+JSG1&U=V%X1*X_@54]JK-$T?[S"
M.:@X_@<@3BB''2_J_Q$9:>Q4LU5?@K+JJ2Y7$[<W>^VBE0*\Y@T8[:_Y-#K#
M#TS +84)OXW:QT, >*YU-[[Q":Z!\>J@ZU>CMR8=<\5-+>_L$XRD_P$R;:#F
M8AB',JJT'&A511T'8[NO-HR7Q]N$VW\<O$;T-R_V_T*_\=[6P'JEH;;EH;,>
M8!9#.@^5H3M0;&A7I[WT0+<J_8Q)[;$O><@-8"X%^.&33?GX#UR?9M:MJ#G>
M9[KUIJ8+EE2,]B>F3R>YJKPSKGPW8(%C8CX%XNVT2^VES,*%*OP]+Z=P\E[-
MU<(R4K*>VOE+M3@I5=G(Y0.!HKG6J3[)QWDZ^Q/<&3\,O=#__"3D^!/_214G
M4]QVC8"43F#2#V4Q6)***W,FB,$0W,74.<NSDR9354\=^FEPBV@TR<^=DQWY
M8YOC ,JV!'NC^JE59XB[8"M]]Y!RERL;<.H ]S:Y3C/V^1G3.VOV^>91?;7'
MZ:B@@))W? _#XC8&YG'-KCK3@'06>7 A_+A?#PE0OL-=Z%+HLW\R&@!X?C$0
ML+H6ZD5 "^[UV_9S'[!+OW/G<Z!X_Q>NW5Q[\8.BR)T?WRZ86VV6>#17>K-(
M6,3Q7$MX!5?.@ST0P9*C7%'-R)%M->&'SOQ/$;,K=BEDOIH;V*Y3(2G5T/,X
M;WBDX34K/'G[?I' &8):7/DMK-,P&)LE)$&^ -^1*TTS)H@4]#GVR6O"-C-H
MGB]4(?!VKN#N^%*1GO29RQ/B)FT\3LR-5\G$\?G$T%9YW'G/G5^"9AK+0,D*
M%"0XU^@/4Q!GQ<05WTV_B.5+&SUM9S@LH/6(&7U'$4"%GG6-\=W&5I>2FR9C
M<HU7T",L#@TZC[*B;1K4?FW=9_PF.S.Q4LF5)4J3QC6WOE <:\;=YS'J,&9I
MH4/3I7@%]*"KPJSB*^S*NQ90VL/0I"F?X(!F%[.[A^S<6C;V3.T759T.-A1*
M3C)QX!H:Q]DB2@*:Y.^H1, :6NYP1/P]&Y.SR%K7TY^ZX6+XG3?BES& 8P>X
MB08R?]O,0BMB=,RTOJTETWD@^@&MQ5D[B1^')EA#T_''SJ^HZNT5E\_-LQ<B
M:MR+;W*5N-W";ZD=XUHII<-^"Z,LSYB.0R5":9UI&<_@0>NLM?E[B)GJ72;B
MQ\$;";0RJ=D5Y(-&UQ-*G%K3P<K%>@*@.=XO\S#!77SJO1PM#]GP,3VQDTA(
MJ5-#1W/*BR]/OQ@VT8X-I=2@#[J[ +0QAW 05PJF<("@Y?RCUQAA=.CI$,;)
M:/FA,'!2L"2@8"LY&_#[%=<4R<Y2WM^DVJ-9W[8TB+#_Y7FHKV4PA>P-M<0D
MEFP+S'\JJDF4CG"^0][-1=IU63AY#!,E\&35E5]U[Z& H"YFG_$_)_S*XQ4Q
M,5';"5X#DM99CVJUY_#,<1*H3JJXZ76H7%LK7%UDECGBLS1[(6*&[Z><OT7J
MQ9>PLP-0R;LDI[% 2N[97P?H\4Z,I1RU3GXVMJ7I P1<QP4+."B=$I2GW5&8
MRI9>&$"R]#-.GD9L8J+>F40F?:QU66B4!"B[C8 O#09<X&N5WN89DS$7V*HF
M65]:@NJ(+8OH6@HF8'U0 T7:KG@QB!-IH0@]V0@TQFQO5J,^.U*SYRC-(X\3
M D@ ]KS_JYMY Q+;Z\Q>L:3>B9KW+MS)W%#%PF\Q1N\YB1*[/H625]*BP/2N
M_P$BH6"*3+UFKTZE%-22=%MGTM0X7DTT-TKI5X C!SC5_^PC?SO_4EV-%%&]
MPX9ED2U.D[-_"97^0<^/Y\LL/@1S <L*SP3(W&M7.O*O-"X)<)>$JE!:'Q4S
M<[MB*@,!D!G3R<C=<RG3G'YJG*;&&3C5AG_E,B=Q%64.>U'<G0BI!9GT6Y'.
M^3'8ZN>59-:X"V*N_RJF5XRXFQA $ZSY 7!R!#>01V86^(3VWMS@(E-PC2AI
M\P9%HXU9@]Z%9VF\*U7:NHQNLXAW.:BO3]BACH)\;O?,XD<=-D2!?HOOV/HO
MHO^Q(4_-.'/R.53Z<XX+TK72>F&5<)X63/1=OWVO?:$4.5K'G6?=JQS1&?A*
MYA-_^]N."\,Q)_0X&]L0+4*64 'H__3L5C79MT@=^MK+)1[2]="9M]8M%8%Q
MJH.?N )*FD2A!!RQ.W;?H,8;&TI6PIG$W<EJ3*U2K (NK+@8.F,]GV4(L)G^
M9_AD+,DR.[Q0+FP,Z>4Y&8Q&[V2KZ!X*/7Y75&(=Z=<(NL#&HNSI=[FV[GT+
M9AVZ_YLCETCC/S.&!1+ZR88UU0Y&:9;@5-&6HX6038 VB0,$JC_4(L!>F7B#
M_#GTD;RNA9KOAYD3OEENS9H'J%\-1)32?ONS7N*=<!9*N_>3Z3T1.]H^RCQ<
M U-92(Y6A"S1:F>=67<!_F75Y*BLLWF]BW7J*E>4@']5#;"52Q(6LV^#W-^.
MA=CM:K:UI$P-0P]6#K.P@5=1L5N>S,1A2?RHM>(4PUB%VJ8E_Q'8Y[?.2XZ(
M_4JP6GC':)QI3;CW63<6"]^XW"06.VK&Z4[^M[-+\UF@W]B4H@%'8KM4DB1
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MTQHPZ5-H'WZ]8\7P'L,PG-X0219T1#4!,;+I:FW)7G!6_+!]Q>@^A1<F4,'
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M#MO7T>1@Z^5%KTSO:V)\1Y^D#\PQ;PQAK/4NS&-$A-S1V+@=33YX&CZ<6,+
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M0<-[J._SX'<_+MB[D.1-D@-3(*4G;4C<-/$GI]$G\:%M'AFT.T[[/1K)$0Z
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M<&:5<_A,#9' >+/3YA6IX&_4+/#U*W86<7U82)[-D!_F8/)=)WKS6:OK@E9
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MA$WLST?)_SQU^<N8D$GX,$(<K)>X;IH7I%0-#H_\?9;7("J 6JK<TI 1#+8
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MDA NVA(8T@7PBI6#/WQOYNLB]4+NHX _+-<%]U\1MO6CR;!)DLO*]0U_QF'
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MOC&LGW1)"/,DNR\7A@LYN&/Z)<M39'3,X[J?I-;O$RSUX"-0G,P".%]@>=R
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MUU21LFJ.%0+MXF8J7TG8-?/XD.#R526XG)X<,ER^X@R7776DNPS7_%(EOTZ
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M(-!@+FBD"R2'C0-%V0]H7*]+>BFSH268W1H;Z_I>*?1'3$NB>76@:%W3:;"
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M("8#%H;]ZV <J+BW"7Z$NY[0I[!>P'5P$(O)UHM@E2HF4&; N*\,_)\C@7X
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M.3:Y"79>=[D1:M/V1U*LE\ X@!/Y'\/6W-="W)-)8O2=@Z9>^/8B:?2U/AP
M-Y'5=[HU/;@.7+LRQD]WFO >-@W>?,_V-I'\I3"?T>?3%%<>0G(F"#B;;"5W
MH@,-#;VO!L@&OL &LN158\BL:1T'MP5;]$TI0!.]^I- .[C/13J>3Q/SV7"Z
M,_$6?@,CQKAL:-$WE0PREL2#/8YB**AL6XD(1Q"<UZ$</;^:G,.G>E%TD20
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MJN4G4TL.$+$35 ?]4S[56?OOA^H]OS@!/<9\8DU!'/<?4[;X+6<$'0HH;EQ
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MZGXN<0CD-^CRZ"M>M_D&604G3>G(K"^*CJBKW+NXI)NJ&@@&!JC][.3T11
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MBR3F-2ANH,Q5Z1PU'\ Q&V]",1MO(-SQH%.M]Q=O-HZ'<P"L=="!XSB0[S4
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MYN;),!=5GFW+A7DZJ;(K^,>B719__7]02P,$%     @ LX !5Q ;/.261P
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MYWMPV[ LEZ!O^#04Y(J1-63G"D2V,>0@4RGY4P2C\3 %+)DZ.G1R\.+2PQ&
M=#Z#(8'?XYE.W_,)+:?Y&8.4.$^*"6?$,&%JR&:3'7@2NY>?/60W.!(&1&!"
M9[@.$XJEV4-8'E_O1S_,]&CH*.5_C<//)7OMCIF=Z>[=*"/D8^:+43SVUN95
MO"9DTK_YI2Y3W!9R3S_/#BJG4NIC-[ZKH!>R N#'!/'<:"((KLXR2>NMCK^Q
MP=T0OA2LHH/9LFD>$X!PG@3N,\P0/R?)8\[5NXB#.V,_3;BB]WTD/U^A,U$V
M,M^.=NZXY^OV/4$.FD3NN"ZSQ/$XMO$:(@;K) O"\;0>^*9KJA#"P0\D1*2S
ME!1V&'V_>7XQ=-/&IFZU>'>PHB,;L>FQ-^.-EG95]$@K2?H?,JRHD6ZQI?24
MCOL$AG5P]>[+5GJGMF8*.CI09**^230(&=2A_CP+.85E1M^,%#[%"R>N873O
MYZ*E7""]9XXTG.GP=+IWC'_!%EG$J[F*+L&ZH(C#> 6!!']AR&3PM.Y+>CQ?
MB_&3*"7+4/]9S</^15.%JD]'@ZS'ALJWTI851HMKO2Q*U:=DJCN*H<;G\7/H
MSK/X"B9)S&"@J[C.P2FN"-5R[Y'&^$$DJ>!YLEM%(ZL\I4Z> H*M<>3.A>*D
M9A785\+I1)?;J..;=OI A_Y)J8N+Q?MGX6SZ9I5CHLIU@'!/POE=7 @Y_XC=
MB"G8!G=SQC0Q^2QW#N5">FO4^;!4^]'?=8!]HXUQAX_N.JL-2LE-%9B.6UXI
MFUEWGV(:./=8:N!,Z\2F?"I>"WH[?0_P"../B@#O,8=$X(("?MI]%.VS=?P^
MX.G"G=(TXP?W>\MM)]GZSW[6>HNMX[DDKE'N6D*GG(.7V_BP6 F1QV4F^EKB
MN9AV\NHA)@.ZYVM#]QP-Z)X!W;,%NJ>@<JIIJ>,9KJ$BT+N.4L 9"?749$.D
M <]D?W,TDU.CQ3@@7WU6?5&$P6V\GT3#)^TT2L%VCI;,015P\0'C<<0KE)(<
M,>H)!A6JS>$[+V$(KMJRD,CU%+,0E+$E=Z:C9L'SPC(ZE,Y ?IQX63^"YUF0
MC;1^[R!=]R)=G]P3"09F19S*(E%I4THZ'=RM/7BM%<D1+;47^L63S+JDDA7P
M>40 \6R\UMX1J2+7=9_>M&K#\;X@M3 'JXBS&/@-RB:7N*1TDJ$C"-P%2]\(
M3 1/K42G80:UN/:]-J> C<[C>)Z(<W!-/T4U<O>RMXMI=OWLWYHRJ]*,U.?%
M+=79^E!#Q=FT$7B'F4BGZX;;2:.8UM+4-2V+%,XXB3BP[I&_:)]+S!:Q&\]$
M@&=.O%HL ?O'I,9GNHA57<5<6-MZWT>PZYX"QC)IDS_HJI?#@],MR!Q>,^(6
M=Q5&Y1UHT_2[(1AXO]#'C0NE25:(P^G#8@-JNB3\APX1; N9ULA!^J.B?-"&
M:XFM@)^:MK#7NOJ/[VL0O!.QZ2MQ*(U2Z7_.Q*)^R>TH55V@MH&/J@I4H&6\
MXMD@169#$]X0O5&YP$OS"/R5F4MZ*3!7EBS!J6OD#^B0WY[F*W?$SL]ASN(&
M3OXE; @?SCEBI-D,WF^5J,HO\Y>A.W!HF@@Z)Z$Q"%^-<!W.N,?[T>7*"(E,
M</=X->@4AI)S5 )& J:[R!M)(+)G9E!HM[IFDJ1%BT(\#8A<P0'CO][*N=)'
MS!CV[#!F()W]&F1^XF(@X _8)%FUD*)89\W$,RS5%7N?'2LH[]Z2%?<^#I2/
M=AS(82PWDR7ETEB8F*0I815K. AUU()Y=<1VB!UOY(^8G]RQO67P3G34O,<C
ML,!/0GMOI[Z=5,HKXU?98@=/N"/97PXC2WU=F%CBSS!ZPREDL,L,\4S@_5+K
MLOD)'!08-XGS""3D*?AH:0]!5XNABSX][_ST1=>GYP?;L'51@-G4UYC8\FLX
MOE2Z])C8/70,WH!%-+HZ-NPA&GZ=\"?+. W4.,C@O"A V\<H?NZ9Q0FTH[*"
MM9%\@10\<!T/VY\9#"*?1-.,<TWR8+#7%1HK_#'\3E@2!B&^%R%66VFY5ZAZ
M<L;+T[*]4WO_I5EHW-,T"MU^Q*'#GZ5LPTK12DZK'4YDR^:^I'(/1JMX$/N)
MP9^01U27V4>-9-$)&B>?R;PU$U,!DM";]/Q,^YE$[V:\.+EW\*PY]?41MC;*
MX;&#T%$7TT6<D>$#1&73H5R0NQQ@W8@4<I*)#GB@%7FC634</!SH0TMB?'3T
M0:Y5#K\:'1Z-P0:MZ@6Z'!G'DO45X+"LZH'#XS%R>!S?QN&Q X09[QET]M[/
MUQ)X:R#/V!'>T7=J=GAT^N+%Z?/SHPZ.T>/SP[,7)P=G6W@MM-I@/8A(DXU%
MJP=3Z#_IS[4'M?-^P9,X_F@I<#:FSAC>&?0;S^<E1U]NQ>22!?81IV#N$=S)
M0_#Q%N*&(E 9?G@R.3L_F1P<'.B;?QZS92"K-!N:Q%+[.(,PWN]97*R%+R#6
M03(X'1MFZXA-(E=:.4<Q!'<T^;W)..%/0'=3E@VGF&ZR5B*!FT0__[_W;^@K
M^*UVN7["?B.YV2?'!\>7^P?GD^CRIS?_U_SHOQK,4.G?G!T>6K?/R:LC['(B
MJ37PPPR^V<B\XQFW-M5VV.C=E]VG8$ZGW>;T^.3D^/E1ISDE4WOV_&0;SNYW
MBBI!.?@KFT-<J Y3RSH+,P!>PE!.94@&J,/(/M5!)F 0]6F=E9Q,M6AZ4\=F
M 7!.(%,D,L&*51O5=^\.YQ3<78PY-#4&N.?YH;"1N?R5HA!T3AIMSKEF^QB!
MR[Z;M."24HE1\6U@I0W?-IVDQA/>;?2>4HSDU<R5,A3ACL2MB L MZ$CF>S)
MD3<_Q6P&%XVW*TDQ&=N-6WA  7YE*,#C 04XH "W0 ':NJ<?.!36HV8\Q\E7
M]@*RF2E"SZ \H4&A7)NM^W+:$>%3IBJ)&T-^@4'BO"DI(;A4"O09D1; XA"]
M!2%05HS3ML 4^"TEQDC_RJ@U',@%P6.%L6M8C,*T8P[&ZGA,J+>X;@#><XZ9
M/A@Y)M^V+":[M#,*TIS8JDIW,K!@F6IO)-2&DQ)_(MN(D3HBR)W".FHT^JK#
M&C-$'/S$TE)DNS%0MPK/B7UVER?\D3<=?,/=(=%^7\!**^O@V>QB938SK6A0
M *2S+E8'.# %+.=I5M;?<N39U10NGL)(?J\>*'AK%FO8HTN.@+NNT!!$?HQ!
MY)-'$$1FLG/R[8:H\0Y3+COK1/;G/1?O)2%?/.BW6WGA&$1,A/H:'-S!>9^J
M*BFSJ<\6>H@!3 _-=(W0JW;A1-77:$#.V!:A;/+OY-NCNKRUU0 =NQTR_R_0
M>F [++)FX--GY"X6OJ#+!KQ*Q^3J>><;XSA>D:/7%$T%DUU>D6."ZR;%FA*+
M7<>8*=6]>?R\)5&\]K5/PM?DJ,#)P7-](:QJ@Z6/,*!+9%:3_.A(^/XJRY>8
MWW!YOT_E6.%#".K-K;UDD)6,O]0=T/A.>M2W,(R,9E0S$<-<J8EQD ,!8ZB\
MGF,WSHTN<[G&30H7P?>5.).<E,5ZR6J-?91F,_?KL<US>S/*,="JR1GRP:*(
M]9H(*4-*L68%FWM"F6]3L2FHR_9LX9AM>*.+#,5IZ)0B&#&;-JZW;^K0^V9O
M\#\?+#9)^*,6*DECSY\?; --NM2U#>_\8C#!(W4V<=.;0# CB"'J9_H459LY
M3)ZIR_6)/]Z"YC,:_-%'Z(\^W_W&),\/=0Y[=QJ3O+4X[G=.ZE;W]>KQFO_,
MMMFN(@W:/*.02Y_G-TB\+/ L?:+-Q!!2":,!&&*0*=9?<290$(8<;.JL<71*
MT^[>"^U#"Q]?*?!MT&CKVW3R0V];-#;I\-24,Q^VTDM/ ,T(+.M(-V9"4#\[
M$A*+<L:+/B]\,KVQ-0HZYN9D(EO/<H_T8PVI1R0=!REH@#H2:+J8VL>^I"#V
M8-EWX#CV 38)V^6?BW"/2:B11(!K4C@ J3-CN,2'!]&-BL'FFF:=*<J^]'>0
M-H6ECND6)=Y%&M1:VA:1N%#,AO3T#C5S>*/CSF\QUFP#D&X\.D3BJ@[%301"
M#%Z%-T?/1&N*[5"S :N+W%W"CJGF4I6/,T/@N _R7>.1Q.!]63F5:EX0N1$,
M1B[2/?+$'66\2 L,G'-9V9=\B6S&^Z0U>/]<B"B5JA%.&+@[%X6!;-:-R13$
M*X:3%&N3M6:^0[!U6-S,9S%<W^#,^<J<.3\X9TYF9+<TX[=7B0WGNEW)*[1<
MTY.C;6 E;W5NB?8["97K*++CT\H_^>2:.IW@BIB?PYJU]]TZSM))0&+O8;("
M_E+*Y'E!B[!LI9.62DI4DF(Y#?B0EZI>%"E)\3KFP%VEJ!0>))UIAWN[V'@E
M@VS]M!M(KEM:D (4Z@,')&/=I(['^VB24CK\\@,EE J/P^B2[GPJ-QEKLH^.
MH4@DA@L7?/(Q'9Z4F\;"T=#D<2EW=D8G/K!9H8[Q$YJEDG<<VN[<,WP7)!VQ
M3I,H62A,YTWCU<<H+<&CX[K#E;J1;NRP7BY3GXC!@'"]9X2K;Y'!KL+N78*"
MNP+=L[8-[$W[DNB#$#0OFYSKG$4#?J\0/I!K!*!323^Q13Z4Q- @  W9Z_=2
ML'X9P\B$S7#*NPA7MR85P@"]8@"I?74@M9,!I#: U+8 J9$E&K>P(RU-DI78
MM8E]O<PM3\;,;WP35)8$)S3?BMD 115C!RABKU)I-5BW^VYF-"4F"Q#5\B9<
MHY&3^TEJ+*0POZ0>-S5V]J(T9S^ >EC0>^YM1(DZR9BO5&VVH4Z3QV6)-<YT
M$G!=&^XXX"X_G:4V5;5T@5@9][8NG B-Z!4XKLP14,JMEEHWDT*@=L1&3FK"
M0BR599M4S><$\UOOCWVBUH28]>K!]5G*J#&/1]L[+4L-?*F6<!2DPHHX=[V[
M7HU)%-D$7,W8B:1P%"V(2\YG9Y)GMC)%)Z8@:U]7HH0K)I#4*"]6<R8Y\LB\
M=2S 9'0D;^*&HFO+D>2_MVX*8L##W=*!I]&F$OB0&)%@(L* 18=T3[1X(Z>@
M+KHJE598EFS(72>";;#_3(+(E2::U(!::[[R[D:0897[=/[]4.(+D)=!_=UK
M1R_I?\2;E')OL+ :5.,"N-VR5M[C[EE;*"%7'6F1#8FX(4-RSS0_&U-I&#"?
MP7)+2 [DH!4Q-3QC_7SYV7)=:,9>C[.>I:'N?8J?VY:FGQ(4)6I\CA=62DP!
M \E\;J" <Z_0T4%X:BGD^#92J0.16PZ/K1L(\\T0 =PA]LEWP2IJ,1:TULI+
MX(DYMJN<*]TC;"K^2U%:_XL991& 2V'@5>J# 4=<PV),K>VZ5#&$D2RBTWYI
M$KE<4JY3D#:&]SS/9HI8"#6\US' C""^"3\/20 E/J]?4]]))^:<3!AI]8P]
M17#S%MDT:Z<IT&*3:K<P59P;MS65^H2_SNJ.)BA"MNCE28)UL+R^CL5Y#*FV
M)['-MMMGKPL8--Q6L%<HX[]@*$F#W?U@J]L&SRIDZCZ6-LA :>MX?IG-P&<M
M.U+8KGB$+JWM9P)''1E9:49&02YL)@BW)O;IN,33C%O['!LTD <=?75T(@!1
M<W0!^2M*X<]B<!3O(HSG+(?69 \1@]DHJ7^C+H.P[N5-]%I5<.>X-G2"7T).
M/95,SI"-":$6UZWK0,NU WD3P\2^M-QF021Q)*'$5$:/ORB+CZH<3^QG<)-Z
MD<%H,;MY@V?9B<&1J+A>=-B/21=++R+ZB)O Y?UUS 4S '/_QQ82Q&P2_[#
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MDLB)LS%]8A;ZPJN-Y< SGHR94 OYL#L2;'S\M_1X(F[DMFRJ3,3;;!@I:XF
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M+-1J#Q21Z8CJP*P'UL)=ZKWK$#/\&%^3E#"*HD=R*J4^$H1D2AE#!GK'S$:
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M,O+1@\JO/^X'%MSQV)&H=5%5>.30%8=X()5EEM6UG0,<1[ZU?'=<NHDF4"#
MI[!!D/LW;>!P@2/BRB"0OT6VWO;)KA#@\W6'N9/1M&,0%WZ]0^8>O+K(%,#3
MWC/;-_7=@U9J&QO<18>GT[UCO;W="/X&0SW4'7XU=8='0]WA4'<XN,9W=(WK
MP37V76/+HL]1OE^HK&Y'W&-T)+C,;PZ>1.BI/31_ZPGU'7R89[L . YW&:_,
MIS00^<I6:&+0_1<2RC5CXWFZ-P+HHY.CHR!B-L0)GH0R; 9EZ"C#7_A O2.J
MS]2V,/L=\J%U'_@W[]W#T\X3Q "9?2I[^&K8P^X>WB7O)>IUK]![ 4\&-B0V
M?*16C2T40I?'8R#OP_9](MOW>MB^K>T;76J:AEW9R)N;[+G=M\!.\TLLX(VH
M?R[V;$TT)2K34^ /L<];9EI0F<MXV^]';^)D$8738;+B08?=OKL.ZN*IJ8M/
M@[IHJ0O>:;NB*L1M-PUJS,;.JHTF/<)R.F0[-G0T0HCHDBW1:0#?EP\$3M,\
M?LBPT9_*1K\9-KJST1U&IEW=YQ[7U9^[UYTG#1O^J6SX?P\;WMWPL$MV8Z=C
M/P(]DGO$%$8/ AG<T"<'&_$U"1]#<'6H(""K-7^?%!(.^NBIZ*,X'A22!\*J
MZC)+T**S^?UU!<)/-OB!]=0#-Q^Y[[?6_A=A.ER6OYXP*@._-CAD?<$3CS[L
M=#0=[T"Y\^M__.NGYZ:Z9="T3T+33J>#IMU.T^Y,8/@KU;EW"(-'$O^F,MM-
M2[IM@'SC3=R@^5;R\X<CZ4/B_*FHW21Y"+7;O[M%Z5KH]VZ<?QTHNELQ86F4
M?6X9;A!@>/QQ7]D[\)EQ%2FBII3:$A@R[3[X=S@]/I7-E::#3^/L;;^>:#<V
M=D>=$S-#';O,4#MRZ#D]&0X]3TI!*+63UM=)K>P$T1%9TU:HHQ,GYC<V")HI
M_V(:)FYTI ?W]LELL-ELL,"N!7:RL[L21?@C\#*O.>?69V?W[=VS<N>L?#;*
M[(%=A5OCHT.1[%=3)'OLCO!^BV0_OR+VJLC2VPIBGTV+] ;^6=3+_+O_#U!+
M P04    " "S@ %7E 'F1_DM   TEP( &    ')I9VPM,C R,S V,S!X97@Q
M,&0S+FAT;>U]"W/:2-;V7^G/6S,;IT#FX@O&F501C!-F;>P",MFIJ:E4(S5&
M$R%I=3'A_?7?.=V2D,3=!B-,SVX2D-3JTWUN3S]])#[\OWR^80ZHJ3*-?.G>
MW1+-4OTA,SVB.HQZ<'2D>P/2M6R;FN2..8YN&.23HVN/C)!+I7BJ%)3+\WS^
MXP>X53UH8YE5<G%2+IZ4"J4R*52JA;/J:84\W)%W7[OU8W[U]7V]^^=#0_3Z
M\/73;;-.CO(G)]_*]9.3Z^ZU. &W+Y*N0TU7]W3+I,;)2:-U1(X&GF=73TY&
MHY$R*BN6\WC2;9\,O*%Q>F)8ELL4S=../G[ (_ WH]K'#T/F4:(.J.,R[[>C
MK]V;? 6N\'3/8!\_G(3_BFM[EC;^^$'3GXCKC0WVV]&0.H^ZF?<LNUHNV-X5
MM#R!TZEK?N9'NN8-JL5"X9<KFVJ:;C[F#=;WJL6B<G$^.>;HCX/)04L,KNHP
M@WKZ$\.[Q^ZK&HPZU9[E#:[27<QJ:8?M^I;IY?MTJ!OCZK^[^I"YI,5&I&T-
MJ?GOG#@"_[K,T?O_ON)7N_K_,;@U#-#0398?,"&G4KR\\MA/+T\-_1%ZPZ-7
M8DJJP6ST$KV.1,.>96APLO%SH/=TCQ0+2OG#20^FSMZ$F*4E8O[CNY[>'Z<$
MQ1LDNN8WJ\#))]T%,0W=&U<'NJ8Q$R[_]5^54J%\]>$$+]V0X)7GR%UOM+NU
M9HO4[ULWS>M&J]NLW9)FZ^:^?5?K-N_Y";R@<0U'2?=+LT/ P[[>P94Y<E=K
M_P=.?/J3_/7^_?N_<^1+K4,^-1HM<G_7[';Q5*->^]IID&:70,M/]]TOY%WS
MF+3NN]"XVVAC;[76-1R$HW!%]TN#</?M?JEU^;=VXW.STVW76O"UW:AU.P3Z
M>&@W_X#FY+Z=$%S9D 4L,U05 AESQ!$/@TC?<H95W[:9HU*7A3.,ED3@7B3\
ML,R@:W?,U'B4+!+/(A"Z&BV8/)P@G(%.DVNDTVC_ 6=@(CZW&PW4!-F@]2\;
M>VA%_)!N@CE[U?*Y'??;])B[ ]TE-1#TF@O+Q^8-&+G582)=1JBIQ6(QZ3#G
M"<Y DT>',3X=O3&_J,>\$6,F:>N/S" /$'.'5&6^IZO4<'.D::H*>8=W1O<J
M%:[JUA#2RYA_*UX=\WO<@*HHZ0Z80VW>-&H8-.(71$TTGGA^]XTQ*5WD""2>
M4J*+2,:H!8QU2#4Q*FXGT%XW^9#A5*GTP?7MZ4!QH9QAJ& .'TPPUY 68/I,
M[<,)M/D(LHR)U2?73&7#'G-F"#,,["<4YK4<XAE&\>U+ ]RY$^@#)PL'$F@,
MT($[0#.A.")^9F(,O@U&@H=@;H<N;ZI:IL:-Q\6/'@51<=+%E$>SHL \%<\+
M5]F=E-;]-PQZ[0;$WT8.1P##<74-C)6[!F@?!P[AACU:D/#YX.$;@20.!O%H
M61H_]$0-G_8,EFR>XXT=,!\=>L3K#/9(#>+Z_;ZNZLQ4N7V-!KHZ(-1A!.[)
MT/74'Z8U,AA@,RT'WU1FHU/@#2AJ!11DY>8H,KP%7D>H"\(:AC5RJUP',3"2
MT$(=)K#GZ! @8%X3<X[3-Q4XIY00H"J -IXU% D].,1!4V'R'8$7/S^EI%1*
MUW37-NBXJIN\MYYAJ3^N7F0Z0^A>8"[>'Q= 8ZHE=)7';JJF9;*$:(7PREEI
M!Q3GL;QK0TR$EB,(<#"*HA*"C"F$\ES)XPHP4>L&SUU!?.^\2H?QL=H.RP>C
M)63CG0>6(J!U844\E\;PFP6C2^P[%F2X@:/0R55#)32C^9$JSR]:V0MFV?6D
MFYCUSC12>CQ7;9,;(Y"@'NFH Z;Y$-N*2KE"WC5^ZB \A,*F^01]6,[X.,07
M,?S B,8,YHFLH'LN9F;=89[ %0Z#4:GAHK3-0,/P986.J.=1O(J'.<]22-(
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M]<D=_ ,W+"=O"#?3XC=4MFZ#25V&JE,*H5<6LI5M7VR4LT;V[4NCW:AU O-
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M$32F6J(.-15VTF>QGRJO0<!/4Z<%"\!?EP$=G;@GI V0Z0;RR?C#B;^K ;<
MU%7CDNQ$BJ[NP=R0QA\/.?*Y+@WX^3-Y<P\!@3]:67O@84$&A?T*"K5'+%0U
MR1TL,*BY\\B0%F>7X:'^\,<#A"H X->ZRRB2\*V6>")1>T)Z1PM>_, K^1IX
M\:]T:%]=ORJH?#F"?+)T;1F /.E9VAC^&7A#X^/_!U!+ P04    " "S@ %7
M!Q:N81\)  "?/0  &    ')I9VPM,C R,S V,S!X97@S,60Q+FAT;>U;;4_C
M.A;^*]Y>[0Y(3=-2F!E2!HD!9A=IWA85K7:_.8G36#AQKNVT]/[Z/<=.VK3
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M27M.5M,$<LN 3B6OCSK>'?;V!PM@N[*^/=1PGQ[;;YF/_P]02P,$%     @
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M"][D(#+ %BT%CVP27A=CS2-.%<<)<!>+6+F484^%QOC ,JJVP805$U(S,,B
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MC-YB0.+R$C8DL1D5^P5)]=KW44119E;=^ZPMXH!&T%"SA3:XEU3*/ PT 6:
MO=%V49&&D$@7*6PM\(J=3*G)MKX@;W1#PQQ[S!Q[E\<]@\ F5O#\;@..F54=
MP 3V"ZZ2,MHN+N#95(HIP^ @HY/R0S15"A66YD+.&=R=)=))$[I"2$ @WR5R
MZCPYM'_\5^1X@,(.\*Z%,&]5Z-T)DFXTW.VET7CP KT(MJ[24G>Y&<M3'1M
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MK](<;XX[+WL+6+NRKDUHN /_]O\@</I_4$L#!!0    ( +.  5=__CVM 0<
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M1Q"7+[!<6NW*,*!805UA; @3+C+>''3),BR_&$FW#U*T:B(MH"1,(*&"!BO
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M2P$"% ,4    " "S@ %72]8Q_EL.   VQ   %0              @ $8$P
M<FEG;"TR,#(S,#8S,%]C86PN>&UL4$L! A0#%     @ LX !5WP+/GVO,@
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M2P$"% ,4    " "S@ %76! F5A-C   'LP( &               @ ''K 4
M<FEG;"TR,#(S,#8S,'AE>#$P9#$N:'1M4$L! A0#%     @ LX !5Q ;/.26
M1P  B"T" !@              ( !$! & ')I9VPM,C R,S V,S!X97@Q,&0R
M+FAT;5!+ 0(4 Q0    ( +.  5>4 >9'^2T  #27 @ 8              "
M =Q7!@!R:6=L+3(P,C,P-C,P>&5X,3!D,RYH=&U02P$"% ,4    " "S@ %7
M!Q:N81\)  "?/0  &               @ $+A@8 <FEG;"TR,#(S,#8S,'AE
M>#,Q9#$N:'1M4$L! A0#%     @ LX !5XT>+040"0  %4$  !@
M     ( !8(\& ')I9VPM,C R,S V,S!X97@S,60R+FAT;5!+ 0(4 Q0    (
M +.  5=__CVM 0<  /@B   8              "  ::8!@!R:6=L+3(P,C,P
D-C,P>&5X,S)D,2YH=&U02P4&      T #0!X P  W9\&

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
